fluorouracil has been researched along with Colorectal Cancer in 6297 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although phase III studies have investigated the effect of adding bevacizumab to the 3-weekly capecitabine plus irinotecan (XELIRI) combination in the first-line treatment of metastatic colorectal cancer (mCRC), no phase III studies investigating the effects of adding bevacizumab to biweekly XELIRI have been published." | 10.27 | Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials. ( Alvarez Suarez, S; Blanco Codeidido, M; García Alfonso, P; López Martín, P; Martin, M; Mondejar Solis, R; Muñoz Martin, A; Tapia Rico, G, 2013) |
| "In DaVINCI, a randomised phase II trial, patients with advanced colorectal cancer were randomly allocated to: Combination therapy (FOLFIRI), irinotecan (180 mg/m(2) IV over 90 min, day 1), 5-fluorouracil (400mg/m(2) IV bolus and 2400 mg/m(2) by 46-hour infusion from day 1) and folinic acid (20mg/m(2) IV bolus, day 1), 2-weekly; or Single-agent, irinotecan (350 mg/m(2) IV over 90 min), 3-weekly." | 10.25 | Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. ( Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J, 2011) |
| "The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer." | 10.23 | A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008) |
| "The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer." | 10.21 | Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. ( Adamo, V; Bianco, AR; Carlomagno, C; Cortesi, E; De Placido, S; De Vita, F; Farris, A; Ficorella, C; Gallo, C; Gebbia, N; Gemini, M; Iannace, C; Ianniello, GP; Lopez, M; Manzione, L; Palazzo, S; Palmeri, S; Paoletti, G; Perrone, F; Persico, G; Pistillucci, G, 2005) |
| "The French contribution to the development of 5-fluorouracil (5-FU) infusion in advanced colorectal cancer includes five randomized trials and specific researches on the 48-hour bimonthly regimen, chronotherapy, and individual dose adaptation." | 10.18 | The French experience with infusional 5-fluorouracil in advanced colorectal cancer. ( de Gramont, A; Krulik, M; Louvet, C, 1996) |
| "Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab is the standard second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to fluoropyrimidines and oxaliplatin." | 9.69 | Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer. ( Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H, 2023) |
| "The PanaMa trial demonstrated significant benefit in progression-free survival with the addition of panitumumab (Pmab) to fluorouracil and folinic acid (FU/FA) as maintenance therapy following first-line induction therapy with FOLFOX/Pmab in patients with RAS wild-type metastatic colorectal cancer." | 9.69 | Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. ( Alig, AHS; Ballhausen, A; Fruehauf, S; Goekkurt, E; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; Kasper, S; König, AO; Kurreck, A; Meyer-Knees, JW; Modest, DP; Müller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023) |
| "Combination irinotecan and cetuximab is approved for irinotecan-refractory metastatic colorectal cancer (mCRC)." | 9.51 | Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. ( Bekaii-Saab, T; Dakhil, SR; Faggen, M; Fuchs, CS; Heying, EN; Lipsyc-Sharf, M; Meyerhardt, JA; Ng, K; Noble, S; Ou, FS; Rubinson, DA; Schrag, D; Schuetz, SR; Stella, PJ; Weckstein, DJ; Wender, DB; Yurgelun, MB; Zemla, TJ, 2022) |
| " Patients with colorectal cancer scheduled to receive adjuvant chemotherapy with capecitabine plus oxaliplatin are enrolled, and topical hydrocortisone butyrate 0." | 9.51 | Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC s ( Ahiko, Y; Aikou, S; Boku, N; Furukawa, N; Iimura, Y; Ishibashi, M; Kuroda, S; Nojima, M; Shida, D; Tanabe, T, 2022) |
| "The randomised open-label phase III XELAVIRI trial failed to demonstrate non-inferiority of the sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A) versus initial combination of all agents (Arm B) for untreated metastatic colorectal cancer in the initial analysis of time-to-failure-of-strategy (TFS, 90% confidence boundary of 0." | 9.51 | First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S, 2022) |
| "The XELAVIRI trial compared sequential (fluoropyrimidine and bevacizumab; irinotecan (Iri) at progression) versus initial combination therapy (fluoropyrimidine, bevacizumab, Iri) of treatment-naïve metastatic colorectal cancer (mCRC)." | 9.41 | Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kumbrink, J; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schuster, V; Schwaner, I; Stahler, A; Stintzing, S, 2021) |
| " CASE REPORT We report the case of a patient who was diagnosed with stage IV colorectal cancer and who underwent chemotherapy with a high dose of 5-FU as part of the FOLFIRI (Folinic Acid, Fluorouracil, Irinotecan) treatment plan." | 9.41 | Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review. ( Gofir, A; Hutajulu, SH; Nugroho, DB; Yuwono, KA, 2023) |
| "Although 5‑fluorouracil (5‑FU)‑based chemotherapy is the major treatment for colorectal cancer, it has disadvantages such as systemic toxicity, lack of effectiveness and selectivity, and development of resistance." | 9.41 | 5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review). ( Al Doghaither, HA; Al-Ghafari, AB; Alzahrani, SM; Pushparaj, PN, 2023) |
| " This article presents a systematic review of studies evaluating the efficacy and safety of chemotherapy regimens combining fluorouracil and standard or low-dose leucovorin in treating colorectal cancer." | 9.41 | High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy. ( Goněc, R; Juřica, J; Šuverová, P; Synek, S; Turjap, M, 2023) |
| " The trial TyRosine kinase Inhibitor for the treatment of Chemorefractory Colorectal Cancer (TRICC-C) trial evaluates the addition of nintedanib to mFOLFOX6 (fluorouracil, folinic acid and oxaliplatin) in patients with metastatic colorectal cancer (mCRC)." | 9.41 | Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). ( Berger, AW; Büchner-Steudel, P; Decker, T; Ettrich, TJ; Güthle, M; Hannig, CV; Hebart, HF; Heinemann, V; Hermann, PC; Herrmann, T; Hoffmann, T; Hofheinz, RD; Perkhofer, L; Seufferlein, T, 2021) |
| "The aim was to explore the correlation between increasing doses of [6R]-5,10-methylenetetrahydrofolate (arfolitixorin) and plasma concentrations of deoxyuridine (dUr) in patients with metastatic colorectal cancer (mCRC), subjected to 5-fluorouracil (5-FU)-based chemotherapy." | 9.41 | Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin. ( Carlsson, G; Gustavsson, B; Odin, E; Taflin, H; Tell, R; Wettergren, Y, 2021) |
| "The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with epidermal growth factor receptor-detectable metastatic colorectal cancer (mCRC) that progressed on first-line fluoropyrimidine- and oxaliplatin-based chemotherapy; we report the outcomes of patients with RAS-wild-type (wt) disease." | 9.41 | Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. ( Burris, H; Chen, W; Eng, C; Esser, R; Lenz, HJ; Middleton, G; Nippgen, J; Scheithauer, W; Sobrero, A, 2021) |
| "In patients with metastatic colorectal cancer (mCRC) refractory to standard therapies, S-1 plus raltitrexed showed a good objective response rate (ORR) and significant survival benefit in our previous study." | 9.41 | Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. ( Bi, F; Cao, D; Chen, Y; Cheng, K; Gou, HF; Li, Q; Li, ZP; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Yang, Y; Zhou, YW, 2021) |
| "The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 9.41 | Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III ( Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2021) |
| " Eligible patients aged ≥70 with unresectable metastatic, untreated, RAS/BRAF wildtype metastatic colorectal cancer will be randomised 1:1 to receive panitumumab alone or panitumumab plus infusional 5-fluorouracil." | 9.41 | MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). ( Bailey, L; Briscoe, K; Burge, M; Caird, S; Chantrill, L; Cuff, J; Espinoza, D; Francesconi, A; Karapetis, C; Ladwa, R; Pavlakis, N; Price, T; Segelov, E; Shannon, J; Siu, HWD; Sjoquist, K; Srivastav, R; Steer, C; Tebbutt, N; Thavaneswaran, S; Tie, J; Wilson, K; Wuttke, M; Yip, S, 2021) |
| "Both regorafenib and reduced-intensity FOLFOXIRI (riFOLFOXIRI) prolong survival in patients with metastatic colorectal cancer (mCRC)." | 9.34 | Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. ( Chang, SC; Chao, Y; Chen, WS; Cheng, HH; Huang, SC; Jiang, JK; Lan, YT; Lin, CC; Lin, HH; Tai, CC; Teng, HW; Wang, HS; Yang, SH, 2020) |
| "BACKGROUND The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer." | 9.34 | Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. ( Chen, J; Chen, Z; Huang, J; Ma, X; Wei, L; Wen, J; Wu, D, 2020) |
| "Fluorouracil and leucovorin combined with oxaliplatin or irinotecan plus bevacizumab (Bmab) or cetuximab (Cmab) are now widely accepted treatment options as first-line or second-line chemotherapy for metastatic colorectal cancer (mCRC)." | 9.34 | Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial. ( Doi, S; Fujiwara, H; Kawamura, T; Mikami, R; Nakamoto, Y; Noda, M; Okumoto, T; Tokunaga, Y; Tomita, N, 2020) |
| " 130 male and 63 female eligible patients with metastatic colorectal cancer were randomized to receive chronomodulated Irinotecan with peak delivery rate at 1 of 6 clock hours staggered by 4 hours on day 1, then fixed-time chronomodulated Fluorouracil-Leucovorin-Oxaliplatin for 4 days, q3 weeks." | 9.34 | Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. ( Adam, R; Ballesta, A; Bouchahda, M; Chollet, P; Focan, C; Garufi, C; Giacchetti, S; Huang, Q; Innominato, PF; Karaboué, A; Lévi, FA, 2020) |
| "We designed an open-label, noncomparative phase II study to assess the safety and efficacy of first-line treatment with trifluridine/tipiracil plus bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B) in untreated patients with unresectable metastatic colorectal cancer (mCRC) who were not candidates for combination with cytotoxic chemotherapies." | 9.34 | Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. ( Amellal, N; Argilés, G; Aubel, P; Borg, C; Danielewicz, I; Egorov, A; Falcone, A; Fedyanin, M; Garcia-Alfonso, P; Glynne-Jones, R; Kanehisa, A; Kroening, H; Moiseenko, V; Pfeiffer, P; Punt, CJA; Saunders, MP; Stroyakovskiy, D; Van Cutsem, E; Van de Wouw, AJ; Wasan, H, 2020) |
| "Chemo-embolisation with drug-eluting beads loaded with irinotecan (DEBIRI) increased survival as compared with intravenous irinotecan in chemorefractory patients with liver-dominant metastases from colorectal cancer (LMCRC)." | 9.34 | Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. ( Artru, P; Dahan, L; De La Fouchardière, C; Guimbaud, R; Jouve, JL; Lepage, C; Montérymard, C; Pellerin, O; Pernot, S; Raoul, JL; Sefrioui, D; Smith, D; Taieb, J; Tougeron, D, 2020) |
| "Cetuximab has been shown to be clinically active when given in combination with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC)." | 9.34 | Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). ( Baba, E; Boku, N; Denda, T; Esaki, T; Fujii, H; Goto, M; Hara, H; Hironaka, S; Hosokawa, A; Hyodo, I; Ishida, H; Kadowaki, S; Kishimoto, J; Koh, Y; Kuramochi, H; Makiyama, A; Matsumoto, S; Moriwaki, T; Muro, K; Nishina, T; Okuda, H; Otsu, S; Ozaki, Y; Sakai, D; Sakamoto, T; Sato, M; Satoh, T; Shimokawa, H; Shinozaki, K; Sugimoto, N; Tamagawa, H; Tamura, T; Taniguchi, H; Tokunaga, S; Tsuda, T; Tsuji, A; Tsushima, T; Yamazaki, K; Yasui, H, 2020) |
| "To evaluate the safety and tolerability of escalating doses of selinexor plus 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) in metastatic colorectal cancer (mCRC) patients." | 9.34 | Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL. ( Amberg, S; Bokemeyer, C; Kranich, AL; Mann, J; Nilsson, S; Papadimitriou, K; Rolfo, C; Stein, A; Theile, S, 2020) |
| "The addition of aflibercept (AFL) or ramucirumab (RAM) to folinic acid, fluorouracil, and irinotecan (FOLFIRI) prolongs overall survival and progression-free survival compared with FOLFIRI alone in patients with metastatic colorectal cancer (mCRC) as second-line therapy." | 9.34 | Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. ( Kashiwa, M; Matsushita, R, 2020) |
| "Combination of chemotherapies (fluoropirimidines, oxaliplatin and irinotecan) with biologic drugs (bevacizumab, panitumumab, cetuximab) have improved clinical responses and survival of metastatic colorectal cancer (mCRC)." | 9.30 | Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. ( Albino, V; Amore, A; Avallone, A; Belli, A; Botti, G; Capozzi, M; Casaretti, R; Cassata, A; Chiodini, P; D'Alterio, C; De Feo, G; De Stefano, A; Delrio, P; Di Marzo, M; Izzo, F; Napolitano, M; Nappi, A; Nasti, G; Normanno, N; Ottaiano, A; Pace, U; Palaia, R; Petrillo, A; Picone, C; Portella, L; Rachiglio, AM; Roma, C; Romano, C; Scala, S; Silvestro, L; Tafuto, S; Tamburini, M; Trotta, AM, 2019) |
| "Regorafenib is an oral multikinase inhibitor for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, irinotecan, oxaliplatin, monoclonal antibodies targeting vascular endothelial growth factor, and monoclonal antibodies targeting epidermal growth factor receptor." | 9.30 | Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. ( Chang, TK; Chang, YT; Huang, CW; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yeh, YS, 2019) |
| "Background This phase I/II trial evaluated toxicity and antitumor activity of everolimus plus mFOLFOX6 + bevacizumab for first-line treatment of metastatic colorectal cancer (mCRC)." | 9.30 | Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. ( Boucher, KM; Garrido-Laguna, I; McGregor, K; Orgain, N; Sharma, S; Stenehjem, DD; Thorne, K; Wade, ML; Weis, J; Weldon Gilcrease, G; Whisenant, J, 2019) |
| " As hydrogen gas was recently reported to activate PGC‑1α, the present study investigated whether it restores exhausted CD8+ T cells to improve prognosis in patients with stage IV colorectal cancer." | 9.30 | Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis. ( Akagi, J; Baba, H, 2019) |
| "The study investigated the potential prophylactic effect of L-carnosine against acute oxaliplatin neurotoxicity in colorectal cancer patients with emphasis on the redox (Nrf-2, MDA), inflammatory (NF-κB, TNF-α), and apoptotic (caspase-3) parameters." | 9.30 | L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways. ( El Abhar, H; Saad, AS; Saleh, S; Schaalan, M; Yehia, R, 2019) |
| "The 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational." | 9.30 | CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. ( Bai, L; Bi, F; Chen, Y; Cheng, Y; He, X; Hu, X; Li, J; Li, Y; Liu, W; Liu, Y; Luo, Y; Ouyang, X; Qin, S; Shi, Y; Sun, G; Sun, Y; Wang, L; Wang, Z; Xu, J; Yao, Q; Zhang, Y; Zheng, R, 2019) |
| "Curcumin is a safe and tolerable adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer." | 9.30 | Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. ( Barber, S; Brown, K; Foreman, N; Gescher, A; Griffin-Teall, N; Howells, LM; Irving, GRB; Iwuji, COO; Morgan, B; Patel, SR; Sidat, Z; Singh, R; Steward, WP; Thomas, AL; Walter, H, 2019) |
| " This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer." | 9.30 | Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. ( Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019) |
| "Chemotherapy-induced nausea and vomiting (CINV) causes significant morbidity among colorectal cancer patients, receiving fluorouracil, oxaliplatin, and leucovorin (FOLFOX) chemotherapy even with standard antiemetic prophylaxis." | 9.27 | Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. ( Blanke, C; Bubalo, JS; Chen, E; Edwards, MS; Fisher, A; Herrington, JD; Lopez, CD; Palumbo, A; Takemoto, M; Williams, C; Willman, P, 2018) |
| "Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)." | 9.27 | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018) |
| "To investigate the association between UDP-glucuronosyltransferase (UGT)1A polymorphisms and irinotecan-treatment efficacy in a Chinese population with metastatic colorectal cancer (mCRC)." | 9.27 | UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy. ( Chen, J; Feng, J; Huang, L; Liu, B; Peng, P; Qiu, H; Xie, C; Yu, Q; Yuan, X; Zang, A; Zhang, T, 2018) |
| "Regorafenib, a multikinase inhibitor that inhibits angiogenesis, growth, and proliferation, prolongs survival as monotherapy in patients with refractory colorectal cancer." | 9.27 | Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. ( Bekaii-Saab, TS; Cohn, AL; El-Rayes, BF; Fernando, NH; Goldberg, RM; Grogan, W; Horgan, AM; Ivanova, A; Kasbari, SS; Kim, RD; Leonard, G; McCaffrey, J; McDermott, R; Moore, DT; O'Neil, BH; O'Reilly, S; Olowokure, OO; Ryan, T; Sanoff, HK; Sherrill, GB; Yacoub, GH; Zamboni, W, 2018) |
| "Metformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy." | 9.27 | Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. ( El-Fatatry, BM; Hussien, FZ; Ibrahim, OM; Mostafa, TM, 2018) |
| "This randomized phase III trial compared hepatic arterial infusion (HAI) chemotherapy with 5-fluorouracil (5-FU) followed by uracil/tegafur (UFT) and leucovorin (LV) versus UFT/LV alone for patients with curatively resected liver metastases from colorectal cancer (CRC)." | 9.27 | A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio ( Aoyama, T; Asahara, T; Hirata, K; Kusano, M; Nakamori, S; Oba, K; Ohashi, Y; Okabayashi, K; Saji, S; Sakamoto, J; Tsuji, Y; Yoshikawa, T, 2018) |
| "This study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan." | 9.24 | Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Chang, SN; Hsieh, LL; Lai, CY; Lin, YK; Sung, FC; Tang, R; Yeh, CC, 2017) |
| "Fluorouracil and folinic acid with irinotecan (FOLFIRI) plus bevacizumab (BV) is widely used as second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, oxaliplatin, and BV." | 9.24 | Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. ( Ando, M; Araida, T; Hamano, M; Hayashi, K; Hirai, E; Itabashi, M; Kameoka, S; Kawakami, K; Kuramochi, H; Nakajima, G; Okuyama, R; Yokomizo, H; Yoshimatsu, K, 2017) |
| "There are no published cases about bullous pyoderma gangrenosum induced by leucovorin, fluorouracil and oxaliplatin (FOLFOX) chemotherapy." | 9.22 | Leukocytoclastic vasculitis presenting clinically as bullous pyoderma gangrenosum following leucovorin, fluorouracil and oxaliplatin chemotherapy: a rare case report and literature review. ( Abdollahimajd, F; Diab, R; Kaddah, A; Mirzaei, HR; Rakhshan, A, 2022) |
| "The purpose of this systematic review is to analyze the published data on the efficacy and safety of doses higher than 180 mg/m2 of irinotecan recommended in the drug's summary of product characteristics in metastatic colorectal cancer patients with genotypes UGT1A1*1/*1 or *1/*28 who are treated with the FOLFIRI regimen." | 9.22 | Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review. ( García-Gil, S; Gutiérrez-Nicolás, F; Miarons, M; Riera, P, 2022) |
| "The efficacy of irinotecan as the adjunctive therapy to fluorouracil and leucovorin remains controversial in patients with colorectal cancer." | 9.22 | The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies. ( Jiang, W; Liu, Q; Yang, D; Yang, SB, 2022) |
| "A multicenter, open-label, noncomparative, randomized phase II study (PEPCOL) was conducted to evaluate the efficacy and safety of the irinotecan or PEP02 (MM-398, nanoliposomal irinotecan) with leucovorin (LV)/5-fluorouracil (5-FU) combination as second-line treatment in patients with metastatic colorectal cancer (mCRC)." | 9.22 | PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. ( André, T; Arbaud, C; Bachet, JB; Bennamoun, M; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Dupuis, O; Garcia, ML; Hammel, P; Khalil, A; Larsen, AK; Louvet, C; Maindrault-Gœbel, F; Tournigand, C; Wang, YW; Yeh, CG, 2016) |
| " This study was to evaluate the efficacy and safety of maintenance therapy with capecitabine versus observation following inductive chemotherapy in patients with metastatic colorectal cancer." | 9.22 | Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. ( Hu, XH; Jia, J; Li, YH; Lin, DR; Lin, YC; Luo, HY; Ma, D; Peng, JW; Wang, FH; Wang, W; Wang, ZQ; Xu, RH; Yuan, X; Zhang, DS, 2016) |
| " The present study was initiated to validate the use of therapeutic drug management (TDM) to personalize 5-fluorouracil (5-FU) dosing in patients with metastatic colorectal cancer treated in routine clinical practice." | 9.22 | Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. ( Bertsch, T; Birkmann, J; Braess, J; Holdenrieder, S; Jaehde, U; Kraff, S; Kunzmann, V; Link, K; Miller, MC; Moritz, B; Mueller, L; Roessler, M; Salamone, SJ; Stoetzer, OJ; Suttmann, I; Wilhelm, M, 2016) |
| "Observational and preclinical studies have suggested that metformin has antitumor effects in solid tumors, including colorectal cancer (CRC)." | 9.22 | Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer. ( Alex, A; Bariani, G; Bezerra Neto, JE; Braghiroli, MI; Capareli, FC; Faria, LD; Hoff, PM; Lobo Dos Santos, JF; Miranda, VC; Riechelmann, RP; Sabbaga, J, 2016) |
| "The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer." | 9.22 | Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. ( Ciftci, R; Iner-Koksal, U; Kaytan-Saglam, E; Namal, E; Okyar, A; Ordu, C; Pala-Kara, Z; Pilancı, KN; Saglam, S; Yucel, S, 2016) |
| " This randomized phase II study evaluated the antitumor activity and safety of icrucumab and ramucirumab each in combination with mFOLFOX-6 in patients with metastatic colorectal cancer after disease progression on first-line therapy with a fluoropyrimidine and irinotecan." | 9.22 | Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. ( Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K, 2016) |
| "The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint." | 9.20 | A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015) |
| "5-Fluorouracil (5-FU) is chemotherapeutic agent widely used for the treatment of colorectal cancer." | 9.20 | Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer. ( Chang, SW; Chen, TH; Huang, CC; Lee, H; Wu, DW, 2015) |
| "A UGT1A1 genotype-directed dose escalation of irinotecan (CPT-11) was performed in patients with metastatic colorectal cancer receiving first-line FOLFIRI chemotherapy." | 9.20 | A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI. ( Bae, KS; Hong, YS; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG, 2015) |
| "The aim of this study was to determine the recommended dose (RD) of a triweekly capecitabine, oxaliplatin, irinotecan, and bevacizumab (XELOXIRI/bevacizumab) regimen that was easier to administer than FOLFOXIRI/bevacizumab, using capecitabine instead of 5-fuorouracil (5-FU), in patients with metastatic colorectal cancer (mCRC)." | 9.20 | A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer. ( Furuhata, T; Hayashi, T; Hirakawa, M; Hirata, K; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Miyanishi, K; Mizuguchi, T; Murase, K; Ohnuma, H; Okagawa, Y; Okita, K; Osuga, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takimoto, R, 2015) |
| "The phase III CRYSTAL study demonstrated that addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival, progression-free survival, and objective response in the first-line treatment of patients with KRAS codon 12/13 (exon 2) wild-type metastatic colorectal cancer (mCRC)." | 9.20 | Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. ( Beier, F; Ciardiello, F; Heinemann, V; Köhne, CH; Lenz, HJ; Melezínek, I; Rougier, P; Stroh, C; Tejpar, S; Van Cutsem, E; van Krieken, JH, 2015) |
| "This study was conducted to evaluate the efficacy and safety of the combination of capecitabine and oral leucovorin (LV) as a third-line chemotherapy for patients with metastatic colorectal cancer (CRC) showing resistance to irinotecan- and oxaliplatin-containing regimens." | 9.20 | A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. ( Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY, 2015) |
| "A dose-finding phase I/II trial that evaluated the maximum tolerated doses of a combination of three drugs with irinotecan, oxaliplatin and capecitabine (COI regimen) has been conducted in patients with metastatic colorectal cancer (mCRC)." | 9.20 | Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. ( Aitini, E; Bajetta, E; Barni, S; Bertolini, A; Ciarlo, A; Di Bartolomeo, M; Dotti, KF; Iacovelli, R; Maggi, C; Perrone, F; Pietrantonio, F; Verusio, C, 2015) |
| "The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments have failed." | 9.20 | Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. ( Argilés, G; Benson, A; Cascinu, S; Ciardiello, F; Grunert, J; Guillén Ponce, C; Köhne, CH; Luigi Garosi, V; Macpherson, IR; Rivera, F; Saunders, MP; Sobrero, A; Strumberg, D; Tabernero, J; Van Cutsem, E; Wagner, A; Zalcberg, J, 2015) |
| " We included patients older than 18 years with previously untreated metastatic colorectal cancer, with stable disease or better after induction treatment with six 3-weekly cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOX-B), WHO performance status of 0 or 1, and adequate bone marrow, liver, and renal function." | 9.20 | Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. ( Braun, HJ; Cats, A; Creemers, GJ; de Jongh, FE; Derleyn, VA; Erdkamp, FL; Erjavec, Z; Haasjes, JG; Honkoop, AH; Jansen, RL; Koopman, M; Loosveld, OJ; May, A; Mol, L; Nieboer, P; Punt, CJ; Simkens, LH; ten Tije, AJ; Tol, J; van der Hoeven, JJ; van der Torren, AM; van Tinteren, H; Wals, J, 2015) |
| "This study is the first to combine daily oral curcumin with standard care FOLFOX-based (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in colorectal cancer patients with inoperable liver metastases: the CUFOX trial." | 9.20 | Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. ( Berry, DP; Brown, K; Howells, LM; Irving, GR; Iwuji, CO; Morgan, B; Steward, WP; Thomas, A, 2015) |
| "The current study aimed to evaluate the short-term efficacy and safety of endostar plus irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) in treatment of advanced colorectal cancer (CRC)." | 9.20 | Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study. ( Hu, XL; Li, BL; Sun, HG; Zhang, Y; Zhao, XH; Zhou, CY, 2015) |
| "The aprepitant therapy was more effective than the control therapy for prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen." | 9.20 | Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ide, Y; Kudo, T; Miyake, Y; Mizushima, T; Mori, M; Morita, S; Nakata, K; Nezu, R; Nishimura, J; Ohno, Y; Sakai, D; Satoh, T; Sekimoto, M; Takemasa, I; Takemoto, H; Uemura, M; Yamamoto, H; Yasui, M, 2015) |
| "S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC)." | 9.20 | S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. ( Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H, 2015) |
| "This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with chemotherapy, relative to bevacizumab plus chemotherapy as first-line therapy in patients with metastatic colorectal cancer (mCRC)." | 9.20 | A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. ( Bennouna, J; Bouché, O; Capdevila, J; Carrato, A; D'Haens, G; Dressler, H; Ducreux, M; Latini, L; Oum'Hamed, Z; Prenen, H; Sobrero, A; Staines, H; Studeny, M; Van Cutsem, E, 2015) |
| "The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy." | 9.20 | Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015) |
| "The purpose of this randomised phase III trial was to evaluate whether the addition of simvastatin, a synthetic 3-hydroxy-3methyglutaryl coenzyme A reductase inhibitor, to XELIRI/FOLFIRI chemotherapy regimens confers a clinical benefit to patients with previously treated metastatic colorectal cancer." | 9.20 | A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. ( Han, SW; Hong, YS; Hwang, IG; Jung, SH; Kang, HJ; Kang, WK; Kim, HS; Kim, ST; Kim, TW; Lee, J; Lee, JY; Lee, KH; Lim, HY; Lim, SH; Park, JO; Park, SH; Park, YS, 2015) |
| "The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen." | 9.19 | Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. ( Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014) |
| " We conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab (CapeOx/bevacizumab), with an expansion cohort in metastatic colorectal cancer (CRC)." | 9.19 | Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. ( Arrowood, C; Blobe, GC; Brady, JC; Cohn, A; Haley, S; Hsu, SD; Hurwitz, HI; McCall, S; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Rushing, C; Starodub, A; Strickler, JH; Uronis, HE; Zafar, SY, 2014) |
| "Efatutazone, a novel oral highly-selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, has demonstrated some inhibitory effects on disease stabilization in patients with metastatic colorectal cancer (mCRC) enrolled in previous phase I studies." | 9.19 | Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. ( Hyodo, I; Komatsu, Y; Machida, N; Ohtsu, A; Onuma, H; Sasaki, T; Yachi, Y; Yamazaki, K; Yoshino, T; Yuki, S, 2014) |
| "We investigated the efficacy and safety of capecitabine and gemcitabin (GemCap) in heavily pre-treated, therapy-resistant metastatic colorectal cancer (mCRC) patients and the clinical importance of cell-free DNA (cfDNA) measurement." | 9.19 | Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study. ( Andersen, RF; Jakobsen, A; Pallisgaard, N; Ploen, J; Spindler, KL, 2014) |
| " This phase I study used radiolabeled huA33 in combination with capecitabine to target chemoradiation to metastatic colorectal cancer." | 9.19 | Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. ( Cavicchiolo, T; Chappell, B; Gill, S; Herbertson, RA; Hopkins, W; Lee, FT; Lee, ST; Murphy, R; O'Keefe, GJ; Poon, A; Saunder, T; Scott, AM; Scott, FE; Tebbutt, NC, 2014) |
| "Irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil administered every two weeks (FOLFIRI regimen) is active in patients with metastatic colorectal cancer." | 9.19 | Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. ( Arai, T; Goto, A; Hamaguchi, T; Muro, K; Sasaki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2014) |
| " This study examined the efficacy and safety of combining bevacizumab and panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer (mCRC)." | 9.19 | Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer. ( Hu, AP; Li, SL; Liang, HL; Liu, JY, 2014) |
| "Data collected from 20 elderly patients (75-92 years old) with breast or colorectal cancer who received oral capecitabine were analyzed." | 9.19 | Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer. ( Daher Abdi, Z; Lavau-Denes, S; Leobon, S; Marquet, P; Martin, J; Prémaud, A; Rousseau, A; Sauvage, FL; Tubiana-Mathieu, N; Urien, S, 2014) |
| "We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC)." | 9.19 | Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. ( Fan, Z; Han, G; He, L; Qin, Z; Xie, S; Xu, W, 2014) |
| "The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival compared to FOLFIRI in patients with metastatic colorectal cancer (mCRC)." | 9.19 | Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. ( Ehninger, G; Folprecht, G; Hamann, S; Schütte, K; Stoehlmacher-Williams, J; Trarbach, T, 2014) |
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 9.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 9.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| " A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC)." | 9.19 | Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. ( Adams, J; Deva, S; Findlay, MP; Hinder, VA; Isaacs, R; Jackson, CG; O'Donnell, A; Perez, DJ; Robinson, BA; Sharples, K; Thompson, PI, 2014) |
| "We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer." | 9.19 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2014) |
| "The purpose of this phase II study was to evaluate the safety and efficacy of weekly irinotecan and capecitabine (wXELIRI) treatment in patients with metastatic colorectal cancer, specifically the rate of severe diarrhea." | 9.19 | Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. ( Chen, Z; Guo, W; Li, J; Li, W; Liu, T; Shen, L; Xu, J; Zhang, W; Zhu, X, 2014) |
| "BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine." | 9.19 | The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. ( Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K, 2014) |
| "This randomized phase II trial investigated the efficacy and safety of capecitabine/oxaliplatin (CapOx) plus bevacizumab and dose-modified capecitabine/irinotecan (mCapIri) plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer (mCRC)." | 9.17 | Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. ( Arnold, D; Dietrich, G; Freier, W; Geißler, M; Graeven, U; Hegewisch-Becker, S; Hinke, A; Kubicka, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schmoll, HJ; Tannapfel, A, 2013) |
| "Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan." | 9.17 | Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. ( Boix, O; Ehrenberg, R; Fischer, R; Folprecht, G; Hacker, UT; Hamann, S; Köhne, CH; Kornacker, M; Krauss, J; Kuhlmann, J; Lettieri, J; Mross, KB; Schultheis, B; Strumberg, D, 2013) |
| "This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)." | 9.17 | Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. ( Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013) |
| " In this study, we determined the dose, efficacy, and tolerability of irinotecan according to UGT1A1 genotypes when combined with capecitabine in patients with metastatic colorectal cancer." | 9.17 | A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ( Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG; Sym, SJ, 2013) |
| "In this multicenter, open-label, randomized phase 2 trial, the authors evaluated the vascular endothelial growth factor receptor inhibitor axitinib, bevacizumab, or both in combination with chemotherapy as first-line treatment of metastatic colorectal cancer (mCRC)." | 9.17 | Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. ( Cartwright, TH; Cescon, TP; Cohn, AL; Edenfield, WJ; Hamm, JT; Infante, JR; Kim, S; Malik, IA; McGee, PJ; Rado, TA; Reid, TR; Richards, DA; Rosbrook, B; Tarazi, J, 2013) |
| "A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial." | 9.17 | Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. ( Amara, A; Bulusu, A; Honeycutt, W; Hurwitz, HI; Liu, Y; Nixon, AB; Pang, H; Starr, MD; Wong, NS, 2013) |
| "To investigate the safety and efficacy of pemetrexed combined with chemotherapy as second or third line in patients with stage IV colorectal cancer (CRC)." | 9.17 | Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. ( Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX, 2013) |
| "The aim of this study was to evaluate 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET for early prediction of the standard anatomic response and survival outcomes in patients with metastatic colorectal cancer (mCRC) receiving leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX)." | 9.17 | 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer. ( Hong, YS; Kim, HJ; Kim, HO; Kim, JS; Kim, KP; Kim, TW; Lee, JL; Lee, SJ; Moon, DH; Oh, SJ; Ryu, JS, 2013) |
| " This phase I/II trial assessed the safety and efficacy of capecitabine plus oxaliplatin (XELOX) plus bevacizumab and imatinib in the first-line treatment of patients with metastatic colorectal cancer." | 9.17 | Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. ( Arnold, D; Hacker, UT; Hallek, M; Hinke, A; Hochhaus, A; Hoehler, T; Hofheinz, R; Kanzler, S; Moehler, MH; Schimanski, C; Seufferlein, T; Siebler, J; von Wichert, G, 2013) |
| " This study investigated the effects of 5-fluorouracil (5-FU) chemotherapy on the levels of lipid peroxidation, reduced glutathione (GSH), glutathione peroxidase (GSH-Px), antioxidant vitamins, and elements in colorectal cancer patients." | 9.17 | Effects of 5-fluorouracil on oxidative stress and calcium levels in the blood of patients with newly diagnosed colorectal cancer. ( Koçer, M; Nazıroğlu, M, 2013) |
| "Twenty-nine unresectable colorectal cancer patients were stratified to either ≥70 or <60 years of age, where the disposition of capecitabine and its metabolites were compared." | 9.17 | Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). ( Albain, KS; Blanke, CD; Coleman, D; Ely, B; Gold, PJ; Gotay, C; Lenz, HJ; Louie, SG; Raghavan, D; Shields, AF, 2013) |
| "The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen for elderly patients with metastatic colorectal cancer." | 9.17 | Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. ( Andre, N; Cunningham, D; Jonker, D; Lang, I; Lorusso, V; Marcuello, E; Ocvirk, J; Osborne, S; Saunders, MP; Shin, DB; Waterkamp, D, 2013) |
| "The combination of oxaliplatin and oral capecitabine (XELOX) has shown to be an active regimen in metastatic colorectal cancer (MCRC)." | 9.17 | Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer. ( Alvarez, E; Campos, B; Candamio, S; Casal, J; Gallardo, E; Grande, C; Mel, JR; París Bouzas, L; Quintero, G; Villanueva, MJ, 2013) |
| "Current guidelines recommend treatment with capecitabine and bevacizumab for patients (pts) with non-resectable metastatic colorectal cancer (mCRC), although clinical data in this particular patient group are lacking." | 9.17 | Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial. ( Arnold, D; Behringer, D; Hegewisch-Becker, S; Kettner, E; Kirsch, A; Kretzschmar, A; Pflüger, KH; Stein, A; Wolff, T; Zimber, J, 2013) |
| "This study evaluated the activity of 2 schedules of erlotinib in combination with chemotherapy, and the prognostic significance of serum amphiregulin (AREG) and transforming growth factor alpha (TGFa) in metastatic colorectal cancer." | 9.17 | Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. ( Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC, 2013) |
| "The prognostic and predictive value of multiple serum biomarkers was evaluated using samples from a randomised phase III study (HORIZON II) investigating chemotherapy with or without cediranib in metastatic colorectal cancer (mCRC)." | 9.17 | Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy. ( Barry, ST; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Pommier, AJ; Robertson, JD; Spencer, SK, 2013) |
| " This randomized, multicenter, parallel-group, open-label phase II trial compared axitinib with bevacizumab each in combination with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) for second-line treatment of metastatic colorectal cancer." | 9.17 | Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. ( Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA, 2013) |
| "It was the aim of this study to evaluate maintenance therapy with bevacizumab + capecitabine following induction with bevacizumab + capecitabine + oxaliplatin (XELOX) versus bevacizumab + XELOX until progression as first-line therapy in metastatic colorectal cancer (mCRC)." | 9.17 | Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. ( Buyukberber, S; Buyukunal, E; Camci, C; Cevik, D; Dane, F; Kilickap, S; Ozdener, F; Sencan, O; Uslu, R; Yalcin, S; Yilmaz, U; Zengin, N, 2013) |
| "This study aims to determine the efficacy and tolerability of capecitabine (CAP) plus bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in frail and/or elderly patients." | 9.17 | A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer. ( Chan, D; Dichmann, R; Hecht, JR; Hu, EH; Liem, AK; Naeim, A; Patel, R; Tchekmedyian, NS; Wainberg, ZA; Wang, HJ; Ward, PR, 2013) |
| "This phase II trial investigated the efficacy of an induction regimen of bevacizumab, capecitabine plus oxaliplatin (XELOX) followed by maintenance therapy with bevacizumab plus erlotinib as first-line therapy in patients with metastatic colorectal cancer." | 9.17 | Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. ( Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A, 2013) |
| "The phase III CONFIRM clinical trials demonstrated that metastatic colorectal cancer patients with elevated serum lactate dehydrogenase (LDH) had improved outcome when the vascular endothelial growth factor receptor (VEGFR) inhibitor PTK/ZK (Vatalanib) was added to FOLFOX4 chemotherapy." | 9.17 | Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). ( Azuma, M; Danenberg, KD; Danenberg, PV; Folprecht, G; Ladner, RD; Lebwohl, D; Lenz, HJ; Meinhardt, G; Sherrod, A; Shi, MM; Trarbach, T; Wilson, PM; Yang, D; Zhang, W, 2013) |
| "This randomized, multicenter phase II study involved 80 metastatic colorectal cancer patients aged 70 years and above (performance status [PS] 0-2) or 65 years and above (PS 2), randomly assigned to arm A (capecitabine 1250 mg/m twice daily on days 1-14) or arm B (capecitabine 1000 mg/m twice daily on days 1-14, oxaliplatin 100 mg/m on day 1 initially, 130 mg/m for subsequent cycles)." | 9.17 | Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01. ( Ahn, JB; Hong, YS; Jung, KH; Kim, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Park, YS; Shim, BY; Zang, DY, 2013) |
| "To investigate the association of colonic methane, formed by methanogenic achaea, and pH with gastrointestinal symptoms during colorectal cancer chemotherapy." | 9.17 | Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "The objective of this study was to compare the pharmacokinetics and safety of two tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in patients with colon, colorectal or breast cancer." | 9.17 | Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer. ( Chachad, S; Malhotra, G; Naidu, R; Purandare, S, 2013) |
| "The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)." | 9.17 | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013) |
| "This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)." | 9.17 | Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. ( Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA, 2013) |
| " We aimed at identifying novel genetic markers that would improve prediction of irinotecan toxicity and response in advanced colorectal cancer patients treated with folic acid (leucovorin), fluorouracil (5-FU), and irinotecan (camptosar)-based regimens." | 9.17 | Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. ( Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G, 2013) |
| "To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC)." | 9.16 | Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. ( Gill, JF; Hentschel, P; Higby, DJ; Khan, MQ; Leichman, CG; Madajewicz, S; Malik, SK; Nicol, SJ; Ritch, PS; Waterhouse, DM; Zhao, L, 2012) |
| "The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated metastatic colorectal cancer harboring wild-type KRAS." | 9.16 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012) |
| "We conducted a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of CKD-732 [6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate] in combination with capecitabine and oxaliplatin (XELOX) in nine metastatic colorectal cancer patients who had progressed on irinotecan-based chemotherapy." | 9.16 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. ( Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ, 2012) |
| "The authors evaluated the influence of 5-fluorouracil (5-FU) on treatment tolerability in 81 colorectal cancer patients given adjuvant 5-FU intravenously plus folinic acid for 6 cycles." | 9.16 | Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. ( Amadori, D; Amatori, F; Danesi, R; Del Tacca, M; Di Paolo, A; Flamini, E; Ibrahim, T; Mercatali, L; Ravaioli, E; Sacanna, E, 2012) |
| " The primary objectives of this study were to determine the maximum tolerated dose of vandetanib with capecitabine and oxaliplatin, without and with bevacizumab, for the first line treatment of metastatic colorectal cancer (mCRC), and to define the dose limiting toxicities." | 9.16 | A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. ( Cabebe, EC; Fisher, GA; Sikic, BI, 2012) |
| "This study was intended to ascertain the feasibility of a combination therapy with irinotecan by 24-h intravenous infusion (24-h CPT-11) and 5-fluorouracil (5-FU) for patients with metastatic colorectal cancer, to estimate the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD), to determine the recommended dose (RD) for the Phase II study, and to evaluate the efficacy of the combination therapy." | 9.16 | Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. ( Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T, 2012) |
| " From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily." | 9.16 | Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012) |
| "Patients with refractory metastatic colorectal cancer were randomized in a two-stage design to receive vorinostat at 800 or 1,400 mg/day once a day × 3, every 2 weeks." | 9.16 | A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. ( Fakih, MG; Groman, A; McMahon, J; Muindi, JR; Wilding, G, 2012) |
| " This phase 2 study assessed enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab as maintenance therapy for metastatic colorectal cancer (MCRC)." | 9.16 | A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. ( Di Bartolomeo, M; Fuchs, M; Heinemann, V; Hossain, AM; Nicol, S; Stoffregen, C; Wolff, RA, 2012) |
| " This phase II study tested the efficacy and safety of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as first-line treatment for metastatic colorectal cancer patients." | 9.16 | A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. ( Burtness, B; Cohen, SJ; Denlinger, CS; Dotan, E; Lee, J; Meropol, NJ; Mintzer, D; Ruth, K; Sylvester, J; Tuttle, H; Zhu, F, 2012) |
| "Previous phase III studies raised concern about the safety of the combination of capecitabine and irinotecan in patients with metastatic colorectal cancer (mCRC)." | 9.16 | A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. ( Chen, E; Feld, R; Knox, J; Krzyzanowska, MK; Liu, G; MacKay, H; Moore, MJ; Petronis, J; Renouf, DJ; Wang, L; Welch, S, 2012) |
| "Using the recommended doses obtained from our previous phase 1 trial of a modified Saltz chemotherapy regimen for metastatic colorectal cancer (weekly irinotecan and bolus 5-fluorouracil/l-leucovorin for 3 weeks every 28 days), we performed the present phase 2 trial to evaluate efficacy and toxicity." | 9.16 | Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients. ( Akashi, K; Baba, E; Esaki, T; Fujishima, H; Kusaba, H; Makiyama, A; Mitsugi, K; Nakano, S; Tanaka, R; Uchino, K, 2012) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 9.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "The NORDIC-VII multicenter phase III trial investigated the efficacy of cetuximab when added to bolus fluorouracil/folinic acid and oxaliplatin (Nordic FLOX), administered continuously or intermittently, in previously untreated metastatic colorectal cancer (mCRC)." | 9.16 | Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. ( Birkemeyer, E; Christoffersen, T; Dahl, O; Dajani, O; Erdal, AB; Fokstuen, T; Glimelius, B; Guren, T; Hansen, F; Hofsli, E; Ikdahl, T; Johnsson, A; Keldsen, N; Kure, E; Pfeiffer, P; Pyrhonen, S; Sigurdsson, F; Skovlund, E; Sorbye, H; Starkhammar, H; Tveit, KM; Yilmaz, MK, 2012) |
| "To evaluate the safety and efficacy of combination chemotherapy with 5-fluorouracil (5-FU), leucovorin, irinotecan and oxaliplatin (FOLFOXIRI) in Japanese patients with advanced colorectal cancer." | 9.16 | A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28. ( Akiyama, Y; Araki, K; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Nagashima, F; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K, 2012) |
| "To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC)." | 9.16 | Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ( Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC, 2012) |
| "Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B)." | 9.16 | Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial. ( Hasegawa, H; Hisa, A; Kitagawa, Y; Ohishi, T; Okabayashi, K; Watanabe, M, 2012) |
| "Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody." | 9.16 | Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. ( Allegra, C; Castan, R; Ferry, D; Lakomy, R; Macarulla, T; McKendrick, J; Moiseyenko, V; Polikoff, J; Prausová, J; Prenen, H; Ruff, P; Tabernero, J; Tellier, A; Van Cutsem, E; van Hazel, GA, 2012) |
| "To compare the efficacy of cediranib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKI]) with that of bevacizumab (anti-VEGF-A monoclonal antibody) in combination with chemotherapy as first-line treatment for advanced metastatic colorectal cancer (mCRC)." | 9.16 | Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). ( Barker, P; Bodoky, G; Bondarenko, I; Cunningham, D; Karapetis, CS; Kocakova, I; Koski, SL; Mainwaring, P; Mookerjee, B; Robertson, J; Rougier, P; Salazar, R; Schmoll, HJ; Sobrero, A; Van Cutsem, E, 2012) |
| " HORIZON II [Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer] assessed infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (FOLFOX/CAPOX) with or without cediranib in patients with previously untreated metastatic colorectal cancer (mCRC)." | 9.16 | Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). ( Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B, 2012) |
| "Capecitabine plus oxaliplatin (CapeOX) is one of the reference doublet cytotoxic chemotherapy treatments for patients with metastatic colorectal cancer." | 9.16 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2012) |
| "The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC)." | 9.16 | Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. ( Dahl, O; Elsaleh, H; Fluge, Ø; Knudsen, ES; Leh, S; Li, Z; Myklebust, MP; Myrvold, HE; Pestell, RG; Rui, H; Tran, TH; Tveit, KM; Vonen, B, 2012) |
| "Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal cancer." | 9.15 | Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. ( Berglund, A; Berglund, M; Byström, P; Fredriksson, LA; Garmo, H; Glimelius, B; Kohnke, H; Sørbye, H; Wadelius, M, 2011) |
| "A regimen consisting of 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) is widely used in France in the first-line treatment of metastatic colorectal cancer (MCRC)." | 9.15 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M, 2011) |
| "To evaluate the efficacy and tolerability of systemic chemotherapy with irinotecan (CPT-11), UFT and leucovorin (LV) combined with hepatic arterial infusion (HAI) consisting of 5-fluorouracil (5-FU) in colorectal cancer patients with unresectable liver metastases." | 9.15 | Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. ( Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M, 2011) |
| "To evaluate the efficacy, safety and quality of life of a short course of oxaliplatin plus capecitabine (XELOX) followed by single-agent capecitabine in patients with previously untreated, inoperable, metastatic colorectal cancer." | 9.15 | Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. ( Allen, J; Bentley, D; Gollins, S; Lloyd, A; Morris, J; Saunders, MP; Soe, W; Swindell, R; Taylor, MB; Valle, J; Waddell, T, 2011) |
| "The primary aim of the high-dose 5-fluorouracil (5-FU) and leucovorin (LV; HDFL48) phase I study was to determine the maximum tolerated dose and dose-limiting toxicity of 5-FU and LV with modified tri-monthly 48-h continuous infusion of high-dose 5-FU/LV in patients with metastatic colorectal cancer." | 9.15 | Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. ( Chen, RR; Cheng, AL; Ho, YF; Lu, WC; Yeh, KH, 2011) |
| "This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin, levoforinate, and infusional 5-fluorouracil (FOLFOX4) as a second-line therapy for Japanese patients with unresectable advanced or metastatic colorectal cancer." | 9.15 | A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience. ( Emi, Y; Fujita, F; Hasegawa, H; Inomata, M; Kakeji, Y; Kitazono, M; Maehara, Y; Morikita, T; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Samura, H; Shirabe, K; Shirouzu, K; Tanaka, T; Tokunaga, S; Yamamoto, M, 2011) |
| "This study was designed to determine the efficacy and tolerability of capecitabine, oxaliplatin and bevacizumab in combination with cetuximab as first-line therapy for advanced colorectal cancer." | 9.15 | A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. ( Aklilu, M; Ashton, J; Bendell, JC; Blobe, GC; Cushman, S; Fernando, NH; Hurwitz, HI; Morse, MA; Nixon, AB; Pang, H; Wong, NS, 2011) |
| "The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine and irinotecan (CAPIRI) or capecitabine and oxaliplatin (CAPOX) in the first-line treatment of metastatic colorectal cancer (mCRC)." | 9.15 | Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K, 2011) |
| "The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease." | 9.15 | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. ( Cascinu, S; Celik, I; Ciardiello, F; Cunningham, D; Folprecht, G; Köhne, CH; Láng, I; Maurel, J; Nowacki, MP; Rougier, P; Schlichting, M; Shchepotin, I; Tejpar, S; Van Cutsem, E; Zubel, A, 2011) |
| "The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC)." | 9.15 | Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K, 2011) |
| "This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer." | 9.15 | A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. ( Bendell, JC; Blobe, GC; Fernando, NH; Honeycutt, W; Hurwitz, HI; Morse, MA; Pang, H; Wong, NS, 2011) |
| " However, circadian chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no survival benefit as compared with the non-time-stipulated FOLFOX2, in an international randomized trial involving patients with previously untreated metastatic colorectal cancer (EORTC 05963)." | 9.15 | Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Smaaland, R; Tampellini, M; Tumolo, S, 2011) |
| "A week on/week off capecitabine schedule with oxaliplatin/bevacizumab was evaluated in patients with metastatic colorectal cancer (mCRC)." | 9.15 | A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer. ( Balaban, EP; Crandall, TL; Kane, P; Lembersky, BC; Pinkerton, RA; Potter, DM; Rajasenan, KK; Ramanathan, RK; Schmotzer, A; Sehgal, R; Zeh, H, 2011) |
| "The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer." | 9.15 | Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. ( André, T; Artru, P; Bengrine-Lefevre, L; Bonnetain, F; Chibaudel, B; de Gramont, A; Desramé, J; Larsen, AK; Louvet, C; Teixeira, L; Tournigand, C, 2011) |
| "The AIO KRK 0110/ML22011 trial is a two-arm, multicenter, open-label randomized phase III trial comparing the efficacy and safety of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in the first-line treatment of metastatic colorectal cancer." | 9.15 | A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. ( Aubele, P; Bangerter, M; Denzlinger, C; Freiberg-Richter, J; Giessen, C; Heinemann, V; Hinke, A; Kullmann, F; Mayerle, J; Modest, DP; Moosmann, N; Schulz, C; Sieber, M; Stintzing, S; Teschendorf, C; Vehling-Kaiser, U; von Weikersthal, LF, 2011) |
| "Efforts to improve efficacy and minimize toxicity have led to pharmacokinetic monitoring of plasma 5-Fluorouracil (5-FU) levels in colorectal cancer patients undergoing chemotherapy." | 9.15 | Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. ( Beachler, C; El-Deiry, WS; Finnberg, NK; Gingrich, R; Kline, CL; Liao, J; Scicchitano, A; Sheikh, HS; Sivik, J, 2011) |
| "This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin in combination with levofolinate and infusion 5-fluorouracil (FOLFOX4) as first-line therapy for Japanese patients with unresectable metastatic colorectal cancer." | 9.15 | A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. ( Baba, H; Egashira, A; Emi, Y; Fujita, F; Hasegawa, H; Hayashi, N; Higashi, H; Inomata, M; Kakeji, Y; Kohakura, F; Kohnoe, S; Maehara, Y; Niwa, K; Ogata, Y; Ohga, T; Oki, E; Samura, H; Shirabe, K; Tokunaga, S; Toyama, T; Yamamoto, M, 2011) |
| "In a multicenter, double-blind phase II trial, we compared the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorectal cancer (mCRC) who had progressed after as many as two prior therapies." | 9.15 | Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. ( Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ, 2011) |
| "This study investigated the antitumour and chemosensitizing effects of celecoxib in the treatment of advanced colorectal cancer." | 9.15 | Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer. ( Chen, JM; Jin, CH; Li, RX; Liu, XM; Wang, AH; Wang, GP; Xing, LQ, 2011) |
| "Irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) is accepted as a reference treatment for the first-line treatment of patients with metastatic colorectal cancer (MCRC)." | 9.14 | Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the ( Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M, 2009) |
| "Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients." | 9.14 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009) |
| "The combination of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX-4) is still a reference regimen in advanced colorectal cancer; however, the addition of new biologic compounds represents a significant way forward." | 9.14 | An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. ( Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C, 2009) |
| "Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)." | 9.14 | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009) |
| "This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients." | 9.14 | Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009) |
| "5-Fluorouracil refractory metastatic colorectal cancer patients were intravenously treated with HA-Irinotecan (300 mg/m(2) irinotecan with 1,000 mg/m(2) HA) on day 1 of a 21-day cycle." | 9.14 | A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. ( Brown, TJ; Cinc, E; Fox, RM; Gibbs, P; Jennens, R; Michael, M; Ng, R; Pho, M, 2009) |
| "Thirty-one patients with non-resectable, colorectal cancer (CRC) liver metastases received irinotecan 120 mg/m(2), followed by leucovorin (LV) 20 mg/m(2) and 5-fluorouracil (5-FU) 500 mg/m(2) administered by HAI every 2 weeks, plus UFT (tegafur-uracil) 200 mg/m(2)/day with LV 30 mg/day on days 1-22, followed by a 6-day rest." | 9.14 | Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. ( Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S, 2009) |
| "For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used." | 9.14 | A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. ( Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP, 2009) |
| "This phase II study was conducted to determine the efficacy and safety of capecitabine and bevacizumab in untreated elderly metastatic colorectal cancer patients." | 9.14 | A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. ( Fakih, MG; Khushalani, N; Mashtare, T; Puthillath, A; Romano, K; Ross, ME; Steinbrenner, L; Wilding, G; Wisniewski, M, 2009) |
| "This study assessed radiotherapy combined with capecitabine and oxaliplatin in patients with primary, inextirpable colorectal adenocarcinoma." | 9.14 | Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study. ( Anderson, H; Berglund, K; Byström, P; Ekelund, M; Fernebro, E; Glimelius, B; Gunnlaugsson, A; Holm, T; Johnsson, A; Kjellén, E; Påhlman, L, 2009) |
| "This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer." | 9.14 | Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. ( Aparicio, J; Bokemeyer, C; Bondarenko, I; de Braud, F; Donea, S; Hartmann, JT; Koralewski, P; Loos, AH; Ludwig, H; Makhson, A; Schuch, G; Stroh, C; Zubel, A, 2009) |
| "Second-line irinotecan-based chemotherapy is commonly used in metastatic colorectal cancers after first-line oxaliplatin-based chemotherapy." | 9.14 | Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. ( André, T; Bengrine-Lefevre, L; Bidard, FC; Cervantes, A; de Gramont, A; Figer, A; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2009) |
| "This Simon 2-stage phase II trial was designed to document antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer (CRC)." | 9.14 | Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. ( Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C, 2009) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 9.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "Irinotecan-based chemotherapy regimens are 1 option for treatment of metastatic colorectal cancer (mCRC)." | 9.14 | Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. ( Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X, 2009) |
| "The present study aimed at investigating whether the simultaneous evaluation of pharmacokinetic, pharmacogenetic and demographic factors could improve prediction on toxicity and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil (5FU)/leucovorin therapy." | 9.14 | Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. ( Barile, C; Bolzonella, C; Bononi, A; Crepaldi, G; Ferrazzi, E; Frigo, AC; Gusella, M; Marinelli, R; Menon, D; Padrini, R; Pasini, F; Stievano, L; Toso, S, 2009) |
| "Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)." | 9.14 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009) |
| "Bevacizumab (BV) prolongs the survival of colorectal cancer patients when combined with irinotecan (CPT-11)-based regimens." | 9.14 | Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy. ( Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Nakajima, T; Shimada, Y; Yamada, Y, 2010) |
| "Studies indicate that adjuvant 5-fluorouracil (5-FU) with folinic acid (FA) in colorectal cancer patients with completely resectable liver-limited metastases (LMCRC) offers clinical benefit over surgery alone." | 9.14 | A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. ( Bokemeyer, C; Hohenberger, W; Kwok-Keung Choi, C; Maurel, J; Navarro, M; Rivera, F; Santoro, A; Shacham-Shmueli, E; Thezenas, S; Ychou, M, 2009) |
| "To evaluate the efficacy of bevacizumab in combination of irinotecan,fluorouracil and leucovorin for metastatic colorectal cancer treated by failed prior oxaliplatin -based regiment." | 9.14 | [Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer]. ( Chen, B; Chen, JZ; Cui, F; Luo, RC; Wan, C; Zheng, H, 2009) |
| "To evaluate the efficacy and safety of irinotecan combined with xeloda (CAPIRI regimen) in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin." | 9.14 | [Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin]. ( Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF, 2009) |
| "The aim of the current study was the investigation of the value of bevacizumab+5-fluorouracil(5-FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options." | 9.14 | Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. ( Caricato, M; Coppola, R; Gasparro, S; Rizzo, S; Russo, A; Santini, D; Spoto, C; Tonini, G; Valeri, S; Venditti, O; Vincenzi, B; Zobel, BB, 2009) |
| "Bevacizumab (Avastin) significantly improves overall survival (OS) and progression-free survival (PFS) when combined with first-line irinotecan (IFL) plus bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer (CRC)." | 9.14 | Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. ( Ackland, S; Chiara, S; Clarke, S; Gapski, J; Langer, B; Mainwaring, P; Perez-Carrión, R; Sobrero, A; Young, S, 2009) |
| "To determine the efficacy and tolerability of capecitabine combined with oxaliplatin (CAPOX) or irinotecan (CAPIRI) as first-line treatment in patients with advanced/metastatic colorectal cancer aged > or =70 years." | 9.14 | Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. ( Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G, 2010) |
| "To determine the efficacy and tolerability of oral fluoropyrimidine S-1 plus irinotecan in patients with previously untreated advanced colorectal cancer." | 9.14 | Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N, 2009) |
| "To assess the resectability rate of patients with initially unresectable liver-only metastases from colorectal cancer (CRC) after treatment with irinotecan/capecitabine." | 9.14 | A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. ( Cai, J; Ji, X; Li, Q; Tucker, S; Wan, F; Wang, D; Zhao, R; Zhong, B; Zhu, J, 2010) |
| "We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI + B) in a phase II trial in patients previously untreated for metastatic colorectal cancer (mCRC), and changes during treatment in plasma cytokines and angiogenic factors (CAFs) as potential markers of treatment response and therapeutic resistance." | 9.14 | Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. ( Abbruzzese, JL; Adinin, R; Ellis, LM; Eng, C; Glover, KY; Heymach, JV; Hoff, PM; Kopetz, S; Lieu, C; Morris, JS; Overman, MJ; Tran, HT; Valero, V; Wen, S; Wolff, RA; Yan, S, 2010) |
| "The primary objective of this study was to determine the activity and safety profile of biweekly oxaliplatin combined with continuous oral capecitabine in the first-line treatment of metastatic colorectal cancer." | 9.14 | Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. ( Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R, 2010) |
| " PATIENTS AND METHODS Patients undergoing first-line treatment for metastatic colorectal cancer (CRC) eligible for treatment with irinotecan plus infusional fluorouracil/leucovorin (FOLFIRI) were screened for the UGT1A1*28/*28 genotype and excluded from the study." | 9.14 | Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. ( Azzarello, G; Basso, U; Buonadonna, A; Cecchin, E; D'Andrea, M; De Mattia, E; De Paoli, P; Gasparini, G; Innocenti, F; Lo Re, G; Mini, E; Nobili, S; Pessa, S; Toffoli, G, 2010) |
| "We conducted a phase I/II clinical trial to determine the safety and feasibility of combining vorinostat with 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer (mCRC) and elevated intratumoral thymidylate synthase (TS)." | 9.14 | A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. ( Cole, S; Danenberg, KD; El-Khoueiry, A; Fazzone, W; Groshen, S; Iqbal, S; Kornacki, M; LaBonte, MJ; Ladner, RD; Lenz, HJ; Wilson, PM; Yang, D, 2010) |
| "This phase I/II study was conducted to assess the maximal tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of gefitinib in combination with capecitabine in patients with advanced colorectal cancer (aCRC)." | 9.14 | Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). ( Frieling, T; Graeven, U; Hegewisch-Becker, S; Lehnert, L; Reinacher-Schick, A; Schmiegel, W; Trarbach, T; Vanhoefer, U, 2010) |
| "A dose-finding study was performed to evaluate the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD) and the recommended dose (RD) of escalating the doses of capecitabine and fixed doses of irinotecan and oxaliplatin on a biweekly schedule for metastatic colorectal cancer patients (mCRC)." | 9.14 | Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. ( Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R, 2010) |
| "Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial." | 9.14 | Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies. ( Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S, 2010) |
| "The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a phase II, open, multicentre, uncontrolled study." | 9.14 | Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. ( Bolaños, M; Bosch, C; Castro-Carpeño, J; Escudero, P; Feliu, J; García-Girón, C; Gil, M; González-Barón, M; Llombart, A; López, R; Losa, F; Madroñal, C; Safont, MJ; Salud, A, 2010) |
| "A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association." | 9.14 | Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. ( Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M, 2010) |
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 9.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "A phase I multicentre trial was conducted to define the recommended dose of capecitabine in combination with oxaliplatin and irinotecan (OCX) in metastatic colorectal cancer." | 9.14 | Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). ( Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L, 2010) |
| "The impact of thymidylate synthase (TYMS) and UDP-glucoronosyltransferase 1A (UGT1A) germline polymorphisms on the outcome of colorectal cancer (CRC) patients treated with irinotecan plus 5-fluorouracil (irinotecan/5FU) is still controversial." | 9.14 | UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. ( Abad, A; Aranda, E; Benavides, M; Carrato, A; Ginés, A; Layos, L; Manzano, JL; Marcuello, E; Martinez-Balibrea, E; Martínez-Cardús, A; Massutí, B; Moreno, V; Navarro, M; Valladares, M, 2010) |
| "Capecitabine has shown similar efficacy to 5-fluorouracil (5-FU); a regimen containing 2 weeks of capecitabine/oxaliplatin (CapOx) has demonstrated noninferiority to infusional 5-FU/oxaliplatin/leucovorin (FOLFOX) for the treatment of metastatic colorectal cancer (mCRC)." | 9.14 | A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. ( Eickhoff, JC; Holen, KD; Jumonville, A; Loconte, NK; Lubner, SJ; Mulkerin, DL; Schelman, W; Seo, S; Thomas, JP, 2010) |
| "The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 trial in patients with metastatic colorectal cancer." | 9.14 | Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. ( Amoroso, D; Andreuccetti, M; Ciarlo, A; Cortesi, E; Cremolini, C; Cupini, S; Del Monte, F; Falcone, A; Fontanini, G; Fornaro, L; Granetto, C; Loupakis, F; Lupi, C; Masi, G; Salvatore, L; Sensi, E, 2010) |
| "Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer." | 9.14 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010) |
| "To evaluate the efficacy and safety of bevacizumab plus capecitabine in treating metastatic colorectal cancer(mCRC)." | 9.14 | [Efficacy and safety of bevacizumab plus capecitabine for metastatic colorectal cancer]. ( Ai, B; Ding, L; Li, L; Wu, JY; Wu, XN; Zhao, YB; Zhou, MZ, 2010) |
| "This study reports the long-term follow-up of patients with metastatic colorectal cancer (CRC) participating in a randomised phase II study that compared the efficacy and toxicity of the combination of irinotecan (IRI), fluorouracil (FU) with leucovorin (LV) (arm A) versus sequential chemotherapy with IRI plus FU/LV followed by oxaliplatin (OXA) plus FU/LV (arm B) as first line therapy." | 9.14 | Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. ( Aravantinos, G; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Linardou, H; Makatsoris, T; Papadimitriou, C; Papakostas, P; Papamichael, D; Pectasides, D; Pentheroudakis, G; Samelis, G; Skondra, M; Stavropoulos, M; Syrigos, KN; Varthalitis, I; Vourli, G; Xanthakis, I; Xiros, N, 2010) |
| "Fluorouracil (FU) is a cornerstone of colorectal cancer treatment; however, it has clinical and subclinical influence on the heart." | 9.14 | Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. ( Hasbak, P; Jensen, SA; Mortensen, J; Sørensen, JB, 2010) |
| "601 patients with advanced or metastatic colorectal cancer receiving first-, second-, or third-line irinotecan-based therapy were regularly analyzed for response and toxicity until the end of therapy." | 9.14 | Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study. ( Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K, 2010) |
| "This phase I study was conducted to determine the maximum tolerated dose (MTD) of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) in patients with advanced colorectal cancer (CRC)." | 9.14 | Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ( Carducci, M; Dancey, J; Donehower, RC; Hidalgo, M; Iacobuzio-Donahue, C; Jacene, H; Jimeno, A; Kahn, Y; Kulesza, P; Laheru, DA; Messersmith, WA; Rudek, MA; Spira, A; Zhao, M, 2010) |
| "The results indicate that the modified CAPOX regimen is safe and effective as salvage treatment in patients with advanced colorectal cancer who were previously treated with irinotecan-based frontline therapy." | 9.13 | Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. ( Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N, 2008) |
| "To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy." | 9.13 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. ( Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL, 2008) |
| "The aim of the study was to investigate the associations between UGT1A1(*)28 genotype and (1) response rates, (2) febrile neutropenia and (3) dose intensity in patients with metastatic colorectal cancer treated with irinotecan." | 9.13 | UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T, 2008) |
| " This randomized phase II trial investigates the feasibility and efficacy of gefitinib and 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) in patients with metastatic colorectal cancer." | 9.13 | A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. ( Carnaghi, C; Comandone, A; Granetti, C; Lorusso, V; Mari, E; Oliva, C; Pressiani, T; Rimassa, L; Ronzoni, M; Santoro, A; Siena, S; Zuradelli, M, 2008) |
| "To determine the maximum tolerated dose (MTD), characterize the principal toxicities, and assess the pharmacokinetics of EKB-569, an oral selective irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with capecitabine in patients with advanced colorectal cancer." | 9.13 | A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. ( Abbas, R; Boni, J; Bukowski, R; Croghan, G; Donehower, R; Erlichman, C; Hidalgo, M; Jimeno, A; Laheru, D; Martins, P; Messersmith, W; Pelley, R; Rudek, M; Zacharchuk, C, 2008) |
| "To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies." | 9.13 | Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. ( Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ, 2008) |
| " Progression-free survival (PFS) and toxicity were determined in 267 metastatic colorectal cancer (MCRC) patients who were treated with first-line capecitabine (CAP) plus irinotecan (CAPIRI), or CAP single agent in a prospective randomised phase III trial (CAIRO)." | 9.13 | GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Koopman, M; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T, 2008) |
| "We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer." | 9.13 | A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. ( Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI, 2008) |
| " Effects of the ABCC2 genotype on the pharmacokinetics (PK) of irinotecan and the metabolites were examined in Japanese patients with metastatic colorectal cancer receiving irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)." | 9.13 | Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Matsunaga, M; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K, 2008) |
| "This study was conducted to assess the tolerability and efficacy of a ternary bimonthly irinotecan (CPT-11) - oxaliplatin (OHP) - infusional 5-fluorouracil (5-FU)/folinic acid (FA) combination in advanced colorectal cancer patients who had received prior CPT-11 and/or OHP-based chemotherapy regimen." | 9.13 | Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. ( Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S, 2008) |
| "XELIRI (capecitabine/irinotecan) is effective and well tolerated in metastatic colorectal cancer (mCRC)." | 9.13 | Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. ( Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S, 2008) |
| "Since the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin." | 9.13 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. ( Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ, 2008) |
| " A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer." | 9.13 | Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008) |
| "Patients with histologically proven primary colorectal cancer and bidimensionally measurable liver metastasis, not fully resectable based on technical inability to achieve R(0) resection, but potentially resectable after tumor reduction, were given FOLFIRINOX: oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), bolus fluorouracil 400 mg/m(2) and fluorouracil 46-h continuous IV infusion 2,400 mg/m(2), every 2 weeks for a maximum of 12 cycles." | 9.13 | Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. ( Delpero, JR; Desseigne, F; Guimbaud, R; Kramar, A; Mitry, E; Nordlinger, B; Portier, G; Quénet, F; Rivoire, M; Viret, F; Ychou, M, 2008) |
| "The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)." | 9.13 | Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008) |
| "The objectives of this phase I/II study were to determine the maximum tolerated dose (MTD), characterise the principal toxicities in the phase I part and assess the efficacy in the phase II part of gefitinib, an oral selective inhibitor of the epidermal growth factor receptor, in combination with capecitabine in patients with advanced colorectal cancer (CRC)." | 9.13 | Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. ( Alonso, V; Bovio, H; Colomer, R; Cortés-Funes, H; Escudero, P; García-Carbonero, R; Grávalos, C; Jimeno, A; Juez, I; Sevilla, I; Vega-Villegas, ME, 2008) |
| "The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer." | 9.13 | Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008) |
| "We evaluated the outcome of 140 patients aged > or = 70 years of age who received first-line treatment for metastatic colorectal cancer within the German phase III trial of FUFOX (5-fluorouracil/leucovorin/oxaliplatin) versus CAPOX (capecitabine/oxaliplatin)." | 9.13 | Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. ( Arkenau, HT; Englisch-Fritz, C; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2008) |
| "Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC)." | 9.13 | Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. ( Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M, 2008) |
| "This two-part phase Ib/II study investigated the feasibility of administering cetuximab in combination with oxaliplatin and infusional 5-fluorouracil (5-FU)/folinic acid (FA) in a weekly schedule (AIO FUFOX protocol) as first-line treatment in patients with epidermal growth factor receptor-detectable advanced colorectal cancer." | 9.13 | Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ( Arnold, D; Dittrich, C; Herrmann, T; Höhler, T; Lordick, F; Riemann, J; Schmoll, HJ; Seufferlein, T; Wöll, E; Zubel, A, 2008) |
| " For this purpose, 110 XELOX (capecitabine/oxaliplatin)- or FUOX (fluorouracil/oxaliplatin)-treated metastatic colorectal cancer patients were selected prospectively for genotyping." | 9.13 | Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. ( Abad, A; Aparicio, J; Aranda, E; Díaz-Rubio, E; García, T; Ginés, A; Gómez-España, A; Guino, E; Maestu, I; Manzano, JL; Martinez-Balibrea, E; Martínez-Cardús, A; Sastre, J, 2008) |
| "Oxaliplatin combined with 5-fluorouracil (5-FU), with or without leucovorin (LV), is effective and well tolerated for first-line therapy of advanced colorectal cancer (CRC)." | 9.13 | A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. ( Bernard, SA; Bjarnason, GA; Braich, T; Desimone, P; Evars, JP; Hrushesky, WJ; Jolivet, J; Ramanathan, RK, 2008) |
| "Guidelines recommend combined doublet backbone chemotherapy based on 5-fluorouracil and oxaliplatin (OX) or irinotecan (IR) as the first-line treatment options for metastatic colorectal cancer." | 9.12 | Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. ( Hui, F; Qi, X; Ren, T; Shen, Z; Wang, S; Xu, C; Zhang, Y; Zhao, Q, 2021) |
| "The antimetabolite, 5-Fluorouracil (5-FU), is the only chemotherapeutic drug to significantly improve 12-month survival rates of patients with Colorectal Cancer (CRC)." | 9.12 | Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer. ( Gong, J; Xu, H, 2021) |
| "The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established." | 9.12 | Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ( Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D, 2006) |
| "A total of 630 patients with previously untreated metastatic colorectal cancer were randomised in a 2:1 fashion to receive bolus 5-fluorouracil (5-FU) and leucovorin (LV) plus either 3H1 (n = 422) or placebo (n = 208)." | 9.12 | Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. ( Bhatnagar, A; Bridgewater, J; Carmichael, J; Cassidy, J; Chong, G; Coleman, R; Cosgriff, TM; Coxon, F; Cunningham, D; Harper, PG; Hawkins, R; Jones, JJ; Moore, M; Northfelt, D; Redfern, CH; Sreedharan, S; Steward, W; Valone, F, 2006) |
| "We treated 74 patients with unresectable metastatic colorectal cancer (not selected for a neoadjuvant approach) with irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin (FOLFOXIRI and simplified FOLFOXIRI)." | 9.12 | Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M, 2006) |
| "Oxaliplatin and 5-fluorouracil (5-FU) act synergistically in colorectal cancer." | 9.12 | Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ( Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK, 2006) |
| "Irinotecan or oxaliplatin combined with 5-fluorouracil (5-FU) +/- folinic acid (FA) has changed the treatment standards for metastatic colorectal cancer (CRC)." | 9.12 | Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. ( Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E, 2006) |
| "To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC)." | 9.12 | FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog ( Androulakis, N; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalykaki, A; Kouroussis, Ch; Mavroudis, D; Polyzos, A; Samonis, G; Souglakos, J; Syrigos, K; Tsousis, S; Vamvakas, L; Ziras, N, 2006) |
| " We evaluated oral rubitecan (5 days on, 2 days rest per week) on a continuous schedule, in patients with advanced colorectal cancer (CRC), who progressed after 5-fluorouracil based chemotherapy." | 9.12 | Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. ( Auber, M; Cai, C; Kiefer, G; Matin, K; Patel, H; Potter, D; Ramanathan, RK; Schmotzer, A; Stoller, R; Zamboni, W, 2006) |
| "The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity." | 9.12 | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. ( Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R, 2006) |
| "The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the elderly patients with metastatic colorectal cancer (MCRC)." | 9.12 | XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. ( Bolaños, M; Casado, E; De Castro, J; de Mon, MA; Escudero, P; Feliu, J; Galán, A; González-Barón, M; Lopez-Gómez, L; Losa, F; Salud, A; Vicent, JM; Yubero, A, 2006) |
| "Determine the toxicity, tolerability, and pharmacokinetics of SU5416, a vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, coadministered with bolus 5-fluorouracil (5-FU), leucovorin, and irinotecan (IFL) in untreated patients with metastatic colorectal cancer." | 9.12 | Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. ( Berlin, JD; Cropp, GF; Donnelly, E; Fleischer, AC; Hande, KR; Hannah, AL; Lockhart, AC; Rothenberg, ML; Schaaf, LJ; Schumaker, RD, 2006) |
| "To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer." | 9.12 | Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX, 2006) |
| "In advanced colorectal cancer previously treated with oxaliplatin, efficacy of irinotecan-based chemotherapy is poor and the best regimen is not defined." | 9.12 | A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. ( André, T; Artru, P; de Gramont, A; Flesch, M; Landi, B; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Plantade, A, 2006) |
| "The purpose of this study was to evaluate the antitumor activity and toxicity of fixed sequences of capecitabine/oxaliplatin followed by capecitabine/irinotecan in patients with previously untreated metastatic colorectal cancer." | 9.12 | Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer. ( Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F, 2006) |
| "To evaluate the efficacy and tolerance of the gemcitabine/oxaliplatin (GEMOX) combination as second-line chemotherapy for patients with advanced colorectal cancer (CRC) pretreated with an irinotecan (CPT-11)/5-fluorouracil (5-FU)/leucovorin (LV) regimen." | 9.12 | Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. ( Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N, 2006) |
| "To examine whether carbogen and nicotinamide increases 5-fluorouracil (5-FU) delivery to colorectal cancer metastases." | 9.12 | Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. ( Aboagye, EO; Gupta, N; Hoskin, PJ; Jones, T; Kötz, B; Osman, S; Phillips, R; Price, PM; Saleem, A; Vernon, C; Wasan, H, 2006) |
| "COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib." | 9.12 | Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006) |
| "The aim of the study was to verify the efficacy and safety of the addition of celecoxib to FOLFIRI combination therapy in patients affected by advanced colorectal cancer." | 9.12 | FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). ( Colucci, G; Di Renzo, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Mallamaci, R; Pezzella, G; Romito, S, 2006) |
| "To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer." | 9.12 | [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. ( Chen, JZ; Liao, WJ; Luo, RC; Zheng, H, 2006) |
| "We conducted two phase II trials evaluating the combination of 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) as first-line treatment in 74 metastatic colorectal cancer patients." | 9.12 | First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. ( Allegrini, G; Andreuccetti, M; Barbara, C; Brunetti, IM; Bursi, S; Cerri, E; Cupini, S; Falcone, A; Loupakis, F; Marcucci, L; Masi, G; Murr, R; Ricci, S, 2006) |
| "In a prospective study, 250 metastatic colorectal cancer patients were treated with irinotecan, fluorouracil, and leucovorin as first-line treatment." | 9.12 | The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. ( Biason, P; Boccalon, M; Bonura, S; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Pangher, V; Errante, D; Frustaci, S; Gaion, F; Galligioni, E; Giusto, M; Medici, M; Pasetto, LM; Pessa, S; Russo, A; Sandri, P; Toffoli, G, 2006) |
| "LV5FU2 with high-dose leucovorin (LV), weekly infusional 5-fluorouracil (5FU) (AIO schedule) and raltitrexed have been demonstrated to be active agents in first-line treatment of colorectal cancer." | 9.12 | Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial. ( Bedenne, L; Berger, C; Bouche, O; Cassan, P; Ducreux, M; Dunant, A; Fournet, J; Leduc, B; Mousseau, M; Pignon, JP; Raoul, JL, 2006) |
| "Previously, we reported results of Intergroup N9741, which compared standard bolus fluorouracil (FU), leucovorin, plus irinotecan (IFL) with infused FU, leucovorin, plus oxaliplatin (FOLFOX4) and irinotecan plus oxaliplatin in patients with untreated metastatic colorectal cancer." | 9.12 | Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. ( Alberts, S; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2006) |
| "To provide bevacizumab (BV) -based therapy to patients with advanced colorectal cancers (CRC) who had exhausted standard chemotherapy options, and to evaluate the response to BV combined with fluorouracil (FU) and leucovorin (LV) in this patient population." | 9.12 | Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. ( Boron, M; Chen, HX; Grochow, L; Jaffe, C; Kaplan, RS; Mooney, M; Mosby, K; Rubinstein, L; Vena, D; Zwiebel, J, 2006) |
| " Capecitabine plus irinotecan appears to be a feasible first-line treatment for patients with advanced colorectal carcinoma." | 9.12 | Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. ( Akkermans-Vogelaar, JM; Antonini, NF; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Punt, CJ; Rodenburg, CJ; Vreugdenhil, G; Wals, J, 2006) |
| "Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxicity profiles are not overlapping, and both drugs have shown at least additivity with folinic acid-modulated 5-fluorouracil (5FU)." | 9.12 | Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. ( Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C, 2006) |
| "To evaluate the clinical activity and toxicity of capecitabine plus irinotecan as first-line therapy for patients with metastatic colorectal cancer (mCRC), and to describe the association of expression of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) with antitumor activity." | 9.12 | Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. ( Andria, M; Dhami, M; Diasio, RB; Godfrey, T; Gold, PJ; Kovatich, AJ; Lund, KA; Meropol, NJ; Mitchell, E; Schwarting, R, 2006) |
| "Until recently, fluorouracil (F) and leucovorin (L) had been considered the standard therapy for patients with colorectal cancer." | 9.12 | Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. ( Aabo, K; Bjerregaard, B; Eckhoff, L; Jakobsen, A; Mortensen, JP; Pfeiffer, P; Sandberg, E; Schønnemann, K, 2006) |
| "The aim of the study was to assess the impact of an eicosapentanoic acid-containing protein and energy dense oral nutritional supplement (EPA-ONS) on nutritional and inflammatory status, quality of life (QOL), plasma phospholipids (PPL) and cytokine profile, tolerance of irinotecan-containing chemotherapy and EPA-ONS in patients with advanced colorectal cancer (CRC) receiving chemotherapy." | 9.12 | Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. ( Beale, PJ; Childs, A; Clarke, SJ; Read, JA; Smith, N; Volker, DH, 2007) |
| "In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer." | 9.12 | Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. ( Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX, 2006) |
| "Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)." | 9.12 | Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007) |
| "To characterize the efficacy and safety of palifermin in reducing the incidence of oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal cancer (CRC) receiving fluorouracil/leucovorin (FU/LV) chemotherapy." | 9.12 | Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. ( Abdi, E; Cesano, A; Chen, MG; Clarke, S; Davis, ID; Gayko, U; Gutheil, J; Rosen, LS; Schnell, FM; Zalcberg, J, 2006) |
| "This phase II randomised trial compares oxaliplatin plus protracted infusion of 5-fluorouracil (pviFOX) or oxaliplatin plus capecitabine (XELOX) in the first-line treatment of advanced colorectal cancer (ACRC)." | 9.12 | Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). ( Ballardini, P; Di Fabio, F; Gentile, AL; Giaquinta, S; Lelli, G; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL, 2006) |
| "To assess the toxicity and dose delivery of weekly bolus 5-fluorouracil (5-FU) at 425 mg/m(2) plus low-dose folinic acid (FA) for 24 weeks as adjuvant treatment for colorectal cancer." | 9.12 | Weekly fluorouracil at 425 mg/m(2) plus low-dose folinic acid for 24 weeks as adjuvant treatment for colorectal cancer: assessment of toxicity and delivery. ( Gollins, SW; Ramani, VS; Wong, H, 2006) |
| "Irinotecan at 180 mg/m2 combined with an infusional 5-fluorouracil/leucovorin (5-FU/LV) regimen (FOLFIRI) is a standard first line therapy for metastatic colorectal cancer (mCRC)." | 9.12 | Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. ( Bressole, F; Chalbos, P; Debrigode, C; Desseigne, F; Duffour, J; Gourgou, S; Mineur, L; Pinguet, F; Poujol, S; Ychou, M, 2007) |
| "The purpose of this study was to compare the activity and toxicity of an irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) combination with a standard regimen of 5FU and LV, in patients with advanced colorectal carcinoma." | 9.12 | A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Andreadis, C; Gennatas, C; Michalaki, V; Mouratidou, D; Pafiti, A; Papaxoinis, G; Tsavaris, N, 2006) |
| "Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall survival in advanced colorectal cancer (CRC)." | 9.12 | Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. ( Barone, C; Basso, M; Cassano, A; D'Argento, E; Di Leonardo, G; Landriscina, M; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N, 2007) |
| " This phase I/II dose-finding study evaluated gefitinib in combination with a 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI-AIO) regimen in patients with metastatic colorectal cancer." | 9.12 | Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). ( Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J, 2006) |
| "To determine the maximum tolerated doses (MTD), toxicities, efficacy, and pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and leucovorin (IFL) in patients with previously untreated advanced colorectal cancer." | 9.12 | Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ( Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX, 2007) |
| "This study was designed to measure the dihydrouracil (UH(2))/uracil (U) ratio in plasma as a surrogate marker for dihydropyrimidine dehydrogenase (DPD) activity and to investigate the relationships of the UH(2)/U ratios in plasma with the toxicities of 5-fluorouracil (5-FU)-based adjuvant chemotherapy and 5-FU plasma concentrations in colorectal cancer patients." | 9.12 | The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. ( Chen, G; Chen, YB; Li, S; Lu, ZH; Pan, ZZ; Wan, de S; Wang, GQ; Zhou, ZW, 2007) |
| "A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan/5-fluorouracil/leucovorin (CPT-11/5-FU/LV (AIO schedule)) as salvage treatment in patients with metastatic colorectal cancer." | 9.12 | Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Pallis, A; Souglakos, J; Vardakis, N, 2007) |
| "Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone." | 9.12 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. ( Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007) |
| "The objective of the present study was to evaluate the gene expression of the DNA mismatch repair gene MSH2 as a predictive marker in advanced colorectal cancer (CRC) treated with first-line capecitabine." | 9.12 | Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Jensen, LH, 2007) |
| "To compare the use of capecitabine plus oxaliplatin (CAPOX) with infusional fluorouracil (FU)/folinic acid plus oxaliplatin (FUFOX) as first-line therapy for patients with metastatic colorectal cancer (MCRC)." | 9.12 | Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. ( Arkenau, HT; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2007) |
| "The aim of this phase III trial was to compare the efficacy and safety of capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion high-dose fluorouracil (FU) plus oxaliplatin (FUOX) regimens as first-line therapy for metastatic colorectal cancer (MCRC)." | 9.12 | Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri ( Abad, A; Aparicio, J; Aranda, E; Carrato, A; Chaves, M; Díaz-Rubio, E; Gómez-España, A; González-Flores, E; Losa, F; Massutí, B; Maurel, J; Queralt, B; Reina, JJ; Rivera, F; Sastre, J; Tabernero, J, 2007) |
| "Individually, oxaliplatin and irinotecan have substantial activity in metastatic colorectal cancer (CRC) in combination with 5-fluorouracil/leucovorin." | 9.12 | Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. ( Ames, MM; Erlichman, C; Goetz, MP; Krook, JE; McWilliams, RR; Morlan, BW; Rowland, KM; Salim, M, 2007) |
| "We randomly assigned 820 patients with advanced colorectal cancer to receive either first-line treatment with capecitabine, second-line irinotecan, and third-line capecitabine plus oxaliplatin (sequential treatment; n=410) or first-line treatment capecitabine plus irinotecan and second-line capecitabine plus oxaliplatin (combination treatment; n=410)." | 9.12 | Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. ( Antonini, NF; Creemers, GM; Dalesio, O; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Loosveld, OJ; Mol, L; Punt, CJ; Rodenburg, CJ; Sinnige, HA; Slee, PHTJ; Tesselaar, ME; van Bochove, A; Vreugdenhil, G; Wals, J; Werter, MJ, 2007) |
| "To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide." | 9.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "This study was designed as a multicentre phase II trial to assess the efficacy and safety of gefitinib in association with capecitabine and oxaliplatin in patients with untreated metastatic colorectal cancer." | 9.12 | A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. ( Cognetti, F; Di Costanzo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Gasperoni, S; Gelibter, AJ; Giannarelli, D; Nuzzo, C; Pollera, CF; Signorelli, C; Zeuli, M, 2007) |
| "prospective, randomized, open-label trial in group of 204 patients with advanced colorectal cancer randomized to either chemotherapy with irinotecan+5-FU+leucovorin or supportive care alone (control group) between January 1999--January 2005 was performed." | 9.12 | Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer. ( Klek, S; Kulig, J; Popiela, T; Richter, P, 2007) |
| "Capecitabine results in superior response rate, improved safety, and improved convenience compared with 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (MCRC)." | 9.12 | Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. ( Bexon, A; Diamandidis, D; Eckhardt, SG; Javle, M; Justice, GR; Keiser, W; Lee, FC; Liebmann, JE; Lin, E; Patt, YZ; Salvatore, JR, 2007) |
| "To evaluate the maximum tolerated dose and dose-limiting toxicity (DLT) of 10-hydroxy-camptothecin (10-HCPT) in HFL regimen for the treatment of advanced colorectal cancer (CRC)." | 9.12 | [10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer]. ( Cai, RG; Chen, SS; Chu, DT; Wu, F; Zhang, HG, 2007) |
| "To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer." | 9.12 | A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study ( Adenis, A; Bécouarn, Y; Boucher, E; Cany, L; Cvitkovic, F; Jacob, JH; Montoto-Grillot, C; Senesse, P; Thézenas, S; Ychou, M, 2007) |
| "A phase I/II study was performed to determine the safety and activity of a capecitabine plus oxaliplatin and irinotecan (COI) regimen using capecitabine concurrently with oxaliplatin and irinotecan in previously untreated patients with metastatic colorectal cancer." | 9.12 | Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. ( Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S, 2007) |
| "To evaluate the efficacy and toxicity of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every 2 weeks on previously untreated advanced colorectal cancer patients in Chinese population." | 9.12 | A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience. ( Bao, HY; Fang, WJ; Huang, S; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC, 2007) |
| "Capecitabine and oxaliplatin are both synergistically active against metastatic colorectal cancer (MCRC)." | 9.12 | Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. ( Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Er, O; Kaya, AO; Ozturk, B; Polat, M; Uner, A; Yamac, D; Yaman, E; Yildiz, R, 2007) |
| "We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers." | 9.12 | A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. ( Chang, HM; Kang, YK; Kim, MK; Kim, TW; Koo, DH; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ, 2007) |
| "This phase II study investigated the efficacy and safety of cetuximab combined with standard oxaliplatin-based chemotherapy (infusional fluorouracil, leucovorin, and oxaliplatin [FOLFOX-4]) in the first-line treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer (mCRC)." | 9.12 | Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. ( André, T; Casado, E; Cervantes, A; Ciardiello, F; de Gramont, A; Díaz-Rubio, E; Humblet, Y; Kisker, O; Soulié, P; Tabernero, J; Tortora, G; Valera, JS; Van Cutsem, E; Van Laethem, JL; Verslype, C, 2007) |
| "To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin." | 9.12 | Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. ( Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY, 2007) |
| "This multicenter, randomized trial compared overall response rate between pemetrexed plus irinotecan (ALIRI) and leucovorin-modulated 5-fluorouracil plus irinotecan (FOLFIRI) in patients with advanced colorectal cancer." | 9.12 | A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. ( Bazin, IS; Biakhov, MY; Blatter, J; Goldstein, D; Gorbounova, VA; Granov, DA; Hossain, AM; Kaiser, C; Ma, D; Underhill, C, 2007) |
| "Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin." | 9.11 | A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. ( Alberts, SR; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2004) |
| "This Nordic multicenter phase II study evaluated the efficacy and safety of oxaliplatin combined with the Nordic bolus schedule of fluorouracil (FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 9.11 | Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. ( Berglund, A; Braendengen, M; Dahl, O; Fokstuen, T; Glimelius, B; Sørbye, H; Tveit, KM; Øgreid, D, 2004) |
| "The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC)." | 9.11 | Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. ( Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G, 2004) |
| "The current study was designed to evaluate the antitumor activity and toxicity of capecitabine and oxaliplatin in previously untreated patients with advanced colorectal carcinoma." | 9.11 | Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. ( Marshall, JL; Meropol, NJ; Shields, AF; Zalupski, MM, 2004) |
| "The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed." | 9.11 | A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004) |
| "Our objective was to determine the maximum tolerated dose (MTD) of sequential raltitrexed (Tomudex) and 5-fluorouracil (5-FU) by bolus administration every 3 weeks in patients with advanced colorectal cancer (aCRC) and appendiceal adenocarcinoma." | 9.11 | Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer. ( Bertino, J; Dimery, I; Endres, S; Kelsen, DK; Kemeny, N; Saltz, L; Schwartz, GK; Tong, W; Welch, M, 2004) |
| "This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer." | 9.11 | A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004) |
| "As single agents, irinotecan and oxaliplatin are active in colorectal cancer after fluorouracil (FU)-containing regimen failure." | 9.11 | Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. ( Bajetta, E; Beretta, E; Buzzoni, R; Cortinovis, D; Di Bartolomeo, M; Dognini, G; Ferrario, E; Toffolatti, L, 2004) |
| "Irinotecan has proven anti-tumor activity as induction treatment in combination with 5-fluorouracil (5-FU) or as second-line treatment after 5-FU in patients with metastatic colorectal cancer." | 9.11 | Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. ( Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ, 2004) |
| "Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC)." | 9.11 | XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. ( Brunet, R; Butts, C; Cassidy, J; Conroy, T; Debraud, F; Díaz-Rubio, E; Figer, A; Grossmann, J; Sawada, N; Schöffski, P; Sobrero, A; Tabernero, J; Twelves, C; Van Cutsem, E, 2004) |
| "Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo." | 9.11 | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. ( Baron, A; Berlin, J; Cartwright, T; Fehrenbacher, L; Ferrara, N; Fyfe, G; Griffing, S; Hainsworth, J; Heim, W; Holmgren, E; Hurwitz, H; Kabbinavar, F; Novotny, W; Rogers, B; Ross, R, 2004) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 9.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 9.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients with advanced colorectal cancer (CRC)." | 9.11 | Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. ( Cunningham, D; Hill, ME; Norman, AR; Oates, J; Price, T; Rao, S; Ross, PJ; Shellito, P; Tebbutt, N, 2004) |
| "FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity." | 9.11 | Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004) |
| " In an effort to improve the therapeutic effect of a MAb-based regimen in colorectal carcinoma (CRC) patients, the effects of a combination of alpha-interferon (alpha-IFN), 5-fluorouracil (5-FU), granulocyte-macrophage colony-stimulating factor (GM-CSF) and mouse MAb17-1A was evaluated in 27 patients with metastatic disease." | 9.11 | Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. ( Frödin, JE; Liljefors, M; Mellstedt, H; Nilsson, B; Ragnhammar, P; Ullenhag, G, 2004) |
| "Bowel mucosal injury associated with 5-fluorouracil (5-FU) treatment might result in secondary lactose intolerance." | 9.11 | Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. ( Elomaa, I; Ikonen, M; Joensuu, H; Korpela, R; Ollus, A; Osterlund, P; Peuhkuri, K; Ruotsalainen, T, 2004) |
| "The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma." | 9.11 | First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. ( Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB, 2004) |
| "To evaluate the safety and efficacy of irinotecan (CPT-11) alternated with a weekly treatment for 4 weeks of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour 5-fluorouracil infusion (5-FU 48 h) as first-line chemotherapy for patients with advanced colorectal cancer (ACC)." | 9.11 | A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. ( Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A, 2004) |
| "The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)." | 9.11 | Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004) |
| " Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15)-->l-OHP+FU (days 2 and 16) (200, 85 and 600 mg m(-2), respectively) followed by 3 weeks of CI FU (200 mg m(-2) day(-1)) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m(-2))." | 9.11 | Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. ( Barni, S; Belvedere, O; Beretta, GD; Frontini, L; Grossi, F; Guglielmi, A; Labianca, R; Pella, N; Puglisi, F; Sobrero, A; Zaniboni, A, 2004) |
| "Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC)." | 9.11 | Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. ( Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E, 2004) |
| "This multicentre phase II study was designed to evaluate the antitumour activity and toxicity of bifractionated camptothecin (CPT-11) and 5-fluorouracil/ leucovorin (5-FU/LV) in the treatment of patients with metastatic colorectal cancer (MCC) who had been pretreated with 5-FU/LV-oxaliplatin (FOLFOX regimen)." | 9.11 | Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. ( Cesta, A; Lalli, A; Lullo, LD; Nuzzo, A; Rea, S; Recchia, F; Saggio, G, 2004) |
| "A combination of irinotecan 125 mg/m2, 5-fluorouracil (5-FU) 500 mg/m2, and leucovorin (LV) 20 mg/m2 (Saltz regimen; treatment on days 1, 8, 15, and 22 every 6 weeks) is widely used for the treatment of metastatic colorectal cancer." | 9.11 | Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. ( Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2004) |
| "In a previous phase I-II study we demonstrated that the FOLFOXIRI regimen [irinotecan 125-175 mg/m2 day 1, oxaliplatin 100 mg/m2 day 1, l-leucovorin (l-LV) 200 mg/m2 day 1, 5-fluorouracil (5-FU) 3800 mg/m2 as a 48-h chronomodulated continuous infusion starting on day 1, repeated every 2 weeks] has promising activity and efficacy in metastatic colorectal cancer." | 9.11 | First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. ( Allegrini, G; Andreuccetti, M; Brunetti, I; Cerri, E; Cupini, S; Falcone, A; Fontana, E; Marcucci, L; Masi, G; Ricci, S, 2004) |
| "The addition of oxaliplatin to fluorouracil (FU) and leucovorin (LV) improves the outcome of patients with colorectal cancer (CRC)." | 9.11 | Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. ( Benson, A; Brandt, DS; Burger, B; Garay, CA; Gupta, S; Gurtler, J; Hallman, D; Hochster, H; Kemeny, N; Kennedy, P; Polikoff, J; Shumaker, G; Wertheim, M, 2004) |
| "A weekly continuous 24-h infusion therapy with 5-fluorouracil (5-FU) preceded by a 2-h infusion of calcium folinate (CA-FA) was shown to be an effective first- and secondline treatment in advanced metastatic colorectal cancer." | 9.11 | Second-line treatment of advanced colorectal cancer with a weekly simultaneous 24-hour infusion of 5-fluorouracil and sodium-folinate: a multicentre phase II trial. ( Fritze, D; Kreuser, ED; Kuhfahl, J; Link, H; Pichlmeier, U; Schulte, F; Steinbrecher, C; Wagner, H; Wagner, T, 2004) |
| "The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the first-line treatment of metastatic colorectal cancer (MCRC)." | 9.11 | Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. ( Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A, 2005) |
| "To determine the efficacy, impact on quality-of-life (QoL) and tolerability of two different irinotecan administration schedules in combination with capecitabine as first-line treatment of metastatic colorectal cancer." | 9.11 | A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. ( Bernhard, J; Borner, MM; Brauchli, P; Dietrich, D; Herrmann, R; Honegger, H; Koeberle, D; Lanz, D; Popescu, R; Rauch, D; Roth, AD; Saletti, P; Wernli, M, 2005) |
| "We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of protracted venous infusion (PVI) 5-fluorouracil (5-FU) against the standard bolus monthly regimen of 5-FU/leucovorin (LV) given for 6 months as adjuvant treatment in colorectal cancer (CRC)." | 9.11 | A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, JR; Ross, PJ; Tait, D; Webb, A, 2005) |
| "Capecitabine and irinotecan are commonly used in the treatment of metastatic colorectal cancer (CRC)." | 9.11 | UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. ( Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H, 2005) |
| "Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC)." | 9.11 | Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. ( Hamm, JT; Hecht, JR; Kabbinavar, FF; Mass, R; McCleod, M; Nelson, B; Novotny, WF; Patel, T; Perrou, B; Schulz, J, 2005) |
| "Although irinotecan 350 mg m(-2) is a standard option for relapsed/refractory advanced colorectal cancer, there is some evidence that suggests that a higher dose may be more effective, with acceptable tolerability, following 5-fluorouracil (5-FU)." | 9.11 | Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. ( Bleiberg, H; Borner, M; Dirix, L; Gonzalez Baron, M; Gruia, G; Joosens, E; Morant, R; Roth, A; Sibaud, D; Van Belle, S; Van Cutsem, E; Van Laethem, JL, 2005) |
| "The objective of this study was to assess the efficacy and safety of two regimens of irinotecan, combined or alternated with bolus 5-fluorouracil (5-FU) and folinic acid (FA), and the Mayo Clinic regimen as first-line therapy for colorectal cancer (CRC)." | 9.11 | Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer. ( Artandi, M; Borner, M; Boussard, B; Carlsson, G; Espana, P; Graeven, U; Ridwelski, K; Rosales, AM; Schmiegel, W; Schölmerich, J, 2005) |
| "The aim of this study was to investigate the therapeutic value and safety of third-line treatment with mitomycin-C (MMC) and capecitabine (Xeloda) in patients with advanced colorectal cancer pretreated with combination regimens including 5-fluorouracil (5-FU), folinic acid (FA) and irinotecan (CPT-11) or 5-FU, FA and oxaliplatin (L-OHP)." | 9.11 | Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. ( Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS, 2005) |
| "The combination of 5-fluorouracil (5-FU) plus leucovorin (LV) with oxaliplatin has become one of the standard treatments for advanced colorectal cancer (CRC)." | 9.11 | Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Cervantes, A; Diaz-Rubio, E; Guallar, JL; Manzano, JL; Marcuello, E; Martinez-Villacampa, M; Massutí, B; Navarro, M; Sastre, J, 2005) |
| "A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC)." | 9.11 | Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. ( Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C, 2005) |
| "Irinotecan (IRI) and oxaliplatin (OXA) are effective in the treatment of colorectal cancer." | 9.11 | Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. ( Aravantinos, G; Bacoyiannis, C; Bamias, A; Basdanis, G; Chalkidou, S; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Kalfarentzos, F; Kalofonos, HP; Karina, M; Kosmidis, P; Koutras, A; Papakostas, P; Pectasides, D; Samantas, E; Samelis, GF; Skarlos, D, 2005) |
| "To determine the tolerability of capecitabine in elderly patients with advanced colorectal cancer (CRC)." | 9.11 | Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. ( Bolaños, M; Casado, E; Escudero, P; Feliu, J; Gómez-Reina, MJ; González-Baron, M; Llosa, F; Lopez, R; Lopez-Gómez, L; Sanz-Lacalle, JJ; Vicent, JM; Yubero, A, 2005) |
| "Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody that inhibits tumor angiogenesis, has demonstrated survival benefit in patients with previously untreated metastatic colorectal cancer when combined with irinotecan/fluorouracil (FU)/leucovorin (LV; IFL)." | 9.11 | Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. ( Bergsland, E; Hambleton, J; Hurwitz, HI; Kabbinavar, FF; Mass, RD; Sarkar, S, 2005) |
| "Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma." | 9.11 | Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005) |
| "In a phase III trial, combining bevacizumab (BV)--a recombinant, humanized, monoclonal antibody targeting vascular endothelial growth factor--with irinotecan, bolus fluorouracil (FU), and leucovorin (LV; IFL) increased survival compared with IFL alone in first-line treatment of patients with metastatic colorectal cancer (CRC)." | 9.11 | Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. ( Berlin, J; Fehrenbacher, L; Hainsworth, JD; Hambleton, J; Heim, W; Holmgren, E; Hurwitz, HI; Kabbinavar, F; Novotny, WF, 2005) |
| "Irinotecan combined with continuous-infusion 5-fluorouracil (5FU) has been shown to be an effective and tolerable regimen in the treatment of metastatic colorectal cancer (MCRC)." | 9.11 | Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer. ( Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I, 2005) |
| "Between July 2001 and September 2002, 49 eligible patients were enrolled in an open-label phase II study to assess the efficacy and safety of first-line treatment with capecitabine/irinotecan in metastatic colorectal cancer." | 9.11 | Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. ( Asmar, L; Boehm, KA; Cartwright, T; Encarnacion, C; Lopez, T; Vukelja, SJ, 2005) |
| "Seventy-two patients suffering from a metastatic colorectal cancer received, as first line treatment, a combination chronotherapy with 5-FU and folinic acid (infused from 10 pm to 10 am with a peak at 4 am, respectively at doses of 700 and 300 mg/m2 per day) and carboplatin (infused at the dose of 40 mg/m2 per day from 10 am to 10 pm with a peak at 4 pm)." | 9.11 | [Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study]. ( Biquet, JF; David, A; Delforge, M; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Materne, R; Moeneclaey, N; Weerts, J, 2005) |
| "Seventeen colorectal cancer patients received as first (12 cases) or second line (5 cases) treatment a combined chronotherapy with CPT 11 (infused at day 1 from 2 to 8 am; peak at 5 am), given with 5 FU (700 mg/m2 per day ; days 2-5) and folinic acid (300 mg/m2 per day, days 2-5) both infused from 10 pm to 10 am with a peak at 4 am, and carboplatin (40 mg/m3/day - days 2-5 ; infused from 10 am to 10 pm - peak at 4 pm)." | 9.11 | [Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer]. ( David, A; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2005) |
| "The aim of this study was to determine in patients with previously untreated advanced colorectal cancer the maximum tolerated dose (MTD) and safety profile of irinotecan in combination with capecitabine, to identify a recommended dose and to determine the response rate and time to disease progression." | 9.11 | A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ( Bakker, JM; Falk, S; Groenewegen, G; Kerr, DJ; Maughan, T; Nortier, JW; Punt, CJ; Rea, DW; Richel, DJ; Semiond, D; Smit, JM; Steven, N; Ten Bokkel Huinink, WW, 2005) |
| "To verify the effectiveness of oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) in improving the surgical cure rate in advanced colorectal cancer, a multicenter randomized comparative study was conducted." | 9.11 | A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer. ( Kodaira, S; Kotake, K; Koyama, Y; Ohashi, Y, 2005) |
| "This study was designed to determine the effectiveness and tolerance of oxaliplatin, folinic acid (FA) and infusional 5-fluorouracil (5-FU) (FOLFOX-4) chemotherapy when used as a second-line treatment in patients with advanced colorectal cancer for whom an irinotecan-containing regimen failed." | 9.11 | Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience. ( Baek, JH; Bang, SM; Cho, EK; Han, SH; Lee, JH; Oh, JH; Park, SH; Shin, DB; Sung, JY, 2005) |
| " Glutamine may decrease chemotherapy-associated diarrhea." | 9.11 | A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. ( Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J, 2005) |
| "Protracted venous infusion 5-fluorouracil (5FU) combined with mitomycin C (MMC) has demonstrated significant activity against metastatic colorectal cancer." | 9.11 | Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. ( Chong, G; Cunningham, D; Dickson, JL; Hill, ME; Norman, AR; Oates, J; Price, TJ; Rao, S; Tebbutt, N, 2005) |
| "To investigate the gefitinib, fluorouracil (FU), leucovorin, and oxaliplatin regimen (IFOX) in previously treated patients with metastatic colorectal cancer." | 9.11 | Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. ( Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA, 2005) |
| "5-Fluorouracil remains a key drug in the treatment of colorectal cancer, and the development of a simple and effective test for selecting patients likely to benefit from postoperative adjuvant chemotherapy is an important objective." | 9.11 | Correlation between expression of orotate phosphoribosyl transferase and 5-fluorouracil sensitivity, as measured by apoptosis index in colorectal cancer tissue. ( Kamano, T; Kawai, K; Matsuda, M; Sakamoto, K; Watabe, S, 2005) |
| "The aim of the current study was to evaluate the activity and toxicity of a combination of oxaliplatin with bolus fluorouracil and leucovorin in colorectal cancer (CRC) patients pretreated for advanced disease with various schedules including continuous fluorouracil infusion." | 9.11 | Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study. ( Buccilli, A; Ciccarese, M; Ferraresi, V; Gabriele, A; Gamucci, T; Giampaolo, MA; Giannarelli, D; Mansueto, G, 2005) |
| "HLA-A2-positive patients with confirmed newly diagnosed metastatic colorectal cancer and elevated serum carcinoembryonic antigen (CEA) were randomized to receive three cycles of standard chemotherapy (irinotecan/high-dose 5-fluorouracil/leucovorin) and vaccinations with CEA-derived CAP-1 peptide admixed with different adjuvants [CAP-1/granulocyte macrophage colony-stimulating factor/interleukin-2 (IL-2), CAP-1/dSLIM/IL-2, and CAP-1/IL-2]." | 9.11 | Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. ( Anderson, KS; Ansén, S; Bohlen, H; Diehl, V; Geisen, C; Gracien, E; Jurkiewicz, E; Nadler, LM; Schmidt, M; Weihrauch, MR; Wittig, B; Wolf, J; Xia, Z, 2005) |
| "We examined patients with previously untreated metastatic colorectal cancer, who were enrolled into two phase I/II trials of combination chemotherapy (irinotecan, leucovorin, and 5-fluorouracil) and daily oral gefitinib." | 9.11 | Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. ( Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP, 2005) |
| "A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 plus 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2 was assessed in 2 consecutive randomized trials in metastatic colorectal cancer (CRC)." | 9.11 | Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials. ( Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S, 2005) |
| "We tested the hypothesis that the combination of trimetrexate (TMTX) and capecitabine (CAP) would be active in patients with previously treated metastatic colorectal cancer (CRC)." | 9.11 | A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. ( Earle, M; Evans, T; Ferri, W; Friedland, D; Jacobs, SA; Matin, K; Pinkerton, R; Ramanathan, RK; Richards, T; Troetschel, M; Volkin, R; Wieand, S; Wong, MK, 2005) |
| "This randomised, open-label trial compared oral tegafur (FT)/leucovorin (LV) with the intravenous bolus 5-fluorouracil (5-FU)/LV as first-line chemotherapy for advanced colorectal cancer (CRC)." | 9.11 | Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. ( Arcusa, A; Batiste-Alentorn, E; Boleda, M; Campos, JM; Cirera, L; de Mendizábal, EV; de Olaguer, JP; Escudero, P; Galan, A; Guasch, I; Losa, F; Manzano, H; Méndez, M; Nogué, M; Saigí, E; Salud, A; Vicente, P, 2005) |
| "Patients with liver-only metastases from colorectal cancer deemed not optimally resectable by a surgeon with expertise in liver surgery received fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)." | 9.11 | Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. ( Alberts, SR; Dakhil, SR; Donohue, JH; Goldberg, RM; Horvath, WL; Levitt, R; Mahoney, MR; Nair, S; Rowland, K; Sargent, DJ; Sternfeld, WC, 2005) |
| "com) and infusional 5-fluorouracil (5-FU) as second-line therapy in metastatic colorectal cancer (MCRC)." | 9.11 | Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. ( Gamucci, T; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Morabito, A; Sarmiento, R; Torino, F; Vitale, S, 2005) |
| "To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients." | 9.11 | An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with bolus and continuous infusion of 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI regimen) as first-line treatment of elderly patients with metastatic colorectal cancer (MCC)." | 9.11 | Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N, 2005) |
| "Pemetrexed and irinotecan have demonstrated antitumor activity as single agents in lung, pancreatic, breast, and colorectal cancer (CRC)." | 9.11 | Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. ( Becker, K; Hochster, H; Hong, S; John, W; Kettner, E; Kroning, H; Lordick, F; Macdonald, J; Ramanathan, RK; Schmoll, HJ, 2005) |
| "Irinotecan and raltitrexed are active against advanced colorectal cancer, act through different mechanisms, and have non-overlapping toxicity profiles." | 9.10 | Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. ( Aparicio, J; de las Peñas, R; Farrés, J; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM; Yuste, AL, 2002) |
| "We evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV + 5-FU." | 9.10 | Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer. ( Diamantis, T; Dimitrakopoulos, A; Gennatas, K; Kosmas, C; Paliaros, P; Papastratis, G; Tsavaris, N; Tsipras, H; Vadiaka, M, 2002) |
| "To determine the feasibility, recommended doses, plasma pharmacokinetics, and antitumor activity of a biweekly chemotherapy regimen with oxaliplatin (L-OHP), irinotecan (CPT-11), infusional fluorouracil (5-FU), and leucovorin (LV) in metastatic colorectal cancer patients." | 9.10 | Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Conte, P; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Pfanner, E, 2002) |
| "Overall results of this study indicate that the administration of clinically relevant single-agent doses of both capecitabine and oxaliplatin is feasible and seems to result in promising therapeutic activity in patients with advanced colorectal cancer." | 9.10 | Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. ( Huber, H; Kornek, GV; Längle, F; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B, 2002) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 9.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| "In the present study, we evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5-FU." | 9.10 | Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer. ( Gennatas, K; Kosmas, C; Kouraklis, G; Margaris, E; Papastratis, G; Rokana, S; Skopelitis, E; Tsavaris, N; Vadiaka, M; Xila, V; Zografos, G, 2002) |
| "Irinotecan (CPT-11) has been shown to prolong survival and improve quality of life in comparison to best supportive care in colorectal cancer patients with pretreatment of bolus 5-fluorouracil (5-FU)." | 9.10 | Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. ( Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F, 2002) |
| "We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting." | 9.10 | Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002) |
| "Most patients with colorectal cancer (CRC) who have failed initial 5-fluorouracil (5-FU) chemotherapy have worsening of disease-related symptoms (DRS) and quality of life (QOL)." | 9.10 | The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. ( Feld, R; Fields, A; Goel, R; Hedley, D; Jolivet, J; Lee, IM; Maroun, J; Michael, M; Moore, MJ; Oza, A; Pintilie, M, 2002) |
| "This multicentre phase II study evaluated the efficacy and safety of irinotecan combined with the Nordic schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line therapy in patients with advanced colorectal cancer." | 9.10 | Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. ( Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM, 2002) |
| "The efficacy and safety of preoperative chemotherapy with carmofur (HCFU) for colorectal cancer were evaluated in a randomized controlled study involving 63 institutes in the Kanto area." | 9.10 | [Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study]. ( Ishikawa, H; Iwasaki, Y; Kanazawa, K; Kitajima, M; Kodaira, S; Kotake, K; Koyama, Y; Miyata, M; Nagamachi, Y; Omoto, R; Shida, S; Tajima, Y; Tamakuma, S, 2002) |
| "The purpose of this study was to evaluate the efficacy and tolerance of the bimonthly administration of oxaliplatin in combination with high-dose leucovorin and infusional 5-fluorouracil (5-FU) (FOLFOX2 regimen) in patients with advanced colorectal cancer (ACC) who did not respond or whose disease progressed within 3 months after front-line treatment with CPT-11-containing regimens." | 9.10 | Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). ( Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Panopoulos, C; Papadouris, S; Sarra, E; Souglakos, J; Vardakis, N, 2002) |
| "This phase II trial investigated the safety and efficacy of two doses of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, plus fluorouracil (FU)/leucovorin (LV) versus FU/LV alone in patients with metastatic colorectal cancer." | 9.10 | Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. ( Bergsland, E; Fehrenbacher, L; Griffing, S; Hurwitz, HI; Kabbinavar, F; Lieberman, G; Meropol, NJ; Novotny, WF, 2003) |
| "The effect of different dose intensities of 5-fluorouracil (5-FU) in advanced colorectal cancer was investigated." | 9.10 | Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. ( Berglund, A; Carlsson, G; Frödin, JE; Glimelius, B; Gustavsson, B; Hansen, F; Jakobsen, A; Kjaer, M; Madsen, EL; Poulsen, JP; Sandberg, E, 2002) |
| "The aim of this study was to investigate whether N-(phosphonacetyl)-L-aspartic acid (PALA) can enhance the activity of low-dose methotrexate (LD-MTX) modulated infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer." | 9.10 | High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. ( Baron, B; Bleiberg, H; Blijham, GH; Couvreur, ML; De Greve, J; Genicot, B; Jansen, RL; Kok, TC; Nortier, JW; Wagener, T; Wils, J, 2003) |
| "To evaluate the efficacy and safety of neoadjuvant treatment comprising weekly high-dose 5-fluorouracil (5-FU) as a 24-hour infusion, folinic acid (FA) and biweekly oxaliplatin (L-OHP), followed by metastatic resection in patients with primarily resectable liver metastases of colorectal cancer (CRC)." | 9.10 | Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. ( Baum, U; Brückl, W; Fuchs, F; Günther, K; Hahn, EG; Hanke, B; Hohenberger, W; Merkel, S; Ott, R; Papadopoulos, T; Reck, T; Riedel, C; Wein, A, 2003) |
| " We did a randomised trial to compare an intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of the colon or rectum, with metastases confined to the liver." | 9.10 | Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. ( Buckels, J; Cain, D; Kerr, DJ; Ledermann, J; Mayer, D; McArdle, CS; Schlag, PM; Sherlock, DJ; Stephens, RJ; Taylor, I, 2003) |
| "This phase II study was designed to evaluate the efficacy and toxicities of oral doxifluridine plus leucovorin as a randomized trial with those of intravenous 5-fluorouracil (5-FU) plus leucovorin in previously untreated metastatic colorectal cancer (CRC)." | 9.10 | Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin. ( Ahn, JH; Kang, YK; Kim, JC; Kim, JG; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Min, YJ; Yu, CS, 2003) |
| "To assess the relationship between systemic exposure to capecitabine metabolites and parameters of efficacy and safety in patients with advanced or metastatic colorectal cancer from two phase III studies." | 9.10 | Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. ( Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003) |
| "Capecitabine and oxaliplatin, two new agents with potential synergistic activity, have demonstrated promising antitumor efficacy in advanced colorectal cancer (ACC)." | 9.10 | Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. ( Depisch, D; Kornek, GV; Kovats, E; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B, 2003) |
| "Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC)." | 9.10 | Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. ( Boehme, M; Galle, PR; Gutzler, F; Moehler, M; Raeth, U; Rudi, J; Steinmann, S; Stremmel, W, 2003) |
| "Because no consensus exists regarding recommendable dose levels for irinotecan, an intrapatient dose escalation phase I-II study was initiated in previously treated patients with colorectal cancer." | 9.10 | Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage. ( Alvarez, E; Buesa, JM; Carrasco, J; Esteban, E; Fra, J; Jiménez Lacave, A; Muñiz, I; Sala, M; Viéitez, JM, 2003) |
| " In preclinical models, there appears to be additive or synergistic effects when combining 5-Fluorouracil (5-FU) with nonsteroidal anti-inflammatory agents (NSAIDs) for the treatment of colorectal neoplasms." | 9.10 | Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. ( Ashfaq, R; Becerra, CR; Frenkel, EP; Gaynor, RB, 2003) |
| "In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)." | 9.10 | Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. ( Berlin, JD; Bigelow, RH; Burger, BG; Garay, CA; Gupta, S; Haller, DG; Hart, LL; Le Bail, N; Marshall, JL; Oza, AM; Ramanathan, RK; Rothenberg, ML, 2003) |
| "Our results suggest that irinotecan and MMC combination therapy is effective and well tolerated in patients with fluoropyrimidine-resistant metastatic colorectal cancer." | 9.10 | Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. ( Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y, 2003) |
| "Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil." | 9.10 | Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003) |
| "We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard bolus regimen of 5-FU and folinic acid (5-FU/FA) given for 6 months as adjuvant treatment in colorectal cancer." | 9.10 | Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, J; Ross, PJ; Saini, A; Tait, D, 2003) |
| "In this multicenter phase II study the efficacy and safety of the alternating schedule of irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and leucovorin (LV) were assessed as first-line chemotherapy in patients with metastatic colorectal cancer (CRC)." | 9.10 | A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer. ( Aparicio, J; Borrega, P; de la Puente, CG; Lorenzo, A; Moreno-Nogueira, JA; Pica, JM; Reina, JJ; Rueda, A; Salvador, J, 2003) |
| "Irinotecan (CPT-11) and raltitrexed are active against advanced colorectal cancer (ACC), act through different mechanisms, and have only partially overlapping toxicity profiles." | 9.10 | Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. ( Aparicio, J; Bosch, C; Busquier, I; Díaz, R; Fernández-Martos, C; Galán, A; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM, 2003) |
| "Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy of advanced colorectal cancer." | 9.10 | A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. ( Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J, 2003) |
| "To determine the activity of biweekly oxaliplatin, combined with weekly bolus fluorouracil (FU) and low-dose leucovorin (LV) chemotherapy (bFOL), as first-line therapy for patients with metastatic colorectal cancer." | 9.10 | Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. ( Chachoua, A; Escalon, J; Hochster, H; Muggia, F; Speyer, J; Zeleniuch-Jacquotte, A, 2003) |
| "The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer." | 9.10 | Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study. ( Changchien, CR; Chen, JS; Chiang, JM; Hsieh, PS; Tang, R; Yang, TS; Yeh, CY, 2003) |
| "This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer." | 9.10 | Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003) |
| "Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer." | 9.10 | Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. ( Cognetti, F; Ferraresi, V; Gabriele, A; Gamucci, T; Giannarelli, D; Nardoni, C; Pino, MS; Zeuli, M, 2003) |
| "To define the maximum-tolerated dose (MTD) and to evaluate the dose-limiting toxicities (DLTs) of the combination of capecitabine and irinotecan in patients with metastatic colorectal cancer." | 9.10 | Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. ( Achterrath, W; Frings, S; Harstrick, A; Rustum, YM; Schleucher, N; Seeber, S; Tewes, M; Vanhoefer, U; Wilke, HJ, 2003) |
| " irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) with hepatic arterial infusion (HAI) of pirarubicin in non-resectable liver metastases from colorectal cancer." | 9.10 | Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). ( Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L, 2003) |
| "To evaluate the toxicity and efficacy of a modified deGramont regimen of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in patients with advanced colorectal cancer who have progressed on at least one but not more than two prior chemotherapy regimens." | 9.10 | A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003) |
| "The tolerance and efficacy of oxaliplatin and irinotecan for metastatic colorectal cancer are unknown in elderly patients." | 9.10 | Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. ( Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L, 2003) |
| "The combination of irinotecan (CPT-11), oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) is one of the possibilities to overcome chemoresistance in advanced colorectal cancer (ACRC) patients." | 9.10 | A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. ( Bria, E; Garufi, C; Sperduti, I; Terzoli, E; Vanni, B; Zappalà, AM, 2003) |
| "We investigated the pharmacokinetics (PK), preliminary clinical results and toxicity of chronomodulated oxaliplatin (OHP) plus 5-fluorouracil (5-FU) without folinic acid (FA) in 13 patients with metastatic colorectal cancer." | 9.10 | Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer. ( Arpicco, S; Brusa, P; Bumma, C; Cattel, L; Infante, L; La Grotta, G; Passera, R, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 9.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "This multicenter, open-label, phase II study was performed to assess the efficacy and toxicity of irinotecan 350 mg/m2 intravenously every 3 weeks in patients with advanced colorectal cancer (CRC) previously treated with 5-fluorouracil (5-FU)." | 9.10 | A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil. ( Arizcun, A; Cruz, JJ; de la Torre, A; Diz, P; Duarte, I; España, P; García López, MJ; García-Girón, C; Martínez del Prado, P; Méndez, M; Navalon, M; Pujol, E; Salut, A, 2003) |
| "This study combined oxaliplatin with the Nordic bolus schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 9.10 | Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. ( Dahl, O; Sørbye, H, 2003) |
| ") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options." | 9.10 | Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002) |
| "Twenty-two patients with unresectable liver metastases from colorectal cancer were treated with continuous HAI of 300 mg/m2 5-fluorouracil for 5 days a week and 6 mg/m2 cisplatin for 2 hours on 5 consecutive days a week." | 9.10 | Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer. ( Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Okamura, T; Tajima, T; Toh, Y; Yamamoto, M, 2002) |
| "The combination of CPT-11 with 5-fluorouracil (5-FU) in advanced colorectal cancer (ACC) represents an attractive approach." | 9.10 | Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. ( Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kandilis, K; Kouroussis, C; Mavroudis, D; Sarra, E; Souglakos, J; Vamvakas, L; Ziras, N, 2002) |
| "Hand-foot syndrome (HFS) has been previously reported as a side effect in 45-56% of patients treated with capecitabine." | 9.10 | Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. ( Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED, 2002) |
| "The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)." | 9.10 | Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002) |
| "Two randomised studies were performed with trimetrexate (TMTX) as a biochemical modulator of 5-fluorouracil (5-FU)/leucovorin (LV) in advanced colorectal cancer (ACC), one in Europe and one in the United States." | 9.10 | Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer. ( Blanke, CD; Hammershaimb, L; Punt, CJ; Zhang, J, 2002) |
| "To study tolerability and efficacy of an intensified chronomodulated schedule of fluorouracil (5-FU) and l-folinic acid (l-FA) as first-line treatment of metastatic colorectal cancer, 5-FU was given near individually determined dose-limiting toxicity in a multicenter phase II trial." | 9.10 | Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. ( Adenis, A; Chevalier, V; Chipponi, J; Chollet, P; Coudert, B; Curé, H; Focan, C; Kwiatkowski, F; Lévi, F; Niezgodzki, G; Perpoint, B; Pezet, D; Tubiana-Mathieu, N, 2002) |
| "Cimetidine has been shown to have beneficial effects in colorectal cancer patients." | 9.10 | Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. ( Imaeda, Y; Kobayashi, K; Matsumoto, S; Okamoto, T; Suzuki, H; Umemoto, S, 2002) |
| "To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer." | 9.10 | Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. ( Ansari, RH; Bell, WN; Colwell, B; Levin, J; McGuirt, PV; Pazdur, R; Schilsky, RL; Thirlwell, MP; West, WH; White, RL; Wong, A; Yates, BB, 2002) |
| "To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer." | 9.10 | Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. ( Borner, MM; Brauchli, P; Castiglione-Gertsch, M; Dietrich, D; Goldhirsch, A; Hanselmann, S; Herrmann, R; Honegger, H; Morant, R; Müller, S; Pestalozzi, BC; Roth, AD; Saletti, P; Stupp, R; Wernli, M, 2002) |
| "This phase II study was designed to evaluate the efficacy and toxicity of 3-h interval sequential methotrexate (MTX) and 5-fluorouracil (5-FU) with leucovorin (LV) rescue in the treatment of patients with metastatic colorectal cancer." | 9.10 | Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer. ( Hamaguchi, T; Haruyama, K; Matsumura, Y; Muro, K; Shimada, Y; Shirao, K; Sugano, K; Yamada, Y, 2002) |
| "5-fluorouracil remains the standard therapy for patients with advanced/metastatic colorectal cancer." | 9.10 | Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study. ( Blackstock, AW; Case, D; Higgs, V; Melin, SA; Savage, P; Tomlinson, SK; White, DR, 2002) |
| "A phase II trial investigated the activity and toxicity of a bolus administration schedule of oxaliplatin, fluorouracil (5-FU), and leucovorin (LV) therapy in patients with untreated advanced colorectal cancer." | 9.10 | Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. ( Amadori, D; Cruciani, G; Giovanis, P; Marangolo, M; Nicolini, M; Oliverio, G; Panzini, I; Pasquini, E; Ravaioli, A; Rossi, A; Tassinari, D; Turci, D; Zumaglini, F, 2002) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC)." | 9.10 | Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. ( Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N, 2002) |
| "To evaluate the safety profile of capecitabine using data from a large, well-characterized population of patients with metastatic colorectal cancer treated in two phase II studies." | 9.10 | First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. ( Bajetta, E; Boyer, M; Bugat, R; Burger, U; Cassidy, J; Garin, A; Graeven, U; Hoff, P; Maroun, J; Marshall, J; McKendric, J; Osterwalder, B; Pérez-Manga, G; Rosso, R; Rougier, P; Schilsky, RL; Twelves, C; Van Cutsem, E, 2002) |
| "The aim of this multicenter prospective study was to evaluate the role of intratumoral parameters related to fluorouracil (FU) sensitivity in 103 metastatic colorectal cancer patients receiving FU-folinic acid." | 9.10 | Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. ( Bourgeon, A; Chamorey, E; Chazal, M; Delpero, JR; Etienne, MC; Formento, JL; Formento, P; Francoual, M; Laurent-Puig, P; Letoublon, C; Magné, N; Milano, G; Pezet, D; Renée, N; Rosty, C; Seitz, JF, 2002) |
| "To evaluate the activity and safety of an alternating schedule of irinotecan (CPT-11) with high-dose 5-fluorouracil (5-FU) given as a weekly 48-hour infusion in combination with leucovorin (LV) in the first-line treatment of metastatic colorectal cancer (MCRC) patients." | 9.10 | A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. ( Manzione, L; Reggiardo, G; Rosati, G; Rossi, A, 2002) |
| "The combination of irinotecan plus 5-fluorouracil and folinic acid has clinical and survival benefits over 5-fluorouracil and folinic acid alone in the setting of first line treatment of metastatic colorectal cancer." | 9.10 | Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. ( Cunningham, D; Falk, S; Jackson, D, 2002) |
| "To determine the maximum-tolerated dose (MTD) of a weekly schedule of irinotecan (CPT-11), leucovorin (LV), and a 24-hour infusion of fluorouracil (5-FU24h) as first-line chemotherapy in advanced colorectal cancer and to assess preliminary data on the antitumor activity." | 9.09 | Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. ( Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H, 1999) |
| "The aim of this prospective study was to assess the efficacy, clinical benefit and safety of CPT-11 (irinotecan) in patients with stringently-defined 5-fluorouracil-resistant metastatic colorectal cancer (CRC)." | 9.09 | Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). ( Alexopoulos, CG; Blanc, C; Bleiberg, H; Blijham, GH; Cholet, P; Cote, C; Cunningham, D; Dirix, L; Fillet, G; Hérait, P; Levi, F; Panagos, G; Punt, CJ; Symann, M; Ten Bokkel Huinink, WW; Unger, C; Van Cutsem, E; Van Groeningen, C; Vannetzel, JM; Wils, J, 1999) |
| "In a prospective multicenter trial, 279 patients with metastatic colorectal cancer who had failed 5-fluorouracil therapy were randomized 2:1 to receive either best supportive care (BSC) plus treatment with the topoisomerase I inhibitor, irinotecan (CPT-11; Rhône-Poulenc Rorer, Antony, France), at a dose of 350 mg/m2 every 3 weeks or BSC alone." | 9.09 | A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. ( Cunningham, D; Glimelius, B, 1999) |
| "In a multicenter phase III trial, 267 patients with nonbulky metastatic colorectal cancer who had failed first-line 5-fluorouracil (5-FU) therapy were randomized to receive second-line treatment with either the new topoisomerase agent, irinotecan (Rhône-Poulenc Rorer, Antony, France), or a high-dose infusional 5-FU regimen." | 9.09 | Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. ( Blijham, GH; Van Cutsem, E, 1999) |
| "Our objective was to establish the balance between costs and effects of treatment with Tomudex (raltitrexed) as an alternative to treatment with 5-fluorouracil (5-FU) plus leucovorin (LV) in patients with advanced colorectal cancer." | 9.09 | An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. ( Byttebier, G; Groener, MG; Rutten, FF; van Hout, BA; van Ineveld, BM, 1999) |
| "The combination of 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (I-OHP) was shown to be both more active against metastatic colorectal carcinoma and better tolerated if the drug delivery rate was chronomodulated according to circadian rhythms rather than constant." | 9.09 | A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. ( Brienza, S; Chollet, P; Dogliotti, L; Focan, C; Le Rol, A; Letourneau, Y; Lévi, F; Llory, JF; Perpoint, B; Rotarski, M; Zidani, R, 1999) |
| "This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil (5-FU)/leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer." | 9.09 | A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Agostinelli, R; Baldelli, AM; Barni, S; Cascinu, S; Catalano, G; Catalano, V; Frontini, L; Gasparini, G; Giuliodori, L; Labianca, R; Martignoni, G; Mattioli, R; Silva, RR, 1999) |
| "To evaluate the objective tumor response rates and toxicities of leucovorin (LV) plus fluorouracil (5-FU) cancer regimen combined with oxaliplatin (85 mg/m(2)) every 2 weeks on metastatic colorectal cancer patients with documented proof of progression while on bimonthly LV and 5-FU alone." | 9.09 | Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. ( André, T; Beerblock, K; Bensmaine, MA; Bouché, O; Carola, E; de Gramont, A; Desseigne, F; Dupont-André, G; François, E; Louvet, C; Lucas, V; Merrouche, Y; Morvan, F, 1999) |
| "To determine whether immunohistochemical thymidylate synthase (TS) quantitation predicts for clinical outcome in patients with advanced colorectal cancer treated by fluorouracil (FUra)-based chemotherapy." | 9.09 | Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. ( Antonelli, G; Aschele, C; Baldo, C; Casazza, S; Debernardis, D; Lionetto, R; Maley, F; Sobrero, A; Tunesi, G, 1999) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 9.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "To study how adding oxaliplatin (l-OHP) to chronomodulated fluorouracil (5-FU)-leucovorin (LV) affected the objective response rate, as first-line treatment of metastatic colorectal cancer." | 9.09 | Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. ( Adam, R; Bertheaut-Cvitkovic, F; Chollet, P; Coudert, B; Faggiuolo, R; Focan, C; Giacchetti, S; Larregain-Fournier, D; Le Bail, N; Le Rol, A; Letourneau, Y; Lévi, F; Llory, JF; Misset, JL; Perpoint, B; Walter, S; Zidani, R, 2000) |
| "The potential of raltitrexed (Tomudex) in combination with 5-fluorouracil (5-FU) as treatment for advanced colorectal cancer has been investigated in two phase I clinical trials." | 9.09 | Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials. ( González Barón, M; Harstrick, A; Schwartz, GK, 1999) |
| "Thirty-seven colorectal cancer patients with grade 1-4 diarrhea (NCICTC) caused by chemotherapy with 5-FU-containing regimens, received oral loperamide at the initial dose of 4 mg followed by 4 mg every 8 h (total dose 16 mg/24 h)." | 9.09 | High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. ( Agostinelli, R; Amadori, D; Bichisao, E; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Luppi, G; Sansoni, E; Silingardi, V, 2000) |
| "CPT-11 (irinotecan) has shown activity in patients with advanced colorectal cancer resistant to leucovorin (LV) and 5-fluorouracil (5-FU)." | 9.09 | CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. ( André, T; Carola, E; Couteau, C; de Gramont, A; Gilles-Amar, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 1999) |
| "The aim of this study was to develop a phase II study gauging the contribution of a daily low-dose of carboplatin combined with 5-fluorouracil (5-FU) and folinic acid (FOL) in a chronotherapy schedule for advanced colorectal cancer patients." | 9.09 | Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial. ( Focan, C; Focan-Henrard, D; Kreutz, F; Moeneclaey, N, 2000) |
| "To evaluate in patients with advanced colorectal cancer (CRC) three treatment regimens of oral capecitabine in order to select the most appropriate regimen for testing in phase III." | 9.09 | Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. ( Allman, D; Burger, HU; Cassidy, J; Dalley, D; Dirix, L; Findlay, M; Kocha, W; Osterwalder, B; Pazdur, R; Schölmerich, J; Seitz, JF; Twelves, C; Van Cutsem, E; Verweij, J, 2000) |
| "Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil." | 9.09 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. ( Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P, 2000) |
| "It has been shown that irinotecan is superior to infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer after 5-FU failure." | 9.09 | Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. ( Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C, 2000) |
| "MF (protracted infusion 5-fluorouracil (5-FU), 300 mg/m2/24 hours plus bolus mitomycin, 7 mg/m2 every 6 weeks, maximum 4 doses), was recently shown in a randomised trial to be superior to protracted 5-FU alone, as first-line chemotherapy for metastatic colorectal cancer (Ross et al." | 9.09 | Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. ( Chester, JD; Dent, JT; Ride, E; Seymour, MT; Wilson, G, 2000) |
| " One hundred thirty-six patients with metastatic colorectal cancer who failed to respond to a 5-fluorouracil-based treatment received 714 cycles of irinotecan." | 9.09 | Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. ( Adenis, A; Burki, F; Douillard, JY; Dufour, P; Marty, M; Mignard, D; Mousseau, M; Rougier, P; Wendling, JL; Ychou, M, 2000) |
| "The purpose of this study was to evaluate the efficacy, toxicity, and safety of outpatient chemotherapy with weekly high-dose 5-fluorouracil (HD-5FU) in previously treated patients (pts) with metastatic colorectal cancer." | 9.09 | Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer. ( Cohen, Y; Lavrenkov, K; Mermershtain, W, 2000) |
| "The aim of this study was to clarify whether increased 5-fluorouracil (5-FU) uptake by tumor tissue following preoperative UFT administration is a prognostic factor after surgery in colorectal cancer patients." | 9.09 | Preoperative UFT administration for patients with advanced colorectal cancer--increased uptake of 5-fluorouracil by tumor tissue is a prognostic factor. ( Ayabe, H; Eida, K; Furukawa, M; Ino, M; Ishikawa, H; Kunisaki, T; Nakagoe, T; Nakamura, Y; Nogawa, T; Sawai, T; Tobinaga, K; Tsuji, T, 2000) |
| "We performed combination chemotherapy adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in 11 patients with gastric cancer and 7 with colorectal cancer." | 9.09 | [The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer]. ( Iesato, H; Kamoshita, N; Kato, Y; Morishita, Y; Nagaoka, H; Ohwada, S; Ohya, T; Okabe, T; Takeyoshi, I; Yokomori, T, 2000) |
| "To evaluate the safety and efficacy of a five-day regimen of oral 5-fluorouracil (5-FU) plus eniluracil (776C85) in patients with metastatic colorectal cancer (CRC)." | 9.09 | A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. ( Bonny, T; Bukowski, R; Burris, H; Hochster, H; Hohneker, J; Levin, J; Mani, S; O'Rourke, M; Schilsky, RL; Wall, JG, 2000) |
| "We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer." | 9.09 | Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure. ( Blijham, G; Jolain, B; Rougier, P; Schmitt, C; Van Cutsem, E, 1999) |
| "To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer." | 9.09 | Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. ( Beck, T; Bell, WN; Chevlen, EM; Hochster, H; Hohneker, J; Levin, J; Lokich, J; Mani, S; McGuirt, C; O'Rourke, MA; Schilsky, RL; Weaver, CH; White, R, 2000) |
| "In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen." | 9.09 | Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000) |
| "To analyse patients' travel and time costs associated with 2 alternative drug therapies for advanced colorectal cancer: raltitrexed and fluorouracil plus folinic acid (leucovorin) [5FU + FA]." | 9.09 | Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. ( Heyes, A; Palmer, MK; Sculpher, M, 2000) |
| "The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer." | 9.09 | Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000) |
| "The purpose of this study was to determine the efficacy of twice weekly hypo-fractionated radiation therapy (RT) plus continuous infusion 5-fluorouracil for unresectable or locally advanced colorectal cancer with synchronous metastases." | 9.09 | Avoidance of colostomy placement in advanced colorectal cancer with twice weekly hypofractionated radiation plus continuous infusion 5-fluorouracil. ( Breslin, T; Janjan, NA; Lenzi, R; Rich, TA; Skibber, J, 2000) |
| "QUASAR is a large trial of adjuvant chemotherapy for colorectal cancer in which clinicians could choose to deliver a standard adjuvant cytotoxic chemotherapy regimen, 5-fluorouracil (5-FU) and L-folinic acid (L-FA), in either a once-weekly or a four-weekly schedule." | 9.09 | Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group. ( Barnwell, J; Gray, R; Kerr, DJ; McConkey, C, 2000) |
| "A phase II study was carried out to evaluate the efficacy and toxicity of a double biochemical modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and leucovorin (LV) in patients with advanced unresectable colorectal cancer." | 9.09 | Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer. ( Cizej, TE; Markovic, A; Plesnicar, A; Stabuc, B, 2000) |
| "The aim of this phase II study was to investigate the therapeutic value of second-line treatment with oxaliplatin, irinotecan (CPT-11) and mitomycin C (MMC) in patients with metastatic colorectal cancer pretreated with 5-fluorouracil (5-FU)-based chemotherapy." | 9.09 | Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. ( Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC, 2000) |
| "Univariate and multivariate analyses were performed on data from 370 5-fluorouracil (5-FU)-resistant advanced colorectal cancer patients treated with oxaliplatin (Eloxatin)/5-FU+/-folinic acid (FA) to identify prognostic factors for oxaliplatin-based treatment." | 9.09 | Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients. ( Bleiberg, H; Bleuzen, P; Brienza, S; Cvitkovic, E; de Gramont, A; Ducreux, M; François, E; Gamelin, E; Lévi, F; Marty, M; Simon, J, 2000) |
| "Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)." | 9.09 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000) |
| "Irinotecan is a topoisomerase I inhibitor that prolongs survival in patients with colorectal cancer refractory to fluorouracil (5-FU) and leucovorin (LV)." | 9.09 | Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. ( Alakl, M; Awad, L; Douillard, JY; Elfring, GL; Gruia, G; Locker, PK; Miller, LL; Pirotta, N; Saltz, LB, 2001) |
| "The aim of the study was to evaluate the efficacy, tolerability and quality of life in 5-fluorouracil (5-FU) pretreated colorectal cancer patients after combined 5-FU and Ginkgo biloba extract GBE 761 ONC (i." | 9.09 | Phase II study of combined 5-fluorouracil/ Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer. ( Häring, B; Hauns, B; Köhler, S; Mross, K; Unger, C, 2001) |
| "Irinotecan (CPT11) has established activity in the treatment of advanced colorectal cancer without cross-resistance with established 5-fluorouracil/folinic acid-based therapy." | 9.09 | Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. ( Adam, R; Bismuth, H; Castaing, D; Coeffic, D; Durrani, AK; Gil-Delgado, MA; Guinet, F; Khayat, D, 2001) |
| "Sixty eligible patients who had previously untreated, measurable, metastatic colorectal carcinoma were treated with oral eniluracil 50 mg on Days 1-7, 5-FU 20 mg/m(2) on Days 2-6, and LV 50 mg on Days 2-6." | 9.09 | Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. ( Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001) |
| "To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer." | 9.09 | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 9.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| " 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin." | 9.09 | Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001) |
| "This phase II study examined a regimen (FOLFOX7) of leucovorin (LV), high-dose intensity oxaliplatin, and 5-fluorouracil (5-FU), as second-line therapy for metastatic colorectal cancer." | 9.09 | High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 2001) |
| "Patients with isolated hepatic metastases from colorectal cancer were treated every three weeks with increasing doses of oxaliplatin (4 hours; starting dose 25 mg/m2, escalation in steps of 25 mg/m2) in combination with folinic acid (1 hour, 200 mg/m2) and 5-fluorouracil (2 hour, 600 mg/m2)." | 9.09 | Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ( Beckert, B; Beykirch, M; Braess, J; Goecke, E; Hiddemann, W; Kern, W; Lang, N; Schalhorn, A; Stein, J; Stemmler, J; Waggershauser, T, 2001) |
| "To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)." | 9.09 | Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001) |
| "Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding palliative chemotherapy with fluoropyrimidines leucovorin +/- irinotecan, participated in this study." | 9.09 | Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. ( Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H, 2001) |
| "A multi-institutional study was performed to evaluate the appropriate duration of oral administration of Carmofur (1-hexylcarbamoyl-5-fluorouracil, HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative operation." | 9.09 | Optimal duration of oral adjuvant chemotherapy with Carmofur in the colorectal cancer patients: the Kansai Carmofur Study Group trial III. ( Fujii, H; Kamigaki, T; Kuroda, Y; Nakamura, T; Ohno, M; Tabuchi, Y; Yamagishi, H, 2001) |
| "The primary objective of this trial was to determine the objective response of two regimens with CDDP administered every 2 weeks immediately before or after an 'optimal' 48-hour chronomodulated infusion of 5-fluorouracil (5-FU) modulated with leucovorin (LV) in metastatic colorectal cancer patients." | 9.09 | 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ( Allegrini, G; Bocci, G; Brunetti, I; Conte, P; Danesi, R; Del Tacca, M; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001) |
| "To evaluate the efficacy and safety of oxaliplatin (L-OHP) in combination with leucovorin (LV)-modulated bolus plus infusional 5-fluorouracil (5-FU; de Gramont schedule) every 2 weeks in chemotherapy-naive patients with advanced colorectal cancer (CRC)." | 9.09 | Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. ( Agelaki, A; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malamos, N; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N, 2001) |
| "Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV." | 9.09 | Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. ( Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001) |
| "A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin(R)) + 5-fluorouracil (5-FU) +/- folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorectal cancer (ACRC)." | 9.09 | Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. ( Bensmaïne, MA; Bleiberg, H; Brienza, S; Cvitkovic, E; de Gramont, A; Ducreux, M; François, E; Gamelin, E; Lévi, F; Marty, M, 2001) |
| "To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Laboratories, Inc, Nutley, NJ), a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion but with preferential activation at the tumor site, with that of intravenous (IV) 5-FU plus leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer." | 9.09 | Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. ( Allman, D; Bajetta, E; Boyer, M; Bugat, R; Cassidy, J; Findlay, M; Frings, S; Harper, P; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Twelves, C; Van Cutsem, E; Vieitez, JM; Weitzel, C, 2001) |
| "A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium - folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer." | 9.09 | Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer. ( Drees, M; Fritze, D; Hartung, G; Hehlmann, R; Hofheinz, RD; Kreuser, ED; Kühnel, J; Queisser, W; Riedel, C; Rost, A; Wein, A, 2001) |
| "38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5-fluorouracil/leucovorin or the specific thymidilate synthase inhibitor raltitrexed were enrolled in this study." | 9.09 | Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. ( Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 9.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "Thirty-one patients with advanced colorectal cancer were treated with a regimen of epirubicin, cisplatin and continuous-infusion (c." | 9.09 | Epirubicin, cisplatin and continuous-infusion 5-fluorouracil (ECF regimen) in the treatment of advanced colorectal cancer. ( Caporale, A; Franchi, F; Gargano, L; Konstantatoy, E; Marcellini, M; Masciangelo, R; Menichetti, ET; Seminara, P, 2001) |
| "Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer (ACRC)." | 9.09 | Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. ( Carpi, A; Cherubini, R; Cognetti, F; Di Costanzo, E; Gasperoni, S; Moscetti, L; Paoloni, FP; Sdrobolini, A; Zeuli, M, 2001) |
| "Modulation of 5-fluorouracil (FUra) using leucovorin (LV) is a standard treatment approach in patients with metastatic colorectal cancer." | 9.08 | A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer. ( Erlichman, C; Feld, R; Fine, S; Kaizer, L; Moore, MJ; Myers, R; Thiessen, JJ, 1995) |
| "A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil (FU) with both leucovorin (LV) and cisplatin (CDDP) against liver metastases of colorectal cancer was devised." | 9.08 | [A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil with both leucovorin and cisplatin against liver metastases of colorectal cancer]. ( Fukada, D; Kato, M; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tsuji, K; Umemoto, T, 1995) |
| "The combination of 5-fluorouracil (5-FU) and folinic acid (FA) has demonstrated activity in colorectal cancer (CC)." | 9.08 | 5-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: a pilot study. ( Bacoyiannis, C; Daliani, D; Katsikas, M; Kosmas, C; Kosmidis, P; Sakelaropoulos, N; Tentas, K; Tsavaris, N, 1995) |
| "Modulation of 5-fluorouracil (5-FU) is currently being investigated in advanced colorectal cancer." | 9.08 | Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin. ( Astone, A; Barone, C; Cassano, A; Corsi, DC; Fontana, T; Noviello, MR; Pozzo, C, 1995) |
| "The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer." | 9.08 | Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. ( Ahmed, F; Cunningham, D; Findlay, M; Hickish, T; Hill, M; Middleton, G; Nicolson, V; Norman, A; Watson, M; Webb, A, 1995) |
| "We have conducted a retrospective study of high-dose folinic acid and 5-fluorouracil in 96 patients with advanced colorectal cancer." | 9.08 | High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients. ( Adams, M; Hanna, CL; Mason, MD; Maughan, TS; McKinna, FE; Morrey, D; Williams, LB, 1995) |
| "To compare the efficacy and toxicity profiles of a combination of fluorouracil (5-FU) with recombinant human interferon alfa-2a (Roferon-A; Hoffman La-Roche AG, Basel, Switzerland) versus the combination of 5-FU with leucovorin (LV) in the treatment of advanced colorectal cancer." | 9.08 | Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. ( , 1995) |
| "A clinical trial was conducted in order to evaluate the anti-tumor effect and toxicity of a continuous infusion of 5-fluorouracil (5-FU) for metastatic colorectal cancer." | 9.08 | Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer. ( Kondo, H; Ohkura, H; Saito, D; Shimada, Y; Shirao, K; Sugano, K; Yamao, T; Yokota, T; Yoshida, S, 1995) |
| "A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer." | 9.08 | [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995) |
| "Trimetrexate (TMQ), a non-classical folate antagonist, was studied in a randomized controlled trial in patients with advanced colorectal cancer and without prior chemotherapy." | 9.08 | A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study. ( Brown, TD; Fleming, TR; Goodman, PJ; Macdonald, JS; O'Rourke, T; Pugh, RP, 1995) |
| "These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines." | 9.08 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| "No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy." | 9.08 | Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995) |
| "A Phase II study of combination treatment with 5-fluorouracil (5-FU), leucovorin (LV), and interferon alpha-2a (IFN) in patients with previously untreated metastatic colorectal cancer was previously reported by the authors." | 9.08 | 5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. ( Buter, J; de Vries, EG; Mulder, NH; Sinnige, HA; Sleijfer, DT; van der Graaf, WT; Verschueren, RC; Willemse, PH, 1995) |
| "A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks." | 9.08 | 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. ( Dale, J; Fried, G; Haim, N; Stein, M; Tsalik, M, 1995) |
| "Between September 1990 and August 1994, 11 patients (pts) with liver metastases (mets) from colorectal cancer were treated with continuous hepatic arterial infusion chemotherapy of 5-fluorouracil (FU) plus leucovorin (LV)." | 9.08 | [Continuous intraarterial infusion of 5-fluorouracil plus leucovorin for liver metastases from colorectal cancer]. ( Ban, K; Higashi, H; Imanari, T; Ishihara, S; Kitazaki, M; Masuda, K; Matsumoto, M; Noma, M; Ota, M; Shida, H, 1995) |
| "We undertook a multicenter phase II trial of 5-fluorouracil (5FU) + 1-leucovorin (1-LV) in previously untreated patients with metastatic colorectal cancer to determine the response rate, response duration, time to progression, survival, and toxicity." | 9.08 | A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. ( Erlichman, C; Fine, S; Gorg, C; Gustavsson, B; Hoffmann, W; Kerr, I; Preusser, P; Schmoll, HJ; Thuerlimann, B, 1996) |
| "This randomised clinical trial, involving patients with advanced colorectal cancer, was carried out to compare the effectiveness of accelerated folinic acid (FA) plus 5-fluorouracil (5-FU) with that of the conventional regimen of 5-FU alone." | 9.08 | Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. ( Aquino, A; Botta, G; De Martino, A; Frediani, B; Lorenzi, M; Marsili, S; Marzocca, G; Palazzuoli, V; Petrioli, R; Tani, F, 1995) |
| "A joint study was performed by the Tokai HCFU study group, which included 41 institutions to study the usefulness of the concomitant therapy with Mitomycin C (MMC) and Carmofur (HCFU) as a postoperative adjuvant chemotherapy in patients with colorectal cancer who had curative resection." | 9.08 | Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer. ( Ito, K; Kato, T; Koike, A; Miura, K; Takagi, H; Yamaguchi, A, 1996) |
| "To determine the plasma pharmacokinetics and the maximum-tolerated dose (MTD) of intravenous (IV) azidothymidine (AZT) administered 90 to 120 minutes after fluorouracil (5-FU) and leucovorin and to preliminarily evaluate the antitumor activity of this combination in metastatic colorectal cancer." | 9.08 | Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ( Brunetti, I; Conte, PF; Danesi, R; Dargenio, F; Del Tacca, M; Falcone, A; Nethersell, AB; Pfanner, E, 1996) |
| "Phase II studies of fluorouracil (5-FU) administered by protracted intravenous infusion have suggested an improved response rate and decreased toxicity profile when compared with 5-FU given by bolus injection in patients with metastatic colorectal cancer." | 9.08 | Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. ( Anderson, T; Benson, A; Haller, DG; Hansen, RM; Krzywda, B; Quebbeman, E; Ryan, L; Tormey, DC, 1996) |
| "We studied the effect of postoperative chemotherapy using 5-fluorouracil (5-FU) infusions and 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration for curatively resected Stage II to IV colorectal cancer." | 9.08 | Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection. ( Akiyoshi, T; Kakegawa, T; Maehara, Y; Ogawa, M; Sugimachi, K; Tomita, M, 1996) |
| "A phase II prospective trial was carried out to study the concept of 5-fluorouracil (5-FU) dose-intensity in patients with advanced colorectal cancer." | 9.08 | Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. ( Burtin, PC; Danquechin-Dorval, EM; Delva, RG; Dumesnil, YF; Gamelin, EC; Gesta, PH; Goudier, MJ; Larra, FG; Lortholary, AH; Maillart, PJ, 1996) |
| "We evaluated the role of low-dose alpha-2b interferon, added to chemotherapy, for advanced colorectal cancer; we randomized patients, to either a combination chemotherapy of 5-fluorouracil (5-FU) and high-dose folinic acid (HDFA) or the same regimen plus interferon." | 9.08 | Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer. ( Di Lullo, L; Fabiani, F; Fanini, R; Lalli, A; Lombardo, M; Nuzzo, A; Peretti, G; Recchia, F; Torchio, P; Venturoni, L, 1996) |
| "A total of 26 patients with advanced colorectal cancer received 60 mg/m2 methotrexate i." | 9.08 | Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer. ( Alessandroni, P; Casadei, V; Cascinu, S; Catalano, G; Del Ferro, E; Fedeli, A; Rossi, D, 1996) |
| "Methotrexate (MTX) has been described to modulate the activity of fluorouracil (5-FU) in patients with metastatic colorectal cancer." | 9.08 | Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. ( Bleiberg, H; Blijham, G; Buset, M; Collette, L; Dalmark, M; de Greve, J; Lacave, A; Sahmoud, T; Selleslag, J; Wagener, T; Wils, J, 1996) |
| "To determine the effects of interferon alpha-2a (IFN alpha) on the efficacy and toxicity of fluorouracil (FUra) and leucovorin (LV) in patients with advanced colorectal cancer." | 9.08 | Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. ( Cunningham, D; Duffy, AM; Harper, PG; James, RD; Kerr, DJ; Ledermann, JA; McAdam, WA; Neoptolemos, JP; Nicholson, M; Perren, TJ; Seymour, MT; Slevin, ML; Stenning, SP; Stephens, RJ; Taylor, I, 1996) |
| "A phase II study was performed to evaluate the clinical and immunological effects of a regimen of fluorouracil (5-FU) and folinic acid (FA) combined with thymopentin (TP-5) and interleukin-2 (IL-2) in the treatment of patients with metastatic colorectal cancer." | 9.08 | Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects. ( Ameglio, F; Di Lauro, L; Frasca, AM; Gandolfo, GM; Garaci, E; Lopez, M; Paoletti, G; Rasi, G; Santini, S; Vitelli, G, 1995) |
| "With the association of 5-fluorouracil (5-FU) and alpha-interferon (IFN), objective responses as high as 26 63% have been reported in untreated patients with advanced colorectal cancer." | 9.08 | A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. ( Acito, L; Bascioni, R; Bavosi, M; Carle, F; Cascinu, S; Cellerino, R; Del Papa, M; Francini, G; Giustini, L; Latini, L; Marcellini, M; Pancotti, A; Piga, A; Rossi, G, 1996) |
| "A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV." | 9.08 | A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996) |
| "To compare the efficacy and toxicity profiles of a combination of fluorouracil (5-FU) and recombinant human interferon alfa-2a ([IFN alpha 2a] Roferon-A; Hoffmann-LaRoche, Basel, Switzerland) versus 5-FU alone in the treatment of advanced colorectal cancer (ACC)." | 9.08 | Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. ( Buys, SS; Buyse, M; Einhorn, L; Figlin, R; Froimtchuk, MJ; Greco, FA; Man, A; Marshall, EM; Ritter, L; Schilsky, R; Schuchter, L; Schuller, J; Yap, AK; York, M, 1996) |
| "A joint study was performed by the Tokai HCFU study group, which included seven institutions, to examine the value of oral administration of Carmofur (HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative resection." | 9.08 | Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group--third study on colorectal cancer. ( Baba, S; Ishii, M; Ito, K; Kato, T; Matsumoto, S; Miura, K; Takagi, H; Yamaguchi, A, 1996) |
| "5-Fluorouracil (5-FU) remains the most active therapeutic agent in advanced colorectal cancer." | 9.08 | 5-Fluorouracil continuous infusion in metastatic colorectal cancer. ( Ang, PT; Tan, EH, 1996) |
| "In a pilot study we treated 19 patients suffering from recurrent or locally advanced inoperable colorectal cancer, with concurrent hypofractionated radiotherapy (4-5 Gy/fraction, 2 fractions per week) and 5-fluorouracil bolus, 1 hour before RT at doses of 300 mg/m2." | 9.08 | Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. ( Kapsoritakis, A; Kosma, L; Koukourakis, M; Mouder, N; Skarlatos, J; Yannakakis, D; Zambatis, C, 1996) |
| "Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFN alpha-2a) and interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced colorectal cancer." | 9.08 | Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. ( Goey, SH; Gratama, JW; Mertelsmann, RH; Osterwalder, B; Primrose, JN; Stoter, G; Verweij, J; Ward, U, 1996) |
| "This multicenter study compared the therapeutic ratio of a monthly schedule of low-dose leucovorin (LV) and fluorouracil (5-FU) bolus with a bimonthly schedule of high-dose LV and 5-FU bolus plus continuous infusion in patients with advanced colorectal cancer." | 9.08 | Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. ( Bedenne, L; Bosset, JF; Bouché, O; de Gramont, A; Etienne, PL; François, E; Guillot, T; Louvet, C; Milan, C; Morvan, F; Rougier, P, 1997) |
| "To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer." | 9.08 | Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. ( Burger, D; Depisch, D; Greiner, R; Karner, J; Kornek, G; Kovats, E; Marczell, A; Pidlich, J; Raderer, M; Rosen, H; Salem, G; Scheithauer, W; Schneeweiss, B, 1997) |
| "Although leucovorin (LV) + 5-fluorouracil (5-FU) is considered the treatment of choice for advanced colorectal cancer in most countries, the optimal schedule of this combination has not yet been established." | 9.08 | High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer. ( Arnoldi, E; Barni, S; Cascinu, S; Comella, G; Dallavalle, G; Duro, M; Fiorentini, G; Frontini, L; Gottardi, O; Labianca, R; Luporini, G; Martignoni, G; Oliani, C; Pancera, G; Pavanato, G; Piazza, E; Raina, A; Valsecchi, R; Zaniboni, A, 1997) |
| "Fourteen patients with 5-fluorouracil (5-FU) refractory, progressive colorectal cancer metastatic to liver and/or lung were treated with continuous oral trofosfamide, an alkylating agent structurally related to cyclophosphamide and ifosfamide." | 9.08 | Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. ( Eberhardt, W; Harstrick, A; Klaassen, U; Korn, MW; Müller, C; Seeber, S; Strumberg, D; Wilke, H, 1997) |
| "Diarrhea is one of the dose-limiting toxicities for administration of fluorouracil (5FU) in patients with colorectal cancer and can result in severe morbidity and mortality." | 9.08 | Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. ( Ardizzoia, A; Barni, S; Cascinu, S; Catalano, G; Cazzaniga, M; Del Ferro, E; Ghiandoni, G; Labianca, R; Ligi, M; Luporini, G; Pessi, MA; Rocchi, MB; Ugolini, G; Zamparelli, G, 1997) |
| "A three-arm randomized phase III trial in advanced colorectal cancer patients was designed to test whether substitution of an equivalent dose of (1) l-leucovorin or (2) oral leucovorin would more effectively potentiate fluorouracil (5-FU) than standard intravenous (I." | 9.08 | Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. ( Goldberg, RM; Hatfield, AK; Kahn, M; Knost, JA; Krook, JE; Maillard, JA; Moertel, CG; O'Connell, MJ; Sargent, DJ; Schaefer, PL; Tirona, MT; Wiesenfeld, M, 1997) |
| "The aim of this phase I study was to establish the maximum tolerated dose (MTD) of 5-fluorouracil (5-FU), administered as a 5-day chronomodulated infusion in combination with 1-folinic acid (FA) to ambulatory metastatic colorectal cancer patients." | 9.08 | A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer. ( Aschelter, AM; Franchi, F; Gallà, DA; Garufi, C; Giunta, S; Lévi, F; Narduzzi, C; Nisticò, C; Pace, R; Silecchia, GF; Terzoli, E, 1997) |
| "To determine whether high-dose infusional fluorouracil (FU) is effectively modulated by leucovorin (LV), interferon (IFN) alpha-2b, or both when given to patients with metastatic colorectal cancer." | 9.08 | Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. ( Andreesen, R; Bade, J; Dörken, B; Harstick, A; Hecker, H; Hiddemann, W; Horster, A; Käufer, C; Klaasen, U; Köhne, CH; Ohl, U; Schmoll, HJ; Schöffski, P; Schott, G; Schubert, U; Westerhausen, M; Wilke, H, 1998) |
| "The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy." | 9.08 | Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998) |
| "Although the efficacy of 5-fluorouracil (5-FU) modulated by leucovorin is well established for advanced colorectal cancer, the question of the most effective regimen and optimal dose of leucovorin remains unanswered." | 9.08 | A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer. ( Blanc, F; Bons-Rosset, F; Fabbro-Peray, P; Gouze, C; Heran, B; Marçais, O; Perney, P; Ribard, D; Veyrac, M; Ychou, M, 1998) |
| "From February 1995 through October 1996, 25 patients with metastatic colorectal cancer showing a clinical resistance to 5-fluorouracil (5-FU) entered this study." | 9.08 | Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. ( Aapro, MS; Biffi, R; Brienza, S; De Pas, T; deBraud, F; Munzone, E; Nolè, F, 1998) |
| "A wide variety of fluorouracil (FU)-plus-leucovorin (LV) dose schedules are in clinical use for the treatment of advanced colorectal cancer." | 9.08 | The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). ( Bacchi, M; Borner, MM; Castiglione, M; Fey, MF; Goldhirsch, A; Hanselmann, S; Herrmann, R; Leyvraz, S; Morant, R; Pagani, O; Pestalozzi, B; Weber, W, 1998) |
| "5-Fluorouracil and leucovorin combination is the most commonly applied chemotherapy treatment for colorectal cancer patients, both in the adjuvant setting and for advanced disease." | 9.08 | A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracil-pretreated colorectal cancer. ( Botto, F; Ghio, E; Neri, E; Pensa, F; Pronzato, P; Tognoni, A; Vaira, F; Vigani, A, 1998) |
| "Patients with histologically confirmed advanced colorectal cancer were randomized to receive folinic acid (FA; 500 mg/mq in 2-hour intravenous infusion) and 5-fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA), beginning every week for 6 weeks, followed by a 2-week rest period, either without hydroxyurea (HU, arm A) or with HU (35 mg/kg per day) given orally in three administrations (every 8 hours) starting 6 hours after 5FU administration (arm B)." | 9.08 | High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Angiona, S; Belsanti, V; Boni, C; Corgna, E; Di Costanzo, F; Figoli, F; Gasperoni, S; Luppi, G; Malacarne, P; Marzola, M; Passalacqua, R; Sdrobolini, A; Zironi, S, 1998) |
| "To compare raltitrexed (Tomudex; Zeneca Pharmaceuticals Ltd, Macclesfield, United Kingdom) a direct, specific thymidylate synthase (TS) inhibitor with fluorouracil (5-FU) plus high-dose leucovorin (LV) as first-line treatment for advanced colorectal cancer (ACC)." | 9.08 | Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. ( Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G, 1998) |
| "The objective of this multicenter study was to compare the efficacy and toxicity profiles of a combination of 5-fluorouracil (5-FU) given by bolus injection together with intravenous leucovorin (LV) versus high-dose 5-FU in continuous infusion (CI) in the treatment of advanced colorectal cancer." | 9.08 | Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. ( Antón-Torres, A; Aparicio, J; Aranda, E; Barneto, I; Carrato, A; Cervantes, A; Díaz-Rubio, E; García-Conde, J; López-Vega, JM; Massutí, T; Sastre, J; Tabernero, JM; Trés, A, 1998) |
| "Patients with proven metastatic colorectal cancer, which had progressed within 6 months of treatment with fluorouracil, were randomly assigned either 300-350 mg/m2 irinotecan every 3 weeks with supportive care or supportive care alone, in a 2:1 ratio." | 9.08 | Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. ( Awad, L; Cunningham, D; Heikkila, R; Herait, P; Hickish, TF; Jacques, C; James, RD; Johannesen, TB; Punt, CJ; Pyrhönen, S; Starkhammar, H; Topham, CA, 1998) |
| "In phase II trials, irinotecan is active in patients with advanced colorectal cancer, but the survival and clinical benefit of irinotecan compared with second-line fluorouracil by continuous infusion is not known." | 9.08 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. ( Awad, L; Bajetta, E; Bleiberg, H; Herait, P; Jacques, C; Labianca, R; Morant, R; Navarro, M; Niederle, N; Possinger, K; Rougier, P; Van Cutsem, E; Wils, J, 1998) |
| "Data from 12 metastatic colorectal cancer patients who were submitted to a pilot study with a multistep subcutaneous (sc) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) administration were compared with those from 13 historical controls who were comparable for the major prognostic indices." | 9.08 | A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. ( Anselmi, L; Carpi, A; Ferrari, P; Nicolini, A; Sagripanti, A, 1998) |
| "The cumulative pharmacokinetic pattern of oxaliplatin, a new diamminecyclohexane platinum derivative, was studied in patients with metastatic colorectal cancer." | 9.08 | Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ( Allain, P; Boisdron-Celle, M; Bouil, AL; Brienza, S; Cailleux, A; Cvitkovic, E; Delva, R; Gamelin, E; Krikorian, A; Larra, F; Robert, J; Turcant, A, 1997) |
| "We evaluated the pharmacokinetics of 5-fluorouracil (5-FU) combined with recombinant human interferon (IFN)-alpha 2a in 10 previously untreated patients with advanced colorectal carcinoma." | 9.08 | Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma. ( Kim, J; Koss-Twardy, SG; Passe, SM; Patel, IH; Pazdur, R; Satoh, H; Zhi, J, 1998) |
| "Raltitrexed (Tomudex) is currently licensed for first-line treatment of advanced colorectal cancer." | 9.08 | Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer. ( Cunningham, D; Farrugia, DC; Norman, AR, 1998) |
| "This multicenter phase II study was designed to assess the efficacy of the alternating schedule of irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer (CRC)." | 9.08 | A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Barone, C; Cognetti, F; Cote, C; Dirix, L; Filez, L; Garufi, C; Gruia, G; Humblet, Y; Pozzo, C; Starkhammar, H; Terzoli, E; Van Cutsem, E, 1998) |
| "FOLFOX2, a bimonthly regimen of high-dose leucovorin (LV), 48-hour continuous infusion of 5-fluorouracil (5-FU) (LV-5-FU) and oxaliplatin (100 mg/m2) produced a high response rate (46%; 95% confidence interval (95% CI): 31%-60%) in 5-FU pre-treated patients with metastatic colorectal cancer." | 9.08 | Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. ( André, T; de Gramont, A; Louvet, C; Raymond, E; Tournigand, C, 1998) |
| " 439 patients were entered into a phase III trial comparing a novel thymidylate synthase (TS) inhibitor Tomudex (raltitrexed, formerly ZD1694) with 5-FU and leucovorin (LV) for the treatment of advanced colorectal cancer." | 9.08 | Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. ( Kerr, D; Palmer, M; Seymour, L; Zalcberg, J, 1998) |
| "To compare two commonly used schedules of fluorouracil (5FU) and leucovorin in the treatment of patients with advanced metastatic colorectal cancer." | 9.07 | Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. ( Buroker, TR; Gerstner, JB; Gesme, DH; Kardinal, CG; Krook, JE; Levitt, R; Mailliard, JA; O'Connell, MJ; Schaefer, PL; Wieand, HS, 1994) |
| "Eighty-one patients with metastatic or locally advanced colorectal cancer were treated at four oncological centers in Denmark with a regimen consisting of 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 for 5 consecutive days every 4 weeks." | 9.07 | Metastatic or locally advanced colorectal cancer treated with 5-fluorouracil and low dose leucovorin. ( Andersen, LJ; Brunsgaard, NH; Jensen, BB; Mejlholm, I, 1994) |
| "Twenty-one patients with advanced, pretreated colorectal cancer in disease progression were entered in a phase II study to investigate the use of 5-fluorouracil (5FU) + leucovorin with subcutaneous Interleukin-2 + alpha interferon (alpha-IFN)." | 9.07 | A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon. ( Amadori, D; Fedriga, R; Flamini, E; Maltoni, R; Milandri, C; Pezzi, L; Riccobon, A; Ridolfi, R; Santoni, A; Velotti, F, 1994) |
| "In a previous phase II trial, circadian (chronomodulated) delivery of fluorouracil (5-FU), folinic acid (FA; leucovorin), and oxaliplatin (1-OHP; a new platinum complex with no renal and minor hematologic toxic effects) produced an objective response rate of 58% in 93 patients with metastatic colorectal cancer." | 9.07 | Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. ( Chollet, P; Dogliotti, L; Faggiuolo, R; Focan, C; Garufi, C; Itzhaki, M; Lévi, FA; Perpoint, B; Vannetzel, JM; Zidani, R, 1994) |
| "Interferon alpha (IFN-alpha) enhances the activity of 5-fluorouracil (5-FU) in the treatment of advanced colorectal cancer although the mechanism is not understood." | 9.07 | The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer. ( Nichols, PH; Primrose, JN; Ramsden, CW; Ward, U, 1994) |
| "A total of 101 patients with advanced colorectal cancer in two consecutive Southern Italian Oncology Groups (GOIM) studies (8501 and 8801--arm A) were treated with a sequential combination of high dose methotrexate (HDMTX) and fluorouracil (FU)." | 9.07 | Sequential treatment with high-dose methotrexate and fluorouracil in advanced colorectal cancer. Experience of the Southern Italian Oncology Group (GOIM). ( Colucci, G; Giotta, F; Giuliani, F; Leo, S; Maiello, E; Pedicini, A; Pezzella, G; Prete, F; Romito, S; Valori, V, 1994) |
| "In an attempt to evaluate the feasibility of 5-fluorouracil (FU) treatment modulated by (R,S)-leucovorin (LV) and interferon alpha (IFN alpha) in patients with advanced colorectal cancer, we conducted a phase I trial with increasing doses of subcutaneous IFN alpha (3 x 1 x 10(6) U, 3 x 3 x 10(6) U, 3 x 3 x 10(6) U, 3 x 5 x 10(6) U and 3 x 10 x 10(6) U/week) and 500 mg/m2 LV i." | 9.07 | Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration. ( Djavanmard, MP; Gnant, MF; Jakesz, R; Locker, G; Mader, RM; Marosi, C; Rainer, H; Steger, GG, 1994) |
| "The management of patients with advanced colorectal cancer remains dependent on the optimal use of 5-Fluorouracil (5-FU)." | 9.07 | Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer. ( Carter, R; Cunningham, D; Evans, C; Findlay, M; Ford, H; Hill, A; Husband, J; Nicolson, M; Norman, A, 1994) |
| "Twenty-two patients with metastatic colorectal cancer entered a Phase I-II trial to assess the maximum tolerable dose of alpha-2B-interferon administered intramuscularly three times per week in combination with fixed doses of 5-fluorouracil (450 mg/m2 IV for 5 days, and, from day 28, weekly) and folinic acid (200 mg/m2 IV before 5-fluorouracil) and the efficacy of this combination." | 9.07 | Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients. ( Bertuccelli, M; Brunetti, I; Cianci, C; Conte, PF; Falcone, A; Ricci, S, 1994) |
| "5-Fluorouracil (5-FU), when combined with leucovorin (LV) or interferon-alpha (IFN-alpha), may result in improved response rates compared with 5-FU alone in patients with advanced colorectal cancer." | 9.07 | Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study. ( Burghouts, JT; Croles, JJ; de Mulder, PH; Kamm, Y; Punt, CJ; van Liessum, PA, 1993) |
| " The purpose of this study was to compare its therapeutic effect with a standard fluorouracil (FU) regimen in patients with locally advanced or metastatic colorectal cancer." | 9.07 | Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. ( Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993) |
| "25 patients with metastatic colorectal cancer were entered into a phase II trial of combination chemoimmunotherapy using a sequential regimen of 5-fluorouracil (5-FU) and leucovorin and high-dose recombinant human interleukin-2 (rIL-2)." | 9.07 | Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. ( Landry, JG; Ritchey, JL; Rosenberg, SA; Shlasko, E; White, DE; Yang, JC, 1993) |
| "A prospectively randomized trial was performed to determine whether the combination of fluorouracil (FU) plus leucovorin (FU-LV) administered orally is more effective than equitoxic FU for patients with metastatic colorectal cancer." | 9.07 | A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. ( Brenckman, WD; Bukowski, RM; Clendennin, NJ; Collier, MA; Guaspari, A; Laufman, LR; McKinnis, RA; Sullivan, BA, 1993) |
| "Biochemical modulation of bolus fluorouracil (5-FU) by addition of leucovorin to the treatment regimen has increased response in patients with disseminated colorectal cancer from fewer than 20% to more than 40%." | 9.07 | Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. ( Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Rosen, PJ; Spears, CP, 1993) |
| "Thirty-one patients with hepatic metastases from colorectal carcinoma were treated with carboplatin (CBDCA), 55 mg/m2, given in a 4-hour intra-arterial infusion daily for 5 days, and 5-fluorouracil, 900 mg/m2, given in a 20-hour intra-arterial infusion daily for 5 days." | 9.07 | Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma. ( Abuchaibe, O; Bilbao, I; Hidalgo, OF; Pardo, F; Rebollo, J; Tangco, E; Vieitez, JM, 1993) |
| " This prospective phase II study evaluates the efficacy and toxicity of hepatic arterial infusion of 5-Fluorouracil (5-FU) via an implantable Infusaid pump in previously untreated patients with localised but unresectable hepatic metastases from colorectal cancer." | 9.07 | Continuous hepatic artery infusion of 5-fluorouracil for metastatic colorectal cancer localised to the liver. ( Boyle, FM; Levi, JA; Smith, RC, 1993) |
| "We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer." | 9.07 | Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. ( Erlichman, C; Fine, S; Gadalla, T; Steinberg, J; Wong, A, 1992) |
| "From January 31, 1986 to January 31, 1989, 184 eligible patients were enrolled in a randomized study of either infusional or bolus 5-fluorouracil (5-FU) for the treatment of metastatic measurable colorectal cancer." | 9.07 | Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. ( Bogues, W; Cripps, IC; Fields, A; Maroun, J; McCormick, R; Pater, J; Shah, A; Temple, W; Weinerman, B; Wilson, K, 1992) |
| "Because of the different sites and mechanisms of biochemical interaction among 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN), we hypothesized that the concomitant use of IFN could increase the activity of the 5-FU/LV combination in colorectal cancer patients." | 9.07 | Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. ( Cascinu, S; Catalano, G; Fedeli, A; Fedeli, SL, 1992) |
| "15 untreated patients with advanced measurable colorectal cancer along with other 29 patients in progression after failing first line chemotherapy with fluoropyrimidines received 5-fluorouracil (5FU) 500 mg/m2 given as a weekly bolus at mid-infusion of leucovorin (LV), 500 mg/m2 administered intravenously over 2 h and interferon alpha 2b (IFN) 3 x 10(6) U given intramuscularly every other day." | 9.07 | Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer. ( Aschele, C; Bolli, E; Bruzzi, P; Gallo, L; Guglielmi, A; Mori, A; Nobile, MT; Parodi, GC; Sobrero, A; Tixi, L, 1992) |
| "A high rate of response to 5-fluorouracil (5FU) and alpha-interferon (alpha IFN) combination therapy has been reported in metastatic colorectal cancer patients." | 9.07 | Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992) |
| "One hundred sixty consecutive patients with histologically confirmed colorectal cancer (advanced disease) without prior chemotherapy were entered in a randomized trial comparing 5-fluorouracil (5-FU) 1,000 mg/m2 intravenously per day for 5 consecutive days in continuous infusion versus cisplatin (CP) 100 mg/m2 on day 1 plus 5-FU as described on days 2 to 6." | 9.07 | A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). ( Antón, A; Aranda, E; Belón, J; Carrato, A; Cruz-Hernández, J; Díaz-Rubio, E; Jimeno, J; Martin, M; Massuti, B; Sánchez, J, 1992) |
| "Treatment results in advanced colorectal cancer have improved during the last decade since the incorporation of agents like folinic acid, PALA, or interferon as active biomodulation of 5-fluorouracil (5-FU), the most potent drug in this disease." | 9.07 | A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation. ( Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992) |
| "Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2." | 9.07 | Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial. ( Günther, E; Hinrichs, HF; Hirschmann, WD; Koniczek, KH; Natt, F; Sondern, W; Steinke, B; Wagner, T; Wander, HE; Werdier, D, 1992) |
| "Several reports on fluorouracil (5-FU) and alfa interferon (IFN-alpha) combination therapy in patients with advanced colorectal cancer have been published." | 9.07 | Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992) |
| "In a clinical phase II study, 23 patients with progressive metastatic colorectal cancer and failure after first-line chemotherapy with fluorouracil (5-FU) and folinic acid (FA) were treated with a 5-day continuous infusion of recombinant interleukin-2 (IL-2), 3 x 10(6) cetus U/m2/d, followed after a rest period of 2 days by 5-FU, 600 mg/m2/d, and FA, 300 mg/m2/d over an additional 3 days." | 9.07 | Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer--results of a clinical phase II study. ( Hiddemann, W; Koch, O; Musch, E; Ottensmeier, C; Rückle, H; Ruelfs, C; van de Loo, J, 1992) |
| "One hundred eighty-one patients with measurable recurrent or metastatic colorectal cancer, who had not received prior chemotherapy, were randomized in a prospective controlled trial to receive 5-fluorouracil (5FU), 13." | 9.07 | Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). ( Bacchi, M; Bartolucci, R; Belsanti, V; Boni, C; Calabresi, F; Di Costanzo, F; Marzola, M; Sofra, M, 1992) |
| "5-Fluorouracil (5-FU) remains the most effective chemotherapeutic agent in the management of patients with metastatic colorectal cancer." | 9.07 | Treatment of advanced colorectal cancer by 5-fluorouracil-leucovorin combination with or without allopurinol: a prospective randomized study. ( Chaitchik, S; Inbar, M; Merimsky, O, 1991) |
| "To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer." | 9.07 | A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991) |
| "Hepatic intra-arterial (HIA) infusion of floxuridine (FUDR) via an implanted pump has shown promise in the treatment of colorectal cancer metastasized to the liver." | 9.07 | Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. ( Chase, JL; Grobman, BJ; Hohn, DC; Lewis, BJ; Mulvihill, SJ; Rayner, AA; Roh, M; Stagg, RJ; Venook, AP; Warren, RS, 1991) |
| "Effectiveness, toxicity and complications of 5-fluorouracil (FU) and mitomycin-C (MMC) treatment were analyzed in 30 patients with metastatic colorectal cancer confined to the liver." | 9.07 | Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. ( Largiadèr, F; Metzger, U; Röthlin, M; Weder, W, 1991) |
| "A phase I study of 5-fluorouracil 600 mg/m2/week and folinic acid 500 mg/m2/week on day 1 and cisplatin administered weekly on day 2 was carried out on 30 patients with metastatic colorectal carcinoma of which 20 patients were pretreated with 5-fluorouracil." | 9.07 | A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma. ( Creaven, P; Gebbia, N; Gebbia, V; Palmeri, S; Petrelli, N; Rausa, L; Russo, A; Rustum, Y, 1991) |
| "In a previous study (J Clin Oncol 7:1407-1417, 1989), we identified two dosage administration schedules of fluorouracil (5FU) combined with leucovorin that were superior to single-agent 5FU for the treatment of advanced colorectal cancer." | 9.07 | Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. ( Gerstner, JB; Kardinal, CG; Krook, JE; Levitt, R; Mailliard, JA; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1991) |
| "The importance of the interval between methotrexate (MTX) and fluorouracil (5-FU) was studied in 168 patients with previously untreated, measurable, advanced colorectal cancer." | 9.07 | The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. ( Bertino, JR; Capizzi, RL; Davis, CA; Durivage, HJ; Farber, LR; Katz, KH; Marsh, JC; Pasquale, DN; Richards, F; Rome, LS, 1991) |
| "Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection." | 9.06 | Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990) |
| "Pursuant to a promising report suggesting that an allopurinol mouthwash could have a protective effect against 5-fluorouracil (5-FU)-induced stomatitis, the authors performed a randomized, placebo-controlled, double-blind, crossover study." | 9.06 | A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. ( Athmann, LM; Burnham, NL; Cianflone, SG; Cross, M; Dose, AM; Etzell, PS; Gainey, DK; Hagen, L; Loprinzi, CL; Therneau, TM, 1990) |
| "We have performed a prospective randomized controlled study of 5-fluorouracil (5FU) + leucovorin versus 5FU alone in patients with metastatic colorectal cancer." | 9.06 | Fluorouracil and leucovorin for metastatic colorectal cancer. ( Erlichman, C, 1990) |
| "A novel sequential administration schedule of PALA (N-phosphonoacetyl-L-aspartate) and thymidine to enhance the cytotoxic effect of 5-fluorouracil (5FU) was tested in 36 patients with advanced gastric cancer and 21 patients with advanced poorly differentiated (anaplastic) colorectal cancer." | 9.06 | A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. ( Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE, 1990) |
| "A total of 21 untreated patients (5 males, 16 females; median age, 55 years; range, 28-72) with advanced measurable colorectal carcinoma were treated with an association of 5-fluorouracil (1000 mg/weekly) and alpha-2 interferon (three times a week s." | 9.06 | Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer. ( Aversa, SM; Daniele, O; Fiorentino, MV; Fornasiero, A; Ghiotto, C; Morandi, P, 1990) |
| "Four single-arm trials using methotrexate (M), 5-fluorouracil (5FU), and leucovorin (L) were sequentially performed in metastatic measurable colorectal cancer using different dosing and timing schedules for the three drugs." | 9.06 | Sequential methotrexate, 5-fluorouracil, and leucovorin in metastatic measurable colorectal cancer. Does it work? ( Cripps, C; Johnston, J; Maroun, J; Stewart, D; Weinerman, B, 1990) |
| "A prospective controlled randomized trial testing adjuvant postoperative combination chemotherapy (5-fluorouracil, lomustine (CCNU) and vincristine) versus no adjuvant therapy in patients operated on for Dukes' C colorectal cancer is reported." | 9.06 | Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group. ( Asklöf, G; Bergman, L; Domellöf, L; Hafström, L; Hansson, K; Kugelberg, C; Nilsson, T; Norryd, C; Rudenstam, CM; Wählby, L, 1990) |
| "The Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) conducted a randomized clinical trial comparing five different combination chemotherapeutic regimens to single-agent 5-fluorouracil (5-FU), given by intravenous bolus technique (500 mg/m2 for 5 days) as a control, in the treatment of advanced colorectal cancer." | 9.06 | A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. ( O'Connell, MJ, 1989) |
| "Ninety-one patients with metastatic colorectal cancer were treated with continuous ambulatory 5-fluorouracil (5FU) infusion 250-300 mg/m2/day through a chronic indwelling central venous catheter." | 9.06 | Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients. ( Anderson, T; Ausman, R; Beatty, P; Frick, J; Haas, C; Hansen, R; Quebbeman, E; Ritch, P; Schulte, W, 1989) |
| "5-Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal cancer (CRC) in the palliative and adjuvant settings." | 9.05 | 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. ( Buchler, T; Cervena, K; Veskrnova, V; Vodenkova, S; Vodicka, P; Vymetalkova, V, 2020) |
| "We performed the present systematic review and meta-analysis to evaluate the efficacy and safety for S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma (mCRC)." | 9.01 | Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis. ( Chen, J; Wang, J, 2019) |
| "5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers." | 8.98 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018) |
| "The clinical benefit of double-front-line therapy (including oxaliplatin or irinotecan or bevacizumab plus 5-fluorouracil (5FU) or capecitabine) compared to monotherapy (5FU or capecitabine) in elderly (> 70 years) patients with metastatic colorectal cancer (MCRC) is controversial." | 8.98 | Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. ( Aparicio, T; Ghebriou, D; Guetz, GD; Landre, T; Maillard, E; Taleb, C; Zelek, L, 2018) |
| "Nowadays, systemic chemotherapy with intravenous (IV) 5-fluorouracil (5-FU) remains the most commonly prescribed treatment for metastatic colorectal cancers (CRC), in combination with other cytotoxic drugs." | 8.98 | Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis. ( Deng, Y; Wu, Z, 2018) |
| "The antiangiogenic monoclonal antibody aflibercept in association with fluorouracil and irinotecan improves the survival of patients with metastatic colorectal cancer (mCRC) treated previously with oxaliplatin-based therapy." | 8.93 | Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. ( Ciuffreda, L; Fanchini, L; Mecca, C; Pinta, F; Ponzetti, A; Racca, P; Spadi, R; Zanini, M, 2016) |
| "Capecitabine is a tumor-activated oral fluoropyrimidine used in breast and colorectal cancer." | 8.91 | Hypertriglyceridemia and hyperglycemia induced by capecitabine: a report of two cases and review of the literature. ( Han, GH; Huang, JX, 2015) |
| "The relative efficacy and safety of first-line metastatic colorectal cancer (mCRC) treatment regimens, capecitabine with irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI), are not well defined." | 8.91 | Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI). ( Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD, 2015) |
| "The National Institute for Health and Care Excellence (NICE) invited the manufacturer of aflibercept (Sanofi) to submit clinical and cost-effectiveness evidence for aflibercept in combination with irinotecan and fluorouracil-based therapy [irinotecan/5-fluorouracil/folinic acid (FOLFIRI)] for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy, as part of the Institute's Single Technology Appraisal process." | 8.91 | The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of ( Duarte, A; Duffy, S; Rodriguez-Lopez, R; Simmonds, M; Spackman, E; Wade, R; Woolacott, N, 2015) |
| "5-fluorouracil continues to be the cornerstone of treatment for colorectal cancer." | 8.90 | Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. ( Avallone, A; Budillon, A; Di Gennaro, E; Iaffaioli, VR; Silvestro, L, 2014) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 8.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| "Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line treatments of metastatic colorectal cancer." | 8.90 | A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. ( Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P, 2014) |
| "Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based." | 8.89 | Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. ( Cool, M; Deboever, G; Hiltrop, N; Lambrecht, G, 2013) |
| "The aim of this pooled-analysis is to evaluate the benefit of capecitabine (C) versus standard intravenous 5-Fluorouracil (5-FU) as monochemotherapy or combination therapy in advanced colorectal cancer (CRC) in terms of safety and efficacy." | 8.88 | 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials. ( Barni, S; Cabiddu, M; Petrelli, F, 2012) |
| "To evaluate the benefit and safety of fluorouracil implants on colorectal cancer." | 8.88 | [Fluorouracil implants for colorectal cancer: a systematic review and meta-analysis]. ( Chen, JR; Huang, Y; Li, YL; Nie, YL; Zhang, MM, 2012) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "We performed a computerized search using combinations of the following keywords: "metastatic colorectal cancer," "Xeloda," "chemotherapy," "capecitabine," or "5-fluorouracil." | 8.87 | Capecitabine-based chemotherapy for metastatic colorectal cancer. ( Fan, J; Ling, W; Ma, Y; Wang, H, 2011) |
| "We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer." | 8.86 | A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. ( Chen, ML; Dai, LH; Fang, CH; Liang, LS; Wang, XK, 2010) |
| "A meta-analysis of randomized controlled trials (RCT) was carried out to determine the efficacy and safety of capecitabine plus oxaliplatin (CAPOX) or fluorouracil plus oxaliplatin (FUOX) as first-line treatment for metastatic colorectal cancer (MCRC)." | 8.86 | Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis. ( Gao, P; Ma, B; Tian, JH; Yang, KH; Zhao, G, 2010) |
| ", Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC)." | 8.86 | Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. ( Boehm, KA; Cartwright, T; McCollum, D, 2010) |
| "Capecitabine, an oral prodrug of 5-fluorouracil, is indicated for adjuvant treatment in patients with Dukes' C colon cancer and for subsequent lines in metastatic colorectal cancer." | 8.86 | Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer. ( Best, JH; Garrison, LP, 2010) |
| "Capecitabine is an oral fluoropyrimidine that is shown to have similar efficacy to 5-fluorouracil (5-FU) when used both alone and in combination with oxaliplatin in the treatment of colorectal cancer (CRC)." | 8.86 | Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. ( Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F, 2010) |
| "Literature searches from large publication databases (PubMed, ASCO, ASCO GI, ESMO) were performed to capture key data relevant to bevacizumab, irinotecan, and the treatment of colorectal cancer." | 8.86 | Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. ( Heinemann, V; Hoff, PM, 2010) |
| "To compare clinical efficacy and toxicity of irinotecan combined with 5-fluorouracil and leucovorin with those of oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer." | 8.86 | Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis. ( Hou, SH; Li, YP; Liang, XB; Wang, LC; Yang, J; Zhang, X, 2010) |
| "Capecitabine (N -pentyloxycarbonyl-5-deoxy-5-fluorocytidine), an oral prodrug of 5-fluorouracil, has provided compelling efficacy data for the treatment of metastatic breast cancer and stage III or IV colorectal cancer, both as monotherapy and in combination regimens." | 8.85 | Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. ( Aprile, G; Mazzer, M; Moroso, S; Puglisi, F, 2009) |
| "Relevant studies were identified in PubMed, Ovid, Cochrane database and the American Society of Clinical Oncology abstracts using the following search terms: gemcitabine, fluorouracil, capecitabine and colorectal cancer." | 8.85 | Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512). ( Hoimes, C; Merl, M; Pham, T; Saif, MW, 2009) |
| " In this review, we summarized the current status of our knowledge about the effectiveness of curcumin when given in combination with current chemotherapeutics such as 5-fluorouracil, oxaliplatin, and gemcitabine in treatment of gastrointestinal cancers with particular reference to colorectal cancer." | 8.85 | Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. ( Majumdar, AP; Patel, BB, 2009) |
| "Continuous-infusion 5-fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin is a frequently used regimen in metastatic colorectal cancer." | 8.84 | Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer? ( Bennouna, J; Douillard, JY; Senellart, H, 2008) |
| "Six randomized phase II and III trials have investigated the role of oxaliplatin (OX) in combination with capecitabine (CAP) or infusional fluorouracil (FU) in metastatic colorectal cancer." | 8.84 | Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. ( Arkenau, HT; Arnold, D; Cassidy, J; Diaz-Rubio, E; Douillard, JY; Grothey, A; Hinke, A; Hochster, H; Martoni, A; Porschen, R; Schmiegel, W; Schmoll, HJ, 2008) |
| "5-fluorouracil (5FU)-based treatments remain the main chemotherapy for colorectal cancer." | 8.84 | Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. ( Etienne-Grimaldi, MC; Formento, JL; Francoual, M; Milano, G, 2007) |
| "Based on improved safety and efficacy results, advanced colorectal cancer (CRC) treatment has recently shifted from intravenous bolus 5-fluorouracil (5-FU) monotherapy to standard combinations of prolonged intravenous 5-FU infusion with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI)." | 8.84 | Capecitabine plus oxaliplatin for the treatment of colorectal cancer. ( Carrato, A; Gallego-Plazas, J; Guillén-Ponce, C, 2008) |
| "Uncertainty exists about whether elderly patients benefit to the same extent as younger patients from combination therapy with irinotecan in the first-line treatment of metastatic colorectal cancer (CRC)." | 8.84 | Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. ( Douillard, JY; Folprecht, G; Hecker, H; Köhne, CH; Maughan, TS; Mitry, E; Rougier, P; Saltz, L; Schubert, U; Seymour, MT; Stephens, RJ; Van Cutsem, E, 2008) |
| "Capecitabine, an oral prodrug of fluorouracil (5FU), has shown efficacy in terms of progression-free and overall survival at least equivalent to standard folinic acid (leucovorin)-modulated intravenous 5FU bolus regimens in patients with metastatic colorectal cancer." | 8.84 | Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence. ( Avallone, A; Casaretti, R; Comella, P; Franco, L; Sandomenico, C, 2008) |
| "To evaluate three technologies for the management of advanced colorectal cancer: (1) first-line irinotecan combination [with 5-fluorouracil (5-FU)] or second-line monotherapy; (2) first- or second-line oxaliplatin combination (again, with 5-FU); and (3) raltitrexed, where 5-FU is inappropriate." | 8.84 | The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. ( Eggington, S; Hind, D; Ryan, A; Sutcliffe, P; Tappenden, P; Tumur, I, 2008) |
| "In a dozen years of development, irinotecan (CPT11) became one of major therapeutics in the taking care of the metastatic colorectal cancer (CCRM)." | 8.83 | [Irinotecan for the treatment of metastatic colorectal cancer]. ( Assenat, E; Duffour, J; Ychou, M, 2006) |
| "A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients." | 8.83 | [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006) |
| " A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia." | 8.83 | Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006) |
| "Oxaliplatin, fluorouracil, and leucovorin are commonly used to treat advanced and resected colorectal cancer." | 8.83 | Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. ( Andre, T; Bleiberg, H; de Gramont, A; Goldberg, RM; Green, E; Rothenberg, ML; Sargent, DJ; Tabah-Fisch, I; Tournigand, C, 2006) |
| "During the last decade, considerable progress has been made in the development of 5-fluorouracil/leucovorin (5-FU/LV) regimens that optimize antitumor efficacy while minimizing toxicity in the management of colorectal cancer." | 8.82 | Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer. ( de Gramont, A; Kuebler, JP, 2003) |
| "To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens." | 8.82 | Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. ( Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S, 2003) |
| "Four phase III clinical trials comparing a fluorouracil-based regimen with the same regimen plus either CPT-11 or oxaliplatin in advanced colorectal cancer patients were reviewed." | 8.82 | Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. ( Bleiberg, H; Buyse, M; Di Leo, A, 2004) |
| "Fluorouracil (FU)-leucovorin (LV), irinotecan, and oxaliplatin administered alone or in combination have proven effective in the treatment of advanced colorectal cancer (CRC)." | 8.82 | Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. ( Goldberg, RM; Grothey, A; Sargent, D; Schmoll, HJ, 2004) |
| "Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine." | 8.82 | Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). ( Hoff, P; Lassere, Y, 2004) |
| "The modulation of fluorouracil (FU) by folinic acid (leucovorin [LV]) has been shown to be effective in terms of tumor response rate in patients with advanced colorectal cancer, but a meta-analysis of nine trials previously published by our group failed to demonstrate a statistically significant survival difference between FU and FU-LV." | 8.82 | Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. ( Braud, AC; Buyse, M; Carlson, RW; Michiels, S; O'Connell, M; Piedbois, P; Pignon, JP; Sargent, P; Thirion, P, 2004) |
| "Hand-foot syndrome is a localized cutaneous side effect associated with the administration of several chemotherapeutic agents, including the oralfluoropyrimidine capecitabine (Xeloda)." | 8.82 | Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. ( Blum, J; Scheithauer, W, 2004) |
| "New results presented at ASCO Conference in 2003 added further important data to our knowledge on successful use of irinotecan in colorectal cancer (CRC)." | 8.82 | [Recent results of irinotecan therapy in colorectal cancer]. ( Hitre, E; Láng, I, 2004) |
| "Variations of fluorouracil (5-FU) therapy have formed the backbone of chemotherapy for advanced colorectal cancer for many years." | 8.82 | Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics. ( Hwang, JJ, 2004) |
| "In 2002, the UK National Institute for Clinical Excellence (NICE) issued guidance on the use of irinotecan, oxaliplatin and raltitrexed in advanced colorectal cancer." | 8.82 | The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. ( Poston, GJ, 2005) |
| "Irinotecan is a cornerstone drug in the management of metastatic colorectal cancer, as demonstrated by several randomized studies proving a survival benefit for the first time." | 8.82 | Irinotecan-based regimens in the adjuvant therapy of colorectal cancer. ( Douillard, JY, 2005) |
| "Capecitabine is active against anthracycline- and taxane-pretreated metastatic breast cancer." | 8.82 | Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. ( Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V, 2005) |
| "We examined the cardiotoxicity in 153 patients treated with capecitabine and oxaliplatin in two prospective trials for advanced colorectal cancer." | 8.82 | The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). ( Cunningham, D; Ng, M; Norman, AR, 2005) |
| "For more than 40 years, 5-fluorouracil (5-FU) has been considered the most effective systemic agent for managing advanced colorectal cancer." | 8.82 | Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. ( Saif, MW, 2005) |
| "The combination of capecitabine (Xeloda) and oxaliplatin (Eloxatin), or XELOX, is an effective and safe approach to the treatment of advanced colorectal cancer, with the potential advantage of convenience over standard combination regimens." | 8.81 | Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? ( Twelves, C, 2002) |
| "In this review, the clinical rationale and update of the present clinical status of irinotecan in the treatment of colorectal cancer and future prospects of irinotecan-based combinations are discussed." | 8.81 | Irinotecan in the treatment of colorectal cancer: clinical overview. ( Achterrath, W; Cao, S; Harstrick, A; Rustum, YM; Seeber, S; Vanhoefer, U, 2001) |
| "Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) both have demonstrated single-agent activity in patients with colorectal cancer." | 8.81 | Capecitabine/irinotecan combination regimens in colorectal cancer. ( Kerr, DJ, 2002) |
| "The administration of fluorouracil (5-FU) by continuous intravenous infusion (CI) is an alternative to the bolus administration of 5-FU in patients with advanced colorectal cancer." | 8.80 | Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Levy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, J; Rougier, P; Ryan, L; Weinerman, B; Zee, B, 1998) |
| "5-Fluorouracil (5-FU) remains the agent of choice for the treatment of colorectal cancer." | 8.80 | Biomodulation of Fluorouracil in colorectal cancer. ( Ardalan, B; Franceschi, D; Jaime, M; Luis, R, 1998) |
| "Oxaliplatin was first introduced to the clinical setting as a combination therapy with 5-fluorouracil/folinic acid (5-FU/FA) in an attempt to improve the response rate obtained with 5-FU/FA against colorectal cancer." | 8.80 | Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. ( Bleiberg, H; de Gramont, A, 1998) |
| "The addition of leucovorin (LV) to 5-fluorouracil (5-FU) in advanced colorectal cancer has shown improved tumour response rates in many trials, but the optimal LV/5-FU regimen has yet to be determined." | 8.80 | A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). ( André, T; de Gramont, A; Krulik, M; Louvet, C; Tournigand, C, 1998) |
| "But fluorouracil (5-FU) and irinotecan (CPT-11 [Camptosar]) have shown activity in metastatic colorectal cancer and are approved for its treatment in the United States." | 8.80 | Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. ( Erlichman, C; Goldberg, RM, 1998) |
| "Salvage treatment with 5-fluorouracil (5-FU) with or without leucovorin may induce responses in patients with advanced colorectal cancer whose disease progresses after adjuvant therapy with the same drugs." | 8.80 | Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? ( Goldberg, RM, 1998) |
| "Therapeutic options after failure of 5-fluorouracil (5-FU) for the treatment of colorectal cancer include regional treatments, different 5-FU-based regimens, and different chemotherapy regimens." | 8.80 | Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. ( Henderson, CA, 1998) |
| "Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with advanced colorectal cancer, but the survival difference between the two treatments is small and, therefore, the difference in toxicity profile is crucial in choosing a treatment for individual patients." | 8.80 | Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Lévy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, JP; Quinaux, E; Rougier, P; Ryan, L; Thirion, P; Weinerman, B; Zee, B, 1998) |
| "The final results of two very important randomized trials of irinotecan (Campto, Rhône-Poulenc Rorer, Antony, France) as second-line treatment for patients with advanced colorectal cancer are presented." | 8.80 | Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice. ( Cunningham, D, 1999) |
| "Irinotecan, also known as CPT-11, is a topoisomerase I inhibitor currently approved for use as a second-line agent in the treatment of advanced colorectal cancer." | 8.80 | The role of irinotecan in colorectal cancer. ( Saltz, LB, 1999) |
| "Two randomized phase III trials with irinotecan as second-line treatment of metastatic colorectal cancer have shown that irinotecan (CPT-11, Camptosar) significantly improves survival when compared with best supportive care or continuous infusion of fluorouracil (5-FU) after failure of 5-FU." | 8.80 | Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. ( Douillard, JY, 2000) |
| "5-Fluorouracil (5-FU) is the most active single agent for treatment of advanced colorectal cancer, although objective responses occur in only 20% of patients, and there seems to be no impact on overall survival." | 8.79 | Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials. ( Raderer, M; Scheithauer, W, 1995) |
| "Even though fluorouracil (5FU) remains the standard treatment of advanced colorectal cancer, almost 90% of patients treated with 5FU alone do not achieve an objective response to chemotherapy." | 8.79 | Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. ( , 1994) |
| "Possible prognostic variables for tumor response, time to progression (TTP), and survival in 141 patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy were analyzed." | 8.79 | Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. ( Fountzilas, G; Gossios, K; Pavlidis, N; Skarlos, D; Svarna, E; Zisiadis, A, 1996) |
| "CPT-11 (Campto, irinotecan) is a new topoisomerase I inhibitor and one of very few new cytotoxic agents to demonstrate clinical activity in colorectal cancer since the introduction of 5-fluorouracil (5-FU) into clinical practice almost 40 years ago." | 8.79 | CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. ( Khayat, D; Saltz, L; Shimada, Y, 1996) |
| "Several modifications to the administration schedule of 5-fluorouracil (5-FU) alone or in combination with other agents have been investigated in advanced colorectal cancer." | 8.79 | Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies. ( Facendola, G; Labianca, R; Luporini, G; Pessi, A; Pirovano, M, 1996) |
| "All of the published adjuvant studies for colorectal cancer in which 5-FU (either as a single agent or in combination with other cytotoxics or levamisole) was compared to a no-treatment control group were ranked according to the total planned dose of 5-FU (assuming a body weight of 70 kg or a body surface area of 1." | 8.79 | The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. ( Siderov, J; Simes, J; Zalcberg, JR, 1996) |
| "The rational of leucovorin modulation of 5-fluorouracil and the clinical results in colorectal cancer are reviewed with special emphasis on the monthly schedule of low dose leucovorin and 5FU bolus for 5 consecutive days (NCCTG-Mayo Clinic regimen) and the bimonthly schedule of high-dose leucovorin and 5FU bolus plus continuous infusion for two consecutive days (LV5FU2) which is now considered as a new standard." | 8.79 | [Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)]. ( André, T; de Gramont, A; Krulik, M; Louvet, C; Molitor, JL; Raymond, E; Tournigand, C, 1997) |
| "A variety of 5-fluorouracil (5-FU)- based chemotherapy regimens have been investigated in colorectal cancer patients in randomized trials over the past decade." | 8.79 | Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin. ( Grem, JL, 1997) |
| "A meta-analysis was performed on nine randomized clinical trials that compared fluorouracil (5-FU) with 5-FU plus intravenous (IV) leucovorin (LV) for the treatment of advanced colorectal cancer." | 8.78 | Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. ( , 1992) |
| "Three clinical trials have been conducted with fluorouracil (5-FU) and recombinant interferon alfa-2a (rIFN-alpha 2a) in the treatment of advanced colorectal carcinoma." | 8.78 | Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas. ( Bready, B; Moore, DF; Pazdur, R, 1991) |
| "Seventy-five previously untreated patients with measurable advanced colorectal cancer were treated with 5 fluorouracil 1,000 mg/m2 as a 24-hour intravenous (i." | 8.78 | 120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer. ( Aguilo, J; Asencio, F; Candel, MT; Delgado, F; García-Reinoso, J; Martínez-Abad, M; Sánchez, JJ; Sanchis, C; Viciano, V; Villar-Grimalt, A, 1991) |
| "5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent for colorectal cancer (CRC) owing to its potent anticancer effects." | 8.31 | 5-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy. ( Bae, J; Hee Lee, E; Kim, H; Kim, J; Kim, MS; Kwak, D; Lee, J; Phyu Hlaing, S; Ryong Moon, H; Saparbayeva, A; Yoo, JW; Yoon, IS, 2023) |
| "5-Fluorouracil (5-FU) represents the cornerstone for colorectal cancer therapy." | 8.31 | Enhancement of the antitumor effect of 5-fluorouracil with modulation in drug transporters expression using PI3K inhibitors in colorectal cancer cells. ( Abo-Elfadl, MT; Abo-Zeid, MAM; El-Daly, SM; Hussein, J, 2023) |
| "As EIF3D is oncogenic in colorectal cancer (CRC) and is associated with multidrug resistance, this study aims to investigate whether and how EIF3D regulates resistance to 5-fluorouracil (5-Fu) in CRC." | 8.31 | EIF3D promotes resistance to 5-fluorouracil in colorectal cancer through upregulating RUVBL1. ( Du, W; Li, C; Liang, Z; Lu, K; Yang, C, 2023) |
| "5-Fluorouracil (5-Fu) is a first-line drug for colorectal cancer (CRC) therapy." | 8.31 | Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells. ( Chen, A; Chen, W; Chen, Z; Dai, W; Jiang, R; Li, X; Ling, Y; Ma, Y; Ni, M; Wu, J; Yao, Q; Zhou, Y, 2023) |
| " In this study, 5-fluorouracil (5FU) was loaded into ruthenium (Ru)-based nanocarrier (5FU-RuNPs) for the first time to eliminate the disadvantages of 5FU, and its cytotoxic and apoptotic effects on HCT116 colorectal cancer cells were compared with free 5FU." | 8.31 | The Novel 5-Fluorouracil Loaded Ruthenium-based Nanocarriers Enhanced Anticancer and Apoptotic Efficiency while Reducing Multidrug Resistance in Colorectal Cancer Cells. ( Bulut, H; Danişman-Kalindemirtaş, F; Kariper, İA; Özerkan, D, 2023) |
| "We evaluated the pharmacokinetics and pharmacodynamics/toxicodynamics of uracil-tegafur (UFT) after multiple administrations in colorectal cancer (CRC) model rats, and applied a pharmacometric approach to describe the time-course alterations of plasma 5-FU concentrations and tumor shrinkage." | 8.31 | A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model. ( Ito, Y; Kobuchi, S; Nakamura, T; Okamura, M; Tsuda, M, 2023) |
| "Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory BRAFV600E metastatic colorectal cancer (mCRC)." | 8.31 | Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. ( Altucci, L; Anderson, A; Ciardiello, D; Ciardiello, F; Coker, O; De Falco, V; Della Corte, CM; Famiglietti, V; Fowlkes, NW; Kanikarla, P; Kopetz, S; Lee, HM; Martinelli, E; Martini, G; Morris, V; Napolitano, S; Sorokin, A; Tabernero, J; Troiani, T; Villareal, OE; Woods, M, 2023) |
| "5-Fluorouracil (5-FU) is widely used for colorectal cancer (CRC) treatment; however, continuous treatment of CRC cells with 5-FU can result in acquired resistance, and the underlying mechanism of 5-FU resistance remains unclear." | 8.31 | Relationship between anticancer sensitivities and cellular respiration properties in 5-fluorouracil-resistant HCT116 human colorectal cancer cells. ( Kurasaka, C; Nishizawa, N; Ogino, Y; Sato, A; Uozumi, H, 2023) |
| "Insensitivity and resistance to 5-fluorouracil (5FU) remain as major hurdles for effective and durable 5FU-based chemotherapy in colorectal cancer (CRC) patients." | 8.31 | Targeting PTGES/PGE2 axis enhances sensitivity of colorectal cancer cells to 5-fluorouracil. ( Cao, L; Geng, L; Geng, S; Ren, X; Zhan, H, 2023) |
| "To date, oxaliplatin and irinotecan are used in combination with 5-flourouracil (5-FU) for metastatic colorectal cancer." | 8.31 | Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells. ( Bock, F; Cappel, ML; Frerker, B; Hildebrandt, G; Klautke, G; Kriesen, S; Manda, K, 2023) |
| "The gold standard drug for colorectal cancer (CRC) treatment, 5-Fluorouracil (5-FU), induces pharmacological tolerance in long-term management." | 8.31 | Dermatan Sulfate/Chitosan Nanoparticles Loaded with an Anti-Inflammatory Peptide Increase the Response of Human Colorectal Cancer Cells to 5-Fluorouracil. ( Barredo-Vacchelli, GR; Birocco, AM; Blachman, A; Calabrese, GC; Camperi, SA; Cenci, G; Curcio, S; Gianvincenzo, PD; Moya, S; Rodriguez, JA; Sosnik, A, 2023) |
| "In this study, we investigated the combined treatment of 5-fluorouracil (5-FU) and Anatolian propolis extract (PE) on colorectal cancer (CRC)using in vitro and in vivo studies." | 8.31 | Propolis Enhances 5-Fluorouracil Mediated Antitumor Efficacy and Reduces Side Effects in Colorectal Cancer: An in Vitro and in Vivo Study. ( Aydogdu, G; Durmus, E; Goren, AC; Guler, EM; Hekimoglu, ER; Kanimdan, E; Kocyigit, A; Oruc, HH; Ozman, Z; Yasar, O; Yenigun, VB, 2023) |
| "5-Fluorouracil (5-FU) is the first-line treatment for colorectal cancer (CRC) patients, but the development of acquired resistance to 5-FU remains a big challenge." | 8.31 | Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells. ( Chen, X; Ding, W; Jiang, LL; Liu, AC; Liu, BY; Liu, JB; Lou, EZ; Mao, Q; Meng, Y; Peng, GJ; Shi, XP; Tang, DL; Wang, JX; Wu, JZ; Zhang, HC; Zhou, H, 2023) |
| "We found that ABCA2 polymorphism was significantly associated with systemic exposure to capecitabine and capecitabine-induced neutropenia in Japanese patients with CRC." | 8.31 | A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer. ( Fujita, KI; Ishida, H; Kubota, Y; Matsumoto, N; Murase, R; Shibata, Y; Shimada, K, 2023) |
| " Here, we designed a composite liposomal nano-carrier co-loading 5-Fluorouracil (5-FU) with all-trans retinoic acid (ATRA) to assess anticancer efficacy of the combined drugs in colorectal cancer (CRC)." | 8.31 | In vitro co-delivery of 5-fluorouracil and all-trans retinoic acid by PEGylated liposomes for colorectal cancer treatment. ( Afshar, S; Amini, R; Azarifar, Z; Najafi, R; Tanzadehpanah, H, 2023) |
| "The efficacy of fluorouracil + oxaliplatin + irinotecan with bevacizumab (FOLFOXIRI + BV) has been verified for metastatic colorectal cancer (mCRC)." | 8.12 | Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice. ( Aoyama, T; Kazama, K; Numata, M; Oshima, T; Rino, Y; Sato, M; Sato, S; Shiozawa, M; Sugano, N; Tamagawa, H; Uchiyama, M; Yukawa, N, 2022) |
| "To evaluate the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer (mCRC) and explore potential factors of efficacy." | 8.12 | Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. ( Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J, 2022) |
| "Acquired resistance of 5-fluorouracil (5-FU) remains a clinical challenge in colorectal cancer (CRC), and efforts to develop targeted agents to reduce resistance have not yielded success." | 8.12 | ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. ( Cheng, Z; Dong, S; Hu, S; Li, L; Li, S; Liang, S; Luo, L; Xu, Q; Zhang, G; Zhang, W; Zhang, X; Zhong, M; Zhu, J, 2022) |
| "Most patients affected with colorectal cancers (CRC) are treated with 5-fluorouracil (5-FU)-based chemotherapy but its efficacy is often hampered by resistance mechanisms linked to tumor heterogeneity." | 8.12 | CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer. ( Bersuder, E; Brigand, C; Chenard, MP; Delhorme, JB; Duluc, I; Freund, JN; Gross, I; Martin, E; Rohr, S; Terciolo, C; Vlami, O, 2022) |
| "Chemotherapy is used for recurrent and metastatic colorectal cancer, but the response rate of 5-fluorouracil (5-FU), the standard treatment for colorectal cancer, is low." | 8.12 | Effect of Thymidine Phosphorylase Gene Demethylation on Sensitivity to 5-Fluorouracil in Colorectal Cancer Cells. ( Akiyama, N; Eto, K; Koyama, M; Manome, Y; Osada, E, 2022) |
| "Our findings demonstrated that targeting RAS pathway using Valsartan interferes with cell-proliferation, induces apoptosis, reduces migration and synergistically interacts with 5-FU, supporting further studies on this new therapeutic approach for colorectal cancer." | 8.12 | Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer. ( Amerizadeh, F; Asgharzadeh, F; Avan, A; Ebrahimi, S; Fakhraei, M; Farshbaf, A; Ferns, GA; Giovannetti, E; Hassanian, SM; Khazaei, M; Mostafapour, A; Sabbaghzadeh, R, 2022) |
| "To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy." | 8.12 | A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. ( Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS, 2022) |
| "The impact of activating transcription factor 4 (ATF4), differentially expressed in colorectal cancer (CRC), on 5-Fluorouracil (5-FU) chemoresistance has not been fully explained." | 8.12 | ATF4-mediated microRNA-145/HDAC4/p53 axis affects resistance of colorectal cancer cells to 5-fluorouracil by regulating autophagy. ( Chen, H; Hu, H; Ma, J; Xu, L; Zhang, Q; Zhao, L, 2022) |
| "The oral fluoropyrimidine S-1 has shown comparable efficacy to capecitabine in Asian and some Western studies on metastatic colorectal cancer." | 8.12 | Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. ( Kwakman, JJM; Mol, L; Punt, CJA, 2022) |
| "The aim of this study was to improve the direct results of reconstructive surgery in patients operated on for complicated forms of colorectal cancer, by using 5-fluorouracil in the postoperative period." | 8.12 | The Effect of 5-Fluorouracil on the Adhesion Process in Patients Operated on for Colorectal Cancer. ( Irimbetov, S; Osombaev, M; Zhakipbekov, S, 2022) |
| "Clinically, 5-fluorouracil (5-Fu) is a first-line drug for the treatment of patients with colorectal cancer (CRC)." | 8.12 | Synergistic antitumor activity of 5-fluorouracil and atosiban against microsatellite stable colorectal cancer through restoring GATA3. ( Chen, M; Chen, Y; Guo, X; Li, J; Li, Z; Meng, F; Qiu, T; Wang, M; Wang, W; Xu, F; Yang, M; Zhang, H; Zhang, Q; Zhang, Y, 2022) |
| "Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia." | 8.12 | Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. ( Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C, 2022) |
| " In this study, we aimed to determine the changes of autophagy in the cellular model of acquired chemoresistance of colorectal cancer cell lines HCT116 and SW620, induced by 5-fluorouracil (5-FU) or oxaliplatin (OxaPt) treatment, and determine the susceptible factors for autophagy inhibition." | 8.12 | Differential effects of 5-fluorouracil and oxaliplatin on autophagy in chemoresistant colorectal cancer cells. ( Jonusiene, V; Kukcinaviciute, E; Sasnauskiene, A; Starkuviene, V; Zitkute, V, 2022) |
| "To date, 5-fluorouracil-based chemotherapy is very important for locally advanced or metastatic colorectal cancer (CRC)." | 8.12 | Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness. ( Cheng, J; Jin, M; Lin, Z; Ren, J; Wang, L; Wu, G; Yang, K; Yu, D; Zhang, D; Zhang, T; Zhao, L; Zhou, P, 2022) |
| "Surgically resected colorectal cancer specimens from 89 patients were decellularized to produce patient-derived scaffold, which were seeded with HT29 cells, cultured for 3 weeks, and treated with 5-fluorouracil." | 8.12 | 5-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information. ( Bexe Lindskog, E; Holdfeldt, A; Landberg, G; Salerno, S; Ståhlberg, A, 2022) |
| "Five-fluorouracil, folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) regimen is used as the first-line treatment for metastatic colorectal cancer (mCRC)." | 8.12 | Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. ( Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H, 2022) |
| " Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells." | 8.12 | The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022) |
| "a capecitabine and oxaliplatin drug combination regimen has shown a survival benefit in patients with advanced colorectal cancer, yet its administration represents an attractive option for low resource settings." | 8.12 | Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study. ( Begg, W; Kibudde, S, 2022) |
| "5-Fluorouracil (5-FU), a known cardiotoxin, is the backbone for the treatment of colorectal cancer." | 8.12 | Managing life-threatening 5-fluorouracil cardiotoxicity. ( Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A, 2022) |
| " Topoisomerase-I inhibitor irinotecan is used clinically to treat colorectal cancer (CRC), often in combination with 5-fluorouracil (5FU)." | 8.12 | ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. ( Bagby, SM; Cadogan, EB; Davis, SL; Diamond, JR; Durant, ST; Hartman, SJ; Hughes, GD; Leal, AD; Lieu, CH; Messersmith, WA; Pitts, TM; Schlaepfer, M; Simmons, DM; Tse, T; Yacob, BW, 2022) |
| "We experienced 2 cases of Stage Ⅳ colorectal cancer obtained long-term survival by chemotherapy with only capecitabine." | 8.12 | [Two Cases of Stage Ⅳ Colorectal Cancer with Long-Term Survival following Single-Agent Chemotherapy with Capecitabine-A Case Reports]. ( Ando, K; Chiku, T; Fukuyama, M; Hashiba, H; Sano, W; Shinoda, K; Suda, K, 2022) |
| "The aim of this study was to investigate the antitumor effects of quercetin and luteolin combined with 5-Fluorouracil (5-FU) in HT-29 human colorectal cancer cells." | 8.12 | Quercetin and Luteolin Improve the Anticancer Effects of 5-Fluorouracil in Human Colorectal Adenocarcinoma ( Ağca, CA; Aşkın, H; Erdoğan, MK, 2022) |
| "Adjuvant chemotherapy with 5-fluorouracil (5-FU) does not improve survival of patients suffering from a form of colorectal cancer (CRC) characterized by high level of microsatellite instability (MSI-H)." | 8.02 | Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition. ( Behrouj, H; Dastghaib, S; Ghavami, S; Hudecki, J; Khazayel, S; Likus, W; Mokarram, P; Rezaie, S; Siri, M; Zamani, M; Łos, MJ, 2021) |
| "Although effective drugs have been developed, including 5-fluorouracil (5-FU), advanced colorectal cancer (CRC) shows low therapeutic sensitivity resulting from the development of 5-FU resistance." | 8.02 | Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells. ( Choi, J; Hwang, S; Lim, W; Song, G; Song, J; Yang, C, 2021) |
| "5-Fluorouracil (5-FU) resistance has been long considered as an obstacle to the efficacy of chemotherapy in colorectal cancer (CRC)." | 8.02 | Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway. ( Hua, R; Li, X; Ni, Q; Tang, D; Wang, D; Yan, X; Zhang, Y; Zhu, J, 2021) |
| "Currently, 5-Fluorouracil (5-FU) based chemotherapy is the primary option for colorectal cancer after surgery, whereas chemotherapy resistance related mortality is observed in a large proportion of patients." | 8.02 | Anemoside B4 sensitizes human colorectal cancer to fluorouracil-based chemotherapy through src-mediated cell apoptosis. ( Duan, XW; He, X; Hou, XL; Li, HQ; Liao, GB; Liu, W; Tang, J; Wang, JX; Yan, HZ; Yu, SY, 2021) |
| "First-line regimens in the treatment of metastatic colorectal cancer (mCRC) combine a fluoropyrimidine with oxaliplatin (FOLFOX/XELOX) or irinotecan (FOLFIRI)." | 8.02 | Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. ( Carneiro, BA; El-Deiry, WS; Marks, EI; Matera, R; Olszewski, AJ; Safran, H; Yakirevich, E, 2021) |
| " Herein, mesoporous silica nanoparticles, a supported lipid bilayer and cetuximab were integrated to fabricate a hybrid nanoplatform for effectively encapsulating and selectively delivering 5-fluorouracil (5-FU) against colorectal cancer (CRC) cells." | 8.02 | Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment. ( Chen, R; Gu, Q; Huang, Y; Li, J; Peng, C; Peng, W; Shao, G; Sheng, Y; Sun, Y; Tan, Y; Wang, L; Wang, Y; Yang, P; Zhang, Q; Zhou, J, 2021) |
| "Recently the phase 3 BEACON trial showed that the combination of encorafenib, cetuximab, and binimetinib versus cetuximab and irinotecan/FOLFIRI improved overall survival in pre-treated patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutation." | 8.02 | Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA. ( Ding, D; Hu, H; Huang, J; Li, S; Zhu, Y, 2021) |
| "The administration schedule of capecitabine for the treatment of metastatic colorectal cancer (mCRC) in clinical trials has been 14 days of drug with 7 days off in a 21 day cycle (14/7)." | 8.02 | Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. ( Akce, M; Alese, O; Bryson, E; Davis, C; Draper, A; El-Rayes, B; Goyal, S; Hall, K; Patel, U; Sakach, E; Shaib, W; Szabo, S; Watson, M; Wu, C, 2021) |
| " Chemotherapy using 5-fluorouracil (5-FU) has been widely applied to treat colorectal cancer (CRC)." | 8.02 | Low curcumin concentration enhances the anticancer effect of 5-fluorouracil against colorectal cancer. ( Lin, J; Shao, Y; Song, F; Yang, X; Zheng, X, 2021) |
| "Combination therapy comprised of fluoropyrimidine plus irinotecan with an angiogenesis inhibitor is widely used as a second-line treatment for metastatic colorectal cancer (mCRC)." | 8.02 | Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. ( Aoki, K; Hamano, T; Makishima, M; Oki, E; Sano, F; Yamanaka, T; Yamazaki, K; Yuki, S, 2021) |
| "5-Fluorouracil (5-FU) resistance is an urgent problem of colorectal cancer (CRC) chemotherapy that needs to be resolved." | 8.02 | LncRNA ENSG00000254615 Modulates Proliferation and 5-FU Resistance by Regulating p21 and Cyclin D1 in Colorectal Cancer. ( Deng, Y; Fu, Y; Huang, R; Li, J; Xie, X, 2021) |
| "5-Fluorouracil (5-FU)-based chemotherapy is the first-line treatment for colorectal cancer (CRC) but is hampered by chemoresistance." | 8.02 | The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy. ( Chen, C; Chen, J; Fan, G; Liu, X; Lu, H; Na, R; Peng, Z; Song, G; Tang, H; Wang, X; Wang, Y; Xiao, C; Yan, D; Zhuang, G, 2021) |
| "To evaluate the anti-cancer effects of OJe, its possible mechanisms of action were investigated in 5-fluorouracil (5-FU) resistant SNU-C5/5-FUR colorectal cancer cells." | 8.02 | Anti-cancer effects of the aqueous extract of Orostachys japonica A. Berger on 5-fluorouracil-resistant colorectal cancer via MAPK signalling pathways in vitro and in vivo. ( Kim, J; Kim, JW; Kim, SH; Mariappan, R; Moon, D; Yoon, SP, 2021) |
| "BACKGROUND The impact of therapeutic drug management (TDM) on reducing toxicity and improving efficacy in colorectal cancer (CRC) patients receiving fluorouracil-based chemotherapy is still unclear." | 8.02 | Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy. ( Chang, R; Chang, Y; Han, J; Qian, J; Shen, C; Zhao, H; Zhou, X, 2021) |
| "5-Fluorouracil (5-FU) is regarded as the first line treatment for colorectal cancer; however, its effectiveness is limited by drug resistance." | 8.02 | The combined effect of dichloroacetate and 3-bromopyruvate on glucose metabolism in colorectal cancer cell line, HT-29; the mitochondrial pathway apoptosis. ( Alboghobeish, S; Behmanesh, B; Khodayar, MJ; Mahdavinia, M; Nikravesh, H; Teimoori, A; Zeidooni, L, 2021) |
| "The study aimed to explore the efficacy of pharmacokinetic-based 5-fluorouracil dose management by plasma concentration test in advanced colorectal cancer treatment." | 7.96 | Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment. ( Deng, R; Guan, X; Shen, B; Shi, L; Wang, M; Yang, D; Zhu, W, 2020) |
| "For over 50 years, 5-Fluorouracil has played a critical role in the treatment of numerous malignancies, including colorectal cancer." | 7.96 | Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature. ( Gilbar, PJ; Grewal, GD; Holcombe, DJ; Raina, AJ, 2020) |
| "5-fluorouracil (5-FU) is widely used in chemotherapy for colorectal cancer (CRC), but a high rate of chemoresistance reduces its effectiveness in clinical treatment." | 7.96 | FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway. ( Du, Q; He, B; Liu, C; Liu, X; Mi, Q; Peng, S; Qu, X; Wang, J; Yang, Y; Yao, Z; Zhang, X; Zhang, Y; Zhao, S; Zhao, Y; Zhu, Y; Zou, J, 2020) |
| "FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), a 5-fluorouracil (5-FU)-based chemotherapy regimen, is one of most common therapeutic regimens for colorectal cancer." | 7.96 | Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer. ( Chang, CW; Chen, MJ; Chen, YJ; Chiang Chiau, JS; Chuang, WH; Lee, HC; Li, LH; Liu, CY; Shih, SC; Tsai, TH; Wang, HY; Wang, TE, 2020) |
| "5-Fluorouracil-based therapy remains the main approach in colorectal cancer, even though there are still some drawbacks, such as chemoresistance." | 7.96 | Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. ( Achim, M; Banciu, M; Casian, T; Dragos, N; Drotar, DM; Licarete, E; Luput, L; Muntean, D; Patras, L; Porfire, A; Rauca, VF; Sesarman, A; Stejerean, I; Toma, VA; Tomuta, I; Vlase, L, 2020) |
| "The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin." | 7.96 | Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. ( Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D, 2020) |
| "5-Fluorouracil (5-Fu) is used as a conventional chemotherapy drug in chemotherapy for patients with advanced colorectal cancer, but many patients still suffer from treatment failure due to 5-Fu resistance." | 7.96 | CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer. ( Cao, G; Chen, E; Huang, X; Jin, D; Ju, Z; Luo, X; Song, Z; Wang, F; Xu, J; Zhang, G; Zhang, W; Zhou, W, 2020) |
| "When the 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy regimen is used to treat colorectal cancer (CRC), chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin can substantially affect quality of life (QOL) in the CRC patients." | 7.96 | Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study. ( Chen, JL; Chou, PL; Hsu, HT; Huang, YY; Juan, CH; Lin, PC; Wu, LM, 2020) |
| " Casein kinase 2α (CK2α) is highly expressed in 5-fluorouracil (5FU)-resistant colorectal cancer (CRC) cells." | 7.96 | Casein Kinase 2α Enhances 5-Fluorouracil Resistance in Colorectal Cancer Cells by Inhibiting Endoplasmic Reticulum Stress. ( Han, YS; Kim, HJ; Lee, JH; Lee, SH, 2020) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic drug widely used to treat colorectal cancer." | 7.96 | Comparative lipidomics of 5-Fluorouracil-sensitive and -resistant colorectal cancer cells reveals altered sphingomyelin and ceramide controlled by acid sphingomyelinase (SMPD1). ( Akao, Y; Bandu, R; Jung, JH; Kim, KP; Komura, K; Lee, HM; Lee, KY; Lee, MY; Taniguchi, K, 2020) |
| "To analyse the results of fluorouracil (5-FU) plasma concentration monitoring in patients with advanced colorectal cancer after 5-FU treatment, and to provide a reference for the application prospect of 5-FU plasma concentration monitoring technology." | 7.96 | A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer. ( Bi, Y; He, G; Li, X; Liu, Q; Ma, J; Yang, Q; Zhang, C; Zhang, J, 2020) |
| " Herein we revealed a previously unrecognized mechanism of 5-fluorouracil (5-FU) resistance contributed by high SphK2-upregulated dihydropyrimidine dehydrogenase (DPD) in colorectal cancer (CRC), which is evidenced from human CRC specimens, animal models, and cancer cell lines." | 7.96 | SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression. ( Cui, SX; Guo, ZK; Luo, DD; Miao, RR; Qu, XJ; Shi, WN; Sun, SY; Wan, SB; Wang, WY; Wu, SH; Yu, XF; Zhang, YH, 2020) |
| "5-Fluorouracil (5-FU) is one of the most effective drugs for the treatment of colorectal cancer (CRC)." | 7.96 | Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. ( Cai, J; Li, W; Liu, Y; Ma, L; Xu, Y; Yang, Y; Zhang, Y, 2020) |
| "The purpose of this study was to investigate the effect of metformin or the combination of metformin and 5-FU on the growth and metastasis of colorectal cancer (CRC)." | 7.96 | Metformin Inhibited Proliferation and Metastasis of Colorectal Cancer and presented a Synergistic Effect on 5-FU. ( Sang, J; Sun, Q; Tang, R; Yang, M, 2020) |
| "The AXEPT trial demonstrated that modified XELIRI (mXELIRI; capecitabine + irinotecan) was noninferior to standard treatment with FOLFIRI (fluorouracil + leucovorin + irinotecan), both ± bevacizumab, in the treatment of metastatic colorectal cancer (mCRC)." | 7.96 | Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China. ( Li, Q; Liao, W; Wang, X; Wu, Q; Zhang, M; Zhang, P, 2020) |
| "Cancer stem cells (CSCs) from colorectal cancer (CRC), characterized by CD133 expression, have been associated with 5-fluorouracile (5-FU) chemoresistance." | 7.96 | MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression. ( Caba, O; Cabeza, L; Jimenez-Luna, C; Melguizo, C; Mesas, C; Oliver, JA; Ortiz, R; Perazzoli, G; Prados, J, 2020) |
| " In this perspective, we recently developed a multipurpose thermosensitive hydrogel based on reversible thermogelling properties of poloxamers P407 and P188, a bioadhesive excipient and antineoplastic effect of 5-fluorouracil (5-FU) for the local treatment of colorectal cancer (CRC) in ectopic CT26 murine models." | 7.96 | Thermosensitive hydrogels for local delivery of 5-fluorouracil as neoadjuvant or adjuvant therapy in colorectal cancer. ( Agapova, E; Al Sabbagh, C; Boudy, V; Kramerich, D; Mignet, N; Seguin, J, 2020) |
| "To investigate the influence of longan flower extract (LFE) on the sensitization of colorectal cancer (CRC) cells to 5-fluorouracil (5-FU) treatment, HT-29, Colo 320DM and SW480 cells were treated with LFE and 5-FU alone and in combination, and the cell viability was then assessed by trypan blue exclusion, the cell cycle by propidium iodide staining, the mitochondria membrane potential by rhodamine 123 staining, and the expression levels of associated genes by immunoblotting and quantitative real-time polymerase chain reaction." | 7.96 | Synergistic Effect of Combined Treatment with Longan Flower Extract and 5-Fluorouracil on Colorectal Cancer Cells. ( Chang, HL; Chang, HP; Chen, CH; Chen, SJ; Chou, JL; Chung, YC; Hsu, CP; Lin, CC, 2020) |
| "Despite new agent development and short-term benefits in patients with colorectal cancer (CRC), metastatic CRC cure rates have not improved due to high rates of 5-fluorouracil (5-FU)/leucovorin/oxaliplatin (FOLFOX)-resistance and a clinical therapeutic plateau." | 7.91 | ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. ( Amin, S; Jaiswal, AS; Law, BK; Narayan, S; Ramisetti, S; Sharma, AK; Singh, P; Singh-Pillay, A, 2019) |
| "5-Fluorouracil (5-FU) is an important chemotherapeutic agent for the systemic treatment of colorectal cancer (CRC), but its effectiveness against CRC is limited by increased 5-FU resistance caused by the hypoxic tumor microenvironment." | 7.91 | Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer. ( Kim, CW; Kim, HG; Lee, DH; Lee, JS; Oh, ET; Park, HJ, 2019) |
| "The first-line chemotherapy of colorectal cancer (CRC), besides surgery, comprises administration of 5-Fluorouracil (5FU)." | 7.91 | Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo. ( Cumova, A; Galanova, N; Horak, J; Hucl, T; Kostovcikova, K; Kozics, K; Macinga, P; Opattova, A; Rejhova, A; Sliva, D; Turnovcova, K; Vodenkova, S; Vodicka, P; Vodickova, L, 2019) |
| "The high-budding group demonstrated resistance to 5-fluorouracil-based chemotherapy, whereas the low-budding group exhibited significant survival benefits from adjuvant chemotherapy in stage III colorectal cancer." | 7.91 | Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis. ( Hase, K; Kajiwara, Y; Mochizuki, S; Okamoto, K; Shinto, E; Ueno, H; Yamadera, M; Yamamoto, J, 2019) |
| "In the present study, we aimed to determine the efficacy of trabectedin (TRAB) combined with oxaliplatinum (OXA)+5-fluorouracil (5-FU) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (PDOX) mouse model." | 7.91 | Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. ( Bouvet, M; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G, 2019) |
| "The aim of the present study was to determine the efficacy of trabectedin combined with FOLFIRI (irinotecan, leucovorin and 5-fluorouracil) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (iPDOX) mouse model." | 7.91 | Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model. ( Bouvet, M; Clary, B; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G, 2019) |
| "The current study suggests that the identification of predictive signatures of fluorouracil (5-FU) response for stage II and III colorectal cancer (CRC) could be confounded by chemotherapy-irrelevant low relapse risk." | 7.91 | Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit. ( Ao, L; Cai, H; Guo, Y; Guo, Z; Li, N; Song, K; Song, X; Wang, X; Zhao, W; Zheng, W, 2019) |
| "Selected SNPs in the adenosine pathway could affect the clinical outcomes of patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab." | 7.91 | Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. ( Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Lo, JH; Loupakis, F; Millstein, J; Naseem, M; Puccini, A; Soni, S; Stintzing, S; Tokunaga, R; Zhang, W, 2019) |
| "Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU." | 7.91 | Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. ( Chakrabarti, S; Eiring, R; Finnes, H; Grothey, A; Halfdanarson, T; Hartgers, M; Lobo, R; Mitchell, J; Okano, A; Sara, J, 2019) |
| "5-Fluorouracil (5-FU) represents the backbone of systemic therapy regimens of colorectal cancer." | 7.91 | 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer. ( Abdel-Rahman, O, 2019) |
| "Oral uracil-tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer." | 7.91 | Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan. ( Hsu, TC; Wang, CC, 2019) |
| "5-Fluorouracil (5-FU) has been established as the first-line chemotherapy for advanced colorectal cancer (CRC); however, acquired chemoresistance is often the cause of poor therapeutic response." | 7.91 | Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. ( Goel, A; Sakatani, A; Sonohara, F, 2019) |
| " We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response." | 7.91 | Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. ( Bader, JE; Carson, JA; Carson, M; Chatzistamou, I; Enos, RT; Kubinak, JL; Murphy, EA; Nagarkatti, M; Pena, MM; Sougiannis, AT; VanderVeen, BN; Velazquez, KT; Walla, M, 2019) |
| "The efficacy of Fluorouracil (FU) in the treatment of colorectal cancer (CRC) is greatly limited by drug resistance." | 7.91 | ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield. ( Chen, Y; Hao, J; Li, F; Li, J; Liang, H; Luo, X; Ou, J; Peng, Y; Sun, W; Wang, L; Wu, S; Xie, G; Xie, X; Yang, W; Zha, L; Zhang, Y; Zhao, Y; Zhou, Q, 2019) |
| "5-Fluorouracil (5-FU) is an anticancer drug that is most frequently used to treat colorectal cancer (CRC) patients, but unfortunately it shows limited efficacy." | 7.91 | Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase. ( Klopotowska, D; Kutner, A; Milczarek, M; Rossowska, J; Stachowicz, M; Wietrzyk, J, 2019) |
| "Colorectal cancer (CRC) is still the third most common cancer in the world with a limited prognosis due to the chemoresistance of CRC cells to 5-fluorouracil (5-FU)-based chemotherapy." | 7.91 | Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling. ( Fan, D; He, H; Lei, M; Liang, Y; Shen, L; Wu, H; Zhou, Q; Zou, Q, 2019) |
| "5-Fluorouracil (5-FU) remains the gold standard of first-line treatment for colorectal cancer (CRC)." | 7.91 | Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure. ( Bulanin, D; Francipane, MG; Lagasse, E, 2019) |
| " 5-Fluorouracil is a clinically approved drug which has limited response rate in the realm of colorectal cancer amelioration, hence our study aims to improve its efficacy by aiming the simultaneous delivery of 5-Flurouracil and apigenin which is naturally occurring flavone abundantly present in fruit and vegetables through a single liposome to combat and control colorectal cancer effectively in-vitro and in-vivo." | 7.91 | Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer. ( Banerjee, S; Mandal, M; Sen, K, 2019) |
| "Only 10%-20% of colorectal cancer (CRC) patients observe effective responses to 5-fluorouracil (5-FU) based chemo-treatment." | 7.91 | Epigenetically Down-Regulated Acetyltransferase PCAF Increases the Resistance of Colorectal Cancer to 5-Fluorouracil. ( Fang, X; Fang, Z; Hu, W; Jin, Y; Liu, T; Miao, QR; Wang, X, 2019) |
| "Although DNA-mismatch-repair-deficient (dMMR) status and aberrant expression of miRNAs are both critically implicated in the pathogenesis of resistance to 5-fluorouracil (5-FU) in colorectal cancer (CRC), whether these two factors regulate tumor response to 5-FU in a coordinated manner remains unknown." | 7.91 | MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer. ( Dai, ZJ; Guan, HT; Liu, D; Ma, YG; Yan, CY; Zhao, P; Zhao, Y, 2019) |
| " In the present study, the antitumor effects were investigated, and the possible underlying mechanisms of kaempferol combined with 5‑fluorouracil (5‑FU) in colorectal cancer cells were explored." | 7.91 | Synergistic effect of kaempferol and 5‑fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway. ( Chen, Y; Li, Q; Lin, J; Lin, S; Peng, J; Wei, L, 2019) |
| "We developed a molecular beacon targeting miR-141-3p, aberrantly increased in 5-fluorouracil-resistant colorectal cancer cells (R-CRCCs)." | 7.91 | Theragnosis by a miR-141-3p molecular beacon: simultaneous detection and sensitization of 5-fluorouracil resistant colorectal cancer cells through the activation of the TRIM13-associated apoptotic pathway. ( Heo, HJ; Jeong, SH; Jung, WY; Kim, S; Lee, YS; Moon, SU; Park, MG; Park, Y; Song, SK, 2019) |
| "To assess if CT texture analysis (TA) can serve as a biomarker of liver toxicity in patients with colorectal cancer treated with 5-fluorouracil (5-FU)-based chemotherapy." | 7.91 | 5-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker. ( Alessandrino, F; Cruz, G; Meyerhardt, JA; Qin, L; Rosenthal, MH; Sahu, S; Shinagare, AB, 2019) |
| "5-Fluorouracil (5-FU)-based chemotherapy has always been the first-line treatment of colorectal cancer (CRC)." | 7.91 | The long non-coding RNA HOTAIRM1 suppresses cell progression via sponging endogenous miR-17-5p/ B-cell translocation gene 3 (BTG3) axis in 5-fluorouracil resistant colorectal cancer cells. ( Chen, J; Hou, J; Liu, C; Qin, A; Ren, T; Ren, W; Shan, F; Xiong, X, 2019) |
| "5-Fluorouracil (5-FU) as a chemotherapeutic drug is used to treat colorectal cancer (CRC)." | 7.88 | The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer. ( Dermani, FK; Heydari, K; Najafi, R; Saidijam, M; Shabab, N; Sharifi, MR; Soleimani Asl, S, 2018) |
| "Our objective was to evaluate the benefit of re-exposing patients with refractory metastatic colorectal cancer (mCRC) to a combination of oxaliplatin, irinotecan and 5-fluorouracil treatment." | 7.88 | Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. ( Artioli, M; Braghiroli, MI; Braghiroli, OFM; Costa, FP; Fernandes, GDS; Girardi, DDM; Gumz, BP; Hoff, PM; Paterlini, ACCR; Teixeira, MC, 2018) |
| " The objective of this exploratory study was to examine the association of low skeletal muscle, commonly known as sarcopenia, on the pharmacokinetics (PKs) of 5-fluorouracil (5FU) in patients receiving FOLFOX for colorectal cancer." | 7.88 | The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ( Choi, SK; Deal, AM; McLeod, HL; Muss, HB; O'Neil, B; Patel, JN; Sanoff, HK; Shachar, SS; Walko, CM; Weinberg, MS; Williams, GR, 2018) |
| " The prognostic role of TOPO-1 and CES-2 in patients with metastatic colorectal cancer (mCRC) who underwent irinotecan chemotherapy was largely unknown." | 7.88 | Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. ( Guisheng, L; Haixin, H; Li, H; Shaojun, C, 2018) |
| "To investigate expression of cell cycle-related and expression-elevated protein in tumor (CREPT) in colorectal cancer (CRC) and determine its prognostic value in response to 5-fluorouracil (5-FU)." | 7.88 | Overexpression of CREPT confers colorectal cancer sensitivity to fluorouracil. ( Chang, ZJ; Ding, LD; Jia, BQ; Kuang, YS; Li, J; Liu, HY; Liu, SH; Wang, XN; Wang, Y; Wang, YY; Yang, L; Zhu, BT, 2018) |
| " In this study, we investigated the effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma (CRC) cells and its mechanism." | 7.88 | The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. ( Jiang, GS; Liu, GW; Liu, YH; Ren, WD, 2018) |
| "Fluoropyrimidines, such as 5-fluorouracil (5-FU) and related prodrugs, are considered one of the most successful agents in the treatment of colorectal cancer, yet poor specificity and tumor cell resistance remain the major limiting bottlenecks." | 7.88 | DNA-based nanoscaffolds as vehicles for 5-fluoro-2'-deoxyuridine oligomers in colorectal cancer therapy. ( Aviñó, A; Eritja, R; Fàbrega, C; Jorge, AF; Pais, AACC, 2018) |
| "We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients." | 7.88 | Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy. ( Catalano, C; da Silva Filho, MI; Försti, A; Hemminki, K; Jiraskova, K; Levy, M; Liska, V; Naccarati, A; Vodicka, P; Vodickova, L; Vycital, O; Vymetalkova, V; Weber, ANR, 2018) |
| "To investigate the effects of miR-519d on the 5-fluorouracil resistance in colorectal cancer cells and to explore the mechanism." | 7.88 | MiR-519d reduces the 5-fluorouracil resistance in colorectal cancer cells by down-regulating the expression of CCND1. ( Chi, YJ; Huang, R; Lin, JY, 2018) |
| "Chemotherapeutic 5-fluorouracil (5-FU) combined with oxaliplatin is often used as the standard treatment for colorectal cancer (CRC)." | 7.88 | Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin. ( Chen, CI; Chen, YJ; Cheng, KC; Chien, PH; Hsiang, YP; Hsu, YC; Lin, YM; Lu, CC; Pan, HL, 2018) |
| "BACKGROUND 5-Fluorouracil (5-FU)-based chemotherapy is a conventional therapeutic approach for the treatment of patients with colorectal cancer (CRC)." | 7.88 | miR-106a Reduces 5-Fluorouracil (5-FU) Sensitivity of Colorectal Cancer by Targeting Dual-Specificity Phosphatases 2 (DUSP2). ( Chen, X; Huo, Z; Liu, Z; Qin, Y; Tian, X, 2018) |
| "Capecitabine is a pro-drug of 5-fluorouracil (5-FU), and is an orally available chemotherapeutic used to treat colorectal cancer (CRC)." | 7.88 | Investigation into Enhancing Capecitabine Efficacy in Colorectal Cancer by Inhibiting Focal Adhesion Kinase Signaling. ( Baek, JH; Jeong, KY; Kim, HM; Lee, H; Park, MH; Sim, JJ, 2018) |
| " Median time from initial diagnosis of metastases to the start of regorafenib and treatment duration was 13." | 7.88 | Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). ( Aranda, E; Benavides, M; Durán, G; Falcó, E; García-Alfonso, P; Gómez, A; López, R; López-Ladrón, A; Montagut, C; Muñoz, A; Rivera, F; Ruiz de Mena, I; Salgado, M; Sastre, J, 2018) |
| " Here, the role of PKM2 in the anticancer efficacy of 5-fluorouracil (5-FU) was evaluated in colorectal cancer (CRC)." | 7.88 | Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells. ( Cao, Y; Jin, Y; Lin, Y; Pan, D; Wang, D; Zhang, Y; Zheng, C, 2018) |
| "To evaluate the safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (mFOLFOXIRI) for patients with advanced colorectal cancer (CRC)." | 7.88 | [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer]. ( Cai, Y; Deng, R; Deng, Y; Hu, H; Li, J; Ling, J; Wu, Z; Yang, L; Zhang, J, 2018) |
| "Almost all colorectal cancer (CRC) cell lines are known to overexpress aspartate aminotransferase (GOT1), which potentially regulates the intracellular levels of reactive oxygen species (ROS) via the production of NADPH, and supports tumor growth." | 7.85 | Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil. ( Hong, C; Li, X; Zheng, J, 2017) |
| "Although 5-fluorouracil (5-FU) is known to interfere with the synthesis of ribonucleic acid and deoxyribonucleic acid, the mechanism underlying its therapeutic efficacy in colorectal cancer (CRC) has not been fully elucidated." | 7.85 | 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. ( Cao, L; Du, C; Gu, J; Huang, D; Peng, Y; Wang, H; Yang, Y; Yao, Y; Zhao, Y; Zhu, WG, 2017) |
| "To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy." | 7.85 | Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer. ( Hong, KD; Ji, WB; Joung, SY; Kim, JS; Kim, YS; Lee, JH; Min, BW; Ryu, JS; Um, JW, 2017) |
| "5-Fluorouracil (5-FU) is a widely used chemotherapeutic drug in colorectal cancer." | 7.85 | Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism. ( Auboeuf, D; Bash-Imam, Z; Catez, F; Dalla Venezia, N; David, A; Diaz, JJ; Dutertre, M; Lafôrets, F; Macari, F; Marcel, V; Mertani, HC; Pannequin, J; Pion, N; Polay Espinoza, M; Saurin, JC; Textoris, J; Thérizols, G; Vincent, A, 2017) |
| "Cardiotoxicity is a rare but challenging complication of 5-fluorouracil (5-FU) therapy." | 7.85 | Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. ( Franck, C; Malfertheiner, P; Venerito, M, 2017) |
| "Preclinical evidence demonstrates that mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway inhibition increases sensitivity to 5-fluorouracil (5-FU) in colorectal cancer (CRC) cell lines and xenografts." | 7.85 | MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. ( Chen, Y; Fakih, M; Gong, J; Pillai, R; Shirasawa, S; Yang, L, 2017) |
| "Preoperative 5-fluorouracil- (5-FU-) based chemoradiotherapy is a standard treatment for locally advanced colorectal cancer (CRC)." | 7.85 | Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. ( Ai, YQ; Chen, ZT; Ju, YH; Li, WH; Li, YF; Liu, QY; Qin, JY; Wang, H; Xiong, W; Ye, Q, 2017) |
| "5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents." | 7.85 | Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017) |
| " Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer." | 7.85 | Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer. ( Hama, T; Inoue, A; Kawakami, K; Kobayashi, K; Machida, Y; Suenaga, M; Sugisaki, T; Suzuki, K; Yamaguchi, K; Yamaguchi, T; Yokokawa, T, 2017) |
| " 5-Fluorouracil (5-FU) is the first-line chemotherapeutic agent for colorectal cancer; however, most patients develop resistance to 5-FU through various mechanisms." | 7.85 | Synergistic antitumor effect of 3-bromopyruvate and 5-fluorouracil against human colorectal cancer through cell cycle arrest and induction of apoptosis. ( Chong, D; Huo, Q; Liu, F; Liu, H; Ma, L; Zhang, P; Zhang, Z; Zhao, S; Zheng, H, 2017) |
| "5-Fluorouracil (5-FU) resistance or multidrug resistance (MDR) has become a major obstacle in clinical treatment of cancers including colorectal cancer (CRC)." | 7.85 | Scutellaria barbata D. Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway. ( Feng, J; Jin, Y; Lai, Z; Li, Q; Lin, J; Peng, J; Wei, L; Yan, Z; Yang, H, 2017) |
| "The aim of this study was to explore the effects of single agent treatments and combination of Blu9931 and 5-fluorouracil (5-FU) on the biological characteristics of colorectal cancer cells and its mechanism." | 7.85 | Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells. ( Han, C; Jiang, D; Li, J; Wang, M; Wang, X; Ye, Y; Zhao, C, 2017) |
| "Colorectal cancer (CRC) is one of the leading causes of cancer mortality and 5-Fluorouracil (5-FU) is the most common chemotherapy agent of CRC." | 7.85 | Effect of AICAR and 5-Fluorouracil on X-ray Repair, Cross-Complementing Group 1 Expression, and Consequent Cytotoxicity Regulation in Human HCT-116 Colorectal Cancer Cells. ( Chang, SF; Chen, CN; Huang, WS; Lee, KC; Lin, CT; Liu, JL, 2017) |
| "A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose." | 7.85 | Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses. ( Ardalan, B; Cioffi, JH; Estes, DJ; Florou, V, 2017) |
| "5-fluorouracil (5-FU) is one of the major components of many standard regimens for chemotherapy of colorectal cancer (CRC) and some other malignancies." | 7.85 | The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells. ( Eftekhar, E; Jaberi, H; Mansouri, A; Naghibalhossaini, F; Shefaghat, M; Tatar, M, 2017) |
| "Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC." | 7.85 | Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment. ( Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS, 2017) |
| "We analyzed the results of previously treated patients with metastatic colorectal cancer (mCRC) who received regorafenib plus FOLFIRI with the irinotecan dose escalation on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping." | 7.85 | Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. ( Cheng, TL; Hu, HM; Huang, CW; Ma, CJ; Tsai, HL; Wang, JY; Wu, IC; Yeh, YS, 2017) |
| "5-Fluorouracil (5-FU) is the most commonly used chemotherapeutic agent for colorectal cancer (CRC)." | 7.85 | FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. ( Chen, C; Chen, J; Chen, L; Chen, Y; Chu, X; Dai, T; Geng, J; Huang, M; Liu, X; Mao, X; Ren, L; Wang, L; Wang, Q; Wang, R; Wang, Y; Xie, T; Xue, L; Yu, H; Zhang, K, 2017) |
| "This retrospective study enrolled 131 patients with stage III colorectal cancer who underwent curative resection: 72 received 5-fluorouracil-based adjuvant chemotherapy (chemotherapy group) and 59 did not (surgery-alone group)." | 7.85 | Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer. ( Kameyama, H; Kobayashi, T; Kosugi, SI; Okamura, T; Shimada, Y; Tajima, Y; Wakai, T; Yagi, R, 2017) |
| "High-dose 5-fluorouracil (5-FU) containing chemotherapy occasionally causes hyperammonemia and can be lethal." | 7.85 | Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. ( Funakoshi, T; Horimatsu, T; Matsubara, K; Matsubara, T; Miyamoto, S; Muto, M; Nakagawa, S; Nishikawa, Y; Yanagita, M; Yonezawa, A, 2017) |
| " Hypoxia reduces sensitivity to 5-fluorouracil (5-FU)-chemotherapy for colorectal cancer (CRC)." | 7.85 | Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. ( Adam, J; Bishop, CL; Bundy, JG; Feakins, R; Gammon, L; Jalaly, A; Jeffery, R; Lewis, A; Lowe, R; McDonald, S; Nijhuis, A; Parker, A; Propper, D; Silver, A; Soga, T; Suraweera, N; Thaha, MA; Thompson, H, 2017) |
| "To evaluate the efficiency and safety of hepatic artery infusion chemotherapy (HAIC) using raltitrexed or 5-fluorouracil for colorectal cancer (CRC) liver metastasis (CRCLM)." | 7.85 | Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. ( Chen, H; Gao, S; Guo, JH; Li, XT; Wang, XD; Zhang, HY; Zhang, PJ; Zhu, X, 2017) |
| "The purpose of this study was to evaluate both in vitro and in vivo anticancer activities against colorectal cancer (CRC) of electrospun polylactide (PLA) nanofibers loaded with 5-fluorouracil (5-Flu) and oxaliplatin." | 7.83 | Antitumor activity of electrospun polylactide nanofibers loaded with 5-fluorouracil and oxaliplatin against colorectal cancer. ( Jing, X; Liu, S; Liu, T; Wang, X; Zhang, J, 2016) |
| " This study evaluates the cost-effectiveness of UGT1A1 genotyping in patients with metastatic colorectal cancer undergoing irinotecan-based chemotherapy compared to no testing from the perspective of the German statutory health insurance." | 7.83 | The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance. ( Butzke, B; Giessen-Jung, C; Heinemann, V; Oduncu, FS; Pfeufer, A; Rogowski, WH; Severin, F; Stollenwerk, B, 2016) |
| "We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer." | 7.83 | In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer. ( Kang, J; Kim, IK; Kwon, HY; Lee, KY; Sohn, SK, 2016) |
| "5-Fluorouracil (5-FU) is one among the anti-cancer agents in FOLFORINOX treatment along with oxaliplatin and irinotecan for the treatment of colorectal cancer." | 7.83 | 5-Fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer. ( Kuppusamy, G; Praveen, TK; Satish Kumar, MN; Tummala, S; Wadhwani, A, 2016) |
| "5-Fluorouracil (5-FU), a cell cycle-specific antimetabolite, is one of the most commonly used chemotherapeutic agents for colorectal cancer (CRC)." | 7.83 | Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade. ( Chen, X; Dou, L; Leng, C; Luo, X; Wu, C; Zhang, B; Zhang, Z, 2016) |
| "Irinotecan (CPT-11)-induced neutropenia is associated with UDP-glucuronosyltransferase (UGT) 1A1*6 and *28 polymorphisms." | 7.83 | UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. ( Kusumi, T; Manabe, M; Miyata, Y; Mizunuma, N; Morita, Y; Taniguchi, F; Touyama, T, 2016) |
| "5-Fluorouracil (5-FU) is widely used in chemotherapy for treatment of colorectal cancer." | 7.83 | 5-Fluorouracil induces apoptosis of colorectal cancer cells. ( He, C; Li, CY; Liu, T; Wang, L; Zhang, JT; Zhou, WL, 2016) |
| "To evaluate the safety and efficacy of the combination therapy of fluorouracil, leucovorin and irinotecan (FOLFIRI) and aflibercept in Asian patients with metastatic colorectal cancer (mCRC), who had progressed after oxaliplatin-based chemotherapy." | 7.83 | Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. ( Chong, DQ; Choo, SP; Chua, C; Imperial, M; Manalo, M; Ng, M; Tan, IB; Teo, P; Yong, G, 2016) |
| "Multidrug resistance (MDR), a phenomenon that often occurs with drug treatment and is characterized by relapse or attenuation of drug efficacy, is almost unavoidable in colorectal cancer (CRC) patients receiving 5-fluorouracil (5-FU)-based chemotherapy." | 7.83 | miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1. ( Bian, Z; Feng, Y; Hu, Y; Huang, Z; Li, M; Liu, H; Yao, S; Yin, Y; You, Q, 2016) |
| "A 69-year-old woman presented with arterial hypotension, pulmonary oedema and a severely depressed left ventricular ejection fraction (LVEF) of 25% only 3 days after having received her first treatment for colorectal cancer with 5-fluorouracil (5-FU)-based therapy." | 7.83 | 5-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRI. ( Dalsgaard, M; Fakhri, Y; Lav Madsen, P; Nielsen, D, 2016) |
| " In this study, we investigated the effect of NNMT on 5-fluorouracil (5-FU) sensitivity of colorectal cancer (CRC) cells, and the underlying mechanisms." | 7.83 | Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. ( Li, F; Li, G; Liu, H; Ruan, Z; Wang, X; Wang, Y; Xie, X; Yu, H; Zhang, J; Zhou, Y, 2016) |
| "To analyze the efficacy of last line sorafenib treatment in colorectal cancer patients." | 7.83 | Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. ( Becker, M; Galle, PR; Martchenko, K; Möhler, M; Schimanski, CC; Schmidtmann, I; Thole, V; Thomaidis, T; Wehler, TC, 2016) |
| " In this study, we demonstrated that anisomycin, a JNK activator, stimulates nuclear export of GATA-6 in a colorectal cancer cell line, DLD-1." | 7.83 | Anisomycin-induced GATA-6 degradation accompanying a decrease of proliferation of colorectal cancer cell. ( Horyozaki, A; Maeda, M; Ushijima, H, 2016) |
| "The development of chemoresistance to 5-fluorouracil (5-FU) is a major obstacle for sustained effective treatment of colorectal cancer (CRC), with the mechanisms being not fully understood." | 7.83 | Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine. ( Chen, X; Chen, Y; Hao, L; Hou, A; Li, Y; Liang, H; Luo, P; Miao, H; Ou, J; Ruan, Z; Shi, C; Wang, R; Zhang, X, 2016) |
| "5-fluorouracil (5-FU)-based chemotherapy is the main chemotherapeutic approach for colorectal cancer (CRC) treatment." | 7.83 | Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells. ( Cai, Z; Che, J; Chen, D; Chen, J; He, L; Huang, L; Iwamoto, A; Lan, P; Lin, M; Liu, H; Lou, Q; Qin, Q; Ren, D; Wang, H; Wang, J; Wang, L; Wen, C; Yang, X; Zhang, D, 2016) |
| "The purpose of this study was to compare health-related quality of life (HRQoL) and costs associated with 2 adjuvant chemotherapy regimens [capecitabine-based therapy versus 5-fluorouracil/leucovorin (5-FU/LV)-based therapy] in stage III colorectal cancer patients." | 7.81 | Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients. ( Chen, HC; Chen, HH; Chen, WT; Chou, YH; Fang, CY; Hsu, HH; Huang, CC; Lee, HC; Lin, BW; Lin, JK; Lin, PC; Tan, EC; Ting, WC; Yang, MC; Yeh, CH, 2015) |
| " However, the molecular mechanism as to how miR-203 modulates the chemosensitivity to 5-fluorouracil (5-FU) in colorectal cancer is poorly known." | 7.81 | miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. ( Gao, F; Li, T; Zhang, XP, 2015) |
| " In the present study, we analyzed the cytotoxicity of LA on colorectal cancer (CRC) cells differing in their p53 status and investigated a putative synergistic effect with the anticancer drug 5-fluorouracil (5-FU)." | 7.81 | Lipoic acid induces p53-independent cell death in colorectal cancer cells and potentiates the cytotoxicity of 5-fluorouracil. ( Dörsam, B; Fahrer, J; Göder, A; Kaina, B; Seiwert, N, 2015) |
| "An aptamer (Apt) conjugated hyaluronan/chitosan nanoparticles (HACSNPs) were prepared as carrier for targeted delivery of 5-fluorouracil (5FU) to mucin1 (MUC1) overexpressing colorectal adenocarcinomas." | 7.81 | Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas. ( Atyabi, F; Dinarvand, R; Esfandyari-Manesh, M; Ghasemi, Z; Mottaghitalab, F; Sayari, E, 2015) |
| "Thymidylate synthase (TYMS) is an important enzyme for 5-fluorouracil (5-FU) metabolism in metastatic colorectal cancer (mCRC) patients." | 7.81 | Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. ( Abdallah, EA; Alves, VS; Araújo, DV; Buim, ME; Chinen, LT; Dettino, AL; Fanelli, MF; Gasparini Junior, JL; Machado Netto, MC; Mingues, NB; Ocea, LM; Rocha, BM; Romero, JV; Souza E Silva, V, 2015) |
| "We prospectively evaluated the feasibility of XELOX(oxaliplatin 130 mg/m/(2) on day 1 plus capecitabine 1,000 mg/m(2) twice daily on days 1 to 14 every 3 weeks) for adjuvant treatment in 15 patients with stage III/IV (Japanese classification) colorectal cancer and pathological curability A or B after D2-D3 lymph node dissection." | 7.81 | [A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer]. ( Higashino, K; Noura, S; Ohue, M; Sakai, D; Shingai, T; Sugimoto, N; Takeuchi, Y; Yagi, T; Yamamoto, S; Yano, M; Yoshinami, T, 2015) |
| " Herein, we investigated an alginate-based 3D scaffold for screening of 5-fluorouracil (5-FU) or/and curcumin on malignancy of colorectal cancer cells (CRC)." | 7.81 | Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. ( Buhrmann, C; Goel, A; Kraehe, P; Popper, B; Shakibaei, M; Shayan, P, 2015) |
| "Preoperative 5-fluorouracil (5-FU)-based chemoradiotherapy is a standard treatment for locally advanced colorectal cancer (CRC)." | 7.81 | Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. ( Ai, YQ; Cui, JG; He, WJ; Hou, Y; Jiang, YX; Ju, YH; Li, WH; Li, YF; Liu, S; Liu, Y; Qin, JY; Wang, L; Wang, Y; Wu, XR; Xia, YX; Xiong, W, 2015) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 7.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| " Overexpressing miR-197 could increase the sensitivity of colorectal cancer cells to 5-fluorouracil (5-FU)." | 7.81 | MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer. ( Bai, C; Chen, Y; Han, Q; Sun, Z; Zhao, L; Zhao, RC; Zhou, J; Zhou, N, 2015) |
| "There was performed a molecular genetic study of UGTlAl gene allelic variants polymorphism in patients with colorectal cancer who had had chemotherapy irinotecan-containing regimens FOLFIRI." | 7.81 | [The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer]. ( Abramova, NA; Dvadnenko, KV; Kit, OI; Vladimirova, LY; Vodolazhskiy, DI, 2015) |
| "This study aimed to investigate the association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and the prognosis of colorectal cancer (CRC) patients undergoing 5-fluorouracil (5-FU)-based chemotherapy in Taiwan." | 7.81 | Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer. ( Chang, LC; Chin, J; Hou, CF; Lin, TJ; Liu, WS; Su, SM; Wu, NC; Yang, JY, 2015) |
| " This gene codifies for the target enzyme of 5-fluorouracil (5-FU), the basic treatment in colorectal cancer." | 7.81 | Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS. ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015) |
| "We investigated the synergistic effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor plus radiation therapy, on the proliferation and survival of gastric cancer (GC) and colorectal cancer (CRC) cells." | 7.81 | Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor. ( Kang, WK; Kim, J; Lee, I; Lim, T, 2015) |
| "5-Fluorouracil (5-FU), a common chemotherapeutic agent used for the treatment of colorectal cancer (CRC), by itself has inadequate response rates; highlighting the need for novel and improved treatment regimens for these patients." | 7.81 | Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. ( Buhrmann, C; Goel, A; Kraehe, P; Popper, B; Shakibaei, M; Shayan, P, 2015) |
| "5-Fluorouracil (5-Fu) has been widely used as a first-line drug for colorectal cancer (CRC) treatment but limited by drug resistance and severe toxicity." | 7.81 | Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation. ( Fan, J; Kong, L; Liu, Q; Wang, P; Wang, X; Yang, Q; Yuan, W; Zhang, K, 2015) |
| " Aflibercept is used for the treatment of metastatic colorectal cancer (mCRC) in association with irinotecan." | 7.81 | Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. ( Beltjens, F; Bengrine, L; Ghiringhelli, F; Ladoire, S; Vincent, J, 2015) |
| "The efficacy of 5-fluorouracil (5-FU)-based chemotherapy for colorectal cancer (CRC) widely varies among patients; therefore, it is difficult to accurately predict chemotherapeutic responses." | 7.81 | Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer. ( Bai, W; Wu, Y; Xi, Y; Zhang, P, 2015) |
| "Assessment of oxaliplatin-associated hepatotoxicity in patients receiving oxaliplatin, fluorouracil and leucovorin chemotherapy (FOLFOX) for colorectal cancer remains controversial." | 7.81 | Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate and is an Indicator Of Hepatotoxicity In Patients Receiving FOLFOX for Colorectal Cancer. ( Fujino, S; Hosokawa, Y; Katsumata, K; Makino, H; Maruno, K; Mushiake, H; Sugiyama, Y; Watanabe, M, 2015) |
| "To evaluate the cost-effectiveness of the addition of bevacizumab to the irinotecan-fluorouracil (Douillard regimen-CPT-FUFA-) in first-line treatment of metastatic colorectal cancer in a single-institution population." | 7.80 | Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer. ( Albert-Mari, A; Jimenez-Torres, NV; Ruiz-Millo, O; Sendra-Garcia, A, 2014) |
| "TS mRNA expression levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer." | 7.80 | TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer. ( Guan, W; Hu, J; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Xie, L; Yu, L; Zhang, Q, 2014) |
| "Although FOLFOX (infusional fluorouracil/leucovorin plus oxaliplatin) is established as a standard chemotherapeutic regimen, the long term efficacy of adjuvant XELOX (oral capecitabine plus intravenous oxaliplatin) in Asian colorectal cancer (CRC) patients remains anecdotal." | 7.80 | Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. ( Chiu, J; Chu, KW; Epstein, RJ; Leung, R; Poon, J; Tang, V; Wong, H; Yau, T, 2014) |
| " However, it is still unknown the association of GOLPH3 expression with the prognosis of colorectal cancer (CRC) patients who received 5-fluorouracil (5-FU)-based adjuvant chemotherapy." | 7.80 | GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy. ( Chen, L; Cui, M; Di, J; Dong, B; Ji, J; Jiang, B; Liu, M; Ma, Y; Su, X; Wang, Z; Xing, J; Yang, H; Yao, Z; Zhang, C; Zhang, N, 2014) |
| "This study compared the clinical responses of patients with metastatic colorectal cancer (mCRC) with 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) plus bevacizumab therapy either with or without uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping and irinotecan dose escalation." | 7.80 | Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinote ( Chang, SF; Hu, HM; Huang, CM; Huang, CW; Huang, ML; Huang, MY; Lu, CY; Tsai, HL; Wang, JY; Yu, FJ, 2014) |
| "Patients with colorectal tumors with microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but have a poor response to 5-fluorouracil–based chemotherapy." | 7.80 | Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy. ( Arzouk, H; Bengrine-Lefèvre, L; Biard, DS; Bouvier, AM; Buhard, O; Chapusot, C; Collura, A; Coquelle, A; De Thonel, A; Delarue, P; Dorard, C; Duval, A; Fléjou, JF; Garrido, C; Gaub, MP; Guilloux, A; Iacopetta, B; Lacoste, C; Lagrange, A; Lefèvre, JH; Lepage, C; Loh, M; Marcion, G; Marisa, L; Mews, A; Milano, G; Parc, Y; Platell, C; Saget, A; Seigneuric, R; Selves, J; Senet, P; Soong, R; Svrcek, M; Taieb, A; Tournigand, C; Wanherdrick, K; Zeps, N, 2014) |
| "Weekly cetuximab plus irinotecan-based regiments are standard first- and second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC)." | 7.80 | Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. ( Bi, F; Cao, D; Chen, Y; Li, Q; Qiu, M, 2014) |
| "We retrospectively investigated the relationship between IVS14+1 G > A genotype of the dihydropyrimidine dehydrogenase (DPD) gene with plasma concentration of 5-fluorouracil (5-FU) as well as adverse reactions in 80 patients with locally advanced or metastatic colorectal cancer." | 7.80 | The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: ( Cai, X; Fang, JM; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2014) |
| "Although 5-fluorouracil (5-FU) is an important drug for colorectal cancer (CRC) treatment, no useful biomarker is currently available to predict treatment response." | 7.80 | Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. ( Fukui, T; Iida, T; Miyake, H; Miyoshi, N; Naitou, H; Ochiai, T; Ohno, K; Okumura, M; Sakamoto, M; Takahashi, M; Tokunaga, Y; Tsumura, H; Umeki, M, 2014) |
| "The effectiveness of 5-fluorouracil (5-FU)-based adjuvant chemotherapy is reported in patients with colorectal cancer (CRC), but the usefulness of 5-FU metabolic enzymes as predictive biomarkers of the efficacy of this chemotherapy remains unclear." | 7.80 | Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. ( Hasegawa, H; Ishii, Y; Kitagawa, Y; Okabayashi, K; Shigeta, K, 2014) |
| " Therefore, we hypothesized that SNAI2 (Slug) may mediate 5-fluorouracil (5FU) chemotherapy resistance through inhibition of miR145 in colorectal cancer and thus represents a novel therapeutic target to enhance current colorectal cancer treatment strategies." | 7.80 | SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. ( Camp, ER; Ethier, SP; Findlay, VJ; Hurst, K; Nogueira, LM; Quirk, D; Staveley O'Carroll, KF; Wang, C; Watson, DK, 2014) |
| "Recent observational studies showed that post-operative aspirin use reduces cancer relapse and death in the earliest stages of colorectal cancer." | 7.80 | Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. ( Ali, R; Chan, ML; Chia, WK; Deng, YH; Ho, GF; Jian, X; Mehta, S; Segelov, E; Sharma, A; Soon, SS; Tan, CS; Toh, HC; Wee, HL, 2014) |
| "We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict effectiveness of bevacizumab added to capecitabine and oxaliplatin (CAPEOX) in patients with metastatic colorectal cancer (mCRC)." | 7.80 | Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab. ( Boisen, MK; Dehlendorff, C; Hansen, TF; Holländer, NH; Høgdall, EV; Jensen, BB; Jensen, BV; Johansen, JS; Keldsen, N; Larsen, JS; Linnemann, D; Nielsen, BS; Nielsen, SE; Osterlind, K; Pfeiffer, P; Qvortrup, C; Tarpgaard, LS, 2014) |
| "The triplet combination of fluorouracil, oxaliplatin and irinotecan for metastatic colorectal cancer improves efficacy at the cost of increased toxicity." | 7.80 | Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis. ( Brunner, S; Camenisch Gross, U; Cathomas, R; Freyholdt, T; Mey, U; von Moos, R, 2014) |
| "Effectiveness and toxicity of transcatheter arterial injection of irinotecan-eluting beads (DEBIRI) with and without concurrent capecitabine in pre-treated patients with metastatic colorectal cancer (CRC)." | 7.80 | Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. ( Akinwande, O; Hayes, D; Martin, RC; Miller, A; O'Hara, R; Tomalty, D, 2014) |
| " Herein, we examined the effectiveness of a combination treatment regimen of 5-fluorouracil (5-FU) and curcumin in colorectal cancer (CRC) cells." | 7.79 | Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways. ( Busch, F; Goel, A; Lueders, C; Mobasheri, A; Shakibaei, M; Shayan, P, 2013) |
| "First-line chemotherapeutic treatment of colorectal cancer (CRC) typically comprises oral (capecitabine) or intravenous 5-fluorouracil (5-FU) plus leucovorin (LV), in combination with oxaliplatin (XELOX or FOLFOX, respectively), although debate exists regarding the best course of treatment by modality in clinical practice." | 7.79 | Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice. ( Clingan, PR; Dawber, JP; Eckermann, S; Healey, E; Ranson, M; Stillfried, GE, 2013) |
| " 5-fluorouracil (5-FU) has been a drug of choice for treatment of colorectal cancer (CRC)." | 7.79 | Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. ( Kang, SB; Kim, DG; Kim, IH; Kim, SH; Kim, SL; Kim, SW; Lee, SO; Lee, ST; Trang, KT, 2013) |
| "We investigated the correlation between plasma ratio of dihydrouracil/uracil (UH2/Ura), a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase (DPD) activity, and 5-fluorouracil (5-FU) treatment efficacy in rats with colorectal cancer (CRC)." | 7.79 | Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013) |
| "We developed a pharmacokinetic/pharmacodynamic (PK/PD) model with the value of the plasma ratio of dihydrouracil (UH2)/uracil (Ura), which is a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase activity, determined before 5-fluorouracil (5-FU) treatment to simulate the growth of tumors after 5-FU treatment in rats with colorectal cancer (CRC)." | 7.79 | Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013) |
| "To investigate the use of liposomal irinotecan (Irinophore C™) plus or minus 5-fluorouracil (5-FU) for the treatment of colorectal cancer." | 7.79 | Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil. ( Allen, TM; Anantha, M; Bally, MB; Dos Santos, N; Harasym, N; Hare, JI; Neijzen, RW; Waterhouse, DN; Webb, MS, 2013) |
| "To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer." | 7.79 | Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013) |
| "This retrospective cohort study investigated the association between epidermal growth factor receptor (EGFR) polymorphisms and clinical outcomes in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy." | 7.79 | Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy. ( Chiou, HY; Hsieh, LL; Lai, CY; Sung, FC; Tang, R; Wu, FY; Yeh, CC, 2013) |
| "The relationship between the plasma ratio of dihydrouracil/uracil (UH2/Ura) and hepatic dihydropyrimidine dehydrogenase (DPD) activity after repeated 5-fluorouracil (5-FU) treatment in rats with colorectal cancer (CRC) was investigated." | 7.79 | A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Nishimura, A; Okada, K; Shibata, N; Takada, K, 2013) |
| "The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 7.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "To evaluate gemcitabine plus capecitabine as third-line or later-line therapy in patients with refractory advanced colorectal cancer (CRC) who maintain a good performance status (PS)." | 7.79 | Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study. ( Alonso, MÁ; Jorge, M; Mendez, JC; Montes, AF; Pellón, ML; Quintero, G; Ramos, M; Reboredo, M; Romero, C; Salgado, M; Valladares-Ayerbes, M; Varela, S, 2013) |
| "Mucinous colorectal cancer (CRC) exhibits distinct clinical and pathological features, including poorer response to fluorouracil (FU) compared with non-mucinous tumours." | 7.79 | Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. ( Ardizzoni, A; Azzoni, C; Bottarelli, L; Campanini, N; Cascinu, S; Cunningham, D; Mandolesi, A; Negri, FV; Scartozzi, M; Silini, EM; Tinelli, C; Wotherspoon, A, 2013) |
| "In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality." | 7.79 | Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. ( Gao, F; Guan, M; Xue, Y; Zhang, Q; Zhang, Y; Zheng, Z, 2013) |
| "We analyzed the clinical efficacy and safety of capecitabine plus oxaliplatin( XELOX) and bevacizumab( BV) as neoadjuvant chemotherapy, administered for the treatment of patients with resectable metastatic colorectal cancer between October 2009 and December 2012." | 7.79 | [Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer]. ( Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Mihara, K; Mori, T; Nagashima, A; Ohkubo, Y; Yamamuro, W, 2013) |
| "Capecitabine is one of the most effective oral chemotherapeutic drugs for advanced or recurrent colorectal cancer and gastric cancer." | 7.79 | [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy]. ( Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K, 2013) |
| "The drug fluorouracil (5-FU) is a widely used antimetabolite chemotherapy in the treatment of colorectal cancer." | 7.79 | Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer. ( Ally, AA; Asano, JK; Brown, CJ; Chan, SY; Cheng, GS; Cheung, PY; Chittaranjan, S; Gill, S; Griffith, M; Griffith, OL; Hou, YC; Lee, A; Luk, M; Marra, MA; Miao, L; Moore, R; Morin, GB; Morin, RD; Mwenifumbo, JC; Novik, K; Owen, D; Paul, JE; Pugh, TJ; Severson, T; Tai, IT; Tang, MJ; Taylor, G, 2013) |
| " We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX)." | 7.79 | Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. ( Andreu, M; Baiget, M; Bessa, X; Brea-Fernández, A; Bujanda, L; Candamio, S; Carracedo, A; Castells, A; Castellví-Bel, S; Cazier, JB; Cortejoso, L; Crous-Bou, M; Durán, G; Fernandez-Rozadilla, C; Gallardo, E; García, MI; González, D; Gonzalo, V; Guinó, E; Jover, R; Lamas, MJ; Llor, X; López, R; López-Fernández, LA; Moreno, V; Páez, D; Palles, C; Paré, L; Reñé, JM; Rodrigo, L; Ruiz-Ponte, C; Tomlinson, I; Xicola, R, 2013) |
| "The aim of the study was to analyse the prevalence and characteristics of secondary diabetes induced by 5-fluorouracil (5-FU) based chemotherapy in non-diabetic patients with colorectal cancer (CRC)." | 7.79 | Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. ( Fang, J; Feng, JP; Li, M; Lin, M; Luo, M; Xie, T; Ye, DW; Yuan, XL; Zhou, Y; Zhu, YM, 2013) |
| "We initiated this preclinical study in order to analyze the impact of sorafenib single treatment versus combination treatment in human colorectal cancer." | 7.79 | Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy. ( Berger, MR; Galle, PR; Gockel, I; Graf, C; Hainz, M; Hamdi, S; Maderer, A; Moehler, M; Schimanski, CC; Schmidtmann, I; Theobald, M; Wehler, TC, 2013) |
| "To investigate the hepatic dihydropyrimidine dehydrogenase (DPD) activity in colorectal cancer (CRC), which is critically important to create a patient-specific dosing regimen, we performed 5-FU pharmacokinetic studies in 1,2-dimethylhydrazine-induced CRC model rats (CRC rats)." | 7.79 | Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats. ( Imoto, K; Ito, Y; Kobuchi, S; Okada, K; Takada, K, 2013) |
| "Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy." | 7.79 | Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013) |
| "Resistance to 5-fluorouracil (5FU) poses a constant challenge to the management of colorectal cancer (CRC)." | 7.79 | Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy. ( Chan, EC; Cheah, PY; Ho, HK; Koh, PK; Mal, M; Phua, LC, 2013) |
| "The goal of the present study was to compare the efficacy of the combination of cetuximab and irinotecan to the combination of oxaliplatin and fluoropyrimidines as second-line chemotherapy in patients with irinotecan-refractory and oxaliplatin-naïve metastatic colorectal cancer (mCRC) harboring wild-type KRAS." | 7.79 | Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. ( Baek, JY; Hong, YS; Kim, HJ; Kim, JC; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Lim, SB; Park, JH; Park, SJ; Yu, CS, 2013) |
| "No standard treatment exists for patients with metastatic colorectal cancer who have progressed after treatment with 5-fluorouracil (5-FU), oxaliplatin, irinotecan and an anti-EGFR antibody." | 7.78 | Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer. ( Boisen, MK; Fromm, AL; Jensen, BV; Larsen, FO, 2012) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 7.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| " The aim of this study was to investigate the schedule-dependent effect of 5-fluorouracil (5-FU) and platinum derivatives (cisplatin or oxaliplatin) in colorectal cancer (CRC) cell lines, and to explore factors affecting it." | 7.78 | Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells. ( Fujita, M; Minegaki, T; Okumura, K; Takahashi, M; Takara, K; Yamamoto, K; Yokoyama, T, 2012) |
| "The efficacy of bevacizumab combined with infusional 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan (FOLFIRI) as the second-line treatment for metastatic colorectal cancer (mCRC) has not been fully clarified, although bevacizumab combined with infusional 5-FU/LV plus oxaliplatin (FOLFOX) in the second-line setting has demonstrated a survival benefit." | 7.78 | Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud ( Baba, E; Bando, H; Boku, N; Esaki, T; Fukunaga, M; Hyodo, I; Kato, S; Katsumata, K; Miyake, Y; Moriwaki, T; Ozeki, M; Satoh, T; Takashima, A; Yamashita, K; Yamazaki, K; Yoshida, S, 2012) |
| " We investigated the clinical significance of miR-10b and its involvement in chemotherapeutic resistance to 5-fluorouracil (5-FU), which is a key component of common chemotherapy regimens in colorectal cancer." | 7.78 | MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. ( Doki, Y; Ishii, H; Mimori, K; Mori, M; Nishida, N; Shibata, K; Sudo, T; Tanaka, F; Yamamoto, H; Yamashita, S, 2012) |
| " The aim of the present study was to analyse the possible predictive value of miRNA-126 in relation to first line capecitabine and oxaliplatin (XELOX) in patients with metastatic colorectal cancer (mCRC)." | 7.78 | The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. ( Hansen, TF; Jakobsen, A; Lindebjerg, J; Sørensen, FB, 2012) |
| " We analysed a cohort of 302 patients with colorectal cancer treated with 5-Fluorouracil (5-FU)." | 7.78 | Data-driven assessment of the association of polymorphisms in 5-Fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. ( Afzal, S; Colding-Jørgensen, M; Jensen, SA; Mosekilde, E; Poulsen, HE; Rasmussen, CH; Sarac, SB; Thirstrup, S, 2012) |
| " Deficient mismatch repair, or microsatellite instability, is a potent marker for the ineffectiveness of 5-fluorouracil (5-FU) in colorectal cancer (CRC)." | 7.78 | FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer. ( Fujinaka, Y; Iimori, M; Kakeji, Y; Kitao, H; Maehara, Y; Morita, M; Nakanishi, R; Tokunaga, E; Yamashita, N, 2012) |
| " In this retrospective study, we assessed the efficacy of palonosetron versus granisetron for the incidence of CINV induced by mFOLFOX6 and FOLFIRI in patients with advanced colorectal cancer." | 7.78 | [Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey]. ( Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M, 2012) |
| "Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation." | 7.78 | Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012) |
| "Radiosensitization by vorinostat under hypoxia was studied in four colorectal carcinoma cell lines and in one colorectal carcinoma xenograft model by analysis of clonogenic survival and tumor growth delay, respectively." | 7.78 | Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. ( Flatmark, K; Fleten, KG; Furre, T; Hektoen, HH; Kristian, A; Ree, AH; Saelen, MG, 2012) |
| "To evaluate effects of UDP-glucuronosyltransferase1A1 (UGT1A1) and thymidylate synthetase (TS) gene polymorphisms on irinotecan in metastatic colorectal cancer (mCRC)." | 7.78 | UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. ( Jiao, SC; Liu, ZY; Shen, L; Wang, JW; Wang, Y; Xu, JM; Xu, N, 2012) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 7.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "Capecitabine plus oxaliplatin (CAPOX) is an established treatment option in colorectal cancer, but can be associated with severe toxicities." | 7.77 | Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. ( Baird, R; Barbachano, Y; Biondo, A; Chau, I; Chhaya, V; Cunningham, D; Karpathakis, A; McLachlan, J; Rahman, S, 2011) |
| "Irinotecan (CPT11) at 180 mg/m(2) with LV5FU2 for metastatic colorectal cancer (MCRC) has response rates (RRs) of 56 and 4% as first- and second-line treatments, respectively [1-2], and higher doses of CPT11 result in higher RRs." | 7.77 | Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients. ( Goubely, Y; Kirscher, S; Mineur, L; Molinari, N; Plat, F; Sabatier, R, 2011) |
| "A total of 152 patients with metastatic colorectal cancer who were treated with oxaliplatin and continuous infusion 5-fluorouracil were genotyped for 21 polymorphisms in 13 cancer-related genes by PCR." | 7.77 | Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. ( El-Khouiery, A; Gordon, MA; Iqbal, S; Labonte, M; Ladner, RD; Lenz, HJ; Lurje, G; Nagashima, F; Sherrod, A; Wilson, P; Yang, D; Zhang, W, 2011) |
| " In the present study, we evaluated the characteristics of paclitaxel (PTX) and 5-fluorouracil (5-FU) penetration and their effects on tissue penetration using MCLs of human colorectal cancer cells (DLD-1 and HT-29) grown in Transwell inserts." | 7.77 | Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells. ( Choi, MS; Kim, SH; Kuh, HJ, 2011) |
| "Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer." | 7.77 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 7.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| " In the present study, we aimed to investigate the antitumor effect of DCA combined with 5-Fluorouracil (5-FU) on colorectal cancer (CRC) cells." | 7.77 | Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. ( He, J; Li, J; Liang, H; Pan, F; Tong, J; Xie, G, 2011) |
| " We aimed to evaluate the effect of pretreatment serum metabolic profiles generated by (1)H NMR spectroscopy on toxicity in patients with inoperable colorectal cancer receiving single agent capecitabine." | 7.77 | Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. ( Backshall, A; Clarke, SJ; Keun, HC; Sharma, R, 2011) |
| "Germline DNA was available from 568 previously untreated patients with advanced colorectal cancer participating in the CAIRO2 trial, assigned to capecitabine, oxaliplatin, and bevacizumab ± cetuximab." | 7.77 | Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. ( Beijnen, JH; Burylo, AM; Cats, A; de Boer, A; Deenen, MJ; Doodeman, VD; Guchelaar, HJ; Punt, CJ; Schellens, JH; Smits, PH; Tol, J; Vincent, A, 2011) |
| "Thymidylate synthase (TS) expression levels appear to be related to response to 5-fluorouracil-(5-FU)-based chemotherapy in colorectal cancer (CRC) patients." | 7.77 | Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. ( Cianchi, F; Genuardi, M; Mazzei, T; Mini, E; Morganti, M; Napoli, C; Nobili, S; Papi, L; Putignano, AL; Tonelli, F; Valanzano, R; Vignoli, M, 2011) |
| "We have extensively assessed a biweekly regimen of irinotecan plus folinic acid and fluorouracil bolus (IRIFAFU) in metastatic colorectal cancer (MCRC)." | 7.77 | Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience. ( Barbato, E; Barberis, G; Comella, P; Condemi, G; Filippelli, G; Ionta, MT; Massidda, B; Natale, D; Palmeri, S; Putzu, C; Sandomenico, C; Tafuto, S; Vessia, G, 2011) |
| "The role of the calcium binding protein, Calbindin 2 (CALB2), in regulating the response of colorectal cancer (CRC) cells to 5-Fluorouracil (5-FU) was investigated." | 7.77 | Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway. ( Allen, WL; Johnston, L; Johnston, PG; Longley, DB; McCloskey, K; Proutski, I; Stevenson, L; Stewart, G; Wilson, PM, 2011) |
| "Infusional fluorouracil/leucovorin (FU/LV) plus irinotecan (FOLFIRI) is one of the standard first-line options for patients with metastatic colorectal cancer (mCRC)." | 7.77 | A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. ( Baiget, M; del Rio, E; Marcuello, E; Páez, D; Paré, L; Salazar, J; Sebio, A, 2011) |
| "We studied patterns of DNA damage signaling and cell cycle response to clinically-relevant (bolus) and high doses of 5-fluorouracil (5-FU) in three colorectal cancer cell lines with differing MMR and TP53 status in an attempt to better understand how 5-FU exerts its cytotoxicity." | 7.77 | DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status. ( Adamsen, BL; De Angelis, PM; Kravik, KL, 2011) |
| "FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients." | 7.77 | Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. ( Eshima, K; Horie, H; Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Konishi, T; Matsuda, K; Muto, T; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011) |
| "5-fluorouracil (5FU)-based chemotherapy is the standard treatment for advanced stage colorectal cancer (CRC) patients." | 7.77 | DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. ( Carethers, JM; Iwaizumi, M; Tseng-Rogenski, S, 2011) |
| "For recurrent or metastatic colorectal cancer, a combination of leucovorin and fluorouracil with oxaliplatin (FOLFOX)is a standard first-line regimen." | 7.77 | [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy]. ( Hasegawa, J; Hirota, M; Kim, Y; Nezu, R; Nishimura, J; Yoshida, Y, 2011) |
| "The purpose of this study was to investigate whether specific combinations of polymorphisms in 5-fluorouracil (5-FU) metabolism-related genes were associated with outcome in 5-FU-based adjuvant treatment of colorectal cancer." | 7.77 | The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. ( Adleff, V; Afzal, S; Andersen, JT; Barile, C; Bertolaso, L; Brødbæk, K; Budai, B; Gusella, M; Hitre, E; Jensen, SA; Jimenez-Solem, E; Kralovánszky, J; Láng, I; Orosz, E; Padrini, R; Pasini, F; Petersen, M; Poulsen, HE; Vainer, B; Vogel, U, 2011) |
| " Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)." | 7.77 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994) |
| "Failure rate of colorectal cancer after surgical resection remains around 50% and adjuvant treatments are clearly required." | 7.77 | Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU. ( Nordlinger, B; Rougier, P, 1993) |
| "To investigate the mechanism of enhancing apoptosis-inducing effects of 5-fluorouracil on human colorectal adenocarcinoma cells by stable transfection of extrinsic Fas-associated death domain protein (FADD) gene, both in vitro and in vivo." | 7.76 | Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. ( Jiang, Y; Luo, H; Yin, A; Zhang, X, 2010) |
| "A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC)." | 7.76 | Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. ( Bodnar, L; Stec, R; Szczylik, C, 2010) |
| " We investigated whether p53 polymorphism and mutation were associated with in vitro sensitivity to 5-fluorouracil (5-FU) in patients with colorectal cancer." | 7.76 | Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. ( Higashiguchi, T; Hotta, T; Iwahashi, M; Matsuda, K; Nasu, T; Oku, Y; Takifuji, K; Tominaga, T; Yamaue, H; Yokoyama, S, 2010) |
| "The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (XELOX)." | 7.76 | EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. ( Andersen, RF; Jakobsen, A; Jensen, LH; Ploen, J; Spindler, KG, 2010) |
| " To test this we have addressed the hypothesis that histone deacetylase inhibitors SBHA and MS275 potentiate inhibitory effects of classical anti-colorectal cancer cytostatic, 5-fluorouracil (5-FU), on survival of colorectal cancer (CRC) cells in vitro." | 7.76 | MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. ( Flis, K; Flis, S; Gnyszka, A; Spławiński, J, 2010) |
| "The in vitro chemosensitizing effect of triptolide (PG490) on the cytotoxicity of 5-fluorouracil (5-FU) was determined in three colorectal cancer (CRC) cell lines." | 7.76 | Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. ( Armesilla, AL; Cassidy, J; Darling, JL; Guo, X; Mathew, S; Wang, W; Xu, B, 2010) |
| "The aim was to evaluate the cost of capecitabine vs conventional combination chemotherapics such as 5-fluorouracil (5-FU) for the treatment of metastatic colorectal cancer (mCRC) in Italy." | 7.76 | Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients. ( Bianchessi, C; Bollina, R; Carteni, G; Cozzi, C; De Portu, S; Grimaldi, AM; Mantovani, LG; Ravaioli, A; Tamburini, E; Testa, TE, 2010) |
| "To explore the effect of PI3K p85alpha gene silencing on the 5-fluorouracil (5-FU)-induced apoptosis of colorectal cancer cells." | 7.76 | [PI3K p85alpha gene silencing by RNA interference promotes 5-fluorouracil-induced apoptosis of colorectal cancer LoVo cells]. ( Ma, YQ; Ni, L; Song, YG; Yang, H, 2010) |
| " The SFK inhibitor saracatinib (AZD0530) is currently in phase II trials in patients including those with colorectal cancer (CRC), where links between SFK activity and poor prognosis are particularly striking." | 7.76 | Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. ( Bönisch, H; Bryce, RA; Dive, C; Ghattas, M; Green, TP; Hickinson, DM; Morrow, CJ; Smith, C, 2010) |
| "A hospital based cross-sectional retrospective study was conducted to determine the frequency of hand foot syndrome (HFS) with Capecitabine as a single agent and in combination with Oxaliplatin." | 7.76 | High frequency of hand foot syndrome with capecitabine. ( Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N, 2010) |
| "Resistance to 5-fluorouracil (5-FU) represents a major contributor to cancer-related mortality in advanced colorectal cancer patients." | 7.76 | Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. ( Auman, JT; Deal, AM; Hoskins, JM; Hudson, ML; Ibrahim, JG; McLeod, HL; Meyers, MO; Muhale, F; O'Neil, BH; Thorne, LB; Walko, CM; Watson, RG; Yu, J, 2010) |
| "Although the 2009 edition of the Guidelines for Colorectal Cancer Therapy recommend capecitabine as a standard postoperative adjuvant chemotherapy for colorectal cancer therapy, a characteristic adverse event, hand-foot syndrome, develops at a high incidence, and appropriate management is necessary to continue therapy." | 7.76 | [Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome]. ( Chiba, M; Fujimoto, H; Igawa, A; Iizawa, H; Ikeda, E; Inoue, K; Ishiyama, K; Kobayashi, Y; Matsuda, M; Mori, N; Saito, T; Sato, T; Sugawara, M; Suto, T; Suzuki, Y; Watanabe, T; Yabuki, H, 2010) |
| "Patients with locally advanced and metastatic colorectal cancer treated with capecitabine or 5-fluorouracil/leucovorin (5-FU/LV) as monotherapy or combination therapy with oxaliplatin from 2003-2006 were identified in the Thomson Reuters MarketScan® databases." | 7.76 | Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. ( Cartwright, T; Chu, E; McKenna, EF; Schulman, KL, 2010) |
| "Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC)." | 7.76 | Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. ( Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M, 2010) |
| "The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients." | 7.76 | Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. ( Choi, IK; Choi, YJ; Kang, EJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2010) |
| "This retrospective study evaluated the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil (5-FU) for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy." | 7.76 | Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. ( Arai, Y; Aramaki, T; Boku, N; Inaba, Y; Kichikawa, K; Matsuoka, M; Nishiofuku, H; Otsuji, T; Sato, Y; Tanaka, T, 2010) |
| "In progressive colorectal cancer these treatment results can be regarded as a significant change in the natural history of the disease." | 7.76 | Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer. ( Freund, M; Poliwoda, H; Preusser, P; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, H, 1988) |
| "The aim of this study is to evaluate if mismatch repair (MMR) defective colorectal cancer has a different response to adjuvant 5-fluorouracil (5-FU) chemotherapy in a cohort of patients prospectively followed during 5 years." | 7.75 | The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. ( Alenda, C; Andreu, M; Balaguer, F; Bessa, X; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Jover, R; Llor, X; Morillas, JD; Nicolás-Pérez, D; Payá, A; Pons, E; Reñé, JM; Sempere, L; Xicola, RM; Zapater, P, 2009) |
| "Modifying the capecitabine dosing schedule from 14 days on, 7 days off (14/7) to 7 days on, 7 days off (7/7) may enable higher doses and improved antitumor efficacy in colorectal cancer xenografts." | 7.75 | In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models. ( Dugan, U; Heimbrook, D; Higgins, B; Kohles, J; Kolinsky, K; Packman, K; Shen, BQ; Zhang, YE; Zioncheck, TF, 2009) |
| "To investigate the synergistic effect of epidermal growth factor(EGF) and 5-fluorouracil for the treatment of human colorectal cancer in BALB/C nude mice subcutaneous xenografts model." | 7.75 | [Synergistic use of epidermal growth factor and 5-fluorouracil for the treatment of human colorectal cancer in BALB/C nude mice subcutaneous xenograft model]. ( Tao, KX; Wang, GB; Ye, L, 2009) |
| "Capecitabine, an oral alternative to 5-fluorouracil (5-FU) in patients with colorectal cancer (CRC), has equal clinical efficacy and a favorable safety profile; however, its use may be limited because of unit cost concerns." | 7.75 | Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. ( Chu, E; Schulman, KL; Song, X; Zelt, S, 2009) |
| "A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study." | 7.75 | Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. ( Bae, SH; Chae, YS; Choi, GS; Jeon, SW; Jun, SH; Kang, BM; Kim, JG; Kum, Y; Lim, KH; Moon, JH; Park, IJ; Ryoo, HM; Sohn, SK, 2009) |
| "Panaxadiol enhanced the anti-cancer effects of 5-FU on human colorectal cancer cells through the regulation of cell cycle transition and the induction of apoptotic cells." | 7.75 | Panaxadiol, a purified ginseng component, enhances the anti-cancer effects of 5-fluorouracil in human colorectal cancer cells. ( Li, XL; Mehendale, SR; Sun, S; Wang, CZ; Wang, Q; Yuan, CS, 2009) |
| "The purpose of this study was to assess retrospectively the sequential treatment of hepatic arterial infusion (HAI) chemotherapy followed by systemic therapy using oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin, namely, FOLFOX, for patients with liver metastases from colorectal cancer." | 7.75 | Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer. ( Ozaki, T; Seki, H; Shiina, M, 2009) |
| "The correlations between adenomatous polyposis coli (APC) mutations and 5-fluorouracil (5-FU) adjuvant chemotherapy and colorectal cancer (CRC) patients' prognosis are not well known." | 7.75 | Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects. ( Chen, SP; Chen, YL; Chiu, SC; Harn, HJ; Kang, JC; Lin, PC; Lin, SZ; Pang, CY; Su, CC; Wu, CC, 2009) |
| "A combination of oxaliplatin(L-OHP), folinic acid and 5-fluorouracil(5-FU)(mFOLFOX6)has been widely administered to treat advanced or recurrent colorectal cancer." | 7.75 | [Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction]. ( Chihara, S; Demizu, M; Iwakawa, S; Kimura, F; Maeda, C; Nakanishi, Y; Oosawa, M; Ueda, H; Yano, K, 2009) |
| "We designed a study protocol in 2005 and 16 patients with metastatic colorectal cancer were treated accordingly in the first line setting with XELIRI regimen (capecitabin, irinotecan) + bevacizumab." | 7.75 | [Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer]. ( Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M, 2009) |
| " The aims of the present study were to compare, in vitro and in vivo, the antiangiogenic and antitumor activities of metronomic irinotecan (CPT-11), oxaliplatin (L-OHP) and 5-fluorouracil (5-FU) in colorectal cancer and to investigate the metronomic combination of these drugs." | 7.75 | Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. ( Alì, G; Allegrini, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Emmenegger, U; Falcone, A; Fioravanti, A; Fontanini, G; Orlandi, P, 2009) |
| "To compare chemotherapy-related and total medical costs among patients with colorectal cancer (CRC) receiving capecitabine or 5-fluorouracil (5-FU) monotherapy after surgical resection." | 7.75 | Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. ( Bendell, JC; Cartwright, T; Chu, E; Shi, N; Wei, W, 2009) |
| "To evaluate the efficacy and the safety of combined 5-Fluorouracil, irinotecan, bevacizumab and sirolimus in refractory advanced colorectal carcinoma." | 7.75 | Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study. ( Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S, 2009) |
| "5-Fluorouracil (5-FU) is considered to be the backbone of colorectal cancer (CRC) systemic therapy since the great majority of recommended regimens include its administration." | 7.75 | Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma. ( Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE, 2009) |
| "We describe the case of an HIV-positive 48-year-old male patient with metastatic colorectal cancer, treated with a bevacizumab, irinotecan, fluorouracil, and leucovorin regimen, with concomitant HAART." | 7.74 | Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. ( Bearz, A; Berretta, M; Berretta, S; Fisichella, R; Lleshi, A; Nasti, G; Simonelli, C; Tirelli, U; Zanet, E, 2008) |
| "We investigated the association between thymidylate synthase (TS) germline polymorphisms and response to 5-fluorouracil-based chemotherapy in 80 patients with liver-only metastatic colorectal cancer (MCRC)." | 7.74 | Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. ( Alessandroni, P; Baldi, G; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Fornaro, L; Giordani, P; Giustini, L; Graziano, F; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Ruzzo, A; Santini, D; Tonini, G; Vincenzi, B, 2008) |
| " [Ann Oncol 2002;13:308-317] showed that four prognostic variables can be used to classify patients with metastatic colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)/leucovorin (LV) into three risk groups with different overall survival (OS)." | 7.74 | Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. ( Hurwitz, H; Irl, C; Kabbinavar, F; Zurlo, A, 2008) |
| "In this study, we investigated the efficacy and toxicity of fluorouracil(FU)+Leucovorin(LV)with oxaliplatin (FOLFOX)and irinotecan(FOLFIRI)for patients with advanced or metastatic colorectal cancer." | 7.74 | Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies. ( Adachi, K; Arimoto, Y; Kanamiya, Y; Nakamura, R; Nishio, K; Oba, H; Ohtani, H; Shintani, M; Yui, S, 2008) |
| "The modified irinotecan plus bolus 5-fluorouracil/L-leucovorin (IFL) regimen (irinotecan plus bolus 5-fluorouracil/L-leucovorin) used to be one of the standard treatments for metastatic colorectal cancer until approval of oxaliplatin in Japan." | 7.74 | Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan. ( Chin, K; Hatake, K; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Shouji, D; Suenaga, M; Yamaguchi, T, 2008) |
| "This retrospective study was performed to evaluate a survival benefit of the full administration of 5-fluorouracil (5-FU), irinotecan (CPT-11), and oxaliplatin (L-OHP) to patients with unresectable or recurrent colorectal cancer." | 7.74 | [The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer]. ( Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Matsuki, M; Mitsuhashi, T; Miyazaki, T; Okada, N; Okita, T; Sano, M; Yokoyama, M, 2008) |
| " To meet this demand, a nurse-/pharmacy-led clinic was established at the Beatson Oncology Centre in 2003 for the provision of oral capecitabine to metastatic colorectal cancer patients to provide a controlled and supportive environment." | 7.74 | A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences. ( Branch, A; Cassidy, J; MacDonald, L; MacLeod, A; McDonald, A; Mohammed, N, 2007) |
| "The purpose of this study was to compare the activities of various enzymes, participating in the metabolism of 5-fluorouracil, between colorectal cancer and nontumor tissues and to investigate the association of the enzyme activities with clinicopathological backgrounds." | 7.74 | Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer. ( Fukushima, M; Matsusaka, S; Wakabayashi, I; Yamasaki, H, 2007) |
| "The aim of this study was to investigate the influence of combining thymidylate synthase (TS), X-ray cross complementing factor 1 (XRCC1) and uridine diphosphate glucoronosyltransferase (UGT1A1 *28) polymorphism genotypes in response rate and time to progression (TTP) in metastatic colorectal cancer patients treated with 5-fluorouracil (5-FU) plus irinotecan or oxaliplatin (OXA)." | 7.74 | Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxa ( Abad, A; Catot, S; Cirauqui, B; Manzano, JL; Martinez-Balibrea, E; Martinez-Cardus, A; Moran, T; Taron, M, 2007) |
| "Randomised trials have established the importance of oxaliplatin (O) and irinotecan (I) in advanced colorectal cancer (CRC)." | 7.74 | Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. ( Adena, M; Damianovich, D; Tebbutt, NC, 2007) |
| "In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments." | 7.74 | Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. ( Bareil, C; Bascoul-Mollevi, C; Bibeau, F; Chalbos, P; Conseiller, E; Copois, V; Del Rio, M; Fraslon, C; Granci, V; Kramar, A; Leblanc, B; Martineau, P; Molina, F; Pau, B; Salvetat, N; Ychou, M, 2007) |
| "This study explores the effect of 5-fluorouracil (5FU) exposure on mRNA levels of its target enzyme thymidylate synthase (TS) and the rate-limiting catabolic enzyme dihydropyrimidine dehydrogenase (DPD) in tumors of colorectal cancer patients." | 7.74 | Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. ( Jansen, G; Mauritz, R; Peters, GJ; Pinedo, HM; Smid, K; van Groeningen, CJ, 2007) |
| "To evaluate the efficacy and safety of a regimen using Irinotecan, 5FU and Leucovorin for patients with advanced or recurrent colorectal cancer." | 7.74 | Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. ( Iinuma, N; Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Yanagisawa, Y, 2007) |
| "Primary colorectal cancer tissue from 24 patients was investigated to evaluate the relationship between the mRNA expression level of several 5-fluorouracil (5-FU)-related metabolic enzymes (thymidylate synthase, TS; dihydropyrimidine dehydrogenase, DPD; and thymidine phosphorylase, TP) and chemosensitivity to two different 5-FU doses and duration (1: 5-FU concentration 1." | 7.74 | Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. ( Abe, H; Endo, Y; Kurumi, Y; Mekata, E; Naitoh, H; Okumura, K; Shiomi, H; Tani, T, 2008) |
| "Cetuximab (Erbitux) in combination with irinotecan is the most promising combination in heavily pretreated patients with advanced colorectal cancer." | 7.74 | Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. ( Iversen, A; Jensen, BV; Nielsen, D; Pfeiffer, P; Vejlø, C; Yilmaz, M, 2007) |
| "The oxaliplatin/fluorouracil/leucovorin (FOL-FOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced colorectal cancer." | 7.74 | Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. ( Fukuoka, M; Nakagawa, K; Okamoto, I; Ozaki, T; Satoh, T; Shimizu, T; Tamura, K, 2007) |
| "The objectives of the present study were to evaluate the efficacy and safety of an outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as the first-line treatment for patients with advanced colorectal cancer." | 7.74 | Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer. ( Ahn, BM; Baek, JH; Chae, YS; Cho, YY; Choi, GS; Jun, SH; Kim, JG; Kim, SN; Lee, IT; Lee, SJ; Moon, JH; Sohn, SK, 2007) |
| "Capecitabine is a fluoropyrimidine-based drug that offers physicians a more convenient treatment for advanced colorectal cancer (CRC), with manageable toxicity and antitumor activity comparable to that of continuous-infusion therapies with 5-fluorouracil (5-FU)." | 7.74 | DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Kuramochi, H; Lindebjerg, J; Nielsen, JN; Shimizu, D; Vallböhmer, D; Yang, DY, 2007) |
| "A combination of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) is one of the standard regimens for palliative and adjuvant chemotherapy for colorectal cancer." | 7.74 | Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Kojima, T; Muto, M; Ohtsu, A; Tahara, M; Takeuchi, S; Taku, K; Yoshida, S, 2007) |
| "Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer." | 7.74 | Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007) |
| "To investigate the mechanisms of drug resistance, a set of cell lines with different levels of sensitivity and possessing different mechanisms of resistance to 5-fluorouracil (5-FU) was established from a colorectal cancer cell line." | 7.74 | Swainsonine reduces 5-fluorouracil tolerance in the multistage resistance of colorectal cancer cell lines. ( Deguchi, K; Hamaguchi, J; Kamiyama, N; Kudo, T; Nakagawa, H; Nishimura, S; Oshima, T; Sato, Y; Sun, B; Takahashi, M; Todo, S, 2007) |
| "The addition of bevacizumab to 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) improved the time-to-progression (TTP) and overall survival (OS) in comparison to FOLFOX in the second-line treatment of metastatic colorectal cancer (MCRC)." | 7.74 | 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study. ( Bir, A; Fakih, MG; Lombardo, J; Tan, W; Wilding, GE, 2007) |
| "The clinical efficacy and safety of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer were studied retrospectively." | 7.74 | [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer]. ( Hori, S; Hyodo, I; Iguchi, H; Imamine, S; Kajiwara, T; Kataoka, J; Moriwaki, T; Nasu, J; Nishina, T, 2007) |
| "The authors reported in a previous study that NK012, a 7-ethyl-10-hydroxy-camptothecin (SN-38)-releasing nano-system, exhibited high antitumor activity against human colorectal cancer xenografts." | 7.74 | Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. ( Hamaguchi, T; Kano, Y; Kato, K; Koizumi, F; Matsumura, Y; Nakajima, TE; Shimada, Y; Shirao, K; Yamada, Y; Yasunaga, M, 2008) |
| "To evaluate the effect of thymidylate synthase (TYMS) and methylenetetrahydrofolate reductase (MTHFR) genotypes on toxicity in patients treated with capecitabine for advanced colorectal cancer and to determine the effect of these polymorphisms on the pretreatment levels of serum folate and plasma homocysteine." | 7.74 | Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. ( Clarke, SJ; Hoskins, JM; Liddle, C; London, R; Rivory, LP; Sharma, R; Zucknick, M, 2008) |
| "Low tumour expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) have been linked with improved outcome for colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)." | 7.74 | Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. ( Diasio, RB; Han, HC; Iacopetta, B; Joseph, D; Ng, SS; Salto-Tellez, M; Shah, N; Soo, RA; Soong, R; Tai, BC; Tan, WL; Zeps, N, 2008) |
| "Standard weekly cetuximab and irinotecan (CetIri) is an effective regimen in heavily pretreated patients with advanced colorectal cancer (ACRC)." | 7.74 | Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. ( Bjerregaard, J; Jensen, B; Nielsen, D; Pfeiffer, P; Qvortrup, C; Yilmaz, M, 2008) |
| "5-Fluorouracil (5-FU) is the most commonly used anticancer drug for colorectal cancer (CRC)." | 7.74 | Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. ( Iinuma, H; Watanabe, T; Yamada, H, 2008) |
| "To evaluate 5-fluorouracil (5-FU) and 5-fluoro-5,6-dihydrouracil (5-FDHU) pharmacokinetics and disease-free survival (DFS) in colorectal cancer patients given 5-FU-based adjuvant chemotherapy within a nonrandomized, retrospective, pharmacokinetic study." | 7.74 | 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. ( Amatori, F; Bocci, G; Danesi, R; Del Tacca, M; Di Donato, S; Di Paolo, A; Falcone, A; Federici, F; Iannopollo, M; Lastella, M; Lencioni, M; Orlandini, C; Ricci, S, 2008) |
| "A combination of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) has become one of the global standard chemotherapy regimens for metastatic colorectal cancer." | 7.74 | Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Hamamoto, Y; Minashi, K; Muto, M; Ohtsu, A; Tahara, M; Yano, T; Yoshida, S, 2008) |
| "70 patients with advanced colorectal cancer were treated with irinotecan and 5-fluorouracil." | 7.74 | [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. ( Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS, 2007) |
| "This study evaluated the effects of oral capecitabine on the quality of life (QOL) of Brazilian patients with metastatic colorectal cancer who received capecitabine (1000 or 1250 mg/m2 twice a day on days 1-14, every 3 weeks) in a prospective, multicenter, open-label, noncomparative study." | 7.74 | Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine. ( Cabral, S; Federico, MH; Filho, Ude P; Franke, FA; Gampel, O; Perdicaris, MR; Ribeiro, Rde A; Segalla, JG; Skare, NG; Van Eyll, B, 2008) |
| "Although 5-fluorouracil (5-FU)-based chemotherapy is commonly used in patients with advanced colorectal cancer (CRC), little data exist on the tolerability and benefit of therapy in elderly patients." | 7.73 | 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. ( Buroker, TR; Cha, SS; D'Andre, S; Goldberg, RM; Kugler, JW; O'Connell, MJ; Poon, MA; Sargent, DJ, 2005) |
| "To determine whether the nonselective and relatively inexpensive nonsteroidal anti-inflammatory drug ibuprofen would be effective in inhibiting colorectal cancer and might improve mortality in a mouse model." | 7.73 | Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. ( Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W, 2005) |
| "To clarify the correlation between the expression level of thymidine phosphorylase (TP) and efficacy of doxifluridine (5'-DFUR) and 5-fluorouracil (5-FU), samples from 177 colorectal cancer patients who underwent curative resection were evaluated by immunohistochemical staining using a newly developed monoclonal antibody 1C6-203." | 7.73 | Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. ( Hasegawa, R; Hasegawa, S; Koda, K; Miyazaki, M; Oda, K; Seike, K; Takiguchi, N, 2005) |
| "To investigate the prognostic value of thymidylate synthase (TS), topoisomerase-1 (Topo-1), and proliferating index Ki-67 in advanced colorectal cancer patients on irinotecan (CPT-11) in combination with fluorouracil treatment (5-Fu)." | 7.73 | [Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment]. ( Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, JM; Zhu, BD, 2005) |
| "Although several evidences have demonstrated a synergistic activity of 5-fluorouracil with irinotecan and oxaliplatin, thus explaining the use of this drug combination in the first-line treatment of advanced colorectal cancer, the need for the reintroduction of 5-FU in the second-line setting is more questionable." | 7.73 | The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. ( Barni, S; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Gasparini, G; Graziano, F; Labianca, R; Scartozzi, M; Sobrero, A; Zaniboni, A, 2005) |
| "The aim of the study was to define the feasibility and efficacy of Xelox (capecitabine and oxaliplatin) administered through a new and original schedule in advanced pretreated colorectal cancer (CRC) patients." | 7.73 | Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. ( Caricato, M; Coppola, R; Di Seri, M; La Cesa, A; Rocci, L; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B, 2005) |
| "The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations." | 7.73 | Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. ( Braud, Fd; Brunet, R; Butts, CA; Cassidy, J; Conroy, T; Diaz-Rubio, E; Figer, A; Grossmann, J; Schoffski, P; Sobrero, AF; Tabernero, JM; Twelves, CJ; Van Cutsem, EJ, 2005) |
| "We successfully treated four advanced colorectal cancers with irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and l-leucovorin (l-LV) combination chemotherapy." | 7.73 | [Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. ( Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H, 2005) |
| "The present study aimed to prospectively investigate the influence of thymidylate synthase (TS) polymorphisms (5'-TSER, 3'-TSUTR) on the disease-free survival (DFS) and overall survival (OS) of patients with colorectal cancer (CRC) who were treated with adjuvant 5-fluorouracil (5-FU) therapy." | 7.73 | Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. ( Adleff, V; Budai, B; Czeglédi, F; Gyergyay, F; Hitre, E; Horváth, Z; Kásler, M; Kovács, T; Kralovánszky, J; Láng, I; Lövey, J; Orosz, Z, 2005) |
| "These results suggest that phospho-EGFR levels determine the sensitivity of colorectal cancer cells to gefitinib alone and that chemotherapy-mediated changes in phospho-EGFR levels determine the nature of interaction between gefitinib and chemotherapy." | 7.73 | Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. ( Galligan, L; Johnston, P; Karaiskou-McCaul, A; Kelly, D; Longley, D; Van Cutsem, E; Van Schaeybroeck, S, 2005) |
| "Fluorouracil-based chemotherapy, such as that with 5-fluorouracil (5-FU)/leucovorin, is standard as first-line chemotherapy for advanced colorectal cancer (CRC) in Japan." | 7.73 | In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer. ( Akiyama, T; Hirabayashi, Y; Hirai, T; Ikeda, M; Iki, K; Kubozoe, T; Matsumoto, H; Sadahira, Y; Tsunoda, T; Urakami, A; Yamamura, M; Yamashita, K, 2005) |
| "Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer." | 7.73 | Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. ( Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS, 2005) |
| "Some retrospective studies have shown a lack of benefit of 5-fluorouracil (5-FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer." | 7.73 | Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. ( Alenda, C; Andreu, M; Bessa, X; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Jover, R; Llor, X; Morillas, JD; Nicolás-Pérez, D; Payá, A; Piñol, V; Reñé, JM; Xicola, RM; Zapater, P, 2006) |
| "To report 2 cases of severe hypertriglyceridemia associated with the use of oral capecitabine." | 7.73 | Capecitabine-induced severe hypertriglyceridemia: report of two cases. ( Babaoglu, MO; Guler, N; Kurt, M; Shorbagi, A; Yasar, U, 2006) |
| "Resistance to apoptosis is one of the important determinants of resistance to 5-fluorouracil (5-FU) in colorectal cancer cells." | 7.73 | Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappaB and upregulation of BCL-2 and BCL-XL. ( Kitayama, J; Konishi, T; Nagawa, H; Sasaki, S; Watanabe, T, 2006) |
| "We identified genes related to 5-fluorouracil (5-FU) sensitivity in colorectal cancer and utilized these genes for predicting the 5-FU sensitivity of liver metastases." | 7.73 | Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. ( Endo, I; Hayasizaki, Y; Ichikawa, Y; Ishikawa, T; Kunisaki, C; Matsuyama, R; Momiyama, N; Shimada, H; Shimizu, D; Suzuki, H; Togo, S, 2006) |
| " In this study, we evaluated the correlation between sensitivity to 5-fluorouracil (5-FU) and the mRNA expression level of several 5-FU-related metabolic enzymes [thymidylate synthase, dihydropyrimidine dehydrogenase (DPD), thymidylate phosphorylase (TP), orotate phosphoribosyl transferase, and uridine phosphorylase] in primary colorectal cancer and synchronous liver metastases from ten patients to investigate how colorectal cancer acquires 5-FU resistance during liver metastases." | 7.73 | Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. ( Endo, Y; Kaizuka, M; Kurumi, Y; Mekata, E; Okumura, K; Shiomi, H; Tani, T, 2006) |
| "The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment." | 7.73 | Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. ( Capellá, G; Cuatrecases, M; de Oca, J; Dotor, E; Figueras, A; Germà, JR; Guinó, E; Martínez-Iniesta, M; Molleví, DG; Moreno, V; Navarro, M; Pareja, L; Peinado, MA; Serrano, T; Vilardell, F; Villanueva, A, 2006) |
| "Several variables associated to thymidylate synthase (TS), the biological target of 5-fluorouracil (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients." | 7.73 | Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. ( Fernández-Contreras, ME; Gamallo, C; García de Paredes, ML; Gisbert, JP; Roda-Navarro, P; Sánchez-Hernández, JJ; Sánchez-Prudencio, S, 2006) |
| "To evaluate the regimen of 5-fluorouracil (5-FU) and mitomycin-C (MMC) in terms ofresponse rate and overall survival in advanced colorectal cancer." | 7.73 | 5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer. ( Aphinives, P; Bhudhisawasdi, V; Sae-seow, O; Uttaravichien, T, 2006) |
| "We present two cases of multiple liver metastases from colorectal cancer, which did not respond to hepatic arterial infusion (HAI) using 5-fluorouracil (5-FU 1250 mg/body weekly) alone, but responded to HAI using 5-fluorouracil (5-FU 750 mg/body weekly) and l-leucovorin (l-LV 50 mg/body weekly) achieving a complete response (CR)." | 7.73 | [Two cases of multiple liver metastases from colorectal cancer which responded well to hepatic arterial infusion (HAI) using 5-fluorouracil and l-leucovorin]. ( Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kato, S; Sugihara, K; Uetake, H; Yasuno, M, 2006) |
| "The combination of irinotecan (CPT-11), bolus 5-fluorouracil (5-FU) and folinic acid (FA) (Saltz regimen) has recently been questioned as first-line chemotherapy for metastatic colorectal cancer after high early death rates due to gastrointestinal and thromboembolic events were reported in two US trials." | 7.72 | Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. ( Adami, B; Baldus, M; Burg, H; Ehscheid, P; Galle, PR; Heike, M; Hoffmann, T; Hohl, H; Klein, O; Moehler, M; Schroeder, M; Schwindt, P; Zanke, C, 2003) |
| "The Mayo Clinic regimen of leucovorin 20 mg/m followed immediately by 5-fluorouracil 425 mg/m administered for 5 consecutive days every 4 weeks is commonly used in the treatment of colorectal cancer." | 7.72 | Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. ( Bar-Sela, G; Beny, A; Haim, N; Tsalic, M; Visel, B, 2003) |
| "5-Fluorouracil (5-FU) is the major chemotherapeutic component for colorectal cancer (CRC) and other types of solid tumours." | 7.72 | Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. ( Cassidy, J; McLeod, HL; Wang, W, 2003) |
| "The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 7.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
| "The aim of this study was to investigate the influence of low dosage (131)I-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody C50 ((131)I-C50) on tumor growth and the therapeutic efficacy of combination of low dosage (131)I-C50 with chemotherapy using 5-fluorouracil (5-FU) on human colorectal cancer xenografts in nude mice." | 7.72 | [Influence of combination of low dosage 131I-labeled anti-carcinoembryonic antigen antibody C50 and 5-fluorouracil on tumor growth of colorectal cancer xenografts in nude mice]. ( Cai, SR; He, YL; Lin, ZJ; Zhan, WH; Zheng, CX, 2003) |
| "Loss of DNA mismatch repair (MMR) occurs in 10-15% of sporadic colorectal cancer, is usually caused by hMLH1 hypermethylation, and has been shown to confer resistance to various chemotherapeutic reagents, including 5-fluorouracil (5-FU)." | 7.72 | Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. ( Arnold, CN; Boland, CR; Goel, A, 2003) |
| "To predict the sensitivity of colorectal cancer to 5-fluorouracil (5-FU), we compared the gene expression of surgically obtained colorectal cancer specimens with chemosensitivity to 5-FU as detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) assay." | 7.72 | Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. ( Fukushima, M; Hasegawa, H; Kitajima, M; Kubota, T; Nishibori, H; Takechi, T; Wada, N; Watanabe, M; Yoshinare, K, 2003) |
| "To determine the efficacy of the combination of oxaliplatin and capecitabine in patients with advanced colorectal cancer." | 7.72 | Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience. ( Cunningham, D; Gillbanks, A; Harper-Wynne, C; Hill, M; Norman, AR; Sumpter, K, 2003) |
| "The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)." | 7.72 | Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| "Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m(2)." | 7.72 | Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. ( Kosmas, C; Koufos, C; Margaris, H; Papalambros, E; Papantoniou, N; Retalis, G; Rokana, S; Tsavaris, N; Vadiaka, M; Zografos, G; Zonios, D, 2003) |
| " In this study, we assessed whether or not the TSER genotype is an efficacious marker for tumor sensitivity to 5-fluorouracil (5-FU)-based oral adjuvant chemotherapy for colorectal cancer." | 7.72 | Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. ( Fukuoka, H; Haseba, M; Hidaka, S; Komatsu, H; Nakagoe, T; Nanashima, A; Sawai, T; Shibasaki, S; Shindou, H; Tagawa, Y; Tsuji, T; Yamaguchi, H; Yano, H; Yasutake, T; Yoshinaga, M, 2003) |
| "We herein report the result of a prospective study to investigate the efficacy of cimetidine administration in conjunction with chemotherapy for stage IV colorectal cancer." | 7.72 | [Effect of cimetidine with chemotherapy on stage IV colorectal cancer]. ( Fujimoto, T; Hashimoto, M; Ishibashi, K; Iwasaki, K; Ogawa, K; Umehara, A; Yokomizo, H; Yoshida, K; Yoshimatsu, K, 2003) |
| "The level of the enzyme thymidylate synthase (TS) is known to inversely correlate with the clinical activity of 5-fluorouracil (FU) in advanced colorectal cancer patients." | 7.72 | Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. ( Aschele, C; Belvedere, O; Cataldi, P; Di Loreto, C; Guglielmi, A; Puglisi, F; Sobrero, A, 2004) |
| "5-Fluorouracil improves mortality in stage III colorectal cancer patients." | 7.72 | Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. ( Arnold, CA; Behling, CA; Boland, CR; Cabrera, BL; Carethers, JM; Doctolero, RT; Goel, A; Miyai, K; Nguyen, L; Smith, EJ; Tajima, A, 2004) |
| " For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil." | 7.72 | Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. ( Hahn, P; Jensen, HA; Pfeiffer, P, 2003) |
| " In this study, digital karyotyping was used to search for genomic alterations in liver metastases that were clinically resistant to 5-fluorouracil (5-FU)." | 7.72 | Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. ( Bardelli, A; Choti, M; Diaz, LA; Donehower, R; Galizia, G; Iacobuzio-Donahue, C; Kinzler, KW; Lengauer, C; Parmigiani, G; Romans, K; Saha, S; Shih, IeM; Velculescu, VE; Vogelstein, B; Wang, TL, 2004) |
| "5-Fluorouracil, a widely used drug in cancer treatment, is known to have cardiotoxic effects: chest pain with ECG changes, arrhythmias, arterial hypertension or hypotension, myocardial infarction, cardiogenic shock and sudden death have been described in the literature." | 7.72 | Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases. ( Alberti, A; Corrada, E; Ferrari, S; Mafrici, A; Marenna, B, 2003) |
| "Preclinical in vitro and in vivo studies have demonstrated synergistic interactions between 5-fluorouracil (5-FU) and type I and II IFNs against human colorectal cancer cells." | 7.72 | Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. ( Barsoum, J; Choi, EA; Fraker, DL; Lei, H; Maron, DJ; Mick, R; Spitz, FR; Wilson, JM; Yu, QC, 2004) |
| "To elucidate mechanisms of resistance to chemotherapies currently used in the first-line treatment of advanced colorectal cancer, we have developed a panel of HCT116 p53 wild-type (p53(+/+)) and null (p53(-/-)) isogenic colorectal cancer cell lines resistant to the antimetabolite 5-fluorouracil (5-FU), topoisomerase I inhibitor irinotecan (CPT-11), and DNA-damaging agent oxaliplatin." | 7.72 | Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. ( Aroori, S; Boyer, J; Carey, PD; Johnston, PG; Longley, DB; McCulla, A; McLean, EG; Wilson, P, 2004) |
| "To evaluate the efficacy and safety of capecitabine as first-line therapy in patients with advanced and recurrent colorectal cancer." | 7.72 | [First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer]. ( Feng, FY; Fu, Q; Guan, ZZ; Huang, JJ; Liu, DG; Ruan, QL; Shi, D; Sun, SR; Wei, YQ; Wu, G; Wu, WQ; Wu, XD; Xiong, HH; Yang, CY; Yu, BM; Yu, SY; Zhang, P; Zhao, Y; Zheng, S; Zhuang, W; Zou, LQ, 2004) |
| "Expression of thymidylate synthase (TS) and the 5-fluorouracil (5-FU) metabolic enzymes, including dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), thymidine phosphorylase (TP), and uridine phosphorylase (UP), has been reported to be associated with the sensitivity to 5-FU-based chemotherapy in colorectal cancer." | 7.72 | Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. ( Inokuchi, M; Shirota, Y; Sugihara, K; Tajima, M; Uetake, H; Yamada, H, 2004) |
| "5-Fluorouracil (5-FU) is the chemotherapeutic drug of choice for the treatment of metastatic colorectal cancer, but resistance to 5-FU remains a major obstacle to successful therapy." | 7.72 | Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. ( Beigi, M; Clausen, OP; de Angelis, PM; Fjell, B; Galteland, E; Haug, T; Kravik, KL; Reichelt, W; Stokke, T; Tunheim, SH, 2004) |
| "The aim of this study was to observe the effects of neoadjuvant therapy with irinotecan and 5-fluorouracil (5-FU)/folinic acid (FA) on the resection rate and survival of colorectal cancer patients with initially unresectable hepatic metastases." | 7.72 | Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. ( Barone, C; Basso, M; Cassano, A; Giuliante, F; Nuzzo, G; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N; Vellone, M, 2004) |
| "One hundred and thirty-eight stage II and III colorectal cancer patients were included to evaluate the prognostic significance of genetic markers (including mutations of the p53, K-ras genes, and microsatellite instability) on the response to 5-fluorouracil (FU)-based post-operative adjuvant therapies (PAT)." | 7.72 | p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. ( Changchien, CR; Chen, HH; Chen, JS; Fan, CW; Hsieh, LL; Tang, R; Tsao, KC; Wang, JY; Wu, CM, 2004) |
| "Capecitabine is an oral prodrug of 5-fluorouracil and has been studied for the treatment of colorectal cancer." | 7.72 | Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. ( Brouwers, JR; Jansman, FG; Postma, MJ; van Hartskamp, D; Willemse, PH, 2004) |
| "The purpose of this study was to examine the relation between tumoral expression of dihydropyrimidine dehydrogenase (DPD), the rate limiting enzyme of the degradation pathway 5-fluorouracil (5-FU), and the efficacy of 5-FU based chemotherapy for colorectal cancer." | 7.72 | [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer]. ( Hashimoto, D; Inokuma, S; Ishida, H; Nakada, H; Ohsawa, T; Shirakawa, K; Yamada, H; Yokoyama, M, 2004) |
| "Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated." | 7.72 | [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004) |
| "High expression of thymidylate synthase (TS) is allegedly associated with the chemoresistance to 5-fluorouracil (5-FU) in colorectal cancers." | 7.72 | Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to ( Inada, K; Kamoshida, S; Maruta, M; Matsuoka, H; Matsuyama, A; Shimomura, R; Shiogama, K; Tsutsumi, Y, 2004) |
| "To determine whether deleted in colon cancer (DCC) protein expression in colorectal cancer (CRC) metastases could predict outcome to palliative fluorouracil (FU)-based chemotherapy and to assess whether it is similar to that observed in the corresponding primary tumors." | 7.72 | Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. ( Aschele, C; Bandelloni, R; Casazza, S; Debernardis, D; Gallo, L; Lonardi, S; Monfardini, S, 2004) |
| "The efficacy of a concomitant oxaliplatin/bolus 5-fluorouracil/leucovorin regimen in 123 heavily pretreated patients with advanced colorectal cancer was evaluated." | 7.72 | Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer. ( Amin-Zimmerman, F; Glisson, SD; Hargis, JB; Hicks, RM; Kosfeld, RE; LaRocca, RV; Leaton, KE, 2004) |
| "We retrospectively evaluated the relevance of thymidylate synthase (TS) expression in normal colonic mucosa as a predictive factor of toxicity in colorectal cancer patients receiving adjuvant fluorouracil (5-FU)-based chemotherapy." | 7.72 | Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. ( Borzomati, D; Caricato, M; Coppola, R; Grilli, C; La Cesa, A; Perrone, G; Rabitti, C; Santini, D; Tonini, G; Verzì, A; Vincenzi, B, 2004) |
| "This study was conducted to evaluate the prognostic significance of thymidylate synthase (TS) expression in the tumor tissue of patients with metastatic colorectal cancer (CRC) who received protracted venous infusions of 5-fluorouracil (5-FU)." | 7.72 | Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil. ( Araake, M; Hamaguchi, T; Hosokawa, A; Morita, H; Muro, K; Orita, H; Shimada, Y; Shirao, K; Yamada, Y, 2004) |
| "The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer." | 7.72 | [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004) |
| "5-fluorouracil (5-FU) is a chemotherapeutic agent widely used in the treatment of solid malignancies, especially in colorectal cancer." | 7.72 | Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature. ( Aparicio, J; Calderero, V; Díaz, R; Guerrero, A; Pellín, L; Segura, A, 2004) |
| "We investigated the immune profile of patients with resected Dukes' stage C colorectal cancer (CRC), receiving adjuvant therapy with edrecolomab (Mo17-1A) or first-line 5-fluorouracil (5-FU)-based chemotherapy." | 7.72 | The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study. ( Gouveris, P; Katsoulas, HL; Kosmas, C; Kosmas, N; Papalambros, E; Papantoniou, N; Rokana, S; Skopeliti, M; Tsavaris, NB; Tsitsilonis, OE, 2004) |
| "Combined infusion of 5-FU and mitomycin C by hepatic artery catheter port is an effective treatment for liver metastases from colorectal cancer." | 7.71 | Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. ( Jiang, HC; Liu, LX; Piao, DX; Qi, SY; Wu, LF; Zhang, WH; Zhu, AL, 2002) |
| "TS levels were measured immunohistochemically on archival specimens of colorectal cancer metastases from 124 patients homogeneously treated in a series of clinical trials at our institutions with: (A) leucovorin (LV)-modulated infusional 5-FU (n = 48); (B) LV-modulated bolus 5-FU (n = 41); (C) methotrexate (MTX)-modulated bolus 5-FU (n = 35)." | 7.71 | Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. ( Aschele, C; Bandelloni, R; Barni, S; Cascinu, S; Catalano, V; Debernardis, D; Drudi, G; Gallo, L; Giordani, P; Lonardi, S; Maley, F; Monfardini, S; Turci, D, 2002) |
| "We evaluated the effect of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer." | 7.71 | [Evaluation of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer]. ( Ebisui, C; Fujimoto, T; Fukuchi, N; Izawa, H; Kanai, T; Sakita, I; Soma, I; Yoshida, T, 2002) |
| "LSMs for 5-fluorouracil and 5-fluoro-5,6-dihydrouracil therapeutic monitoring have been developed in 80 patients with colorectal cancer (training set) given 5-fluorouracil, 370 mg/m(2) per day as an intravenous bolus, plus leucovorin, 100 mg/m(2) per day, for 5 days every 4 weeks." | 7.71 | Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. ( Amadori, D; Cionini, L; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Ibrahim, T; Mini, E; Vannozzi, F, 2002) |
| "Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) exhibit single-agent activity in colorectal cancer, have nonoverlapping major toxicities, and exhibit a synergistic effect in tumor xenograft models." | 7.71 | Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. ( Kerr, D, 2002) |
| " We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib." | 7.71 | Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002) |
| "Irinotecan (CPT-11), oxaliplatin (OXA) and different folinic acid(FA) modulated 5-fluorouracil (5-FU) regimens are active as first-and second-line chemotherapy of metastatic colorectal cancer." | 7.71 | Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. ( Galle, PR; Heike, M; Hildner, K; Hoffmann, T; Moehler, M; Siebler, J, 2002) |
| "5-Fluorouracil (5-FU), in association with leucovorin (LV), is the most used chemotherapy agent in the treatment of colorectal cancer." | 7.71 | Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer. ( Barletta, E; Carratù, R; Daniele, B; De Magistris, L; De Vivo, R; Delrio, P; Palaia, R; Pignata, S; Secondulfo, M; Tambaro, R, 2001) |
| "There has been no standard therapy for patients with metastatic colorectal cancer who have failed to first-line fluorouracil-based treatment." | 7.71 | Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer. ( Kang, YK; Kim, HC; Kim, JC; Kim, SH; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Yu, CS, 2001) |
| "Irinotecan (CPT-11) has shown considerable activity in colorectal cancer, and its combination with 5-fluorouracil (5-FU) represents an attractive approach." | 7.71 | A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer. ( Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, A; Koukourakis, M; Kouroussis, C; Mavroudis, D; Romanos, J; Souglakos, J; Vardakis, N, 2001) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 7.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis." | 7.71 | Expression of metallothionein in colorectal cancers and synchronous liver metastases. ( Dhar, DK; Hishikawa, Y; Kimoto, T; Kohno, H; Koji, T; Kubota, H; Nagasue, N; Tachibana, M; Ueda, S, 2001) |
| "To identify the prognostically highest risk patients, DNA content and p53 nuclear or cytoplasmic accumulation, evaluated by monoclonal antibody DO7 and polyclonal antibody CM1, were determined in 94 surgically resected stage II (Dukes B2) colorectal cancers, treated or not with adjuvant 5-fluorouracil-based chemotherapy." | 7.71 | p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. ( Benevolo, M; Brenna, A; Buglioni, S; Cosimelli, M; D'Agnano, I; D'Angelo, C; Mottolese, M; Perrone Donnorso, R; Vasselli, S; Zupi, G, 2001) |
| "High levels of thymidylate synthase (TS) expression have been associated with poor survival of colorectal cancer (CRC) patients to 5-fluorouracil (5-FU)-based chemotherapy." | 7.71 | A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. ( Elsaleh, H; Grieu, F; Iacopetta, B; Joseph, D, 2001) |
| "We investigated whether the efficacy of peroral doxifluridine and hepatic arterial 5-FU infusion on synchronous liver metastasis of colorectal cancer could be predicted based on the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in the primary colorectal lesions." | 7.71 | [Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]. ( Fujioka, M; Hashimoto, D; Hoshino, T; Inokuma, S; Ishida, H; Ishizuka, N; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Takeuchi, I; Yamada, H; Yokoyama, M, 2001) |
| "To test the hypotheses of whether the relative mRNA expression of the thymidylate synthase (TS) gene and the excision cross-complementing (ERCC1) gene are associated with response to and survival of fluorouracil (5-FU)/oxaliplatin chemotherapy in metastatic colorectal cancer." | 7.71 | ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. ( Brabender, J; Danenberg, KD; Danenberg, PV; Groshen, S; Lenz, HJ; Shirota, Y; Stoehlmacher, J; Tsao-Wei, DD; Uetake, H; Xiong, YP, 2001) |
| "The oral, tumour-selective fluoropyrimidine capecitabine represents a major new strategy for the treatment of colorectal cancer." | 7.71 | Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. ( Twelves, C, 2002) |
| "At increasing use of high-dose 5-fluorouracil-based chemotherapy for metastatic colorectal and gastric cancer complicated drug-induced colitis is observed more frequently." | 7.71 | [5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases]. ( Hotz, J; Madisch, A; Marquard, F; Stolte, M; Wiedbrauck, F, 2002) |
| "The aim of this study was to evaluate the objective tumor response rates and toxicities in elderly patients (older than 70 years) with advanced colorectal cancer treated with 5-fluorouracil (5-FU) as a first-line palliative chemotherapy regimen." | 7.71 | Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience. ( Broisin, L; Ferrero, JM; François, E; Guardiola, E; Magné, N; Namer, M; Ramaïoli, A, 2002) |
| "The aim of this study was to assess in patients with advanced colorectal cancer which factors were associated with short-term survival (6 months or less) and progression to first-line 5-fluorouracil (5-FU) chemotherapy." | 7.71 | Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. ( Cellerino, R; Lippe, P; Massacesi, C; Piga, A; Pistilli, B; Rocchi, MB; Valeri, M, 2002) |
| "We investigated the relevance of mdm2 and p53 primary tumour expression to the clinical outcome of a consecutive series of advanced colorectal cancer patients treated with a 5-fluorouracil-based chemotherapy." | 7.71 | mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer. ( Costa, A; De Lena, M; Lacava, J; Leone, A; Paradiso, A; Ranieri, G; Silvestris, N; Simone, G; Vallejo, C, 2002) |
| "5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer." | 7.70 | Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998) |
| "Prior to the administration of 5-fluorouracil chemotherapy, the authors examined 14 colorectal carcinoma patients with unresectable liver metastases using a single PET scan and 18F-labeled fluorouracil (18F-FU)." | 7.70 | 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. ( Dimitrakopoulou-Strauss, A; Gutzler, F; Moehler, M; Raeth, U; Strauss, LG; Stremmel, W, 1998) |
| "The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy." | 7.70 | Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998) |
| "The purpose of this work was to estimate the population pharmacokinetic parameters of 5-fluorouracil (5-FU) in patients with advanced colorectal cancer using circadian change kinetics." | 7.70 | Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. ( Astre, C; Bressolle, F; Duffour, J; Gomeni, R; Joulia, JM; Pinguet, F; Ychou, M, 1999) |
| "The comparative saliva/plasma pharmacokinetics of 5-fluorouracil (5-FU) were investigated in 21 patients with metastatic colorectal cancer receiving high-dose folinic acid (LV (leucovorin) 200 mg/m2) followed by 5-FU bolus (400 mg/m2) and continuous infusion (600, 750, 900 or 1200 mg/m2) on days 1 and 2." | 7.70 | Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. ( Astre, C; Bressolle, F; Duffour, J; Joulia, JM; Pinguet, F; Ychou, M, 1999) |
| "In a recent multicentre, randomised, controlled, open-label study (Rougier and colleagues, Lancet 1998, 352, 1407-1412), irinotecan significantly increased survival without any deterioration in quality of life compared with best-estimated infusional 5-fluorouracil (5-FU) therapy in the setting of second-line treatment for metastatic colorectal cancer." | 7.70 | Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. ( Hickish, T; Iveson, TJ; Schmitt, C; Van Cutsem, E, 1999) |
| "5-fluorouracil (5-FU) is considered the standard antineoplastic drug of choice for metastatic colorectal cancer." | 7.70 | Changes in thymidylate synthase mRNA in blood leukocytes from patients with colorectal cancer after bolus administration of 5-fluorouracil. ( Ehrnrooth, E; Poulsen, JH; Sørensen, B; Sørensen, BS; von der Maase, H, 2000) |
| " In this study, we have determined the expression patterns of dUTPase in normal and neoplastic tissues and examined the association between dUTPase expression and response to 5-fluorouracil (5-FU)-based chemotherapy and overall survival in colorectal cancer." | 7.70 | dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. ( Caradonna, SJ; Groshen, S; Ladner, RD; Lenz, HJ; Lynch, FJ; Sherrod, A; Stoehlmacher, J; Xiong, YP, 2000) |
| "The basis for current clinical trials in the treatment of colorectal cancer with the combination of irinotecan (CPT-11) and 5-fluorouracil (FUra) with or without leucovorin (LV) is their proven activity as single agents, their different mechanisms of action, and lack of CPT-11 cross-resistance to previous FUra/LV treatment." | 7.70 | Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. ( Cao, S; Rustum, YM, 2000) |
| "The addition of oxaliplatin (L-OHP) to a 5-fluorouracil (5-FU)/ leucovorin (FA) regimen was retrospectively evaluated in 35 consecutive advanced colorectal cancer patients after progression of disease." | 7.70 | Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. ( Aschelter, AM; Bertheault-Cvitkovic, F; Brienza, S; Caterino, M; Cosimelli, M; Garufi, C; Giannarelli, D; Giunta, S; Lévi, F; Nisticò, C; Pugliese, P; Terzoli, E, 2000) |
| "The authors describe the retrospective analysis of treatment by 5-fluorouracil and interferon-a aof 34 patients with advanced colorectal cancer." | 7.70 | Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients. ( András, C; Antal, L; Csiki, Z; Gál, I; Szegedi, G; Takács, I, 2000) |
| "Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil." | 7.70 | Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000) |
| "We observed leukoencephalopathy in 1 patient, and progressive dementia in another, during the administration of 5-fluorouracil (5-FU) and levamisole." | 7.69 | Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. ( Dobranowski, J; Fawcet, SE; Figueredo, AT; Molloy, DW; Paulseth, JE, 1995) |
| "One hundred and seven previously untreated patients with measurable metastatic colorectal cancer who were treated with 5-fluorouracil (5FU) and leucovorin (LV) in two different maximum doses and schedules were retrospectively analyzed." | 7.69 | A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer. ( Bacoyannis, C; Basdanis, G; Foutzilas, G; Karvounis, N; Kosmidis, P; Markantonakis, P; Mylonakis, N; Sobolos, K; Tsavaris, N; Zisiadis, A, 1995) |
| "The purpose of this study was to explore the mechanism of interaction between 5-FU and levamisole by investigating the effect of this combination on HLA class I gene expression in the colorectal cancer cell line WiDr." | 7.69 | Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. ( AbdAlla, EE; Blair, GE; Johnston, D; Jones, RA; Sue-Ling, HM, 1995) |
| "To confirm our previous kinetic analysis of the mode of cell-killing action of 5-fluorouracil (5-FU), we carried out a flow cytometric analysis with human colorectal cancer DLD-1 cells." | 7.69 | Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells. ( Inaba, M; Mitsuhashi, J, 1994) |
| "We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats." | 7.69 | Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. ( Garaci, E; Pierimarchi, P; Rasi, G; Silecchia, G; Sinibaldi-Vallebona, P; Sivilia, M; Spaziani, E; Tremiterra, S, 1994) |
| "The purpose of the study was to evaluate the efficacy of long-term continuous administration of 5-fluorouracil (5-FU) in ambulatory patients with colorectal cancer." | 7.69 | [Treatment of advanced colorectal cancer with long-term continuous infusion of 5-fluorouracil]. ( Ando, J; Kotake, K; Koyama, Y; Nasu, J; Ogata, Y; Ozawa, I, 1994) |
| "From September 1989 to September 1992, 17 patients (pts) with non-curative or recurrent colorectal cancer were treated with 5-fluorouracil (FU) plus leucovorin (LV) systemic therapy." | 7.69 | [5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer]. ( Ban, K; Imanari, T; Machida, T; Masuda, K; Matsumoto, M; Noda, Y; Shida, H; Takei, Y; Yamamoto, T, 1994) |
| "In 16 advanced colorectal cancer patients with 5-fluorouracil-associated diarrhea, we evaluated the role of bacterial pathogens in the development of this adverse effect." | 7.69 | Have enteric infections a role in 5-fluorouracil-associated diarrhea? ( Cascinu, S; Catalano, G, 1995) |
| "Patients with colorectal cancer liver metastases were treated with fluorouracil (5FU) as a protracted venous infusion (300 mg/m2/d), with or without interferon-alpha 2b for two 10-week blocks separated by a 2-week break." | 7.69 | Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. ( Cronin, B; Cunningham, D; Findlay, M; Flower, M; Hickish, T; Husband, J; Iveson, A; Ott, R; Pratt, B; Young, H, 1996) |
| "Thirty-seven patients with advanced colorectal cancer were treated with fluorouracil (5-FU) and folinic acid (FA) (Jan 1990-Dec 1992)." | 7.69 | Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department. ( Carey, PD; Farrer, C; Gordon, A; Guillou, PJ; Monson, JR; Pearce, S; Sommers, SS, 1995) |
| "In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally." | 7.69 | Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. ( Kamm, YL; Punt, CJ; Wagener, DJ, 1997) |
| "The authors report a patient with colorectal carcinoma who developed neutropenic enterocolitis after treatment with 5-fluorouracil and leucovorin." | 7.69 | Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report. ( Blumgart, L; Kemeny, NE; Kronawitter, U, 1997) |
| "The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy." | 7.69 | Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997) |
| "5-Fluorouracil (5-FU) has been an accepted effective against colorectal cancer, but combination regimens resulted in a lesser effect than 5-FU alone." | 7.69 | 5-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer. ( Imamura, M; Kawabata, K; Nio, Y, 1997) |
| "This study was conducted to investigate the activity and toxicity of 5fluorouracil folinic acid+mitomycin C combined with alpha 2b interferon in advanced colorectal cancer based upon recent studies suggesting a possible biochemical modulation of 5fluorouracil by interferon." | 7.68 | Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer. ( Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Manocchi, P; Mattioli, R; Mazzanti, P; Pilone, A; Rossini, S; Silva, RR, 1993) |
| "We studied the levamisole toxic effects in adjuvant therapy for colorectal cancer." | 7.68 | [Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer]. ( Beerblock, K; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Navarro-Carola, E; Soubrane, D; Varette, C, 1993) |
| "Interferon (IFN) has been shown to enhance the cytotoxic effects of 5-fluorouracil (5FUra) in colorectal cancer, and clinical trials with this combination resulted in higher response rate with respect to 5FUra alone." | 7.68 | Cytokinetic effects of interferon in colorectal cancer tumors: implications in the design of the interferon/5-fluorouracil combinations. ( Acetoso, M; Bartolucci, M; Cascinu, S; Del Ferro, E; Fedeli, A; Foglietti, G; Grianti, C; Lungarotti, F; Olivieri, Q; Saba, V, 1993) |
| "5-Fluorouracil (5-FU) is the most widely used cytotoxic drug in oncology and the only one useful in the management of colorectal cancer - a leading cause of cancer death worldwide." | 7.68 | The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. ( Collins, DJ; Cunningham, D; Findlay, MP; Glaholm, J; Leach, MO; Mansi, JL; McCready, VR; Payne, GS, 1993) |
| "The efficacy of the protracted infusion of 5-fluorouracil (FU) 200 mg/m2/day admixed with leucovorin (LV) 20 mg/m2/day was assessed for the treatment of advanced colorectal and breast cancer patients." | 7.68 | Continuous intravenous infusion of leucovorin and 5-fluorouracil for the treatment of advanced colorectal and breast cancers. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JM; Tzeng, CH, 1993) |
| "In order to elucidate the effect of tumor vascularity on a various regimens concentration in tumor tissue, correlation among tegafur, 5-fluorouracil (5-FU), uracil concentrations in tissue and the microangiography were examined in 27 patients with colorectal cancer after preoperative administration of UFT (400 mg/day for 7 days)." | 7.68 | [Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer]. ( Ishikawa, H; Kusano, H; Miyashita, K; Nakazaki, T; Ogawa, T; Shimizu, T; Shimoyama, T; Yasutake, T; Yoshida, A; Yoshida, K, 1993) |
| "Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i." | 7.68 | Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992) |
| " UFT (400 mg/day in terms of tegafur) was given preoperatively for 1-6 days in 6 patients with gastric cancer and 13 with colorectal cancer." | 7.68 | [Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT]. ( Inaba, S; Kawai, K; Kondo, Y; Ogino, A; Tsuchiya, K; Ueda, Y; Umeda, T, 1992) |
| " In a literature review of all published data of folinic acid and 5-fluorouracil intravenous bolus therapy in colorectal cancer with comparable dose intensity, an attempt was made to characterize the possible differences of the variations of schedules used." | 7.68 | The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. ( Bokemeyer, C; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992) |
| "The combination of folinic acid (FA) and 5-fluorouracil (5FU) is the most active systemic chemotherapy against advanced colorectal cancer." | 7.68 | High dose alpha-2b interferon + folinic acid in the modulation of 5-fluorouracil. A phase II study in advanced colorectal cancer with evidence of an unfavourable cost/benefit ratio. ( Dallavalle, G; Labianca, R; Luporini, A; Luporini, G; Pancera, G; Tedeschi, L, 1992) |
| "A cohort of 35 patients with advanced colorectal cancer, not previously exposed to chemotherapy, were included in a phase II study exploring the combination of interferon-alpha, 9 MU subcutaneously three times weekly, and 5-fluorouracil 750 mg/m2/day during 5 consecutive days in continuous intravenous infusion followed with weekly bolus injection of fluorouracil 750 mg/m2." | 7.68 | Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis. ( Antón, A; Aranda, E; Blanco, E; Camps, C; Díaz Rubio, E; González Larriba, JL; Jimeno, J; Lízón, J; Massuti, B, 1992) |
| "Twenty-six patients with advanced colorectal cancer were treated with a combination based on multimodal biochemical modulation of 5-fluorouracil by means of high dose folinic acid, low-dose alpha-2b interferon and dipyridamole." | 7.68 | Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study. ( Arcangeli, G; Bonera, F; Braga, M; Marini, G; Marpicati, P; Meriggi, F; Montini, E; Ragni, F; Simoncini, E; Zaniboni, A, 1991) |
| "18 patients with advanced colorectal cancer entered a phase I-II study of high-dose 48 h continuous infusion 5-fluorouracil (5-FU) for 6 weeks." | 7.68 | Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. ( Aranda, E; Barneto, I; Diaz-Rubio, E; Gonzalez-Larriba, J; Gonzalez-Mancha, R; Martin, M, 1990) |
| "Since there is no effective second line chemotherapy in colorectal cancer resistant to fluorouracil, this study was carried out to evaluate the therapeutic activity of the pineal hormone melatonin, which has appeared to have antineoplastic activity in some experimental conditions, in patients with metastatic colorectal carcinoma who did not respond to fluorouracil." | 7.68 | A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates. ( Archili, C; Barni, S; Crispino, S; Lissoni, P; Paolorossi, F; Tancini, G, 1990) |
| "Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action." | 7.68 | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990) |
| "Thirty patients with advanced colorectal adenocarcinoma were treated by chemotherapy with an alternating regimen consisting of 5-fluorouracil (5-FU)-mitomycin C and 5-FU-dacarbazine at 3-week intervals." | 7.67 | Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study. ( Droz, JP; Herait, P; Kac, JL; Rougier, P; Theodore, C, 1989) |
| "Based on in vitro studies that have demonstrated synergy between recombinant alfa-2a-interferon (rIFN alpha-2a) and the fluoropyrimidine, fluorouracil (5FU), against two human colon cancer cell lines, a pilot clinical trial was initiated to determine the effects of the combination of 5FU and rIFN alpha-2a in patients with advanced, unresectable colorectal carcinoma." | 7.67 | Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. ( Goldman, M; Itri, L; Lyver, A; Rader, M; Schwartz, EL; Wadler, S; Weinberg, V; Wiernik, PH; Zimmerman, M, 1989) |
| "27 patients with advanced colorectal cancer were treated in a phase-II trial with high dose sequential methotrexate (MTX), 5-fluorouracil (5-FU), and folinic acid (FA)." | 7.67 | Sequential high dose methotrexate, 5-fluorouracil and folinic acid does not improve response rates in advanced colorectal cancer. ( Flechtner, H; Heim, ME; Queisser, W; Schuster, D; Worst, P, 1989) |
| "Favorable results have been reported for the treatment of advanced colorectal cancer with the combination of 5-fluorouracil (5-FU) and leucovorin (LV)." | 7.67 | Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. ( Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1989) |
| "A total of 24 patients with advanced colorectal adenocarcinoma were entered into a phase I-II study of 5-fluorouracil (5-FU) and cisplatin, 21 of whom had previously received 5-FU." | 7.67 | Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma. ( Creaven, PJ; Herrera, L; Madejewicz, S; Mittelman, A; Petrelli, NJ; Plager, J; Rustum, Y; Soloman, J, 1989) |
| "Following the observation of antitumor activity for the combination of 5-fluorouracil (5-FU) and cisplatin in metastatic colorectal carcinoma, the combination of 5-FU and iproplatin was tested, also in colorectal carcinoma, in the hope of attaining equivalent activity without the nephrotoxicity observed with 5-FU/cisplatin." | 7.67 | Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma. ( Creaven, PJ; Herrera, L; Mittelman, A; Petrelli, NJ, 1989) |
| "An enhanced antineoplastic effect of 5-fluorouracil in patients with advanced colorectal cancer has been produced either by combination with folinic acid or administration by continuous infusion." | 7.67 | High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. ( Cady, J; De Gramont, A; Demuynck, B; Gonzalez-Canali, G; Grange, JD; Krulik, M; Lagadec, B; Loiseau, JP; Louvet, C; Maisani, JE, 1988) |
| " Safety endpoints were rates of any grade and grade 3/4 adverse events during maintenance therapy." | 7.30 | Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212 ( Alig, AHS; Caca, K; Fruehauf, S; Goekkurt, E; Graeven, U; Haas, S; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; König, AO; Kretzschmar, A; Kurreck, A; Modest, DP; Mueller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023) |
| "Mebendazole was well tolerated and its addition to bevacizumab and FOLFOX4 enhanced tumor response to treatment which was translated by significant improvement of overall response rate 12 weeks after intervention [10 % (2) versus 65% (13) for control and mebendazole groups, respectively; p = 0." | 7.11 | Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. ( El-Azab, GA; El-Ghoneimy, RA; Hegazy, SK; Mostafa, MF; Zakaria, F, 2022) |
| "To overcome this problem, patients with colorectal cancer are treated with chemotherapy for a short time, followed by a less aggressive maintenance regimen of the chemotherapy drug 5-fluorouracil and the targeted therapy drug bevacizumab." | 7.01 | Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. ( Cui, K; Gurary, EB; Kim, TW; Lerman, N; Taieb, J; Yoshino, T, 2021) |
| "Capecitabine (Cape) is an oral prodrug of the antimetabolite 5-fluorouracil." | 7.01 | Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer. ( Ali, A; Daily, KC; Dang, LH; George, TJ; Iqbal, A; Ivey, AM; Lee, JH; Ramnaraign, BH; Read, TE; Tan, SA; Terracina, KP; Wang, Y, 2021) |
| " In this phase II study, we prospectively analyzed the efficacy and safety of raltitrexed combined with S-1 (RS regimen) in the treatment of mCRC after the failure of conventional chemotherapy." | 7.01 | A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer. ( Chen, Z; Guo, W; Huang, M; Li, W; Qiu, L; Wang, C; Wang, Y; Yang, Y; Zhang, W; Zhang, X; Zhang, Z; Zhao, X; Zhu, X, 2021) |
| " Overall, grade 3 adverse events, such as leukopenia and neutropenia, were observed in two of three patients (66." | 6.90 | Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. ( Emoto, S; Hata, K; Hiyoshi, M; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Shuno, Y; Tanaka, T, 2019) |
| "Simvastatin 80 mg tablets were taken orally once daily every day during the period of chemotherapy." | 6.90 | A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. ( Ahn, JB; Han, SW; Kang, WK; Kim, ST; Kim, TW; Kim, Y; Lee, J; Lim, HY; Park, JO; Park, YS, 2019) |
| "Metastatic colorectal cancer (mCRC) has low survival rates." | 6.90 | A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. ( Beck, JT; Berlin, JD; Cubillo Gracian, A; Deming, DA; Elez Fernandez, E; Garcia-Alfonso, P; Gorbunova, V; Hofheinz, RD; Luo, Y; Mangel, L; Nechaeva, M; Ramanathan, RK; Sullivan, D; Torres, AH, 2019) |
| " As for the biomarkers, carcinoembryonic antigen and lactate dehydrogenase (LDH) smoothly declined immediately after the initial dosing in patients with a partial response or stable disease." | 6.90 | Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study). ( Hirata, K; Hotta, Y; Imasato, M; Ishibashi, K; Iwamoto, S; Maeda, H; Makiyama, A; Mishima, H; Morita, S; Morita, Y; Munemoto, Y; Nagasaka, T; Nagata, N; Sakamoto, J; Takemoto, H; Tanaka, C; Toyofuku, A; Yoshida, Y, 2019) |
| "For stage II/Dukes B colorectal cancer (CRC), clinical biomarkers are urgently required to direct therapeutic options." | 6.87 | Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. ( Gray, R; Handley, K; Hutchins, GGA; Kerr, D; Magill, L; Quirke, P; Seymour, M; Southward, K; Tinkler-Hundal, E; Treanor, D; Wright, A, 2018) |
| " A prospective clinical trial was designed to evaluate the efficacy and safety of fluorouracil monotherapy combined with panitumumab administered to patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) intolerant to oxaliplatin and irinotecan." | 6.87 | A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial. ( Denda, T; Fukunaga, M; Kanda, M; Kataoka, M; Kim, HM; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Sakamoto, J; Takano, N; Takemoto, H; Tokunaga, Y, 2018) |
| "Many studies have determined colorectal cancer chemoresistance mechanisms such as drug efflux, cell cycle arrest, DNA damage repair, apoptosis, autophagy, vital enzymes, epigenetic, epithelial-mesenchymal transition, stem cells, and immune system suppression." | 6.82 | MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil. ( Gazouli, M; Lampropoulou, DI; Nemati, M; Pouya, FD; Rasmi, Y, 2022) |
| "Metastatic colorectal cancer (mCRC) frequently occurs in elderly patients." | 6.82 | Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). ( Adhoute, X; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Breysacher, G; Charneau, J; Chone, L; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Khemissa, F; Lavau-Denes, S; Lecomte, T; Legoux, JL; Lepère, C; Locher, C; Maillard, E; Michel, P; Mitry, E; Phelip, JM; Provençal, J; Sobhani, I, 2016) |
| "Pharmacokinetically guided (PK-guided) versus body surface area-based 5-fluorouracil (5-FU) dosing results in higher response rates and better tolerability." | 6.79 | A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. ( Atluri, PM; Chay, CH; Deal, AM; Ibrahim, JG; Inzerillo, JJ; McLeod, HL; O'Neil, BH; Olajide, OA; Patel, JN; Sherrill, GB; Walko, CM, 2014) |
| " The most commonly reported adverse events in the FOLFOX6 cohorts included decreased appetite, neutropenia, diarrhea, peripheral neuropathy, and vomiting." | 6.78 | An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. ( Adams, LM; Botbyl, J; Brady, J; Chau, I; Corrie, P; Digumarti, R; Laubscher, KH; Mallath, M; Midgley, RS, 2013) |
| "Thirty-six metastatic colorectal cancer patients received every 2 weeks, as first- (17) or second-line (19) treatment a combined chronotherapy with CPT-11 (infused at day 1 from 2 to 8 a." | 6.78 | Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report ( Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2013) |
| "Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signalling with activity against all three VEGF receptors." | 6.78 | Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. ( Cunningham, D; D'Haens, G; Douillard, JY; Robertson, J; Stone, AM; Van Cutsem, E; Wong, RP, 2013) |
| "Cediranib is an oral, highly potent VEGF signaling inhibitor of all three VEGF receptors." | 6.77 | Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. ( Boku, N; Mishima, H; Okamoto, W; Satoh, T; Shi, X; Shimamura, T; Yamaguchi, K; Yamazaki, K, 2012) |
| "Cediranib is an oral highly potent VEGF signalling inhibitor that inhibits all three VEGF receptors." | 6.77 | Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. ( Amagai, K; Baba, H; Bando, H; Denda, T; Fukase, K; Hazama, S; Kato, T; Mishima, H; Muro, K; Shi, X; Skamoto, J; Yamaguchi, K, 2012) |
| "Fifty-two patients with advanced colorectal cancer were enrolled in an ancillary pharmacogenetic study of the phase II CETUFTIRI trial." | 6.77 | Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. ( Bennouna, J; Chatelut, E; Douillard, JY; El Hannani, C; Etienne-Grimaldi, MC; Faroux, R; Formento, JL; Francois, E; Francoual, M; Hennebelle, I; Jacob, JH; Milano, G, 2012) |
| "Leucovorin Sodium (LV/Na) has a high solubility, and is stable when given with continuous infusion of 5-FU." | 6.77 | A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. ( Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P, 2012) |
| "Patients with metastatic colorectal cancer (mCRC) were randomized to XELOX plus bevacizumab using a standard triweekly cycle (Q3W) or a dose-dense biweekly cycle (Q2W) schedule." | 6.77 | A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). ( Cartwright, T; Hu, S; Hurwitz, H; Kwok, A; McKenna, E; Mitchell, EP; Patt, YZ, 2012) |
| " The most frequently observed adverse events reported with AZD6244 were acneiform dermatitis, diarrhoea, asthenia and peripheral oedema, compared with hand-foot syndrome, diarrhoea, nausea and abdominal pain with capecitabine." | 6.76 | A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. ( Adenis, A; Bennouna, J; Boer, K; Douillard, JY; Escudero, P; Kim, TY; Lang, I; Morris, CD; Pover, GM; Valladares-Ayerbes, M, 2011) |
| "8 or 45 μg/m(2) in combination with capecitabine-oxaliplatin (XELOX)." | 6.76 | Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. ( Andretta, V; Bennicelli, E; Bordignon, C; Caprioni, F; Comandini, D; Fornarini, G; Guglielmi, A; Lambiase, A; Mammoliti, S; Mazzola, G; Pessino, A; Sciallero, S; Sobrero, AF, 2011) |
| " Although skin toxicities are the most common adverse events associated with EGFR inhibitors, the differences in efficacy and safety between pre-emptive and reactive skin treatment according to KRAS tumor status has not been reported." | 6.76 | The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. ( Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M, 2011) |
| "Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5)." | 6.75 | A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ( Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010) |
| "As a project of the Kanagawa Colorectal Cancer Study Group, we performed this study to analyze the efficacy and the safety of modified FOLFIRI (irinotecan: 150 mg/m2) therapy for Japanese patients with metastatic colorectal cancer." | 6.75 | [Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer]. ( Akaike, M; Imada, T; Masuda, M; Matsukawa, H; Ozawa, Y; Rino, Y; Shiozawa, M; Shiraishi, R; Suzuki, H; Takahashi, M; Tamura, I; Yamamoto, N; Yamamoto, Y; Yukawa, N, 2010) |
| " This study aims to achieve an improved disease free survival for patients after resection or resection combined with RFA of colorectal liver metastases by adding the angiogenesis inhibitor bevacizumab to an adjuvant regimen of CAPOX." | 6.75 | A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. ( Bergman, AM; Dalesio, O; Rinkes, IH; Schouten, SB; Snoeren, N; Tollenaar, RA; van der Sijp, JR; van Hillegersberg, R; Verheul, HM; Voest, EE, 2010) |
| "Liver metastasectomies were performed in 26% of all pts and in 39% of pts with LM." | 6.75 | "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. ( Antonucci, A; Baldi, PL; Bruera, G; Cannita, K; De Galitiis, F; Ficorella, C; Mancini, M; Marchetti, P; Ricevuto, E; Santomaggio, A; Tudini, M, 2010) |
| "Tetrathiomolybdate (TM) is an oral copper chelator under development as an anti-angiogenic agent." | 6.74 | A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. ( Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM, 2009) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 6.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| "Cediranib is a highly potent and selective inhibitor of the 3 vascular endothelial growth factor receptors and has a halflife suitable for once-daily oral dosing." | 6.74 | Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. ( Botwood, NA; Robertson, JD; Rothenberg, ML; Schmoll, HJ, 2009) |
| "Cediranib is a potent oral inhibitor of the tyrosine kinase activity associated with all subtypes of vascular endothelial growth factor receptor." | 6.74 | Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. ( Chen, E; Gauthier, I; Jonker, D; MacLean, M; Powers, J; Seymour, L; Wells, J, 2009) |
| "Vorinostat was given orally twice daily for 1 week every 2 weeks." | 6.74 | A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. ( Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009) |
| " Patients exhibited high compliance in dosing administration." | 6.74 | Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009) |
| "Irinotecan is a chemotherapeutic agent used in the treatment of CRC and has demonstrated synergistic potential when used with radiation." | 6.74 | Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. ( Bower, GD; Briggs, GM; George, J; Goldstein, D; Olver, IN; Pavlakis, N; Price, D; Rossleigh, MA; Tapner, MJ; Taylor, DJ; van Hazel, GA, 2009) |
| "The R0 secondary resection rate of metastases was greater in the FOLFOXIRI arm (6% v 15%; P = ." | 6.73 | Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor ( Allegrini, G; Andreuccetti, M; Barbara, C; Benedetti, G; Brunetti, I; Chiara, S; Cortesi, E; Crinò, L; Evangelista, W; Falcone, A; Fanchini, L; Fioretto, L; Granetto, C; Masi, G; Orlandini, C; Pfanner, E; Picone, V; Porcile, G; Ricci, S; Vitello, S, 2007) |
| "To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC)." | 6.73 | Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. ( Agelaki, S; Androulakis, N; Chatzidakis, A; Christophylakis, C; Diamandidou, E; Emmanouilides, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kotsakis, A; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Touroutoglou, N; Vamvakas, L, 2007) |
| " Administration of TroVax alongside chemotherapy was safe and well tolerated with no SAEs attributed to the vaccine and no enhancement of chemo-related toxicity." | 6.73 | Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. ( Carroll, MW; Chikoti, P; Drury, N; Griffiths, R; Harrop, R; Hawkins, RE; Kingsman, SM; Naylor, S; Redchenko, I; Shingler, W; Steven, N, 2008) |
| "Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI." | 6.73 | A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. ( Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K, 2008) |
| "The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible." | 6.73 | A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. ( Antonini, NF; Cats, A; Creemers, GJ; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Rodenburg, CJ; Schrama, JG; Tol, J; Vos, AH, 2008) |
| "Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection." | 6.73 | Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008) |
| "Individual FU dose adjustment based on pharmacokinetic monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities." | 6.73 | Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ( Boisdron-Celle, M; Delva, R; Dorval, E; Gamelin, E; Jacob, J; Merrouche, Y; Morel, A; Pezet, D; Piot, G; Raoul, JL, 2008) |
| "Gefitinib at a dose of 250 mg daily in combination with weekly 5-fluorouracil at 2,000 mg/m(2) or gefitinib at a dose of 500 mg daily with 5-fluorouracil at 1,600 mg/m(2) plus oxaliplatin has an acceptable safety profile." | 6.73 | Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO). ( Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP, 2008) |
| "In patients with advanced colorectal cancer (ACRC), retrospective studies have shown that low expression levels of TS and DPD correlated with response to 5-FU." | 6.72 | Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. ( Dercksen, W; Giaccone, G; Noordhuis, P; Peters, GJ; Pinedo, HM; Smid, K; Smorenburg, CH; van Groeningen, CJ; van Riel, AM, 2006) |
| "Traditionally, metastatic colorectal cancer (MCRC) has been treated with intravenous (i." | 6.72 | A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. ( Gollins, S; Grieve, R; Samuel, L; Twelves, C, 2006) |
| "Thalidomide was escalated individually to 600 mg po QD as tolerated." | 6.72 | The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006) |
| " This PK model could be useful in identifying predictors for PK and pharmacodynamic variability to individualize dosing." | 6.72 | Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. ( Brouwers, JR; Jansman, FG; Kho, Y; Neef, C; Prins, NH, 2006) |
| "Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL." | 6.72 | A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. ( Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ, 2006) |
| " 5-FU pharmacokinetics was determined on day 2 of the first, third, and fifth cycles; type and the grade of adverse reactions were recorded on the next cycle." | 6.72 | Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. ( Barile, C; Bononi, A; Crepaldi, G; Ferrari, M; Ferrazzi, E; Grigoletto, F; Gusella, M; Menon, D; Padrini, R; Scapoli, D; Stievano, L; Toso, S, 2006) |
| "Patients with metastatic colorectal cancer (MCC) usually receive FOLFOX-4, or other oxaliplatin (L-HOP)-based regimens, until the occurrence of progressive disease, with an increase in the incidence of neurotoxicity which is correlated to the cumulative dose of L-HOP." | 6.72 | FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. ( Cioppa, T; Civitelli, S; Francini, E; Francini, G; Intrivici, C; Lorenzi, M; Marsili, S; Nettuno, R; Paolelli, L; Petrioli, R; Roviello, F; Tanzini, G, 2006) |
| "Patients aged 70 or more, with stage IV colorectal cancer, ECOG performance status not worse than 2." | 6.71 | First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. ( Daniele, B; De Maio, E; Gallo, C; Iaffaioli, RV; Manzione, L; Ottaiano, A; Perrone, F; Pignata, S; Rosati, G; Rossi, A; Tambaro, R, 2003) |
| "Postoperative complications were reported in 14 patients (13 occurring within 30 days after resection) and severe complications in 5 cases (including two deaths after extended resection)." | 6.71 | Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. ( Gassel, HJ; Gog, C; Hohenberger, W; Jauch, KW; Lehmann, U; Lorenz, M; Müller, HH; Padberg, W; Proschek, D; Ridwelski, K; Staib-Sebler, E; Vestweber, KH; Zamzow, K, 2003) |
| "The objective of this study was to develop a population pharmacokinetic model and validate it using a Bayesian approach for predicting, a priori and a posteriori, the individual volume of distribution (V(d)) and clearance (Cl) of 5-fluorouracil (5-FU) given as short-term intravenous infusion in weekly and multiple doses." | 6.71 | A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer. ( Almenar-Cubells, D; Climente-Martí, M; Jiménez-Torres, NV; Merino-Sanjuán, M, 2003) |
| "A prospective phase II study was performed to determine the feasibility, efficacy and safety of arterial hepatic infusion (HAI) using pirarubicin combined with intravenous chemotherapy." | 6.71 | Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. ( Adenis, A; Baulieux, J; Colin, P; Couzigou, P; Douillard, JY; Ducreux, M; Fallik, D; Jacob, J; Mahjoubi, M; Mahjoubi, R; Rougier, P; Seitz, JF; Ychou, M, 2003) |
| "Median survival in advanced colorectal cancer patients treated with 5-fluoro-uracil (5FU) and leucovorin (LV) is between 12 and 18 months." | 6.71 | [Long term survival in metastatic colorectal cancer treated with leucovorin and 5-fluoro-uracil chemotherapy]. ( André, T; Artru, P; Carola, E; de Gramont, A; Krulik, M; Louvet, C; Mabro, M; Molitor, JL; Perez, N; Tournigand, C, 2004) |
| "Weekly treatment at these doses is convenient and well-tolerated for the large majority of patients, and achieves DI comparable with the 5 days a month QUASAR schedule and other more toxic standard regimens." | 6.71 | Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. ( Anthoney, DA; Crellin, AM; Messruther, J; Patel, K; Sebag-Montefiore, D; Seymour, MT, 2004) |
| "The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in combination with 5-fluorouracil/leucovorin (5-FU/LV) in cancer patients." | 6.71 | Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004) |
| "Topotecan has shown fewer side effects and higher efficacy when given as a continuous i." | 6.71 | Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer. ( Deckert, PM; Hütter, G; Keilholz, U; Szélenyi, H; Thiel, E, 2004) |
| " Pharmacokinetic studies were performed on cycle 1 and 2 to assess the best sequence and detect any interaction between the two drugs." | 6.71 | Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. ( Adam, R; Bastian, G; Bismuth, H; Castaing, D; Gil-Delgado, MA; Guinet, F; Khayat, D; Rocher, MA; Spano, JP; Taillibert, S; Urien, S, 2004) |
| "Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever." | 6.71 | A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. ( Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML, 2005) |
| "Patients (n=38) with colorectal cancer received IFN-alpha 5 MU/m(2) SC on days 1-6; on days 2-6, LV 200 mg/m(2) IV was given with 5-FU at initial doses of 370-425 mg/m(2)/h." | 6.71 | A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel. ( Ernst, A; Grem, JL; Grogan, L; Grollman, F; Ismail, AS; Kao, V; Kirsch, IR; Parr, A; Quinn, MG; Wright, MA, 2005) |
| " This study was performed to determine the efficacy and safety of irinotecan (CPT-11) in combination with fluorouracil (FU) administered as a 48-hour continuous infusion twice a month in elderly patients." | 6.71 | Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gil, S; Maestu, I; Marcuello, E; Masutti, B; Maurel, J; Navarro, M; Sastre, J; Valladares, M; Vicent, JM, 2005) |
| " Studies of bimonthly regimens of high-dose leucovorin (LV) and 5-fluorouracil (5-FU) by continuous infusion combined with oxaliplatin (L-OHP) have shown encouraging response rates in patients not responding to a bimonthly LV/5-FU regimen." | 6.70 | Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. ( Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002) |
| " A phase II clinical trial of this combination using a continuous dosing schedule was carried out in patients with metastatic colorectal cancer." | 6.70 | Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. ( Benson, AB; Catalano, P; Cornfeld, MJ; Graham, DL; Huang, J; Marsh, JC; O'Dwyer, PJ, 2002) |
| " Therefore, we performed a study of PVI 5FU in 61 patients with advanced colorectal cancer to assess the variability (inter- and intra-subject) in 5FU Css associated with PVI 5FU (300 mg m(-2)day(-1)) and to attempt to correlate pharmacodynamic end-points (anti-tumour activity, toxicity) with 5FU Css as a prelude to 'exposure-guided' 5FU administration." | 6.70 | 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. ( Aird, R; Bowman, A; Jodrell, DI; Knowles, G; McLean, C; Stewart, M; Wall, L, 2001) |
| "164 patients with advanced colorectal cancer were enrolled in this randomised, placebo-controlled, double-blind, multicenter phase III study." | 6.70 | Double-blind randomised placebo-controlled phase III study of an E. coli extract plus 5-fluorouracil versus 5-fluorouracil in patients with advanced colorectal cancer. ( Clemm, C; Clevert, HD; Häring, B; Hockertz, S; Kalousek, MB; Kruse, A; Schneider, B; Thumann, A; Unger, C; Weber, B, 2001) |
| "In palliative first-line treatment of colorectal cancer, the secondary resection of distant metastases after downstaging has constantly gained in importance." | 6.70 | Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. ( Baum, U; Becker, D; Bernatik, T; Brueckl, WM; Hahn, EG; Hänsler, J; Hohenberger, W; Köckerling, F; Martus, P; Ott, R; Reck, T; Riedel, C; Schneider, T; Wein, A, 2001) |
| "Trimetrexate (TMTX) is a biochemical modulator of 5-fluorouracil (5-FU) and leucovorin (LV)." | 6.70 | Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. ( Croles, JJ; Douma, J; Hammershaimb, L; Keizer, HJ; Lochs, H; Muller, EW; Punt, CJ; Schüller, J; Skovsgaard, T; Ten Napel, CH; Zhang, J, 2002) |
| "Furthermore, presence of lung metastases, a primary rectal cancer and presence of lymph node metastases all predicted a better outcome in the multivariate setting." | 6.70 | Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. ( Aranda, E; Baron, B; Blijham, G; Cunningham, D; Di Costanzo, F; Glimelius, B; Hecker, H; Köhne, CH; Micheel, S; Palmer, M; Pignatti, F; Rougier, P; Scheithauer, W; Schöffski, P; Wils, J, 2002) |
| " Eight episodes of grade 3 or 4 stomatitis were observed, and were responsible for dosage modifications of MTX and 5-FU." | 6.69 | Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer. ( Acuña, JM; Acuña, LA; Amato, S; Barbieri, MR; Cuevas, MA; DeLena, M; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Lorusso, V; Machiavelli, MR; Ortiz, EH; Perez, JE; Rodriguez, R; Romero, AO; Sabatini, CL; Salvadori, MA; Vallejo, CT, 1998) |
| "Diarrhea was experienced by six of 10 patients, and only three patients were able to receive six weekly chemotherapy treatments without dose reduction or delay." | 6.69 | Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. ( Blumenson, LE; Creaven, PJ; Meropol, NJ, 1998) |
| "Only patients with colorectal cancer who had evidence of unresectable metastases confined to the liver were eligible." | 6.69 | Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. ( Bernath, AM; Bolton, JS; Burch, P; Colon-Otero, G; Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Nagorney, DM; O'Connell, MJ; Schroeder, G, 1998) |
| "203 patients with measurable advanced colorectal cancer were randomised to bolus 5-FU either as an injection for 2-4 min or as a short-term infusion lasting 10-20 min." | 6.69 | Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. ( Berglund, A; Brunsgaard, N; Gadeberg, C; Glimelius, B; Graf, W; Gustavsson, B; Hansen, P; Jakobsen, A; Kjaer, M; Lindberg, B; Lorentz, T; Påhlman, L; Sandberg, E; Sellström, H, 1998) |
| " Four episodes of grade 2 stomatitis were observed, causing dosage modifications." | 6.69 | Biomodulation with sequential intravenous IFN-alpha2b and 5-fluorouracil as second-line treatment in patients with advanced colorectal cancer. ( Amato, S; Barbieri, MR; Domínguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Marrone, N; Ortiz, EH; Pérez, JE; Rodríguez, R; Romero Acuña, JM; Romero Acuña, LA; Romero, AO; Vallejo, CT, 1998) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | 6.69 | Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| "16 patients with advanced colorectal cancer were treated with 650 mg/m2/d fluorouracil as 5 day continuous infusion and randomized to receive either 20 mg/m2 or 100 mg/m2 calcium folinate as short infusion twice daily." | 6.69 | Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer. ( Jaehde, U; Kreuser, ED; Schunack, W; Streit, M; Stremetzne, S, 1999) |
| " To predict 5-FU catabolic deficiencies and toxic side effects, we conducted a prospective study of patients treated for advanced colorectal cancer by high-dose 5-FU." | 6.69 | Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. ( Boisdron-Celle, M; Delva, R; Gamelin, E; Genevieve, F; Guérin-Meyer, V; Ifrah, N; Larra, F; Lortholary, A; Robert, J, 1999) |
| "Recent advances in the management of colorectal cancer have improved the quality of life and the survival of patients treated with chemotherapy." | 6.69 | [Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients]. ( Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M; Maindrault-Goebel, F, 1999) |
| "Six of 40 patients with metastatic colorectal cancer obtained an objective response (15%; 95% confidence interval, 6-30%)." | 6.69 | Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. ( Avallone, A; Blackie, R; Budillon, A; Caponigro, F; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lucia, L; De Vita, F; Gravina, A; McLeod, H; Morsman, J, 1999) |
| "In primary colorectal tumors, the concentration of 5-FU was on average 3." | 6.69 | Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. ( Banken, L; Cassidy, J; Dumont, E; Durston, S; Mori, K; Reigner, B; Roos, B; Schüller, J; Utoh, M; Weidekamm, E, 2000) |
| "Cimetidine has demonstrated a survival benefit in a randomized trial as adjuvant therapy for gastric cancer." | 6.68 | A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer. ( Adams, WJ; Clingan, PR; Legge, J; Links, M; Morris, DL; O'Baugh, J; Phadke, K; Ross, WB, 1995) |
| "Site of metastases included liver (n = 16), lung (n = 7), abdomen (n = 2), pelvic recurrences (n = 2), cutaneous (n = 1)." | 6.68 | Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen. French Northern Oncology Group. ( Adenis, A; Bonneterre, J; Carlier, D; Darloy, F; Demaille, A; Pion, JM, 1995) |
| "Thirty-five patients with metastatic colorectal cancer were treated; 15 (41%) had received previous therapy, 22 (63%) had W." | 6.68 | A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. ( Adam, R; Bismuth, H; Caussanel, JP; Jasmin, C; Lévi, F; Metzger, G; Misset, JL; Smolensky, M; Soussan, A, 1995) |
| " These results show that there is no pharmacokinetic advantage to the use of 6S-LV rather than 6R,S-LV as a modulator of 5-FU." | 6.68 | A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. ( Berghorn, E; Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1995) |
| "Metastatic colorectal cancer is generally incurable." | 6.68 | Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer. ( Abbruzzese, JL; Brown, BW; Gross, HM; Jones, DV; Levin, B; Levy, LB; Pendergrass, KB; Pugh, RP; Wade, JL; Winn, RJ, 1995) |
| " The dosage was as follows: group A received FA i." | 6.68 | Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. ( Archimandritis, A; Bacoyiannis, C; Giannopoulos, A; Kalahanis, N; Karatzas, G; Kosmas, C; Kosmidis, P; Papachristodoulou, A; Papadimas, V; Polyzos, A; Sakelaropoulos, N; Tsavaris, N, 1996) |
| "To determine the most effective dose of leucovorin (folinic acid [FA]) within a weekly bolus fluorouracil (FU) schedule, we conducted a randomized multicenter trial to compare therapeutic effects and toxicity of high-dose FA versus low-dose FA combined with FU at equal doses in both treatment groups." | 6.68 | Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. ( Bernhard, G; Bernhard, H; Heike, M; Jäger, E; Klein, O; Knuth, A; Lautz, D; Meyer zum Büschenfelde, KH; Michaelis, J, 1996) |
| "Sixty-eight patients with advanced colorectal cancer received every 2 weeks hydroxyurea per os 1." | 6.68 | Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. ( Beerblock, K; Bennamoun, M; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Mal, F; Moreau, S; Soubrane, D; Varette, C; Zylberait, D, 1996) |
| "Ukrain is a new effective drug in the therapy of colorectal cancer." | 6.68 | Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer. ( Korsh, OB; Kravchenco, OB; Susak, YM; Yaremchuk, OY; Yatsyk, IM; Zemskov, VS, 1996) |
| "Residual metastases were surgically removed in 13 patients (26%)." | 6.68 | Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Brummer, PD; Ithzaki, M; Jami, A; Kunstlinger, F; Lévi, F; Misset, JL, 1996) |
| "Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively." | 6.68 | The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996) |
| "Chemotherapy pretreated patients with colorectal cancer seem to have a substantial survival benefit with this salvage protocol." | 6.68 | High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer. ( Hausamen, TU; Loeffler, TM, 1996) |
| "Colorectal carcinoma is one of the most common neoplasms in Western societies, being second only to lung cancer as a cause of death from malignancy." | 6.68 | First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer. ( Beuzeboc, P; Deffontaines, D; Diéras, V; Dorval, T; Garcia-Giralt, E; Jouve, M; Palangie, T; Pouillart, P; Scholl, S, 1996) |
| "These studies demonstrate that the present dose and schedule of AZT in combination with 5-FU + LV has significant activity in metastatic colorectal cancer and that the combination of 5-FU + LV with AZT increases the amount of DNA damage." | 6.68 | Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand break ( Allegrini, G; Andreuccetti, M; Antonuzzo, A; Brunetti, I; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Lencioni, M; Malvaldi, G; Pfanner, E, 1997) |
| "Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues." | 6.68 | Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997) |
| "Two hundred patients with advanced colorectal cancer received PVI 5-FU 300 mg/m2/day for a maximum of 24 weeks and were randomised to PVI 5-FU alone or PVI 5-FU + MMC 10 mg/m2 (7 mg/m2 from June 1995) 6 weekly for 4 courses." | 6.68 | A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. ( Cunningham, D; Iveson, T; Massey, A; Norman, A; Oates, J; Padhani, A; Popescu, R; Prendiville, J; Ross, P; Watson, M; Webb, A, 1997) |
| "Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals." | 6.67 | A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993) |
| " in 15' x 5 days) every 4 weeks (Arm A), or to 5-FU alone at the same dosage (Arm B)." | 6.67 | Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). ( Aitini, E; Barni, S; Beretta, A; Beretta, GD; Cesana, B; Comella, G; Cozzaglio, L; Cristoni, M; Labianca, R; Pancera, G, 1991) |
| "In 28 patients with advanced colorectal cancer, in progression under FA-5FU, we continued treatment with FA-5FU plus DIP." | 6.67 | Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with allopurinol, folinic acid and dipyridamol. ( Antonopoulos, A; Bacoyannis, C; Beldecos, D; Karvounis, N; Kosmidis, P; Mylonacis, N; Tsavaris, N; Valilis, P; Zamanis, N; Zinelis, A, 1990) |
| "Thirty one gastric cancer pts." | 6.67 | [High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer. High-Dose Leucovorin and 5-FU Study Group]. ( Akazawa, S; Matsuoka, T; Mukaiyama, T; Ogawa, M; Ota, K; Sakai, Y; Sakata, Y; Sasaki, T; Wakui, A; Yoshino, M, 1990) |
| "5-Fluorouracil (5-FU) has become one of the most widely employed antimetabolite chemotherapeutic agents in recent decades." | 6.66 | Recent Advances in Designing 5-Fluorouracil Delivery Systems: A Stepping Stone in the Safe Treatment of Colorectal Cancer. ( Entezar-Almahdi, E; Farjadian, F; Mohammadi-Samani, S; Tayebi, L, 2020) |
| "Sixty patients with advanced colorectal cancer were randomized between cisplatin (60 mg/mq i." | 6.66 | Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. ( Cesana, B; Clerici, M; Labianca, R; Luporini, G; Montinari, F; Pancera, G, 1988) |
| "5-fluorouracil is a chemotherapeutic agent that plays an important role in the treatment of various cancers including head and neck and gastrointestinal malignancies." | 6.53 | Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review. ( Mahipal, A; Markey, KR; Saneeymehri, SS, 2016) |
| "To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings." | 6.53 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016) |
| "Pharmacokinetic guided dosing of 5-fluorouracil chemotherapies to bring plasma 5-fluorouracil into a desired therapeutic range may lead to fewer side effects and better patient outcomes." | 6.53 | Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review. ( Clarke, A; Connock, M; Court, R; Freeman, K; Gurung, T; Saunders, MP; Sutcliffe, P; Taylor-Phillips, S; Uthman, OA, 2016) |
| " The risk of mortality, therapeutic efficacy, and adverse effect were meta-analyzed." | 6.53 | Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. ( Chen, K; Gong, Y; Shen, Y; Zhang, Q; Zhou, T, 2016) |
| " Herein, we critically discuss the current data on the efficacy and safety profile of bevacizumab in combination with fluoropyrimidine-based chemotherapy for first-line and maintenance treatment of metastatic CRC and briefly comment on existing controversies and future perspectives." | 6.52 | Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. ( Grapsa, D; Saif, MW; Syrigos, K, 2015) |
| "Capecitabine has previously been compared to 5-fluorouracil-either as a monotherapy or in combination with oxaliplatin, irinotecan, or biological drugs-and has been found to have comparable efficacy and safety profiles." | 6.50 | Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? ( Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ, 2014) |
| "Capecitabine is an orally administered fluoropyrimidine carbamate that is absorbed intact from the gastrointestinal tract and becomes metabolically activated to 5-FU within the tumor." | 6.46 | Evolution of capecitabine dosing in colorectal cancer. ( Sun, W, 2010) |
| "Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration." | 6.46 | Update on capecitabine alone and in combination regimens in colorectal cancer patients. ( Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S, 2010) |
| "Capecitabine is an oral prodrug of 5-fluorouracil." | 6.44 | Capecitabine in the treatment of colorectal cancer. ( Cassidy, J; Kelly, C, 2007) |
| "For instance, in patients with colorectal cancer, higher enzyme activity of topoisomerase-I seems to be predictive of a better response to irinotecan." | 6.43 | Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. ( Lentz, F; Pons, G; Rey, E; Tran, A; Tréluyer, JM, 2005) |
| "Irinotecan was first developed in patients refractory to fluorouracil." | 6.43 | Benefit-risk assessment of irinotecan in advanced colorectal cancer. ( Glimelius, B, 2005) |
| "Worldwide, colorectal cancer is a common cancer and a major cause of morbidity and mortality." | 6.43 | Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. ( Jefford, M; Khamly, K; Michael, M; Zalcberg, J, 2005) |
| "Capecitabine is an oral fluoropyrimidine which is converted to 5-fluorouracil primarily in tumor tissue, and has the advantages of ease-of-administration, acceptable toxicity and significant antineoplastic activity." | 6.43 | Capecitabine in the treatment of colorectal cancer. ( Cassidy, J; O'Neill, VJ, 2005) |
| "The chemotherapy of metastatic colorectal cancer (CRC) has undergone a succession of refinements." | 6.42 | Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. ( Carnaghi, C; Comella, P; Díaz-Rubio, E; Douillard, JY; Santoro, A; Sobrero, A; Van Cutsem, E, 2003) |
| " The use of irinotecan together with raltitrexed is also being investigated, as is its combination with oxaliplatin." | 6.42 | Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. ( Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U, 2003) |
| " DPD-inhibiting oral fluoropyrimidines showing promise in early clinical studies included UFT (the 5-FU prodrug, tegafur, plus the DPD substrate, uracil), eniluracil (an irreversible DPD inhibitor that improves the oral bioavailability of 5-FU) and S-1 (tegafur plus a reversible DPD inhibitor, 5-chloro-2,4-dihydroxypyridine, and oxonic acid)." | 6.42 | Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. ( Schmoll, HJ, 2003) |
| "Colorectal cancer is a leading cause of cancer death worldwide." | 6.42 | Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. ( Gill, S; Goldberg, RM, 2004) |
| "Colorectal cancer is the second leading cause of cancer death in the USA and fluoropyrimidines have been the mainstay of treatment for over 40 years." | 6.42 | Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. ( Iqbal, S; Lenz, HJ, 2004) |
| "Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells." | 6.41 | Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002) |
| "Capecitabine (Xeloda)(R) was developed as a tumour-selective fluoropyrimidine carbamate to achieve higher intratumoural 5-FU level and lower toxicity than 5-FU." | 6.41 | Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer. ( Di Costanzo, F; Gasperoni, S; Sdrobolini, A, 2000) |
| "Metastatic colorectal cancer remains incurable with available systemic therapeutic options." | 6.41 | Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. ( Grivicich, I; Mans, DR; Peters, GJ; Schwartsmann, G, 2001) |
| "Unusual aspect of the development of oxaliplatin was that substantial evidence of its activity was gathered when used in combination with protracted infusion of 5FU combined with leucovorin, preceeding the formal demonstration of its single activity in this disease." | 6.41 | [Oxaliplatin in combination with 5-fluoro-uracil and folinic acid as treatment of metastatic colorectal cancer]. ( André, T; Gramont, AD; Louvet, C; Maindrault-Goebel, F, 2001) |
| "Capecitabine is an orally administered fluoropyrimidine which is selectively activated in tumour tissue to the active moiety fluorouracil and is cytotoxic through inhibition of DNA synthesis." | 6.41 | Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. ( Goa, KL; McGavin, JK, 2001) |
| "Trimetrexate is a nonclassical antifolate that has demonstrated antitumor activity against a number of malignancies, including those resistant to the classical antifolate methotrexate." | 6.40 | Trimetrexate: review and current clinical experience in advanced colorectal cancer. ( Blanke, CD; Messenger, M; Taplin, SC, 1997) |
| "Over the last 40 years the treatment of colorectal cancer has not achieved the same progress as treatment for other types of tumors." | 6.40 | Beyond 5-fluorouracil monochemotherapy in colorectal cancer--it is time. ( Franchi, F; Satta, F, 1997) |
| "In human colorectal cancer cell lines and various animal tumour model systems 5-fluoro-2'-deoxyuridine (FdUrd) is more effective than 5-fluorouracil (5-FU)." | 6.40 | Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. ( Ackland, SP; Peters, GJ; Rustum, YM; van Groeningen, CJ; van Laar, JA, 1998) |
| "Colorectal cancer is one of the most frequent cancers in the western world." | 6.40 | 5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules. ( Kamm, YJ; Punt, CJ; Rietjens, IM; Wagener, DJ, 1998) |
| "Irinotecan or CPT11 is a topoisomerase 1 inhibitor." | 6.40 | [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials]. ( Peeters, M; Van Cutsem, E, 1998) |
| "Irinotecan treated patients lived for significantly longer than those on 5FU: median time of survival was 10." | 6.40 | [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. ( Ducreux, M; Mitry, E; Rougier, P, 1998) |
| "Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours." | 6.40 | Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil. ( Hoff, PM; Lassere, Y; Pazdur, R, 1999) |
| "Although phase III studies have investigated the effect of adding bevacizumab to the 3-weekly capecitabine plus irinotecan (XELIRI) combination in the first-line treatment of metastatic colorectal cancer (mCRC), no phase III studies investigating the effects of adding bevacizumab to biweekly XELIRI have been published." | 6.27 | Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials. ( Alvarez Suarez, S; Blanco Codeidido, M; García Alfonso, P; López Martín, P; Martin, M; Mondejar Solis, R; Muñoz Martin, A; Tapia Rico, G, 2013) |
| "In DaVINCI, a randomised phase II trial, patients with advanced colorectal cancer were randomly allocated to: Combination therapy (FOLFIRI), irinotecan (180 mg/m(2) IV over 90 min, day 1), 5-fluorouracil (400mg/m(2) IV bolus and 2400 mg/m(2) by 46-hour infusion from day 1) and folinic acid (20mg/m(2) IV bolus, day 1), 2-weekly; or Single-agent, irinotecan (350 mg/m(2) IV over 90 min), 3-weekly." | 6.25 | Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. ( Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J, 2011) |
| "The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer." | 6.23 | A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008) |
| "This study was conducted before the approval of oxaliplatin, cetuximab, and bevacizumab and was designed to evaluate a novel microtubule targeting agent, T138067, in patients with metastatic colorectal cancer (CRC) previously treated with irinotecan and 5-fluorouracil." | 6.23 | Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. ( Bergsland, E; Berlin, JD; Lockhart, AC; Rosen, L; Rothenberg, M; Venook, A, 2008) |
| "The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer." | 6.21 | Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. ( Adamo, V; Bianco, AR; Carlomagno, C; Cortesi, E; De Placido, S; De Vita, F; Farris, A; Ficorella, C; Gallo, C; Gebbia, N; Gemini, M; Iannace, C; Ianniello, GP; Lopez, M; Manzione, L; Palazzo, S; Palmeri, S; Paoletti, G; Perrone, F; Persico, G; Pistillucci, G, 2005) |
| "The French contribution to the development of 5-fluorouracil (5-FU) infusion in advanced colorectal cancer includes five randomized trials and specific researches on the 48-hour bimonthly regimen, chronotherapy, and individual dose adaptation." | 6.18 | The French experience with infusional 5-fluorouracil in advanced colorectal cancer. ( de Gramont, A; Krulik, M; Louvet, C, 1996) |
| "17 patients with metastasizing colorectal cancer were treated in a phase II-study with systemic intravenous chemotherapy (Petrelli N, Proc ASCO 286, 1987) consisting of leucovorin 500 mg/m2 in a 2 hr infusion and 5-fluorouracil (5-FU) 600 mg/m2 bolus one hour after the commencement of the leucovorin infusion." | 6.16 | [5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma]. ( Baur, M; Dittrich, C; Havelec, L; Mader, R; Marosi, C; Scheithauer, W; Schlappack, O, 1991) |
| "The purpose of this study was to evaluate the effectiveness of several new approaches designed to enhance the activity of fluorouracil (5-FU) in the management of advanced colorectal cancer." | 6.16 | Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. ( Cullinan, SA; Everson, LK; Krook, JE; Laurie, JA; Mailliard, JA; Moertel, CG; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1989) |
| "Xenografted patient-derived colon cancer tissues with MSI also show variable patterns of HDAC2 expression in mice." | 5.91 | The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. ( Brachetti, C; Brenner, W; Kiweler, N; Krämer, OH; Linnebacher, M; Matschos, S; Mullins, C; Nguyen, A; Piée-Staffa, A; Roos, WP; Schneider, G; Schwarz, H, 2023) |
| "Colorectal cancer has risen to the third occurring cancer in the world." | 5.91 | The Gut Microbiota Metabolite Urolithin B Prevents Colorectal Carcinogenesis by Remodeling Microbiota and PD-L1/HLA-B. ( Chen, J; Chen, Q; Jin, S; Song, H; Song, X; Wang, L; Wang, Z; Xing, W; Yang, H; Zhao, W, 2023) |
| "Colorectal cancer (CRC) is the third most common cancer in the world, but current chemotherapy options are limited due to adverse effects and low oral bioavailability of drugs." | 5.91 | Development and cytotoxicity evaluation of multiple nanoemulsions for oral co-delivery of 5-fluorouracil and short chain triglycerides for colorectal cancer. ( Barreto, T; Branco, PC; Fukumori, C; Ishida, K; Lopes, LB, 2023) |
| "Blastocystis is an enteric protozoan parasite with extensive genetic variation and unclear pathogenicity." | 5.91 | Blastocystis sp. reduces the efficacy of 5-fluorouracil as a colorectal cancer chemotherapeutic treatment. ( Govind, SK; Jayalakshmi, P; Kumarasamy, V; Kuppusamy, UR, 2023) |
| "Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent." | 5.91 | In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells. ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023) |
| "Metformin is an old, inexpensive, and relatively safe anti-diabetic medication that can decrease the risk of several types of cancer in patients with diabetes." | 5.72 | The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer. ( Ala, M, 2022) |
| "5-Fluorouracil is an anticancer drug with a short biological half-life." | 5.72 | The development of a novel oral 5-Fluorouracil in-situ gelling nanosuspension to potentiate the anticancer activity against colorectal cancer cells. ( Abdullah, S; Aldahlawi, A; El Hadad, S, 2022) |
| " The efficacy and adverse effects of maintenance treatment were compared between the two groups." | 5.72 | Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer. ( Cha, Y; Huang, W; Tian, Y; Xiong, H; Yuan, X; Zhang, H, 2022) |
| "Chemotherapy resistance of colorectal cancer stem cells (CRC-SCs) has become a major challenge in clinical treatment of cancer." | 5.72 | Methionine restriction enhances the chemotherapeutic sensitivity of colorectal cancer stem cells by miR-320d/c-Myc axis. ( Liu, C; Wang, JL; Wu, DZ; Xin, L; Yuan, YW, 2022) |
| "But its role in the development of colorectal cancer (CRC) cancer remains unknown." | 5.72 | FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis. ( Deng, H; He, Z; Li, G; Mou, T; Shi, J; Sui, C; Sun, K; Wang, T; Wang, Y; Xu, Z; Yang, J; Zhang, P; Zhuang, B, 2022) |
| "Chemoresistance is a main obstacle for colorectal cancer treatment." | 5.72 | Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells. ( Li, J; Liu, J; Liu, K; Luo, F, 2022) |
| "5-Fluorouracil (5-FU) has long been used as a standard first-line treatment for CRC patients." | 5.72 | Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer. ( Duan, T; Feng, J; Huang, X; Jin, W; Ke, K; Mei, R; Mou, Y; Shou, L; Sui, X; Sun, X; Wu, Q; Xie, T; Yu, S; Zhang, R; Zhu, Q, 2022) |
| " Data from experiments for 48 h showed that Bru, alone or in combination with 5-FU, is capable of causing an increase in the percentage of apoptotic cells in HT-29 cells compared to those of Erio alone or in combination with 5-FU." | 5.72 | Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell. ( Alper, M; Ardıl, B, 2022) |
| " However, during CRC treatment, long-term use of traditional chemotherapeutic drugs will reduce the sensitivity of chemotherapy." | 5.72 | A serum metabolomics study based on LC-MS: Chemosensitization effects of Rauvolfia vomitoria Afzel. combined with 5- fluorouracil on colorectal cancer mice. ( Kong, WR; Wang, JF; Wang, N; Wang, SQ; Wang, ZF; You, YL, 2022) |
| "On day 2 of re-treatment, serous retinal detachment recurred and treatment was discontinued." | 5.72 | [A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer]. ( Ajihara, T; Fukuya, Y; Hanada, M; Koike, T; Kono, T; Miyata, R; Naritomi, T; Shiozawa, S; Yoshimatsu, K, 2022) |
| "Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab is the standard second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to fluoropyrimidines and oxaliplatin." | 5.69 | Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer. ( Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H, 2023) |
| "AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC), with a modest benefit among proficient mismatch repair (pMMR)." | 5.69 | An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. ( Antoniotti, C; Bensi, M; Bergamo, F; Boccaccino, A; Boquet, I; Catteau, A; Conca, V; Cremolini, C; Galon, J; Giordano, M; Leonetti, S; McGregor, K; Morano, F; Murgioni, S; Nielsen, TJ; Papiani, G; Passardi, A; Pietrantonio, F; Ross, DT; Rossini, D; Salvatore, L; Schweitzer, BL; Seitz, R; Tamburini, E; Varga, MG, 2023) |
| "The phase Ia/b trials investigated the safety and tolerability and antitumor activities of suvemcitug for pretreated advanced solid tumors and in combination with FOLFIRI (leucovorin and fluorouracil plus irinotecan) in second-line treatment of metastatic colorectal cancer using a 3 + 3 dose-escalation design." | 5.69 | Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials. ( Cao, J; Ding, Y; Feng, X; Ji, D; Liu, L; Mao, C; Song, L; Song, W; Wu, Y; Xu, N; Zhang, J; Zhang, Y, 2023) |
| "In this prospective randomized crossover trial of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma, patients did not derive clinical benefit from fluorouracil-based chemotherapy, given there were no objective responses, no difference in OS when treatment was delayed 6 months, and no difference in the rate of tumor growth while receiving chemotherapy." | 5.69 | Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. ( Beaty, KA; Eng, C; Foo, WC; Fournier, K; Hornstein, N; Lano, E; Mansfield, P; Matamoros, A; Overman, MJ; Rafeeq, S; Raghav, KP; Scally, C; Scofield, LC; Shen, JP; Taggart, M; Tidwell, RS; Uppal, A; Yousef, AM; Zeineddine, FA; Zeineddine, MA, 2023) |
| "The PanaMa trial demonstrated significant benefit in progression-free survival with the addition of panitumumab (Pmab) to fluorouracil and folinic acid (FU/FA) as maintenance therapy following first-line induction therapy with FOLFOX/Pmab in patients with RAS wild-type metastatic colorectal cancer." | 5.69 | Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. ( Alig, AHS; Ballhausen, A; Fruehauf, S; Goekkurt, E; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; Kasper, S; König, AO; Kurreck, A; Meyer-Knees, JW; Modest, DP; Müller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023) |
| "The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects." | 5.62 | NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study. ( Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C, 2021) |
| "Regorafenib, which has been approved as a salvage line for metastatic colorectal cancer, features many adverse events, and there are few cases in which the approved dose can be administered." | 5.62 | [A Case of Long-Term Survival after Administration of Regorafenib for Stage Ⅳ Colorectal Cancer]. ( Koike, T; Kono, T; Miyano, Y; Oyama, K; Shiozawa, S; Yokokawa, H; Yoshimatsu, K, 2021) |
| "Fatty liver is a side effect of chemotherapy that limits the ability to treat colorectal cancer (CRC) patients in the most effective way." | 5.62 | Alterations in hepatic fatty acids reveal depletion of total polyunsaturated fatty acids following irinotecan plus 5-fluorouracil treatment in an animal model of colorectal cancer. ( Bathe, O; Jacobs, R; Mazurak, VC; Monirujjaman, M; Nelson, R; Pant, A, 2021) |
| "Colorectal cancer is the second most common malignant tumor in China." | 5.62 | [Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer]. ( , 2021) |
| "Drug resistance in colorectal cancer is a great challenge in clinic." | 5.62 | MicroRNA-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer. ( Fang, Y; Liu, P; Shen, X; Wang, W; Wu, S; Zhang, H; Zhou, Y, 2021) |
| "Zotarolimus is a semi-synthetic derivative of rapamycin and an inhibitor of mammalian target of rapamycin (mTOR) signaling." | 5.62 | Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice. ( Chang, GR; Chen, CH; Kuo, CY; Liao, HJ; Lin, TC; Lin, WL; Tsai, MY; Wang, YC, 2021) |
| " Although curcumin is known to have anti-tumor, hepatoprotective, and hypoglycemic-like actions, its low water solubility, oral absorption, and bioavailability impede its therapeutic uses." | 5.62 | Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids. ( Abugomaa, A; Ayame, H; Elbadawy, M; Hayashi, K; Hayashi, SM; Hazama, S; Ishihara, Y; Kaneda, M; Nagano, H; Nakajima, M; Sasaki, K; Shibutani, M; Shinohara, Y; Suzuki, N; Takenouchi, H; Tsunedomi, R; Usui, T; Yamawaki, H, 2021) |
| "Developing new drugs for killing colorectal cancer (CRC) cells is urgently needed." | 5.56 | Toosendanin-induced apoptosis in colorectal cancer cells is associated with the κ-opioid receptor/β-catenin signaling axis. ( Chen, J; Chen, S; He, L; Huang, L; Li, W; Liu, H; Liu, R; Wang, F; Wang, H; Wen, C; Yang, X; Yu, WK; Zhou, Q, 2020) |
| " Chemotherapy-induced side effects were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE Version 5." | 5.56 | Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. ( Abdhaghighi, MJ; Jalali, H; Janbabaei, G; Negarandeh, R; Nosrati, A; Saghafi, F; Salehifar, E, 2020) |
| " We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale)." | 5.56 | FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study. ( Costa, BA; da Rocha Filho, DR; de Albuquerque Ribeiro Gondinho, P; de Barros Silva, PG; Gifoni, MAC; Junior, RCPL; Lima, MVA; Lisboa, MRP; Vale, ML, 2020) |
| " Whether a patient who experienced a major cardiac side effect from 5-FU can be safely rechallenged with this drug is a clinical dilemma." | 5.56 | 5-Fluorouracil Rechallenge After Cardiotoxicity. ( Almnajam, M; Desai, A; Kim, AS; Mohammed, T; Patel, KN, 2020) |
| "Glycine has been shown to protect livers from CTx-induced injury and oxidative stress, and it reduces platelet aggregation and improves microperfusion." | 5.56 | Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats. ( Bausys, A; Feldbacher, N; Hoefler, G; Kolb-Lenz, D; Leber, B; Maneikyte, J; Schemmer, P; Stiegler, P; Strupas, K, 2020) |
| " In the attempt to better define prechemotherapy baseline clinical and biomolecular predictors of drug toxicity, we trained and compared five ML algorithms starting from clinical, blood biochemistry, and genotype data derived from a previous phase Ib study aimed to define the maximum tolerated dose of irinotecan (FOLFIRI (folinic acid, fluorouracil, and irinotecan) plus bevacizumab regimen) in patients with metastatic colorectal cancer." | 5.51 | Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinical-Biomolecular Markers Significantly Associated With Toxicity. ( Bedon, L; Buonadonna, A; Cecchin, E; Dal Bo, M; Fabbiani, E; Polano, M; Toffoli, G, 2022) |
| "Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated." | 5.51 | Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial. ( Aranda, E; Díaz, IA; Élez, E; García-Alfonso, P; Gómez-España, MA; Graña, B; Grávalos, C; Losa, F; Martínez de Castro, E; Ortiz-Morales, MJ; Polo, E; Riesco, MDC; Rodriguez-Ariza, A; Ruiz-Casado, A; Safont, MJ; Salgado, M; Salud, A; Tabernero, J; Toledano-Fonseca, M; Valladares-Ayerbes, M, 2022) |
| "Combination irinotecan and cetuximab is approved for irinotecan-refractory metastatic colorectal cancer (mCRC)." | 5.51 | Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. ( Bekaii-Saab, T; Dakhil, SR; Faggen, M; Fuchs, CS; Heying, EN; Lipsyc-Sharf, M; Meyerhardt, JA; Ng, K; Noble, S; Ou, FS; Rubinson, DA; Schrag, D; Schuetz, SR; Stella, PJ; Weckstein, DJ; Wender, DB; Yurgelun, MB; Zemla, TJ, 2022) |
| "Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients with metastatic colorectal cancer (mCRC) RAS wild-type (wt); however, the efficacy of cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX) had never been demonstrated in a prospective, randomized, controlled phase III study." | 5.51 | [The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab]. ( Colombo, A; Porretto, CM; Rosati, G, 2022) |
| " Patients with colorectal cancer scheduled to receive adjuvant chemotherapy with capecitabine plus oxaliplatin are enrolled, and topical hydrocortisone butyrate 0." | 5.51 | Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC s ( Ahiko, Y; Aikou, S; Boku, N; Furukawa, N; Iimura, Y; Ishibashi, M; Kuroda, S; Nojima, M; Shida, D; Tanabe, T, 2022) |
| "Initial systemic therapy for patients with metastatic colorectal cancer (mCRC) is usually based on two- or three-drug chemotherapy regimens with fluoropyrimidine (5-fluorouracil (5-FU) or capecitabine), oxaliplatin and/or irinotecan, combined with either anti-VEGF (bevacizumab) or, for RAS wild-type (WT) tumors, anti-EGFR antibodies (panitumumab or cetuximab)." | 5.51 | Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line tre ( Dechow, T; Ettrich, TJ; Fruehauf, S; Fuchs, M; Heinemann, V; Hoyer, I; Kaiser, F; Karthaus, M; Kiani, A; König, A; Kurreck, A; Modest, DP; Müller, L; Quante, M; Reinacher-Schick, A; Roderburg, C; Schwaner, I; Sommerhäuser, G; Stahler, A; Stintzing, S; von Weikersthal, LF, 2022) |
| "The randomised open-label phase III XELAVIRI trial failed to demonstrate non-inferiority of the sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A) versus initial combination of all agents (Arm B) for untreated metastatic colorectal cancer in the initial analysis of time-to-failure-of-strategy (TFS, 90% confidence boundary of 0." | 5.51 | First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S, 2022) |
| "This trial investigates the addition of panitumumab to chemotherapy with fluorouracil/folinic acid and oxaliplatin (FOLFOX) in a 2:1 randomised, controlled, open-label, phase II trial in RAS wild-type colorectal cancer patients with R0/1-resected liver metastases." | 5.51 | FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314). ( Fischer V Weikersthal, L; Fuchs, M; Heinemann, V; Held, S; Jacobasch, L; Jung, A; Junghanß, C; Kaczirek, K; Kaiser, F; Karthaus, M; Kasper, S; Keitel, V; Kiani, A; Lerchenmüller, C; Lorenzen, S; Modest, DP; Moosmann, N; Sent, D; Stintzing, S; Uhlig, J, 2022) |
| "The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin." | 5.51 | Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. ( Acar, R; Akbas, S; Akinci, MB; Araz, M; Arslan, C; Artac, M; Bahceci, A; Bilgetekin, I; Bilici, A; Cakir, E; Celik, E; Cilbir, E; Cincin, I; Dede, DS; Demirkiran, A; Deniz, GI; Dogan, I; Erdem, D; Erdogan, AP; Eren, OO; Erol, C; Garbioglu, DB; Gulmez, A; Hacibekiroglu, I; Hamdard, J; Hizal, M; Inal, A; Kahraman, S; Kaya, AO; Koca, S; Kubilay, P; Kucukarda, A; Kut, E; Mandel, NM; Menekse, S; Nayir, E; Oksuzoglu, B; On, S; Oyman, A; Ozyukseler, DT; Paydas, S; Sakin, A; Sen, E; Sendur Mehmet, AN; Sevinc, A; Taskaynatan, H; Tastekin, D; Turhal, S; Uncu, D; Yalcin, B; Yildirim, ME, 2022) |
| "Platinum was readily detectable in skin biopsies more than 60 months post-completion of FOLFOX." | 5.51 | Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. ( Cao, Y; Chang, Q; Chen, EX; Hedley, D; Ornatsky, O; Zhang, W, 2019) |
| "Chemotherapy is currently used to treat colorectal cancer (CRC), the most common cancer worldwide." | 5.51 | Identification of bioactive compounds in Lactobacillus paracasei subsp. paracasei NTU 101-fermented reconstituted skimmed milk and their anti-cancer effect in combination with 5-fluorouracil on colorectal cancer cells. ( Chang, CY; Pan, TM, 2019) |
| "Irinotecan (CPT-11) is a drug used against a wide range of tumor types." | 5.51 | Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| " Through univariate and multivariate logistic regression analyses, factors predicting the development of serious adverse events, fatal adverse events, and toxicity-related hospitalizations were determined." | 5.51 | Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer. ( Abdel-Rahman, O; Ahmed, O, 2019) |
| "Korean female patients with colorectal cancer who received 5-FU chemotherapy experienced more frequent adverse drug reactions including alopecia and leukopenia than male patients." | 5.51 | Sex-Dependent Adverse Drug Reactions to 5-Fluorouracil in Colorectal Cancer. ( Jung, J; Kim, KS; Kim, SY; Lee, E; Lee, S; Lim, H; Moon, A; Oh, S, 2019) |
| "Cancer stem cells (CSCs) residing in colorectal cancer tissues have tumorigenic capacity and contribute to chemotherapeutic resistance and disease relapse." | 5.51 | Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells. ( Agaimy, A; Ballout, F; Çapci, A; Chanvorachote, P; El-Baba, C; Erlenbach-Wuensch, K; Gali-Muhtasib, H; Geppert, CI; Hartmann, A; Huebner, K; Klein, V; Muenzner, JK; Ndreshkjana, B; Roehe, AV; Schneider-Stock, R; Steinmann, S; Tsogoeva, SB, 2019) |
| "Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity, possibly leading to the delay or suspension of the cycle, with the consequent impact on the prognosis of survival." | 5.51 | Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| "Melatonin has antitumor activity via several mechanisms including its anti-proliferative and pro-apoptotic effects." | 5.48 | Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. ( Bejarano, I; Espino, J; Pariente, JA; Pariente, R; Rodríguez, AB, 2018) |
| "Significant inter-individual variation in the sensitivity to 5-fluorouracil (5-FU) represents a major therapeutic hindrance either by impairing drug response or inducing adverse drug reactions (ADRs)." | 5.48 | DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. ( Ahmed, MU; Apu, MNH; Chowdhury, SM; Hasnat, A; Islam, MR; Islam, MS; Nahar, Z; Nahid, NA; Shabnaz, S, 2018) |
| " Pretreatment with the pan-caspase inhibitor, z-VAD-FMK, attenuated the caspase-dependent apoptosis induced by circularly permuted tumor necrosis factor-related apoptosis-inducing ligand alone or combined with 5-fluorouracil." | 5.48 | Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480. ( Liang, X; Sun, T; Yang, S; Zhao, R; Zhu, T, 2018) |
| "Colorectal cancer is one of the most common malignancies both in men and women." | 5.48 | A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo. ( Chen, CQ; Ding, HW; Li, DD; Ren, TS; Wang, J; Wu, Q; Zhao, CH; Zhao, QC, 2018) |
| "Here, we show that colorectal cancers (CRCs) display negligible expression of OTC and, in subset of cases, ASS1 proteins." | 5.48 | Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes. ( Al-Aqbi, SS; Alexandrou, C; Andreadi, C; Blades, M; Boyle, W; Brown, K; Cheng, PN; Higgins, JA; Howells, LM; Karmokar, A; Luo, JL; Moore, DA; Murray, GI; Rufini, A; Thomas, A; Viskaduraki, M, 2018) |
| "Crocin was able to ameliorate the severe inflammation with mucosal ulcers and high-grade dysplastic crypts as detected by inflammation score, crypt loss, pathological changes and histology scores." | 5.48 | Crocin synergistically enhances the antiproliferative activity of 5-flurouracil through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer. ( Amerizadeh, F; Avan, A; Boroumand, N; Ferns, GA; Fiuji, H; Ghayour-Mobarhan, M; Hassanian, SM; Khazaei, M; Moradi-Marjaneh, R; Nosrati-Tirkani, A; Rahmani, F; Rezaei, N, 2018) |
| "Background Early relapse in colorectal cancer (CRC) after curative resection is mainly attributed to the key determinants such as tumor histology, stage, lymphovascular invasion, and the response to chemotherapy." | 5.48 | Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy. ( Ajaj, AR; Al-Hiary, R; Al-Yacoub, S; Kadi, T; Majdalawi, K; Mukred, R; Tantawi, D; Yousef, AM; Yousef, M; Zawiah, M, 2018) |
| "Colorectal cancer is one of the most frequently diagnosed cancers worldwide." | 5.48 | The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer. ( An, C; Li, H; Mushtaq, N; Shi, Y; Ullah, S; Xu, J; Yang, F; Yuan, L; Zhang, S, 2018) |
| "Isoliquiritigenin (ISL) is a natural flavonoid that exhibits anticancer properties in various carcinoma cell types." | 5.48 | Isoliquiritigenin-mediated p62/SQSTM1 induction regulates apoptotic potential through attenuation of caspase-8 activation in colorectal cancer cells. ( Jin, H; Lee, SH; Seo, GS, 2018) |
| "Curcumin has been reported to be an effective compound in the reversal of MDR in colorectal cancer cells." | 5.48 | Nrf2 is a key factor in the reversal effect of curcumin on multidrug resistance in the HCT‑8/5‑Fu human colorectal cancer cell line. ( Chen, YY; He, LJ; Jia, YW; Liu, DF; Liu, XP; Miao, DD; Shen, J; Ye, HZ; Zhang, C; Zhang, SP; Zhu, YB, 2018) |
| "Right-sided colorectal cancer (RSCRC) were associated with reduced overall response rate (ORR) (4." | 5.46 | The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. ( Antoniotti, C; Cascinu, S; Cremolini, C; Demurtas, L; Falcone, A; Gelsomino, F; Giampieri, R; Loretelli, C; Mandolesi, A; Masi, G; Meriggi, F; Pusceddu, V; Puzzoni, M; Scartozzi, M; Zaniboni, A; Ziranu, P, 2017) |
| "Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab." | 5.46 | Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017) |
| "Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD)." | 5.43 | Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. ( André, T; Bonnet, I; Bouché, O; Boucher, E; Chibaudel, B; Dauba, J; Faroux, R; Garcia, ML; Guering-Meyer, V; Hug de Larauze, M; Lapeyre-Prost, A; Lièvre, A; Malka, D; Obled, S; Taieb, J; Ychou, M, 2016) |
| "Capecitabine is a chemotherapeutic agent used in the treatment of metastatic colon cancer and metastatic breast cancer." | 5.43 | Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy. ( Aladağ, E; Karakulak, UN; Maharjan, N; Övünç, K, 2016) |
| "Here we will show that, in a colorectal cancer patient cohort, both poor and ultra-rapid metabolizers have significantly increased the risk of developing severe toxicity (grade3-4)." | 5.43 | Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. ( Borro, M; Botticelli, A; Gentile, G; La Torre, M; Lionetto, L; Marchetti, L; Marchetti, P; Mazzotti, E; Mazzuca, F; Simmaco, M, 2016) |
| " We evaluated treatment-related adverse events (AEs), progression-free survival (PFS) and overall survival (OS)." | 5.43 | Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer. ( Abdullah, NM; Sharial, MM; Yusof, MM; Zaatar, A, 2016) |
| "Treatment with lenalidomide reduced tumor vessel density (p = 0." | 5.43 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016) |
| "Among the advanced colorectal cancer patients who received treatment with FOLFOX or FOLFIRI at Koyama Memorial Hospital, patients older than 65 years of age were selected in order to assess the effectiveness of aprepitant as an antiemetic supportive therapy." | 5.43 | [Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer]. ( Hanaka, J; Nakayama, H; Takahashi, M; Terashima, T, 2016) |
| "However, the expression of tmTNF-α in colorectal cancer (CRC) and its association with clinical outcome in CRC have remained unclear." | 5.43 | Molecular correlates and prognostic value of tmTNF-α expression in colorectal cancer of 5-Fluorouracil-Based Adjuvant Therapy. ( Huang, K; Li, N; Li, X; Liu, C; Ma, J; Ming, L; Ren, H; Sun, X; Wang, S; Xu, M, 2016) |
| "Most colorectal cancer (CRC) cell lines are identified to overexpress phosphoserine phosphatase (PSPH), which regulates the intracellular synthesis of serine and glycine, and supports tumor growth." | 5.43 | Inhibition of phosphoserine phosphatase enhances the anticancer efficacy of 5-fluorouracil in colorectal cancer. ( Li, X; Xun, Z; Yang, Y, 2016) |
| "Andrographolide is a natural diterpenoid from Andrographis paniculata which has anti-bacterial, anti-antiviral and anti-inflammation activities." | 5.43 | Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression. ( Fu, Z; Gao, J; Gu, Y; Guo, W; Li, L; Liu, W; Shu, Y; Sun, Y; Wang, W; Xu, Q, 2016) |
| "Capecitabine is an oral 5-fluorouracil (5-FU) pro-drug commonly used to treat colorectal carcinoma and other tumours." | 5.42 | A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. ( Carracedo, A; Castells, A; Castellvi-Bel, S; Domingo, E; Fernández-Rozadilla, C; Freeman-Mills, L; Gonzalez-Neira, A; Howarth, K; Johnstone, E; Jones, A; Julier, P; Kaur, K; Kerr, D; Kerr, R; Love, S; Martin, M; Pagnamenta, A; Palles, C; Pita, G; Rosmarin, D; Ruiz-Ponte, C; Scudder, C; Taylor, J; Tomlinson, I; Wang, H, 2015) |
| "Using the Tet-OFF system and a human colorectal cancer cell line, DLD-1, we first constructed an in vitro system in which TS expression is dynamically controllable." | 5.42 | Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells. ( Fukushima, M; Hattori, H; Kawabata, R; Maehara, Y; Nakao, S; Oda, S; Taguchi, K; Uchida, J; Wakasa, K; Yamanaka, T, 2015) |
| "The role of MCTs in the survival of colorectal cancer (CRC) cells is scarce and poorly understood." | 5.42 | Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells. ( Amorim, R; Baltazar, F; Miranda-Gonçalves, V; Moyer, MP; Pereira, H; Pinheiro, C; Preto, A, 2015) |
| "However, the role of KLF8 in colorectal cancer remains unknown." | 5.42 | Suppression of KLF8 induces cell differentiation and sensitizes colorectal cancer to 5-fluorouracil. ( Bai, Y; Chen, C; Chen, Y; Cheng, T; Liu, S; Luo, X; Peng, Y; Shi, X; Wang, J; Wu, Y; Yan, Q; Zhang, M; Zhang, W; Zhang, Y; Zhao, J, 2015) |
| "Most liver metastases from colorectal cancer (CRC) are unresectable at diagnosis." | 5.42 | Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial. ( Artru, P; Chalabreysse, P; Desramé, J; Lledo, G; Marsot, J; Mithieux, F; Pellerin, O; Pernot, S; Taieb, J; Watkin, E, 2015) |
| "However, the potential role of GA in colorectal cancer and its ability to overcome the chemotherapeutic resistance in CRC cells have not been well studied." | 5.42 | Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells. ( Chen, J; Huang, L; Iwamoto, A; Li, W; Lin, M; Liu, H; Lu, B; Rutnam, ZJ; Wang, Z; Wen, C; Yang, X, 2015) |
| "Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area." | 5.42 | Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015) |
| "We present 2 patients with metastatic colorectal cancer who had progressed despite treatment with first-line FOLFOX and second-line FOLFIRI combination chemotherapy regimens." | 5.42 | Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. ( El-Deiry, WS; Marks, EI; Scicchitano, A; Tan, C; Yang, Z; Zhang, J; Zhou, L, 2015) |
| "The XELAVIRI trial compared sequential (fluoropyrimidine and bevacizumab; irinotecan (Iri) at progression) versus initial combination therapy (fluoropyrimidine, bevacizumab, Iri) of treatment-naïve metastatic colorectal cancer (mCRC)." | 5.41 | Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kumbrink, J; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schuster, V; Schwaner, I; Stahler, A; Stintzing, S, 2021) |
| " CASE REPORT We report the case of a patient who was diagnosed with stage IV colorectal cancer and who underwent chemotherapy with a high dose of 5-FU as part of the FOLFIRI (Folinic Acid, Fluorouracil, Irinotecan) treatment plan." | 5.41 | Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review. ( Gofir, A; Hutajulu, SH; Nugroho, DB; Yuwono, KA, 2023) |
| "Aflibercept; a decoy receptor for vascular endothelial growth factors (VEGFs) and placental growth factor (PLGF), in combination with FOLFIRI (leucovorin calcium, fluorouracil, irinotecan hydrochloride) chemotherapy regime, was FDA approved in 2012 as second-line salvage chemotherapy for metastatic colorectal cancer (mCRC)." | 5.41 | A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety. ( Chorawala, MR; Patel, RS; Thakur, A, 2023) |
| "Although 5‑fluorouracil (5‑FU)‑based chemotherapy is the major treatment for colorectal cancer, it has disadvantages such as systemic toxicity, lack of effectiveness and selectivity, and development of resistance." | 5.41 | 5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review). ( Al Doghaither, HA; Al-Ghafari, AB; Alzahrani, SM; Pushparaj, PN, 2023) |
| " This article presents a systematic review of studies evaluating the efficacy and safety of chemotherapy regimens combining fluorouracil and standard or low-dose leucovorin in treating colorectal cancer." | 5.41 | High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy. ( Goněc, R; Juřica, J; Šuverová, P; Synek, S; Turjap, M, 2023) |
| " The trial TyRosine kinase Inhibitor for the treatment of Chemorefractory Colorectal Cancer (TRICC-C) trial evaluates the addition of nintedanib to mFOLFOX6 (fluorouracil, folinic acid and oxaliplatin) in patients with metastatic colorectal cancer (mCRC)." | 5.41 | Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). ( Berger, AW; Büchner-Steudel, P; Decker, T; Ettrich, TJ; Güthle, M; Hannig, CV; Hebart, HF; Heinemann, V; Hermann, PC; Herrmann, T; Hoffmann, T; Hofheinz, RD; Perkhofer, L; Seufferlein, T, 2021) |
| "Irinotecan/5-fluorouracil (5-FU; FOLFIRI) or oxaliplatin/5-FU (FOLFOX), combined with bevacizumab or cetuximab, are approved, first-line treatments for metastatic colorectal cancer (mCRC)." | 5.41 | Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). ( Auman, JT; Bertagnolli, MM; Blanke, CD; Casey, G; Etheridge, AS; Furukawa, Y; Howell, SD; Innocenti, F; Jiang, C; Kubo, M; Lenz, HJ; McLeod, HL; Ou, FS; Owzar, K; Parker, JS; Patil, SA; Plummer, SJ; Ratain, MJ; Sibley, AB; Venook, AP, 2021) |
| "The aim was to explore the correlation between increasing doses of [6R]-5,10-methylenetetrahydrofolate (arfolitixorin) and plasma concentrations of deoxyuridine (dUr) in patients with metastatic colorectal cancer (mCRC), subjected to 5-fluorouracil (5-FU)-based chemotherapy." | 5.41 | Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin. ( Carlsson, G; Gustavsson, B; Odin, E; Taflin, H; Tell, R; Wettergren, Y, 2021) |
| "The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with epidermal growth factor receptor-detectable metastatic colorectal cancer (mCRC) that progressed on first-line fluoropyrimidine- and oxaliplatin-based chemotherapy; we report the outcomes of patients with RAS-wild-type (wt) disease." | 5.41 | Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. ( Burris, H; Chen, W; Eng, C; Esser, R; Lenz, HJ; Middleton, G; Nippgen, J; Scheithauer, W; Sobrero, A, 2021) |
| " We analyzed the differential impact of PPI use on capecitabine and fluorouracil using the data set from the AXEPT trial, a phase III randomized trial that demonstrated the noninferiority of mXELIRI (modified XELIRI: capecitabine plus irinotecan) to FOLFIRI (leucovorin, fluorouracil, and irinotecan), either with or without bevacizumab in patients with metastatic colorectal cancer." | 5.41 | Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT). ( Kang, J; Kim, SY; Kim, TW; Lee, JS; Morita, S; Muro, K; Park, YS; Sakamoto, J; Xu, RH, 2021) |
| "In patients with metastatic colorectal cancer (mCRC) refractory to standard therapies, S-1 plus raltitrexed showed a good objective response rate (ORR) and significant survival benefit in our previous study." | 5.41 | Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. ( Bi, F; Cao, D; Chen, Y; Cheng, K; Gou, HF; Li, Q; Li, ZP; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Yang, Y; Zhou, YW, 2021) |
| "The aim of the present study was to characterize the pharmacokinetics of irinotecan and its four main metabolites (SN-38, SN-38G, APC and NPC) in metastatic colorectal cancer patients treated with FOLFIRI and FOLFIRINOX regimens and to quantify and explain the inter-individual pharmacokinetic variability in this context." | 5.41 | Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen. ( Barbolosi, D; Deyme, L; Evrard, A; Gattacceca, F; Mbatchi, LC; Tubiana-Mathieu, N; Ychou, M, 2021) |
| "The purpose was to determine whether adding Pmab versus no Pmab to an adjuvant regimen of hepatic arterial infusion (HAI) of floxuridine (FUDR) plus systemic (SYS) leucovorin, fluorouracil, and irinotecan (FOLFIRI) improves 15-month recurrence-free survival for patients with RAS wild-type colorectal cancer." | 5.41 | A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer. ( Capanu, M; Chatila, WK; Chou, JF; Connell, LC; D'Angelica, MI; Jarnagin, WR; Kemeny, NE; Kingham, TP; Sanchez-Vega, F; Shi, H, 2021) |
| "Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients." | 5.41 | A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab. ( Chang, TK; Chen, PJ; Chen, YC; Cheng, TL; Chuang, KH; Huang, CW; Li, CC; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yin, TC, 2021) |
| "The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 5.41 | Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III ( Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2021) |
| "The phase III AXEPT study showed the noninferiority of modified capecitabine plus irinotecan (mXELIRI) with or without bevacizumab relative to fluorouracil, leucovorin, and irinotecan (FOLFIRI) with or without bevacizumab as a second-line treatment for metastatic colorectal cancer." | 5.41 | Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. ( Ahn, JB; Bai, L; Cho, SH; Fang, WJ; Han, SW; Hong, YS; Iwasa, S; Kim, TW; Kotaka, M; Lee, KW; Matsuoka, H; Morita, S; Muro, K; Nakamura, M; Nishina, T; Park, YS; Sakamoto, J; Yamada, Y; Yuan, XL; Yuan, Y; Zhang, DS, 2021) |
| " Eligible patients aged ≥70 with unresectable metastatic, untreated, RAS/BRAF wildtype metastatic colorectal cancer will be randomised 1:1 to receive panitumumab alone or panitumumab plus infusional 5-fluorouracil." | 5.41 | MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). ( Bailey, L; Briscoe, K; Burge, M; Caird, S; Chantrill, L; Cuff, J; Espinoza, D; Francesconi, A; Karapetis, C; Ladwa, R; Pavlakis, N; Price, T; Segelov, E; Shannon, J; Siu, HWD; Sjoquist, K; Srivastav, R; Steer, C; Tebbutt, N; Thavaneswaran, S; Tie, J; Wilson, K; Wuttke, M; Yip, S, 2021) |
| "Berberine is an alkaloid isolated from the Chinese herbal medicine Huanglian, and has long been used as an antibiotic." | 5.40 | Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. ( Cai, Y; Huang, P; Jiang, W; Luo, R; Shi, Y; Sun, Y; Xia, Q, 2014) |
| "Gefitinib was cytostatic." | 5.40 | Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line. ( Aristei, C; Calzuola, M; Cecchini, D; Contavalli, P; Falzetti, F; Marini, V; Palumbo, I; Piattoni, S; Valentini, V; Vecchio, FM, 2014) |
| "We enrolled 234 patients with Stage III colorectal cancer who underwent curative resection." | 5.40 | Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status. ( Fukazawa, S; Hase, K; Hashiguchi, Y; Kubo, T; Naito, Y; Okamoto, K; Shikina, A; Shinto, E; Ueno, H; Yamamoto, J, 2014) |
| "Cinnamaldehyde is an active monomer isolated from the stem bark of Cinnamomum cassia, a traditional oriental medicinal herb, which is known to possess marked antitumor effects in vitro and in vivo." | 5.40 | Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer. ( Liu, SL; Qi, MH; Yu, C; Zou, X, 2014) |
| "5-Fluorouracil (5-FU) is a first line chemotherapeutic medication used in the treatment of gallbladder cancer; however, the efficacy is below satisfactory." | 5.40 | Icariin-mediated inhibition of NF-κB activity enhances the in vitro and in vivo antitumour effect of 5-fluorouracil in colorectal cancer. ( Cai, GX; Cai, SJ; Gu, WL; Guan, ZQ; Li, DW; Li, XX; Peng, JJ; Shi, DB; Xu, Y; Zheng, HT, 2014) |
| "0144) adverse effects in stage II/III patients." | 5.40 | Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. ( Beachler, C; El-Deiry, WS; Harvey, HA; Kline, CL; Mackley, HB; McKenna, K; Messaris, E; Poritz, L; Schiccitano, A; Sheikh, H; Sivik, J; Staveley-O'Carroll, K; Stewart, D; Zhu, J, 2014) |
| "A total of 102 metastatic colorectal cancer patients treated with a oxaliplatin (XELOX) ±Bevacizumab combination were retrospectively evaluated." | 5.40 | Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy. ( Berk, V; Bozkurt, O; Duran, AO; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M, 2014) |
| "A primary challenge in identifying replicable pharmacogenomic markers from clinical genomewide association study (GWAS) trials in oncology is the difficulty in performing a second large clinical trial with the same drugs and dosage regimen." | 5.40 | Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. ( Alba, E; Alonso, R; de la Torre-Montero, JC; Dolan, ME; González-Neira, A; Lopez-Fernandez, LA; Martín, M; Pita, G; Wheeler, HE, 2014) |
| "Colorectal cancer metastasis is a major cause of mortality worldwide, which may only be controlled with novel methods limiting tumor dissemination and chemoresistance." | 5.40 | Unbiased proteomic and transcript analyses reveal that stathmin-1 silencing inhibits colorectal cancer metastasis and sensitizes to 5-fluorouracil treatment. ( Chung, MC; Lim, TK; Tan, HT; Tan, XF; Wu, W, 2014) |
| "Sampling of saliva is a quick, noninvasive, safe and painless process that gives information about patients Ura and UH₂ levels prior to chemotherapeutical treatment." | 5.40 | Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2014) |
| " A randomized trial showed increased OS and decreased toxicity with PK-guided compared with BSA-based 5-FU dosing in patients with mCRC." | 5.40 | Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. ( Ayer, T; Chen, Q; El-Rayes, BF; Flowers, CR; Goldstein, DA; Harvey, RD; Howard, DH; Lipscomb, J, 2014) |
| " All patients were genotyped for MTHFR 1298A>C and 677C>T polymorphisms and analysed in both cohorts separately for the association between the MTHFR genotype and incidence of grade 3-4 overall toxicity and specific adverse events, as well as efficacy parameters." | 5.39 | MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. ( Gelderblom, H; Guchelaar, HJ; Punt, CJ; van Huis-Tanja, LH, 2013) |
| "5-fluorouracil (5-FU) has been widely used since the 1980s, and it remains the backbone of many chemotherapeutic combination regimens." | 5.39 | DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity. ( Amadori, A; Boldrin, E; Rumiato, E; Saggioro, D, 2013) |
| " Clinical data demonstrated that there was higher correlation between DPD activity and toxic effects of 5-FU (p<0." | 5.39 | Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China. ( Lu, Z; Sun, B; Zhang, X, 2013) |
| "In 5-fluorouracil (5-FU)-treated patients, the tumour overexpression of SOX9 correlated with markedly poorer survival (HR=8." | 5.39 | Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients. ( Candy, PA; Colley, SM; Davidson, JA; Leedman, PJ; Phillips, MR; Redfern, AD; Stuart, LM; Wood, BA; Zeps, N, 2013) |
| " Pharmacogenotyping is therefore recommended to guide dosing of 5-FU and prevent neutropenia." | 5.39 | Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients. ( Bannur, Z; Fijeraid, H; Hamzah, S; Hasbullani, Z; Hashim, H; Md Nor, A; Ngow, H; Ramasamy, P; Salleh, MZ; Shia, JK; Sood, S; Teh, LK; Zailani, M; Zakaria, ZA, 2013) |
| "Elderly patients with metastatic colorectal cancer (mCRC) differ from the general population and are underrepresented in clinical trials." | 5.39 | Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients. ( Aprile, G; Bearz, A; Berretta, M; Borsatti, E; Canzonieri, V; Ferrari, L; Fiorica, F; Fisichella, R; Foltran, L; Lestuzzi, C; Lleshi, A; Lutrino, S; Nasti, G; Talamini, R; Tirelli, U; Urbani, M, 2013) |
| "Capecitabine is a member of the fluoropyrimidine family of chemotherapeutic agents that selectively delivers 5-fluorouracil (5-FU) to tumors." | 5.38 | Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm. ( Rather, A; Shah, A; Shah, NR, 2012) |
| "Population-based studies of adverse events are scarce." | 5.38 | Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. ( Cen, P; Du, XL; Liu, C, 2012) |
| ", Salt Lake City, UT) that measures plasma 5-FU concentration and reports an AUC in mg · h/L has been developed to optimize therapy using pharmacokinetic (PK) dosing." | 5.38 | Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. ( Grier, CE; Hamilton, SA; Haregewoin, A; Kaldate, RR; McLeod, HL, 2012) |
| " We also observed bioavailability of ursolic acid in the serum and tissue of animals." | 5.38 | Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. ( Aggarwal, BB; Baladandayuthapani, V; Deorukhkar, A; Diagaradjane, P; Guha, S; Kannappan, R; Krishnan, S; Prasad, S; Reuter, S; Sung, B; Wei, C; Yadav, VR, 2012) |
| "Patients with CIMP-positive colorectal tumors do not benefit from 5-FU-based adjuvant chemotherapy." | 5.37 | 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. ( Alenda, C; Andreu, M; Balaguer, F; Bessa, X; Boland, CR; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Goel, A; Jover, R; Llor, X; Morillas, JD; Nguyen, TP; Nicolás-Pérez, D; Payá, A; Pérez-Carbonell, L; Reñé, JM; Rojas, E; Xicola, RM; Zapater, P, 2011) |
| "In metastatic colorectal cancer patients treated with mFolfox-6, the combination of haplotype XPD Lys751Gln-GSTP1 105Val seems to predict the risk of progression." | 5.37 | Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. ( Balboa, E; Barros, F; Bernardez, B; Carracedo, A; Duran, G; Gallardo, E; Lamas, MJ; Lopez, R; Touris, M; Vidal, Y, 2011) |
| " The drug combination elevated the plasma level of PHT in a patient on chemotherapy with capecitabine for colorectal cancer." | 5.37 | [A case of toxicity caused by drug interaction between capecitabine and phenytoin in patient with colorectal cancer]. ( Fukui, E; Kawahara, K; Sakurai, M; Ueda, R; Yamada, R, 2011) |
| "Acriflavine was active in cell spheroids, indicating good drug penetration and activity against hypoxic cells." | 5.37 | Novel activity of acriflavine against colorectal cancer tumor cells. ( Fayad, W; Felth, J; Fryknäs, M; Glimelius, B; Graf, W; Gullbo, J; Hassan, S; Larsson, R; Laryea, D; Linder, S; Mahteme, H; Nygren, P; Påhlman, L; Rickardson, L, 2011) |
| "Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity." | 5.36 | Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. ( Ahmad, A; Gounaris, I, 2010) |
| "Here we adapted an orthotopic colorectal cancer model, in which HT-29 colorectal cancer cells form tumors in the rectal lining and metastasize to the para-aortic lymph nodes with high frequency." | 5.36 | Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging. ( Prewett, M; Steiner, P; Surguladze, D; Tonra, JR, 2010) |
| "Colorectal cancer is the most common form of malignancy in Taiwan and the third leading cause of death from cancer, preceded only by lung and hepatic cancers." | 5.36 | rTSbeta as a novel 5-fluorouracil resistance marker of colorectal cancer: a preliminary study. ( Chow, KC; Lin, YL, 2010) |
| "Capecitabine is an oral fluoropyrimidine which is transformed to 5-Fluorouracil inside tumor cells, where it achieves high drug concentrations." | 5.36 | Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect? ( Emiliani, A; Losanno, T; Manna, G; Seminara, P, 2010) |
| "We compared clinical outcome and pharmacokinetic (pK) parameters of a new pharmacokinetically-guided dosing strategy in two groups of patients (age < or >65 years) with metastatic colorectal cancer (mCRC)." | 5.36 | Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer. ( Abderrahim, AG; Bressolle, F; Duffour, J; Pinguet, F; Poujol, S; Roca, L; Ychou, M, 2010) |
| "Colorectal cancer is (CRC) one of the commonest cancers and its therapy is still based on few drugs." | 5.36 | 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. ( Bodmer, WF; Bracht, K; Liu, Y; Nicholls, AM, 2010) |
| "Colorectal cancer is one of the leading malignancies in the world." | 5.36 | Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. ( Fu, ZX; Shen, W; Tu, JK; Wang, XH, 2010) |
| " Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment." | 5.35 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009) |
| "Capecitabine is a chemotherapeutic prodrug that is metabolised to 5-fluorouracil." | 5.35 | Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction. ( Curzen, NP; Ferchow, L; Hobson, A; Scott, PA, 2008) |
| "Patients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study." | 5.35 | Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. ( Agrogiannis, G; Arapogiannis, G; Gouveris, P; Kavantzas, N; Kopterides, P; Kosmas, C; Kyriakou, V; Lazaris, A; Papathomas, T; Patsouris, E; Tsavaris, N; Zorzos, H, 2009) |
| "Using HCT-116 human colorectal cancer cells, we compared the efficacy of WG and RG." | 5.35 | Asian ginseng enhances the anti-proliferative effect of 5-fluorouracil on human colorectal cancer: comparison between white and red ginseng. ( Aung, HH; Fishbein, AB; Li, XL; Mehendale, SR; Sun, S; Wang, CZ; Yuan, CS, 2009) |
| " Coadministration of S-1 changed the pharmacokinetic behavior of CPT-11 and its metabolites." | 5.35 | Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer. ( Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K, 2009) |
| " Grade 3 or 4 hematological toxicities were leukocytopenia in four patients, and neutropenia in 12 patients, while non-hematological toxicities such as nausea, anorexia and sensory neuropathy occurred in only one patient each adverse event." | 5.35 | The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. ( Hattori, M; Honda, I; Kato, N; Kobayashi, D; Matsushita, H; Okochi, O; Tsuboi, K, 2009) |
| "To understand the mechanisms of the effects of combination treatments, we established animal models showing antitumor activity of bevacizumab as a monotherapy and in combination with capecitabine or capecitabine and oxaliplatin and measured thymidine phosphorylase (TP) and vascular endothelial growth factor (VEGF) levels." | 5.35 | Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models. ( Fujimoto-Ouchi, K; Mori, K; Yamashita, Y; Yanagisawa, M; Yorozu, K, 2009) |
| "Both regorafenib and reduced-intensity FOLFOXIRI (riFOLFOXIRI) prolong survival in patients with metastatic colorectal cancer (mCRC)." | 5.34 | Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. ( Chang, SC; Chao, Y; Chen, WS; Cheng, HH; Huang, SC; Jiang, JK; Lan, YT; Lin, CC; Lin, HH; Tai, CC; Teng, HW; Wang, HS; Yang, SH, 2020) |
| "Cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX-4) is superior to FOLFOX-4 alone as a first-line treatment for patients with metastatic colorectal cancer with RAS wild-type (RAS wt mCRC), with significantly improved survival benefit by TAILOR, an open-label, randomised, multicentre, phase III trial." | 5.34 | Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. ( Ding, H; Fang, L; Gao, P; Huang, L; Wang, H; Ye, W; Zhu, Z, 2020) |
| "The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not increase survival." | 5.34 | Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. ( Banzi, M; Cardellino, GG; Cinieri, S; Ciuffreda, L; Corallo, S; Corsi, D; Galli, F; Labianca, R; Lonardi, S; Maiello, E; Mambrini, A; Marchetti, P; Mattioli, R; Petrelli, F; Pusceddu, V; Rimassa, L; Ronzoni, M; Rosati, G; Rulli, E; Sobrero, A; Zagonel, V; Zampino, M; Zaniboni, A, 2020) |
| "BACKGROUND The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer." | 5.34 | Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. ( Chen, J; Chen, Z; Huang, J; Ma, X; Wei, L; Wen, J; Wu, D, 2020) |
| "Biweekly schedule of XELOX-2 (capecitabine plus oxaliplatin) showed interesting results in first-line therapy of patients with metastatic colorectal cancer (mCRC)." | 5.34 | Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). ( Aieta, M; Bordonaro, R; Cinieri, S; Colucci, G; Cordio, S; Di Maggio, G; Di Maio, M; Febbraro, A; Giuliani, F; Latiano, TP; Maiello, E; Pisconti, S; Rinaldi, A; Rizzi, D; Rossi, A, 2020) |
| "Fluorouracil and leucovorin combined with oxaliplatin or irinotecan plus bevacizumab (Bmab) or cetuximab (Cmab) are now widely accepted treatment options as first-line or second-line chemotherapy for metastatic colorectal cancer (mCRC)." | 5.34 | Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial. ( Doi, S; Fujiwara, H; Kawamura, T; Mikami, R; Nakamoto, Y; Noda, M; Okumoto, T; Tokunaga, Y; Tomita, N, 2020) |
| " 130 male and 63 female eligible patients with metastatic colorectal cancer were randomized to receive chronomodulated Irinotecan with peak delivery rate at 1 of 6 clock hours staggered by 4 hours on day 1, then fixed-time chronomodulated Fluorouracil-Leucovorin-Oxaliplatin for 4 days, q3 weeks." | 5.34 | Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. ( Adam, R; Ballesta, A; Bouchahda, M; Chollet, P; Focan, C; Garufi, C; Giacchetti, S; Huang, Q; Innominato, PF; Karaboué, A; Lévi, FA, 2020) |
| "We designed an open-label, noncomparative phase II study to assess the safety and efficacy of first-line treatment with trifluridine/tipiracil plus bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B) in untreated patients with unresectable metastatic colorectal cancer (mCRC) who were not candidates for combination with cytotoxic chemotherapies." | 5.34 | Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. ( Amellal, N; Argilés, G; Aubel, P; Borg, C; Danielewicz, I; Egorov, A; Falcone, A; Fedyanin, M; Garcia-Alfonso, P; Glynne-Jones, R; Kanehisa, A; Kroening, H; Moiseenko, V; Pfeiffer, P; Punt, CJA; Saunders, MP; Stroyakovskiy, D; Van Cutsem, E; Van de Wouw, AJ; Wasan, H, 2020) |
| "Chemo-embolisation with drug-eluting beads loaded with irinotecan (DEBIRI) increased survival as compared with intravenous irinotecan in chemorefractory patients with liver-dominant metastases from colorectal cancer (LMCRC)." | 5.34 | Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. ( Artru, P; Dahan, L; De La Fouchardière, C; Guimbaud, R; Jouve, JL; Lepage, C; Montérymard, C; Pellerin, O; Pernot, S; Raoul, JL; Sefrioui, D; Smith, D; Taieb, J; Tougeron, D, 2020) |
| "Cetuximab has been shown to be clinically active when given in combination with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC)." | 5.34 | Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). ( Baba, E; Boku, N; Denda, T; Esaki, T; Fujii, H; Goto, M; Hara, H; Hironaka, S; Hosokawa, A; Hyodo, I; Ishida, H; Kadowaki, S; Kishimoto, J; Koh, Y; Kuramochi, H; Makiyama, A; Matsumoto, S; Moriwaki, T; Muro, K; Nishina, T; Okuda, H; Otsu, S; Ozaki, Y; Sakai, D; Sakamoto, T; Sato, M; Satoh, T; Shimokawa, H; Shinozaki, K; Sugimoto, N; Tamagawa, H; Tamura, T; Taniguchi, H; Tokunaga, S; Tsuda, T; Tsuji, A; Tsushima, T; Yamazaki, K; Yasui, H, 2020) |
| "Twenty-eight colorectal cancer patients who received infusional 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) therapy were randomly and evenly assigned to the cystine and theanine group and the control group." | 5.34 | Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial. ( Abe, T; Akazawa, N; Hirashima, T; Ichikawa, H; Kakita, T; Kobayashi, M; Komura, T; Oikawa, M; Okada, T; Otake, S; Sato, R; Tsuchiya, T; Yazawa, T, 2020) |
| "To evaluate the safety and tolerability of escalating doses of selinexor plus 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) in metastatic colorectal cancer (mCRC) patients." | 5.34 | Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL. ( Amberg, S; Bokemeyer, C; Kranich, AL; Mann, J; Nilsson, S; Papadimitriou, K; Rolfo, C; Stein, A; Theile, S, 2020) |
| "The addition of aflibercept (AFL) or ramucirumab (RAM) to folinic acid, fluorouracil, and irinotecan (FOLFIRI) prolongs overall survival and progression-free survival compared with FOLFIRI alone in patients with metastatic colorectal cancer (mCRC) as second-line therapy." | 5.34 | Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. ( Kashiwa, M; Matsushita, R, 2020) |
| "The phase III West Japan Oncology Group (WJOG) 4407G study showed noninferiority of folinic acid, bolus/continuous fluorouracil, and irinotecan plus bevacizumab to modified folinic acid, bolus/continuous fluorouracil, and oxaliplatin 6 plus bevacizumab in progression-free survival (PFS) as first-line chemotherapy for patients with metastatic colorectal cancer." | 5.34 | Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study. ( Hironaka, S; Hosokawa, A; Kusaba, H; Matsuda, C; Morita, S; Muro, K; Okamura, S; Shinozaki, K; Shirakawa, T; Tamura, T; Tsuda, M; Tsuda, T; Tsushima, T; Ueda, S; Yamashita, H; Yamazaki, K, 2020) |
| "FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with previously treated metastatic colorectal cancer (mCRC)." | 5.34 | Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). ( Aparicio, T; Caroli-Bosc, FX; Dahan, L; Desrame, J; Doat, S; Lapeyre-Prost, A; Le Malicot, K; Lecomte, T; Lepage, C; Marthey, L; Mary, F; Pernot, S; Sigrand, J; Taieb, J, 2020) |
| "In this phase 3, open-label trial, 307 patients with metastatic MSI-H-dMMR colorectal cancer who had not previously received treatment were randomly assigned, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks or chemotherapy (5-fluorouracil-based therapy with or without bevacizumab or cetuximab) every 2 weeks." | 5.34 | Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. ( André, T; Benavides, M; Bendell, J; de la Fouchardiere, C; Diaz, LA; Elez, E; Farooqui, MZH; Garcia-Carbonero, R; Gibbs, P; Jensen, BV; Jensen, LH; Kim, TW; Le, DT; Marinello, P; Punt, C; Rivera, F; Shiu, KK; Smith, D; Van Cutsem, E; Yang, P; Yoshino, T, 2020) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent for the treatment of colorectal cancer that interferes with the growth of cancer cells." | 5.34 | Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. ( Aung, HH; He, TC; Luo, X; Mehendale, S; Ni, M; Song, WX; Wang, CZ; Xie, JT; Yuan, CS; Zhang, B, 2007) |
| "Familial Mediterranean Fever is a chronic hereditary disease which is relatively prevalent in the Middle East and is associated with recurrent episodes of serosal, synovial or cutaneous inflammations." | 5.34 | Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever. ( Brenner, B; Purim, O; Sulkes, A, 2007) |
| "Although colorectal cancer has the third highest cancer mortality rate, the treatment remains far from optimized with patients showing variable responses to standard treatment." | 5.33 | Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. ( Kidd, EA; Li, X; McLeod, HL; Shannon, WD; Watson, MA; Yu, J, 2005) |
| "Gene expression profiling of 3 colorectal cancer cell lines (DLD-1, HT-29 and NUGC-3) and the corresponding 5-FU-resistant sublines (DLD-1/FU, HT-29/FU and NUGC-3/5FU/L) showed 81 genes that were differentially expressed." | 5.33 | Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. ( Danenberg, PV; Hayasizaki, Y; Ichikawa, Y; Ishikawa, T; Okazaki, Y; Shimada, H; Shimizu, D; Togo, S, 2005) |
| "Metastatic/advanced colorectal cancer is considered a resistant disease and oncologic emergencies secondary to advanced disease may be regarded with a nihilistic attitude." | 5.33 | Oncologic emergencies secondary to advanced colorectal cancer successfully treated with oxaliplatin/5-fluorouracil/leucovorin: report of three cases. ( Anselmi, E; Bertè, R; Bidin, L; Cavanna, L; Civardi, G; Lazzaro, A; Moroni, CF; Palladino, MA; Rodinò, C; Vallisa, D, 2005) |
| "However, standard treatment for Dukes C colorectal cancer patients currently involves the administration of 5-fluorouracil (5-FU)-based adjuvant chemotherapy after surgery." | 5.33 | SMAD4 levels and response to 5-fluorouracil in colorectal cancer. ( Aaltonen, LA; Alazzouzi, H; Alhopuro, P; Arango, D; Dávalos, V; Hemminki, A; Järvinen, H; Mecklin, JP; Salovaara, R; Sammalkorpi, H; Schwartz, S, 2005) |
| "Irinotecan (CPT11) is a prodrug activated in humans mainly by carboxylesterase 2 (CES2) generating the SN38 metabolite responsible for the drug efficacy and toxicity." | 5.33 | Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ( Biason, P; Buonadonna, A; Cattarossi, G; Cecchin, E; Colussi, A; Corona, G; Frustaci, S; Masier, S; Toffoli, G, 2005) |
| "Capecitabine is an oral prodrug to 5-fluorouracil (5-FU)." | 5.33 | Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. ( Hoeffding, LD; Jakobsen, A; Lindebjerg, J; Nielsen, JN, 2005) |
| "The subjects were 31 patients with colorectal cancer who underwent surgical excision between December 2003 and July 2004 at our department." | 5.33 | The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer. ( Hata, M; Kamano, T; Kitajima, M; Maeda, T; Ochiai, T; Sakamoto, K; Takita, N, 2006) |
| "Capecitabine was approved for funding in the province of British Columbia in the spring of 2002 as an oral chemotherapeutic option for metastatic CRC." | 5.33 | Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. ( Gill, S; Ho, C; Ng, K; O'Reilly, S, 2005) |
| "The treatment of metastatic colorectal cancer by chemotherapy alone was considered palliative and without the potential to cure patients unless patients were rendered resectable." | 5.33 | Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. ( Kemeny, NE; Leonard, GD, 2006) |
| "Microsatellite instability is a recognised pathway of colorectal carcinogenesis responsible for about 15% of all sporadic colorectal cancers." | 5.33 | 5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. ( Kaufman, A; Ramanathan, P; Robinson, BG; Schnitzler, M; Warusavitarne, J, 2006) |
| " Our data suggest that GSTT1-null is associated with a greater probability of developing toxicity to 5-Fu/CPT-11/Lv treatments, indicating a potential application of this genetic analysis in predicting adverse effects of this regimen." | 5.33 | Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. ( Aranda, E; Bandres, E; De la Haba, J; Garcia, F; García-Foncillas, J; Gómez, A; Huarriz, M; Morales, R; Romero, RZ, 2006) |
| "Median time to disease progression was 9." | 5.32 | Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Aparicio, J; Calderero, V; Díaz, R; Gironés, R; López-Tendero, P; Pérez-Fidalgo, JA; Segura, A; Yuste, AL, 2003) |
| "These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer." | 5.32 | Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. ( Clark, JW; Gococo, KO; Haller, DG; Kardinal, CG; Kemeny, NE; Lenz, HJ; Mitchell, EP; Ramanathan, RK, 2003) |
| "Patients with liver metastases of colorectal cancer were treated with 5-FU (500/600 mg/m)+folinic acid with or without trimetrexate." | 5.32 | 19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. ( Heerschap, A; Kamm, YJ; van den Bergh, EJ; Wagener, DJ, 2004) |
| "Patients with stage III/IV colorectal cancer were treated by bolus intravenous (I." | 5.32 | Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. ( Chabner, BA; Charlat, O; Clark, JW; Kelly, P; Kreconus, E; Nesbitt, S; Puchalski, TA; Ryan, DP; Stanton, VP; Supko, JG; Zhu, AX, 2004) |
| "Catheter-related deep venous thrombosis is a complication that can occur in patients receiving chemotherapy." | 5.32 | Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review. ( Albertsson, M; Tham, J, 2004) |
| " We have examined the effect of this CDO alone and in combination with a range of common chemotherapeutic agents in colorectal cancer cell lines." | 5.32 | The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines. ( Liu, WM; Propper, DJ; Scott, KA; Shahin, S, 2004) |
| "We evaluated the cytotoxic effect of ZD0473 administered alone or in combination with 5-Fluorouracil (5FU) or SN38 in a panel of sensitive and 5FU-resistant colorectal cell lines (HT29/HT29-5FUR and LoVo/LoVo-5FUR)." | 5.32 | Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines. ( Abad, A; Martinez-Balibrea, E; Plasencia, C; Taron, M, 2004) |
| "Objective responses in colorectal cancer patients were: 1st-line MdG (22 assessable): PR=36%, NC=32%, PD=32%." | 5.31 | A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. ( Cheeseman, SL; Chester, JD; Dent, JT; Joel, SP; Richards, FJ; Seymour, MT; Wilson, G, 2002) |
| " In order to evaluate the clinical relevance of SMAD4 deletion, gene copy alterations were determined by copy dosage using real-time quantitative PCR in 202 colorectal tumour biopsies from a previous randomised study of adjuvant chemotherapy." | 5.31 | SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. ( Boulay, JL; Herrmann, R; Laffer, U; Lagrange, M; Lowy, A; Mild, G; Reuter, J; Rochlitz, C; Terracciano, L, 2002) |
| "Cerivastatin may allow successful 5FU therapy in chemoresistant patients." | 5.31 | Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. ( Cassidy, J; Collie-Duguid, E; Wang, W, 2002) |
| "Colorectal carcinoma is one of the most common malignancies in the western world, and although fluorouracil (5-FU) has been used in its treatment for almost 40 years, new agents with significant activity have been introduced recently." | 5.31 | The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. ( Antoine, EC; Bastian, G; Gil-Delgado, M; Khayat, D; Nizri, D, 2001) |
| "It has previously been shown that colorectal cancer patients who are homozygous for the triple tandem repeats (L/L) have significantly higher thymidylate synthase mRNA expression than those homozygous for the double repeat variant (S/S)." | 5.31 | Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. ( Groshen, S; Lenz, HJ; Park, DJ; Stoehlmacher, J; Tsao-Wei, D; Zhang, W, 2002) |
| "Fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (FOLFOX) plus panitumumab therapy is a commonly used first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 5.30 | SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. ( Fukunaga, M; Kato, T; Kotaka, M; Kuramochi, H; Kuroda, H; Kurosawa, S; Minagawa, N; Mishima, H; Miura, T; Miwa, K; Munemoto, Y; Nagata, N; Nakamura, M; Noura, S; Oba, K; Sakamoto, J; Satake, H; Takahashi, M; Takahashi, T; Touyama, T, 2019) |
| "Combination of chemotherapies (fluoropirimidines, oxaliplatin and irinotecan) with biologic drugs (bevacizumab, panitumumab, cetuximab) have improved clinical responses and survival of metastatic colorectal cancer (mCRC)." | 5.30 | Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. ( Albino, V; Amore, A; Avallone, A; Belli, A; Botti, G; Capozzi, M; Casaretti, R; Cassata, A; Chiodini, P; D'Alterio, C; De Feo, G; De Stefano, A; Delrio, P; Di Marzo, M; Izzo, F; Napolitano, M; Nappi, A; Nasti, G; Normanno, N; Ottaiano, A; Pace, U; Palaia, R; Petrillo, A; Picone, C; Portella, L; Rachiglio, AM; Roma, C; Romano, C; Scala, S; Silvestro, L; Tafuto, S; Tamburini, M; Trotta, AM, 2019) |
| "Regorafenib is an oral multikinase inhibitor for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, irinotecan, oxaliplatin, monoclonal antibodies targeting vascular endothelial growth factor, and monoclonal antibodies targeting epidermal growth factor receptor." | 5.30 | Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. ( Chang, TK; Chang, YT; Huang, CW; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yeh, YS, 2019) |
| "Background This phase I/II trial evaluated toxicity and antitumor activity of everolimus plus mFOLFOX6 + bevacizumab for first-line treatment of metastatic colorectal cancer (mCRC)." | 5.30 | Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. ( Boucher, KM; Garrido-Laguna, I; McGregor, K; Orgain, N; Sharma, S; Stenehjem, DD; Thorne, K; Wade, ML; Weis, J; Weldon Gilcrease, G; Whisenant, J, 2019) |
| " The main eligibility criterion was disease progression after bevacizumab plus fluorouracil with irinotecan or oxaliplatin in patients with wild-type KRAS exon 2 metastatic colorectal cancer." | 5.30 | Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. ( Adenis, A; Artru, P; Bennouna, J; Bertaut, A; Borel, C; Borg, C; Bouché, O; Conroy, T; Denis, MG; Deplanque, G; des Guetz, G; François, E; Ghiringhelli, F; Hebbar, M; Hiret, S; Seitz, JF; Stanbury, T, 2019) |
| " As hydrogen gas was recently reported to activate PGC‑1α, the present study investigated whether it restores exhausted CD8+ T cells to improve prognosis in patients with stage IV colorectal cancer." | 5.30 | Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis. ( Akagi, J; Baba, H, 2019) |
| "First-line treatment for metastatic colorectal cancer (mCRC) typically entails a biologic such as bevacizumab (BEV) with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI)." | 5.30 | Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). ( Bendell, J; Hochster, HS; Hurwitz, HI; Lee, JJ; Lenz, HJ; Nicholas, A; Palma, JF; Price, R; Reeves, JA; Scappaticci, F; Somer, B; Sommer, N; Tan, BR; Xiong, H, 2019) |
| "A phase II trial (planned n=58) using second-line therapy for metastatic colorectal cancer with either oxaliplatin-based (mFOLFOX6) or irinotecan-based (FOLFIRI) combination chemotherapy and 100 mg erlotinib daily on days 3-8 after each infusion (days 1 and 2) every 14 days." | 5.30 | A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer. ( Burt, A; Chen, EY; Donovan, J; Kampa-Schittenhelm, KM; Kearney, MR; Lopez, CD; Strother, J; Todd, K; Vaccaro, GM, 2019) |
| "The study investigated the potential prophylactic effect of L-carnosine against acute oxaliplatin neurotoxicity in colorectal cancer patients with emphasis on the redox (Nrf-2, MDA), inflammatory (NF-κB, TNF-α), and apoptotic (caspase-3) parameters." | 5.30 | L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways. ( El Abhar, H; Saad, AS; Saleh, S; Schaalan, M; Yehia, R, 2019) |
| "Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the second‑line therapy of patients with metastatic colorectal cancer (mCRC)." | 5.30 | Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study. ( André, T; Auby, D; Bachet, JB; Bonnetain, F; Chibaudel, B; Dauba, J; De Gramont, A; Deplanque, G; Desramé, J; Dubreuil, O; Garcia, ML; Hamed, NB; Larsen, AK; Lebrun-Ly, V; Lecaille, C; Lledo, G; Louvet, C; Meurisse, A; Tijeras-Raballand, A; Tournigand, C, 2019) |
| "The 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational." | 5.30 | CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. ( Bai, L; Bi, F; Chen, Y; Cheng, Y; He, X; Hu, X; Li, J; Li, Y; Liu, W; Liu, Y; Luo, Y; Ouyang, X; Qin, S; Shi, Y; Sun, G; Sun, Y; Wang, L; Wang, Z; Xu, J; Yao, Q; Zhang, Y; Zheng, R, 2019) |
| "Curcumin is a safe and tolerable adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer." | 5.30 | Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. ( Barber, S; Brown, K; Foreman, N; Gescher, A; Griffin-Teall, N; Howells, LM; Irving, GRB; Iwuji, COO; Morgan, B; Patel, SR; Sidat, Z; Singh, R; Steward, WP; Thomas, AL; Walter, H, 2019) |
| " This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer." | 5.30 | Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. ( Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019) |
| "Data from a trial of first-line panitumumab plus FOLFIRI (folinic acid, infusional 5-fluorouracil and irinotecan) in metastatic colorectal cancer were retrospectively analysed to investigate the effects of primary tumour location and early tumour shrinkage on outcomes." | 5.30 | Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab. ( Berkhout, M; Gallego, J; Hofheinz, RD; Karthaus, M; Köhne, CH; Koukakis, R; Mineur, L; Thaler, J; Van den Eynde, M, 2019) |
| " The mean total dosage was 6." | 5.30 | [Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]. ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997) |
| "Forty-six disseminated colorectal cancer patients had measurable tumor biopsies for polymerase chain reaction (PCR)-based determination of TS mRNA pretreatment." | 5.30 | Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. ( Baranda, J; Boswell, W; Danenberg, K; Danenberg, PV; Groshen, S; Leichman, CG; Leichman, L; Lenz, HJ; Metzger, R; Tan, M, 1997) |
| " Gastrimmune immunisation may be a therapeutic option for the treatment of colorectal cancer in combination with 5-FU/leucovorin." | 5.30 | Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model. ( Clarke, PA; Grimes, S; Hardcastle, JD; Justin, TA; Michael, D; Morris, TM; Robinson, G; Watson, SA, 1998) |
| "When tegafur was injected, the concentration of 5-FU in cancer tissue or lymphnodes was significantly higher than in normal tissue." | 5.30 | [Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer]. ( Inamura, Y; Kanemitsu, T; Kojima, T; Miyashita, A; Naruse, T; Owa, Y; Suzumura, K, 1998) |
| "Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU) within the tumor." | 5.30 | Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ( Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E, 1999) |
| "The outlook for patients with advanced colorectal cancer remains poor." | 5.29 | Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon. ( Patel, N; Perren, T; Pittman, K; Primrose, J; Selby, P; Slevin, M; Ward, U, 1993) |
| "Five cases of colorectal cancer with unresectable liver metastases treated from April 1992 to April 1993 in Osaka National Hospital were summarized in this paper." | 5.29 | [Continuous intra-hepatic-arterial infusion of low dose 5-fluorouracil for colorectal cancer patients with unresectable liver metastases]. ( Imamura, H; Kanoh, T; Kikkawa, N; Miyazaki, M; Nakayama, T; Tamaki, Y; Taniguchi, K; Tohno, K; Utsunomiya, T, 1993) |
| "The benefits from medical treatment in colorectal cancer are limited." | 5.28 | Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid. ( Bajetta, E; Colleoni, M; de Braud, F; Nelli, P; Nolè, F; Zilembo, N, 1992) |
| "Twenty-five patients with pretreated advanced colorectal carcinoma were subjected to second-line chemotherapy with sequential high-dose methotrexate and 5-fluorouracil." | 5.28 | Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil. ( Airoma, G; Bianco, AR; Caponigro, F; Gridelli, C; Incoronato, P; Palmieri, G; Pepe, R, 1991) |
| " The dosage of raIFN-2a could not be further escalated above 12 x 10(6) IU." | 5.28 | 5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study. ( Gebbia, V; Palmeri, S; Rausa, L, 1990) |
| "Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based therapy." | 5.27 | Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. ( Dochy, E; Lakomy, R; Macarulla, T; Magherini, E; Moiseyenko, VM; Papamichael, D; Prausova, J; Ruff, P; Soussan-Lazard, K; Van Cutsem, E; van Hazel, GA, 2018) |
| "Chemotherapy-induced nausea and vomiting (CINV) causes significant morbidity among colorectal cancer patients, receiving fluorouracil, oxaliplatin, and leucovorin (FOLFOX) chemotherapy even with standard antiemetic prophylaxis." | 5.27 | Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. ( Blanke, C; Bubalo, JS; Chen, E; Edwards, MS; Fisher, A; Herrington, JD; Lopez, CD; Palumbo, A; Takemoto, M; Williams, C; Willman, P, 2018) |
| "The authors hypothesized that patients with metastatic colorectal cancer (mCRC) who had tumors with low thymidylate synthase (TS-L) expression would have a higher response rate to combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab (FOLFOX/Bev) than those with high TS (TS-H) expression and that combined irinotecan and oxaliplatin (IROX) plus bevacizumab (IROX/Bev) would be more effective than FOLFOX/Bev in those with TS-H tumors." | 5.27 | Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). ( Benson, AB; Catalano, PJ; Cheema, PS; Chiorean, EG; Feng, Y; George, TJ; Grem, JL; Hall, MJ; Kauh, JS; Meropol, NJ; Mulcahy, MF; O'Dwyer, PJ; Saltzman, JN; Zangmeister, J, 2018) |
| "Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)." | 5.27 | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018) |
| "The PANDA study is a prospective, open-label, multicenter, randomized phase II trial of first-line therapy with panitumumab in combination with dose-adjusted FOLFOX or with 5-fluorouracil monotherapy, in previously untreated elderly patients (≥70 years) with RAS and BRAF wild-type unresectable metastatic colorectal cancer." | 5.27 | The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. ( Arnoldi, E; Battaglin, F; Bergamo, F; Boni, L; Boscolo, G; Buggin, F; Cremolini, C; Lonardi, S; Loupakis, F; Lucchetti, J; Lutrino, ES; Morano, F; Passardi, A; Pella, N; Pietrantonio, F; Salvatore, L; Scartozzi, M; Schirripa, M; Tonini, G; Zagonel, V, 2018) |
| "The prospective, randomized, open-label FIRE-3/AIO KRK0306 trial evaluated the first-line therapy of patients with KRAS exon 2 wild-type metastatic colorectal cancer with fluorouracil, folinic acid and irinotecan plus either cetuximab or bevacizumab." | 5.27 | Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial. ( Baumann, AB; D'Anastasi, M; Heinemann, V; Hesse, N; Hofmann, FO; Holch, JW; Modest, DP; Reiser, MF; Ricard, I; Sommer, WH; Stintzing, S, 2018) |
| "FOLFOXIRI (Fluorouracil, folinate, oxaliplatin, and irinotecan) plus bevacizumab improved progression-free survival (PFS) and overall survival in patients with metastatic colorectal cancer (mCRC), compared with FOLFIRI (fluorouracil, folinate, and irinotecan) plus bevacizumab, but significantly increased the incidences of adverse events." | 5.27 | A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. ( Bando, H; Emi, Y; Iwamoto, S; Kagawa, Y; Kanazawa, A; Kato, T; Kotaka, M; Muro, K; Nakamura, M; Nakayama, G; Oki, E; Sakisaka, H; Taniguchi, H; Touyama, T; Tsuji, A; Yamaguchi, T; Yamanaka, T; Yamazaki, K; Yoshino, T, 2018) |
| "Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared with FOLFIRI alone in the pivotal VELOUR (aflibercept vs." | 5.27 | Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. ( Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C, 2018) |
| " Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine." | 5.27 | 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. ( Allan, K; Azzabi, A; Boyd, KA; Bridgewater, J; Briggs, A; Cassidy, J; Cunningham, D; Dhadda, AS; Ellis, R; Essapen, S; Falk, S; Farrugia, D; Glimelius, B; Gollins, S; Harkin, A; Harrison, M; Haydon, A; Hickish, T; Hollander, NH; Iveson, TJ; Kerr, RS; McQueen, J; Medley, L; Olesen, RK; Paul, J; Propper, D; Raouf, S; Rees, C; Saunders, MP; Scudder, C; Tabernero, J; Wasan, HS; Waterston, A; Weaver, A; Webb, A; Wilson, C, 2018) |
| "To investigate the association between UDP-glucuronosyltransferase (UGT)1A polymorphisms and irinotecan-treatment efficacy in a Chinese population with metastatic colorectal cancer (mCRC)." | 5.27 | UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy. ( Chen, J; Feng, J; Huang, L; Liu, B; Peng, P; Qiu, H; Xie, C; Yu, Q; Yuan, X; Zang, A; Zhang, T, 2018) |
| "Regorafenib, a multikinase inhibitor that inhibits angiogenesis, growth, and proliferation, prolongs survival as monotherapy in patients with refractory colorectal cancer." | 5.27 | Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. ( Bekaii-Saab, TS; Cohn, AL; El-Rayes, BF; Fernando, NH; Goldberg, RM; Grogan, W; Horgan, AM; Ivanova, A; Kasbari, SS; Kim, RD; Leonard, G; McCaffrey, J; McDermott, R; Moore, DT; O'Neil, BH; O'Reilly, S; Olowokure, OO; Ryan, T; Sanoff, HK; Sherrill, GB; Yacoub, GH; Zamboni, W, 2018) |
| "Irinotecan (CPT-11) in combination with 5-fluorouracil (5FU) is widely used in the treatment of colorectal cancer." | 5.27 | Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. ( Bosman, F; Brauchli, P; Delorenzi, M; Dietrich, D; Fiocca, R; Klingbiel, D; Piessevaux, H; Roth, AD; Tejpar, S; Yan, P, 2018) |
| "Metformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy." | 5.27 | Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. ( El-Fatatry, BM; Hussien, FZ; Ibrahim, OM; Mostafa, TM, 2018) |
| "The efficacy and safety of the FOLFIRI (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) regimen combined with aflibercept has not been studied in the first-line management of patients with metastatic colorectal cancer (mCRC)." | 5.27 | AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. ( Aravantinos, G; Bafaloukos, D; Efstratiou, I; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeropoulou, L; Karavasilis, V; Kentepozidis, N; Koliou, GA; Kotoula, V; Koumakis, G; Laschos, K; Pectasides, D; Pentheroudakis, G; Petraki, C; Poulios, C; Samantas, E; Sgouros, J; Souglakos, I; Tikas, I; Voutsina, A; Vrettou, E; Zarkavelis, G, 2018) |
| "This analysis investigated the cost-effectiveness of panitumumab plus mFOLFOX6 (oxaliplatin, 5-fluorouracil, and leucovorin) compared with bevacizumab plus mFOLFOX6 in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC)." | 5.27 | A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. ( Christodoulopoulou, A; Garawin, T; Graham, CN; Hechmati, G; Knox, HN; Sabatelli, L; Strickler, JH, 2018) |
| " We sought to generate a comprehensive inherited pharmacogenetic profile for oxaliplatin and 5FU/capecitabine therapy in advanced colorectal cancer (aCRC)." | 5.27 | Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. ( Adams, RA; Cheadle, JP; Colley, JP; Fisher, D; Harris, R; Humphreys, V; Idziaszczyk, S; Kaplan, RS; Madi, A; Maughan, TS; Maynard, J; Meade, AM; Wasan, H, 2018) |
| "This randomized phase III trial compared hepatic arterial infusion (HAI) chemotherapy with 5-fluorouracil (5-FU) followed by uracil/tegafur (UFT) and leucovorin (LV) versus UFT/LV alone for patients with curatively resected liver metastases from colorectal cancer (CRC)." | 5.27 | A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio ( Aoyama, T; Asahara, T; Hirata, K; Kusano, M; Nakamori, S; Oba, K; Ohashi, Y; Okabayashi, K; Saji, S; Sakamoto, J; Tsuji, Y; Yoshikawa, T, 2018) |
| "Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months." | 5.27 | [Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988) |
| "To determine if the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer." | 5.24 | Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. ( Atkins, JN; Benson, AB; Berry, S; Bertagnolli, MM; Blanke, C; El-Khoueiry, AB; Fruth, B; Goldberg, RM; Greene, C; Hochster, HS; Innocenti, F; Lenz, HJ; Mayer, RJ; Meyerhardt, JA; Mulkerin, DL; Niedzwiecki, D; O'Neil, BH; O'Reilly, EM; Polite, BN; Schilsky, RL; Schrag, D; Venook, AP; Watson, P, 2017) |
| "In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]." | 5.24 | First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). ( Abad, A; Aranda, E; Carrato, A; Dueñas, R; Escudero, P; Gallego, J; García-Paredes, B; Gómez, A; González, E; Grávalos, C; Longo-Muñoz, F; Losa, F; Manzano, JL; Massuti, B; Pericay, C; Rivera, F; Safont, MJ; Valladares-Ayerbes, M, 2017) |
| "The hepatic artery infusion (HAI) of irinotecan, oxaliplatin and 5-fluorouracil with intravenous cetuximab achieved outstanding efficacy in previously treated patients with initially unresectable liver metastases from colorectal cancer." | 5.24 | Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). ( Adam, R; Boige, V; Bouchahda, M; Carvalho, C; Desterke, C; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Lemoine, A; Lévi, F; Milano, G; Saffroy, R; Smith, D; Taieb, J, 2017) |
| "The combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin with intravenous cetuximab has safely achieved prolonged survival in colorectal cancer patients with extensive liver metastases and prior treatment." | 5.24 | Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study. ( Bouchahda, M; Chatelut, E; Etienne-Grimaldi, MC; Focan, C; Innominato, P; Karaboué, A; Lévi, F; Milano, G; Paintaud, G, 2017) |
| "This study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan." | 5.24 | Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Chang, SN; Hsieh, LL; Lai, CY; Lin, YK; Sung, FC; Tang, R; Yeh, CC, 2017) |
| "To assess the cost-effectiveness of panitumumab in combination with mFOLFOX6 (oxaliplatin, 5-fluorouracil, and leucovorin) vs bevacizumab in combination with mFOLFOX6 as first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC) in Spain." | 5.24 | Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. ( Gea, S; López-Martínez, N; Rivera, F; Valladares, M, 2017) |
| "Fluorouracil and folinic acid with irinotecan (FOLFIRI) plus bevacizumab (BV) is widely used as second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, oxaliplatin, and BV." | 5.24 | Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. ( Ando, M; Araida, T; Hamano, M; Hayashi, K; Hirai, E; Itabashi, M; Kameoka, S; Kawakami, K; Kuramochi, H; Nakajima, G; Okuyama, R; Yokomizo, H; Yoshimatsu, K, 2017) |
| "In Japan, oxaliplatin (OXA)/5-fluorouracil (5-FU)/leucovorin (LV)-the mFOLFOX6 regimen-is the most frequently used first-line chemotherapy backbone for metastatic colorectal cancer." | 5.24 | mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design ( Kurosawa, S; Mishima, H; Nagata, N; Oba, K; Sakamoto, J, 2017) |
| "There are no published cases about bullous pyoderma gangrenosum induced by leucovorin, fluorouracil and oxaliplatin (FOLFOX) chemotherapy." | 5.22 | Leukocytoclastic vasculitis presenting clinically as bullous pyoderma gangrenosum following leucovorin, fluorouracil and oxaliplatin chemotherapy: a rare case report and literature review. ( Abdollahimajd, F; Diab, R; Kaddah, A; Mirzaei, HR; Rakhshan, A, 2022) |
| "Carmofur, 1-hexylcarbamoyl-5-fluorouracil (HCFU) is an antineoplastic drug, which has been in clinics in Japan since 1981 for the treatment of colorectal cancer." | 5.22 | Versatile use of Carmofur: A comprehensive review of its chemistry and pharmacology. ( Islam, MM; Mirza, SP, 2022) |
| "The purpose of this systematic review is to analyze the published data on the efficacy and safety of doses higher than 180 mg/m2 of irinotecan recommended in the drug's summary of product characteristics in metastatic colorectal cancer patients with genotypes UGT1A1*1/*1 or *1/*28 who are treated with the FOLFIRI regimen." | 5.22 | Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review. ( García-Gil, S; Gutiérrez-Nicolás, F; Miarons, M; Riera, P, 2022) |
| "The efficacy of irinotecan as the adjunctive therapy to fluorouracil and leucovorin remains controversial in patients with colorectal cancer." | 5.22 | The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies. ( Jiang, W; Liu, Q; Yang, D; Yang, SB, 2022) |
| "The purpose of this phase II study was to explore the efficacy and safety of an alternating regimen consisting of folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (mFOLFOX6) plus bevacizumab, and folinic acid, 5-FU and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer." | 5.22 | Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). ( Akagi, Y; Emi, Y; Higashi, H; Ishikawa, H; Kusumoto, T; Maehara, Y; Matsuda, H; Miwa, K; Ogata, Y; Oki, E; Saeki, H; Samura, H; Sueyoshi, S; Tanaka, T; Tokunaga, S; Touyama, T, 2016) |
| "The aim of this multicenter, open-label, randomized phase II trial was to evaluate the efficacy of a dose-dense capecitabine and oxaliplatin (XELOX) regimen in patients with metastatic colorectal cancer (mCRC) for whom reintroduction of oxaliplatin had been planned as a third- or later-line regimen." | 5.22 | Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). ( Bando, H; Fujii, A; Fukunaga, M; Hata, T; Honda, M; Ishibashi, K; Kobayashi, M; Matsuda, C; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Oshiro, M; Tanaka, C; Tokunaga, Y, 2016) |
| "Panitumumab plus infusional 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) significantly improved overall survival versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer (mCRC)." | 5.22 | Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer. ( Barber, B; Dong, J; Douillard, JY; Hechmati, G; Maglinte, GA; Wang, J, 2016) |
| "The HE6C/05 trial randomized 441 patients with stage II-III colorectal adenocarcinoma to adjuvant XELOX (capecitabine, oxaliplatin) or modified FOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin)." | 5.22 | Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. ( Cohen, SA; Fountzilas, G; Gkakou, C; Gourgioti, G; Grady, WM; Kalogeras, KT; Karavasilis, V; Kotoula, V; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Raptou, G; Wirtz, R; Wu, C; Yu, M, 2016) |
| "gov NCT00561470) was to investigate the treatment effect of adding aflibercept to second-line infusional 5-fluorouracil (5-FU), leucovorin and irinotecan (FOLFIRI) in patients with metastatic colorectal cancer (mCRC) who had failed any prior oxaliplatin-containing regimen." | 5.22 | Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing A ( Andria, M; Arnold, D; Cunningham, D; Dochy, E; Grávalos, C; Hoff, PM; Humblet, Y; Joulain, F; Kröning, H; Lakomý, R; Le-Guennec, S; Macarulla, T; McKendrick, J; Mitchell, E; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Tabernero, J; Ten Tije, AJ; Van Cutsem, E; van Hazel, G; Vishwanath, RL, 2016) |
| "The purpose of this study was to assess the efficacy and tolerance of induction chemotherapy combining LV5FU2 with increased doses of irinotecan adapted to UGT1A1 genotyping and cetuximab in untreated potentially resectable liver metastases of colorectal cancer." | 5.22 | High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT). ( Buc, E; Chatelut, E; De la Fouchardière, C; Mendoza, C; Mineur, L; Pezet, D; Phelip, JM; Quesada, JL; Rivoire, M; Roblin, X, 2016) |
| "A multicenter, open-label, noncomparative, randomized phase II study (PEPCOL) was conducted to evaluate the efficacy and safety of the irinotecan or PEP02 (MM-398, nanoliposomal irinotecan) with leucovorin (LV)/5-fluorouracil (5-FU) combination as second-line treatment in patients with metastatic colorectal cancer (mCRC)." | 5.22 | PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. ( André, T; Arbaud, C; Bachet, JB; Bennamoun, M; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Dupuis, O; Garcia, ML; Hammel, P; Khalil, A; Larsen, AK; Louvet, C; Maindrault-Gœbel, F; Tournigand, C; Wang, YW; Yeh, CG, 2016) |
| "SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy in patients with previously untreated metastatic colorectal cancer." | 5.22 | SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. ( Boucher, E; Bower, G; Cade, DN; Eliadis, P; Ferguson, T; Findlay, MP; Ganju, V; Gebski, V; Gibbs, P; Heinemann, V; Isaacs, R; Kröning, H; Moeslein, F; Peeters, M; Perez, D; Powell, A; Price, D; Ricke, J; Robinson, BA; Rodríguez, J; Shacham-Shmueli, E; Sharma, NK; Strickland, AH; Taieb, J; Thurston, K; Tichler, T; Van Buskirk, M; van Hazel, GA; Walpole, E; Wolf, I, 2016) |
| " This study was to evaluate the efficacy and safety of maintenance therapy with capecitabine versus observation following inductive chemotherapy in patients with metastatic colorectal cancer." | 5.22 | Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. ( Hu, XH; Jia, J; Li, YH; Lin, DR; Lin, YC; Luo, HY; Ma, D; Peng, JW; Wang, FH; Wang, W; Wang, ZQ; Xu, RH; Yuan, X; Zhang, DS, 2016) |
| "Patients with 5-fluorouracil-refractory metastatic colorectal cancer at the MD Anderson Cancer Center were offered screening in the Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) program to identify eligibility for companion phase I or II clinical trials with a therapy targeted to an aberration detected in the patient, based on testing by immunohistochemistry, targeted gene sequencing panels, and CpG island methylation phenotype assays." | 5.22 | Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. ( Abbruzzese, J; Dasari, A; Eng, C; Fogelman, D; Hamilton, S; Kee, B; Kopetz, S; Liang, L; Maru, D; Mazard, T; Meric-Bernstam, F; Mills, GB; Morris, J; Morris, V; Overman, MJ; Raghav, K; Shaw, K; Shroff, R; Shureiqi, I; Vilar, E; Wolff, RA; Xiao, L, 2016) |
| " The present study was initiated to validate the use of therapeutic drug management (TDM) to personalize 5-fluorouracil (5-FU) dosing in patients with metastatic colorectal cancer treated in routine clinical practice." | 5.22 | Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. ( Bertsch, T; Birkmann, J; Braess, J; Holdenrieder, S; Jaehde, U; Kraff, S; Kunzmann, V; Link, K; Miller, MC; Moritz, B; Mueller, L; Roessler, M; Salamone, SJ; Stoetzer, OJ; Suttmann, I; Wilhelm, M, 2016) |
| "Observational and preclinical studies have suggested that metformin has antitumor effects in solid tumors, including colorectal cancer (CRC)." | 5.22 | Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer. ( Alex, A; Bariani, G; Bezerra Neto, JE; Braghiroli, MI; Capareli, FC; Faria, LD; Hoff, PM; Lobo Dos Santos, JF; Miranda, VC; Riechelmann, RP; Sabbaga, J, 2016) |
| "The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer." | 5.22 | Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. ( Ciftci, R; Iner-Koksal, U; Kaytan-Saglam, E; Namal, E; Okyar, A; Ordu, C; Pala-Kara, Z; Pilancı, KN; Saglam, S; Yucel, S, 2016) |
| "We previously showed that a sequential chemotherapy with dose-dense oxaliplatin (FOLFOX7) and irinotecan (FOLFIRI; irinotecan plus 5-fluorouracil/leucovorin) is not superior to FOLFOX4 in patients at advanced stage of colorectal cancer with liver metastases." | 5.22 | Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial. ( André, T; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Garcia-Larnicol, ML; Hamidou, Z; Hebbar, M; Hug de Larauze, M; Louvet, C, 2016) |
| "It is now widely accepted that therapeutic antibodies targeting epidermal growth factor receptor (EGFR) can have efficacy in KRAS wild-type advanced colorectal cancer (CRC) patients." | 5.22 | TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. ( Brünner, N; Christensen, IJ; Glimelius, B; Guren, TK; Ikdahl, T; Kure, EH; Moreira, JM; Nielsen, HJ; Noer, J; Nordgaard, C; Pfeiffer, P; Sorbye, H; Tarpgaard, LS; Tveit, KM; Ørum-Madsen, MS, 2016) |
| "FIRE-3 compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer." | 5.22 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. ( Al-Batran, SE; Decker, T; Giessen-Jung, C; Heinemann, V; Heintges, T; Held, S; Jagenburg, A; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerch, MM; Lerchenmüller, C; Modest, DP; Moehler, M; Rossius, L; Scheithauer, W; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF, 2016) |
| "This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second-line chemotherapy for wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and to explore the values of oncogenes in circulating tumor DNA (ctDNA) and serum proteins as predictive biomarkers." | 5.22 | Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. ( Boku, N; Denda, T; Hyodo, I; Moriwaki, T; Muro, K; Nishina, T; Nishio, K; Okuda, H; Sakai, K; Shitara, K; Takano, T; Tokunaga, S; Tsuda, M; Yamanaka, T; Yamazaki, K; Yonesaka, K, 2016) |
| " This randomized phase II study evaluated the antitumor activity and safety of icrucumab and ramucirumab each in combination with mFOLFOX-6 in patients with metastatic colorectal cancer after disease progression on first-line therapy with a fluoropyrimidine and irinotecan." | 5.22 | Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. ( Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K, 2016) |
| "A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy for stage III colorectal cancer." | 5.22 | Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer. ( Kaiho, T; Kobayashi, S; Koda, K; Kosugi, C; Maruyama, T; Matsubara, H; Miyauchi, H; Takiguchi, N, 2016) |
| "The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint." | 5.20 | A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015) |
| "5-Fluorouracil (5-FU) is chemotherapeutic agent widely used for the treatment of colorectal cancer." | 5.20 | Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer. ( Chang, SW; Chen, TH; Huang, CC; Lee, H; Wu, DW, 2015) |
| "Perioperative FOLFOX4 (oxaliplatin plus 5-fluorouracil/leucovorin) chemotherapy is the current standard in patients with resectable metastases from colorectal cancer (CRC)." | 5.20 | FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized ( André, T; Auby, D; Bonnetain, F; Brucker, P; Brusquant, D; Carola, E; Chibaudel, B; Dalban, C; de Gramont, A; Dutel, JL; Faroux, R; Flesch, M; Gayet, B; Hadengue, A; Hebbar, M; Khalil, A; Landi, B; Legoux, JL; Louvet, C; Mabro, M; Martin, P; Mineur, L; Paye, F; Pruvot, FR; Smith, D; Taieb, J; Truant, S; Vaillant, E; Ychou, M, 2015) |
| "A UGT1A1 genotype-directed dose escalation of irinotecan (CPT-11) was performed in patients with metastatic colorectal cancer receiving first-line FOLFIRI chemotherapy." | 5.20 | A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI. ( Bae, KS; Hong, YS; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG, 2015) |
| "The results for efficacy and safety over the time course of the VEGF Trap (aflibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen trial were analysed based on data from 1226 patients randomised to receive FOLFIRI plus either aflibercept (n=612) or placebo (n=614)." | 5.20 | Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. ( Arnold, D; Bhargava, P; Chevalier, S; Cunningham, D; Ferry, DR; Hoff, PM; Lakomỳ, R; Macarulla, T; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Ten Tije, AJ; Van Cutsem, E; Van Hazel, GA; Vishwanath, RL, 2015) |
| "The aim of this study was to determine the recommended dose (RD) of a triweekly capecitabine, oxaliplatin, irinotecan, and bevacizumab (XELOXIRI/bevacizumab) regimen that was easier to administer than FOLFOXIRI/bevacizumab, using capecitabine instead of 5-fuorouracil (5-FU), in patients with metastatic colorectal cancer (mCRC)." | 5.20 | A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer. ( Furuhata, T; Hayashi, T; Hirakawa, M; Hirata, K; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Miyanishi, K; Mizuguchi, T; Murase, K; Ohnuma, H; Okagawa, Y; Okita, K; Osuga, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takimoto, R, 2015) |
| "The phase III CRYSTAL study demonstrated that addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival, progression-free survival, and objective response in the first-line treatment of patients with KRAS codon 12/13 (exon 2) wild-type metastatic colorectal cancer (mCRC)." | 5.20 | Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. ( Beier, F; Ciardiello, F; Heinemann, V; Köhne, CH; Lenz, HJ; Melezínek, I; Rougier, P; Stroh, C; Tejpar, S; Van Cutsem, E; van Krieken, JH, 2015) |
| " We therefore conducted a multicenter randomized phase III trial to compare fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) with and without Goshajinkigan (GJG), a traditional Japanese herbal medicine (Kampo), to determine GJG's potential for reducing peripheral neuropathy in patients with colorectal cancer." | 5.20 | Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. ( Baba, H; Emi, Y; Higashijima, J; Ishida, H; Kakeji, Y; Kato, T; Kojima, H; Kon, M; Kono, T; Maehara, Y; Miyake, Y; Ogata, Y; Oki, E; Saeki, H; Sakaguchi, Y; Shirabe, K; Takahashi, K; Tomita, N; Yamanaka, T, 2015) |
| "This study was conducted to evaluate the efficacy and safety of the combination of capecitabine and oral leucovorin (LV) as a third-line chemotherapy for patients with metastatic colorectal cancer (CRC) showing resistance to irinotecan- and oxaliplatin-containing regimens." | 5.20 | A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. ( Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY, 2015) |
| "A dose-finding phase I/II trial that evaluated the maximum tolerated doses of a combination of three drugs with irinotecan, oxaliplatin and capecitabine (COI regimen) has been conducted in patients with metastatic colorectal cancer (mCRC)." | 5.20 | Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. ( Aitini, E; Bajetta, E; Barni, S; Bertolini, A; Ciarlo, A; Di Bartolomeo, M; Dotti, KF; Iacovelli, R; Maggi, C; Perrone, F; Pietrantonio, F; Verusio, C, 2015) |
| "The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments have failed." | 5.20 | Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. ( Argilés, G; Benson, A; Cascinu, S; Ciardiello, F; Grunert, J; Guillén Ponce, C; Köhne, CH; Luigi Garosi, V; Macpherson, IR; Rivera, F; Saunders, MP; Sobrero, A; Strumberg, D; Tabernero, J; Van Cutsem, E; Wagner, A; Zalcberg, J, 2015) |
| " We included patients older than 18 years with previously untreated metastatic colorectal cancer, with stable disease or better after induction treatment with six 3-weekly cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOX-B), WHO performance status of 0 or 1, and adequate bone marrow, liver, and renal function." | 5.20 | Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. ( Braun, HJ; Cats, A; Creemers, GJ; de Jongh, FE; Derleyn, VA; Erdkamp, FL; Erjavec, Z; Haasjes, JG; Honkoop, AH; Jansen, RL; Koopman, M; Loosveld, OJ; May, A; Mol, L; Nieboer, P; Punt, CJ; Simkens, LH; ten Tije, AJ; Tol, J; van der Hoeven, JJ; van der Torren, AM; van Tinteren, H; Wals, J, 2015) |
| "This study is the first to combine daily oral curcumin with standard care FOLFOX-based (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in colorectal cancer patients with inoperable liver metastases: the CUFOX trial." | 5.20 | Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. ( Berry, DP; Brown, K; Howells, LM; Irving, GR; Iwuji, CO; Morgan, B; Steward, WP; Thomas, A, 2015) |
| "The current study aimed to evaluate the short-term efficacy and safety of endostar plus irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) in treatment of advanced colorectal cancer (CRC)." | 5.20 | Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study. ( Hu, XL; Li, BL; Sun, HG; Zhang, Y; Zhao, XH; Zhou, CY, 2015) |
| " We assessed the efficacy and safety of ramucirumab versus placebo in combination with second-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) for metastatic colorectal cancer in patients with disease progression during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine." | 5.20 | Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin ( Bodoky, G; Chang, SC; Ciuleanu, TE; Clingan, PR; Cohn, AL; Garcia-Alfonso, P; Garcia-Carbonero, R; Grothey, A; Kim, TW; Lonardi, S; Nasroulah, F; Obermannova, R; Portnoy, DC; Prausová, J; Simms, L; Tabernero, J; Van Cutsem, E; Yamazaki, K; Yoshino, T, 2015) |
| "The aprepitant therapy was more effective than the control therapy for prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen." | 5.20 | Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ide, Y; Kudo, T; Miyake, Y; Mizushima, T; Mori, M; Morita, S; Nakata, K; Nezu, R; Nishimura, J; Ohno, Y; Sakai, D; Satoh, T; Sekimoto, M; Takemasa, I; Takemoto, H; Uemura, M; Yamamoto, H; Yasui, M, 2015) |
| "The OPUS study demonstrated that addition of cetuximab to 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX4) significantly improved objective response and progression-free survival (PFS) in the first-line treatment of patients with KRAS exon 2 wild-type metastatic colorectal cancer (mCRC)." | 5.20 | FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. ( Beier, F; Bokemeyer, C; Ciardiello, F; Duecker, K; Heinemann, V; Klinkhardt, U; Köhne, CH; Lenz, HJ; Tejpar, S; van Krieken, JH, 2015) |
| "In vitro and pre-clinical studies have suggested that addition of the diet-derived agent curcumin may provide a suitable adjunct to enhance efficacy of chemotherapy in models of colorectal cancer." | 5.20 | Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. ( Berry, DP; Brown, K; Cai, H; Dennison, A; Garcea, G; Greaves, P; Griffin-Teal, N; Higgins, JA; Howells, LM; Irving, G; Iwuji, C; James, MI; Karmokar, A; Lloyd, DM; Metcalfe, M; Morgan, B; Patel, SR; Steward, WP; Thomas, A, 2015) |
| "S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC)." | 5.20 | S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. ( Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H, 2015) |
| "This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with chemotherapy, relative to bevacizumab plus chemotherapy as first-line therapy in patients with metastatic colorectal cancer (mCRC)." | 5.20 | A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. ( Bennouna, J; Bouché, O; Capdevila, J; Carrato, A; D'Haens, G; Dressler, H; Ducreux, M; Latini, L; Oum'Hamed, Z; Prenen, H; Sobrero, A; Staines, H; Studeny, M; Van Cutsem, E, 2015) |
| "In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved progression-free survival of patients with metastatic colorectal cancer compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab." | 5.20 | FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. ( Allegrini, G; Antoniotti, C; Boni, L; Carlomagno, C; Cazzaniga, M; Chiara, S; Cremolini, C; D'Amico, M; Falcone, A; Fontanini, G; Granetto, C; Lonardi, S; Loupakis, F; Lupi, C; Mezi, S; Ronzoni, M; Sensi, E; Tomasello, G; Tonini, G; Zaniboni, A, 2015) |
| "We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials." | 5.20 | Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. ( André, T; Cervantes, A; Chan, E; Ciuleanu, TE; Ducreux, M; He, P; Hotko, Y; Jung, AS; Koukakis, R; Lordick, F; Oliner, KS; Patterson, SD; Peeters, M; Price, TJ; Punt, CJ; Roman, L; Sidhu, R; Sobrero, AF; Strickland, AH; Terwey, JH; Van Cutsem, E; Wilson, G; Yu, H, 2015) |
| "The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy." | 5.20 | Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015) |
| "The purpose of this randomised phase III trial was to evaluate whether the addition of simvastatin, a synthetic 3-hydroxy-3methyglutaryl coenzyme A reductase inhibitor, to XELIRI/FOLFIRI chemotherapy regimens confers a clinical benefit to patients with previously treated metastatic colorectal cancer." | 5.20 | A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. ( Han, SW; Hong, YS; Hwang, IG; Jung, SH; Kang, HJ; Kang, WK; Kim, HS; Kim, ST; Kim, TW; Lee, J; Lee, JY; Lee, KH; Lim, HY; Lim, SH; Park, JO; Park, SH; Park, YS, 2015) |
| "The conventional first-line chemotherapy for metastatic colorectal cancer (mCRC) consists of fluorouracil (5-FU) in combination with either oxaliplatin or irinotecan." | 5.19 | Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. ( Guren, T; Ikdahl, T; Kjersem, JB; Kure, EH; Lingjaerde, OC; Tveit, KM, 2014) |
| "The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen." | 5.19 | Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. ( Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014) |
| " We conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab (CapeOx/bevacizumab), with an expansion cohort in metastatic colorectal cancer (CRC)." | 5.19 | Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. ( Arrowood, C; Blobe, GC; Brady, JC; Cohn, A; Haley, S; Hsu, SD; Hurwitz, HI; McCall, S; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Rushing, C; Starodub, A; Strickler, JH; Uronis, HE; Zafar, SY, 2014) |
| "Efatutazone, a novel oral highly-selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, has demonstrated some inhibitory effects on disease stabilization in patients with metastatic colorectal cancer (mCRC) enrolled in previous phase I studies." | 5.19 | Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. ( Hyodo, I; Komatsu, Y; Machida, N; Ohtsu, A; Onuma, H; Sasaki, T; Yachi, Y; Yamazaki, K; Yoshino, T; Yuki, S, 2014) |
| "We investigated the efficacy and safety of capecitabine and gemcitabin (GemCap) in heavily pre-treated, therapy-resistant metastatic colorectal cancer (mCRC) patients and the clinical importance of cell-free DNA (cfDNA) measurement." | 5.19 | Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study. ( Andersen, RF; Jakobsen, A; Pallisgaard, N; Ploen, J; Spindler, KL, 2014) |
| "Patients with colorectal cancer starting adjuvant or first-line treatment with a chemotherapy combination containing fluorouracil, capecitabine, and/or irinotecan were randomly assigned to receive octreotide LAR 30 mg intramuscularly every 4 weeks (experimental arm) or the physician's treatment of choice in case of diarrhea (control arm)." | 5.19 | Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. ( Andrade, AC; Barrios, CH; Chinen, RN; Correa, M; Coutinho, AK; del Giglio, A; Dutra, C; Forones, NM; Hoff, PM; Passos, VQ; Portella, Mdo S; Saragiotto, DF; van Eyll, B, 2014) |
| " This phase I study used radiolabeled huA33 in combination with capecitabine to target chemoradiation to metastatic colorectal cancer." | 5.19 | Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. ( Cavicchiolo, T; Chappell, B; Gill, S; Herbertson, RA; Hopkins, W; Lee, FT; Lee, ST; Murphy, R; O'Keefe, GJ; Poon, A; Saunder, T; Scott, AM; Scott, FE; Tebbutt, NC, 2014) |
| "To evaluate panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated wild-type (WT) KRAS exon 2 (codons 12 and 13) metastatic colorectal cancer (mCRC)." | 5.19 | PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal ( Canon, JL; Fasola, G; Go, WY; Hecht, JR; Karthaus, M; Oliner, KS; Rivera, F; Schwartzberg, LS; Yu, H, 2014) |
| "Irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil administered every two weeks (FOLFIRI regimen) is active in patients with metastatic colorectal cancer." | 5.19 | Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. ( Arai, T; Goto, A; Hamaguchi, T; Muro, K; Sasaki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2014) |
| " This study examined the efficacy and safety of combining bevacizumab and panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer (mCRC)." | 5.19 | Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer. ( Hu, AP; Li, SL; Liang, HL; Liu, JY, 2014) |
| "Data collected from 20 elderly patients (75-92 years old) with breast or colorectal cancer who received oral capecitabine were analyzed." | 5.19 | Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer. ( Daher Abdi, Z; Lavau-Denes, S; Leobon, S; Marquet, P; Martin, J; Prémaud, A; Rousseau, A; Sauvage, FL; Tubiana-Mathieu, N; Urien, S, 2014) |
| " Three of six patients in cohort 2B-1 experienced grade 3 mucositis, and further study of the combination of everolimus, mFOLFOX6 and panitumumab was aborted." | 5.19 | A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. ( Bernard, S; Davies, JM; Dees, EC; Goldberg, RM; Ivanova, A; Keller, K; McRee, AJ; O'Neil, BH; Sanoff, HG, 2014) |
| "We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC)." | 5.19 | Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. ( Fan, Z; Han, G; He, L; Qin, Z; Xie, S; Xu, W, 2014) |
| "The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival compared to FOLFIRI in patients with metastatic colorectal cancer (mCRC)." | 5.19 | Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. ( Ehninger, G; Folprecht, G; Hamann, S; Schütte, K; Stoehlmacher-Williams, J; Trarbach, T, 2014) |
| "Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (FOLFIRI) is unknown." | 5.19 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. ( Al-Batran, SE; Decker, T; Heinemann, V; Heintges, T; Hielscher, J; Höffkes, HG; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Lindig, RU; Link, H; Modest, DP; Moehler, M; Müller, S; Niederle, N; Rossius, L; Rost, A; Scheithauer, W; Scholz, M; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF, 2014) |
| " From August 2012 to August 2013, 34 patients with pathologically documented advanced colorectal cancer (T3/T4 with metastases or nodal status up to N3) and measurable metastatic disease, who required palliative chemotherapy based on the combination of 5-fluorouracil, oxaliplatin and irinotecan, were prospectively recruited in this study." | 5.19 | Association between chemotherapy and plasma adipokines in patients with colorectal cancer. ( Kasperczyk, S; Malinowska-Borowska, J; Nowak, P; Rogalska, A; Świętochowska, E; Słomian, G, 2014) |
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 5.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 5.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| " A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC)." | 5.19 | Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. ( Adams, J; Deva, S; Findlay, MP; Hinder, VA; Isaacs, R; Jackson, CG; O'Donnell, A; Perez, DJ; Robinson, BA; Sharples, K; Thompson, PI, 2014) |
| " The incidence of adverse events frequently associated with irinotecan and capecitabine were neutropenia (any grade, 55." | 5.19 | A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). ( Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K, 2014) |
| "This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) as first-line treatment of metastatic wild-type KRAS colorectal cancer." | 5.19 | Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). ( Alonso, V; Cirera, L; Fernandez-Plana, J; Mendez, M; Pericay, C; Quintero, G; Saigi, E; Salgado, M; Salud, A, 2014) |
| "We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer." | 5.19 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2014) |
| "The purpose of this phase II study was to evaluate the safety and efficacy of weekly irinotecan and capecitabine (wXELIRI) treatment in patients with metastatic colorectal cancer, specifically the rate of severe diarrhea." | 5.19 | Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. ( Chen, Z; Guo, W; Li, J; Li, W; Liu, T; Shen, L; Xu, J; Zhang, W; Zhu, X, 2014) |
| "BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine." | 5.19 | The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. ( Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K, 2014) |
| "Elderly patients with previously untreated metastatic colorectal cancer (mCRC) were randomly assigned to receive fluorouracil (FU) -based chemotherapy either alone or in combination with irinotecan (IRI) in the Fédération Francophone de Cancérologie Digestive (FFCD) 2001-02 study." | 5.17 | Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. ( Aparicio, T; Bouché, O; Breysacher, G; Charneau, J; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Le Brun-Ly, V; Lecomte, T; Locher, C; Mitry, E; Ramdani, M; Seitz, JF; Stefani, L; Subtil, F; Teillet, L, 2013) |
| "This randomized phase II trial investigated the efficacy and safety of capecitabine/oxaliplatin (CapOx) plus bevacizumab and dose-modified capecitabine/irinotecan (mCapIri) plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer (mCRC)." | 5.17 | Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. ( Arnold, D; Dietrich, G; Freier, W; Geißler, M; Graeven, U; Hegewisch-Becker, S; Hinke, A; Kubicka, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schmoll, HJ; Tannapfel, A, 2013) |
| "Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan." | 5.17 | Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. ( Boix, O; Ehrenberg, R; Fischer, R; Folprecht, G; Hacker, UT; Hamann, S; Köhne, CH; Kornacker, M; Krauss, J; Kuhlmann, J; Lettieri, J; Mross, KB; Schultheis, B; Strumberg, D, 2013) |
| "The use of bevacizumab in combination with fluoropyrimidine-containing chemotherapy is a well-established first-line and second-line treatment for patients with metastatic colorectal cancer (mCRC)." | 5.17 | An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. ( Burge, M; Clarke, S; Cordwell, C; Gibbs, P; Reece, W; Tebbutt, N, 2013) |
| "This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)." | 5.17 | Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. ( Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013) |
| "After resection of their primary tumors, patients with KRAS wild-type synchronous nonresectable liver-limited metastases from colorectal cancer were randomly assigned to receive chemotherapy (FOLFIRI [fluorouracil, leucovorin, and irinotecan] or mFOLFOX6 [modified fluorouracil, leucovorin, and oxaliplatin]) plus cetuximab (arm A) or chemotherapy alone (arm B)." | 5.17 | Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. ( Liu, TS; Qin, XY; Ren, L; Wei, Y; Xu, B; Xu, J; Ye, LC; Ye, QH; Yu, Y; Zai, SY; Zhu, DX, 2013) |
| " In this study, we determined the dose, efficacy, and tolerability of irinotecan according to UGT1A1 genotypes when combined with capecitabine in patients with metastatic colorectal cancer." | 5.17 | A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ( Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG; Sym, SJ, 2013) |
| "In this multicenter, open-label, randomized phase 2 trial, the authors evaluated the vascular endothelial growth factor receptor inhibitor axitinib, bevacizumab, or both in combination with chemotherapy as first-line treatment of metastatic colorectal cancer (mCRC)." | 5.17 | Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. ( Cartwright, TH; Cescon, TP; Cohn, AL; Edenfield, WJ; Hamm, JT; Infante, JR; Kim, S; Malik, IA; McGee, PJ; Rado, TA; Reid, TR; Richards, DA; Rosbrook, B; Tarazi, J, 2013) |
| "A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial." | 5.17 | Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. ( Amara, A; Bulusu, A; Honeycutt, W; Hurwitz, HI; Liu, Y; Nixon, AB; Pang, H; Starr, MD; Wong, NS, 2013) |
| "To investigate the safety and efficacy of pemetrexed combined with chemotherapy as second or third line in patients with stage IV colorectal cancer (CRC)." | 5.17 | Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. ( Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX, 2013) |
| "Newly diagnosed K-RAS wild-type colorectal cancer patients with unresectable liver-only metastases were treated with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) plus cetuximab every 2 weeks for a maximum of 12 cycles." | 5.17 | Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. ( Baek, JY; Hong, YS; Ji, JH; Kang, HJ; Kim, KP; Kim, SY; Kim, TW; Lee, J; Park, SH; Park, YS; Shim, BY; Shin, SJ, 2013) |
| "The aim of this study was to evaluate 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET for early prediction of the standard anatomic response and survival outcomes in patients with metastatic colorectal cancer (mCRC) receiving leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX)." | 5.17 | 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer. ( Hong, YS; Kim, HJ; Kim, HO; Kim, JS; Kim, KP; Kim, TW; Lee, JL; Lee, SJ; Moon, DH; Oh, SJ; Ryu, JS, 2013) |
| " This phase I/II trial assessed the safety and efficacy of capecitabine plus oxaliplatin (XELOX) plus bevacizumab and imatinib in the first-line treatment of patients with metastatic colorectal cancer." | 5.17 | Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. ( Arnold, D; Hacker, UT; Hallek, M; Hinke, A; Hochhaus, A; Hoehler, T; Hofheinz, R; Kanzler, S; Moehler, MH; Schimanski, C; Seufferlein, T; Siebler, J; von Wichert, G, 2013) |
| " This study investigated the effects of 5-fluorouracil (5-FU) chemotherapy on the levels of lipid peroxidation, reduced glutathione (GSH), glutathione peroxidase (GSH-Px), antioxidant vitamins, and elements in colorectal cancer patients." | 5.17 | Effects of 5-fluorouracil on oxidative stress and calcium levels in the blood of patients with newly diagnosed colorectal cancer. ( Koçer, M; Nazıroğlu, M, 2013) |
| "Twenty-nine unresectable colorectal cancer patients were stratified to either ≥70 or <60 years of age, where the disposition of capecitabine and its metabolites were compared." | 5.17 | Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). ( Albain, KS; Blanke, CD; Coleman, D; Ely, B; Gold, PJ; Gotay, C; Lenz, HJ; Louie, SG; Raghavan, D; Shields, AF, 2013) |
| "The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen for elderly patients with metastatic colorectal cancer." | 5.17 | Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. ( Andre, N; Cunningham, D; Jonker, D; Lang, I; Lorusso, V; Marcuello, E; Ocvirk, J; Osborne, S; Saunders, MP; Shin, DB; Waterkamp, D, 2013) |
| " We prospectively evaluated the impact of UGT1A genotypes and haplotypes on severe toxicity and efficacy in patients treated with fluorouracil, leucovorin, and irinotecan combination chemotherapy (FOLFIRI) for metastatic colorectal cancer (mCRC) from the two prospective multicenter phase II studies in Japan." | 5.17 | UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. ( Ando, H; Fujita, Y; Hamamoto, Y; Hazama, S; Hinoda, Y; Inoue, Y; Kanekiyo, S; Kato, T; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Oka, M; Okayama, N; Okuyama, Y; Sakamoto, J; Takahashi, K; Takemoto, H; Tsunedomi, R, 2013) |
| "The purpose of this multicenter phase II study was to evaluate the efficacy and safety of a combination of irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) plus bevacizumab as first-line chemotherapy in Japanese patients with metastatic colorectal cancer." | 5.17 | FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. ( Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F, 2013) |
| "The combination of oxaliplatin and oral capecitabine (XELOX) has shown to be an active regimen in metastatic colorectal cancer (MCRC)." | 5.17 | Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer. ( Alvarez, E; Campos, B; Candamio, S; Casal, J; Gallardo, E; Grande, C; Mel, JR; París Bouzas, L; Quintero, G; Villanueva, MJ, 2013) |
| "Current guidelines recommend treatment with capecitabine and bevacizumab for patients (pts) with non-resectable metastatic colorectal cancer (mCRC), although clinical data in this particular patient group are lacking." | 5.17 | Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial. ( Arnold, D; Behringer, D; Hegewisch-Becker, S; Kettner, E; Kirsch, A; Kretzschmar, A; Pflüger, KH; Stein, A; Wolff, T; Zimber, J, 2013) |
| "This study evaluated the activity of 2 schedules of erlotinib in combination with chemotherapy, and the prognostic significance of serum amphiregulin (AREG) and transforming growth factor alpha (TGFa) in metastatic colorectal cancer." | 5.17 | Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. ( Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC, 2013) |
| "Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survival (PFS) compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer." | 5.17 | Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. ( Bechstein, WO; Finch-Jones, M; Glimelius, B; Gruenberger, T; Jaeck, D; Mauer, M; Mirza, D; Nordlinger, B; Parks, RW; Poston, GJ; Primrose, JN; Rougier, P; Scheithauer, W; Schlag, PM; Sorbye, H; Tanis, E; Van Cutsem, E; Walpole, ET, 2013) |
| "The prognostic and predictive value of multiple serum biomarkers was evaluated using samples from a randomised phase III study (HORIZON II) investigating chemotherapy with or without cediranib in metastatic colorectal cancer (mCRC)." | 5.17 | Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy. ( Barry, ST; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Pommier, AJ; Robertson, JD; Spencer, SK, 2013) |
| " This randomized, multicenter, parallel-group, open-label phase II trial compared axitinib with bevacizumab each in combination with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) for second-line treatment of metastatic colorectal cancer." | 5.17 | Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. ( Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA, 2013) |
| "It was the aim of this study to evaluate maintenance therapy with bevacizumab + capecitabine following induction with bevacizumab + capecitabine + oxaliplatin (XELOX) versus bevacizumab + XELOX until progression as first-line therapy in metastatic colorectal cancer (mCRC)." | 5.17 | Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. ( Buyukberber, S; Buyukunal, E; Camci, C; Cevik, D; Dane, F; Kilickap, S; Ozdener, F; Sencan, O; Uslu, R; Yalcin, S; Yilmaz, U; Zengin, N, 2013) |
| "This study aims to determine the efficacy and tolerability of capecitabine (CAP) plus bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in frail and/or elderly patients." | 5.17 | A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer. ( Chan, D; Dichmann, R; Hecht, JR; Hu, EH; Liem, AK; Naeim, A; Patel, R; Tchekmedyian, NS; Wainberg, ZA; Wang, HJ; Ward, PR, 2013) |
| "This phase II trial investigated the efficacy of an induction regimen of bevacizumab, capecitabine plus oxaliplatin (XELOX) followed by maintenance therapy with bevacizumab plus erlotinib as first-line therapy in patients with metastatic colorectal cancer." | 5.17 | Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. ( Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A, 2013) |
| " This investigation analyzed the value of Cet-ST for treatment efficacy in a randomized trial comparing cetuximab plus capecitabine/irinotecan to cetuximab plus capecitabine/oxaliplatin as first-line treatment of metastatic colorectal cancer." | 5.17 | Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu ( Giessen, C; Heinemann, V; Jung, A; Kapaun, C; Kirchner, T; Laubender, RP; Modest, DP; Moosmann, N; Neumann, J; Stintzing, S; Wollenberg, A, 2013) |
| "The phase III CONFIRM clinical trials demonstrated that metastatic colorectal cancer patients with elevated serum lactate dehydrogenase (LDH) had improved outcome when the vascular endothelial growth factor receptor (VEGFR) inhibitor PTK/ZK (Vatalanib) was added to FOLFOX4 chemotherapy." | 5.17 | Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). ( Azuma, M; Danenberg, KD; Danenberg, PV; Folprecht, G; Ladner, RD; Lebwohl, D; Lenz, HJ; Meinhardt, G; Sherrod, A; Shi, MM; Trarbach, T; Wilson, PM; Yang, D; Zhang, W, 2013) |
| "This randomized, multicenter phase II study involved 80 metastatic colorectal cancer patients aged 70 years and above (performance status [PS] 0-2) or 65 years and above (PS 2), randomly assigned to arm A (capecitabine 1250 mg/m twice daily on days 1-14) or arm B (capecitabine 1000 mg/m twice daily on days 1-14, oxaliplatin 100 mg/m on day 1 initially, 130 mg/m for subsequent cycles)." | 5.17 | Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01. ( Ahn, JB; Hong, YS; Jung, KH; Kim, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Park, YS; Shim, BY; Zang, DY, 2013) |
| "To investigate the association of colonic methane, formed by methanogenic achaea, and pH with gastrointestinal symptoms during colorectal cancer chemotherapy." | 5.17 | Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "The objective of this study was to compare the pharmacokinetics and safety of two tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in patients with colon, colorectal or breast cancer." | 5.17 | Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer. ( Chachad, S; Malhotra, G; Naidu, R; Purandare, S, 2013) |
| " The present study was an open-label, sequential-cohort, dose-escalation trial of intravenous aflibercept administered every 2 weeks in combination with 5-fluorouracil, levofolinate, and irinotecan (FOLFIRI) in patients with previously treated metastatic colorectal cancer (mCRC)." | 5.17 | A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ( Asayama, M; Boku, N; Doi, T; Fujino, T; Machida, N; Ohtsu, A; Onozawa, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T, 2013) |
| "The objective of this economic evaluation, which was based on patients from two randomized controlled clinical trials (NO16966 and NO16967), was to compare direct medical costs to the Australian health-care system of capecitabine plus oxaliplatin (XELOX) and bolus and/or infusional 5-fluorouracil (5-FU) plus folinic acid combined with oxaliplatin (modified [m] FOLFOX-6) in first-line and second-line treatment of advanced or metastatic colorectal cancer (mCRC)." | 5.17 | Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia. ( Gibbs, P; Hack, SP; Kerr, A; Price, T; Stokes, L; Todd, C; Tran, G, 2013) |
| "The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)." | 5.17 | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013) |
| "This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)." | 5.17 | Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. ( Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA, 2013) |
| " We aimed at identifying novel genetic markers that would improve prediction of irinotecan toxicity and response in advanced colorectal cancer patients treated with folic acid (leucovorin), fluorouracil (5-FU), and irinotecan (camptosar)-based regimens." | 5.17 | Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. ( Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G, 2013) |
| "The optimal chemotherapeutic regimen suitable for metastatic colorectal cancer (mCRC) patients previously treated with 5-fluorouracil (5FU), oxaliplatin, irinotecan and biotherapies remains an unresolved issue." | 5.16 | Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. ( Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S; Vincent, J, 2012) |
| "To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC)." | 5.16 | Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. ( Gill, JF; Hentschel, P; Higby, DJ; Khan, MQ; Leichman, CG; Madajewicz, S; Malik, SK; Nicol, SJ; Ritch, PS; Waterhouse, DM; Zhao, L, 2012) |
| "The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated metastatic colorectal cancer harboring wild-type KRAS." | 5.16 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012) |
| "We conducted a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of CKD-732 [6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate] in combination with capecitabine and oxaliplatin (XELOX) in nine metastatic colorectal cancer patients who had progressed on irinotecan-based chemotherapy." | 5.16 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. ( Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ, 2012) |
| "The authors evaluated the influence of 5-fluorouracil (5-FU) on treatment tolerability in 81 colorectal cancer patients given adjuvant 5-FU intravenously plus folinic acid for 6 cycles." | 5.16 | Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. ( Amadori, D; Amatori, F; Danesi, R; Del Tacca, M; Di Paolo, A; Flamini, E; Ibrahim, T; Mercatali, L; Ravaioli, E; Sacanna, E, 2012) |
| " The primary objectives of this study were to determine the maximum tolerated dose of vandetanib with capecitabine and oxaliplatin, without and with bevacizumab, for the first line treatment of metastatic colorectal cancer (mCRC), and to define the dose limiting toxicities." | 5.16 | A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. ( Cabebe, EC; Fisher, GA; Sikic, BI, 2012) |
| " This prospective study was undertaken to examine the generation of oxidative stress, in 106 colorectal cancer patients, by 5-fluorouracil and oxaliplatin combination (FOLFOX) therapy as measured by urinary excretion of 8-oxo-7,8-dihydro-2-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydro-guanosine (8-oxoGuo)." | 5.16 | Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin. ( Afzal, S; Henriksen, T; Jensen, SA; Poulsen, HE; Sørensen, JB; Weimann, A, 2012) |
| "This study was intended to ascertain the feasibility of a combination therapy with irinotecan by 24-h intravenous infusion (24-h CPT-11) and 5-fluorouracil (5-FU) for patients with metastatic colorectal cancer, to estimate the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD), to determine the recommended dose (RD) for the Phase II study, and to evaluate the efficacy of the combination therapy." | 5.16 | Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. ( Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T, 2012) |
| " From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily." | 5.16 | Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012) |
| "Patients with refractory metastatic colorectal cancer were randomized in a two-stage design to receive vorinostat at 800 or 1,400 mg/day once a day × 3, every 2 weeks." | 5.16 | A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. ( Fakih, MG; Groman, A; McMahon, J; Muindi, JR; Wilding, G, 2012) |
| "Molecular markers to predict response to 5-fluorouracil (FU)-based treatment of recurrent or metastasised colorectal cancer (mCRC) are not established." | 5.16 | Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: results of a randomised multicentre trial. ( Danenberg, K; Danenberg, P; Goeb, R; Hebart, H; Henne-Bruns, D; Kornmann, M; Kron, M; Link, KH; Staib, L, 2012) |
| " This phase 2 study assessed enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab as maintenance therapy for metastatic colorectal cancer (MCRC)." | 5.16 | A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. ( Di Bartolomeo, M; Fuchs, M; Heinemann, V; Hossain, AM; Nicol, S; Stoffregen, C; Wolff, RA, 2012) |
| "The AIO KRK-0306 trial compares the efficacy of infusional 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)." | 5.16 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. ( Decker, T; Fischer von Weikersthal, L; Giessen, C; Heinemann, V; Heintges, T; Jäger, E; Jung, A; Kirchner, T; Modest, DP; Neumann, J; Scheithauer, W; Stintzing, S; Stoll, C; Vehling-Kaiser, U, 2012) |
| "The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with metastatic colorectal cancer (mCRC)." | 5.16 | First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. ( Abad, A; Antón, A; Aranda, E; Arrivi, A; Benavides, M; Cervantes, A; Díaz-Rubio, E; Dueñas, R; Escudero, P; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Lacasta, A; Llanos, M; López-Ladrón, A; Losa, F; Marcuello, E; Martínez de Prado, P; Massutí, B; Rivera, F; Safont, MJ; Sastre, J; Tabernero, JM; Valladares, M, 2012) |
| " This phase II study tested the efficacy and safety of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as first-line treatment for metastatic colorectal cancer patients." | 5.16 | A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. ( Burtness, B; Cohen, SJ; Denlinger, CS; Dotan, E; Lee, J; Meropol, NJ; Mintzer, D; Ruth, K; Sylvester, J; Tuttle, H; Zhu, F, 2012) |
| "Previous phase III studies raised concern about the safety of the combination of capecitabine and irinotecan in patients with metastatic colorectal cancer (mCRC)." | 5.16 | A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. ( Chen, E; Feld, R; Knox, J; Krzyzanowska, MK; Liu, G; MacKay, H; Moore, MJ; Petronis, J; Renouf, DJ; Wang, L; Welch, S, 2012) |
| "Using the recommended doses obtained from our previous phase 1 trial of a modified Saltz chemotherapy regimen for metastatic colorectal cancer (weekly irinotecan and bolus 5-fluorouracil/l-leucovorin for 3 weeks every 28 days), we performed the present phase 2 trial to evaluate efficacy and toxicity." | 5.16 | Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients. ( Akashi, K; Baba, E; Esaki, T; Fujishima, H; Kusaba, H; Makiyama, A; Mitsugi, K; Nakano, S; Tanaka, R; Uchino, K, 2012) |
| "The addition of irinotecan to infusional 5 fluorouracil and leucovorin significantly improves the response rate and survival compared with 5 fluorouracil/leucovorin alone in metastatic colorectal cancer." | 5.16 | First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study. ( Assy, N; Basher, W; Chetver, L; Shnaider, J; Zidan, J, 2012) |
| "This phase I study evaluated sunitinib plus modified FOLFOX6 (mFOLFOX6: 5-fluorouracil, leucovorin and oxaliplatin) in Japanese patients with treatment-naïve metastatic colorectal cancer." | 5.16 | Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer. ( Boku, N; Hamaguchi, T; Hashigaki, S; Hirohashi, T; Kato, K; Lechuga, MJ; Li, Y; Ohtsu, A; Shibata, A; Shimada, Y; Yamazaki, K; Yasui, H; Yoshino, T, 2012) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 5.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "The NORDIC-VII multicenter phase III trial investigated the efficacy of cetuximab when added to bolus fluorouracil/folinic acid and oxaliplatin (Nordic FLOX), administered continuously or intermittently, in previously untreated metastatic colorectal cancer (mCRC)." | 5.16 | Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. ( Birkemeyer, E; Christoffersen, T; Dahl, O; Dajani, O; Erdal, AB; Fokstuen, T; Glimelius, B; Guren, T; Hansen, F; Hofsli, E; Ikdahl, T; Johnsson, A; Keldsen, N; Kure, E; Pfeiffer, P; Pyrhonen, S; Sigurdsson, F; Skovlund, E; Sorbye, H; Starkhammar, H; Tveit, KM; Yilmaz, MK, 2012) |
| " Treatment consisted of first-line chronomodulated or conventional delivery of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer." | 5.16 | Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. ( Bjarnason, GA; Coudert, B; Durando, X; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Lévi, FA; Mormont, MC; Tampellini, M; Waterhouse, J, 2012) |
| "To evaluate the safety and efficacy of combination chemotherapy with 5-fluorouracil (5-FU), leucovorin, irinotecan and oxaliplatin (FOLFOXIRI) in Japanese patients with advanced colorectal cancer." | 5.16 | A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28. ( Akiyama, Y; Araki, K; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Nagashima, F; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K, 2012) |
| "The primary objective of this study is to evaluate the safety, tolerance, and pharmacokinetic profile of liver-directed therapy with drug-eluting beads irinotecan (DEBIRI) in combination with systemic modified FOLFOX in the treatment of unresectable liver metastases in chemotherapy-naive patients with colorectal cancer." | 5.16 | Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ( Martin, RC; Metzger, T; Schreeder, M; Scoggins, CR; Sharma, V; Tatum, C; Tomalty, D, 2012) |
| "To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC)." | 5.16 | Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ( Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC, 2012) |
| "Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B)." | 5.16 | Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial. ( Hasegawa, H; Hisa, A; Kitagawa, Y; Ohishi, T; Okabayashi, K; Watanabe, M, 2012) |
| "S-1 is effective in sequential combination with irinotecan (IRIS) in treating metastatic colorectal cancer." | 5.16 | Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients. ( Akiyama, S; Andoh, H; Gamoh, M; Ishioka, C; Kato, S; Maeda, S; Mori, T; Murakawa, Y; Ohori, H; Sasaki, Y; Shimodaira, H; Suzuki, T; Takahashi, S; Yamaguchi, T; Yoshioka, T, 2012) |
| "A total of 106 patients planned for palliative single-agent capecitabine (53 in each arm, 65%/35% colorectal/breast cancer) were randomised to receive either concomitant pyridoxine (50 mg po) or matching placebo three times daily." | 5.16 | A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. ( Ahmad, A; Armstrong, G; Blesing, C; Bond, S; Bulusu, R; Corrie, PG; Daniel, F; Hardy, R; Hill, M; Lao-Sirieix, S; McAdam, K; Moody, AM; Osborne, M; Parashar, D; Wilson, CB; Wilson, G, 2012) |
| "Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody." | 5.16 | Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. ( Allegra, C; Castan, R; Ferry, D; Lakomy, R; Macarulla, T; McKendrick, J; Moiseyenko, V; Polikoff, J; Prausová, J; Prenen, H; Ruff, P; Tabernero, J; Tellier, A; Van Cutsem, E; van Hazel, GA, 2012) |
| "To compare the efficacy of cediranib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKI]) with that of bevacizumab (anti-VEGF-A monoclonal antibody) in combination with chemotherapy as first-line treatment for advanced metastatic colorectal cancer (mCRC)." | 5.16 | Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). ( Barker, P; Bodoky, G; Bondarenko, I; Cunningham, D; Karapetis, CS; Kocakova, I; Koski, SL; Mainwaring, P; Mookerjee, B; Robertson, J; Rougier, P; Salazar, R; Schmoll, HJ; Sobrero, A; Van Cutsem, E, 2012) |
| " HORIZON II [Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer] assessed infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (FOLFOX/CAPOX) with or without cediranib in patients with previously untreated metastatic colorectal cancer (mCRC)." | 5.16 | Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). ( Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B, 2012) |
| "Capecitabine plus oxaliplatin (CapeOX) is one of the reference doublet cytotoxic chemotherapy treatments for patients with metastatic colorectal cancer." | 5.16 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2012) |
| "The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC)." | 5.16 | Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. ( Dahl, O; Elsaleh, H; Fluge, Ø; Knudsen, ES; Leh, S; Li, Z; Myklebust, MP; Myrvold, HE; Pestell, RG; Rui, H; Tran, TH; Tveit, KM; Vonen, B, 2012) |
| "In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression." | 5.16 | Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. ( Aranda, E; Arrivi, A; Bando, I; Benavides, M; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Gómez-España, A; González, E; Manzano, JL; Marcuello, E; Martínez de Prado, P; Massutí, B; Montagut, C; Reboredo, M; Rivera, F; Safont, MJ; Sastre, J, 2012) |
| "Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal cancer." | 5.15 | Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. ( Berglund, A; Berglund, M; Byström, P; Fredriksson, LA; Garmo, H; Glimelius, B; Kohnke, H; Sørbye, H; Wadelius, M, 2011) |
| "A regimen consisting of 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) is widely used in France in the first-line treatment of metastatic colorectal cancer (MCRC)." | 5.15 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M, 2011) |
| "To evaluate the efficacy and tolerability of systemic chemotherapy with irinotecan (CPT-11), UFT and leucovorin (LV) combined with hepatic arterial infusion (HAI) consisting of 5-fluorouracil (5-FU) in colorectal cancer patients with unresectable liver metastases." | 5.15 | Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. ( Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M, 2011) |
| "In view of a potential gain in anticancer activity in advanced colorectal cancer (ACRC), there has been considerable interest in using a higher than the approved standard dose of capecitabine (CCB) combined with oxaliplatin." | 5.15 | Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen. ( Czejka, M; Farkouh, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2011) |
| "To evaluate the efficacy, safety and quality of life of a short course of oxaliplatin plus capecitabine (XELOX) followed by single-agent capecitabine in patients with previously untreated, inoperable, metastatic colorectal cancer." | 5.15 | Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. ( Allen, J; Bentley, D; Gollins, S; Lloyd, A; Morris, J; Saunders, MP; Soe, W; Swindell, R; Taylor, MB; Valle, J; Waddell, T, 2011) |
| "Infusional 5-fluorouracil and leucovorin with oxaliplatin is one of the standard regimens for patients with pretreated metastatic colorectal cancer, as well as for first-line chemotherapy." | 5.15 | A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer. ( Esaki, T; Fujii, H; Inaba, Y; Kato, K; Kusaba, H; Mizuno, T; Mizunuma, N; Muro, K; Shimada, Y; Shirao, K; Tsuji, Y; Yoshioka, A, 2011) |
| "This phase I/II study determined the recommended dose of FOLFIRI (irinotecan, infusional 5-fluorouracil and leucovorin) for Japanese patients with advanced colorectal cancer, and evaluated safety at the recommended dose in patients without the UDP-glucuronosyltransferase 1A1*28 allele which caused reduced enzyme expression." | 5.15 | Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer. ( Akiyama, Y; Ando, M; Ando, Y; Endo, H; Fujita, K; Kawara, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W; Yamashita, K, 2011) |
| "The aim of the present trial was to evaluate whether an intermittent chemotherapy with levo-leucovorin + 5-fluorouracil (5-FU) + irinotecan (CPT-11) was at least as effective as the same regimen given continuously, both administered until progression, in patients affected with advanced colorectal cancer and not previously exposed to chemotherapy for metastatic disease." | 5.15 | Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. ( Aglietta, M; Barni, S; Beretta, GD; Corsi, D; Cortesi, E; Dapretto, E; Floriani, I; Fornarini, G; Isa, L; Labianca, R; Lonardi, S; Nicolella, D; Sobrero, A; Turci, D; Zaniboni, A, 2011) |
| "The primary aim of the high-dose 5-fluorouracil (5-FU) and leucovorin (LV; HDFL48) phase I study was to determine the maximum tolerated dose and dose-limiting toxicity of 5-FU and LV with modified tri-monthly 48-h continuous infusion of high-dose 5-FU/LV in patients with metastatic colorectal cancer." | 5.15 | Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. ( Chen, RR; Cheng, AL; Ho, YF; Lu, WC; Yeh, KH, 2011) |
| "This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin, levoforinate, and infusional 5-fluorouracil (FOLFOX4) as a second-line therapy for Japanese patients with unresectable advanced or metastatic colorectal cancer." | 5.15 | A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience. ( Emi, Y; Fujita, F; Hasegawa, H; Inomata, M; Kakeji, Y; Kitazono, M; Maehara, Y; Morikita, T; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Samura, H; Shirabe, K; Shirouzu, K; Tanaka, T; Tokunaga, S; Yamamoto, M, 2011) |
| "The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC)." | 5.15 | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. ( Bokemeyer, C; Bondarenko, I; Celik, I; de Braud, F; Hartmann, JT; Koralewski, P; Schlichting, M; Schuch, G; Zubel, A, 2011) |
| "This study was designed to determine the efficacy and tolerability of capecitabine, oxaliplatin and bevacizumab in combination with cetuximab as first-line therapy for advanced colorectal cancer." | 5.15 | A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. ( Aklilu, M; Ashton, J; Bendell, JC; Blobe, GC; Cushman, S; Fernando, NH; Hurwitz, HI; Morse, MA; Nixon, AB; Pang, H; Wong, NS, 2011) |
| "The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine and irinotecan (CAPIRI) or capecitabine and oxaliplatin (CAPOX) in the first-line treatment of metastatic colorectal cancer (mCRC)." | 5.15 | Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K, 2011) |
| "0 mg/kg q2w, concomitantly with a combination of capecitabine and oxaliplatin (XELOX) and FOLFOX-4 (oxaliplatin in combination with infusional 5-FU/LV), respectively, in patients with metastatic colorectal cancer (mCRC)." | 5.15 | A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. ( Abt, M; Burns, I; Chen, E; Goldstein, D; Major, P; McKendrick, J; Rittweger, K; Robinson, B; Zhi, J, 2011) |
| "To observe the effect of modified Sijunzi Decoction (SJZD) on immune function in patients with colorectal cancer undergoing chemotherapy (CM) with FOLFOX4 protocol (oxaliplatin + calcium folinate + 5-fluorouracil)." | 5.15 | [Immune enhancing effect of modified sijunzi decoction on patients with colorectal cancer undergoing chemotherapy]. ( Xiao, H; Yang, J, 2011) |
| "A combination of fluorouracil and leucovorin (5-FU/LV) with oxaliplatin (FOLFOX) is an established first-line therapy for metastatic colorectal cancer (mCRC)." | 5.15 | Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study. ( Fujiwara, M; Iwata, N; Kodera, Y; Koike, M; Nakao, A; Nakayama, G; Ohashi, N; Okuda, N; Tanaka, C; Watanabe, T; Yokoyama, H, 2011) |
| "The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease." | 5.15 | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. ( Cascinu, S; Celik, I; Ciardiello, F; Cunningham, D; Folprecht, G; Köhne, CH; Láng, I; Maurel, J; Nowacki, MP; Rougier, P; Schlichting, M; Shchepotin, I; Tejpar, S; Van Cutsem, E; Zubel, A, 2011) |
| "A subgroup of patients from the CAIRO2 study (randomized phase III study on capecitabine, oxaliplatin, bevacizumab with or without cetuximab in first-line advanced colorectal cancer) that received capecitabine plus oxaliplatin (CAPOX) treatment in combination with bevacizumab was selected." | 5.15 | Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer. ( De Bruijn, MT; Hinrichs, J; Kranenburg, O; Punt, CJ; Raats, DA; Rinkes, IH; Teerenstra, S; Tol, J, 2011) |
| "We report updated overall survival (OS) data from study NO16966, which compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as first-line therapy in metastatic colorectal cancer." | 5.15 | XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. ( Cassidy, J; Clarke, S; Díaz-Rubio, E; Figer, A; Gilberg, F; Koski, S; Rittweger, K; Saltz, L; Scheithauer, W; Wong, R, 2011) |
| "The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC)." | 5.15 | Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K, 2011) |
| "This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer." | 5.15 | A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. ( Bendell, JC; Blobe, GC; Fernando, NH; Honeycutt, W; Hurwitz, HI; Morse, MA; Pang, H; Wong, NS, 2011) |
| " However, circadian chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no survival benefit as compared with the non-time-stipulated FOLFOX2, in an international randomized trial involving patients with previously untreated metastatic colorectal cancer (EORTC 05963)." | 5.15 | Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Smaaland, R; Tampellini, M; Tumolo, S, 2011) |
| "A week on/week off capecitabine schedule with oxaliplatin/bevacizumab was evaluated in patients with metastatic colorectal cancer (mCRC)." | 5.15 | A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer. ( Balaban, EP; Crandall, TL; Kane, P; Lembersky, BC; Pinkerton, RA; Potter, DM; Rajasenan, KK; Ramanathan, RK; Schmotzer, A; Sehgal, R; Zeh, H, 2011) |
| "The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer." | 5.15 | Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. ( André, T; Artru, P; Bengrine-Lefevre, L; Bonnetain, F; Chibaudel, B; de Gramont, A; Desramé, J; Larsen, AK; Louvet, C; Teixeira, L; Tournigand, C, 2011) |
| "The AIO KRK 0110/ML22011 trial is a two-arm, multicenter, open-label randomized phase III trial comparing the efficacy and safety of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in the first-line treatment of metastatic colorectal cancer." | 5.15 | A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. ( Aubele, P; Bangerter, M; Denzlinger, C; Freiberg-Richter, J; Giessen, C; Heinemann, V; Hinke, A; Kullmann, F; Mayerle, J; Modest, DP; Moosmann, N; Schulz, C; Sieber, M; Stintzing, S; Teschendorf, C; Vehling-Kaiser, U; von Weikersthal, LF, 2011) |
| "In this open-label, randomised, phase 3 trial, we randomly assigned patients (1:1 ratio) with advanced, measurable, non-resectable colorectal cancer and WHO performance status 0-2 to receive either first-line treatment with bolus (400 mg/m(2)) and infusional (2400 mg/m(2)) fluorouracil plus leucovorin (400 mg/m(2)) (simplified LV5FU2 regimen), second-line LV5FU2 plus oxaliplatin (100 mg/m(2)) (FOLFOX6), and third-line LV5FU2 plus irinotecan (180 mg/m(2)) (FOLFIRI) or first-line FOLFOX6 and second-line FOLFIRI." | 5.15 | Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. ( Abbas, M; Auby, D; Azzedine, A; Bedenne, L; Bouché, O; Castaing, M; Denis, B; Ducreux, M; Etienne, PL; Gargot, D; Gasmi, M; Geoffroy, P; Lombard-Bohas, C; Malka, D; Mendiboure, J; Michel, P; Pignon, JP; Rougier, P; Texereau, P, 2011) |
| "Efforts to improve efficacy and minimize toxicity have led to pharmacokinetic monitoring of plasma 5-Fluorouracil (5-FU) levels in colorectal cancer patients undergoing chemotherapy." | 5.15 | Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. ( Beachler, C; El-Deiry, WS; Finnberg, NK; Gingrich, R; Kline, CL; Liao, J; Scicchitano, A; Sheikh, HS; Sivik, J, 2011) |
| "An ancillary phase II study was conducted to study interindividual variability in cetuximab pharmacokinetics and its influence on progression-free survival (PFS) in metastatic colorectal cancer patients cotreated with irinotecan and 5-fluorouracil." | 5.15 | Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ( Azzopardi, N; Boisdron-Celle, M; Gamelin, E; Gouilleux-Gruart, V; Lecomte, T; Morel, A; Paintaud, G; Piller, F; Ternant, D; Vignault-Desvignes, C; Watier, H, 2011) |
| "The efficacy and safety of bevacizumab with modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion (mIFL) in the first-line treatment of metastatic colorectal cancer (mCRC) has not been well evaluated in randomized clinical trials in Chinese patients." | 5.15 | Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. ( Ba, Y; Feng, FY; Guan, ZZ; He, J; Liang, J; Luo, RC; Qi, C; Qin, SK; Shen, L; Wang, D; Wang, JJ; Wang, LW; Xu, JM; Xu, RH; Yu, SY, 2011) |
| "This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin in combination with levofolinate and infusion 5-fluorouracil (FOLFOX4) as first-line therapy for Japanese patients with unresectable metastatic colorectal cancer." | 5.15 | A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. ( Baba, H; Egashira, A; Emi, Y; Fujita, F; Hasegawa, H; Hayashi, N; Higashi, H; Inomata, M; Kakeji, Y; Kohakura, F; Kohnoe, S; Maehara, Y; Niwa, K; Ogata, Y; Ohga, T; Oki, E; Samura, H; Shirabe, K; Tokunaga, S; Toyama, T; Yamamoto, M, 2011) |
| "In a multicenter, double-blind phase II trial, we compared the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorectal cancer (mCRC) who had progressed after as many as two prior therapies." | 5.15 | Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. ( Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ, 2011) |
| " We evaluated the efficacy and safety of cetuximab plus 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), the ERBIRINOX regimen, as first-line treatment in patients with unresectable metastatic colorectal cancer (mCRC)." | 5.15 | Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. ( Assenat, E; Bibeau, F; Bleuse, JP; Crapez-Lopez, E; Desseigne, F; Kramar, A; Mineur, L; Portales, F; Samalin, E; Thezenas, S; Viret, F; Ychou, M, 2011) |
| "This study investigated the antitumour and chemosensitizing effects of celecoxib in the treatment of advanced colorectal cancer." | 5.15 | Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer. ( Chen, JM; Jin, CH; Li, RX; Liu, XM; Wang, AH; Wang, GP; Xing, LQ, 2011) |
| "To observe the efficacy, side effects and impact on the quality of life of Aidi Injection combined with leucovorin calcium/5-fluorouracil/oxaliplatin (FOLFOX4 regimen) in the treatment of advanced colorectal cancer patients." | 5.15 | A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. ( Huang, XE; Li, CG; Li, Y; Tang, JH; Xu, HX, 2011) |
| "Irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) is accepted as a reference treatment for the first-line treatment of patients with metastatic colorectal cancer (MCRC)." | 5.14 | Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the ( Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M, 2009) |
| "Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients." | 5.14 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009) |
| "The combination of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX-4) is still a reference regimen in advanced colorectal cancer; however, the addition of new biologic compounds represents a significant way forward." | 5.14 | An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. ( Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C, 2009) |
| "Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)." | 5.14 | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009) |
| "This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients." | 5.14 | Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009) |
| "5-Fluorouracil refractory metastatic colorectal cancer patients were intravenously treated with HA-Irinotecan (300 mg/m(2) irinotecan with 1,000 mg/m(2) HA) on day 1 of a 21-day cycle." | 5.14 | A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. ( Brown, TJ; Cinc, E; Fox, RM; Gibbs, P; Jennens, R; Michael, M; Ng, R; Pho, M, 2009) |
| "Thirty-one patients with non-resectable, colorectal cancer (CRC) liver metastases received irinotecan 120 mg/m(2), followed by leucovorin (LV) 20 mg/m(2) and 5-fluorouracil (5-FU) 500 mg/m(2) administered by HAI every 2 weeks, plus UFT (tegafur-uracil) 200 mg/m(2)/day with LV 30 mg/day on days 1-22, followed by a 6-day rest." | 5.14 | Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. ( Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S, 2009) |
| "For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used." | 5.14 | A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. ( Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP, 2009) |
| "This phase II study was conducted to determine the efficacy and safety of capecitabine and bevacizumab in untreated elderly metastatic colorectal cancer patients." | 5.14 | A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. ( Fakih, MG; Khushalani, N; Mashtare, T; Puthillath, A; Romano, K; Ross, ME; Steinbrenner, L; Wilding, G; Wisniewski, M, 2009) |
| "A total of 91 ACC patients received capecitabine and oxaliplatin (CAPOX) as a part of a multicentre phase-III study of the Dutch Colorectal Cancer Group." | 5.14 | Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T, 2009) |
| "This study assessed radiotherapy combined with capecitabine and oxaliplatin in patients with primary, inextirpable colorectal adenocarcinoma." | 5.14 | Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study. ( Anderson, H; Berglund, K; Byström, P; Ekelund, M; Fernebro, E; Glimelius, B; Gunnlaugsson, A; Holm, T; Johnsson, A; Kjellén, E; Påhlman, L, 2009) |
| "This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer." | 5.14 | Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. ( Aparicio, J; Bokemeyer, C; Bondarenko, I; de Braud, F; Donea, S; Hartmann, JT; Koralewski, P; Loos, AH; Ludwig, H; Makhson, A; Schuch, G; Stroh, C; Zubel, A, 2009) |
| "Second-line irinotecan-based chemotherapy is commonly used in metastatic colorectal cancers after first-line oxaliplatin-based chemotherapy." | 5.14 | Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. ( André, T; Bengrine-Lefevre, L; Bidard, FC; Cervantes, A; de Gramont, A; Figer, A; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2009) |
| "We randomly assigned 755 patients with previously untreated metastatic colorectal cancer to capecitabine, oxaliplatin, and bevacizumab (CB regimen, 378 patients) or the same regimen plus weekly cetuximab (CBC regimen, 377 patients)." | 5.14 | Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. ( Antonini, NF; Cats, A; Creemers, GJ; Dalesio, O; Dijkstra, JR; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Richel, DJ; Rodenburg, CJ; Schrama, JG; Sinnige, HA; Tol, J; van Groeningen, CJ; van Krieken, JH; Vink-Börger, ME; Voest, EE; Vos, AH, 2009) |
| "This Simon 2-stage phase II trial was designed to document antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer (CRC)." | 5.14 | Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. ( Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C, 2009) |
| "An economic analysis (based on interim data from a long-term, randomised, multi-centre, controlled, clinical trial) to evaluate chemotherapy with XELOX (capecitabine/oxaliplatin) versus FOLFOX6 (5Fluorouracil/leucovorin/oxaliplatin) as an adjuvant treatment for high risk colorectal cancer patients in Greece." | 5.14 | XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. ( Fountzilas, G; Fragoulakis, V; Maniadakis, N; Pectasides, D, 2009) |
| " This phase III randomized multicenter trial investigated the benefit of adding ED to fluorouracil (FU) based therapy in patients with stage III colorectal cancer." | 5.14 | Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. ( Bernard, S; Cohen, A; Eisenberg, P; Fields, AL; Forster, J; Kardinal, C; Keller, A; Schulz, J; Schwartzberg, L; Wissel, P, 2009) |
| "Oxaliplatin is a promising drug for cancer therapy and the oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) regimen has become the standard adjuvant treatment for colorectal cancer." | 5.14 | Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. ( Airoldi, M; Cattel, L; Drescher, A; Jaehde, U; Milla, P; Weber, G, 2009) |
| "We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab." | 5.14 | Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. ( Bodoky, G; Chang Chien, CR; D'Haens, G; Folprecht, G; Hitre, E; Köhne, CH; Lim, R; Makhson, A; Nippgen, J; Pintér, T; Roh, JK; Rougier, P; Ruff, P; Schlichting, M; Stroh, C; Tejpar, S; Van Cutsem, E; Zaluski, J, 2009) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 5.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "Irinotecan-based chemotherapy regimens are 1 option for treatment of metastatic colorectal cancer (mCRC)." | 5.14 | Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. ( Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X, 2009) |
| "The present study aimed at investigating whether the simultaneous evaluation of pharmacokinetic, pharmacogenetic and demographic factors could improve prediction on toxicity and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil (5FU)/leucovorin therapy." | 5.14 | Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. ( Barile, C; Bolzonella, C; Bononi, A; Crepaldi, G; Ferrazzi, E; Frigo, AC; Gusella, M; Marinelli, R; Menon, D; Padrini, R; Pasini, F; Stievano, L; Toso, S, 2009) |
| "Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)." | 5.14 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009) |
| "The purpose of the study was to evaluate the cost-effectiveness of capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX4) as first-line or second-line chemotherapy in patients with metastatic colorectal cancer." | 5.14 | Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. ( Fukuda, T; Shiroiwa, T; Tsutani, K, 2009) |
| "To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with efficacy and toxicity in patients receiving oxaliplatin and capecitabine for advanced colorectal cancer (ACC)." | 5.14 | Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ, 2009) |
| "Bevacizumab (BV) prolongs the survival of colorectal cancer patients when combined with irinotecan (CPT-11)-based regimens." | 5.14 | Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy. ( Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Nakajima, T; Shimada, Y; Yamada, Y, 2010) |
| "Studies indicate that adjuvant 5-fluorouracil (5-FU) with folinic acid (FA) in colorectal cancer patients with completely resectable liver-limited metastases (LMCRC) offers clinical benefit over surgery alone." | 5.14 | A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. ( Bokemeyer, C; Hohenberger, W; Kwok-Keung Choi, C; Maurel, J; Navarro, M; Rivera, F; Santoro, A; Shacham-Shmueli, E; Thezenas, S; Ychou, M, 2009) |
| "To evaluate the efficacy of bevacizumab in combination of irinotecan,fluorouracil and leucovorin for metastatic colorectal cancer treated by failed prior oxaliplatin -based regiment." | 5.14 | [Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer]. ( Chen, B; Chen, JZ; Cui, F; Luo, RC; Wan, C; Zheng, H, 2009) |
| "To evaluate the efficacy and safety of irinotecan combined with xeloda (CAPIRI regimen) in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin." | 5.14 | [Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin]. ( Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF, 2009) |
| "The aim of the current study was the investigation of the value of bevacizumab+5-fluorouracil(5-FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options." | 5.14 | Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. ( Caricato, M; Coppola, R; Gasparro, S; Rizzo, S; Russo, A; Santini, D; Spoto, C; Tonini, G; Valeri, S; Venditti, O; Vincenzi, B; Zobel, BB, 2009) |
| "Bevacizumab (Avastin) significantly improves overall survival (OS) and progression-free survival (PFS) when combined with first-line irinotecan (IFL) plus bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer (CRC)." | 5.14 | Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. ( Ackland, S; Chiara, S; Clarke, S; Gapski, J; Langer, B; Mainwaring, P; Perez-Carrión, R; Sobrero, A; Young, S, 2009) |
| "In the present study, either modified IFL regimen (modified irinotecan, fluorouracil and leucovorin, mIFL) alone or in combination with bevacizumab was used to treat patients with metastatic colorectal cancer (CRC)." | 5.14 | Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin. ( Huang, YT; Liao, WJ; Luo, W; Ma, L; Shi, M; Wang, XN; Wen, Q, 2010) |
| "Combination chemotherapy with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) has become a standard regimen for colorectal cancer." | 5.14 | Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. ( Ikeguchi, M; Kanazawa, A; Katano, K; Kidani, A; Makino, M; Ozaki, N; Sugimoto, S; Takeda, H; Tanaka, T; Yoshimura, H, 2009) |
| "To determine the efficacy and tolerability of capecitabine combined with oxaliplatin (CAPOX) or irinotecan (CAPIRI) as first-line treatment in patients with advanced/metastatic colorectal cancer aged > or =70 years." | 5.14 | Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. ( Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G, 2010) |
| "A subgroup analysis of oxaliplatin (LOHP)+irinotecan (CPT-11)+5-fluorouracil (5FU) and leucovorin (LV) (FOLFOXIRI regimen) versus irinotecan+5FU/LV (FOLFIRI regimen) as first-line treatment of patients >65 years old with metastatic colorectal cancer is presented." | 5.14 | Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). ( Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karampeazis, A; Kouroussis, Ch; Polyzos, A; Souglakos, J; Vamvakas, L; Ziras, N, 2010) |
| "To determine the efficacy and tolerability of oral fluoropyrimidine S-1 plus irinotecan in patients with previously untreated advanced colorectal cancer." | 5.14 | Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N, 2009) |
| "To assess the resectability rate of patients with initially unresectable liver-only metastases from colorectal cancer (CRC) after treatment with irinotecan/capecitabine." | 5.14 | A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. ( Cai, J; Ji, X; Li, Q; Tucker, S; Wan, F; Wang, D; Zhao, R; Zhong, B; Zhu, J, 2010) |
| "This study compared chemotherapy discontinuation with maintenance therapy with leucovorin and fluorouracil after six cycles of folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy in the first-line treatment of metastatic colorectal cancer." | 5.14 | Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. ( Afchain, P; André, T; Artru, P; Bennamoun, M; Carola, E; Chibaudel, B; Colin, P; de Gramont, A; Dupuis, O; Flesch, M; Larsen, AK; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Mineur, L; Tournigand, C, 2009) |
| "A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) in terms of efficacy in first-line treatment of metastatic colorectal cancer." | 5.14 | Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Llédo, G; Rebischung, C; Ychou, M, 2010) |
| "We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI + B) in a phase II trial in patients previously untreated for metastatic colorectal cancer (mCRC), and changes during treatment in plasma cytokines and angiogenic factors (CAFs) as potential markers of treatment response and therapeutic resistance." | 5.14 | Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. ( Abbruzzese, JL; Adinin, R; Ellis, LM; Eng, C; Glover, KY; Heymach, JV; Hoff, PM; Kopetz, S; Lieu, C; Morris, JS; Overman, MJ; Tran, HT; Valero, V; Wen, S; Wolff, RA; Yan, S, 2010) |
| "The primary objective of this study was to determine the activity and safety profile of biweekly oxaliplatin combined with continuous oral capecitabine in the first-line treatment of metastatic colorectal cancer." | 5.14 | Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. ( Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R, 2010) |
| " PATIENTS AND METHODS Patients undergoing first-line treatment for metastatic colorectal cancer (CRC) eligible for treatment with irinotecan plus infusional fluorouracil/leucovorin (FOLFIRI) were screened for the UGT1A1*28/*28 genotype and excluded from the study." | 5.14 | Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. ( Azzarello, G; Basso, U; Buonadonna, A; Cecchin, E; D'Andrea, M; De Mattia, E; De Paoli, P; Gasparini, G; Innocenti, F; Lo Re, G; Mini, E; Nobili, S; Pessa, S; Toffoli, G, 2010) |
| " Oxaliplatin combined with capecitabine has demonstrated activity in advanced colorectal cancer." | 5.14 | Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI- ( Alberts, SR; Bolton, JS; Dentchev, T; Lai, LL; Mahoney, MR; Molina, R; Nagorney, DM; O'Connell, MJ; Roh, MS; Schwarz, RE; Smyrk, TC; Wagman, L; Weiland, TL, 2010) |
| "We conducted a phase I/II clinical trial to determine the safety and feasibility of combining vorinostat with 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer (mCRC) and elevated intratumoral thymidylate synthase (TS)." | 5.14 | A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. ( Cole, S; Danenberg, KD; El-Khoueiry, A; Fazzone, W; Groshen, S; Iqbal, S; Kornacki, M; LaBonte, MJ; Ladner, RD; Lenz, HJ; Wilson, PM; Yang, D, 2010) |
| "This phase I/II study was conducted to assess the maximal tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of gefitinib in combination with capecitabine in patients with advanced colorectal cancer (aCRC)." | 5.14 | Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). ( Frieling, T; Graeven, U; Hegewisch-Becker, S; Lehnert, L; Reinacher-Schick, A; Schmiegel, W; Trarbach, T; Vanhoefer, U, 2010) |
| "A dose-finding study was performed to evaluate the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD) and the recommended dose (RD) of escalating the doses of capecitabine and fixed doses of irinotecan and oxaliplatin on a biweekly schedule for metastatic colorectal cancer patients (mCRC)." | 5.14 | Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. ( Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R, 2010) |
| "Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial." | 5.14 | Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies. ( Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S, 2010) |
| "Adding irinotecan and/or oxaliplatin to every-2-week 5-fluorouracil (5-FU)/leucovorin (LV) prolongs survival in patients with colorectal cancer (CRC) but increases neutropenia frequency." | 5.14 | A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. ( Dreiling, L; Gollard, R; Hecht, JR; Heim, W; Malik, I; Mo, M; Patel, R; Pillai, M; Swan, F, 2010) |
| "This phase II trial evaluated the efficacy and safety of cetuximab combined with FOLFOX6 (leucovorin [LV] 5-fluorouracil [5-FU]/oxaliplatin) in the first-line treatment of patients with advanced or metastatic colorectal cancer." | 5.14 | A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. ( Badarinath, S; Boccia, RV; Cosgriff, TM; Dakhil, SR; Headley, DL, 2010) |
| "The aim was to investigate whether germline polymorphisms within candidate genes known or suspected to be involved in fluorouracil (FU), oxaliplatin, and irinotecan pathways were associated with toxicity and clinical outcome in patients with metastatic colorectal cancer (mCRC)." | 5.14 | Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. ( Barrois, M; Beaune, P; Boige, V; Bouché, O; Castaing, M; Ducreux, M; Laurent-Puig, P; Le Corre, D; Loriot, MA; Malka, D; Mendiboure, J; Miran, I; Mulot, C; Pignon, JP; Trégouët, DA, 2010) |
| "To compare the efficacy and toxicity of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin (5-Fu/LV) plus oxaliplatin (FOLFOX4) regimens as adjuvant chemotherapy for stage III colorectal cancer." | 5.14 | [Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer]. ( Fang, F; Li, DC; Lu, GC, 2010) |
| "Twenty-one patients with advanced colorectal cancer were treated with intravenous infusion of endostar (15 mg/day for 14 consecutive days) and irinotecan (250 mg/m(2), single dose on the first day), and oral administration of capecitabine (1." | 5.14 | [Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer]. ( Liao, WJ; Luo, RC; Shen, P; Shi, M; Wu, Wy, 2010) |
| "The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a phase II, open, multicentre, uncontrolled study." | 5.14 | Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. ( Bolaños, M; Bosch, C; Castro-Carpeño, J; Escudero, P; Feliu, J; García-Girón, C; Gil, M; González-Barón, M; Llombart, A; López, R; Losa, F; Madroñal, C; Safont, MJ; Salud, A, 2010) |
| "A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association." | 5.14 | Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. ( Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M, 2010) |
| "This Phase I study was designed to determine a safe combination dose of 5-fluorouracil (5-FU) and arsenic trioxide (ATO) to treat 5-FU-resistant relapsed/refractory colorectal cancer patients." | 5.14 | A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. ( Ardalan, B; Duncan, R; Fernandez, A; Ganjei-Azar, P; Gonzalez, M; Lee, K; Lima, M; Mezentsev, D; Podolsky, L; Ramos, Y; Reis, I; Subbarayan, PR, 2010) |
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 5.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "A phase I multicentre trial was conducted to define the recommended dose of capecitabine in combination with oxaliplatin and irinotecan (OCX) in metastatic colorectal cancer." | 5.14 | Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). ( Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L, 2010) |
| "The impact of thymidylate synthase (TYMS) and UDP-glucoronosyltransferase 1A (UGT1A) germline polymorphisms on the outcome of colorectal cancer (CRC) patients treated with irinotecan plus 5-fluorouracil (irinotecan/5FU) is still controversial." | 5.14 | UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. ( Abad, A; Aranda, E; Benavides, M; Carrato, A; Ginés, A; Layos, L; Manzano, JL; Marcuello, E; Martinez-Balibrea, E; Martínez-Cardús, A; Massutí, B; Moreno, V; Navarro, M; Valladares, M, 2010) |
| "Capecitabine has shown similar efficacy to 5-fluorouracil (5-FU); a regimen containing 2 weeks of capecitabine/oxaliplatin (CapOx) has demonstrated noninferiority to infusional 5-FU/oxaliplatin/leucovorin (FOLFOX) for the treatment of metastatic colorectal cancer (mCRC)." | 5.14 | A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. ( Eickhoff, JC; Holen, KD; Jumonville, A; Loconte, NK; Lubner, SJ; Mulkerin, DL; Schelman, W; Seo, S; Thomas, JP, 2010) |
| "The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 trial in patients with metastatic colorectal cancer." | 5.14 | Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. ( Amoroso, D; Andreuccetti, M; Ciarlo, A; Cortesi, E; Cremolini, C; Cupini, S; Del Monte, F; Falcone, A; Fontanini, G; Fornaro, L; Granetto, C; Loupakis, F; Lupi, C; Masi, G; Salvatore, L; Sensi, E, 2010) |
| "Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer." | 5.14 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010) |
| "To evaluate the efficacy and safety of bevacizumab plus capecitabine in treating metastatic colorectal cancer(mCRC)." | 5.14 | [Efficacy and safety of bevacizumab plus capecitabine for metastatic colorectal cancer]. ( Ai, B; Ding, L; Li, L; Wu, JY; Wu, XN; Zhao, YB; Zhou, MZ, 2010) |
| "Patients with histologically confirmed breast cancer or colorectal cancer receiving single agent capecitabine started at 2000 to 2500 mg/m(2) daily from day 1 to 14 every 3 weeks were randomly assigned to receive 200 mg or 400 mg daily of pyridoxine for PPE prophylaxis." | 5.14 | Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. ( Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N, 2010) |
| "Colorectal cancer (CRC) patients whose tumours have microsatellite instability (MSI) do not benefit from adjuvant 5-fluorouracil." | 5.14 | Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX. ( Bennamoun, M; Boisseau, A; Cucherousset, J; Des Guetz, G; Lagorce, C; Lecaille, C; Mariani, P; Morere, JF; Nicolas, P; Sastre, X; Schischmanoff, PO; Uzzan, B, 2010) |
| "This study reports the long-term follow-up of patients with metastatic colorectal cancer (CRC) participating in a randomised phase II study that compared the efficacy and toxicity of the combination of irinotecan (IRI), fluorouracil (FU) with leucovorin (LV) (arm A) versus sequential chemotherapy with IRI plus FU/LV followed by oxaliplatin (OXA) plus FU/LV (arm B) as first line therapy." | 5.14 | Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. ( Aravantinos, G; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Linardou, H; Makatsoris, T; Papadimitriou, C; Papakostas, P; Papamichael, D; Pectasides, D; Pentheroudakis, G; Samelis, G; Skondra, M; Stavropoulos, M; Syrigos, KN; Varthalitis, I; Vourli, G; Xanthakis, I; Xiros, N, 2010) |
| "Fluorouracil (FU) is a cornerstone of colorectal cancer treatment; however, it has clinical and subclinical influence on the heart." | 5.14 | Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. ( Hasbak, P; Jensen, SA; Mortensen, J; Sørensen, JB, 2010) |
| "Colorectal cancer patients receiving FOLFOX-4 or capecitabine plus oxaliplatin were randomized to (Arm A) calcium gluconate 1g +15% magnesium sulphate 1g diluted in 100 mL of dextrose 5% or (Arm B) placebo." | 5.14 | Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. ( Chay, WY; Choo, SP; Gao, F; Koo, WH; Lo, YL; Ng, HC; Ong, SY; Tan, SH, 2010) |
| "601 patients with advanced or metastatic colorectal cancer receiving first-, second-, or third-line irinotecan-based therapy were regularly analyzed for response and toxicity until the end of therapy." | 5.14 | Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study. ( Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K, 2010) |
| "This phase I study was conducted to determine the maximum tolerated dose (MTD) of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) in patients with advanced colorectal cancer (CRC)." | 5.14 | Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ( Carducci, M; Dancey, J; Donehower, RC; Hidalgo, M; Iacobuzio-Donahue, C; Jacene, H; Jimeno, A; Kahn, Y; Kulesza, P; Laheru, DA; Messersmith, WA; Rudek, MA; Spira, A; Zhao, M, 2010) |
| "In a recent randomized study, we demonstrated that XELOX (oxaliplatin + oral capecitabine) was well tolerated and not inferior in terms of efficacy to the infusional FOLFOX-6 regimen in first-line treatment of metastatic colorectal cancer (mCRC)." | 5.14 | Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6. ( Bennouna, J; Conroy, T; Dominguez, S; Douillard, JY; Ducreux, M; Faroux, R; Florentin, V; Hebbar, M; Lledo, G; Perrocheau, G; Ychou, M, 2010) |
| "The results indicate that the modified CAPOX regimen is safe and effective as salvage treatment in patients with advanced colorectal cancer who were previously treated with irinotecan-based frontline therapy." | 5.13 | Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. ( Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N, 2008) |
| "To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy." | 5.13 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. ( Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL, 2008) |
| "The aim of the study was to investigate the associations between UGT1A1(*)28 genotype and (1) response rates, (2) febrile neutropenia and (3) dose intensity in patients with metastatic colorectal cancer treated with irinotecan." | 5.13 | UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T, 2008) |
| " This randomized phase II trial investigates the feasibility and efficacy of gefitinib and 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) in patients with metastatic colorectal cancer." | 5.13 | A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. ( Carnaghi, C; Comandone, A; Granetti, C; Lorusso, V; Mari, E; Oliva, C; Pressiani, T; Rimassa, L; Ronzoni, M; Santoro, A; Siena, S; Zuradelli, M, 2008) |
| "Patients with metastatic colorectal cancer were treated with fluorouracil, leucovorin, and irinotecan and were also given ALVAC-CEA/B7." | 5.13 | Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. ( Benson, AB; Berinstein, NL; Caterini, J; Conry, RM; Cripps, C; Dalfen, R; Debenedette, M; Elias, I; Garett, C; Heim, WJ; Kaufman, HL; Kim-Schulze, S; Lenz, HJ; Marshall, J; Moore, M; Salha, D; Singh, D; Urba, WJ; Vogel, T; von Mehren, M; Yu, M, 2008) |
| "Stages I-III colorectal cancer patients (n = 753) were randomized to receive either surgery alone (control arm), surgery plus postoperative portal venous infusion of 5-FU 500 mg/m(2) plus heparin given for 24 hours for seven consecutive days plus mitomycin C 10 mg/m(2) given on the first day (arm 2), or surgery and the same chemotherapy regimen administered by peripheral venous route (arm 3)." | 5.13 | Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. ( Aeberhard, P; Harder, F; Herrmann, R; Laffer, U; Lorenz, M; Maibach, R; Metzger, U; Zuber, M, 2008) |
| "To determine the maximum tolerated dose (MTD), characterize the principal toxicities, and assess the pharmacokinetics of EKB-569, an oral selective irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with capecitabine in patients with advanced colorectal cancer." | 5.13 | A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. ( Abbas, R; Boni, J; Bukowski, R; Croghan, G; Donehower, R; Erlichman, C; Hidalgo, M; Jimeno, A; Laheru, D; Martins, P; Messersmith, W; Pelley, R; Rudek, M; Zacharchuk, C, 2008) |
| "To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies." | 5.13 | Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. ( Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ, 2008) |
| " Progression-free survival (PFS) and toxicity were determined in 267 metastatic colorectal cancer (MCRC) patients who were treated with first-line capecitabine (CAP) plus irinotecan (CAPIRI), or CAP single agent in a prospective randomised phase III trial (CAIRO)." | 5.13 | GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Koopman, M; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T, 2008) |
| "PURPOSE To determine whether irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidines." | 5.13 | Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. ( Bodoky, G; Garay, C; Habboubi, N; Haller, DG; Koralewski, PM; Miller, WH; Olivatto, LO; Rothenberg, ML; Wong, AO, 2008) |
| "To evaluate the antitumor activity and toxicity of 5-fluorouracil (FU)/leucovorin (LV) and capecitabine (C) given with either oxaliplatin (OX) or camptothecin (CPT-11) in the treatment of chemotherapy naive patients with metastatic colorectal cancer." | 5.13 | Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. ( Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F, 2008) |
| "We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer." | 5.13 | A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. ( Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI, 2008) |
| " Effects of the ABCC2 genotype on the pharmacokinetics (PK) of irinotecan and the metabolites were examined in Japanese patients with metastatic colorectal cancer receiving irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)." | 5.13 | Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Matsunaga, M; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K, 2008) |
| "This study was conducted to assess the tolerability and efficacy of a ternary bimonthly irinotecan (CPT-11) - oxaliplatin (OHP) - infusional 5-fluorouracil (5-FU)/folinic acid (FA) combination in advanced colorectal cancer patients who had received prior CPT-11 and/or OHP-based chemotherapy regimen." | 5.13 | Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. ( Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S, 2008) |
| "XELIRI (capecitabine/irinotecan) is effective and well tolerated in metastatic colorectal cancer (mCRC)." | 5.13 | Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. ( Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S, 2008) |
| "Since the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin." | 5.13 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. ( Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ, 2008) |
| " A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer." | 5.13 | Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008) |
| "Patients with histologically proven primary colorectal cancer and bidimensionally measurable liver metastasis, not fully resectable based on technical inability to achieve R(0) resection, but potentially resectable after tumor reduction, were given FOLFIRINOX: oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), bolus fluorouracil 400 mg/m(2) and fluorouracil 46-h continuous IV infusion 2,400 mg/m(2), every 2 weeks for a maximum of 12 cycles." | 5.13 | Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. ( Delpero, JR; Desseigne, F; Guimbaud, R; Kramar, A; Mitry, E; Nordlinger, B; Portier, G; Quénet, F; Rivoire, M; Viret, F; Ychou, M, 2008) |
| "The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)." | 5.13 | Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008) |
| "A phase II trial was initiated to evaluate the efficacy and toxicity of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic colorectal cancer." | 5.13 | Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6. ( Au, GK; Chan, RT; Choi, CK; Ho, JW; Law, WL; Lui, L; Siu, S; Tung, SY, 2008) |
| "The objectives of this phase I/II study were to determine the maximum tolerated dose (MTD), characterise the principal toxicities in the phase I part and assess the efficacy in the phase II part of gefitinib, an oral selective inhibitor of the epidermal growth factor receptor, in combination with capecitabine in patients with advanced colorectal cancer (CRC)." | 5.13 | Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. ( Alonso, V; Bovio, H; Colomer, R; Cortés-Funes, H; Escudero, P; García-Carbonero, R; Grávalos, C; Jimeno, A; Juez, I; Sevilla, I; Vega-Villegas, ME, 2008) |
| "The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer." | 5.13 | Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008) |
| "We evaluated the outcome of 140 patients aged > or = 70 years of age who received first-line treatment for metastatic colorectal cancer within the German phase III trial of FUFOX (5-fluorouracil/leucovorin/oxaliplatin) versus CAPOX (capecitabine/oxaliplatin)." | 5.13 | Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. ( Arkenau, HT; Englisch-Fritz, C; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2008) |
| "Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC)." | 5.13 | Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. ( Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M, 2008) |
| "Food and Drug Administration reviewed a single, open-label, multicenter trial in which 463 patients with epidermal growth factor receptor-expressing metastatic colorectal cancer who had progressed on or following treatment with a regimen containing a fluoropyrimidine, oxaliplatin, and irinotecan were randomized (1:1) to receive best supportive care (BSC) with or without panitumumab (6 mg/kg every other week) administered until disease progression or intolerable toxicity." | 5.13 | U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. ( Cordoba-Rodriguez, R; Fuchs, C; Giusti, RM; Hughes, M; Keegan, P; Koti, K; Men, AY; Pazdur, R; Pilaro, AM; Rothmann, M; Shastri, K; Weiss, KD; Zhao, H, 2008) |
| "To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC)." | 5.13 | Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. ( Cassidy, J; Clarke, S; Couture, F; Díaz-Rubio, E; Figer, A; Koski, S; Lichinitser, M; Rivera, F; Saltz, LB; Scheithauer, W; Sirzén, F; Wong, R; Yang, TS, 2008) |
| "This two-part phase Ib/II study investigated the feasibility of administering cetuximab in combination with oxaliplatin and infusional 5-fluorouracil (5-FU)/folinic acid (FA) in a weekly schedule (AIO FUFOX protocol) as first-line treatment in patients with epidermal growth factor receptor-detectable advanced colorectal cancer." | 5.13 | Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ( Arnold, D; Dittrich, C; Herrmann, T; Höhler, T; Lordick, F; Riemann, J; Schmoll, HJ; Seufferlein, T; Wöll, E; Zubel, A, 2008) |
| " For this purpose, 110 XELOX (capecitabine/oxaliplatin)- or FUOX (fluorouracil/oxaliplatin)-treated metastatic colorectal cancer patients were selected prospectively for genotyping." | 5.13 | Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. ( Abad, A; Aparicio, J; Aranda, E; Díaz-Rubio, E; García, T; Ginés, A; Gómez-España, A; Guino, E; Maestu, I; Manzano, JL; Martinez-Balibrea, E; Martínez-Cardús, A; Sastre, J, 2008) |
| "Oxaliplatin combined with 5-fluorouracil (5-FU), with or without leucovorin (LV), is effective and well tolerated for first-line therapy of advanced colorectal cancer (CRC)." | 5.13 | A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. ( Bernard, SA; Bjarnason, GA; Braich, T; Desimone, P; Evars, JP; Hrushesky, WJ; Jolivet, J; Ramanathan, RK, 2008) |
| "TRIBE and TRIBE-2 studies demonstrated higher benefit from FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan)/bevacizumab compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX/bevacizumab as an upfront option for metastatic colorectal cancer patients, with more toxicities." | 5.12 | Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO. ( Antonuzzo, A; Boccaccino, A; Borelli, B; Buonadonna, A; Caponnetto, S; Conca, V; Cremolini, C; Daniel, F; Falcone, A; Lonardi, S; Marmorino, F; Masi, G; Pietrantonio, F; Raimondi, A; Rossini, D; Santini, D; Sbrana, A; Tomasello, G; Zaniboni, A, 2021) |
| "Guidelines recommend combined doublet backbone chemotherapy based on 5-fluorouracil and oxaliplatin (OX) or irinotecan (IR) as the first-line treatment options for metastatic colorectal cancer." | 5.12 | Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. ( Hui, F; Qi, X; Ren, T; Shen, Z; Wang, S; Xu, C; Zhang, Y; Zhao, Q, 2021) |
| "The antimetabolite, 5-Fluorouracil (5-FU), is the only chemotherapeutic drug to significantly improve 12-month survival rates of patients with Colorectal Cancer (CRC)." | 5.12 | Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer. ( Gong, J; Xu, H, 2021) |
| "Notwithstanding recent treatment advances in metastatic colorectal cancer (mCRC), chemotherapy with a combination of a fluoropyrimidine and a folate agent, often 5-fluorouracil (5-FU) and leucovorin, remains the backbone of treatment regimens for the majority of patients with mCRC." | 5.12 | Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. ( de Gramont, A; Glimelius, B; Marshall, J; Stintzing, S; Yoshino, T, 2021) |
| " In this review, we mainly focused on a multiple strategies by employing 5-Fluorouracil, curcumin, and lipids in Nano formulation for the possible treatment of colorectal cancer and its metastasis." | 5.12 | Multiple strategies with the synergistic approach for addressing colorectal cancer. ( Abdel-Daim, MM; Akhtar, MF; Akter, R; Albadrani, GM; Hari, B; Karthika, C; Najda, A; Rahman, MH; Sayed, AA, 2021) |
| "It is necessary to systematically evaluate the clinical efficacy and safety of bevacizumab (BEV) combined with 5-fluorouracil + leucovorin + oxaliplatin (FOLFOX) regimen in the treatment of advanced colorectal cancer." | 5.12 | The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis. ( Chen, D; Liu, W; Wang, X; You, J; Zhang, H; Zhang, S, 2021) |
| "Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer." | 5.12 | Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? ( Altés, A; Baiget, M; Marcuello, E; Menoyo, A; Rio, ED, 2006) |
| "The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established." | 5.12 | Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ( Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D, 2006) |
| "To investigate the safety/tolerability of the EGFR-antibody cetuximab when added to irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) for first-line treatment in patients with metastatic colorectal cancer (mCRC)." | 5.12 | Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. ( Folprecht, G; Köhne, CH; Lutz, MP; Nolting, A; Pollert, P; Schöffski, P; Seufferlein, T, 2006) |
| "A total of 630 patients with previously untreated metastatic colorectal cancer were randomised in a 2:1 fashion to receive bolus 5-fluorouracil (5-FU) and leucovorin (LV) plus either 3H1 (n = 422) or placebo (n = 208)." | 5.12 | Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. ( Bhatnagar, A; Bridgewater, J; Carmichael, J; Cassidy, J; Chong, G; Coleman, R; Cosgriff, TM; Coxon, F; Cunningham, D; Harper, PG; Hawkins, R; Jones, JJ; Moore, M; Northfelt, D; Redfern, CH; Sreedharan, S; Steward, W; Valone, F, 2006) |
| "We treated 74 patients with unresectable metastatic colorectal cancer (not selected for a neoadjuvant approach) with irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin (FOLFOXIRI and simplified FOLFOXIRI)." | 5.12 | Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M, 2006) |
| "Oxaliplatin and 5-fluorouracil (5-FU) act synergistically in colorectal cancer." | 5.12 | Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ( Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK, 2006) |
| "In metastatic colorectal cancer, a combination of leucovorin (LV) and fluorouracil (FU) with oxaliplatin (FOLFOX) 4 is a standard first-line regimen." | 5.12 | OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. ( André, T; Buyse, M; Carola, E; Cervantes, A; Chirivella, I; de Gramont, A; Etienne, PL; Figer, A; Flesch, M; Lledo, G; Louvet, C; Mineur, L; Perez-Staub, N; Rivera, F; Tabah-Fisch, I; Tournigand, C, 2006) |
| "Irinotecan or oxaliplatin combined with 5-fluorouracil (5-FU) +/- folinic acid (FA) has changed the treatment standards for metastatic colorectal cancer (CRC)." | 5.12 | Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. ( Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E, 2006) |
| "To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC)." | 5.12 | FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog ( Androulakis, N; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalykaki, A; Kouroussis, Ch; Mavroudis, D; Polyzos, A; Samonis, G; Souglakos, J; Syrigos, K; Tsousis, S; Vamvakas, L; Ziras, N, 2006) |
| " We evaluated oral rubitecan (5 days on, 2 days rest per week) on a continuous schedule, in patients with advanced colorectal cancer (CRC), who progressed after 5-fluorouracil based chemotherapy." | 5.12 | Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. ( Auber, M; Cai, C; Kiefer, G; Matin, K; Patel, H; Potter, D; Ramanathan, RK; Schmotzer, A; Stoller, R; Zamboni, W, 2006) |
| "The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity." | 5.12 | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. ( Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R, 2006) |
| "The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the elderly patients with metastatic colorectal cancer (MCRC)." | 5.12 | XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. ( Bolaños, M; Casado, E; De Castro, J; de Mon, MA; Escudero, P; Feliu, J; Galán, A; González-Barón, M; Lopez-Gómez, L; Losa, F; Salud, A; Vicent, JM; Yubero, A, 2006) |
| "Determine the toxicity, tolerability, and pharmacokinetics of SU5416, a vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, coadministered with bolus 5-fluorouracil (5-FU), leucovorin, and irinotecan (IFL) in untreated patients with metastatic colorectal cancer." | 5.12 | Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. ( Berlin, JD; Cropp, GF; Donnelly, E; Fleischer, AC; Hande, KR; Hannah, AL; Lockhart, AC; Rothenberg, ML; Schaaf, LJ; Schumaker, RD, 2006) |
| "To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer." | 5.12 | Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX, 2006) |
| "In advanced colorectal cancer previously treated with oxaliplatin, efficacy of irinotecan-based chemotherapy is poor and the best regimen is not defined." | 5.12 | A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. ( André, T; Artru, P; de Gramont, A; Flesch, M; Landi, B; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Plantade, A, 2006) |
| "The purpose of this study was to evaluate the antitumor activity and toxicity of fixed sequences of capecitabine/oxaliplatin followed by capecitabine/irinotecan in patients with previously untreated metastatic colorectal cancer." | 5.12 | Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer. ( Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F, 2006) |
| "To evaluate the efficacy and tolerance of the gemcitabine/oxaliplatin (GEMOX) combination as second-line chemotherapy for patients with advanced colorectal cancer (CRC) pretreated with an irinotecan (CPT-11)/5-fluorouracil (5-FU)/leucovorin (LV) regimen." | 5.12 | Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. ( Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N, 2006) |
| "To examine whether carbogen and nicotinamide increases 5-fluorouracil (5-FU) delivery to colorectal cancer metastases." | 5.12 | Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. ( Aboagye, EO; Gupta, N; Hoskin, PJ; Jones, T; Kötz, B; Osman, S; Phillips, R; Price, PM; Saleem, A; Vernon, C; Wasan, H, 2006) |
| "Oxaliplatin (OXA), raltitrexed (RTX), 5-fluorouracil (FU) and folinic acid (FA) have shown activity in metastatic colorectal cancer, radioenhancing effect and synergism when combined." | 5.12 | Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study. ( Avallone, A; Budillon, A; Cascini, LG; Comella, P; Delrio, P; Guida, C; Lastoria, S; Marone, P; Morrica, B; Parisi, V; Petrillo, A; Tatangelo, F, 2006) |
| "COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib." | 5.12 | Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006) |
| "The aim of the study was to verify the efficacy and safety of the addition of celecoxib to FOLFIRI combination therapy in patients affected by advanced colorectal cancer." | 5.12 | FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). ( Colucci, G; Di Renzo, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Mallamaci, R; Pezzella, G; Romito, S, 2006) |
| "The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluorouracil/levofolinic acid combination regimen as first-line chemotherapy for elderly patients with advanced/metastatic colorectal cancer." | 5.12 | Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas. ( Bordonaro, R; Borsellino, N; Callari, A; Caruso, M; Cicero, G; Ferraù, F; Gebbia, V; Tirrito, ML; Tralongo, P; Valenza, R; Verderame, F, 2006) |
| "To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer." | 5.12 | [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. ( Chen, JZ; Liao, WJ; Luo, RC; Zheng, H, 2006) |
| "We conducted two phase II trials evaluating the combination of 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) as first-line treatment in 74 metastatic colorectal cancer patients." | 5.12 | First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. ( Allegrini, G; Andreuccetti, M; Barbara, C; Brunetti, IM; Bursi, S; Cerri, E; Cupini, S; Falcone, A; Loupakis, F; Marcucci, L; Masi, G; Murr, R; Ricci, S, 2006) |
| "The purpose of the study was to evaluate the influence of baseline haemoglobin level in predicting response to 5-fluorouracil (5FU)-based first-line chemotherapy in advanced colorectal cancer patients." | 5.12 | The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. ( Aglietta, M; Alabiso, I; Alabiso, O; Berruti, A; Bitossi, R; Brizzi, MP; Dogliotti, L; Forti, L; Gorzegno, G; Harris, A; Magnino, A; Miraglia, S; Saini, A; Sculli, CM; Sperti, E; Tampellini, M, 2006) |
| "In a prospective study, 250 metastatic colorectal cancer patients were treated with irinotecan, fluorouracil, and leucovorin as first-line treatment." | 5.12 | The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. ( Biason, P; Boccalon, M; Bonura, S; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Pangher, V; Errante, D; Frustaci, S; Gaion, F; Galligioni, E; Giusto, M; Medici, M; Pasetto, LM; Pessa, S; Russo, A; Sandri, P; Toffoli, G, 2006) |
| "LV5FU2 with high-dose leucovorin (LV), weekly infusional 5-fluorouracil (5FU) (AIO schedule) and raltitrexed have been demonstrated to be active agents in first-line treatment of colorectal cancer." | 5.12 | Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial. ( Bedenne, L; Berger, C; Bouche, O; Cassan, P; Ducreux, M; Dunant, A; Fournet, J; Leduc, B; Mousseau, M; Pignon, JP; Raoul, JL, 2006) |
| "We investigated whether the determination of orotate phosphoribosyltransferase (OPRT) and thymidylate synthase (TYMS) polymorphisms could predict the toxicity of 5-fluorouracil (5-FU) in colorectal cancer patients." | 5.12 | Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. ( Hirayama, R; Ichikawa, W; Sasaki, Y; Suto, K; Takahashi, T, 2006) |
| "Previously, we reported results of Intergroup N9741, which compared standard bolus fluorouracil (FU), leucovorin, plus irinotecan (IFL) with infused FU, leucovorin, plus oxaliplatin (FOLFOX4) and irinotecan plus oxaliplatin in patients with untreated metastatic colorectal cancer." | 5.12 | Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. ( Alberts, S; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2006) |
| "To provide bevacizumab (BV) -based therapy to patients with advanced colorectal cancers (CRC) who had exhausted standard chemotherapy options, and to evaluate the response to BV combined with fluorouracil (FU) and leucovorin (LV) in this patient population." | 5.12 | Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. ( Boron, M; Chen, HX; Grochow, L; Jaffe, C; Kaplan, RS; Mooney, M; Mosby, K; Rubinstein, L; Vena, D; Zwiebel, J, 2006) |
| " Capecitabine plus irinotecan appears to be a feasible first-line treatment for patients with advanced colorectal carcinoma." | 5.12 | Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. ( Akkermans-Vogelaar, JM; Antonini, NF; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Punt, CJ; Rodenburg, CJ; Vreugdenhil, G; Wals, J, 2006) |
| "We determined whether hepatic intra-arterial infusion of 5-fluorouracil (5-FU) in patients with synchronous hepatic metastases from colorectal cancer, in whom the primary lesion was resectable but hepatic metastatic lesions were non-resectable helped improve survival time when administered on the basis of the results of the anticancer drug sensitivity test." | 5.12 | Repeated hepatic intra-arterial chemotherapy based on results of anticancer drug sensitivity test in patients with synchronous hepatic metastases from colorectal cancer. ( Isogai, A; Kubota, S; Matsuoka, H; Nagaya, M; Tsukikawa, S; Yanagi, Y, 2006) |
| "Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxicity profiles are not overlapping, and both drugs have shown at least additivity with folinic acid-modulated 5-fluorouracil (5FU)." | 5.12 | Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. ( Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C, 2006) |
| "To evaluate the clinical activity and toxicity of capecitabine plus irinotecan as first-line therapy for patients with metastatic colorectal cancer (mCRC), and to describe the association of expression of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) with antitumor activity." | 5.12 | Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. ( Andria, M; Dhami, M; Diasio, RB; Godfrey, T; Gold, PJ; Kovatich, AJ; Lund, KA; Meropol, NJ; Mitchell, E; Schwarting, R, 2006) |
| "Until recently, fluorouracil (F) and leucovorin (L) had been considered the standard therapy for patients with colorectal cancer." | 5.12 | Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. ( Aabo, K; Bjerregaard, B; Eckhoff, L; Jakobsen, A; Mortensen, JP; Pfeiffer, P; Sandberg, E; Schønnemann, K, 2006) |
| "The aim of the study was to assess the impact of an eicosapentanoic acid-containing protein and energy dense oral nutritional supplement (EPA-ONS) on nutritional and inflammatory status, quality of life (QOL), plasma phospholipids (PPL) and cytokine profile, tolerance of irinotecan-containing chemotherapy and EPA-ONS in patients with advanced colorectal cancer (CRC) receiving chemotherapy." | 5.12 | Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. ( Beale, PJ; Childs, A; Clarke, SJ; Read, JA; Smith, N; Volker, DH, 2007) |
| "In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer." | 5.12 | Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. ( Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX, 2006) |
| "Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)." | 5.12 | Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007) |
| "To characterize the efficacy and safety of palifermin in reducing the incidence of oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal cancer (CRC) receiving fluorouracil/leucovorin (FU/LV) chemotherapy." | 5.12 | Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. ( Abdi, E; Cesano, A; Chen, MG; Clarke, S; Davis, ID; Gayko, U; Gutheil, J; Rosen, LS; Schnell, FM; Zalcberg, J, 2006) |
| "In a multicenter trial, we randomly assigned 173 patients with completely resected (R0) hepatic metastases from colorectal cancer to surgery alone and observation (87 patients) or to surgery followed by 6 months of systemic adjuvant chemotherapy with a fluorouracil and folinic acid monthly regimen (86 patients)." | 5.12 | Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. ( Bedenne, L; Belghiti, J; Bosset, JF; Bouche, O; Bugat, R; Elias, D; Guimbaud, R; Lazorthes, F; Nordlinger, B; Piedbois, P; Portier, G; Rougier, P; Saric, J, 2006) |
| "This study provides strong arguments indicating that IPCH with oxaliplatin is better tolerated than EPIC with mitomycin C and 5-FU, and is twice as efficient in curing residual peritoneal carcinomatosis measuring less than 1 mm." | 5.12 | Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. ( Benizri, E; Di Pietrantonio, D; Elias, D; Malka, D; Menegon, P; Raynard, B, 2007) |
| "This phase II randomised trial compares oxaliplatin plus protracted infusion of 5-fluorouracil (pviFOX) or oxaliplatin plus capecitabine (XELOX) in the first-line treatment of advanced colorectal cancer (ACRC)." | 5.12 | Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). ( Ballardini, P; Di Fabio, F; Gentile, AL; Giaquinta, S; Lelli, G; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL, 2006) |
| "To assess the toxicity and dose delivery of weekly bolus 5-fluorouracil (5-FU) at 425 mg/m(2) plus low-dose folinic acid (FA) for 24 weeks as adjuvant treatment for colorectal cancer." | 5.12 | Weekly fluorouracil at 425 mg/m(2) plus low-dose folinic acid for 24 weeks as adjuvant treatment for colorectal cancer: assessment of toxicity and delivery. ( Gollins, SW; Ramani, VS; Wong, H, 2006) |
| "Irinotecan at 180 mg/m2 combined with an infusional 5-fluorouracil/leucovorin (5-FU/LV) regimen (FOLFIRI) is a standard first line therapy for metastatic colorectal cancer (mCRC)." | 5.12 | Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. ( Bressole, F; Chalbos, P; Debrigode, C; Desseigne, F; Duffour, J; Gourgou, S; Mineur, L; Pinguet, F; Poujol, S; Ychou, M, 2007) |
| "The purpose of this study was to compare the activity and toxicity of an irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) combination with a standard regimen of 5FU and LV, in patients with advanced colorectal carcinoma." | 5.12 | A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Andreadis, C; Gennatas, C; Michalaki, V; Mouratidou, D; Pafiti, A; Papaxoinis, G; Tsavaris, N, 2006) |
| "Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall survival in advanced colorectal cancer (CRC)." | 5.12 | Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. ( Barone, C; Basso, M; Cassano, A; D'Argento, E; Di Leonardo, G; Landriscina, M; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N, 2007) |
| " This phase I/II dose-finding study evaluated gefitinib in combination with a 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI-AIO) regimen in patients with metastatic colorectal cancer." | 5.12 | Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). ( Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J, 2006) |
| "To determine the maximum tolerated doses (MTD), toxicities, efficacy, and pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and leucovorin (IFL) in patients with previously untreated advanced colorectal cancer." | 5.12 | Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ( Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX, 2007) |
| "This open-label, phase IB study was undertaken to determine the safety/toxicity profile and recommended dose of oral once-daily PTK787/ZK 222584 (PTK/ZK) combined with oxaliplatin/5-fluorouracil (5-FU)/leucovorin (FOLFOX4) chemotherapy in patients with advanced colorectal cancer." | 5.12 | A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. ( Bartel, C; Henry, A; Laurent, D; Masson, E; Poethig, M; Steward, W; Thomas, AL; Trarbach, T; Vanhoefer, U; Wang, J; Wiedenmann, B, 2007) |
| " Infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) is a standard therapy for colorectal cancer." | 5.12 | Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. ( Bolling, C; Brennscheidt, U; Cassidy, J; Díaz-Rubio, E; Fettner, S; Feyereislova, A; Hanauske, AR; Jones, RJ; Rakhit, A; Sastre, J, 2007) |
| "This study was designed to measure the dihydrouracil (UH(2))/uracil (U) ratio in plasma as a surrogate marker for dihydropyrimidine dehydrogenase (DPD) activity and to investigate the relationships of the UH(2)/U ratios in plasma with the toxicities of 5-fluorouracil (5-FU)-based adjuvant chemotherapy and 5-FU plasma concentrations in colorectal cancer patients." | 5.12 | The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. ( Chen, G; Chen, YB; Li, S; Lu, ZH; Pan, ZZ; Wan, de S; Wang, GQ; Zhou, ZW, 2007) |
| "A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan/5-fluorouracil/leucovorin (CPT-11/5-FU/LV (AIO schedule)) as salvage treatment in patients with metastatic colorectal cancer." | 5.12 | Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Pallis, A; Souglakos, J; Vardakis, N, 2007) |
| "We conducted a randomised phase II study to compare irinotecan monotherapy with irinotecan in combination with infusional 5-fluorouracil/folinic acid (5-FU/FA) regarding efficacy and safety of these regimens in second-line therapy after failed fluoropyrimidine therapy in patients with metastatic colorectal cancer (mCRC)." | 5.12 | A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. ( Arnold, D; Graeven, U; Heuer, T; Nusch, A; Porschen, R; Reinacher-Schick, A; Schmiegel, W, 2007) |
| "Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone." | 5.12 | Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. ( Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007) |
| "Patients with previously untreated metastatic colorectal cancer were enrolled in a phase II trial of infusional 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), bevacizumab and erlotinib." | 5.12 | Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. ( Battu, S; Bhargava, P; Blaszkowsky, L; Earle, CC; Enzinger, P; Fuchs, CS; Lawrence, C; Mayer, RJ; Meyerhardt, JA; Ryan, DP; Stuart, K; Zhu, AX, 2007) |
| "The purpose of the present study was to evaluate the differences in the sequence of administration of 5-fluorouracil (5-FU)/leucovorin (LV) followed by irinotecan (CPT-11), or CPT-11 followed by 5-FU/LV in advanced colorectal cancer (ACC)." | 5.12 | Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study. ( Adoniou, E; Bacoyiannis, C; Felekouras, E; Gryniatsos, J; Kosmas, C; Papadoniou, N; Papalambros, E; Papastratis, G; Polyzos, A; Sigala, F; Skopelitis, H; Tsavaris, N; Zacharakis, M; Zografos, G, 2007) |
| "The objective of the present study was to evaluate the gene expression of the DNA mismatch repair gene MSH2 as a predictive marker in advanced colorectal cancer (CRC) treated with first-line capecitabine." | 5.12 | Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Jensen, LH, 2007) |
| "To compare the use of capecitabine plus oxaliplatin (CAPOX) with infusional fluorouracil (FU)/folinic acid plus oxaliplatin (FUFOX) as first-line therapy for patients with metastatic colorectal cancer (MCRC)." | 5.12 | Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. ( Arkenau, HT; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2007) |
| "The aim of this phase III trial was to compare the efficacy and safety of capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion high-dose fluorouracil (FU) plus oxaliplatin (FUOX) regimens as first-line therapy for metastatic colorectal cancer (MCRC)." | 5.12 | Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri ( Abad, A; Aparicio, J; Aranda, E; Carrato, A; Chaves, M; Díaz-Rubio, E; Gómez-España, A; González-Flores, E; Losa, F; Massutí, B; Maurel, J; Queralt, B; Reina, JJ; Rivera, F; Sastre, J; Tabernero, J, 2007) |
| "Individually, oxaliplatin and irinotecan have substantial activity in metastatic colorectal cancer (CRC) in combination with 5-fluorouracil/leucovorin." | 5.12 | Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. ( Ames, MM; Erlichman, C; Goetz, MP; Krook, JE; McWilliams, RR; Morlan, BW; Rowland, KM; Salim, M, 2007) |
| "Gefitinib, an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, combined with chemotherapy, has shown efficacy as second-line treatment for advanced colorectal cancer (CRC)." | 5.12 | First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. ( Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L, 2007) |
| "We randomly assigned 820 patients with advanced colorectal cancer to receive either first-line treatment with capecitabine, second-line irinotecan, and third-line capecitabine plus oxaliplatin (sequential treatment; n=410) or first-line treatment capecitabine plus irinotecan and second-line capecitabine plus oxaliplatin (combination treatment; n=410)." | 5.12 | Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. ( Antonini, NF; Creemers, GM; Dalesio, O; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Loosveld, OJ; Mol, L; Punt, CJ; Rodenburg, CJ; Sinnige, HA; Slee, PHTJ; Tesselaar, ME; van Bochove, A; Vreugdenhil, G; Wals, J; Werter, MJ, 2007) |
| "To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide." | 5.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "This study was designed as a multicentre phase II trial to assess the efficacy and safety of gefitinib in association with capecitabine and oxaliplatin in patients with untreated metastatic colorectal cancer." | 5.12 | A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. ( Cognetti, F; Di Costanzo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Gasperoni, S; Gelibter, AJ; Giannarelli, D; Nuzzo, C; Pollera, CF; Signorelli, C; Zeuli, M, 2007) |
| "In the OPTIMOX1 trial, previously untreated patients with advanced colorectal cancer were randomly assigned to two different schedules of leucovorin, fluorouracil, and oxaliplatin that were administered until progression in the control arm or in a stop-and-go fashion in the experimental arm." | 5.12 | Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. ( Abrahantes, JC; André, T; Burzykowski, T; Buyse, M; Carola, E; Cervantes, A; Chirivella, I; de Gramont, A; Etienne, PL; Figer, A; Flesch, M; Lledo, G; Louvet, C; Mineur, L; Perez-Staub, N; Quinaux, E; Rivera, F; Tabah-Fisch, I; Tournigand, C, 2007) |
| "prospective, randomized, open-label trial in group of 204 patients with advanced colorectal cancer randomized to either chemotherapy with irinotecan+5-FU+leucovorin or supportive care alone (control group) between January 1999--January 2005 was performed." | 5.12 | Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer. ( Klek, S; Kulig, J; Popiela, T; Richter, P, 2007) |
| "The objective was to evaluate the efficacy and toxicity of leucovorin plus 5-fluorouracil combined with oxaliplatin (modified FOLFOX regimen) every 2 weeks on previously untreated advanced colorectal cancer patients in the Chinese population." | 5.12 | A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. ( Qiu, F; Tang, XM; Tao, QS; Xiang, XJ; Xiong, JP; Xu, J; Yu, F; Zhang, L; Zhong, LX, 2007) |
| "An economic evaluation of the irinotecan, leucovorin, 5-fluorouracil (FOLFIRI) combination versus the irinotecan, oxaliplatin, leucovorin, 5-fluorouracil (FOLFOXIRI) regimen in patients with metastatic colorectal cancer was performed in the context of a randomised phase III study." | 5.12 | Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece. ( Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P, 2007) |
| "Capecitabine results in superior response rate, improved safety, and improved convenience compared with 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (MCRC)." | 5.12 | Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. ( Bexon, A; Diamandidis, D; Eckhardt, SG; Javle, M; Justice, GR; Keiser, W; Lee, FC; Liebmann, JE; Lin, E; Patt, YZ; Salvatore, JR, 2007) |
| "To evaluate the maximum tolerated dose and dose-limiting toxicity (DLT) of 10-hydroxy-camptothecin (10-HCPT) in HFL regimen for the treatment of advanced colorectal cancer (CRC)." | 5.12 | [10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer]. ( Cai, RG; Chen, SS; Chu, DT; Wu, F; Zhang, HG, 2007) |
| "To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer." | 5.12 | A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study ( Adenis, A; Bécouarn, Y; Boucher, E; Cany, L; Cvitkovic, F; Jacob, JH; Montoto-Grillot, C; Senesse, P; Thézenas, S; Ychou, M, 2007) |
| "A phase I/II study was performed to determine the safety and activity of a capecitabine plus oxaliplatin and irinotecan (COI) regimen using capecitabine concurrently with oxaliplatin and irinotecan in previously untreated patients with metastatic colorectal cancer." | 5.12 | Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. ( Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S, 2007) |
| "To evaluate the efficacy and toxicity of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every 2 weeks on previously untreated advanced colorectal cancer patients in Chinese population." | 5.12 | A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience. ( Bao, HY; Fang, WJ; Huang, S; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC, 2007) |
| "Capecitabine and oxaliplatin are both synergistically active against metastatic colorectal cancer (MCRC)." | 5.12 | Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. ( Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Er, O; Kaya, AO; Ozturk, B; Polat, M; Uner, A; Yamac, D; Yaman, E; Yildiz, R, 2007) |
| "Two consecutive studies have evaluated the efficacy of oxaliplatin combined with the Nordic bolus schedule of 5-fluorouracil and folinic acid as first-line treatment in metastatic non-resectable colorectal cancer." | 5.12 | Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. ( Berglund, A; Dahl, O; Glimelius, B; Ogreid, D; Sørbye, H; Tveit, KM; Wanderås, EH; Wentzel-Larsen, T, 2007) |
| "Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer." | 5.12 | A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ( Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007) |
| "We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers." | 5.12 | A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. ( Chang, HM; Kang, YK; Kim, MK; Kim, TW; Koo, DH; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ, 2007) |
| "This phase III study compared the safety and efficacy of the following three different irinotecan-containing regimens in the first-line treatment of metastatic colorectal cancer: irinotecan plus infusional fluorouracil (FU)/leucovorin (LV) (FOLFIRI), irinotecan plus bolus FU/LV (mIFL), and irinotecan plus oral capecitabine (CapeIRI)." | 5.12 | Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. ( Barrueco, J; Fuchs, CS; Ganju, V; Jeffery, M; Marshall, J; Mitchell, E; Richards, D; Schulz, J; Soufi-Mahjoubi, R; Wang, B; Wierzbicki, R, 2007) |
| "Tissue samples from patients with pathologic ((p)) stage III colorectal cancer were tested for sensitivity to 5-fluorouracil (5-FU)." | 5.12 | An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer. ( Isogai, A; Kubota, S; Matsuoka, H; Nagaya, M; Tsukikawa, S; Watanabe, T, 2007) |
| "This phase II study investigated the efficacy and safety of cetuximab combined with standard oxaliplatin-based chemotherapy (infusional fluorouracil, leucovorin, and oxaliplatin [FOLFOX-4]) in the first-line treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer (mCRC)." | 5.12 | Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. ( André, T; Casado, E; Cervantes, A; Ciardiello, F; de Gramont, A; Díaz-Rubio, E; Humblet, Y; Kisker, O; Soulié, P; Tabernero, J; Tortora, G; Valera, JS; Van Cutsem, E; Van Laethem, JL; Verslype, C, 2007) |
| "1) To confirm the efficacy of irinotecan plus folinic acid/continuous 5-fluorouracil as bimonthly FOLFIRI regimen in metastatic colorectal cancer patients." | 5.12 | FOLFIRI chemotherapy for metastatic colorectal cancer patients. ( Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Tonusin, A, 2007) |
| "To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin." | 5.12 | Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. ( Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY, 2007) |
| "Chemotherapy with fluorouracil and folinic acid could improve survival of patients with stage II colorectal cancer, although the absolute improvements are small: assuming 5-year mortality without chemotherapy is 20%, the relative risk of death seen here translates into an absolute improvement in survival of 3." | 5.12 | Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. ( Barnwell, J; Gray, R; Hills, RK; Kerr, DJ; McConkey, C; Williams, NS, 2007) |
| "This multicenter, randomized trial compared overall response rate between pemetrexed plus irinotecan (ALIRI) and leucovorin-modulated 5-fluorouracil plus irinotecan (FOLFIRI) in patients with advanced colorectal cancer." | 5.12 | A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. ( Bazin, IS; Biakhov, MY; Blatter, J; Goldstein, D; Gorbounova, VA; Granov, DA; Hossain, AM; Kaiser, C; Ma, D; Underhill, C, 2007) |
| "In metastatic colorectal cancer, phase III studies have demonstrated the superiority of fluorouracil (FU) with leucovorin (LV) in combination with irinotecan or oxaliplatin over FU + LV alone." | 5.11 | FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. ( Achille, E; André, T; Buyse, M; Colin, P; Couteau, C; de Gramont, A; Flesh, M; Ganem, G; Landi, B; Lledo, G; Louvet, C; Mery-Mignard, D; Quinaux, E; Tournigand, C, 2004) |
| "Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin." | 5.11 | A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. ( Alberts, SR; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2004) |
| "This Nordic multicenter phase II study evaluated the efficacy and safety of oxaliplatin combined with the Nordic bolus schedule of fluorouracil (FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 5.11 | Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. ( Berglund, A; Braendengen, M; Dahl, O; Fokstuen, T; Glimelius, B; Sørbye, H; Tveit, KM; Øgreid, D, 2004) |
| "The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC)." | 5.11 | Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. ( Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G, 2004) |
| " In all, 18 patients with peritoneal and/or local metastases from colorectal adenocarcinoma underwent debulking surgery followed by 5-fluorouracil (5-FU) 550 mg m(-2) day(-1) i." | 5.11 | Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. ( Berglund, A; Glimelius, B; Graf, W; Hansson, J; Mahteme, H; Nygren, P; Påhlman, L, 2004) |
| "The current study was designed to evaluate the antitumor activity and toxicity of capecitabine and oxaliplatin in previously untreated patients with advanced colorectal carcinoma." | 5.11 | Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. ( Marshall, JL; Meropol, NJ; Shields, AF; Zalupski, MM, 2004) |
| "The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed." | 5.11 | A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004) |
| "Our objective was to determine the maximum tolerated dose (MTD) of sequential raltitrexed (Tomudex) and 5-fluorouracil (5-FU) by bolus administration every 3 weeks in patients with advanced colorectal cancer (aCRC) and appendiceal adenocarcinoma." | 5.11 | Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer. ( Bertino, J; Dimery, I; Endres, S; Kelsen, DK; Kemeny, N; Saltz, L; Schwartz, GK; Tong, W; Welch, M, 2004) |
| "This study evaluates the efficacy of capecitabine using data from a large, well-characterised population of patients with metastatic colorectal cancer (mCRC) treated in two identically designed phase III studies." | 5.11 | Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. ( Bukowski, RM; Cunningham, D; Dufour, P; Graeven, U; Harper, P; Hoff, PM; Lokich, J; Madajewicz, S; Maroun, JA; Marshall, JL; Mitchell, EP; Perez-Manga, G; Rougier, P; Schilsky, RL; Schmiegel, W; Schoelmerich, J; Sobrero, A; Van Cutsem, E, 2004) |
| "The purpose of this report is to evaluate the efficacy and toxicity (Tx) of a double modulation of 5-fluorouracil (5-FU) by trimetrexate (TMTX) and leucovorin (LV) in patients with advanced recurrent (inoperable) or metastatic colorectal cancer (ACC)." | 5.11 | Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. ( Bologna, F; Dominguez, ME; Lacava, JA; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Romero, AO; Salum, G; Vallejo, CT, 2004) |
| "This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer." | 5.11 | A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004) |
| "Irinotecan (CPT-11) and bolus 5-fluorouracil (5-FU)/leucovorin (LV) administered weekly for 4 weeks every 42 days (Saltz regimen) is active but substantially toxic in patients with metastatic colorectal cancer (CRC)." | 5.11 | Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer. ( Baba, E; Fujishima, H; Harada, M; Kikuchi, I; Mitsugi, K; Miyanaga, O; Nakano, S; Ueda, A, 2004) |
| "As single agents, irinotecan and oxaliplatin are active in colorectal cancer after fluorouracil (FU)-containing regimen failure." | 5.11 | Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. ( Bajetta, E; Beretta, E; Buzzoni, R; Cortinovis, D; Di Bartolomeo, M; Dognini, G; Ferrario, E; Toffolatti, L, 2004) |
| "Oxaliplatin (L-OHP), irinotecan (CPT-11) and 5-fluorouracil (5-FU) have shown their efficacy in metastatic colorectal cancer." | 5.11 | Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors. ( Abad, A; Antón, A; Carrato, A; Diaz-Rubio, E; Gallego, J; Manzano, JL; Marfa, X; Massutí, B; Yuste, AL, 2004) |
| "Irinotecan has proven anti-tumor activity as induction treatment in combination with 5-fluorouracil (5-FU) or as second-line treatment after 5-FU in patients with metastatic colorectal cancer." | 5.11 | Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. ( Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ, 2004) |
| "Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC)." | 5.11 | XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. ( Brunet, R; Butts, C; Cassidy, J; Conroy, T; Debraud, F; Díaz-Rubio, E; Figer, A; Grossmann, J; Sawada, N; Schöffski, P; Sobrero, A; Tabernero, J; Twelves, C; Van Cutsem, E, 2004) |
| "Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo." | 5.11 | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. ( Baron, A; Berlin, J; Cartwright, T; Fehrenbacher, L; Ferrara, N; Fyfe, G; Griffing, S; Hainsworth, J; Heim, W; Holmgren, E; Hurwitz, H; Kabbinavar, F; Novotny, W; Rogers, B; Ross, R, 2004) |
| "While several studies have reported that thymidylate synthase (TS) tumour expression can be a reliable predictive marker of clinical response to 5-Fluorouracil (5-FU) for advanced colorectal cancer patients, only a few studies that searched for predictive factors of irinotecan (CPT-11) clinical response are available." | 5.11 | Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. ( Chiriatti, A; Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, J; Zito, A, 2004) |
| "This phase II study examined bimonthly oxaliplatin (85 mg/m2) added to a continuous infusion of fluorouracil (3000 mg/m2 for 46 h following a 400 mg/m2 bolus), with leucovorin (LV) (150 mg/m2) administrated in a simplified way to patients with metastatic colorectal cancers (CRC) refractory or resistant to 5-fluorouracil (5-FU)." | 5.11 | Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens. ( Chao, TY; Chen, LT; Chen, PM; Chen, WS; Hsieh, RK; Liu, JH; Yang, TS, 2004) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 5.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 5.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients with advanced colorectal cancer (CRC)." | 5.11 | Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. ( Cunningham, D; Hill, ME; Norman, AR; Oates, J; Price, T; Rao, S; Ross, PJ; Shellito, P; Tebbutt, N, 2004) |
| "FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity." | 5.11 | Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004) |
| " In an effort to improve the therapeutic effect of a MAb-based regimen in colorectal carcinoma (CRC) patients, the effects of a combination of alpha-interferon (alpha-IFN), 5-fluorouracil (5-FU), granulocyte-macrophage colony-stimulating factor (GM-CSF) and mouse MAb17-1A was evaluated in 27 patients with metastatic disease." | 5.11 | Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. ( Frödin, JE; Liljefors, M; Mellstedt, H; Nilsson, B; Ragnhammar, P; Ullenhag, G, 2004) |
| "Bowel mucosal injury associated with 5-fluorouracil (5-FU) treatment might result in secondary lactose intolerance." | 5.11 | Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. ( Elomaa, I; Ikonen, M; Joensuu, H; Korpela, R; Ollus, A; Osterlund, P; Peuhkuri, K; Ruotsalainen, T, 2004) |
| "The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma." | 5.11 | First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. ( Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB, 2004) |
| "To evaluate the safety and efficacy of irinotecan (CPT-11) alternated with a weekly treatment for 4 weeks of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour 5-fluorouracil infusion (5-FU 48 h) as first-line chemotherapy for patients with advanced colorectal cancer (ACC)." | 5.11 | A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. ( Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A, 2004) |
| "The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)." | 5.11 | Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004) |
| "We evaluated quantitative measurement series (MS) with 18F-FDG and PET and compared different quantification methods for prediction of individual survival in patients with metastatic colorectal cancer receiving chemotherapy with 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX)." | 5.11 | Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. ( Burger, C; Dimitrakopoulou-Strauss, A; Irngartinger, G; Rudi, J; Rühl, A; Strauss, LG; Stremmel, W, 2004) |
| "To compare the effect of 5-fluorouracil (5-FU) portal vein infusion (PVI) for 7 days after radical resection, with intraluminal chemotherapy during operation for eliminating liver metastasis and elevating long-term prognosis in colorectal cancer." | 5.11 | [Comparing the effect of adjuvant chemotherapy by portal vein infusion with intraluminal chemotherapy for colorectal cancer]. ( Chen, G; Ding, PR; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, FL; Wu, XJ; Zhou, ZW, 2004) |
| " Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15)-->l-OHP+FU (days 2 and 16) (200, 85 and 600 mg m(-2), respectively) followed by 3 weeks of CI FU (200 mg m(-2) day(-1)) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m(-2))." | 5.11 | Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. ( Barni, S; Belvedere, O; Beretta, GD; Frontini, L; Grossi, F; Guglielmi, A; Labianca, R; Pella, N; Puglisi, F; Sobrero, A; Zaniboni, A, 2004) |
| "A phase II trial was designed to determine whether mistletoe extract can induce objective tumor response in patients with metastatic colorectal cancer resistant to 5-fluorouracil and leucovorin (5FU/LCV)-based chemotherapy." | 5.11 | Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. ( Bar-Sela, G; Haim, N, 2004) |
| "Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC)." | 5.11 | Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. ( Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E, 2004) |
| "This multicentre phase II study was designed to evaluate the antitumour activity and toxicity of bifractionated camptothecin (CPT-11) and 5-fluorouracil/ leucovorin (5-FU/LV) in the treatment of patients with metastatic colorectal cancer (MCC) who had been pretreated with 5-FU/LV-oxaliplatin (FOLFOX regimen)." | 5.11 | Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. ( Cesta, A; Lalli, A; Lullo, LD; Nuzzo, A; Rea, S; Recchia, F; Saggio, G, 2004) |
| "This phase I study was conducted to establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in combination with FOLFIRI, a standard regimen of irinotecan, leucovorin, and infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer." | 5.11 | Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. ( Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN, 2004) |
| "The combination of irinotecan and a fluoropyrimidine has been widely accepted as a treatment for advanced colorectal carcinoma." | 5.11 | Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy. ( Hiro, J; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Mori, K; Shirane, M; Tanaka, K; Yanagi, H, 2004) |
| "A combination of irinotecan 125 mg/m2, 5-fluorouracil (5-FU) 500 mg/m2, and leucovorin (LV) 20 mg/m2 (Saltz regimen; treatment on days 1, 8, 15, and 22 every 6 weeks) is widely used for the treatment of metastatic colorectal cancer." | 5.11 | Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. ( Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2004) |
| "In a previous phase I-II study we demonstrated that the FOLFOXIRI regimen [irinotecan 125-175 mg/m2 day 1, oxaliplatin 100 mg/m2 day 1, l-leucovorin (l-LV) 200 mg/m2 day 1, 5-fluorouracil (5-FU) 3800 mg/m2 as a 48-h chronomodulated continuous infusion starting on day 1, repeated every 2 weeks] has promising activity and efficacy in metastatic colorectal cancer." | 5.11 | First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. ( Allegrini, G; Andreuccetti, M; Brunetti, I; Cerri, E; Cupini, S; Falcone, A; Fontana, E; Marcucci, L; Masi, G; Ricci, S, 2004) |
| "The addition of oxaliplatin to fluorouracil (FU) and leucovorin (LV) improves the outcome of patients with colorectal cancer (CRC)." | 5.11 | Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. ( Benson, A; Brandt, DS; Burger, B; Garay, CA; Gupta, S; Gurtler, J; Hallman, D; Hochster, H; Kemeny, N; Kennedy, P; Polikoff, J; Shumaker, G; Wertheim, M, 2004) |
| "A weekly continuous 24-h infusion therapy with 5-fluorouracil (5-FU) preceded by a 2-h infusion of calcium folinate (CA-FA) was shown to be an effective first- and secondline treatment in advanced metastatic colorectal cancer." | 5.11 | Second-line treatment of advanced colorectal cancer with a weekly simultaneous 24-hour infusion of 5-fluorouracil and sodium-folinate: a multicentre phase II trial. ( Fritze, D; Kreuser, ED; Kuhfahl, J; Link, H; Pichlmeier, U; Schulte, F; Steinbrecher, C; Wagner, H; Wagner, T, 2004) |
| " Two clinical trials show that the addition of bevacizumab to a regimen of either fluorouracil plus leucovorin (FL) or FL combined with irinotecan (IFL), significantly improves response rate and time to tumour progression and increases overall survival for patients with advanced colorectal cancer (ACC)." | 5.11 | Bevacizumab for advanced colorectal cancer. ( Hadj Tahar, A, 2004) |
| "The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the first-line treatment of metastatic colorectal cancer (MCRC)." | 5.11 | Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. ( Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A, 2005) |
| "To determine the efficacy, impact on quality-of-life (QoL) and tolerability of two different irinotecan administration schedules in combination with capecitabine as first-line treatment of metastatic colorectal cancer." | 5.11 | A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. ( Bernhard, J; Borner, MM; Brauchli, P; Dietrich, D; Herrmann, R; Honegger, H; Koeberle, D; Lanz, D; Popescu, R; Rauch, D; Roth, AD; Saletti, P; Wernli, M, 2005) |
| "Fluorouracil (5-FU), oxaliplatin and irinotecan combinations improve time to tumor progression (TTP), objective response and overall survival (OS) in patients with metastatic colorectal cancer (MCRC)." | 5.11 | Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. ( Alberts, SR; Delaunoit, T; Findlay, BP; Fuchs, C; Goldberg, RM; Green, E; Krook, J; Morton, RF; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2005) |
| "We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of protracted venous infusion (PVI) 5-fluorouracil (5-FU) against the standard bolus monthly regimen of 5-FU/leucovorin (LV) given for 6 months as adjuvant treatment in colorectal cancer (CRC)." | 5.11 | A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, JR; Ross, PJ; Tait, D; Webb, A, 2005) |
| "Capecitabine and irinotecan are commonly used in the treatment of metastatic colorectal cancer (CRC)." | 5.11 | UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. ( Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H, 2005) |
| "Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC)." | 5.11 | Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. ( Hamm, JT; Hecht, JR; Kabbinavar, FF; Mass, R; McCleod, M; Nelson, B; Novotny, WF; Patel, T; Perrou, B; Schulz, J, 2005) |
| "Although irinotecan 350 mg m(-2) is a standard option for relapsed/refractory advanced colorectal cancer, there is some evidence that suggests that a higher dose may be more effective, with acceptable tolerability, following 5-fluorouracil (5-FU)." | 5.11 | Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. ( Bleiberg, H; Borner, M; Dirix, L; Gonzalez Baron, M; Gruia, G; Joosens, E; Morant, R; Roth, A; Sibaud, D; Van Belle, S; Van Cutsem, E; Van Laethem, JL, 2005) |
| "The objective of this study was to assess the efficacy and safety of two regimens of irinotecan, combined or alternated with bolus 5-fluorouracil (5-FU) and folinic acid (FA), and the Mayo Clinic regimen as first-line therapy for colorectal cancer (CRC)." | 5.11 | Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer. ( Artandi, M; Borner, M; Boussard, B; Carlsson, G; Espana, P; Graeven, U; Ridwelski, K; Rosales, AM; Schmiegel, W; Schölmerich, J, 2005) |
| "The aim of this study was to investigate the therapeutic value and safety of third-line treatment with mitomycin-C (MMC) and capecitabine (Xeloda) in patients with advanced colorectal cancer pretreated with combination regimens including 5-fluorouracil (5-FU), folinic acid (FA) and irinotecan (CPT-11) or 5-FU, FA and oxaliplatin (L-OHP)." | 5.11 | Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. ( Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS, 2005) |
| "The combination of 5-fluorouracil (5-FU) plus leucovorin (LV) with oxaliplatin has become one of the standard treatments for advanced colorectal cancer (CRC)." | 5.11 | Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Cervantes, A; Diaz-Rubio, E; Guallar, JL; Manzano, JL; Marcuello, E; Martinez-Villacampa, M; Massutí, B; Navarro, M; Sastre, J, 2005) |
| "A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC)." | 5.11 | Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. ( Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C, 2005) |
| "Although intravenous (IV) 5-fluorouracil (5-FU) and uracil/futraful (UFT) have comparable antitumour efficacy in the treatment of metastatic colorectal cancer (MCC), we wanted to assess which of these two regimens would be preferred by our patients." | 5.11 | Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. ( del Giglio, A; Lima, AP, 2005) |
| "Irinotecan (IRI) and oxaliplatin (OXA) are effective in the treatment of colorectal cancer." | 5.11 | Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. ( Aravantinos, G; Bacoyiannis, C; Bamias, A; Basdanis, G; Chalkidou, S; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Kalfarentzos, F; Kalofonos, HP; Karina, M; Kosmidis, P; Koutras, A; Papakostas, P; Pectasides, D; Samantas, E; Samelis, GF; Skarlos, D, 2005) |
| "To determine the tolerability of capecitabine in elderly patients with advanced colorectal cancer (CRC)." | 5.11 | Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. ( Bolaños, M; Casado, E; Escudero, P; Feliu, J; Gómez-Reina, MJ; González-Baron, M; Llosa, F; Lopez, R; Lopez-Gómez, L; Sanz-Lacalle, JJ; Vicent, JM; Yubero, A, 2005) |
| "Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody that inhibits tumor angiogenesis, has demonstrated survival benefit in patients with previously untreated metastatic colorectal cancer when combined with irinotecan/fluorouracil (FU)/leucovorin (LV; IFL)." | 5.11 | Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. ( Bergsland, E; Hambleton, J; Hurwitz, HI; Kabbinavar, FF; Mass, RD; Sarkar, S, 2005) |
| "Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma." | 5.11 | Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005) |
| "In a phase III trial, combining bevacizumab (BV)--a recombinant, humanized, monoclonal antibody targeting vascular endothelial growth factor--with irinotecan, bolus fluorouracil (FU), and leucovorin (LV; IFL) increased survival compared with IFL alone in first-line treatment of patients with metastatic colorectal cancer (CRC)." | 5.11 | Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. ( Berlin, J; Fehrenbacher, L; Hainsworth, JD; Hambleton, J; Heim, W; Holmgren, E; Hurwitz, HI; Kabbinavar, F; Novotny, WF, 2005) |
| "Irinotecan combined with continuous-infusion 5-fluorouracil (5FU) has been shown to be an effective and tolerable regimen in the treatment of metastatic colorectal cancer (MCRC)." | 5.11 | Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer. ( Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I, 2005) |
| "Between July 2001 and September 2002, 49 eligible patients were enrolled in an open-label phase II study to assess the efficacy and safety of first-line treatment with capecitabine/irinotecan in metastatic colorectal cancer." | 5.11 | Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. ( Asmar, L; Boehm, KA; Cartwright, T; Encarnacion, C; Lopez, T; Vukelja, SJ, 2005) |
| "Seventy-two patients suffering from a metastatic colorectal cancer received, as first line treatment, a combination chronotherapy with 5-FU and folinic acid (infused from 10 pm to 10 am with a peak at 4 am, respectively at doses of 700 and 300 mg/m2 per day) and carboplatin (infused at the dose of 40 mg/m2 per day from 10 am to 10 pm with a peak at 4 pm)." | 5.11 | [Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study]. ( Biquet, JF; David, A; Delforge, M; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Materne, R; Moeneclaey, N; Weerts, J, 2005) |
| "Seventeen colorectal cancer patients received as first (12 cases) or second line (5 cases) treatment a combined chronotherapy with CPT 11 (infused at day 1 from 2 to 8 am; peak at 5 am), given with 5 FU (700 mg/m2 per day ; days 2-5) and folinic acid (300 mg/m2 per day, days 2-5) both infused from 10 pm to 10 am with a peak at 4 am, and carboplatin (40 mg/m3/day - days 2-5 ; infused from 10 am to 10 pm - peak at 4 pm)." | 5.11 | [Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer]. ( David, A; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2005) |
| "The aim of this study was to determine in patients with previously untreated advanced colorectal cancer the maximum tolerated dose (MTD) and safety profile of irinotecan in combination with capecitabine, to identify a recommended dose and to determine the response rate and time to disease progression." | 5.11 | A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ( Bakker, JM; Falk, S; Groenewegen, G; Kerr, DJ; Maughan, T; Nortier, JW; Punt, CJ; Rea, DW; Richel, DJ; Semiond, D; Smit, JM; Steven, N; Ten Bokkel Huinink, WW, 2005) |
| "We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer." | 5.11 | Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. ( Agostara, B; Borsellino, N; Brunetti, C; Carrozza, F; Cartenì, G; Caruso, M; Chiarenza, M; Colucci, G; Cordio, S; Cramarossa, A; Di Bisceglie, M; Di Seri, M; Durini, E; Filippelli, G; Fortunato, S; Gebbia, N; Gebbia, V; Giuliani, F; Guida, T; Leonardi, V; Lopez, M; Lorusso, V; Maiello, E; Mancarella, S; Manzione, L; Misino, A; Montemurro, S; Nettis, G; Paoletti, G; Pezzella, G; Pisconti, S; Romito, S; Rosati, G; Valdesi, M; Valerio, MR, 2005) |
| "To verify the effectiveness of oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) in improving the surgical cure rate in advanced colorectal cancer, a multicenter randomized comparative study was conducted." | 5.11 | A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer. ( Kodaira, S; Kotake, K; Koyama, Y; Ohashi, Y, 2005) |
| "During surgery, 753 patients with stage II-III colorectal cancer were randomly assigned to systemic chemotherapy alone (379 with fluorouracil and folinic acid, and 374 with fluorouracil and levamisole), and 748 to postoperative regional chemotherapy with fluorouracil followed by systemic chemotherapy with fluorouracil and folinic acid (n=368) or with fluorouracil and levamisole (n=380)." | 5.11 | Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. ( Arnaud, JP; Baila, L; Bedenne, L; Bleiberg, H; Bouché, O; Conroy, T; Debois, M; Grobost, O; Guimares dos Santos, J; Lacourt, J; Lasser, P; Mackiewickz, R; Morin, T; Nordlinger, B; Ollier, JC; Rougier, P; Seitz, JF; van Cutsem, E; Wals, J; Wils, J, 2005) |
| "l-leucovorin (LV)/5-fluorouracil (5FU) may play an important role, as an adjuvant chemotherapy, in improving the survival of patients with stage III colorectal cancer." | 5.11 | Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer. ( Arii, K; Higashiguchi, T; Hotta, T; Matsuda, K; Oku, Y; Takifuji, K; Tominaga, T; Yamaue, H; Yokoyama, S, 2005) |
| "This study was designed to determine the effectiveness and tolerance of oxaliplatin, folinic acid (FA) and infusional 5-fluorouracil (5-FU) (FOLFOX-4) chemotherapy when used as a second-line treatment in patients with advanced colorectal cancer for whom an irinotecan-containing regimen failed." | 5.11 | Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience. ( Baek, JH; Bang, SM; Cho, EK; Han, SH; Lee, JH; Oh, JH; Park, SH; Shin, DB; Sung, JY, 2005) |
| " Glutamine may decrease chemotherapy-associated diarrhea." | 5.11 | A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. ( Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J, 2005) |
| "Protracted venous infusion 5-fluorouracil (5FU) combined with mitomycin C (MMC) has demonstrated significant activity against metastatic colorectal cancer." | 5.11 | Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. ( Chong, G; Cunningham, D; Dickson, JL; Hill, ME; Norman, AR; Oates, J; Price, TJ; Rao, S; Tebbutt, N, 2005) |
| "Building on results from Southwest Oncology Group trial 8905, this trial was designed to compare low-dose continuous infusion (LDCI) of 5-fluorouracil (5-FU) versus intermittent high-dose infusion (HDI) of 5-FU in disseminated colorectal cancer (CRC) for evidence of survival advantage based on dose intensity." | 5.11 | Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study. ( Bearden Iii, JD; Benedetti, JK; Hochster, H; Leichman, CG; Lenz, HJ; Macdonald, JS; Shields, AF; Wade Iii, JL; Zalupski, MM, 2005) |
| "To investigate the gefitinib, fluorouracil (FU), leucovorin, and oxaliplatin regimen (IFOX) in previously treated patients with metastatic colorectal cancer." | 5.11 | Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. ( Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA, 2005) |
| "5-Fluorouracil remains a key drug in the treatment of colorectal cancer, and the development of a simple and effective test for selecting patients likely to benefit from postoperative adjuvant chemotherapy is an important objective." | 5.11 | Correlation between expression of orotate phosphoribosyl transferase and 5-fluorouracil sensitivity, as measured by apoptosis index in colorectal cancer tissue. ( Kamano, T; Kawai, K; Matsuda, M; Sakamoto, K; Watabe, S, 2005) |
| "The aim of the current study was to evaluate the activity and toxicity of a combination of oxaliplatin with bolus fluorouracil and leucovorin in colorectal cancer (CRC) patients pretreated for advanced disease with various schedules including continuous fluorouracil infusion." | 5.11 | Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study. ( Buccilli, A; Ciccarese, M; Ferraresi, V; Gabriele, A; Gamucci, T; Giampaolo, MA; Giannarelli, D; Mansueto, G, 2005) |
| "HLA-A2-positive patients with confirmed newly diagnosed metastatic colorectal cancer and elevated serum carcinoembryonic antigen (CEA) were randomized to receive three cycles of standard chemotherapy (irinotecan/high-dose 5-fluorouracil/leucovorin) and vaccinations with CEA-derived CAP-1 peptide admixed with different adjuvants [CAP-1/granulocyte macrophage colony-stimulating factor/interleukin-2 (IL-2), CAP-1/dSLIM/IL-2, and CAP-1/IL-2]." | 5.11 | Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. ( Anderson, KS; Ansén, S; Bohlen, H; Diehl, V; Geisen, C; Gracien, E; Jurkiewicz, E; Nadler, LM; Schmidt, M; Weihrauch, MR; Wittig, B; Wolf, J; Xia, Z, 2005) |
| "We examined patients with previously untreated metastatic colorectal cancer, who were enrolled into two phase I/II trials of combination chemotherapy (irinotecan, leucovorin, and 5-fluorouracil) and daily oral gefitinib." | 5.11 | Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. ( Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP, 2005) |
| "A detailed questionnaire was completed after each chemotherapy cycle for patients with metastatic colorectal cancer enrolled in a phase I trial of oxaliplatin and capecitabine." | 5.11 | Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. ( Fioravanti, S; Grem, JL; Harold, N; Leonard, GD; Quinn, MG; Schuler, B; Thomas, RR; Wright, MA, 2005) |
| "A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 plus 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2 was assessed in 2 consecutive randomized trials in metastatic colorectal cancer (CRC)." | 5.11 | Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials. ( Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S, 2005) |
| "We tested the hypothesis that the combination of trimetrexate (TMTX) and capecitabine (CAP) would be active in patients with previously treated metastatic colorectal cancer (CRC)." | 5.11 | A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. ( Earle, M; Evans, T; Ferri, W; Friedland, D; Jacobs, SA; Matin, K; Pinkerton, R; Ramanathan, RK; Richards, T; Troetschel, M; Volkin, R; Wieand, S; Wong, MK, 2005) |
| "This randomised, open-label trial compared oral tegafur (FT)/leucovorin (LV) with the intravenous bolus 5-fluorouracil (5-FU)/LV as first-line chemotherapy for advanced colorectal cancer (CRC)." | 5.11 | Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. ( Arcusa, A; Batiste-Alentorn, E; Boleda, M; Campos, JM; Cirera, L; de Mendizábal, EV; de Olaguer, JP; Escudero, P; Galan, A; Guasch, I; Losa, F; Manzano, H; Méndez, M; Nogué, M; Saigí, E; Salud, A; Vicente, P, 2005) |
| "Patients with liver-only metastases from colorectal cancer deemed not optimally resectable by a surgeon with expertise in liver surgery received fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)." | 5.11 | Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. ( Alberts, SR; Dakhil, SR; Donohue, JH; Goldberg, RM; Horvath, WL; Levitt, R; Mahoney, MR; Nair, S; Rowland, K; Sargent, DJ; Sternfeld, WC, 2005) |
| "com) and infusional 5-fluorouracil (5-FU) as second-line therapy in metastatic colorectal cancer (MCRC)." | 5.11 | Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. ( Gamucci, T; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Morabito, A; Sarmiento, R; Torino, F; Vitale, S, 2005) |
| "To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients." | 5.11 | An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with bolus and continuous infusion of 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI regimen) as first-line treatment of elderly patients with metastatic colorectal cancer (MCC)." | 5.11 | Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N, 2005) |
| "Pemetrexed and irinotecan have demonstrated antitumor activity as single agents in lung, pancreatic, breast, and colorectal cancer (CRC)." | 5.11 | Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. ( Becker, K; Hochster, H; Hong, S; John, W; Kettner, E; Kroning, H; Lordick, F; Macdonald, J; Ramanathan, RK; Schmoll, HJ, 2005) |
| "5-fluorouracil (5-FU), irinotecan, and oxaliplatin are the most active drugs in advanced colorectal cancer (CRC), and survival is improved with patient exposure to all of them." | 5.11 | FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. ( Aparicio, J; Balcells, M; Busquier, I; Campos, JM; Fernandez-Martos, C; Llorca, C; Maestu, I; Perez-Enguix, D; Vincent, JM, 2005) |
| "Raltitrexed (Tomudex) is proven effective in metastatic colorectal cancer." | 5.10 | Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics. ( Balteskard, L; Edna, TH; Laino, R; Norum, J; Rønning, G; Wählby, L, 2002) |
| "Irinotecan and raltitrexed are active against advanced colorectal cancer, act through different mechanisms, and have non-overlapping toxicity profiles." | 5.10 | Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. ( Aparicio, J; de las Peñas, R; Farrés, J; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM; Yuste, AL, 2002) |
| "We evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV + 5-FU." | 5.10 | Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer. ( Diamantis, T; Dimitrakopoulos, A; Gennatas, K; Kosmas, C; Paliaros, P; Papastratis, G; Tsavaris, N; Tsipras, H; Vadiaka, M, 2002) |
| "To determine the feasibility, recommended doses, plasma pharmacokinetics, and antitumor activity of a biweekly chemotherapy regimen with oxaliplatin (L-OHP), irinotecan (CPT-11), infusional fluorouracil (5-FU), and leucovorin (LV) in metastatic colorectal cancer patients." | 5.10 | Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Conte, P; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Pfanner, E, 2002) |
| "We have investigated the efficacy, safety and quality of life profiles of three therapeutic combinations [irinotecan + leucovorin (LV)/5-fluorouracil (5-FU), oxaliplatin + LV/5-FU and irinotecan +oxaliplatin] in patients with metastatic colorectal cancer after failure of a 5-FU-based regimen, or whose disease had progressed within 6 months of the end of treatment." | 5.10 | Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. ( Bennouna, J; Ducreux, M; Hua, A; Lepille, D; Marre, A; Méry-Mignard, D; Mignot, L; Rougier, P, 2002) |
| "Overall results of this study indicate that the administration of clinically relevant single-agent doses of both capecitabine and oxaliplatin is feasible and seems to result in promising therapeutic activity in patients with advanced colorectal cancer." | 5.10 | Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. ( Huber, H; Kornek, GV; Längle, F; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B, 2002) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 5.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| "In the present study, we evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5-FU." | 5.10 | Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer. ( Gennatas, K; Kosmas, C; Kouraklis, G; Margaris, E; Papastratis, G; Rokana, S; Skopelitis, E; Tsavaris, N; Vadiaka, M; Xila, V; Zografos, G, 2002) |
| "Irinotecan (CPT-11) has been shown to prolong survival and improve quality of life in comparison to best supportive care in colorectal cancer patients with pretreatment of bolus 5-fluorouracil (5-FU)." | 5.10 | Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. ( Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F, 2002) |
| "We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting." | 5.10 | Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002) |
| "Most patients with colorectal cancer (CRC) who have failed initial 5-fluorouracil (5-FU) chemotherapy have worsening of disease-related symptoms (DRS) and quality of life (QOL)." | 5.10 | The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. ( Feld, R; Fields, A; Goel, R; Hedley, D; Jolivet, J; Lee, IM; Maroun, J; Michael, M; Moore, MJ; Oza, A; Pintilie, M, 2002) |
| "The purpose of this study was to evaluate the efficacy and tolerance of a combination of irinotecan, oxaliplatin, and 5-fluorouracil (5-FU)/leucovorin in advanced colorectal cancer (ACC)." | 5.10 | Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. ( Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; García-Foncillas, J; Martín-Algarra, S; Martínez-Monge, R; Rebollo, J; Rodríguez, J, 2002) |
| "This multicentre phase II study evaluated the efficacy and safety of irinotecan combined with the Nordic schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line therapy in patients with advanced colorectal cancer." | 5.10 | Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. ( Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM, 2002) |
| "Oxaliplatin (OXA) and irinotecan (IRI) are active drugs in first-line as well as second-line treatment of advanced colorectal cancer patients, their toxicity profiles are not overlapping, and both drugs have shown synergism with folinic acid-modulated 5-fluorouracil (5-FU)." | 5.10 | Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. ( Avallone, A; Casaretti, R; Comella, G; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Lapenta, L, 2002) |
| "The efficacy and safety of preoperative chemotherapy with carmofur (HCFU) for colorectal cancer were evaluated in a randomized controlled study involving 63 institutes in the Kanto area." | 5.10 | [Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study]. ( Ishikawa, H; Iwasaki, Y; Kanazawa, K; Kitajima, M; Kodaira, S; Kotake, K; Koyama, Y; Miyata, M; Nagamachi, Y; Omoto, R; Shida, S; Tajima, Y; Tamakuma, S, 2002) |
| "The purpose of this study was to evaluate the efficacy and tolerance of the bimonthly administration of oxaliplatin in combination with high-dose leucovorin and infusional 5-fluorouracil (5-FU) (FOLFOX2 regimen) in patients with advanced colorectal cancer (ACC) who did not respond or whose disease progressed within 3 months after front-line treatment with CPT-11-containing regimens." | 5.10 | Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). ( Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Panopoulos, C; Papadouris, S; Sarra, E; Souglakos, J; Vardakis, N, 2002) |
| "This phase II trial investigated the safety and efficacy of two doses of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, plus fluorouracil (FU)/leucovorin (LV) versus FU/LV alone in patients with metastatic colorectal cancer." | 5.10 | Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. ( Bergsland, E; Fehrenbacher, L; Griffing, S; Hurwitz, HI; Kabbinavar, F; Lieberman, G; Meropol, NJ; Novotny, WF, 2003) |
| "The effect of different dose intensities of 5-fluorouracil (5-FU) in advanced colorectal cancer was investigated." | 5.10 | Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. ( Berglund, A; Carlsson, G; Frödin, JE; Glimelius, B; Gustavsson, B; Hansen, F; Jakobsen, A; Kjaer, M; Madsen, EL; Poulsen, JP; Sandberg, E, 2002) |
| "The aim of this study was to investigate whether N-(phosphonacetyl)-L-aspartic acid (PALA) can enhance the activity of low-dose methotrexate (LD-MTX) modulated infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer." | 5.10 | High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. ( Baron, B; Bleiberg, H; Blijham, GH; Couvreur, ML; De Greve, J; Genicot, B; Jansen, RL; Kok, TC; Nortier, JW; Wagener, T; Wils, J, 2003) |
| "To evaluate the efficacy and safety of neoadjuvant treatment comprising weekly high-dose 5-fluorouracil (5-FU) as a 24-hour infusion, folinic acid (FA) and biweekly oxaliplatin (L-OHP), followed by metastatic resection in patients with primarily resectable liver metastases of colorectal cancer (CRC)." | 5.10 | Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. ( Baum, U; Brückl, W; Fuchs, F; Günther, K; Hahn, EG; Hanke, B; Hohenberger, W; Merkel, S; Ott, R; Papadopoulos, T; Reck, T; Riedel, C; Wein, A, 2003) |
| " We did a randomised trial to compare an intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of the colon or rectum, with metastases confined to the liver." | 5.10 | Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. ( Buckels, J; Cain, D; Kerr, DJ; Ledermann, J; Mayer, D; McArdle, CS; Schlag, PM; Sherlock, DJ; Stephens, RJ; Taylor, I, 2003) |
| "This phase II study was designed to evaluate the efficacy and toxicities of oral doxifluridine plus leucovorin as a randomized trial with those of intravenous 5-fluorouracil (5-FU) plus leucovorin in previously untreated metastatic colorectal cancer (CRC)." | 5.10 | Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin. ( Ahn, JH; Kang, YK; Kim, JC; Kim, JG; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Min, YJ; Yu, CS, 2003) |
| "To assess the relationship between systemic exposure to capecitabine metabolites and parameters of efficacy and safety in patients with advanced or metastatic colorectal cancer from two phase III studies." | 5.10 | Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. ( Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003) |
| "Capecitabine and oxaliplatin, two new agents with potential synergistic activity, have demonstrated promising antitumor efficacy in advanced colorectal cancer (ACC)." | 5.10 | Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. ( Depisch, D; Kornek, GV; Kovats, E; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B, 2003) |
| "Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC)." | 5.10 | Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. ( Boehme, M; Galle, PR; Gutzler, F; Moehler, M; Raeth, U; Rudi, J; Steinmann, S; Stremmel, W, 2003) |
| "Because no consensus exists regarding recommendable dose levels for irinotecan, an intrapatient dose escalation phase I-II study was initiated in previously treated patients with colorectal cancer." | 5.10 | Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage. ( Alvarez, E; Buesa, JM; Carrasco, J; Esteban, E; Fra, J; Jiménez Lacave, A; Muñiz, I; Sala, M; Viéitez, JM, 2003) |
| "The purpose of this study was to evaluate the prognostic value of quantitative dynamic FDG PET studies in patients with metastastic colorectal cancer receiving FOLFOX (fluorouracil, folinic acid and oxaliplatin) chemotherapy." | 5.10 | PET-FDG as predictor of therapy response in patients with colorectal carcinoma. ( Dimitrakopoulou-Strauss, A; Rudi, J; Strauss, LG, 2003) |
| "To test the activity of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in patients with colorectal cancer treated with adjuvant 5-fluorouracil (5-FU) plus leucovorin (LV) and suffering from mucositis." | 5.10 | Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature. ( Colarusso, D; Manzione, L; Rosati, G; Rossi, A, 2003) |
| " In preclinical models, there appears to be additive or synergistic effects when combining 5-Fluorouracil (5-FU) with nonsteroidal anti-inflammatory agents (NSAIDs) for the treatment of colorectal neoplasms." | 5.10 | Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. ( Ashfaq, R; Becerra, CR; Frenkel, EP; Gaynor, RB, 2003) |
| "In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)." | 5.10 | Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. ( Berlin, JD; Bigelow, RH; Burger, BG; Garay, CA; Gupta, S; Haller, DG; Hart, LL; Le Bail, N; Marshall, JL; Oza, AM; Ramanathan, RK; Rothenberg, ML, 2003) |
| "Our results suggest that irinotecan and MMC combination therapy is effective and well tolerated in patients with fluoropyrimidine-resistant metastatic colorectal cancer." | 5.10 | Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. ( Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y, 2003) |
| "Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil." | 5.10 | Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003) |
| "We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard bolus regimen of 5-FU and folinic acid (5-FU/FA) given for 6 months as adjuvant treatment in colorectal cancer." | 5.10 | Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, J; Ross, PJ; Saini, A; Tait, D, 2003) |
| "In this multicenter phase II study the efficacy and safety of the alternating schedule of irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and leucovorin (LV) were assessed as first-line chemotherapy in patients with metastatic colorectal cancer (CRC)." | 5.10 | A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer. ( Aparicio, J; Borrega, P; de la Puente, CG; Lorenzo, A; Moreno-Nogueira, JA; Pica, JM; Reina, JJ; Rueda, A; Salvador, J, 2003) |
| "Irinotecan (CPT-11) and raltitrexed are active against advanced colorectal cancer (ACC), act through different mechanisms, and have only partially overlapping toxicity profiles." | 5.10 | Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. ( Aparicio, J; Bosch, C; Busquier, I; Díaz, R; Fernández-Martos, C; Galán, A; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM, 2003) |
| "Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy of advanced colorectal cancer." | 5.10 | A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. ( Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J, 2003) |
| "To determine the activity of biweekly oxaliplatin, combined with weekly bolus fluorouracil (FU) and low-dose leucovorin (LV) chemotherapy (bFOL), as first-line therapy for patients with metastatic colorectal cancer." | 5.10 | Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. ( Chachoua, A; Escalon, J; Hochster, H; Muggia, F; Speyer, J; Zeleniuch-Jacquotte, A, 2003) |
| "The aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil." | 5.10 | Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. ( Bamias, A; Papamichael, D; Pavlidis, N; Syrigos, K, 2003) |
| "The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer." | 5.10 | Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study. ( Changchien, CR; Chen, JS; Chiang, JM; Hsieh, PS; Tang, R; Yang, TS; Yeh, CY, 2003) |
| "Although recent trials have raised concerns about the toxicity of raltitrexed monotherapy in patients with advanced colorectal cancer (aCRC), similar concerns have also been raised with other chemotherapy regimens in aCRC." | 5.10 | Lessons learned from raltitrexed--quality assurance, patient education and intensive supportive drugs to optimise tolerability. ( Garcia-Vargas, J; Thomas, RJ; Williams, M, 2003) |
| "This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer." | 5.10 | Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003) |
| "Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer." | 5.10 | Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. ( Cognetti, F; Ferraresi, V; Gabriele, A; Gamucci, T; Giannarelli, D; Nardoni, C; Pino, MS; Zeuli, M, 2003) |
| "To define the maximum-tolerated dose (MTD) and to evaluate the dose-limiting toxicities (DLTs) of the combination of capecitabine and irinotecan in patients with metastatic colorectal cancer." | 5.10 | Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. ( Achterrath, W; Frings, S; Harstrick, A; Rustum, YM; Schleucher, N; Seeber, S; Tewes, M; Vanhoefer, U; Wilke, HJ, 2003) |
| " irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) with hepatic arterial infusion (HAI) of pirarubicin in non-resectable liver metastases from colorectal cancer." | 5.10 | Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). ( Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L, 2003) |
| "To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after 5-fluorouracil (5-FU) plus leucovorin (LV) standard chemotherapy." | 5.10 | Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. ( Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N, 2003) |
| "To evaluate the toxicity and efficacy of a modified deGramont regimen of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in patients with advanced colorectal cancer who have progressed on at least one but not more than two prior chemotherapy regimens." | 5.10 | A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003) |
| "The tolerance and efficacy of oxaliplatin and irinotecan for metastatic colorectal cancer are unknown in elderly patients." | 5.10 | Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. ( Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L, 2003) |
| "The combination of irinotecan (CPT-11), oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) is one of the possibilities to overcome chemoresistance in advanced colorectal cancer (ACRC) patients." | 5.10 | A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. ( Bria, E; Garufi, C; Sperduti, I; Terzoli, E; Vanni, B; Zappalà, AM, 2003) |
| "We investigated the pharmacokinetics (PK), preliminary clinical results and toxicity of chronomodulated oxaliplatin (OHP) plus 5-fluorouracil (5-FU) without folinic acid (FA) in 13 patients with metastatic colorectal cancer." | 5.10 | Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer. ( Arpicco, S; Brusa, P; Bumma, C; Cattel, L; Infante, L; La Grotta, G; Passera, R, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 5.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "This multicenter, open-label, phase II study was performed to assess the efficacy and toxicity of irinotecan 350 mg/m2 intravenously every 3 weeks in patients with advanced colorectal cancer (CRC) previously treated with 5-fluorouracil (5-FU)." | 5.10 | A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil. ( Arizcun, A; Cruz, JJ; de la Torre, A; Diz, P; Duarte, I; España, P; García López, MJ; García-Girón, C; Martínez del Prado, P; Méndez, M; Navalon, M; Pujol, E; Salut, A, 2003) |
| "This study combined oxaliplatin with the Nordic bolus schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 5.10 | Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. ( Dahl, O; Sørbye, H, 2003) |
| ") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options." | 5.10 | Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002) |
| "Twenty-two patients with unresectable liver metastases from colorectal cancer were treated with continuous HAI of 300 mg/m2 5-fluorouracil for 5 days a week and 6 mg/m2 cisplatin for 2 hours on 5 consecutive days a week." | 5.10 | Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer. ( Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Okamura, T; Tajima, T; Toh, Y; Yamamoto, M, 2002) |
| "The combination of CPT-11 with 5-fluorouracil (5-FU) in advanced colorectal cancer (ACC) represents an attractive approach." | 5.10 | Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. ( Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kandilis, K; Kouroussis, C; Mavroudis, D; Sarra, E; Souglakos, J; Vamvakas, L; Ziras, N, 2002) |
| "Hand-foot syndrome (HFS) has been previously reported as a side effect in 45-56% of patients treated with capecitabine." | 5.10 | Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. ( Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED, 2002) |
| "The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)." | 5.10 | Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002) |
| "Two randomised studies were performed with trimetrexate (TMTX) as a biochemical modulator of 5-fluorouracil (5-FU)/leucovorin (LV) in advanced colorectal cancer (ACC), one in Europe and one in the United States." | 5.10 | Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer. ( Blanke, CD; Hammershaimb, L; Punt, CJ; Zhang, J, 2002) |
| "To study tolerability and efficacy of an intensified chronomodulated schedule of fluorouracil (5-FU) and l-folinic acid (l-FA) as first-line treatment of metastatic colorectal cancer, 5-FU was given near individually determined dose-limiting toxicity in a multicenter phase II trial." | 5.10 | Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. ( Adenis, A; Chevalier, V; Chipponi, J; Chollet, P; Coudert, B; Curé, H; Focan, C; Kwiatkowski, F; Lévi, F; Niezgodzki, G; Perpoint, B; Pezet, D; Tubiana-Mathieu, N, 2002) |
| "Cimetidine has been shown to have beneficial effects in colorectal cancer patients." | 5.10 | Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. ( Imaeda, Y; Kobayashi, K; Matsumoto, S; Okamoto, T; Suzuki, H; Umemoto, S, 2002) |
| "To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer." | 5.10 | Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. ( Ansari, RH; Bell, WN; Colwell, B; Levin, J; McGuirt, PV; Pazdur, R; Schilsky, RL; Thirlwell, MP; West, WH; White, RL; Wong, A; Yates, BB, 2002) |
| "To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer." | 5.10 | Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. ( Borner, MM; Brauchli, P; Castiglione-Gertsch, M; Dietrich, D; Goldhirsch, A; Hanselmann, S; Herrmann, R; Honegger, H; Morant, R; Müller, S; Pestalozzi, BC; Roth, AD; Saletti, P; Stupp, R; Wernli, M, 2002) |
| "This phase II study was designed to evaluate the efficacy and toxicity of 3-h interval sequential methotrexate (MTX) and 5-fluorouracil (5-FU) with leucovorin (LV) rescue in the treatment of patients with metastatic colorectal cancer." | 5.10 | Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer. ( Hamaguchi, T; Haruyama, K; Matsumura, Y; Muro, K; Shimada, Y; Shirao, K; Sugano, K; Yamada, Y, 2002) |
| "Results of recent trials comparing combination chemotherapy consisting of 5-fluorouracil (5-FU), folinic acid (FOL), and oxaliplatin, given either as flat (A) or chronomodulated (B) infusion for metastatic colorectal cancer, were subjected to pharmaco-economic evaluation." | 5.10 | Pharmaco-economic comparative evaluation of combination chronotherapy vs. standard chemotherapy for colorectal cancer. ( Focan, C, 2002) |
| "5-fluorouracil remains the standard therapy for patients with advanced/metastatic colorectal cancer." | 5.10 | Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study. ( Blackstock, AW; Case, D; Higgs, V; Melin, SA; Savage, P; Tomlinson, SK; White, DR, 2002) |
| "A phase II trial investigated the activity and toxicity of a bolus administration schedule of oxaliplatin, fluorouracil (5-FU), and leucovorin (LV) therapy in patients with untreated advanced colorectal cancer." | 5.10 | Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. ( Amadori, D; Cruciani, G; Giovanis, P; Marangolo, M; Nicolini, M; Oliverio, G; Panzini, I; Pasquini, E; Ravaioli, A; Rossi, A; Tassinari, D; Turci, D; Zumaglini, F, 2002) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC)." | 5.10 | Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. ( Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N, 2002) |
| "To evaluate the safety profile of capecitabine using data from a large, well-characterized population of patients with metastatic colorectal cancer treated in two phase II studies." | 5.10 | First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. ( Bajetta, E; Boyer, M; Bugat, R; Burger, U; Cassidy, J; Garin, A; Graeven, U; Hoff, P; Maroun, J; Marshall, J; McKendric, J; Osterwalder, B; Pérez-Manga, G; Rosso, R; Rougier, P; Schilsky, RL; Twelves, C; Van Cutsem, E, 2002) |
| "The aim of this multicenter prospective study was to evaluate the role of intratumoral parameters related to fluorouracil (FU) sensitivity in 103 metastatic colorectal cancer patients receiving FU-folinic acid." | 5.10 | Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. ( Bourgeon, A; Chamorey, E; Chazal, M; Delpero, JR; Etienne, MC; Formento, JL; Formento, P; Francoual, M; Laurent-Puig, P; Letoublon, C; Magné, N; Milano, G; Pezet, D; Renée, N; Rosty, C; Seitz, JF, 2002) |
| "To evaluate the activity and safety of an alternating schedule of irinotecan (CPT-11) with high-dose 5-fluorouracil (5-FU) given as a weekly 48-hour infusion in combination with leucovorin (LV) in the first-line treatment of metastatic colorectal cancer (MCRC) patients." | 5.10 | A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. ( Manzione, L; Reggiardo, G; Rosati, G; Rossi, A, 2002) |
| "The combination of irinotecan plus 5-fluorouracil and folinic acid has clinical and survival benefits over 5-fluorouracil and folinic acid alone in the setting of first line treatment of metastatic colorectal cancer." | 5.10 | Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. ( Cunningham, D; Falk, S; Jackson, D, 2002) |
| "To determine the maximum-tolerated dose (MTD) of a weekly schedule of irinotecan (CPT-11), leucovorin (LV), and a 24-hour infusion of fluorouracil (5-FU24h) as first-line chemotherapy in advanced colorectal cancer and to assess preliminary data on the antitumor activity." | 5.09 | Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. ( Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H, 1999) |
| "The aim of this prospective study was to assess the efficacy, clinical benefit and safety of CPT-11 (irinotecan) in patients with stringently-defined 5-fluorouracil-resistant metastatic colorectal cancer (CRC)." | 5.09 | Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). ( Alexopoulos, CG; Blanc, C; Bleiberg, H; Blijham, GH; Cholet, P; Cote, C; Cunningham, D; Dirix, L; Fillet, G; Hérait, P; Levi, F; Panagos, G; Punt, CJ; Symann, M; Ten Bokkel Huinink, WW; Unger, C; Van Cutsem, E; Van Groeningen, C; Vannetzel, JM; Wils, J, 1999) |
| "In a prospective multicenter trial, 279 patients with metastatic colorectal cancer who had failed 5-fluorouracil therapy were randomized 2:1 to receive either best supportive care (BSC) plus treatment with the topoisomerase I inhibitor, irinotecan (CPT-11; Rhône-Poulenc Rorer, Antony, France), at a dose of 350 mg/m2 every 3 weeks or BSC alone." | 5.09 | A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. ( Cunningham, D; Glimelius, B, 1999) |
| "In a multicenter phase III trial, 267 patients with nonbulky metastatic colorectal cancer who had failed first-line 5-fluorouracil (5-FU) therapy were randomized to receive second-line treatment with either the new topoisomerase agent, irinotecan (Rhône-Poulenc Rorer, Antony, France), or a high-dose infusional 5-FU regimen." | 5.09 | Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. ( Blijham, GH; Van Cutsem, E, 1999) |
| "Our objective was to establish the balance between costs and effects of treatment with Tomudex (raltitrexed) as an alternative to treatment with 5-fluorouracil (5-FU) plus leucovorin (LV) in patients with advanced colorectal cancer." | 5.09 | An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. ( Byttebier, G; Groener, MG; Rutten, FF; van Hout, BA; van Ineveld, BM, 1999) |
| "Twenty-six patients with metastatic colorectal cancer were given cisplatin (CDDP) and dacarbazine (DTIC)." | 5.09 | Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil. ( Akbulut, H; Arican, A; Cay, F; Demirkazik, A; Dinçol, D; Içli, F; Karaoğuz, H, 1999) |
| "The combination of 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (I-OHP) was shown to be both more active against metastatic colorectal carcinoma and better tolerated if the drug delivery rate was chronomodulated according to circadian rhythms rather than constant." | 5.09 | A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. ( Brienza, S; Chollet, P; Dogliotti, L; Focan, C; Le Rol, A; Letourneau, Y; Lévi, F; Llory, JF; Perpoint, B; Rotarski, M; Zidani, R, 1999) |
| "Data from a multinational phase III trial were analyzed to evaluate the use of in- and outpatient services for 373 patients with metastatic colorectal cancer being administered uracil/tegafur (in a molar ratio of 4:1 [UFT]) plus oral calcium folinate (Orzel) (N = 188) vs 5-fluorouracil (5-FU) plus oral calcium folinate (N = 185)." | 5.09 | Impact of uracil/tegafur plus oral calcium folinate on resource utilization. ( Ollendorf, D, 1999) |
| "This study was designed to determine if histopathologic evaluation of patients with resectable colorectal cancer following preoperative chemotherapy with uracil and tegafur with a molar ratio of 4:1 (UFT) could predict chemosensitivity to postoperative fluoropyrimidines to prevent recurrence of disease." | 5.09 | Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer. ( Fujii, M, 1999) |
| "To determine the maximum tolerable doses (MTDs) of irinotecan (CPT-11) and 5-fluorouracil (5-FU) plus levofolinic acid (LFA) administered together every two weeks, to define the toxicity profile of this regimen, and to have a preliminary evidence of its activity in the first-line management of advanced colorectal cancer patients." | 5.09 | Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group. ( Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Comis, S; De Vita, F; Faranda, A; Gravina, A; Orditura, M; Petrillo, A, 1999) |
| "This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil (5-FU)/leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer." | 5.09 | A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Agostinelli, R; Baldelli, AM; Barni, S; Cascinu, S; Catalano, G; Catalano, V; Frontini, L; Gasparini, G; Giuliodori, L; Labianca, R; Martignoni, G; Mattioli, R; Silva, RR, 1999) |
| "To evaluate the objective tumor response rates and toxicities of leucovorin (LV) plus fluorouracil (5-FU) cancer regimen combined with oxaliplatin (85 mg/m(2)) every 2 weeks on metastatic colorectal cancer patients with documented proof of progression while on bimonthly LV and 5-FU alone." | 5.09 | Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. ( André, T; Beerblock, K; Bensmaine, MA; Bouché, O; Carola, E; de Gramont, A; Desseigne, F; Dupont-André, G; François, E; Louvet, C; Lucas, V; Merrouche, Y; Morvan, F, 1999) |
| "To determine whether immunohistochemical thymidylate synthase (TS) quantitation predicts for clinical outcome in patients with advanced colorectal cancer treated by fluorouracil (FUra)-based chemotherapy." | 5.09 | Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. ( Antonelli, G; Aschele, C; Baldo, C; Casazza, S; Debernardis, D; Lionetto, R; Maley, F; Sobrero, A; Tunesi, G, 1999) |
| "Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs." | 5.09 | A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999) |
| "We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone." | 5.09 | Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. ( Bertino, JR; Blumgart, LH; Brennan, MF; Cohen, AM; Conti, JA; Fong, Y; Huang, Y; Kemeny, N; Shi, W; Stockman, J; Sullivan, D; Turnbull, AD, 1999) |
| "To study how adding oxaliplatin (l-OHP) to chronomodulated fluorouracil (5-FU)-leucovorin (LV) affected the objective response rate, as first-line treatment of metastatic colorectal cancer." | 5.09 | Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. ( Adam, R; Bertheaut-Cvitkovic, F; Chollet, P; Coudert, B; Faggiuolo, R; Focan, C; Giacchetti, S; Larregain-Fournier, D; Le Bail, N; Le Rol, A; Letourneau, Y; Lévi, F; Llory, JF; Misset, JL; Perpoint, B; Walter, S; Zidani, R, 2000) |
| "The potential of raltitrexed (Tomudex) in combination with 5-fluorouracil (5-FU) as treatment for advanced colorectal cancer has been investigated in two phase I clinical trials." | 5.09 | Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials. ( González Barón, M; Harstrick, A; Schwartz, GK, 1999) |
| "Thirty-seven colorectal cancer patients with grade 1-4 diarrhea (NCICTC) caused by chemotherapy with 5-FU-containing regimens, received oral loperamide at the initial dose of 4 mg followed by 4 mg every 8 h (total dose 16 mg/24 h)." | 5.09 | High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. ( Agostinelli, R; Amadori, D; Bichisao, E; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Luppi, G; Sansoni, E; Silingardi, V, 2000) |
| "CPT-11 (irinotecan) has shown activity in patients with advanced colorectal cancer resistant to leucovorin (LV) and 5-fluorouracil (5-FU)." | 5.09 | CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. ( André, T; Carola, E; Couteau, C; de Gramont, A; Gilles-Amar, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 1999) |
| "To investigate the pharmacokinetics of levamisole and a metabolite, p-hydroxylevamisole in patients with colorectal cancer treated with 5-fluorouracil (5-FU)." | 5.09 | Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil. ( Connolly, M; Ding, C; Gwilt, P; Kremer, A; Tempero, M, 2000) |
| "The aim of this study was to develop a phase II study gauging the contribution of a daily low-dose of carboplatin combined with 5-fluorouracil (5-FU) and folinic acid (FOL) in a chronotherapy schedule for advanced colorectal cancer patients." | 5.09 | Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial. ( Focan, C; Focan-Henrard, D; Kreutz, F; Moeneclaey, N, 2000) |
| "To evaluate in patients with advanced colorectal cancer (CRC) three treatment regimens of oral capecitabine in order to select the most appropriate regimen for testing in phase III." | 5.09 | Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. ( Allman, D; Burger, HU; Cassidy, J; Dalley, D; Dirix, L; Findlay, M; Kocha, W; Osterwalder, B; Pazdur, R; Schölmerich, J; Seitz, JF; Twelves, C; Van Cutsem, E; Verweij, J, 2000) |
| "In patients with colorectal cancer, selective high 5-fluorouracil concentration in the cancer tissue could be achieved by a combination of 5'-deoxy-5-fluorouridine and local immunotherapy with a mixture of OK-432 and fibrinogen." | 5.09 | Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen. ( Amano, M; Haba, A; Monden, M; Monden, T; Ohue, M; Sakita, I; Sekimoto, M; Tamaki, Y; Tomita, N, 2000) |
| "Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil." | 5.09 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. ( Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P, 2000) |
| "It has been shown that irinotecan is superior to infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer after 5-FU failure." | 5.09 | Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. ( Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C, 2000) |
| "Oxaliplatin is a novel platinum derivative, which, combined with 5-fluorouracil (5-FU), and folinic acid (FA), demonstrates synergistic activity in metastatic colorectal cancer (MCC)." | 5.09 | Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. ( Fountzilas, G; Janinis, J; Papagianopoulos, P; Papakostas, P; Samelis, G; Skarlos, D, 2000) |
| "MF (protracted infusion 5-fluorouracil (5-FU), 300 mg/m2/24 hours plus bolus mitomycin, 7 mg/m2 every 6 weeks, maximum 4 doses), was recently shown in a randomised trial to be superior to protracted 5-FU alone, as first-line chemotherapy for metastatic colorectal cancer (Ross et al." | 5.09 | Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. ( Chester, JD; Dent, JT; Ride, E; Seymour, MT; Wilson, G, 2000) |
| " One hundred thirty-six patients with metastatic colorectal cancer who failed to respond to a 5-fluorouracil-based treatment received 714 cycles of irinotecan." | 5.09 | Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. ( Adenis, A; Burki, F; Douillard, JY; Dufour, P; Marty, M; Mignard, D; Mousseau, M; Rougier, P; Wendling, JL; Ychou, M, 2000) |
| "The purpose of this study was to evaluate the efficacy, toxicity, and safety of outpatient chemotherapy with weekly high-dose 5-fluorouracil (HD-5FU) in previously treated patients (pts) with metastatic colorectal cancer." | 5.09 | Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer. ( Cohen, Y; Lavrenkov, K; Mermershtain, W, 2000) |
| "The aim of this study was to clarify whether increased 5-fluorouracil (5-FU) uptake by tumor tissue following preoperative UFT administration is a prognostic factor after surgery in colorectal cancer patients." | 5.09 | Preoperative UFT administration for patients with advanced colorectal cancer--increased uptake of 5-fluorouracil by tumor tissue is a prognostic factor. ( Ayabe, H; Eida, K; Furukawa, M; Ino, M; Ishikawa, H; Kunisaki, T; Nakagoe, T; Nakamura, Y; Nogawa, T; Sawai, T; Tobinaga, K; Tsuji, T, 2000) |
| "We performed combination chemotherapy adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in 11 patients with gastric cancer and 7 with colorectal cancer." | 5.09 | [The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer]. ( Iesato, H; Kamoshita, N; Kato, Y; Morishita, Y; Nagaoka, H; Ohwada, S; Ohya, T; Okabe, T; Takeyoshi, I; Yokomori, T, 2000) |
| " A regimen of sequential TMTX, FA and 5-fluorouracil (5-FU) has shown efficacy in patients with colorectal cancer." | 5.09 | Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO. ( Berdel, WE; Haboubi, N; Hohenberger, P; Kreuser, ED; Lochs, H; Szelényi, H; Thiel, E, 2000) |
| "To evaluate the safety and efficacy of a five-day regimen of oral 5-fluorouracil (5-FU) plus eniluracil (776C85) in patients with metastatic colorectal cancer (CRC)." | 5.09 | A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. ( Bonny, T; Bukowski, R; Burris, H; Hochster, H; Hohneker, J; Levin, J; Mani, S; O'Rourke, M; Schilsky, RL; Wall, JG, 2000) |
| "We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer." | 5.09 | Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure. ( Blijham, G; Jolain, B; Rougier, P; Schmitt, C; Van Cutsem, E, 1999) |
| "To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer." | 5.09 | Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. ( Beck, T; Bell, WN; Chevlen, EM; Hochster, H; Hohneker, J; Levin, J; Lokich, J; Mani, S; McGuirt, C; O'Rourke, MA; Schilsky, RL; Weaver, CH; White, R, 2000) |
| "In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen." | 5.09 | Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000) |
| "To analyse patients' travel and time costs associated with 2 alternative drug therapies for advanced colorectal cancer: raltitrexed and fluorouracil plus folinic acid (leucovorin) [5FU + FA]." | 5.09 | Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. ( Heyes, A; Palmer, MK; Sculpher, M, 2000) |
| "The aim of this study was to investigate the clinical pharmacokinetics of 5-fluorouracil (5-FU) and its major metabolite 5-fluoro-5,6-dihydrouracil (5-FDHU) in 20 colorectal cancer patients given two dose levels of 5-FU, 250 and 370 mg/m2, administered by i." | 5.09 | Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ( Allegrini, G; Barsanti, G; Battistoni, M; Bocci, G; Conte, PF; Danesi, R; Del Tacca, M; Di Paolo, AD; Falcone, A; Innocenti, F; Melosi, A, 2000) |
| "The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer." | 5.09 | Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000) |
| "The purpose of this study was to determine the efficacy of twice weekly hypo-fractionated radiation therapy (RT) plus continuous infusion 5-fluorouracil for unresectable or locally advanced colorectal cancer with synchronous metastases." | 5.09 | Avoidance of colostomy placement in advanced colorectal cancer with twice weekly hypofractionated radiation plus continuous infusion 5-fluorouracil. ( Breslin, T; Janjan, NA; Lenzi, R; Rich, TA; Skibber, J, 2000) |
| "In a randomized trial, the authors evaluated the possible adjuvant activity of intraportal chemotherapy (with 5-fluorouracil 500 mg/m2/day in continuous infusion for 7 days and mitomycin C 10 mg/m2 at day 7) administered after surgery to half of the patients who underwent a full resection for Dukes B2 or C colorectal cancer." | 5.09 | Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium). ( Beauduin, M; Brohée, D; Bury, J; Focan, C; Herman, ML; Lecomte, M; Vindevoghel, A, 2000) |
| "QUASAR is a large trial of adjuvant chemotherapy for colorectal cancer in which clinicians could choose to deliver a standard adjuvant cytotoxic chemotherapy regimen, 5-fluorouracil (5-FU) and L-folinic acid (L-FA), in either a once-weekly or a four-weekly schedule." | 5.09 | Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group. ( Barnwell, J; Gray, R; Kerr, DJ; McConkey, C, 2000) |
| "A phase II study was carried out to evaluate the efficacy and toxicity of a double biochemical modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and leucovorin (LV) in patients with advanced unresectable colorectal cancer." | 5.09 | Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer. ( Cizej, TE; Markovic, A; Plesnicar, A; Stabuc, B, 2000) |
| "The aim of this phase II study was to investigate the therapeutic value of second-line treatment with oxaliplatin, irinotecan (CPT-11) and mitomycin C (MMC) in patients with metastatic colorectal cancer pretreated with 5-fluorouracil (5-FU)-based chemotherapy." | 5.09 | Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. ( Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC, 2000) |
| "Univariate and multivariate analyses were performed on data from 370 5-fluorouracil (5-FU)-resistant advanced colorectal cancer patients treated with oxaliplatin (Eloxatin)/5-FU+/-folinic acid (FA) to identify prognostic factors for oxaliplatin-based treatment." | 5.09 | Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients. ( Bleiberg, H; Bleuzen, P; Brienza, S; Cvitkovic, E; de Gramont, A; Ducreux, M; François, E; Gamelin, E; Lévi, F; Marty, M; Simon, J, 2000) |
| "The aim of this randomised trial was to evaluate the activity and toxicity of a biweekly regimen including 6S-leucovorin-modulated 5-fluorouracil (LFA-5-FU), combined with either irinotecan (CPT-11 + LFA 5-FU) or raltitrexed (Tomudex) (TOM + LFA-5-FU), in advanced colorectal cancer patients, and to make a preliminary comparison of both these experimental regimens with a biweekly administration of LFA-5-FU modulated by methotrexate (MTX + LFA-5-FU)." | 5.09 | Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. ( Avallone, A; Biglietto, M; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lena, M; De Lucia, L; De Vita, F; Farris, A; Ianniello, GP; Leo, SS; Lorusso, V; Mancarella, S, 2000) |
| "Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)." | 5.09 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000) |
| "The purpose of this prospective study was to assess the efficacy, clinical benefit and safety of irinotecan (CPT-11) in patients with 5-fluorouracil-resistant metastatic colorectal cancer (CRC)." | 5.09 | Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy. ( Jirajarus, M; Ratanatharathorn, V; Sirachainan, E; Sirilerttrakul, S, 2000) |
| "Irinotecan is a topoisomerase I inhibitor that prolongs survival in patients with colorectal cancer refractory to fluorouracil (5-FU) and leucovorin (LV)." | 5.09 | Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. ( Alakl, M; Awad, L; Douillard, JY; Elfring, GL; Gruia, G; Locker, PK; Miller, LL; Pirotta, N; Saltz, LB, 2001) |
| "The aim of the study was to evaluate the efficacy, tolerability and quality of life in 5-fluorouracil (5-FU) pretreated colorectal cancer patients after combined 5-FU and Ginkgo biloba extract GBE 761 ONC (i." | 5.09 | Phase II study of combined 5-fluorouracil/ Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer. ( Häring, B; Hauns, B; Köhler, S; Mross, K; Unger, C, 2001) |
| "Irinotecan (CPT11) has established activity in the treatment of advanced colorectal cancer without cross-resistance with established 5-fluorouracil/folinic acid-based therapy." | 5.09 | Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. ( Adam, R; Bismuth, H; Castaing, D; Coeffic, D; Durrani, AK; Gil-Delgado, MA; Guinet, F; Khayat, D, 2001) |
| "We have recently evaluated the combination of raltitrexed, levofolinic acid (LFA) and 5-fluorouracil (5-FU) in advanced head and neck and colorectal cancer, and we have shown that this combination is well tolerated and has clinical activity." | 5.09 | Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours. ( Avallone, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Ionna, F; Rivellini, F, 2001) |
| "Standard adjuvant chemotherapy for colorectal cancer consists of 5-fluorouracil with leucovorin or levamisole." | 5.09 | A United Kingdom coordinating committee on cancer research study of adjuvant chemotherapy for colorectal cancer: preliminary results. ( Kerr, DJ, 2001) |
| "Sixty eligible patients who had previously untreated, measurable, metastatic colorectal carcinoma were treated with oral eniluracil 50 mg on Days 1-7, 5-FU 20 mg/m(2) on Days 2-6, and LV 50 mg on Days 2-6." | 5.09 | Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. ( Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001) |
| "Standard therapy for advanced or metastatic colorectal cancer consists of 5-fluorouracil plus leucovorin (5-FU/LV) administered intravenously (i." | 5.09 | Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. ( Barker, C; Boyer, M; Cassidy, J; Findlay, M; Hieke, K; Jamieson, C; Osterwalder, B; Twelves, C; Weitzel, C, 2001) |
| "To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer." | 5.09 | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 5.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| "A multicenter phase II trial was initiated in order to evaluate the weekly, high-dose 24-hour infusion of 5-fluorouracil (5-FU) plus folinic acid (FA) in patients with unresectable colorectal cancer hepatic metastases." | 5.09 | Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas. ( Gassel, HJ; Heinrich, S; Junginger, T; Köhne, CH; Lorenz, M; Mattes, E; Mueller, HH; Saeger, HD; Schramm, H; Staib-Sebler, E; Vetter, G, 2001) |
| " 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin." | 5.09 | Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001) |
| "This phase II study examined a regimen (FOLFOX7) of leucovorin (LV), high-dose intensity oxaliplatin, and 5-fluorouracil (5-FU), as second-line therapy for metastatic colorectal cancer." | 5.09 | High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 2001) |
| "Patients with isolated hepatic metastases from colorectal cancer were treated every three weeks with increasing doses of oxaliplatin (4 hours; starting dose 25 mg/m2, escalation in steps of 25 mg/m2) in combination with folinic acid (1 hour, 200 mg/m2) and 5-fluorouracil (2 hour, 600 mg/m2)." | 5.09 | Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ( Beckert, B; Beykirch, M; Braess, J; Goecke, E; Hiddemann, W; Kern, W; Lang, N; Schalhorn, A; Stein, J; Stemmler, J; Waggershauser, T, 2001) |
| "To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)." | 5.09 | Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001) |
| "Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding palliative chemotherapy with fluoropyrimidines leucovorin +/- irinotecan, participated in this study." | 5.09 | Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. ( Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H, 2001) |
| "A multi-institutional study was performed to evaluate the appropriate duration of oral administration of Carmofur (1-hexylcarbamoyl-5-fluorouracil, HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative operation." | 5.09 | Optimal duration of oral adjuvant chemotherapy with Carmofur in the colorectal cancer patients: the Kansai Carmofur Study Group trial III. ( Fujii, H; Kamigaki, T; Kuroda, Y; Nakamura, T; Ohno, M; Tabuchi, Y; Yamagishi, H, 2001) |
| "The primary objective of this trial was to determine the objective response of two regimens with CDDP administered every 2 weeks immediately before or after an 'optimal' 48-hour chronomodulated infusion of 5-fluorouracil (5-FU) modulated with leucovorin (LV) in metastatic colorectal cancer patients." | 5.09 | 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ( Allegrini, G; Bocci, G; Brunetti, I; Conte, P; Danesi, R; Del Tacca, M; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001) |
| "To evaluate the efficacy and safety of oxaliplatin (L-OHP) in combination with leucovorin (LV)-modulated bolus plus infusional 5-fluorouracil (5-FU; de Gramont schedule) every 2 weeks in chemotherapy-naive patients with advanced colorectal cancer (CRC)." | 5.09 | Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. ( Agelaki, A; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malamos, N; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N, 2001) |
| "Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV." | 5.09 | Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. ( Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001) |
| "A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin(R)) + 5-fluorouracil (5-FU) +/- folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorectal cancer (ACRC)." | 5.09 | Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. ( Bensmaïne, MA; Bleiberg, H; Brienza, S; Cvitkovic, E; de Gramont, A; Ducreux, M; François, E; Gamelin, E; Lévi, F; Marty, M, 2001) |
| " We measured DPD activities represented as DPD protein levels (units/mg protein) and the associated mRNA levels in tumorous and normal tissues from 40 colorectal cancer patients, and we studied the relation to 5-FU concentrations in the same samples after treatment with doxifluridine, a prodrug of 5-FU." | 5.09 | Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. ( Kato, S; Onda, M; Tanaka, N; Tanaka-Nozaki, M, 2001) |
| "To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Laboratories, Inc, Nutley, NJ), a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion but with preferential activation at the tumor site, with that of intravenous (IV) 5-FU plus leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer." | 5.09 | Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. ( Allman, D; Bajetta, E; Boyer, M; Bugat, R; Cassidy, J; Findlay, M; Frings, S; Harper, P; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Twelves, C; Van Cutsem, E; Vieitez, JM; Weitzel, C, 2001) |
| "A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium - folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer." | 5.09 | Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer. ( Drees, M; Fritze, D; Hartung, G; Hehlmann, R; Hofheinz, RD; Kreuser, ED; Kühnel, J; Queisser, W; Riedel, C; Rost, A; Wein, A, 2001) |
| "38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5-fluorouracil/leucovorin or the specific thymidilate synthase inhibitor raltitrexed were enrolled in this study." | 5.09 | Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. ( Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 5.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "Thirty-one patients with advanced colorectal cancer were treated with a regimen of epirubicin, cisplatin and continuous-infusion (c." | 5.09 | Epirubicin, cisplatin and continuous-infusion 5-fluorouracil (ECF regimen) in the treatment of advanced colorectal cancer. ( Caporale, A; Franchi, F; Gargano, L; Konstantatoy, E; Marcellini, M; Masciangelo, R; Menichetti, ET; Seminara, P, 2001) |
| "Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer (ACRC)." | 5.09 | Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. ( Carpi, A; Cherubini, R; Cognetti, F; Di Costanzo, E; Gasperoni, S; Moscetti, L; Paoloni, FP; Sdrobolini, A; Zeuli, M, 2001) |
| "Modulation of 5-fluorouracil (FUra) using leucovorin (LV) is a standard treatment approach in patients with metastatic colorectal cancer." | 5.08 | A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer. ( Erlichman, C; Feld, R; Fine, S; Kaizer, L; Moore, MJ; Myers, R; Thiessen, JJ, 1995) |
| "A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil (FU) with both leucovorin (LV) and cisplatin (CDDP) against liver metastases of colorectal cancer was devised." | 5.08 | [A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil with both leucovorin and cisplatin against liver metastases of colorectal cancer]. ( Fukada, D; Kato, M; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tsuji, K; Umemoto, T, 1995) |
| "The combination of 5-fluorouracil (5-FU) and folinic acid (FA) has demonstrated activity in colorectal cancer (CC)." | 5.08 | 5-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: a pilot study. ( Bacoyiannis, C; Daliani, D; Katsikas, M; Kosmas, C; Kosmidis, P; Sakelaropoulos, N; Tentas, K; Tsavaris, N, 1995) |
| "A randomized early phase II study using l-leucovorin (l-LV) and 5-fluorouracil (5-FU) against gastric cancer and colorectal cancer was conducted on a multi-institutional basis in Japan." | 5.08 | [Clinical evaluation of leucovorin and 5-fluorouracil]. ( Sasaki, T, 1995) |
| "Between 1966 and 1983 we selected 209 patients with colorectal adenocarcinomas, stage B (14%) and C (86%) of Dukes, treated with convenient surgery in 100% of cases, 5-fluorouracil in 85% and postoperative radiotherapy with telecobalt in 46." | 5.08 | [Is radiotherapy necessary in the control of colorectal cancer?]. ( Molina Esquivel, J; Rodríguez del Rincón, E; Vargas Sandoval, G; Velázquez López, J, 1995) |
| "Modulation of 5-fluorouracil (5-FU) is currently being investigated in advanced colorectal cancer." | 5.08 | Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin. ( Astone, A; Barone, C; Cassano, A; Corsi, DC; Fontana, T; Noviello, MR; Pozzo, C, 1995) |
| "The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer." | 5.08 | Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. ( Ahmed, F; Cunningham, D; Findlay, M; Hickish, T; Hill, M; Middleton, G; Nicolson, V; Norman, A; Watson, M; Webb, A, 1995) |
| "We have conducted a retrospective study of high-dose folinic acid and 5-fluorouracil in 96 patients with advanced colorectal cancer." | 5.08 | High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients. ( Adams, M; Hanna, CL; Mason, MD; Maughan, TS; McKinna, FE; Morrey, D; Williams, LB, 1995) |
| "135 patients with locally advanced or metastatic colorectal cancer were entered into a phase III trial evaluating the efficacy of chemoimmunotherapy [recombinant interleukin 2 (rIL2)/5-fluorouracil (5-FU) and leucovorin (LV)] versus chemotherapy alone (5-FU/LV)." | 5.08 | A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma. ( de Peuter, RA; Eremin, O; Franks, CR; Heys, SD; Oskam, R; Palmer, PA; Pein, F; Rainer, H; Ruggeri, EM, 1995) |
| "To compare the efficacy and toxicity profiles of a combination of fluorouracil (5-FU) with recombinant human interferon alfa-2a (Roferon-A; Hoffman La-Roche AG, Basel, Switzerland) versus the combination of 5-FU with leucovorin (LV) in the treatment of advanced colorectal cancer." | 5.08 | Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. ( , 1995) |
| "A clinical trial was conducted in order to evaluate the anti-tumor effect and toxicity of a continuous infusion of 5-fluorouracil (5-FU) for metastatic colorectal cancer." | 5.08 | Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer. ( Kondo, H; Ohkura, H; Saito, D; Shimada, Y; Shirao, K; Sugano, K; Yamao, T; Yokota, T; Yoshida, S, 1995) |
| "A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer." | 5.08 | [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995) |
| "Trimetrexate (TMQ), a non-classical folate antagonist, was studied in a randomized controlled trial in patients with advanced colorectal cancer and without prior chemotherapy." | 5.08 | A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study. ( Brown, TD; Fleming, TR; Goodman, PJ; Macdonald, JS; O'Rourke, T; Pugh, RP, 1995) |
| "These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines." | 5.08 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| "No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy." | 5.08 | Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995) |
| "A Phase II study of combination treatment with 5-fluorouracil (5-FU), leucovorin (LV), and interferon alpha-2a (IFN) in patients with previously untreated metastatic colorectal cancer was previously reported by the authors." | 5.08 | 5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. ( Buter, J; de Vries, EG; Mulder, NH; Sinnige, HA; Sleijfer, DT; van der Graaf, WT; Verschueren, RC; Willemse, PH, 1995) |
| "A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks." | 5.08 | 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. ( Dale, J; Fried, G; Haim, N; Stein, M; Tsalik, M, 1995) |
| "Between September 1990 and August 1994, 11 patients (pts) with liver metastases (mets) from colorectal cancer were treated with continuous hepatic arterial infusion chemotherapy of 5-fluorouracil (FU) plus leucovorin (LV)." | 5.08 | [Continuous intraarterial infusion of 5-fluorouracil plus leucovorin for liver metastases from colorectal cancer]. ( Ban, K; Higashi, H; Imanari, T; Ishihara, S; Kitazaki, M; Masuda, K; Matsumoto, M; Noma, M; Ota, M; Shida, H, 1995) |
| "From May 1988 to June 1992, 129 eligible patients suffering from measurable advanced colorectal cancer were enrolled in a randomized study comparing bolus fluorouracil plus leucovorin (FU-FA); continuous fluorouracil infusion (FU-cont); FUcont plus cyclophosphamide and mitomycin C (FUMIC)." | 5.08 | A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. ( Bonnel, C; Caudry, M; Caudry, Y; Dujols, JP; Floquet, A; Marsault, C; Maton, O; Pujol, J; Quétin, P; Skawinski, P, 1995) |
| "A phase I and pharmacokinetic trial was performed between October 1993 and June 1994 to determine the maximum-tolerated dose of hepatic arterial infusion (HAI) of fluorouracil (5-FU) and intravenous (IV) leucovorin (folinic acid; FA) in patients with hepatic metastases from colorectal cancer." | 5.08 | Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. ( Buckels, J; Budden, J; Doughty, J; Kerr, DJ; Ledermann, JA; McArdle, CS; Neoptolemos, J; Seymour, M; Taylor, I, 1995) |
| "We undertook a multicenter phase II trial of 5-fluorouracil (5FU) + 1-leucovorin (1-LV) in previously untreated patients with metastatic colorectal cancer to determine the response rate, response duration, time to progression, survival, and toxicity." | 5.08 | A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. ( Erlichman, C; Fine, S; Gorg, C; Gustavsson, B; Hoffmann, W; Kerr, I; Preusser, P; Schmoll, HJ; Thuerlimann, B, 1996) |
| "This randomised clinical trial, involving patients with advanced colorectal cancer, was carried out to compare the effectiveness of accelerated folinic acid (FA) plus 5-fluorouracil (5-FU) with that of the conventional regimen of 5-FU alone." | 5.08 | Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. ( Aquino, A; Botta, G; De Martino, A; Frediani, B; Lorenzi, M; Marsili, S; Marzocca, G; Palazzuoli, V; Petrioli, R; Tani, F, 1995) |
| "A joint study was performed by the Tokai HCFU study group, which included 41 institutions to study the usefulness of the concomitant therapy with Mitomycin C (MMC) and Carmofur (HCFU) as a postoperative adjuvant chemotherapy in patients with colorectal cancer who had curative resection." | 5.08 | Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer. ( Ito, K; Kato, T; Koike, A; Miura, K; Takagi, H; Yamaguchi, A, 1996) |
| "To determine the plasma pharmacokinetics and the maximum-tolerated dose (MTD) of intravenous (IV) azidothymidine (AZT) administered 90 to 120 minutes after fluorouracil (5-FU) and leucovorin and to preliminarily evaluate the antitumor activity of this combination in metastatic colorectal cancer." | 5.08 | Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ( Brunetti, I; Conte, PF; Danesi, R; Dargenio, F; Del Tacca, M; Falcone, A; Nethersell, AB; Pfanner, E, 1996) |
| "Phase II studies of fluorouracil (5-FU) administered by protracted intravenous infusion have suggested an improved response rate and decreased toxicity profile when compared with 5-FU given by bolus injection in patients with metastatic colorectal cancer." | 5.08 | Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. ( Anderson, T; Benson, A; Haller, DG; Hansen, RM; Krzywda, B; Quebbeman, E; Ryan, L; Tormey, DC, 1996) |
| "We studied the effect of postoperative chemotherapy using 5-fluorouracil (5-FU) infusions and 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration for curatively resected Stage II to IV colorectal cancer." | 5.08 | Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection. ( Akiyoshi, T; Kakegawa, T; Maehara, Y; Ogawa, M; Sugimachi, K; Tomita, M, 1996) |
| "A phase II prospective trial was carried out to study the concept of 5-fluorouracil (5-FU) dose-intensity in patients with advanced colorectal cancer." | 5.08 | Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. ( Burtin, PC; Danquechin-Dorval, EM; Delva, RG; Dumesnil, YF; Gamelin, EC; Gesta, PH; Goudier, MJ; Larra, FG; Lortholary, AH; Maillart, PJ, 1996) |
| "We evaluated the role of low-dose alpha-2b interferon, added to chemotherapy, for advanced colorectal cancer; we randomized patients, to either a combination chemotherapy of 5-fluorouracil (5-FU) and high-dose folinic acid (HDFA) or the same regimen plus interferon." | 5.08 | Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer. ( Di Lullo, L; Fabiani, F; Fanini, R; Lalli, A; Lombardo, M; Nuzzo, A; Peretti, G; Recchia, F; Torchio, P; Venturoni, L, 1996) |
| "A total of 26 patients with advanced colorectal cancer received 60 mg/m2 methotrexate i." | 5.08 | Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer. ( Alessandroni, P; Casadei, V; Cascinu, S; Catalano, G; Del Ferro, E; Fedeli, A; Rossi, D, 1996) |
| "We undertook a randomized trial in patients with advanced colorectal cancer, comparing 5-fluorouracil and leucovorin versus combination of these agents with additional cisplatin." | 5.08 | [Evaluation of chemotherapy in the treatment of advanced colorectal cancer--pilot study of 5-FU by biochemical modulation]. ( Katsumata, K; Ohno, M; Shibata, K; Yamamoto, K; Yamashita, S, 1996) |
| "Despite its low antineoplastic activity 5-fluorouracil remains the most active compound for the treatment of patient with metastatic colorectal cancer." | 5.08 | [Progress in development of chemotherapy of colorectal carcinoma]. ( Köhne, CH, 1996) |
| "Methotrexate (MTX) has been described to modulate the activity of fluorouracil (5-FU) in patients with metastatic colorectal cancer." | 5.08 | Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. ( Bleiberg, H; Blijham, G; Buset, M; Collette, L; Dalmark, M; de Greve, J; Lacave, A; Sahmoud, T; Selleslag, J; Wagener, T; Wils, J, 1996) |
| "To determine the effects of interferon alpha-2a (IFN alpha) on the efficacy and toxicity of fluorouracil (FUra) and leucovorin (LV) in patients with advanced colorectal cancer." | 5.08 | Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. ( Cunningham, D; Duffy, AM; Harper, PG; James, RD; Kerr, DJ; Ledermann, JA; McAdam, WA; Neoptolemos, JP; Nicholson, M; Perren, TJ; Seymour, MT; Slevin, ML; Stenning, SP; Stephens, RJ; Taylor, I, 1996) |
| "A phase II study was performed to evaluate the clinical and immunological effects of a regimen of fluorouracil (5-FU) and folinic acid (FA) combined with thymopentin (TP-5) and interleukin-2 (IL-2) in the treatment of patients with metastatic colorectal cancer." | 5.08 | Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects. ( Ameglio, F; Di Lauro, L; Frasca, AM; Gandolfo, GM; Garaci, E; Lopez, M; Paoletti, G; Rasi, G; Santini, S; Vitelli, G, 1995) |
| "The primary objective of this study was to determine the response rate of patients with metastatic colorectal cancer to combined therapy with 5-fluorouracil (5-FU), leucovorin, and intravenous azidothymidine (AZT), a thymidine nucleoside analog." | 5.08 | Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. ( Akerley, W; Beitz, J; Bigley, J; Browne, M; Clark, J; Cole, B; Cummings, F; Darnowski, J; Kennedy, T; Sikov, W; Wanebo, H; Weitberg, A, 1996) |
| "With the association of 5-fluorouracil (5-FU) and alpha-interferon (IFN), objective responses as high as 26 63% have been reported in untreated patients with advanced colorectal cancer." | 5.08 | A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. ( Acito, L; Bascioni, R; Bavosi, M; Carle, F; Cascinu, S; Cellerino, R; Del Papa, M; Francini, G; Giustini, L; Latini, L; Marcellini, M; Pancotti, A; Piga, A; Rossi, G, 1996) |
| "To evaluate ambulatory cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 32 patients with non-curative or recurrent colorectal cancer who were treated by l-Leucovorin (l-LV) plus 5-fluorouracil for the past four years." | 5.08 | [Clinical study of ambulatory cancer chemotherapy for advanced colorectal cancer]. ( Kunii, Y; Ota, K; Takahashi, N, 1995) |
| "A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV." | 5.08 | A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996) |
| "To compare the efficacy and toxicity profiles of a combination of fluorouracil (5-FU) and recombinant human interferon alfa-2a ([IFN alpha 2a] Roferon-A; Hoffmann-LaRoche, Basel, Switzerland) versus 5-FU alone in the treatment of advanced colorectal cancer (ACC)." | 5.08 | Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. ( Buys, SS; Buyse, M; Einhorn, L; Figlin, R; Froimtchuk, MJ; Greco, FA; Man, A; Marshall, EM; Ritter, L; Schilsky, R; Schuchter, L; Schuller, J; Yap, AK; York, M, 1996) |
| "A joint study was performed by the Tokai HCFU study group, which included seven institutions, to examine the value of oral administration of Carmofur (HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative resection." | 5.08 | Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group--third study on colorectal cancer. ( Baba, S; Ishii, M; Ito, K; Kato, T; Matsumoto, S; Miura, K; Takagi, H; Yamaguchi, A, 1996) |
| "5-Fluorouracil (5-FU) remains the most active therapeutic agent in advanced colorectal cancer." | 5.08 | 5-Fluorouracil continuous infusion in metastatic colorectal cancer. ( Ang, PT; Tan, EH, 1996) |
| "In a pilot study we treated 19 patients suffering from recurrent or locally advanced inoperable colorectal cancer, with concurrent hypofractionated radiotherapy (4-5 Gy/fraction, 2 fractions per week) and 5-fluorouracil bolus, 1 hour before RT at doses of 300 mg/m2." | 5.08 | Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. ( Kapsoritakis, A; Kosma, L; Koukourakis, M; Mouder, N; Skarlatos, J; Yannakakis, D; Zambatis, C, 1996) |
| "Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFN alpha-2a) and interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced colorectal cancer." | 5.08 | Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. ( Goey, SH; Gratama, JW; Mertelsmann, RH; Osterwalder, B; Primrose, JN; Stoter, G; Verweij, J; Ward, U, 1996) |
| " To evaluate these effects, 17 patients with advanced colorectal cancer took part in a randomised, parallel group study of rIL-2 with chemotherapy (5-fluorouracil and leucovorin) and chemotherapy alone." | 5.08 | The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments. ( Eremin, O; Heys, SD; Lolley, J; Walker, LG; Walker, MB; Wesnes, KP, 1996) |
| "This multicenter study compared the therapeutic ratio of a monthly schedule of low-dose leucovorin (LV) and fluorouracil (5-FU) bolus with a bimonthly schedule of high-dose LV and 5-FU bolus plus continuous infusion in patients with advanced colorectal cancer." | 5.08 | Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. ( Bedenne, L; Bosset, JF; Bouché, O; de Gramont, A; Etienne, PL; François, E; Guillot, T; Louvet, C; Milan, C; Morvan, F; Rougier, P, 1997) |
| "To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer." | 5.08 | Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. ( Burger, D; Depisch, D; Greiner, R; Karner, J; Kornek, G; Kovats, E; Marczell, A; Pidlich, J; Raderer, M; Rosen, H; Salem, G; Scheithauer, W; Schneeweiss, B, 1997) |
| "Although leucovorin (LV) + 5-fluorouracil (5-FU) is considered the treatment of choice for advanced colorectal cancer in most countries, the optimal schedule of this combination has not yet been established." | 5.08 | High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer. ( Arnoldi, E; Barni, S; Cascinu, S; Comella, G; Dallavalle, G; Duro, M; Fiorentini, G; Frontini, L; Gottardi, O; Labianca, R; Luporini, G; Martignoni, G; Oliani, C; Pancera, G; Pavanato, G; Piazza, E; Raina, A; Valsecchi, R; Zaniboni, A, 1997) |
| "Fourteen patients with 5-fluorouracil (5-FU) refractory, progressive colorectal cancer metastatic to liver and/or lung were treated with continuous oral trofosfamide, an alkylating agent structurally related to cyclophosphamide and ifosfamide." | 5.08 | Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. ( Eberhardt, W; Harstrick, A; Klaassen, U; Korn, MW; Müller, C; Seeber, S; Strumberg, D; Wilke, H, 1997) |
| "The basic immunological indexes were investigated in patients with disseminated colorectal cancer after conduction of magnetothermia and chemotherapy using fluorouracil." | 5.08 | [Immunological monitoring of patients with disseminated colorectal cancer under thermochemotherapy]. ( Chernenko, OD; Iaremchuk, AIa; Kamenets, LIa; Kravchenko, AV, 1997) |
| "Diarrhea is one of the dose-limiting toxicities for administration of fluorouracil (5FU) in patients with colorectal cancer and can result in severe morbidity and mortality." | 5.08 | Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. ( Ardizzoia, A; Barni, S; Cascinu, S; Catalano, G; Cazzaniga, M; Del Ferro, E; Ghiandoni, G; Labianca, R; Ligi, M; Luporini, G; Pessi, MA; Rocchi, MB; Ugolini, G; Zamparelli, G, 1997) |
| "A three-arm randomized phase III trial in advanced colorectal cancer patients was designed to test whether substitution of an equivalent dose of (1) l-leucovorin or (2) oral leucovorin would more effectively potentiate fluorouracil (5-FU) than standard intravenous (I." | 5.08 | Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. ( Goldberg, RM; Hatfield, AK; Kahn, M; Knost, JA; Krook, JE; Maillard, JA; Moertel, CG; O'Connell, MJ; Sargent, DJ; Schaefer, PL; Tirona, MT; Wiesenfeld, M, 1997) |
| "The aim of this phase I study was to establish the maximum tolerated dose (MTD) of 5-fluorouracil (5-FU), administered as a 5-day chronomodulated infusion in combination with 1-folinic acid (FA) to ambulatory metastatic colorectal cancer patients." | 5.08 | A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer. ( Aschelter, AM; Franchi, F; Gallà, DA; Garufi, C; Giunta, S; Lévi, F; Narduzzi, C; Nisticò, C; Pace, R; Silecchia, GF; Terzoli, E, 1997) |
| " To evaluate these effects, 17 patients with advanced colorectal cancer took part in a randomised, parallel group study of rIL-2 with chemotherapy (5-fluorouracil and leucovorin) versus chemotherapy alone." | 5.08 | The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial. ( Eremin, O; Heys, SD; Lolley, J; Walker, LG; Walker, MB; Wesnes, K, 1997) |
| "To determine whether high-dose infusional fluorouracil (FU) is effectively modulated by leucovorin (LV), interferon (IFN) alpha-2b, or both when given to patients with metastatic colorectal cancer." | 5.08 | Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. ( Andreesen, R; Bade, J; Dörken, B; Harstick, A; Hecker, H; Hiddemann, W; Horster, A; Käufer, C; Klaasen, U; Köhne, CH; Ohl, U; Schmoll, HJ; Schöffski, P; Schott, G; Schubert, U; Westerhausen, M; Wilke, H, 1998) |
| "The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy." | 5.08 | Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998) |
| " Patients with advanced colorectal cancer who participated in two international comparative studies of raltitrexed ('Tomudex') vs standard 5-fluorouracil (5-FU) plus leucovorin (LV) completed previously validated quality-of-life questionnaires (EORTC questionnaire, EuroQol and Rotterdam Symptom Check List) at various times during the studies." | 5.08 | Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. ( Anderson, H; Palmer, MK, 1998) |
| "Although the efficacy of 5-fluorouracil (5-FU) modulated by leucovorin is well established for advanced colorectal cancer, the question of the most effective regimen and optimal dose of leucovorin remains unanswered." | 5.08 | A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer. ( Blanc, F; Bons-Rosset, F; Fabbro-Peray, P; Gouze, C; Heran, B; Marçais, O; Perney, P; Ribard, D; Veyrac, M; Ychou, M, 1998) |
| "From February 1995 through October 1996, 25 patients with metastatic colorectal cancer showing a clinical resistance to 5-fluorouracil (5-FU) entered this study." | 5.08 | Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. ( Aapro, MS; Biffi, R; Brienza, S; De Pas, T; deBraud, F; Munzone, E; Nolè, F, 1998) |
| "A wide variety of fluorouracil (FU)-plus-leucovorin (LV) dose schedules are in clinical use for the treatment of advanced colorectal cancer." | 5.08 | The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). ( Bacchi, M; Borner, MM; Castiglione, M; Fey, MF; Goldhirsch, A; Hanselmann, S; Herrmann, R; Leyvraz, S; Morant, R; Pagani, O; Pestalozzi, B; Weber, W, 1998) |
| "5-Fluorouracil and leucovorin combination is the most commonly applied chemotherapy treatment for colorectal cancer patients, both in the adjuvant setting and for advanced disease." | 5.08 | A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracil-pretreated colorectal cancer. ( Botto, F; Ghio, E; Neri, E; Pensa, F; Pronzato, P; Tognoni, A; Vaira, F; Vigani, A, 1998) |
| "The aim of this study was to evaluate the efficacy and tolerance of second-line continuous 5-fluorouracil (5FU) chemotherapy combined with folinic acid and mitomycin C in patients with advanced colorectal cancer who progressed on first-line chemotherapy." | 5.08 | 5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma. ( Bardou, VJ; Bernardini, D; Capodano, G; Giovannini, M; Perrier, H; Seitz, JF, 1998) |
| "Patients with histologically confirmed advanced colorectal cancer were randomized to receive folinic acid (FA; 500 mg/mq in 2-hour intravenous infusion) and 5-fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA), beginning every week for 6 weeks, followed by a 2-week rest period, either without hydroxyurea (HU, arm A) or with HU (35 mg/kg per day) given orally in three administrations (every 8 hours) starting 6 hours after 5FU administration (arm B)." | 5.08 | High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Angiona, S; Belsanti, V; Boni, C; Corgna, E; Di Costanzo, F; Figoli, F; Gasperoni, S; Luppi, G; Malacarne, P; Marzola, M; Passalacqua, R; Sdrobolini, A; Zironi, S, 1998) |
| "To compare raltitrexed (Tomudex; Zeneca Pharmaceuticals Ltd, Macclesfield, United Kingdom) a direct, specific thymidylate synthase (TS) inhibitor with fluorouracil (5-FU) plus high-dose leucovorin (LV) as first-line treatment for advanced colorectal cancer (ACC)." | 5.08 | Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. ( Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G, 1998) |
| "The objective of this multicenter study was to compare the efficacy and toxicity profiles of a combination of 5-fluorouracil (5-FU) given by bolus injection together with intravenous leucovorin (LV) versus high-dose 5-FU in continuous infusion (CI) in the treatment of advanced colorectal cancer." | 5.08 | Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. ( Antón-Torres, A; Aparicio, J; Aranda, E; Barneto, I; Carrato, A; Cervantes, A; Díaz-Rubio, E; García-Conde, J; López-Vega, JM; Massutí, T; Sastre, J; Tabernero, JM; Trés, A, 1998) |
| "We measured plasma total homocysteine (tHcy) in 14 patients (13 patients with colorectal cancer and 1 patient with breast cancer) during their first treatment with 5-fluorouracil (5-FU) plus leucovorin [LV (5-FULV)]." | 5.08 | Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. ( Geisler, J; Geisler, SB; Lønning, PE; Refsum, H; Smaaland, R; Tveit, KM; Ueland, PM, 1998) |
| "Patients with proven metastatic colorectal cancer, which had progressed within 6 months of treatment with fluorouracil, were randomly assigned either 300-350 mg/m2 irinotecan every 3 weeks with supportive care or supportive care alone, in a 2:1 ratio." | 5.08 | Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. ( Awad, L; Cunningham, D; Heikkila, R; Herait, P; Hickish, TF; Jacques, C; James, RD; Johannesen, TB; Punt, CJ; Pyrhönen, S; Starkhammar, H; Topham, CA, 1998) |
| "In phase II trials, irinotecan is active in patients with advanced colorectal cancer, but the survival and clinical benefit of irinotecan compared with second-line fluorouracil by continuous infusion is not known." | 5.08 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. ( Awad, L; Bajetta, E; Bleiberg, H; Herait, P; Jacques, C; Labianca, R; Morant, R; Navarro, M; Niederle, N; Possinger, K; Rougier, P; Van Cutsem, E; Wils, J, 1998) |
| "Data from 12 metastatic colorectal cancer patients who were submitted to a pilot study with a multistep subcutaneous (sc) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) administration were compared with those from 13 historical controls who were comparable for the major prognostic indices." | 5.08 | A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. ( Anselmi, L; Carpi, A; Ferrari, P; Nicolini, A; Sagripanti, A, 1998) |
| "The cumulative pharmacokinetic pattern of oxaliplatin, a new diamminecyclohexane platinum derivative, was studied in patients with metastatic colorectal cancer." | 5.08 | Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ( Allain, P; Boisdron-Celle, M; Bouil, AL; Brienza, S; Cailleux, A; Cvitkovic, E; Delva, R; Gamelin, E; Krikorian, A; Larra, F; Robert, J; Turcant, A, 1997) |
| "We evaluated the pharmacokinetics of 5-fluorouracil (5-FU) combined with recombinant human interferon (IFN)-alpha 2a in 10 previously untreated patients with advanced colorectal carcinoma." | 5.08 | Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma. ( Kim, J; Koss-Twardy, SG; Passe, SM; Patel, IH; Pazdur, R; Satoh, H; Zhi, J, 1998) |
| "Raltitrexed (Tomudex) is currently licensed for first-line treatment of advanced colorectal cancer." | 5.08 | Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer. ( Cunningham, D; Farrugia, DC; Norman, AR, 1998) |
| "This multicenter phase II study was designed to assess the efficacy of the alternating schedule of irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer (CRC)." | 5.08 | A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Barone, C; Cognetti, F; Cote, C; Dirix, L; Filez, L; Garufi, C; Gruia, G; Humblet, Y; Pozzo, C; Starkhammar, H; Terzoli, E; Van Cutsem, E, 1998) |
| "FOLFOX2, a bimonthly regimen of high-dose leucovorin (LV), 48-hour continuous infusion of 5-fluorouracil (5-FU) (LV-5-FU) and oxaliplatin (100 mg/m2) produced a high response rate (46%; 95% confidence interval (95% CI): 31%-60%) in 5-FU pre-treated patients with metastatic colorectal cancer." | 5.08 | Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. ( André, T; de Gramont, A; Louvet, C; Raymond, E; Tournigand, C, 1998) |
| " 439 patients were entered into a phase III trial comparing a novel thymidylate synthase (TS) inhibitor Tomudex (raltitrexed, formerly ZD1694) with 5-FU and leucovorin (LV) for the treatment of advanced colorectal cancer." | 5.08 | Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. ( Kerr, D; Palmer, M; Seymour, L; Zalcberg, J, 1998) |
| "Cell ingrowth, hydroxyproline accumulation, and mRNA expression of collagen I were measured in two polytetrafluoroethylene grafts implanted subcutaneously at the time of colorectal cancer surgery to evaluate the influence of early postoperative chemotherapy on human wound healing." | 5.07 | The influence of early postoperative intraperitoneal chemotherapy on human wound healing. ( Gerdin, B; Glimelius, B; Graf, W; Hellsing, K; Ivarsson, M; Påhlman, L, 1994) |
| "To compare two commonly used schedules of fluorouracil (5FU) and leucovorin in the treatment of patients with advanced metastatic colorectal cancer." | 5.07 | Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. ( Buroker, TR; Gerstner, JB; Gesme, DH; Kardinal, CG; Krook, JE; Levitt, R; Mailliard, JA; O'Connell, MJ; Schaefer, PL; Wieand, HS, 1994) |
| "Eighty-one patients with metastatic or locally advanced colorectal cancer were treated at four oncological centers in Denmark with a regimen consisting of 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 for 5 consecutive days every 4 weeks." | 5.07 | Metastatic or locally advanced colorectal cancer treated with 5-fluorouracil and low dose leucovorin. ( Andersen, LJ; Brunsgaard, NH; Jensen, BB; Mejlholm, I, 1994) |
| "Twenty-one patients with advanced, pretreated colorectal cancer in disease progression were entered in a phase II study to investigate the use of 5-fluorouracil (5FU) + leucovorin with subcutaneous Interleukin-2 + alpha interferon (alpha-IFN)." | 5.07 | A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon. ( Amadori, D; Fedriga, R; Flamini, E; Maltoni, R; Milandri, C; Pezzi, L; Riccobon, A; Ridolfi, R; Santoni, A; Velotti, F, 1994) |
| "The disposition of 5-fluorouracil (FUra) was studied in 19 colorectal cancer patients during treatment with FUra and high-dose leucovorin (LV) with or without interferon alpha 2a (IFN-alpha)." | 5.07 | Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ( Joel, SP; Johnston, A; Patel, N; Seymour, MT; Slevin, ML, 1994) |
| "5-Fluorouracil (5-FU) activity for various carcinomas of adults has been enhanced through the synergistic effect of leucovorin." | 5.07 | Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors. ( Bowman, LC; Douglass, EC; Houghton, JA; Howlett, N; Kun, LE; Meyer, WH; Mounce, K; Poe, D; Pratt, CB, 1994) |
| "In a previous phase II trial, circadian (chronomodulated) delivery of fluorouracil (5-FU), folinic acid (FA; leucovorin), and oxaliplatin (1-OHP; a new platinum complex with no renal and minor hematologic toxic effects) produced an objective response rate of 58% in 93 patients with metastatic colorectal cancer." | 5.07 | Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. ( Chollet, P; Dogliotti, L; Faggiuolo, R; Focan, C; Garufi, C; Itzhaki, M; Lévi, FA; Perpoint, B; Vannetzel, JM; Zidani, R, 1994) |
| "Interferon alpha (IFN-alpha) enhances the activity of 5-fluorouracil (5-FU) in the treatment of advanced colorectal cancer although the mechanism is not understood." | 5.07 | The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer. ( Nichols, PH; Primrose, JN; Ramsden, CW; Ward, U, 1994) |
| "Pharmacokinetics of total platinum, 5-fluorouracil, l-folinic and d-folinic acid, and 5-methyltetrahydrofolate were studied in plasma from nine patients with advanced colorectal cancer treated with oxaliplatin (20 mg/m2/day), 5-fluorouracil (600 mg/m2/day), and folinic acid (300 mg/m2/day)." | 5.07 | Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. ( Bastian, G; Brienza, S; Comisso, M; Etienne, MC; Lévi, F; Massari, C; Metzger, G; Milano, G; Misset, JL; Touitou, Y, 1994) |
| "A total of 101 patients with advanced colorectal cancer in two consecutive Southern Italian Oncology Groups (GOIM) studies (8501 and 8801--arm A) were treated with a sequential combination of high dose methotrexate (HDMTX) and fluorouracil (FU)." | 5.07 | Sequential treatment with high-dose methotrexate and fluorouracil in advanced colorectal cancer. Experience of the Southern Italian Oncology Group (GOIM). ( Colucci, G; Giotta, F; Giuliani, F; Leo, S; Maiello, E; Pedicini, A; Pezzella, G; Prete, F; Romito, S; Valori, V, 1994) |
| "In an attempt to evaluate the feasibility of 5-fluorouracil (FU) treatment modulated by (R,S)-leucovorin (LV) and interferon alpha (IFN alpha) in patients with advanced colorectal cancer, we conducted a phase I trial with increasing doses of subcutaneous IFN alpha (3 x 1 x 10(6) U, 3 x 3 x 10(6) U, 3 x 3 x 10(6) U, 3 x 5 x 10(6) U and 3 x 10 x 10(6) U/week) and 500 mg/m2 LV i." | 5.07 | Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration. ( Djavanmard, MP; Gnant, MF; Jakesz, R; Locker, G; Mader, RM; Marosi, C; Rainer, H; Steger, GG, 1994) |
| "The management of patients with advanced colorectal cancer remains dependent on the optimal use of 5-Fluorouracil (5-FU)." | 5.07 | Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer. ( Carter, R; Cunningham, D; Evans, C; Findlay, M; Ford, H; Hill, A; Husband, J; Nicolson, M; Norman, A, 1994) |
| "Twenty-two patients with metastatic colorectal cancer entered a Phase I-II trial to assess the maximum tolerable dose of alpha-2B-interferon administered intramuscularly three times per week in combination with fixed doses of 5-fluorouracil (450 mg/m2 IV for 5 days, and, from day 28, weekly) and folinic acid (200 mg/m2 IV before 5-fluorouracil) and the efficacy of this combination." | 5.07 | Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients. ( Bertuccelli, M; Brunetti, I; Cianci, C; Conte, PF; Falcone, A; Ricci, S, 1994) |
| "A joint multicenter comparative study of carmofur (HCFU) alone or HCFU+dipyridamole (DP) concurrent administration was conducted by the Kinki Colorectal Cancer Chemotherapy Society." | 5.07 | [Some problems of TS measurement after administration of fluoropyrimidines in colorectal cancer. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma]. ( Fukuda, I; Hioki, K; Imaoka, S; Kameyama, M; Kikkawa, N; Mori, T; Nakamori, S; Oshima, A; Utsunomiya, J; Yasutomi, M, 1993) |
| "To increase the knowledge about the palliative effects of chemotherapy in patients with symptomatic advanced colorectal cancer, physician- and patient-rated "quality of life" was studied in a randomized multicenter trial comparing a regimen of methotrexate/5-fluorouracil (5-FU) followed by leucovorin rescue (MFL) with a regimen of 5-FU/leucovorin (FLV)." | 5.07 | Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. ( Glimelius, B; Graf, W; Hoffman, K; Påhlman, L; Sjödén, PO, 1994) |
| "Potentiation of the antitumor activity of 5-fluorouracil (5-FU) by folinic acid has been demonstrated in patients with colorectal adenocarcinoma." | 5.07 | 5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens. ( André, T; Goldschmidt, E; Grison, X; Hannoun, L; Lotz, JP; Machover, D; Marquet, J; Metzger, G; Richaud, J; Zittoun, J, 1993) |
| "A prospective, controlled randomized trial of hepatic arterial infusion of 5-fluorouracil (5-FU), adriamycin (ADM) and mitomycin C (MMC) [FAM group] versus 5-FU, epirubicin (EPIR) and MMC [FEM group] in patients with unresectable liver metastasis from colorectal cancer is reported." | 5.07 | [A randomized trial of intrahepatic infusion chemotherapy for unresectable colorectal liver metastases. Sendai Study Group]. ( Kunii, Y; Mashiko, H; Momono, S; Muto, I; Nakagawa, K; Ouchi, A; Shiiba, K; Wada, M; Yamamoto, K; Yamazaki, T, 1993) |
| "5-Fluorouracil (5-FU), when combined with leucovorin (LV) or interferon-alpha (IFN-alpha), may result in improved response rates compared with 5-FU alone in patients with advanced colorectal cancer." | 5.07 | Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study. ( Burghouts, JT; Croles, JJ; de Mulder, PH; Kamm, Y; Punt, CJ; van Liessum, PA, 1993) |
| " The purpose of this study was to compare its therapeutic effect with a standard fluorouracil (FU) regimen in patients with locally advanced or metastatic colorectal cancer." | 5.07 | Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. ( Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993) |
| "25 patients with metastatic colorectal cancer were entered into a phase II trial of combination chemoimmunotherapy using a sequential regimen of 5-fluorouracil (5-FU) and leucovorin and high-dose recombinant human interleukin-2 (rIL-2)." | 5.07 | Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. ( Landry, JG; Ritchey, JL; Rosenberg, SA; Shlasko, E; White, DE; Yang, JC, 1993) |
| "A prospectively randomized trial was performed to determine whether the combination of fluorouracil (FU) plus leucovorin (FU-LV) administered orally is more effective than equitoxic FU for patients with metastatic colorectal cancer." | 5.07 | A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. ( Brenckman, WD; Bukowski, RM; Clendennin, NJ; Collier, MA; Guaspari, A; Laufman, LR; McKinnis, RA; Sullivan, BA, 1993) |
| "Biochemical modulation of bolus fluorouracil (5-FU) by addition of leucovorin to the treatment regimen has increased response in patients with disseminated colorectal cancer from fewer than 20% to more than 40%." | 5.07 | Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. ( Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Rosen, PJ; Spears, CP, 1993) |
| "Thirty-one patients with hepatic metastases from colorectal carcinoma were treated with carboplatin (CBDCA), 55 mg/m2, given in a 4-hour intra-arterial infusion daily for 5 days, and 5-fluorouracil, 900 mg/m2, given in a 20-hour intra-arterial infusion daily for 5 days." | 5.07 | Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma. ( Abuchaibe, O; Bilbao, I; Hidalgo, OF; Pardo, F; Rebollo, J; Tangco, E; Vieitez, JM, 1993) |
| " This prospective phase II study evaluates the efficacy and toxicity of hepatic arterial infusion of 5-Fluorouracil (5-FU) via an implantable Infusaid pump in previously untreated patients with localised but unresectable hepatic metastases from colorectal cancer." | 5.07 | Continuous hepatic artery infusion of 5-fluorouracil for metastatic colorectal cancer localised to the liver. ( Boyle, FM; Levi, JA; Smith, RC, 1993) |
| "A Nordic multicenter study in asymptomatic patients with advanced colorectal cancer compared initial chemotherapy with sequential methotrexate-5-FU with leucovorin rescue (MFL) for 6 months versus primary expectancy with chemotherapy only after the appearance of symptoms." | 5.07 | General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study. ( Glimelius, B; Graf, W; Hoffman, K; Påhlman, L; Sjödén, PO; Wennberg, A, 1992) |
| "We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer." | 5.07 | Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. ( Erlichman, C; Fine, S; Gadalla, T; Steinberg, J; Wong, A, 1992) |
| "148 patients with advanced untreated colorectal cancer were randomised to receive a weekly bolus of 5-fluorouracil (5-FU) 600 mg/m2 alone, with or without leucovorin (LV) 500 mg/m2." | 5.07 | Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. ( Canobbio, L; Fassio, T; Gallo, L; Guglielmi, A; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Venturini, M; Vidili, MG, 1992) |
| "From January 31, 1986 to January 31, 1989, 184 eligible patients were enrolled in a randomized study of either infusional or bolus 5-fluorouracil (5-FU) for the treatment of metastatic measurable colorectal cancer." | 5.07 | Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. ( Bogues, W; Cripps, IC; Fields, A; Maroun, J; McCormick, R; Pater, J; Shah, A; Temple, W; Weinerman, B; Wilson, K, 1992) |
| "Because of the different sites and mechanisms of biochemical interaction among 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN), we hypothesized that the concomitant use of IFN could increase the activity of the 5-FU/LV combination in colorectal cancer patients." | 5.07 | Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. ( Cascinu, S; Catalano, G; Fedeli, A; Fedeli, SL, 1992) |
| "15 untreated patients with advanced measurable colorectal cancer along with other 29 patients in progression after failing first line chemotherapy with fluoropyrimidines received 5-fluorouracil (5FU) 500 mg/m2 given as a weekly bolus at mid-infusion of leucovorin (LV), 500 mg/m2 administered intravenously over 2 h and interferon alpha 2b (IFN) 3 x 10(6) U given intramuscularly every other day." | 5.07 | Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer. ( Aschele, C; Bolli, E; Bruzzi, P; Gallo, L; Guglielmi, A; Mori, A; Nobile, MT; Parodi, GC; Sobrero, A; Tixi, L, 1992) |
| "A high rate of response to 5-fluorouracil (5FU) and alpha-interferon (alpha IFN) combination therapy has been reported in metastatic colorectal cancer patients." | 5.07 | Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992) |
| "Thirty-eight patients with advanced colorectal adenocarcinoma were entered on a phase II trial of 5-fluorouracil (5-FU) in continuous infusion, using a portable pump." | 5.07 | Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma. ( Ammarguellat, H; Benhamed, M; Ghosn, M; Goldberg, J; Kac, J; Laplaige, P; Piot, G; Rougier, P; Theodore, C; Tigaud, JM, 1992) |
| "One hundred sixty consecutive patients with histologically confirmed colorectal cancer (advanced disease) without prior chemotherapy were entered in a randomized trial comparing 5-fluorouracil (5-FU) 1,000 mg/m2 intravenously per day for 5 consecutive days in continuous infusion versus cisplatin (CP) 100 mg/m2 on day 1 plus 5-FU as described on days 2 to 6." | 5.07 | A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). ( Antón, A; Aranda, E; Belón, J; Carrato, A; Cruz-Hernández, J; Díaz-Rubio, E; Jimeno, J; Martin, M; Massuti, B; Sánchez, J, 1992) |
| "Treatment results in advanced colorectal cancer have improved during the last decade since the incorporation of agents like folinic acid, PALA, or interferon as active biomodulation of 5-fluorouracil (5-FU), the most potent drug in this disease." | 5.07 | A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation. ( Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992) |
| "Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2." | 5.07 | Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial. ( Günther, E; Hinrichs, HF; Hirschmann, WD; Koniczek, KH; Natt, F; Sondern, W; Steinke, B; Wagner, T; Wander, HE; Werdier, D, 1992) |
| "Several reports on fluorouracil (5-FU) and alfa interferon (IFN-alpha) combination therapy in patients with advanced colorectal cancer have been published." | 5.07 | Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992) |
| "In a clinical phase II study, 23 patients with progressive metastatic colorectal cancer and failure after first-line chemotherapy with fluorouracil (5-FU) and folinic acid (FA) were treated with a 5-day continuous infusion of recombinant interleukin-2 (IL-2), 3 x 10(6) cetus U/m2/d, followed after a rest period of 2 days by 5-FU, 600 mg/m2/d, and FA, 300 mg/m2/d over an additional 3 days." | 5.07 | Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer--results of a clinical phase II study. ( Hiddemann, W; Koch, O; Musch, E; Ottensmeier, C; Rückle, H; Ruelfs, C; van de Loo, J, 1992) |
| "A total of 183 patients with advanced, but asymptomatic colorectal cancer were randomly allocated to receive either initial treatment with sequential methotrexate 250 mg/m2 during the first 2 hours, and fluorouracil (5-FU) 500 mg/m2 at hours 3 and 23 followed by leucovorin rescue initiated at hour 24 (MFL) for 12 courses or to primary expectancy with chemotherapy not considered until symptoms appeared." | 5.07 | Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. ( , 1992) |
| "One hundred eighty-one patients with measurable recurrent or metastatic colorectal cancer, who had not received prior chemotherapy, were randomized in a prospective controlled trial to receive 5-fluorouracil (5FU), 13." | 5.07 | Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). ( Bacchi, M; Bartolucci, R; Belsanti, V; Boni, C; Calabresi, F; Di Costanzo, F; Marzola, M; Sofra, M, 1992) |
| "The mechanisms of biochemical modulation of 5-fluorouracil (5-FU) cytotoxicity by folinic acid (FA) have been elucidated, and the clinical use of this combination has improved response rates and survival in patients with metastatic colorectal cancer." | 5.07 | A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma. ( Bauer, L; Budd, GT; Bukowski, RM; Gibson, V; Inoshita, G; Murthy, S; Prestifilippo, J; Sergi, JS; Yalavarthi, P, 1992) |
| "5-Fluorouracil (5-FU) remains the most effective chemotherapeutic agent in the management of patients with metastatic colorectal cancer." | 5.07 | Treatment of advanced colorectal cancer by 5-fluorouracil-leucovorin combination with or without allopurinol: a prospective randomized study. ( Chaitchik, S; Inbar, M; Merimsky, O, 1991) |
| "To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer." | 5.07 | A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991) |
| "Hepatic intra-arterial (HIA) infusion of floxuridine (FUDR) via an implanted pump has shown promise in the treatment of colorectal cancer metastasized to the liver." | 5.07 | Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. ( Chase, JL; Grobman, BJ; Hohn, DC; Lewis, BJ; Mulvihill, SJ; Rayner, AA; Roh, M; Stagg, RJ; Venook, AP; Warren, RS, 1991) |
| "Effectiveness, toxicity and complications of 5-fluorouracil (FU) and mitomycin-C (MMC) treatment were analyzed in 30 patients with metastatic colorectal cancer confined to the liver." | 5.07 | Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. ( Largiadèr, F; Metzger, U; Röthlin, M; Weder, W, 1991) |
| "A phase I study of 5-fluorouracil 600 mg/m2/week and folinic acid 500 mg/m2/week on day 1 and cisplatin administered weekly on day 2 was carried out on 30 patients with metastatic colorectal carcinoma of which 20 patients were pretreated with 5-fluorouracil." | 5.07 | A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma. ( Creaven, P; Gebbia, N; Gebbia, V; Palmeri, S; Petrelli, N; Rausa, L; Russo, A; Rustum, Y, 1991) |
| "Fourteen patients (group A) with unresectable metastasis to the liver from colorectal cancers (11 patients) and gastric cancers (3 patients) were treated with the combined application of hyperthermia and intra-hepato-arterial (IHA) chemotherapy with cisplatinum and 5-fluorouracil." | 5.07 | A phase II pilot study of the combined application of hyperthermia and intra-hepato-arterial chemotherapy using cisplatinum and 5-fluorouracil. ( Hamazoe, R; Hirooka, Y; Kaibara, N; Maeta, M; Murakami, A, 1991) |
| "In a previous study (J Clin Oncol 7:1407-1417, 1989), we identified two dosage administration schedules of fluorouracil (5FU) combined with leucovorin that were superior to single-agent 5FU for the treatment of advanced colorectal cancer." | 5.07 | Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. ( Gerstner, JB; Kardinal, CG; Krook, JE; Levitt, R; Mailliard, JA; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1991) |
| "One hundred eighty-four patients with advanced measurable colorectal cancer not previously treated with chemotherapy were entered into a prospective randomized clinical trial by the Mid-Atlantic Oncology Program (MAOP) to assess the value of weekly cisplatin (20 mg/m2) when added to a protracted schedule of 5-fluorouracil (5-FU) infusion (PIF) at 300 mg/m2/d for 10 weeks of every 12 weeks." | 5.07 | A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study. ( Ahlgren, JD; Alt, DE; Cantrell, J; Fryer, JG; Gullo, JJ; Heim, WJ; Lokich, JJ; Wampler, GL, 1991) |
| "The importance of the interval between methotrexate (MTX) and fluorouracil (5-FU) was studied in 168 patients with previously untreated, measurable, advanced colorectal cancer." | 5.07 | The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. ( Bertino, JR; Capizzi, RL; Davis, CA; Durivage, HJ; Farber, LR; Katz, KH; Marsh, JC; Pasquale, DN; Richards, F; Rome, LS, 1991) |
| "Forty four patients who had documented progression of metastatic colorectal cancer while receiving 5-fluorouracil (5-FU) monotherapy were treated with continuous infusion 5-FU, 300 mg/mg2/day, plus weekly low-dose cisplatin, 20 mg/m2." | 5.07 | Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. ( Ahlgren, JD; Goldberg, R; Gullo, JJ; Muir, WA; Schacter, L; Sisk, R; Trocki, O, 1991) |
| "Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection." | 5.06 | Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990) |
| "Protection by prolonged administration of allopurinol against high-dose 5-fluorouracil (5-FU) administered with folinic acid in 74 patients with colorectal cancer was investigated." | 5.06 | Folinic acid plus high-dose 5-fluorouracil with allopurinol protection in the treatment of advanced colorectal carcinoma. ( Bacoyannis, C; Kosmidis, P; Magoulas, D; Milonakis, N; Sarafidou, M; Tsavaris, N; Zamanis, N, 1990) |
| "Pursuant to a promising report suggesting that an allopurinol mouthwash could have a protective effect against 5-fluorouracil (5-FU)-induced stomatitis, the authors performed a randomized, placebo-controlled, double-blind, crossover study." | 5.06 | A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. ( Athmann, LM; Burnham, NL; Cianflone, SG; Cross, M; Dose, AM; Etzell, PS; Gainey, DK; Hagen, L; Loprinzi, CL; Therneau, TM, 1990) |
| "We have performed a prospective randomized controlled study of 5-fluorouracil (5FU) + leucovorin versus 5FU alone in patients with metastatic colorectal cancer." | 5.06 | Fluorouracil and leucovorin for metastatic colorectal cancer. ( Erlichman, C, 1990) |
| "A novel sequential administration schedule of PALA (N-phosphonoacetyl-L-aspartate) and thymidine to enhance the cytotoxic effect of 5-fluorouracil (5FU) was tested in 36 patients with advanced gastric cancer and 21 patients with advanced poorly differentiated (anaplastic) colorectal cancer." | 5.06 | A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. ( Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE, 1990) |
| "A total of 21 untreated patients (5 males, 16 females; median age, 55 years; range, 28-72) with advanced measurable colorectal carcinoma were treated with an association of 5-fluorouracil (1000 mg/weekly) and alpha-2 interferon (three times a week s." | 5.06 | Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer. ( Aversa, SM; Daniele, O; Fiorentino, MV; Fornasiero, A; Ghiotto, C; Morandi, P, 1990) |
| "Four single-arm trials using methotrexate (M), 5-fluorouracil (5FU), and leucovorin (L) were sequentially performed in metastatic measurable colorectal cancer using different dosing and timing schedules for the three drugs." | 5.06 | Sequential methotrexate, 5-fluorouracil, and leucovorin in metastatic measurable colorectal cancer. Does it work? ( Cripps, C; Johnston, J; Maroun, J; Stewart, D; Weinerman, B, 1990) |
| "We conducted a phase II clinical trial of fluorouracil (5FU) and recombinant interferon alfa-2a (rIFN alpha-2a) in 52 previously untreated patients with bidimensionally measurable metastatic colorectal cancer." | 5.06 | Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. ( Ajani, JA; Campos, L; DuBrow, R; Faintuch, J; Jackson, D; Patt, YZ; Pazdur, R; Quaraishi, M; Shepard, B; Winn, R, 1990) |
| "A prospective controlled randomized trial testing adjuvant postoperative combination chemotherapy (5-fluorouracil, lomustine (CCNU) and vincristine) versus no adjuvant therapy in patients operated on for Dukes' C colorectal cancer is reported." | 5.06 | Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group. ( Asklöf, G; Bergman, L; Domellöf, L; Hafström, L; Hansson, K; Kugelberg, C; Nilsson, T; Norryd, C; Rudenstam, CM; Wählby, L, 1990) |
| "We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion." | 5.06 | Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. ( Beart, RW; Fitzgibbons, RJ; Leigh, JE; Moertel, CG; van Heerden, JA; Wieand, HS; Windschitl, HE; Wolff, BG, 1990) |
| "The Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) conducted a randomized clinical trial comparing five different combination chemotherapeutic regimens to single-agent 5-fluorouracil (5-FU), given by intravenous bolus technique (500 mg/m2 for 5 days) as a control, in the treatment of advanced colorectal cancer." | 5.06 | A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. ( O'Connell, MJ, 1989) |
| "Ninety-one patients with metastatic colorectal cancer were treated with continuous ambulatory 5-fluorouracil (5FU) infusion 250-300 mg/m2/day through a chronic indwelling central venous catheter." | 5.06 | Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients. ( Anderson, T; Ausman, R; Beatty, P; Frick, J; Haas, C; Hansen, R; Quebbeman, E; Ritch, P; Schulte, W, 1989) |
| "A total of 249 patients with advanced, symptomatic colorectal cancer who received no previous cytostatic therapy were randomly allocated to receive either fluorouracil (5-FU), 600 mg/m2, for 2 days or the following regimen: sequential methotrexate, 250 mg/m2, during the first 2 hours and 5-FU, 500 mg/m2, at hours 3 and 23 followed by leucovorin rescue initiated at hour 24 (15 mg x 8) (MFL)." | 5.06 | Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. ( , 1989) |
| "The effect of hepatic irradiation (RT) after intraarterial 5-fluorouracil (5-FU) was evaluated in 37 randomized patients with colorectal adenocarcinoma hepatic metastases." | 5.06 | Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. A randomized study. ( Demets, D; Lee, JW; Ramirez, G; Stephenson, JA; Wiley, AL; Wirtanen, GW, 1989) |
| "5-Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal cancer (CRC) in the palliative and adjuvant settings." | 5.05 | 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. ( Buchler, T; Cervena, K; Veskrnova, V; Vodenkova, S; Vodicka, P; Vymetalkova, V, 2020) |
| "We included one randomised clinical trial with 61 participants (43 male and 18 female) with colorectal cancer with liver metastases: 22 received transarterial embolisation (TAE; hepatic artery embolisation), 19 received transarterial chemoembolisation (TACE; 5-fluorouracil hepatic artery infusion chemotherapy with degradable microspheres), and 20 received 'no active therapeutic intervention' as a control." | 5.05 | Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. ( Bala, MM; Kleijnen, J; Mitus, JW; Pedziwiatr, M; Riemsma, RP; Storman, D; Swierz, MJ; Wolff, R, 2020) |
| "The clinical benefits of a combination of leucovorin and fluorouracil have been established in the treatment of colorectal cancer." | 5.05 | Efficacy and safety of high-dose vs low-dose leucovorin in patients with colorectal cancer: systematic review and meta-analysis. ( Chen, CY; Hsu, CY; Lin, YM; Tam, KW, 2020) |
| "The combination of oxaliplatin, irinotecan, fluorouracil (5-FU), and leucovorin (FOLFOXIRI) results in improved outcomes compared with standard chemotherapy when used in frontline to treat patients with metastatic colorectal cancer (mCRC)." | 5.01 | FOLFOXIRI plus biologics in advanced colorectal cancer. ( Gallego, I; García, G; García-Alfonso, P; Lloansí, A; Muñoz, A; Ortega, L; Sandoval, C; Torres, G, 2019) |
| "We performed the present systematic review and meta-analysis to evaluate the efficacy and safety for S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma (mCRC)." | 5.01 | Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis. ( Chen, J; Wang, J, 2019) |
| "5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers." | 4.98 | Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018) |
| "The clinical benefit of double-front-line therapy (including oxaliplatin or irinotecan or bevacizumab plus 5-fluorouracil (5FU) or capecitabine) compared to monotherapy (5FU or capecitabine) in elderly (> 70 years) patients with metastatic colorectal cancer (MCRC) is controversial." | 4.98 | Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. ( Aparicio, T; Ghebriou, D; Guetz, GD; Landre, T; Maillard, E; Taleb, C; Zelek, L, 2018) |
| "5-Fluorouracil- and leucovorin-based chemotherapy regimens are the backbone of colorectal cancer treatment." | 4.98 | Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment? ( Bironzo, P; Di Maio, M; Scagliotti, GV; Tampellini, M, 2018) |
| "Nowadays, systemic chemotherapy with intravenous (IV) 5-fluorouracil (5-FU) remains the most commonly prescribed treatment for metastatic colorectal cancers (CRC), in combination with other cytotoxic drugs." | 4.98 | Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis. ( Deng, Y; Wu, Z, 2018) |
| "The last decade has seen the increasing use of biological medicines in combination with chemotherapy containing 5-fluorouracil/oxaliplatin or irinotecan for the treatment of metastatic colorectal cancer (mCRC)." | 4.98 | Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. ( Almeida, PHRF; Andrade, EIG; Cherchiglia, ML; da Silva, WC; de Araujo, VE; de Assis Acurcio, F; Dos Santos, JBR; Godman, B; Kurdi, A; Lima, EMEA; Silva, MRRD, 2018) |
| "The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer." | 4.95 | FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. ( Barni, S; Ghidini, M; Passalacqua, R; Petrelli, F; Russo, A; Tomasello, G, 2017) |
| ", folinic acid (FOL), fluorouracil (F) and oxaliplatin (OX), is a drug cocktail that is used to treat gastric and colorectal cancers." | 4.95 | Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient. ( De Weerdt, A; Dendooven, A; Jorens, PG; Lammens, M; Pen, J; Snoeckx, A, 2017) |
| "Recent studies suggest that 5-fluorouracil (5-FU) dosing by use of pharmacokinetic (PK) parameters is superior to the traditional body surface area (BSA) method in colorectal cancer therapy." | 4.93 | Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis. ( Han, Y; Lyu, Y; Tong, Q; Yang, P; Yang, R; Zhang, P; Zhang, Y; Zhou, H, 2016) |
| "The antiangiogenic monoclonal antibody aflibercept in association with fluorouracil and irinotecan improves the survival of patients with metastatic colorectal cancer (mCRC) treated previously with oxaliplatin-based therapy." | 4.93 | Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. ( Ciuffreda, L; Fanchini, L; Mecca, C; Pinta, F; Ponzetti, A; Racca, P; Spadi, R; Zanini, M, 2016) |
| "This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety." | 4.93 | XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis. ( Cheng, Y; Guo, Y; Ma, L; Xiong, BH; Zhang, T, 2016) |
| " Here, we carried out a network meta-analysis to assess the clinical efficacy and safety of CHIs combined with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for advanced colorectal cancer (CRC)." | 4.93 | Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer. ( Ge, L; Mao, L; Shen, XP; Tian, JH; Wang, YF; Yang, KH; Zhang, J; Zhang, JH, 2016) |
| "Folate was identified as an essential micronutrient early in the twentieth century and anti-folate chemotherapy such as 5-fluorouracil (5-FU) has been central to the medical management of solid tumours including colorectal cancer for more than five decades." | 4.91 | How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy. ( Jennings, BA; Willis, G, 2015) |
| "Capecitabine is a tumor-activated oral fluoropyrimidine used in breast and colorectal cancer." | 4.91 | Hypertriglyceridemia and hyperglycemia induced by capecitabine: a report of two cases and review of the literature. ( Han, GH; Huang, JX, 2015) |
| "The relative efficacy and safety of first-line metastatic colorectal cancer (mCRC) treatment regimens, capecitabine with irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI), are not well defined." | 4.91 | Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI). ( Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD, 2015) |
| "The National Institute for Health and Care Excellence (NICE) invited the manufacturer of aflibercept (Sanofi) to submit clinical and cost-effectiveness evidence for aflibercept in combination with irinotecan and fluorouracil-based therapy [irinotecan/5-fluorouracil/folinic acid (FOLFIRI)] for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy, as part of the Institute's Single Technology Appraisal process." | 4.91 | The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of ( Duarte, A; Duffy, S; Rodriguez-Lopez, R; Simmonds, M; Spackman, E; Wade, R; Woolacott, N, 2015) |
| "Oxaliplatin and either capecitabine or infusional/bolus 5-fluorouracil (5FU)-based chemotherapy + bevacizumab (XELOX + B and FOLFOX + B) represent 2 of the approved first-line treatments for advanced colorectal cancer (CRC)." | 4.91 | Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials. ( Barni, S; Cabiddu, M; Coinu, A; Ghilardi, M; Petrelli, F; Zaniboni, A, 2015) |
| "The clinical benefit of first-line doublet chemotherapy (including oxaliplatin or irinotecan) compared to single-drug therapy (5FU) in elderly patients (>70 or >75 years old) with metastatic colorectal cancer (MCRC) is controversial." | 4.91 | Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. ( Aparicio, T; Des Guetz, G; Landre, T; Mary, F; Nicolas, P; Taleb, C; Uzzan, B; Zelek, L, 2015) |
| "5-fluorouracil continues to be the cornerstone of treatment for colorectal cancer." | 4.90 | Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. ( Avallone, A; Budillon, A; Di Gennaro, E; Iaffaioli, VR; Silvestro, L, 2014) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 4.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| "We tested candidate polymorphisms identified from a systematic literature search for associations with capecitabine toxicity in 927 patients with colorectal cancer in the Quick and Simple and Reliable trial (QUASAR2)." | 4.90 | Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. ( Afzal, S; Boige, V; Braun, M; Church, D; Domingo, E; Enghusen, H; Etienne-Grimaldi, MC; Garcia-Foncillas, J; Garmo, H; Glimelius, B; Gonzalez-Neira, A; Green, E; Gusella, M; Jensen, SA; Johnstone, E; Jones, A; Julier, P; Kerr, D; Kleibl, Z; Lacas, B; Laurent-Puig, P; Lecomte, T; Love, S; Martin, M; Martinez-Balibrea, E; McLeod, H; Midgley, R; Milano, G; Morel, A; Nicholson, G; Palles, C; Pignon, JP; Ribelles, N; Rosmarin, D; Sargent, D; Schwab, M; Scudder, C; Seymour, M; Sharma, R; Thompson, L; Tomlinson, I; Wadelius, M; Wang, H; Zanger, UM, 2014) |
| " All included patients who were treated for colorectal cancer, mainly with oxaliplatin in combination with 5-fluorouracil/leucovorin." | 4.90 | A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. ( Beijers, AJ; Mols, F; Vreugdenhil, G, 2014) |
| "Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line treatments of metastatic colorectal cancer." | 4.90 | A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. ( Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P, 2014) |
| "While 5-fluorouracil used as single agent in patients with metastatic colorectal cancer has an objective response rate around 20%, the administration of combinations of irinotecan with 5-fluorouracil/folinic acid or oxaliplatin with 5-fluorouracil/folinic acid results in significantly increased response rates and improved survival." | 4.90 | FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy. ( Melichar, B; Mohelnikova-Duchonova, B; Soucek, P, 2014) |
| "Thymidylate synthetase is the major target of 5-fluorouracil (5-FU), which is widely used for the treatment of gastric cancer (GC) and colorectal cancer (CRC)." | 4.89 | An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens. ( Fang, JY; Wang, YC; Wang, ZH; Xue, HP, 2013) |
| "Irinotecan and infusional bolus 5-fluorouracil (5-FU)-based chemotherapy (FOLFIRI [5-fluorouracil, folinic acid, irinotecan]) + bevacizumab (FOLFIRI-B) is 1 of the cornerstones of first-line treatment of advanced colorectal cancer (CRC)." | 4.89 | FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. ( Barni, S; Beretta, GD; Borgonovo, K; Cabiddu, M; Ghilardi, M; Lonati, V; Maspero, F; Petrelli, F; Sauta, MG, 2013) |
| "This meta-analysis was performed to determine whether the addition of monoclonal antibodies (mAbs) of epidermal growth factor receptor (EGFR) to oxaliplatin-based chemotherapy treatment improves efficacy in KRAS wild-type metastatic colorectal cancer (mCRC), and whether infusional 5-fluorouracil (5-FU) and oxaliplatin is a preferred combination for EGFR mAbs." | 4.89 | Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody. ( Du, Z; He, X; Hu, Q; Li, M; Li, Q; Sang, Y; Tang, R; Wen, F; Zhang, P; Zhou, Y, 2013) |
| "Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based." | 4.89 | Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. ( Cool, M; Deboever, G; Hiltrop, N; Lambrecht, G, 2013) |
| "Irinotecan and infusional 5-fluorouracil-based chemotherapy (FOLFIRI) plus bevacizumab (FOLFIRI-B) is one of the most effective treatments of advanced colorectal cancer (CRC)." | 4.89 | FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. ( Barni, S; Beretta, GD; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F; Squadroni, M; Stinco, S, 2013) |
| "The aim of this pooled-analysis is to evaluate the benefit of capecitabine (C) versus standard intravenous 5-Fluorouracil (5-FU) as monochemotherapy or combination therapy in advanced colorectal cancer (CRC) in terms of safety and efficacy." | 4.88 | 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials. ( Barni, S; Cabiddu, M; Petrelli, F, 2012) |
| "Many primary studies have considered the association of polymorphisms of folate metabolism and response to 5-fluorouracil (5-FU) and capecitabine in patients with colorectal cancer." | 4.88 | Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. ( Jennings, BA; Kwok, CS; Loke, YK; Matthews, V; Wawruch, P; Willis, G, 2012) |
| "Bevacizumab has efficacy in first-line treatment of advanced colorectal cancer, but the current data are insufficient to support efficacy in all regimens, especially infusional fluorouracil regimens, like FOLFIRI and FOLFOX." | 4.88 | Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. ( da Costa Lima, AB; Macedo, LT; Sasse, AD, 2012) |
| "To evaluate the benefit and safety of fluorouracil implants on colorectal cancer." | 4.88 | [Fluorouracil implants for colorectal cancer: a systematic review and meta-analysis]. ( Chen, JR; Huang, Y; Li, YL; Nie, YL; Zhang, MM, 2012) |
| " In the USA, the approval of cetuximab has been recently expanded to include the first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer (mCRC) when used in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin [folinic acid])." | 4.88 | Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA. ( Lyseng-Williamson, KA, 2012) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "The simultaneous administration of irinotecan, 5-fluorouracil, folinic acid and oxaliplatin (FOLFOXIRI) has been compared with standard 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) in randomized trials in metastatic colorectal cancer patients." | 4.87 | A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. ( Chiriatti, A; Fiorentini, G; Francini, G; Montagnani, F; Turrisi, G, 2011) |
| "Colorectal cancer (CRC) treatment has evolved significantly over the last ten years with the use of active chemotherapeutic agents including fluoropyrimidines, oxaliplatin and irinotecan plus targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab." | 4.87 | Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. ( Charles, KA; Chua, W; Clarke, SJ; Kho, PS; Moore, MM, 2011) |
| "We performed a computerized search using combinations of the following keywords: "metastatic colorectal cancer," "Xeloda," "chemotherapy," "capecitabine," or "5-fluorouracil." | 4.87 | Capecitabine-based chemotherapy for metastatic colorectal cancer. ( Fan, J; Ling, W; Ma, Y; Wang, H, 2011) |
| "The demonstrated efficacy of adding irinotecan, bevacizumab, or cetuximab to fluorouracil-based regimens in the treatment of patients with metastatic colorectal cancer led to several multicenter phase III trials investigating the efficacy of these agents in the adjuvant setting." | 4.87 | Adjuvant treatment of colon cancer: what is next? ( Van Loon, K; Venook, AP, 2011) |
| "We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy." | 4.87 | Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. ( Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM, 2011) |
| "For decades 5-fluorouracil (5-FU) has remained the treatment of choice in the adjuvant and palliative setting of colorectal cancer (CRC)." | 4.87 | DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens. ( Giaccone, G; Giovannetti, E; Hanauske, AR; Leon, LG; Peters, GJ; Smid, K; van Houte, BP, 2011) |
| "This meta-analysis was performed to evaluate the efficacy and safety of capecitabine plus oxaliplatin vs fluorouracil (FU) plus oxaliplatin as first line treatment for metastatic or advanced colorectal cancer." | 4.86 | Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials. ( Cao, Y; Gao, F; Liao, C; Liu, L; Mo, Z; Tan, A, 2010) |
| "We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer." | 4.86 | A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. ( Chen, ML; Dai, LH; Fang, CH; Liang, LS; Wang, XK, 2010) |
| "A meta-analysis of randomized controlled trials (RCT) was carried out to determine the efficacy and safety of capecitabine plus oxaliplatin (CAPOX) or fluorouracil plus oxaliplatin (FUOX) as first-line treatment for metastatic colorectal cancer (MCRC)." | 4.86 | Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis. ( Gao, P; Ma, B; Tian, JH; Yang, KH; Zhao, G, 2010) |
| ", Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC)." | 4.86 | Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. ( Boehm, KA; Cartwright, T; McCollum, D, 2010) |
| "Capecitabine, an oral prodrug of 5-fluorouracil, is indicated for adjuvant treatment in patients with Dukes' C colon cancer and for subsequent lines in metastatic colorectal cancer." | 4.86 | Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer. ( Best, JH; Garrison, LP, 2010) |
| "5-Fluorouracil (5-FU) is a mainstay for treating colorectal cancer, alone or more frequently as part of combination therapies." | 4.86 | Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? ( Ciccolini, J; Dahan, L; Gross, E; Lacarelle, B; Mercier, C, 2010) |
| "Capecitabine is an oral fluoropyrimidine that is shown to have similar efficacy to 5-fluorouracil (5-FU) when used both alone and in combination with oxaliplatin in the treatment of colorectal cancer (CRC)." | 4.86 | Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. ( Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F, 2010) |
| "Literature searches from large publication databases (PubMed, ASCO, ASCO GI, ESMO) were performed to capture key data relevant to bevacizumab, irinotecan, and the treatment of colorectal cancer." | 4.86 | Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. ( Heinemann, V; Hoff, PM, 2010) |
| "To compare clinical efficacy and toxicity of irinotecan combined with 5-fluorouracil and leucovorin with those of oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer." | 4.86 | Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis. ( Hou, SH; Li, YP; Liang, XB; Wang, LC; Yang, J; Zhang, X, 2010) |
| " For colorectal liver metastases (mCRC), in a salvage setting, response was 79% for (90)Y-RE combined with 5-fluorouracil/leucovorin (5-FU/LV), and 79% when combined with 5-FU/LV/oxaliplatin or 5-FU/LV/irinotecan, and in a first-line setting 91% and 91%, respectively." | 4.85 | Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. ( Lam, MG; Nijsen, JF; van den Bosch, MA; van der Tweel, I; van Het Schip, AD; Vente, MA; Wondergem, M; Zonnenberg, BA, 2009) |
| "Capecitabine (N -pentyloxycarbonyl-5-deoxy-5-fluorocytidine), an oral prodrug of 5-fluorouracil, has provided compelling efficacy data for the treatment of metastatic breast cancer and stage III or IV colorectal cancer, both as monotherapy and in combination regimens." | 4.85 | Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. ( Aprile, G; Mazzer, M; Moroso, S; Puglisi, F, 2009) |
| "For many years, 5-fluorouracil was the unique drug approved in the management of colorectal cancer." | 4.85 | [Colorectal cancers: prognostic and predictive factors of response to treatment]. ( Italiano, A; Sablin, MP; Spano, JP, 2009) |
| ", the fluoropyrimidine 5-fluorouracil (5-FU) has remained the mainstay of therapeutic regimens used in the treatment of colorectal cancer and other human malignancies, with single-agent response rates of 20% to 25% in advanced disease stage." | 4.85 | Thymidylate synthase gene variations: predictive and prognostic markers. ( Lenz, HJ; Lurje, G; Manegold, PC; Ning, Y; Pohl, A; Zhang, W, 2009) |
| "Over the past decades, significant progress has been achieved in the cytotoxic treatment of colorectal cancer (CRC) by the use of fluoropyrimidines, irinotecan and oxaliplatin." | 4.85 | A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? ( Koopman, M; Nagtegaal, ID; Punt, CJ; van Krieken, JH; Venderbosch, S, 2009) |
| "Relevant studies were identified in PubMed, Ovid, Cochrane database and the American Society of Clinical Oncology abstracts using the following search terms: gemcitabine, fluorouracil, capecitabine and colorectal cancer." | 4.85 | Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512). ( Hoimes, C; Merl, M; Pham, T; Saif, MW, 2009) |
| " In this review, we summarized the current status of our knowledge about the effectiveness of curcumin when given in combination with current chemotherapeutics such as 5-fluorouracil, oxaliplatin, and gemcitabine in treatment of gastrointestinal cancers with particular reference to colorectal cancer." | 4.85 | Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. ( Majumdar, AP; Patel, BB, 2009) |
| "Continuous-infusion 5-fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin is a frequently used regimen in metastatic colorectal cancer." | 4.84 | Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer? ( Bennouna, J; Douillard, JY; Senellart, H, 2008) |
| "Six randomized phase II and III trials have investigated the role of oxaliplatin (OX) in combination with capecitabine (CAP) or infusional fluorouracil (FU) in metastatic colorectal cancer." | 4.84 | Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. ( Arkenau, HT; Arnold, D; Cassidy, J; Diaz-Rubio, E; Douillard, JY; Grothey, A; Hinke, A; Hochster, H; Martoni, A; Porschen, R; Schmiegel, W; Schmoll, HJ, 2008) |
| "The treatment of metastatic colorectal cancer (mCRC) has changed dramatically from the 1980s, when only fluorouracil (5-FU) was available for treatment and the median survival was at best 12 months, to a time when mCRC is considered more of a chronic disease in which the median survival is now reported in excess of 2 years." | 4.84 | First-line therapeutic strategies in metastatic colorectal cancer. ( Davies, JM; Goldberg, RM, 2008) |
| "5-fluorouracil (5FU)-based treatments remain the main chemotherapy for colorectal cancer." | 4.84 | Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. ( Etienne-Grimaldi, MC; Formento, JL; Francoual, M; Milano, G, 2007) |
| "Based on improved safety and efficacy results, advanced colorectal cancer (CRC) treatment has recently shifted from intravenous bolus 5-fluorouracil (5-FU) monotherapy to standard combinations of prolonged intravenous 5-FU infusion with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI)." | 4.84 | Capecitabine plus oxaliplatin for the treatment of colorectal cancer. ( Carrato, A; Gallego-Plazas, J; Guillén-Ponce, C, 2008) |
| "Uncertainty exists about whether elderly patients benefit to the same extent as younger patients from combination therapy with irinotecan in the first-line treatment of metastatic colorectal cancer (CRC)." | 4.84 | Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. ( Douillard, JY; Folprecht, G; Hecker, H; Köhne, CH; Maughan, TS; Mitry, E; Rougier, P; Saltz, L; Schubert, U; Seymour, MT; Stephens, RJ; Van Cutsem, E, 2008) |
| "Capecitabine, an oral prodrug of fluorouracil (5FU), has shown efficacy in terms of progression-free and overall survival at least equivalent to standard folinic acid (leucovorin)-modulated intravenous 5FU bolus regimens in patients with metastatic colorectal cancer." | 4.84 | Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence. ( Avallone, A; Casaretti, R; Comella, P; Franco, L; Sandomenico, C, 2008) |
| "To evaluate three technologies for the management of advanced colorectal cancer: (1) first-line irinotecan combination [with 5-fluorouracil (5-FU)] or second-line monotherapy; (2) first- or second-line oxaliplatin combination (again, with 5-FU); and (3) raltitrexed, where 5-FU is inappropriate." | 4.84 | The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. ( Eggington, S; Hind, D; Ryan, A; Sutcliffe, P; Tappenden, P; Tumur, I, 2008) |
| "Modern chemotherapy combinations for metastatic colorectal cancer (mCRC) comprise infusional 5-fluorouracil (5-FU), leucovorin, and irinotecan or oxaliplatin." | 4.84 | Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer. ( Heinemann, V; Moosmann, N, 2008) |
| "In Western countries, efficacy of 5-fluorouracil (5-FU)+leucovorin (LV) as adjuvant chemotherapy for colorectal cancer has been already established." | 4.83 | [Adjuvant chemotherapy for colorectal cancer]. ( Akasu, T, 2006) |
| "We reviewed published studies reporting phase II and III clinical trials of dose-dense regimens for breast cancer and NHL, TAC (docetaxel, adriamycin, cyclophosphamide) chemotherapy for breast cancer, and infusional 5-fluorouracil-based regimens for colorectal cancer." | 4.83 | Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. ( Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M, 2006) |
| "In a dozen years of development, irinotecan (CPT11) became one of major therapeutics in the taking care of the metastatic colorectal cancer (CCRM)." | 4.83 | [Irinotecan for the treatment of metastatic colorectal cancer]. ( Assenat, E; Duffour, J; Ychou, M, 2006) |
| "A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients." | 4.83 | [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006) |
| "An IFL regimen combining irinotecan, a bolus administration of 5-fluorouracil (5-FU) and leucovorin (LV) was associated with a significantly better response rate, progression-free survival and median overall survival, compared to 5-FU/LV against metastatic colorectal cancer." | 4.83 | [IFL]. ( Boku, N; Yamazaki, K; Yoshino, T, 2006) |
| " A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia." | 4.83 | Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006) |
| "Oxaliplatin, fluorouracil, and leucovorin are commonly used to treat advanced and resected colorectal cancer." | 4.83 | Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. ( Andre, T; Bleiberg, H; de Gramont, A; Goldberg, RM; Green, E; Rothenberg, ML; Sargent, DJ; Tabah-Fisch, I; Tournigand, C, 2006) |
| "Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, was approved in 2004 for use in combination with intravenous 5-fluorouracil-based chemotherapy for the treatment of metastatic colorectal cancer." | 4.83 | Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. ( Hochster, HS, 2006) |
| "The synergism between oxaliplatin and 5-fluorouracil (5FU)/leucovorin in the treatment of colorectal cancer raises the prospect of further clinically effective combinations." | 4.82 | New oxaliplatin-based combinations in the treatment of colorectal cancer. ( Cassidy, J; Hochster, H, 2003) |
| "5-Fluorouracil (5-FU) and irinotecan are now widely used for the treatment of advanced colorectal cancer." | 4.82 | Optimal use of the combination of irinotecan and 5-fluorouracil. ( Benson, AB; Goldberg, RM, 2003) |
| "Since its synthesis over 40 years ago, several studies including patients with colorectal cancer have shown that prolonged exposure to 5-fluorouracil (5-FU) is associated with better antitumor activity and decreased toxicity." | 4.82 | Practical considerations in the use of oral fluoropyrimidines. ( Hoff, PM, 2003) |
| "In patients with stage III colorectal cancer (CRC) who have undergone potentially curative resection, adjuvant treatment with 6 months' of 5-fluorouracil (5-FU) plus folinic acid (FA) is generally accepted as standard treatment and leads to a 5% to 10% improvement in absolute survival when compared with a no-chemotherapy control." | 4.82 | Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. ( Cascinu, S; Georgoulias, V; Kerr, D; Labianca, R; Maughan, T; Ychou, M, 2003) |
| "5-Fluorouracil (5-FU), used according to several types of administration and several modulations, remained the standard treatment of colorectal cancer for many years." | 4.82 | Colorectal cancer: integrating oxaliplatin. ( de Gramont, A; Louvet, C, 2003) |
| "During the last decade, considerable progress has been made in the development of 5-fluorouracil/leucovorin (5-FU/LV) regimens that optimize antitumor efficacy while minimizing toxicity in the management of colorectal cancer." | 4.82 | Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer. ( de Gramont, A; Kuebler, JP, 2003) |
| "Irinotecan (CPT-11, Camptosar) is one of the new generation of chemotherapeutic agents that has activity in advanced colorectal cancer." | 4.82 | Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule. ( Eisenberg, SG; Hwang, JJ; Marshall, JL, 2003) |
| "To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens." | 4.82 | Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. ( Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S, 2003) |
| "5-fluorouracil (5-FU) plus leucovorin (LV) therapy is the most widely used regimen with a high evidence as the first-line treatment for advanced colorectal cancer (CRC), as well as CPT-11 as the second-line." | 4.82 | [Chemotherapy for colorectal carcinoma]. ( Enomoto, M; Higuchi, T; Sugihara, K; Uetake, H, 2003) |
| " Oral prodrugs of 5-FU, such as capecitabine and uracil, have been developed in order to mimic the protracted infusion schedule of 5-FU, and these drugs may change the daily practice of palliative chemotherapy for colorectal cancer in the coming years." | 4.82 | New developments in systemic chemotherapy in advanced colorectal cancer. ( Cats, A, 2003) |
| "Four phase III clinical trials comparing a fluorouracil-based regimen with the same regimen plus either CPT-11 or oxaliplatin in advanced colorectal cancer patients were reviewed." | 4.82 | Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. ( Bleiberg, H; Buyse, M; Di Leo, A, 2004) |
| "Fluorouracil (FU)-leucovorin (LV), irinotecan, and oxaliplatin administered alone or in combination have proven effective in the treatment of advanced colorectal cancer (CRC)." | 4.82 | Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. ( Goldberg, RM; Grothey, A; Sargent, D; Schmoll, HJ, 2004) |
| "For advanced colorectal cancer (ACC), 5-fluorouracil (5-FU) based chemotherapy has been the standard for some decades." | 4.82 | Systemic treatment of advanced colorectal carcinoma. ( Punt, CJ; van Laarhoven, HW, 2004) |
| "Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine." | 4.82 | Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). ( Hoff, P; Lassere, Y, 2004) |
| "Switching patients from intravenous 5-FU/LV to oral capecitabine (Xeloda) for the treatment of metastatic colorectal cancer is associated with a reduction in the need for hospitalisations to manage 5-FU-associated delivery and complications, with resulting healthcare savings." | 4.82 | Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. ( Deery, P; Faithfull, S, 2004) |
| "The modulation of fluorouracil (FU) by folinic acid (leucovorin [LV]) has been shown to be effective in terms of tumor response rate in patients with advanced colorectal cancer, but a meta-analysis of nine trials previously published by our group failed to demonstrate a statistically significant survival difference between FU and FU-LV." | 4.82 | Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. ( Braud, AC; Buyse, M; Carlson, RW; Michiels, S; O'Connell, M; Piedbois, P; Pignon, JP; Sargent, P; Thirion, P, 2004) |
| " Although fluorouracil (5-FU) has been used for over 40 years, only in the last decade has its value been recognized in the treatment of advanced colorectal cancer." | 4.82 | Evidence-based update of chemotherapy options for metastatic colorectal cancer. ( Damjanovic, D; Findlay, MP; Thompson, P, 2004) |
| "Hand-foot syndrome is a localized cutaneous side effect associated with the administration of several chemotherapeutic agents, including the oralfluoropyrimidine capecitabine (Xeloda)." | 4.82 | Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. ( Blum, J; Scheithauer, W, 2004) |
| "New results presented at ASCO Conference in 2003 added further important data to our knowledge on successful use of irinotecan in colorectal cancer (CRC)." | 4.82 | [Recent results of irinotecan therapy in colorectal cancer]. ( Hitre, E; Láng, I, 2004) |
| "Variations of fluorouracil (5-FU) therapy have formed the backbone of chemotherapy for advanced colorectal cancer for many years." | 4.82 | Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics. ( Hwang, JJ, 2004) |
| "5-Fluorouracil (5-FU) plus leucovorin (LV) has been the mainstay of treatment for colorectal cancer (CRC), with infused schedules more widely adopted in Europe and bolus schedules preferred in North America." | 4.82 | Oral capecitabine: bridging the Atlantic divide in colon cancer treatment. ( Tejpar, S; Van Cutsem, E; Verslype, C, 2005) |
| "Fluorouracil (FU) has been the mainstay of treatment for metastatic colorectal cancer (mCRC) for many years." | 4.82 | Critical evaluation of current treatments in metastatic colorectal cancer. ( Venook, A, 2005) |
| "In 2002, the UK National Institute for Clinical Excellence (NICE) issued guidance on the use of irinotecan, oxaliplatin and raltitrexed in advanced colorectal cancer." | 4.82 | The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. ( Poston, GJ, 2005) |
| "Since the introduction of combined systemic chemotherapy with 5-folinic-acid (FA) and/or oxaliplatin or irinotecan, the median survival in patients with advanced colorectal cancer has increased to more than 20 months." | 4.82 | Indications and effect on survival of standard chemotherapy in advanced colorectal cancer. ( Kallinowski, B, 2005) |
| "Irinotecan is a cornerstone drug in the management of metastatic colorectal cancer, as demonstrated by several randomized studies proving a survival benefit for the first time." | 4.82 | Irinotecan-based regimens in the adjuvant therapy of colorectal cancer. ( Douillard, JY, 2005) |
| "In recent years, oxaliplatin-based chemotherapy protocols, particularly oxaliplatin in combination with infusional 5-fluorouracil/leucovorin (FOLFOX or FUFOX), have emerged as the standard of care in first- and second-line therapy of advanced-stage colorectal cancer." | 4.82 | Clinical management of oxaliplatin-associated neurotoxicity. ( Grothey, A, 2005) |
| " Of these, capecitabine is the most established, with registrations in most countries for breast and colorectal cancer." | 4.82 | Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer. ( Cassidy, J, 2005) |
| "Capecitabine is active against anthracycline- and taxane-pretreated metastatic breast cancer." | 4.82 | Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. ( Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V, 2005) |
| "Significant advances have been made in the treatment of advanced colorectal cancer over the past 5 years, namely due to the introduction of three novel cytotoxic agents-capecitabine (Xeloda), irinotecan (Camptosar), and oxaliplatin (Eloxatin)-and the recent approval of two biologic agents-bevacizumab (Avastin) and cetuximab (Erbitux)." | 4.82 | Current therapies for advanced colorectal cancer. ( Aggarwal, S; Chu, E, 2005) |
| "We examined the cardiotoxicity in 153 patients treated with capecitabine and oxaliplatin in two prospective trials for advanced colorectal cancer." | 4.82 | The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). ( Cunningham, D; Ng, M; Norman, AR, 2005) |
| "For the last four decades, fluorouracil (FU) has been the main treatment of choice in colorectal cancer (CRC) in both the advanced and adjuvant settings." | 4.82 | Role of genomic markers in colorectal cancer treatment. ( Allen, WL; Johnston, PG, 2005) |
| "For more than 40 years, 5-fluorouracil (5-FU) has been considered the most effective systemic agent for managing advanced colorectal cancer." | 4.82 | Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. ( Saif, MW, 2005) |
| "For several decades, 5-fluorouracil (5-FU) with or without leucovorin defined the standard of care for the treatment of metastatic colorectal cancer (CRC)." | 4.82 | Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. ( Hurwitz, H; Kabbinavar, F, 2005) |
| "For four decades, 5-fluorouracil was the only option available for patients with metastatic colorectal cancer." | 4.82 | Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy. ( Hoff, PM; Varadhachary, GR, 2005) |
| "The addition of oxaliplatin and irinotecan to the armamentarium for the treatment of colorectal cancer (CRC) has resulted in significant improvements in response rates and survival." | 4.82 | The role of bevacizumab as first-line therapy for colon cancer. ( Marshall, J, 2005) |
| "Recent trials have established the IFL combination (fluorouracil [5-FU], leucovorin, and irinotecan [CPT-11, Camptosar]) as a new standard first-line therapy for patients with metastatic colorectal cancer." | 4.81 | Targeting vascular endothelial growth factor in colorectal cancer. ( Berlin, JD, 2002) |
| "In the last 50 years, 5-fluorouracil-based therapy has been the mainstay of adjuvant and palliative treatment for colorectal cancer but response rates and median survival have been dismal despite the introduction of thymidylate synthase modulators such as leucovorin." | 4.81 | The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. ( Schmoll, HJ, 2002) |
| "5-Fluorouracil (5-FU) has been utilized as part of standard chemotherapy for treatment of early-stage and metastatic colorectal cancer for more than 4 decades." | 4.81 | Oral fluoropyrimidine treatment of colorectal cancer. ( Eng, C; Kindler, HL; Schilsky, RL, 2001) |
| "The combination of capecitabine (Xeloda) and oxaliplatin (Eloxatin), or XELOX, is an effective and safe approach to the treatment of advanced colorectal cancer, with the potential advantage of convenience over standard combination regimens." | 4.81 | Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? ( Twelves, C, 2002) |
| "For nearly 40 years, the medical treatment of colorectal cancer had been limited to the fluoropyrimidines until the recent development of irinotecan (CPT-11)." | 4.81 | Oxaliplatin: a new agent for colorectal cancer. ( Pelley, RJ, 2001) |
| "Randomized studies have tested a variety of strategies to improve the activity of 5-fluorouracil (5-FU) in colorectal cancer patients." | 4.81 | Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer. ( Grem, JL, 2001) |
| "In this review, the clinical rationale and update of the present clinical status of irinotecan in the treatment of colorectal cancer and future prospects of irinotecan-based combinations are discussed." | 4.81 | Irinotecan in the treatment of colorectal cancer: clinical overview. ( Achterrath, W; Cao, S; Harstrick, A; Rustum, YM; Seeber, S; Vanhoefer, U, 2001) |
| "In colorectal cancer, leucovorin-modulated 5-fluorouracil (5-FU) has been the mainstay of both adjuvant treatment and treatment of metastatic disease for many years." | 4.81 | Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. ( Cunningham, D; James, RD, 2001) |
| "For several decades fluoropyrimidines, especially 5-fluorouracil (5-FU), have played a role in standard chemotherapy regimens for a range of solid tumours, including breast and colorectal cancers." | 4.81 | New options for outpatient chemotherapy--the role of oral fluoropyrimidines. ( Coleman, R; Cunningham, D, 2001) |
| "Oxaliplatin, a third-generation platinum analogue, is a novel compound with proven anti-tumor activity in colorectal cancer that has demonstrated synergy with 5-fluorouracil (5-FU) in human tumor xenograft models." | 4.81 | Integrating oxaliplatin into the management of colorectal cancer. ( Cassidy, J; Schmoll, HJ, 2001) |
| "Although 5-fluorouracil (5-FU) has been used to treat breast and colorectal cancers for several decades, bolus 5-FU has disappointing efficacy." | 4.81 | Capecitabine: a novel agent for the treatment of solid tumors. ( Johnston, PG; Kaye, S, 2001) |
| "Irinotecan (CPT-11) is a potent inhibitor of topoisomerase I, and has demonstrated antitumor activity against metastatic colorectal cancer." | 4.81 | [Standard therapy of CPT-11 for colorectal cancer]. ( Saitoh, S; Sakata, Y, 2001) |
| "Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) both have demonstrated single-agent activity in patients with colorectal cancer." | 4.81 | Capecitabine/irinotecan combination regimens in colorectal cancer. ( Kerr, DJ, 2002) |
| "Raltitrexed ('Tomudex') monotherapy is a conveniently administered alternative to 5-fluorouracil (5-FU) in the first-line treatment of advanced colorectal cancer (CRC), and has single-agent activity in a variety of advanced solid tumours." | 4.81 | Raltitrexed: current clinical status and future directions. ( Cervantes, A; Cunningham, D; Glimelius, B; Maroun, J; Van Cutsem, E, 2002) |
| "Although significant advances have been made in the treatment of advanced/metastatic colorectal cancer, 5-fluorouracil (5-FU) still forms the basis of chemotherapy." | 4.81 | Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? ( Cassidy, J; Twelves, CJ, 2002) |
| "The administration of fluorouracil (5-FU) by continuous intravenous infusion (CI) is an alternative to the bolus administration of 5-FU in patients with advanced colorectal cancer." | 4.80 | Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Levy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, J; Rougier, P; Ryan, L; Weinerman, B; Zee, B, 1998) |
| "5-Fluorouracil (5-FU) remains the agent of choice for the treatment of colorectal cancer." | 4.80 | Biomodulation of Fluorouracil in colorectal cancer. ( Ardalan, B; Franceschi, D; Jaime, M; Luis, R, 1998) |
| "Oxaliplatin was first introduced to the clinical setting as a combination therapy with 5-fluorouracil/folinic acid (5-FU/FA) in an attempt to improve the response rate obtained with 5-FU/FA against colorectal cancer." | 4.80 | Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. ( Bleiberg, H; de Gramont, A, 1998) |
| " Synergistic effects with traditional therapy 5-fluorouracil/folinic acid have increased response rates significantly, improved time-sensitive response parameters, and facilitated the removal of previously unresectable hepatic metastases, thus changing the natural history of the disease." | 4.80 | Oxaliplatin for the treatment of advanced colorectal cancer: future directions. ( Bekradda, M; Cvitkovic, E; Ducreux, M; Louvet, C, 1998) |
| "The addition of leucovorin (LV) to 5-fluorouracil (5-FU) in advanced colorectal cancer has shown improved tumour response rates in many trials, but the optimal LV/5-FU regimen has yet to be determined." | 4.80 | A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). ( André, T; de Gramont, A; Krulik, M; Louvet, C; Tournigand, C, 1998) |
| "But fluorouracil (5-FU) and irinotecan (CPT-11 [Camptosar]) have shown activity in metastatic colorectal cancer and are approved for its treatment in the United States." | 4.80 | Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. ( Erlichman, C; Goldberg, RM, 1998) |
| "Although 5-fluorouracil (5-FU) has been used to treat advanced colorectal cancer for 45 years, the drug has only a modest response rate and impact on survival." | 4.80 | Therapy for advanced colorectal cancer. ( Benson, AB, 1998) |
| "Salvage treatment with 5-fluorouracil (5-FU) with or without leucovorin may induce responses in patients with advanced colorectal cancer whose disease progresses after adjuvant therapy with the same drugs." | 4.80 | Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? ( Goldberg, RM, 1998) |
| "Therapeutic options after failure of 5-fluorouracil (5-FU) for the treatment of colorectal cancer include regional treatments, different 5-FU-based regimens, and different chemotherapy regimens." | 4.80 | Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. ( Henderson, CA, 1998) |
| "Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with advanced colorectal cancer, but the survival difference between the two treatments is small and, therefore, the difference in toxicity profile is crucial in choosing a treatment for individual patients." | 4.80 | Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Lévy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, JP; Quinaux, E; Rougier, P; Ryan, L; Thirion, P; Weinerman, B; Zee, B, 1998) |
| "The treatment of advanced colorectal cancer has been evaluated in a series of randomized trials, including infusional and modulated 5-fluorouracil (5-FU), and three meta-analyses encompassing trials of 5-FU plus leucovorin, continuous-infusion 5-FU, and intra-arterial fluoropyrimidines." | 4.80 | Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results. ( Benson, AB, 1998) |
| "5-Fluorouracil (5-FU) has been the mainstay of systemic therapy for colorectal cancer since its initial development 40 years ago." | 4.80 | Oral fluoropyrimidines in the treatment of colorectal cancer. ( Meropol, NJ, 1998) |
| " Chemotherapy with fluorouracil (5FU) plus leucovorin remains a standard in the treatment of patients with metastatic colorectal cancer." | 4.80 | [Irinotecan in combination for colon cancer]. ( André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M, 1998) |
| "The final results of two very important randomized trials of irinotecan (Campto, Rhône-Poulenc Rorer, Antony, France) as second-line treatment for patients with advanced colorectal cancer are presented." | 4.80 | Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice. ( Cunningham, D, 1999) |
| "5-Fluorouracil (5-FU) has been available for over 40 years and has been used in a wide variety of different regimens for the treatment of advanced colorectal cancer, a malignancy with a poor prognosis that is common in industrialized countries." | 4.80 | Which 5-fluorouracil regimen?--the great debate. ( Harper, P; Labianca, R; Vincent, M, 1999) |
| "After nearly four decades of clinical experience with the fluoropyrimidines, 5-fluorouracil (5-FU) remains an integral part of chemotherapy for colorectal cancer." | 4.80 | Fluoropyrimidines: a critical evaluation. ( Brito, RA; Hoff, PM; Medgyesy, D; Pazdur, R; Ravandi-Kashani, F; Royce, ME; Zukowski, TH, 1999) |
| "For over four decades, 5-fluorouracil (5-FU) has been the mainstay of therapy for colorectal cancer and a major cytotoxic agent for treating gastrointestinal tumors and a variety of others, including breast and head and neck cancers." | 4.80 | Potential of Xeloda in colorectal cancer and other solid tumors. ( Cassidy, J, 1999) |
| "The evolution of and rationale for fluorouracil-based strategies in the treatment of metastatic colorectal cancer are discussed, and the role of the new oral fluoropyrimidines is described." | 4.80 | Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer. ( Ignoffo, RJ, 1999) |
| "For nearly four decades, 5-fluorouracil (5-FU) has been the mainstay of treatment for colorectal cancer." | 4.80 | Where do we stand with 5-fluorouracil? ( Büchele, T; Dempke, W; Grothey, A; Schmoll, HJ, 1999) |
| "For years, 5-fluorouracil (5-FU) was the only chemotherapeutic agent for the treatment of patients with advanced colorectal cancer." | 4.80 | New drugs in therapy of colorectal cancer: preclinical studies. ( Cao, S; Rustum, YM, 1999) |
| "Protracted intravenous infusions of fluorouracil (5-FU) in the treatment of colorectal cancer have been associated with a reduction in toxicity and enhanced clinical activity compared with bolus 5-FU schedules." | 4.80 | Oral fluoropoyrimidines. ( Brito, R; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, M, 1999) |
| "The combination of 5-fluorouracil (5-FU) and leucovorin has been the unofficial "standard" therapy for patients with colorectal cancer for over a decade." | 4.80 | The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. ( Papamichael, D, 1999) |
| "Today, adjuvant 5-fluorouracil based therapy is known to significantly reduce the relapse rates and the risks of dying from resected colon cancer; chemotherapy approximately doubles overall survival of advanced colorectal cancer and second line treatment prolongs the survival of patients compared with best supportive care." | 4.80 | New directions in the treatment of colorectal cancer: a look to the future. ( Aapro, M; Glimelius, B; Kerr, D; Milano, G; Pritchard, DM; Rougier, P; Sobrero, A; Van Cutsem, E, 2000) |
| "The combination of 5-fluorouracil (5-FU) and leucovorin has been the unofficial "standard" therapy for patients with colorectal cancer for over a decade." | 4.80 | The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. ( Papamichael, D, 2000) |
| " This review describes several oral fluoropyrimidine regimens with activity in colorectal cancer: capecitabine (Xeloda), tegafur, UFT, S-1, and eniluracil plus 5-FU." | 4.80 | Oral therapy for colorectal cancer: how to choose. ( Damjanov, N; Meropol, NJ, 2000) |
| "Fluorouracil has been the mainstay of treatment for colorectal cancer (CRC) for almost 40 years." | 4.80 | Progress in colorectal cancer chemotherapy: how far have we come, how far to go? ( Hoff, PM; Pazdur, R; Royce, ME, 2000) |
| "Oxaliplatin in combination with fluorouracil/folinic acid is an effective treatment option for patients with metastatic colorectal cancer, both as a first-line therapy and in patients refractory to previous chemotherapy." | 4.80 | Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. ( Clemett, D; Culy, CR; Wiseman, LR, 2000) |
| "For several years, fluorinated pyrimidines have been used in the treatment of advanced colorectal cancer, mainly in the form of intravenous injections of 5-fluorouracil (5-FU), alone or in combination with leucovorin." | 4.80 | [Fluorinated pyrimidines in oral treatment of advanced colorectal cancer]. ( Harboe, K; Lind, A; Ogreid, D; Todnem, K; Zotova, L, 2000) |
| "Irinotecan, also known as CPT-11, is a topoisomerase I inhibitor currently approved for use as a second-line agent in the treatment of advanced colorectal cancer." | 4.80 | The role of irinotecan in colorectal cancer. ( Saltz, LB, 1999) |
| " This hypothesis has been tested mostly in 5-fluorouracil (5-FU)-based regimens in colorectal cancer." | 4.80 | [Molecular markers as basis for chemotherapy?]. ( Brabender, J; Danenberg, PV; Lenz, HJ, 2000) |
| "Fluorouracil (5-FU) has remained the standard therapy for the treatment of advanced colorectal cancer for over 40 years." | 4.80 | Colorectal cancer: chemotherapy treatment overview. ( Dwivedy, S; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, ME; Zukowski, TH, 2000) |
| " Phase II studies have shown that this agent has significant single-agent activity against both chemotherapy-naive and fluorouracil (5-FU)-refractory colorectal cancer." | 4.80 | Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer. ( Saltz, L, 2000) |
| "Two randomized phase III trials with irinotecan as second-line treatment of metastatic colorectal cancer have shown that irinotecan (CPT-11, Camptosar) significantly improves survival when compared with best supportive care or continuous infusion of fluorouracil (5-FU) after failure of 5-FU." | 4.80 | Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. ( Douillard, JY, 2000) |
| " Although retreatment with fluorouracil (5-FU) is common, offering colorectal cancer patients a different chemotherapeutic agent as second-line therapy is a fairly recent strategy." | 4.80 | Second-line therapy in colorectal cancer. ( Berlin, J, 2000) |
| "No adequate second- or third-line therapy is available in the United States for patients with metastatic colorectal cancer and disease progression following treatment with fluorouracil (5-FU)-based therapy and an irinotecan (CPT-11, Camptosar)-containing regimen, or a combination of the two." | 4.80 | Oxaliplatin with 5-FU or as a single agent in advanced/metastatic colorectal cancer. ( Mitchell, EP, 2000) |
| "5-Fluorouracil (5-FU) is the most active single agent for treatment of advanced colorectal cancer, although objective responses occur in only 20% of patients, and there seems to be no impact on overall survival." | 4.79 | Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials. ( Raderer, M; Scheithauer, W, 1995) |
| "We report a patient who developed multifocal cerebral demyelination with the use of 5-fluorouracil, levamisole, and leucovorin as adjuvant treatment for intestinal adenocarcinoma." | 4.79 | Cerebral demyelination with 5-fluorouracil and levamisole. ( Fassas, AB; Gattani, AM; Morgello, S, 1994) |
| "Even though fluorouracil (5FU) remains the standard treatment of advanced colorectal cancer, almost 90% of patients treated with 5FU alone do not achieve an objective response to chemotherapy." | 4.79 | Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. ( , 1994) |
| "Possible prognostic variables for tumor response, time to progression (TTP), and survival in 141 patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy were analyzed." | 4.79 | Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. ( Fountzilas, G; Gossios, K; Pavlidis, N; Skarlos, D; Svarna, E; Zisiadis, A, 1996) |
| "Since the late 1950s, 5-fluorouracil (5-FU) has remained the most effective chemotherapeutic agent in the treatment of advanced colorectal cancer, although response rates to 5-FU monotherapy are typically no more than 15%." | 4.79 | Role of chemotherapy for advanced colorectal cancer: new opportunities. ( Bleiberg, H, 1996) |
| " This demonstration was achieved using a 5-day infusion of 5-fluorouracil, leucovorin, and oxaliplatin in patients with colorectal cancer metastases." | 4.79 | Chronotherapy for gastrointestinal cancers. ( Lévi, F, 1996) |
| "CPT-11 (Campto, irinotecan) is a new topoisomerase I inhibitor and one of very few new cytotoxic agents to demonstrate clinical activity in colorectal cancer since the introduction of 5-fluorouracil (5-FU) into clinical practice almost 40 years ago." | 4.79 | CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. ( Khayat, D; Saltz, L; Shimada, Y, 1996) |
| "Several modifications to the administration schedule of 5-fluorouracil (5-FU) alone or in combination with other agents have been investigated in advanced colorectal cancer." | 4.79 | Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies. ( Facendola, G; Labianca, R; Luporini, G; Pessi, A; Pirovano, M, 1996) |
| "All of the published adjuvant studies for colorectal cancer in which 5-FU (either as a single agent or in combination with other cytotoxics or levamisole) was compared to a no-treatment control group were ranked according to the total planned dose of 5-FU (assuming a body weight of 70 kg or a body surface area of 1." | 4.79 | The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. ( Siderov, J; Simes, J; Zalcberg, JR, 1996) |
| "We undertook a meta-analysis to assess the effects on recurrence and survival of administering fluorouracil (5-FU)-based chemotherapy by PVI after colorectal cancer surgery." | 4.79 | Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group. ( , 1997) |
| "5-fluorouracil (5-FU) is the best available drug for the treatment of advanced colorectal cancer." | 4.79 | High-dose infusional 5-FU in the treatment of advanced colorectal cancer: a summary of the European experience. ( Wils, JA, 1996) |
| "The rational of leucovorin modulation of 5-fluorouracil and the clinical results in colorectal cancer are reviewed with special emphasis on the monthly schedule of low dose leucovorin and 5FU bolus for 5 consecutive days (NCCTG-Mayo Clinic regimen) and the bimonthly schedule of high-dose leucovorin and 5FU bolus plus continuous infusion for two consecutive days (LV5FU2) which is now considered as a new standard." | 4.79 | [Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)]. ( André, T; de Gramont, A; Krulik, M; Louvet, C; Molitor, JL; Raymond, E; Tournigand, C, 1997) |
| "Since the clinical introduction of 5-fluorouracil (5-FU) in 1958, improvements in the treatment of advanced colorectal cancer have been modest." | 4.79 | Chemotherapy of colorectal cancer: history and new themes. ( Bertino, JR, 1997) |
| "A variety of 5-fluorouracil (5-FU)- based chemotherapy regimens have been investigated in colorectal cancer patients in randomized trials over the past decade." | 4.79 | Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin. ( Grem, JL, 1997) |
| "In patients with metastatic colorectal cancer (CRC), conventional chemotherapy with 5-fluorouracil (5-FU) plus leucovorin provides an overall response rate of approximately 25% but has had little effect on survival." | 4.79 | Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. ( Clark, JW, 1997) |
| "5-Fluorouracil (5-FU) is still the mainstay of chemotherapy in patients with metastatic colorectal cancer." | 4.78 | Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. ( Harstrick, A; Köhne-Wömpner, CH; Rustum, YM; Schmoll, HJ, 1992) |
| "A meta-analysis was performed on nine randomized clinical trials that compared fluorouracil (5-FU) with 5-FU plus intravenous (IV) leucovorin (LV) for the treatment of advanced colorectal cancer." | 4.78 | Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. ( , 1992) |
| "The systemic management of patients with colorectal cancer continues to center on the use of 5-fluorouracil (5-FU)." | 4.78 | Systemic therapy for colorectal cancer: an overview. ( Mayer, RJ, 1991) |
| "Three clinical trials have been conducted with fluorouracil (5-FU) and recombinant interferon alfa-2a (rIFN-alpha 2a) in the treatment of advanced colorectal carcinoma." | 4.78 | Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas. ( Bready, B; Moore, DF; Pazdur, R, 1991) |
| "Seventy-five previously untreated patients with measurable advanced colorectal cancer were treated with 5 fluorouracil 1,000 mg/m2 as a 24-hour intravenous (i." | 4.78 | 120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer. ( Aguilo, J; Asencio, F; Candel, MT; Delgado, F; García-Reinoso, J; Martínez-Abad, M; Sánchez, JJ; Sanchis, C; Viciano, V; Villar-Grimalt, A, 1991) |
| " Studies show a definite therapeutic advantage for folinic acid/5-fluorouracil (5-FU) regimen compared with single agent 5-FU given intravenously in the management of advanced colorectal cancer." | 4.78 | Clinical trials with 5-fluorouracil, folinic acid and cisplatin in patients with gastrointestinal malignancies. ( Avvento, L; Madajewicz, S, 1990) |
| "Fluorouracil-based chemotherapy regimens have been utilized in metastatic colorectal cancer for more than 30 years." | 4.78 | Systemic therapy in metastatic colorectal cancer. ( Hansen, RM, 1990) |
| "To evaluate the safety and effectiveness of aflibercept in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in Korean patients with metastatic colorectal cancer (mCRC) who progressed with oxaliplatin-containing regimen." | 4.31 | Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. ( Ahn, MS; Bae, BN; Baik, SH; Beom, SH; Han, SW; Jeon, SY; Jo, HJ; Kang, MH; Kim, DH; Kim, HK; Kim, JG; Kim, JH; Kim, JS; Kim, JY; Lee, MA; Lee, S; Oh, J; Park, I; Park, YS; Shin, SH; Yoon, JA; Zang, DY, 2023) |
| "Safety and effectiveness of aflibercept with 5-fluorouracil/levofolinate/irinotecan have not been reported in Japanese patients with metastatic colorectal cancer (mCRC) in a real-world clinical setting." | 4.31 | Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance. ( Kazama, H; Terazawa, T; Uetake, H; Watanabe, J; Yamane, S; Yoshino, T, 2023) |
| "Using WES after a doublet chemotherapy regimen comprising irinotecan and 5-fluorouracil (n = 15), seven single nucleotide polymorphisms (SNPs) were identified as candidate biomarkers for irinotecan-associated toxicity of neutropenia." | 4.31 | Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. ( Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S, 2023) |
| "5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent for colorectal cancer (CRC) owing to its potent anticancer effects." | 4.31 | 5-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy. ( Bae, J; Hee Lee, E; Kim, H; Kim, J; Kim, MS; Kwak, D; Lee, J; Phyu Hlaing, S; Ryong Moon, H; Saparbayeva, A; Yoo, JW; Yoon, IS, 2023) |
| "5-Fluorouracil (5-FU) is one of the frequently used chemotherapeutic agents against colorectal cancer (CRC)." | 4.31 | microRNA-143 interferes the EGFR-stimulated glucose metabolism to re-sensitize 5-FU resistant colon cancer cells via targeting hexokinase 2. ( Chen, W; Chen, Y; Hui, T, 2023) |
| " However, the role of LOXL2 in the 5-fluorouracil (5-FU) resistance of colorectal cancer (CRC) remains unclear." | 4.31 | LOXL2 reduces 5-FU sensitivity through the Hedgehog/BCL2 signaling pathway in colorectal cancer. ( Chang, H; Lin, W; Mao, W; Peng, Q; Qiu, S; Qiu, Z, 2023) |
| "5-Fluorouracil (5-FU) represents the cornerstone for colorectal cancer therapy." | 4.31 | Enhancement of the antitumor effect of 5-fluorouracil with modulation in drug transporters expression using PI3K inhibitors in colorectal cancer cells. ( Abo-Elfadl, MT; Abo-Zeid, MAM; El-Daly, SM; Hussein, J, 2023) |
| "As EIF3D is oncogenic in colorectal cancer (CRC) and is associated with multidrug resistance, this study aims to investigate whether and how EIF3D regulates resistance to 5-fluorouracil (5-Fu) in CRC." | 4.31 | EIF3D promotes resistance to 5-fluorouracil in colorectal cancer through upregulating RUVBL1. ( Du, W; Li, C; Liang, Z; Lu, K; Yang, C, 2023) |
| "Capecitabine is a molecule of choice in the therapeutic arsenal of anticancer drugs used in Morocco for the treatment of breast cancer and colorectal cancer." | 4.31 | Assessment of patients' knowledge of their treatment with capecitabine at the National Institute of Oncology in Rabat. ( Bechar, H; Belahcen, MJ; Cherif Chefchaouni, A; Nouibi, C; Rahali, Y, 2023) |
| "5-Fluorouracil (5-Fu) is a first-line drug for colorectal cancer (CRC) therapy." | 4.31 | Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells. ( Chen, A; Chen, W; Chen, Z; Dai, W; Jiang, R; Li, X; Ling, Y; Ma, Y; Ni, M; Wu, J; Yao, Q; Zhou, Y, 2023) |
| "Chemoresistance to 5-fluorouracil (5-Fu)-based chemotherapy is one of the primary reasons for the failure of colorectal cancer (CRC) management." | 4.31 | STAT3 regulates 5-Fu resistance in human colorectal cancer cells by promoting Mcl-1-dependent cytoprotective autophagy. ( Sun, Z; Wang, X; Yue, Y; Zhang, Q, 2023) |
| " In this study, 5-fluorouracil (5FU) was loaded into ruthenium (Ru)-based nanocarrier (5FU-RuNPs) for the first time to eliminate the disadvantages of 5FU, and its cytotoxic and apoptotic effects on HCT116 colorectal cancer cells were compared with free 5FU." | 4.31 | The Novel 5-Fluorouracil Loaded Ruthenium-based Nanocarriers Enhanced Anticancer and Apoptotic Efficiency while Reducing Multidrug Resistance in Colorectal Cancer Cells. ( Bulut, H; Danişman-Kalindemirtaş, F; Kariper, İA; Özerkan, D, 2023) |
| "We evaluated the pharmacokinetics and pharmacodynamics/toxicodynamics of uracil-tegafur (UFT) after multiple administrations in colorectal cancer (CRC) model rats, and applied a pharmacometric approach to describe the time-course alterations of plasma 5-FU concentrations and tumor shrinkage." | 4.31 | A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model. ( Ito, Y; Kobuchi, S; Nakamura, T; Okamura, M; Tsuda, M, 2023) |
| "This study aims to evaluate the value of tissue inhibitors of MMPs-2 (TIMP-2) to indicate 5-Fluorouracil (5-Fu) resistance status in colorectal cancer." | 4.31 | TIMP-2 as a predictive biomarker in 5-Fu-resistant colorectal cancer. ( Hu, G; Li, Y; Lu, Z; Shen, L; Tao, F; Tao, K; Xu, C; Zhang, G; Zhu, R, 2023) |
| " 5-Fluorouracil (5FU) is widely used as the first-line treatment of colorectal cancer (CRC)." | 4.31 | Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids. ( Castañeda-Patlán, MC; Macías-Silva, M; Moreno-Londoño, AP; Robles-Flores, M; Sarabia-Sánchez, MA, 2023) |
| " The use of the oral FP S-1 has been approved by the European Medicines Agency as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic CRC in whom it is not possible to continue treatment with another FP due to hand-foot syndrome (HFS) or cardiovascular toxicity (CVT)." | 4.31 | Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer. ( André, T; Bodoky, G; Cremolini, C; Heinemann, V; Maughan, T; McDermott, R; Osterlund, P; Pfeiffer, P; Punt, CJA; Teske, AJ; Van Cutsem, E, 2023) |
| "Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory BRAFV600E metastatic colorectal cancer (mCRC)." | 4.31 | Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. ( Altucci, L; Anderson, A; Ciardiello, D; Ciardiello, F; Coker, O; De Falco, V; Della Corte, CM; Famiglietti, V; Fowlkes, NW; Kanikarla, P; Kopetz, S; Lee, HM; Martinelli, E; Martini, G; Morris, V; Napolitano, S; Sorokin, A; Tabernero, J; Troiani, T; Villareal, OE; Woods, M, 2023) |
| "5-Fluorouracil (5-FU) is widely used for colorectal cancer (CRC) treatment; however, continuous treatment of CRC cells with 5-FU can result in acquired resistance, and the underlying mechanism of 5-FU resistance remains unclear." | 4.31 | Relationship between anticancer sensitivities and cellular respiration properties in 5-fluorouracil-resistant HCT116 human colorectal cancer cells. ( Kurasaka, C; Nishizawa, N; Ogino, Y; Sato, A; Uozumi, H, 2023) |
| "MicroRNA (miR)-19b is deregulated in colorectal cancer (CRC) and locally advanced rectal cancer (LARC), predicting worse outcome and disease progression in CRC patients, and acting as a promising prognostic marker of patient recurrence and pathological response to 5-fluorouracil (5-FU)-based neoadjuvant chemoradiotherapy in LARC." | 4.31 | Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells. ( Caramés, C; Cristóbal, I; García-Foncillas, J; Luque, M; Madoz-Gúrpide, J; Rojo, F; Santos, A; Sanz-Álvarez, M, 2023) |
| "Fluorouracil infusion for 46±5h from the central venous(CV)port is required for mFOLFOX6, FOLFIRI, and FOLFOXIRI in patients with advanced colorectal cancer(CRC), followed by self-removal of the needle by patients." | 4.31 | [Educational Project of Self-Removal of the Intravenous Central Venous Access Port Guided by Patients with Advanced Colorectal Cancer Instructed by a Nurse in the University Hospital]. ( Beppu, N; Hirata, M; Ikeda, M; Ikeuchi, H; Kataoka, K; Kimura, K; Kuribayashi, M; Nishimura, Y; Nomura, K; Ohashi, E; Song, J; Takenaka, Y; Uchino, M; Yanagawa, T; Yarimizu, A, 2023) |
| "5-Fluorouracil (5-Fu) is the preferred drug in colorectal cancer treatment." | 4.31 | Atorvastatin calcium alleviates 5-fluorouracil-induced intestinal damage by inhibiting cellular senescence and significantly enhances its antitumor efficacy. ( Dai, Q; Ge, Y; He, S; Jia, H; Wang, X; Xia, J; Zhou, M, 2023) |
| "Immunosuppressive factors within the tumor microenvironment (TME), such as Transforming growth factor beta (TGF-β), constitute a crucial hindrance to immunotherapeutic approaches in colorectal cancer (CRC)." | 4.31 | Dual targeting of TGF-β and PD-L1 inhibits tumor growth in TGF-β/PD-L1-driven colorectal carcinoma. ( Anvari, K; Asgharzadeh, F; Avan, A; Batra, J; Ferns, GA; Fiuji, H; Gharib, M; Giovannetti, E; Hassanian, SM; Khalili-Tanha, G; Khalili-Tanha, N; Khazaei, M; Maftooh, M; Moghbeli, M; Mozafari, MR; Rahmani, F; Shahidsales, S; Shakour, N, 2023) |
| "Insensitivity and resistance to 5-fluorouracil (5FU) remain as major hurdles for effective and durable 5FU-based chemotherapy in colorectal cancer (CRC) patients." | 4.31 | Targeting PTGES/PGE2 axis enhances sensitivity of colorectal cancer cells to 5-fluorouracil. ( Cao, L; Geng, L; Geng, S; Ren, X; Zhan, H, 2023) |
| "To date, oxaliplatin and irinotecan are used in combination with 5-flourouracil (5-FU) for metastatic colorectal cancer." | 4.31 | Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells. ( Bock, F; Cappel, ML; Frerker, B; Hildebrandt, G; Klautke, G; Kriesen, S; Manda, K, 2023) |
| "This retrospective study included 289 patients with metastatic colorectal cancer treated with second-line folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors." | 4.31 | Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors. ( Chin, K; Fukuda, K; Fukuoka, S; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yoshino, K, 2023) |
| "The gold standard drug for colorectal cancer (CRC) treatment, 5-Fluorouracil (5-FU), induces pharmacological tolerance in long-term management." | 4.31 | Dermatan Sulfate/Chitosan Nanoparticles Loaded with an Anti-Inflammatory Peptide Increase the Response of Human Colorectal Cancer Cells to 5-Fluorouracil. ( Barredo-Vacchelli, GR; Birocco, AM; Blachman, A; Calabrese, GC; Camperi, SA; Cenci, G; Curcio, S; Gianvincenzo, PD; Moya, S; Rodriguez, JA; Sosnik, A, 2023) |
| "In this study, we investigated the combined treatment of 5-fluorouracil (5-FU) and Anatolian propolis extract (PE) on colorectal cancer (CRC)using in vitro and in vivo studies." | 4.31 | Propolis Enhances 5-Fluorouracil Mediated Antitumor Efficacy and Reduces Side Effects in Colorectal Cancer: An in Vitro and in Vivo Study. ( Aydogdu, G; Durmus, E; Goren, AC; Guler, EM; Hekimoglu, ER; Kanimdan, E; Kocyigit, A; Oruc, HH; Ozman, Z; Yasar, O; Yenigun, VB, 2023) |
| "5-Fluorouracil (5-FU) is the first-line treatment for colorectal cancer (CRC) patients, but the development of acquired resistance to 5-FU remains a big challenge." | 4.31 | Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells. ( Chen, X; Ding, W; Jiang, LL; Liu, AC; Liu, BY; Liu, JB; Lou, EZ; Mao, Q; Meng, Y; Peng, GJ; Shi, XP; Tang, DL; Wang, JX; Wu, JZ; Zhang, HC; Zhou, H, 2023) |
| "To assess the cost-effectiveness of cetuximab in combination with chemotherapy fluorouracil, oxaliplatin, and leucovorin (FOLFOX) or fluorouracil, irinotecan and leucovorin (FOLFIRI) compared to standard chemotherapy alone as a first-line treatment for metastatic colorectal cancer (mCRC) with positive KRAS wild type patients in Indonesia." | 4.31 | Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting. ( Armansyah, A; Khoe, LC; Megraini, A; Nadjib, M; Nugraha, RR; Permanasari, VY; Putri, S; Saldi, SRF; Santatiwongchai, B; Sastroasmoro, S; Setiawan, E, 2023) |
| "5-Fluorouracil (5-FU) is a conventional and effective drug for colorectal cancer patients, and it is an important part of combined chemotherapy and adjuvant chemotherapy." | 4.31 | Peficitinib ameliorates 5-fluorouracil-induced intestinal damage by inhibiting aging, inflammatory factors and oxidative stress. ( Chen, C; Dai, Q; He, S; Jia, H; Wang, XB; Xia, J; Zhou, Y, 2023) |
| "Treatment with 5-fluorouracil (5-FU) based therapy is still used for colorectal cancer (CRC)." | 4.31 | Rebound increase in microRNA levels at the end of 5-FU-based therapy in colorectal cancer patients. ( Badr, D; Fouad, MA; Hussein, M; Salem, S; Shouman, S; Zekri, A, 2023) |
| "We found that ABCA2 polymorphism was significantly associated with systemic exposure to capecitabine and capecitabine-induced neutropenia in Japanese patients with CRC." | 4.31 | A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer. ( Fujita, KI; Ishida, H; Kubota, Y; Matsumoto, N; Murase, R; Shibata, Y; Shimada, K, 2023) |
| " Here, we designed a composite liposomal nano-carrier co-loading 5-Fluorouracil (5-FU) with all-trans retinoic acid (ATRA) to assess anticancer efficacy of the combined drugs in colorectal cancer (CRC)." | 4.31 | In vitro co-delivery of 5-fluorouracil and all-trans retinoic acid by PEGylated liposomes for colorectal cancer treatment. ( Afshar, S; Amini, R; Azarifar, Z; Najafi, R; Tanzadehpanah, H, 2023) |
| "The efficacy of fluorouracil + oxaliplatin + irinotecan with bevacizumab (FOLFOXIRI + BV) has been verified for metastatic colorectal cancer (mCRC)." | 4.12 | Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice. ( Aoyama, T; Kazama, K; Numata, M; Oshima, T; Rino, Y; Sato, M; Sato, S; Shiozawa, M; Sugano, N; Tamagawa, H; Uchiyama, M; Yukawa, N, 2022) |
| "To evaluate the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer (mCRC) and explore potential factors of efficacy." | 4.12 | Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. ( Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J, 2022) |
| "Acquired resistance of 5-fluorouracil (5-FU) remains a clinical challenge in colorectal cancer (CRC), and efforts to develop targeted agents to reduce resistance have not yielded success." | 4.12 | ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. ( Cheng, Z; Dong, S; Hu, S; Li, L; Li, S; Liang, S; Luo, L; Xu, Q; Zhang, G; Zhang, W; Zhang, X; Zhong, M; Zhu, J, 2022) |
| "5-Fluorouracil (5-Fu) is the first-line chemotherapeutic option for colorectal cancer." | 4.12 | TIMP-2 regulates 5-Fu resistance via the ERK/MAPK signaling pathway in colorectal cancer. ( Chen, E; Huang, X; Luo, X; Meng, Q; Song, Z; Wang, D; Wang, Z; Xu, J; Zhang, G; Zhang, W; Zhou, W, 2022) |
| "Most patients affected with colorectal cancers (CRC) are treated with 5-fluorouracil (5-FU)-based chemotherapy but its efficacy is often hampered by resistance mechanisms linked to tumor heterogeneity." | 4.12 | CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer. ( Bersuder, E; Brigand, C; Chenard, MP; Delhorme, JB; Duluc, I; Freund, JN; Gross, I; Martin, E; Rohr, S; Terciolo, C; Vlami, O, 2022) |
| "Chemotherapy is used for recurrent and metastatic colorectal cancer, but the response rate of 5-fluorouracil (5-FU), the standard treatment for colorectal cancer, is low." | 4.12 | Effect of Thymidine Phosphorylase Gene Demethylation on Sensitivity to 5-Fluorouracil in Colorectal Cancer Cells. ( Akiyama, N; Eto, K; Koyama, M; Manome, Y; Osada, E, 2022) |
| "Our findings demonstrated that targeting RAS pathway using Valsartan interferes with cell-proliferation, induces apoptosis, reduces migration and synergistically interacts with 5-FU, supporting further studies on this new therapeutic approach for colorectal cancer." | 4.12 | Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer. ( Amerizadeh, F; Asgharzadeh, F; Avan, A; Ebrahimi, S; Fakhraei, M; Farshbaf, A; Ferns, GA; Giovannetti, E; Hassanian, SM; Khazaei, M; Mostafapour, A; Sabbaghzadeh, R, 2022) |
| "To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy." | 4.12 | A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. ( Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS, 2022) |
| "The impact of activating transcription factor 4 (ATF4), differentially expressed in colorectal cancer (CRC), on 5-Fluorouracil (5-FU) chemoresistance has not been fully explained." | 4.12 | ATF4-mediated microRNA-145/HDAC4/p53 axis affects resistance of colorectal cancer cells to 5-fluorouracil by regulating autophagy. ( Chen, H; Hu, H; Ma, J; Xu, L; Zhang, Q; Zhao, L, 2022) |
| "The oral fluoropyrimidine S-1 has shown comparable efficacy to capecitabine in Asian and some Western studies on metastatic colorectal cancer." | 4.12 | Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. ( Kwakman, JJM; Mol, L; Punt, CJA, 2022) |
| "The aim of this study was to improve the direct results of reconstructive surgery in patients operated on for complicated forms of colorectal cancer, by using 5-fluorouracil in the postoperative period." | 4.12 | The Effect of 5-Fluorouracil on the Adhesion Process in Patients Operated on for Colorectal Cancer. ( Irimbetov, S; Osombaev, M; Zhakipbekov, S, 2022) |
| "Clinically, 5-fluorouracil (5-Fu) is a first-line drug for the treatment of patients with colorectal cancer (CRC)." | 4.12 | Synergistic antitumor activity of 5-fluorouracil and atosiban against microsatellite stable colorectal cancer through restoring GATA3. ( Chen, M; Chen, Y; Guo, X; Li, J; Li, Z; Meng, F; Qiu, T; Wang, M; Wang, W; Xu, F; Yang, M; Zhang, H; Zhang, Q; Zhang, Y, 2022) |
| " 5-fluorouracil (5-FU) is commonly used for the treatment of colorectal cancer (CRC) in patients who receive concurrent chemoradiotherapy." | 4.12 | SPOCK1 silencing decreases 5-FU resistance through PRRX1 in colorectal cancer. ( Liu, XL; Qu, YL; Zhai, XF; Zhao, SY, 2022) |
| "Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia." | 4.12 | Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. ( Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C, 2022) |
| " In this study, we aimed to determine the changes of autophagy in the cellular model of acquired chemoresistance of colorectal cancer cell lines HCT116 and SW620, induced by 5-fluorouracil (5-FU) or oxaliplatin (OxaPt) treatment, and determine the susceptible factors for autophagy inhibition." | 4.12 | Differential effects of 5-fluorouracil and oxaliplatin on autophagy in chemoresistant colorectal cancer cells. ( Jonusiene, V; Kukcinaviciute, E; Sasnauskiene, A; Starkuviene, V; Zitkute, V, 2022) |
| "To date, 5-fluorouracil-based chemotherapy is very important for locally advanced or metastatic colorectal cancer (CRC)." | 4.12 | Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness. ( Cheng, J; Jin, M; Lin, Z; Ren, J; Wang, L; Wu, G; Yang, K; Yu, D; Zhang, D; Zhang, T; Zhao, L; Zhou, P, 2022) |
| "Surgically resected colorectal cancer specimens from 89 patients were decellularized to produce patient-derived scaffold, which were seeded with HT29 cells, cultured for 3 weeks, and treated with 5-fluorouracil." | 4.12 | 5-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information. ( Bexe Lindskog, E; Holdfeldt, A; Landberg, G; Salerno, S; Ståhlberg, A, 2022) |
| " This study aims to investigate the role of the hypoxia-induced miR-675-5p in 5-Fluorouracil (5-FU) resistance on colorectal cancer (CRC) cells." | 4.12 | Mir-675-5p supports hypoxia-induced drug resistance in colorectal cancer cells. ( Alessandro, R; Barreca, MM; Conigliaro, A; Cordaro, A; Corrado, C; Zichittella, C, 2022) |
| "Five-fluorouracil, folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) regimen is used as the first-line treatment for metastatic colorectal cancer (mCRC)." | 4.12 | Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. ( Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H, 2022) |
| "5-fluorouracil (5-FU) is a widely used drug for chemotherapy in colorectal cancer." | 4.12 | Investigation of ( Cagatay, P; Cevik, M; Ciftci, C; Deliorman, G; Karaalp, A; Koksal, UI; Namal, E; Sener, ND; Susleyici, B, 2022) |
| "5-Fluorouracil (5-FU) is a key component of chemotherapy for colorectal cancer (CRC)." | 4.12 | SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis. ( Arcangeli, A; Caselli, A; Chiarugi, P; Cirri, P; Colantuoni, V; Leo, A; Lottini, T; Maddocks, ODK; Muccillo, L; Nesi, I; Paoli, P; Pardella, E; Parri, M; Pranzini, E; Raugei, G; Sabatino, L; Santi, A; Taddei, ML; Uribe, AH; Zhang, T, 2022) |
| " To identify functional phosphorylation sites involved in 5-fluorouracil (5-FU) resistance during its treatment of colorectal cancer cells, CRISPR-mediated cytosine base editor (CBE) and adenine base editor (ABE) are utilized for functional screens by mutating phosphorylated amino acids with two libraries specifically targeting 7779 and 10 149 phosphorylation sites." | 4.12 | Functional Phosphoproteomics in Cancer Chemoresistance Using CRISPR-Mediated Base Editors. ( Guo, J; Huang, S; Huang, X; Li, J; Li, M; Lin, J; Qiao, Y; Yu, W; Zhang, P; Zhao, Y, 2022) |
| "The drug, 5-fluorouracil (5FU) is a standard first-line treatment for colorectal cancer (CRC) patients." | 4.12 | Long-term resistance to 5-fluorouracil promotes epithelial-mesenchymal transition, apoptosis evasion, autophagy, and reduced proliferation rate in colon cancer cells. ( Arregui Ramos, DA; de-Freitas-Junior, JCM; Morgado-Díaz, JA; Sousa-Squiavinato, ACM; Tessmann, JW; Wagner, MS, 2022) |
| " Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells." | 4.12 | The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022) |
| "a capecitabine and oxaliplatin drug combination regimen has shown a survival benefit in patients with advanced colorectal cancer, yet its administration represents an attractive option for low resource settings." | 4.12 | Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study. ( Begg, W; Kibudde, S, 2022) |
| "This cross-sectional study aims to elucidate the association between genetic variations in the DPYD gene and 5-fluorouracil toxicity among Jordanians with colorectal cancer (CRC)." | 4.12 | Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer. ( Almashagbah, NA; Bodoor, KG; Mahasneh, AA, 2022) |
| "5-Fluorouracil (5-FU), a known cardiotoxin, is the backbone for the treatment of colorectal cancer." | 4.12 | Managing life-threatening 5-fluorouracil cardiotoxicity. ( Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A, 2022) |
| " Topoisomerase-I inhibitor irinotecan is used clinically to treat colorectal cancer (CRC), often in combination with 5-fluorouracil (5FU)." | 4.12 | ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. ( Bagby, SM; Cadogan, EB; Davis, SL; Diamond, JR; Durant, ST; Hartman, SJ; Hughes, GD; Leal, AD; Lieu, CH; Messersmith, WA; Pitts, TM; Schlaepfer, M; Simmons, DM; Tse, T; Yacob, BW, 2022) |
| "Despite the fact that 5-fluorouracil (5-FU) is the backbone for chemotherapy in colorectal cancer (CRC), the response rates in patients is limited to 50%." | 4.12 | Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRAS ( Burgering, BMT; Clevers, H; Drost, J; Gevers, S; Gulersonmez, MC; Ludikhuize, MC; Meerlo, M; Nguyen, NTB; Rodríguez Colman, MJ; Roudbari, SKS; Stigter, ECA, 2022) |
| "We experienced 2 cases of Stage Ⅳ colorectal cancer obtained long-term survival by chemotherapy with only capecitabine." | 4.12 | [Two Cases of Stage Ⅳ Colorectal Cancer with Long-Term Survival following Single-Agent Chemotherapy with Capecitabine-A Case Reports]. ( Ando, K; Chiku, T; Fukuyama, M; Hashiba, H; Sano, W; Shinoda, K; Suda, K, 2022) |
| "Recent evidence from randomized trials suggests that FOLFOXIRI (fluorouracil, oxaliplatin, and irinotecan) ± bevacizumab is associated with higher response rates, with the potential for conversion of unresectable to resectable disease in metastatic colorectal cancer (mCRC)." | 4.12 | Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience. ( Ahmed, S; Bhatti, T; Chalchal, H; Gill, D; Le, D; Moser, M; Shaw, J; Souied, O; Tan, KT; Zaidi, A, 2022) |
| "The aim of this study was to investigate the antitumor effects of quercetin and luteolin combined with 5-Fluorouracil (5-FU) in HT-29 human colorectal cancer cells." | 4.12 | Quercetin and Luteolin Improve the Anticancer Effects of 5-Fluorouracil in Human Colorectal Adenocarcinoma ( Ağca, CA; Aşkın, H; Erdoğan, MK, 2022) |
| "5-Fluorouracil (5-FU) and its prodrugs are the essential clinical drugs for colorectal cancer (CRC) treatment." | 4.02 | Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer. ( Cui, S; Guo, Z; Han, G; Liu, S; Liu, X; Luo, D; Lv, Y; Qu, X; Tian, X; Wan, S; Wang, W; Yang, S; Zhang, Y, 2021) |
| "Triplet chemotherapy with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) is an effective first-line treatment option for patients with metastatic colorectal cancer (mCRC)." | 4.02 | Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. ( Bol, GM; Bond, MJ; Buffart, TE; Kessels, R; Koopman, M; Lemmens, VE; Mekenkamp, LJ; Scheerman, I; Valkenburg-van Iersel, LB; van Breeschoten, J; van Nassau, SC; Verheul, HM, 2021) |
| "Adjuvant chemotherapy with 5-fluorouracil (5-FU) does not improve survival of patients suffering from a form of colorectal cancer (CRC) characterized by high level of microsatellite instability (MSI-H)." | 4.02 | Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition. ( Behrouj, H; Dastghaib, S; Ghavami, S; Hudecki, J; Khazayel, S; Likus, W; Mokarram, P; Rezaie, S; Siri, M; Zamani, M; Łos, MJ, 2021) |
| "Although effective drugs have been developed, including 5-fluorouracil (5-FU), advanced colorectal cancer (CRC) shows low therapeutic sensitivity resulting from the development of 5-FU resistance." | 4.02 | Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells. ( Choi, J; Hwang, S; Lim, W; Song, G; Song, J; Yang, C, 2021) |
| "5-Fluorouracil (5-FU) resistance has been long considered as an obstacle to the efficacy of chemotherapy in colorectal cancer (CRC)." | 4.02 | Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway. ( Hua, R; Li, X; Ni, Q; Tang, D; Wang, D; Yan, X; Zhang, Y; Zhu, J, 2021) |
| " In this context, tumor-associated macrophages (TAM) have been related to chemoresistance to 5-fluorouracil (5-FU), the first-line chemotherapeutic agent used in treating colorectal cancers." | 4.02 | Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer. ( Decaens, T; Gharzeddine, K; Laverriere, MH; Malier, M; Marsili, S; Millet, A; Roth, G; Thomas, F, 2021) |
| " p130Cas was inducible by 5-fluorouracil (5-FU) and FOLFIRI (folinic acid, 5-FU, irinotecan), and p130Cas and EREG were upregulated in distant metastases (GSE121418)." | 4.02 | p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy. ( Jung, A; Kirchner, T; Klauschen, F; Kumbrink, J; Li, P; Pók-Udvari, A, 2021) |
| "Currently, 5-Fluorouracil (5-FU) based chemotherapy is the primary option for colorectal cancer after surgery, whereas chemotherapy resistance related mortality is observed in a large proportion of patients." | 4.02 | Anemoside B4 sensitizes human colorectal cancer to fluorouracil-based chemotherapy through src-mediated cell apoptosis. ( Duan, XW; He, X; Hou, XL; Li, HQ; Liao, GB; Liu, W; Tang, J; Wang, JX; Yan, HZ; Yu, SY, 2021) |
| "We aimed to screen DPD level and the changes of plasma antioxidant capacity of colorectal cancer patients on 5-fluorouracil regimen." | 4.02 | Does dihydropyrimidine dehydrogenase level modify plasma antioxidant capacity in colorectal cancer patients treated with fluoropyrimidines? ( Angelov, M; Atanasova, L; Hristova-Avakumova, N; Kamenova, K; Minchev, V; Nikolov, R; Surcheva, S; Todorov, L, 2021) |
| "To evaluate the changes in left ventricular myocardial function in patients with colorectal cancer undergoing chemotherapy with mFOLFOX6 (oxaliplatin + 5-fluorouracil + calcium folinate) using three-dimensional speckle-tracking echocardiography (3D-STE)." | 4.02 | Use of spectral tracking technique to evaluate the changes in left ventricular function in patients undergoing chemotherapy for colorectal cancer. ( Dong, S; Feng, J; Guo, X; Huang, L; Liu, K; Lu, G; Qin, W; Wang, Z; Zhai, Z; Zhang, C, 2021) |
| "First-line regimens in the treatment of metastatic colorectal cancer (mCRC) combine a fluoropyrimidine with oxaliplatin (FOLFOX/XELOX) or irinotecan (FOLFIRI)." | 4.02 | Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. ( Carneiro, BA; El-Deiry, WS; Marks, EI; Matera, R; Olszewski, AJ; Safran, H; Yakirevich, E, 2021) |
| "Chemotherapy regimens that include 5-fluorouracil (5-FU) are central to colorectal cancer treatment; however, risk/benefit concerns limit 5-FU's use, necessitating development of improved fluoropyrimidine (FP) drugs." | 4.02 | Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties. ( Brody, JR; Caudell, DL; D'Agostino, R; Deng, Z; Dominijanni, A; Ghiraldeli, LP; Gmeiner, WH; Haber, AO; Kiren, S; Mani, C; Palle, K; Pasche, BC; Smith, TL, 2021) |
| "FOLFOX is a combinational regimen of folinic acid (FnA, FOL), fluorouracil (5-Fu, F) and oxaliplatin (OxP, OX), and has been long considered as the standard treatment of colorectal cancer (CRC) and hepatocellular carcinoma (HCC)." | 4.02 | Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. ( Guo, J; Huang, L; Liu, Y; Sun, D; Yu, Z; Zou, Y, 2021) |
| " The present study aimed to evaluate the anticancer activity of MJ‑33 in fluorouracil (5FU)‑resistant colorectal cancer cells (HT‑29/5FUR) and to investigate the underlying molecular mechanisms." | 4.02 | Novel quinazolinone MJ‑33 induces AKT/mTOR‑mediated autophagy‑associated apoptosis in 5FU‑resistant colorectal cancer cells. ( Bau, DT; Chiang, JH; Ha, HA; Hour, MJ; Juan, YN; Lo, YH; Tsai, FJ; Yang, JS, 2021) |
| "5-Fluorouracil (5-FU) is one of the most frequently used pharmacological agents in the treatment of colorectal cancer (CRC)." | 4.02 | KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer. ( Harada, K; Hinoi, T; Honma, R; Maruyama, R; Naka, K; Ohdan, H; Sakamoto, N; Shimizu, W; Takakura, Y; Taniyama, D; Ukai, S; Yasui, W, 2021) |
| "To create a cost-effectiveness model to compare doublet therapy (encorafenib plus cetuximab) with standard chemotherapy (cetuximab plus irinotecan or cetuximab plus folinic acid, fluorouracil, and irinotecan) in treating patients with metastatic BRAF variant colorectal cancer." | 4.02 | Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. ( Huntington, SF; Lacy, J; O'Hara, M; Patel, KK; Stein, S, 2021) |
| "5-Fluorouracil (5-FU) is an essential drug in systemic chemotherapy treatments for colorectal cancer (CRC)." | 4.02 | GABA-producing Lactobacillus plantarum inhibits metastatic properties and induces apoptosis of 5-FU-resistant colorectal cancer cells via GABA ( An, J; Ha, EM; Seok, H, 2021) |
| " Herein, mesoporous silica nanoparticles, a supported lipid bilayer and cetuximab were integrated to fabricate a hybrid nanoplatform for effectively encapsulating and selectively delivering 5-fluorouracil (5-FU) against colorectal cancer (CRC) cells." | 4.02 | Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment. ( Chen, R; Gu, Q; Huang, Y; Li, J; Peng, C; Peng, W; Shao, G; Sheng, Y; Sun, Y; Tan, Y; Wang, L; Wang, Y; Yang, P; Zhang, Q; Zhou, J, 2021) |
| "Combination therapy of tegafur/uracil (UFT) and leucovorin (LV) is widely used to treat colorectal cancers." | 4.02 | Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy. ( Endo, Y; Hirashita, T; Inomata, M; Itoh, H; Iwao, M; Iwashita, Y; Masuda, T; Shiraiwa, K; Suzuki, Y; Tada, K; Tanaka, R; Uchida, H, 2021) |
| "The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the factors associated with the duration of antitumor drug treatment from second-line antiangiogenic therapy in Japan." | 4.02 | Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database. ( Cai, Z; Kagawa, Y; Makiyama, A; Piao, Y; Satake, H; Shinozaki, E; Tanizawa, Y, 2021) |
| "Recently the phase 3 BEACON trial showed that the combination of encorafenib, cetuximab, and binimetinib versus cetuximab and irinotecan/FOLFIRI improved overall survival in pre-treated patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutation." | 4.02 | Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA. ( Ding, D; Hu, H; Huang, J; Li, S; Zhu, Y, 2021) |
| "We aim to compare the efficiency and toxicity of three different 5-fluorouracil (5-FU) administration types in 5-FU, leucovorin, and oxaliplatin (FOLFOX) combination treatment for adjuvant therapy in colorectal cancer (CRC)." | 4.02 | The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study. ( Açıkgöz, Ö; Akdeniz, N; Bilici, M; Dane, F; Demirci, A; Durnalı, AG; Erol, C; İnanç, M; Işıkdoğan, A; Kaplan, MA; Kaya, S; Koral, L; Küçüköner, M; Laçin, Ş; Ölmez, ÖF; Şahinli, H; Şendur, MAN; Türkmen, E; Uncu, D; Urakçı, Z, 2021) |
| " 5-fluorouracil (5FU) and albumin-bound PTX (Abraxane, ABX) for colorectal cancer treatment." | 4.02 | Albumin-stabilized layered double hydroxide nanoparticles synergized combination chemotherapy for colorectal cancer treatment. ( Han, FY; Li, L; Qian, Y; Sun, L; Wang, PY; Xu, ZP; Zhang, R, 2021) |
| " Loading of oxaliplatin (Ox) and 5-Fluorouracil (5-FU) into the thermogel were able to significantly decreased peritoneal carcinomatosis index (PCI) (-58%) and ascites (-70%) in a murine model of peritoneal metastases." | 4.02 | Combination of tumor cell anti-adhesion and anti-tumor effect to prevent recurrence after cytoreductive surgery in a mice model. ( Al Sabbagh, C; Boudy, V; Mignet, N; Pimpie, C; Pocard, M; Roy, P; Seguin, J, 2021) |
| "The administration schedule of capecitabine for the treatment of metastatic colorectal cancer (mCRC) in clinical trials has been 14 days of drug with 7 days off in a 21 day cycle (14/7)." | 4.02 | Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. ( Akce, M; Alese, O; Bryson, E; Davis, C; Draper, A; El-Rayes, B; Goyal, S; Hall, K; Patel, U; Sakach, E; Shaib, W; Szabo, S; Watson, M; Wu, C, 2021) |
| " The present study investigated the mechanisms underlying the response and resistance to 5‑fluorouracil (5‑FU) in colorectal cancer (CRC) cell lines." | 4.02 | Inhibition of chaperone‑mediated autophagy reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer. ( Xiang, L; Xiao, X; Xuan, Y; Zhao, S; Zheng, HC, 2021) |
| " This study aims to examine the combined effects of 5-fluorouracil (5FU) and propolis on colorectal cancer (CRC) in mouse models." | 4.02 | Co-administration of 5FU and propolis on AOM/DSS induced colorectal cancer in BALB-c mice. ( Alipour, M; Bandegi, AR; Pakdel, A; Sameni, HR; Semnani, V; Torabizadeh, N; Yosefi, S, 2021) |
| " Chemotherapy using 5-fluorouracil (5-FU) has been widely applied to treat colorectal cancer (CRC)." | 4.02 | Low curcumin concentration enhances the anticancer effect of 5-fluorouracil against colorectal cancer. ( Lin, J; Shao, Y; Song, F; Yang, X; Zheng, X, 2021) |
| "Combination therapy comprised of fluoropyrimidine plus irinotecan with an angiogenesis inhibitor is widely used as a second-line treatment for metastatic colorectal cancer (mCRC)." | 4.02 | Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. ( Aoki, K; Hamano, T; Makishima, M; Oki, E; Sano, F; Yamanaka, T; Yamazaki, K; Yuki, S, 2021) |
| "5-Fluorouracil (5-FU) resistance is an urgent problem of colorectal cancer (CRC) chemotherapy that needs to be resolved." | 4.02 | LncRNA ENSG00000254615 Modulates Proliferation and 5-FU Resistance by Regulating p21 and Cyclin D1 in Colorectal Cancer. ( Deng, Y; Fu, Y; Huang, R; Li, J; Xie, X, 2021) |
| "5-Fluorouracil (5-FU)-based chemotherapy is the first-line treatment for colorectal cancer (CRC) but is hampered by chemoresistance." | 4.02 | The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy. ( Chen, C; Chen, J; Fan, G; Liu, X; Lu, H; Na, R; Peng, Z; Song, G; Tang, H; Wang, X; Wang, Y; Xiao, C; Yan, D; Zhuang, G, 2021) |
| "FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab is the preferred first-line treatment for right-sided metastatic colorectal cancer with RAS mutation." | 4.02 | Multiple stage IV colorectal cancers in a patient who received multidisciplinary treatment, including chemotherapy and Japanese Kampo medicine: A case report. ( Aomatsu, N; Ikeda, K; Kurihara, S; Maeda, K; Matsutani, S; Miyamoto, H; Nishii, T; Okada, T; Tachimori, A; Takeuchi, K; Tsujio, G; Uchima, Y, 2021) |
| "The efficacy of folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus ramucirumab (F-RAM) or aflibercept (F-AFL) as a second-line treatment in metastatic colorectal cancer (mCRC) is established." | 4.02 | Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2021) |
| "To evaluate the anti-cancer effects of OJe, its possible mechanisms of action were investigated in 5-fluorouracil (5-FU) resistant SNU-C5/5-FUR colorectal cancer cells." | 4.02 | Anti-cancer effects of the aqueous extract of Orostachys japonica A. Berger on 5-fluorouracil-resistant colorectal cancer via MAPK signalling pathways in vitro and in vivo. ( Kim, J; Kim, JW; Kim, SH; Mariappan, R; Moon, D; Yoon, SP, 2021) |
| " Although exposure measures have been implemented for the preparation and administration of the infusion pump(IP)used for continuous fluorouracil administration for 46-hour in FOLFOX and FOLFIRI therapies, which are standard chemotherapies for colorectal cancer, needle-removal procedures after the end of administration have not been investigated." | 4.02 | [Establishment of a Needle-Removal Method Considering Anticancer Drug Exposure after Continuous Administration of Fluorouracil Using an Infusion Pump]. ( Anami, S; Furihata, S; Ohno, R; Takamatsu, N; Yatsu, N, 2021) |
| "BACKGROUND The impact of therapeutic drug management (TDM) on reducing toxicity and improving efficacy in colorectal cancer (CRC) patients receiving fluorouracil-based chemotherapy is still unclear." | 4.02 | Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy. ( Chang, R; Chang, Y; Han, J; Qian, J; Shen, C; Zhao, H; Zhou, X, 2021) |
| "5-Fluorouracil (5-FU) is regarded as the first line treatment for colorectal cancer; however, its effectiveness is limited by drug resistance." | 4.02 | The combined effect of dichloroacetate and 3-bromopyruvate on glucose metabolism in colorectal cancer cell line, HT-29; the mitochondrial pathway apoptosis. ( Alboghobeish, S; Behmanesh, B; Khodayar, MJ; Mahdavinia, M; Nikravesh, H; Teimoori, A; Zeidooni, L, 2021) |
| "The present study aimed to investigate the influence of circular RNA nuclear receptor‑interacting protein 1 (circNRIP1) on the chemotherapeutic effect of 5‑fluorouracil (5‑FU) in colorectal cancer (CRC) and reveal its potential molecular mechanisms." | 4.02 | Knockdown of circNRIP1 sensitizes colorectal cancer to 5‑FU via sponging miR‑532‑3p. ( He, M; Li, R; Liu, F; Zhang, R; Zhang, Y, 2021) |
| "The study aimed to explore the efficacy of pharmacokinetic-based 5-fluorouracil dose management by plasma concentration test in advanced colorectal cancer treatment." | 3.96 | Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment. ( Deng, R; Guan, X; Shen, B; Shi, L; Wang, M; Yang, D; Zhu, W, 2020) |
| "For over 50 years, 5-Fluorouracil has played a critical role in the treatment of numerous malignancies, including colorectal cancer." | 3.96 | Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature. ( Gilbar, PJ; Grewal, GD; Holcombe, DJ; Raina, AJ, 2020) |
| "FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) is one of the main chemotherapy regimens for colorectal cancer (CRC), but only half of CRC patients respond to this regimen." | 3.96 | Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy. ( Cheng, J; Guan, Q; Guo, Z; He, J; Li, Y; Wang, X; Yan, H; Zhao, W, 2020) |
| "5-fluorouracil (5-FU) is widely used in chemotherapy for colorectal cancer (CRC), but a high rate of chemoresistance reduces its effectiveness in clinical treatment." | 3.96 | FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway. ( Du, Q; He, B; Liu, C; Liu, X; Mi, Q; Peng, S; Qu, X; Wang, J; Yang, Y; Yao, Z; Zhang, X; Zhang, Y; Zhao, S; Zhao, Y; Zhu, Y; Zou, J, 2020) |
| " Normal adjacent gut epithelium tissue was collected during resection surgery from a cohort of 35 patients with stage II-III colorectal cancer (CRC) who were subsequently treated with capecitabine, XELOX or FOLFOX." | 3.96 | Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea. ( Bacon, O; Burke, JP; Carberry, S; Choudhry, A; Cremona, M; Doherty, G; Hennessy, BT; Lee, CS; Lindner, AU; McNamara, D; Oficjalska, K; Prehn, JHM; Resler, AJ; Ryan, EJ; Sheahan, K, 2020) |
| "The NCT00339183 trial demonstrated that adding panitumumab to fluorouracil, leucovorin and irinotecan (FOLFIRI) as a second-line therapy of wild-type RAS metastatic colorectal cancer (mCRC) increases the median progression-free survival (PFS)." | 3.96 | Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. ( Li, J; Peng, L; Shi, Y; Tan, C; Wan, X, 2020) |
| "FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), a 5-fluorouracil (5-FU)-based chemotherapy regimen, is one of most common therapeutic regimens for colorectal cancer." | 3.96 | Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer. ( Chang, CW; Chen, MJ; Chen, YJ; Chiang Chiau, JS; Chuang, WH; Lee, HC; Li, LH; Liu, CY; Shih, SC; Tsai, TH; Wang, HY; Wang, TE, 2020) |
| "5-Fluorouracil-based therapy remains the main approach in colorectal cancer, even though there are still some drawbacks, such as chemoresistance." | 3.96 | Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. ( Achim, M; Banciu, M; Casian, T; Dragos, N; Drotar, DM; Licarete, E; Luput, L; Muntean, D; Patras, L; Porfire, A; Rauca, VF; Sesarman, A; Stejerean, I; Toma, VA; Tomuta, I; Vlase, L, 2020) |
| "The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin." | 3.96 | Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. ( Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D, 2020) |
| "The authors sought to forecast survival and enhance treatment decisions for patients with liver metastatic colorectal cancer by using on-treatment radiomics signature to predict tumor sensitiveness to irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) alone (F) or in combination with cetuximab (FC)." | 3.96 | Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway. ( Dercle, L; Eggleton, P; Lu, L; Piessevaux, H; Qian, M; Schwartz, LH; Tejpar, S; Zhao, B, 2020) |
| "5-Fluorouracil (5-Fu) is used as a conventional chemotherapy drug in chemotherapy for patients with advanced colorectal cancer, but many patients still suffer from treatment failure due to 5-Fu resistance." | 3.96 | CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer. ( Cao, G; Chen, E; Huang, X; Jin, D; Ju, Z; Luo, X; Song, Z; Wang, F; Xu, J; Zhang, G; Zhang, W; Zhou, W, 2020) |
| "When the 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy regimen is used to treat colorectal cancer (CRC), chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin can substantially affect quality of life (QOL) in the CRC patients." | 3.96 | Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study. ( Chen, JL; Chou, PL; Hsu, HT; Huang, YY; Juan, CH; Lin, PC; Wu, LM, 2020) |
| "Patients with RAS wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive either bevacizumab or an anti-epidermal growth factor receptor (EGFR) combined with first-line, 5-fluorouracil-based chemotherapy." | 3.96 | Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). ( Baba-Hamed, N; Bignon-Bretagne, AL; Bouche, O; Buecher, B; Coriat, R; des Guetz, G; Dior, M; Doat, S; Galais, MP; Gornet, JM; Goujon, G; Granger, V; Henriques, J; Lievre, A; Locher, C; Manfredi, S; Metges, JP; Michel, P; Mineur, L; Obled, S; Palmieri, LJ; Pernot, S; Phelip, JM; Rousseau, B; Saban-Roche, L; Smith, D; Soularue, E; Tougeron, D; Trouilloud, I; Vernery, D; Vitellius, C, 2020) |
| " Casein kinase 2α (CK2α) is highly expressed in 5-fluorouracil (5FU)-resistant colorectal cancer (CRC) cells." | 3.96 | Casein Kinase 2α Enhances 5-Fluorouracil Resistance in Colorectal Cancer Cells by Inhibiting Endoplasmic Reticulum Stress. ( Han, YS; Kim, HJ; Lee, JH; Lee, SH, 2020) |
| "The aim of this study was to clarify the risk benefits of folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus ramucirumab (F-RAM) as third-line and later-line treatment for metastatic colorectal cancer (mCRC)." | 3.96 | Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2020) |
| " MTT assay, cell counting, cell death analysis, cell cycle analysis, and Western blotting were done on colorectal cancer cells with or without 5-fluorouracil resistance (SNU-C5 and SNU-C5/5-FUR)." | 3.96 | Yeast Extract Induces Apoptosis and Cell Cycle Arrest via Activating p38 Signal Pathway in Colorectal Cancer Cells. ( Kang, HK; Kim, J; Moon, D; Yoon, SP, 2020) |
| "Capecitabine is a prodrug of 5-fluorouracil (5-FU) used for the treatment of colorectal cancer, with a two-week course of administration." | 3.96 | Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model. ( Ito, Y; Kobuchi, S; Sakaeda, T; Sakai, S, 2020) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic drug widely used to treat colorectal cancer." | 3.96 | Comparative lipidomics of 5-Fluorouracil-sensitive and -resistant colorectal cancer cells reveals altered sphingomyelin and ceramide controlled by acid sphingomyelinase (SMPD1). ( Akao, Y; Bandu, R; Jung, JH; Kim, KP; Komura, K; Lee, HM; Lee, KY; Lee, MY; Taniguchi, K, 2020) |
| "To analyse the results of fluorouracil (5-FU) plasma concentration monitoring in patients with advanced colorectal cancer after 5-FU treatment, and to provide a reference for the application prospect of 5-FU plasma concentration monitoring technology." | 3.96 | A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer. ( Bi, Y; He, G; Li, X; Liu, Q; Ma, J; Yang, Q; Zhang, C; Zhang, J, 2020) |
| "This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice." | 3.96 | Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. ( Chin, K; Kitagawa, Y; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Ota, Y; Shinozaki, E; Suenaga, M; Suzuki, T; Takahari, D; Wakatsuki, T; Yamaguchi, K, 2020) |
| "Cetuximab plus FOLFIRI (leucovorin, fluorouracil, and irinotecan) is the preferred first-line therapy for RAS and BRAF wild-type (RBWT) metastatic colorectal cancer (mCRC)." | 3.96 | Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study. ( Chen, H; Du, B; Hou, P; Jiang, T; Lai, J; Lin, M; Lin, X; Liu, Q; Wang, H; Wang, X; Yang, B; Zheng, J; Zhong, D, 2020) |
| "We studied the predictive value for response and toxicity of functional polymorphisms in genes involved in the oxaliplatin/fluorouracil pathway in colorectal cancer patients." | 3.96 | Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics? ( Anido, U; Barros, F; Bernárdez, B; Candamio, S; Carracedo, Á; Cruz, R; Duran, G; Giráldez, JM; Lamas, MJ; López-López, R; Simoes, AR, 2020) |
| "The combination of folinic acid, 5-fluorouracil, oxaliplatin and/or irinotecan (FOLFOXIRI) is the standard of care for metastatic colorectal cancer (CRC)." | 3.96 | Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. ( Nowak-Sliwinska, P; Ramzy, GM; Rausch, M; Zoetemelk, M, 2020) |
| " Herein we revealed a previously unrecognized mechanism of 5-fluorouracil (5-FU) resistance contributed by high SphK2-upregulated dihydropyrimidine dehydrogenase (DPD) in colorectal cancer (CRC), which is evidenced from human CRC specimens, animal models, and cancer cell lines." | 3.96 | SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression. ( Cui, SX; Guo, ZK; Luo, DD; Miao, RR; Qu, XJ; Shi, WN; Sun, SY; Wan, SB; Wang, WY; Wu, SH; Yu, XF; Zhang, YH, 2020) |
| "5-Fluorouracil (5-FU) is one of the most effective drugs for the treatment of colorectal cancer (CRC)." | 3.96 | Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. ( Cai, J; Li, W; Liu, Y; Ma, L; Xu, Y; Yang, Y; Zhang, Y, 2020) |
| "The purpose of this study was to investigate the effect of metformin or the combination of metformin and 5-FU on the growth and metastasis of colorectal cancer (CRC)." | 3.96 | Metformin Inhibited Proliferation and Metastasis of Colorectal Cancer and presented a Synergistic Effect on 5-FU. ( Sang, J; Sun, Q; Tang, R; Yang, M, 2020) |
| "High interindividual variability was reported with capecitabine toxicities among colorectal cancer (CRC) patients." | 3.96 | Genetic influence of ( Dubashi, B; Jayanthi, M; Shewade, DG; Sundaram, R; Varma, A, 2020) |
| "The AXEPT trial demonstrated that modified XELIRI (mXELIRI; capecitabine + irinotecan) was noninferior to standard treatment with FOLFIRI (fluorouracil + leucovorin + irinotecan), both ± bevacizumab, in the treatment of metastatic colorectal cancer (mCRC)." | 3.96 | Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China. ( Li, Q; Liao, W; Wang, X; Wu, Q; Zhang, M; Zhang, P, 2020) |
| "To assess the efficacy and safety of cetuximab (CE) versus bevacizumab (BE) maintenance treatment after prior 8-cycle modified 5-fluorouracil, folinate, oxaliplatin, and irinotecan (FOLFOXIRI) plus CE induction therapy in treatment-naive KRAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC)." | 3.96 | Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer. ( Chen, B; Han, G; Huang, C; Ye, J; Yu, W; Zheng, D; Zhuang, J, 2020) |
| "Cancer stem cells (CSCs) from colorectal cancer (CRC), characterized by CD133 expression, have been associated with 5-fluorouracile (5-FU) chemoresistance." | 3.96 | MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression. ( Caba, O; Cabeza, L; Jimenez-Luna, C; Melguizo, C; Mesas, C; Oliver, JA; Ortiz, R; Perazzoli, G; Prados, J, 2020) |
| " The biomarkers identified by our approach accurately predict the drug responses of 114 colorectal cancer patients treated with 5-fluorouracil and 77 bladder cancer patients treated with cisplatin." | 3.96 | Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients. ( Ha, D; Han, SK; Kim, D; Kim, S; Kong, J; Lee, H; Shin, K, 2020) |
| " In this perspective, we recently developed a multipurpose thermosensitive hydrogel based on reversible thermogelling properties of poloxamers P407 and P188, a bioadhesive excipient and antineoplastic effect of 5-fluorouracil (5-FU) for the local treatment of colorectal cancer (CRC) in ectopic CT26 murine models." | 3.96 | Thermosensitive hydrogels for local delivery of 5-fluorouracil as neoadjuvant or adjuvant therapy in colorectal cancer. ( Agapova, E; Al Sabbagh, C; Boudy, V; Kramerich, D; Mignet, N; Seguin, J, 2020) |
| "In the treatment of metastatic colorectal cancer (mCRC), exposure to all three active cytotoxic agents, 5-fluorouracil/capecitabine, irinotecan and oxaliplatin, improves overall survival." | 3.96 | Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. ( Ananda, S; Cooray, P; Delahunty, R; Desai, J; Gibbs, P; Johns, J; Kosmider, S; Lee, B; Lee, M; Mckendrick, J; Tie, J; Tran, B; Wong, HL; Wong, R, 2020) |
| "This study is an ancillary study from the PRODIGE-9 multicentre prospective study for which 491 patients with metastatic colorectal cancer (mCRC) treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab had been analysed." | 3.96 | Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. ( Aparicio, T; Barbier, E; Ben Abdelghani, M; Bennouna, J; Boige, V; Borel, C; Bouché, O; Desseigne, F; Dohan, A; Faroux, R; François, E; Gallix, B; Genet, D; Ghiringhelli, F; Guiu, B; Hoeffel, C; Jacquot, S; Jouve, JL; Khemissa-Akouz, F; Le Malicot, K; Lepage, C; Phelip, JM; Reinhold, C; Rinaldi, Y; Seitz, JF; Soyer, P; Suc, E; Taieb, J; Texereau, P, 2020) |
| "To investigate the influence of longan flower extract (LFE) on the sensitization of colorectal cancer (CRC) cells to 5-fluorouracil (5-FU) treatment, HT-29, Colo 320DM and SW480 cells were treated with LFE and 5-FU alone and in combination, and the cell viability was then assessed by trypan blue exclusion, the cell cycle by propidium iodide staining, the mitochondria membrane potential by rhodamine 123 staining, and the expression levels of associated genes by immunoblotting and quantitative real-time polymerase chain reaction." | 3.96 | Synergistic Effect of Combined Treatment with Longan Flower Extract and 5-Fluorouracil on Colorectal Cancer Cells. ( Chang, HL; Chang, HP; Chen, CH; Chen, SJ; Chou, JL; Chung, YC; Hsu, CP; Lin, CC, 2020) |
| "Despite new agent development and short-term benefits in patients with colorectal cancer (CRC), metastatic CRC cure rates have not improved due to high rates of 5-fluorouracil (5-FU)/leucovorin/oxaliplatin (FOLFOX)-resistance and a clinical therapeutic plateau." | 3.91 | ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. ( Amin, S; Jaiswal, AS; Law, BK; Narayan, S; Ramisetti, S; Sharma, AK; Singh, P; Singh-Pillay, A, 2019) |
| "5-Fluorouracil (5-FU) is an important chemotherapeutic agent for the systemic treatment of colorectal cancer (CRC), but its effectiveness against CRC is limited by increased 5-FU resistance caused by the hypoxic tumor microenvironment." | 3.91 | Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer. ( Kim, CW; Kim, HG; Lee, DH; Lee, JS; Oh, ET; Park, HJ, 2019) |
| "This study investigated the potential of single nucleotide polymorphisms as predictors of survival in two cohorts comprising 417 metastatic colorectal cancer (mCRC) patients treated with the FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) regimen." | 3.91 | Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. ( Allain, EP; Buonadonna, A; Cecchin, E; Couture, F; D'Andrea, M; De Mattia, E; Guillemette, C; Jonker, D; Labriet, A; Lévesque, É; Rouleau, M; Simonyan, D; Toffoli, G; Villeneuve, L, 2019) |
| "Clinically, one of the principal factors in the failure of advanced colorectal cancer (CRC) treatment is chemoresistance to 5-fluorouracil (5FU)-based chemotherapy." | 3.91 | miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells. ( Chen, X; He, B; Liu, X; Pan, B; Pan, Y; Qin, J; Sun, H; Sun, L; Wang, S; Xu, M; Xu, T; Xu, X; Zeng, K, 2019) |
| "The first-line chemotherapy of colorectal cancer (CRC), besides surgery, comprises administration of 5-Fluorouracil (5FU)." | 3.91 | Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo. ( Cumova, A; Galanova, N; Horak, J; Hucl, T; Kostovcikova, K; Kozics, K; Macinga, P; Opattova, A; Rejhova, A; Sliva, D; Turnovcova, K; Vodenkova, S; Vodicka, P; Vodickova, L, 2019) |
| "The high-budding group demonstrated resistance to 5-fluorouracil-based chemotherapy, whereas the low-budding group exhibited significant survival benefits from adjuvant chemotherapy in stage III colorectal cancer." | 3.91 | Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis. ( Hase, K; Kajiwara, Y; Mochizuki, S; Okamoto, K; Shinto, E; Ueno, H; Yamadera, M; Yamamoto, J, 2019) |
| "In the present study, we aimed to determine the efficacy of trabectedin (TRAB) combined with oxaliplatinum (OXA)+5-fluorouracil (5-FU) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (PDOX) mouse model." | 3.91 | Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. ( Bouvet, M; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G, 2019) |
| "To investigate the influence of organic cation transporter 3 (OCT3) expression on the effect of the combination regimen of 5-fluorouracil, folinic acid and oxaliplatin ((m)FOLFOX6) in colorectal cancer (CRC) patients." | 3.91 | Upregulated OCT3 has the potential to improve the survival of colorectal cancer patients treated with (m)FOLFOX6 adjuvant chemotherapy. ( Dong, D; Feng, S; Gu, J; Jiang, X; Li, T; Long, E; Tang, S; Wang, L, 2019) |
| "The aim of the present study was to determine the efficacy of trabectedin combined with FOLFIRI (irinotecan, leucovorin and 5-fluorouracil) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (iPDOX) mouse model." | 3.91 | Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model. ( Bouvet, M; Clary, B; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G, 2019) |
| "The current study suggests that the identification of predictive signatures of fluorouracil (5-FU) response for stage II and III colorectal cancer (CRC) could be confounded by chemotherapy-irrelevant low relapse risk." | 3.91 | Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit. ( Ao, L; Cai, H; Guo, Y; Guo, Z; Li, N; Song, K; Song, X; Wang, X; Zhao, W; Zheng, W, 2019) |
| "Selected SNPs in the adenosine pathway could affect the clinical outcomes of patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab." | 3.91 | Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. ( Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Lo, JH; Loupakis, F; Millstein, J; Naseem, M; Puccini, A; Soni, S; Stintzing, S; Tokunaga, R; Zhang, W, 2019) |
| "Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU." | 3.91 | Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. ( Chakrabarti, S; Eiring, R; Finnes, H; Grothey, A; Halfdanarson, T; Hartgers, M; Lobo, R; Mitchell, J; Okano, A; Sara, J, 2019) |
| "5-Fluorouracil (5-FU) represents the backbone of systemic therapy regimens of colorectal cancer." | 3.91 | 5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer. ( Abdel-Rahman, O, 2019) |
| "First-line adjuvant chemotherapy options for early-stage colorectal cancer (CRC) include CapeOx (capecitabine, intravenous oxaliplatin) and FOLFOX (intravenous 5-fluorouracil, leucovorin, oxaliplatin)." | 3.91 | Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer. ( Chambers, CR; Chu, MP; Dersch-Mills, D; Ghosh, S; Ha, V; Sawyer, MB; Wong, GG, 2019) |
| "Oral uracil-tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer." | 3.91 | Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan. ( Hsu, TC; Wang, CC, 2019) |
| "5-Fluorouracil (5-FU) has been established as the first-line chemotherapy for advanced colorectal cancer (CRC); however, acquired chemoresistance is often the cause of poor therapeutic response." | 3.91 | Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. ( Goel, A; Sakatani, A; Sonohara, F, 2019) |
| " By performing a series of experiments in chemoresistant colorectal cancer cell lines, we demonstrate that oligomeric proanthocyanidins (OPCs) from grape seed extracts can sensitize both acquired (HCT116-FOr cells) and innately chemoresistant (H716 cells) cancer cells to chemotherapeutic drugs, 5-fluorouracil (5FU) and oxaliplatin, by inhibiting adenosine triphosphate-binding cassette (ABC) transporter proteins." | 3.91 | Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells. ( Goel, A; Pasham, D; Ravindranathan, P, 2019) |
| "Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment of colorectal cancer (CRC)." | 3.91 | Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. ( Bono, P; Hänninen, UA; Karhunen, M; Lamminmäki, A; Osterlund, P; Soveri, LM, 2019) |
| "To evaluate the impact of sex on toxicity and efficacy outcomes among patients with metastatic colorectal cancer receiving first-line 5-fluorouracil-based regimens." | 3.91 | Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. ( Abdel-Rahman, O, 2019) |
| " The studies observed patients with wild-type [Kirsten] rat sarcoma viral oncogene homolog ([K]RAS/RAS) metastatic colorectal cancer (mCRC), who had been treated with panitumumab in combination with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in the first line or with panitumumab combined with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the second line following fluoropyrimidine-based chemotherapy." | 3.91 | Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC. ( Bjorklof, K; Buchler, T; Csoszi, T; Demonty, G; Hebart, H; Kafatos, G; Kiehl, M; Koukakis, R; Kuhn, A; Tomasek, J, 2019) |
| " We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response." | 3.91 | Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. ( Bader, JE; Carson, JA; Carson, M; Chatzistamou, I; Enos, RT; Kubinak, JL; Murphy, EA; Nagarkatti, M; Pena, MM; Sougiannis, AT; VanderVeen, BN; Velazquez, KT; Walla, M, 2019) |
| "The efficacy of Fluorouracil (FU) in the treatment of colorectal cancer (CRC) is greatly limited by drug resistance." | 3.91 | ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield. ( Chen, Y; Hao, J; Li, F; Li, J; Liang, H; Luo, X; Ou, J; Peng, Y; Sun, W; Wang, L; Wu, S; Xie, G; Xie, X; Yang, W; Zha, L; Zhang, Y; Zhao, Y; Zhou, Q, 2019) |
| "Colorectal cancer is one of the primary causes of cancer-related deaths and 5-fluorouracil (5-FU) therapy remains the cornerstone of treatment in these patients." | 3.91 | RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer. ( Bachvarov, CH; Bogdanova, MK; Chaushev, BG; Conev, NV; Dimitrova, EG; Donev, IS; Georgiev, KD; Kalchev, KP; Kashlov, YK; Manev, RR; Petrov, DP; Popov, HB; Radanova, MA; Todorov, GN, 2019) |
| "5-Fluorouracil (5-FU) is an anticancer drug that is most frequently used to treat colorectal cancer (CRC) patients, but unfortunately it shows limited efficacy." | 3.91 | Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase. ( Klopotowska, D; Kutner, A; Milczarek, M; Rossowska, J; Stachowicz, M; Wietrzyk, J, 2019) |
| "Colorectal cancer (CRC) is still the third most common cancer in the world with a limited prognosis due to the chemoresistance of CRC cells to 5-fluorouracil (5-FU)-based chemotherapy." | 3.91 | Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling. ( Fan, D; He, H; Lei, M; Liang, Y; Shen, L; Wu, H; Zhou, Q; Zou, Q, 2019) |
| "We used data of 7 treatment cycles of capecitabine in patients with metastatic colorectal cancer." | 3.91 | Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. ( Aldaz, A; Bueno, L; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| "We enrolled patients administered adjuvant capecitabine plus oxaliplatin (CapeOX) for postoperative colorectal cancer (CRC) patients and metastatic CRC patients receiving CapeOX with/without bevacizumab." | 3.91 | Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil. ( Fujita, KI; Ishida, H; Ishikawa, F; Kubota, Y; Ohkuma, R; Sasaki, Y; Sekido, M; Shibanuma, M; Takahashi, T; Tsunoda, T, 2019) |
| "5-Fluorouracil (5-FU) remains the gold standard of first-line treatment for colorectal cancer (CRC)." | 3.91 | Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure. ( Bulanin, D; Francipane, MG; Lagasse, E, 2019) |
| " 5-Fluorouracil is a clinically approved drug which has limited response rate in the realm of colorectal cancer amelioration, hence our study aims to improve its efficacy by aiming the simultaneous delivery of 5-Flurouracil and apigenin which is naturally occurring flavone abundantly present in fruit and vegetables through a single liposome to combat and control colorectal cancer effectively in-vitro and in-vivo." | 3.91 | Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer. ( Banerjee, S; Mandal, M; Sen, K, 2019) |
| "Only 10%-20% of colorectal cancer (CRC) patients observe effective responses to 5-fluorouracil (5-FU) based chemo-treatment." | 3.91 | Epigenetically Down-Regulated Acetyltransferase PCAF Increases the Resistance of Colorectal Cancer to 5-Fluorouracil. ( Fang, X; Fang, Z; Hu, W; Jin, Y; Liu, T; Miao, QR; Wang, X, 2019) |
| "Although DNA-mismatch-repair-deficient (dMMR) status and aberrant expression of miRNAs are both critically implicated in the pathogenesis of resistance to 5-fluorouracil (5-FU) in colorectal cancer (CRC), whether these two factors regulate tumor response to 5-FU in a coordinated manner remains unknown." | 3.91 | MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer. ( Dai, ZJ; Guan, HT; Liu, D; Ma, YG; Yan, CY; Zhao, P; Zhao, Y, 2019) |
| "Patients with advanced colorectal cancer often are treated with systemic cytotoxic therapy using fluorouracil (5-FU), oxaliplatin, irinotecan, and FOLFOX or FOLFIRI combination protocols." | 3.91 | In vivo effects of chemotherapy on oncogenic pathways in colorectal cancer. ( Elmasry, M; Horst, D; Kirchner, T; Schmidt, EM; Schulz, GB; Spartalis, C, 2019) |
| "The VELOUR study evaluated the efficacy and safety of adding aflibercept to FOLFIRI (fluorouracil, leucovorin, irinotecan) in second-line therapy for metastatic colorectal cancer (mCRC)." | 3.91 | Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis. ( Argilés Martínez, G; Carmona-Bayonas, A; Castañón López, C; Fernández Montes, A; Gallego Plazas, J; García Paredes, B; Gutiérrez Abad, D; Jiménez Fonseca, P; Juez Martel, I; Llorente Ayala, B; López Doldán, MC; López Flores, M; López López, C; López Muñoz, AM; Martínez de Castro, E; Páez López, D; Sánchez Cánovas, M; Tobeña Puyal, M, 2019) |
| " In the present study, the antitumor effects were investigated, and the possible underlying mechanisms of kaempferol combined with 5‑fluorouracil (5‑FU) in colorectal cancer cells were explored." | 3.91 | Synergistic effect of kaempferol and 5‑fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway. ( Chen, Y; Li, Q; Lin, J; Lin, S; Peng, J; Wei, L, 2019) |
| "We developed a molecular beacon targeting miR-141-3p, aberrantly increased in 5-fluorouracil-resistant colorectal cancer cells (R-CRCCs)." | 3.91 | Theragnosis by a miR-141-3p molecular beacon: simultaneous detection and sensitization of 5-fluorouracil resistant colorectal cancer cells through the activation of the TRIM13-associated apoptotic pathway. ( Heo, HJ; Jeong, SH; Jung, WY; Kim, S; Lee, YS; Moon, SU; Park, MG; Park, Y; Song, SK, 2019) |
| "5-fluorouracil in combination with the folate leucovorin is the cornerstone in treatment of colorectal cancer." | 3.91 | Folate pathway genes linked to mitochondrial biogenesis and respiration are associated with outcome of patients with stage III colorectal cancer. ( Carlsson, G; Gustavsson, B; Odin, E; Sondén, A; Wettergren, Y, 2019) |
| "To assess if CT texture analysis (TA) can serve as a biomarker of liver toxicity in patients with colorectal cancer treated with 5-fluorouracil (5-FU)-based chemotherapy." | 3.91 | 5-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker. ( Alessandrino, F; Cruz, G; Meyerhardt, JA; Qin, L; Rosenthal, MH; Sahu, S; Shinagare, AB, 2019) |
| "5-Fluorouracil (5-FU)-based chemotherapy has always been the first-line treatment of colorectal cancer (CRC)." | 3.91 | The long non-coding RNA HOTAIRM1 suppresses cell progression via sponging endogenous miR-17-5p/ B-cell translocation gene 3 (BTG3) axis in 5-fluorouracil resistant colorectal cancer cells. ( Chen, J; Hou, J; Liu, C; Qin, A; Ren, T; Ren, W; Shan, F; Xiong, X, 2019) |
| "Precision medicine might be the response to the recent questioning of the use of metformin as an anticancer drug in colorectal cancer (CRC)." | 3.91 | A more physiological approach to lipid metabolism alterations in cancer: CRC-like organoids assessment. ( Cruz-Gil, S; Pape, K; Ramírez de Molina, A; Sánchez-Martínez, R; Schölch, S; Stange, D; Wagner-Reguero, S, 2019) |
| "5-Fluorouracil (5-FU) as a chemotherapeutic drug is used to treat colorectal cancer (CRC)." | 3.88 | The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer. ( Dermani, FK; Heydari, K; Najafi, R; Saidijam, M; Shabab, N; Sharifi, MR; Soleimani Asl, S, 2018) |
| "Our objective was to evaluate the benefit of re-exposing patients with refractory metastatic colorectal cancer (mCRC) to a combination of oxaliplatin, irinotecan and 5-fluorouracil treatment." | 3.88 | Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. ( Artioli, M; Braghiroli, MI; Braghiroli, OFM; Costa, FP; Fernandes, GDS; Girardi, DDM; Gumz, BP; Hoff, PM; Paterlini, ACCR; Teixeira, MC, 2018) |
| " The objective of this exploratory study was to examine the association of low skeletal muscle, commonly known as sarcopenia, on the pharmacokinetics (PKs) of 5-fluorouracil (5FU) in patients receiving FOLFOX for colorectal cancer." | 3.88 | The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ( Choi, SK; Deal, AM; McLeod, HL; Muss, HB; O'Neil, B; Patel, JN; Sanoff, HK; Shachar, SS; Walko, CM; Weinberg, MS; Williams, GR, 2018) |
| " The prognostic role of TOPO-1 and CES-2 in patients with metastatic colorectal cancer (mCRC) who underwent irinotecan chemotherapy was largely unknown." | 3.88 | Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. ( Guisheng, L; Haixin, H; Li, H; Shaojun, C, 2018) |
| "To investigate expression of cell cycle-related and expression-elevated protein in tumor (CREPT) in colorectal cancer (CRC) and determine its prognostic value in response to 5-fluorouracil (5-FU)." | 3.88 | Overexpression of CREPT confers colorectal cancer sensitivity to fluorouracil. ( Chang, ZJ; Ding, LD; Jia, BQ; Kuang, YS; Li, J; Liu, HY; Liu, SH; Wang, XN; Wang, Y; Wang, YY; Yang, L; Zhu, BT, 2018) |
| "Regorafenib is a multi-kinase inhibitor, which was shown to be effective for patients with metastatic colorectal cancer refractory to standard therapies." | 3.88 | Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study. ( Gonoi, W; Hashimoto, M; Kondoh, C; Kuroyanagi, H; Matoba, S; Nishioka, Y; Ozaki, Y; Shindoh, J; Takano, T; Tanabe, Y, 2018) |
| "We describe a metastatic colorectal cancer patient, treated with first-line 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIr-BFOx) therapy, with aggressive and resistant disease." | 3.88 | KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. ( Alesse, E; Bruera, G; Calvisi, G; Cannita, K; Cocciolone, V; Cortellini, A; Dal Mas, A; Ficorella, C; Mastroiaco, V; Ricevuto, E; Tessitore, A; Zazzeroni, F, 2018) |
| " Furthermore, upregulating TFAP2C enhances spheroids formation ability, the fraction of SP cells, expression of stem cell factors and the mitochondrial potential, and reduces the apoptosis induced by 5-fluorouracil in colorectal cancer cells in vitro, and promotes stemness and chemoresistance of CRC cells in vivo; while silencing TFAP2C yields an opposite effect." | 3.88 | TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway. ( Chen, S; Ren, D; Sun, D; Tai, J; Wang, L; Wang, X; Yu, M, 2018) |
| " In this study, we investigated the effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma (CRC) cells and its mechanism." | 3.88 | The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. ( Jiang, GS; Liu, GW; Liu, YH; Ren, WD, 2018) |
| "The aim of this study was to investigate the efficacy and safety of first-line panitumumab plus folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in patients with wild-type KRAS and wild-type NRAS metastatic colorectal cancer (mCRC)." | 3.88 | FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. ( Geredeli, C; Yasar, N, 2018) |
| "Fluoropyrimidines, such as 5-fluorouracil (5-FU) and related prodrugs, are considered one of the most successful agents in the treatment of colorectal cancer, yet poor specificity and tumor cell resistance remain the major limiting bottlenecks." | 3.88 | DNA-based nanoscaffolds as vehicles for 5-fluoro-2'-deoxyuridine oligomers in colorectal cancer therapy. ( Aviñó, A; Eritja, R; Fàbrega, C; Jorge, AF; Pais, AACC, 2018) |
| "5-fluorouracil (5-FU) and oxaliplatin (OxaPt) are the main chemotherapeutics for colorectal cancer (CRC)." | 3.88 | Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116. ( Dabkeviciene, D; Eidenaite, E; Jonusiene, V; Kukcinaviciute, E; Laurinavicius, A; Sasnauskiene, A, 2018) |
| "We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients." | 3.88 | Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy. ( Catalano, C; da Silva Filho, MI; Försti, A; Hemminki, K; Jiraskova, K; Levy, M; Liska, V; Naccarati, A; Vodicka, P; Vodickova, L; Vycital, O; Vymetalkova, V; Weber, ANR, 2018) |
| "To investigate the effects of miR-519d on the 5-fluorouracil resistance in colorectal cancer cells and to explore the mechanism." | 3.88 | MiR-519d reduces the 5-fluorouracil resistance in colorectal cancer cells by down-regulating the expression of CCND1. ( Chi, YJ; Huang, R; Lin, JY, 2018) |
| "Chemotherapeutic 5-fluorouracil (5-FU) combined with oxaliplatin is often used as the standard treatment for colorectal cancer (CRC)." | 3.88 | Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin. ( Chen, CI; Chen, YJ; Cheng, KC; Chien, PH; Hsiang, YP; Hsu, YC; Lin, YM; Lu, CC; Pan, HL, 2018) |
| "The FIRE-3 [5-fluorouracil, folinic acid, and irinotecan (FOLFIRI) plus cetuximab versus FOLFIRI plus bevacizumab in first line treatment colorectal cancer (CRC)] study reported that first-line FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab resulted in similar progression-free survival (PFS) but improved overall survival (OS)." | 3.88 | Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. ( Burge, M; Dean, AP; Eastgate, M; Gibbs, P; Kosmider, S; Lee, B; Lee, M; Lok, SW; Ma, B; Semira, C; Shapiro, J; Steel, SA; Torres, J; Wong, HL; Wong, R; Zimet, AS, 2018) |
| "BACKGROUND 5-Fluorouracil (5-FU)-based chemotherapy is a conventional therapeutic approach for the treatment of patients with colorectal cancer (CRC)." | 3.88 | miR-106a Reduces 5-Fluorouracil (5-FU) Sensitivity of Colorectal Cancer by Targeting Dual-Specificity Phosphatases 2 (DUSP2). ( Chen, X; Huo, Z; Liu, Z; Qin, Y; Tian, X, 2018) |
| "Capecitabine is a pro-drug of 5-fluorouracil (5-FU), and is an orally available chemotherapeutic used to treat colorectal cancer (CRC)." | 3.88 | Investigation into Enhancing Capecitabine Efficacy in Colorectal Cancer by Inhibiting Focal Adhesion Kinase Signaling. ( Baek, JH; Jeong, KY; Kim, HM; Lee, H; Park, MH; Sim, JJ, 2018) |
| "Curcumin, a well-studied component in turmeric, exhibits potent antitumor effects in colorectal cancer." | 3.88 | Turmeric extract, with absorbable curcumin, has potent anti-metastatic effect in vitro and in vivo. ( Fung, KP; Lau, CB; Li, M; Tsui, SK; Yue, GG, 2018) |
| " Median time from initial diagnosis of metastases to the start of regorafenib and treatment duration was 13." | 3.88 | Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). ( Aranda, E; Benavides, M; Durán, G; Falcó, E; García-Alfonso, P; Gómez, A; López, R; López-Ladrón, A; Montagut, C; Muñoz, A; Rivera, F; Ruiz de Mena, I; Salgado, M; Sastre, J, 2018) |
| " Here, the role of PKM2 in the anticancer efficacy of 5-fluorouracil (5-FU) was evaluated in colorectal cancer (CRC)." | 3.88 | Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells. ( Cao, Y; Jin, Y; Lin, Y; Pan, D; Wang, D; Zhang, Y; Zheng, C, 2018) |
| "The intent of this article is to evaluate the effect of oral cryotherapy on the prevention of oral mucositis and pain among patients with colorectal cancer undergoing fluorouracil-based chemotherapy." | 3.88 | Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy. ( Hsien Chan, CM; Idayu Mat Nawi, R; Lei Chui, P; Wan Ishak, WZ, 2018) |
| "To evaluate the safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (mFOLFOXIRI) for patients with advanced colorectal cancer (CRC)." | 3.88 | [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer]. ( Cai, Y; Deng, R; Deng, Y; Hu, H; Li, J; Ling, J; Wu, Z; Yang, L; Zhang, J, 2018) |
| "The benefit of IFL (irinotecan, fluorouracil and leucovorin) regimen for metastatic colorectal cancer patients (mCRCs) with high levels of microsatellite instability (MSI-H) or loss of mismatch repair (dMMR) protein expression, is uncertain." | 3.88 | Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen. ( Bendardaf, R; Pyrhönen, S; Sharif-Askari, FS; Sharif-Askari, NS; Syrjänen, K, 2018) |
| " Interestingly, the panel also revealed that he had mismatch-repair(MMR)deficiency with MSH2 mutation, which is reported as a possible cause of resistance to 5-fluorouracil in colorectal cancer." | 3.88 | [A Case of Resistance to Systemic Therapy in Hypermutation of Colorectal Cancer]. ( Hotta, S; Ichikawa, H; Kameyama, H; Maruyama, S; Miura, K; Nagahashi, M; Nakano, M; Nogami, H; Shimada, Y; Tajima, Y; Takii, Y; Tanaka, K; Wakai, T; Yamada, S, 2018) |
| "More than half of patients with colorectal cancer will develop metastatic disease either evident at the time of initial diagnosis or during their course of disease." | 3.86 | Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. ( Arnold, D; Edelmann, T; Glockzin, G; Hildebrandt, B; Hollerbach, S; Illerhaus, G; Königsrainer, A; Richter, M; Schlitt, HJ; Schmoll, HJ; Stein, A; Wienke, A, 2012) |
| "Almost all colorectal cancer (CRC) cell lines are known to overexpress aspartate aminotransferase (GOT1), which potentially regulates the intracellular levels of reactive oxygen species (ROS) via the production of NADPH, and supports tumor growth." | 3.85 | Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil. ( Hong, C; Li, X; Zheng, J, 2017) |
| "Although 5-fluorouracil (5-FU) is known to interfere with the synthesis of ribonucleic acid and deoxyribonucleic acid, the mechanism underlying its therapeutic efficacy in colorectal cancer (CRC) has not been fully elucidated." | 3.85 | 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. ( Cao, L; Du, C; Gu, J; Huang, D; Peng, Y; Wang, H; Yang, Y; Yao, Y; Zhao, Y; Zhu, WG, 2017) |
| "To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy." | 3.85 | Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer. ( Hong, KD; Ji, WB; Joung, SY; Kim, JS; Kim, YS; Lee, JH; Min, BW; Ryu, JS; Um, JW, 2017) |
| "5-Fluorouracil (5-FU) is the chemotherapeutic agent of first choice for the treatment ofcolorectal cancer, however, treatment-related liver toxicity remains a major concern." | 3.85 | Hepatoprotective Effect of Carboxymethyl Pachyman in Fluorouracil-Treated CT26-Bearing Mice. ( Gao, L; Huo, X; Li, C; Sun, G; Wang, C, 2017) |
| "5-Fluorouracil (5-FU) is a widely used chemotherapeutic drug in colorectal cancer." | 3.85 | Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism. ( Auboeuf, D; Bash-Imam, Z; Catez, F; Dalla Venezia, N; David, A; Diaz, JJ; Dutertre, M; Lafôrets, F; Macari, F; Marcel, V; Mertani, HC; Pannequin, J; Pion, N; Polay Espinoza, M; Saurin, JC; Textoris, J; Thérizols, G; Vincent, A, 2017) |
| "The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic colorectal cancer." | 3.85 | Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer. ( Colville-Ebeling, B; Jensen, BV; Larsen, FO; Markussen, A; Nielsen, D; Riis, LB, 2017) |
| "Cardiotoxicity is a rare but challenging complication of 5-fluorouracil (5-FU) therapy." | 3.85 | Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. ( Franck, C; Malfertheiner, P; Venerito, M, 2017) |
| "Electronic Health Records at a UK oncology centre were included if they had (i) a diagnosis of metastatic breast cancer and received adjuvant epirubicin and cyclosphosphamide chemotherapy or (ii) colorectal cancer and received palliative oxaliplatin and infusional 5-fluorouracil chemotherapy, and (iii) were first diagnosed with cancer between January 2004 and February 2013." | 3.85 | Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy. ( Baker, K; Dunwoodie, E; Hall, G; Johnson, O; Jones, RG; Leal, J; McGinley, P; Newsham, A; Price, CP; Twelves, C; Wolstenholme, J, 2017) |
| "Preclinical evidence demonstrates that mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway inhibition increases sensitivity to 5-fluorouracil (5-FU) in colorectal cancer (CRC) cell lines and xenografts." | 3.85 | MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. ( Chen, Y; Fakih, M; Gong, J; Pillai, R; Shirasawa, S; Yang, L, 2017) |
| " In this study, we chose human colorectal adenocarcinoma cell line HT-29 as the experimental model, and investigated the differential biological effects between 250 mGy single dose LDIR and 250 mGy intermittent LDIR pretreatments in high dose irradiation (HDIR) radiotherapy and 5-fluorouracil (5-FU) based chemotherapy." | 3.85 | Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29. ( Li, Y; Wang, Y; Yang, L; Yin, D, 2017) |
| "Preoperative 5-fluorouracil- (5-FU-) based chemoradiotherapy is a standard treatment for locally advanced colorectal cancer (CRC)." | 3.85 | Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. ( Ai, YQ; Chen, ZT; Ju, YH; Li, WH; Li, YF; Liu, QY; Qin, JY; Wang, H; Xiong, W; Ye, Q, 2017) |
| "5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents." | 3.85 | Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017) |
| " Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer." | 3.85 | Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer. ( Hama, T; Inoue, A; Kawakami, K; Kobayashi, K; Machida, Y; Suenaga, M; Sugisaki, T; Suzuki, K; Yamaguchi, K; Yamaguchi, T; Yokokawa, T, 2017) |
| "MicroRNAs (miRNAs) are increasingly involved in the development of drug resistance, including 5-fluorouracil (5-FU) resistance in colorectal cancer (CRC)." | 3.85 | Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway. ( Jia, L; Li, Y; Liu, B; Liu, Y; Pan, Y; Shan, Y; Zhao, L, 2017) |
| " 5-Fluorouracil (5-FU) is the first-line chemotherapeutic agent for colorectal cancer; however, most patients develop resistance to 5-FU through various mechanisms." | 3.85 | Synergistic antitumor effect of 3-bromopyruvate and 5-fluorouracil against human colorectal cancer through cell cycle arrest and induction of apoptosis. ( Chong, D; Huo, Q; Liu, F; Liu, H; Ma, L; Zhang, P; Zhang, Z; Zhao, S; Zheng, H, 2017) |
| "5-Fluorouracil (5-FU) resistance or multidrug resistance (MDR) has become a major obstacle in clinical treatment of cancers including colorectal cancer (CRC)." | 3.85 | Scutellaria barbata D. Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway. ( Feng, J; Jin, Y; Lai, Z; Li, Q; Lin, J; Peng, J; Wei, L; Yan, Z; Yang, H, 2017) |
| "We enrolled 103 consecutive patients with stage III and high-risk stage II colorectal cancer treated with mFOLFOX6 (n = 37) or oral fluorouracil and leucovorin (n = 66) after curative surgery." | 3.85 | Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX. ( Hara, K; Iwai, T; Koizumi, M; Ohta, K; Shinji, S; Takahashi, G; Takeda, K; Uchida, E; Yamada, T; Yokoyama, Y, 2017) |
| "The aim of this study was to explore the effects of single agent treatments and combination of Blu9931 and 5-fluorouracil (5-FU) on the biological characteristics of colorectal cancer cells and its mechanism." | 3.85 | Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells. ( Han, C; Jiang, D; Li, J; Wang, M; Wang, X; Ye, Y; Zhao, C, 2017) |
| "Colorectal cancer (CRC) is one of the leading causes of cancer mortality and 5-Fluorouracil (5-FU) is the most common chemotherapy agent of CRC." | 3.85 | Effect of AICAR and 5-Fluorouracil on X-ray Repair, Cross-Complementing Group 1 Expression, and Consequent Cytotoxicity Regulation in Human HCT-116 Colorectal Cancer Cells. ( Chang, SF; Chen, CN; Huang, WS; Lee, KC; Lin, CT; Liu, JL, 2017) |
| "A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose." | 3.85 | Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses. ( Ardalan, B; Cioffi, JH; Estes, DJ; Florou, V, 2017) |
| "5-fluorouracil (5-FU) is one of the major components of many standard regimens for chemotherapy of colorectal cancer (CRC) and some other malignancies." | 3.85 | The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells. ( Eftekhar, E; Jaberi, H; Mansouri, A; Naghibalhossaini, F; Shefaghat, M; Tatar, M, 2017) |
| "Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC." | 3.85 | Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment. ( Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS, 2017) |
| "Metastatic colorectal cancer (mCRC) is a lethal disease and fluorouracil-leucovorin-irinotecan (FOLFIRI) plus bevacizumab (bev) is a standard approach." | 3.85 | Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab. ( Artaç, M; Börüban, MC; Bozcuk, H; Er, Z; Güler, T; Karaağaç, M; Korkmaz, L; Uysal, M, 2017) |
| " Our results showed that GLPs reactivated mutant p53 in colorectal cancer HT29 (p53R273H) and SW480 (p53R273H&P309S) cells while applied alone or together with 5-fluorouracil (5-FU)." | 3.85 | Restoration of the tumor-suppressor function to mutant p53 by Ganoderma lucidum polysaccharides in colorectal cancer cells. ( Cai, Y; Jiang, D; Jin, J; Wang, F; Wang, L; Zhang, R; Zhang, Z; Zhao, T, 2017) |
| "We analyzed the results of previously treated patients with metastatic colorectal cancer (mCRC) who received regorafenib plus FOLFIRI with the irinotecan dose escalation on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping." | 3.85 | Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. ( Cheng, TL; Hu, HM; Huang, CW; Ma, CJ; Tsai, HL; Wang, JY; Wu, IC; Yeh, YS, 2017) |
| " The upregulation of the Ca2+-permeable transient receptor potential channel 5 (TrpC5) activates the Wnt/β-catenin signaling pathway in 5-fluorouracil (5-Fu)-resistant human colorectal cancer (CRC) HCT-8 (HCT-8/5-Fu) cells." | 3.85 | Elevated expression of TrpC5 and GLUT1 is associated with chemoresistance in colorectal cancer. ( Hua, D; Lu, TX; Ning, K; Wang, T, 2017) |
| "To investigate the possibility of enhancing an anti-metastatic effect of 5-fluorouracil (5-FU) on colorectal cancer (CRC) cells by combining it with continuous calcium supplementation." | 3.85 | Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis. ( Jeong, KY; Kim, HM; Park, M; Sim, JJ; Sundaramoorthy, P, 2017) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent used in the treatment of colorectal cancer." | 3.85 | 5-Fluorouracil inhibits cell migration by induction of Sestrin2 in colon cancer cells. ( Ki, SH; Park, EY; Seo, K; Shin, SM, 2017) |
| "5-Fluorouracil (5-FU) is the most commonly used chemotherapeutic agent for colorectal cancer (CRC)." | 3.85 | FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. ( Chen, C; Chen, J; Chen, L; Chen, Y; Chu, X; Dai, T; Geng, J; Huang, M; Liu, X; Mao, X; Ren, L; Wang, L; Wang, Q; Wang, R; Wang, Y; Xie, T; Xue, L; Yu, H; Zhang, K, 2017) |
| "We retrospectively investigated 156 patients with unresectable colorectal cancer who received oxaliplatin- or irinotecan-based first-line systemic chemotherapy with or without antibodies in our department between January 2007 and December 2015." | 3.85 | Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases. ( Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Murono, K; Nakajima, J; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Tanaka, T; Watanabe, T; Yasuda, K, 2017) |
| " A retrospective analysis of the cost of toxicity management was conducted on 243 metastatic colorectal cancer patients enrolled in a clinical trial and treated with standard of care FOLFIRI (5-fluorouracil combined with irinotecan)." | 3.85 | Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype. ( Buonadonna, A; Cecchin, E; De Mattia, E; Giodini, L; Innocenti, F; Montico, M; Roncato, R; Solfrini, V; Toffoli, G, 2017) |
| "Adding cetuximab to FOLFIRI (5-fluorouracil, leucovorin, irinotecan) significantly improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with KRAS or RAS (KRAS/NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC) in the first-line CRYSTAL study." | 3.85 | Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy. ( Ando, M; Beier, F; Guenther, S; Ooki, A; Van Cutsem, E; von Hohnhorst, P; Yamaguchi, K, 2017) |
| "This retrospective study enrolled 131 patients with stage III colorectal cancer who underwent curative resection: 72 received 5-fluorouracil-based adjuvant chemotherapy (chemotherapy group) and 59 did not (surgery-alone group)." | 3.85 | Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer. ( Kameyama, H; Kobayashi, T; Kosugi, SI; Okamura, T; Shimada, Y; Tajima, Y; Wakai, T; Yagi, R, 2017) |
| " To test this phenomenon, we investigated the differential responses of three secondary colorectal cancer cell lines of different origins (HCT116, HT29, and SW620 cells) and four novel primary cell lines obtained from different colorectal cancer patients to 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) and explored the differences in gene expression among the primary cell lines in response to exposure to cytotoxic drugs." | 3.85 | Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro. ( Arul, M; Cheah, SH; Roslani, AC, 2017) |
| "High-dose 5-fluorouracil (5-FU) containing chemotherapy occasionally causes hyperammonemia and can be lethal." | 3.85 | Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. ( Funakoshi, T; Horimatsu, T; Matsubara, K; Matsubara, T; Miyamoto, S; Muto, M; Nakagawa, S; Nishikawa, Y; Yanagita, M; Yonezawa, A, 2017) |
| " Hypoxia reduces sensitivity to 5-fluorouracil (5-FU)-chemotherapy for colorectal cancer (CRC)." | 3.85 | Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. ( Adam, J; Bishop, CL; Bundy, JG; Feakins, R; Gammon, L; Jalaly, A; Jeffery, R; Lewis, A; Lowe, R; McDonald, S; Nijhuis, A; Parker, A; Propper, D; Silver, A; Soga, T; Suraweera, N; Thaha, MA; Thompson, H, 2017) |
| "To evaluate the efficiency and safety of hepatic artery infusion chemotherapy (HAIC) using raltitrexed or 5-fluorouracil for colorectal cancer (CRC) liver metastasis (CRCLM)." | 3.85 | Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. ( Chen, H; Gao, S; Guo, JH; Li, XT; Wang, XD; Zhang, HY; Zhang, PJ; Zhu, X, 2017) |
| " Bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor (VEGF), is used in a combination with FOLFOX [FOL - Folinic acid; F - Fluorouracil (5-FU); OX - Oxaliplatin] as a first-line treatment for patients with metastatic colorectal cancer." | 3.83 | Posterior Reversible Encephalopathy Syndrome (PRES) Presenting as Status Epilepticus: A Case Report and Literature Review. ( Abbas, MK; Huynh, M; Sharma, P, 2016) |
| "The purpose of this study was to evaluate both in vitro and in vivo anticancer activities against colorectal cancer (CRC) of electrospun polylactide (PLA) nanofibers loaded with 5-fluorouracil (5-Flu) and oxaliplatin." | 3.83 | Antitumor activity of electrospun polylactide nanofibers loaded with 5-fluorouracil and oxaliplatin against colorectal cancer. ( Jing, X; Liu, S; Liu, T; Wang, X; Zhang, J, 2016) |
| " This study evaluates the cost-effectiveness of UGT1A1 genotyping in patients with metastatic colorectal cancer undergoing irinotecan-based chemotherapy compared to no testing from the perspective of the German statutory health insurance." | 3.83 | The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance. ( Butzke, B; Giessen-Jung, C; Heinemann, V; Oduncu, FS; Pfeufer, A; Rogowski, WH; Severin, F; Stollenwerk, B, 2016) |
| "We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer." | 3.83 | In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer. ( Kang, J; Kim, IK; Kwon, HY; Lee, KY; Sohn, SK, 2016) |
| "5-Fluorouracil (5-FU) is one among the anti-cancer agents in FOLFORINOX treatment along with oxaliplatin and irinotecan for the treatment of colorectal cancer." | 3.83 | 5-Fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer. ( Kuppusamy, G; Praveen, TK; Satish Kumar, MN; Tummala, S; Wadhwani, A, 2016) |
| "5-Fluorouracil (5-FU), a cell cycle-specific antimetabolite, is one of the most commonly used chemotherapeutic agents for colorectal cancer (CRC)." | 3.83 | Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade. ( Chen, X; Dou, L; Leng, C; Luo, X; Wu, C; Zhang, B; Zhang, Z, 2016) |
| "We investigated mechanisms of colorectal cancer (CRC) chemoresistance to first-line chemotherapy (capecitabine plus oxaliplatin (XELOX)) and identified two putative chemoresistant microRNAs, miR-1914* and -1915, that are downregulated in plasma samples from patients with chemoresistant CRC." | 3.83 | The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX. ( Cai, G; Cai, S; Hu, J; Xu, Y, 2016) |
| "Irinotecan (CPT-11)-induced neutropenia is associated with UDP-glucuronosyltransferase (UGT) 1A1*6 and *28 polymorphisms." | 3.83 | UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. ( Kusumi, T; Manabe, M; Miyata, Y; Mizunuma, N; Morita, Y; Taniguchi, F; Touyama, T, 2016) |
| "The purpose of this study was to characterize imaging biomarkers for the potential benefit of hypoxia-inducible factor-1 (HIF-1)α inhibition (by PX-12) during 5-fluorouracil (5-FU) chemotherapy in the treatment of colorectal cancer (CRC)." | 3.83 | Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model. ( De Bruycker, S; Pauwels, P; Staelens, S; Stroobants, S; Van den Wyngaert, T; Vangestel, C; Wouters, A; Wyffels, L, 2016) |
| " We investigated development of splenomegaly and its association with treatment outcome and genetic polymorphisms following adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in colorectal cancer (CRC) patients." | 3.83 | Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. ( Bang, YJ; Cha, Y; Han, SW; Im, SA; Kim, MJ; Kim, SH; Kim, TY; Lee, DW; Lee, KH; Oh, DY, 2016) |
| "Oxaliplatin is frequently used as part of a chemotherapeutic regimen with 5-fluorouracil in the treatment of colorectal cancer (CRC)." | 3.83 | SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients. ( Balavarca, Y; Becker, N; Benner, A; Brenner, H; Burwinkel, B; Chang-Claude, J; Habermann, N; Hoffmeister, M; Jansen, L; Kap, EJ; Scherer, D; Seibold, P; Ulrich, A; Ulrich, CM; Zucknick, M, 2016) |
| "Adjuvant chemotherapy for colorectal cancer is mainly based on the combination of 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4)." | 3.83 | Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study. ( Balayssac, D; Buc, E; Déchelotte, P; Le Roy, B; Pereira, B; Pétorin, C; Pezet, D; Sauvanet, P; Tixier, L, 2016) |
| "5-Fluorouracil (5-FU) is widely used in chemotherapy for treatment of colorectal cancer." | 3.83 | 5-Fluorouracil induces apoptosis of colorectal cancer cells. ( He, C; Li, CY; Liu, T; Wang, L; Zhang, JT; Zhou, WL, 2016) |
| "To evaluate the safety and efficacy of the combination therapy of fluorouracil, leucovorin and irinotecan (FOLFIRI) and aflibercept in Asian patients with metastatic colorectal cancer (mCRC), who had progressed after oxaliplatin-based chemotherapy." | 3.83 | Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. ( Chong, DQ; Choo, SP; Chua, C; Imperial, M; Manalo, M; Ng, M; Tan, IB; Teo, P; Yong, G, 2016) |
| " We applied ToxT analysis to adverse event data from two completed North Central Cancer Treatment Group (NCCTG/Alliance) trials: N9741 (NCT00003594), in which different combinations of oxaliplatin, 5-fluorouracil, and irinotecan were investigated for metastatic colorectal cancer, and 979254, in which survivors of breast cancer were given venlafaxine or placebo for control of hot flashes." | 3.83 | Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. ( Atherton, PJ; Grothey, A; Loprinzi, CL; Novotny, PJ; Sloan, JA; Thanarajasingam, G, 2016) |
| " The combination of epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan was originally designed for the treatment of metastatic colorectal cancer." | 3.83 | Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report. ( Chai, CY; Chien, TM; Huang, CN; Lin, CH; Lu, YM, 2016) |
| " Here we show that TruMBD4 plays an important role for enhancing 5-fluorouracil (5FU) sensitivity in MMR-deficient colorectal cancer cells." | 3.83 | Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status. ( Carethers, JM; Hamaya, Y; Iwaizumi, M; Kanaoka, S; Miyajima, H; Sugimoto, K; Suzuki, S; Tseng-Rogenski, S, 2016) |
| "Ten patients with histologically diagnosed peritoneal metastases of adenocarcinoma or pseudomyxoma peritonei underwent cytoreductive surgery and received HIPEC with 5-fluorouracil for 90 min, delivered via our modified system." | 3.83 | Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin. ( Cavazos, M; Cravioto-Villanueva, A; Esquivel, J; Luna-Perez, P; Martinez-Gomez, H; Montiel, H; Ramirez, ML; Solorzano, J, 2016) |
| "Multidrug resistance (MDR), a phenomenon that often occurs with drug treatment and is characterized by relapse or attenuation of drug efficacy, is almost unavoidable in colorectal cancer (CRC) patients receiving 5-fluorouracil (5-FU)-based chemotherapy." | 3.83 | miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1. ( Bian, Z; Feng, Y; Hu, Y; Huang, Z; Li, M; Liu, H; Yao, S; Yin, Y; You, Q, 2016) |
| "5-fluorouracil (5-Fu) is still recognized as the mainstay in colorectal cancer chemotherapy, but the response rate of 5-Fu in colorectal cancer is less than 50%." | 3.83 | B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu. ( Hua, D; Jiang, B; Liu, F; Ning, K; Sun, ZZ; Tang, SC; Zhang, T; Zhu, R, 2016) |
| "A 69-year-old woman presented with arterial hypotension, pulmonary oedema and a severely depressed left ventricular ejection fraction (LVEF) of 25% only 3 days after having received her first treatment for colorectal cancer with 5-fluorouracil (5-FU)-based therapy." | 3.83 | 5-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRI. ( Dalsgaard, M; Fakhri, Y; Lav Madsen, P; Nielsen, D, 2016) |
| "A 54-year-old white male diagnosed with Stage IV colorectal cancer was treated with folinic acid, leucovorin, fluorouracil, oxaliplatin (FOLFOX) and bevacizumab." | 3.83 | When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab. ( Chen, J; Nadesan, S; Smalligan, RD, 2016) |
| " In this study, we investigated the effect of NNMT on 5-fluorouracil (5-FU) sensitivity of colorectal cancer (CRC) cells, and the underlying mechanisms." | 3.83 | Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. ( Li, F; Li, G; Liu, H; Ruan, Z; Wang, X; Wang, Y; Xie, X; Yu, H; Zhang, J; Zhou, Y, 2016) |
| "To analyze the efficacy of last line sorafenib treatment in colorectal cancer patients." | 3.83 | Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. ( Becker, M; Galle, PR; Martchenko, K; Möhler, M; Schimanski, CC; Schmidtmann, I; Thole, V; Thomaidis, T; Wehler, TC, 2016) |
| " In this study, we demonstrated that anisomycin, a JNK activator, stimulates nuclear export of GATA-6 in a colorectal cancer cell line, DLD-1." | 3.83 | Anisomycin-induced GATA-6 degradation accompanying a decrease of proliferation of colorectal cancer cell. ( Horyozaki, A; Maeda, M; Ushijima, H, 2016) |
| "Protein content of ABCC10 and ABCC11 was assessed in tumor tissue blocks of 140 colorectal cancer patients and associated with survival of patients with regard to 5-fluorouracil-based therapy." | 3.83 | Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients. ( Bruha, J; Daum, O; Dubova, M; Krizkova, V; Liska, V; Skala, M; Soucek, P; Susova, S; Vycital, O, 2016) |
| "The development of chemoresistance to 5-fluorouracil (5-FU) is a major obstacle for sustained effective treatment of colorectal cancer (CRC), with the mechanisms being not fully understood." | 3.83 | Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine. ( Chen, X; Chen, Y; Hao, L; Hou, A; Li, Y; Liang, H; Luo, P; Miao, H; Ou, J; Ruan, Z; Shi, C; Wang, R; Zhang, X, 2016) |
| "Fluorouracil (5-FU) has been wildly used as a primary medication in the treatment of solid tumors including colorectal cancer." | 3.83 | Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients. ( Fang, L; Jiang, H; Jiang, Y; Lin, L; Yang, Y; Zhang, S; Zheng, J; Zheng, Y; Zhuang, X, 2016) |
| "5-fluorouracil (5-FU)-based chemotherapy is the main chemotherapeutic approach for colorectal cancer (CRC) treatment." | 3.83 | Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells. ( Cai, Z; Che, J; Chen, D; Chen, J; He, L; Huang, L; Iwamoto, A; Lan, P; Lin, M; Liu, H; Lou, Q; Qin, Q; Ren, D; Wang, H; Wang, J; Wang, L; Wen, C; Yang, X; Zhang, D, 2016) |
| "The two key aspects associated with the microsatellite instability (MSI) as genetic phenomenon in colorectal cancer (CRC) are better survival prognosis, and the varying response to 5-fluorouracil (5-FU)-based chemotherapy." | 3.83 | Microsatellite instability & survival in patients with stage II/III colorectal carcinoma. ( Branimir, Z; Daniela, B; Ivan, D; Jadranka, A; Petar, S; Srdjan, M; Velimir, M; Zoran, K, 2016) |
| "5-Fluorouracil (5FU) is still a major drug in combinations regimens for the treatment of colorectal cancer (CRC) both in the adjuvant and palliative setting." | 3.83 | Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil. ( Leon, LG; Meijer, E; Peters, GJ; Smid, K; van Groeningen, CJ, 2016) |
| "The purpose of this study was to compare health-related quality of life (HRQoL) and costs associated with 2 adjuvant chemotherapy regimens [capecitabine-based therapy versus 5-fluorouracil/leucovorin (5-FU/LV)-based therapy] in stage III colorectal cancer patients." | 3.81 | Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients. ( Chen, HC; Chen, HH; Chen, WT; Chou, YH; Fang, CY; Hsu, HH; Huang, CC; Lee, HC; Lin, BW; Lin, JK; Lin, PC; Tan, EC; Ting, WC; Yang, MC; Yeh, CH, 2015) |
| "Different combinations of 5-fluorouracil (5-FU), oxaliplatin, irinotecan and other newly developed agents have been used to treat colorectal cancer." | 3.81 | Gene signatures of drug resistance predict patient survival in colorectal cancer. ( Tong, Y; Zheng, Y; Zhou, J, 2015) |
| " We simulated phase II trials by resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer, and compared the power of various end points to detect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin])." | 3.81 | Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. ( Goldberg, RM; Gray, E; Karrison, TG; Sargent, DJ; Sharma, MR, 2015) |
| " Here, we showed that miR-22 inhibited autophagy and promoted apoptosis to increase the sensitivity of colorectal cancer (CRC) cells to 5-fluorouracil (5-FU) treatment both in vitro and in vivo." | 3.81 | MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. ( Kong, J; Lai, M; Li, C; Tang, J; Wang, J; Wu, Y; Xu, E; Zhang, H, 2015) |
| " However, the molecular mechanism as to how miR-203 modulates the chemosensitivity to 5-fluorouracil (5-FU) in colorectal cancer is poorly known." | 3.81 | miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. ( Gao, F; Li, T; Zhang, XP, 2015) |
| " In the present study, we analyzed the cytotoxicity of LA on colorectal cancer (CRC) cells differing in their p53 status and investigated a putative synergistic effect with the anticancer drug 5-fluorouracil (5-FU)." | 3.81 | Lipoic acid induces p53-independent cell death in colorectal cancer cells and potentiates the cytotoxicity of 5-fluorouracil. ( Dörsam, B; Fahrer, J; Göder, A; Kaina, B; Seiwert, N, 2015) |
| "An aptamer (Apt) conjugated hyaluronan/chitosan nanoparticles (HACSNPs) were prepared as carrier for targeted delivery of 5-fluorouracil (5FU) to mucin1 (MUC1) overexpressing colorectal adenocarcinomas." | 3.81 | Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas. ( Atyabi, F; Dinarvand, R; Esfandyari-Manesh, M; Ghasemi, Z; Mottaghitalab, F; Sayari, E, 2015) |
| "The addition of bevacizumab to fluorouracil-based chemotherapy is a standard of care for previously untreated metastatic colorectal cancer." | 3.81 | First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. ( Ayer, T; Chen, Q; El-Rayes, BF; Flowers, CR; Goldstein, DA; Howard, DH; Lipscomb, J, 2015) |
| " This study evaluates the influence of common genetic variations within the VEGF pathway in the clinical outcomes of 172 metastatic colorectal cancer (mCRC) patients treated with first-line oxaliplatin/5-fluorouracil chemotherapy." | 3.81 | Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. ( Baiget, M; Barnadas, A; Berenguer-Llergo, A; Páez, D; Paré-Brunet, L; Río, E; Salazar, J; Sebio, A, 2015) |
| "Thymidylate synthase (TYMS) is an important enzyme for 5-fluorouracil (5-FU) metabolism in metastatic colorectal cancer (mCRC) patients." | 3.81 | Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. ( Abdallah, EA; Alves, VS; Araújo, DV; Buim, ME; Chinen, LT; Dettino, AL; Fanelli, MF; Gasparini Junior, JL; Machado Netto, MC; Mingues, NB; Ocea, LM; Rocha, BM; Romero, JV; Souza E Silva, V, 2015) |
| "We prospectively evaluated the feasibility of XELOX(oxaliplatin 130 mg/m/(2) on day 1 plus capecitabine 1,000 mg/m(2) twice daily on days 1 to 14 every 3 weeks) for adjuvant treatment in 15 patients with stage III/IV (Japanese classification) colorectal cancer and pathological curability A or B after D2-D3 lymph node dissection." | 3.81 | [A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer]. ( Higashino, K; Noura, S; Ohue, M; Sakai, D; Shingai, T; Sugimoto, N; Takeuchi, Y; Yagi, T; Yamamoto, S; Yano, M; Yoshinami, T, 2015) |
| "To explore the changes of anticancer efficiency of 5'-deoxy-5-fluorouridine (5'-DFUR) and 5-fluorouracil (5-Fu) in colorectal cancer cell line HT29 and LS174T cells after transfection of thymidine phosphorylase (TP) cDNA with a lentiviral vector." | 3.81 | [Transfection of thymidine phosphorylase cDNA with lentiviral vector enhances the anticancer effect of 5'-deoxy-5-fluorouridine on colorectal cancer cell lines HT29 and LS174T]. ( Liu, Q; Wang, Q; Ye, D; Zhang, J, 2015) |
| " Herein, we investigated an alginate-based 3D scaffold for screening of 5-fluorouracil (5-FU) or/and curcumin on malignancy of colorectal cancer cells (CRC)." | 3.81 | Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. ( Buhrmann, C; Goel, A; Kraehe, P; Popper, B; Shakibaei, M; Shayan, P, 2015) |
| "Preoperative 5-fluorouracil (5-FU)-based chemoradiotherapy is a standard treatment for locally advanced colorectal cancer (CRC)." | 3.81 | Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. ( Ai, YQ; Cui, JG; He, WJ; Hou, Y; Jiang, YX; Ju, YH; Li, WH; Li, YF; Liu, S; Liu, Y; Qin, JY; Wang, L; Wang, Y; Wu, XR; Xia, YX; Xiong, W, 2015) |
| "The purpose of this study is to evaluate the influence of germline polymorphisms of cytochrome P450 (CYP450) on objective response, progression-free survival (PFS) and overall suruvival (OS) in metastatic colorectal cancer (mCRC) receiving the combination chemotherapy of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI)." | 3.81 | Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer. ( Cui, Y; Dong, N; Meng, F; Wang, M; Wu, Y; Zhang, S, 2015) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 3.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| " Overexpressing miR-197 could increase the sensitivity of colorectal cancer cells to 5-fluorouracil (5-FU)." | 3.81 | MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer. ( Bai, C; Chen, Y; Han, Q; Sun, Z; Zhao, L; Zhao, RC; Zhou, J; Zhou, N, 2015) |
| "There was performed a molecular genetic study of UGTlAl gene allelic variants polymorphism in patients with colorectal cancer who had had chemotherapy irinotecan-containing regimens FOLFIRI." | 3.81 | [The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer]. ( Abramova, NA; Dvadnenko, KV; Kit, OI; Vladimirova, LY; Vodolazhskiy, DI, 2015) |
| "This study aimed to investigate the association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and the prognosis of colorectal cancer (CRC) patients undergoing 5-fluorouracil (5-FU)-based chemotherapy in Taiwan." | 3.81 | Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer. ( Chang, LC; Chin, J; Hou, CF; Lin, TJ; Liu, WS; Su, SM; Wu, NC; Yang, JY, 2015) |
| "Colorectal cancer is commonly treated with 5-fluorouracil and 5-formyltetrahydrofolate (leucovorin)." | 3.81 | Expression of Folate Pathway Genes in Stage III Colorectal Cancer Correlates with Recurrence Status Following Adjuvant Bolus 5-FU-Based Chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Sondén, A; Wettergren, Y, 2015) |
| " This gene codifies for the target enzyme of 5-fluorouracil (5-FU), the basic treatment in colorectal cancer." | 3.81 | Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS. ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015) |
| " In addition, the effect of chemotherapeutics (5-fluorouracil and paclitaxel) released from the Fmoc-FF gel (with addition before and after gelation) on colorectal cancer cells were investigated using this methodology, demonstrating enhanced activity of these drugs compared to bulk control." | 3.81 | Dissolution and degradation of Fmoc-diphenylalanine self-assembled gels results in necrosis at high concentrations in vitro. ( Braet, F; Gloria, D; Su, Y; Thordarson, P; Truong, WT, 2015) |
| "Acquired drug resistance (ADR) can be developed in colorectal cancer cells after 5-fluorouracil (5-FU) treatment and diminish the effectiveness of chemotherapy." | 3.81 | Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles. ( Chen, L; Duan, W; He, L; Kong, L; She, X; Shigdar, S; Wang, T, 2015) |
| "We investigated the synergistic effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor plus radiation therapy, on the proliferation and survival of gastric cancer (GC) and colorectal cancer (CRC) cells." | 3.81 | Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor. ( Kang, WK; Kim, J; Lee, I; Lim, T, 2015) |
| "5-Fluorouracil (5-FU), a common chemotherapeutic agent used for the treatment of colorectal cancer (CRC), by itself has inadequate response rates; highlighting the need for novel and improved treatment regimens for these patients." | 3.81 | Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. ( Buhrmann, C; Goel, A; Kraehe, P; Popper, B; Shakibaei, M; Shayan, P, 2015) |
| "5-Fluorouracil (5-Fu) has been widely used as a first-line drug for colorectal cancer (CRC) treatment but limited by drug resistance and severe toxicity." | 3.81 | Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation. ( Fan, J; Kong, L; Liu, Q; Wang, P; Wang, X; Yang, Q; Yuan, W; Zhang, K, 2015) |
| "Systemic FOLFOX (folinic acid (leucovorin (LV)), 5-fluorouracil (5-FU), and oxaliplatin), FOLFIRI (LV, 5-FU, and irinotecan), or FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and irinotecan) chemotherapy regimens and additional molecular-target treatments, including anti-vascular endothelial growth factor, anti-epidermal growth factor receptor, and anti-multi-kinase antibodies, have been recommended for unresectable recurrent colorectal cancers." | 3.81 | Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer. ( Fujimoto, D; Goi, T; Kimura, Y; Koneri, K; Morikawa, M; Naruse, T; Yamaguchi, A, 2015) |
| "We have analyzed the association between disease-free survival (DFS) and obesity/body weight change during treatment in Korean stage III or high-risk stage II colorectal cancer patients treated with adjuvant 5-fluorouracil/ leucovorin/oxaliplatin." | 3.81 | Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. ( Bang, YJ; Cha, Y; Han, SW; Im, SA; Jeong, SY; Kang, GH; Kim, TY; Lee, DW; Lee, KH; Oh, DY; Park, JW; Park, KJ; Ryoo, SB, 2015) |
| " Aflibercept is used for the treatment of metastatic colorectal cancer (mCRC) in association with irinotecan." | 3.81 | Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. ( Beltjens, F; Bengrine, L; Ghiringhelli, F; Ladoire, S; Vincent, J, 2015) |
| " Here, we defined differentially expressed genes (DEGs) between pre-chemotherapy colorectal cancer (CRC) tissue samples of non-responders and responders for 5-fluorouracil and oxaliplatin-based therapy as clinically relevant drug resistance genes (CRG5-FU/L-OHP)." | 3.81 | Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues. ( Ao, L; Cai, H; Chi, P; Guan, Q; Guo, Y; Guo, Z; Li, M; Li, X; Lu, X; Tong, M; Yan, H; Zheng, W, 2015) |
| "12 patients with unresectable liver metastases from colorectal cancer were enrolled and received neoadjuvant FOLFIRI (5-fluorouracil, leucovorin, irinotecan) plus bevacizumab therapy." | 3.81 | Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging. ( Amato, DM; Avallone, A; Catalano, O; Filice, S; Fusco, R; Granata, V; Izzo, F; Nasti, G; Petrillo, A, 2015) |
| "The efficacy of 5-fluorouracil (5-FU)-based chemotherapy for colorectal cancer (CRC) widely varies among patients; therefore, it is difficult to accurately predict chemotherapeutic responses." | 3.81 | Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer. ( Bai, W; Wu, Y; Xi, Y; Zhang, P, 2015) |
| "Assessment of oxaliplatin-associated hepatotoxicity in patients receiving oxaliplatin, fluorouracil and leucovorin chemotherapy (FOLFOX) for colorectal cancer remains controversial." | 3.81 | Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate and is an Indicator Of Hepatotoxicity In Patients Receiving FOLFOX for Colorectal Cancer. ( Fujino, S; Hosokawa, Y; Katsumata, K; Makino, H; Maruno, K; Mushiake, H; Sugiyama, Y; Watanabe, M, 2015) |
| "Assessment of oxaliplatin-associated hepatotoxicity in patients receiving oxaliplatin, fluorouracil and leucovorin chemotherapy (FOLFOX) for colorectal cancer remains controversial." | 3.81 | Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate. ( Fujino, S; Hosokawa, Y; Katsumata, K; Makino, H; Maruno, K; Mushiake, H; Sugiyama, Y; Watanabe, M, 2015) |
| "Past reports have suggested that the addition of bevacizumab (BV) to oxaliplatin combined with 5-fluorouracil (5-FU) and folinic acid (leucovorin) (FOLFOX4) provides a limited survival benefit in metastatic colorectal cancer (mCRC)." | 3.80 | Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer. ( Matsusaka, S; Mizunuma, N; Shinozaki, E; Suenaga, M; Ueno, M; Yamaguchi, T, 2014) |
| "5-Fluorouracil (5-FU) is a cornerstone of chemotherapy for colorectal cancer (CRC), and the major targets of 5-FU are thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and reduced folate carrier 1 (RFC1)." | 3.80 | Polymorphisms of folate metabolism-related genes and survival of patients with colorectal cancer in the Korean population. ( Cho, YK; Chong, SY; Hong, SP; Hwang, SG; Jang, MJ; Jeon, YJ; Ji, YG; Kim, JW; Kim, NK; Oh, D, 2014) |
| "Despite the use of 5-fluorouracil (5-FU)-based adjuvant treatments, a large proportion of patients with high-risk stage II/III colorectal cancer will relapse." | 3.80 | AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. ( Arthur, K; Blayney, JK; Dunne, PD; Greer, S; Johnston, PG; Kalimutho, M; Longley, DB; Loughrey, M; McArt, DG; Ong, CW; Redmond, K; Salto-Tellez, M; Srivastava, S; Van Schaeybroeck, S; Wang, T, 2014) |
| "To evaluate the cost-effectiveness of the addition of bevacizumab to the irinotecan-fluorouracil (Douillard regimen-CPT-FUFA-) in first-line treatment of metastatic colorectal cancer in a single-institution population." | 3.80 | Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer. ( Albert-Mari, A; Jimenez-Torres, NV; Ruiz-Millo, O; Sendra-Garcia, A, 2014) |
| "TS mRNA expression levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer." | 3.80 | TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer. ( Guan, W; Hu, J; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Xie, L; Yu, L; Zhang, Q, 2014) |
| " Here, we found that colorectal cancer (CRC) cells treated with oxaliplatin (OXA) and/or 5-fluorouracil (5-Fu) released high levels of high-mobility group box 1 (HMGB1) and heat shock protein 70 (HSP70)." | 3.80 | TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. ( Ang, B; Cao, X; Fang, H; Huang, X; Li, N; Sun, Y; Wan, T; Wang, W; Wu, Y; Xu, X, 2014) |
| "Although FOLFOX (infusional fluorouracil/leucovorin plus oxaliplatin) is established as a standard chemotherapeutic regimen, the long term efficacy of adjuvant XELOX (oral capecitabine plus intravenous oxaliplatin) in Asian colorectal cancer (CRC) patients remains anecdotal." | 3.80 | Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. ( Chiu, J; Chu, KW; Epstein, RJ; Leung, R; Poon, J; Tang, V; Wong, H; Yau, T, 2014) |
| " However, it is still unknown the association of GOLPH3 expression with the prognosis of colorectal cancer (CRC) patients who received 5-fluorouracil (5-FU)-based adjuvant chemotherapy." | 3.80 | GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy. ( Chen, L; Cui, M; Di, J; Dong, B; Ji, J; Jiang, B; Liu, M; Ma, Y; Su, X; Wang, Z; Xing, J; Yang, H; Yao, Z; Zhang, C; Zhang, N, 2014) |
| "This study compared the clinical responses of patients with metastatic colorectal cancer (mCRC) with 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) plus bevacizumab therapy either with or without uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping and irinotecan dose escalation." | 3.80 | Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinote ( Chang, SF; Hu, HM; Huang, CM; Huang, CW; Huang, ML; Huang, MY; Lu, CY; Tsai, HL; Wang, JY; Yu, FJ, 2014) |
| "To explore genes of the killer-cell immunoglobulin-like receptor (KIR) and of the HLA ligand and their relationship with the outcome of metastatic colorectal cancer (mCRC) patients treated with first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI)." | 3.80 | Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. ( Buonadonna, A; Caggiari, L; Cecchin, E; D' Andrea, M; De Re, V; De Zorzi, M; Innocenti, F; Racanelli, V; Talamini, R; Toffoli, G; Zagonel, V, 2014) |
| "Patients with colorectal tumors with microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but have a poor response to 5-fluorouracil–based chemotherapy." | 3.80 | Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy. ( Arzouk, H; Bengrine-Lefèvre, L; Biard, DS; Bouvier, AM; Buhard, O; Chapusot, C; Collura, A; Coquelle, A; De Thonel, A; Delarue, P; Dorard, C; Duval, A; Fléjou, JF; Garrido, C; Gaub, MP; Guilloux, A; Iacopetta, B; Lacoste, C; Lagrange, A; Lefèvre, JH; Lepage, C; Loh, M; Marcion, G; Marisa, L; Mews, A; Milano, G; Parc, Y; Platell, C; Saget, A; Seigneuric, R; Selves, J; Senet, P; Soong, R; Svrcek, M; Taieb, A; Tournigand, C; Wanherdrick, K; Zeps, N, 2014) |
| " Decreases in the rates of ascites and jaundice were confirmed by ultrasound and bilirubin levels." | 3.80 | Whole-liver radiotherapy concurrent with chemotherapy as a palliative treatment for colorectal patients with massive and multiple liver metastases: a retrospective study. ( Lu, K; Qiao, WB; Sun, D; Yin, H; You, QS; Zhang, HY, 2014) |
| "To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping." | 3.80 | FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping. ( Chang, SF; Chen, CF; Hu, HM; Huang, ML; Wang, JY; Yeh, YS, 2014) |
| "Weekly cetuximab plus irinotecan-based regiments are standard first- and second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC)." | 3.80 | Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. ( Bi, F; Cao, D; Chen, Y; Li, Q; Qiu, M, 2014) |
| "Patients with breast or colorectal cancer receiving capecitabine completed a symptom, temperature and dose diary twice a day using a mobile phone application." | 3.80 | A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes. ( Brooks, C; Gibson, O; Grainger, L; Larsen, M; Love, SB; Shanyinde, M; Shearwood, V; Tarassenko, L; Waters, R; Weaver, A; Young, AM, 2014) |
| "Capecitabine is a safe chemotherapeutic agent with moderate activity for first-line treatment of older metastatic colorectal cancer patients with limited performance status." | 3.80 | First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer. ( Alacacioglu, A; Barutca, S; Degirmenci, M; Dirican, A; Karabulut, B; Oktay, E; Uslu, R; Varol, U; Yildiz, I, 2014) |
| "We retrospectively investigated the relationship between IVS14+1 G > A genotype of the dihydropyrimidine dehydrogenase (DPD) gene with plasma concentration of 5-fluorouracil (5-FU) as well as adverse reactions in 80 patients with locally advanced or metastatic colorectal cancer." | 3.80 | The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: ( Cai, X; Fang, JM; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2014) |
| "Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC)." | 3.80 | Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. ( Abrahamova, J; Benesova, V; Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kohoutek, M; Melichar, B; Obermannova, R; Pavlik, T; Usiakova, Z; Vyzula, R, 2014) |
| " The purpose of the present study was to investigate whether hypoxia-driven triple suicide gene TK/CD/UPRT expression enhances cytotoxicity to ganciclovir (GCV) and 5-fluorocytosine (5-FC), and sensitizes human colorectal cancer to radiation in vitro and in vivo." | 3.80 | Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cells. ( Deng, X; Hsiao, HT; Li, GC; Ling, CC; Sun, X; Xing, L, 2014) |
| " This study evaluated the anti-proliferative effects of ginger and Gelam honey and its efficacy in enhancing the anti-cancer effects of 5-FU (5-fluorouracil) against a colorectal cancer cell line, HCT 116." | 3.80 | Gelam honey and ginger potentiate the anti cancer effect of 5-FU against HCT 116 colorectal cancer cells. ( Alias, E; Hakim, L; Makpol, S; Morad, NA; Ngah, WZ; Yusof, YA, 2014) |
| "The aim of this study was to investigate the antitumor effect of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signaling, combined with 5-fluorouracil treatment on CT-26 colorectal adenocarcinoma cells implanted into BALB/c mice." | 3.80 | The synergistic effect of rapamycin combined with 5-fluorouracil in BALB/cByJNarl mice bearing CT-26 tumor cells. ( Chang, GR; Chao, TH; Chen, PL; Chen, WY; Mao, FC, 2014) |
| "Capecitabine, designed as a pro-drug to the cytotoxic agent 5-fluorouracil, is widely used in the management of colorectal cancer." | 3.80 | Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab. ( Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2014) |
| "Although 5-fluorouracil (5-FU) is an important drug for colorectal cancer (CRC) treatment, no useful biomarker is currently available to predict treatment response." | 3.80 | Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. ( Fukui, T; Iida, T; Miyake, H; Miyoshi, N; Naitou, H; Ochiai, T; Ohno, K; Okumura, M; Sakamoto, M; Takahashi, M; Tokunaga, Y; Tsumura, H; Umeki, M, 2014) |
| "49 consecutive patients bearing unresectable metastatic colorectal cancer and who experienced failure to oxaliplatin- and irinotecan-based chemotherapy were treated with oxaliplatin (85 mg/m(2)), irinotecan (180 mg/m(2)), leucovorin (400 mg/m(2)), and fluorouracil (400 mg/m(2) bolus then 2,400 mg/m(2)) repeated every 2 weeks." | 3.80 | FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer. ( Chaix, M; Ghiringhelli, F; Lorgis, V; Vincent, J, 2014) |
| "The effectiveness of 5-fluorouracil (5-FU)-based adjuvant chemotherapy is reported in patients with colorectal cancer (CRC), but the usefulness of 5-FU metabolic enzymes as predictive biomarkers of the efficacy of this chemotherapy remains unclear." | 3.80 | Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. ( Hasegawa, H; Ishii, Y; Kitagawa, Y; Okabayashi, K; Shigeta, K, 2014) |
| "To investigate the cost-effectiveness of panitumumab plus mFOLFOX6 (oxaliplatin, 5-fluorouracil and leucovorin) compared with bevacizumab plus mFOLFOX6 in first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC)." | 3.80 | Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. ( Barber, B; de Liège, F; Graham, CN; Hechmati, G; Hjelmgren, J; Knox, H; Lanier, J, 2014) |
| " Therefore, we hypothesized that SNAI2 (Slug) may mediate 5-fluorouracil (5FU) chemotherapy resistance through inhibition of miR145 in colorectal cancer and thus represents a novel therapeutic target to enhance current colorectal cancer treatment strategies." | 3.80 | SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. ( Camp, ER; Ethier, SP; Findlay, VJ; Hurst, K; Nogueira, LM; Quirk, D; Staveley O'Carroll, KF; Wang, C; Watson, DK, 2014) |
| "Recent observational studies showed that post-operative aspirin use reduces cancer relapse and death in the earliest stages of colorectal cancer." | 3.80 | Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. ( Ali, R; Chan, ML; Chia, WK; Deng, YH; Ho, GF; Jian, X; Mehta, S; Segelov, E; Sharma, A; Soon, SS; Tan, CS; Toh, HC; Wee, HL, 2014) |
| "5-fluorouracil (5-FU) is the first line component used in colorectal cancer (CRC) therapy however even in combination with other chemotherapeutic drugs recurrence is common." | 3.80 | Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy. ( Brocardo, MG; Henderson, BR; Martino-Echarri, E, 2014) |
| "We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict effectiveness of bevacizumab added to capecitabine and oxaliplatin (CAPEOX) in patients with metastatic colorectal cancer (mCRC)." | 3.80 | Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab. ( Boisen, MK; Dehlendorff, C; Hansen, TF; Holländer, NH; Høgdall, EV; Jensen, BB; Jensen, BV; Johansen, JS; Keldsen, N; Larsen, JS; Linnemann, D; Nielsen, BS; Nielsen, SE; Osterlind, K; Pfeiffer, P; Qvortrup, C; Tarpgaard, LS, 2014) |
| "5-Fluorouracil (5-FU) and its pro-drug Capecitabine have been widely used in treating colorectal cancer." | 3.80 | Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients. ( Chong, SS; Choo, SP; Lee, CG; Ong, SJ; Ong, SY; Teo, YY; Wang, J; Wang, X; Zhao, M, 2014) |
| "The triplet combination of fluorouracil, oxaliplatin and irinotecan for metastatic colorectal cancer improves efficacy at the cost of increased toxicity." | 3.80 | Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis. ( Brunner, S; Camenisch Gross, U; Cathomas, R; Freyholdt, T; Mey, U; von Moos, R, 2014) |
| "Effectiveness and toxicity of transcatheter arterial injection of irinotecan-eluting beads (DEBIRI) with and without concurrent capecitabine in pre-treated patients with metastatic colorectal cancer (CRC)." | 3.80 | Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. ( Akinwande, O; Hayes, D; Martin, RC; Miller, A; O'Hara, R; Tomalty, D, 2014) |
| " Food and Drug Administration in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer who have previously received an oxaliplatin-containing chemotherapy regimen." | 3.79 | Aflibercept. ( Berlin, J; Chan, E; Ciombor, KK, 2013) |
| "To identify changes in peripheral immune responses in patients with metastatic colorectal cancer (mCRC) treated with irinotecan/5-fluorouracil/leucovorin (IFL) alone or in combination with cetuximab (C-IFL)." | 3.79 | Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer. ( Amptoulach, S; Gritzapis, AD; Karadima, ML; Kosmas, C; Skopelitis, E; Tsavaris, N; Voutsas, IF; Xynos, ID, 2013) |
| " Herein, we examined the effectiveness of a combination treatment regimen of 5-fluorouracil (5-FU) and curcumin in colorectal cancer (CRC) cells." | 3.79 | Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways. ( Busch, F; Goel, A; Lueders, C; Mobasheri, A; Shakibaei, M; Shayan, P, 2013) |
| "First-line chemotherapeutic treatment of colorectal cancer (CRC) typically comprises oral (capecitabine) or intravenous 5-fluorouracil (5-FU) plus leucovorin (LV), in combination with oxaliplatin (XELOX or FOLFOX, respectively), although debate exists regarding the best course of treatment by modality in clinical practice." | 3.79 | Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice. ( Clingan, PR; Dawber, JP; Eckermann, S; Healey, E; Ranson, M; Stillfried, GE, 2013) |
| "The FFCD 2000-05 randomised trial included 410 patients with advanced colorectal cancer and compared a sequential arm S treated with 5-fluorouracil and leucovorin (LV5FU2) followed by FOLFOX (LV5FU2+oxaliplatin) and then FOLFIRI (LV5FU2+irinotecan) and a combination arm C that begins directly with FOLFOX followed by FOLFIRI." | 3.79 | Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. ( Auby, D; Bouché, O; Ducreux, M; Etienne, PL; Michiels, S; Pénichoux, J; Pignon, JP; Rougier, P; Texereau, P, 2013) |
| " 5-fluorouracil (5-FU) has been a drug of choice for treatment of colorectal cancer (CRC)." | 3.79 | Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. ( Kang, SB; Kim, DG; Kim, IH; Kim, SH; Kim, SL; Kim, SW; Lee, SO; Lee, ST; Trang, KT, 2013) |
| "We retrospectively analyzed ABCG2 expression levels in patients with metastatic colorectal cancer (CRC) to investigate the interaction between ABCG2 expression and the tumor response to oxaliplatin and 5-fluorouracil (FOLFOX)." | 3.79 | Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence. ( Chang, SC; Chen, WS; Li, AF; Lin, CC; Lin, HH; Lin, JK; Lin, PC; Yang, SH, 2013) |
| "We investigated the correlation between plasma ratio of dihydrouracil/uracil (UH2/Ura), a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase (DPD) activity, and 5-fluorouracil (5-FU) treatment efficacy in rats with colorectal cancer (CRC)." | 3.79 | Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013) |
| "We developed a pharmacokinetic/pharmacodynamic (PK/PD) model with the value of the plasma ratio of dihydrouracil (UH2)/uracil (Ura), which is a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase activity, determined before 5-fluorouracil (5-FU) treatment to simulate the growth of tumors after 5-FU treatment in rats with colorectal cancer (CRC)." | 3.79 | Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013) |
| "To investigate the use of liposomal irinotecan (Irinophore C™) plus or minus 5-fluorouracil (5-FU) for the treatment of colorectal cancer." | 3.79 | Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil. ( Allen, TM; Anantha, M; Bally, MB; Dos Santos, N; Harasym, N; Hare, JI; Neijzen, RW; Waterhouse, DN; Webb, MS, 2013) |
| "To measure global gene expression in primary advanced colorectal cancer patients who have undergone fluorouracil, leucovorin and oxaliplatin (FOLFOX4) chemotherapy and screen valuable biomarkers to predict the effects of chemotherapy." | 3.79 | Identification of HOXB8 and KLK11 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy. ( Chi, P; Li, S; Lu, X; Pan, J, 2013) |
| "There have been controversies in prognostic impact of mucinous histology on colorectal cancer, and its implication in patients treated with adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is unclear." | 3.79 | Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. ( Bae, JM; Bang, YJ; Cho, NY; Han, SW; Im, SA; Jeong, SY; Kang, GH; Kim, TY; Lee, DW; Lee, HJ; Lee, KH; Oh, DY; Park, JG; Park, KJ; Rhee, YY, 2013) |
| " Compared to SW480 and HCT116 colorectal cancer cells, P6C cells were highly resistant to Camptothecin and 5-fluorouracil, the commonly used chemotherapeutic agents to treat colorectal cancers." | 3.79 | Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs. ( Chen, Q; Du, L; Hao, JJ; Jin, HJ; Li, BW; Liu, HM; Rao, GH; Wang, J; Wang, MR; Wang, XH; Yang, YL, 2013) |
| "To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer." | 3.79 | Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013) |
| "This retrospective cohort study investigated the association between epidermal growth factor receptor (EGFR) polymorphisms and clinical outcomes in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy." | 3.79 | Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy. ( Chiou, HY; Hsieh, LL; Lai, CY; Sung, FC; Tang, R; Wu, FY; Yeh, CC, 2013) |
| "The relationship between the plasma ratio of dihydrouracil/uracil (UH2/Ura) and hepatic dihydropyrimidine dehydrogenase (DPD) activity after repeated 5-fluorouracil (5-FU) treatment in rats with colorectal cancer (CRC) was investigated." | 3.79 | A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Nishimura, A; Okada, K; Shibata, N; Takada, K, 2013) |
| "The efficacy and safety of bevacizumab(BV), combined with infusional 5-fluorouracil/leucovorin(5-FU/LV)plus irinotecan(FOLFIRI)as the second-line treatment for metastatic colorectal cancer(mCRC)after resection of the primary lesion, have not been fully clarified." | 3.79 | [Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion]. ( Abe, H; Abe, M; Hirata, T; Mafune, K; Minamimura, K; Umemura, A, 2013) |
| "Kirsten rat sarcoma virus (KRAS) wild-type status determined using a locked nucleic acid (LNA)-mediated quantitative polymerase chain reaction (qPCR) clamping assay (LNA assay) predicted response to therapy in the CRYSTAL (Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) study." | 3.79 | Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay. ( Bray, C; Celik, I; Chang, SC; Denne, J; Green, G; Harbison, C; Horak, C; Khambata-Ford, S; Van Cutsem, E; Zhao, L, 2013) |
| "The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer." | 3.79 | Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013) |
| "To evaluate gemcitabine plus capecitabine as third-line or later-line therapy in patients with refractory advanced colorectal cancer (CRC) who maintain a good performance status (PS)." | 3.79 | Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study. ( Alonso, MÁ; Jorge, M; Mendez, JC; Montes, AF; Pellón, ML; Quintero, G; Ramos, M; Reboredo, M; Romero, C; Salgado, M; Valladares-Ayerbes, M; Varela, S, 2013) |
| " We report the detailed assessment of few cardiac parameter of toxicity in patients of advanced colorectal carcinoma subjected to two Schedules of high and low dose Folinic Acid, 5-Fluorouracil, bolus and continuous infusion." | 3.79 | Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma. ( Bano, N; Mateen, A; Najam, R, 2013) |
| "Mucinous colorectal cancer (CRC) exhibits distinct clinical and pathological features, including poorer response to fluorouracil (FU) compared with non-mucinous tumours." | 3.79 | Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. ( Ardizzoni, A; Azzoni, C; Bottarelli, L; Campanini, N; Cascinu, S; Cunningham, D; Mandolesi, A; Negri, FV; Scartozzi, M; Silini, EM; Tinelli, C; Wotherspoon, A, 2013) |
| "In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality." | 3.79 | Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. ( Gao, F; Guan, M; Xue, Y; Zhang, Q; Zhang, Y; Zheng, Z, 2013) |
| "To evaluate efficacy, safety, and feasibility of maintenance therapy with capecitabine after fluoropyrimidines/oxaliplatin or fluoropyrimidines/irinotecan chemotherapy in patients with incurable colorectal cancer." | 3.79 | [Efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer]. ( Jiang, W; Li, Y; Liu, J; Ma, D; Yang, D, 2013) |
| "We analyzed the clinical efficacy and safety of capecitabine plus oxaliplatin( XELOX) and bevacizumab( BV) as neoadjuvant chemotherapy, administered for the treatment of patients with resectable metastatic colorectal cancer between October 2009 and December 2012." | 3.79 | [Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer]. ( Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Mihara, K; Mori, T; Nagashima, A; Ohkubo, Y; Yamamuro, W, 2013) |
| "Capecitabine is one of the most effective oral chemotherapeutic drugs for advanced or recurrent colorectal cancer and gastric cancer." | 3.79 | [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy]. ( Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K, 2013) |
| " We hypothesized that gene expression levels and germline variations in CD133 will predict clinical outcome in patients with metastatic colorectal cancer (mCRC), treated in first-line setting with 5-fluorouracil, oxaliplatin and bevacizumab (BV), and we investigated whether there is a correlation with gene expression levels of CD133, vascular endothelial growth factor (VEGF) and its receptors." | 3.79 | Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. ( Danenberg, KD; El-Khoueiry, A; Hu-Lieskoven, S; Iqbal, S; Kahn, M; Lenz, HJ; Lurje, G; Ning, Y; Pohl, A; Shriki, J; Stebbing, J; Teo, JL; Winder, T; Yang, D; Zhang, W, 2013) |
| "The drug fluorouracil (5-FU) is a widely used antimetabolite chemotherapy in the treatment of colorectal cancer." | 3.79 | Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer. ( Ally, AA; Asano, JK; Brown, CJ; Chan, SY; Cheng, GS; Cheung, PY; Chittaranjan, S; Gill, S; Griffith, M; Griffith, OL; Hou, YC; Lee, A; Luk, M; Marra, MA; Miao, L; Moore, R; Morin, GB; Morin, RD; Mwenifumbo, JC; Novik, K; Owen, D; Paul, JE; Pugh, TJ; Severson, T; Tai, IT; Tang, MJ; Taylor, G, 2013) |
| " We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX)." | 3.79 | Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. ( Andreu, M; Baiget, M; Bessa, X; Brea-Fernández, A; Bujanda, L; Candamio, S; Carracedo, A; Castells, A; Castellví-Bel, S; Cazier, JB; Cortejoso, L; Crous-Bou, M; Durán, G; Fernandez-Rozadilla, C; Gallardo, E; García, MI; González, D; Gonzalo, V; Guinó, E; Jover, R; Lamas, MJ; Llor, X; López, R; López-Fernández, LA; Moreno, V; Páez, D; Palles, C; Paré, L; Reñé, JM; Rodrigo, L; Ruiz-Ponte, C; Tomlinson, I; Xicola, R, 2013) |
| "The aim of the study was to analyse the prevalence and characteristics of secondary diabetes induced by 5-fluorouracil (5-FU) based chemotherapy in non-diabetic patients with colorectal cancer (CRC)." | 3.79 | Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. ( Fang, J; Feng, JP; Li, M; Lin, M; Luo, M; Xie, T; Ye, DW; Yuan, XL; Zhou, Y; Zhu, YM, 2013) |
| "We initiated this preclinical study in order to analyze the impact of sorafenib single treatment versus combination treatment in human colorectal cancer." | 3.79 | Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy. ( Berger, MR; Galle, PR; Gockel, I; Graf, C; Hainz, M; Hamdi, S; Maderer, A; Moehler, M; Schimanski, CC; Schmidtmann, I; Theobald, M; Wehler, TC, 2013) |
| "The prognostic impact of CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) on the treatment outcome of colon cancer patients receiving adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) is unclear." | 3.79 | Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. ( Bae, JM; Bang, YJ; Cho, NY; Han, SW; Im, SA; Jeong, SY; Kang, GH; Kim, TY; Lee, HJ; Lee, KH; Oh, DY; Park, JG; Park, KJ, 2013) |
| "Pharmacokinetics, biodistribution and antitumour activity of 5-fluorouracil (5-FU)-loaded polyhydroxybutyrate (PHB) and cellulose acetate phthalate (CAP) blend microspheres were investigated in chemically induced colorectal cancer in albino male Wistar rats and compared with pristine 5-FU given as a suspension." | 3.79 | Cytotoxicity and antitumour activity of 5-fluorouracil-loaded polyhydroxybutyrate and cellulose acetate phthalate blend microspheres. ( Aminabhavi, TM; Chaturvedi, K; Kulkarni, AR; Tripathi, SK, 2013) |
| "To investigate the hepatic dihydropyrimidine dehydrogenase (DPD) activity in colorectal cancer (CRC), which is critically important to create a patient-specific dosing regimen, we performed 5-FU pharmacokinetic studies in 1,2-dimethylhydrazine-induced CRC model rats (CRC rats)." | 3.79 | Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats. ( Imoto, K; Ito, Y; Kobuchi, S; Okada, K; Takada, K, 2013) |
| " The correlation of G1249A ABCC2 polymorphism with the development of colorectal cancer (CRC) and poor prognosis was evaluated in patients who were treated with fluorouracil/-leucovorin (FL) plus oxaliplatin (FOLFOX-4)." | 3.79 | Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy. ( Abdullah, S; Khoshzaban, A; Mirakhorli, M; Rahman, SA; Rozafzon, R; Vakili, M, 2013) |
| "Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy." | 3.79 | Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013) |
| "Resistance to 5-fluorouracil (5FU) poses a constant challenge to the management of colorectal cancer (CRC)." | 3.79 | Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy. ( Chan, EC; Cheah, PY; Ho, HK; Koh, PK; Mal, M; Phua, LC, 2013) |
| "The goal of the present study was to compare the efficacy of the combination of cetuximab and irinotecan to the combination of oxaliplatin and fluoropyrimidines as second-line chemotherapy in patients with irinotecan-refractory and oxaliplatin-naïve metastatic colorectal cancer (mCRC) harboring wild-type KRAS." | 3.79 | Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. ( Baek, JY; Hong, YS; Kim, HJ; Kim, JC; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Lim, SB; Park, JH; Park, SJ; Yu, CS, 2013) |
| "5-Fluorouracil (5-FU), together with other drugs such as oxaliplatin, is one of the most important pharmacological agents in the treatment of colorectal cancer." | 3.78 | P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. ( Arias-González, L; Callejas-Valera, JL; de la Cruz-Morcillo, MA; Galán-Moya, EM; García-Cano, J; García-Gil, E; Melgar-Rojas, P; Sánchez-Prieto, R; Valero, ML, 2012) |
| "FOLFOXIRI demonstrated higher efficacy compared to 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) as first-line treatment of metastatic colorectal cancer." | 3.78 | Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. ( Allegrini, G; Baldi, GG; Brunetti, IM; Cortesi, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Ricci, S; Salvatore, L; Tuzi, A; Vasile, E, 2012) |
| "No standard treatment exists for patients with metastatic colorectal cancer who have progressed after treatment with 5-fluorouracil (5-FU), oxaliplatin, irinotecan and an anti-EGFR antibody." | 3.78 | Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer. ( Boisen, MK; Fromm, AL; Jensen, BV; Larsen, FO, 2012) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 3.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| "The impact of thymidylate synthase (TYMS), methylenetetrahydrofolate reductase (MTHFR), and serine hydroxymethyltransferase 1 (SHMT1) gene polymorphisms and that of dihydropyrimidine dehydrogenase (DPD) enzyme activity, serum total homocysteine level, and estimated serum creatinine clearance on first-line 5-fluorouracil, leucovorin, irinotecan, and bevacizumab (FOLFIRI+bevacizumab) regimen efficacy in metastatic colorectal cancer patients was investigated." | 3.78 | Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab. ( Adleff, V; Budai, B; Hitre, E; Komlósi, V; Kralovánszky, J; Láng, I; Nagy, T; Pap, É; Réti, A, 2012) |
| "We assessed DNA repair efficiency over time, in vitro, in human colon adenocarcinoma HT-29 (wild-type KRAS) and HCT-116 (mutated KRAS) cell lines treated with Dbait in combination with 5-fluorouracil and/or camptothecin." | 3.78 | Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer. ( Berger, F; Biau, J; Bousquet, G; Devun, F; Dutreix, M; Herbette, A; Robine, S; Roulin, C; Sun, JS, 2012) |
| "004) of colorectal cancer patients receiving 5-fluorouracil based chemotherapy and significantly outperformed common uni- and multi-variate statistical approaches." | 3.78 | Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy. ( Concannon, CG; Dicker, P; Hector, S; Huber, HJ; Kay, EW; Kehoe, J; McCawley, N; McNamara, D; Murray, F; Prehn, JH; Rehm, M; Schmid, J, 2012) |
| "Oxaliplatin-based therapy, notably FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin), is a standard regimen approved globally for the treatment of metastatic colorectal cancer, and as adjuvant treatment of colon cancer." | 3.78 | Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. ( André, T; Brienza, S; de Gramont, A; Goldberg, RM; Gomi, K; Lee, PH; Mizunuma, N; Ohtsu, A; Rothenberg, ML; Shimada, Y; Sugihara, K, 2012) |
| " The aim of this study was to investigate the schedule-dependent effect of 5-fluorouracil (5-FU) and platinum derivatives (cisplatin or oxaliplatin) in colorectal cancer (CRC) cell lines, and to explore factors affecting it." | 3.78 | Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells. ( Fujita, M; Minegaki, T; Okumura, K; Takahashi, M; Takara, K; Yamamoto, K; Yokoyama, T, 2012) |
| "This exploratory retrospective study examined the effects of polymorphisms in transporter genes related to irinotecan pharmacokinetics and those in genes related to irinotecan pharmacodynamics on the efficacy of first-line combination chemotherapy with irinotecan, 5-fluorouracil, and folinic acid (leucovorin) (FOLFIRI) in Japanese patients with advanced colorectal cancer." | 3.78 | Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. ( Akiyama, Y; Fujita, K; Ishida, H; Kawara, K; Miwa, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K, 2012) |
| "The efficacy of bevacizumab combined with infusional 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan (FOLFIRI) as the second-line treatment for metastatic colorectal cancer (mCRC) has not been fully clarified, although bevacizumab combined with infusional 5-FU/LV plus oxaliplatin (FOLFOX) in the second-line setting has demonstrated a survival benefit." | 3.78 | Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud ( Baba, E; Bando, H; Boku, N; Esaki, T; Fukunaga, M; Hyodo, I; Kato, S; Katsumata, K; Miyake, Y; Moriwaki, T; Ozeki, M; Satoh, T; Takashima, A; Yamashita, K; Yamazaki, K; Yoshida, S, 2012) |
| "To assess the value for money of alternative chemotherapy strategies for managing advanced colorectal cancer using irinotecan or oxaliplatin, either in sequence or in combination with fluorouracil." | 3.78 | The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS). ( Asseburg, C; Bravo Vergel, Y; Manca, A; Meade, A; Parmar, M; Sculpher, MJ; Seymour, MT; Stephens, R, 2012) |
| "Patients with a diagnosis of breast or colorectal cancer and prescribed capecitabine were recruited from a UK teaching hospital." | 3.78 | Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. ( Bhattacharya, D; Easthall, C; Small, M; Watson, S; Willoughby, KA, 2012) |
| " We investigated the clinical significance of miR-10b and its involvement in chemotherapeutic resistance to 5-fluorouracil (5-FU), which is a key component of common chemotherapy regimens in colorectal cancer." | 3.78 | MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. ( Doki, Y; Ishii, H; Mimori, K; Mori, M; Nishida, N; Shibata, K; Sudo, T; Tanaka, F; Yamamoto, H; Yamashita, S, 2012) |
| " Breast cancer patients were receiving a 5-fluorouracil/epirubicin/cyclophosphamide (FEC) regimen (6 chemotherapy cycles), and colorectal cancer patients were receiving either an oxaliplatin/5-fluorouracil/folinic acid (FOLFOX) regimen (12 cycles) or a 5-fluorouracil/folinic acid (Mayo) regimen (6 cycles)." | 3.78 | Infections of Blastocystis hominis and microsporidia in cancer patients: are they opportunistic? ( Anita, ZB; Chandramathi, S; Kuppusamy, UR; Suresh, K, 2012) |
| " The aim of the present study was to analyse the possible predictive value of miRNA-126 in relation to first line capecitabine and oxaliplatin (XELOX) in patients with metastatic colorectal cancer (mCRC)." | 3.78 | The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. ( Hansen, TF; Jakobsen, A; Lindebjerg, J; Sørensen, FB, 2012) |
| "Human colorectal cancer cells, HT-29 and SW480, were cultured under hypoxic conditions and the sensitivity to 5-fluorouracil (FU), oxaliplatin, and SN-38 (active metabolite of irinotecan) was tested." | 3.78 | SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha. ( Hiyoshi, M; Hongo, K; Kaneko, M; Kawai, K; Kitayama, J; Murono, K; Nirei, T; Sasaki, K; Sunami, E; Tada, N; Takahashi, K; Tsuno, NH, 2012) |
| " We analysed a cohort of 302 patients with colorectal cancer treated with 5-Fluorouracil (5-FU)." | 3.78 | Data-driven assessment of the association of polymorphisms in 5-Fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. ( Afzal, S; Colding-Jørgensen, M; Jensen, SA; Mosekilde, E; Poulsen, HE; Rasmussen, CH; Sarac, SB; Thirstrup, S, 2012) |
| "Here we performed a systematic analysis of the immunohistochemical expression of the key proteins involved in apoptosome-dependent caspase activation (APAF1, Pro-caspases 9 and 3, SMAC, and XIAP) in a cohort of Stage II and III colorectal cancer patients from a Phase III trial of adjuvant 5-fluorouracil-based chemotherapy vs postoperative observation alone." | 3.78 | Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer. ( Concannon, CG; Conlon, S; Cummins, RJ; Dicker, P; Hector, S; Johnston, PG; Kay, EW; Prehn, JH; Schmid, J, 2012) |
| "Perifosine is a novel targeted oral Akt inhibitor currently in Phase III clinical development for treatment of colorectal cancer (CRC, in combination with capecitabine) and multiple myeloma (MM, in combination with bortezomib and dexamethasone)." | 3.78 | Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. ( Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG, 2012) |
| " Deficient mismatch repair, or microsatellite instability, is a potent marker for the ineffectiveness of 5-fluorouracil (5-FU) in colorectal cancer (CRC)." | 3.78 | FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer. ( Fujinaka, Y; Iimori, M; Kakeji, Y; Kitao, H; Maehara, Y; Morita, M; Nakanishi, R; Tokunaga, E; Yamashita, N, 2012) |
| " Here, we aimed to investigate the role of CQ in potentiating the effect of 5-fluorouracil (5-FU), the chemotherapeutic agent of first choice for the treatment of colorectal cancer, in an animal model of colon cancer." | 3.78 | Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study. ( Hiyoshi, M; Hongo, K; Kaneko, M; Kawai, K; Kitayama, J; Murono, K; Nirei, T; Sasaki, K; Sunami, E; Tada, N; Takahashi, K; Tsuno, NH, 2012) |
| " We aimed to assess the prognostic role of VEGF, bFGF, PDGF-AA, EGF, HGF, and E-selectin in patients with metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) chemotherapy protocol." | 3.78 | Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer. ( Berk, V; Elmalı, F; Er, O; Inanç, M; Karaca, H; Ozkan, M; Saraymen, R, 2012) |
| " It was analyzed in 12 colorectal cancer cells for associations with radiation or 5-fluorouracil susceptibility by Western blotting, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium Bromide assay, and small interfering RNA transfection." | 3.78 | Hydroxymethylglutaryl-coenzyme a synthase 2 expression is associated with chemoradiotherapy responses in colorectal cancer. ( Cho, MJ; Kim, DY; Kim, ES; Kim, JS; Kim, KH; Ku, JL; Yeo, SG; Yoo, BC, 2012) |
| "Capecitabine plus oxaliplatin combination (XELOX) is the first-line treatment in metastatic colorectal cancer." | 3.78 | Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. ( Alì, G; Calabrese, R; Lenzi, P; Moretti, P; Orsucci, D; Petrozzi, L; Pizzanelli, C; Ricci, G; Siciliano, G, 2012) |
| "A combination of 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX) is a standard regimen for the chemotherapy of metastatic colorectal cancer." | 3.78 | Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. ( Ando, T; Fukuoka, J; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, Y; Ogawa, K; Sugiyama, T; Suzuki, N; Tsukioka, Y; Ueda, A; Yabushita, K, 2012) |
| "Oxaliplatin is effective when used with 5-fluorouracil (5-FU) and leucovorin, or with capecitabine (COX) for the treatment of colorectal cancer." | 3.78 | Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo. ( Kobunai, T; Nakagawa, F; Nukatsuka, M; Saito, H; Sakamoto, K; Shiraishi, K; Takechi, T; Uchida, J, 2012) |
| "A colorectal cancer patient receiving chemotherapy (5-fluorouracil and oxaliplatin) plus bevacizumab developed acute, severe thrombocytopenia." | 3.78 | A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia. ( Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Dior, M; Goldwasser, F; Mir, O; Perkins, G, 2012) |
| " In this retrospective study, we assessed the efficacy of palonosetron versus granisetron for the incidence of CINV induced by mFOLFOX6 and FOLFIRI in patients with advanced colorectal cancer." | 3.78 | [Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey]. ( Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M, 2012) |
| "Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation." | 3.78 | Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012) |
| "We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment of colorectal cancer (CRC)." | 3.78 | Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. ( Aloia, TA; Andreou, A; Brouquet, A; Chen, SS; Curley, SA; Garrett, C; Kopetz, S; Maru, DM; Overman, MJ; Shindoh, J; Vauthey, JN; Zimmitti, G, 2012) |
| "Radiosensitization by vorinostat under hypoxia was studied in four colorectal carcinoma cell lines and in one colorectal carcinoma xenograft model by analysis of clonogenic survival and tumor growth delay, respectively." | 3.78 | Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. ( Flatmark, K; Fleten, KG; Furre, T; Hektoen, HH; Kristian, A; Ree, AH; Saelen, MG, 2012) |
| "To evaluate effects of UDP-glucuronosyltransferase1A1 (UGT1A1) and thymidylate synthetase (TS) gene polymorphisms on irinotecan in metastatic colorectal cancer (mCRC)." | 3.78 | UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. ( Jiao, SC; Liu, ZY; Shen, L; Wang, JW; Wang, Y; Xu, JM; Xu, N, 2012) |
| " The aim of this study was to investigate the possible predictive value of the VEGF-A SNPs, in patients with metastatic colorectal cancer (mCRC) treated with first-line capecitabine and oxaliplatin (XELOX)." | 3.77 | The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. ( Andersen, RF; Brandslund, I; Garm Spindler, KL; Hansen, TF; Jakobsen, A; Lindebjerg, J, 2011) |
| "The efficacy and safety of generic and brand name levofolinate injectable drugs were evaluated in 42 chemotherapy-naïve patients with colorectal cancer who received the combination chemotherapy of levofolinate, 5-fluorouracil, and oxaliplatin with or without bevacizumab." | 3.77 | Evaluation of efficacy and safety of generic levofolinate in patients who received colorectal cancer chemotherapy. ( Fujii, H; Iihara, H; Itoh, Y; Matsuura, K; Takahashi, T; Yasuda, K; Yoshida, K, 2011) |
| " We investigated associations between polymorphisms in both miRNA-containing genomic regions (primary and precursor miRNA) and in genes related to miRNA biogenesis with clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5-fluorouracil and irinotecan (CPT-11)." | 3.77 | Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. ( Aranda, E; Bandrés, E; Boni, V; Garcia-Foncillas, J; Gomez, MA; Maiello, E; Villa, JC; Zarate, R, 2011) |
| "The aim was to evaluate the association between plasma tissue inhibitor of metalloproteinase-1 (TIMP-1) and serum carcinoembryonic antigen (CEA) levels and outcome in patients with metastatic colorectal cancer (mCRC) receiving XELOX (combination chemotherapy with capecitabine and oxaliplatin) as first-line treatment." | 3.77 | Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer. ( Berglund, A; Brünner, N; Christensen, IJ; Frederiksen, C; Glimelius, B; Jensen, BV; Keldsen, N; Nielsen, HJ; Nielsen, SE; Pfeiffer, P; Qvortrup, C, 2011) |
| "5-Fluorouracil remains widely used in colorectal cancer treatment more than 40 years after its development." | 3.77 | Can localised (19)F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response? ( Griffiths, JR; Howe, FA; Ladroue, C; Lofts, F; McIntyre, DJ; Stubbs, M, 2011) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 3.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| " The authors of this report determined the frequency of reporting of time-to-event endpoints and tumor response outcomes in advanced colorectal cancer and examined the relation between the year of publication and the reported effectiveness of 5-fluorouracil or equivalent agents." | 3.77 | Reporting time-to-event endpoints and response rates in 4 decades of randomized controlled trials in advanced colorectal cancer. ( Arkenau, HT; Dobbins, T; Nordman, I; Ward, R, 2011) |
| "Patients with advanced colorectal cancer who received irinotecan combined with 5-fluorouracil plus l-leucovorin (FOLFIRI) as first-line therapy were divided into two groups: those with UGT1A1*1/*1 genotype and those with UGT1A1*1/*6 or *1/*28 genotype." | 3.77 | UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. ( Akiyama, Y; Ando, Y; Araki, K; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K, 2011) |
| "Capecitabine plus oxaliplatin (CAPOX) is an established treatment option in colorectal cancer, but can be associated with severe toxicities." | 3.77 | Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. ( Baird, R; Barbachano, Y; Biondo, A; Chau, I; Chhaya, V; Cunningham, D; Karpathakis, A; McLachlan, J; Rahman, S, 2011) |
| "Irinotecan (CPT11) at 180 mg/m(2) with LV5FU2 for metastatic colorectal cancer (MCRC) has response rates (RRs) of 56 and 4% as first- and second-line treatments, respectively [1-2], and higher doses of CPT11 result in higher RRs." | 3.77 | Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients. ( Goubely, Y; Kirscher, S; Mineur, L; Molinari, N; Plat, F; Sabatier, R, 2011) |
| "Several long-standing chemotherapy regimens are available to treat metastatic colorectal cancer (mCRC) including: oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (FOLFOX); and irinotecan plus 5-FU and leucovorin (FOLFIRI)." | 3.77 | Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. ( Barber, B; Gregory, C; Long, SR; Song, X; Wang, PF; Zhao, Z, 2011) |
| "A total of 152 patients with metastatic colorectal cancer who were treated with oxaliplatin and continuous infusion 5-fluorouracil were genotyped for 21 polymorphisms in 13 cancer-related genes by PCR." | 3.77 | Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. ( El-Khouiery, A; Gordon, MA; Iqbal, S; Labonte, M; Ladner, RD; Lenz, HJ; Lurje, G; Nagashima, F; Sherrod, A; Wilson, P; Yang, D; Zhang, W, 2011) |
| " In the present study, we evaluated the characteristics of paclitaxel (PTX) and 5-fluorouracil (5-FU) penetration and their effects on tissue penetration using MCLs of human colorectal cancer cells (DLD-1 and HT-29) grown in Transwell inserts." | 3.77 | Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells. ( Choi, MS; Kim, SH; Kuh, HJ, 2011) |
| " The purpose of this pharmacogenetic trial was to study the relevance of thymidylate synthase (TS) genotyping and of the isoform 1A1 of uridine diphosphate glucuronosyltransferase (UGT1A1) in order to tailor a combination chemotherapy regimen of 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in metastatic colorectal cancer." | 3.77 | Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. ( Chatelut, E; Delord, JP; Duret, A; Etienne, MC; Falandry, C; Freyer, G; Lledo, G; Merrouche, Y; Milano, G; Rebischung, C, 2011) |
| "We examined the feasibility of regimen selection for first-line irinotecan, 5-fluorouracil and leucovorin or oxaliplatin, 5-fluorouracil and leucovorin in Japanese patients with advanced colorectal cancer based on UDP-glucuronosyltransferase 1A1 genotype as well as physical status of patients related to diarrhea." | 3.77 | Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. ( Akiyama, Y; Ando, Y; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K, 2011) |
| "To examine cost and mortality among stage IV colorectal cancer (CRC) patients treated with 5-fluorouracil (5FU)/leucovorin/oxaliplatin (FOLFOX) or 5FU/leucovorin/irinotecan (FOLFIRI)." | 3.77 | A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer. ( Harley, C; Kulakodlu, M; Nelson, MA; Seal, B; Shetty, S, 2011) |
| "Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer." | 3.77 | A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 3.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| "Combined chemotherapy with 5-fluorouracil and leucovorin (LV) has been widely used for the treatment of patients with colorectal cancer." | 3.77 | In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin. ( Fukushima, M; Kiniwa, M; Nakagawa, F; Saito, H; Sakamoto, E; Tsujimoto, H; Tsukioka, S; Uchida, J, 2011) |
| " In the present study, we aimed to investigate the antitumor effect of DCA combined with 5-Fluorouracil (5-FU) on colorectal cancer (CRC) cells." | 3.77 | Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. ( He, J; Li, J; Liang, H; Pan, F; Tong, J; Xie, G, 2011) |
| "The aim of this study was to evaluate the potential of fluorine-18 (F)-5-fluorouracil (F-5-FU) positron emission tomography/computed tomography (PET/CT) to show differences in 5-FU activity in metastatic colorectal cancer before and after treatment with bevacizumab." | 3.77 | 18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. ( Chin, FT; Conti, PS; Fisher, GA; Kunz, P; Quon, A; Subbarayan, M; Zissen, MH, 2011) |
| " We aimed to evaluate the effect of pretreatment serum metabolic profiles generated by (1)H NMR spectroscopy on toxicity in patients with inoperable colorectal cancer receiving single agent capecitabine." | 3.77 | Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. ( Backshall, A; Clarke, SJ; Keun, HC; Sharma, R, 2011) |
| "When applying the topoisomerase inhibitor irinotecan (CPT) with the infusional fluorouracil/levofolinate (FOLFIRI) ± bevacizumab chemotherapy regimen in cases of advanced colorectal carcinoma, the international standard dose for CPT is 180 mg/m(2)." | 3.77 | Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma. ( Akutsu, N; Fujii, H; Hamamoto, Y; Miyamoto, J; Nagase, M; Nishi, T; Warita, E; Yamanaka, Y, 2011) |
| "Germline DNA was available from 568 previously untreated patients with advanced colorectal cancer participating in the CAIRO2 trial, assigned to capecitabine, oxaliplatin, and bevacizumab ± cetuximab." | 3.77 | Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. ( Beijnen, JH; Burylo, AM; Cats, A; de Boer, A; Deenen, MJ; Doodeman, VD; Guchelaar, HJ; Punt, CJ; Schellens, JH; Smits, PH; Tol, J; Vincent, A, 2011) |
| "Thymidylate synthase (TS) expression levels appear to be related to response to 5-fluorouracil-(5-FU)-based chemotherapy in colorectal cancer (CRC) patients." | 3.77 | Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. ( Cianchi, F; Genuardi, M; Mazzei, T; Mini, E; Morganti, M; Napoli, C; Nobili, S; Papi, L; Putignano, AL; Tonelli, F; Valanzano, R; Vignoli, M, 2011) |
| "We have extensively assessed a biweekly regimen of irinotecan plus folinic acid and fluorouracil bolus (IRIFAFU) in metastatic colorectal cancer (MCRC)." | 3.77 | Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience. ( Barbato, E; Barberis, G; Comella, P; Condemi, G; Filippelli, G; Ionta, MT; Massidda, B; Natale, D; Palmeri, S; Putzu, C; Sandomenico, C; Tafuto, S; Vessia, G, 2011) |
| " It was motivated by an attempt to develop a model-based dose adaptation tool for clinical use in colorectal cancer patients receiving capecitabine, which induces severe hand-and-foot syndrome (HFS) toxicity in more than a half of the patients." | 3.77 | Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data. ( Girard, P; Paule, I; Tod, M, 2011) |
| "The antivascular endothelial growth factor monoclonal antibody bevacizumab with infusional 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) is a standard first-line treatment option for metastatic colorectal cancer." | 3.77 | Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI. ( Boc, M; Ocvirk, J; Rebersek, M, 2011) |
| "The role of the calcium binding protein, Calbindin 2 (CALB2), in regulating the response of colorectal cancer (CRC) cells to 5-Fluorouracil (5-FU) was investigated." | 3.77 | Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway. ( Allen, WL; Johnston, L; Johnston, PG; Longley, DB; McCloskey, K; Proutski, I; Stevenson, L; Stewart, G; Wilson, PM, 2011) |
| " Here we show that ATP-binding cassette member B5 (ABCB5) identifies therapy-refractory tumor cells in colorectal cancer patients following fluorouracil (5-FU)-based chemoradiation therapy and provide evidence for a functional role of ABCB5 in colorectal cancer 5-FU resistance." | 3.77 | ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. ( Frank, MH; Frank, NY; Gasser, M; Gold, JS; Huang, Q; Ma, J; Murphy, GF; Saab, KR; Schanche, R; Schatton, T; Waaga-Gasser, AM; Wilson, BJ; Zhan, Q, 2011) |
| "Infusional fluorouracil/leucovorin (FU/LV) plus irinotecan (FOLFIRI) is one of the standard first-line options for patients with metastatic colorectal cancer (mCRC)." | 3.77 | A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. ( Baiget, M; del Rio, E; Marcuello, E; Páez, D; Paré, L; Salazar, J; Sebio, A, 2011) |
| "We studied patterns of DNA damage signaling and cell cycle response to clinically-relevant (bolus) and high doses of 5-fluorouracil (5-FU) in three colorectal cancer cell lines with differing MMR and TP53 status in an attempt to better understand how 5-FU exerts its cytotoxicity." | 3.77 | DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status. ( Adamsen, BL; De Angelis, PM; Kravik, KL, 2011) |
| "After resection of CRC and synchronous metastases, 53 (84%) out of 63 patients without chemotherapy, and 38 (83%) out of 46 that received 5-fluorouracil (5-FU) alone or with leucovorin (LV) developed recurrent tumors." | 3.77 | FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer. ( Kanazawa, T; Kawai, K; Kazama, S; Kitayama, J; Mori, K; Nagawa, H; Nozawa, H; Saito, S; Sunami, E; Yazawa, K, 2011) |
| "FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients." | 3.77 | Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. ( Eshima, K; Horie, H; Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Konishi, T; Matsuda, K; Muto, T; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011) |
| "Regimens containing bevacizumab and 5-fluorouracil have achieved substantial progress in the treatment of colorectal cancer." | 3.77 | Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. ( Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Matsuda, K; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011) |
| "XELOX (capecitabine + oxaliplatin) and FOLFOX 4 (5-FU + folinic acid + oxaliplatin) have shown similar improvements in survival in patients with metastatic colorectal cancer (MCRC)." | 3.77 | Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. ( Chau, J; Chua, DT; Lee, AW; Lee, V; McGhee, SM; Ng, WT; Tse, VC, 2011) |
| "Injectable combination chemotherapy with 5-fluorouracil (5-FU)/Leucovorin (LV), oxaliplatin (OHP), and irinotecan (CPT-11) has been a standard treatment for advanced colorectal cancer (CRC)." | 3.77 | [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer]. ( Matsueda, S; Sasaki, H; Tokunaga, Y, 2011) |
| "5-fluorouracil (5FU)-based chemotherapy is the standard treatment for advanced stage colorectal cancer (CRC) patients." | 3.77 | DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. ( Carethers, JM; Iwaizumi, M; Tseng-Rogenski, S, 2011) |
| "For recurrent or metastatic colorectal cancer, a combination of leucovorin and fluorouracil with oxaliplatin (FOLFOX)is a standard first-line regimen." | 3.77 | [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy]. ( Hasegawa, J; Hirota, M; Kim, Y; Nezu, R; Nishimura, J; Yoshida, Y, 2011) |
| "The purpose of this study was to investigate whether specific combinations of polymorphisms in 5-fluorouracil (5-FU) metabolism-related genes were associated with outcome in 5-FU-based adjuvant treatment of colorectal cancer." | 3.77 | The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. ( Adleff, V; Afzal, S; Andersen, JT; Barile, C; Bertolaso, L; Brødbæk, K; Budai, B; Gusella, M; Hitre, E; Jensen, SA; Jimenez-Solem, E; Kralovánszky, J; Láng, I; Orosz, E; Padrini, R; Pasini, F; Petersen, M; Poulsen, HE; Vainer, B; Vogel, U, 2011) |
| "The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively." | 3.77 | Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer. ( Cho, YB; Choi, SH; Chun, HK; Chung, HJ; Kim, HC; Lee, WY; Yun, SH, 2011) |
| "It has been reported that thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), and excision repair cross-complementing-1 (ERCC-1) were useful markers to predict the efficacy of anti cancer agents including 5-fluorouracil (5-FU) and oxaliplatin for unresectable advanced colorectal cancer." | 3.77 | [The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer]. ( Haga, N; Ishibashi, K; Ishida, H; Ishiguro, T; Kumamoto, K; Kuwabara, K; Miura, I; Ohsawa, T; Okada, N, 2011) |
| " This study was performed to evaluate the efficacy and safety of Endostar plus leucovorin calcium/ 5-fluorouracil/oxaliplatin (FOLFOX4) in treating patients with advanced colorectal cancer." | 3.77 | Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. ( Huang, XE; Li, CG; Li, Y; Qian, ZY; Xu, HX; Xu, X, 2011) |
| " Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)." | 3.77 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994) |
| "Failure rate of colorectal cancer after surgical resection remains around 50% and adjuvant treatments are clearly required." | 3.77 | Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU. ( Nordlinger, B; Rougier, P, 1993) |
| "To investigate the mechanism of enhancing apoptosis-inducing effects of 5-fluorouracil on human colorectal adenocarcinoma cells by stable transfection of extrinsic Fas-associated death domain protein (FADD) gene, both in vitro and in vivo." | 3.76 | Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. ( Jiang, Y; Luo, H; Yin, A; Zhang, X, 2010) |
| "A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC)." | 3.76 | Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. ( Bodnar, L; Stec, R; Szczylik, C, 2010) |
| "Oxaliplatin-associated neuropathy remains a dose-limiting toxicity of the standard chemotherapy regimen of oxaliplatin and capecitabine for metastatic colorectal cancer." | 3.76 | Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? ( Cathomas, R; Köberle, D; Mayer, G; Mey, U; Räss, A; Ruhstaller, T; von Moos, R, 2010) |
| " We investigated whether p53 polymorphism and mutation were associated with in vitro sensitivity to 5-fluorouracil (5-FU) in patients with colorectal cancer." | 3.76 | Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. ( Higashiguchi, T; Hotta, T; Iwahashi, M; Matsuda, K; Nasu, T; Oku, Y; Takifuji, K; Tominaga, T; Yamaue, H; Yokoyama, S, 2010) |
| "The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (XELOX)." | 3.76 | EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. ( Andersen, RF; Jakobsen, A; Jensen, LH; Ploen, J; Spindler, KG, 2010) |
| " To test this we have addressed the hypothesis that histone deacetylase inhibitors SBHA and MS275 potentiate inhibitory effects of classical anti-colorectal cancer cytostatic, 5-fluorouracil (5-FU), on survival of colorectal cancer (CRC) cells in vitro." | 3.76 | MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. ( Flis, K; Flis, S; Gnyszka, A; Spławiński, J, 2010) |
| "The in vitro chemosensitizing effect of triptolide (PG490) on the cytotoxicity of 5-fluorouracil (5-FU) was determined in three colorectal cancer (CRC) cell lines." | 3.76 | Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. ( Armesilla, AL; Cassidy, J; Darling, JL; Guo, X; Mathew, S; Wang, W; Xu, B, 2010) |
| " In this study, we investigated the expressions of FAK, Akt and NF-kappaB in human colorectal cancer (CRC), and the effects of FAK gene silencing on MCSs formation and 5-fluorouracil (5-FU) chemosensitivity in colon carcinoma MCSs culture cells." | 3.76 | The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas. ( Bian, Z; Chang, P; Chen, Y; Jiang, J; Li, J; Liang, H; Pan, F; Wang, Z; Xiang, L; Yang, L; Zou, L, 2010) |
| "To test prospectively the predictive value of germinal gene polymorphisms related to fluorouracil (FU) and oxaliplatin (Oxa) pharmacodynamics on toxicity and responsiveness of colorectal cancer (CRC) patients receiving FOLFOX therapy." | 3.76 | Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. ( André, T; Carola, E; Chibaudel, B; de Gramont, A; Etienne-Grimaldi, MC; Flesch, M; Formento, JL; Francoual, M; Lledo, G; Mabro, M; Maindrault-Goebel, F; Milano, G; Mineur, L, 2010) |
| "A 78-year-old male with stage III colorectal adenocarcinoma was prescribed with weekly iv 5-fluorouracil and folinic acid (FU/FA)." | 3.76 | Do 5-fluorouracil therapies alter CYP2C19 metaboliser status? ( Helsby, NA; Laking, GR; Lo, WY; Thompson, P, 2010) |
| "The purpose of our study was to estimate the out-of-pocket payment and cost-effectiveness of capecitabine plus oxaliplatin (XELOX) or XELOX plus bevacizumab from the perspective of patients with metastatic colorectal cancer (MCRC)." | 3.76 | Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan. ( Fukuda, T; Shiroiwa, T; Tsutani, K, 2010) |
| "Oxaliplatin and 5-fluorouracil (5-FU) currently form the backbone of conservative treatment in patients with metastatic colorectal cancer." | 3.76 | Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. ( Borel Rinkes, IH; Cameron, K; de Bruijn, MT; Hoogwater, FJ; Kranenburg, O; Medema, JP; Raats, DA; van Houdt, WJ, 2010) |
| "To assess the potential of Lactobacillus acidophilus and Lactobacillus casei strains to increase the apoptosis of a colorectal cancer cell line in the presence of 5-fluorouracil (5-FU), LS513 colorectal cancer cells were treated for 48 h with increasing concentrations of these lactic acid bacteria (LAB) in the presence of 100 mu g/ml of 5-FU." | 3.76 | Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. ( Baldwin, C; Lacroix, M; Luquet, FM; Millette, M; Oth, D; Ruiz, MT, 2010) |
| " Based on these data, we investigated whether patient's gender and TS polymorphism exert an interactive effect on the clinical evolution of patients with advanced colorectal cancer (CRC) subjected to 5 fluorouracil (5FU)-based adjuvant chemotherapy." | 3.76 | Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer. ( Fernández-Contreras, ME; Gamallo, C; García de Paredes, ML; Gisbert, JP; Guijarro, M; Hinojar-Gutiérrez, A; Rivas, N; Sánchez-Hernández, JJ, 2010) |
| "5-Fluorouracil has been the chemotherapy agent of first-choice for colorectal cancer for many years, but since there are no proven predictors of a patient's response to therapy, all patients receive similar treatment." | 3.76 | HnRNP K and PDI marked response to chemotherapy to human colorectal cancer cells. ( Chen, HQ; Chu, ZX; Huang, L; Ma, YL; Peng, JY; Qin, HL; Shen, TY; Zhang, M; Zhang, P; Zhou, YK, 2010) |
| "The aim was to evaluate the cost of capecitabine vs conventional combination chemotherapics such as 5-fluorouracil (5-FU) for the treatment of metastatic colorectal cancer (mCRC) in Italy." | 3.76 | Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients. ( Bianchessi, C; Bollina, R; Carteni, G; Cozzi, C; De Portu, S; Grimaldi, AM; Mantovani, LG; Ravaioli, A; Tamburini, E; Testa, TE, 2010) |
| "To explore the effect of PI3K p85alpha gene silencing on the 5-fluorouracil (5-FU)-induced apoptosis of colorectal cancer cells." | 3.76 | [PI3K p85alpha gene silencing by RNA interference promotes 5-fluorouracil-induced apoptosis of colorectal cancer LoVo cells]. ( Ma, YQ; Ni, L; Song, YG; Yang, H, 2010) |
| " 5-Fluorouracil (5-FU) is the drug of choice in managing colorectal cancer (CRC) patients." | 3.76 | Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance. ( Ardalan, B; Benitez, E; Nelson, G; Sarkar, M; Singhal, S; Subbarayan, PR, 2010) |
| " The SFK inhibitor saracatinib (AZD0530) is currently in phase II trials in patients including those with colorectal cancer (CRC), where links between SFK activity and poor prognosis are particularly striking." | 3.76 | Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. ( Bönisch, H; Bryce, RA; Dive, C; Ghattas, M; Green, TP; Hickinson, DM; Morrow, CJ; Smith, C, 2010) |
| "A hospital based cross-sectional retrospective study was conducted to determine the frequency of hand foot syndrome (HFS) with Capecitabine as a single agent and in combination with Oxaliplatin." | 3.76 | High frequency of hand foot syndrome with capecitabine. ( Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N, 2010) |
| "Accurate description of current practice within advanced colorectal cancer (CRC) specialties were needed to inform an economic evaluation of the UGT1A1 pharmacogenetic test for irinotecan in the United Kingdom." | 3.76 | Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. ( Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW, 2010) |
| "Oxaliplatin with 5-fluorouracil plus leucovorin (FOLFOX) has become the standard treatment in patients with colorectal cancer." | 3.76 | [Interstitial lung disease associated with combination chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin]. ( Jung, JJ; Kim, GB; Ko, JE; Ko, SH; Lee, YS; Park, S; Yoon, HS, 2010) |
| "Resistance to 5-fluorouracil (5-FU) represents a major contributor to cancer-related mortality in advanced colorectal cancer patients." | 3.76 | Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. ( Auman, JT; Deal, AM; Hoskins, JM; Hudson, ML; Ibrahim, JG; McLeod, HL; Meyers, MO; Muhale, F; O'Neil, BH; Thorne, LB; Walko, CM; Watson, RG; Yu, J, 2010) |
| " As proof of principle, we used the approach to compare fluorouracil-resistant and -nonresistant human colorectal cancer cell lines." | 3.76 | Alternative expression analysis by RNA sequencing. ( Ally, A; Asano, JK; Chan, SY; Chittaranjan, S; Corbett, R; Delaney, A; Goya, R; Griffith, M; Griffith, OL; Hirst, M; Hou, YC; Jones, SJ; Li, HI; Marra, MA; McDonald, H; Morin, GB; Morin, RD; Morrissy, AS; Mwenifumbo, J; Pugh, TJ; Robertson, G; Tai, IT; Tang, MJ; Teague, K; Zeng, T; Zhao, Y, 2010) |
| "Although the 2009 edition of the Guidelines for Colorectal Cancer Therapy recommend capecitabine as a standard postoperative adjuvant chemotherapy for colorectal cancer therapy, a characteristic adverse event, hand-foot syndrome, develops at a high incidence, and appropriate management is necessary to continue therapy." | 3.76 | [Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome]. ( Chiba, M; Fujimoto, H; Igawa, A; Iizawa, H; Ikeda, E; Inoue, K; Ishiyama, K; Kobayashi, Y; Matsuda, M; Mori, N; Saito, T; Sato, T; Sugawara, M; Suto, T; Suzuki, Y; Watanabe, T; Yabuki, H, 2010) |
| " In this study, we investigated antitumor effects of the combined therapy using DC vaccine and irinotecan plus infusional 5-fluorouracil and leucovorin (FOLFIRI) which have been clinically used for the treatment of colorectal cancer." | 3.76 | Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. ( Kim, HJ; Kim, HS; Kim, SG; Kim, TG; Oh, ST; Park, HM; Park, JS; Sohn, HJ, 2010) |
| "Patients with locally advanced and metastatic colorectal cancer treated with capecitabine or 5-fluorouracil/leucovorin (5-FU/LV) as monotherapy or combination therapy with oxaliplatin from 2003-2006 were identified in the Thomson Reuters MarketScan® databases." | 3.76 | Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. ( Cartwright, T; Chu, E; McKenna, EF; Schulman, KL, 2010) |
| "Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC)." | 3.76 | Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. ( Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M, 2010) |
| "Infusional 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus bevacizumab chemotherapy is commonly implemented in the first-line treatment of metastatic colorectal cancer." | 3.76 | Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. ( Fakih, MG; Groman, A; Vaidyanathan, G; Wilding, G, 2010) |
| "The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients." | 3.76 | Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. ( Choi, IK; Choi, YJ; Kang, EJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2010) |
| "To find out whether SNPs in the transporter gene ATP-binding casette B1 (ABCB1) were related to adverse effects in colorectal cancer patients treated with 5-fluorouracil (5-FU) or capecitabine." | 3.76 | ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. ( Alvarez, S; Barrueco, N; Cortejoso, L; García, MI; García-Alfonso, P; Gonzalez-Haba, E; Jiménez, JL; López-Fernández, LA; López-Lillo, C; Martín, ML; Muñóz-Fernández, MA; Sanjurjo, M, 2010) |
| "Data on patients with colorectal cancer who received FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) treatment between June 2005 and June 2009 were retrieved from the prospective cohort database of the Outpatient Oncology Unit of the Kyoto University Hospital." | 3.76 | Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. ( Chiba, T; Fukushima, M; Hazama, M; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Mori, Y; Nagayama, S; Nishimura, T; Sakai, Y; Teramukai, S; Yanagihara, K; Yoshimura, K, 2010) |
| "This retrospective study evaluated the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil (5-FU) for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy." | 3.76 | Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. ( Arai, Y; Aramaki, T; Boku, N; Inaba, Y; Kichikawa, K; Matsuoka, M; Nishiofuku, H; Otsuji, T; Sato, Y; Tanaka, T, 2010) |
| "We modelled a theoretical population treated with combined 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) for metastatic colorectal cancer." | 3.76 | Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer. ( Blasco, H; Bourgoin, H; Le Guellec, C; Le Louarn, A; Lecomte, T; Pichereau, S, 2010) |
| "Palmar-Plantar syndrome (PPS) is a common side effect of oral capecitabine--a chemotherapeutic agent used as an adjuvant treatment for colorectal cancer." | 3.76 | Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome. ( Begent, R; Gafson, AR; Goodkin, O, 2010) |
| "In progressive colorectal cancer these treatment results can be regarded as a significant change in the natural history of the disease." | 3.76 | Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer. ( Freund, M; Poliwoda, H; Preusser, P; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, H, 1988) |
| "The aim of this study is to evaluate if mismatch repair (MMR) defective colorectal cancer has a different response to adjuvant 5-fluorouracil (5-FU) chemotherapy in a cohort of patients prospectively followed during 5 years." | 3.75 | The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. ( Alenda, C; Andreu, M; Balaguer, F; Bessa, X; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Jover, R; Llor, X; Morillas, JD; Nicolás-Pérez, D; Payá, A; Pons, E; Reñé, JM; Sempere, L; Xicola, RM; Zapater, P, 2009) |
| "Patients with histologically proven, metastatic colorectal cancer receiving bevacizumab as first-line therapy in combination with irinotecan and 5-fluorouracil were eligible for our analysis." | 3.75 | Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. ( Berardi, R; Cascinu, S; Chiorrini, S; Galizia, E; Giampieri, R; Pierantoni, C; Scartozzi, M, 2009) |
| "5-Fluorouracil (5-FU)-based regimens remain a cornerstone in the treatment of colorectal cancer (CRC)." | 3.75 | Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. ( Carlsson, G; Gustavsson, B; Kaiser, C; Lindskog, EB; Ma, D; Niyikiza, C; Odin, E; Wettergren, Y, 2009) |
| "Modifying the capecitabine dosing schedule from 14 days on, 7 days off (14/7) to 7 days on, 7 days off (7/7) may enable higher doses and improved antitumor efficacy in colorectal cancer xenografts." | 3.75 | In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models. ( Dugan, U; Heimbrook, D; Higgins, B; Kohles, J; Kolinsky, K; Packman, K; Shen, BQ; Zhang, YE; Zioncheck, TF, 2009) |
| "To investigate the synergistic effect of epidermal growth factor(EGF) and 5-fluorouracil for the treatment of human colorectal cancer in BALB/C nude mice subcutaneous xenografts model." | 3.75 | [Synergistic use of epidermal growth factor and 5-fluorouracil for the treatment of human colorectal cancer in BALB/C nude mice subcutaneous xenograft model]. ( Tao, KX; Wang, GB; Ye, L, 2009) |
| "We investigated the efficacy and toxicity of metronomic capecitabine administered at a fixed dose of 1,000 mg daily in three elderly or poor performance status patients with advanced colorectal cancer (CRC) and gastric cancer." | 3.75 | To widen the setting of cancer patients who could benefit from metronomic capecitabine. ( Biasco, G; Brandi, G; Di Cicilia, R; Maleddu, A; Nannini, M; Nobili, E; Pantaleo, MA, 2009) |
| "MSI in five reference loci, MMR enzymes (hMSH2, hMSH6, hMLH1 and hPMS2), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) expression were assessed in paraffin embedded tumor specimens, and associated with outcome in 340 consecutive patients completely resected for colorectal cancer stages II-IV and subsequently receiving adjuvant 5-fluorouracil therapy." | 3.75 | Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression. ( Jensen, SA; Kruhøffer, M; Sørensen, JB; Vainer, B, 2009) |
| "The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/oxaliplatin chemotherapy." | 3.75 | Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. ( Choi, HJ; Kim, DC; Kim, HJ; Kim, SH; Kwon, HC; Lee, DM; Lee, JH; Lee, S; Oh, SY; Park, KJ; Roh, MS, 2009) |
| "Capecitabine, an oral alternative to 5-fluorouracil (5-FU) in patients with colorectal cancer (CRC), has equal clinical efficacy and a favorable safety profile; however, its use may be limited because of unit cost concerns." | 3.75 | Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. ( Chu, E; Schulman, KL; Song, X; Zelt, S, 2009) |
| "In patients suffering from colorectal cancer liver metastases, 5-fluorouracil-based chemotherapy plus oxaliplatin ensures superior response rates at the cost of hepatic injury." | 3.75 | Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. ( Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Klinger, M; Koelblinger, C; Tamandl, D, 2009) |
| "A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study." | 3.75 | Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. ( Bae, SH; Chae, YS; Choi, GS; Jeon, SW; Jun, SH; Kang, BM; Kim, JG; Kum, Y; Lim, KH; Moon, JH; Park, IJ; Ryoo, HM; Sohn, SK, 2009) |
| "5-Fluorouracil (5FU) and oxaliplatin are standard therapy for metastatic colorectal cancer (CRC), but the development of chemoresistance is inevitable." | 3.75 | Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. ( Dallas, NA; Ellis, LM; Fan, F; Gaur, P; Gray, MJ; Kim, MP; Lim, SJ; Samuel, S; van Buren, G; Xia, L, 2009) |
| " Using this library, we identify a range of small RNA-encoding gene inserts that overcome resistance to 5-fluorouracil (5-FU)- or tumour necrosis factor alpha (TNF-alpha)- induced cell death in colorectal cancer cells." | 3.75 | RNA modulators of complex phenotypes in mammalian cells. ( Arndt, GM; Cairns, MJ; Cullen, L; Lai, A; Tran, N; Zhang, HP, 2009) |
| "Panaxadiol enhanced the anti-cancer effects of 5-FU on human colorectal cancer cells through the regulation of cell cycle transition and the induction of apoptotic cells." | 3.75 | Panaxadiol, a purified ginseng component, enhances the anti-cancer effects of 5-fluorouracil in human colorectal cancer cells. ( Li, XL; Mehendale, SR; Sun, S; Wang, CZ; Wang, Q; Yuan, CS, 2009) |
| "The purpose of this study was to assess retrospectively the sequential treatment of hepatic arterial infusion (HAI) chemotherapy followed by systemic therapy using oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin, namely, FOLFOX, for patients with liver metastases from colorectal cancer." | 3.75 | Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer. ( Ozaki, T; Seki, H; Shiina, M, 2009) |
| " She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer." | 3.75 | 5 flourouracil-induced apical ballooning syndrome: a case report. ( Dentali, F; Gianni, M; Lonn, E, 2009) |
| "The correlations between adenomatous polyposis coli (APC) mutations and 5-fluorouracil (5-FU) adjuvant chemotherapy and colorectal cancer (CRC) patients' prognosis are not well known." | 3.75 | Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects. ( Chen, SP; Chen, YL; Chiu, SC; Harn, HJ; Kang, JC; Lin, PC; Lin, SZ; Pang, CY; Su, CC; Wu, CC, 2009) |
| "The purpose of this study was to investigate the association of methylation in the promoter regions of adenomatous polyposis coli (APC) and O(6)-methylguanine-DNA methyltransferase (MGMT) and the survival of Taiwanese colorectal cancer (CRC) subjects who received 5-fluorouracil (5-FU) adjuvant chemotherapy." | 3.75 | The association of methylation in the promoter of APC and MGMT and the prognosis of Taiwanese CRC patients. ( Chen, SP; Chen, YL; Chiu, SC; Harn, HJ; Kang, JC; Lin, PC; Lin, SZ; Pang, CY; Wu, CC, 2009) |
| "Stage II-III colorectal cancer patients treated with adjuvant FOLFOX or fluorouracil/leucovorin (5-FU/LV) at Roswell Park Cancer Institute between 2002 and 2006 were identified." | 3.75 | Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. ( Angitapalli, R; Fakih, MG; Kumar, PR; Litwin, AM; Lombardo, J; Mashtare, T; Nasser, E; Wilding, GE, 2009) |
| " Additionally, unsupervised clustering using the MMP/TIMP profile of N=25 colorectal cancer liver metastases was performed and the response to palliative 5-fluorouracil (5-FU)-based chemotherapy was assessed using radiological response criteria." | 3.75 | Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. ( Brueckl, WM; Croner, RS; Dimmler, A; Dorlaque, L; Gentner, B; Hahn, EG; Hohenberger, W; Roedel, F; Wein, A; Wirtz, RM; Zeittraeger, I, 2009) |
| " demonstrated that irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in advanced colorectal cancer." | 3.75 | Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer. ( Sobrero, A, 2009) |
| "The aim of this study was to determine the significance of three most common single-nucleotide polymorphisms (SNPs) of ABCB1 gene in the development of colorectal cancer and to estimate the influence of these SNPs to surviving patients' treatment combination adjuvant therapy 5-fluorouracil/leucovorin." | 3.75 | ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. ( Balcerczak, E; Jamroziak, K; Mirowski, M; Panczyk, M; Pasz-Walczak, G; Piaskowski, S, 2009) |
| " We analyzed the influence of codon 751 Lys-->Gln polymorphism of XPD on its protein expression levels, clinico-pathological features, and outcome of 188 Chinese patients with metastatic colorectal carcinoma (CRC) that had been treated with first-line Oxaliplatin + Leucovorin + 5-Fluorouracil (FOLFOX-4) chemotherapy." | 3.75 | Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. ( Chen, PM; Chen, WS; Jiang, JK; Lai, JI; Lin, JK; Lin, TC; Tzeng, CH; Wang, HS; Wang, WS, 2009) |
| "We have tested several biomarkers [dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), thymidine phosphorylase (TP), thymidylate synthase (TS) and excision cross-complementing gene (ERCC1)] for their prognostic and predictive value in relation to the outcome of chemotherapy in tumour tissues of 556 advanced colorectal cancer (ACC) patients who were randomised between sequential treatment and combination treatment in the CApecitabine, IRinotecan, Oxaliplatin (CAIRO) study." | 3.75 | Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. ( Koopman, M; Ligtenberg, MJ; Nagtegaal, I; Punt, CJ; Van Krieken, JH; van Tinteren, H; Venderbosch, S, 2009) |
| "A combination of oxaliplatin(L-OHP), folinic acid and 5-fluorouracil(5-FU)(mFOLFOX6)has been widely administered to treat advanced or recurrent colorectal cancer." | 3.75 | [Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction]. ( Chihara, S; Demizu, M; Iwakawa, S; Kimura, F; Maeda, C; Nakanishi, Y; Oosawa, M; Ueda, H; Yano, K, 2009) |
| "We designed a study protocol in 2005 and 16 patients with metastatic colorectal cancer were treated accordingly in the first line setting with XELIRI regimen (capecitabin, irinotecan) + bevacizumab." | 3.75 | [Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer]. ( Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M, 2009) |
| "We developed a longitudinal exposure-response tumor-growth inhibition (TGI) model of drug effect (and resistance) using phase II data of capecitabine (n = 34) and historical phase III data of fluorouracil (FU; n = 252) in colorectal cancer (CRC); and we developed a parametric survival model that related change in tumor size and patient characteristics to survival time using historical phase III data (n = 245)." | 3.75 | Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. ( Bruno, R; Claret, L; Fagerberg, J; Girard, P; Hoff, PM; Jorga, K; Van Cutsem, E; Zuideveld, KP, 2009) |
| "Bevacizumab was the first anti-angiogenic drug to be licensed in malignant disease, based on the results of a randomised trial in advanced colorectal cancer, in which the addition of bevacizumab to chemotherapy with irinotecan plus fluorouracil/leucovorin (IFL) significantly improved tumour response, progression-free survival (PFS) and overall survival (median 15." | 3.75 | Current perspective: bevacizumab in colorectal cancer--a time for reappraisal? ( Cunningham, D; Okines, A, 2009) |
| " We performed retrospective study that examined the efficacy of preventive treatment (granisetron+dexamethasone+domperidone) for delayed emesis induced by FOLFOX4 chemotherapy for advanced and recurrent colorectal cancer." | 3.75 | [Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy]. ( Hama, T; Hatake, K; Imada, H; Kamisugi, K; Kawakami, K; Matsusaka, S; Mizunuma, N; Nakamoto, E; Shinozaki, E; Shirai, T; Shouji, D; Suenaga, M; Suzuki, W; Takahashi, G; Yokokawa, T, 2009) |
| " The aims of the present study were to compare, in vitro and in vivo, the antiangiogenic and antitumor activities of metronomic irinotecan (CPT-11), oxaliplatin (L-OHP) and 5-fluorouracil (5-FU) in colorectal cancer and to investigate the metronomic combination of these drugs." | 3.75 | Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. ( Alì, G; Allegrini, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Emmenegger, U; Falcone, A; Fioravanti, A; Fontanini, G; Orlandi, P, 2009) |
| "We studied 150 surgically resected colorectal adenocarcinoma patients who received postoperative 5-Fluorouracil (5-FU) chemotherapy." | 3.75 | Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma. ( Bronner, MP; Chang, SJ; Cho, MY; Eom, M; Kim, IY; Kim, MD; Koh, SB; Ren, DN; Seong, SH; Yi, SY, 2009) |
| "In this study, we investigated the possible synergistic chemopreventive effects of American ginseng berry extract (AGBE) and 5-fluorouracil (5-FU) on human colorectal cancer cell lines, SW-480, HCT-116 and HT-29." | 3.75 | American ginseng berry enhances chemopreventive effect of 5-FU on human colorectal cancer cells. ( Du, W; He, TC; Li, XL; Mehendale, SR; Sun, S; Wang, CZ; Yuan, CS, 2009) |
| "To compare chemotherapy-related and total medical costs among patients with colorectal cancer (CRC) receiving capecitabine or 5-fluorouracil (5-FU) monotherapy after surgical resection." | 3.75 | Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. ( Bendell, JC; Cartwright, T; Chu, E; Shi, N; Wei, W, 2009) |
| "To evaluate the efficacy and the safety of combined 5-Fluorouracil, irinotecan, bevacizumab and sirolimus in refractory advanced colorectal carcinoma." | 3.75 | Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study. ( Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S, 2009) |
| "Oxaliplatin is a platinum compound that is clinically effective for colorectal cancer (CRC), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), and it is widely used for metastatic disease and for the adjuvant treatment of stage III CRC." | 3.75 | Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. ( Akashi, K; Ariyama, H; Baba, E; Esaki, T; Kusaba, H; Mitsugi, K; Nakano, S; Shibata, Y; Takii, Y; Tsuchiya, T, 2009) |
| "5-Fluorouracil (5-FU) is considered to be the backbone of colorectal cancer (CRC) systemic therapy since the great majority of recommended regimens include its administration." | 3.75 | Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma. ( Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE, 2009) |
| "5-Fluorouracil(5FU) and oral analogues, such as capecitabine, remain one of the most useful agents for the treatment of colorectal adenocarcinoma." | 3.75 | APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. ( Aly, E; Binnie, N; Collie-Duguid, ES; Gilbert, F; Loudon, M; MacDonald, G; McKinlay, A; Murray, GI; O'Kelly, T; Petty, RD; Samuel, LM; Semple, S; Wang, W, 2009) |
| "Tumor control, reflected in lower CEA, resulted in suppression of the acute phase response and generally in favorable effects on laboratory parameters indicative of risk factors of atherosclerosis, including lower homocysteine concentrations, and lower total and LDL cholesterol." | 3.75 | Serum homocysteine, cholesterol, retinol, alpha-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin. ( Hyspler, R; Kalábová, H; Kasparová, M; Krcmová, L; Malírová, E; Melichar, B; Melicharová, K; Pecka, M; Solichová, D, 2009) |
| "Randomized, controlled trials (RCTs) in 220 patients with advanced colorectal cancer reported no significant differences in survival periods between folinic acid/5-fluorouracil/irinotecan (FOLFIRI) and folinic acid/5-fluorouracil/oxaliplatin (FOLFOX6) therapies, irrespective of the treatment sequence." | 3.75 | Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan. ( Akase, T; Arakawa, I; Harada, T; Inoue, T; Miyazaki, Y, 2009) |
| "Candidate predictive biomarkers for irinotecan and oxaliplatin were assessed in 1,628 patients in Fluorouracil, Oxaliplatin, CPT-11: Use and Sequencing (FOCUS), a large randomized trial of fluorouracil alone compared with fluorouracil and irinotecan and compared with fluorouracil and oxaliplatin in advanced colorectal cancer." | 3.74 | Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. ( Adlard, JW; Barrett, JH; Braun, MS; Daly, C; Elliott, F; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Selby, P; Seymour, MT; Stephens, RJ, 2008) |
| " A major obstacle in the treatment of colorectal cancer is relative insensitivity to the chemotherapeutic agent 5-Fluorouracil (5-FU)." | 3.74 | Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors. ( Augenlicht, LH; Gandhi, SJ; Pestell, RG; Pezo, RC; Shirley, LA; Singer, RH, 2008) |
| "We describe the case of an HIV-positive 48-year-old male patient with metastatic colorectal cancer, treated with a bevacizumab, irinotecan, fluorouracil, and leucovorin regimen, with concomitant HAART." | 3.74 | Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. ( Bearz, A; Berretta, M; Berretta, S; Fisichella, R; Lleshi, A; Nasti, G; Simonelli, C; Tirelli, U; Zanet, E, 2008) |
| " This study aimed to assess the range of gene copies per nucleus of thymidylate synthase (TYMS), thymidine phosphorylase (TP) and dihydrofolate reductase (DHFR) in colorectal cancer, and to evaluate its prognostic significance following adjuvant chemotherapy, since these enzymes are closely related to efficacy of 5-fluorouracil (5FU)." | 3.74 | Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer. ( Jensen, SA; Jørgensen, JT; Sørensen, JB; Vainer, B; Witton, CJ, 2008) |
| "We investigated the association between thymidylate synthase (TS) germline polymorphisms and response to 5-fluorouracil-based chemotherapy in 80 patients with liver-only metastatic colorectal cancer (MCRC)." | 3.74 | Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. ( Alessandroni, P; Baldi, G; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Fornaro, L; Giordani, P; Giustini, L; Graziano, F; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Ruzzo, A; Santini, D; Tonini, G; Vincenzi, B, 2008) |
| "Human colorectal cancer cells were treated, individually and in combination, with Rosco, taxol, 5-Fluorouracil (5-FU), doxorubicine or vinblastine." | 3.74 | Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells. ( Abaza, MS; Al-Attiyah, RJ; Bahman, AM, 2008) |
| "Although a variety of FOLFOX regimens (5-fluorouracil and L-leucovorin combined with oxaliplatin) are widely used for the treatment of advanced colorectal cancer, the neurotoxicity caused by oxaliplatin is often problematic." | 3.74 | Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study. ( Chiba, T; Fukushima, M; Ishiguro, H; Kanai, M; Kawamura, J; Kitano, T; Matsumoto, S; Miyamoto, S; Mori, Y; Nagayama, S; Nishimura, T; Nomura, A; Sakai, Y; Teramukai, S; Yanagihara, K, 2008) |
| " [Ann Oncol 2002;13:308-317] showed that four prognostic variables can be used to classify patients with metastatic colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)/leucovorin (LV) into three risk groups with different overall survival (OS)." | 3.74 | Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. ( Hurwitz, H; Irl, C; Kabbinavar, F; Zurlo, A, 2008) |
| "In this study, we investigated the efficacy and toxicity of fluorouracil(FU)+Leucovorin(LV)with oxaliplatin (FOLFOX)and irinotecan(FOLFIRI)for patients with advanced or metastatic colorectal cancer." | 3.74 | Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies. ( Adachi, K; Arimoto, Y; Kanamiya, Y; Nakamura, R; Nishio, K; Oba, H; Ohtani, H; Shintani, M; Yui, S, 2008) |
| "The modified irinotecan plus bolus 5-fluorouracil/L-leucovorin (IFL) regimen (irinotecan plus bolus 5-fluorouracil/L-leucovorin) used to be one of the standard treatments for metastatic colorectal cancer until approval of oxaliplatin in Japan." | 3.74 | Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan. ( Chin, K; Hatake, K; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Shouji, D; Suenaga, M; Yamaguchi, T, 2008) |
| "5-fluorouracil (5-FU) and oxaliplatin play important roles in chemotherapy for patients with colorectal cancer." | 3.74 | Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis. ( Azuma, M; Danenberg, KD; Danenberg, PV; Enomoto, M; Higuchi, T; Iida, S; Kobayashi, H; Lenz, HJ; Mori, R; Omori, A; Sugihara, K; Uetake, H; Yasuno, M, 2008) |
| "In patients with colorectal cancer (CRC), modulation of 5-fluorouracil (5-FU) by folinic acid (FA) improves response rate and overall survival compared with 5-FU alone." | 3.74 | Tissue levels of reduced folates in patients with colorectal carcinoma after infusion of folinic acid at various dose levels. ( Hentrich, M; Jauch, KW; Kuehl, M; Rauch, J; Schalhorn, A; Schlemmer, M, 2008) |
| "This retrospective study was performed to evaluate a survival benefit of the full administration of 5-fluorouracil (5-FU), irinotecan (CPT-11), and oxaliplatin (L-OHP) to patients with unresectable or recurrent colorectal cancer." | 3.74 | [The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer]. ( Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Matsuki, M; Mitsuhashi, T; Miyazaki, T; Okada, N; Okita, T; Sano, M; Yokoyama, M, 2008) |
| "We have evaluated the 5-fluorouracil sensitivity of cancer cells from colorectal cancer patients using the collagen gel droplet embedded drug sensitivity test under multiple drug concentrations and contact durations." | 3.74 | Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis. ( Futagawa, S; Kitajima, M; Konishi, N; Nagaoka, I; Nishimura, K; Noguchi, H; Ochiai, T; Sato, G; Watanabe, T, 2007) |
| " To meet this demand, a nurse-/pharmacy-led clinic was established at the Beatson Oncology Centre in 2003 for the provision of oral capecitabine to metastatic colorectal cancer patients to provide a controlled and supportive environment." | 3.74 | A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences. ( Branch, A; Cassidy, J; MacDonald, L; MacLeod, A; McDonald, A; Mohammed, N, 2007) |
| "The purpose of this study was to compare the activities of various enzymes, participating in the metabolism of 5-fluorouracil, between colorectal cancer and nontumor tissues and to investigate the association of the enzyme activities with clinicopathological backgrounds." | 3.74 | Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer. ( Fukushima, M; Matsusaka, S; Wakabayashi, I; Yamasaki, H, 2007) |
| "The aim of this study was to investigate the influence of combining thymidylate synthase (TS), X-ray cross complementing factor 1 (XRCC1) and uridine diphosphate glucoronosyltransferase (UGT1A1 *28) polymorphism genotypes in response rate and time to progression (TTP) in metastatic colorectal cancer patients treated with 5-fluorouracil (5-FU) plus irinotecan or oxaliplatin (OXA)." | 3.74 | Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxa ( Abad, A; Catot, S; Cirauqui, B; Manzano, JL; Martinez-Balibrea, E; Martinez-Cardus, A; Moran, T; Taron, M, 2007) |
| "Randomised trials have established the importance of oxaliplatin (O) and irinotecan (I) in advanced colorectal cancer (CRC)." | 3.74 | Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. ( Adena, M; Damianovich, D; Tebbutt, NC, 2007) |
| "FOLFOX (oxaliplatin/leucovorin/5-fluorouracil) and FOLFIRI (irinotecan/leucovorin/5-fluorouracil) are important regimens for the treatment of advanced-stage colorectal cancer (CRC)." | 3.74 | Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool. ( Dranitsaris, G; Shah, A; Spirovski, B; Vincent, M, 2007) |
| "Capecitabine is an orally active fluoropyrimidine that has been approved for first-line treatment of metastatic colorectal cancer when fluoropyrimidines alone are indicated." | 3.74 | Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine. ( DeSimone, P; Sapp, CM, 2007) |
| "In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments." | 3.74 | Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. ( Bareil, C; Bascoul-Mollevi, C; Bibeau, F; Chalbos, P; Conseiller, E; Copois, V; Del Rio, M; Fraslon, C; Granci, V; Kramar, A; Leblanc, B; Martineau, P; Molina, F; Pau, B; Salvetat, N; Ychou, M, 2007) |
| "This study explores the effect of 5-fluorouracil (5FU) exposure on mRNA levels of its target enzyme thymidylate synthase (TS) and the rate-limiting catabolic enzyme dihydropyrimidine dehydrogenase (DPD) in tumors of colorectal cancer patients." | 3.74 | Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. ( Jansen, G; Mauritz, R; Peters, GJ; Pinedo, HM; Smid, K; van Groeningen, CJ, 2007) |
| " The aim of this study was to develop colon-specific compression coated systems of 5-fluorouracil (5-FU) for the treatment of colorectal cancer using xanthan gum, boswellia gum and hydroxypropyl methylcellulose (HPMC) as the coating materials." | 3.74 | Compression coated systems for colonic delivery of 5-fluorouracil. ( Bhinge, JR; Singh, A; Singh, S; Sinha, VR, 2007) |
| "The objective is to investigate whether polymorphisms with putative influence on fluorouracil/oxaliplatin activity are associated with clinical outcomes of patients with advanced colorectal cancer treated with first-line oxaliplatin, folinic acid, and fluorouracil palliative chemotherapy." | 3.74 | Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. ( Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Ficarelli, R; Floriani, I; Giordani, P; Giustini, L; Graziano, F; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Mattioli, R; Rulli, E; Ruzzo, A; Santini, D; Schiavon, G; Silva, R; Tonini, G, 2007) |
| "Oxaliplatin in combination with infusional 5-fluorouracil/leucovorin (FOLFOX) have emerged as the standard of care in the therapy of advanced-stage colorectal cancer." | 3.74 | [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions]. ( Akashi, T; Ando, H; Hanaoka, T; Itagaki, H; Kobayashi, Y; Muto, O; Ono, T; Onuki, M; Tanaka, Y, 2007) |
| "To evaluate the efficacy and safety of a regimen using Irinotecan, 5FU and Leucovorin for patients with advanced or recurrent colorectal cancer." | 3.74 | Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. ( Iinuma, N; Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Yanagisawa, Y, 2007) |
| "Primary colorectal cancer tissue from 24 patients was investigated to evaluate the relationship between the mRNA expression level of several 5-fluorouracil (5-FU)-related metabolic enzymes (thymidylate synthase, TS; dihydropyrimidine dehydrogenase, DPD; and thymidine phosphorylase, TP) and chemosensitivity to two different 5-FU doses and duration (1: 5-FU concentration 1." | 3.74 | Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. ( Abe, H; Endo, Y; Kurumi, Y; Mekata, E; Naitoh, H; Okumura, K; Shiomi, H; Tani, T, 2008) |
| "Over the past decade, new cytotoxic and biologic therapies beyond the old standard-of-care, biomodulated fluorouracil (5-FU), have become available for the treatment of metastatic colorectal cancer (mCRC)." | 3.74 | Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy. ( Grothey, A; Marshall, JL, 2007) |
| "The primary end point of the study was the analysis of associations between polymorphisms with putative influence on 5-fluorouracil/irinotecan activity and progression-free survival (PFS) of patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy." | 3.74 | Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. ( Alessandroni, P; Andreoni, F; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Ficarelli, R; Fontana, A; Giustini, L; Graziano, F; Lippe, P; Loupakis, F; Magnani, M; Maltese, P; Mari, D; Menichetti, ET; Pizzagalli, F; Ruzzo, A; Santini, D; Schiavon, G; Testa, E; Tonini, G, 2008) |
| "Cetuximab (Erbitux) in combination with irinotecan is the most promising combination in heavily pretreated patients with advanced colorectal cancer." | 3.74 | Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. ( Iversen, A; Jensen, BV; Nielsen, D; Pfeiffer, P; Vejlø, C; Yilmaz, M, 2007) |
| "The oxaliplatin/fluorouracil/leucovorin (FOL-FOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced colorectal cancer." | 3.74 | Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. ( Fukuoka, M; Nakagawa, K; Okamoto, I; Ozaki, T; Satoh, T; Shimizu, T; Tamura, K, 2007) |
| "The objectives of the present study were to evaluate the efficacy and safety of an outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as the first-line treatment for patients with advanced colorectal cancer." | 3.74 | Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer. ( Ahn, BM; Baek, JH; Chae, YS; Cho, YY; Choi, GS; Jun, SH; Kim, JG; Kim, SN; Lee, IT; Lee, SJ; Moon, JH; Sohn, SK, 2007) |
| "Capecitabine is a fluoropyrimidine-based drug that offers physicians a more convenient treatment for advanced colorectal cancer (CRC), with manageable toxicity and antitumor activity comparable to that of continuous-infusion therapies with 5-fluorouracil (5-FU)." | 3.74 | DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Kuramochi, H; Lindebjerg, J; Nielsen, JN; Shimizu, D; Vallböhmer, D; Yang, DY, 2007) |
| " 5-fluorouracil (5-FU) is still the most effective adjuvant therapy for patients with colorectal cancer." | 3.74 | Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer. ( Liu, X; Qin, X; Wang, Y; Yao, L; Zhang, Y; Zhao, L, 2008) |
| "A combination of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) is one of the standard regimens for palliative and adjuvant chemotherapy for colorectal cancer." | 3.74 | Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Kojima, T; Muto, M; Ohtsu, A; Tahara, M; Takeuchi, S; Taku, K; Yoshida, S, 2007) |
| "Oxaliplatin, Irinotecan, 5-fluorouracil and leucovorin are commonly used to treat advanced colorectal cancer in Western countries." | 3.74 | Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer. ( Aso, M; Higashi, H; Imamura, S; Kakeji, Y; Katoh, H; Maehara, S; Maehara, Y; Makino, I; Saeki, H; Tanaka, J, 2007) |
| "We report a 59-year-old woman diagnosed with metastasic colorectal cancer who developed immune hemolytic anemia during FOLFOX chemotherapy (oxaliplatin/leucovorin/5-fluorouracil)." | 3.74 | Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature. ( Albiol, S; Cobo, F; De Celis, G; Latorre, X; Pereira, A; Pujadas, J, 2007) |
| "Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer." | 3.74 | Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007) |
| "FOLFOX-4 (folinic acid/5-fluorouracil/oxaliplatin) chemotherapy is used to treat patients with colorectal liver metastases." | 3.74 | The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. ( Aithal, GP; Aloysius, MM; Beckingham, IJ; Bessell, EM; Lobo, DN; Neal, KR; Zaitoun, AM, 2007) |
| "A 59-year-old patient with a coexisting primary choroidal melanoma and colorectal cancer was treated with external beam radiation (EBR) of his choroidal melanoma and systemic chemotherapy with leukovorin/5 fluorouracil (FU) for treatment of his metastatic colorectal cancer." | 3.74 | Regression of radiation-induced macular edema after systemic bevacizumab. ( Bakri, SJ; Pulido, JS; Solano, JM, 2007) |
| "To investigate the mechanisms of drug resistance, a set of cell lines with different levels of sensitivity and possessing different mechanisms of resistance to 5-fluorouracil (5-FU) was established from a colorectal cancer cell line." | 3.74 | Swainsonine reduces 5-fluorouracil tolerance in the multistage resistance of colorectal cancer cell lines. ( Deguchi, K; Hamaguchi, J; Kamiyama, N; Kudo, T; Nakagawa, H; Nishimura, S; Oshima, T; Sato, Y; Sun, B; Takahashi, M; Todo, S, 2007) |
| " 5-fluorouracil (5-FU) or 5-FU plus oxaliplatin (FOLFOX) remains the backbone of colorectal cancer chemotherapeutics, but with limited success." | 3.74 | Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. ( Majumdar, AP; Patel, BB; Qazi, S; Rishi, AK; Sengupta, R; Vachhani, H; Yu, Y, 2008) |
| "Colorectal cancer (CRC) cell lines displaying microsatellite instability (MSI) are resistant to 5-fluorouracil (5-FU) in vitro, which can be overcome by restoring DNA mismatch repair (MMR) competence." | 3.74 | Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases. ( Bendardaf, R; Korkeila, E; Lamlum, H; Pyrhönen, S; Ristamäki, R; Syrjänen, K, 2008) |
| " The aims of this study were to determine whether p53 mutation status and p53 and p33(ING1b) protein expression can predict which patients with Dukes' C colorectal cancer following curative surgical resection respond to adjuvant chemotherapy with 5-fluorouracil (5-FU)." | 3.74 | The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer. ( Ahmed, IA; Anderson, JJ; Angus, B; Challen, C; Kelly, SB; Lunec, J, 2008) |
| "Combination therapy with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin is widely used for the treatment of metastatic colorectal cancer." | 3.74 | Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient. ( Akiyama, S; Gotoh, H; Gotoh, Y; Nakayama, H; Takami, H, 2007) |
| "The addition of bevacizumab to 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) improved the time-to-progression (TTP) and overall survival (OS) in comparison to FOLFOX in the second-line treatment of metastatic colorectal cancer (MCRC)." | 3.74 | 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study. ( Bir, A; Fakih, MG; Lombardo, J; Tan, W; Wilding, GE, 2007) |
| "The clinical efficacy and safety of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer were studied retrospectively." | 3.74 | [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer]. ( Hori, S; Hyodo, I; Iguchi, H; Imamine, S; Kajiwara, T; Kataoka, J; Moriwaki, T; Nasu, J; Nishina, T, 2007) |
| "In the phase III study AVF2107g, bevacizumab (BV) demonstrated a survival benefit when added to irinotecan, fluorouracil, and leucovorin (IFL) in first-line metastatic colorectal cancer (mCRC)." | 3.74 | Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. ( Goldberg, RM; Grothey, A; Hedrick, EE; Hurwitz, HI; Mass, RD; Ramanathan, RK; Sargent, DJ; Sarkar, S; Suzuki, S, 2008) |
| "The authors reported in a previous study that NK012, a 7-ethyl-10-hydroxy-camptothecin (SN-38)-releasing nano-system, exhibited high antitumor activity against human colorectal cancer xenografts." | 3.74 | Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. ( Hamaguchi, T; Kano, Y; Kato, K; Koizumi, F; Matsumura, Y; Nakajima, TE; Shimada, Y; Shirao, K; Yamada, Y; Yasunaga, M, 2008) |
| "To compare efficacy and tolerability of weekly irinotecan combined with 5-fluorouracil (5-FU) bolus and folinic acid (FA) regimen (IFL) versus biweekly irinotecan with infusional 5-FU and FA (FOLFIRI) in patients (pts) with advanced stage colorectal cancer." | 3.74 | Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience. ( Ariad, S; Gluzman, A; Lavrenkov, K; Man, S; Mermershtain, W; Rubinov, K, 2007) |
| "To evaluate the effect of thymidylate synthase (TYMS) and methylenetetrahydrofolate reductase (MTHFR) genotypes on toxicity in patients treated with capecitabine for advanced colorectal cancer and to determine the effect of these polymorphisms on the pretreatment levels of serum folate and plasma homocysteine." | 3.74 | Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. ( Clarke, SJ; Hoskins, JM; Liddle, C; London, R; Rivory, LP; Sharma, R; Zucknick, M, 2008) |
| "Low tumour expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) have been linked with improved outcome for colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)." | 3.74 | Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. ( Diasio, RB; Han, HC; Iacopetta, B; Joseph, D; Ng, SS; Salto-Tellez, M; Shah, N; Soo, RA; Soong, R; Tai, BC; Tan, WL; Zeps, N, 2008) |
| "Standard weekly cetuximab and irinotecan (CetIri) is an effective regimen in heavily pretreated patients with advanced colorectal cancer (ACRC)." | 3.74 | Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. ( Bjerregaard, J; Jensen, B; Nielsen, D; Pfeiffer, P; Qvortrup, C; Yilmaz, M, 2008) |
| "5-Fluorouracil (5-FU) is the most commonly used anticancer drug for colorectal cancer (CRC)." | 3.74 | Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. ( Iinuma, H; Watanabe, T; Yamada, H, 2008) |
| "Oxaliplatin (L-OHP) in combination with infusional 5-fluorouracil/leucovorin (FOLFOX), has been established as a key drug for advanced colorectal cancer." | 3.74 | [Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer]. ( Chin, K; Hatake, K; Itimura, T; Kuboki, Y; Matsuda, M; Matsusaka, S; Mizunuma, N; Ogura, M; Suenaga, M; Syouji, D; Watanabe, C, 2008) |
| "The chemotherapy regimen suitable for advanced colorectal cancer patients previously treated with 5 fluorouracil (5FU); oxaliplatin and irinotecan remains an unresolved issue." | 3.74 | A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies. ( Borg, C; Chaigneau, L; Demarchi, MF; Legat, C; Limat, S; Nguyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Viel, E, 2008) |
| "Treatment-related safety data from three phase III clinical studies were analyzed by multivariate analysis: two comparing capecitabine with bolus FU/LV in metastatic colorectal cancer (MCRC) and one comparing capecitabine plus oxaliplatin (XELOX) with bolus FU/LV as adjuvant treatment for colon cancer." | 3.74 | Potential regional differences for the tolerability profiles of fluoropyrimidines. ( Allegra, C; Bertino, JR; Cassidy, J; Clarke, SJ; Cunningham, D; Douillard, JY; Gilberg, F; Gustavsson, BG; Haller, DG; Hoff, PM; Milano, G; O'Connell, M; Rothenberg, ML; Rustum, Y; Saltz, LB; Schmoll, HJ; Sirzén, F; Tabernero, J; Twelves, C; Van Cutsem, E, 2008) |
| "To evaluate 5-fluorouracil (5-FU) and 5-fluoro-5,6-dihydrouracil (5-FDHU) pharmacokinetics and disease-free survival (DFS) in colorectal cancer patients given 5-FU-based adjuvant chemotherapy within a nonrandomized, retrospective, pharmacokinetic study." | 3.74 | 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. ( Amatori, F; Bocci, G; Danesi, R; Del Tacca, M; Di Donato, S; Di Paolo, A; Falcone, A; Federici, F; Iannopollo, M; Lastella, M; Lencioni, M; Orlandini, C; Ricci, S, 2008) |
| "A combination of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) has become one of the global standard chemotherapy regimens for metastatic colorectal cancer." | 3.74 | Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Hamamoto, Y; Minashi, K; Muto, M; Ohtsu, A; Tahara, M; Yano, T; Yoshida, S, 2008) |
| "Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (mCRC)." | 3.74 | XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer. ( Argon, A; Aykan, NF; Basaran, M; Gumus, M; Guney, N; Saglam, S; Sakar, B; Tenekeci, AN; Ustaoglu, MA; Ustuner, Z, 2007) |
| "70 patients with advanced colorectal cancer were treated with irinotecan and 5-fluorouracil." | 3.74 | [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. ( Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS, 2007) |
| "Oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin (FOLFOX) has emerged as the treatment of choice for advanced-stage colorectal cancer." | 3.74 | [Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan]. ( Hibino, M; Imano, H; Nakamura, M; Shindo, Y; Tenma, K; Yoshino, K, 2008) |
| "This study evaluated the effects of oral capecitabine on the quality of life (QOL) of Brazilian patients with metastatic colorectal cancer who received capecitabine (1000 or 1250 mg/m2 twice a day on days 1-14, every 3 weeks) in a prospective, multicenter, open-label, noncomparative study." | 3.74 | Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine. ( Cabral, S; Federico, MH; Filho, Ude P; Franke, FA; Gampel, O; Perdicaris, MR; Ribeiro, Rde A; Segalla, JG; Skare, NG; Van Eyll, B, 2008) |
| "Although 5-fluorouracil (5-FU)-based chemotherapy is commonly used in patients with advanced colorectal cancer (CRC), little data exist on the tolerability and benefit of therapy in elderly patients." | 3.73 | 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. ( Buroker, TR; Cha, SS; D'Andre, S; Goldberg, RM; Kugler, JW; O'Connell, MJ; Poon, MA; Sargent, DJ, 2005) |
| "Patients undergoing cytoreductive surgery and perioperative hyperthermic chemotherapy (mitomycin C, intraoperatively; 5-fluorouracil early post-operatively) for peritoneal carcinomatosis from colorectal cancer from 1996 to 2003 were evaluated retrospectively." | 3.73 | Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. ( Ceranic, MS; Kecmanovic, DM; Kovacevic, PA; Pavlov, MJ; Sepetkovski, AV; Stamenkovic, AB, 2005) |
| ", the Mayo-Clinic and AIO/Ardalan regimens, under real-life conditions in settings routinely used for chemotherapy administration in Germany (inpatient, day-clinic or office-based oncologists) and 2) to investigate the cost implications of the routine use of capecitabine, an oral alternative for the treatment of metastatic colorectal cancer." | 3.73 | Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds. ( Grothey, A; Hieke, K; Kleeberg, UR; Stauch, M, 2005) |
| "To determine whether the nonselective and relatively inexpensive nonsteroidal anti-inflammatory drug ibuprofen would be effective in inhibiting colorectal cancer and might improve mortality in a mouse model." | 3.73 | Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. ( Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W, 2005) |
| "To clarify the correlation between the expression level of thymidine phosphorylase (TP) and efficacy of doxifluridine (5'-DFUR) and 5-fluorouracil (5-FU), samples from 177 colorectal cancer patients who underwent curative resection were evaluated by immunohistochemical staining using a newly developed monoclonal antibody 1C6-203." | 3.73 | Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. ( Hasegawa, R; Hasegawa, S; Koda, K; Miyazaki, M; Oda, K; Seike, K; Takiguchi, N, 2005) |
| "We examined Drg1 expression by immunohistochemistry in 131 patients with metastatic colorectal cancer enrolled in a clinical trial of adjuvant fluorouracil-based therapy from 1991 to 1995." | 3.73 | Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. ( Cordon-Cardo, C; Drobnjak, M; Gonen, M; Hummer, A; Kemeny, N; Motwani, M; Schwartz, GK; Shah, MA, 2005) |
| "To investigate the prognostic value of thymidylate synthase (TS), topoisomerase-1 (Topo-1), and proliferating index Ki-67 in advanced colorectal cancer patients on irinotecan (CPT-11) in combination with fluorouracil treatment (5-Fu)." | 3.73 | [Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment]. ( Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, JM; Zhu, BD, 2005) |
| "Oxaliplatin-5-fluorouracil combinations have increased responses in first-line therapy up to 40% in advanced colorectal cancer." | 3.73 | FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. ( Castells, A; Gallego, R; Gascón, P; Longarón, R; Marmol, M; Martin-Richard, M; Maurel, J; Molina, R; Nadal, C; Sanz, S, 2005) |
| "Although several evidences have demonstrated a synergistic activity of 5-fluorouracil with irinotecan and oxaliplatin, thus explaining the use of this drug combination in the first-line treatment of advanced colorectal cancer, the need for the reintroduction of 5-FU in the second-line setting is more questionable." | 3.73 | The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. ( Barni, S; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Gasparini, G; Graziano, F; Labianca, R; Scartozzi, M; Sobrero, A; Zaniboni, A, 2005) |
| " We examined TS expression in tumours from 86 patients with advanced colorectal cancer who received one of two chemotherapy regimes (either irinotecan alone or irinotecan and 5-flurouracil with folinic acid)." | 3.73 | Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer. ( Bendardaf, R; Elzagheid, A; Lamlum, H; Pyrhönen, S; Ristamäki, R, 2005) |
| "The aim of the study was to define the feasibility and efficacy of Xelox (capecitabine and oxaliplatin) administered through a new and original schedule in advanced pretreated colorectal cancer (CRC) patients." | 3.73 | Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. ( Caricato, M; Coppola, R; Di Seri, M; La Cesa, A; Rocci, L; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B, 2005) |
| "The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations." | 3.73 | Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. ( Braud, Fd; Brunet, R; Butts, CA; Cassidy, J; Conroy, T; Diaz-Rubio, E; Figer, A; Grossmann, J; Schoffski, P; Sobrero, AF; Tabernero, JM; Twelves, CJ; Van Cutsem, EJ, 2005) |
| "We successfully treated four advanced colorectal cancers with irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and l-leucovorin (l-LV) combination chemotherapy." | 3.73 | [Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. ( Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H, 2005) |
| "The present study aimed to prospectively investigate the influence of thymidylate synthase (TS) polymorphisms (5'-TSER, 3'-TSUTR) on the disease-free survival (DFS) and overall survival (OS) of patients with colorectal cancer (CRC) who were treated with adjuvant 5-fluorouracil (5-FU) therapy." | 3.73 | Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. ( Adleff, V; Budai, B; Czeglédi, F; Gyergyay, F; Hitre, E; Horváth, Z; Kásler, M; Kovács, T; Kralovánszky, J; Láng, I; Lövey, J; Orosz, Z, 2005) |
| "These results suggest that phospho-EGFR levels determine the sensitivity of colorectal cancer cells to gefitinib alone and that chemotherapy-mediated changes in phospho-EGFR levels determine the nature of interaction between gefitinib and chemotherapy." | 3.73 | Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. ( Galligan, L; Johnston, P; Karaiskou-McCaul, A; Kelly, D; Longley, D; Van Cutsem, E; Van Schaeybroeck, S, 2005) |
| "Fluorouracil-based chemotherapy, such as that with 5-fluorouracil (5-FU)/leucovorin, is standard as first-line chemotherapy for advanced colorectal cancer (CRC) in Japan." | 3.73 | In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer. ( Akiyama, T; Hirabayashi, Y; Hirai, T; Ikeda, M; Iki, K; Kubozoe, T; Matsumoto, H; Sadahira, Y; Tsunoda, T; Urakami, A; Yamamura, M; Yamashita, K, 2005) |
| "Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer." | 3.73 | Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. ( Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS, 2005) |
| "Some retrospective studies have shown a lack of benefit of 5-fluorouracil (5-FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer." | 3.73 | Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. ( Alenda, C; Andreu, M; Bessa, X; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Jover, R; Llor, X; Morillas, JD; Nicolás-Pérez, D; Payá, A; Piñol, V; Reñé, JM; Xicola, RM; Zapater, P, 2006) |
| "BALB/c nu/nu mice bearing LoVo and HT-29 (colon cancer), A-431 (vulval cancer), and KPL-4 and MAXF401 (breast cancer) human tumors were treated with erlotinib 100 mg/kg/day and/or capecitabine 359 or 90 mg/kg/day, by oral administration once daily for 14 days." | 3.73 | Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. ( Ouchi, KF; Sekiguchi, F; Tanaka, Y; Yanagisawa, M, 2006) |
| "To report 2 cases of severe hypertriglyceridemia associated with the use of oral capecitabine." | 3.73 | Capecitabine-induced severe hypertriglyceridemia: report of two cases. ( Babaoglu, MO; Guler, N; Kurt, M; Shorbagi, A; Yasar, U, 2006) |
| "The combination of irinotecan and a fluoro-pyrimidine is widely accepted as a treatment for advanced colorectal cancer." | 3.73 | in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer. ( Eguchi, T; Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Tanaka, K; Toiyama, Y; Yoshiyama, S, 2006) |
| "(1) In patients with metastatic colorectal cancer initially treated with irinotecan combination therapy, second-line therapy with a combination of fluorouracil, folinic acid and oxaliplatin resulted in a median survival time of 21 months after the start of first-line chemotherapy, in one clinical trial." | 3.73 | Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation. ( , 2005) |
| "Resistance to apoptosis is one of the important determinants of resistance to 5-fluorouracil (5-FU) in colorectal cancer cells." | 3.73 | Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappaB and upregulation of BCL-2 and BCL-XL. ( Kitayama, J; Konishi, T; Nagawa, H; Sasaki, S; Watanabe, T, 2006) |
| "The cost of chemotherapy has dramatically increased in advanced colorectal cancer patients, and the schedule of fluorouracil administration appears to be a determining factor." | 3.73 | Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer. ( Bracco-Nolin, CH; Chaigneau, L; Huchet, B; Legat-Fagnoni, C; Limat, S; Pivot, X; Stein, U; Woronoff-Lemsi, MC, 2006) |
| "We identified genes related to 5-fluorouracil (5-FU) sensitivity in colorectal cancer and utilized these genes for predicting the 5-FU sensitivity of liver metastases." | 3.73 | Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. ( Endo, I; Hayasizaki, Y; Ichikawa, Y; Ishikawa, T; Kunisaki, C; Matsuyama, R; Momiyama, N; Shimada, H; Shimizu, D; Suzuki, H; Togo, S, 2006) |
| "Hepatic arterial infusion chemotherapy with levofolinate (l-leucovorin) and fluorouracil regimen was performed using an implanted port system on unresectable hepatic metastasis patients with colorectal cancer." | 3.73 | [Method of levofolinate.5-FU administration by hepatic arterial infusion therapy for hepatic metastasis from colorectal cancer]. ( Fujino, H; Hata, K; Kitamura, N; Kobuchi, T; Maruhashi, K; Nakamura, T; Shimomatsuya, T; Shiraishi, S, 2006) |
| " In this study, we evaluated the correlation between sensitivity to 5-fluorouracil (5-FU) and the mRNA expression level of several 5-FU-related metabolic enzymes [thymidylate synthase, dihydropyrimidine dehydrogenase (DPD), thymidylate phosphorylase (TP), orotate phosphoribosyl transferase, and uridine phosphorylase] in primary colorectal cancer and synchronous liver metastases from ten patients to investigate how colorectal cancer acquires 5-FU resistance during liver metastases." | 3.73 | Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. ( Endo, Y; Kaizuka, M; Kurumi, Y; Mekata, E; Okumura, K; Shiomi, H; Tani, T, 2006) |
| "The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment." | 3.73 | Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. ( Capellá, G; Cuatrecases, M; de Oca, J; Dotor, E; Figueras, A; Germà, JR; Guinó, E; Martínez-Iniesta, M; Molleví, DG; Moreno, V; Navarro, M; Pareja, L; Peinado, MA; Serrano, T; Vilardell, F; Villanueva, A, 2006) |
| "Several variables associated to thymidylate synthase (TS), the biological target of 5-fluorouracil (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients." | 3.73 | Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. ( Fernández-Contreras, ME; Gamallo, C; García de Paredes, ML; Gisbert, JP; Roda-Navarro, P; Sánchez-Hernández, JJ; Sánchez-Prudencio, S, 2006) |
| "We have previously shown that human colorectal cancer tissue is able to inactivate the anticancer drug paclitaxel through cytochrome P450 (CYP)2C8 and CYP3A4 metabolisms." | 3.73 | Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. ( Agúndez, JA; García-Martín, E; Gutierrez-Martín, Y; Jover, R; Martínez, C; Pérez, G; Pizarro, RM, 2006) |
| " Blood samples were collected from 20 patients, who had received continuous intravenous infusion (CIV) of 5-FU (320 mg/m2/24 hr) after resection of colorectal cancer, and the FBAL level was determined by high performance liquid chromatography (HPLC), after derivatizing into o-phthalaldehyde (OPA) and detecting fluorescence." | 3.73 | Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kawakami, M; Kihara, C; Kimura, Y; Ohmura, T; Okita, K; Sasaki, K; Tsuruma, T; Yamaguchi, K, 2006) |
| "Pyrrolidinedithiocarbamate (PDTC) enhanced the activity of 5-fluorouracil (5-FU) in a colorectal cancer xenograft model." | 3.73 | Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut. ( Bach, SP; O'Dwyer, ST; Potten, CS; Watson, AJ; Williamson, SE, 2006) |
| "African-American patients with colorectal cancer were observed to have increased 5-fluorouracil (5-FU)-associated toxicity (leukopenia and anemia) and decreased overall survival compared with Caucasian patients." | 3.73 | Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. ( Desmond, RA; Diasio, RB; Fourie, J; Mattison, LK; Modak, A; Saif, MW, 2006) |
| "Bevacizumab (Avastin) in combination with intravenous 5-fluorouracil-based chemotherapy as first-line as well as second-line treatment of metastatic colorectal cancer improves survival." | 3.73 | Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. ( Gotlib, V; Khaled, S; Lapko, I; Mar, N; Saif, MW, 2006) |
| "To evaluate the regimen of 5-fluorouracil (5-FU) and mitomycin-C (MMC) in terms ofresponse rate and overall survival in advanced colorectal cancer." | 3.73 | 5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer. ( Aphinives, P; Bhudhisawasdi, V; Sae-seow, O; Uttaravichien, T, 2006) |
| "We present two cases of multiple liver metastases from colorectal cancer, which did not respond to hepatic arterial infusion (HAI) using 5-fluorouracil (5-FU 1250 mg/body weekly) alone, but responded to HAI using 5-fluorouracil (5-FU 750 mg/body weekly) and l-leucovorin (l-LV 50 mg/body weekly) achieving a complete response (CR)." | 3.73 | [Two cases of multiple liver metastases from colorectal cancer which responded well to hepatic arterial infusion (HAI) using 5-fluorouracil and l-leucovorin]. ( Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kato, S; Sugihara, K; Uetake, H; Yasuno, M, 2006) |
| "The combination of irinotecan (CPT-11), bolus 5-fluorouracil (5-FU) and folinic acid (FA) (Saltz regimen) has recently been questioned as first-line chemotherapy for metastatic colorectal cancer after high early death rates due to gastrointestinal and thromboembolic events were reported in two US trials." | 3.72 | Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. ( Adami, B; Baldus, M; Burg, H; Ehscheid, P; Galle, PR; Heike, M; Hoffmann, T; Hohl, H; Klein, O; Moehler, M; Schroeder, M; Schwindt, P; Zanke, C, 2003) |
| "The Mayo Clinic regimen of leucovorin 20 mg/m followed immediately by 5-fluorouracil 425 mg/m administered for 5 consecutive days every 4 weeks is commonly used in the treatment of colorectal cancer." | 3.72 | Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. ( Bar-Sela, G; Beny, A; Haim, N; Tsalic, M; Visel, B, 2003) |
| "5-Fluorouracil (5-FU) is the major chemotherapeutic component for colorectal cancer (CRC) and other types of solid tumours." | 3.72 | Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. ( Cassidy, J; McLeod, HL; Wang, W, 2003) |
| "The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 3.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
| " Data from 40 patients receiving oxaliplatin combined with 5-fluorouracil and levofolinic acid as standard treatment for advanced colorectal cancer were analysed." | 3.72 | Population pharmacokinetics of oxaliplatin. ( Bugat, R; Canal, P; Chatelut, E; Delord, JP; Grégoire, N; Guimbaud, R; Lafont, T; Umlil, A, 2003) |
| " We investigated the combination effect of 5-fluorouracil (5-FU), a first-choice drug for the treatment of colorectal cancer and adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells." | 3.72 | 5-Fluorouracil efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells. ( Hamada, H; Kitayama, J; Nagawa, H; Shinoura, N; Uchida, H; Watanabe, T, 2003) |
| "The association oxaliplatin (OXA)-5-fluorouracil/folinic acid (FUFA) is currently a standard first-line treatment for advanced colorectal cancer." | 3.72 | Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status. ( Dubreuil, A; Etienne, MC; Fischel, JL; Formento, P; Lagrange, JL; Magné, N; Marcié, S; Milano, G, 2003) |
| "The aim of this study was to investigate the influence of low dosage (131)I-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody C50 ((131)I-C50) on tumor growth and the therapeutic efficacy of combination of low dosage (131)I-C50 with chemotherapy using 5-fluorouracil (5-FU) on human colorectal cancer xenografts in nude mice." | 3.72 | [Influence of combination of low dosage 131I-labeled anti-carcinoembryonic antigen antibody C50 and 5-fluorouracil on tumor growth of colorectal cancer xenografts in nude mice]. ( Cai, SR; He, YL; Lin, ZJ; Zhan, WH; Zheng, CX, 2003) |
| " To characterise the genomic changes that induce the development of resistance to fluoropyrimidines, we used comparative genomic hybridisation (CGH) to analyse and compare the parent DLD-1 human colorectal cancer cell line and two cell lines, DLD-1/5-FU and DLD-1/FdUrd, which were resistant to 5-fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd), respectively." | 3.72 | Chromosomal imbalances associated with acquired resistance to fluoropyrimidines in human colorectal cancer cells. ( Ayabe, H; Fukushima, M; Haseba, M; Hidaka, S; Nakagoe, T; Sawai, T; Tagawa, Y; Tsuji, T; Yamaguchi, H; Yano, H; Yasutake, T, 2003) |
| "Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer." | 3.72 | Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. ( Batist, G; Cohen, V; Morin, I; Panet-Raymond, V; Rozen, R; Sabbaghian, N, 2003) |
| "Loss of DNA mismatch repair (MMR) occurs in 10-15% of sporadic colorectal cancer, is usually caused by hMLH1 hypermethylation, and has been shown to confer resistance to various chemotherapeutic reagents, including 5-fluorouracil (5-FU)." | 3.72 | Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. ( Arnold, CN; Boland, CR; Goel, A, 2003) |
| "To evaluate the therapeutic effects of hydroxycamptothecin (H) combined with leucovorin (L), fluorouracil (F) and cisplatin (P) on advanced cancer of gastric cardia and colorectal cancer." | 3.72 | [The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer]. ( Jin, ML; Li, J; Li, Y; Shen, L; Yang, BQ; Zhang, XD, 2003) |
| "To predict the sensitivity of colorectal cancer to 5-fluorouracil (5-FU), we compared the gene expression of surgically obtained colorectal cancer specimens with chemosensitivity to 5-FU as detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) assay." | 3.72 | Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. ( Fukushima, M; Hasegawa, H; Kitajima, M; Kubota, T; Nishibori, H; Takechi, T; Wada, N; Watanabe, M; Yoshinare, K, 2003) |
| "To determine the efficacy of the combination of oxaliplatin and capecitabine in patients with advanced colorectal cancer." | 3.72 | Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience. ( Cunningham, D; Gillbanks, A; Harper-Wynne, C; Hill, M; Norman, AR; Sumpter, K, 2003) |
| "The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)." | 3.72 | Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003) |
| "5-Fluorouracil (5-FU) has been used for more than 40 years in the treatment of neoplastic disease, and remains the standard first-line treatment for colorectal cancer in combination with irinotecan and leucovorin." | 3.72 | Quantitation of dihydropyrimidine dehydrogenase (DPD) mRNA expression levels in normal colon and colorectal cancer tumor paraffin-embedded tissue specimens. ( Bender, RA; Liu, JY; Sferruzza, AD; Zhou, W, 2003) |
| "Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m(2)." | 3.72 | Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. ( Kosmas, C; Koufos, C; Margaris, H; Papalambros, E; Papantoniou, N; Retalis, G; Rokana, S; Tsavaris, N; Vadiaka, M; Zografos, G; Zonios, D, 2003) |
| " In this study, we assessed whether or not the TSER genotype is an efficacious marker for tumor sensitivity to 5-fluorouracil (5-FU)-based oral adjuvant chemotherapy for colorectal cancer." | 3.72 | Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. ( Fukuoka, H; Haseba, M; Hidaka, S; Komatsu, H; Nakagoe, T; Nanashima, A; Sawai, T; Shibasaki, S; Shindou, H; Tagawa, Y; Tsuji, T; Yamaguchi, H; Yano, H; Yasutake, T; Yoshinaga, M, 2003) |
| "Hepatic intra-arterial infusion chemotherapy of 5-fluorouracil (5-FU) or fluorodeoxyuridine (FUDR) has been a treatment option for liver metastasis from colorectal cancer." | 3.72 | Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model. ( Ishikawa, K; Makuuchi, H; Masuda, T; Murayama, C; Nakamura, T; Sadahiro, S; Suzuki, T; Tanaka, Y; Yasuda, S, 2003) |
| "Although the expression of thymidylate synthase (TS) in metastatic colorectal cancer (CRC) may be a better predictor of response to 5-fluorouracil chemotherapy than TS expression in primary CRC, this enzyme has not been well studied in tumor-draining regional lymph nodes." | 3.72 | Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: impact on adjuvant treatment. ( Bilchik, AJ; Morton, DL; Saha, SS; Thompson, J; Trocha, SD; Wiese, D, 2003) |
| "The significance of hepatic arterial infusion chemotherapy for unresectable liver metastases from colorectal cancer was evaluated in 50 patients, who received either of the following regimens: 1 shot 5-FU + epirubicin + MMC (FAM group); hepatic arterial infusion of 5-FU for 2 hours + MMC (MF group); hepatic arterial infusion of 5-FU for 2 hours (5-FU group)." | 3.72 | [Validity of two-hour continuous hepatic arterial infusion chemotherapy with low-dose 5-FU for unresectable liver metastasis from colorectal cancer]. ( Hirakawa, K; Kosaka, K; Nishihara, T; Nishino, H; Ohira, M; Yamada, N, 2003) |
| "We herein report the result of a prospective study to investigate the efficacy of cimetidine administration in conjunction with chemotherapy for stage IV colorectal cancer." | 3.72 | [Effect of cimetidine with chemotherapy on stage IV colorectal cancer]. ( Fujimoto, T; Hashimoto, M; Ishibashi, K; Iwasaki, K; Ogawa, K; Umehara, A; Yokomizo, H; Yoshida, K; Yoshimatsu, K, 2003) |
| "In metastatic colorectal cancer the oral 5-fluorouracil (5FU) prodrug capecitabine is used with increasing frequency as an alternative to i." | 3.72 | In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. ( Heerschap, A; Kamm, YJ; Klomp, DW; Punt, CJ; van Laarhoven, HW, 2003) |
| "The level of the enzyme thymidylate synthase (TS) is known to inversely correlate with the clinical activity of 5-fluorouracil (FU) in advanced colorectal cancer patients." | 3.72 | Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. ( Aschele, C; Belvedere, O; Cataldi, P; Di Loreto, C; Guglielmi, A; Puglisi, F; Sobrero, A, 2004) |
| "5-Fluorouracil improves mortality in stage III colorectal cancer patients." | 3.72 | Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. ( Arnold, CA; Behling, CA; Boland, CR; Cabrera, BL; Carethers, JM; Doctolero, RT; Goel, A; Miyai, K; Nguyen, L; Smith, EJ; Tajima, A, 2004) |
| " For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil." | 3.72 | Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. ( Hahn, P; Jensen, HA; Pfeiffer, P, 2003) |
| " In this study, digital karyotyping was used to search for genomic alterations in liver metastases that were clinically resistant to 5-fluorouracil (5-FU)." | 3.72 | Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. ( Bardelli, A; Choti, M; Diaz, LA; Donehower, R; Galizia, G; Iacobuzio-Donahue, C; Kinzler, KW; Lengauer, C; Parmigiani, G; Romans, K; Saha, S; Shih, IeM; Velculescu, VE; Vogelstein, B; Wang, TL, 2004) |
| "5-Fluorouracil, a widely used drug in cancer treatment, is known to have cardiotoxic effects: chest pain with ECG changes, arrhythmias, arterial hypertension or hypotension, myocardial infarction, cardiogenic shock and sudden death have been described in the literature." | 3.72 | Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases. ( Alberti, A; Corrada, E; Ferrari, S; Mafrici, A; Marenna, B, 2003) |
| "Preclinical in vitro and in vivo studies have demonstrated synergistic interactions between 5-fluorouracil (5-FU) and type I and II IFNs against human colorectal cancer cells." | 3.72 | Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. ( Barsoum, J; Choi, EA; Fraker, DL; Lei, H; Maron, DJ; Mick, R; Spitz, FR; Wilson, JM; Yu, QC, 2004) |
| "Microsatellite instability (MSI) is a characteristic feature of up to 15% of colorectal cancers (CRC) and is associated with better response to adjuvant chemotherapy with 5-fluorouracil (5-FU)." | 3.72 | Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer. ( Alessandro, R; Büttner, R; Gullotti, L; Hans, V; Houshdaran, F; Mathiak, M; Merkelbach-Bruse, S; Rüschoff, J; Sanguedolce, R, 2004) |
| "To elucidate mechanisms of resistance to chemotherapies currently used in the first-line treatment of advanced colorectal cancer, we have developed a panel of HCT116 p53 wild-type (p53(+/+)) and null (p53(-/-)) isogenic colorectal cancer cell lines resistant to the antimetabolite 5-fluorouracil (5-FU), topoisomerase I inhibitor irinotecan (CPT-11), and DNA-damaging agent oxaliplatin." | 3.72 | Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. ( Aroori, S; Boyer, J; Carey, PD; Johnston, PG; Longley, DB; McCulla, A; McLean, EG; Wilson, P, 2004) |
| "To evaluate the efficacy and safety of capecitabine as first-line therapy in patients with advanced and recurrent colorectal cancer." | 3.72 | [First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer]. ( Feng, FY; Fu, Q; Guan, ZZ; Huang, JJ; Liu, DG; Ruan, QL; Shi, D; Sun, SR; Wei, YQ; Wu, G; Wu, WQ; Wu, XD; Xiong, HH; Yang, CY; Yu, BM; Yu, SY; Zhang, P; Zhao, Y; Zheng, S; Zhuang, W; Zou, LQ, 2004) |
| "Expression of thymidylate synthase (TS) and the 5-fluorouracil (5-FU) metabolic enzymes, including dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), thymidine phosphorylase (TP), and uridine phosphorylase (UP), has been reported to be associated with the sensitivity to 5-FU-based chemotherapy in colorectal cancer." | 3.72 | Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. ( Inokuchi, M; Shirota, Y; Sugihara, K; Tajima, M; Uetake, H; Yamada, H, 2004) |
| "5-Fluorouracil (5-FU) is the chemotherapeutic drug of choice for the treatment of metastatic colorectal cancer, but resistance to 5-FU remains a major obstacle to successful therapy." | 3.72 | Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. ( Beigi, M; Clausen, OP; de Angelis, PM; Fjell, B; Galteland, E; Haug, T; Kravik, KL; Reichelt, W; Stokke, T; Tunheim, SH, 2004) |
| "The aim of this study was to observe the effects of neoadjuvant therapy with irinotecan and 5-fluorouracil (5-FU)/folinic acid (FA) on the resection rate and survival of colorectal cancer patients with initially unresectable hepatic metastases." | 3.72 | Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. ( Barone, C; Basso, M; Cassano, A; Giuliante, F; Nuzzo, G; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N; Vellone, M, 2004) |
| "One hundred and thirty-eight stage II and III colorectal cancer patients were included to evaluate the prognostic significance of genetic markers (including mutations of the p53, K-ras genes, and microsatellite instability) on the response to 5-fluorouracil (FU)-based post-operative adjuvant therapies (PAT)." | 3.72 | p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. ( Changchien, CR; Chen, HH; Chen, JS; Fan, CW; Hsieh, LL; Tang, R; Tsao, KC; Wang, JY; Wu, CM, 2004) |
| "Capecitabine is an oral prodrug of 5-fluorouracil and has been studied for the treatment of colorectal cancer." | 3.72 | Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. ( Brouwers, JR; Jansman, FG; Postma, MJ; van Hartskamp, D; Willemse, PH, 2004) |
| "In this marker evaluation study, we tested whether distinct patterns of functional genomic polymorphisms in genes involved in drug metabolic pathways and DNA repair that predict clinical outcome to 5-fluorouracil (5-FU)/oxaliplatin chemotherapy in patients with advanced colorectal cancer could be identified." | 3.72 | A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. ( Groshen, S; Lenz, HJ; Park, DJ; Stoehlmacher, J; Yang, D; Zahedy, S; Zhang, W, 2004) |
| "The purpose of this study was to examine the relation between tumoral expression of dihydropyrimidine dehydrogenase (DPD), the rate limiting enzyme of the degradation pathway 5-fluorouracil (5-FU), and the efficacy of 5-FU based chemotherapy for colorectal cancer." | 3.72 | [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer]. ( Hashimoto, D; Inokuma, S; Ishida, H; Nakada, H; Ohsawa, T; Shirakawa, K; Yamada, H; Yokoyama, M, 2004) |
| "Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated." | 3.72 | [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004) |
| "High expression of thymidylate synthase (TS) is allegedly associated with the chemoresistance to 5-fluorouracil (5-FU) in colorectal cancers." | 3.72 | Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to ( Inada, K; Kamoshida, S; Maruta, M; Matsuoka, H; Matsuyama, A; Shimomura, R; Shiogama, K; Tsutsumi, Y, 2004) |
| "Seventy-five patients with advanced colorectal cancer and treated with CPT-11 and 5-fluorouracil, entered the study." | 3.72 | Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. ( Boisdron-Celle, M; Dumont, A; Gamelin, E; Guérin, O; Morel, A; Rouits, E, 2004) |
| "The goal of this study was to develop a simple and rapid in vitro drug resistance assay to ascertain the effectiveness of 5-fluorouracil (5-FU) for the individual therapy of colorectal cancer." | 3.72 | An in vitro short time-high dose drug exposure assay for predicting 5FU-resistance of colorectal cancer. ( Chan, CC; Chan, EC; Chen, SY; Fan, CW; Fan, HA; Hsu, SH; Hsu, YH, 2004) |
| "To determine whether deleted in colon cancer (DCC) protein expression in colorectal cancer (CRC) metastases could predict outcome to palliative fluorouracil (FU)-based chemotherapy and to assess whether it is similar to that observed in the corresponding primary tumors." | 3.72 | Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. ( Aschele, C; Bandelloni, R; Casazza, S; Debernardis, D; Gallo, L; Lonardi, S; Monfardini, S, 2004) |
| "The efficacy of a concomitant oxaliplatin/bolus 5-fluorouracil/leucovorin regimen in 123 heavily pretreated patients with advanced colorectal cancer was evaluated." | 3.72 | Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer. ( Amin-Zimmerman, F; Glisson, SD; Hargis, JB; Hicks, RM; Kosfeld, RE; LaRocca, RV; Leaton, KE, 2004) |
| "We retrospectively evaluated the relevance of thymidylate synthase (TS) expression in normal colonic mucosa as a predictive factor of toxicity in colorectal cancer patients receiving adjuvant fluorouracil (5-FU)-based chemotherapy." | 3.72 | Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. ( Borzomati, D; Caricato, M; Coppola, R; Grilli, C; La Cesa, A; Perrone, G; Rabitti, C; Santini, D; Tonini, G; Verzì, A; Vincenzi, B, 2004) |
| "This study was conducted to evaluate the prognostic significance of thymidylate synthase (TS) expression in the tumor tissue of patients with metastatic colorectal cancer (CRC) who received protracted venous infusions of 5-fluorouracil (5-FU)." | 3.72 | Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil. ( Araake, M; Hamaguchi, T; Hosokawa, A; Morita, H; Muro, K; Orita, H; Shimada, Y; Shirao, K; Yamada, Y, 2004) |
| "The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer." | 3.72 | [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004) |
| "5-fluorouracil (5-FU) is a chemotherapeutic agent widely used in the treatment of solid malignancies, especially in colorectal cancer." | 3.72 | Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature. ( Aparicio, J; Calderero, V; Díaz, R; Guerrero, A; Pellín, L; Segura, A, 2004) |
| "We investigated the immune profile of patients with resected Dukes' stage C colorectal cancer (CRC), receiving adjuvant therapy with edrecolomab (Mo17-1A) or first-line 5-fluorouracil (5-FU)-based chemotherapy." | 3.72 | The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study. ( Gouveris, P; Katsoulas, HL; Kosmas, C; Kosmas, N; Papalambros, E; Papantoniou, N; Rokana, S; Skopeliti, M; Tsavaris, NB; Tsitsilonis, OE, 2004) |
| "A 60-year-old woman with a history of unresectable colon adenocarcinoma was treated by chemotherapy with a combination of oxaliplatin with leucovorin and fluorouracil." | 3.71 | Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. ( Carrie, E; Gagnadoux, F; Lebeau, B; Monnier-Cholley, L; Roiron, C, 2002) |
| "Combined infusion of 5-FU and mitomycin C by hepatic artery catheter port is an effective treatment for liver metastases from colorectal cancer." | 3.71 | Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. ( Jiang, HC; Liu, LX; Piao, DX; Qi, SY; Wu, LF; Zhang, WH; Zhu, AL, 2002) |
| "To verify whether fluorouracil (FU) clearance (CL) and volume of distribution (V(ss)) are better correlated with specific body compartments, such as body cell mass (BCM), total body water (TBW) or fat free mass (FFM), rather than with body surface area (BSA) or total body weight (BW)." | 3.71 | Relationships between body composition parameters and fluorouracil pharmacokinetics. ( Ferrari, M; Ferrazzi, E; Gusella, M; Padrini, R; Toso, S, 2002) |
| "We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1." | 3.71 | Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002) |
| "The goal of this study was to ascertain the first cycle intolerability rate of the standard Mayo Clinic regimen, 5-fluorouracil (5-FU) 425 mg/m2 with low-dose folinic acid (FA) 20 mg/m2, as a rapid bolus intravenous injection (5-FU/FA) for 5 days every 4-5 weeks for advanced colorectal cancer chemotherapy." | 3.71 | Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose. ( Ho, C; Stitt, L; Tomiak, A; Vincent, M; Whiston, F; Winquist, E, 2002) |
| "TS levels were measured immunohistochemically on archival specimens of colorectal cancer metastases from 124 patients homogeneously treated in a series of clinical trials at our institutions with: (A) leucovorin (LV)-modulated infusional 5-FU (n = 48); (B) LV-modulated bolus 5-FU (n = 41); (C) methotrexate (MTX)-modulated bolus 5-FU (n = 35)." | 3.71 | Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. ( Aschele, C; Bandelloni, R; Barni, S; Cascinu, S; Catalano, V; Debernardis, D; Drudi, G; Gallo, L; Giordani, P; Lonardi, S; Maley, F; Monfardini, S; Turci, D, 2002) |
| "We evaluated the effect of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer." | 3.71 | [Evaluation of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer]. ( Ebisui, C; Fujimoto, T; Fukuchi, N; Izawa, H; Kanai, T; Sakita, I; Soma, I; Yoshida, T, 2002) |
| "We administered interleukin (IL)-2 with mitomycin C (MMC) and 5-fluorouracil (5-FU) by hepatic arterial infusion for the treatment of liver recurrence from colorectal cancer." | 3.71 | [Hepatic arterial infusion of IL-2 and chemotherapy for unresectable liver metastasis from colorectal cancer]. ( Hazama, S; Iizuka, N; Matsuoka, K; Oka, M; Takano, N; Tangoku, A; Yoshimura, K, 2002) |
| "LSMs for 5-fluorouracil and 5-fluoro-5,6-dihydrouracil therapeutic monitoring have been developed in 80 patients with colorectal cancer (training set) given 5-fluorouracil, 370 mg/m(2) per day as an intravenous bolus, plus leucovorin, 100 mg/m(2) per day, for 5 days every 4 weeks." | 3.71 | Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. ( Amadori, D; Cionini, L; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Ibrahim, T; Mini, E; Vannozzi, F, 2002) |
| "Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) exhibit single-agent activity in colorectal cancer, have nonoverlapping major toxicities, and exhibit a synergistic effect in tumor xenograft models." | 3.71 | Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. ( Kerr, D, 2002) |
| " We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib." | 3.71 | Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002) |
| "Irinotecan (CPT-11), oxaliplatin (OXA) and different folinic acid(FA) modulated 5-fluorouracil (5-FU) regimens are active as first-and second-line chemotherapy of metastatic colorectal cancer." | 3.71 | Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. ( Galle, PR; Heike, M; Hildner, K; Hoffmann, T; Moehler, M; Siebler, J, 2002) |
| "The clinical relevance of bax and bcl-2 protein expression has been investigated in 84 patients with recurrent or metastatic colorectal cancer submitted to a chemotherapy regimen including methotrexate and fluorouracil/leucovorin." | 3.71 | Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. ( Costa, A; Daidone, MG; Dellapasqua, S; Lacava, J; Lena, MD; Leone, B; Paradiso, A; Simone, G; Vallejo, C, 2001) |
| "5-Fluorouracil (5-FU), in association with leucovorin (LV), is the most used chemotherapy agent in the treatment of colorectal cancer." | 3.71 | Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer. ( Barletta, E; Carratù, R; Daniele, B; De Magistris, L; De Vivo, R; Delrio, P; Palaia, R; Pignata, S; Secondulfo, M; Tambaro, R, 2001) |
| "There has been no standard therapy for patients with metastatic colorectal cancer who have failed to first-line fluorouracil-based treatment." | 3.71 | Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer. ( Kang, YK; Kim, HC; Kim, JC; Kim, SH; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Yu, CS, 2001) |
| "Irinotecan (CPT-11) has shown considerable activity in colorectal cancer, and its combination with 5-fluorouracil (5-FU) represents an attractive approach." | 3.71 | A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer. ( Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, A; Koukourakis, M; Kouroussis, C; Mavroudis, D; Romanos, J; Souglakos, J; Vardakis, N, 2001) |
| "In our institution, patients with multiple unresectable liver metastases from colorectal cancer have received 24-h continuous arterial infusion therapy of 5-fluorouracil (5-FU) 250 mg/body/day every 2 weeks for the past 11 years." | 3.71 | [Results and limitations of arterial infusion therapy for liver metastases from colorectal cancer]. ( Mori, T; Ohue, M; Takahashi, K; Yamaguchi, T, 2001) |
| "The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer." | 3.71 | A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001) |
| "The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis." | 3.71 | Expression of metallothionein in colorectal cancers and synchronous liver metastases. ( Dhar, DK; Hishikawa, Y; Kimoto, T; Kohno, H; Koji, T; Kubota, H; Nagasue, N; Tachibana, M; Ueda, S, 2001) |
| "To identify the prognostically highest risk patients, DNA content and p53 nuclear or cytoplasmic accumulation, evaluated by monoclonal antibody DO7 and polyclonal antibody CM1, were determined in 94 surgically resected stage II (Dukes B2) colorectal cancers, treated or not with adjuvant 5-fluorouracil-based chemotherapy." | 3.71 | p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. ( Benevolo, M; Brenna, A; Buglioni, S; Cosimelli, M; D'Agnano, I; D'Angelo, C; Mottolese, M; Perrone Donnorso, R; Vasselli, S; Zupi, G, 2001) |
| "High levels of thymidylate synthase (TS) expression have been associated with poor survival of colorectal cancer (CRC) patients to 5-fluorouracil (5-FU)-based chemotherapy." | 3.71 | A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. ( Elsaleh, H; Grieu, F; Iacopetta, B; Joseph, D, 2001) |
| "For patients with incurable stage IV colorectal cancer, minimally symptomatic primary tumours were left in situ and 5-fluorouracil-based chemotherapy was administered systemically." | 3.71 | Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. ( Guillou, PJ; Guthrie, JA; O'Riordain, DS; Ride, E; Sarela, AI; Seymour, MT, 2001) |
| "Adjuvant chemotherapy with 5-fluorouracil (5-FU) and mitomycin C (MMC) has commonly been used after resection of colorectal cancer." | 3.71 | The potential clinical value of GML and the p53 gene as a predictor of chemosensitivity for colorectal cancer. ( Hashimoto, Y; Minami, K; Ueda, K; Watatani, M, 2001) |
| "We investigated whether the efficacy of peroral doxifluridine and hepatic arterial 5-FU infusion on synchronous liver metastasis of colorectal cancer could be predicted based on the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in the primary colorectal lesions." | 3.71 | [Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]. ( Fujioka, M; Hashimoto, D; Hoshino, T; Inokuma, S; Ishida, H; Ishizuka, N; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Takeuchi, I; Yamada, H; Yokoyama, M, 2001) |
| "To test the hypotheses of whether the relative mRNA expression of the thymidylate synthase (TS) gene and the excision cross-complementing (ERCC1) gene are associated with response to and survival of fluorouracil (5-FU)/oxaliplatin chemotherapy in metastatic colorectal cancer." | 3.71 | ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. ( Brabender, J; Danenberg, KD; Danenberg, PV; Groshen, S; Lenz, HJ; Shirota, Y; Stoehlmacher, J; Tsao-Wei, DD; Uetake, H; Xiong, YP, 2001) |
| " Because increased DNA repair plays an important role in chemoresistance to platinum-based compounds, we assessed the aforementioned polymorphisms in 73 patients with metastatic colorectal cancer and determined their outcome to 5-fluorouracil/oxaliplatin." | 3.71 | A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. ( Groshen, S; Lenz, HJ; Park, DJ; Stoehlmacher, J; Tsao-Wei, DD; Zhang, W, 2001) |
| "The oral, tumour-selective fluoropyrimidine capecitabine represents a major new strategy for the treatment of colorectal cancer." | 3.71 | Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. ( Twelves, C, 2002) |
| "At increasing use of high-dose 5-fluorouracil-based chemotherapy for metastatic colorectal and gastric cancer complicated drug-induced colitis is observed more frequently." | 3.71 | [5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases]. ( Hotz, J; Madisch, A; Marquard, F; Stolte, M; Wiedbrauck, F, 2002) |
| " thymidylate synthase (TS) and thymidine kinase (TK), in human colorectal cancers to compare their possible relationship with demographic and pathologic characteristics of the patients and their tumors, and moreover to evaluate their predictive significance regarding 5-fluorouracil (5-FU) sensitivity and the overall survival of patients, respectively." | 3.71 | Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors. ( Budai, B; Czeglédi, F; Hullán, L; Jeney, A; Katona, C; Kovács, T; Köves, I; Kralovánszky, J; Orosz, Z; Rahóty, P; Tóth, K, 2002) |
| "The aim of this study was to evaluate the objective tumor response rates and toxicities in elderly patients (older than 70 years) with advanced colorectal cancer treated with 5-fluorouracil (5-FU) as a first-line palliative chemotherapy regimen." | 3.71 | Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience. ( Broisin, L; Ferrero, JM; François, E; Guardiola, E; Magné, N; Namer, M; Ramaïoli, A, 2002) |
| "The aim of this study was to assess in patients with advanced colorectal cancer which factors were associated with short-term survival (6 months or less) and progression to first-line 5-fluorouracil (5-FU) chemotherapy." | 3.71 | Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. ( Cellerino, R; Lippe, P; Massacesi, C; Piga, A; Pistilli, B; Rocchi, MB; Valeri, M, 2002) |
| "The objective of this study was to investigate the possible prognostic factors in patients with metastatic colorectal cancer (CRC) treated with protracted venous infusion (PVI) of 5-fluorouracil (5-FU)." | 3.71 | Prognostic factors for patients with metastatic colorectal cancer receiving protracted venous infusion of 5-FU. ( Gotoh, M; Hamaguchi, T; Matsumura, Y; Mizuno, T; Muro, K; Namiki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2002) |
| "Since its introduction over 40 years ago, 5-fluorouracil (5-FU) has remained the only effective chemotherapy option available for the treatment of colorectal cancer (CRC)." | 3.71 | A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier. ( Jian, CH; Lee, YH; Lin, FH; Shieh, MJ; Wang, CY; Wong, JM, 2002) |
| "We investigated the relevance of mdm2 and p53 primary tumour expression to the clinical outcome of a consecutive series of advanced colorectal cancer patients treated with a 5-fluorouracil-based chemotherapy." | 3.71 | mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer. ( Costa, A; De Lena, M; Lacava, J; Leone, A; Paradiso, A; Ranieri, G; Silvestris, N; Simone, G; Vallejo, C, 2002) |
| " High DPD mRNA levels in liver metastasis and advanced colorectal cancer may have clinical importance for 5-fluorouracil-based chemosensitivity." | 3.71 | Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer. ( Ichikawa, W; Nihei, Z; Shirota, Y; Sugihara, K; Uetake, H; Yamada, H, 2002) |
| "Dynamic PET and [18F]fluorouracil (18F-FU) were used in patients with liver metastases from colorectal cancer to examine the pharmacokinetics of the drug up to 120 min after intravenous and intra-arterial injection of the same dose of fluorouracil (FU)." | 3.70 | Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma. ( Dimitrakopoulou-Strauss, A; Doll, J; Hohenberger, P; Irngartinger, G; Oberdorfer, F; Schlag, P; Strauss, LG; van Kaick, G, 1998) |
| "It has been observed previously that the pulmonary metastases of colorectal adenocarcinoma are less responsive to therapy with fluorouracil (FUra) as compared with other sites of metastasis (liver, local)." | 3.70 | Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. ( Banerjee, D; Bertino, JR; Danenberg, KD; Danenberg, PV; Fu, J; Gorlick, R; Jhanwar, S; Kemeny, N; Klimstra, D; Longo, GS; Metzger, R; Miles, JS; Salonga, D, 1998) |
| "5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer." | 3.70 | Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998) |
| " It is the first drug since fluorouracil to possess consistent antitumour activity against metastatic colorectal cancer." | 3.70 | A risk-benefit assessment of irinotecan in solid tumours. ( Rowinsky, EK; Siu, LL, 1998) |
| "Prior to the administration of 5-fluorouracil chemotherapy, the authors examined 14 colorectal carcinoma patients with unresectable liver metastases using a single PET scan and 18F-labeled fluorouracil (18F-FU)." | 3.70 | 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. ( Dimitrakopoulou-Strauss, A; Gutzler, F; Moehler, M; Raeth, U; Strauss, LG; Stremmel, W, 1998) |
| "Spectral analysis could distinguish tumour kinetics from normal tissue kinetics in an individual [11C]-temozolomide study and demonstrated a markedly greater volume of distribution (VD) in glioma than in normal brain, although there was no appreciable difference in mean residence time." | 3.70 | Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. ( Brock, CS; Cunningham, VJ; Harte, RJ; Jones, T; Matthews, JC; Meikle, SR; Price, P; Wells, P, 1998) |
| "7% in patients with advanced colorectal cancer refractory to 5-fluorouracil [5-FU])." | 3.70 | Irinotecan: toward clinical end points in drug development. ( Pazdur, R, 1998) |
| "In all patients with advanced colorectal cancer, disease eventually progresses following fluorouracil (5-FU) therapy, with a worsening of disease-related symptoms and quality of life (QOL)." | 3.70 | Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer. ( Michael, M; Moore, MJ, 1998) |
| "The combination of oxaliplatin (LOHP)-5-fluorouracil (FU)-folinic acid (FA) has provided high response rates in pretreated patients with advanced colorectal cancer that is resistant to FU-FA." | 3.70 | Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. ( Etienne, MC; Fischel, JL; Formento, P; Milano, G, 1998) |
| "The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy." | 3.70 | Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998) |
| "We studied the effect of immunotherapy using recombinant interleukin-2 (rIL-2) in combination with a differentiating agent, sodium butyrate (NaBut), on experimental 5-fluorouracil (5-FU)-resistant liver metastasis from colorectal cancer in rats." | 3.70 | Interleukin-2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5-fluorouracil resistance. ( Cordel, S; Douillard, JY; Dupas, B; Meflah, K, 1998) |
| "In an effort to improve the therapeutic selectivity of 5-fluorouracil (FUra) against colorectal cancer, S-1, a combination agent including a prodrug of FUra with two modulators, was recently developed by Taiho Pharmaceuticals Co." | 3.70 | Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. ( Cao, S; Lu, K; Rustum, YM; Shirasaka, T; Slocum, HK; Tóth, K, 1999) |
| " The aim of this work was to investigate the role of p53 in the apoptosis of colorectal cancer cells in vitro, induced by 5-fluorouracil (5-FU) and hydroxy-camptothecin (HCPT)." | 3.70 | The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells. ( Li, N; Ou, Q; Shen, B; Wang, H; Yu, B; Zhang, H; Zheng, M, 1999) |
| "We have used chemo-immunotherapy with 5-fluorouracil (5-FU), thymosin alpha1 (T alpha1) and interleukin-2 (IL-2) to treat multiple liver metastases from colorectal cancer induced by DHD/K12 cells in syngeneic BDIX rats, comparing one and two cycles of treatment, and different treatment combinations." | 3.70 | Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery. ( Bernard, P; Garaci, E; Guarino, E; Pierimarchi, P; Rasi, G; Restuccia, A; Silecchia, G; Sinibaldi-Vallebona, P; Spaziani, E; Tuthill, C, 1999) |
| "Although treatment with 5-fluorouracil (5-FU) plus calcium folinate has been reported to prolong survival in patients with metastatic colorectal cancer, it can also cause significant toxicity, potentially, resulting in hospitalization." | 3.70 | Hospitalization for 5-FU toxicity in metastatic colorectal cancer: incidence and cost. ( Oster, G, 1999) |
| "The purpose of this work was to estimate the population pharmacokinetic parameters of 5-fluorouracil (5-FU) in patients with advanced colorectal cancer using circadian change kinetics." | 3.70 | Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. ( Astre, C; Bressolle, F; Duffour, J; Gomeni, R; Joulia, JM; Pinguet, F; Ychou, M, 1999) |
| "The comparative saliva/plasma pharmacokinetics of 5-fluorouracil (5-FU) were investigated in 21 patients with metastatic colorectal cancer receiving high-dose folinic acid (LV (leucovorin) 200 mg/m2) followed by 5-FU bolus (400 mg/m2) and continuous infusion (600, 750, 900 or 1200 mg/m2) on days 1 and 2." | 3.70 | Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. ( Astre, C; Bressolle, F; Duffour, J; Joulia, JM; Pinguet, F; Ychou, M, 1999) |
| "Diarrhea and oral mucositis are the most frequently reported gastrointestinal side effects caused by 5-fluorouracil (5-FU)." | 3.70 | 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. ( Fata, F; Kelsen, DP; Kemeny, N; Klimstra, D; O'Reilly, E; Ron, IG, 1999) |
| "In a recent multicentre, randomised, controlled, open-label study (Rougier and colleagues, Lancet 1998, 352, 1407-1412), irinotecan significantly increased survival without any deterioration in quality of life compared with best-estimated infusional 5-fluorouracil (5-FU) therapy in the setting of second-line treatment for metastatic colorectal cancer." | 3.70 | Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. ( Hickish, T; Iveson, TJ; Schmitt, C; Van Cutsem, E, 1999) |
| "The efficacy of oxaliplatin combined with high-dose 5-fluorouracil (5-FU) and folinic acid (FA) as an outpatient salvage treatment for patients with metastasized colorectal cancer was retrospectively analyzed in one center." | 3.70 | Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma. ( Galle, PR; Gödderz, W; Heike, M; Hofmann, MA; Kallen, KJ; Timm, A, 2000) |
| "5-fluorouracil (5-FU) is considered the standard antineoplastic drug of choice for metastatic colorectal cancer." | 3.70 | Changes in thymidylate synthase mRNA in blood leukocytes from patients with colorectal cancer after bolus administration of 5-fluorouracil. ( Ehrnrooth, E; Poulsen, JH; Sørensen, B; Sørensen, BS; von der Maase, H, 2000) |
| " In this study, we have determined the expression patterns of dUTPase in normal and neoplastic tissues and examined the association between dUTPase expression and response to 5-fluorouracil (5-FU)-based chemotherapy and overall survival in colorectal cancer." | 3.70 | dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. ( Caradonna, SJ; Groshen, S; Ladner, RD; Lenz, HJ; Lynch, FJ; Sherrod, A; Stoehlmacher, J; Xiong, YP, 2000) |
| "The basis for current clinical trials in the treatment of colorectal cancer with the combination of irinotecan (CPT-11) and 5-fluorouracil (FUra) with or without leucovorin (LV) is their proven activity as single agents, their different mechanisms of action, and lack of CPT-11 cross-resistance to previous FUra/LV treatment." | 3.70 | Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. ( Cao, S; Rustum, YM, 2000) |
| "The addition of oxaliplatin (L-OHP) to a 5-fluorouracil (5-FU)/ leucovorin (FA) regimen was retrospectively evaluated in 35 consecutive advanced colorectal cancer patients after progression of disease." | 3.70 | Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. ( Aschelter, AM; Bertheault-Cvitkovic, F; Brienza, S; Caterino, M; Cosimelli, M; Garufi, C; Giannarelli, D; Giunta, S; Lévi, F; Nisticò, C; Pugliese, P; Terzoli, E, 2000) |
| "The authors describe the retrospective analysis of treatment by 5-fluorouracil and interferon-a aof 34 patients with advanced colorectal cancer." | 3.70 | Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients. ( András, C; Antal, L; Csiki, Z; Gál, I; Szegedi, G; Takács, I, 2000) |
| "Adjuvant 5-fluorouracil (5-FU)-based chemotherapy is standard treatment for stage C colorectal cancer (CRC)." | 3.70 | Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. ( Aaltonen, LA; Hemminki, A; Järvinen, H; Joensuu, H; Mecklin, JP, 2000) |
| "Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil." | 3.70 | Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000) |
| "Twenty-four patients with metastatic colorectal cancer were treated with recombinant IL-2 (rIL-2) by continuous intravenous infusion for 5 days (18 x 10(6) U/m2 per 24 h), followed by three injections of 5-fluorouracil (600 mg/m2) and folinic acid (25 mg/m2) at weekly intervals." | 3.69 | Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. ( Broom, J; Eremin, O; Heys, SD; Simpson, WG; Whiting, PH, 1995) |
| "We observed leukoencephalopathy in 1 patient, and progressive dementia in another, during the administration of 5-fluorouracil (5-FU) and levamisole." | 3.69 | Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. ( Dobranowski, J; Fawcet, SE; Figueredo, AT; Molloy, DW; Paulseth, JE, 1995) |
| "One hundred and seven previously untreated patients with measurable metastatic colorectal cancer who were treated with 5-fluorouracil (5FU) and leucovorin (LV) in two different maximum doses and schedules were retrospectively analyzed." | 3.69 | A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer. ( Bacoyannis, C; Basdanis, G; Foutzilas, G; Karvounis, N; Kosmidis, P; Markantonakis, P; Mylonakis, N; Sobolos, K; Tsavaris, N; Zisiadis, A, 1995) |
| "This study was designed to examine the optimal regimen of 5-fluorouracil (5-FU), uracil and degradable starch microspheres (DSM) to prevent the hepatic metastasis of colorectal cancer." | 3.69 | Inhibitory effect of simultaneous intraportal administration of 5-fluorouracil, uracil and degradable starch microspheres on experimental hepatic micrometastasis, is of colon cancer. ( Fujii, K; Hanaue, H; Kurosawa, T; Mitomi, T; Nakasaki, H; Tajima, T; Yasuda, S, 1994) |
| "The purpose of this study was to explore the mechanism of interaction between 5-FU and levamisole by investigating the effect of this combination on HLA class I gene expression in the colorectal cancer cell line WiDr." | 3.69 | Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. ( AbdAlla, EE; Blair, GE; Johnston, D; Jones, RA; Sue-Ling, HM, 1995) |
| "To confirm our previous kinetic analysis of the mode of cell-killing action of 5-fluorouracil (5-FU), we carried out a flow cytometric analysis with human colorectal cancer DLD-1 cells." | 3.69 | Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells. ( Inaba, M; Mitsuhashi, J, 1994) |
| " We present herein the cases of three patients with multiple liver metastases from colorectal cancer in whom complete remission was achieved by treatment with an HAI of IL-2 in combination with mitomycin C (MMC) and 5-fluorouracil (5-FU)." | 3.69 | Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases. ( Akabane, Y; Koh, K; Kurooka, K; Nakajima, I; Ohnishi, H; Okuno, K; Shindo, K; Yasutomi, M, 1994) |
| "We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats." | 3.69 | Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. ( Garaci, E; Pierimarchi, P; Rasi, G; Silecchia, G; Sinibaldi-Vallebona, P; Sivilia, M; Spaziani, E; Tremiterra, S, 1994) |
| "The purpose of the study was to evaluate the efficacy of long-term continuous administration of 5-fluorouracil (5-FU) in ambulatory patients with colorectal cancer." | 3.69 | [Treatment of advanced colorectal cancer with long-term continuous infusion of 5-fluorouracil]. ( Ando, J; Kotake, K; Koyama, Y; Nasu, J; Ogata, Y; Ozawa, I, 1994) |
| "From September 1989 to September 1992, 17 patients (pts) with non-curative or recurrent colorectal cancer were treated with 5-fluorouracil (FU) plus leucovorin (LV) systemic therapy." | 3.69 | [5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer]. ( Ban, K; Imanari, T; Machida, T; Masuda, K; Matsumoto, M; Noda, Y; Shida, H; Takei, Y; Yamamoto, T, 1994) |
| "In 16 advanced colorectal cancer patients with 5-fluorouracil-associated diarrhea, we evaluated the role of bacterial pathogens in the development of this adverse effect." | 3.69 | Have enteric infections a role in 5-fluorouracil-associated diarrhea? ( Cascinu, S; Catalano, G, 1995) |
| "The optimal schedule for the administration of 5-fluorouracil (5-FU) in the management of advanced colorectal cancer remains to be determined." | 3.69 | Bioavailability of subcutaneous 5-fluorouracil: a case report. ( Carlin, W; Dunlop, DJ; Eatock, MM; Soukop, M; Watson, DG, 1996) |
| "Patients with colorectal cancer liver metastases were treated with fluorouracil (5FU) as a protracted venous infusion (300 mg/m2/d), with or without interferon-alpha 2b for two 10-week blocks separated by a 2-week break." | 3.69 | Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. ( Cronin, B; Cunningham, D; Findlay, M; Flower, M; Hickish, T; Husband, J; Iveson, A; Ott, R; Pratt, B; Young, H, 1996) |
| "Thirty-seven patients with advanced colorectal cancer were treated with fluorouracil (5-FU) and folinic acid (FA) (Jan 1990-Dec 1992)." | 3.69 | Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department. ( Carey, PD; Farrer, C; Gordon, A; Guillou, PJ; Monson, JR; Pearce, S; Sommers, SS, 1995) |
| "The pharmacokinetics after 20 min intravenous infusion or a 2 min bolus (push) injection of 5-fluorouracil (500 mg/m2) were studied in 14 colorectal cancer patients." | 3.69 | Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects. ( Carlsson, G; Glimelius, B; Graf, W; Gustavsson, B; Larsson, PA, 1996) |
| "Although intrahepatic infusion therapy with 5-fluorouracil for unresectable colorectal liver metastases may lead to improved overall survival for some patients, it is not clear why a response is not observed in others." | 3.69 | p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. ( Benhattar, J; Cerottini, JP; Givel, JC; Metthez, G; Saraga, E, 1996) |
| "The in vitro cytotoxicity of the combination of azidothymidine (AZT) and 5-fluorouracil (5-FU) against the human colorectal cancer cells SW-480, SW-620 and COLO-320DM was evaluated." | 3.69 | Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks. ( Allegrini, G; Andreuccetti, M; Antonuzzo, A; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Malvaldi, G, 1996) |
| "We determined the chemosensitivity for cisplatin, mitomycin C, adriamycin, and 5-fluorouracil in vitro in 93 fresh human colorectal cancers using the MTT assay and performed chemotherapy according to results of the MTT assay." | 3.69 | Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay. ( Hotta, T; Ishimoto, K; Iwahashi, M; Murakami, K; Nakamori, M; Noguchi, K; Tani, M; Tanimura, H; Yamaue, H, 1996) |
| " In patients with colorectal cancer, the administration of adjuvant intraportal chemotherapy (with mitomycin and fluorouracil) has been reported to improve long-term survival in comparison with patients who are not given this treatment." | 3.69 | Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer. ( Bonistalli, L; Costantini, M; Messori, A; Tendi, E; Trallori, G, 1996) |
| " An audit of the total monthly costs of 'Tomudex' (raltitrexed; administered every 3 weeks), a drug recently introduced for the treatment of advanced colorectal cancer, and three 5-fluorouracil-based regimens [5-day daily bolus (Mayo); continuous ambulatory pump; 48-h continuous infusion (De Gramont)] was undertaken." | 3.69 | Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. ( Cunningham, D; Heron, J; Ross, P, 1996) |
| "In a series of 71 patients with advanced colorectal cancer treated with biochemically modulated 5-fluorouracil (5-FU) and methotrexate (MTX), we investigated the relationship between the proliferating-cell nuclear antigen (PCNA) (PC10) and p53 (Pab1801) primary-tumor immunohistochemical expression with respect to clinical response and long-term prognosis." | 3.69 | p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. ( Cuevas, MA; De Lena, M; Lacava, J; Leone, B; Machiavelli, M; Paradiso, A; Perez, J; Rabinovich, M; Rodriquez, R; Romero, A; Sapia, MG; Simone, G; Vallejo, C, 1996) |
| "Electroporation was applied in vitro and in vivo in the treatment of human colorectal cancer cell lines to study whether it can enhance the effect of bleomycin (BLM), 5-fluorouracil (5-FU) and cis-platinum (CDDP)." | 3.69 | Enhancing the effect of anticancer drugs against the colorectal cancer cell line with electroporation. ( Arita, D; Funato, T; Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Murakawa, Y; Tezuka, F, 1996) |
| "In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally." | 3.69 | Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. ( Kamm, YL; Punt, CJ; Wagener, DJ, 1997) |
| " A high incidence of colorectal adenocarcinomas with varied grades of cell differentiation can be induced by 1,2-dimethylhydrazine (DMH) in rats." | 3.69 | Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats. ( Iwama, T; Kawachi, Y; Kudo, H; Murakami, S; Okayasu, I; Sagara, T; Sakamoto, S; Tsukada, K, 1997) |
| "The authors report a patient with colorectal carcinoma who developed neutropenic enterocolitis after treatment with 5-fluorouracil and leucovorin." | 3.69 | Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report. ( Blumgart, L; Kemeny, NE; Kronawitter, U, 1997) |
| "In the chemotherapy of colorectal cancers the most frequently given drug is 5-fluorouracil, which in certain cases reduces or delays the appearance of the local recurrence or metastasis." | 3.69 | [Determination of dihydropyrimidine dehydrogenase in the prediction of toxic side effects of 5-fluorouracil]. ( Fónyad, G; Jeney, A; Katona, C; Kralovánszky, J; Pandi, E; Rosta, A; Tóth, K, 1997) |
| "The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy." | 3.69 | Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997) |
| "Use of chlorhexidine intraperitoneal therapy at the time of the operation for perforated colorectal cancer significantly decreases the frequency of gross tumor recurrence but not total recurrences." | 3.69 | Use of intraperitoneal 5-fluorouracil and chlorhexidine for prevention of recurrence of perforated colorectal carcinoma in a rat model. ( Ong, J; Stabile, B; Stamos, M; Stuntz, M; Wilmoth, G, 1997) |
| "5-Fluorouracil (5-FU) has been an accepted effective against colorectal cancer, but combination regimens resulted in a lesser effect than 5-FU alone." | 3.69 | 5-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer. ( Imamura, M; Kawabata, K; Nio, Y, 1997) |
| " In order to evaluate the HDRA with the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide end point for clinical use, chemosensitivity to mitomycin C, doxorubicin, 5-fluorouracil, and cisplatin of 107 advanced gastric and 109 advanced colorectal cancers was determined in vitro in a correlative clinical trial." | 3.69 | Clinical applications of the histoculture drug response assay. ( Furukawa, T; Hoffman, RM; Kubota, T, 1995) |
| "Multiple studies have shown that leucovorin-fluorouracil regimens are modestly superior to fluorouracil alone in the treatment of advanced colorectal cancer." | 3.69 | Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine. ( DeLap, RJ; Marshall, JL; Richmond, E, 1996) |
| "This study was conducted to investigate the activity and toxicity of 5fluorouracil folinic acid+mitomycin C combined with alpha 2b interferon in advanced colorectal cancer based upon recent studies suggesting a possible biochemical modulation of 5fluorouracil by interferon." | 3.68 | Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer. ( Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Manocchi, P; Mattioli, R; Mazzanti, P; Pilone, A; Rossini, S; Silva, RR, 1993) |
| "We studied the levamisole toxic effects in adjuvant therapy for colorectal cancer." | 3.68 | [Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer]. ( Beerblock, K; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Navarro-Carola, E; Soubrane, D; Varette, C, 1993) |
| "Interferon (IFN) has been shown to enhance the cytotoxic effects of 5-fluorouracil (5FUra) in colorectal cancer, and clinical trials with this combination resulted in higher response rate with respect to 5FUra alone." | 3.68 | Cytokinetic effects of interferon in colorectal cancer tumors: implications in the design of the interferon/5-fluorouracil combinations. ( Acetoso, M; Bartolucci, M; Cascinu, S; Del Ferro, E; Fedeli, A; Foglietti, G; Grianti, C; Lungarotti, F; Olivieri, Q; Saba, V, 1993) |
| "5-Fluorouracil (5-FU) is the most widely used cytotoxic drug in oncology and the only one useful in the management of colorectal cancer - a leading cause of cancer death worldwide." | 3.68 | The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. ( Collins, DJ; Cunningham, D; Findlay, MP; Glaholm, J; Leach, MO; Mansi, JL; McCready, VR; Payne, GS, 1993) |
| "The efficacy of the protracted infusion of 5-fluorouracil (FU) 200 mg/m2/day admixed with leucovorin (LV) 20 mg/m2/day was assessed for the treatment of advanced colorectal and breast cancer patients." | 3.68 | Continuous intravenous infusion of leucovorin and 5-fluorouracil for the treatment of advanced colorectal and breast cancers. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JM; Tzeng, CH, 1993) |
| "A total of 77 patients with advanced colorectal cancer, including postoperative patients with liver, lung and peritoneal metastases, were treated with single or multiple injections of monoclonal antibody A7-neocarzinostatin (A7-NCS)." | 3.68 | Follow-up study of patients treated with monoclonal antibody-drug conjugate: report of 77 cases with colorectal cancer. ( Honda, M; Kitamura, K; Noguchi, A; Otsuji, E; Takahashi, T; Yamaguchi, T, 1993) |
| "In order to elucidate the effect of tumor vascularity on a various regimens concentration in tumor tissue, correlation among tegafur, 5-fluorouracil (5-FU), uracil concentrations in tissue and the microangiography were examined in 27 patients with colorectal cancer after preoperative administration of UFT (400 mg/day for 7 days)." | 3.68 | [Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer]. ( Ishikawa, H; Kusano, H; Miyashita, K; Nakazaki, T; Ogawa, T; Shimizu, T; Shimoyama, T; Yasutake, T; Yoshida, A; Yoshida, K, 1993) |
| "Various factors, including thymidylate synthase, thymidine kinase, 5-fluorouracil phosphorylation and degradation pathways, folate concentrations, and the stability of ternary complex, which influence thymidylate synthase inhibition rate of fluoropyrimidines, were studied in 87 human adenocarcinoma tissues." | 3.68 | Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues. ( Dohden, K; Ohmura, K; Watanabe, Y, 1993) |
| "Twenty-four patients with advanced or relapsed gastric or colorectal cancer were treated with a combination of 5-fluorouracil (5-FU), leucovorin (LV) and interferon-alpha (IFN-alpha)." | 3.68 | [Treatment of advanced gastric and colorectal cancer with 5-FU, leucovorin and interferon-alpha]. ( Ezaki, K; Hatanaka, T; Hobara, R; Iwase, K; Kawase, K; Nakano, H; Ohara, K; Okamoto, M; Ono, Y; Tsujimura, T, 1993) |
| "Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i." | 3.68 | Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992) |
| " UFT (400 mg/day in terms of tegafur) was given preoperatively for 1-6 days in 6 patients with gastric cancer and 13 with colorectal cancer." | 3.68 | [Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT]. ( Inaba, S; Kawai, K; Kondo, Y; Ogino, A; Tsuchiya, K; Ueda, Y; Umeda, T, 1992) |
| " In a literature review of all published data of folinic acid and 5-fluorouracil intravenous bolus therapy in colorectal cancer with comparable dose intensity, an attempt was made to characterize the possible differences of the variations of schedules used." | 3.68 | The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. ( Bokemeyer, C; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992) |
| "Twenty-four patients with advanced colorectal cancer received two cycles of combination chemotherapy consisting of mitomycin 10 mg/m2 for 5 days continuous infusion and allopurinol 300 mg x 3/day p." | 3.68 | Continuous 24-hour infusion of folinic acid does not increase the response rate of 5-fluorouracil but only the toxicity. ( Karvounis, N; Kosmidis, P; Tsavaris, N; Tzannou, I, 1992) |
| "The combination of folinic acid (FA) and 5-fluorouracil (5FU) is the most active systemic chemotherapy against advanced colorectal cancer." | 3.68 | High dose alpha-2b interferon + folinic acid in the modulation of 5-fluorouracil. A phase II study in advanced colorectal cancer with evidence of an unfavourable cost/benefit ratio. ( Dallavalle, G; Labianca, R; Luporini, A; Luporini, G; Pancera, G; Tedeschi, L, 1992) |
| "A cohort of 35 patients with advanced colorectal cancer, not previously exposed to chemotherapy, were included in a phase II study exploring the combination of interferon-alpha, 9 MU subcutaneously three times weekly, and 5-fluorouracil 750 mg/m2/day during 5 consecutive days in continuous intravenous infusion followed with weekly bolus injection of fluorouracil 750 mg/m2." | 3.68 | Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis. ( Antón, A; Aranda, E; Blanco, E; Camps, C; Díaz Rubio, E; González Larriba, JL; Jimeno, J; Lízón, J; Massuti, B, 1992) |
| "Eighty-seven colorectal adenocarcinomas from untreated patients were investigated by short term tumor cultures to test in vitro sensitivity to 5-fluorouracil and mitomycin C." | 3.68 | 5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures. ( Barone, C; Codacci-Pisanelli, G; Codacci-Pisanelli, M; Ferri, GM; Franchi, F; Garufi, C; Grieco, A; Pagani, V; Seminara, P, 1991) |
| "Because of conflicting reports of clinical synergy, we used the tetrazolium-based colorimetric (MTT) assay to test in vitro combination effects of methotrexate (MTX) plus 5-fluorouracil (FUra) in 4 schedules on 2 human non-small-cell lung cancer cell lines (adenocarcinoma, NC1-H23; bronchio-alveolar-cell carcinoma, NC1-H358), and 1 human colorectal adenocarcinoma cell line (SNU-C1)." | 3.68 | Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines. ( Gazdar, AF; Kramer, BS; Perng, RP; Tsai, CM, 1991) |
| "Twenty-six patients with advanced colorectal cancer were treated with a combination based on multimodal biochemical modulation of 5-fluorouracil by means of high dose folinic acid, low-dose alpha-2b interferon and dipyridamole." | 3.68 | Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study. ( Arcangeli, G; Bonera, F; Braga, M; Marini, G; Marpicati, P; Meriggi, F; Montini, E; Ragni, F; Simoncini, E; Zaniboni, A, 1991) |
| "18 patients with advanced colorectal cancer entered a phase I-II study of high-dose 48 h continuous infusion 5-fluorouracil (5-FU) for 6 weeks." | 3.68 | Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. ( Aranda, E; Barneto, I; Diaz-Rubio, E; Gonzalez-Larriba, J; Gonzalez-Mancha, R; Martin, M, 1990) |
| "Forty-five consecutive patients with advanced colorectal cancer were treated with 5-fluorouracil and high dose folinic acid." | 3.68 | [Fluorouracil and high-dose folinic acid in the treatment of advanced colorectal carcinoma]. ( Angelini, F; Carassai, A; Carpano, S; D'Aprile, M; Leggio, M; Lopez, M; Natali, M; Tonini, G; Vici, P, 1990) |
| "Twenty-nine evaluable patients with colorectal adenocarcinoma were treated in a phase I-II trial of combination chemotherapy with a 72-h continuous infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU) with an infusion of VP-16 given at 24 and 48 h after the start of therapy." | 3.68 | A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma. ( Browne, MJ; Calabresi, P; Clark, JW; Cummings, FJ; Curt, G; Posner, M; Slapak, CA; Urba, S; Weitberg, A; Wiemann, M, 1990) |
| "Intensive therapy with 5-fluorouracil (FU) and leucovorin (LV) has proved to be effective in the treatment of advanced colorectal cancer." | 3.68 | Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. ( Anderson, I; Mortimer, JE, 1990) |
| "5-fluorouracil (5-FU) concentrations in peripheral blood, portal blood, normal and cancer tissues were evaluated in 26 patients with colorectal cancer after SF-SP administration (800 mg/day for 10 days)." | 3.68 | [Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration]. ( Haruyama, K; Hase, S; Ishizawa, T; Katsura, Y; Niwa, K; Sameshima, T; Shimazu, H; Yamada, K; Yoshimura, A, 1990) |
| "Since there is no effective second line chemotherapy in colorectal cancer resistant to fluorouracil, this study was carried out to evaluate the therapeutic activity of the pineal hormone melatonin, which has appeared to have antineoplastic activity in some experimental conditions, in patients with metastatic colorectal carcinoma who did not respond to fluorouracil." | 3.68 | A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates. ( Archili, C; Barni, S; Crispino, S; Lissoni, P; Paolorossi, F; Tancini, G, 1990) |
| "Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action." | 3.68 | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990) |
| "Thirty patients with advanced colorectal adenocarcinoma were treated by chemotherapy with an alternating regimen consisting of 5-fluorouracil (5-FU)-mitomycin C and 5-FU-dacarbazine at 3-week intervals." | 3.67 | Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study. ( Droz, JP; Herait, P; Kac, JL; Rougier, P; Theodore, C, 1989) |
| "Based on in vitro studies that have demonstrated synergy between recombinant alfa-2a-interferon (rIFN alpha-2a) and the fluoropyrimidine, fluorouracil (5FU), against two human colon cancer cell lines, a pilot clinical trial was initiated to determine the effects of the combination of 5FU and rIFN alpha-2a in patients with advanced, unresectable colorectal carcinoma." | 3.67 | Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. ( Goldman, M; Itri, L; Lyver, A; Rader, M; Schwartz, EL; Wadler, S; Weinberg, V; Wiernik, PH; Zimmerman, M, 1989) |
| "27 patients with advanced colorectal cancer were treated in a phase-II trial with high dose sequential methotrexate (MTX), 5-fluorouracil (5-FU), and folinic acid (FA)." | 3.67 | Sequential high dose methotrexate, 5-fluorouracil and folinic acid does not improve response rates in advanced colorectal cancer. ( Flechtner, H; Heim, ME; Queisser, W; Schuster, D; Worst, P, 1989) |
| "Two trials of leucovorin (LV) and 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer were done, both using a 3-day loading dose and then weekly doses to minimize toxicity." | 3.67 | Clinical experience with leucovorin and 5-fluorouracil. ( Brenckman, WD; Collier, M; Duch, DS; Ferone, R; Knick, VB; Laufman, LR; Morgan, ED; Mullin, R; Stydnicki, KA, 1989) |
| "Favorable results have been reported for the treatment of advanced colorectal cancer with the combination of 5-fluorouracil (5-FU) and leucovorin (LV)." | 3.67 | Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. ( Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1989) |
| "A total of 24 patients with advanced colorectal adenocarcinoma were entered into a phase I-II study of 5-fluorouracil (5-FU) and cisplatin, 21 of whom had previously received 5-FU." | 3.67 | Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma. ( Creaven, PJ; Herrera, L; Madejewicz, S; Mittelman, A; Petrelli, NJ; Plager, J; Rustum, Y; Soloman, J, 1989) |
| "Following the observation of antitumor activity for the combination of 5-fluorouracil (5-FU) and cisplatin in metastatic colorectal carcinoma, the combination of 5-FU and iproplatin was tested, also in colorectal carcinoma, in the hope of attaining equivalent activity without the nephrotoxicity observed with 5-FU/cisplatin." | 3.67 | Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma. ( Creaven, PJ; Herrera, L; Mittelman, A; Petrelli, NJ, 1989) |
| "The concentration of Tegafur, 5-FU and Uracil in tumor and normal tissue were measured in 47 colorectal cancer patients who had been administered UFT (400/mg) for seven days before operation." | 3.67 | [Pre- and post-operative adjuvant chemotherapy of colorectal cancer. Part 1. Drug concentration in tissues following UFT administration]. ( Eida, K; Fukuda, Y; Hirano, T; Ishii, T; Kotake, Y; Kusano, H; Nakagoe, T; Shimizu, T; Shimoyama, T; Tomita, M, 1988) |
| "An enhanced antineoplastic effect of 5-fluorouracil in patients with advanced colorectal cancer has been produced either by combination with folinic acid or administration by continuous infusion." | 3.67 | High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. ( Cady, J; De Gramont, A; Demuynck, B; Gonzalez-Canali, G; Grange, JD; Krulik, M; Lagadec, B; Loiseau, JP; Louvet, C; Maisani, JE, 1988) |
| "In metastatic colorectal cancer (mCRC), ETS gains relevance as an early available surrogate for patient survival." | 3.30 | Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306. ( D'Anastasi, M; Decker, T; Gesenhues, AB; Heinemann, V; Heintges, T; Hesse, N; Hofmann, FO; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Link, H; Modest, DP; Moehler, M; Scheithauer, W; Stintzing, S; von Weikersthal, LF, 2023) |
| " This Phase I/II study examined the toxicity and efficacy of high-dose pulsed AZD8931, an EGFR/HER2/HER3 inhibitor, combined with chemotherapy, in metastatic colorectal cancer (CRC)." | 3.30 | PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer. ( Barber, PR; Forsyth, S; Gao, F; Hackett, LD; Hartley, JA; Hochhauser, D; Lopes, A; Lowe, HL; Ng, TT; Pearce, S; Propper, DJ; Sarker, D; Saunders, MP; Spanswick, VJ; Weitsman, GE; White, L, 2023) |
| "In metastatic colorectal cancer (mCRC), the role of Trop-2 and Nectin-4 has been poorly investigated." | 3.30 | Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development. ( Bergamo, F; Conca, V; Cremolini, C; Di Donato, S; Fanotto, V; Fontanini, G; Germani, MM; Giordano, M; Latiano, TP; Lonardi, S; Masi, G; Moretto, R; Niccoli, C; Passardi, A; Pietrantonio, F; Prisciandaro, M; Proietti, A; Tamburini, E; Ugolini, C; Zaniboni, A, 2023) |
| "In clinical trials, the assessment of safety is traditionally focused on the overall rate of high-grade and serious adverse events (AEs)." | 3.30 | Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials. ( Boccaccino, A; Bustreo, S; Carullo, M; Clavarezza, M; Cremolini, C; Cupini, S; Daniel, F; Libertini, M; Lonardi, S; Morano, F; Niger, M; Palermo, F; Pietrantonio, F; Procaccio, L; Raimondi, A; Rossini, D; Santini, D; Tomasello, G; Zaniboni, A, 2023) |
| " Safety endpoints were rates of any grade and grade 3/4 adverse events during maintenance therapy." | 3.30 | Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212 ( Alig, AHS; Caca, K; Fruehauf, S; Goekkurt, E; Graeven, U; Haas, S; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; König, AO; Kretzschmar, A; Kurreck, A; Modest, DP; Mueller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023) |
| "The prognosis of mCRC (metastatic colorectal cancer) patients with RAS mutation is poor and capecitabine and oxaliplatin (CapeOx) plus bevacizumab has shown to be one of the standard therapeutic regimens as first line for these patients with objective response rate (ORR) of ~ 50% and median progression-free survival (mPFS) of 8-9 months." | 3.30 | Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study. ( Ding, K; Dong, C; Fang, X; Hu, H; Li, J; Liao, X; Sun, L; Wang, J; Weng, S; Xiao, Q; Xu, D; Yuan, Y; Zhang, S; Zhong, C, 2023) |
| "Main eligibility criteria are colorectal cancer, unresectable liver metastasis, no extra-hepatic metastases except pulmonary nodules if ≤3 and <10 mm, ECOG performance status 0 or 1." | 3.11 | Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. ( Audemar, F; De Baere, T; Ducreux, M; Gallois, C; Khemissa Akouz, F; Lapuyade, B; Lecaille, C; Lepage, C; Louafi, S; Mineur, L; Monterymard, C; Pellerin, O; Pernot, S; Simon, M; Smith, D; Taieb, J; Thirot-Bidault, A; Tougeron, D, 2022) |
| "Mebendazole was well tolerated and its addition to bevacizumab and FOLFOX4 enhanced tumor response to treatment which was translated by significant improvement of overall response rate 12 weeks after intervention [10 % (2) versus 65% (13) for control and mebendazole groups, respectively; p = 0." | 3.11 | Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. ( El-Azab, GA; El-Ghoneimy, RA; Hegazy, SK; Mostafa, MF; Zakaria, F, 2022) |
| " Patient characteristics were evaluated with multiple regression analyses for survival outcomes, using the Cox proportional hazard model and linear regression analyses for the worst grade of adverse events." | 3.11 | Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years. ( Amagai, K; Bando, Y; Denda, T; Endo, S; Hatachi, Y; Hyodo, I; Ikezawa, K; Ishida, H; Kobayashi, K; Kuramochi, H; Morimoto, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Sakai, Y; Sato, M; Shimada, M; Tsuji, A; Yamamoto, Y, 2022) |
| "This multicenter single-arm, phase II study evaluated the efficacy and safety of uninterrupted panitumumab usage combined with cytotoxic doublets for unresectable/metastatic colorectal cancer (mCRC)." | 3.11 | Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA. ( Akazawa, N; Ando, T; Hirata, K; Kagawa, Y; Kato, T; Maeda, H; Mishima, H; Nagasaka, T; Nagata, N; Oba, K; Sakamoto, J; Shiozawa, M; Watanabe, J; Yamada, T; Yokota, M, 2022) |
| "This study aimed to investigate the effect of the mFOLFOX6 regimen combined with SHR-1210 on immune function and prognosis in patients with microsatellite instability CRC." | 3.11 | Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer. ( Lu, P; Sun, J; Wang, Y; Yao, N, 2022) |
| "44 patients with metastatic colorectal cancer were enrolled in this study." | 3.11 | Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study). ( Fukazawa, A; Hasegawa, S; Hirata, K; Koda, K; Kosugi, C; Kuramochi, H; Matsuda, A; Matsuoka, H; Ohta, R; Otsuka, T; Sakamoto, K; Sonoda, H; Takahashi, M; Watanabe, T; Yamada, T; Yoshida, H; Yoshida, Y, 2022) |
| "The outcomes of treatment of metastatic colorectal cancer (mCRC) is still unsatisfactory." | 3.11 | Triplet (FOLFOXIRI) Versus Doublet (FOLFOX or FOLFIRI) Regimen as First Line Treatment in Metastatic Colorectal Carcinoma, a Prospective Phase II, Randomized Controlled Trial. ( Hassan, MA; Khalil, KA; Mahmoud, IA; Musallam, HS, 2022) |
| " Patients exhibiting EWL had worse survival and higher frequencies of adverse events." | 3.11 | Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). ( Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF, 2022) |
| "To overcome this problem, patients with colorectal cancer are treated with chemotherapy for a short time, followed by a less aggressive maintenance regimen of the chemotherapy drug 5-fluorouracil and the targeted therapy drug bevacizumab." | 3.01 | Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. ( Cui, K; Gurary, EB; Kim, TW; Lerman, N; Taieb, J; Yoshino, T, 2021) |
| "The treatment of colorectal cancer (CRC) has evolved and become more personalized during the past several years." | 3.01 | Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review. ( Damato, A; Dottorini, L; Ghidini, A; Ghidini, M; Iaculli, A; Luciani, A; Petrelli, F; Tomasello, G, 2023) |
| "The incidence of chemotherapy-related adverse events in colorectal cancer patients with renal insufficiency has been compared to patients with normal renal function in only a few studies." | 3.01 | Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials. ( Aoyama, T; Honda, M; Kanda, M; Kashiwabara, K; Maeda, H; Mayanagi, S; Muto, M; Oba, K; Sakamoto, J; Tanaka, K; Yamagishi, H; Yoshikawa, T, 2023) |
| "The meta-analysis aimed to assess the clinical efficacy of chemotherapeutic triplet-drug regimen combined with anti-EGFR antibody in patients with initially unresectable metastatic colorectal cancer (mCRC)." | 3.01 | Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis. ( Dong, W; Jiang, T; Jiang, X; Li, H; Li, Y; Lv, Y; Tian, M; Xiao, J; Yin, Z; Zeng, J, 2023) |
| "Capecitabine (Cape) is an oral prodrug of the antimetabolite 5-fluorouracil." | 3.01 | Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer. ( Ali, A; Daily, KC; Dang, LH; George, TJ; Iqbal, A; Ivey, AM; Lee, JH; Ramnaraign, BH; Read, TE; Tan, SA; Terracina, KP; Wang, Y, 2021) |
| " In this phase II study, we prospectively analyzed the efficacy and safety of raltitrexed combined with S-1 (RS regimen) in the treatment of mCRC after the failure of conventional chemotherapy." | 3.01 | A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer. ( Chen, Z; Guo, W; Huang, M; Li, W; Qiu, L; Wang, C; Wang, Y; Yang, Y; Zhang, W; Zhang, X; Zhang, Z; Zhao, X; Zhu, X, 2021) |
| " Efficacy endpoints were progression-free survival (PFS), overall survival (OS) and overall response rate (ORR); safety endpoints were rates of any grade and grade 3/4 adverse events (AEs)." | 3.01 | Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. ( Amatu, A; Antoniotti, C; Berenato, R; Clavarezza, M; Corallo, S; Di Bartolomeo, M; Di Maio, M; Fucà, G; Leone, AG; Lonardi, S; Morano, F; Murialdo, R; Pietrantonio, F; Raimondi, A; Ratti, M; Ritorto, G; Smiroldo, V; Tampellini, M; Zaniboni, A, 2021) |
| " The secondary endpoints were chronic cumulative neurotoxicity (EORTC QLQ-CIPN20), time to grade 2 neurotoxicity (NCI-CTCAE or the oxaliplatin-specific neuropathy scale), acute neurotoxicity (analog scale), rates of dose reduction or withdrawal due to OIPN, 3-year disease-free survival (DFS) and adverse events." | 2.94 | Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. ( Chen, G; Deng, YH; Ding, PR; Fan, WH; Feng, F; Jin, Y; Li, YH; Liang, HL; Lu, ZH; Peng, JW; Ren, C; Shi, SM; Wang, DS; Wang, F; Wang, FH; Wang, W; Wang, ZQ; Xie, CB; Xu, RH; Zhang, JW, 2020) |
| "Chemotherapy in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy is under debate." | 2.94 | Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). ( Fukunaga, M; Ide, Y; Ikumoto, T; Iwamoto, S; Kanazawa, A; Kato, T; Konishi, K; Kotaka, M; Kudo, T; Kurata, T; Sakai, D; Sano, Y; Satake, H; Satoh, T; Sugimoto, N; Tomita, N; Tsuji, A; Yamanaka, T, 2020) |
| " In 15 patients (40%) 21 serious adverse events related to debulking were reported." | 2.94 | Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer. ( Bakkerus, L; Buffart, TE; de Groot, JB; Gootjes, EC; Grunhagen, DJ; Haasbeek, CJA; Hendriks, MP; Labots, M; Meijerink, MR; Nuyttens, JJME; Ten Tije, AJ; Tuynman, JB; van de Ven, PM; van der Stok, EP; van Meerten, E; Verheul, HMW; Verhoef, C; Zonderhuis, BM, 2020) |
| "A total of 137 patients with advanced colorectal cancer were recruited." | 2.94 | The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer. ( Chang, L; Fu, X; Han, G; Han, Z; Hui, D; Jia, R; Li, Q; Li, Y; Liu, H; Liu, N; Zhang, H; Zhang, Y; Zhu, H, 2020) |
| "AtezoTRIBE is a prospective, open label, phase II, comparative trial in which initially unresectable and previously untreated mCRC patients, irrespective of microsatellite status, are randomized in a 1:2 ratio to receive up to 8 cycles of FOLFOXIRI/bevacizumab alone or in combination with atezolizumab, followed by maintenance with bevacizumab plus 5-fluoruracil/leucovorin with or without atezolizumab according to treatment arm until disease progression." | 2.94 | AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. ( Antoniotti, C; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Brunella, DS; Corallo, S; Cremolini, C; Falcone, A; Grassi, E; Lonardi, S; Marmorino, F; Morano, F; Moretto, R; Pietrantonio, F; Racca, P; Rossini, D; Salvatore, L; Tamberi, S; Tamburini, E; Tortora, G, 2020) |
| " with mCRC RAS/BRAF mutated, in first line will receive nivolumab in combination with FOLFOXIRI/bevacizumab every 2 weeks for 8 cycles followed by maintenance with bevacizumab plus nivolumab every 2 weeks." | 2.94 | Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018). ( Antonuzzo, L; Bergamo, F; Berselli, A; Bordonaro, R; Damato, A; Iachetta, F; Maiello, E; Nasti, G; Normanno, N; Pinto, C; Romagnani, A; Tonini, G; Zaniboni, A, 2020) |
| "gov, NCT01506167) that recruited patients with metastatic colorectal cancer scheduled to receive bevacizumab in combination with first-line chemotherapy as part of routine clinical practice." | 2.90 | ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. ( Baijal, S; Chau, I; Cunningham, D; Ellis, R; Harrison, M; Khakoo, S; Ograbek, A; Pedley, I; Raouf, S; Ross, P; Steward, W; Tahir, S, 2019) |
| " The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs)." | 2.90 | Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. ( Allegrini, G; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Buonadonna, A; Cordio, S; Cremolini, C; Dell'Aquila, E; Falcone, A; Latiano, TP; Libertini, M; Lonardi, S; Marmorino, F; Masi, G; Moretto, R; Passardi, A; Pella, N; Randon, G; Ratti, M; Ricci, V; Ronzoni, M; Rossini, D; Tamburini, E; Urbano, F; Zucchelli, G, 2019) |
| " Overall, grade 3 adverse events, such as leukopenia and neutropenia, were observed in two of three patients (66." | 2.90 | Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. ( Emoto, S; Hata, K; Hiyoshi, M; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Shuno, Y; Tanaka, T, 2019) |
| "Simvastatin 80 mg tablets were taken orally once daily every day during the period of chemotherapy." | 2.90 | A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. ( Ahn, JB; Han, SW; Kang, WK; Kim, ST; Kim, TW; Kim, Y; Lee, J; Lim, HY; Park, JO; Park, YS, 2019) |
| "Metastatic colorectal cancer (mCRC) has low survival rates." | 2.90 | A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. ( Beck, JT; Berlin, JD; Cubillo Gracian, A; Deming, DA; Elez Fernandez, E; Garcia-Alfonso, P; Gorbunova, V; Hofheinz, RD; Luo, Y; Mangel, L; Nechaeva, M; Ramanathan, RK; Sullivan, D; Torres, AH, 2019) |
| "Dose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition." | 2.90 | Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. ( Aikawa, T; Akashi, K; Ariyama, H; Baba, E; Doi, Y; Esaki, T; Ito, M; Kobayashi, K; Kusaba, H; Makiyama, A; Mitsugi, K; Shimokawa, H; Takayoshi, K; Tsuchihashi, K; Uenomachi, M; Yoshihiro, T, 2019) |
| " As for the biomarkers, carcinoembryonic antigen and lactate dehydrogenase (LDH) smoothly declined immediately after the initial dosing in patients with a partial response or stable disease." | 2.90 | Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study). ( Hirata, K; Hotta, Y; Imasato, M; Ishibashi, K; Iwamoto, S; Maeda, H; Makiyama, A; Mishima, H; Morita, S; Morita, Y; Munemoto, Y; Nagasaka, T; Nagata, N; Sakamoto, J; Takemoto, H; Tanaka, C; Toyofuku, A; Yoshida, Y, 2019) |
| "Metastatic colorectal cancer (mCRC) is a heterogeneous disease where prognosis is dependent both on tumor biology and host factors." | 2.90 | Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. ( Dajani, O; Glimelius, B; Guren, TK; Hamfjord, J; Johansen, JS; Kure, EH; Lingjærde, OC; Pallisgaard, N; Pfeiffer, P; Sorbye, H; Spindler, KG; Tveit, KM, 2019) |
| " Treatment-emergent adverse events (TEAEs) were evaluated, and HRQL was assessed at baseline, cycle 3, and every other cycle using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-CR29, and EuroQol 5-Dimensions 3-Levels questionnaires (NCT01571284)." | 2.90 | Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). ( Aparicio, J; Bordonaro, R; Bury, D; Chau, I; Cicin, I; Di Bartolomeo, M; Drea, E; Fedyanin, MY; García-Alfonso, P; Heinemann, V; Karthaus, M; Kavan, P; Ko, YJ; Maiello, E; Martos, CF; Peeters, M; Picard, P; Riechelmann, RP; Sobrero, A; Srimuninnimit, V; Ter-Ovanesov, M; Yalcin, S, 2019) |
| "For stage II/Dukes B colorectal cancer (CRC), clinical biomarkers are urgently required to direct therapeutic options." | 2.87 | Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. ( Gray, R; Handley, K; Hutchins, GGA; Kerr, D; Magill, L; Quirke, P; Seymour, M; Southward, K; Tinkler-Hundal, E; Treanor, D; Wright, A, 2018) |
| "Metastatic colorectal cancer frequently occurs in elderly patients." | 2.87 | Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. ( Aparicio, T; Baconnier, M; Bedenne, L; Bouché, O; El Hajbi, F; Etienne, PL; Faroux, R; François, E; Genet, D; Khemissa Akouz, F; Kirscher, S; Lavau-Denes, S; Lecomte, T; Locher, C; Maillard, E; Oden-Gangloff, A; Paillaud, E; Retornaz, F; Rinaldi, Y; Taieb, J, 2018) |
| "The actual resection rate of metastases was significantly associated with treatment setting (P = 0." | 2.87 | Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. ( Becker, T; Bemelmans, M; Bruns, CJ; Denecke, T; Folprecht, G; Gebauer, B; Heinemann, V; Held, S; Lang, H; Modest, DP; Modest, HI; Neumann, UP; Pratschke, J; Rentsch, M; Ricard, I; Seehofer, D, 2018) |
| "Acne-like skin rash is a frequently occurring adverse event associated with drugs against the epidermal growth factor receptor." | 2.87 | EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. ( Al-Batran, SE; Ettrich, TJ; Feustel, HP; Heeger, S; Hofheinz, RD; Homann, N; Kripp, M; Lorenzen, S; Merx, K; Ocvirk, J; Schatz, M; Schulte, N; Schulz, H; Tetyusheva, M; Trojan, J; Vlassak, S, 2018) |
| "The primary end point was the 10-month progression-free rate (PFR); secondary end points included progression-free and overall survival, response rate, rate of metastases resection, and adverse events." | 2.87 | Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. ( Antoniotti, C; Aprile, G; Bergamo, F; Boni, L; Cardellino, GG; Coltelli, L; Corsi, DC; Cremolini, C; Dell'Aquila, E; Di Fabio, F; Falcone, A; Fontanini, G; Gemma, D; Grande, R; Lonardi, S; Lupi, C; Mancini, ML; Marcucci, L; Marmorino, F; Masi, G; Mescoli, C; Ronzoni, M; Salvatore, L; Tonini, G; Zagonel, V, 2018) |
| " A prospective clinical trial was designed to evaluate the efficacy and safety of fluorouracil monotherapy combined with panitumumab administered to patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) intolerant to oxaliplatin and irinotecan." | 2.87 | A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial. ( Denda, T; Fukunaga, M; Kanda, M; Kataoka, M; Kim, HM; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Sakamoto, J; Takano, N; Takemoto, H; Tokunaga, Y, 2018) |
| " Patients were randomly assigned (1:1) to either BEVZ92 or reference bevacizumab (5 mg/kg on day 1 of each cycle every 2 weeks) in combination with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or fluorouracil, leucovorin, and irinotecan (FOLFIRI)." | 2.87 | Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. ( Abdalla, KC; Bondarenko, I; Del Campo García, A; Franke, F; Huerga, C; Melo Cruz, F; Mendonça Bariani, G; Millán, S; Ostwal, V; Paravisini, A; Peredpaya, S; Rahuman, SA; Ramesh, A; Roca, E; Romera, A; Shah, P; Shparyk, Y, 2018) |
| "From January 2011 to January 2016, 696 colorectal cancer patients were enrolled in this study: 341 patients were randomly assigned to the intraoperative chemotherapy, which consist of portal vein chemotherapy, intraluminal chemotherapy and intraperitoneal chemotherapy, plus surgery group, whereas 344 patients were randomized to the control group to undergo surgery alone." | 2.84 | Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC). ( Chen, G; Ding, PR; Fan, WH; Huang, JQ; Jiang, W; Ke, CF; Kong, LH; Lei, J; Li, C; Li, LR; Lin, JZ; Liu, Q; Lu, ZH; Pan, ZZ; Wan, DS; Wang, FL; Wu, XJ; Zhang, RX; Zhou, WH, 2017) |
| "Several predictors of metastatic colorectal cancer (mCRC) outcomes have been described." | 2.84 | Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. ( Aparicio, T; Auby, D; Bachet, JB; Bouché, O; Boulat, O; Breysacher, G; Cretin, J; Faroux, R; Gargot, D; Gasmi, M; Genet, D; Jouve, JL; Khemissa, F; Lecomte, T; Lepère, C; Locher, C; Maillard, E; Mitry, E; Ramdani, M; Seitz, JF; Sobhani, I; Stefani, L; Teillet, L, 2017) |
| "Cetuximab-induced skin rash Gd3+ occurs in ≥16% patients (pts) (Heinemann et al." | 2.84 | Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. ( Boller, E; Dingeldein, G; Ehscheidt, P; Flohr, T; Galle, PR; Geer, T; Göhler, T; Hebart, H; Heike, M; Indorf, M; Josten, KM; Karthaus, M; Lang, C; Moehler, M; Neise, M; Rudi, J; Schimanski, CC; Schmittel, A; Staib, F; Wierecky, J; Wörns, MA, 2017) |
| "One-hundred twenty-seven patients were randomly assigned to parsatuzumab, 400 mg, or placebo, in combination with mFOLFOX6 plus bevacizumab, 5 mg/kg." | 2.84 | Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. ( Anderson, M; Argiles, G; Braiteh, F; Chang, I; Chen, D; Funke, R; García-Carbonero, R; Gore, I; Hegde, P; Hurwitz, H; Jassem, J; McCall, B; Rhee, I; Rivera, F; Stroh, M; Tebbutt, N; van Cutsem, E; Wainberg, ZA; Wakshull, E; Ye, W, 2017) |
| "Doublet or triplet chemotherapy regimens in combination with anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mAb), such as cetuximab or panitumumab, or the anti-vascular endothelial growth factor mAb bevacizumab, are the current recommended standard of care therapies for unresectable metastatic colorectal cancer (mCRC)." | 2.82 | Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. ( Cremolini, C; Esser, R; Falcone, A; Folprecht, G; Martinelli, E; Mazard, T; Modest, DP; Tsuji, A, 2022) |
| "Aflibercept in combination with FOLFIRI chemotherapy is an established safe and efficacious regimen for the treatment of mCRC as second-line chemotherapy." | 2.82 | Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. ( Chau, I; Lau, DK; Mencel, J, 2022) |
| "The treatment of colorectal cancer liver metastases has seen significant improvement in recent years and, for certain patients, the long-term survival and even cure are possible." | 2.82 | Chemotherapy in resectable or potentially resectable colon cancer with liver metastases. ( Naher, SK; Samoon, Z; Sjoquist, KM; Zalcberg, J, 2022) |
| "Many studies have determined colorectal cancer chemoresistance mechanisms such as drug efflux, cell cycle arrest, DNA damage repair, apoptosis, autophagy, vital enzymes, epigenetic, epithelial-mesenchymal transition, stem cells, and immune system suppression." | 2.82 | MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil. ( Gazouli, M; Lampropoulou, DI; Nemati, M; Pouya, FD; Rasmi, Y, 2022) |
| "Metastatic colorectal cancer (mCRC) frequently occurs in elderly patients." | 2.82 | Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). ( Adhoute, X; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Breysacher, G; Charneau, J; Chone, L; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Khemissa, F; Lavau-Denes, S; Lecomte, T; Legoux, JL; Lepère, C; Locher, C; Maillard, E; Michel, P; Mitry, E; Phelip, JM; Provençal, J; Sobhani, I, 2016) |
| " A nonrandomized phase 1 dose-escalation study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conducted to define the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics in patients with advanced colorectal cancer." | 2.82 | Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer. ( Dasari, A; Donehower, RC; He, P; Hidalgo, M; Jimeno, A; Jin, R; Laheru, D; Messersmith, WA; Purcell, WT; Rudek, MA; Taylor, GE; Walker, R, 2016) |
| "Patients with liver-only metastatic colorectal cancer (mCRC) who are not candidates for potentially curative resection may become resectable with more aggressive chemotherapy regimens." | 2.82 | A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only. ( Bendell, JC; Boccia, R; Earwood, C; Gian, V; Lane, CM; Lipman, A; LoCicero, R; Meluch, A; Moskowitz, M; Peyton, JD; Waterhouse, D; Zakari, A, 2016) |
| " This study aimed to evaluate the drug safety and tolerability of continuous intravenous infusion (CIV) of endostar in combination with modified FOLFOX6 (mFOLFOX6) as an initial therapy in advanced colorectal cancer patients." | 2.80 | Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. ( Cao, J; Chen, Z; Guo, W; Ji, D; Li, J; Li, W; Lv, F; Qiu, L; Wang, J; Xia, Z; Zhang, S; Zhang, W, 2015) |
| "Sleep disorders are prevalent in patients with advanced cancer." | 2.80 | Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer. ( Bjarnason, GA; Giacchetti, S; Innominato, PF; Lévi, F; Palesh, O; Spiegel, D; Ulusakarya, A, 2015) |
| "We assessed circulating tumor cells (CTCs) as a prognostic biomarker in patients treated with a 4-drug regimen." | 2.80 | Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. ( Ashcroft, L; Backen, A; Beech, J; Chau, I; Dive, C; Gollins, S; Hasan, J; Krebs, MG; Morris, K; Renehan, AG; Saunders, MP; Valle, JW, 2015) |
| " No difference in other treatment toxicity was observed between the two groups, and patients exhibited high compliance in dosing administration." | 2.80 | Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. ( Aoyama, T; Kataoka, M; Kono, T; Matsuda, C; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Oshiro, M; Sakamoto, J, 2015) |
| " All patients experienced at least one grade 3 or higher adverse event: neutropenia (five patients, 83%), proteinuria (two patients; 33%) and anemia, thrombocytopenia and hypertension (one patient each, 17%)." | 2.80 | Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. ( Gao, L; Gotoh, M; Nasroulah, F; Ohtsu, A; Yamazaki, K; Yoshino, T; Yoshizuka, N, 2015) |
| "Mucositis was the most common dose-limiting toxicity." | 2.80 | A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors. ( Evande, RE; Grem, JL; Kos, ME; Meza, JL; Schwarz, JK, 2015) |
| " Despite heterogeneity in response to aflibercept, no biomarkers for efficacy or adverse effects have been identified." | 2.80 | Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. ( Chiron, M; Folprecht, G; Lambrechts, D; Margherini, E; Moisse, M; Pericay, C; Peuteman, G; Sagaert, X; Thienpont, B; Thuillier, V; Van Cutsem, E; Zalcberg, J; Zilocchi, C, 2015) |
| " Then the recovery time of bowel function, the incidence of adverse reactions and complications, and the pre- and post-chemotherapy routine blood tests and hepatorenal functions were compared." | 2.80 | [Safety evaluation of intraoperative peritoneal chemotherapy with Lobaplatin for advanced colorectal cancers]. ( Feng, L; Liu, Q; Liu, Y; Wu, X; Xia, D; Xu, L, 2015) |
| "Surgical excision of colorectal cancer at early clinical stages is highly effective, but 20-30% of patients relapse." | 2.79 | Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. ( Artl, M; Balic, M; Böhm, G; Dandachi, N; Dietze, O; Filipits, M; Gnant, M; Graf, R; Greil, R; Heitzer, E; Hofbauer, F; Höfler, G; Lax, S; Resel, M; Samonigg, H; Schaberl-Moser, R; Weißenbacher, B; Wrba, F, 2014) |
| "Twenty-one Japanese colorectal cancer patients received intravenous FOLFIRI (bolus irinotecan, folinic acid, and fluorouracil followed by 46-hour fluorouracil infusion) followed by bevacizumab (5 mg/kg) in Cycle 1." | 2.79 | Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ( Doi, T; Fuse, N; Hamamoto, Y; Hatake, K; Iwasaki, J; Matsumoto, H; Mizunuma, N; Motomura, S; Ohtsu, A; Suenaga, M; Yamaguchi, T; Yamanaka, Y, 2014) |
| "An IO dosing schedule had a significant benefit on both TTF and TTP versus CO dosing in this trial despite the very attenuated sample." | 2.79 | Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. ( Alberts, S; Ansari, R; Childs, BH; Chowhan, N; Grothey, A; Hainsworth, JD; Hart, L; Hochster, HS; Keaton, M; Ramanathan, RK; Rowland, K, 2014) |
| " The most frequent grade 3-4 adverse events included neutropenia (grade 3: 33." | 2.79 | An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. ( Asmis, TR; Ayoub, JP; Ballal, S; Cervantes, A; Garcia-Carbonero, R; Maurel, J; Moore, MJ; Nasroulah, F; Rivera, F; Schwartz, JD; Tabernero, J, 2014) |
| "Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments." | 2.79 | Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. ( Adams, R; Butler, R; Fisher, D; Kaplan, R; Lowdell, C; Madi, A; Maughan, T; Meade, AM; Middleton, G; Pugh, C; Sizer, B; Sydes, B; Wasan, H; Wilson, R, 2014) |
| "Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years." | 2.79 | Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. ( Bowers, M; Bridgewater, J; Butler, R; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Little, L; Maughan, T; O'Reilly, D; Peterson, M; Primrose, J; Pugh, S; Rees, M; Siriwardena, A; Stanton, L; Valle, J, 2014) |
| "Over 50% of colorectal cancer (CRC) patients develop metastases." | 2.79 | FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. ( Aitouferoukh, S; Béchade, D; Bécouarn, Y; Beyssac, R; Brunet, R; Cany, L; Fonck, M; Lalet, C; Le Morvan, V; Mathoulin-Pélissier, S; Pulido, M; Robert, J; Texereau, P, 2014) |
| "The aim of this study was the evaluation of pharmacokinetic parameters, biomarkers, clinical outcome, and imaging parameters in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI plus sunitinib." | 2.79 | FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. ( Büchert, M; Burkholder, I; Jaehde, U; Kanefendt, F; Kuhlmann, J; Moritz, B; Mross, K; Scheulen, M; Sörgel, F; Strumberg, D, 2014) |
| "Pharmacokinetically guided (PK-guided) versus body surface area-based 5-fluorouracil (5-FU) dosing results in higher response rates and better tolerability." | 2.79 | A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. ( Atluri, PM; Chay, CH; Deal, AM; Ibrahim, JG; Inzerillo, JJ; McLeod, HL; O'Neil, BH; Olajide, OA; Patel, JN; Sherrill, GB; Walko, CM, 2014) |
| "A total of 18 patients, 14 with colorectal cancer and 4 with pancreatic cancer, were included in this study." | 2.79 | Oxaliplatin and ototoxicity: is it really safe for hearing? ( Babacan, NA; Doğan, M; Kaçan, T; Kiliçkap, S; Koç, S; Seker, MM; Uysal, IO; Yüce, S, 2014) |
| " The most commonly reported adverse events in the FOLFOX6 cohorts included decreased appetite, neutropenia, diarrhea, peripheral neuropathy, and vomiting." | 2.78 | An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. ( Adams, LM; Botbyl, J; Brady, J; Chau, I; Corrie, P; Digumarti, R; Laubscher, KH; Mallath, M; Midgley, RS, 2013) |
| " We evaluated the efficacy and safety of conatumumab (an agonistic monoclonal antibody against human death receptor 5) and ganitumab (a monoclonal antibody against the type 1 insulin-like growth factor receptor) combined with standard FOLFIRI chemotherapy as a second-line treatment in patients with mutant KRAS mCRC." | 2.78 | A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. ( Choo, SP; Chuah, BYS; Cohn, AL; Cottrell, S; Dubey, S; Galimi, F; Hei, YJ; Kopp, MV; Loberg, R; Maurel, J; McCaffery, I; Mitchell, EP; Nowara, E; Pan, Y; Sakaeva, DD; Sastre, J; Suzuki, S; Tabernero, J, 2013) |
| "We compared the results of stage IV colorectal cancer patients treated within a large Dutch phase III trial (CAIRO), in which standard chemotherapy and standard safety eligibility criteria were used, to patients treated outside the trial during the trial accrual period in a representative selection of 29 Dutch hospitals." | 2.78 | Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. ( Koopman, M; Mol, L; Ottevanger, PB; Punt, CJ; van Gils, CW, 2013) |
| "Fluorouracil dose was reduced to 2400 mg/m² after two of the first three patients reported grade 3-4 diarrhoea (in one case with febrile neutropenia)." | 2.78 | FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). ( Aprile, G; Bergamo, F; Bracarda, S; Cremolini, C; Falcone, A; Fontanini, G; Fornaro, L; Lonardi, S; Loupakis, F; Lupi, C; Masi, G; Morvillo, M; Salvatore, L; Schirripa, M; Sensi, E; Vivaldi, C; Zagonel, V; Zaniboni, A, 2013) |
| " We present the treatment rationale and protocol for an ongoing randomized multicenter placebo-controlled phase II study designed to evaluate the efficacy and safety of MetMAb combined with bevacizumab and mFOLFOX-6 (5-fluoruracil, leucovorin, and oxaliplatin)." | 2.78 | Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. ( Bendell, JC; Ervin, TJ; Gallinson, D; Hack, SP; Phan, SC; Saleh, MN; Singh, J; Vallone, M; Wallace, JA, 2013) |
| "A single-center colorectal cancer database was queried for c-stage II-III rectal cancer patients undergoing neoadjuvant chemoradiation followed by proctectomy between 1997 and 2007." | 2.78 | Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think! ( Buta, M; de Campos-Lobato, LF; de Sousa, JB; Dietz, DW; Fazio, VW; Kalady, MF; Lavery, IC; Stocchi, L, 2013) |
| "Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy." | 2.78 | Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. ( Barugel, M; Bodoky, G; Burkes, R; Błasińska-Morawiec, M; Canon, JL; Cunningham, D; Douillard, JY; Humblet, Y; Jassem, J; Kocákova, I; Oliner, KS; Patterson, SD; Rivera, F; Rong, A; Rother, M; Ruff, P; Sidhu, R; Siena, S; Šmakal, M; Tabernero, J; Wiezorek, J; Williams, R, 2013) |
| "The study objectives were to evaluate the safety, tolerability, and preliminary efficacy of multiple doses of dulanermin in combination with modified FOLFOX6 and bevacizumab in previously untreated patients with locally advanced, recurrent, or metastatic colorectal cancer." | 2.78 | A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. ( Ashkenazi, A; Kapp, AV; Kozloff, MF; Messersmith, WA; Peddi, PF; Portera, CC; Royer-Joo, S; Wainberg, ZA, 2013) |
| " The severity of OPN was assessed according to the Common Toxicity Criteria for Adverse Events at baseline, every 2 weeks until the 8th cycle, and every 4 weeks thereafter until the 26th week." | 2.78 | Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy. ( Fukunaga, M; Hata, T; Kojima, H; Kono, T; Matsui, T; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Sakamoto, J; Shimada, M; Takemoto, H, 2013) |
| "Thirty-six metastatic colorectal cancer patients received every 2 weeks, as first- (17) or second-line (19) treatment a combined chronotherapy with CPT-11 (infused at day 1 from 2 to 8 a." | 2.78 | Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report ( Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2013) |
| " This phase I study aimed to assess the maximal tolerated dose (MTD) of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer and to identify pharmacokinetic (PK) interactions and toxicities." | 2.78 | A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer. ( Copeman, M; Gibbs, P; Gouillou, M; Jefford, M; Lipton, L; Lynch, K; McArthur, G; Michael, M; Tebbutt, NC; Zalcberg, J, 2013) |
| "This prospective observational study assessed the efficacy of bevacizumab in combination with chemotherapy as preoperative treatment to downsize tumours for radical resection in patients with unresectable metastatic colorectal cancer (mCRC)." | 2.78 | Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma. ( Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J, 2013) |
| " Patients were treated with cetuximab combined with either CAPIRI or CAPOX." | 2.78 | Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. ( Giessen, C; Haas, M; Heinemann, V; Laubender, RP; Mansmann, U; Modest, DP; Schulz, C; Stintzing, S, 2013) |
| "Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signalling with activity against all three VEGF receptors." | 2.78 | Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. ( Cunningham, D; D'Haens, G; Douillard, JY; Robertson, J; Stone, AM; Van Cutsem, E; Wong, RP, 2013) |
| "This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i." | 2.77 | A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ( Aranda, E; Carrato, A; Chau, I; Countouriotis, AM; Cunningham, D; Guillen-Ponce, C; Iveson, TJ; Ramos, FJ; Ruiz-Garcia, A; Saunders, MP; Starling, N; Tabernero, J; Tursi, JM; Vázquez-Mazón, F; Wei, G, 2012) |
| "Cediranib is an oral, highly potent VEGF signaling inhibitor of all three VEGF receptors." | 2.77 | Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. ( Boku, N; Mishima, H; Okamoto, W; Satoh, T; Shi, X; Shimamura, T; Yamaguchi, K; Yamazaki, K, 2012) |
| " We conducted a phase II trial to confirm the pharmacokinetic parameters from 3-Tesla dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as surrogate biomarkers of BV + FOLFIRI regimen efficacy in colorectal cancer with liver metastases." | 2.77 | Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. ( Akiyoshi, K; Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Miyake, M; Nakajima, T; Okita, N; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Tateishi, U; Yamada, Y, 2012) |
| "Cediranib is an oral highly potent VEGF signalling inhibitor that inhibits all three VEGF receptors." | 2.77 | Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. ( Amagai, K; Baba, H; Bando, H; Denda, T; Fukase, K; Hazama, S; Kato, T; Mishima, H; Muro, K; Shi, X; Skamoto, J; Yamaguchi, K, 2012) |
| "We randomly assigned 287 Stage III colorectal cancer patients after curative resection between 2002 and 2008 to receive 2 cycles of HAIC plus 4 cycles of systemic chemotherapy (combined therapy) or 6 cycles of systemic chemotherapy alone (monotherapy)." | 2.77 | Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from Stage III colorectal cancer after curative resection. ( Bao, Y; Feng, WM; Huang, SX; Tang, CW; Tao, YL; Wang, Y; Zheng, YY, 2012) |
| "Up to 25% of patients with metastatic colorectal cancer (CRC) present with peritoneal carcinomatosis (PC) as the only site of metastases." | 2.77 | The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. ( Bertrand, C; Ceelen, W; D'Hoore, A; Fieuws, S; Hompes, D; Kerger, J; Legendre, H; Peeters, M; Van Cutsem, E; Van der Speeten, K, 2012) |
| "KRAS p." | 2.77 | Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis. ( Brodowicz, T; Giessen, C; Heinemann, V; Knittelfelder, R; Laubender, RP; Modest, DP; Reinacher-Schick, A; Schmiegel, W; Stintzing, S; Tannapfel, A; Vrbanec, D; Zielinski, CC, 2012) |
| "Fifty-two patients with advanced colorectal cancer were enrolled in an ancillary pharmacogenetic study of the phase II CETUFTIRI trial." | 2.77 | Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. ( Bennouna, J; Chatelut, E; Douillard, JY; El Hannani, C; Etienne-Grimaldi, MC; Faroux, R; Formento, JL; Francois, E; Francoual, M; Hennebelle, I; Jacob, JH; Milano, G, 2012) |
| "Leucovorin Sodium (LV/Na) has a high solubility, and is stable when given with continuous infusion of 5-FU." | 2.77 | A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. ( Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P, 2012) |
| "As part of a colorectal cancer long-term survivor study (LTS-01), long-term neurotoxicity was assessed in 353 patients on NSABP Protocol C-07 (cross-sectional sample)." | 2.77 | Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. ( Cecchini, RS; Ganz, PA; Kidwell, KM; Ko, CY; Kopec, JA; Land, SR; Wolmark, N; Yothers, G, 2012) |
| "Patients with metastatic colorectal cancer (mCRC) were randomized to XELOX plus bevacizumab using a standard triweekly cycle (Q3W) or a dose-dense biweekly cycle (Q2W) schedule." | 2.77 | A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). ( Cartwright, T; Hu, S; Hurwitz, H; Kwok, A; McKenna, E; Mitchell, EP; Patt, YZ, 2012) |
| "The Maintenance in Colorectal Cancer trial was a phase III study to assess maintenance therapy with single-agent bevacizumab versus bevacizumab plus chemotherapy in patients with metastatic colorectal cancer." | 2.77 | Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. ( Abad, A; Aranda, E; Arrivi, A; Benavides, M; Díaz-Rubio, E; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Maestro, ML; Marcuello, E; Massuti, B; Rivera, F; Sastre, J; Tabernero, JM; Valladares, M; Vidaurreta, M, 2012) |
| " standard body-surface-area (BSA) dosing in a FOLFOX (folinic acid, fluorouracil, oxaliplatin) regimen in metastatic colorectal cancer (mCRC)." | 2.77 | Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ( Asevoaia, A; Boisdron-Celle, M; Capitain, O; Gamelin, E; Morel, A; Poirier, AL, 2012) |
| "In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle." | 2.77 | Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. ( Amler, LC; Baranda, JC; Bayraktar, S; Flores, AM; MacIntyre, J; Montero, A; Portera, C; Raja, R; Rocha Lima, CM; Royer-Joo, S; Stern, H; Wallmark, J, 2012) |
| "One hundred and twenty patients with colorectal cancer at Ruijin Hospital, Shanghai Jiaotong University School of Medicine were randomly assigned to the pure chemotherapy group (as the control group) and the QM + chemotherapy group (as the treatment group), 60 in each group." | 2.77 | [Effects of qisheng mixture on chemotherapy induced myelosuppression in patients with colorectal cancer]. ( Chen, JX; Shen, XH, 2012) |
| " We designed a pilot study in order to explore the optimal dosing period for indisetron during modified FOLFOX6 (mFOLFOX6)." | 2.77 | Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study. ( Asaka, M; Kato, K; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Muto, S; Nakatsumi, H; Oba, K; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2012) |
| " The most frequently observed adverse events reported with AZD6244 were acneiform dermatitis, diarrhoea, asthenia and peripheral oedema, compared with hand-foot syndrome, diarrhoea, nausea and abdominal pain with capecitabine." | 2.76 | A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. ( Adenis, A; Bennouna, J; Boer, K; Douillard, JY; Escudero, P; Kim, TY; Lang, I; Morris, CD; Pover, GM; Valladares-Ayerbes, M, 2011) |
| "The addition of cetuximab to chronotherapy allowed safe and effective therapeutic control of metastases, including their complete resection, despite previous failure of several treatment regimens." | 2.76 | Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. ( Adam, R; Bouchahda, M; Giacchetti, S; Gorden, L; Guettier, C; Hauteville, D; Innominato, PF; Karaboué, A; Lévi, F; Saffroy, R, 2011) |
| "8 or 45 μg/m(2) in combination with capecitabine-oxaliplatin (XELOX)." | 2.76 | Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. ( Andretta, V; Bennicelli, E; Bordignon, C; Caprioni, F; Comandini, D; Fornarini, G; Guglielmi, A; Lambiase, A; Mammoliti, S; Mazzola, G; Pessino, A; Sciallero, S; Sobrero, AF, 2011) |
| "Peripheral sensory neurotoxicity is a frequent and potentially debilitating side effect of oxaliplatin treatment." | 2.76 | The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. ( Imholz, AL; Knijn, N; Koopman, M; Mol, L; Punt, CJ; Teerenstra, S; Tol, J; Valster, FA; Vincent, AD; Werter, MJ, 2011) |
| "Risk of recurrence was also significantly higher for KRAS mutant than KRAS wild-type tumors (28% [150 of 542] v 21% [219 of 1,041]; RR, 1." | 2.76 | Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. ( Beaumont, C; Chambers, P; Gray, R; Handley, K; Hutchins, G; Kerr, D; Magill, L; Quirke, P; Richman, S; Seymour, M; Southward, K; Stahlschmidt, J, 2011) |
| "Capecitabine and lapatinib were given orally at escalating doses, starting at capecitabine 1500 mg/m(2)/day on days 1-14 and lapatinib 1000 mg daily on days 1-21." | 2.76 | A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. ( Alberti, D; Bowen, CJ; Dar, MM; Dennie, TW; Fleming, RA; Holen, KD; Loconte, N; Mulkerin, D; Oliver, K, 2011) |
| "Obesity is associated with an increased risk of development and recurrence of colorectal cancer." | 2.76 | Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. ( Derleyn, VA; Koopman, M; Mol, L; Muller, EW; Punt, CJ; Simkens, LH; Teerenstra, S; Ten Bokkel Huinink, D; Veldhuis, GJ, 2011) |
| "While the most frequent, surgery for colorectal cancer is avoided in patients with metastases to the regional lymph nodes (stage III) or distant ones (stage IV)." | 2.76 | [Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer]. ( Eropkin, PV; Kashnikov, VN; Panina, MV; Rybakov, EG, 2011) |
| "To evaluate the efficacy and safety of yiqi zhuyu decoction (YZD) combined with oxaliplatin plus 5-flurouracil/leucovorin (FOLFOX-4) in the patients with metastatic colorectal cancer (MCRC)." | 2.76 | Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer. ( Cao, B; Deng, WL; Li, ST; Li, Z, 2011) |
| " Although skin toxicities are the most common adverse events associated with EGFR inhibitors, the differences in efficacy and safety between pre-emptive and reactive skin treatment according to KRAS tumor status has not been reported." | 2.76 | The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. ( Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M, 2011) |
| "Patients with metastatic colorectal cancer received either FOLFOX-4 + bev or FOLFIRI + bev." | 2.75 | Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. ( Chin, K; Fujiwara, Y; Hatake, K; Ichimura, T; Kobayashi, K; Konishi, F; Kuboki, Y; Matsueda, K; Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M, 2010) |
| "Patients suffering from advanced colorectal cancer can experience unintended weight loss and/or treatment-induced gastrointestinal toxicity." | 2.75 | Early supplementation of parenteral nutrition is capable of improving quality of life, chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: results from a prospective, randomize ( Essenbreis, M; Hasenberg, T; Herold, A; Post, S; Shang, E, 2010) |
| "This phase I dose-escalation study was designed to determine the maximum tolerated dose (MTD) and recommended dose of cetuximab administered on an every-second-week schedule to patients with metastatic colorectal cancer, on the basis of safety, pharmacokinetic and pharmacodynamic evaluation." | 2.75 | Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. ( Baselga, J; Cervantes, A; Ciardiello, F; Kisker, O; Liebscher, S; Macarulla, T; Martinelli, E; Ramos, FJ; Rivera, F; Rodriguez-Braun, E; Roselló, S; Tabernero, J; Vega-Villegas, ME, 2010) |
| "Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5)." | 2.75 | A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ( Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010) |
| "Stage IV colorectal cancer encompasses a broad patient population in which both curative and palliative management strategies may be used." | 2.75 | Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. ( Ashley, S; Brown, G; Chau, I; Cunningham, D; Gillbanks, A; Karanjia, N; Mudan, SS; Norman, AR; Watkins, DJ, 2010) |
| "Vorinostat doses were escalated in a standard 3 x 3 phase I design." | 2.75 | A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. ( Diasio, RB; Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Muindi, JR; Wang, K; Zwiebel, JA, 2010) |
| "Peritoneal carcinomatosis from colorectal cancer treated with chemotherapy alone results in median survival of 5 to 13 months, whereas CRS with HIPEC for early peritoneal carcinomatosis from colorectal cancer resulted in median survival of 48-63 months and 5 year survival of 51%." | 2.75 | Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. ( Avital, I; Davis, JL; Kemp, CD; Ripley, RT; Steinberg, SM; Toomey, MA, 2010) |
| "Forty patients with metastatic colorectal cancer were enrolled." | 2.75 | Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. ( Cortesi, E; Gazzaniga, P; Gradilone, A; Iacovelli, R; Naso, G; Nicolazzo, C; Petracca, A; Raimondi, C, 2010) |
| "As a project of the Kanagawa Colorectal Cancer Study Group, we performed this study to analyze the efficacy and the safety of modified FOLFIRI (irinotecan: 150 mg/m2) therapy for Japanese patients with metastatic colorectal cancer." | 2.75 | [Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer]. ( Akaike, M; Imada, T; Masuda, M; Matsukawa, H; Ozawa, Y; Rino, Y; Shiozawa, M; Shiraishi, R; Suzuki, H; Takahashi, M; Tamura, I; Yamamoto, N; Yamamoto, Y; Yukawa, N, 2010) |
| "A total of 43 patients with advanced colorectal cancer were included." | 2.75 | [Influence of FOLFOX regimen on the immunologic function in patients with advanced colorectal cancer]. ( Duan, GL; Huang, CX; Jiang, YQ; Li, ZY; Wang, QQ, 2010) |
| " This study aims to achieve an improved disease free survival for patients after resection or resection combined with RFA of colorectal liver metastases by adding the angiogenesis inhibitor bevacizumab to an adjuvant regimen of CAPOX." | 2.75 | A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. ( Bergman, AM; Dalesio, O; Rinkes, IH; Schouten, SB; Snoeren, N; Tollenaar, RA; van der Sijp, JR; van Hillegersberg, R; Verheul, HM; Voest, EE, 2010) |
| "Liver metastasectomies were performed in 26% of all pts and in 39% of pts with LM." | 2.75 | "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. ( Antonucci, A; Baldi, PL; Bruera, G; Cannita, K; De Galitiis, F; Ficorella, C; Mancini, M; Marchetti, P; Ricevuto, E; Santomaggio, A; Tudini, M, 2010) |
| "Tetrathiomolybdate (TM) is an oral copper chelator under development as an anti-angiogenic agent." | 2.74 | A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. ( Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM, 2009) |
| "Twelve subjects with metastatic colorectal cancer within the liver failing first-line chemotherapy were treated in four cohorts with a single dose (3 x 10(6) to 1 x 10(8) particles) of NV1020, a multimutated, replication-competent HSV." | 2.74 | A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. ( Bhargava, A; Brody, L; Brown, K; Covey, A; Fong, Y; Getrajdman, G; Jarnagin, W; Karrasch, M; Kemeny, N; Kim, T; Mescheder, A; Schwartz, L, 2009) |
| "Simvastatin 40 mg tablet was given once daily per oral everyday during the period of chemotherapy without a rest." | 2.74 | Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. ( Ahn, JB; Byun, JH; Hong, YS; Im, SA; Jung, KH; Kang, WK; Kim, TW; Lee, J; Lee, N; Lim, HY; Oh, DY; Park, JO; Park, SH; Park, YS; Shin, DB; Shin, SJ, 2009) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 2.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| "Cediranib is a highly potent and selective inhibitor of the 3 vascular endothelial growth factor receptors and has a halflife suitable for once-daily oral dosing." | 2.74 | Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. ( Botwood, NA; Robertson, JD; Rothenberg, ML; Schmoll, HJ, 2009) |
| "Cediranib is a potent oral inhibitor of the tyrosine kinase activity associated with all subtypes of vascular endothelial growth factor receptor." | 2.74 | Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. ( Chen, E; Gauthier, I; Jonker, D; MacLean, M; Powers, J; Seymour, L; Wells, J, 2009) |
| "All the patients with metastatic colorectal cancer treated with at least one line of chemotherapy for metastatic disease and progressed after I line chemotherapy were considered eligible and enrolled into the trial." | 2.74 | [Role of sequential chemotherapy in the treatment of metastatic colorectal cancer]. ( Carloni, F; Nicoletti, S; Ravaioli, A; Tamburini, E; Tassinari, D, 2009) |
| "Irinotecan therapy was associated with more grade 3 nausea, vomiting, diarrhea, and febrile neutropenia; FOLFOX4 was associated with more neutropenia and paresthesias." | 2.74 | Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. ( Alberts, SR; Fitch, TR; Goldberg, RM; Kim, GP; Mahoney, MR; Mathews, AP; Mitchell, E; Philip, PA; Pitot, HC; Rowland, KM; Sargent, DJ, 2009) |
| "Vorinostat was given orally twice daily for 1 week every 2 weeks." | 2.74 | A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. ( Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009) |
| " Serious/grade 3-5 adverse events of interest for bevacizumab included bleeding (3%), gastrointestinal perforation (2%), arterial thromboembolism (1%), hypertension (5." | 2.74 | Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. ( Berry, S; Bridgewater, J; Canon, JL; Cunningham, D; DiBartolomeo, M; Georgoulias, V; Kretzschmar, A; Mazier, MA; Michael, M; Peeters, M; Rivera, F; Van Cutsem, E, 2009) |
| "Racial disparities in colorectal cancer (CRC) survival are documented, but there are few data on comparative response to chemotherapy." | 2.74 | Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. ( Goldberg, RM; Green, EM; McLeod, HL; Sanoff, HK; Sargent, DJ, 2009) |
| " Patients exhibited high compliance in dosing administration." | 2.74 | Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009) |
| "Irinotecan is a chemotherapeutic agent used in the treatment of CRC and has demonstrated synergistic potential when used with radiation." | 2.74 | Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. ( Bower, GD; Briggs, GM; George, J; Goldstein, D; Olver, IN; Pavlakis, N; Price, D; Rossleigh, MA; Tapner, MJ; Taylor, DJ; van Hazel, GA, 2009) |
| "To compare the therapeutic effect and toxicity of chemotherapy, used alone or in combined with Shenqi Fuzheng Injection (SFI), for the treatment of advanced colorectal carcinoma (ACRC)." | 2.74 | [Effect of Shenqi Fuzheng injection combined with chemotherapy in treating advanced colorectal carcinoma]. ( Liang, QL; Pan, DC; Xie, JR, 2009) |
| " The primary toxicity outcome measure was toxicity-induced delay or dose reduction; the secondary outcome was Common Terminology Criteria of Adverse Events grade >or= 3 toxicity." | 2.74 | Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. ( Adlard, JW; Allan, JM; Braun, MS; Daly, CL; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Seymour, MT; Thompson, L, 2009) |
| "The treatment of peritoneal carcinomatosis is based on cytoreduction followed by hyperthermic intraperitoneal chemotherapy and combined with adjuvant chemotherapy." | 2.73 | 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. ( Boot, H; Bruin, S; van Slooten, G; van Tinteren, H; Verwaal, VJ, 2008) |
| "After 40 of the planned 74 patients had been randomly assigned, real-time adverse event monitoring led to early trial closure because of excess sequence-specific toxicity." | 2.73 | Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin. ( Anthoney, DA; Bradley, C; Brown, JM; Brown, S; Crawford, SM; Hennig, IM; Jackson, DP; Melcher, AM; Naik, JD; Seymour, MT; Szubert, A, 2008) |
| " Incidence of grade 3/4 treatment-related adverse events during the first 12 weeks of treatment were 59%, 36%, and 67% for mFOLFOX6, bFOL, and CapeOx, respectively, (TREE-1) and 59%, 51%, and 56% for the corresponding treatments plus bevacizumab (TREE-2; primary end point)." | 2.73 | Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. ( Abubakr, Y; Childs, BH; Cohn, AL; Fehrenbacher, L; Hainsworth, JD; Hart, LL; Hedrick, E; Hochster, HS; Ramanathan, RK; Saif, MW; Schwartzberg, L; Wong, L, 2008) |
| "Forty patients with colorectal cancer were included in this randomized prospective study." | 2.73 | Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer. ( Aydiner, A; Aykan, F; Can, G; Cevikbaş, A; Cinar, S; Deniz, G; Derin, D; Dişçi, R; Durna, Z; Guney, N; Gürer, U; Kürklü, E; Saglam, S; Sakar, B; Tanyeri, H; Taş, F; Topuz, E, 2008) |
| "There is strong evidence that colorectal cancer survival differs between socioeconomic groups." | 2.73 | No socioeconomic inequalities in colorectal cancer survival within a randomised clinical trial. ( Coleman, MP; Cooper, N; James, R; Lepage, C; Northover, JM; Nur, U; Parmar, MK; Rachet, B; Sydes, MR, 2008) |
| "Celecoxib was administered as 400 mg, twice daily starting on day 2 of cycle 1." | 2.73 | Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. ( Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF, 2007) |
| "The aim of the present study was to investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of a 5-fluorouracil derivative (TS-1) in advanced gastric or colorectal carcinoma patients." | 2.73 | Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. ( Fujiwara, T; Harada, M; Homma, S; Ikeda, Y; Ishihara, Y; Itoh, K; Maeda, Y; Mine, T; Sato, Y; Shomura, H; Tanaka, N; Todo, S; Tokunaga, N; Yamada, A, 2007) |
| "The R0 secondary resection rate of metastases was greater in the FOLFOXIRI arm (6% v 15%; P = ." | 2.73 | Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor ( Allegrini, G; Andreuccetti, M; Barbara, C; Benedetti, G; Brunetti, I; Chiara, S; Cortesi, E; Crinò, L; Evangelista, W; Falcone, A; Fanchini, L; Fioretto, L; Granetto, C; Masi, G; Orlandini, C; Pfanner, E; Picone, V; Porcile, G; Ricci, S; Vitello, S, 2007) |
| "To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC)." | 2.73 | Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. ( Agelaki, S; Androulakis, N; Chatzidakis, A; Christophylakis, C; Diamandidou, E; Emmanouilides, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kotsakis, A; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Touroutoglou, N; Vamvakas, L, 2007) |
| " The relation between adverse events on IROX to selected characteristics was analyzed." | 2.73 | Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. ( Alberts, SR; Ashley, AC; Campbell, ME; Findlay, BP; Fuchs, CS; Goldberg, RM; Grothey, A; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2007) |
| "We studied patients with advanced colorectal cancer, starting treatment with non-curative intent." | 2.73 | Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. ( Ferry, DR; Griffiths, GO; Gwyther, SJ; James, R; Ledermann, JA; Maraveyas, A; Maughan, TS; Meade, AM; Parmar, MK; Seymour, MT; Shepherd, S; Smith, DB; Stephens, RJ; Thompson, L; Topham, C, 2007) |
| "Patients diagnosed with colorectal cancer (n=150) were randomly allocated to receive monthly 5-FU and leucovorin bolus injections (the Mayo regimen) or a bimonthly 5-FU bolus plus continuous infusion (the simplified de Gramont regimen) for 24 weeks as postoperative adjuvant therapy." | 2.73 | Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. ( Elomaa, I; Joensuu, H; Korpela, R; Kouri, M; Ollus, A; Osterlund, P; Ruotsalainen, T; Saxelin, M; Valta, P, 2007) |
| "Sites of metastasis were as follows: liver (n = 10), lung (n = 8), skin (n = 1), and non-regional lymph nodes (n = 1)." | 2.73 | Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study. ( Chang, AY; Fong, FK; Hsin, KW; Lim, R; Lopes, G; Wong, J, 2007) |
| " Administration of TroVax alongside chemotherapy was safe and well tolerated with no SAEs attributed to the vaccine and no enhancement of chemo-related toxicity." | 2.73 | Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. ( Carroll, MW; Chikoti, P; Drury, N; Griffiths, R; Harrop, R; Hawkins, RE; Kingsman, SM; Naylor, S; Redchenko, I; Shingler, W; Steven, N, 2008) |
| " Three sequential skin biopsies were obtained in selected patients to assess the pharmacodynamic effects on EGFR signaling of FOLFIRI alone and with EKB-569." | 2.73 | Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with ( Abbas, R; Andreu, J; Baselga, J; Casado, E; Cortes-Funes, H; Folprecht, G; Köhne, CH; Lejeune, C; Marimón, I; Paz-Ares, L; Quinn, S; Rojo, F; Salazar, R; Tabernero, J; Ubbelohde, U; Zacharchuk, C, 2008) |
| "To evaluate the therapeutic efficacy and adverse reaction of Aidi Injection (ADI) combined with FOLFOX4 regimen for treatment of patients with advanced colorectal cancer, and controlled with those of FOLFOX4 regimen alone." | 2.73 | [Comparative study on treatment of advanced colorectal cancer by Aidi injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone]. ( Dong, L; Fu, SY; Li, HJ, 2007) |
| "Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI." | 2.73 | A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. ( Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K, 2008) |
| "The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible." | 2.73 | A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. ( Antonini, NF; Cats, A; Creemers, GJ; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Rodenburg, CJ; Schrama, JG; Tol, J; Vos, AH, 2008) |
| "364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group)." | 2.73 | Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. ( Bechstein, WO; Bethe, U; Collette, L; Finch-Jones, M; Glimelius, B; Gruenberger, T; Jaeck, D; Mirza, D; Nordlinger, B; Parks, RW; Poston, GJ; Praet, M; Primrose, JN; Rougier, P; Scheithauer, W; Schlag, PM; Sorbye, H; Van Cutsem, E; Walpole, ET, 2008) |
| "Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection." | 2.73 | Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008) |
| "Individual FU dose adjustment based on pharmacokinetic monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities." | 2.73 | Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ( Boisdron-Celle, M; Delva, R; Dorval, E; Gamelin, E; Jacob, J; Merrouche, Y; Morel, A; Pezet, D; Piot, G; Raoul, JL, 2008) |
| "Gefitinib at a dose of 250 mg daily in combination with weekly 5-fluorouracil at 2,000 mg/m(2) or gefitinib at a dose of 500 mg daily with 5-fluorouracil at 1,600 mg/m(2) plus oxaliplatin has an acceptable safety profile." | 2.73 | Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO). ( Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP, 2008) |
| "For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX)." | 2.72 | Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. ( Aranda Aguilar, E; Élez Fernández, E; Fernández Montes, A; García-Alfonso, P; González Astorga, B; González Flores, E; López Muñoz, AM; Salud Salvia, A; Salvà Ballabrera, F; Vera García, R, 2021) |
| "In patients with advanced colorectal cancer (ACRC), retrospective studies have shown that low expression levels of TS and DPD correlated with response to 5-FU." | 2.72 | Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. ( Dercksen, W; Giaccone, G; Noordhuis, P; Peters, GJ; Pinedo, HM; Smid, K; Smorenburg, CH; van Groeningen, CJ; van Riel, AM, 2006) |
| "Traditionally, metastatic colorectal cancer (MCRC) has been treated with intravenous (i." | 2.72 | A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. ( Gollins, S; Grieve, R; Samuel, L; Twelves, C, 2006) |
| "Losartan was used as a marker to assess CYP2C9 activity." | 2.72 | Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. ( Babaoglu, MO; Boruban, C; Bozkurt, A; Coskun, U; Gunel, N; Gunes, A; Hassan, M; Rane, A; Sencan, O; Yasar, U; Zengil, H, 2006) |
| "Thalidomide was escalated individually to 600 mg po QD as tolerated." | 2.72 | The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006) |
| "Capecitabine was administered orally according to following schedule: 1/4 of dose at 8:00 a." | 2.72 | Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. ( Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B, 2006) |
| " This PK model could be useful in identifying predictors for PK and pharmacodynamic variability to individualize dosing." | 2.72 | Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. ( Brouwers, JR; Jansman, FG; Kho, Y; Neef, C; Prins, NH, 2006) |
| "Twenty-nine colorectal cancer patients with non-resectable hepatic metastases were consecutively enrolled for HAI alternating with systemic chemotherapy (HA + SC group)." | 2.72 | Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer. ( Chang, HM; Ha, HK; Kim, HC; Kim, JC; Kim, JH; Kim, TW; Lee, KH; Lee, MG; Ryu, MH; Yu, CS, 2006) |
| "Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL." | 2.72 | A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. ( Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ, 2006) |
| " 5-FU pharmacokinetics was determined on day 2 of the first, third, and fifth cycles; type and the grade of adverse reactions were recorded on the next cycle." | 2.72 | Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. ( Barile, C; Bononi, A; Crepaldi, G; Ferrari, M; Ferrazzi, E; Grigoletto, F; Gusella, M; Menon, D; Padrini, R; Scapoli, D; Stievano, L; Toso, S, 2006) |
| "Patients with metastatic colorectal cancer (MCC) usually receive FOLFOX-4, or other oxaliplatin (L-HOP)-based regimens, until the occurrence of progressive disease, with an increase in the incidence of neurotoxicity which is correlated to the cumulative dose of L-HOP." | 2.72 | FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. ( Cioppa, T; Civitelli, S; Francini, E; Francini, G; Intrivici, C; Lorenzi, M; Marsili, S; Nettuno, R; Paolelli, L; Petrioli, R; Roviello, F; Tanzini, G, 2006) |
| " A weekly 5 hour-administration of 5-FU (1500 mg) which was repeated for 8 weeks showed a comparable effect to a continuous infusion group with an identical total dosage of 5-FU." | 2.72 | [Prophylactic hepatic arterial infusion chemotherapy after curative surgery of colorectal liver metastases--the viewpoint from patients' quality of life]. ( Hoshino, H; Iwazawa, T; Kanoh, T; Kimura, Y; Matsushita, M; Miyazaki, S; Monden, T; Nakano, Y; Ohnishi, T; Shiozaki, K; Takemoto, H; Tono, T; Yano, H, 2006) |
| "Patients aged 70 or more, with stage IV colorectal cancer, ECOG performance status not worse than 2." | 2.71 | First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. ( Daniele, B; De Maio, E; Gallo, C; Iaffaioli, RV; Manzione, L; Ottaiano, A; Perrone, F; Pignata, S; Rosati, G; Rossi, A; Tambaro, R, 2003) |
| "Postoperative complications were reported in 14 patients (13 occurring within 30 days after resection) and severe complications in 5 cases (including two deaths after extended resection)." | 2.71 | Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. ( Gassel, HJ; Gog, C; Hohenberger, W; Jauch, KW; Lehmann, U; Lorenz, M; Müller, HH; Padberg, W; Proschek, D; Ridwelski, K; Staib-Sebler, E; Vestweber, KH; Zamzow, K, 2003) |
| "The objective of this study was to develop a population pharmacokinetic model and validate it using a Bayesian approach for predicting, a priori and a posteriori, the individual volume of distribution (V(d)) and clearance (Cl) of 5-fluorouracil (5-FU) given as short-term intravenous infusion in weekly and multiple doses." | 2.71 | A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer. ( Almenar-Cubells, D; Climente-Martí, M; Jiménez-Torres, NV; Merino-Sanjuán, M, 2003) |
| "Doxifluridine (5'-DFUR) is an intermediate of capecitabine approved in Europe and USA to treat metastatic colorectal cancer." | 2.71 | A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. ( Koda, K; Kodaira, S; Miyazaki, M; Nakazato, H; Ogawa, K; Saito, N; Sarashina, H; Suwa, T; Suzuki, M; Watanabe, S, 2003) |
| "A prospective phase II study was performed to determine the feasibility, efficacy and safety of arterial hepatic infusion (HAI) using pirarubicin combined with intravenous chemotherapy." | 2.71 | Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. ( Adenis, A; Baulieux, J; Colin, P; Couzigou, P; Douillard, JY; Ducreux, M; Fallik, D; Jacob, J; Mahjoubi, M; Mahjoubi, R; Rougier, P; Seitz, JF; Ychou, M, 2003) |
| "Thirteen patients had limited extrahepatic cancer." | 2.71 | A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases. ( Blind, PJ; Gustavsson, B; Hafström, L; Lindnér, P; Naredi, P; Oman, M, 2003) |
| " A Bayesian methodology was used to assess individual pharmacokinetic parameters using the NONMEM computer program." | 2.71 | Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ( Bressolle, F; Debrigode, C; Duffour, J; Gourgou, S; Kramar, A; Pinguet, F; Ychou, M, 2003) |
| "Median survival in advanced colorectal cancer patients treated with 5-fluoro-uracil (5FU) and leucovorin (LV) is between 12 and 18 months." | 2.71 | [Long term survival in metastatic colorectal cancer treated with leucovorin and 5-fluoro-uracil chemotherapy]. ( André, T; Artru, P; Carola, E; de Gramont, A; Krulik, M; Louvet, C; Mabro, M; Molitor, JL; Perez, N; Tournigand, C, 2004) |
| "Weekly treatment at these doses is convenient and well-tolerated for the large majority of patients, and achieves DI comparable with the 5 days a month QUASAR schedule and other more toxic standard regimens." | 2.71 | Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. ( Anthoney, DA; Crellin, AM; Messruther, J; Patel, K; Sebag-Montefiore, D; Seymour, MT, 2004) |
| "The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in combination with 5-fluorouracil/leucovorin (5-FU/LV) in cancer patients." | 2.71 | Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004) |
| "Topotecan has shown fewer side effects and higher efficacy when given as a continuous i." | 2.71 | Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer. ( Deckert, PM; Hütter, G; Keilholz, U; Szélenyi, H; Thiel, E, 2004) |
| "Colorectal peritoneal carcinomatosis (PC) is a frequent and very lethal event." | 2.71 | Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. ( Baton, O; Benhamou, E; Delperro, JR; Elias, D; Giovannini, M; Lasser, P; Pocard, M; Sideris, L, 2004) |
| "Peritoneal carcinomatosis in the absence of distant metastasis occurs in approximately 8 per cent of patients with colorectal cancer." | 2.71 | Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. ( van Ruth, S; van Tinteren, H; Verwaal, VJ; Zoetmulder, FA, 2004) |
| "Capecitabine is an oral fluoropyrimidine converted to fluourouracil (FU) preferentially in tumor tissue." | 2.71 | Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. ( Abbruzzese, JL; Carter, S; Hoff, PM; Lassere, Y; Pazdur, R; Polito, D; Samid, D, 2004) |
| " Pharmacokinetic studies were performed on cycle 1 and 2 to assess the best sequence and detect any interaction between the two drugs." | 2.71 | Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. ( Adam, R; Bastian, G; Bismuth, H; Castaing, D; Gil-Delgado, MA; Guinet, F; Khayat, D; Rocher, MA; Spano, JP; Taillibert, S; Urien, S, 2004) |
| " In 10 of 19 patients who had not responded (SD, PD), three additional courses of chemotherapy were combined with sCMT (with 25 sCMT applications)." | 2.71 | Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study. ( Ahlers, O; Deja, M; Dräger, J; Felix, R; Hildebrandt, B; Kerner, T; Löffel, J; Riess, H; Stroszczynski, C; Wust, P, 2004) |
| "All patients had advanced/metastatic colorectal cancer." | 2.71 | Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ( Aslanis, V; Chatelut, E; Davis, T; Joel, SP; Locke, K; Papamichael, D; Richards, F; Seymour, MT; Slevin, ML, 2004) |
| " Pharmacokinetic analyses for both BAY 12-9566 and 5-fluorouracil were performed." | 2.71 | An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. ( Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005) |
| "As the number of active drugs for colorectal cancer increases, we continually revisit the question of how best to integrate them." | 2.71 | Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC). ( Babic, DR; Grbic, B; Jelic, SB; Matijasevic, MM; Popov, IP, 2004) |
| "Forty-seven patients with resectable metastases of colorectal cancer were prospectively enrolled onto this study." | 2.71 | Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. ( André, T; Artru, P; de Gramont, A; Gayet, B; Goebel, FM; Hebbar, M; Louvet, C; Parc, R; Paye, F; Perez, N; Taïeb, J; Tournigand, C, 2005) |
| "Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever." | 2.71 | A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. ( Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML, 2005) |
| "Patients (n=38) with colorectal cancer received IFN-alpha 5 MU/m(2) SC on days 1-6; on days 2-6, LV 200 mg/m(2) IV was given with 5-FU at initial doses of 370-425 mg/m(2)/h." | 2.71 | A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel. ( Ernst, A; Grem, JL; Grogan, L; Grollman, F; Ismail, AS; Kao, V; Kirsch, IR; Parr, A; Quinn, MG; Wright, MA, 2005) |
| " This study was performed to determine the efficacy and safety of irinotecan (CPT-11) in combination with fluorouracil (FU) administered as a 48-hour continuous infusion twice a month in elderly patients." | 2.71 | Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gil, S; Maestu, I; Marcuello, E; Masutti, B; Maurel, J; Navarro, M; Sastre, J; Valladares, M; Vicent, JM, 2005) |
| "To explore the efficacy and safety of CPT-11 combined with fluoropyrimidine in treatment for advanced or metastatic colorectal carcinoma." | 2.71 | [Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma]. ( Wu, WQ; Yu, BM, 2005) |
| "Isolated hepatic metastases of colorectal cancer constitute a frequent and serious therapeutic problem that has led to the evaluation of hepatic arterial infusion (HAI) of different drugs." | 2.71 | Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. ( Boige, V; Delperro, JR; Ducreux, M; Elias, D; Gamelin, E; Husseini, F; Jacob, JH; Laplanche, A; Lasser, P; Luboinski, M; Quenet, F; Viret, F; Ychou, M, 2005) |
| " We therefore reanalyzed a pharmacokinetic study in order to develop a limited sampling schedule." | 2.71 | Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity. ( Codacci-Pisanelli, G; Lankelma, J; Peters, GJ; Pinedo, HM; Van Gennip, AH; Van Groeningen, CJ; Van Kuilenburg, AB, 2005) |
| "In patients with metastatic colorectal cancer that have previously received treatment with 5-FU based chemotherapy, treatment with SIR-spheres has demonstrated encouraging activity." | 2.71 | A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. ( Bailey, W; Dowling, R; Gibbs, P; Liechtenstein, M; Lim, L; Little, A; Shapiro, JD; Smith, D; Yip, D, 2005) |
| " Studies of bimonthly regimens of high-dose leucovorin (LV) and 5-fluorouracil (5-FU) by continuous infusion combined with oxaliplatin (L-OHP) have shown encouraging response rates in patients not responding to a bimonthly LV/5-FU regimen." | 2.70 | Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. ( Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002) |
| "Capecitabine (Xeloda; CAP) is a recently developed oral antineoplastic prodrug of 5-fluorouracil (5-FU) with enhanced tumor selectivity." | 2.70 | Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine. ( Desmoulin, F; Gilard, V; Malet-Martino, M; Martino, R, 2002) |
| "Forty-two gastric cancer patients at T(3)II-T(4)III( B) stages and 96 patients with colorectal cancer at B to D stages admitted from January 1996 to October 1998 were randomly divided into control group (group I, 65 cases) receiving intraperitoneal thermochemotherapy, and group II (73 cases) receiving both intraperitoneal thermochemotherapy and intraperitoneal IL-2 immunotherapy." | 2.70 | Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. ( Fu, QG; Guo, RX; Meng, FD; Shen, XD, 2002) |
| "Most colorectal cancers metastatic to the liver are resistant to chemotherapy and are not amenable to surgical resection." | 2.70 | Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. ( Bilchik, AJ; Chawla, SP; Chung, MH; Foshag, LJ; Ramming, KP; Rose, DM; Stern, SS; Wood, TF, 2001) |
| " A phase II clinical trial of this combination using a continuous dosing schedule was carried out in patients with metastatic colorectal cancer." | 2.70 | Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. ( Benson, AB; Catalano, P; Cornfeld, MJ; Graham, DL; Huang, J; Marsh, JC; O'Dwyer, PJ, 2002) |
| " We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma." | 2.70 | Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002) |
| "Patients with advanced colorectal cancer who had received prior therapy were eligible for the trial." | 2.70 | Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer. ( Lange, LM; Shields, AF; Zalupski, MM, 2001) |
| " Therefore, we performed a study of PVI 5FU in 61 patients with advanced colorectal cancer to assess the variability (inter- and intra-subject) in 5FU Css associated with PVI 5FU (300 mg m(-2)day(-1)) and to attempt to correlate pharmacodynamic end-points (anti-tumour activity, toxicity) with 5FU Css as a prelude to 'exposure-guided' 5FU administration." | 2.70 | 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. ( Aird, R; Bowman, A; Jodrell, DI; Knowles, G; McLean, C; Stewart, M; Wall, L, 2001) |
| "Irinotecan (CPT-11) is an active drug in the treatment of patients with advanced colorectal carcinoma." | 2.70 | Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study. ( Aschelter, AM; Comis, S; D'Attino, RM; Dogliotti, L; Garufi, C; Nisticó, C; Perrone, M; Pugliese, P; Tampellini, M; Terzoli, E, 2001) |
| "Treatment with fluorouracil (with or without folinic acid or levamisole) at outpatient clinic or at home." | 2.70 | Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial. ( Borras, JM; Espinas, JA; Germa, JR; Martinez, M; Mendez, E; Navarro, M; Ponton, JL; Sanchez-Hernandez, A, 2001) |
| " The effect of food on the oral bioavailability of UFT (2 x 100 mg capsules; dose in terms of FT) and leucovorin (2 x 15 mg tablets) was evaluated in a single-dose, randomized, two-way crossover study." | 2.70 | Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. ( Alberts, D; Brooks, D; Damle, B; Ferreira, I; Kaul, S; Pazdur, R; Ravandi, F; Sonnichsen, D; Stewart, D, 2001) |
| "164 patients with advanced colorectal cancer were enrolled in this randomised, placebo-controlled, double-blind, multicenter phase III study." | 2.70 | Double-blind randomised placebo-controlled phase III study of an E. coli extract plus 5-fluorouracil versus 5-fluorouracil in patients with advanced colorectal cancer. ( Clemm, C; Clevert, HD; Häring, B; Hockertz, S; Kalousek, MB; Kruse, A; Schneider, B; Thumann, A; Unger, C; Weber, B, 2001) |
| " The severity of adverse events was associated with increased 5-FU/5-FDHU AUC ratio and reduced 5-FU CL, while 5-FU and 5-FDHU pharmacokinetics were not related to DPD activity." | 2.70 | Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. ( Allegrini, G; Bocci, G; Cionini, L; Conte, PF; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Mini, E; Vannozzi, F, 2001) |
| "Gemcitabine was administered as a 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break." | 2.70 | Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. ( Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ, 2002) |
| "In palliative first-line treatment of colorectal cancer, the secondary resection of distant metastases after downstaging has constantly gained in importance." | 2.70 | Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. ( Baum, U; Becker, D; Bernatik, T; Brueckl, WM; Hahn, EG; Hänsler, J; Hohenberger, W; Köckerling, F; Martus, P; Ott, R; Reck, T; Riedel, C; Schneider, T; Wein, A, 2001) |
| "Trimetrexate (TMTX) is a biochemical modulator of 5-fluorouracil (5-FU) and leucovorin (LV)." | 2.70 | Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. ( Croles, JJ; Douma, J; Hammershaimb, L; Keizer, HJ; Lochs, H; Muller, EW; Punt, CJ; Schüller, J; Skovsgaard, T; Ten Napel, CH; Zhang, J, 2002) |
| "Furthermore, presence of lung metastases, a primary rectal cancer and presence of lymph node metastases all predicted a better outcome in the multivariate setting." | 2.70 | Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. ( Aranda, E; Baron, B; Blijham, G; Cunningham, D; Di Costanzo, F; Glimelius, B; Hecker, H; Köhne, CH; Micheel, S; Palmer, M; Pignatti, F; Rougier, P; Scheithauer, W; Schöffski, P; Wils, J, 2002) |
| "Patients with one to three potentially resectable metastases were randomized preoperatively to receive no further therapy (control arm, 56 patients) or postoperative hepatic arterial floxuridine combined with intravenous continuous-infusion fluorouracil (chemotherapy arm, 53 patients)." | 2.70 | Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. ( Adak, S; Benson, AB; Gray, B; Kemeny, MM; Lipsitz, S; Macdonald, JS; O'Dwyer, PJ; Sigurdson, ER; Smith, T, 2002) |
| " As a result, both the host tolerance and antitumor efficacy of 5-fluorouracil (5-FU) and oxaliplatin (L-OHP), like 30 other anticancer drugs, vary largely according to the dosing time in laboratory rodents." | 2.70 | Chronotherapy of colorectal cancer. ( Giacchetti, S, 2002) |
| " Eight episodes of grade 3 or 4 stomatitis were observed, and were responsible for dosage modifications of MTX and 5-FU." | 2.69 | Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer. ( Acuña, JM; Acuña, LA; Amato, S; Barbieri, MR; Cuevas, MA; DeLena, M; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Lorusso, V; Machiavelli, MR; Ortiz, EH; Perez, JE; Rodriguez, R; Romero, AO; Sabatini, CL; Salvadori, MA; Vallejo, CT, 1998) |
| "Diarrhea was experienced by six of 10 patients, and only three patients were able to receive six weekly chemotherapy treatments without dose reduction or delay." | 2.69 | Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. ( Blumenson, LE; Creaven, PJ; Meropol, NJ, 1998) |
| "Capecitabine (Ro 09-1978) is a novel oral fluoropyrimidine carbamate that was rationally designed to generate 5-fluorouracil (5-FU) selectively in tumors." | 2.69 | Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. ( Allman, D; Banken, L; Cassidy, J; Dirix, L; Osterwalder, B; Reigner, B; Roos, B; Twelves, C; Utoh, M; Verweij, J; Weidekamm, E, 1998) |
| "Only patients with colorectal cancer who had evidence of unresectable metastases confined to the liver were eligible." | 2.69 | Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. ( Bernath, AM; Bolton, JS; Burch, P; Colon-Otero, G; Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Nagorney, DM; O'Connell, MJ; Schroeder, G, 1998) |
| "The 24 patients with advanced colorectal cancer were divided into 2 groups randomly and both were treated with 5-FU 250 mg/day by continuous hepatic arterial infusion for three weeks." | 2.69 | [Method of preventing hepatic artery occlusion during continuous intrahepatic arterial infusion chemotherapy of 5-FU]. ( Ishida, H; Ishikawa, K; Itoh, I; Iwase, H; Kameya, T; Makuuchi, H; Mukai, M; Ohtaki, M; Sadahiro, S; Suzuki, T; Tajima, T; Tokunaga, N; Yasuda, S, 1998) |
| "203 patients with measurable advanced colorectal cancer were randomised to bolus 5-FU either as an injection for 2-4 min or as a short-term infusion lasting 10-20 min." | 2.69 | Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. ( Berglund, A; Brunsgaard, N; Gadeberg, C; Glimelius, B; Graf, W; Gustavsson, B; Hansen, P; Jakobsen, A; Kjaer, M; Lindberg, B; Lorentz, T; Påhlman, L; Sandberg, E; Sellström, H, 1998) |
| " Four episodes of grade 2 stomatitis were observed, causing dosage modifications." | 2.69 | Biomodulation with sequential intravenous IFN-alpha2b and 5-fluorouracil as second-line treatment in patients with advanced colorectal cancer. ( Amato, S; Barbieri, MR; Domínguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Marrone, N; Ortiz, EH; Pérez, JE; Rodríguez, R; Romero Acuña, JM; Romero Acuña, LA; Romero, AO; Vallejo, CT, 1998) |
| "The cases with esophageal cancer, stomach cancer, pancreatic cancer, hepatocellular carcinoma or colonic cancer co-existing with their inoperable lesion(s) were considered in this chemotherapy." | 2.69 | [Biochemical modulation of 5-FU--effect of low dose CDDP]. ( Denno, R; Hirata, K; Kimura, H; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Tsuji, A; Yamamitsu, S, 1999) |
| "The potential for site of metastasis as a predictive variable for response to chemotherapy and survival was examined, in addition to other clinical parameters." | 2.69 | Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. ( Assersohn, L; Benepal, T; Cunningham, D; Norman, A; Oates, J; Ross, PJ, 1999) |
| "Nonresectable colorectal cancer metastases in the liver respond to chemotherapy in 20-25% only." | 2.69 | Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. ( Bangard, M; Bangard, N; Bender, H; Biersack, HJ; Metten, N; Mezger, J; Schomburg, A, 1999) |
| " The levels of free platin decreased triphasically, with a mean terminal half-life of 27." | 2.69 | Oxaliplatin pharmacokinetics during a four-hour infusion. ( Böttger, B; Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Schleyer, E, 1999) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | 2.69 | Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| "A total of 99 patients with advanced colorectal cancer were treated with carboplatin (80 mg/m2, day 1-7), 5-FU (750 mg/m2, day 1-5), leucovorin (100 mg/m2, day 1-5) every 4 weeks." | 2.69 | The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category? ( Jelić, S; Nikolić-Tomasević, Z; Popov, I; Radosavljević, D, 1999) |
| "16 patients with advanced colorectal cancer were treated with 650 mg/m2/d fluorouracil as 5 day continuous infusion and randomized to receive either 20 mg/m2 or 100 mg/m2 calcium folinate as short infusion twice daily." | 2.69 | Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer. ( Jaehde, U; Kreuser, ED; Schunack, W; Streit, M; Stremetzne, S, 1999) |
| "Twelve colorectal cancer patients with small volume disease metastatic to the liver (all lesions < or = 2." | 2.69 | Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. ( Angerstein, C; Becker, H; Becker, W; Béhé, M; Behr, TM; Blumenthal, RD; Fayyazi, A; Goldenberg, DM; Hiddemann, W; Liersch, T; Ringe, B; Salib, AL; Sharkey, RM; Wörmann, B, 1999) |
| "Twenty-two colorectal cancer patients (infusion group) in Dukes' C stage were given hepatic arterial infusion of 5-FU (500 mg/body for 1 hr per week, repeated 50 times) and peroral UFT-E (2." | 2.69 | [Clinical trial of prophylactic hepatic arterial chemotherapy for liver metastases in patients with Dukes' C colorectal cancer]. ( Fujioka, M; Idezuki, Y; Inokuma, S; Ishida, H; Kamano, T; Kishi, T; Kondo, K; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Shimomura, K; Suzuki, T; Takeuchi, I; Yamada, H, 1999) |
| " Also, groups receiving a dosage of 15 g or greater of 5-FU showed prolonged survival rates." | 2.69 | [Cooperative study of intraarterial preventive chemotherapy after resection of hepatic metastasis from colorectal cancer]. ( Hamada, H; Ishizaki, A; Itou, Y; Kassai, S; Katsuki, Y; Kimura, J; Kino, S; Kusano, M; Nakasaki, H; Suzuki, K; Suzuki, S; Tsuji, Y; Tsujita, K; Watanabe, M; Yamamoto, Y, 1999) |
| " To predict 5-FU catabolic deficiencies and toxic side effects, we conducted a prospective study of patients treated for advanced colorectal cancer by high-dose 5-FU." | 2.69 | Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. ( Boisdron-Celle, M; Delva, R; Gamelin, E; Genevieve, F; Guérin-Meyer, V; Ifrah, N; Larra, F; Lortholary, A; Robert, J, 1999) |
| "Recent advances in the management of colorectal cancer have improved the quality of life and the survival of patients treated with chemotherapy." | 2.69 | [Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients]. ( Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M; Maindrault-Goebel, F, 1999) |
| "Six of 40 patients with metastatic colorectal cancer obtained an objective response (15%; 95% confidence interval, 6-30%)." | 2.69 | Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. ( Avallone, A; Blackie, R; Budillon, A; Caponigro, F; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lucia, L; De Vita, F; Gravina, A; McLeod, H; Morsman, J, 1999) |
| " Four patients who suffered from PMC-related side effects of grade 1-2 wanted to decrease their dosage of UFT and/or 5-FU." | 2.69 | [Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report]. ( Izumi, S; Nakagawa, J; Nishihara, M; Onoda, Y; Shimizu, N; Shiota, K; Suzuka, I, 1999) |
| "Five patients, two with gastric cancer and three with colorectal cancer, who had metastatic tumor nodules in their livers were studied dynamically in vivo after 5-FU injection." | 2.69 | Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. ( Presant, CA; Shani, J; Waluch, V; Weitz, I; Wiseman, CL; Wolf, W, 2000) |
| "In primary colorectal tumors, the concentration of 5-FU was on average 3." | 2.69 | Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. ( Banken, L; Cassidy, J; Dumont, E; Durston, S; Mori, K; Reigner, B; Roos, B; Schüller, J; Utoh, M; Weidekamm, E, 2000) |
| "Pharmacokinetic modulating chemotherapy (PMC) is a new therapeutic concept in combination with continuous 5-fluorouracil (5-FU) infusion and UFT." | 2.69 | Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. ( Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H; Yoshikawa, R, 2000) |
| "A pharmacokinetic population approach was used to analyze the data from 21 patients with colorectal cancer." | 2.69 | Dose and time dependencies of 5-fluorouracil pharmacokinetics. ( Boisdron-Celle, M; Bugat, R; Canal, P; Chatelut, E; Erdociain, E; Féty-Deporte, R; Gamelin, E; Guimbaud, R; Lafont, T; McLeod, HL; Terret, C, 2000) |
| "Out of 213 consecutive cases of colorectal cancer patients, 39 patients had liver metastasis (31 synchronous metastases and 8 metachronous metastases)." | 2.68 | [Experience in intra-hepatic-arterial chemotherapy and hepatic resection for metastatic colorectal cancer]. ( Ariga, T; Kinoshita, H; Maruyama, T; Ooshima, I; Ozaki, M; Shimada, H; Shouko, T; Takeda, A; Yoshimura, S, 1995) |
| "Cimetidine has demonstrated a survival benefit in a randomized trial as adjuvant therapy for gastric cancer." | 2.68 | A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer. ( Adams, WJ; Clingan, PR; Legge, J; Links, M; Morris, DL; O'Baugh, J; Phadke, K; Ross, WB, 1995) |
| " As a result, the extent of toxicity of cancer chemotherapy varies by 50% or more according to dosing time in mice or rats." | 2.68 | [Chrono-chemotherapy and dose intensity]. ( Lévi, F, 1995) |
| "These findings suggest that colorectal cancer with aneuploidy and a DI above 1." | 2.68 | Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer. ( Hoshino, K; Kaibara, N; Kimura, O; Kurayoshi, K; Makino, M; Sugezawa, A, 1995) |
| " Dosing decisions in older patients are difficult and must integrate assessments of organ function, comorbidities, overall physical status, and goals of treatment, in an effort to ensure the best possible outcome for these patients." | 2.68 | Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. ( Arcangeli, G; Douglass, HO; Driscoll, DL; Meropol, NJ; Petrelli, NJ; Stein, BN, 1995) |
| "There were 51 patients with colorectal cancer and 130 patients with appendiceal cancer." | 2.68 | Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Jablonski, KA; Sugarbaker, PH, 1995) |
| "Site of metastases included liver (n = 16), lung (n = 7), abdomen (n = 2), pelvic recurrences (n = 2), cutaneous (n = 1)." | 2.68 | Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen. French Northern Oncology Group. ( Adenis, A; Bonneterre, J; Carlier, D; Darloy, F; Demaille, A; Pion, JM, 1995) |
| "Thirty-five patients with metastatic colorectal cancer were treated; 15 (41%) had received previous therapy, 22 (63%) had W." | 2.68 | A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. ( Adam, R; Bismuth, H; Caussanel, JP; Jasmin, C; Lévi, F; Metzger, G; Misset, JL; Smolensky, M; Soussan, A, 1995) |
| "The purpose of this study was to evaluate a potential pharmacokinetic (PK) interaction between fluorouracil (5-FU) and the biomodulating agent interferon alpha (IFN-alpha) in patients with metastatic colorectal carcinoma." | 2.68 | Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid. ( b1p6uller, J; Czejka, M, 1995) |
| " Patients who received Tomudex spent a substantially shorter time in hospital for dosing and had significantly lower rates of grade 3 and 4 toxicities such as leucopenia and mucositis." | 2.68 | 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. ( Cunningham, D; Harper, P; Kerr, D; Olver, I; Perez-Manga, G; Rath, U; Seitz, JF; Svensson, C; Van Cutsem, E; Zalcberg, JR, 1995) |
| " These results show that there is no pharmacokinetic advantage to the use of 6S-LV rather than 6R,S-LV as a modulator of 5-FU." | 2.68 | A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. ( Berghorn, E; Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1995) |
| "Metastatic colorectal cancer is generally incurable." | 2.68 | Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer. ( Abbruzzese, JL; Brown, BW; Gross, HM; Jones, DV; Levin, B; Levy, LB; Pendergrass, KB; Pugh, RP; Wade, JL; Winn, RJ, 1995) |
| " The dosage was as follows: group A received FA i." | 2.68 | Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. ( Archimandritis, A; Bacoyiannis, C; Giannopoulos, A; Kalahanis, N; Karatzas, G; Kosmas, C; Kosmidis, P; Papachristodoulou, A; Papadimas, V; Polyzos, A; Sakelaropoulos, N; Tsavaris, N, 1996) |
| "To determine the most effective dose of leucovorin (folinic acid [FA]) within a weekly bolus fluorouracil (FU) schedule, we conducted a randomized multicenter trial to compare therapeutic effects and toxicity of high-dose FA versus low-dose FA combined with FU at equal doses in both treatment groups." | 2.68 | Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. ( Bernhard, G; Bernhard, H; Heike, M; Jäger, E; Klein, O; Knuth, A; Lautz, D; Meyer zum Büschenfelde, KH; Michaelis, J, 1996) |
| "5-Fluorouracil (5-FU) was measured in hair samples to assess patient exposure to 5-FU, and its potential usefulness is discussed as an index of compliance with postoperative adjuvant chemotherapy." | 2.68 | Measurement of 5-fluorouracil in scalp hair: a possible index of patient compliance with oral adjuvant chemotherapy. ( Fujii, M; Hamano, K; Kato, T; Kodaira, S; Kotake, K; Masuike, T; Nakashima, M; Oka, H; Uematsu, T; Yasutomi, M, 1996) |
| "Sixty-eight patients with advanced colorectal cancer received every 2 weeks hydroxyurea per os 1." | 2.68 | Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. ( Beerblock, K; Bennamoun, M; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Mal, F; Moreau, S; Soubrane, D; Varette, C; Zylberait, D, 1996) |
| "Forty-six patients with colorectal cancer were studied for the effects of intraportal chemotherapy in terms of the administered dose of 5-FU." | 2.68 | [The effect of intraportal chemotherapy in terms of administered dose of 5-FU]. ( Akaishi, O; Hanai, A; Kikuchi, K; Matsuzaki, H; Miyake, H; Oikawa, H; Ozasa, T; Seo, K; Tanaka, K; Tsukikawa, S; Yamaguchi, S; Yamamura, T, 1996) |
| "Ukrain is a new effective drug in the therapy of colorectal cancer." | 2.68 | Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer. ( Korsh, OB; Kravchenco, OB; Susak, YM; Yaremchuk, OY; Yatsyk, IM; Zemskov, VS, 1996) |
| "Residual metastases were surgically removed in 13 patients (26%)." | 2.68 | Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Brummer, PD; Ithzaki, M; Jami, A; Kunstlinger, F; Lévi, F; Misset, JL, 1996) |
| "Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively." | 2.68 | The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996) |
| "Chemotherapy pretreated patients with colorectal cancer seem to have a substantial survival benefit with this salvage protocol." | 2.68 | High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer. ( Hausamen, TU; Loeffler, TM, 1996) |
| "Colorectal carcinoma is one of the most common neoplasms in Western societies, being second only to lung cancer as a cause of death from malignancy." | 2.68 | First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer. ( Beuzeboc, P; Deffontaines, D; Diéras, V; Dorval, T; Garcia-Giralt, E; Jouve, M; Palangie, T; Pouillart, P; Scholl, S, 1996) |
| "These studies demonstrate that the present dose and schedule of AZT in combination with 5-FU + LV has significant activity in metastatic colorectal cancer and that the combination of 5-FU + LV with AZT increases the amount of DNA damage." | 2.68 | Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand break ( Allegrini, G; Andreuccetti, M; Antonuzzo, A; Brunetti, I; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Lencioni, M; Malvaldi, G; Pfanner, E, 1997) |
| "Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues." | 2.68 | Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997) |
| "The response rate was 56." | 2.68 | [Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey]. ( Aiba, K; Araki, H; Chung, Y; Hirata, K; Saji, S; Sasaki, K; Shirasaka, T; Sowa, M; Tanaka, M; Toge, T; Wada, H; Yamamitsu, S; Yasumoto, K, 1997) |
| "5-Fluorouracil (5-FU) was delivered via a surgically placed hepatic artery catheter." | 2.68 | A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases. ( Buckles, J; Budden, J; Gallagher, HJ; Howell, JD; Kerr, DJ; Ledermann, JA; McArdle, CS; Taylor, I, 1997) |
| "Two hundred patients with advanced colorectal cancer received PVI 5-FU 300 mg/m2/day for a maximum of 24 weeks and were randomised to PVI 5-FU alone or PVI 5-FU + MMC 10 mg/m2 (7 mg/m2 from June 1995) 6 weekly for 4 courses." | 2.68 | A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. ( Cunningham, D; Iveson, T; Massey, A; Norman, A; Oates, J; Padhani, A; Popescu, R; Prendiville, J; Ross, P; Watson, M; Webb, A, 1997) |
| "Trimetrexate (TMTX) is a dihydrofolate reductase inhibitor, which, like methotrexate (MTX), has been shown to potentiate fluorouracil (FU) cytotoxicity by increasing phosphoribosylpyrophosphate (PRPP) levels." | 2.67 | Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. ( André, M; Bertino, JR; Conti, JA; Goker, E; Kemeny, N; Ragusa, K; Seiter, K; Tong, W, 1994) |
| " There was an improvement in survival with increased 5-FU dosage (500 mg m-2) [relative hazard (RH) = 0." | 2.67 | Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK? ( Canney, PA; Cassidy, J; Jodrell, DI; Kaye, SB; Murray, LS; Reed, NS, 1994) |
| " Drug concentrations in both peritoneal and plasma compartments followed a first-order model with similar half-life value of 1." | 2.67 | Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma. ( Dobbie, JW; el Eini, DI; Kerr, DJ; McArdle, CS; O'Gorman, P; Vinké, BJ; Warren, H; Watson, D; Wotherspoon, HA, 1994) |
| "Second-line therapy of patients with colorectal cancer metastatic to the liver is unsatisfactory." | 2.67 | Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. ( Bakal, CW; Cynamon, J; Haynes, H; Kaleya, R; Martinelli, DJ; Rozenblit, A; Wadler, S; Wiernik, PH, 1994) |
| "Eight patients with advanced colorectal cancer received 5-FU (initial dose of 500 mg/m2/day) and FA (20 mg/m2/day) as a continuous intravenous infusion over 5 consecutive days." | 2.67 | Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma. Results of a chronopharmacologic phase I trial. ( Adler, S; Eibl-Eibesfeldt, B; Emmerich, B; Hallek, M; Lang, S; Langenmayer, I; Rump, W, 1994) |
| "Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals." | 2.67 | A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993) |
| " The pharmacokinetic interaction between alpha-IF and LV may play a role in the activity of this regimen." | 2.67 | Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin. ( Buter, J; de Vries, EG; Mulder, NH; Roenhorst, HW; Sinnige, HA; Sleijfer, DT; Uges, DR; Verschueren, RC; Willemse, PH, 1993) |
| "In patients with colorectal cancer, we have done a multicentre, randomised controlled trial comparing five-year survival after intraportal infusion of fluorouracil (1 g per day) plus heparin (10,000 U per day) (130 patients) or heparin alone (123) during curative resection and for 7 days thereafter, or after resection alone (145)." | 2.67 | Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. ( Fielding, LP; Fry, JS; Grace, RH; Hittinger, R, 1992) |
| "One patient with metastatic colon cancer who received 5-FU at 540 mg/m2 achieved a partial response." | 2.67 | Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor. ( Moore, DF; Pazdur, R, 1992) |
| "Twenty-nine patients with advanced cancer (75% colon or pancreatic cancer) were treated." | 2.67 | A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy. ( Alberts, DS; Hersh, EM; Marcus, SG; Modiano, MR; Taylor, CW; Woodson, ME, 1992) |
| "Seventeen patients with colorectal cancer who failed local chemotherapy received 5-FU as a 4-hour infusion, preceded by a bolus of FA and IFN." | 2.67 | A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ( Boese-Landgraf, J; Boewer, C; Hilgenfeld, RU; Hoksch, B; Knauf, WU; Kreuser, ED; Matthias, M; Oldenkott, B; Schalhorn, A; Zeitz, M, 1992) |
| "In a prospective randomized multicentre trial 139 patients with metastatic colorectal carcinoma (70 men, 69 women; age 35-81 years) were given palliative treatment with fluorouracil (400 mg/m2 daily for 5 days) alone or combined with folic acid (100 mg/m2 before each dose of fluorouracil)." | 2.67 | [Fluorouracil as monotherapy or combined with folinic acid in the treatment of metastasizing colorectal carcinoma]. ( Aulbert, E; Burghardt, F; Hausamen, TU; Korsten, FW; Lindemann, W; Löffler, TM; Planker, M; Reis, HE; Schröder, M; Strohmeyer, G, 1992) |
| "The possibility of a deleterious effect of the unnatural stereoisomer on the modulation of 5-FU led us to carry out a phase I-II study of 5-FU combined with the (6S)-stereoisomer of folinic acid given in high doses for treatment of patients with advanced colorectal carcinoma." | 2.67 | Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. ( Goldschmidt, E; Grison, X; Guillot, T; Hannoun, L; Lotz, JP; Machover, D; Marquet, J; Metzger, G; Richaud, J; Zittoun, J, 1992) |
| " in 15' x 5 days) every 4 weeks (Arm A), or to 5-FU alone at the same dosage (Arm B)." | 2.67 | Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). ( Aitini, E; Barni, S; Beretta, A; Beretta, GD; Cesana, B; Comella, G; Cozzaglio, L; Cristoni, M; Labianca, R; Pancera, G, 1991) |
| "Phase II studies in metastatic colorectal cancer in 345 patients have demonstrated an average response rate of 36% (range 15-59%) and a prospective randomized study performed by the Mid-Atlantic Oncology Program (MAOP) has confirmed a higher response rate with 5FU infusion compared with a bolus schedule." | 2.67 | 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies. ( Hansen, RM, 1991) |
| "Ninety-six patients with colorectal cancer (stage B2-C) were randomized to the control arm or to receive adjuvant chemotherapy with folinic acid, FU and MMC." | 2.67 | 5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity. ( Astone, A; Barone, C; Cassano, A; Coco, C; Franchi, F; Netri, G; Pozzo, C; Ratto, C; Ricevuto, E; Sofo, L, 1991) |
| "After curative resection of colorectal cancer, immediate short-term postoperative intraportal adjuvant chemotherapy reduces the relative risk of recurrence and death in the non-transfused patient significantly, when compared to transfused patients without chemotherapy." | 2.67 | [Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients]. ( Berres, M; Harder, F; Jäggi, P; Laffer, U; Metzger, U, 1990) |
| "In 28 patients with advanced colorectal cancer, in progression under FA-5FU, we continued treatment with FA-5FU plus DIP." | 2.67 | Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with allopurinol, folinic acid and dipyridamol. ( Antonopoulos, A; Bacoyannis, C; Beldecos, D; Karvounis, N; Kosmidis, P; Mylonacis, N; Tsavaris, N; Valilis, P; Zamanis, N; Zinelis, A, 1990) |
| "5-Fluorouracil (5-FU) has been the treatment of choice for colorectal carcinoma with an overall response rate of about 20%." | 2.67 | A phase I-II study on the toxicity and therapeutic efficacy of 5-fluorouracil in combination with leucovorin and cisplatinum in patients with advanced colorectal carcinoma. ( Borsellino, N; Gebbia, N; Gebbia, V; Palmeri, S; Rausa, L; Russo, A; Rustum, Y, 1990) |
| "Among 13 patients with colorectal cancer, 4 partial responses were observed." | 2.67 | Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination. ( Comis, RL; Cornfeld, MJ; O'Dwyer, PJ; Peter, R, 1990) |
| "Thirty one gastric cancer pts." | 2.67 | [High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer. High-Dose Leucovorin and 5-FU Study Group]. ( Akazawa, S; Matsuoka, T; Mukaiyama, T; Ogawa, M; Ota, K; Sakai, Y; Sakata, Y; Sasaki, T; Wakui, A; Yoshino, M, 1990) |
| "Metastatic colorectal cancer (mCRC) is one of the most common and deadly cancers worldwide." | 2.66 | Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis. ( Dong, Y; Fan, Q; Lv, W; Wang, J; Xiang, Z; Xu, Y, 2020) |
| " In addition, grade 3 and 4 adverse events are found to be higher in panitumumab group than those in control group (RR = 1." | 2.66 | The efficacy and safety of panitumumab supplementation for colorectal cancer: A meta-analysis of randomized controlled studies. ( Chen, S; Chen, X; Tan, C; Wang, C, 2020) |
| "Pharmacological treatment of colorectal carcinoma currently proceeds through the administration of a combination of different chemotherapeutic agents." | 2.66 | The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments. ( Bossi, G; Fratantonio, D; Piastra, V; Pranteda, A; Stramucci, L, 2020) |
| " The use of polymers tailors the desorption profile, improving drug bioavailability and enhancing the local treatment of CRC via oral administration." | 2.66 | Recent Advances in Polymer Nanomaterials for Drug Delivery of Adjuvants in Colorectal Cancer Treatment: A Scientific-Technological Analysis and Review. ( Castro, C; Martinez, E; Naranjo, T; Osorio, M, 2020) |
| "Colorectal cancer is one of the most frequent cancers in the world and between 50% and 60% of patients will develop colorectal liver metastases (CRLM) during the disease." | 2.66 | The actual management of colorectal liver metastases. ( Dorcaratto, D; Garcés-Albir, M; Huerta Álvaro, M; Muñoz-Forner, E; Pérez-Santiago, L; Roselló Keranën, S; Sabater, L, 2020) |
| "5-Fluorouracil (5-FU) has become one of the most widely employed antimetabolite chemotherapeutic agents in recent decades." | 2.66 | Recent Advances in Designing 5-Fluorouracil Delivery Systems: A Stepping Stone in the Safe Treatment of Colorectal Cancer. ( Entezar-Almahdi, E; Farjadian, F; Mohammadi-Samani, S; Tayebi, L, 2020) |
| " However, the optimal protocol for neoadjuvant therapy has not been determined yet, and it remains a source of controversy about whether systemic chemotherapy combined with cetuximab can increase the surgical resection rate and obtain more clinical benefits." | 2.66 | Potentially Resectable mCRC-treated with Cetuximab Combined with Chemotherapy. ( Hong, L; Kong, Y; Xu, X, 2020) |
| "Thirty-two patients with untreated advanced colorectal carcinoma received high-dose methotrexate pretreatment followed sequentially by 5-fluorouracil (5-FU)." | 2.66 | High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals. ( Ajani, JA; Bedikian, AY; Kanojia, MD, 1989) |
| "Indications and contraindications for treatment of colorectal carcinomas with chemotherapeutic agents are described." | 2.66 | [Chemotherapy of inoperable colorectal cancer]. ( Herrmann, R, 1988) |
| "Sixty patients with advanced colorectal cancer were randomized between cisplatin (60 mg/mq i." | 2.66 | Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. ( Cesana, B; Clerici, M; Labianca, R; Luporini, G; Montinari, F; Pancera, G, 1988) |
| "5-Fluorouracil (5-FU) has been commonly prescribed for patients with CRC, but resistance to 5-FU is one of the main reasons for failure in the treatment of this condition." | 2.61 | The role of microRNAs in 5-FU resistance of colorectal cancer: Possible mechanisms. ( Aghaee-Bakhtiari, SH; Avan, A; Ferns, GA; Khazaei, M; Marjaneh, RM, 2019) |
| "Among 2636 patients with stage III colon cancer treated with FOLFOX, MMR status was available for 2501." | 2.58 | Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. ( Alberts, SR; Folprecht, G; Goldberg, RM; Julie, C; Laurent-Puig, P; Le Malicot, K; Meyers, JP; Mini, E; Sargent, DJ; Shi, Q; Sinicrope, FA; Smyrk, TC; Tabernero, J; Taieb, J; Van Laethem, JL; Zaanan, A; Zawadi, A, 2018) |
| " We calculated the incidence of "any-grade" and "severe" toxicity for haematological and non-haematological adverse events of each group." | 2.58 | A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. ( Baratelli, C; Brizzi, MP; Di Maio, M; Scagliotti, GV; Sonetto, C; Tampellini, M; Zichi, C, 2018) |
| "Treatment with eniluracil with oral 5-FU was associated with inferior PFS and OS among participants treated with palliative intent for CRC, and eniluracil is no longer being developed." | 2.55 | Oral versus intravenous fluoropyrimidines for colorectal cancer. ( Chionh, F; Lau, D; Price, T; Tebbutt, N; Yeung, Y, 2017) |
| " The present systematic review and meta-analysis evaluated the efficacy and safety data of bevacizumab combined with first-line fluoropyrimidine monochemotherapy for these complex patients." | 2.55 | Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. ( Antonuzzo, L; Aprile, G; Barni, S; Maiello, E; Masi, G; Petrelli, F; Pinto, C; Porcu, L; Scartozzi, M; Torri, V, 2017) |
| "5-fluorouracil is a chemotherapeutic agent that plays an important role in the treatment of various cancers including head and neck and gastrointestinal malignancies." | 2.53 | Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review. ( Mahipal, A; Markey, KR; Saneeymehri, SS, 2016) |
| "The survival improvement in metastatic colorectal cancer, achieved with more intensive chemotherapy regimens, has recently led clinicians to question the optimal duration of therapies and to consider the role of maintenance." | 2.53 | Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy. ( Aprile, G; Bonotto, M; Fasola, G; Fontanella, C; Giuliani, F; Lutrino, SE; Rihawi, K, 2016) |
| "The management of metastatic colorectal cancer substantially improved over the last 10 years and median overall survival of patients might exceed 30 months." | 2.53 | Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. ( Lenz, HJ; Schirripa, M; Sunakawa, Y, 2016) |
| "To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings." | 2.53 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016) |
| "Colorectal cancer is one of the most frequent solid tumors in the western world, with low survival rates in patients with metastatic disease." | 2.53 | Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. ( Bekaii-Saab, T; Stintzing, S; Sunakawa, Y, 2016) |
| "Pharmacokinetic guided dosing of 5-fluorouracil chemotherapies to bring plasma 5-fluorouracil into a desired therapeutic range may lead to fewer side effects and better patient outcomes." | 2.53 | Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review. ( Clarke, A; Connock, M; Court, R; Freeman, K; Gurung, T; Saunders, MP; Sutcliffe, P; Taylor-Phillips, S; Uthman, OA, 2016) |
| "The objective of the treatment of colorectal cancer patients with unresectable liver metastases should be clearly defined at the outset." | 2.53 | Unresectable liver metastases in colorectal cancer: review of current strategies. ( Pellerin, O; Pernot, S; Pointet, AL; Sueur, B; Taieb, J; Voron, T, 2016) |
| " The risk of mortality, therapeutic efficacy, and adverse effect were meta-analyzed." | 2.53 | Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. ( Chen, K; Gong, Y; Shen, Y; Zhang, Q; Zhou, T, 2016) |
| "Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%-30% of patients." | 2.52 | Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. ( Berenato, R; Bernardi, FF; Bossi, I; Caporale, M; Cheli, S; Clementi, E; de Braud, F; Di Bartolomeo, M; Falvella, FS; Maggi, C; Martinetti, A; Niger, M; Pietrantonio, F; Ricchini, F; Sottotetti, E, 2015) |
| " Herein, we critically discuss the current data on the efficacy and safety profile of bevacizumab in combination with fluoropyrimidine-based chemotherapy for first-line and maintenance treatment of metastatic CRC and briefly comment on existing controversies and future perspectives." | 2.52 | Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. ( Grapsa, D; Saif, MW; Syrigos, K, 2015) |
| "5-Fluorouracil (5-FU) is a chemotherapy used in colorectal, head and neck (H&N) and other cancers." | 2.52 | Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion. ( Clarke, A; Connock, M; Court, R; Cummins, E; Freeman, K; Gurung, T; Saunders, M; Sutcliffe, P; Taylor-Phillips, S, 2015) |
| "Based on the individual genomic profile, the oncologists will have new possibilities, based on the individual genetic profile, to make treatment decisions for their patients and to redefine scheduling and dosage of FluOx-based therapy." | 2.52 | Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy. ( Berretta, M; De Lucia, L; De Monaco, A; Del Pup, L; Di Francia, R; Di Martino, S; Di Paolo, M; Lleshi, A, 2015) |
| "Colorectal cancer is the third most common cancer, with recent advances in the management of unresectable metastatic lesions." | 2.50 | Options for metastatic colorectal cancer beyond the second line of treatment. ( Foubert, F; Matysiak-Budnik, T; Touchefeu, Y, 2014) |
| "Metastatic colorectal cancer remains a lethal disease with a poor prognosis in the majority of patients." | 2.50 | Methods of overcoming treatment resistance in colorectal cancer. ( Alameddine, R; Mukherji, D; Shamseddine, A; Temraz, S, 2014) |
| " Seven electronic databases were searched for randomized controlled trials (RCTs) of FOLFOX4 combined with HMs compared to FOLFOX4 alone." | 2.50 | FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review. ( Chen, M; May, BH; Xue, CC; Zhang, AL; Zhou, IW, 2014) |
| "The management of metastatic colorectal cancer remains a significant clinical challenge to oncologists worldwide." | 2.50 | Sequencing of treatment in metastatic colorectal cancer: where to fit the target. ( Mukherji, D; Shamseddine, A; Temraz, S, 2014) |
| "Chemotherapy-induced diarrhea (CID) is a common and often severe side effect experienced by colorectal cancer (CRC) patients during their treatment." | 2.50 | Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. ( Doherty, GA; Lee, CS; Ryan, EJ, 2014) |
| "The treatment of metastatic colorectal cancer (mCRC) has evolved considerably in the last decade, currently allowing most mCRC patients to live more than two years." | 2.50 | Role of cetuximab in first-line treatment of metastatic colorectal cancer. ( Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ, 2014) |
| "Capecitabine has previously been compared to 5-fluorouracil-either as a monotherapy or in combination with oxaliplatin, irinotecan, or biological drugs-and has been found to have comparable efficacy and safety profiles." | 2.50 | Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? ( Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ, 2014) |
| "Colorectal cancer is the third most common cancer worldwide." | 2.50 | Use of microRNAs in directing therapy and evaluating treatment response in colorectal cancer. ( Andreoli, SC; de Andrade, RV; de Carvalho, GP; Garicochea, B; Gasparini, NJ; Pogue, RE, 2014) |
| "Survival of patients with metastatic colorectal cancer (mCRC) has been significantly improved with the introduction of the monoclonal antibodies targeting the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR)." | 2.50 | Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. ( Kirstein, MM; Kubicka, S; Lange, A; Manns, MP; Prenzler, A; Vogel, A, 2014) |
| " With a more capillary use of this new class of agents comes the recognition of diverse adverse events related to disturbance of critical biological pathways involved in physiological functions." | 2.49 | Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer. ( Cipriani, G; Fioretto, L; Marinozzi, C; Pino, MS; Ribecco, AS, 2013) |
| "Capecitabine is an orally administered prodrug that converts preferentially to 5-FU within tumors, resulting in enhanced concentrations of 5-FU in tumor tissue." | 2.49 | Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy. ( Endo, A; Nakashima, R; Takahashi, N; Tanabe, K; Yoshida, Y, 2013) |
| "Microsatellite instability is the consequence of a deficient mismatch repair system." | 2.49 | Role of microsatellite instability in the management of colorectal cancers. ( Buecher, B; Cacheux, W; Dieumegard, B; Lièvre, A; Mitry, E; Rouleau, E, 2013) |
| "What are the colorectal cancer prognostic factors which would guide the chemotherapy? TNM classification, number of examined lymph nodes, MSI status, and presence or not of a perforation or a perinervous, lymphatic or venous invasion is recognized prognostic factors." | 2.48 | [Is there alternative to FOLFOX adjuvant chemotherapy for stage III colorectal cancer patients?]. ( Brezault, C; Chaussade, S; Coriat, R; Esch, A; Perkins, G, 2012) |
| "Liver metastasis from colorectal cancer has become a common disease associated with the increase of primary colorectal cancer in Japan." | 2.48 | Chemotherapy and molecular-targeted treatment for unresectable hepatic metastases: a Japanese perspective. ( Shimada, Y, 2012) |
| "Metastatic colorectal cancer has evolved from a paradigm that was previously centered upon the use of systemic chemotherapy to one of multimodality therapy." | 2.47 | Surgical therapies in metastatic colorectal cancer with a potential for cure. ( Chua, TC; Esquivel, J; Koong, HN; Liauw, W, 2011) |
| "Capecitabine is a prodrug of 5-fluorouracil, more easily administered by mouth; its transformation in 5-fluorouracil is performed in the liver." | 2.47 | Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. ( Bagli, L; Drudi, F; Fantini, M; Gianni, L; Nicoletti, S; Possenti, C; Ravaioli, A; Sintini, M; Tamburini, E; Tassinari, D, 2011) |
| "Recently its role in colorectal cancer has become more established in both the metastatic and adjuvant setting." | 2.47 | XELOX in colorectal cancer: a convenient option for the future? ( Cassidy, J; Lindsay, CR, 2011) |
| "Colorectal cancer is the second leading cause of cancer-related deaths in the world." | 2.47 | Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. ( Crea, F; Danesi, R; Landini, I; Mini, E; Napoli, C; Nobili, S; Paolicchi, E; Perrone, G, 2011) |
| "Patients with surgically resected colorectal cancer with high risk of recurrence." | 2.46 | Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer. ( Des Guetz, G; Morere, JF; Nicolas, P; Perret, G; Uzzan, B, 2010) |
| "Capecitabine is an orally administered fluoropyrimidine carbamate that is absorbed intact from the gastrointestinal tract and becomes metabolically activated to 5-FU within the tumor." | 2.46 | Evolution of capecitabine dosing in colorectal cancer. ( Sun, W, 2010) |
| "Chemotherapy for colorectal cancer (CRC) was representative of the cancer unable to expect achieving response in previous times." | 2.46 | [Transition of chemotherapy for metastatic colorectal cancer and recent advances]. ( Muro, K, 2010) |
| "The prognosis of metastatic colorectal cancer remains poor despite advances made in recent years, particularly with new treatments directed towards molecular targets." | 2.46 | Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. ( Díaz-Rubio, E; García-Foncillas, J, 2010) |
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer based on the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process." | 2.46 | Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. ( Pandor, A; Rees, A; Stevenson, M; Whyte, S, 2010) |
| "Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration." | 2.46 | Update on capecitabine alone and in combination regimens in colorectal cancer patients. ( Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S, 2010) |
| "Risk factors for colorectal cancer are mainly dietary and genetic." | 2.46 | Colorectal cancer treatment. ( Landau, D; Qureshi, A; Ross, P; Verma, A, 2010) |
| "A form of non-alcoholic steatohepatitis (NASH) related to chemotherapy and otherwise known as chemotherapy-associated steatohepatitis (CASH) is closely linked to irinotecan-based therapy and is associated with inferior outcomes following hepatic surgery mainly due to hepatic insufficiency and poor regeneration." | 2.45 | Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. ( Khan, AZ; Makuuchi, M; Morris-Stiff, G, 2009) |
| "Liver metastases from colorectal cancer (CRC) have a poor prognosis." | 2.45 | Treatment of colorectal liver metastases: a review. ( Hendlisz, A; Van den Eynde, M, 2009) |
| "The median age at diagnosis of colorectal cancer is during the seventh decade, and the incidence of the disease increases continuously with age." | 2.45 | Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use. ( Belda, C; Casado, E; Castro, JD; Feliu, J; González-Barón, M; Sereno, M, 2009) |
| "Chemotherapy is widely used in colorectal cancer that has relapsed or failed to respond to first-line treatment." | 2.45 | Second-line chemotherapy in advanced and metastatic CRC. ( Bonfill Cosp, X; López, JJ; Martin-Richard, M; Roqué I Figuls, M; Solà, I, 2009) |
| "Chemotherapy options of metastatic colorectal cancer (mCRC) have been progressed rapidly in the last years." | 2.45 | [The development of the first line treatment of metastatic colorectal cancer (mCRC)]. ( Landherr, L; Nagykálnai, T, 2009) |
| "Large randomized trials of metastatic colorectal cancer have demonstrated significant clinical benefit with bevacizumab (inhibiting the vascular endothelial growth factor VEGF) and inhibitors of epidermal growth factor receptor (EGFR), namely cetuximab and the panitumumab." | 2.45 | [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis]. ( Assenat, E; Ychou, M, 2009) |
| "The development of chemoresistance in colorectal cancer (CRC) cells was usually thought to be inevitable as a result of continuing exposure to chemotherapeutic drugs." | 2.44 | Expression of CD44 is regulated by ELF3 in 5-FU treated colorectal cancer cells. ( Du, B; Fan, X; Guo, Y; Li, F; Liu, S; Qiu, F; Xi, X; Yu, Q; Zhu, Y, 2024) |
| " Many drugs have been used for the treatment of this disease, but there is little information about how predictive factors can be used to aid treatment response and anticipate toxic effects related to anticancer treatment in colorectal cancer." | 2.44 | Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. ( Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B, 2008) |
| "Data on colorectal cancer in HIV-positive patients are limited." | 2.44 | FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature. ( Bearz, A; Berretta, M; Berretta, S; Del Ben, C; Di Benedetto, F; Martellotta, F; Simonelli, C; Spina, M; Tirelli, U, 2008) |
| "The CTS plays a role in cancer processes and their treatments through the downregulation of malignant growth and the generation of large and predictable 24 hour changes in toxicity and efficacy of anti-cancer drugs." | 2.44 | Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. ( Altinok, A; Clairambault, J; Goldbeter, A; Lévi, F, 2008) |
| "Resectability of liver-limited colorectal cancer metastases should be considered as an endpoint for all patients." | 2.44 | Regional chemotherapy for liver-limited metastatic colorectal cancer. ( Healey-Bird, BR; Kemeny, NE; Power, DG, 2008) |
| " In addition to demonstrated survival benefits, the convenient dosing schedule and lack of interactions should ensure the successful integration of this novel agent into clinical practice." | 2.44 | Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. ( Krämer, I; Lipp, HP, 2007) |
| "Capecitabine is an oral prodrug of 5-fluorouracil." | 2.44 | Capecitabine in the treatment of colorectal cancer. ( Cassidy, J; Kelly, C, 2007) |
| "Gemcitabine is a well-tolerated anti-tumour drug with broad-spectrum activity." | 2.44 | [Gemcitabine and digestive carcinomas]. ( André, T; Blanchard, P; Huguet, F, 2007) |
| "Colorectal cancers have been the first cancers to benefit from an efficient anti-angiogenic treatment, represented by bevacizumab, which has been approved for first-line metastatic treatment in combination with reference chemotherapies and which is under study in the adjuvant setting." | 2.44 | [Angiogenesis targeting in gastro-intestinal cancers]. ( Meric, JB, 2007) |
| "The role of surgery in advanced colorectal cancer in the elderly is restricted to the relief of bowel obstruction and where appropriate resection of hepatic metastasis." | 2.44 | Treatment of advanced colorectal cancer in the elderly. ( Audisio, RA; Bruce, C; Köhne, CH, 2007) |
| "There are 3 450 new cases of colorectal cancer in Norway annually." | 2.44 | [Palliative chemotherapy and radiotherapy for metastatic colorectal cancer]. ( Balteskard, L; Braendengen, M; Sørbye, H, 2008) |
| "Metastatic colorectal cancer (CRC) is most frequently seen in the liver." | 2.44 | Advances in neoadjuvant therapy for colorectal cancer with liver metastases. ( Barone, C; Kemeny, NE; Pozzo, C, 2008) |
| "Advances in the medical treatment of colorectal cancer patients have resulted in considerable improvements through the introduction of new cytotoxic drugs." | 2.44 | [Antibody treatment in colorectal cancer--what the surgeon needs to know]. ( Bueter, M; Fein, M; Gasser, M; Illert, B; Meyer, D; Reimer, P; Thalheimer, A; Thiede, A; Waaga-Gasser, AM, 2008) |
| " Although patients can take the drug orally in the convenience of their own home, the key to successful management of capecitabine is the clinician's awareness of its severe, but low in incidence, adverse effects, and the patients' education, emphasizing compliance with the treatment plan, prevention and timely recognition of its toxicities." | 2.44 | Capecitabine: an overview of the side effects and their management. ( Katirtzoglou, NA; Saif, MW; Syrigos, KN, 2008) |
| "Advances in systemic therapy for colorectal cancer have dramatically improved prognosis." | 2.44 | The role of molecular markers in predicting response to therapy in patients with colorectal cancer. ( Benson, AB; Mulcahy, MF; Shankaran, V; Wisinski, KB, 2008) |
| "Colorectal cancer is the fourth most common noncutaneous malignancy in the United States and the second most frequent cause of cancer-related death." | 2.44 | Systemic treatment of colorectal cancer. ( Mayer, RJ; Wolpin, BM, 2008) |
| "The outcome of patients with advanced colorectal cancer has significantly improved in the past decade because of the development of new treatment strategies." | 2.44 | Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group. ( Antonini, N; Koopman, M; Mol, L; Punt, C; Simkens, L; Tol, J; van Krieken, H, 2008) |
| "Chemotherapy for advanced colorectal cancer is much improved in this decade." | 2.43 | [Second-line chemotherapy for advanced colorectal cancer]. ( Enomoto, M; Higuchi, T; Iida, S; Sugihara, K; Tsunozaki, H; Uetake, H; Yasuno, M, 2005) |
| "For instance, in patients with colorectal cancer, higher enzyme activity of topoisomerase-I seems to be predictive of a better response to irinotecan." | 2.43 | Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. ( Lentz, F; Pons, G; Rey, E; Tran, A; Tréluyer, JM, 2005) |
| "Irinotecan was first developed in patients refractory to fluorouracil." | 2.43 | Benefit-risk assessment of irinotecan in advanced colorectal cancer. ( Glimelius, B, 2005) |
| "Since colorectal cancer is the second most prevalent cancer worldwide, its treatment remains a major challenge for researchers, gastroenterologists and oncologists." | 2.43 | New chemotherapeutic strategies in colorectal cancer. ( Galle, PR; Moehler, M; Teufel, A, 2005) |
| "Overall survival in metastatic colorectal cancer improves with the availability of multiple effective chemotherapeutic agents." | 2.43 | Management of advanced colorectal cancer in older patients. ( Lichtman, SM, 2005) |
| "Capecitabine has significantly less serious toxicity than 5-FU when used alone or in combination with other cytotoxic agents." | 2.43 | Capecitabine: effective oral fluoropyrimidine chemotherapy. ( Coutsouvelis, J; McKendrick, J, 2005) |
| "Worldwide, colorectal cancer is a common cancer and a major cause of morbidity and mortality." | 2.43 | Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. ( Jefford, M; Khamly, K; Michael, M; Zalcberg, J, 2005) |
| "Colorectal cancer is a frequently occurring malignancy in the western world." | 2.43 | [Chemotherapy of patients with colorectal carcinoma]. ( Punt, CJ, 2005) |
| "If almost all colorectal cancers (CRC) correspond to the same histopathological type (adenocarcinoma), molecular biology allowed the identification of two different molecular mechanisms of colorectal carcinogenesis: chromosomal instability characterized by recurrent allelic losses on chromosomes 17, 5, 18, 8 and 22 that contribute to the inactivation of tumor suppressor genes, and genetic instability characterized by the instability of microsatellite loci due to an alteration of DNA mismatch repair leading to the accumulation of mutations in genes involved in the control of cell cycle and apoptosis." | 2.43 | [Molecular biology in clinical cancer research: the example of digestive cancers]. ( Laurent-Puig, P; Lièvre, A, 2005) |
| "Colorectal cancer is one of the most common cancers affecting men and women in the United States." | 2.43 | Advanced colorectal cancer: current treatment and nursing management with economic considerations. ( Fung, A; Viale, PH; Zitella, L, 2005) |
| "For the treatment of metastatic colorectal cancer, improved response rates and prolonged survival have been reported when irinotecan or oxaliplatin was added to 5-FU/FA; a further increase in efficacy was shown when bevacizumab, an antibody to vascular endothelial growth factor, was added to chemotherapy." | 2.43 | Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting. ( Folprecht, G; Köhne, CH, 2005) |
| "Irinotecan was developed for gastrointestinal cancer." | 2.43 | [Recent progress of chemotherapy for colorectal cancer]. ( Ishiguro, A; Munakata, M; Saitoh, S; Sakata, Y; Shitara, K, 2005) |
| "A patient with metastatic colorectal cancer should today be expected to have a median survival of 18-20 months compared to that of 11-14 months only a few years ago." | 2.43 | Chemotherapy for colorectal cancer. ( Goyle, S; Maraveyas, A, 2005) |
| "Advanced colorectal cancer is a common disease with an high mortality rate." | 2.43 | Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience. ( Aquino, A; Bonmassar, E; Correale, P; Cusi, MG; Del Vecchio, MT; Francini, G; Giorgi, G; Micheli, L; Nencini, C; Torino, F, 2006) |
| "About 50% of patients with colorectal cancer (CCR) are destined to develop hepatic metastases during the course of the disease." | 2.43 | Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. ( Biasco, G; Brandi, G; Derenzini, E; Ercolani, G; Grazi, G; Pantaleo, MA; Ravaioli, M, 2006) |
| "Capecitabine is an oral fluoropyrimidine which is converted to 5-fluorouracil primarily in tumor tissue, and has the advantages of ease-of-administration, acceptable toxicity and significant antineoplastic activity." | 2.43 | Capecitabine in the treatment of colorectal cancer. ( Cassidy, J; O'Neill, VJ, 2005) |
| "The modern treatment of colorectal cancer." | 2.43 | [The modern treatment of colorectal cancer. Present and future]. ( András, C; Farczádi, E; Szántó, J, 2006) |
| "Colorectal cancer is the second leading cause of cancer-related deaths in the Western world." | 2.43 | Predicting the outcome of chemotherapy for colorectal cancer. ( Allen, WL; Coyle, VM; Johnston, PG, 2006) |
| "In the USA, colorectal cancer is the fourth most prevalent cancer and is the second leading cause of cancer death after lung cancer." | 2.43 | First- and second-line therapy of metastatic colorectal cancer. ( Grothey, A; Terstriep, S, 2006) |
| "As the treatment for metastatic colorectal cancer, capecitabine showed at least comparable efficacy with a favorable safety profile to bolus 5-FU/LV." | 2.43 | [Capecitabine]. ( Shimamura, T; Tada, M; Yamaguchi, K, 2006) |
| "In stage II colon cancer, treatment strategies are more debated." | 2.43 | [Adjuvant treatment of colorectal cancer]. ( Afchain, P; André, T; de Gramont, A; Segura, C, 2006) |
| "5-Fluorouracil has been the mainstay of therapy for the last four decades." | 2.43 | Surgical adjuvant therapy for colorectal cancer: current approaches and future directions. ( Monga, DK; O'Connell, MJ, 2006) |
| "Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | 2.43 | [S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006) |
| "However, genotyping of cancer patients with reduced or normal DPD activity showed that only 17% of those patients had a molecular basis for their deficient phenotype, which emphasized the complex nature of the molecular mechanisms controlling polymorphic DPD activity in vivo,suggesting that it is difficult to identify DPD deficiency by genotyping." | 2.43 | [Dihydropyrimidine dehydrogenase activity and its genetic aberrations]. ( Ogura, K, 2006) |
| "Colorectal carcinoma is one of the most common cancers in Hungary, responsible for about 5000 deaths each year." | 2.43 | [Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma]. ( Gyôrffy, B; Tegze, B; Tulassay, Z, 2006) |
| "Metastatic colorectal cancer has a poor prognosis, and the majority of patients are left with palliative measures." | 2.42 | Palliative treatment of patients with colorectal cancer. ( Glimelius, B, 2003) |
| "Half of the patients with colorectal cancer present with liver metastases at some point in their illness." | 2.42 | Hepatic resection after down-staging of unresectable hepatic colorectal metastases. ( Adam, R; Azoulay, D; Bismuth, H; Castaing, D; Huguet, E; Kunstlinger, F; Levi, F, 2003) |
| "The chemotherapy of metastatic colorectal cancer (CRC) has undergone a succession of refinements." | 2.42 | Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. ( Carnaghi, C; Comella, P; Díaz-Rubio, E; Douillard, JY; Santoro, A; Sobrero, A; Van Cutsem, E, 2003) |
| " The use of irinotecan together with raltitrexed is also being investigated, as is its combination with oxaliplatin." | 2.42 | Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. ( Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U, 2003) |
| "In untreated metastatic gastric cancer, median survival is 3-4 months." | 2.42 | Current treatments and future perspectives in colorectal and gastric cancer. ( Van Cutsem, E; Wilke, HJ, 2003) |
| "Colorectal cancer is a leading cause of cancer death world-wide." | 2.42 | Review article: colorectal cancer chemotherapy. ( Gill, S; Goldberg, RM; Thomas, RR, 2003) |
| " DPD-inhibiting oral fluoropyrimidines showing promise in early clinical studies included UFT (the 5-FU prodrug, tegafur, plus the DPD substrate, uracil), eniluracil (an irreversible DPD inhibitor that improves the oral bioavailability of 5-FU) and S-1 (tegafur plus a reversible DPD inhibitor, 5-chloro-2,4-dihydroxypyridine, and oxonic acid)." | 2.42 | Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. ( Schmoll, HJ, 2003) |
| "Systemic therapy for metastatic colorectal cancer is evolving rapidly after many years without significant change." | 2.42 | Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents. ( O'Neil, BH, 2003) |
| "Fluorouracil has been the mainstay of treatment in this setting for the past few decades." | 2.42 | First-line treatment strategies to improve survival in patients with advanced colorectal cancer. ( Gill, S; Goldberg, RM, 2004) |
| "The treatment of colorectal cancer has evolved dramatically over the last 15 years." | 2.42 | Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy. ( Grann, VR; Matasar, MJ; Neugut, AI; Sundararajan, V, 2004) |
| "New targets in the treatment of colorectal cancer are the EGF and VEGF receptor." | 2.42 | The role of new agents in the treatment of colorectal cancer. ( Folprecht, G; Köhne, CH, 2004) |
| "Patients with a partial DPD deficiency have an increased risk of developing grade IV neutropenia." | 2.42 | Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. ( van Kuilenburg, AB, 2004) |
| "Adjuvant therapy for colorectal cancer has been one of the most important contributions of medical oncology to the health of the population, saving more lives annually than more effective therapy for less common cancers, such as Hodgkin's disease." | 2.42 | Adjuvant therapy for rectal cancer in the elderly. ( Cohen, SM; Neugut, AI, 2004) |
| "5-fluorouracil (5-FU) has been a pivotal and a single active agent in the treatment of colorectal cancer." | 2.42 | [Chemotherapy]. ( Aiba, K, 2004) |
| "The medical treatment of colorectal cancer (CRC) has rapidly evolved in recent years with the introduction of novel cytotoxic drugs into clinical practice such as irinotecan, oxaliplatin, and capecitabine." | 2.42 | Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. ( Goetz, MP; Grothey, A, 2004) |
| "Survival in patients with advanced colorectal cancer is on a positive trajectory." | 2.42 | Current strategies in previously untreated advanced colorectal cancer. ( Goldberg, RM; Penland, SK, 2004) |
| "Patients with colorectal cancer commonly succumb to the sequelae of hepatic metastases." | 2.42 | Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. ( Barber, FD; Kurzrock, R; Mavligit, G, 2004) |
| "capecitabine) are a convenient alternative but have to prove a comparable efficacy to infusional 5-FU." | 2.42 | [New therapy options in colorectal carcinoma]. ( Folprecht, G; Köhne, CH, 2004) |
| "Colorectal cancer is a leading cause of cancer death worldwide." | 2.42 | Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. ( Gill, S; Goldberg, RM, 2004) |
| "In Westernised countries, colorectal cancer (CRC) is second only to lung cancer as a cause of death from malignancy, with only 60% of patients alive at 5 years." | 2.42 | Which drug combination for colorectal cancer? ( Doggrell, SA, 2004) |
| "Colorectal Cancer is one of the leading causes for cancer related death in the industrialized world." | 2.42 | [Colorectal cancer: current treatment options]. ( Andre, N; Graeven, U; Schmiegel, W, 2004) |
| "Colorectal cancer is the second leading cause of cancer death in the USA and fluoropyrimidines have been the mainstay of treatment for over 40 years." | 2.42 | Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. ( Iqbal, S; Lenz, HJ, 2004) |
| "Metastatic colorectal cancer has long been considered as a short-term, poor prognosis, chemoresistant disease." | 2.41 | Therapeutic advances in the management of metastatic colorectal cancer. ( Descos, L; Freyer, G; Kraft, D; Ligneau, B; Trillet-Lenoir, V, 2001) |
| "Colorectal cancer is one of the most common tumors worldwide." | 2.41 | The role of genomic instabilities in affecting treatment responses of colorectal cancer. ( Bazzoli, F; Ricciardiello, L, 2002) |
| "Many patients who develop metastases are offered systemic chemotherapy to try to extend survival and maintain or improve quality of life." | 2.41 | Chemotherapy for metastatic colorectal cancer. ( , 2002) |
| "Adjuvant therapy for colorectal cancer includes chemotherapy, radiotherapy and immunotherapy." | 2.41 | Adjuvant therapy of colorectal cancer: the next step forward. ( Kumar, D; Prabhudesai, AG, 2002) |
| "Colorectal cancer is the second most common cause of cancer-related mortality in Europe and North America." | 2.41 | Chemotherapy in colorectal cancer: new options and new challenges. ( Chau, I; Cunningham, D, 2002) |
| " The safety of capecitabine and optimal dosing schedules have been explored in phase I/II studies, resulting in the evaluation of the intermittent schedule (1250 mg/m2 twice daily for 14 days, every 3 weeks) in most subsequent clinical trials." | 2.41 | Capecitabine (Xeloda): from the laboratory to the patient's home. ( Pentheroudakis, G; Twelves, C, 2002) |
| "Metastatic colorectal cancer is a major cause of cancer-related mortality." | 2.41 | Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer. ( Goldberg, RM; Hobday, TJ, 2002) |
| "Adjuvant radiation therapy for rectal cancer is not widely used in Japan, while chemotherapy is considered the adjuvant treatment of choice." | 2.41 | [Progress in adjuvant therapy for colorectal cancer]. ( Kakeji, Y; Kohnoe, S; Maehara, Y, 2002) |
| "Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells." | 2.41 | Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002) |
| "Progression of colorectal cancer can occur primarily isolated in the liver." | 2.41 | Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries. ( Gog, C; Heinrich, S; Lorenz, M; Müller, HH; Petrowsky, H; Staib-Sebler, E; Vetter, G, 2000) |
| "Capecitabine (Xeloda)(R) was developed as a tumour-selective fluoropyrimidine carbamate to achieve higher intratumoural 5-FU level and lower toxicity than 5-FU." | 2.41 | Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer. ( Di Costanzo, F; Gasperoni, S; Sdrobolini, A, 2000) |
| "Survival, disease progression, quality of life, and toxicity." | 2.41 | Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. ( Simmonds, PC, 2000) |
| "In advanced colorectal cancer, liver metastases are a major problem." | 2.41 | Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. ( Giaccone, G; Pinedo, HM; van Groeningen, CJ; van Riel, JM, 2000) |
| "Treatment of advanced colorectal cancer has progressed substantially." | 2.41 | Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. ( Burzykowski, T; Buyse, M; Carlson, RW; Molenberghs, G; Piedbois, P; Thirion, P, 2000) |
| " Fluorodeoxyuridine (FUDR) or 5-fluorouracil (5-FU) was used as the agent and a total dosage of 10-20 g was administered for 6-12 months in most studies." | 2.41 | [The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer]. ( Monden, T; Tono, T, 2000) |
| "Capecitabine (Xeloda) is a new, orally administered, enzyme-activated fluoropyrimidine carbamate designed to generate high levels of fluorouracil (5-FU) in tumor cells." | 2.41 | Pharmacology and clinical status of capecitabine. ( Schilsky, RL, 2000) |
| "Among colorectal cancer patients with recurrent or metastatic sites, survival was significantly prolonged for a group undergoing LV/5-FU therapy based on biochemical modulation compared with a group receiving no chemotherapy (best supportive care)." | 2.41 | [Progress in chemotherapy for colorectal cancer]. ( Maeda, Y; Sasaki, T, 2000) |
| "A significant number of patients with colorectal cancer will present with hepatic metastases as their only site of metastatic disease." | 2.41 | Intrahepatic therapy for resected hepatic metastases from colorectal carcinoma. ( Alberts, SR, 2000) |
| "The mainstay of chemotherapy in colorectal cancer patients for the past 40 years has been fluorouracil (5-FU)." | 2.41 | Efficacy of oxaliplatin in the treatment of colorectal cancer. ( Rothenberg, ML, 2000) |
| " Phase I studies have been completed showing the tolerability of two dosing schedules, including (1) a chronic schedule with twice-daily administration of eniluracil plus oral fluorouracil (5-FU) (10:1 ratio) for 28 days, and (2) a schedule of eniluracil administered daily on days 1-7 with oral 5-FU once daily on days 2-6." | 2.41 | Oral eniluracil/5-FU for advanced colon and breast carcinomas. ( Benson, AB, 2001) |
| "Capecitabine is a novel oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety fluorouracil (5-fluorouracil; 5-FU) in target tumour tissue through a series of 3 metabolic steps." | 2.41 | Clinical pharmacokinetics of capecitabine. ( Blesch, K; Reigner, B; Weidekamm, E, 2001) |
| "Colorectal cancer is usually diagnosed in patients around 70 years of age." | 2.41 | Chemotherapy in elderly patients with colorectal cancer. ( Aapro, M; Bokemeyer, C; Bontke, N; Grothey, A; Köhne, CH, 2001) |
| "Metastatic colorectal cancer remains incurable with available systemic therapeutic options." | 2.41 | Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. ( Grivicich, I; Mans, DR; Peters, GJ; Schwartsmann, G, 2001) |
| "Unusual aspect of the development of oxaliplatin was that substantial evidence of its activity was gathered when used in combination with protracted infusion of 5FU combined with leucovorin, preceeding the formal demonstration of its single activity in this disease." | 2.41 | [Oxaliplatin in combination with 5-fluoro-uracil and folinic acid as treatment of metastatic colorectal cancer]. ( André, T; Gramont, AD; Louvet, C; Maindrault-Goebel, F, 2001) |
| " The dosage and administration is referred to the weekly method developed at RPMI." | 2.41 | [Levofolinate and fluorouracil combination therapy]. ( Murakami, M; Takeuchi, S, 2001) |
| "Capecitabine is an oral fluoropyrimidine that was developed in response to the clinical need for new therapeutic options offering improved efficacy, tolerability, and convenience for patients." | 2.41 | The evolution of fluoropyrimidine therapy: from intravenous to oral. ( Cassidy, J; Hoff, PM; Schmoll, HJ, 2001) |
| "Metastatic colorectal cancer has traditionally been treated with i." | 2.41 | Answering patients' needs: oral alternatives to intravenous therapy. ( Borner, M; Maroun, J; Scheithauer, W; Twelves, C; Wilke, H, 2001) |
| " Since 5-FU seems to have dual, mechanisms of cell kill; DNA and RNA directed cytotoxicity, it is important to know how to maximize or improve therapeutic ratio by dosing or scheduling 5-FU administration, even modulating 5-FU with other agents." | 2.41 | [5-fluorouracil]. ( Aiba, K, 2001) |
| "Colorectal cancer is still a majorhealth and social problem." | 2.41 | Disease management considerations: disease management considerations. ( Beretta, GD; Labianca, RF; Pessi, MA, 2001) |
| "Capecitabine is an orally administered fluoropyrimidine which is selectively activated in tumour tissue to the active moiety fluorouracil and is cytotoxic through inhibition of DNA synthesis." | 2.41 | Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. ( Goa, KL; McGavin, JK, 2001) |
| "Capecitabine is a fluoropyrimidine carbamate that was rationally designed as an oral drug capable of mimicking continuous infusion 5-fluorouracil (5-FU) and delivering 5-FU preferentially to tumour tissue." | 2.41 | Rational development of capecitabine. ( Venturini, M, 2002) |
| "Colorectal cancer is the second leading cause of cancer death and it is clear that patients with metastatic disease have better quality of life and survival when given treatment." | 2.41 | New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. ( Holen, KD; Saltz, LB, 2001) |
| "The treatment of advanced colorectal cancer has long been a dilemma for clinicians." | 2.41 | Randomized clinical trials in advanced and metastatic colorectal carcinoma. ( Dangelica, MI; Nissan, A; Shoup, MC, 2002) |
| "Targeted treatment of colorectal cancer based on TS quantitation has thus been hypothesized similar to the use of hormone receptor in breast cancer." | 2.41 | Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. ( Aschele, C; Lonardi, S; Monfardini, S, 2002) |
| "Capecitabine is a synthetic oral fluoropyrimidine carbamate that is sequentially activated in a three-step process, which results in the preferential production of 5-fluorouracil in tumours, rather than in the normal surrounding tissue." | 2.41 | Capecitabine: fulfilling the promise of oral chemotherapy. ( Hwang, JJ; Marshall, JL, 2002) |
| "Colorectal cancer is the third leading cause of cancer mortality for men and women in the United States." | 2.40 | Experimental chemotherapeutic agents for the treatment of colorectal carcinoma. ( O'Reilly, S; Rowinsky, EK, 1997) |
| "Approximately 50% of patients with colorectal cancer develop locally recurrent or distant metastatic disease during the course of their illness and eventually die." | 2.40 | Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. ( Borud, K; Isacoff, WH, 1997) |
| " Optimal dosing and administration strategies remain to be determined." | 2.40 | A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. ( Machover, D, 1997) |
| "Patients with advanced colorectal cancer can only benefit from these important advances, however, if a truly multidisciplinary approach to patient care is adopted which requires integration of the roles of the surgeon, medical oncologist and radiotherapist." | 2.40 | The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon. ( Neoptolemos, JP; Rougier, P, 1997) |
| "Colorectal cancer is one of the most frequent cancers in western countries." | 2.40 | [Colorectal cancer: a controllable disease]. ( Bleiberg, H; Gerard, B, 1997) |
| "Trimetrexate is a nonclassical antifolate that has demonstrated antitumor activity against a number of malignancies, including those resistant to the classical antifolate methotrexate." | 2.40 | Trimetrexate: review and current clinical experience in advanced colorectal cancer. ( Blanke, CD; Messenger, M; Taplin, SC, 1997) |
| "Over the last 40 years the treatment of colorectal cancer has not achieved the same progress as treatment for other types of tumors." | 2.40 | Beyond 5-fluorouracil monochemotherapy in colorectal cancer--it is time. ( Franchi, F; Satta, F, 1997) |
| " A North American study (study 10) was originally set up to compare two raltitrexed dosage arms (3." | 2.40 | Mature results from three large controlled studies with raltitrexed ('Tomudex'). ( Cunningham, D, 1998) |
| "In human colorectal cancer cell lines and various animal tumour model systems 5-fluoro-2'-deoxyuridine (FdUrd) is more effective than 5-fluorouracil (5-FU)." | 2.40 | Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. ( Ackland, SP; Peters, GJ; Rustum, YM; van Groeningen, CJ; van Laar, JA, 1998) |
| "Colorectal cancer is the second leading cause of cancer death in western countries." | 2.40 | [Adjuvant therapy of colorectal carcinoma--1998 status]. ( Borner, M; Maurer, C, 1998) |
| "Colorectal cancer is one of the most frequent cancers in the western world." | 2.40 | 5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules. ( Kamm, YJ; Punt, CJ; Rietjens, IM; Wagener, DJ, 1998) |
| "Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (DPD), which is the first enzyme in the degradative pathway of systemically administered 5-fluorouracil (5-FU)." | 2.40 | Clinical development of eniluracil: current status. ( Hohneker, JA, 1998) |
| "Irinotecan (CPT11) is a synthetic camptothecin-derived DNA topoisomerase I inhibitor." | 2.40 | [Irinotecan: various administration schedules, study of drug combinations, phase I experience]. ( Armand, JP; Boige, V; Raymond, E, 1998) |
| "Irinotecan or CPT11 is a topoisomerase 1 inhibitor." | 2.40 | [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials]. ( Peeters, M; Van Cutsem, E, 1998) |
| "Irinotecan treated patients lived for significantly longer than those on 5FU: median time of survival was 10." | 2.40 | [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. ( Ducreux, M; Mitry, E; Rougier, P, 1998) |
| "Capecitabine was converted to 5'-DFUR by either human carboxyestelase or cytidine deaminase, which were mainly localized in human liver." | 2.40 | [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine]. ( Saeki, T; Takashima, S, 1999) |
| "This article describes two cases of colorectal cancer in adolescents and reviews the literature regarding this rare condition." | 2.40 | Colorectal cancer in adolescents. ( Renaut, AJ; Shankar, A; Taylor, I; Whelan, J, 1999) |
| "5-fluorouracil has been the major chemotherapeutic agent for the treatment of colorectal carcinoma for the past four decades." | 2.40 | A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. ( Adjei, AA, 1999) |
| "Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours." | 2.40 | Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil. ( Hoff, PM; Lassere, Y; Pazdur, R, 1999) |
| " Low dose and either continuous infusion or repetitive dosing of leucovorin, as well as the effect of treatment sequence and intervals between drugs, require additional investigation." | 2.39 | Preclinical and clinical aspects of biomodulation of 5-fluorouracil. ( Allegra, CJ; Grogan, L; Sotos, GA, 1994) |
| "Fifty per cent of patients with colorectal cancer develop hepatic metastases but only a minority are candidates for potentially curative surgical resection." | 2.39 | Hepatic artery chemotherapy for colorectal liver metastases. ( Jorgensen, JO; McCall, JL; Morris, DL, 1995) |
| "Colorectal cancer is the second most common cancer in the Western world, and yet the survival after potentially curative excisional surgery has improved little over the last half century." | 2.39 | Adjuvant chemotherapy for colorectal cancer. ( Leicester, RJ; Mansi, JL; Rayter, Z, 1995) |
| "The current EORTC study for colorectal cancer investigates the role of the combination of short time regional and long term systemic chemotherapy." | 2.39 | Colorectal carcinoma: current problems and future perspectives. ( Schmoll, HJ, 1994) |
| "Survival from colorectal cancer has not improved over the last four decades despite advances in surgery and anaesthesia." | 2.39 | Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study? ( Houston, RF; Moorehead, RJ; Wilson, RH, 1994) |
| "Chemotherapy for advanced colorectal cancer is reviewed stressing the historical development of combination chemotherapy and the application of a new idea called biochemical modulation based upon a preclinical biochemical and molecular pharmacological rationale." | 2.39 | [Recent advance in chemotherapy for advanced colorectal cancer]. ( Aiba, K, 1996) |
| " In many countries patients with CRC do not receive chemotherapy because some clinicians perceive that the benefits of such treatment do not compensate for the potential negative effects on patient quality of life in terms of toxicity and inconvenient dosage schedules." | 2.39 | Colorectal cancer--an undertreated disease. ( Kemeny, N, 1996) |
| "5-Fluorouracil (5-FU) has been studied over the past two decades in five prospective randomized trials comparing bolus with infusional schedules." | 2.39 | Infusional 5-FU for advanced colorectal cancer. ( Lokich, J, 1995) |
| "Colorectal cancer is a common cancer and a common cause of death." | 2.39 | Colorectal cancer: the challenge. ( Bleiberg, H, 1996) |
| "The treatment of advanced colorectal cancer has improved in recent years." | 2.38 | Recent advances in the treatment of advanced colorectal cancer. ( Ahlgren, JD; Anderson, N; Kemeny, N; Lokich, JJ, 1993) |
| "Advanced colorectal cancer belongs to the most chemotherapy-resistant human malignancies." | 2.38 | Chemotherapy of colorectal cancer. ( Blijham, GH, 1991) |
| "The substantial recurrence rate of colorectal cancer following potentially curative resection has fuelled the search for effective adjuvant therapy." | 2.38 | Adjuvant therapy of colorectal cancer: an overview. ( Green, M; Wirth, A; Zalcberg, JR, 1991) |
| "In the case of multi-site metastases, outside of trials, the decision to employ chemotherapy must be taken on an individual basis." | 2.38 | [Therapy of advanced colorectal cancer]. ( Schalhorn, A, 1991) |
| "Oxaliplatin utilized in colorectal neoplasms treatment could induce acute peripheral neuropathy (APN) which is a dreadful and frequent adverse event." | 1.91 | Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients. ( Ben Ayed, W; Ben Mahmoud, IT; Ben Said, A; Berguiga, S; Cherif, I; Hamdi, A; Houij, R; Limayem, I, 2023) |
| "Xenografted patient-derived colon cancer tissues with MSI also show variable patterns of HDAC2 expression in mice." | 1.91 | The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. ( Brachetti, C; Brenner, W; Kiweler, N; Krämer, OH; Linnebacher, M; Matschos, S; Mullins, C; Nguyen, A; Piée-Staffa, A; Roos, WP; Schneider, G; Schwarz, H, 2023) |
| "Moreover, E2 fraction potentialized colorectal cancer cells to 5-FU treatment." | 1.91 | Anti-tumoral Effect of ( Borie, N; Chazee, L; Devarenne-Charpentier, E; El Btaouri, H; Hammami, M; Martiny, L; Remy, S; Renault, JH; Toumi, I; Yatouji, S, 2023) |
| "5-Fluorouracil (5-FU) is an essential component of systemic chemotherapy for CRC." | 1.91 | ( Amor, D; Belaid, I; Ben Ahmed, S; Ben Rejeb, N; Bouslama, A; Chouchane, S; Khalij, Y; Omezzine, A, 2023) |
| "Of patients with colon cancer treated with an initial lower 5-FU dose, 18% had a therapeutic 5-FU blood level." | 1.91 | Initiating Treatment with Low Fluorouracil Dose and Titrating According to Blood Levels in Patients Treated with a 46-Hour Continuous Infusion. ( Baranseh, J; Khatib, AW; Selub, SM; Shai, A; Uryvaey, A, 2023) |
| "Colorectal cancer is the fourth most common cancer worldwide and the third most frequently diagnosed form of cancer associated with high mortality rates." | 1.91 | Folic-Acid-Conjugated Thermoresponsive Polymeric Particles for Targeted Delivery of 5-Fluorouracil to CRC Cells. ( Car, H; Lazny, R; Markiewicz, KH; Milewska, S; Misztalewska-Turkowicz, I; Niemirowicz-Laskowska, K; Sawicka, D; Siemiaszko, G; Szymczuk, D; Wilczewska, AZ, 2023) |
| " We utilized an in vitro dataset of cancer cell lines treated with 5FU and used the reported area under the dose-response curve values to determine the therapeutic response to 5FU treatment." | 1.91 | New Transcriptomic Biomarkers of 5-Fluorouracil Resistance. ( Fekete, JT; Győrffy, B, 2023) |
| "Three datasets of colorectal cancer patients (GSE28691, GSE81006, and GSE77932) from the Gene Expression Omnibus (GEO) database were analyzed and volcano plots for DEGs were generated using the GEO2R tool." | 1.91 | Gamma-Aminobutyric Acid Type A Receptor Subunit Pi is a potential chemoresistance regulator in colorectal cancer. ( Chen, C; Chen, J; Feng, Y; Huang, Z; Jin, L; Wang, T; Wu, T; Yao, S; Zhen, Q, 2023) |
| "Colorectal cancer has risen to the third occurring cancer in the world." | 1.91 | The Gut Microbiota Metabolite Urolithin B Prevents Colorectal Carcinogenesis by Remodeling Microbiota and PD-L1/HLA-B. ( Chen, J; Chen, Q; Jin, S; Song, H; Song, X; Wang, L; Wang, Z; Xing, W; Yang, H; Zhao, W, 2023) |
| "Body surface area (BSA)-based dosing of 5-fluorouracil (5-FU) results in marked inter-individual variability in drug levels, whereas determination of plasma 5-FU concentration and area under the curve (AUC) is a more precise dosing method but has not been integrated into clinical routine." | 1.91 | Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study. ( Burkholder, I; Frank-Gleich, S; Fries, S; Hebart, H; Hofheinz, RD; Hutzschenreuter, U; Kollendt, M; Lamberti, C; Lathan, B; Li, M; Lorentz, C; Lück, A; Mindt, S; Sandner, R; Sick, C; Stein, W; Stosiek, C; Tesch, H; Zingerle, M; Zöller, T, 2023) |
| "Colorectal cancer (CRC) is the third most common cancer in the world, but current chemotherapy options are limited due to adverse effects and low oral bioavailability of drugs." | 1.91 | Development and cytotoxicity evaluation of multiple nanoemulsions for oral co-delivery of 5-fluorouracil and short chain triglycerides for colorectal cancer. ( Barreto, T; Branco, PC; Fukumori, C; Ishida, K; Lopes, LB, 2023) |
| "Blastocystis is an enteric protozoan parasite with extensive genetic variation and unclear pathogenicity." | 1.91 | Blastocystis sp. reduces the efficacy of 5-fluorouracil as a colorectal cancer chemotherapeutic treatment. ( Govind, SK; Jayalakshmi, P; Kumarasamy, V; Kuppusamy, UR, 2023) |
| "To evaluate the association of age with treatment-related adverse events and survival in patients with mCRC and explore the potential underlying factors." | 1.91 | Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer. ( Delgado, MG; Gomez, MF; Hubbard, JM; Ji, R; Kim, RD; Knepper, TC; Laber, DA; Meng, L; Permuth, JB; Thapa, R; Wang, X; Xie, H, 2023) |
| "Chemoresistance mechanisms of colorectal cancer remain largely elusive." | 1.91 | Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells. ( Chen, JY; Islam Khan, MZ; Law, HK; Tam, SY; Tam, TY; Yan, HY; Yip, JH, 2023) |
| "Four databases were compared for colorectal cancer (CRC) cases and stage IV CRC cases: American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative (GENIE-BPC), The Cancer Genome Atlas (TCGA), SEER-Medicare, and MarketScan Commercial and Medicare Supplemental claims databases." | 1.91 | Evaluation and Comparison of Real-World Databases for Conducting Research in Patients With Colorectal Cancer. ( Amonkar, MM; Bortnichak, EA; Liu, X; McDonald, AC; Shao, C; Wang, CY; Zhou, W, 2023) |
| "BRAF V600E mutant-metastatic colorectal cancer (mCRC) is characterized by its short survival time." | 1.91 | Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China. ( Chang, W; Fu, J; Lin, Q; Lv, Y; Tang, W; Wang, G; Xu, J; Xu, Y; Zhang, T; Zheng, X; Zhu, Z, 2023) |
| "RNA sequencing of primary colorectal cancer specimens vs adjacent liver tissue vs synchronous and asynchronous liver metastases." | 1.91 | Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids. ( Blandino, G; Canu, V; Caricato, M; Cioce, M; Crescenzi, A; Diodoro, MG; Donzelli, S; Fanciulli, M; Fazio, VM; Fumagalli, MR; Goeman, F; Grazi, GL; La Porta, C; Levrero, M; Morrone, A; Orlandi, G; Palcau, AC; Pulito, C; Rutigliano, D; Sacconi, A; Strano, S; Verri, M; Zapperi, S, 2023) |
| "Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent." | 1.91 | In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells. ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023) |
| " We investigated whether plasma angiogenesis factors could predict the efficacy of biologics combined with chemotherapy in first-line (1L) treatment in patients with RAS wild-type mCRC and the dynamics of plasma angiogenesis factors at progression during 1L treatment." | 1.91 | Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study. ( Abe, Y; Asano, C; Bando, H; Denda, T; Esaki, T; Kagawa, Y; Kato, T; Kawakami, H; Matsuhashi, N; Nishina, T; Nomura, S; Satake, H; Shiozawa, M; Sunakawa, Y; Takahashi, N; Takashima, A; Taniguchi, H; Yamazaki, K; Yasui, H; Yoshino, T; Yuki, S, 2023) |
| " Using cell models of colorectal and pancreatic cancers, we show that cotreatment with Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone, AcB), a natural flavone from Achyrocline bogotensis, allows for four-fold reduction in 5-Fu dosage without loss of efficacy." | 1.91 | Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers. ( Cartwright, BM; Corso, JN; Krishnan, K; Lightner, J; Palau, VE; Torrenegra, RD; Whitted, C, 2023) |
| " Number of cycles, dose delays for any cause, and dose reductions for adverse events (AEs) were comparable between age classes." | 1.91 | Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study. ( Anchisi, S; Bohanes, P; Derigs, HG; Geffriaud-Ricouard, C; Grünberger, B; Gueldner, M; Hofheinz, RD; Piringer, G; Scholten, F; Schwarz, L; Thaler, J; von Moos, R, 2023) |
| "Silencing HCG11 inhibited colon cancer cell proliferation, migration, invasion and glucose metabolism and sensitized CRC cells to 5-FU." | 1.72 | LncRNA HCG11 promotes 5-FU resistance of colon cancer cells through reprogramming glucose metabolism by targeting the miR-144-3p-PDK4 axis. ( Cui, Z; Deng, MH; Han, QL; Wang, Q, 2022) |
| "To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC)." | 1.72 | Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. ( Aprile, G; Avallone, A; Bilancia, D; Brugnatelli, S; Carlomagno, C; Cicero, G; Cinausero, M; Colombo, A; Corsi, D; Dell'Aquila, E; Pinto, C; Rapisardi, S; Reggiardo, G; Rosati, G, 2022) |
| "Metformin is an old, inexpensive, and relatively safe anti-diabetic medication that can decrease the risk of several types of cancer in patients with diabetes." | 1.72 | The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer. ( Ala, M, 2022) |
| "Cardiotoxicity is a severe side effect for colorectal cancer (CRC) patients undergoing fluoropyrimidine-based chemotherapy." | 1.72 | Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy. ( Chen, L; Chou, C; Li, C; Ngorsuraches, S; Qian, J, 2022) |
| "Combining colorectal resection with HAI pump implantation is a safe surgical approach for management of unresectable CRLM." | 1.72 | Combined Primary Resection with Hepatic Artery Infusion Pump Implantation Is Safe for Unresectable Colorectal Liver Metastases. ( Allen, PJ; Creasy, JM; Lan, B; Lidsky, ME; Mantyh, CR; Migaly, J; Moore, C; Sharib, J; Thacker, JKM; Turley, MC; Zani, S, 2022) |
| "5-Fluorouracil is an anticancer drug with a short biological half-life." | 1.72 | The development of a novel oral 5-Fluorouracil in-situ gelling nanosuspension to potentiate the anticancer activity against colorectal cancer cells. ( Abdullah, S; Aldahlawi, A; El Hadad, S, 2022) |
| "During the development of colorectal cancer, tumor cells will generate some cancer stem cells with self-renewal ability because they adapt to the environment." | 1.72 | BIX-01294 enhances the effect of chemotherapy on colorectal cancer by inhibiting the expression of stemness genes. ( Han, Y; Hua, Z; Jiang, Y; Liu, S; Nie, S; Shu, X; Wang, X; Xu, G; Xu, S; Yang, H; Zhou, C, 2022) |
| "The incidence of colorectal cancer (CRC) in individuals of fertile age is increasing." | 1.72 | Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. ( Berglund, Å; Eberhard, J; Falk, P; Guren, MG; Hofsli, E; Österlund, P; Severin, M; Sorbye, H; Tandberg, A, 2022) |
| "Fifteen percent of colorectal cancer (CRC) cells exhibit a mucin hypersecretory phenotype, which is suggested to provide resistance to immune surveillance and chemotherapy." | 1.72 | Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion. ( Alonso-Marañón, J; Cantero-Recasens, G; Espinosa, L; Garrido, M; Iglesias, M; Lobo-Jarne, T; Malhotra, V, 2022) |
| " Based on the T helper 17(Th17)/regulatory T cell(Treg) balance, the present study explored the possible mechanism of AR-CR combined with 5-fluorouracil(5-FU) on the tumor growth of orthotopic xenograft model mice of colorectal carcinoma." | 1.72 | [Effect of Astragali Radix-Curcumae Rhizoma compatibility combined with 5-fluorouracil on Th17/Treg balance and tumor-related mRNA and protein expression in orthotopic xenograft model mice of CT26.WT colorectal carcinoma]. ( Guan, HQ; Guo, WH; Liang, L; Liang, Y; Liu, TT; Qi, ZC; Tang, DC; Yu, QH, 2022) |
| " The efficacy and adverse effects of maintenance treatment were compared between the two groups." | 1.72 | Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer. ( Cha, Y; Huang, W; Tian, Y; Xiong, H; Yuan, X; Zhang, H, 2022) |
| " Common Terminology Criteria for Adverse Events v4." | 1.72 | Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study. ( Alyami, M; Bakrin, N; Bardet, SM; Dumont, F; Durand Fontanier, S; Eveno, C; Gagniere, J; Glehen, O; Hübner, M; Pache, B; Pocard, M; Quenet, F; Sgarbura, O; Taibi, A; Teixeira Farinha, H; Thibaudeau, E, 2022) |
| "Most of Stage II/III colorectal cancer (CRC) patients can be cured by surgery alone, and only certain CRC patients benefit from adjuvant chemotherapy." | 1.72 | A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer. ( Jonnagaddala, J; Li, X; Xu, XS; Yang, S; Zhang, H, 2022) |
| "Chemotherapy resistance of colorectal cancer stem cells (CRC-SCs) has become a major challenge in clinical treatment of cancer." | 1.72 | Methionine restriction enhances the chemotherapeutic sensitivity of colorectal cancer stem cells by miR-320d/c-Myc axis. ( Liu, C; Wang, JL; Wu, DZ; Xin, L; Yuan, YW, 2022) |
| "But its role in the development of colorectal cancer (CRC) cancer remains unknown." | 1.72 | FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis. ( Deng, H; He, Z; Li, G; Mou, T; Shi, J; Sui, C; Sun, K; Wang, T; Wang, Y; Xu, Z; Yang, J; Zhang, P; Zhuang, B, 2022) |
| "It revealed a peritoneal recurrence in the pouch of Douglas." | 1.72 | [A Case Report for Peritoneal Recurrences by Laparoscopic Surgery after Colorectal Cancer Resection]. ( Arakawa, A; Ii, Y; Irie, T; Kawaguchi, M; Kawai, M; Kobari, A; Kojima, Y; Momose, H; Sakamoto, K; Sugimoto, K; Terao, Y; Tomiki, Y; Tsukamoto, R, 2022) |
| " The most frequent grade 3/4 adverse events were: asthenia (21." | 1.72 | Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen. ( Alonso de Castro, B; Cameselle García, S; Carmona Campos, M; Cousillas Castiñeiras, A; De la Cámara Gómez, JC; Fernández-Montes, A; Gómez-Randulfe Rodríguez, MI; González Villarroel, P; Martínez-Lago, N; Méndez Méndez, JC; Romero Reinoso, C; Salgado Fernández, M; Vidal Insua, Y, 2022) |
| "Colorectal cancer is one of the most commonly diagnosed malignancies globally and nearly half of these patients develop metastatic colorectal cancer (mCRC)." | 1.72 | Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy. ( Liu, JY; Liu, X; Long, YX; Qiu, M; Zhou, YW, 2022) |
| "However, its role and mechanism in colorectal cancer (CRC) remained unknown." | 1.72 | circEXOC6B interacting with RRAGB, an mTORC1 activator, inhibits the progression of colorectal cancer by antagonizing the HIF1A-RRAGB-mTORC1 positive feedback loop. ( Chen, L; Chen, Y; Dai, P; Li, X; Lin, W; Long, H; Lu, Y; Wang, H; Wang, J; Yuan, Q, 2022) |
| "Chemoresistance is a main obstacle for colorectal cancer treatment." | 1.72 | Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells. ( Li, J; Liu, J; Liu, K; Luo, F, 2022) |
| "5-Fluorouracil (5-FU) has long been used as a standard first-line treatment for CRC patients." | 1.72 | Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer. ( Duan, T; Feng, J; Huang, X; Jin, W; Ke, K; Mei, R; Mou, Y; Shou, L; Sui, X; Sun, X; Wu, Q; Xie, T; Yu, S; Zhang, R; Zhu, Q, 2022) |
| " Treatment regimens, body surface area, dosage, number of treatment courses, and adverse events( AEs) were evaluated." | 1.72 | [Comparative Safety Assessment of Ramucirumab plus FOLFIRI and Bevacizumab plus FOLFIRI in Second- and Later-Line Treatment in Japanese Patients with Metastatic Colorectal Carcinoma]. ( Iwai, M; Kimura, M; Usami, E; Yoshimura, T, 2022) |
| " Data from experiments for 48 h showed that Bru, alone or in combination with 5-FU, is capable of causing an increase in the percentage of apoptotic cells in HT-29 cells compared to those of Erio alone or in combination with 5-FU." | 1.72 | Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell. ( Alper, M; Ardıl, B, 2022) |
| "More and more patients with advanced colorectal cancer (CRC) have benefited from surgical resection or ablation following neoadjuvant chemoradiotherapy (nCRT), but nCRT may be ineffective and have potential risks to some patients." | 1.72 | Kif4A mediates resistance to neoadjuvant chemoradiotherapy in patients with advanced colorectal cancer via regulating DNA damage response. ( Ding, C; Dong, Z; Gong, B; Jin, S; Liu, S; Xie, W; Xu, C; Xu, L; Zhang, R; Zhao, Y; Zheng, Y, 2022) |
| "Grade ≥ 3 neutropenia was significantly more common in patients with than without osteopenia (p = 0." | 1.72 | Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study. ( Kashihara, H; Nakao, T; Nishi, M; Shimada, M; Takasu, C; Tokunaga, T; Wada, Y; Yamashita, S; Yoshikawa, K; Yoshimoto, T, 2022) |
| " However, during CRC treatment, long-term use of traditional chemotherapeutic drugs will reduce the sensitivity of chemotherapy." | 1.72 | A serum metabolomics study based on LC-MS: Chemosensitization effects of Rauvolfia vomitoria Afzel. combined with 5- fluorouracil on colorectal cancer mice. ( Kong, WR; Wang, JF; Wang, N; Wang, SQ; Wang, ZF; You, YL, 2022) |
| " Treatment was started with 30 mg of prednisolone, and the dosage was gradually decreased." | 1.72 | [A Case of Unilateral Interstitial Lung Disease in a Patient Treated with Oxaliplatin, 5-Fluorouracil, and Leucovorin]. ( Aisaki, K; Aoki, K; Doumoto, Y; Funatsu, K; Hosaka, M; Kimura, T; Kobori, S; Minoshima, K; Ushiku, H; Wakabayashi, M; Yoshida, H, 2022) |
| "On day 2 of re-treatment, serous retinal detachment recurred and treatment was discontinued." | 1.72 | [A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer]. ( Ajihara, T; Fukuya, Y; Hanada, M; Koike, T; Kono, T; Miyata, R; Naritomi, T; Shiozawa, S; Yoshimatsu, K, 2022) |
| " By combining high content light microscopy imaging and processing with rapid multiwell plate bioprinting, dose-response profiles are generated from CRC spheroids challenged with oxaliplatin (OX) and fluorouracil (5FU), as well as radiotherapy." | 1.72 | A rapid high throughput bioprinted colorectal cancer spheroid platform for ( Alibhai, D; Bayley, H; Chambers, AC; Collard, TJ; Johnson, PA; Menegatti, S; Perriman, AW; Williams, AC, 2022) |
| "Case 2: A 72-year-old man underwent sigmoid colon cancer resection with duodenal infiltration." | 1.72 | [Cases of Advanced Colorectal Cancer with Nephrotic Syndrome after FOLFIRI plus Ramucirumab Administration]. ( Fujimura, T; Nakura, M; Nojima, K; Sasaki, S; Takenaka, S; Takeshita, M; Watanabe, T; Yamazaki, H, 2022) |
| "A total of 48 consecutive patients with colorectal cancer (CRC) with hepatic metastasis were retrospectively reviewed, and factors such as metastatic tumor vascular microenvironment, chemotherapy response and hepatic resection, were analyzed." | 1.62 | Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response. ( Ichikawa, D; Iino, H; Okamoto, H; Shiba, S; Sudoh, M, 2021) |
| "The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects." | 1.62 | NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study. ( Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C, 2021) |
| " Doctors should be aware of the sex difference in the incidence of early DLTs, adjust the CAPOX dosage and provide supportive care for female CRC patients." | 1.62 | Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer. ( Abe, S; Anzai, H; Emoto, S; Ishihara, S; Kawai, K; Kishikawa, J; Murono, K; Nagai, Y; Nozawa, H; Ozawa, T; Sasaki, K; Sonoda, H; Yokoyama, Y, 2021) |
| "Among patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled." | 1.62 | Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk. ( Fukunaga, M; Hayashi, T; Kogawa, T; Matsui, R; Mizuki, F; Nishimura, J; Satoh, T; Shimokawa, M; Tsuji, Y, 2021) |
| "Regorafenib, which has been approved as a salvage line for metastatic colorectal cancer, features many adverse events, and there are few cases in which the approved dose can be administered." | 1.62 | [A Case of Long-Term Survival after Administration of Regorafenib for Stage Ⅳ Colorectal Cancer]. ( Koike, T; Kono, T; Miyano, Y; Oyama, K; Shiozawa, S; Yokokawa, H; Yoshimatsu, K, 2021) |
| "Fatty liver is a side effect of chemotherapy that limits the ability to treat colorectal cancer (CRC) patients in the most effective way." | 1.62 | Alterations in hepatic fatty acids reveal depletion of total polyunsaturated fatty acids following irinotecan plus 5-fluorouracil treatment in an animal model of colorectal cancer. ( Bathe, O; Jacobs, R; Mazurak, VC; Monirujjaman, M; Nelson, R; Pant, A, 2021) |
| "Colorectal cancer is one of the most common cancers in the world." | 1.62 | Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report. ( Akkuş, E; Gürbüz, M; Utkan, G, 2021) |
| "The enterocyte subtype of colorectal cancer (CRC) responds favorably to oxaliplatin-based adjuvant treatment for stage III CRC." | 1.62 | Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. ( Barzi, A; Berger, MD; Cao, S; Lenz, HJ; Matsusaka, S; Miyamoto, Y; Okazaki, S; Schirripa, M; Suenaga, M; Yamaguchi, T; Yamamoto, N; Zhang, W, 2021) |
| "Individuals with Stages II and III colorectal cancer who underwent major resection from 2014 to 2015 were identified." | 1.62 | Addressing the variation in adjuvant chemotherapy treatment for colorectal cancer: Can a regional intervention promote national change? ( Birch, RJ; Brown, V; Dent, J; Dewdney, A; Morris, EJA; Quirke, P; Rossington, HL; Seligmann, JF; Swinson, D; Taylor, JC, 2021) |
| "All breast and colorectal cancer patients enrolled in the POG program between July 1, 2012 and November 30, 2016 were eligible for inclusion." | 1.62 | Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer. ( Abadi, S; Chia, S; Guenter, J; Jones, M; Laskin, J; Lim, H; Marra, M; Rebic, N; Renouf, DJ; Woods, R, 2021) |
| "5-Fluorouracil is an antineoplastic agent generally used to treat various types of solid tumors." | 1.62 | Case report on 5-fluorouracil induced cerebrovascular accident. ( Ashok, AM; Babu, CM; Karthikeyan, K; Madhu, CS; Shaji, S, 2021) |
| "The distinct features among BRAF mutant colorectal cancers make these tumor groups hard to treat for oncologists." | 1.62 | The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study. ( Artac, M; Ates, O; Beypinar, I; Demir, H; Eren, T; Ergun, Y; Korkmaz, M; Sakalar, T; Sakin, A; Taskoylu, BY; Turhal, S, 2021) |
| "A considerable proportion of metastatic colorectal cancer patients who received active chemotherapy in this population-based study received only one line of therapy." | 1.62 | Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer. ( Abdel-Rahman, O; Koski, S; Mulder, K, 2021) |
| "Colorectal cancer is a major health problem with a significant impact on the patients' quality of life." | 1.62 | 5-FU inhibits migration and invasion of CRC cells through PI3K/AKT pathway regulated by MARCH1. ( Dai, J; Jia, X; Liu, C; Wang, N; Wu, Y; Yang, L; Zhang, R, 2021) |
| "In patients with metastatic colorectal cancer (mCRC) receiving highly active first-line combination treatments, early tumor shrinkage (ETS) and depth of response (DoR) are associated with survival, but their influence on outcomes during maintenance therapy is unknown." | 1.62 | Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. ( Antista, M; Antoniotti, C; Bergamo, F; Calareso, G; Clavarezza, M; Corallo, S; Cremolini, C; de Braud, F; Di Bartolomeo, M; Greco, FG; Lonardi, S; Manca, P; Morano, F; Murialdo, R; Pagani, F; Palermo, F; Pietrantonio, F; Prisciandaro, M; Racca, P; Raimondi, A; Randon, G; Rimassa, L; Smiroldo, V; Tampellini, M; Tomasello, G; Vaiani, M; Zaniboni, A, 2021) |
| " Although the survival benefits when combined with chemotherapy have been determined, there are no studies comparing the two agents with chemotherapy in the second-line treatment." | 1.62 | The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience. ( Almuradova, E; Çakar, B; Doğanavşargil, B; Gürsoy, P; Harman, M; Karabulut, B; Karateke, M; Sezak, M, 2021) |
| "The use of sodium levofolinate (Na-Lev) is safe in combination with continuous infusion 5-fluorouracil in patients with gastrointestinal tumors treated with the FOLFIRI regimen." | 1.62 | Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen. ( Bartolini, G; Crudi, L; Donati, C; Foca, F; Frassineti, GL; Masini, C; Matteucci, L; Monti, M; Pagan, F; Passardi, A; Rapposelli, I; Ruscelli, S; Sbaffi, S; Sullo, F; Valgiusti, M, 2021) |
| "Oesophageal cancer is categorised among the most fatal cancers across the world with a mortality ranking of sixth position." | 1.62 | Rare presentation of subglottic soft-tissue swelling following FOLFOX therapy in a patient with metastatic oesophageal cancer. ( Govero, AB; Kukhon, FR; Sanghavi, DK; Yarrarapu, SNS, 2021) |
| "42 L/h/kg after intravenous administration, oral bioavailability of 13." | 1.62 | Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts. ( Altenhofen, S; Basso, LA; Bizarro, CV; Bonan, CD; Borsoi, AF; da Silva Dadda, A; de Sousa, JT; de Souza, APD; Freitas, DDN; Freitas, RDS; Machado, P; Nabinger, DD; Perelló, MA; Picada, JN; Rodrigues-Junior, VS; Roth, CD; Silva, RBM; Sperotto, NDM, 2021) |
| "It is used to treat metastatic colorectal carcinoma." | 1.62 | A rare presentation of panitumumab-involved interstitial lung disease: Spontaneous pneumomediastinum. ( Ates, UC; Comert, B; Ergun, B; Gezer, S; Ugur, L; Yakar, N, 2021) |
| "Emerging data show a rise in colorectal cancer (CRC) incidence in young men and women that is often chemoresistant." | 1.62 | Mice with dysfunctional TGF-β signaling develop altered intestinal microbiome and colorectal cancer resistant to 5FU. ( Hopson, LM; Jogunoori, W; Lin, P; Mazumder, R; Miller, L; Mishra, L; Nguyen, BN; Obias, V; Rao, S; Singleton, SS; Wang, Z; White, J; Yang, X; Yao, M, 2021) |
| "Colorectal cancer is the second most common malignant tumor in China." | 1.62 | [Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer]. ( , 2021) |
| "Drug resistance in colorectal cancer is a great challenge in clinic." | 1.62 | MicroRNA-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer. ( Fang, Y; Liu, P; Shen, X; Wang, W; Wu, S; Zhang, H; Zhou, Y, 2021) |
| "Zotarolimus is a semi-synthetic derivative of rapamycin and an inhibitor of mammalian target of rapamycin (mTOR) signaling." | 1.62 | Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice. ( Chang, GR; Chen, CH; Kuo, CY; Liao, HJ; Lin, TC; Lin, WL; Tsai, MY; Wang, YC, 2021) |
| " Although curcumin is known to have anti-tumor, hepatoprotective, and hypoglycemic-like actions, its low water solubility, oral absorption, and bioavailability impede its therapeutic uses." | 1.62 | Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids. ( Abugomaa, A; Ayame, H; Elbadawy, M; Hayashi, K; Hayashi, SM; Hazama, S; Ishihara, Y; Kaneda, M; Nagano, H; Nakajima, M; Sasaki, K; Shibutani, M; Shinohara, Y; Suzuki, N; Takenouchi, H; Tsunedomi, R; Usui, T; Yamawaki, H, 2021) |
| "Metastatic colorectal cancer patients treated with aflibercept beyond second-line therapy were included." | 1.56 | Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. ( Artru, P; Auclin, E; Auvray, M; Coriat, R; Hammel, P; Hautefeuille, V; Lecaille, C; Lecomte, T; Locher, C; Moulin, V; Pernot, S; Sickersen, G; Taieb, J; Tougeron, D; Vernerey, D, 2020) |
| "Although the colorectal cancer (CRC) mortality rates are decreasing in virtue of CRC screening and improved therapeutic methods, CRC is still a leading cause of cancer deaths." | 1.56 | Ferritin Light Chain (FTL) competes with long noncoding RNA Linc00467 for miR-133b binding site to regulate chemoresistance and metastasis of colorectal cancer. ( Chen, H; Huang, L; Li, Z; Liu, J; Shen, R; Shi, H; Tao, J; Wang, T; Zhang, Y, 2020) |
| "Over 50% of colorectal cancer patients develop resistance after a transient response to therapy." | 1.56 | Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. ( Cao, Y; Li, Q; Liu, Y; Zhang, Y; Zhou, J, 2020) |
| "In metastatic colorectal cancer (MCRC), mucinous histology has been associated with poor response rate and prognosis." | 1.56 | Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. ( Alessandroni, P; Bergamo, F; Borelli, B; Catalano, V; Cremolini, C; Falcone, A; Giordani, P; Graziano, F; Intini, R; Lonardi, S; Mattioli, R; Negri, F; Rocchi, MBL; Rossini, D; Santini, D; Sarti, D; Stragliotto, S; Vincenzi, B; Zagonel, V, 2020) |
| "Truncating mutations in adenomatous polyposis coli (APC) are well-described events in CRC carcinogenesis." | 1.56 | APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy. ( Abduljabbar, A; Ahmed, SO; Al-Dayel, F; Al-Kuraya, KS; Al-Sanea, N; Ashari, LH; Begum, R; Concepcion, RMJA; Kumar Parvathareddy, S; Melosantos, R; Padmaja Divya, S; Pratheeshkumar, P; Siraj, AK, 2020) |
| "5-Fluorouracil (5-FU) is a typical CRC treatment." | 1.56 | BET inhibitor bromosporine enhances 5-FU effect in colorectal cancer cells. ( Cheng, X; Huang, Z; Jin, W; Long, D, 2020) |
| "Untreated colorectal tumors contain a population of quiescent/slow cycling cells with stem cell features (quiescent cancer stem cells, QCSCs) characterized by a predetermined mesenchymal-like chemoresistant phenotype." | 1.56 | A pre-existing population of ZEB2 ( Baiocchi, M; Boe, A; Careccia, S; Ciardi, A; Colace, L; Contavalli, P; D'Andrea, V; De Angelis, ML; De Maria, R; Francescangeli, F; Giuliani, A; Guardiola, O; Haas, TL; La Torre, F; Medema, J; Minchiotti, G; Pagliuca, A; Salaris, F; Signore, M; Tcheremenskaia, O; Zeuner, A, 2020) |
| "The chemotherapeutic efficacy in colorectal cancer (CRC) is limited due to the inter-individual variability in drug response and the development of tumour resistance." | 1.56 | Expression quantitative trait loci in ABC transporters are associated with survival in 5-FU treated colorectal cancer patients. ( Bartu, L; Bendova, P; Buchler, T; Hughes, DJ; Kral, J; Kumar, R; Levy, M; Naccarati, A; Pardini, B; Rosa, F; Soucek, P; Susova, S; Vodicka, P; Vodickova, L; Vymetalkova, V, 2020) |
| " A modified FOLFOXIRI regimen is also widely used to reduce adverse events." | 1.56 | Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience. ( Adachi, T; Eguchi, S; Enjoji, T; Hidaka, M; Inoue, Y; Ito, S; Kanetaka, K; Kobayashi, K; Kosaka, T; Kuba, S; Okada, S; Takatsuki, M; Tetsuo, H; Torashima, Y; Yamaguchi, S; Yamanouchi, K, 2020) |
| " Physiological information of treatment response derived via diffuse reflectance spectroscopy (DRS) from murine primary CRC tumors provide a better understanding for the development of new drugs and dosing strategies in CRC." | 1.56 | Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response. ( Bullard, EA; Fahr, MJ; Greening, GJ; Hale, LN; Muldoon, TJ; Mundo, AI; Rajaram, N, 2020) |
| "TUSC3 gene plays an oncogenic role in colorectal cancer (CRC), however, the role of TUSC3 in drug resistance of CRC is still unclear." | 1.56 | TUSC3 induces drug resistance and cellular stemness via Hedgehog signaling pathway in colorectal cancer. ( Cai, R; Deng, R; Ding, Y; Lin, J; Lu, X; Luo, Y; Ren, Y; Wang, Z; Yin, M; Zhu, Y, 2020) |
| "Some metastatic colorectal cancer (mCRC) patients receive conversion surgery (CS), including metastasectomy after palliative chemotherapy." | 1.56 | Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases. ( Chang, W; Cho, JY; Cho, S; Jheon, S; Kang, SB; Kim, DW; Kim, JH; Kim, JW; Kim, K; Kim, SA; Lee, KW; Oh, HK; Suh, KJ, 2020) |
| "FOLFOX therapy has been used for gastric cancer in Japan since 2017." | 1.56 | [Clinical Efficacy of mFOLFOX6 for Advanced Gastric Cancer]. ( Cho, H; Funasaka, C; Kanemasa, Y; Omuro, Y; Shimoyama, T, 2020) |
| "Developing new drugs for killing colorectal cancer (CRC) cells is urgently needed." | 1.56 | Toosendanin-induced apoptosis in colorectal cancer cells is associated with the κ-opioid receptor/β-catenin signaling axis. ( Chen, J; Chen, S; He, L; Huang, L; Li, W; Liu, H; Liu, R; Wang, F; Wang, H; Wen, C; Yang, X; Yu, WK; Zhou, Q, 2020) |
| "Thirty metastatic colorectal cancer patients without RAS and BRAF mutations were prospectively enrolled and treated with cytotoxic agents and EGFR blockade as first-line therapy." | 1.56 | Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy. ( Iwai, T; Koizumi, M; Kuriyama, S; Matsuda, A; Ohta, R; Shinji, S; Takahashi, G; Takeda, K; Ueda, K; Yamada, T; Yokoyama, Y; Yoshida, H, 2020) |
| "Cutaneous metastases from colorectal cancer are extremely rare and generally appear several years after diagnosis or resection of the primary colorectal tumor." | 1.56 | Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report. ( Cheng, Q; Liao, L; Pei, F; Ye, S; Zhu, G, 2020) |
| " Chemotherapy-induced side effects were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE Version 5." | 1.56 | Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. ( Abdhaghighi, MJ; Jalali, H; Janbabaei, G; Negarandeh, R; Nosrati, A; Saghafi, F; Salehifar, E, 2020) |
| "Treatment options for locally advanced rectal cancer have continued to consist largely of chemotherapy, chemoradiation, and/or surgical resection." | 1.56 | Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. ( Cho, M; Damle, N; Dayyani, F; Demisse, R; Eng, C; Fakih, M; Gholami, S; Gong, J; Halabi, W; Ji, J; Kim, E; Liu, J; Louie, R; McKenny, M; Monjazeb, A; Oesterich, L; Tam, K, 2020) |
| "The overexpression of CTCF promoted colorectal cancer cell proliferation and tumor growth, while the opposite effects were observed in CTCF knockdown cells." | 1.56 | CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis. ( Cai, J; Ding, J; Fang, Y; He, C; He, J; Lai, Q; Li, A; Li, Q; Lin, S; Liu, S; Liu, Y; Wang, X; Wu, C; Yan, Q; Zhang, Y; Zhong, Q, 2020) |
| "Fifty patients with metastatic colorectal cancer were prospectively followed-up during the first 4 cycles of fluoropyrimidine-based treatment to assess AEs." | 1.56 | Association of C677T and A1298C ( Chinchilla, R; Ramos-Esquivel, A; Valle, M, 2020) |
| " We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale)." | 1.56 | FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study. ( Costa, BA; da Rocha Filho, DR; de Albuquerque Ribeiro Gondinho, P; de Barros Silva, PG; Gifoni, MAC; Junior, RCPL; Lima, MVA; Lisboa, MRP; Vale, ML, 2020) |
| "Eighteen cases of stage IV CAC (7 ulcerative colitis, 11 Crohn disease) and 18 CRC were identified." | 1.56 | Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis. ( Bates, DDB; Capanu, M; Chatila, W; Chou, J; Hersch, J; Kelsen, D; Paroder, V; Schultz, N; Tang, L; Yaeger, R, 2020) |
| " Whether a patient who experienced a major cardiac side effect from 5-FU can be safely rechallenged with this drug is a clinical dilemma." | 1.56 | 5-Fluorouracil Rechallenge After Cardiotoxicity. ( Almnajam, M; Desai, A; Kim, AS; Mohammed, T; Patel, KN, 2020) |
| "Glycine has been shown to protect livers from CTx-induced injury and oxidative stress, and it reduces platelet aggregation and improves microperfusion." | 1.56 | Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats. ( Bausys, A; Feldbacher, N; Hoefler, G; Kolb-Lenz, D; Leber, B; Maneikyte, J; Schemmer, P; Stiegler, P; Strupas, K, 2020) |
| "Patients with PM from colorectal cancer and PCI >20 that were treated with CRS and HIPEC experience a one year longer and doubled overall survival compared with open-close/debulking patients." | 1.56 | Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ( Artursson, S; Birgisson, H; Cashin, P; Enblad, M; Ghanipour, L; Graf, W, 2020) |
| "The study includes the total of 60 colorectal cancer metastases operated patients, divided into two groups of 30 patients: the group of patients who were treated with "bevacizumab plus FOLFOX IV" protocol as a neoadjuvant therapy - prior to liver metastases surgery and the control group, patients with the liver resection done without previous neoadjuvant chemotherapy." | 1.56 | Molecular mechanisms of liver damage during neoadjuvant treatment for hepatic metastases of colorectal cancer. ( Gmijovic, M; Pecic, V; Stojanovic, M, 2020) |
| "At the time of disease progression, FOLFIRI cetuximab regimen was reintroduced resulting in stabilization of disease and he continued with capecitabine cetuximab therapy until disease progression in October 2016." | 1.56 | Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report. ( Antonuzzo, L; Castiglione, F; Di Costanzo, F; Lastraioli, E; Lavacchi, D; Messerini, L; Palmieri, VE, 2020) |
| " Although several biomarkers predicted different toxic effects, they cannot be considered as risk factors for severe toxicity." | 1.56 | Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma. ( Cañadas-Garre, M; Carrasco-Campos, MI; Pérez-Ramírez, C; Puerta-García, E; Segura-Pérez, A; Urbano-Pérez, D, 2020) |
| "In half of all CRC patients, colorectal cancer liver metastases (CRLM) can be observed." | 1.56 | Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. ( Alawi, M; David, K; Ewald, F; Fischer, L; Indenbirken, D; Izbicki, JR; Jücker, M; Juhl, H; Molloy, MP; Nashan, B; Omidi, M; Sauter, G; Schlüter, H; Simon, R; Smit, DJ; Spohn, M; Voß, H; Wurlitzer, M, 2020) |
| "However, the effect of tazemetostat on colorectal cancer (CRC) and 5-FU sensitivity remains unclear." | 1.56 | Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer. ( Liu, P; Shen, L; Tan, X; Tong, JS; Yao, H; Zhang, Z, 2020) |
| "However, to date, the role of KHSRP in colorectal cancer (CRC) progression has not been reported." | 1.56 | Inhibition of KHSRP sensitizes colorectal cancer to 5-fluoruracil through miR-501-5p-mediated ERRFI1 mRNA degradation. ( Cai, W; Li, P; Pan, R; Sun, J; Yu, C; Zheng, M, 2020) |
| "The central role of CD44v6 in colorectal cancer has been previously reported." | 1.51 | Downregulation of CD44v6 Enhances Chemosensitivity by Promoting Apoptosis and Inhibiting Autophagy in Colorectal Cancer HT29 Cells. ( Bhandari, A; Liu, HG; Lv, L; Pan, XX; Sun, YH; Wang, OC; Wang, QX; Ye, DR; Zhang, XH, 2019) |
| "Treatment of B/U liver metastases from CRC with conversion chemotherapy using mFLOX regimen followed by surgical resection was associated with a high R0 resection rate and favorable survival outcomes." | 1.51 | Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings. ( Amor Divino, PH; Bonadio, RC; Capareli, FC; Hoff, PM; Kruger, JAP; Lima, KCA; Obando, JSM; Recchimuzzi, DZ; Saragiotto, DF, 2019) |
| " Older age was associated with a higher probability of serious adverse events (OR (odds ratio) 0." | 1.51 | Impact of age on toxicity and efficacy of 5-FU-based combination chemotherapy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials. ( Abdel-Rahman, O; Karachiwala, H, 2019) |
| "Colorectal cancer is the third leading cause of cancer death worldwide." | 1.51 | In-Vivo Retention of 5-Fluorouracil Using ( Albert, MS; Davenport, E; Davenport, K; Fox, MS; Li, T; Shepelytskyi, Y, 2019) |
| "Platinum was readily detectable in skin biopsies more than 60 months post-completion of FOLFOX." | 1.51 | Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. ( Cao, Y; Chang, Q; Chen, EX; Hedley, D; Ornatsky, O; Zhang, W, 2019) |
| "Studies of patients treated with bevacizumab and other vascular epithelial growth factor (VEGF) inhibitors have reported that hypertension adverse events (AEs) are associated with improved overall survival (OS) or progression-free survival (PFS)." | 1.51 | Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab. ( Hopkins, AM; Karapetis, CS; Lim, HH; Rowland, A; Sorich, MJ; Yuen, HY, 2019) |
| "For the quantification of circulating tumor cells in the peripheral blood, we used the maintrac method." | 1.51 | Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2. ( Agrawal, AK; Agrawal, S; Banach, J; Gamian, A; Makuch, S; Pielka, E; Pizon, M; Wietrzyk, J; Woźniak, M; Ziółkowski, P; Łuc, M, 2019) |
| "Chemotherapy is currently used to treat colorectal cancer (CRC), the most common cancer worldwide." | 1.51 | Identification of bioactive compounds in Lactobacillus paracasei subsp. paracasei NTU 101-fermented reconstituted skimmed milk and their anti-cancer effect in combination with 5-fluorouracil on colorectal cancer cells. ( Chang, CY; Pan, TM, 2019) |
| " Within multivariable logistic regression analysis, patients with an ECOG score of 0 have a lower probability of serious adverse events (OR 0." | 1.51 | ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials. ( Abdel-Rahman, O, 2019) |
| "HER2-positve patients with stage II colorectal cancer can benefit from 5-fluorouracial based adjuvant chemotherapy, especially for patients with pMMR status." | 1.51 | HER2 as a potential biomarker guiding adjuvant chemotherapy in stage II colorectal cancer. ( Cai, S; Feng, Y; Huang, D; Li, Y; Peng, J, 2019) |
| "Irinotecan (CPT-11) is a drug used against a wide range of tumor types." | 1.51 | Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| " Severe adverse events were equivalent across age groups." | 1.51 | Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study. ( Bernard, MA; Coutureau, J; Droz, C; Duc, S; Forrier-Réglat, A; Gérard, S; Gouverneur, A; Grelaud, A; Jové, J; Lassalle, R; Noize, P; Ravaud, A; Rouyer, M; Smith, D, 2019) |
| "Here, we have analyzed STK17A in colorectal cancer and demonstrated decreased expression of STK17A in primary tumors, which is further reduced in metastatic lesions, indicating a potential role in regulating the metastatic cascade." | 1.51 | Serine Threonine Kinase 17A Maintains the Epithelial State in Colorectal Cancer Cells. ( Bilotta, AJ; Chen, X; Revetta, FL; Short, SP; Thompson, JJ; Washington, MK; Williams, CS, 2019) |
| " Through univariate and multivariate logistic regression analyses, factors predicting the development of serious adverse events, fatal adverse events, and toxicity-related hospitalizations were determined." | 1.51 | Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer. ( Abdel-Rahman, O; Ahmed, O, 2019) |
| "In human colorectal cancer tissue specimens, a strong correlation of FOXM1 and TYMS staining was observed." | 1.51 | FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression. ( Harada-Shoji, N; Kenny, LM; Lam, EW; Magnani, L; Mauri, F; Szydlo, RM; Varghese, V; Yao, S, 2019) |
| "Although hepatectomy for metastatic colorectal cancer (mCRC) prolongs survival in up to 40% of people, recurrence rates approach 70%." | 1.51 | Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer-a retrospective observational study. ( Hanai, T; Hayashi, T; Ikeda, Y; Kato, Y; Katsuno, H; Koide, Y; Maeda, K; Masumori, K; Matsuoka, H; Morise, Z; Nakajima, S; Sugioka, A; Tanahashi, Y; Tanaka, C; Uyama, I, 2019) |
| " Neurological adverse effects were assessed by CTC v2." | 1.51 | Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens. ( Bano, N; Ikram, R, 2019) |
| " To test this hypothesis, we analyzed CEA and CA19-9 serum levels in patients with advanced colorectal cancer who received cetuximab in combination with chemotherapy." | 1.51 | The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer. ( Dai, G; Gou, M; Jia, J; Qian, N; Yang, F; Zhang, P, 2019) |
| "Aiming to address the issue of poor bioavailability of most anti-tumor medicines against colorectal cancer, we developed a targeted anticancer nanocarrier using biocarriers able to both bind and easily release their load in a controlled manner." | 1.51 | Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer. ( Costache, M; Galateanu, B; Georgiana Nitu, S; Ginghina, O; Hudita, A; Iovu, H; Negrei, C; Radu, IC; Shtilman, M; Tanasa, EV; Tsatsakis, A; Velonia, K; Zaharia, C, 2019) |
| "Korean female patients with colorectal cancer who received 5-FU chemotherapy experienced more frequent adverse drug reactions including alopecia and leukopenia than male patients." | 1.51 | Sex-Dependent Adverse Drug Reactions to 5-Fluorouracil in Colorectal Cancer. ( Jung, J; Kim, KS; Kim, SY; Lee, E; Lee, S; Lim, H; Moon, A; Oh, S, 2019) |
| "To overcome the problem of overlooking colorectal tumors, a new and highly sensitive modality of colonoscopy is needed." | 1.51 | Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models. ( Fujimoto, S; Kida, Y; Kitamura, S; Miyamoto, H; Miyamoto, Y; Muguruma, N; Nakagawa, T; Nakamura, F; Okada, Y; Okamoto, K; Sato, Y; Takayama, T; Tanaka, K, 2019) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic drug used to treat cancer, including CRC." | 1.51 | Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer. ( Lee, JH; Lee, SW, 2019) |
| "Peritoneal carcinomatosis (PC) from colorectal cancer is associated with poor prognosis." | 1.51 | Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. ( Burnett, A; Cloutier, AS; Dubé, P; Gervais, MK; Lecompte, MA; Sideris, L; Trabulsi, N; Trilling, B, 2019) |
| "Cancer stem cells (CSCs) residing in colorectal cancer tissues have tumorigenic capacity and contribute to chemotherapeutic resistance and disease relapse." | 1.51 | Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells. ( Agaimy, A; Ballout, F; Çapci, A; Chanvorachote, P; El-Baba, C; Erlenbach-Wuensch, K; Gali-Muhtasib, H; Geppert, CI; Hartmann, A; Huebner, K; Klein, V; Muenzner, JK; Ndreshkjana, B; Roehe, AV; Schneider-Stock, R; Steinmann, S; Tsogoeva, SB, 2019) |
| "Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity, possibly leading to the delay or suspension of the cycle, with the consequent impact on the prognosis of survival." | 1.51 | Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| "Sarcopenia was defined as SMI ≤38." | 1.51 | Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer. ( Block, C; Gorsuch, K; Gupta, D; Hill, D; Vashi, PG; Wan, L, 2019) |
| "Our study included 90 cases of colorectal cancer liver metastasis resected after preoperative chemotherapy." | 1.51 | Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis. ( Akagi, Y; Akiba, J; Fujita, F; Fukahori, M; Goto, Y; Hisaka, T; Ishikawa, H; Kawahara, R; Kinugasa, T; Miwa, K; Mizobe, T; Naito, Y; Nakashima, O; Nomura, Y; Okuda, K; Sakai, H; Tanaka, H; Tanigawa, M; Yano, H; Yasunaga, M, 2019) |
| "Chemotherapy-induced interstitial lung disease in colorectal cancer patients is rare but represents a life-threatening adverse reaction." | 1.48 | Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report. ( Aizawa, K; Furukawa, T; Kozakai, H; Mitsuboshi, S; Nagai, K; Yamada, H, 2018) |
| "Forty patients with metastatic colorectal cancer receiving FOLFOX4 chemotherapy with or without bevacizumab and 40 healthy volunteers were included in the study." | 1.48 | Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment. ( Aleknavicius, E; Baltruskeviciene, E; Didziapetriene, J; Kazbariene, B; Krikstaponiene, A; Stratilatovas, E; Suziedelis, K; Venceviciene, L, 2018) |
| "Melatonin has antitumor activity via several mechanisms including its anti-proliferative and pro-apoptotic effects." | 1.48 | Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. ( Bejarano, I; Espino, J; Pariente, JA; Pariente, R; Rodríguez, AB, 2018) |
| "Among 496 consecutive M1c colorectal cancer patients, R0 resection was achieved for 94 patients (19%)." | 1.48 | Long-Term Outcomes After R0 Resection of Synchronous Peritoneal Metastasis from Colorectal Cancer Without Cytoreductive Surgery or Hyperthermic Intraperitoneal Chemotherapy. ( Kanemitsu, Y; Ochiai, H; Shida, D; Tsukamoto, S, 2018) |
| "Significant inter-individual variation in the sensitivity to 5-fluorouracil (5-FU) represents a major therapeutic hindrance either by impairing drug response or inducing adverse drug reactions (ADRs)." | 1.48 | DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. ( Ahmed, MU; Apu, MNH; Chowdhury, SM; Hasnat, A; Islam, MR; Islam, MS; Nahar, Z; Nahid, NA; Shabnaz, S, 2018) |
| "Two cohorts of metastatic colorectal cancer (CRC) were analyzed: a nonrandomized exploratory cohort of 184 patients treated at a single institution from 2003 to 2010 and a confirmatory cohort of 200 patients from a multi-institutional randomized trial (NO16966)." | 1.48 | The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. ( Ferrarotto, R; George, B; Hobbs, B; Hoff, PM; Kopetz, S; Loyer, EM; Machado, KK; Mazard, T; Overman, MJ; Qiao, W; Raghav, K; Saltz, LB; Vauthey, JN, 2018) |
| "Early disease progression in the chemotherapy to LR interval occurred in approximately 15% of patients and was associated with extremely poor survival." | 1.48 | Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? ( Carnaghi, C; Cimino, M; Darwish, SS; Del Fabbro, D; Donadon, M; Personeni, N; Procopio, F; Rimassa, L; Santoro, A; Torzilli, G; Vigano, L, 2018) |
| "non-mutated) metastatic colorectal cancer, not eligible for liver resection at baseline, from the UK National Health Service and Personal Social Services perspective." | 1.48 | Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. ( Crathorne, L; Hoyle, M; Huxley, N; Napier, M; Snowsill, T; Tikhonova, IA; Varley-Campbell, J, 2018) |
| "However, its role in colorectal cancer (CRC) remains poorly understood." | 1.48 | β‑arrestin2 promotes 5‑FU‑induced apoptosis via the NF‑κB pathway in colorectal cancer. ( Gao, F; He, X; Liu, F; Liu, Y; Ren, W; Wang, T; Zhang, Q; Zhang, Y; Zhou, J, 2018) |
| "Successful treatment of colorectal cancer (CRC) is greatly impeded by metastasis and chemoresistance, particularly to 5-fluoruracil (5-Fu), one of the staples of clinical intervention in advanced CRC." | 1.48 | GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer. ( Feng, C; Li, X; Liu, L; Lou, Y; Sun, Y; Wang, Y; Zhan, L; Zhang, L; Zhang, Y, 2018) |
| "In patients with metastatic colorectal cancer, combination treatment with several anti-cancer drugs is employed and improves overall survival in some patients." | 1.48 | Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture. ( Elbadawy, M; Hazama, S; Kaneda, M; Nagano, H; Nakajima, M; Ohama, T; Sakurai, M; Sasaki, K; Sato, K; Suzuki, N; Takenouchi, H; Tsunedomi, R; Umata, K; Usui, T; Yamawaki, H, 2018) |
| " Dosage was more often reduced in patients receiving FOLFOX based therapy." | 1.48 | Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects. ( Evert, M; Fest, P; Fichtner-Feigl, S; Gerken, M; Herr, W; Klinkhammer-Schalke, M; Munker, S; Ott, C; Reng, M; Schlitt, HJ; Schnoy, E; Stroszczynski, C; Teufel, A; Vogelhuber, M; Wiggermann, P, 2018) |
| " Pretreatment with the pan-caspase inhibitor, z-VAD-FMK, attenuated the caspase-dependent apoptosis induced by circularly permuted tumor necrosis factor-related apoptosis-inducing ligand alone or combined with 5-fluorouracil." | 1.48 | Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480. ( Liang, X; Sun, T; Yang, S; Zhao, R; Zhu, T, 2018) |
| "Colorectal carcinoma is a common malignant tumor occurring in the alimentary system." | 1.48 | Beta-elemene increases chemosensitivity to 5-fluorouracil through down-regulating microRNA-191 expression in colorectal carcinoma cells. ( Guo, Z; Liu, Z; Wang, J; Yue, H, 2018) |
| "HCT116 colorectal cancer cells were treated with cobimetinib, and MTT assay, colony formation assay, and flow cytometry were used to evaluate cell viability, cell cycle, and apoptosis, respectively." | 1.48 | Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells. ( Gong, S; Peng, R; Xu, D; Zhu, J; Zou, F, 2018) |
| "5-Fluorouracil (5-FU) is a cornerstone of chemotherapy for CRC and the major targets of 5-FU are folate-metabolizing enzymes." | 1.48 | The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer. ( Al-Ramadhani, H; Al-Yacoub, S; Kadi, T; Tantawi, DA; Yousef, AM; Zawiah, M, 2018) |
| "Its influence on colorectal cancer (CRC), however, has never been evaluated." | 1.48 | Overcoming stemness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling. ( Chen, Y; Hu, H; Huang, Q; Jin, Y; Wang, G; Wang, M, 2018) |
| "Colorectal cancer is one of the most common malignancies both in men and women." | 1.48 | A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo. ( Chen, CQ; Ding, HW; Li, DD; Ren, TS; Wang, J; Wu, Q; Zhao, CH; Zhao, QC, 2018) |
| "While early stage colorectal cancer can be removed by surgery, patients with advanced disease are treated by chemotherapy, with 5-Fluorouracil (5-FU) as a main ingredient." | 1.48 | Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer. ( Gu, D; Liu, B; Song, R; Xie, J; Yu, B; Zhang, L; Zhang, X, 2018) |
| "Here, we show that colorectal cancers (CRCs) display negligible expression of OTC and, in subset of cases, ASS1 proteins." | 1.48 | Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes. ( Al-Aqbi, SS; Alexandrou, C; Andreadi, C; Blades, M; Boyle, W; Brown, K; Cheng, PN; Higgins, JA; Howells, LM; Karmokar, A; Luo, JL; Moore, DA; Murray, GI; Rufini, A; Thomas, A; Viskaduraki, M, 2018) |
| "Crocin was able to ameliorate the severe inflammation with mucosal ulcers and high-grade dysplastic crypts as detected by inflammation score, crypt loss, pathological changes and histology scores." | 1.48 | Crocin synergistically enhances the antiproliferative activity of 5-flurouracil through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer. ( Amerizadeh, F; Avan, A; Boroumand, N; Ferns, GA; Fiuji, H; Ghayour-Mobarhan, M; Hassanian, SM; Khazaei, M; Moradi-Marjaneh, R; Nosrati-Tirkani, A; Rahmani, F; Rezaei, N, 2018) |
| "The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified." | 1.48 | Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients. ( de Miguel-Pérez, D; Delgado-Ramirez, M; Delgado-Ureña, M; Exposito-Hernandez, J; García-Puche, JL; Garrido-Navas, MC; Ilyine, H; Lorente, JA; Ortega, FG; Rodriguez-Martínez, A; Serrano, MJ, 2018) |
| "Background Early relapse in colorectal cancer (CRC) after curative resection is mainly attributed to the key determinants such as tumor histology, stage, lymphovascular invasion, and the response to chemotherapy." | 1.48 | Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy. ( Ajaj, AR; Al-Hiary, R; Al-Yacoub, S; Kadi, T; Majdalawi, K; Mukred, R; Tantawi, D; Yousef, AM; Yousef, M; Zawiah, M, 2018) |
| "Colorectal cancer is one of the most frequently diagnosed cancers worldwide." | 1.48 | The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer. ( An, C; Li, H; Mushtaq, N; Shi, Y; Ullah, S; Xu, J; Yang, F; Yuan, L; Zhang, S, 2018) |
| "Chemotherapy-induced oral mucositis impairs the quality of life." | 1.48 | Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study. ( Dote, S; Hira, D; Itakura, S; Kamei, K; Kobayashi, Y; Noda, S; Terada, T, 2018) |
| "Isoliquiritigenin (ISL) is a natural flavonoid that exhibits anticancer properties in various carcinoma cell types." | 1.48 | Isoliquiritigenin-mediated p62/SQSTM1 induction regulates apoptotic potential through attenuation of caspase-8 activation in colorectal cancer cells. ( Jin, H; Lee, SH; Seo, GS, 2018) |
| "Curcumin has been reported to be an effective compound in the reversal of MDR in colorectal cancer cells." | 1.48 | Nrf2 is a key factor in the reversal effect of curcumin on multidrug resistance in the HCT‑8/5‑Fu human colorectal cancer cell line. ( Chen, YY; He, LJ; Jia, YW; Liu, DF; Liu, XP; Miao, DD; Shen, J; Ye, HZ; Zhang, C; Zhang, SP; Zhu, YB, 2018) |
| "First-line chemotherapy for metastatic colorectal cancer (mCRC) is effective and feasible in selected older patients." | 1.48 | Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study. ( Dehlendorff, C; Johansen, JS; Lund, CM; Nielsen, DL; Rønholt, F; Vistisen, KK, 2018) |
| "Systemic EGFRi may increase dry eye signs as well as decrease CEBD and CNFD." | 1.48 | Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial. ( Adán, A; Castellà, C; Eixarch, A; Reguart, N; Saint-Jean, A; Sainz-de-la-Maza, M; Sánchez-Dalmau, B, 2018) |
| "A total of 80 cases of colorectal cancer tissues were examined by immunohistochemistry for MTA3 protein expression." | 1.46 | MTA3 regulates malignant progression of colorectal cancer through Wnt signaling pathway. ( Feng, M; Gao, T; Jiao, T; Li, Y; Liu, M; Sun, M; Zhang, Y; Zhou, H, 2017) |
| " Potential correlation between treatment modalities (regimen, dosage and route of administration of L-OHP, and injection timing for dexamethasone administration) and HSRs was assessed." | 1.46 | Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer. ( Ando, Y; Hayashi, T; Ikeda, Y; Ito, K; Kawada, K; Kumazawa, S; Maeda, K; Matsuoka, H; Murai, S; Ohta, H; Shiouchi, H; Yamada, S; Yasuda, K, 2017) |
| "Right-sided colorectal cancer (RSCRC) were associated with reduced overall response rate (ORR) (4." | 1.46 | The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. ( Antoniotti, C; Cascinu, S; Cremolini, C; Demurtas, L; Falcone, A; Gelsomino, F; Giampieri, R; Loretelli, C; Mandolesi, A; Masi, G; Meriggi, F; Pusceddu, V; Puzzoni, M; Scartozzi, M; Zaniboni, A; Ziranu, P, 2017) |
| "We screened international colorectal cancer therapeutic guidelines and determined distinct functional tumor behaviors (proliferation, metastasis, and angiogenesis) and differential sensitivities to standard therapy." | 1.46 | Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. ( Carvalho, T; Ferreira, MG; Figueiredo, N; Fior, R; Gomes, A; Mendes, RV; Póvoa, V, 2017) |
| "Metastatic colorectal cancer (mCRC) patients with mutant KRAS or NRAS are ineligible for anti-epidermal growth factor receptor (anti-EGFR) therapy, as RAS mutations activate downstream pathways independently of EGFR and induce primary resistance." | 1.46 | Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. ( Amar, Y; Berger, F; Bieche, I; Cacheux, W; Canet, J; Cartier, A; de Koning, L; Guimbaud, R; Guyetant, S; Lecomte, T; Lièvre, A; Mariani, O; Ouine, B; Selves, J, 2017) |
| "5-fluorouracil (5-FU) is a specific anti-cancer agent that is generally used to treat gastrointestinal, colorectal, and breast cancer." | 1.46 | Preparation and Bioactivity Assessment of Chitosan-1-Acetic Acid-5-Flurouracil Conjugates as Cancer Prodrugs. ( Haj, NQ; Hussain, KS; Mohammed, MO, 2017) |
| "Collectively, SGK1 promotes colorectal cancer development via regulation of CRC cell proliferation, migration and survival." | 1.46 | Therapeutic inhibition of SGK1 suppresses colorectal cancer. ( An, Y; Chen, T; Fu, W; Huang, Q; Jiao, G; Lan, C; Li, Y; Liang, X; Long, X; Wang, K; Xiao, J; Xu, B; Xu, J; Zhou, J, 2017) |
| "Surgical resection combined with adjuvant chemotherapy is considered as the gold-standard treatment for advanced colorectal cancer patients." | 1.46 | Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment. ( Chen, L; Huang, L; Lin, X; Xie, Y; Zheng, Q, 2017) |
| "We describe 4 cases of locally advanced colorectal cancer resected successfully after neoadjuvant chemotherapy(NAC) conducted between April 2015 and August 2016." | 1.46 | [Four Cases of Locally Advanced Colorectal Cancer Resected after Neoadjuvant Chemotherapy with mFOLFOX6 plus Bevacizumab]. ( Doi, Y; Kameda, Y; Masuda, M; Matsuura, H; Rino, Y; Sugano, N; Suzuki, Y; Takata, K; Yamaoku, K; Yoneyama, K, 2017) |
| "Peritoneal carcinomatosis (PC) from colorectal cancers (CRC) either at initial presentation or at subsequent recurrence presents a significant treatment challenge." | 1.46 | Peritoneal Carcinomatosis in Colorectal Cancers - Management Perspective Needs a Change. ( Bhamre, R; Bhandare, M; Engineer, R; Ostwal, V; Pai, V; Patil, P; Saklani, A, 2017) |
| "In patients with colorectal cancer (CRC), the BRAF V600E mutation has been reported to be associated with several clinicopathological features and poor survival." | 1.46 | BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status. ( Han, HS; Hwang, DY; Hwang, TS; Jang, MH; Kim, S; Kim, WS; Kim, WY; Lim, SD, 2017) |
| "Forty-seven cases of stage III colorectal cancer who received adjuvant chemotherapy with oxaliplatin after curative surgery between January 2010 and August 2014 were retrospectively reviewed." | 1.46 | Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy. ( Horiuchi, T; Kimura, M; Maeda, T; Shirai, Y; Tanishima, H; Tominaga, T, 2017) |
| "Cetuximab has activity against colorectal cancers." | 1.46 | Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. ( Hazama, S; Iida, M; Inoue, Y; Kanekiyo, S; Nagano, H; Sakamoto, K; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Tomochika, S; Tsunedomi, R; Ueno, T; Yoshino, S, 2017) |
| "Aberrantly expressed BORIS relates to colorectal cancer, but its function in colorectal cancer cells remains unclear." | 1.46 | Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer. ( Fang, J; Fang, M; Ren, J; Song, Y; Wang, X; Zhang, Y, 2017) |
| "A historical cohort of 112 RAS mutated colorectal cancer patients treated with FOLFOX6 alone served as control group." | 1.46 | IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. ( Barone, C; Basso, M; Berenato, R; Bossi, I; Capoluongo, E; Caporale, M; Danesi, R; de Braud, F; Del Re, M; Di Salvatore, M; Guarino, D; Martinetti, A; Mennitto, A; Mennitto, R; Orlandi, A; Pietrantonio, F; Rossi, E; Santonocito, C; Schinzari, G, 2017) |
| "Both patients presented with colorectal cancer with synchronous liver metastasis." | 1.46 | A New Technique of Radiofrequency-assisted Ultrasound-guided Needle-localized Laparoscopic Resection of Disappearing Colorectal Liver Metastases. ( Aydin, N; Berber, E; Dural, C; Okoh, AK; Taskin, HE; Yazici, P; Yigitbas, H, 2017) |
| "The CONCERT study (observational cohort study of patients with metastatic colorectal cancer initiating chemotherapy in combination with bevacizumab) aimed to describe patient characteristics, bevacizumab use, its efficacy in terms of progression-free survival (PFS) and overall survival (OS), and its safety in patients with metastatic colorectal cancer (mCRC) treated in daily medical practice." | 1.46 | Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). ( André, T; Asselain, B; Bennouna, J; Ducreux, M; Phelip, JM, 2017) |
| "Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab." | 1.46 | Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017) |
| "These findings suggest the potential roles of HM781-36B as the treatment for EGFR-overexpressing colon cancer, singly or in combination with chemotherapeutic agents." | 1.43 | Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. ( Kang, MH; Kim, JH; Kim, JW; Lee, HS; Lee, JS; Lee, KW; Moon, SU; Sung, JH, 2016) |
| "Colorectal cancer is the third most common cancer diagnosed in the USA each year." | 1.43 | Systemic capillary leak syndrome in a patient receiving adjuvant oxaliplatin for locally advanced colon cancer. ( Anderson, BJ; Peterson, LL, 2016) |
| "Metastatic liver disease from colorectal cancer is a significant clinical problem." | 1.43 | The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis. ( Denys, A; Devun, F; Dutreix, M; Herath, NI; Herbette, A; Lienafa, MC; Sun, JS, 2016) |
| "The location of the colorectal cancer was classified into 4 regions (the right‑ and left-sided colon, rectosigmoid and rectum) and was compared with gene expression." | 1.43 | Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis. ( Fukushima, M; Nukatsuka, M; Shimamoto, Y; Takechi, T, 2016) |
| "Patients with metastatic colorectal cancer (mCRC) with BRAF mutation (BRAF MT) generally have a poorer prognosis." | 1.43 | BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education? ( Amitesh, R; Beeke, C; Karapetis, C; Lo, L; Maddern, G; Moore, J; Padbury, R; Price, TJ; Roder, D; Townsend, AR, 2016) |
| "Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD)." | 1.43 | Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. ( André, T; Bonnet, I; Bouché, O; Boucher, E; Chibaudel, B; Dauba, J; Faroux, R; Garcia, ML; Guering-Meyer, V; Hug de Larauze, M; Lapeyre-Prost, A; Lièvre, A; Malka, D; Obled, S; Taieb, J; Ychou, M, 2016) |
| " The primary objective was to investigate the incidence of adverse drug reactions, particularly those of interest for bevacizumab." | 1.43 | Bevacizumab safety in Japanese patients with colorectal cancer. ( Doi, T; Hatake, K; Ishihara, Y; Shirao, K; Takahashi, Y; Uetake, H, 2016) |
| "Of them, 315 node-negative stage II colorectal cancer cases were enrolled." | 1.43 | Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial. ( Doki, Y; Fukunaga, M; Ikeda, M; Kato, T; Matsuura, N; Miyake, Y; Mizushima, T; Monden, M; Mori, M; Murata, K; Nakamura, Y; Nezu, R; Noura, S; Ohnishi, T; Ohtsuka, M; Ohue, M; Sekimoto, M; Takemasa, I; Yamamoto, H, 2016) |
| "Targeting cancer stem cells (CSCs) in colorectal cancer (CRC) remains a difficult problem, as the regulation of CSCs in CRC is poorly understood." | 1.43 | KCTD12 Regulates Colorectal Cancer Cell Stemness through the ERK Pathway. ( Duan, T; Huang, H; Kang, T; Li, L; Wang, F; Wang, S; Wang, X; Wu, Y; Zhang, M; Zhang, RH, 2016) |
| "Capecitabine is a chemotherapeutic agent used in the treatment of metastatic colon cancer and metastatic breast cancer." | 1.43 | Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy. ( Aladağ, E; Karakulak, UN; Maharjan, N; Övünç, K, 2016) |
| "5-Fluorouracil (5FU) was able to stimulate the activation of SMAD3 and the transcription of specific genes such as ACVRL1, FN1 and TGFB1." | 1.43 | The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells. ( Bianco, MR; Bugarin, C; Cerrito, MG; Gaipa, G; Garanzini, C; Giovannoni, R; Giuffrè, MR; Grassilli, E; Lavitrano, M; Leone, BE; Leoni, S; Papa, M; Pettinato, M; Romano, G; Santi, L; Savarese, L, 2016) |
| "Here we will show that, in a colorectal cancer patient cohort, both poor and ultra-rapid metabolizers have significantly increased the risk of developing severe toxicity (grade3-4)." | 1.43 | Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. ( Borro, M; Botticelli, A; Gentile, G; La Torre, M; Lionetto, L; Marchetti, L; Marchetti, P; Mazzotti, E; Mazzuca, F; Simmaco, M, 2016) |
| "Using a tissue microarray of 89 colorectal cancer cases, we found that SIRT4 was significantly downregulated in colorectal cancer tissues compared with that noted in the corresponding normal tissue (P<0." | 1.43 | Clinical and therapeutic significance of sirtuin-4 expression in colorectal cancer. ( Chen, X; Cheng, J; Huang, G; Liu, C; Liu, X; Peng, Z; Yu, F; Yuan, C, 2016) |
| "Studies of human colorectal cancer cells where the VEGF gene has been deleted suggest an intracellular role of VEGF as a cell survival factor." | 1.43 | Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells. ( Bhattacharya, R; Boulbes, D; Ellis, LM; Fan, F; Ling, X; McManus, M; Wang, R; Ye, XC, 2016) |
| "Despite being the standard anti-colorectal cancer drug, 5-fluorouracil (5-FU) exhibits only limited therapeutic benefits." | 1.43 | Paricalcitol Enhances the Chemopreventive Efficacy of 5-Fluorouracil on an Intermediate-Term Model of Azoxymethane-Induced Colorectal Tumors in Rats. ( Ahmad, J; El-Shemi, AG; Idris, S; Kensara, OA; Mohamed, AM; Refaat, B, 2016) |
| " We evaluated treatment-related adverse events (AEs), progression-free survival (PFS) and overall survival (OS)." | 1.43 | Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer. ( Abdullah, NM; Sharial, MM; Yusof, MM; Zaatar, A, 2016) |
| "4% experienced grade 3/4 adverse events." | 1.43 | Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort. ( Becouarn, Y; Fourrier-Réglat, A; Grelaud, A; Guimbaud, R; Jové, J; Moore, N; Noize, P; Ravaud, A; Robinson, P; Rouyer, M; Smith, D; Tubiana-Mathieu, N, 2016) |
| "Patients who underwent metastasectomy or those with Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤1 had longer PFS and OS independent of the type of chemotherapy regimen." | 1.43 | Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. ( Artaç, M; Avcı, N; Çabuk, D; Coşkun, HŞ; Dane, F; Doruk, H; Faruk Aykan, N; Karaağaç, M; Karabulut, B; Karabulut, S; Korkmaz, L; Turhal, NS, 2016) |
| " We found that cetuximab, in combination with chemotherapy, fostered ICD in CRC cells, which we measured via the endoplasmic reticulum (ER) stress response and an increase in phagocytosis by dendritic cells." | 1.43 | The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. ( Bardelli, A; Bonaldi, T; Cancelliere, C; Conte, A; Cuomo, A; Di Fiore, PP; Magni, E; Penna, G; Pozzi, C; Ravenda, PS; Rescigno, M; Sigismund, S; Silvola, A; Spadoni, I; Zampino, MG, 2016) |
| "First-line use of EGFRI in metastatic colorectal cancer is not cost effective at its current pricing relative to Bev." | 1.43 | Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. ( Berry, SR; Chan, KK; Giotis, A; Ko, YJ; Lien, K; Mittmann, N; Riesco-Martínez, MC; Wong, WW, 2016) |
| "Treatment with lenalidomide reduced tumor vessel density (p = 0." | 1.43 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016) |
| "The human colorectal cancer cell lines HCT116, SW480, DLD1, and KM12SM were engineered to stably express a green fluorescent molecule fused to the degron of ornithine decarboxylase, resulting in an accumulation of the fluorescence in LPACs." | 1.43 | Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity. ( Carethers, JM; Doki, Y; Fukusumi, T; Hata, T; Ikenaga, M; Kano, Y; Kato, T; Kawai, K; Kitahara, T; Miyo, M; Mizushima, T; Mori, M; Munakata, K; Murata, K; Nishikawa, S; Nishimura, J; Takahashi, Y; Takemasa, I; Tanaka, S; Uemura, M; Yamamoto, H, 2016) |
| "Among the advanced colorectal cancer patients who received treatment with FOLFOX or FOLFIRI at Koyama Memorial Hospital, patients older than 65 years of age were selected in order to assess the effectiveness of aprepitant as an antiemetic supportive therapy." | 1.43 | [Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer]. ( Hanaka, J; Nakayama, H; Takahashi, M; Terashima, T, 2016) |
| "However, the expression of tmTNF-α in colorectal cancer (CRC) and its association with clinical outcome in CRC have remained unclear." | 1.43 | Molecular correlates and prognostic value of tmTNF-α expression in colorectal cancer of 5-Fluorouracil-Based Adjuvant Therapy. ( Huang, K; Li, N; Li, X; Liu, C; Ma, J; Ming, L; Ren, H; Sun, X; Wang, S; Xu, M, 2016) |
| "Cachexia affects the majority of cancer patients, with currently no effective treatments." | 1.43 | Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. ( Barreto, R; Bonetto, A; Gao, H; Liu, Y; Waning, DL; Zimmers, TA, 2016) |
| " In particular, oxaliplatin(L-OHP), one such platinum-based chemotherapeutic drug, has a synergistic effect in combination with 5-FU and Leucovorin for the treatment of advanced colorectal cancer." | 1.43 | [The Molecular Aspect of the Antitumor Effect of Oxaliplatin in Combination with 5-FU]. ( Akiyama, S; Edahiro, K; Iimori, M; Kakeji, Y; Kanaji, S; Kataoka, Y; Kitao, H; Kiyonari, S; Maehara, Y; Nakanishi, R; Niimi, S; Oki, E; Saeki, H; Tokunaga, E, 2016) |
| "Most colorectal cancer (CRC) cell lines are identified to overexpress phosphoserine phosphatase (PSPH), which regulates the intracellular synthesis of serine and glycine, and supports tumor growth." | 1.43 | Inhibition of phosphoserine phosphatase enhances the anticancer efficacy of 5-fluorouracil in colorectal cancer. ( Li, X; Xun, Z; Yang, Y, 2016) |
| " This relationship favors new treatment strategies with white blood cell growth factors or chemotherapy dosing based on muscle value." | 1.43 | Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. ( Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A, 2016) |
| "Data were validated in the rectal cancer cohort treated in the neoadjuvant setting." | 1.43 | Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer. ( Bacon, O; Carberry, S; Concannon, CG; Fay, J; Hector, S; Kay, EW; Lindner, AU; McCawley, N; McNamara, DA; Murphy, ÁC; Prehn, JH; Ryan, D, 2016) |
| "The treatment of metastatic colorectal cancer (mCRC) has changed substantially in the last 2 decades, but to the authors' knowledge, the effect of age and comorbidities on chemotherapy use has not been well studied to date." | 1.43 | Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. ( Cohen, SJ; Dotan, E; Hall, MJ; Li, T; Vijayvergia, N; Wong, YN, 2016) |
| "Primary cultures of colorectal cancer cells from a patient's tumors were studied using the flow cytometry and cytological methods." | 1.43 | Primary cultures of human colon cancer as a model to study cancer stem cells. ( Bajenova, O; Danilova, A; Koshkin, S; O'Brien, SJ; Petrov, N; Raskin, G; Tolkunova, E; Tomilin, A, 2016) |
| " A strong antitumorigenic effect of FOXK1-shRNA was enhanced when combined with 5-FU treatment." | 1.43 | Knockdown of FOXK1 alone or in combination with apoptosis-inducing 5-FU inhibits cell growth in colorectal cancer. ( Ba, Y; Chen, Y; Li, A; Liu, S; Liu, X; Nan, Q; Peng, Y; Tang, W; Wang, J; Wu, M; Wu, Y; Xie, R; Zhang, P; Zhao, J, 2016) |
| "Andrographolide is a natural diterpenoid from Andrographis paniculata which has anti-bacterial, anti-antiviral and anti-inflammation activities." | 1.43 | Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression. ( Fu, Z; Gao, J; Gu, Y; Guo, W; Li, L; Liu, W; Shu, Y; Sun, Y; Wang, W; Xu, Q, 2016) |
| "PSB-603 alters cellular metabolism in colorectal cancer cells and increases their sensitivity to chemotherapy." | 1.43 | The A ( Coates, JL; Failla, LM; Heath, JK; Hollande, F; Mølck, C; Pascussi, JM; Ryall, J; Stewart, G, 2016) |
| "Capecitabine is an oral 5-fluorouracil (5-FU) pro-drug commonly used to treat colorectal carcinoma and other tumours." | 1.42 | A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. ( Carracedo, A; Castells, A; Castellvi-Bel, S; Domingo, E; Fernández-Rozadilla, C; Freeman-Mills, L; Gonzalez-Neira, A; Howarth, K; Johnstone, E; Jones, A; Julier, P; Kaur, K; Kerr, D; Kerr, R; Love, S; Martin, M; Pagnamenta, A; Palles, C; Pita, G; Rosmarin, D; Ruiz-Ponte, C; Scudder, C; Taylor, J; Tomlinson, I; Wang, H, 2015) |
| " By exclusion the pseudo-obstruction was attributed to a toxic oxaliplatin-induced autonomic neuropathy which slowly improved during months of follow-up." | 1.42 | A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity. ( Bleecker, JD; Pauwels, W; Vandamme, M, 2015) |
| "Patients with KRAS wild-type metastatic colorectal cancer in the CORECT registry who initiated treatment with bevacizumab between 2008 and 2012 were enrolled." | 1.42 | Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data. ( Bortlíček, Z; Kubáčková, K; Linke, Z; Pikus, T; Pokorná, P; Prausová, J; Vyzula, R, 2015) |
| "INK-128 inhibited colorectal cancer cell growth and survival, and induced both apoptotic and non-apoptotic cancer cell death." | 1.42 | The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent. ( Chen, MB; Cui, JF; Li, C; Liu, CY; Liu, F; Lu, PH; Zhang, QD; Zou, J, 2015) |
| "Knockdown of CRY2 increased colorectal cancer sensitivity to oxaliplatin in colorectal cancer cells." | 1.42 | Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer. ( Deng, Y; Fang, L; Hsiao, CD; Lee, MH; Tung, JY; Wang, J; Wang, L; Wang, P; Yang, Z; Zhou, J, 2015) |
| "The KRAS gene frequently mutates in colorectal cancer (CRC)." | 1.42 | KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. ( Cai, Y; Chen, D; Deng, Y; Dou, R; Fu, X; Kim, GP; Tan, S; Wang, J; Wang, L; Zhu, J, 2015) |
| "Using the Tet-OFF system and a human colorectal cancer cell line, DLD-1, we first constructed an in vitro system in which TS expression is dynamically controllable." | 1.42 | Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells. ( Fukushima, M; Hattori, H; Kawabata, R; Maehara, Y; Nakao, S; Oda, S; Taguchi, K; Uchida, J; Wakasa, K; Yamanaka, T, 2015) |
| "Colorectal cancer is common." | 1.42 | Growth inhibitory effect of polyunsaturated fatty acids (PUFAs) on colon cancer cells via their growth inhibitory metabolites and fatty acid composition changes. ( Das, UN; Ni, X; Shen, S; Yu, H; Zhang, C, 2015) |
| "Metastasis of colorectal cancer (CRC) in an adrenal gland develops in 1." | 1.42 | [Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava]. ( Andreĭtseva, OI; Gritsiuta, AI; Kalinin, DV; Kharazov, AF; Vishnevskiĭ, AV; Zhavoronkova, OI, 2015) |
| "The role of MCTs in the survival of colorectal cancer (CRC) cells is scarce and poorly understood." | 1.42 | Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells. ( Amorim, R; Baltazar, F; Miranda-Gonçalves, V; Moyer, MP; Pereira, H; Pinheiro, C; Preto, A, 2015) |
| "Colon cancer in pregnancy is uncommon." | 1.42 | Chemotherapeutic treatment of colorectal cancer in pregnancy: case report. ( Al-Khatani, K; Al-Mohaisen, F; Makoshi, Z; Perrott, C, 2015) |
| " Most grade ≥ 3 adverse events (AEs) were reported during the initial cycles of treatment." | 1.42 | Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program. ( Díaz de Corcuera, I; García de la Torre, M; Pérez Hoyos, MT; Salgado Fernández, M; Vidal Arbués, A, 2015) |
| " The remission rate, control rate and time to disease progression were compared among patients receiving cetuximab combined with different chemotherapy regimens in different periods." | 1.42 | [Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma]. ( Bai, L; Han, C; Jiao, S; Li, J; Su, D; Wang, Y; Zhang, T, 2015) |
| "Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC)." | 1.42 | Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience. ( Fausti, V; Gallo, P; Imperatori, M; Picardi, A; Santini, D; Spalato Ceruso, M; Tonini, G; Vespasiani Gentilucci, U; Vincenzi, B, 2015) |
| "However, the role of KLF8 in colorectal cancer remains unknown." | 1.42 | Suppression of KLF8 induces cell differentiation and sensitizes colorectal cancer to 5-fluorouracil. ( Bai, Y; Chen, C; Chen, Y; Cheng, T; Liu, S; Luo, X; Peng, Y; Shi, X; Wang, J; Wu, Y; Yan, Q; Zhang, M; Zhang, W; Zhang, Y; Zhao, J, 2015) |
| "Most liver metastases from colorectal cancer (CRC) are unresectable at diagnosis." | 1.42 | Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial. ( Artru, P; Chalabreysse, P; Desramé, J; Lledo, G; Marsot, J; Mithieux, F; Pellerin, O; Pernot, S; Taieb, J; Watkin, E, 2015) |
| "Importantly, studies of colorectal cancer specimens indicate that the expression of miR-587 and PPP2R1B positively and inversely correlates with chemoresistance, respectively, in colorectal cancer." | 1.42 | MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. ( Talmon, G; Wang, J; Zhang, Y, 2015) |
| "For different stages of colorectal cancer, expression of VMP1 had a negative correlation with the malignancy of the cancer." | 1.42 | Downregulation of VMP1 confers aggressive properties to colorectal cancer. ( Cai, YJ; Che, XH; Chen, F; Guo, XZ; Liu, XJ; Wei, XN; Xiao, WZ; Ye, XL; You, QH; Yu, MH; Yuan, H, 2015) |
| "However, the potential role of GA in colorectal cancer and its ability to overcome the chemotherapeutic resistance in CRC cells have not been well studied." | 1.42 | Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells. ( Chen, J; Huang, L; Iwamoto, A; Li, W; Lin, M; Liu, H; Lu, B; Rutnam, ZJ; Wang, Z; Wen, C; Yang, X, 2015) |
| "The diagnosis and treatment of colorectal cancer is one of the main diseases of gastrointestinal surgeons." | 1.42 | [Gastrointestinal surgeons should master the adjuvant therapy of colorectal cancer]. ( Chen, P; Gu, J, 2015) |
| "Its role in tumorigenesis is more controversial and both the presence and the absence of autophagy have been implicated." | 1.42 | Autophagy is upregulated during colorectal carcinogenesis, and in DNA microsatellite stable carcinomas. ( Benincasa, M; Magnani, G; Mancini, S; Mariani, F; Palumbo, C; Pedroni, M; Roncucci, L; Sena, P, 2015) |
| "Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area." | 1.42 | Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015) |
| "We present 2 patients with metastatic colorectal cancer who had progressed despite treatment with first-line FOLFOX and second-line FOLFIRI combination chemotherapy regimens." | 1.42 | Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. ( El-Deiry, WS; Marks, EI; Scicchitano, A; Tan, C; Yang, Z; Zhang, J; Zhou, L, 2015) |
| "The optimal cutoff affecting recurrence was 276×10(9)/L." | 1.42 | [Impact of platelet count on prognosis of stage II-III colorectal cancer receiving adjuvant chemotherapy]. ( Cai, Z; Guan, H; Hong, C; Liang, Z; Luo, D; Luo, P; Tan, Z; Wei, Y; Yang, Z; Zeng, Z, 2015) |
| "The SCAN colorectal cancer systemic therapy workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for colorectal cancer in Singapore." | 1.42 | Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer. ( , 2015) |
| "Approximately 20% of the patients with colorectal cancer have distant metastasis during diagnosis." | 1.42 | Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients. ( Albayrak, D; Cicin, I; Erdogan, B; Hacibekiroglu, I; Kodaz, H; Tozkir, H; Turkmen, E; Uzunoglu, S, 2015) |
| "Berberine is an alkaloid isolated from the Chinese herbal medicine Huanglian, and has long been used as an antibiotic." | 1.40 | Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. ( Cai, Y; Huang, P; Jiang, W; Luo, R; Shi, Y; Sun, Y; Xia, Q, 2014) |
| "Gefitinib was cytostatic." | 1.40 | Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line. ( Aristei, C; Calzuola, M; Cecchini, D; Contavalli, P; Falzetti, F; Marini, V; Palumbo, I; Piattoni, S; Valentini, V; Vecchio, FM, 2014) |
| "The HT-29 colorectal cancer cell line was cultured and exposed with 5-FU in three stages based on Bolus protocol." | 1.40 | Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer. ( Bandehpour, M; Karbasi, A; Kazemi, B; Manoochehri, M, 2014) |
| "We enrolled 234 patients with Stage III colorectal cancer who underwent curative resection." | 1.40 | Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status. ( Fukazawa, S; Hase, K; Hashiguchi, Y; Kubo, T; Naito, Y; Okamoto, K; Shikina, A; Shinto, E; Ueno, H; Yamamoto, J, 2014) |
| "According to treatment, ORR, metastasectomies, PFS and OS were significantly favourable in triplet CT plus targeted agent compared to triplet, respectively: 80%, 40%, 13 months, not reached; 28%, 6%, 8 months, 11 months." | 1.40 | Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype. ( Bruera, G; Cannita, K; Ficorella, C; Giordano, AV; Ricevuto, E; Vicentini, R, 2014) |
| "Human colorectal cancer specimens (n=94) and human colorectal cancer cell lines HRT18 and HT115 were used." | 1.40 | Death associated protein 1 is correlated with the clinical outcome of patients with colorectal cancer and has a role in the regulation of cell death. ( Davies, ML; Hargest, R; Ji, J; Ji, K; Jia, Y; Jiang, WG; Ruge, F; Toms, AM; Ye, L, 2014) |
| "We found that oxaliplatin resistance in colorectal cancer cells depends on the DNA methylation-associated inactivation of the BRCA1 interactor SRBC gene." | 1.40 | Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. ( Abad, A; Carmona, FJ; Cassingena, A; Elez, E; Esteller, M; Martínez-Balibrea, E; Martinez-Cardús, A; Moutinho, C; Musulen, E; Navarro-Pérez, V; Salazar, R; Santos, C; Sartore-Bianchi, A; Siena, S; Tabernero, J, 2014) |
| "Cinnamaldehyde is an active monomer isolated from the stem bark of Cinnamomum cassia, a traditional oriental medicinal herb, which is known to possess marked antitumor effects in vitro and in vivo." | 1.40 | Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer. ( Liu, SL; Qi, MH; Yu, C; Zou, X, 2014) |
| "Cardiac toxicity an uncommon but serious side-effect of some fluoropyrimides." | 1.40 | Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. ( Ferry, D; Fournier, M; Gebski, V; Gordon, S; Karapetis, CS; Price, TJ; Ransom, D; Simes, RJ; Tebbutt, N; Wilson, K; Yip, D, 2014) |
| "In the clinic, predicting metastasis and chemoresistance takes high priority, but has not been well established." | 1.40 | Predicting distant metastasis and chemoresistance using plasma miRNAs. ( Chen, J; Chen, Y; Hu, T; Wang, W; Zhang, Y, 2014) |
| "Patients with stage IV colorectal cancer and peritoneal carcinomatosis are increasingly treated with curative intent and perioperative systemic chemotherapy combined with targeted therapy." | 1.40 | Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. ( Elias, D; Eveno, C; Gayat, E; Glehen, O; Goéré, D; Passot, G; Pocard, M; Soyer, P, 2014) |
| "Ninety-two metastatic colorectal cancer patients treated with first-line 5-fluoropyrimidine (5-FU), leucovorin, and oxaliplatin (FOLFOX), capecitabine, and oxaliplatin (XELOX) and sixty-two patients receiving 5-FU, leucovorin, and irinotecan (FOLFIRI) were reviewed." | 1.40 | Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. ( Cai, S; Li, W; Sun, M; Yu, Q; Zhang, W; Zhang, Z; Zhao, J; Zhu, D, 2014) |
| "Despite curative surgery for colorectal cancer, some patients experience tumor recurrence." | 1.40 | Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer. ( Chang, SC; Chen, WS; Chiou, SH; Jiang, JK; Lan, YT; Lin, CC; Lin, JK; Lin, TC; Wang, HS; Yang, SH, 2014) |
| "We found that S100P expression of colorectal cancer tissue was significantly higher than that of normal colorectal mucosal tissues." | 1.40 | Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro. ( Chen, L; Dong, L; Jiang, L; Jin, R; Li, G; Lin, F; Ni, W; Wang, F; Wu, J; Yin, X, 2014) |
| "Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy." | 1.40 | Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K, 2014) |
| "Twelve to 13% of patients with colorectal cancer (CRC) develop peritoneal carcinomatosis (PC), the majority of whom present with unresectable disease." | 1.40 | A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer. ( Aalbers, A; Boot, H; Hompes, D; Prevoo, W; van Tinteren, H; van Velthuysen, ML; Verwaal, V; Vogel, W, 2014) |
| "5-Fluorouracil (5-FU) is a first line chemotherapeutic medication used in the treatment of gallbladder cancer; however, the efficacy is below satisfactory." | 1.40 | Icariin-mediated inhibition of NF-κB activity enhances the in vitro and in vivo antitumour effect of 5-fluorouracil in colorectal cancer. ( Cai, GX; Cai, SJ; Gu, WL; Guan, ZQ; Li, DW; Li, XX; Peng, JJ; Shi, DB; Xu, Y; Zheng, HT, 2014) |
| "0144) adverse effects in stage II/III patients." | 1.40 | Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. ( Beachler, C; El-Deiry, WS; Harvey, HA; Kline, CL; Mackley, HB; McKenna, K; Messaris, E; Poritz, L; Schiccitano, A; Sheikh, H; Sivik, J; Staveley-O'Carroll, K; Stewart, D; Zhu, J, 2014) |
| "The incidence of colorectal cancer has been increasing every year in Korea." | 1.40 | FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience. ( Kim, JH; Kim, SE; Ku, KH; Moon, W; Park, MI; Park, SJ; Song, SE, 2014) |
| "Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II." | 1.40 | Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. ( Artells, R; Cordeiro, A; Diaz, T; Ferrer, G; Hernandez, R; Monzo, M; Moreno, I; Navarro, A; Tapia, G; Tejero, R, 2014) |
| "A total of 102 metastatic colorectal cancer patients treated with a oxaliplatin (XELOX) ±Bevacizumab combination were retrospectively evaluated." | 1.40 | Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy. ( Berk, V; Bozkurt, O; Duran, AO; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M, 2014) |
| "We have planned a multicentre prospective study to examine the relative impact of the efficacy and adverse events of cetuximab plus first-line chemotherapy on the quality of life in Japanese patients with KRAS wild-type unresectable colorectal cancer." | 1.40 | A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial. ( Ando, M; Fujii, H; Ooki, A; Sakamoto, J; Sato, A; Yamaguchi, K, 2014) |
| "A 67-year-old man diagnosed with colorectal cancer in 2008 presented in April 2011 to Appalachian Regional Healthcare Cancer Center with obstructive jaundice and weight loss." | 1.40 | Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction. ( Craig, J; Elsoueidi, R; Mourad, H; Richa, EM, 2014) |
| "A primary challenge in identifying replicable pharmacogenomic markers from clinical genomewide association study (GWAS) trials in oncology is the difficulty in performing a second large clinical trial with the same drugs and dosage regimen." | 1.40 | Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. ( Alba, E; Alonso, R; de la Torre-Montero, JC; Dolan, ME; González-Neira, A; Lopez-Fernandez, LA; Martín, M; Pita, G; Wheeler, HE, 2014) |
| "Biological characteristics of colorectal cancer liver metastases (CRCLM) are increasingly recognized as major determinants of patient outcome." | 1.40 | Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver. ( Christophi, C; Lau, LF; Lee, ST; Muralidharan, V; Scott, AM; Williams, DS, 2014) |
| "Hepatic resection of metastatic colorectal cancer (CRC) has become the treatment of choice for patients after resection of the primary CRC." | 1.40 | Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases. ( Araki, K; Asao, T; Fujii, T; Kubo, N; Kuwano, H; Suzuki, H; Tsukagoshi, M; Tsutsumi, S; Wada, S; Watanabe, A, 2014) |
| "The formation of liver metastases in colorectal cancer patients is the primary cause of patient death." | 1.40 | Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells. ( Ahn, JH; Hong, SW; Kim, JS; Kim, SJ; Lee, HJ; Yu, HK, 2014) |
| "Patients with inoperable tumors due to metastasis at the time of diagnosis who were treated with oxaliplatin or irinotecan as the first-line treatment were included in this study." | 1.40 | Prognostic factors for metastatic colorectal cancer after first-line chemotherapy with FOLFOX-4 or FOLFIRI regimen. ( Choi, PR; Kim, JH; Kim, SE; Lee, GW; Moon, W; Park, MI; Park, SJ, 2014) |
| "Long-term OS after CRS and HIPEC for colorectal cancer is associated with CC and neoadjuvant therapy containing bevacizumab." | 1.40 | Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. ( Ceelen, W; Pattyn, P; Putte, DV; Van Nieuwenhove, Y, 2014) |
| "The treatment of colorectal cancer (CRC) might be improved by the identification of a signalling pathway that could be targeted with novel therapeutics." | 1.40 | Role of SLC6A6 in promoting the survival and multidrug resistance of colorectal cancer. ( Matsumura, Y; Yasunaga, M, 2014) |
| "Patients with colorectal cancer who received adjuvant CAPOX from January 2005 to August 2011 were reviewed." | 1.40 | Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. ( Altaf, R; Kristensen, B; Lund Brixen, A; Nielsen, SE, 2014) |
| "Adjuvant chemotherapy use in stage II colorectal cancer (CRC) is debated." | 1.40 | The role of adjuvant chemotherapy in stage II colorectal cancer patients. ( Chang, SC; Chang, YY; Chen, WS; Jiang, JK; Lan, YT; Lin, CC; Lin, HH; Lin, JK; Lin, TC; Wang, HS; Yang, SH, 2014) |
| "We enrolled 36 patients with colorectal cancer, treated with adjuvant mFOLFOX6 or XELOX chemotherapy, and 22 healthy volunteers." | 1.40 | The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system. ( Basdanis, G; Dermitzakis, EV; Eleftheraki, A; Fountzilas, G; Georgiadis, G; Kimiskidis, VK; Konstantis, A; Lazaridis, G; Tsiptsios, I, 2014) |
| "Diarrhea is a common toxicity of chemotherapy, but the practice of reporting only severe grades (≥ 3) in clinical trials results in misleading conclusions of significance." | 1.40 | Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. ( Aprile, G; Barsevick, A; Bonaventura, A; Elting, LS; Grunberg, SM; Keefe, DM; Koczwara, B; Nguyen, HT; Selva-Nayagam, S; Sonis, ST, 2014) |
| "Colorectal cancer metastasis is a major cause of mortality worldwide, which may only be controlled with novel methods limiting tumor dissemination and chemoresistance." | 1.40 | Unbiased proteomic and transcript analyses reveal that stathmin-1 silencing inhibits colorectal cancer metastasis and sensitizes to 5-fluorouracil treatment. ( Chung, MC; Lim, TK; Tan, HT; Tan, XF; Wu, W, 2014) |
| "Sampling of saliva is a quick, noninvasive, safe and painless process that gives information about patients Ura and UH₂ levels prior to chemotherapeutical treatment." | 1.40 | Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2014) |
| " The comparison revealed no significant differences in response rate, progression-free survival, overall survival, and the frequency of overall adverse events after the start of second-line chemotherapy, although the frequency of anemia(Bgrade 3, p=0." | 1.40 | [The efficacy and safety of FOLFIRI or combined FOLFIRI and bevacizumab treatment as second-line chemotherapy for metastatic colorectal cancer patients aged 75 years and older]. ( Baba, H; Chika, N; Haga, N; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Okada, N; Sano, M; Tajima, Y, 2014) |
| "To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin." | 1.40 | [Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer]. ( Abad, A; Echave, M; Frías, C; Giménez, E; Joulain, F; Lamas, MJ; Naoshy, S; Oyagüez, I; Pericay, C; Rubio, M, 2014) |
| " OBJECTIVE response rates (ORRs), progression-free survival (PFS), overall survival (OS) and adverse events were recorded, and the relationships between various clinical factors and PFS or OS were evaluated by Cox proportional hazards models." | 1.40 | Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer. ( Chen, L; Ju, HX; Liu, BX; Liu, LY; Luo, C; Xu, Q; Yang, YS; Ying, JE; Zhao, YZ; Zhong, HJ; Zhu, LM, 2014) |
| "The aim of this retrospectively study was to evaluate the clinical efficacy of Aidi injection (ADI) combined with FOLFOX4 chemothreapy regimen in the treatment of advanced colorectal carcinoma." | 1.40 | Aidi injection combined with FOLFOX4 chemotherapy regimen in the treatment of advanced colorectal carcinoma. ( Li, Y; Nan, H; Wang, T; Wang, Y; Zhang, C; Zhang, X, 2014) |
| "Mechanistic studies in a colorectal cancer mouse model revealed that FOLFIRI-like therapy including the drugs CPT11 and 5-fluorouracil (5FU) damaged host immunocompetence in a manner that limits treatment outcomes." | 1.40 | Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. ( Baniyash, M; Biton, M; Goldshtein, A; Hubert, A; Ish-Shalom, E; Kanterman, J; Lasry, A; Sade-Feldman, M, 2014) |
| "Unlike metastatic colorectal cancer (CRC) there are to date few reports concerning the predictive value of molecular biomarkers on the clinical outcome in stage II/III CRC patients receiving adjuvant chemotherapy." | 1.40 | Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial. ( Bauer, S; Formentini, A; Galle, PR; Hoffman, A; Kittner, JM; Kornmann, M; Link, KH; Maderer, A; Moehler, M; Neumann, W; Rey, JW; Schad, A; Schwarz, M; Thomaidis, T; Trautmann, M; Weinmann, A, 2014) |
| " A randomized trial showed increased OS and decreased toxicity with PK-guided compared with BSA-based 5-FU dosing in patients with mCRC." | 1.40 | Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. ( Ayer, T; Chen, Q; El-Rayes, BF; Flowers, CR; Goldstein, DA; Harvey, RD; Howard, DH; Lipscomb, J, 2014) |
| "We examined Sdc-1 shedding in colorectal cancer by enzyme-linked immunosorbent assay (ELISA), Dot blot, reverse transcription-PCR (RT-PCR), immunohistochemistry and so on, its impact on chemotherapeutic sensitivity by collagen gel droplet embedded culture-drug sensitivity test (CD-DST) and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), and potential mechanisms of action by Dot blot, western blot and immunofluorescence." | 1.40 | Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer. ( Ba, Y; Chen, Y; Deng, T; He, Y; Li, W; Liu, R; Ren, L; Wang, X; Ying, G; Zhou, L; Zuo, D, 2014) |
| "In practice, patients with metastatic colorectal cancer in treatment failure or relapse after first-line therapy should not expect too much from the addition of aflibercept or bevacizumab to a second-line protocol." | 1.40 | Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab. ( , 2014) |
| "To assess the frequency and severity of gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with four different schedules of FOLFOX." | 1.40 | Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX. ( Bano, N; Mateen, A; Najam, R; Qazi, F, 2014) |
| " Radiofrequency ablation (RFA) is a safe and effective technique for treatment of isolated liver metastasis." | 1.40 | Safety and efficacy of radiofrequency ablation with aflibercept and FOLFIRI in a patient with metastatic colorectal cancer. ( Agarwal, A; Butler-Bowen, H; Daly, KP; Saif, MW, 2014) |
| "Participants were 91 colorectal cancer patients treated with OXA-based chemotherapy." | 1.40 | Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. ( Alberti, P; Argyriou, AA; Bergamo, F; Briani, C; Bruna, J; Cacciavillani, M; Campagnolo, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Frigeni, B; Izquierdo, C; Kalofonos, HP; Velasco, R, 2014) |
| "All unresectable metastatic colorectal cancer patients who began receiving bevacizumab at participating facilities from 2006 to 2011 were retrospectively analyze to determine the safety and efficacy." | 1.40 | Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer. ( Asao, T; Fujii, T; Kato, T; Kuwano, H; Morita, H; Suto, T; Tsutsumi, S; Yajima, R; Yamaguchi, S, 2014) |
| "When co-cultured with colorectal cancer cells in the presence of 5-FC, HB1." | 1.39 | Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-β via their tumor-tropic effect in cellular and xenograft mouse models. ( Choi, KC; Choi, KJ; Kang, NH; Kim, SU; Lee, HR; Park, MA; Yi, BR, 2013) |
| " All patients were genotyped for MTHFR 1298A>C and 677C>T polymorphisms and analysed in both cohorts separately for the association between the MTHFR genotype and incidence of grade 3-4 overall toxicity and specific adverse events, as well as efficacy parameters." | 1.39 | MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. ( Gelderblom, H; Guchelaar, HJ; Punt, CJ; van Huis-Tanja, LH, 2013) |
| " The use of combined neoadjuvant chemotherapy is safe before hepatic resection." | 1.39 | Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment. ( Baranyai, ZS; Besznyák, I; Bursics, A; Dede, K; Jakab, F; Landherr, L; Mersich, T; Salamon, F; Zaránd, A, 2013) |
| "Patients with metastatic colorectal cancer (n = 543) from an international phase 3 trial comparing FOLFOX2 with chronoFLO4 were categorized into 4 subgroups according to the occurrence of FWL or other clinically relevant toxicities during the initial 2 courses of chemotherapy." | 1.39 | Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Poncet, A; Smaaland, R; Spiegel, D; Tampellini, M; Tumolo, S, 2013) |
| " The frequency of grade 3 and 4 adverse effects were comparatively assessed in each treatment arm." | 1.39 | Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX. ( Bano, N; Mateen, A; Najam, R, 2013) |
| "The genome expression profiles of colorectal cancer tissues were examined using DNA microarray analysis, and differential gene expression was identified using a significance analysis of the microarray." | 1.39 | Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis. ( Chi, P; Huang, S; Huang, Y; Li, S; Lin, H; Lu, X; Pan, J; Shen, S; Xu, Z, 2013) |
| "5-fluorouracil (5-FU) has been widely used since the 1980s, and it remains the backbone of many chemotherapeutic combination regimens." | 1.39 | DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity. ( Amadori, A; Boldrin, E; Rumiato, E; Saggioro, D, 2013) |
| " Clinical data demonstrated that there was higher correlation between DPD activity and toxic effects of 5-FU (p<0." | 1.39 | Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China. ( Lu, Z; Sun, B; Zhang, X, 2013) |
| " Grade 3/4 adverse events were: neutropenia (54." | 1.39 | Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer. ( Maruyama, S; Takii, Y, 2013) |
| "In 5-fluorouracil (5-FU)-treated patients, the tumour overexpression of SOX9 correlated with markedly poorer survival (HR=8." | 1.39 | Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients. ( Candy, PA; Colley, SM; Davidson, JA; Leedman, PJ; Phillips, MR; Redfern, AD; Stuart, LM; Wood, BA; Zeps, N, 2013) |
| "Thyroid function in colorectal cancer patients receiving fluoropyrimidine-based chemotherapy with or without bevacizumab was evaluated at baseline and monthly." | 1.39 | Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kiyota, N; Minami, H; Mukohara, T; Tomioka, H, 2013) |
| " Pharmacogenotyping is therefore recommended to guide dosing of 5-FU and prevent neutropenia." | 1.39 | Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients. ( Bannur, Z; Fijeraid, H; Hamzah, S; Hasbullani, Z; Hashim, H; Md Nor, A; Ngow, H; Ramasamy, P; Salleh, MZ; Shia, JK; Sood, S; Teh, LK; Zailani, M; Zakaria, ZA, 2013) |
| "As oxaliplatin is a standard agent in colorectal cancer therapy today, all clinicians and pathologists should be aware of such non-neoplastic lesions as one of the rare differential diagnoses of metastatic liver tumor, to prevent overtreatment." | 1.39 | Oxaliplatin-induced liver injury mimicking metastatic tumor on images: a case report. ( Endo, Y; Fujisawa, M; Kai, K; Matsukawa, A; Matsumoto, Y; Nobuhisa, T; Notohara, K; Sato, S; Uchino, K; Watanabe, T, 2013) |
| "Silencing of PI3K p85α in colorectal cancer cells increased disruption of mitochondrial membrane potential and enhanced 5-FU-induced apoptosis." | 1.39 | The effects of silencing of PI3K p85α on 5-FU-induced colorectal cancer cells apoptosis. ( Sun, Y; Tian, H; Wang, L; Yang, H, 2013) |
| "A total of 250 White metastatic colorectal cancer patients homogenously treated with a first-line FOLFIRI regimen were genotyped for a panel of variants in five transporter genes." | 1.39 | Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. ( Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Mattia, E; Dreussi, E; Polesel, J; Toffoli, G; Zagonel, V, 2013) |
| "MC was found in 12." | 1.39 | Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma. ( de Hingh, IH; de Wilt, JH; Hugen, N; Lemmens, VE; Nagtegaal, ID; Pruijt, JF; Radema, SA; Verhoeven, RH, 2013) |
| "Metastatectomy in colorectal cancer (CRC) is now a standard of care with improved survival reported." | 1.39 | Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy. ( Beeke, C; Bishnoi, S; Karapetis, CS; Maddern, G; Padbury, R; Padman, S; Price, TJ; Townsend, AR, 2013) |
| "Elderly patients with metastatic colorectal cancer (mCRC) differ from the general population and are underrepresented in clinical trials." | 1.39 | Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients. ( Aprile, G; Bearz, A; Berretta, M; Borsatti, E; Canzonieri, V; Ferrari, L; Fiorica, F; Fisichella, R; Foltran, L; Lestuzzi, C; Lleshi, A; Lutrino, S; Nasti, G; Talamini, R; Tirelli, U; Urbani, M, 2013) |
| "When treating colorectal cancer with chemotherapy, it is important to elucidate how the prognosis can be improved while maintaining the quality of life( QOL)." | 1.39 | [Protocol for the administration of modified FOLFOX6 (mFOLFOX6) in patients with unresectable/recurrent colorectal cancer]. ( Hagino, S; Iwata, K; Kiriyama, M; Kurata, T; Makita, N; Tsuneda, A, 2013) |
| "Colorectal cancer is the fourth most common cancer worldwide and the second leading cause of cancer-related death." | 1.39 | Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. ( Bi, F; Chen, Q; Ge, XJ; Tang, QL; Xia, HW; Zhang, YC, 2013) |
| "Patients with advanced colorectal cancer (CRC) who have received oxaliplatin, 5-fluoropyrimidine, and irinotecan chemotherapy (with or without bevacizumab) and antiepidermal growth factor receptor therapy (if KRAS is wild type) have no further standard treatment options." | 1.39 | Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. ( Beeke, C; Bishnoi, S; Broadbridge, V; Jain, K; Karapetis, CS; Luke, C; Padbury, R; Price, TJ; Townsend, AR, 2013) |
| " Combined quantification of U and UH(2) with 5-FU and 5-FUH(2) may provide a pre-therapeutic assessment of DPD activity and further guide drug dosing during therapy." | 1.39 | LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. ( Amstutz, U; Büchel, B; Bühr, C; Largiadèr, CR; Rhyn, P; Schürch, S, 2013) |
| " Another option is to use desensitization protocols that induce a temporary state of tolerance by gradually administering small quantities of the antineoplastic drug until the therapeutic dosage is reached." | 1.39 | Effectiveness of oxaliplatin desensitization protocols. ( Aguilella-Vizcaíno, MJ; Calleja-Hernández, MÁ; Cortés-Funes Castro, H; Cortijo-Cascajares, S; García-Escobar, I; Herreros-de-Tejada, A; Nacle-López, I, 2013) |
| "Gastric and colorectal cancers are among the most common cancers worldwide and cause serious cancer mortality." | 1.39 | Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers. ( He, C; Hu, X; Huang, X; Kuang, Y; Li, L; Mo, L; Rong, R; Shi, Q; Shu, X; Su, X; Sui, X; Tao, Q, 2013) |
| "These results suggest that HR + RFA after effective chemotherapy is a safe procedure with low local recurrence at the RFA site and is a potentially effective treatment option for patients with initially unresectable CRLM." | 1.39 | Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Kikuchi, K; Kuroki, H; Mima, K; Miyamoto, Y; Nakagawa, S; Okabe, H; Sakamoto, Y; Watanabe, M, 2013) |
| "Periodontitis has been observed infrequently in bevacizumab-containing chemotherapy in clinical practice." | 1.39 | A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients. ( Akiyoshi, K; Hamaguchi, T; Hosokawa, A; Iwasa, S; Kato, K; Nakajima, TE; Nishitani, H; Ogawa, K; Shimada, Y; Sugiyama, T; Ueno, T; Yamada, Y, 2013) |
| "Patients with colorectal cancer (CRC) and liver metastases benefit from perioperative chemotherapy and liver resection." | 1.39 | Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. ( Asghar, U; Barbachano, Y; Chau, I; Constantinidou, A; Cunningham, D; Khan, A; Mudan, S; Rao, S; Shurmahi, F, 2013) |
| "Major postoperative complications were independently associated with major (≥ 3 segments) resections (57%) and perioperative blood transfusion." | 1.39 | Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. ( Allen, PJ; Bao, F; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; Jarnagin, WR; Kemeny, N; Kingham, TP; Park, JO; Shia, J; Wolf, PS, 2013) |
| "Combined resection of colorectal cancer with surgery for synchronous liver metastases (LM) still remains controversial because of the possible higher morbidity rate, the necessity of an adequate abdominal approach for both resections and the impact on oncological results." | 1.39 | Laparoscopic resection of colorectal cancer facilitates simultaneous surgery of synchronous liver metastases. ( Belghiti, J; Bretagnol, F; Farges, O; Hatwell, C; Panis, Y, 2013) |
| " Gimeracil, a DPD inhibitor, was checked whether it could reverse the reduced bioavailability of 5-FU." | 1.39 | The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil. ( Cao, D; Chen, X; Ding, J; Dong, H; Du, Y; Ge, J; Li, LH; Liu, JY; Luo, WX; Men, HT; Tan, BX; Tang, J; Zhao, F, 2013) |
| "Peritoneal carcinomatosis (PC), considered to have a dismal prognosis, is exclusively sub-classified into stage IVB, even though other metastases to a sole organ are sub-classified into stage IVA, which is considered to be associated with better survival." | 1.39 | Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy? ( Baba, H; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Okada, N, 2013) |
| "Capecitabine is a member of the fluoropyrimidine family of chemotherapeutic agents that selectively delivers 5-fluorouracil (5-FU) to tumors." | 1.38 | Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm. ( Rather, A; Shah, A; Shah, NR, 2012) |
| "Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study." | 1.38 | PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. ( Crucitti, P; Falcone, A; Frezza, AM; Galluzzo, S; Graziano, F; Loupakis, F; Muda, AO; Perrone, G; Rabitti, C; Rizzo, S; Russo, A; Ruzzo, AM; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B; Zoccoli, A, 2012) |
| " However, many toxic effects are evaluated on a categorical scale." | 1.38 | Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation. ( Freyer, G; Girard, P; Hénin, E; Paule, I; Tod, M; You, B, 2012) |
| " We investigated whether there might be a discrepancy between the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) and the Neurotoxicity Criteria of Debiopharm (DEB-NTC), the commonly used oxaliplatin-specific scales, in the evaluation of peripheral neurotoxicity." | 1.38 | Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. ( Inoue, N; Ishibashi, K; Ishida, H; Kishino, T; Kumamoto, K; Okada, N; Sano, M, 2012) |
| "Population-based studies of adverse events are scarce." | 1.38 | Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. ( Cen, P; Du, XL; Liu, C, 2012) |
| "HCT116 colorectal or PPC1 prostate cancer cells were treated with quercetin and the drugs." | 1.38 | Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. ( Fadlalla, K; Katkoori, V; Manne, U; Mosley, L; Samuel, T; Turner, T, 2012) |
| "Fifty seven metastatic colorectal cancer patients were prospectively included and 40 tumors were analyzed." | 1.38 | Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients. ( Brunet, R; Evrard, S; Kauffmann, A; Laroche-Clary, A; Laurand-Quancard, A; Le Morvan, V; Robert, J; Smith, D, 2012) |
| ", Salt Lake City, UT) that measures plasma 5-FU concentration and reports an AUC in mg · h/L has been developed to optimize therapy using pharmacokinetic (PK) dosing." | 1.38 | Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. ( Grier, CE; Hamilton, SA; Haregewoin, A; Kaldate, RR; McLeod, HL, 2012) |
| "Patients with colorectal cancer treated with oxaliplatin based chemotherapy (FOLFOX or XELOX) were retrospectively divided into two groups according to the use of GM1." | 1.38 | The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study. ( Chen, XF; Guo, RH; Li, J; Røe, OD; Shu, YQ; Wang, R; Wu, T; Yin, YM; Zhu, LJ, 2012) |
| "Colorectal carcinoma is rare in the paediatric population but is increasing in incidence." | 1.38 | Metastatic paediatric colorectal carcinoma. ( Kennedy, MJ; Larkin, JO; McCormick, P; Mehigan, B; Muldoon, C; Woods, R, 2012) |
| " Our findings suggest that it is necessary to manage drug dosage for Japanese patients while considering their renal function, and to actively monitor for any side effects." | 1.38 | [Side effect analyses in consideration of renal functions for capecitabine-administered patients]. ( Iwai, M; Kimura, M; Yasuda, T; Yoshimura, T, 2012) |
| "Predictors of the response of colorectal cancer to chemotherapy remain poorly understood." | 1.38 | Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer. ( Goto, T; Hibi, K; Kigawa, G; Kitamura, Y; Nemoto, H; Saito, M; Sakuraba, K; Sanada, Y; Shinmura, K; Shirahata, A; Yokomizo, K, 2012) |
| "A total of 18 colorectal cancer patients who received bevacizumab combined with chemotherapy were included." | 1.38 | Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography. ( Akay, OM; Bal, C; Gulbas, Z; Keskin, M; Kuş, E; Ustuner, Z, 2012) |
| "The efficacy and tolerability of bevacizumab every 2 or 4 weeks using the same dosage in combination with biweekly FOLFIRI were retrospectively evaluated in metastatic colorectal cancer (mCRC) patients in the first-line and second-line therapy." | 1.38 | Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. ( Alkis, N; Benekli, M; Berk, V; Buyukberber, S; Ciltas, A; Coskun, U; Dane, F; Dikilitas, M; Dogu, GG; Durnali, AG; Kaplan, MA; Karaca, H; Ozkan, M; Sevinc, A; Yetisyigit, T; Yildiz, R, 2012) |
| "The 5-FU concentrations in colorectal cancer tissue, liver, lung, and blood were(73." | 1.38 | [Comparison of targeting distribution of two kinds of fluorouracil magnetic albumin microspheres in colorectal neoplasm nude mice in vivo under magnetic field]. ( Gu, J; Jiang, T; Kong, X; Liu, JG; Liu, ZC, 2012) |
| "Metastatic colorectal cancer (CRC) is predominantly a disease of the elderly, therefore the current standards should be evaluated in this population." | 1.38 | Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). ( Doornebal, J; Koopman, M; Lemmens, W; Punt, CJ; Teerenstra, S; Venderbosch, S, 2012) |
| "Human colorectal cancer cell lines HCT116 and DLD-1 were treated with a panel of small interfering RNAs directed against the PI3K/AKT/mTOR and Ras pathways; proliferation, apoptosis, and protein expression were assessed." | 1.38 | Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer. ( Elliott, VA; Evers, BM; Gao, T; Mustain, WC; Rychahou, PG; Valentino, JD; Wang, C; Zaytseva, YY, 2012) |
| " We also observed bioavailability of ursolic acid in the serum and tissue of animals." | 1.38 | Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. ( Aggarwal, BB; Baladandayuthapani, V; Deorukhkar, A; Diagaradjane, P; Guha, S; Kannappan, R; Krishnan, S; Prasad, S; Reuter, S; Sung, B; Wei, C; Yadav, VR, 2012) |
| " Gastro-intestinal adverse events graded according to the WHO criteria were recorded after the first cycle." | 1.38 | Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. ( Bocci, G; Ciccolini, J; Danesi, R; Di Paolo, A; Iliadis, A; Lacarelle, B; Marouani, H; Woloch, C, 2012) |
| "Ellagic acid has been demonstrated to inhibit the growth of several types of cancer cells." | 1.38 | Effects of ellagic acid on chemosensitivity to 5-fluorouracil in colorectal carcinoma cells. ( Chang, HP; Chen, CH; Chou, JL; Chung, YC; Hou, YC; Hsu, CP; Kao, TY; Tsai, YW, 2012) |
| "Metastatic colorectal cancer is the second leading cause of cancer death in the United States." | 1.38 | Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer. ( de Braud, F; Díaz-Rubio, E; Pietrantonio, F, 2012) |
| "The grades of neurosensory adverse events (NSAEs) induced by FOLFOX4 treatment were compared between Asian and Western colorectal cancer patients and correlated with cumulative oxaliplatin doses." | 1.38 | Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. ( André, T; Brienza, S; Goldberg, RM; Gomi, K; Gramont, A; Lee, PH; Mizunuma, N; Ohtsu, A; Rothenberg, ML; Shimada, Y; Sugihara, K, 2012) |
| "Hyporexia/anorexia is a relevant clinical problem affecting the quality of life of many cancer patients." | 1.37 | Steroids, cancer and vertebral fractures: a dreaded combination. ( Uña Cidón, E, 2011) |
| "The authors report two cases of young patients who developed clubbing and hypertrophic osteoarthropathy in one case or lung diffusion disorder in the second, after a long-term use of bevacizumab plus chemotherapy in a palliative setting of metastatic colorectal cancer." | 1.37 | Clubbing and hypertrophic osteoarthropathy in two patients taking long-term bevacizumab for metastatic colorectal cancer. ( Audrain, O; Boucher, E; Kerjouan, M; Le Roux, C; Pracht, M; Raoul, JL, 2011) |
| "Gastric cancer is the third most common cancer worldwide and the second leading cause of cancer deaths." | 1.37 | Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer. ( Abou-Alfa, GK; Al-Olayan, A; Kelsen, D; Lowery, M; Naghy, M; Power, D; Saliba, T; Shah, MA; Shamseddine, A; Smyth, E, 2011) |
| "Twenty-four colorectal and 24 breast cancer patients participated in this study." | 1.37 | Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. ( Braun, M; Jaehde, U; Ko, YD; Kuhn, W; Mey, UJ; Ringsdorf, S; Schmidt-Wolf, I; Schwindt, PF; Simons, S, 2011) |
| "Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease." | 1.37 | Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. ( Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM, 2011) |
| "Patients with CIMP-positive colorectal tumors do not benefit from 5-FU-based adjuvant chemotherapy." | 1.37 | 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. ( Alenda, C; Andreu, M; Balaguer, F; Bessa, X; Boland, CR; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Goel, A; Jover, R; Llor, X; Morillas, JD; Nguyen, TP; Nicolás-Pérez, D; Payá, A; Pérez-Carbonell, L; Reñé, JM; Rojas, E; Xicola, RM; Zapater, P, 2011) |
| "Patients with metastatic colorectal cancers have poor outcomes." | 1.37 | Changing management and survival in patients with stage IV colorectal cancer. ( Ng, S; O'bichere, A; Platell, C; Tebbutt, N, 2011) |
| " The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group." | 1.37 | Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. ( Arai, T; Kobayashi, S; Koike, J; Koizumi, S; Makizumi, R; Miura, K; Miyajima, N; Nakano, H; Otsubo, T; Sakurai, J; Shimamura, T; Yamada, K, 2011) |
| " Adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events." | 1.37 | Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. ( Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S, 2011) |
| "Interstitial lung disease in patients with colorectal cancer during chemotherapy combined with bevacizumab is rare." | 1.37 | Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients. ( Furushima, K; Ishihara, T; Katou, Y; Tanai, C; Tanaka, Y; Usui, K, 2011) |
| "In metastatic colorectal cancer patients treated with mFolfox-6, the combination of haplotype XPD Lys751Gln-GSTP1 105Val seems to predict the risk of progression." | 1.37 | Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. ( Balboa, E; Barros, F; Bernardez, B; Carracedo, A; Duran, G; Gallardo, E; Lamas, MJ; Lopez, R; Touris, M; Vidal, Y, 2011) |
| "We report two cases of advanced colorectal cancer which showed splenomegaly after administration of oxaliplatin-based chemotherapy." | 1.37 | [Two cases of advanced colorectal cancer which demonstrated the reversibility of oxaliplatin-mediated increase in splenic volume]. ( Furuse, J; Hanai, C; Hosokawa, Y; Kawase, T; Kitagawa, N; Konno, T; Motoori, S; Nishimura, H; Saisho, H, 2011) |
| "FOLFOX plus bevacizumab therapy can be given safely to hemodialytic patients with no reduction in the dose of oxaliplatin if hemodialysis is performed soon after the administration of oxaliplatin and the dosing interval is extended to 3 weeks." | 1.37 | Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. ( Chiba, T; Ezoe, Y; Horimatsu, T; Mashimo, Y; Miyamoto, S; Morita, S; Muto, M, 2011) |
| " The drug combination elevated the plasma level of PHT in a patient on chemotherapy with capecitabine for colorectal cancer." | 1.37 | [A case of toxicity caused by drug interaction between capecitabine and phenytoin in patient with colorectal cancer]. ( Fukui, E; Kawahara, K; Sakurai, M; Ueda, R; Yamada, R, 2011) |
| "Here, we report on 2 patients with colorectal cancer and severe liver dysfunction secondary to hepatic metastases." | 1.37 | Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction. ( Bubenzer, J; do O, N; Fuchs, R; Luedde, T; Roderburg, C; Spannbauer, M; Tischendorf, JJ; Trautwein, C, 2011) |
| "About 50% of patients with primary colorectal cancer (CRC) will develop liver metastases (CLM)." | 1.37 | Type IV collagen as a tumour marker for colorectal liver metastases. ( Hafström, L; Naredi, P; Nyström, H; Sund, M, 2011) |
| "For the metastatic colorectal cancer LLD population with K-ras wild-type genotype, mean overall survival estimates were 37." | 1.37 | Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. ( Asseburg, C; Frank, M; Griebsch, I; Hartmann, JT; Köhne, CH; Mittendorf, T; Mohr, A; Osowski, U; Schulten, J, 2011) |
| "However, its role in colorectal cancer (CRC) pathobiology and clinical relevance remains unknown." | 1.37 | Overexpression of neurone glial-related cell adhesion molecule is an independent predictor of poor prognosis in advanced colorectal cancer. ( Chan, JY; Ong, CW; Salto-Tellez, M, 2011) |
| "Metastatic colorectal cancer has a low cure rate." | 1.37 | Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer. ( Afonso, S; Afonso, V; Stefano, E; Viani, G, 2011) |
| "The prognosis of patients with advanced colorectal cancer with icterus is dismally poor, and adequate chemotherapy for these patients has not been established yet." | 1.37 | FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases. ( Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T, 2011) |
| "Especially ischemic colitis can rapidly develop into bowel perforation, so an emergency operation often is needed." | 1.37 | [A case of severe bevacizumab-induced ischemic pancolitis, treated with conservative management]. ( Chun, SH; Kim, SW; Lee, H; Lee, HM; Lee, HN; Lee, MA; Lim, Y; Won, HS, 2011) |
| "Tissues of 82 patients treated for colorectal cancer (CRC) were analyzed using antibodies against AIF, p53, DR4, DR5, cleaved caspase-3 and the TUNEL method to detect apoptosis; whereas staining of Ki-67 was used as a proliferation marker." | 1.37 | Expression of p53 and DR5 in normal and malignant tissues of colorectal cancer: correlation with advanced stages. ( Akil, H; Jauberteau, MO; Labrousse, F; Mathonnet, M; Nouaille, M; Perraud, A; Petit, D, 2011) |
| "Acriflavine was active in cell spheroids, indicating good drug penetration and activity against hypoxic cells." | 1.37 | Novel activity of acriflavine against colorectal cancer tumor cells. ( Fayad, W; Felth, J; Fryknäs, M; Glimelius, B; Graf, W; Gullbo, J; Hassan, S; Larsson, R; Laryea, D; Linder, S; Mahteme, H; Nygren, P; Påhlman, L; Rickardson, L, 2011) |
| "A total of 27 patients with metastatic colorectal cancer received the FOLFOX (n=17) or FOLFIRI (n=10) chemotherapeutic regimen." | 1.37 | Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity. ( Hazama, S; Kamei, R; Kan, S; Maeda, K; Maeda, N; Maeda, Y; Oka, M; Shindo, Y; Tokuno, K; Watanabe, Y; Yoshimura, K; Yoshino, S, 2011) |
| "XELOX for unresectable advanced colorectal cancer has been approved in Japan." | 1.37 | [Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer]. ( Amano, R; Fuyuhiro, Y; Hirakawa, K; Ishikawa, T; Kashiwagi, S; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Nakata, B; Noda, E; Ohira, M; Tanaka, H; Yamada, N; Yashiro, M, 2011) |
| "The subject was 28 patients of colorectal cancer with synchronous unresectable liver metastasis who received mFOLFOX6 as a first-line treatment from 2005 to 2010." | 1.37 | [Therapeutic effect of mFOLFOX6 for synchronous unresectable liver metastases from colorectal cancer]. ( Amano, K; Chikatani, K; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Ishiguro, T; Iwama, T; Kumamoto, K; Kuwabara, K; Ohsawa, T; Okada, N; Sobajima, J; Tajima, Y, 2011) |
| "Cumulative risks of recurrence were 10." | 1.37 | [Recurrance of disappearing colorectal liver metastases after mFOLFOX6 regimen]. ( Haga, N; Ishibashi, K; Ishida, H; Kumamoto, K; Okada, N; Ono, T, 2011) |
| "The outcomes and management of colorectal cancer (CRC) hepatic metastasis have undergone many evolutionary changes." | 1.37 | Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment. ( Chan, KM; Chen, JS; Chiang, JM; Lee, CF; Lee, WC; Wang, JY; Yu, MC, 2011) |
| "Nu/Nu mice were injected IP with HT-29 colorectal cancer cells." | 1.36 | Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo. ( Al-Kasspooles, MF; Broward, M; Cohen, MS; Henry, D; Roby, KF; Williamson, SK, 2010) |
| "Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity." | 1.36 | Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. ( Ahmad, A; Gounaris, I, 2010) |
| "Here we adapted an orthotopic colorectal cancer model, in which HT-29 colorectal cancer cells form tumors in the rectal lining and metastasize to the para-aortic lymph nodes with high frequency." | 1.36 | Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging. ( Prewett, M; Steiner, P; Surguladze, D; Tonra, JR, 2010) |
| " Cardiotoxicity causing angina, arrhythmia and infarction are serious adverse events associated with these agents." | 1.36 | [Cardiotoxicity induced by 5-fluorouracil or capecitabine]. ( Baeksgaard, L; Jensen, SA; Petersen, LN; Reiter, L; Sørensen, JB, 2010) |
| "From April, 2007 to February, 2009, 23 colorectal cancer patients were treated with Bevacizumab." | 1.36 | [Evaluation of bevacizumab for advanced colorectal cancer]. ( Hoshino, S; Matsuo, K; Naito, M; Nakano, M; Noda, N; Shinohara, T; Tanaka, S; Yamashita, Y; Yamauchi, Y, 2010) |
| "Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (uracil reductase), the enzyme that rapidly catabolizes 5-fluorouracil (5-FU)." | 1.36 | A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil. ( Cao, S; Spector, T, 2010) |
| " Adverse events resulting from its use include gastrointestinal perforation, wound-healing complications, hemorrhage, and arterial thromboembolism." | 1.36 | Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer. ( Gamboa, EO; Haller, N; Rehmus, EH, 2010) |
| "Histological response of colorectal cancer liver metastases to chemotherapy may be graded based on the extent of tumor regression." | 1.36 | Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. ( Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Kaczirek, K; Klinger, M; Tamandl, D, 2010) |
| "Capecitabine is an anticancer agent, prodrug of 5 fluorouracil (5-FU) administered orally and with a narrow therapeutic index." | 1.36 | [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency]. ( Bontemps, H; Coursier, S; Emptoz, J; Guillermet, A; Martelet, S; Villier, C, 2010) |
| "Colorectal cancer is the most common form of malignancy in Taiwan and the third leading cause of death from cancer, preceded only by lung and hepatic cancers." | 1.36 | rTSbeta as a novel 5-fluorouracil resistance marker of colorectal cancer: a preliminary study. ( Chow, KC; Lin, YL, 2010) |
| "Chemotherapy-induced interstitial lung disease (ILD) in colorectal cancer (CRC) patients is rarely reported, but its clinical features remain to be clarified." | 1.36 | Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. ( Doi, T; Fuse, N; Joh, T; Minashi, K; Ohtsu, A; Shimura, T; Tahara, M; Yoshino, T, 2010) |
| "In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy." | 1.36 | Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. ( Andres, A; Gervaz, P; Majno, P; Mentha, G; Morel, P; Roth, A; Rubbia-Brandt, L, 2010) |
| "Capecitabine is an oral fluoropyrimidine which is transformed to 5-Fluorouracil inside tumor cells, where it achieves high drug concentrations." | 1.36 | Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect? ( Emiliani, A; Losanno, T; Manna, G; Seminara, P, 2010) |
| "The risk of venous thromboembolism has been reported to increase when receiving bevacizumab." | 1.36 | Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. ( Doi, T; Fuse, N; Ikematsu, H; Kaneko, K; Koike, K; Kojima, T; Minashi, K; Mochizuki, S; Ohtsu, A; Tahara, M; Yano, T; Yoshino, T, 2010) |
| "We compared clinical outcome and pharmacokinetic (pK) parameters of a new pharmacokinetically-guided dosing strategy in two groups of patients (age < or >65 years) with metastatic colorectal cancer (mCRC)." | 1.36 | Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer. ( Abderrahim, AG; Bressolle, F; Duffour, J; Pinguet, F; Poujol, S; Roca, L; Ychou, M, 2010) |
| "42%; P = ." | 1.36 | Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. ( Abdalla, EK; Capussotti, L; Contreras, CM; Curley, SA; Kishi, Y; Kopetz, S; Maru, DM; Motta, M; Ravarino, N; Ribero, D; Risio, M; Vauthey, JN; Zorzi, D, 2010) |
| "However, the role of CSCs in colorectal cancer metastasis is unclear." | 1.36 | A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. ( Cheung, LW; Chow, AK; Chu, AC; Lam, CS; Lan, HY; Lan, XR; Law, WL; Ng, L; Pang, R; Poon, JT; Poon, RT; Tan, VP; Wong, BC; Yau, TC, 2010) |
| "However, economic burden of colorectal cancer is considerable." | 1.36 | Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer. ( Ajima, H; Fujita, K; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Nakayama, H; Ogata, H; Sasaki, Y; Sunakawa, Y; Takahashi, H; Yamashita, K, 2010) |
| "Colorectal cancer is (CRC) one of the commonest cancers and its therapy is still based on few drugs." | 1.36 | 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. ( Bodmer, WF; Bracht, K; Liu, Y; Nicholls, AM, 2010) |
| "5-Fluorouracil/leucovorin-treated CRC patients achieved a significantly longer progression-free survival when presenting with SI-positive tumours before therapy (median 12." | 1.36 | Cellular senescence predicts treatment outcome in metastasised colorectal cancer. ( Dörken, B; Gröne, J; Haugstetter, AM; Lenze, D; Loddenkemper, C; Petersen, I; Schmitt, CA; Standfuss, C, 2010) |
| "Colorectal cancer is one of the leading malignancies in the world." | 1.36 | Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. ( Fu, ZX; Shen, W; Tu, JK; Wang, XH, 2010) |
| "Capecitabine levels were quantified by a simple reversed-phase HPLC system with an external standard method." | 1.36 | A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes. ( Czejka, M; Ettlinger, D; Farkouh, A; Georgopoulos, A; Scheithauer, W; Schueller, J, 2010) |
| " A protocol-defined prohibitive adverse event occurred in 4 patients (6%), including 2 treatment-associated deaths." | 1.36 | Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. ( Chen, HX; Christos, P; Hamilton, A; Horvath, L; Kindler, HL; Matulich, D; Ocean, AJ; Polite, B; Sparano, JA, 2010) |
| "We report two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer." | 1.36 | [Two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer]. ( Hosokawa, T; Iwao, Y; Koshiishi, H; Koshinaga, T; Matsuyama, T; Nishida, K; Okamura, T; Sakamoto, K; Tokita, H, 2010) |
| "Fifty patients with unresectable colorectal cancer treated with mFOLFOX6 therapy were enrolled in this study." | 1.36 | [The expression of thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) protein in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy]. ( Haga, N; Ishibashi, K; Ishida, H; Ishiguro, T; Itoyama, S; Kumamoto, K; Kuwabara, K; Miura, I; Mori, T; Ohsawa, T; Okada, N; Tamaru, J; Yamada, H; Yokoyama, M, 2010) |
| "Recent advances in chemotherapy for colorectal cancer prolonged survival." | 1.36 | [Roles of hepatectomy for colorectal liver metastases with necrotic foci caused by prior anti-cancer therapies]. ( Inoue, T; Ishikawa, H; Ko, S; Kunishige, T; Mukogawa, T; Nakamoto, T; Nishiwada, T; Watanabe, A, 2010) |
| "5-Fluorouracil (5-FU) is a standard chemotherapeutic drug to treat CRC." | 1.35 | Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. ( Au, TC; Chan, AT; Chan, CM; Chan, WH; Cheuk, W; Hui, EP; Lam, MY; Ma, BB; Wong, CS; Wong, MC; Wong, VW, 2008) |
| " The setting of dosage was differed in two hospitals." | 1.35 | [Comparative survey on current status and the differences of treatment using modified FOLFOX6 regimen in patients with colorectal cancer in two general hospitals]. ( Anami, S; Fujii, C; Fukunaga, M; Furukawa, H; Kitada, N; Morimoto, S; Morita, S; Takara, K; Watari, M; Yamasaki, H; Yokoyama, T, 2008) |
| "Liver metastases (n = 93) along with primary tumors (n = 48) were analyzed for K-Ras mutations (codons 12 and 13), p53 mutations (exons 4-9), p53 polymorphism (codon 72), thymidylate synthase (TS) polymorphism (28-bp repeats including G>C mutation), methylenetetrahydrofolate reductase polymorphism (677C>T, 1298A>C), thymidylate synthase (TS) activity, dihydropyrimidine dehydrogenase activity, folylpolyglutamate synthase activity, and p53 protein expression." | 1.35 | K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. ( Benchimol, D; Chazal, M; Delpero, JR; Etienne-Grimaldi, MC; Formento, JL; Formento, P; François, E; Francoual, M; Laurent-Puig, P; Letoublon, C; Milano, G; Pezet, D; Renée, N; Seitz, JF, 2008) |
| " Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment." | 1.35 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009) |
| "Capecitabine is a chemotherapeutic prodrug that is metabolised to 5-fluorouracil." | 1.35 | Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction. ( Curzen, NP; Ferchow, L; Hobson, A; Scott, PA, 2008) |
| "In patients with metastatic colorectal cancer (mCRC), several prognostic factors such as performance status (PS), number of metastatic sites, carcinoembryonic antigen (CEA), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) have been reported." | 1.35 | Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer. ( Asaka, M; Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2008) |
| "CRP was associated with disease progression and factors reflecting nutritional depletion such as serum albumin, lymphocyte count and body weight loss ratio." | 1.35 | Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. ( Inoue, Y; Koike, Y; Kusunoki, M; Miki, C; Okugawa, Y; Tanaka, K; Toiyama, Y; Yokoe, T, 2008) |
| "Hepatic metastasis from colorectal cancer (mCRC) is best treated with a multidisciplinary approach." | 1.35 | Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. ( Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE, 2009) |
| "Of 55 patients with colorectal cancer, 20 had no metastasis and the other 35 had distant metastasis." | 1.35 | Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer. ( Akagi, Y; Hattori, S; Kage, M; Kawahara, A; Kuwano, M; Mizobe, T; Ono, M; Shirouzu, K; Yanagawa, T, 2009) |
| "Patients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study." | 1.35 | Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. ( Agrogiannis, G; Arapogiannis, G; Gouveris, P; Kavantzas, N; Kopterides, P; Kosmas, C; Kyriakou, V; Lazaris, A; Papathomas, T; Patsouris, E; Tsavaris, N; Zorzos, H, 2009) |
| " In addition, relative dose intensity (RDI), therapeutic efficacy, and adverse events in the patients who were given the regimen, we compared between the groups." | 1.35 | [Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer]. ( Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Kuwabara, K; Matsuki, M; Miyazaki, T; Okada, N; Sano, M; Yokoyama, M, 2008) |
| "The increased MMP-7 levels at disease progression support the hypothesis that this protease could play a role in acquired resistance by degrading IGFBP-3." | 1.35 | Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. ( Augé, JM; Carcereny, E; Codony-Servat, J; Gallego, R; García-Albéniz, X; Gascón, P; Longarón, R; Maurel, J; Oliveras, A; Tosca, M, 2009) |
| "The subjects were 13 colorectal cancer patients who had undergone resection of the primary tumor, and showed multiple, unresectable liver metastases and severe liver dysfunction." | 1.35 | [Combination of hepatic arterial infusion therapy and FOLFOX for colorectal cancer with multiple unresectable liver metastases causing severe liver dysfunction]. ( Iizawa, H; Ikeda, E; Ishiyama, K; Mori, N; Saito, K; Sakurai, N; Sato, T; Suto, T; Takano, N, 2009) |
| "Mitomycin was the most frequently active agent for the superficial part." | 1.35 | In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA). ( Ahn, KD; Cho, YB; Choi, SH; Chun, HK; Kim, HC; Lee, JM; Lee, WY; Shin, HJ; Song, SY; Yun, SH, 2009) |
| " Prospective trials are required to assess whether dosing adjustments based on neutropaenia may improve chemotherapy efficacy." | 1.35 | Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. ( Inaba, Y; Matsuo, K; Muro, K; Najima, M; Sato, Y; Shitara, K; Takahari, D; Ura, T; Yamaura, H; Yokota, T, 2009) |
| " Moreover, in combination with 5-fluorouracil modulated by folinic acid (5FU-FA) or with Raltitrexed (RTX), both commonly used in the treatment of this disease, it showed a clear schedule-dependent synergistic antiproliferative interaction as demonstrated by calculating combination indexes." | 1.35 | Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. ( Avallone, A; Bruzzese, F; Budillon, A; Delrio, P; Di Gennaro, E; Leone, A; Pepe, S; Subbarayan, PR, 2009) |
| "Taste disorders are frequent occurrences among those patients under the FOLFOX-FOLFIRI regimen for colorectal cancer." | 1.35 | [Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer]. ( Adachi, M; Iida, A; Mori, K; Sakakibara, T; Sugawara, S; Sugiura, M; Takimoto, N; Yamamura, K, 2009) |
| "Hepatocellular carcinoma was the second most frequent malignancy to be observed--23 patients (18." | 1.35 | [Advanced hepatic resection for malignancy]. ( Kotel'nikov, AG; Patiutko, IuI; Pylev, AL; Sagaĭdak, IV, 2009) |
| "Using HCT-116 human colorectal cancer cells, we compared the efficacy of WG and RG." | 1.35 | Asian ginseng enhances the anti-proliferative effect of 5-fluorouracil on human colorectal cancer: comparison between white and red ginseng. ( Aung, HH; Fishbein, AB; Li, XL; Mehendale, SR; Sun, S; Wang, CZ; Yuan, CS, 2009) |
| " Coadministration of S-1 changed the pharmacokinetic behavior of CPT-11 and its metabolites." | 1.35 | Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer. ( Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K, 2009) |
| " Grade 3 or 4 hematological toxicities were leukocytopenia in four patients, and neutropenia in 12 patients, while non-hematological toxicities such as nausea, anorexia and sensory neuropathy occurred in only one patient each adverse event." | 1.35 | The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. ( Hattori, M; Honda, I; Kato, N; Kobayashi, D; Matsushita, H; Okochi, O; Tsuboi, K, 2009) |
| "1236G>A), which was observed five- out of eight-times in patients with severe adverse effects." | 1.35 | Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. ( Aebi, S; Amstutz, U; Farese, S; Largiadèr, CR, 2009) |
| "Radiation bystander effects induce genomic instability; however, the mechanism driving this instability is unknown." | 1.35 | Radiation and chemotherapy bystander effects induce early genomic instability events: telomere shortening and bridge formation coupled with mitochondrial dysfunction. ( Gorman, S; Howe, O; Hyland, J; Lyng, F; Mulcahy, H; O'Donoghue, D; O'Sullivan, J; Sheahan, K; Tosetto, M, 2009) |
| "Seventy-six metastatic colorectal cancer patients receiving cetuximab plus FOLFIRI or FOLFOX-4 chemotherapy were enrolled." | 1.35 | Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. ( Chang, YT; Chen, CW; Chu, KS; Lin, SR; Lu, CY; Tsai, HL; Wang, HM; Wang, JY; Yeh, YS; Yen, LC, 2009) |
| "Rapamycin suppressed advanced stage colorectal cancer, even with oral administration." | 1.35 | Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1. ( Candinas, D; Egger, B; Hunt, KK; Laemmle, A; Roh, V; Strehlen, M; Stroka, D; Trochsler, M; Vorburger, SA; Wagner, M, 2009) |
| "Genomic instability in colorectal cancer is categorized into two distinct classes: chromosome instability (CIN) and microsatellite instability (MSI)." | 1.35 | Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells. ( Furumai, R; Goodman, BK; Jardim, MJ; Wakeman, T; Wang, Q; Wang, XF, 2009) |
| "To understand the mechanisms of the effects of combination treatments, we established animal models showing antitumor activity of bevacizumab as a monotherapy and in combination with capecitabine or capecitabine and oxaliplatin and measured thymidine phosphorylase (TP) and vascular endothelial growth factor (VEGF) levels." | 1.35 | Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models. ( Fujimoto-Ouchi, K; Mori, K; Yamashita, Y; Yanagisawa, M; Yorozu, K, 2009) |
| " The CPT-11 dosage was 150 mg/m(2)." | 1.35 | [Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI]. ( Fukuoka, T; Hatano, N; Imamura, Y; Morita, Y; Usui, H; Yokoyama, S, 2009) |
| "We measured health utility scores of colorectal cancer (CRC) patients from a societal perspective in Japan." | 1.35 | Health utility scores of colorectal cancer based on societal preference in Japan. ( Fukuda, T; Shiroiwa, T; Tsutani, K, 2009) |
| " Chemotherapy was administered via the penil vein, using the same dosing scheme and duration as the second group." | 1.35 | Effect of early preoperative 5-fluorouracil on the integrity of colonic anastomoses in rats. ( Berber, I; Kara, M; Koyuturk, M; Krand, O; Ozel, L; Ozel, MS; Ozkan, KS; Tellioglu, G; Toros, AB, 2009) |
| "Although colorectal cancer screening is cost-effective, it requires a considerable net investment by governments or insurance companies." | 1.35 | Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. ( Habbema, JD; Kuipers, EJ; Lansdorp-Vogelaar, I; van Ballegooijen, M; Zauber, AG, 2009) |
| "5-Fluorouracil (5-FU) is an antimetabolite that acts during the S phase of the cell cycle." | 1.35 | Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? ( Rajebi, MR; Saif, MW; Shahrokni, A, 2009) |
| "We retrospectively investigated the frequency and severity of adverse events in 124 patients with colorectal cancer who were treated by mFOLFOX6 regimen from August, 2005 to December, 2006." | 1.35 | [Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen]. ( Boku, N; Kato, T; Kimura, H; Kudou, Y; Matsunaga, Y; Motokawa, S; Muramatsu, T; Nagata, N; Nakagaki, S; Ohashi, Y; Shino, M; Yamazaki, K; Yoshida, T, 2009) |
| "To explore the potential markers of colorectal cancer metastasis and the influence of 5-FU on differentially expressed proteins by using proteomic technology, and to elucidate the mechanism of colorectal cancer metastasis." | 1.35 | [Proteomic research of biomarker of colorectal cancer metastasis]. ( Chen, HQ; Chu, ZX; Huang, L; Ma, YL; Peng, JY; Qin, HL; Shen, TY; Zhang, M; Zhang, P; Zhou, YK, 2009) |
| "NAC by FOLFOX for liver metastasis of colorectal cancer showed a high reduction rate, and there was a little influence to hepatectomy indicating that FOLFOX could be an effective therapy." | 1.35 | [Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis]. ( Amano, R; Hirakawa, K; Inoue, T; Ishikawa, T; Kubo, N; Maeda, K; Muguruma, K; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Tanaka, H; Yamada, N; Yashiro, M, 2009) |
| "These patients can also be affected by superior vena cava syndrome causing dyspnea followed by trunk or extremity swelling." | 1.35 | Treatment of superior vena cava (SVC) syndrome and inferior vena cava (IVC) thrombosis in a patient with colorectal cancer: combination of SVC stenting and IVC filter placement to palliate symptoms and pave the way for port implantation. ( Kickuth, R; Sauter, A; Schmidt, F; Triller, J, 2008) |
| "The present study supports the toxic effect of 5-FU on the myocardium, which is largely schedule-dependent, whereas a low but finite risk of such toxicity has been observed with oral capecitabine." | 1.35 | Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. ( Kallistratos, MS; Karabelis, A; Kopterides, P; Kosmas, C; Mylonakis, N; Skopelitis, H; Syrios, J; Tsavaris, N, 2008) |
| " Both coated and uncoated pellets were orally administered to the rats at a dosage equivalent to 15mg/kg." | 1.35 | Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats. ( Cao, DY; Du, Q; Fan, LF; He, W; Xiang, B, 2008) |
| " Administration of 30 mg/kg CS-706 from Day 7 combined with a single intravenous treatment of 10 mg/kg cisplatin on Day 7 completely regressed the tumors in all tumor-bearing mice examined, whereas only in 1 of 10 mice tumor was regressed with cisplatin treatment." | 1.35 | CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents. ( Fujiwara, K; Hanai, M; Inoue, S; Ishida, S; Kimura, T; Kurakata, S; Senzaki, M; Yada, A, 2008) |
| "Capecitabine was administered at a fixed dose of 2000 mg daily without interruptions." | 1.35 | Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. ( Battistelli, S; Civitelli, S; Fiaschi, AI; Francini, E; Francini, G; Lorenzi, M; Marsili, S; Pascucci, A; Petrioli, R; Roviello, F; Tanzini, G, 2008) |
| "Early relapse in colorectal cancer (CRC) patients is attributed mainly to the higher malignant entity (such as an unfavorable genotype, deeper tumor invasion, lymph node metastasis and advance cancer stage) and poor response to chemotherapy." | 1.35 | ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. ( Cheng, TL; Fang, WY; Huang, MY; Lee, SC; Lin, SR; Wang, JY, 2008) |
| "Neoadjuvant chemotherapy for metastatic colorectal cancer may render some unresectable patients resectable, affording these patients the possibility of prolonged survival." | 1.35 | [A successfully resected case of colorectal cancer with multiple liver metastases treated with FOLFIRI after failure of mFOLFOX6]. ( Fukuda, H; Hirokawa, S; Nagata, T; Sawada, S; Tazawa, K; Tsukada, K; Uotani, H; Yamagishi, F, 2008) |
| " Although this patient could accept it relatively safely without any severe side effect, the optimal dosage and the timing of hemodialysis for inoperable metastatic colorectal cancer patients should be determined by a further study using more cases." | 1.35 | [Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer]. ( Ehara, K; Hasebe, S; Hashimoto, M; Hayashi, M; Igarashi, M; Ito, T; Katori, H; Kinoshita, Y; Matoba, S; Matsuda, M; Mine, S; Moriyama, J; Sato, M; Sawada, T; Toda, S; Tsutsumi, K; Udagawa, H; Ueno, M; Watanabe, G; Yokoyama, T, 2008) |
| "When chemotherapy is conducted to treat colorectal carcinoma, especially when 5-FU is included in the regimen, anti-APRIL therapy might be an important assistant treatment to counter the impact of APRIL caused by antitumor drugs." | 1.35 | [Expression of APRIL in colorectal carcinoma tissues and effects of chemotherapeutic agents on APRIL expression in colorectal carcinoma SW480 cells]. ( Feng, ZY; Guo, YW; Li, YW; Wen, ZF; Zheng, FP, 2008) |
| "Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU)." | 1.35 | A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. ( Alba, E; Carabantes, F; Dueñas, R; González, E; López-Siles, J; Márquez, A; Ribelles, N; Sánchez, A; Sánchez, MJ; Sánchez-Rovira, P; Sevilla, I, 2008) |
| " We observed adverse events, time to treatment failure, response rate, reason to discontinue treatment, and dose intensity." | 1.35 | [Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients]. ( Chin, K; Hatake, K; Ichimura, T; Kuboki, Y; Matsuda, M; Matsuzaka, S; Mizunuma, N; Ogura, M; Shinozaki, E; Suenaga, M, 2008) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent for the treatment of colorectal cancer that interferes with the growth of cancer cells." | 1.34 | Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. ( Aung, HH; He, TC; Luo, X; Mehendale, S; Ni, M; Song, WX; Wang, CZ; Xie, JT; Yuan, CS; Zhang, B, 2007) |
| "Ninety-six resections for colorectal cancer hepatic metastases performed from July 2001 to July 2003 (93% > or =2 segments) were reviewed." | 1.34 | Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. ( Cattral, MS; Chan, EK; Dixon, E; Gallinger, S; Grant, DR; Greig, PD; Sahajpal, A; Taylor, BR; Vollmer, CM; Wei, A, 2007) |
| "About 20% of patients with colorectal cancer have synchronous un-resectable liver metastases." | 1.34 | Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? ( Amisano, M; Bouzari, H; Capussotti, L; Massucco, P; Muratore, A; Sperti, E; Zorzi, D, 2007) |
| "The number of elderly patients with colorectal cancer is increasing in Japan." | 1.34 | [Chemotherapy for elderly patients with colorectal cancer]. ( Kuboki, Y; Mizunuma, N, 2007) |
| "We showed in colorectal cancer cell lines that the expression of MV-H/F, but also of RSV-F, as well as VSV-G can synergistically enhance p53-independent clinically relevant chemotherapy (FOLFOX) over most of the cytotoxic dose range." | 1.34 | Mechanistic analysis and comparison of viral fusogenic membrane proteins for their synergistic effects on chemotherapy. ( Grunwald, T; Hoffmann, D; Kuate, S; Wildner, O, 2007) |
| " Adverse drug reactions to 5-FU-based chemotherapy have been reported to be in part the result of polymorphisms in the thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) genes." | 1.34 | Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. ( Cho, HJ; Kang, WK; Kim, JW; Lee, SY; Park, YS, 2007) |
| "A case of colorectal cancer in a 60-year-old man became resectable after downstaging was achieved with mFOLFOX 6 for multiple liver metastases from colorectal cancer." | 1.34 | [A case of liver failure associated with liver damage due to mFOLFOX 6 after resection for multiple liver metastases from colorectal cancer]. ( Abe, T; Aoki, T; Ishizaki, T; Katsumata, K; Koyanagi, Y; Tsuchida, A; Wada, T, 2007) |
| "Malignant cells from the recurrences displayed a statistical significant increase, concerning the levels of topoisomerase I, by comparison with the primary tumors (P=0." | 1.34 | Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy. ( Delladetsima, J; Gouveris, P; Kyriakou, V; Lazaris, AC; Nonni, A; Papathomas, TG; Patsouris, ES; Tsavaris, N, 2007) |
| " In the man, the capecitabine dosage was reduced and metoprolol was prescribed, while in the woman the capecitabine was stopped." | 1.34 | [Myocardial ischaemia as a result of treatment with capecitabine]. ( Liem, AH; Planting, AS; van Halteren, HK, 2007) |
| "8% (3/38) and was accompanied by severe Gr 4 toxic symptoms (neutropenia, mucositis, diarrhea)." | 1.34 | [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer]. ( Adleff, V; Budai, B; Hitre, E; Komlósi, V; Kralovánszky, J; Pap, E; Réti, A, 2007) |
| " In May 2002, we devised a new regimen by intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells, and thirteen patients with advanced colorectal cancer (Stage IV) were treated with this regimen." | 1.34 | [The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007) |
| "All patients died from neoplastic disease progression despite further chemotherapy at 6, 17 and 31 months following the diagnosis of NRH." | 1.34 | Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? ( Canon, JL; Ceratti, A; Gigot, JF; Horsmans, Y; Hubert, C; Humblet, Y; Machiels, JP; Rahier, J; Sempoux, C, 2007) |
| "Familial Mediterranean Fever is a chronic hereditary disease which is relatively prevalent in the Middle East and is associated with recurrent episodes of serosal, synovial or cutaneous inflammations." | 1.34 | Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever. ( Brenner, B; Purim, O; Sulkes, A, 2007) |
| "In human colorectal cancer model CXF280, antitumor activity of the combination at two-thirds of the maximum tolerated dose (MTD) was superior to that of each monotherapy at MTD." | 1.34 | Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts. ( Kondoh, K; Mori, K; Sawada, N, 2007) |
| "Liver metastasis is an important prognostic factor in colorectal cancer." | 1.34 | Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency. ( Higuchi, R; Koda, K; Kosugi, C; Sugimoto, M; Suzuki, M; Takenoue, T; Tezuka, T; Watayo, Y; Yagawa, Y; Yamamoto, S; Yamazaki, M; Yasuda, H, 2007) |
| "At our hospital, 232 patients with colorectal cancer underwent outpatient home chemotherapy by placing a CV-port and using a portable disposable pump for continuous infusion of 5-FU between 1998 and 2005." | 1.34 | Central venous access port-related complications in outpatient chemotherapy for colorectal cancer. ( Inaba, Y; Muro, K; Najima, M; Nishiofuku, H; Sato, Y; Shimamoto, H; Ura, T; Yamaura, H, 2007) |
| "In advanced colorectal cancer (ACC), FOLFOX4 has been accepted as a standard chemotherapeutic regimen." | 1.34 | UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen. ( Brugnatelli, S; Corazza, GR; Gattoni, E; Luchena, G; Riccardi, A; Sagrada, P; Scalamogna, R; Tinelli, C; Tronconi, MC, 2007) |
| "Patients with mucinous colorectal cancer generally have worse prognoses than those with the nonmucinous variety." | 1.33 | Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. ( Carvalho, LP; Fleshman, JW; Glasgow, SC; McLeod, HL; Shannon, WD; Yu, J, 2005) |
| "Advanced colorectal cancer specimens (n=97) were prepared for immunohistochemical staining using monoclonal antibodies against TP, p53, vascular endothelial growth factor (VEGF), factor VIII, CD68 and thymidylate synthase (TS)." | 1.33 | Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma. ( Koike, M; Matsumoto, H; Mori, T; Shimizu, S; Takahashi, K; Takizawa, T; Toi, M; Yamaguchi, T; Yasuno, M, 2005) |
| "The therapeutic efficacy of G207, a replication-competent herpes simplex virus, for malignancies is increased when combined with certain chemotherapies, but the mechanism is unclear and the interaction between G207 and surgical resection has not been extensively studied." | 1.33 | Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. ( Cohen, JB; Glorioso, JC; Kuroki, S; Nakano, K; Tanaka, M; Todo, T; Yamaguchi, K; Zhao, G, 2005) |
| "Colorectal cancer patients with central venous catheters (CVC) for pharmacokinetic modulating chemotherapy (PMC) have a substantial risk of venous thromboembolism (VTE)." | 1.33 | Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy. ( Fujiwara, Y; Gega, M; Hashimoto-Tamaoki, T; Higasa, S; Ikeuchi, H; Inoue, T; Nakano, H; Noda, M; Oshima, T; Sakaki, T; Shoji, Y; Tsukamoto, K; Yamamura, T; Yanagi, H; Yoshikawa, R, 2005) |
| "Although colorectal cancer has the third highest cancer mortality rate, the treatment remains far from optimized with patients showing variable responses to standard treatment." | 1.33 | Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. ( Kidd, EA; Li, X; McLeod, HL; Shannon, WD; Watson, MA; Yu, J, 2005) |
| "Twenty-three patients with colorectal cancer and isolated liver metastases were enrolled in this trial." | 1.33 | Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver. ( Brener, J; Chaitchik, S; Czerniak, A; Hayat, H; Schachter, P; Shimonov, M, 2005) |
| "An HCT-8 colorectal cancer cell line was used and a high concentration of 5-Fluorouracid (5-FU) was introduced at the beginning to induce drug resistance, then the concentration of 5-FU was increased in gradients." | 1.33 | Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line. ( Bu, LM; Han, Y; Ji, X; Liu, CY; Wang, ZH, 2005) |
| "Drug treatment of colorectal cancer has made impressive progress during the past 10 years." | 1.33 | [Systemic therapy for colorectal cancer]. ( Jäger, D; Knuth, A; Pestalozzi, BC, 2005) |
| "To predict the sensitivity of colorectal cancer to 5-FU, mRNA is extracted from surgically obtained cancer specimens and expression of thymidylate synthetase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), uridine phosphorylase (UP), es-nucleoside transporter (NT), and E2F1 are detected by real-time reverse transcription polymerase chain reaction (RT-PCR) (TaqMan)." | 1.33 | Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil. ( Kubota, T, 2005) |
| "Severe steatohepatitis can be associated with preoperative administration of irinotecan or oxaliplatin, especially in the obese." | 1.33 | Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. ( Fernandez, FG; Goodwin, JW; Hawkins, WG; Linehan, DC; Ritter, J; Strasberg, SM, 2005) |
| "Fifty-eight cases of colorectal cancer in stage B2 and C following radical resections were divided into two groups: SMI+IPC group (36 cases) and IPC group (22 cases)." | 1.33 | [Clinical research of intraperitoneal chemotherapy plus Shenmai Injection in treating advanced colorectal cancer]. ( Guo, YB; Shen, XH; Yuan, JM; Zheng, L; Zhu, WR, 2005) |
| "Gene expression profiling of 3 colorectal cancer cell lines (DLD-1, HT-29 and NUGC-3) and the corresponding 5-FU-resistant sublines (DLD-1/FU, HT-29/FU and NUGC-3/5FU/L) showed 81 genes that were differentially expressed." | 1.33 | Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. ( Danenberg, PV; Hayasizaki, Y; Ichikawa, Y; Ishikawa, T; Okazaki, Y; Shimada, H; Shimizu, D; Togo, S, 2005) |
| " In this study, we investigated the anticancer activity of BGC9331 either alone or combined with 5-fluorouracil (5-FU), MTA (multi-target antifolate), oxali-platin and SN-38, the active metabolite of the topoisomerase I inhibitor CPT-11." | 1.33 | Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen ( André, T; Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Kornprobst, M; Larsen, AK; Louvet, C; Raymond, E; Tournigand, C, 2005) |
| "Metastatic/advanced colorectal cancer is considered a resistant disease and oncologic emergencies secondary to advanced disease may be regarded with a nihilistic attitude." | 1.33 | Oncologic emergencies secondary to advanced colorectal cancer successfully treated with oxaliplatin/5-fluorouracil/leucovorin: report of three cases. ( Anselmi, E; Bertè, R; Bidin, L; Cavanna, L; Civardi, G; Lazzaro, A; Moroni, CF; Palladino, MA; Rodinò, C; Vallisa, D, 2005) |
| " We introduce a test statistic to select genes with significant dose-response expression in a monotonic fashion based on a permutation procedure." | 1.33 | Analysis of dose-response effects on gene expression data with comparison of two microarray platforms. ( Coombes, KR; Hamilton, SR; Hu, J; Kapoor, M; Zhang, W, 2005) |
| "However, standard treatment for Dukes C colorectal cancer patients currently involves the administration of 5-fluorouracil (5-FU)-based adjuvant chemotherapy after surgery." | 1.33 | SMAD4 levels and response to 5-fluorouracil in colorectal cancer. ( Aaltonen, LA; Alazzouzi, H; Alhopuro, P; Arango, D; Dávalos, V; Hemminki, A; Järvinen, H; Mecklin, JP; Salovaara, R; Sammalkorpi, H; Schwartz, S, 2005) |
| "Irinotecan (CPT11) is a prodrug activated in humans mainly by carboxylesterase 2 (CES2) generating the SN38 metabolite responsible for the drug efficacy and toxicity." | 1.33 | Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ( Biason, P; Buonadonna, A; Cattarossi, G; Cecchin, E; Colussi, A; Corona, G; Frustaci, S; Masier, S; Toffoli, G, 2005) |
| "Capecitabine is an oral prodrug to 5-fluorouracil (5-FU)." | 1.33 | Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. ( Hoeffding, LD; Jakobsen, A; Lindebjerg, J; Nielsen, JN, 2005) |
| "We developed a method to assess the similarity of pharmacokinetic data between ethnically different populations." | 1.33 | Overlap coefficient for assessing the similarity of pharmacokinetic data between ethnically different populations. ( Fukushima, A; Matsuyama, Y; Mizuno, S; Ohashi, Y; Yamaguchi, T, 2005) |
| "The type of genomic instability could influence the prognosis of CRC, in particular in stages II and III." | 1.33 | Microsatellite instability and colorectal cancer prognosis. ( Barana, D; Benatti, P; Di Gregorio, C; Gafà, R; Guerzoni, L; Lanza, G; Losi, L; Maestri, I; Maffei, S; Marino, M; Menigatti, M; Oliani, C; Pedroni, M; Ponti, G; Ponz de Leon, M; Roncari, B; Roncucci, L; Rossi, G; Santini, A; Scarselli, A, 2005) |
| "The subjects were 31 patients with colorectal cancer who underwent surgical excision between December 2003 and July 2004 at our department." | 1.33 | The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer. ( Hata, M; Kamano, T; Kitajima, M; Maeda, T; Ochiai, T; Sakamoto, K; Takita, N, 2006) |
| "Capecitabine was approved for funding in the province of British Columbia in the spring of 2002 as an oral chemotherapeutic option for metastatic CRC." | 1.33 | Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. ( Gill, S; Ho, C; Ng, K; O'Reilly, S, 2005) |
| "Celecoxib was initiated in the diet at 100 ppm (equivalent to 20 mg/kg/d p." | 1.33 | Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. ( Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM, 2005) |
| "The treatment of metastatic colorectal cancer by chemotherapy alone was considered palliative and without the potential to cure patients unless patients were rendered resectable." | 1.33 | Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. ( Kemeny, NE; Leonard, GD, 2006) |
| "Colorectal cancer is the second most common malignant tumour in Germany with an unfavorable prognosis especially in a locally advanced or metastasizing stage." | 1.33 | [Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials]. ( Bogdanow, M; Gorschlüter, M; Lamberti, C; Lundin, S; Sauerbruch, T; Schmidt-Wolf, IG, 2006) |
| "To study the effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer." | 1.33 | [Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer]. ( Chen, G; Lin, SX; Lu, ZH; Ren, JQ; Tang, SX; Wan, DS; Wang, GQ; Ye, YL; Zhou, ZW, 2006) |
| "Microsatellite instability is a recognised pathway of colorectal carcinogenesis responsible for about 15% of all sporadic colorectal cancers." | 1.33 | 5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. ( Kaufman, A; Ramanathan, P; Robinson, BG; Schnitzler, M; Warusavitarne, J, 2006) |
| " A reduction in irinotecan dosage or use of an alternative agent may be warranted in patients with risk factors for toxicity." | 1.33 | Individualizing chemotherapeutic treatment of colorectal cancer. ( Crews, KR, 2006) |
| "In recent years, chemotherapy for colorectal cancer has advanced rapidly." | 1.33 | [Outpatient based colorectal cancer treatment--the current status, challenges and future outlook]. ( Akazai, Y; Kimura, H; Nitta, Y, 2006) |
| "(1) The prognosis for metastatic colorectal cancer is grim." | 1.33 | Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice. ( , 2006) |
| " Our data suggest that GSTT1-null is associated with a greater probability of developing toxicity to 5-Fu/CPT-11/Lv treatments, indicating a potential application of this genetic analysis in predicting adverse effects of this regimen." | 1.33 | Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. ( Aranda, E; Bandres, E; De la Haba, J; Garcia, F; García-Foncillas, J; Gómez, A; Huarriz, M; Morales, R; Romero, RZ, 2006) |
| "Experimentally, we studied a diploid colorectal cancer line heterozygous at TS to mimic three common TS genotypes of cancers." | 1.33 | Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. ( Brody, JR; Gallmeier, E; Hucl, T; Kern, SE; Murphy, KM; Winter, JM, 2006) |
| "Fifty five patients with advanced colorectal cancer were treated by FOLFIRI or FOLFOX regimen from April 2005 to June 2006." | 1.33 | [Present status of home therapy cancer patients using an infusor]. ( Chiba, H; Honda, K; Kondo, H; Makino, K; Mizushima, T; Ohura, K; Sumiyoshi, T; Tamura, F; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N, 2006) |
| "Chemotherapy for colorectal cancer has changed greatly." | 1.33 | [The future of chemotherapy at home--from outpatient chemotherapy to chemotherapy at home]. ( Takahashi, K, 2006) |
| "Human colorectal cancer cells (SW48) are characterized by the hypermethylation of proapoptotic genes." | 1.33 | The synergistic effect of 5-aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors. ( Iida, S; Kato, K; Morita, S; Sugihara, K; Takagi, Y; Uetake, H, 2006) |
| "Patients with unresectable distant metastasis are not suitable candidates for surgical resection and intraoperative radiation therapy, whereas those with resectable metastasis are potential candidates." | 1.32 | Indicators for surgical resection and intraoperative radiation therapy for pelvic recurrence of colorectal cancer. ( Hashiguchi, Y; Kato, S; Kazumoto, T; Nishimura, Y; Sakamoto, H; Sakura, M; Sekine, T; Tanaka, Y, 2003) |
| "The younger patients with colorectal cancer had more mucin-producing (14." | 1.32 | Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. ( Cheng, AL; Huang, KC; Jeng, YM; Liang, JT; Wang, SM; Wu, MS, 2003) |
| "Median time to disease progression was 9." | 1.32 | Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Aparicio, J; Calderero, V; Díaz, R; Gironés, R; López-Tendero, P; Pérez-Fidalgo, JA; Segura, A; Yuste, AL, 2003) |
| "Liver metastasis from colorectal cancer remains an oncological challenge." | 1.32 | Quality of life in patients with colorectal metastasis and intrahepatic chemotherapy. ( Blair, SL; Chu, DZ; Cullinane, C; Dean, G; Grant, M; Schwarz, RE; Wagman, L, 2003) |
| "Drugs pharmacokinetic control is a usual practice in case of flat continuous infusions." | 1.32 | [Modeling 5-FU clearance during a chronomodulated infusion]. ( Chevalier, V; Chevrier, R; Chollet, P; Cure, H; Kwiatkowski, F; Richard, D, 2003) |
| "Capecitabine is an orally available fluoropyrimidine and is finally converted to 5-FU selectively in tumor tissues." | 1.32 | Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. ( Eda, H; Endo, M; Hattori, K; Ishikawa, T; Ishitsuka, H; Miwa, M; Miyazaki-Nose, T; Shimma, N; Tanimura, H; Ura, M; Yamada-Okabe, H, 2003) |
| "These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer." | 1.32 | Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. ( Clark, JW; Gococo, KO; Haller, DG; Kardinal, CG; Kemeny, NE; Lenz, HJ; Mitchell, EP; Ramanathan, RK, 2003) |
| "3R allele in colorectal cancer was subdivided into around half by the SNP, indicating its commonness among Japanese." | 1.32 | Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. ( Kawakami, K; Watanabe, G, 2003) |
| "5 patients with colorectal cancer with multiple liver metastases underwent resection of primary lesions." | 1.32 | [Evaluation of hepatic arterial infusion chemotherapy with low-dose leucovorin and 5-FU from reservoir for multiple liver metastases by colorectal cancer]. ( Abe, N; Ishii, Y; Itou, T; Nakayama, K; Takahashi, M, 2003) |
| "We performed radiofrequency ablation (RFA) therapy combined with intrahepatic arterial infusion chemotherapy for 7 patients with liver metastasis from colorectal cancer." | 1.32 | [Radiofrequency ablation therapy combined with intrahepatic arterial infusion chemotherapy for liver metastasis of colorectal cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Oosaki, T; Otsuka, S; Sakata, T; Takahashi, M, 2003) |
| "Hemoptysis was negligible until he died 8 months later." | 1.32 | [Clinical benefit of bronchial arterial infusion chemotherapy to pulmonary metastasis from colorectal cancer--report of two cases]. ( Ishigaki, T; Kitai, T; Kojima, N; Miki, A; Nishikawa, S; Nomura, A; Todo, G; Ukikusa, M, 2003) |
| "Among 182 patients with stage II-III colorectal cancers, 89 patients (adjuvant chemotherapy group) received oral 5-FU based-adjuvant chemotherapy, and 93 patients (surgery alone group) did not receive 5-FU." | 1.32 | Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone. ( Hidaka, S; Nagayasu, T; Nakagoe, T; Sawai, T; Tagawa, Y; Takeshita, H; Tsuji, T; Yamaguchi, H; Yasutake, T, 2004) |
| "Patients with liver metastases of colorectal cancer were treated with 5-FU (500/600 mg/m)+folinic acid with or without trimetrexate." | 1.32 | 19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. ( Heerschap, A; Kamm, YJ; van den Bergh, EJ; Wagener, DJ, 2004) |
| "Patients with stage III/IV colorectal cancer were treated by bolus intravenous (I." | 1.32 | Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. ( Chabner, BA; Charlat, O; Clark, JW; Kelly, P; Kreconus, E; Nesbitt, S; Puchalski, TA; Ryan, DP; Stanton, VP; Supko, JG; Zhu, AX, 2004) |
| "Four patients had primary liver cancers." | 1.32 | A longterm follow-up study of thymidylate synthase as a predictor for survival of patients with liver tumours receiving hepatic arterial infusion chemotherapy. ( Danenberg, K; Danenberg, P; Formentini, A; Hillenbrand, A; Kornmann, M; Salonga, D; Sander, S; Staib, L, 2004) |
| "Catheter-related deep venous thrombosis is a complication that can occur in patients receiving chemotherapy." | 1.32 | Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review. ( Albertsson, M; Tham, J, 2004) |
| "Colon and rectal cancer are in France a challenging problem in public health, reaching the second place in cancer related deaths." | 1.32 | [Colorectal cancer: what should be the management of primary tumour?]. ( Delpero, JR; Lelong, B; Moutardier, V, 2004) |
| "The expression of the FasL gene in colorectal cancer cells is related to immune evasion to escape from being killed by immune cells, showing stronger drug-resistance, and it facilitates hepatic metastasis." | 1.32 | Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma. ( An, P; Cai, HY; Li, SY; Wei, JC; Yu, B; Zuo, FY, 2004) |
| "The deleted in colorectal cancer (DCC) gene predicts a poor outcome for patients with colorectal carcinoma." | 1.32 | Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. ( Gal, R; Klein, B; Koren, R; Sadikov, E; Sulkes, J, 2004) |
| " We have examined the effect of this CDO alone and in combination with a range of common chemotherapeutic agents in colorectal cancer cell lines." | 1.32 | The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines. ( Liu, WM; Propper, DJ; Scott, KA; Shahin, S, 2004) |
| "In patients with liver metastases from colorectal cancer, survival can be increased by hepatic resection." | 1.32 | Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy. ( Carlo, WF; Fong, Y; Gonen, M; Hummer, AJ; Jarnagin, W; Kemeny, N; Schwartz, L; Sullivan, D, 2004) |
| "We evaluated the cytotoxic effect of ZD0473 administered alone or in combination with 5-Fluorouracil (5FU) or SN38 in a panel of sensitive and 5FU-resistant colorectal cell lines (HT29/HT29-5FUR and LoVo/LoVo-5FUR)." | 1.32 | Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines. ( Abad, A; Martinez-Balibrea, E; Plasencia, C; Taron, M, 2004) |
| "The study included 32 colorectal cancer patients; apoptosis was determined by annexin-V binding and light-scatter morphology before and after drug infusion." | 1.32 | Fluorouracil induces apoptosis and surface molecule modulation of peripheral blood leukocytes. ( Drucker, L; Kimhi, O; Lahav, M; Lishner, M; Neumann, A; Radnay, J; Shapira, J; Shapiro, H; Yarkoni, S, 2004) |
| "Sigmoid colon cancer and hepatocellular cancer (S5, S6, S8) were diagnosed before surgery." | 1.32 | [The use of radio frequency ablation (RFA) for colorectal liver metastases in one patient]. ( Hamada, H; Katsuki, Y; Takada, J; Tsuji, Y, 2004) |
| "Objective responses in colorectal cancer patients were: 1st-line MdG (22 assessable): PR=36%, NC=32%, PD=32%." | 1.31 | A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. ( Cheeseman, SL; Chester, JD; Dent, JT; Joel, SP; Richards, FJ; Seymour, MT; Wilson, G, 2002) |
| " In order to evaluate the clinical relevance of SMAD4 deletion, gene copy alterations were determined by copy dosage using real-time quantitative PCR in 202 colorectal tumour biopsies from a previous randomised study of adjuvant chemotherapy." | 1.31 | SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. ( Boulay, JL; Herrmann, R; Laffer, U; Lagrange, M; Lowy, A; Mild, G; Reuter, J; Rochlitz, C; Terracciano, L, 2002) |
| "5-Fluorouracil (5-FU) is a widely used for colorectal carcinoma." | 1.31 | Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis. ( Ikeguchi, M; Kaibara, N; Makino, M, 2002) |
| "Cerivastatin may allow successful 5FU therapy in chemoresistant patients." | 1.31 | Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. ( Cassidy, J; Collie-Duguid, E; Wang, W, 2002) |
| "Tissue specimens were obtained from colorectal cancer patients and in vitro chemosensitivity was tested using fluorescein diacetate assay (FDA) or histoculture drug response assay (HDRA)." | 1.31 | Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. ( Gen, T; Isshi, K; Katuyama, T; Kuroda, T; Maekawa, Y; Nakamura, Y; Sakuyama, T, 2002) |
| "The pharmacokinetic parameters obtained for (-)-fTHF following the administration of (-)-fTHF only were: terminal half-life, 1." | 1.31 | Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. ( Braess, J; Ehninger, G; Hiddemann, W; Kern, W; Rudolph, KL; Schleyer, E; Unterhalt, M, 2000) |
| " In this study, the pharmacokinetic parameters of 5-FU are monitored in six patients, who received two chemotherapeutic courses of 2,600 mg/m2 BSA 5FU over 24 h, one course with 700 mg/m2 BSA amifostine prior to the 5-FU infusion and the other without." | 1.31 | Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma. ( Fuhlroth, J; Martens-Lobenhoffer, J; Ridwelski, K, 2000) |
| " Forty-seven patients (35%+/-8%) experienced significant toxicity and were unable to receive the second cycle as scheduled: 76% required dose reduction, 11% discontinued therapy (including two toxic deaths), 11% discontinued therapy during the first cycle, and 2% required dose delay." | 1.31 | Standard dose (Mayo regimen) 5-fluorouracil and low dose folinic acid: prohibitive toxicity? ( Griffeth, S; Keith, B; Kocha, W; Sawyer, M; Stitt, L; Taylor, M; Tomiak, A; Vincent, M; Whiston, F; Winquist, E, 2000) |
| "We investigated the effects of 2'-deoxyinosine (d-Ino), a modulator yielding thymidine phosphorylase activity, on cellular pharmacology of 5-fluorouracil (FUra) in various human colorectal cell lines and its antitumoral activity when combined with FUra in human xenografts." | 1.31 | Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts. ( Aubert, C; Catalin, J; Ciccolini, J; Cuq, P; Evrard, A; Formento, P; Milano, G; Peillard, L; Pelegrin, A, 2000) |
| "Data on 45 patients with colorectal cancer were analyzed." | 1.31 | Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. ( Hinoshita, E; Kinukawa, N; Kuwano, M; Maehara, Y; Sugimachi, K; Taguchi, K; Tsuneyoshi, M; Uchiumi, T, 2000) |
| "A total of 35 patients with primary colorectal cancer who underwent surgical treatment were examined by chemosensitivity test with the viable tumor samples using Histoculture Drug Response Assay (HDRA)." | 1.31 | [Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer]. ( Imaseki, H; Isono, K; Iwasaki, K; Kondo, S; Kouno, T; Makino, H; Nakajima, K; Natsume, T; Ochiai, T; Okazumi, S; Shimada, H; Suzuki, T; Takayama, W; Takeda, A, 2000) |
| "Pretreatment with eniluracil (5-ethynyluracil) prevents catabolism of FU." | 1.31 | Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. ( Alauddin, MM; Bading, JR; Conti, PS; Fissekis, JD; Joung, J; Shahinian, AH; Spector, T, 2000) |
| "As there is no information on UDG in colorectal cancer, this study characterized UDG activity and protein expression in a panel of 20 colorectal tumors and 6 colorectal cell lines." | 1.31 | Analysis of uracil DNA glycosylase in human colorectal cancer. ( Dusseau, C; Keenan, RA; Krokan, HE; McLeod, HL; Murray, GI; O'Kelly, T, 2001) |
| "In other two groups (gastric and colorectal cancer patients) side effects of chemotherapy caused relatively less QL deterioration." | 1.31 | Quality of life in cancer patients treated by chemotherapy. ( Herman, ZS; Machalski, M; Scieszka, M; Zielinski, M, 2000) |
| "Colorectal carcinoma is one of the most common malignancies in the western world, and although fluorouracil (5-FU) has been used in its treatment for almost 40 years, new agents with significant activity have been introduced recently." | 1.31 | The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. ( Antoine, EC; Bastian, G; Gil-Delgado, M; Khayat, D; Nizri, D, 2001) |
| "The subjects were 24 colorectal cancer patients." | 1.31 | A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients. ( Iwase, H; Kameya, T; Makuuchi, H; Sadahiro, S; Suzuki, T; Tajima, T, 2001) |
| "Fluoropyrimidine therapy for elderly colorectal cancer patients remains controversial." | 1.31 | [Tumoral levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in elderly colorectal cancer patients]. ( Fujioka, M; Hashimoto, D; Hoshino, T; Idezuki, Y; Inokuma, S; Ishida, H; Murata, N; Nakada, H; Ohsawa, T; Takeuchi, I, 2001) |
| "Treating elderly patients with colorectal cancer is a challenging task for which many aspects have to be taken into account." | 1.31 | [Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?]. ( Bokemeyer, C; Honecker, F; Kolb, G; Wedding, U, 2001) |
| "Phase I and II trials were performed in colorectal cancer to define the optimal dose and schedule of capecitabine." | 1.31 | Xeloda in colorectal cancer. ( Cassidy, J, 2001) |
| " This is the first report of non-invasive monitoring of toxic 5-FU metabolites in normal human tissues." | 1.31 | Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment. ( Griffiths, JR; Howe, FA; Lofts, F; McIntyre, DJ; McSheehy, PM; Nicholson, G; Noordhuis, P; Peters, GJ; Price, NM; Rodrigues, LM; Smid, K; Stubbs, M; Wadsworth, P, 2001) |
| " Pharmacodynamic changes were thus observed as a result of electrostatic treatment during chemotherapy." | 1.31 | Pharmacodynamics induced by direct electric current for the treatment of 5-fluorouracil resistant tumor: an animal experiment. ( Akiyama, S; Ando, H; Hibi, K; Hidemura, K; Ito, K; Kasai, Y; Nakao, A; Wong, L, 2001) |
| "(1) The reference treatment for colorectal cancer is surgery." | 1.31 | Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage. ( , 2001) |
| "Carbamazepine levels were 4." | 1.31 | [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study]. ( Adelsberger, H; Eckel, F; Erdmann, J; Lersch, C; Quasthoff, S; Schmelz, R, 2002) |
| "Patients were treated for colorectal cancer and received chemotherapy consisting of leucovorin 20 mg m(-2) plus 5-fluorouracil 425 mg m(-2)." | 1.31 | Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ( De Vries, EG; Groen, HJ; Haasjes, J; Maring, JG; Piersma, H; Uges, DR; Van Gennip, AH; van Kuilenburg, AB, 2002) |
| "It has previously been shown that colorectal cancer patients who are homozygous for the triple tandem repeats (L/L) have significantly higher thymidylate synthase mRNA expression than those homozygous for the double repeat variant (S/S)." | 1.31 | Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. ( Groshen, S; Lenz, HJ; Park, DJ; Stoehlmacher, J; Tsao-Wei, D; Zhang, W, 2002) |
| "Only 63." | 1.31 | [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms]. ( Grothey, A; Kellermann, L; Schmoll, HJ, 2002) |
| "In conclusion, many efforts to overcome colorectal cancer will soon open new therapeutic windows." | 1.31 | [Recent advances in the diagnosis and treatment of colorectal cancers]. ( Mimori, K; Mori, M, 2002) |
| " The mean total dosage was 6." | 1.30 | [Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]. ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997) |
| "The purpose of our study was to develop a pharmacokinetic model to quantify the intracellular 5-fluorouracil (5-FU) concentration in liver metastases, which is expected to be closely correlated to therapy response." | 1.30 | Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. ( Bellemann, ME; Brix, G; Dimitrakopoulou-Strauss, A; Haberkorn, U; Kissel, J; Lorenz, WJ; Port, R; Strauss, LG, 1997) |
| "Forty-six disseminated colorectal cancer patients had measurable tumor biopsies for polymerase chain reaction (PCR)-based determination of TS mRNA pretreatment." | 1.30 | Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. ( Baranda, J; Boswell, W; Danenberg, K; Danenberg, PV; Groshen, S; Leichman, CG; Leichman, L; Lenz, HJ; Metzger, R; Tan, M, 1997) |
| " There seemed to be no correlation with the total dosage of 5-FU or the number of administrations." | 1.30 | [Complication due to arterial infusion chemotherapy for liver metastasis from colorectal cancer]. ( Hamada, H; Hashimoto, M; Katsuki, Y; Kawata, S; Kon, H; Sasaki, R; Tomita, I; Tsuji, Y; Yasuda, T, 1997) |
| " Gastrimmune immunisation may be a therapeutic option for the treatment of colorectal cancer in combination with 5-FU/leucovorin." | 1.30 | Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model. ( Clarke, PA; Grimes, S; Hardcastle, JD; Justin, TA; Michael, D; Morris, TM; Robinson, G; Watson, SA, 1998) |
| "When tegafur was injected, the concentration of 5-FU in cancer tissue or lymphnodes was significantly higher than in normal tissue." | 1.30 | [Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer]. ( Inamura, Y; Kanemitsu, T; Kojima, T; Miyashita, A; Naruse, T; Owa, Y; Suzumura, K, 1998) |
| " Participation by both the oncology care team and patients is crucial for effective side effect management." | 1.30 | Managing the side effects of chemotherapy for colorectal cancer. ( Berg, D, 1998) |
| "Forty-four advanced colorectal cancer patients (15 women and 29 men; median age 63, range, 27-78 years) receiving a standard FU-folinic acid protocol were included." | 1.30 | Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data. ( Chazal, M; Cheradame, S; Cure, H; Etienne, MC; Formento, JL; Formento, P; François, E; Francoual, M; Letoublon, C; Milano, G; Mousseau, M; Pezet, D; Richelme, H; Seitz, JF, 1997) |
| " Details are presented here on the methodology of NMRS data acquisition and on their pharmacokinetic analysis." | 1.30 | Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. ( Presant, CA; Waluch, V; Wolf, W, 1998) |
| "5-Fluorouracil (5-FU) is a commonly used anticancer agent for the treatment of gastrointestinal, head and neck, and breast tumours." | 1.30 | Autoregulation of 5-fluorouracil metabolism. ( Cassidy, J; Hardy, SC; Hawksworth, GM; Lock, RE; McLeod, HL; Sludden, J, 1998) |
| "The human colorectal cancer cell line C170HM2 readily forms liver metastases in vivo." | 1.30 | A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2. ( Jackman, AL; Morris, TM; Page, MJ; Rohlff, C; Skelton, L; Watson, SA, 1999) |
| "Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements." | 1.30 | Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. ( Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW, 1999) |
| "A total of 22 patients with primary colorectal cancer who underwent surgical treatment were examined for chemosensitivity with iable tumor samples using the Histoculture Drug Response Assay (HDRA)." | 1.30 | Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. ( Hayashi, H; Imaseki, H; Isono, K; Nakajima, K; Ochiai, T; Shimada, H; Suzuki, T; Takayama, W; Takeda, A, 1999) |
| "Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU) within the tumor." | 1.30 | Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ( Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E, 1999) |
| "We measured the chemosensitivity of colorectal cancer to 5-FU by MTT assay using specimens from colonoscopy, and compared this with the histopathological effects." | 1.30 | [Comparative study of histopathological effects of preoperative chemotherapy using UFT and in vitro MTT assay of colonoscopy specimens from patients with colorectal cancer]. ( Fujii, M; Imai, S; Mochizuki, F, 1999) |
| " The dose-response behaviors of 5-FU and FdUMP[10] toward H630 and H630-10 (human colorectal tumor) cells were first investigated separately." | 1.30 | Positive interaction between 5-FU and FdUMP[10] in the inhibition of human colorectal tumor cell proliferation. ( Anderson, J; Gmeiner, WH; Kolar, C; Kolath, J; Lawson, TA; Liu, J; Talmadge, J, 1999) |
| "The surgical treatment of colorectal cancer (CRC) in elderly patients (age 70 years or older) has improved, but data on adjuvant and palliative chemotherapy tolerability and benefits in this growing population remain scarce." | 1.30 | Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. ( Cunningham, D; Norman, A; Parikh, B; Popescu, RA; Ross, PJ, 1999) |
| "5-Fluorouracil (5-FU) is an antimetabolite frequently used in the treatment of cancer." | 1.29 | Dermatological toxicity from chemotherapy containing 5-fluorouracil. ( Campanella, GA; Carrieri, G; Colucci, G; Leo, S; Tatulli, C; Taveri, R, 1994) |
| " Low drug dosages (relative to the sensitivity of in vivo NMR) or rapid drug elimination create the additional problem of data sparsity where a pharmacokinetic model cannot be fitted individually." | 1.29 | Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach. ( Bachert, P; Port, RE; Schlemmer, HP, 1994) |
| "Two cases of hepatic metastasis of colorectal cancer were treated effectively by intrahepatic-arterial infusion immunotherapy using OK-432 (2 KE/week or 2 weeks), recombinant IL-2 (35 x 10(4) JRU or 40 x 10(4) JRU/week or 2 weeks), MMC (4 mg/week or 2 weeks) and 5-FU (250 mg/day during admission, 250 mg/week or 2 weeks during outpatient treatment)." | 1.29 | [Two cases of hepatic metastasis of colorectal cancer treated effectively by intrahepatic arterial infusion immunotherapy using OK-432, rIL-2, MMC and 5-FU]. ( Akiyama, T; Kiriyama, M; Kita, I; Kosaka, T; Kurosaka, Y; Matsushita, M; Takashima, S; Tomita, F, 1994) |
| " Tumor xenografts composed of CD-expressing cells can selectively generate tumor levels of > 400 microM 5FUra when the host mouse is dosed with nontoxic levels of 5FCyt." | 1.29 | Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. ( Austin, EA; Davis, ST; Good, SS; Huber, BE; Richards, CA, 1994) |
| " Eighty per cent reduction of leucovorin dosage leads to a significant decrease in grade 2 and grade 3 haematological and gastrointestinal toxicity." | 1.29 | Local and systemic toxicity of intra-hepatic-arterial 5-FU and high-dose or low-dose leucovorin for liver metastases of colorectal cancer. ( Klotz, HP; Largiadèr, F; Weder, W, 1994) |
| " Preoperative regimens of HCFU 240 mg/m2/day, given by 14-day oral dosage or HCFU 240 mg/m2/day and DP (Dipyridamole) 300 mg/body/day, both 14-day oral dosage were used." | 1.29 | [TS inhibition rate and flow cytometric analysis of DNA content in preoperative chemotherapy with biochemical modulator]. ( Sakuyama, T; Takahashi, N, 1994) |
| "Fifty-three patients with advanced colorectal cancer were given single oral doses of 5'-DFUR, 400 mg/body, preoperatively to assess the pharmacokinetics of 5'-DFUR in the patients with colorectal cancer and to investigate schedules for 5'-DFUR treatment." | 1.29 | [Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer]. ( Hanyu, F; Hayashi, T; Igarashi, T; Suzuki, M; Watanabe, K; Yoshida, K, 1994) |
| "The outlook for patients with advanced colorectal cancer remains poor." | 1.29 | Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon. ( Patel, N; Perren, T; Pittman, K; Primrose, J; Selby, P; Slevin, M; Ward, U, 1993) |
| "Five cases of colorectal cancer with unresectable liver metastases treated from April 1992 to April 1993 in Osaka National Hospital were summarized in this paper." | 1.29 | [Continuous intra-hepatic-arterial infusion of low dose 5-fluorouracil for colorectal cancer patients with unresectable liver metastases]. ( Imamura, H; Kanoh, T; Kikkawa, N; Miyazaki, M; Nakayama, T; Tamaki, Y; Taniguchi, K; Tohno, K; Utsunomiya, T, 1993) |
| "Since 1980, 89 patients with colorectal cancer showed liver metastasis." | 1.29 | [Efficacy of hepatic arterial and intraportal infusion chemotherapy for liver metastasis of colorectal cancer]. ( Akaike, M; Okamoto, T; Sugimasa, Y; Takemiya, S, 1993) |
| " Rats were dosed p." | 1.29 | 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. ( Baccanari, DP; Cao, S; Davis, ST; Joyner, SS; Rustum, YM; Spector, T, 1995) |
| " Pharmacokinetic evaluation demonstrated that ILP at 21 mg/mL maximally elevated total lung FUDR and 5-fluorouracil levels (508." | 1.29 | Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. ( Burt, ME; Ellis, JL; Lenert, JT; Nawata, S; Ng, B; Port, JL, 1996) |
| "There were 43 colorectal and 104 appendiceal cancer patients." | 1.29 | Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Chang, D; Koslowe, P; Sugarbaker, PH, 1996) |
| "The goals of this study of a hepatic arterial infusion (HAI) regimen of alternating floxuridine and 5-fluorouracil were to evaluate the treatment-related toxic effects, the antitumor response rate, and patient survival." | 1.29 | Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. ( Chase, JL; Curley, SA; Davidson, BS; DuBrow, RA; Hohn, DC; Izzo, F; Patt, Y, 1996) |
| "Twenty-two patients with colorectal cancer and synchronous unresectable hepatic metastases were treated by resection the primary tumour with concurrent insertion of an Infusaid infusaport system for regional chemoperfusion (hepatic arterial 20, portal venous 2)." | 1.29 | Primary resection and synchronous regional hepatic chemotherapy or cryotherapy for colorectal cancer with liver metastases. ( Clingan, PR; Dasappa, V; King, DW; King, J; Morris, DL; Ross, WB, 1996) |
| "Body weight was diminished significantly in rats receiving chemotherapy." | 1.29 | Combined preoperative irradiation and direct postoperative 5-fluorouracil without negative effects on early anastomotic healing in the rat colon. ( Biert, J; de Man, B; Hendriks, T; Hoogenhout, J; Wobbes, T, 1996) |
| "Thirty patients with advanced colorectal cancer were treated preoperatively by combined regional radiofrequency hyperthermia and 5-FU." | 1.28 | [Preoperative regional radiofrequency thermochemotherapy of colorectal cancer: clinical and pathological studies]. ( Wu, GR, 1992) |
| "Hepatectomy has been performed as a treatment for hepatocellular carcinoma (HCC) and metastatic liver carcinoma." | 1.28 | [Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma]. ( Hanawa, S; Hasebe, Y; Kuramoto, S; Maeda, T; Nakazaki, H; Suzuki, Y; Watanabe, M; Yanagita, K; Yoshio, T, 1992) |
| "The benefits from medical treatment in colorectal cancer are limited." | 1.28 | Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid. ( Bajetta, E; Colleoni, M; de Braud, F; Nelli, P; Nolè, F; Zilembo, N, 1992) |
| " The 5-FU concentration was a determinant factor affecting modification of the effects of the drug combination from antagonism (with low 5-FU concentrations) to synergism (high 5-FU concentrations) (P less than 0." | 1.28 | [Cytotoxic effects of the combination of a new nitrosourea, fotemustine, combined with 5-fluorouracil and folinic acid depend on the sequence of their administration]. ( Berille, J; Berlion, M; Bizzari, JP; Fischel, JL; Formento, P; Gioanni, J; Milano, G, 1992) |
| "Thirty-five patients with advanced colorectal cancer received 5-FU (500 mg/m2) at 1 to 48 hours prior to surgery." | 1.28 | Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin. ( Laurensse, E; Meijer, S; Peters, GJ; Pinedo, HM; Smid, K; van der Wilt, CL; van Groeningen, CJ, 1992) |
| "Two groups of patients with colorectal cancer and remote metastases in the liver are presented: one received surgical treatment alone, the other combined therapy." | 1.28 | [A combined method for treating metastases of colorectal carcinoma to the liver]. ( Dimitrov, V; Dudunkov, Z; Kurtev, P; Kurteva, G; Ralchev, K, 1991) |
| "Chemotherapy for colorectal cancer with liver metastases following surgical operation for primary tumor should be selected following surgical intervention." | 1.28 | [Continuous infusion chemotherapy using an infusional port in colorectal cancer with liver metastases]. ( Ishida, Y; Kojima, N; Kusumoto, S; Nakayoshi, A; Oka, H, 1991) |
| "With colorectal cancer, the therapeutic outcome for multiple hepatic metastasis extending to the bilateral lobe, even when various chemotherapies are administered, is extremely poor." | 1.28 | [Intra-arterial infusion chemotherapy using an implantable reservoir in the treatment of hepatic metastases in colorectal cancer]. ( Gotohda, H; Katoh, M; Kinami, Y; Kumaki, T; Saitoh, H; Takashima, S; Takegawa, S; Tomita, F, 1991) |
| "Seventeen patients with colorectal cancer metastatic to the liver underwent hepatic resection." | 1.28 | Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis. ( Furusawa, M; Kakeji, Y; Maehara, Y; Sugimachi, K; Tomoda, H; Tsujitani, S; Watanabe, A, 1991) |
| "5-Fluorouracil (5-FU) was delivered in a dose-intensive schedule to 23 patients with metastatic or unresectable colorectal carcinoma." | 1.28 | A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma. ( Baker, L; Brodfuehrer, J; Kraut, M; Poplin, EA; Vaitkevicius, V, 1991) |
| "Twenty-five patients with pretreated advanced colorectal carcinoma were subjected to second-line chemotherapy with sequential high-dose methotrexate and 5-fluorouracil." | 1.28 | Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil. ( Airoma, G; Bianco, AR; Caponigro, F; Gridelli, C; Incoronato, P; Palmieri, G; Pepe, R, 1991) |
| " The dosage of raIFN-2a could not be further escalated above 12 x 10(6) IU." | 1.28 | 5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study. ( Gebbia, V; Palmeri, S; Rausa, L, 1990) |
| "The cases were comprised of 9 gastric cancers, 6 colorectal cancers, 1 appendiceal carcinoma, and 1 malignant tumor of retroperitoneum, all of which were observed to have peritoneal dissemination during surgical operations." | 1.28 | [Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa]. ( Katsuki, Y; Nishimura, A; Tsuji, Y; Yasuda, T, 1990) |
| "These two cases showed no recurrent liver cancers." | 1.28 | [Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases]. ( Houjo, K; Kawano, N; Moriya, Y; Sugihara, K, 1990) |
| " This was deemed due to the small dosage and a short duration of 5'-DFUR." | 1.28 | [A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum]. ( Harada, T; Hirano, M; Kikkawa, H; Masuda, S; Matsu, T; Saito, H; Sakatoku, M; Tatsuzawa, T, 1990) |
| "Out of 40 patients with colorectal cancer, 34 received leucovorin 50 mg and 6 received 200 mg." | 1.28 | Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer. ( Carlsson, G; Glimelius, B; Graf, W; Gustavsson, BG; Påhlman, L; Spears, PC, 1990) |
| "Excisions of metastatic liver cancer were performed in 36 patients and 23 had nonresectable metastatic liver cancer." | 1.28 | [Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer]. ( Hojo, K; Moriya, Y; Sawada, T, 1989) |
| "Excisions of metastatic liver cancer were performed in 36 patients and 23 had nonresectable metastatic liver cancer." | 1.28 | [Complications of intra-arterial infusion chemotherapy in patients with colorectal cancer with liver metastasis, with special reference to IA-5-FU induced sclerosing cholangitis]. ( Hojo, K; Moriya, Y; Sawada, T, 1989) |
| "Lipiodol-ADM was injected for hepatocellular carcinoma every 2 months and MMC-5-FU was injected for liver metastasis of colorectal carcinoma every one or two weeks." | 1.28 | [Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma]. ( Adachi, W; Hanasaki, K; Horigome, N; Iida, F; Kajikawa, S; Kinosita, T; Kuroda, T; Sodeyama, H, 1989) |
| "Seven patients with metastatic colorectal cancer have been treated with a regimen involving an 120-hour continuous infusion of rIL-2, 3 x 10(6) mu/m2." | 1.28 | A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma. ( Franks, CR; Hamblin, TJ; Inzani, V; Palmer, P; Sadullah, S; Stevenson, FK; van der Plas, J; Williamson, P, 1989) |
| " 5-fluorouracil (5-FU) with a daily dosage of 1 g/m2/day was given continuously for 5 consecutive days at 3-week intervals." | 1.28 | Intrahepatic 5-FU retreatment of liver metastases of colorectal cancer that were progressive under previous systemic chemotherapy. ( Herrmann, R; Hohenberger, P; Räth, U; Schlag, P, 1989) |
| "Fluorouracil (Adrucil) has been used for more than 20 years to treat metastatic colorectal carcinoma and has provided significant palliation of symptoms to some patients." | 1.28 | Treatment of metastatic colorectal carcinoma. Recent advances in use of fluorouracil. ( Joseph, RR; Treat, J, 1989) |
| "Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months." | 1.27 | [Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988) |
| " At these dosage levels, diarrhea was not a limiting toxicity." | 1.27 | High-dose folinic acid and 5-fluorouracil in the treatment of advanced colon cancer. ( Arnold, DJ; Balcueva, EP; Dimitrov, NV; Scholnik, AP; Schwenke, P; Suhrland, LG; Walker, WS, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 103 (1.64) | 18.7374 |
| 1990's | 943 (14.98) | 18.2507 |
| 2000's | 2030 (32.24) | 29.6817 |
| 2010's | 2399 (38.10) | 24.3611 |
| 2020's | 822 (13.05) | 2.80 |
| Authors | Studies |
|---|---|
| Nakagawa, Y | 2 |
| Iinuma, M | 1 |
| Naoe, T | 1 |
| Nozawa, Y | 1 |
| Akao, Y | 3 |
| Ahlskog, JK | 1 |
| Dumelin, CE | 1 |
| Trüssel, S | 1 |
| Mårlind, J | 1 |
| Neri, D | 1 |
| Lu, S | 2 |
| Obianom, ON | 1 |
| Ai, Y | 1 |
| Narayan, S | 1 |
| Ramisetti, S | 1 |
| Jaiswal, AS | 1 |
| Law, BK | 2 |
| Singh-Pillay, A | 1 |
| Singh, P | 1 |
| Amin, S | 1 |
| Sharma, AK | 1 |
| Han, X | 3 |
| Peng, B | 1 |
| Xiao, BB | 1 |
| Yang, CR | 1 |
| Wang, WZ | 1 |
| Wang, FC | 1 |
| Li, HY | 1 |
| Yuan, XL | 4 |
| Shi, R | 1 |
| Liao, J | 2 |
| Wang, H | 27 |
| Li, J | 44 |
| Xu, X | 11 |
| Leong, SW | 1 |
| Chia, SL | 1 |
| Abas, F | 1 |
| Yusoff, K | 1 |
| Liu, ZY | 2 |
| Tang, ML | 1 |
| Ning, JF | 1 |
| Hao, YP | 1 |
| Zhou, L | 10 |
| Sun, X | 11 |
| Yang, J | 9 |
| Cao, C | 1 |
| Luo, D | 3 |
| Lan, S | 1 |
| Luo, M | 4 |
| Shan, H | 1 |
| Ma, X | 4 |
| Liu, Y | 31 |
| Yu, S | 5 |
| Zhong, X | 1 |
| Li, R | 5 |
| Wu, WC | 1 |
| Liu, YM | 1 |
| Liao, YH | 1 |
| Hsu, KC | 2 |
| Lien, ST | 1 |
| Chen, IC | 1 |
| Lai, MJ | 1 |
| Li, YH | 12 |
| Pan, SL | 1 |
| Chen, MC | 1 |
| Liou, JP | 1 |
| Ma, K | 1 |
| Zhang, M | 11 |
| Wu, X | 11 |
| Yang, P | 6 |
| Yin, C | 1 |
| Chang, CK | 1 |
| Chiu, PF | 1 |
| Yang, HY | 2 |
| Juang, YP | 1 |
| Lai, YH | 1 |
| Lin, TS | 1 |
| Hsu, LC | 1 |
| Yu, LC | 1 |
| Liang, PH | 1 |
| Zhang, Y | 61 |
| Yang, S | 7 |
| Tian, X | 2 |
| Lv, Y | 3 |
| Guo, Z | 9 |
| Liu, X | 22 |
| Han, G | 4 |
| Liu, S | 15 |
| Wang, W | 24 |
| Cui, S | 2 |
| Qu, X | 4 |
| Wan, S | 1 |
| Fakhr, E | 1 |
| Zare, F | 1 |
| Azadmanesh, K | 1 |
| Teimoori-Toolabi, L | 1 |
| Okamoto, H | 3 |
| Shiba, S | 1 |
| Iino, H | 1 |
| Sudoh, M | 1 |
| Ichikawa, D | 1 |
| De Luca, R | 1 |
| Volpe, C | 1 |
| Mistretta, O | 1 |
| Paci, R | 1 |
| Ferrera, G | 1 |
| Caputo, V | 1 |
| Rosati, G | 18 |
| Cicero, G | 4 |
| Zhang, W | 54 |
| Sun, R | 2 |
| Hu, R | 1 |
| Li, Q | 21 |
| Wu, W | 5 |
| Cao, X | 2 |
| Zhou, J | 12 |
| Pei, J | 1 |
| Yuan, P | 1 |
| Mosca, L | 1 |
| Pagano, M | 1 |
| Borzacchiello, L | 1 |
| Mele, L | 1 |
| Russo, A | 13 |
| Russo, G | 1 |
| Cacciapuoti, G | 1 |
| Porcelli, M | 1 |
| van Nassau, SC | 1 |
| Bond, MJ | 1 |
| Scheerman, I | 1 |
| van Breeschoten, J | 1 |
| Kessels, R | 1 |
| Valkenburg-van Iersel, LB | 1 |
| Verheul, HM | 3 |
| Buffart, TE | 4 |
| Mekenkamp, LJ | 1 |
| Lemmens, VE | 3 |
| Koopman, M | 27 |
| Bol, GM | 1 |
| Stahler, A | 14 |
| Heinemann, V | 69 |
| Schuster, V | 1 |
| Heinrich, K | 9 |
| Kurreck, A | 10 |
| Gießen-Jung, C | 2 |
| Fischer von Weikersthal, L | 16 |
| Kaiser, F | 12 |
| Decker, T | 22 |
| Held, S | 22 |
| Graeven, U | 26 |
| Schwaner, I | 5 |
| Denzlinger, C | 5 |
| Schenk, M | 3 |
| Neumann, J | 6 |
| Kirchner, T | 25 |
| Jung, A | 26 |
| Kumbrink, J | 2 |
| Stintzing, S | 65 |
| Modest, DP | 46 |
| Nozawa, H | 11 |
| Kawai, K | 14 |
| Sasaki, K | 19 |
| Murono, K | 8 |
| Emoto, S | 4 |
| Yokoyama, Y | 3 |
| Abe, S | 3 |
| Kishikawa, J | 1 |
| Nagai, Y | 2 |
| Sonoda, H | 5 |
| Anzai, H | 1 |
| Ozawa, T | 1 |
| Ishihara, S | 9 |
| Lin, LW | 1 |
| Lai, PS | 1 |
| Chen, YY | 2 |
| Chen, CY | 2 |
| Siri, M | 1 |
| Behrouj, H | 1 |
| Dastghaib, S | 1 |
| Zamani, M | 1 |
| Likus, W | 1 |
| Rezaie, S | 1 |
| Hudecki, J | 1 |
| Khazayel, S | 1 |
| Łos, MJ | 1 |
| Mokarram, P | 1 |
| Ghavami, S | 1 |
| Cui, Z | 1 |
| Wang, Q | 13 |
| Deng, MH | 1 |
| Han, QL | 1 |
| Giuliani, J | 4 |
| Mantoan, B | 1 |
| Bonetti, A | 8 |
| Yang, C | 5 |
| Song, J | 2 |
| Hwang, S | 1 |
| Choi, J | 3 |
| Song, G | 4 |
| Lim, W | 1 |
| Li, G | 11 |
| Fang, S | 3 |
| Shao, X | 1 |
| Li, Y | 42 |
| Tong, Q | 4 |
| Kong, B | 2 |
| Chen, L | 22 |
| Wang, Y | 45 |
| Yu, H | 11 |
| Xie, X | 7 |
| Zhang, J | 24 |
| Pan, R | 3 |
| Lu, M | 4 |
| Zhang, Q | 15 |
| Lin, Z | 6 |
| Qin, Y | 2 |
| Wang, Z | 25 |
| Gong, S | 2 |
| Lin, H | 6 |
| Chong, S | 1 |
| Lu, L | 4 |
| Liao, W | 3 |
| Lu, X | 8 |
| Hua, R | 1 |
| Yan, X | 2 |
| Tang, D | 2 |
| Li, X | 29 |
| Ni, Q | 1 |
| Wang, D | 10 |
| Zhu, J | 8 |
| Othman, MS | 1 |
| Al-Bagawi, AH | 1 |
| Obeidat, ST | 1 |
| Fareid, MA | 1 |
| Habotta, OA | 1 |
| Moneim, AEA | 1 |
| Xu, H | 6 |
| Wong, CC | 3 |
| Li, W | 17 |
| Zhou, Y | 14 |
| Wang, L | 36 |
| Liu, L | 16 |
| Yu, J | 11 |
| Malier, M | 2 |
| Gharzeddine, K | 2 |
| Laverriere, MH | 2 |
| Marsili, S | 7 |
| Thomas, F | 2 |
| Decaens, T | 2 |
| Roth, G | 3 |
| Millet, A | 2 |
| Fuel, M | 1 |
| Mesas, C | 2 |
| Martínez, R | 1 |
| Ortiz, R | 2 |
| Quiñonero, F | 1 |
| Prados, J | 2 |
| Porres, JM | 1 |
| Melguizo, C | 2 |
| Fernández, J | 1 |
| Silván, B | 1 |
| Entrialgo-Cadierno, R | 1 |
| Villar, CJ | 1 |
| Capasso, R | 1 |
| Uranga, JA | 1 |
| Lombó, F | 1 |
| Abalo, R | 1 |
| Shimokawa, M | 4 |
| Hayashi, T | 9 |
| Nishimura, J | 7 |
| Satoh, T | 16 |
| Fukunaga, M | 18 |
| Matsui, R | 1 |
| Tsuji, Y | 25 |
| Mizuki, F | 1 |
| Kogawa, T | 1 |
| Kono, T | 10 |
| Yokokawa, H | 1 |
| Miyano, Y | 1 |
| Oyama, K | 1 |
| Yoshimatsu, K | 12 |
| Koike, T | 2 |
| Shiozawa, S | 4 |
| Claramunt García, R | 1 |
| Muñoz Cid, CL | 1 |
| Sánchez Ruiz, A | 2 |
| Marín Pozo, JF | 1 |
| Wein, A | 11 |
| Stoehr, R | 1 |
| Kersting, S | 1 |
| Siebler, J | 7 |
| Merkel, S | 2 |
| Busse, D | 1 |
| Wolff, K | 1 |
| Ostermeier, N | 1 |
| Neufert, C | 1 |
| Vitali, F | 1 |
| Eckstein, M | 1 |
| Roth, JP | 1 |
| Anhut, P | 1 |
| Schreiner, W | 1 |
| Uder, M | 1 |
| Hartmann, A | 2 |
| Neurath, MF | 2 |
| Grützmann, R | 1 |
| Aggarwal, N | 1 |
| Quaglia, A | 1 |
| McPhail, MJW | 1 |
| Monahan, KJ | 1 |
| Rossini, D | 16 |
| Boccaccino, A | 11 |
| Sbrana, A | 1 |
| Daniel, F | 4 |
| Borelli, B | 10 |
| Raimondi, A | 9 |
| Santini, D | 26 |
| Conca, V | 6 |
| Tomasello, G | 18 |
| Caponnetto, S | 3 |
| Marmorino, F | 15 |
| Zaniboni, A | 42 |
| Buonadonna, A | 19 |
| Masi, G | 50 |
| Lonardi, S | 51 |
| Pietrantonio, F | 33 |
| Falcone, A | 84 |
| Antonuzzo, A | 6 |
| Cremolini, C | 55 |
| Yamamoto, S | 4 |
| Nagashima, K | 8 |
| Kawakami, T | 1 |
| Mitani, S | 3 |
| Komoda, M | 2 |
| Izawa, N | 4 |
| Kawakami, K | 10 |
| Yamamoto, Y | 11 |
| Makiyama, A | 13 |
| Yamazaki, K | 35 |
| Masuishi, T | 5 |
| Esaki, T | 19 |
| Nakajima, TE | 5 |
| Okuda, H | 4 |
| Moriwaki, T | 9 |
| Boku, N | 25 |
| Corsi, D | 5 |
| Avallone, A | 24 |
| Brugnatelli, S | 2 |
| Dell'Aquila, E | 8 |
| Cinausero, M | 1 |
| Aprile, G | 22 |
| Carlomagno, C | 6 |
| Colombo, A | 3 |
| Rapisardi, S | 3 |
| Pinto, C | 7 |
| Reggiardo, G | 6 |
| Bilancia, D | 4 |
| Sofocleous, CT | 1 |
| D'Angelica, MI | 9 |
| Monirujjaman, M | 1 |
| Pant, A | 1 |
| Nelson, R | 1 |
| Bathe, O | 1 |
| Jacobs, R | 1 |
| Mazurak, VC | 1 |
| Ala, M | 1 |
| Kadono, T | 1 |
| Okuyama, Y | 6 |
| Nakatsugawa, Y | 1 |
| Yamada, S | 10 |
| Nishimura, T | 4 |
| Fujii, H | 11 |
| Tomatsuri, N | 1 |
| Sato, H | 4 |
| Kimura, H | 7 |
| Urata, Y | 1 |
| Huang, B | 4 |
| Zhao, X | 3 |
| Cui, D | 1 |
| Yuan, W | 4 |
| Yang, L | 18 |
| Kazama, K | 1 |
| Shiozawa, M | 7 |
| Numata, M | 2 |
| Sugano, N | 4 |
| Sato, S | 5 |
| Uchiyama, M | 1 |
| Sato, M | 6 |
| Aoyama, T | 7 |
| Tamagawa, H | 6 |
| Oshima, T | 4 |
| Yukawa, N | 3 |
| Rino, Y | 4 |
| Kim, TW | 35 |
| Taieb, J | 31 |
| Gurary, EB | 1 |
| Lerman, N | 1 |
| Cui, K | 2 |
| Yoshino, T | 29 |
| Peng, C | 4 |
| Yan, J | 1 |
| Chen, P | 4 |
| Jiang, C | 5 |
| Sang, S | 1 |
| Yuan, Y | 9 |
| Hong, Y | 3 |
| Yao, M | 6 |
| Li, C | 12 |
| Chou, C | 1 |
| Ngorsuraches, S | 1 |
| Qian, J | 3 |
| Oneda, E | 2 |
| Turley, MC | 1 |
| Moore, C | 2 |
| Creasy, JM | 3 |
| Sharib, J | 1 |
| Lan, B | 1 |
| Thacker, JKM | 1 |
| Migaly, J | 1 |
| Zani, S | 3 |
| Allen, PJ | 7 |
| Mantyh, CR | 1 |
| Lidsky, ME | 5 |
| Raghavan, R | 1 |
| Koyande, N | 1 |
| Beher, R | 1 |
| Chetlangia, N | 1 |
| Ramadwar, M | 2 |
| Pawade, S | 1 |
| Thorat, R | 2 |
| van Hengel, J | 1 |
| Sklyarova, T | 1 |
| van Roy, F | 1 |
| Dalal, SN | 2 |
| Li, P | 2 |
| Pók-Udvari, A | 1 |
| Klauschen, F | 1 |
| Folprecht, G | 29 |
| Martinelli, E | 10 |
| Mazard, T | 3 |
| Tsuji, A | 18 |
| Esser, R | 3 |
| Peng, L | 6 |
| Jiang, J | 5 |
| Chen, HN | 1 |
| Huang, Z | 11 |
| Qin, S | 4 |
| Jin, P | 2 |
| Li, B | 4 |
| Shi, J | 4 |
| Xie, N | 2 |
| Deng, LW | 1 |
| Liou, YC | 1 |
| Nice, EC | 2 |
| Huang, C | 4 |
| Wei, Y | 10 |
| He, X | 9 |
| Tang, J | 4 |
| Yan, HZ | 1 |
| Wang, JX | 2 |
| Li, HQ | 1 |
| Duan, XW | 1 |
| Yu, SY | 3 |
| Hou, XL | 1 |
| Liao, GB | 1 |
| Liu, W | 11 |
| Kim, SA | 2 |
| Park, H | 1 |
| Kim, KJ | 2 |
| Kim, JW | 12 |
| Sung, JH | 3 |
| Nam, M | 1 |
| Lee, JH | 15 |
| Jung, EH | 1 |
| Suh, KJ | 2 |
| Lee, JY | 3 |
| Kim, SH | 12 |
| Lee, JO | 2 |
| Kim, YJ | 4 |
| Kim, JH | 26 |
| Bang, SM | 4 |
| Lee, JS | 14 |
| Lee, KW | 12 |
| Buisman, FE | 2 |
| Filipe, WF | 1 |
| Galjart, B | 1 |
| Grünhagen, DJ | 3 |
| Homs, MYV | 1 |
| Moelker, A | 1 |
| Verhoef, C | 6 |
| Groot Koerkamp, B | 1 |
| Lee, J | 14 |
| Koom, WS | 1 |
| Byun, HK | 1 |
| Yang, G | 2 |
| Kim, MS | 4 |
| Park, EJ | 1 |
| Ahn, JB | 15 |
| Beom, SH | 3 |
| Kim, HS | 10 |
| Shin, SJ | 15 |
| Kim, K | 4 |
| Chang, JS | 1 |
| Bedon, L | 1 |
| Cecchin, E | 12 |
| Fabbiani, E | 1 |
| Dal Bo, M | 1 |
| Polano, M | 1 |
| Toffoli, G | 13 |
| Patel, A | 2 |
| Spychalski, P | 1 |
| Antoszewska, M | 1 |
| Regula, J | 1 |
| Kobiela, J | 1 |
| Ben Mahmoud, IT | 1 |
| Ben Said, A | 1 |
| Berguiga, S | 1 |
| Houij, R | 1 |
| Cherif, I | 1 |
| Hamdi, A | 1 |
| Ben Ayed, W | 1 |
| Limayem, I | 1 |
| Baxter, NN | 1 |
| Kennedy, EB | 1 |
| Bergsland, E | 4 |
| Berlin, J | 11 |
| George, TJ | 4 |
| Gill, S | 10 |
| Gold, PJ | 3 |
| Hantel, A | 1 |
| Jones, L | 1 |
| Lieu, C | 2 |
| Mahmoud, N | 1 |
| Morris, AM | 1 |
| Ruiz-Garcia, E | 1 |
| You, YN | 1 |
| Meyerhardt, JA | 17 |
| Élez, E | 10 |
| Gómez-España, MA | 2 |
| Grávalos, C | 9 |
| García-Alfonso, P | 20 |
| Ortiz-Morales, MJ | 2 |
| Losa, F | 11 |
| Díaz, IA | 1 |
| Graña, B | 3 |
| Toledano-Fonseca, M | 2 |
| Valladares-Ayerbes, M | 10 |
| Polo, E | 3 |
| Salgado, M | 8 |
| Martínez de Castro, E | 2 |
| Safont, MJ | 11 |
| Salud, A | 13 |
| Ruiz-Casado, A | 4 |
| Tabernero, J | 41 |
| Riesco, MDC | 1 |
| Rodriguez-Ariza, A | 2 |
| Aranda, E | 41 |
| Peng, SH | 1 |
| Mbarak, HS | 1 |
| Ma, C | 2 |
| Shang, QL | 1 |
| Chen, Z | 11 |
| Bian, DJ | 1 |
| Xiao, EH | 1 |
| Manzoor, S | 1 |
| Saber-Ayad, M | 1 |
| Maghazachi, AA | 1 |
| Hamid, Q | 1 |
| Muhammad, JS | 1 |
| Kim, HJ | 8 |
| An, J | 5 |
| Ha, EM | 5 |
| Sakai, S | 2 |
| Kobuchi, S | 7 |
| Ito, Y | 12 |
| Sakaeda, T | 5 |
| Nixon, AB | 5 |
| Sibley, AB | 2 |
| Hatch, AJ | 1 |
| Mulkey, F | 1 |
| Starr, MD | 2 |
| Brady, JC | 2 |
| Niedzwiecki, D | 13 |
| Venook, AP | 13 |
| Baez-Diaz, L | 1 |
| Lenz, HJ | 73 |
| O'Neil, BH | 14 |
| Innocenti, F | 12 |
| O'Reilly, EM | 5 |
| Owzar, K | 2 |
| Hurwitz, HI | 14 |
| Abdullah, S | 2 |
| El Hadad, S | 1 |
| Aldahlawi, A | 1 |
| Zhang, L | 17 |
| Wu, H | 5 |
| Xiao, X | 2 |
| Chu, F | 1 |
| Hwang, J | 2 |
| Park, A | 1 |
| Kim, C | 2 |
| Yu, D | 4 |
| Byun, H | 1 |
| Ku, M | 1 |
| Kim, TI | 3 |
| Jeong, KS | 1 |
| Kim, KY | 2 |
| Lee, H | 5 |
| Jiang, Z | 4 |
| Hou, Z | 3 |
| Yu, Z | 3 |
| Liang, Z | 5 |
| Chen, S | 8 |
| Jiang, Y | 8 |
| Yang, H | 11 |
| Hua, Z | 1 |
| Han, Y | 10 |
| Zhou, C | 5 |
| Xu, S | 3 |
| Nie, S | 1 |
| Xu, G | 3 |
| Shu, X | 3 |
| Wang, X | 55 |
| Lau, DK | 1 |
| Mencel, J | 1 |
| Chau, I | 23 |
| Ychou, M | 30 |
| Rivoire, M | 4 |
| Thezenas, S | 5 |
| Guimbaud, R | 12 |
| Ghiringhelli, F | 13 |
| Mercier-Blas, A | 1 |
| Mineur, L | 19 |
| Francois, E | 26 |
| Khemissa, F | 4 |
| Chauvenet, M | 1 |
| Kianmanesh, R | 1 |
| Fonck, M | 2 |
| Houyau, P | 1 |
| Aparicio, T | 17 |
| Galais, MP | 4 |
| Audemar, F | 2 |
| Assenat, E | 5 |
| Lopez-Crapez, E | 1 |
| Jouffroy, C | 1 |
| Adenis, A | 15 |
| Adam, R | 28 |
| Bouché, O | 28 |
| Rong, X | 1 |
| Liu, H | 14 |
| Zhao, J | 13 |
| Wang, J | 43 |
| Fernández Montes, A | 5 |
| Vivancos, A | 1 |
| Martínez, N | 1 |
| González, P | 1 |
| Covela, M | 1 |
| de la Cámara, J | 2 |
| Cousillas, A | 1 |
| Méndez, JC | 4 |
| Dong, S | 4 |
| Liang, S | 2 |
| Cheng, Z | 1 |
| Zhang, X | 25 |
| Luo, L | 2 |
| Li, L | 16 |
| Li, S | 7 |
| Xu, Q | 6 |
| Zhong, M | 2 |
| Zhang, G | 8 |
| Hu, S | 3 |
| Therizols, G | 2 |
| Bash-Imam, Z | 2 |
| Panthu, B | 1 |
| Machon, C | 1 |
| Vincent, A | 3 |
| Ripoll, J | 1 |
| Nait-Slimane, S | 1 |
| Chalabi-Dchar, M | 1 |
| Gaucherot, A | 1 |
| Garcia, M | 1 |
| Laforêts, F | 2 |
| Marcel, V | 2 |
| Boubaker-Vitre, J | 1 |
| Monet, MA | 1 |
| Bouclier, C | 1 |
| Vanbelle, C | 1 |
| Souahlia, G | 1 |
| Berthel, E | 1 |
| Albaret, MA | 1 |
| Mertani, HC | 3 |
| Prudhomme, M | 1 |
| Bertrand, M | 1 |
| David, A | 4 |
| Saurin, JC | 2 |
| Bouvet, P | 1 |
| Rivals, E | 1 |
| Ohlmann, T | 1 |
| Guitton, J | 1 |
| Dalla Venezia, N | 2 |
| Pannequin, J | 3 |
| Catez, F | 2 |
| Diaz, JJ | 3 |
| Luo, X | 10 |
| Xu, J | 20 |
| Chen, E | 7 |
| Meng, Q | 2 |
| Huang, X | 11 |
| Zhou, W | 9 |
| Song, Z | 4 |
| Pernot, S | 9 |
| Pellerin, O | 5 |
| Monterymard, C | 2 |
| Smith, D | 14 |
| Lapuyade, B | 1 |
| Gallois, C | 2 |
| Khemissa Akouz, F | 3 |
| De Baere, T | 8 |
| Tougeron, D | 8 |
| Thirot-Bidault, A | 1 |
| Simon, M | 1 |
| Lecaille, C | 7 |
| Louafi, S | 1 |
| Lepage, C | 8 |
| Ducreux, M | 52 |
| Arbag, HC | 1 |
| Sumbul, HE | 1 |
| Buyuksimsek, M | 1 |
| Ogul, A | 1 |
| Yetisir, AE | 1 |
| Koseci, T | 1 |
| Bozkurt Duman, B | 1 |
| Tohumcuoglu, M | 1 |
| Kesen, O | 1 |
| Cil, T | 1 |
| Kagawa, Y | 9 |
| Inoue, A | 2 |
| Nishizawa, Y | 3 |
| Ohta, T | 1 |
| Hata, T | 13 |
| Naito, A | 4 |
| Komatsu, H | 2 |
| Miyazaki, Y | 2 |
| Tomokuni, A | 2 |
| Motoori, M | 1 |
| Fujitani, K | 6 |
| Kato, T | 35 |
| Takeda, Y | 7 |
| Murata, K | 9 |
| Delhorme, JB | 1 |
| Bersuder, E | 1 |
| Terciolo, C | 1 |
| Vlami, O | 1 |
| Chenard, MP | 2 |
| Martin, E | 2 |
| Rohr, S | 1 |
| Brigand, C | 1 |
| Duluc, I | 1 |
| Freund, JN | 1 |
| Gross, I | 2 |
| Zhang, WL | 1 |
| Deng, YX | 1 |
| Hou, ZL | 1 |
| Zhang, LJ | 1 |
| Lin, JZ | 2 |
| Pan, ZZ | 9 |
| Lu, ZH | 8 |
| Peng, JH | 1 |
| Qin, BD | 1 |
| Ye, CY | 1 |
| Wang, MM | 1 |
| Yuan, LY | 1 |
| Dai, WP | 1 |
| Sun, L | 7 |
| Liu, K | 5 |
| Qin, WX | 1 |
| Jiao, XD | 1 |
| Li, XN | 1 |
| Zang, YS | 1 |
| Asgharzadeh, F | 5 |
| Naghibzadeh, N | 1 |
| Hashemzehi, M | 2 |
| Mostafapour, A | 3 |
| Hassanian, SM | 9 |
| Avan, A | 10 |
| Khazaei, M | 9 |
| Koyama, M | 2 |
| Osada, E | 1 |
| Akiyama, N | 1 |
| Eto, K | 1 |
| Manome, Y | 2 |
| McCleary, NJ | 4 |
| Zhang, S | 15 |
| Ou, FS | 4 |
| Bainter, TM | 1 |
| Polite, BN | 2 |
| Hochster, HS | 11 |
| Atkins, JN | 2 |
| Goldberg, RM | 61 |
| Ng, K | 4 |
| Mayer, RJ | 17 |
| Blanke, CD | 12 |
| Fuchs, CS | 22 |
| Yazici, O | 2 |
| Ucar, G | 1 |
| Sütcüoglu, O | 2 |
| Turhal, NS | 3 |
| Yildiz, B | 1 |
| Karamouzis, M | 1 |
| Yavuz, S | 1 |
| Karadurmuş, N | 1 |
| Zengin, N | 4 |
| Geva, R | 2 |
| Abali, H | 2 |
| Falk, P | 1 |
| Severin, M | 1 |
| Berglund, Å | 12 |
| Guren, MG | 1 |
| Hofsli, E | 2 |
| Österlund, P | 13 |
| Tandberg, A | 1 |
| Eberhard, J | 1 |
| Sorbye, H | 12 |
| Cantero-Recasens, G | 1 |
| Alonso-Marañón, J | 1 |
| Lobo-Jarne, T | 1 |
| Garrido, M | 1 |
| Iglesias, M | 1 |
| Espinosa, L | 1 |
| Malhotra, V | 1 |
| Liu, Z | 12 |
| Weng, S | 2 |
| Guo, C | 2 |
| Dang, Q | 1 |
| Lu, T | 1 |
| Sun, Z | 5 |
| Khin, NY | 1 |
| De Silva, M | 1 |
| Clarke, S | 10 |
| Pavlakis, N | 4 |
| Rogan, CM | 1 |
| Ho-Shon, K | 1 |
| Lane, RJ | 1 |
| Tsai, HL | 15 |
| Chen, YC | 5 |
| Yin, TC | 3 |
| Su, WC | 5 |
| Chen, PJ | 3 |
| Chang, TK | 5 |
| Li, CC | 3 |
| Huang, CW | 13 |
| Wang, JY | 25 |
| Guo, WH | 1 |
| Qi, ZC | 1 |
| Guan, HQ | 1 |
| Liu, TT | 1 |
| Liang, L | 4 |
| Yu, QH | 1 |
| Liang, Y | 5 |
| Tang, DC | 1 |
| De Francia, S | 1 |
| Berchialla, P | 1 |
| Armando, T | 1 |
| Storto, S | 1 |
| Allegra, S | 1 |
| Sciannameo, V | 1 |
| Soave, G | 1 |
| Sprio, AE | 1 |
| Racca, S | 1 |
| Caiaffa, MR | 1 |
| Ciuffreda, L | 4 |
| Mussa, MV | 1 |
| Samoon, Z | 1 |
| Naher, SK | 1 |
| Sjoquist, KM | 1 |
| Zalcberg, J | 9 |
| Matsumura, M | 2 |
| Hasegawa, K | 14 |
| Oba, M | 4 |
| Yamaguchi, K | 24 |
| Uetake, H | 19 |
| Morita, S | 27 |
| Takahashi, K | 36 |
| Unno, M | 2 |
| Shimada, Y | 38 |
| Muro, K | 51 |
| Matsuhashi, N | 3 |
| Mori, M | 13 |
| Baba, H | 39 |
| Shimada, M | 9 |
| Mise, Y | 4 |
| Kawaguchi, Y | 2 |
| Kagimura, T | 2 |
| Ishigure, K | 2 |
| Saiura, A | 3 |
| Sugihara, K | 23 |
| Kokudo, N | 5 |
| Pouya, FD | 1 |
| Gazouli, M | 2 |
| Rasmi, Y | 2 |
| Lampropoulou, DI | 1 |
| Nemati, M | 1 |
| Watanabe, G | 6 |
| Inoue, Y | 12 |
| Takahashi, Y | 10 |
| Kishi, Y | 3 |
| Suyama, K | 2 |
| Takayama, T | 8 |
| Noie, T | 1 |
| Nishioka, Y | 4 |
| Akamatsu, N | 2 |
| Arita, J | 1 |
| Huang, W | 1 |
| Zhang, H | 17 |
| Tian, Y | 6 |
| Cha, Y | 4 |
| Xiong, H | 3 |
| Yuan, X | 3 |
| Fasihi, K | 1 |
| Amerizadeh, F | 4 |
| Sabbaghzadeh, R | 3 |
| Heydari, M | 1 |
| Rahmani, F | 5 |
| Rasouli, E | 1 |
| Ferns, GA | 8 |
| Rezayi, M | 1 |
| Matsumura, K | 1 |
| Yamamura, K | 2 |
| Miyamoto, H | 7 |
| Hara, Y | 1 |
| Oda, E | 1 |
| Akahoshi, S | 1 |
| Yoshida, K | 14 |
| Yuki, H | 1 |
| Motohara, T | 2 |
| Sakamoto, K | 14 |
| Komohara, Y | 1 |
| Beppu, T | 12 |
| Ge, P | 1 |
| Reyila, A | 1 |
| Li, XY | 2 |
| Liu, SY | 1 |
| Jiang, YX | 2 |
| Yang, YJ | 1 |
| Li, XL | 7 |
| Bian, Y | 1 |
| Liu, D | 5 |
| Coker, OO | 1 |
| Liu, C | 13 |
| Kang, W | 2 |
| To, KF | 2 |
| Sung, JJ | 2 |
| Ebrahimi, S | 1 |
| Fakhraei, M | 1 |
| Farshbaf, A | 1 |
| Giovannetti, E | 5 |
| Jo, H | 1 |
| Lee, MS | 1 |
| Lee, YP | 1 |
| Kim, H | 9 |
| Hong, JY | 1 |
| Park, SH | 9 |
| Park, JO | 8 |
| Park, YS | 21 |
| Lim, HY | 7 |
| Kang, WK | 9 |
| Kim, ST | 7 |
| Yao, H | 2 |
| Qiu, S | 5 |
| Chen, J | 30 |
| Gao, Q | 2 |
| Chen, X | 20 |
| Xi, C | 1 |
| Huang, D | 6 |
| Zhang, F | 4 |
| Gao, S | 6 |
| Ren, G | 1 |
| Tao, X | 2 |
| Li, M | 15 |
| Chen, W | 7 |
| Suzuki, K | 8 |
| Matsuo, K | 10 |
| Kikuchi, Y | 2 |
| Koda, K | 8 |
| Tanaka, K | 14 |
| Liu, J | 22 |
| Yang, X | 10 |
| Jiang, Q | 1 |
| Ji, F | 2 |
| Xu, Y | 17 |
| Fan, X | 3 |
| Zhou, Z | 4 |
| Fu, C | 4 |
| Gao, Y | 6 |
| Derksen, JWG | 1 |
| Smit, KC | 1 |
| May, AM | 2 |
| Punt, CJA | 10 |
| Liang, YH | 1 |
| Liang, JT | 5 |
| Lin, BR | 1 |
| Huang, J | 4 |
| Hung, JS | 1 |
| Lai, SL | 1 |
| Chen, TC | 1 |
| Tsai, JH | 1 |
| Cheng, YM | 3 |
| Tsao, TH | 1 |
| Hsu, WL | 1 |
| Chen, KH | 1 |
| Yeh, KH | 6 |
| Li, Z | 16 |
| Lin, G | 1 |
| Bekaii-Saab, TS | 3 |
| Zhao, L | 11 |
| Chen, H | 13 |
| Ma, J | 7 |
| Hu, H | 16 |
| Xu, L | 5 |
| Matsubara, Y | 1 |
| Ogata, T | 1 |
| Nakazawa, T | 1 |
| Kato, K | 26 |
| Nozawa, K | 4 |
| Narita, Y | 4 |
| Honda, K | 4 |
| Bando, H | 10 |
| Taniguchi, H | 11 |
| Kadowaki, S | 5 |
| Ando, M | 10 |
| Tajika, M | 2 |
| Taibi, A | 6 |
| Sgarbura, O | 1 |
| Hübner, M | 1 |
| Bardet, SM | 4 |
| Alyami, M | 1 |
| Bakrin, N | 1 |
| Durand Fontanier, S | 4 |
| Eveno, C | 4 |
| Gagniere, J | 1 |
| Pache, B | 1 |
| Pocard, M | 12 |
| Quenet, F | 4 |
| Teixeira Farinha, H | 1 |
| Thibaudeau, E | 1 |
| Dumont, F | 5 |
| Glehen, O | 2 |
| Jonnagaddala, J | 1 |
| Xu, XS | 1 |
| Kwakman, JJM | 1 |
| Mol, L | 11 |
| Kim, JG | 6 |
| Baik, SH | 3 |
| Shin, SH | 2 |
| Park, I | 1 |
| Lee, MA | 5 |
| Lee, S | 6 |
| Jeon, SY | 1 |
| Han, SW | 13 |
| Kang, MH | 3 |
| Oh, J | 1 |
| Kim, JS | 11 |
| Kim, JY | 3 |
| Ahn, MS | 1 |
| Zang, DY | 5 |
| Bae, BN | 1 |
| Jo, HJ | 1 |
| Kim, HK | 3 |
| Yoon, JA | 1 |
| Kim, DH | 2 |
| Zhakipbekov, S | 1 |
| Osombaev, M | 1 |
| Irimbetov, S | 1 |
| Watanabe, M | 23 |
| Katsumata, K | 6 |
| Sumi, T | 1 |
| Ishizaki, T | 2 |
| Enomoto, M | 5 |
| Shigoka, M | 1 |
| Wada, T | 2 |
| Kuwabara, H | 4 |
| Mazaki, J | 1 |
| Kasahara, K | 1 |
| Tago, T | 1 |
| Udo, R | 1 |
| Nagakawa, Y | 1 |
| Kawachi, S | 1 |
| Tsuchida, A | 3 |
| Kato, A | 2 |
| Miyoshi, N | 4 |
| Ohtsuru, T | 1 |
| Sakai, D | 7 |
| Hasegawa, J | 4 |
| Nakata, K | 3 |
| Imasato, M | 4 |
| Ikenaga, M | 6 |
| Kudo, T | 5 |
| Tei, M | 1 |
| Uemura, M | 6 |
| Takahashi, H | 5 |
| Mizushima, T | 12 |
| Yamamoto, H | 10 |
| Doki, Y | 10 |
| Eguchi, H | 3 |
| Ulaş Kahya, B | 1 |
| Özdemir, N | 3 |
| Wu, Z | 6 |
| Gong, Z | 1 |
| Xia, Y | 1 |
| Du, L | 2 |
| Gao, X | 6 |
| Fan, Z | 2 |
| Qian, Q | 1 |
| Ding, Z | 1 |
| Guo, S | 2 |
| Wang, M | 12 |
| Guo, X | 5 |
| Yang, M | 3 |
| Meng, F | 3 |
| Chen, Y | 34 |
| Chen, M | 5 |
| Qiu, T | 1 |
| Xu, F | 4 |
| Hanna, CR | 2 |
| Lemmon, E | 1 |
| Hall, PS | 1 |
| Ennis, H | 1 |
| Morris, E | 1 |
| McLoone, P | 1 |
| Boyd, KA | 4 |
| Jones, RJ | 3 |
| Chauvin, A | 1 |
| Bergeron, D | 1 |
| Vencic, J | 1 |
| Lévesque, D | 1 |
| Paquette, B | 1 |
| Scott, MS | 1 |
| Boisvert, FM | 1 |
| Lipsyc-Sharf, M | 1 |
| Yurgelun, MB | 1 |
| Rubinson, DA | 1 |
| Schrag, D | 7 |
| Dakhil, SR | 4 |
| Stella, PJ | 2 |
| Weckstein, DJ | 1 |
| Wender, DB | 2 |
| Faggen, M | 1 |
| Zemla, TJ | 1 |
| Heying, EN | 1 |
| Schuetz, SR | 1 |
| Noble, S | 1 |
| Bekaii-Saab, T | 4 |
| Satake, H | 6 |
| Shinozaki, E | 20 |
| Tanizawa, Y | 3 |
| Jin, L | 7 |
| Cai, Z | 6 |
| Hegazy, SK | 1 |
| El-Azab, GA | 1 |
| Zakaria, F | 1 |
| Mostafa, MF | 1 |
| El-Ghoneimy, RA | 1 |
| Wang, JL | 2 |
| Wu, DZ | 1 |
| Yuan, YW | 1 |
| Xin, L | 1 |
| Sugarbaker, PH | 10 |
| Du, J | 3 |
| Li, H | 18 |
| Guo, H | 1 |
| Xiong, B | 1 |
| Song, FX | 1 |
| Chen, HL | 1 |
| Wang, XJ | 2 |
| Jin, ZX | 1 |
| Han, TY | 1 |
| Zhang, DK | 1 |
| He, Z | 3 |
| Sui, C | 1 |
| Zhang, P | 13 |
| Wang, T | 13 |
| Mou, T | 1 |
| Sun, K | 3 |
| Xu, Z | 2 |
| Deng, H | 1 |
| Zhuang, B | 1 |
| Ii, Y | 1 |
| Irie, T | 2 |
| Kobari, A | 1 |
| Kawaguchi, M | 1 |
| Momose, H | 1 |
| Tsukamoto, R | 1 |
| Kawai, M | 3 |
| Sugimoto, K | 2 |
| Kojima, Y | 1 |
| Arakawa, A | 1 |
| Terao, Y | 1 |
| Tomiki, Y | 1 |
| Kitazume, Y | 1 |
| Kawazoe, H | 3 |
| Uozumi, R | 1 |
| Yoshizawa, T | 1 |
| Iihara, H | 3 |
| Takahashi, M | 20 |
| Arai, T | 10 |
| Murachi, Y | 1 |
| Sato, Y | 21 |
| Mikami, T | 1 |
| Hashiguchi, K | 1 |
| Yamazaki, T | 2 |
| Fujita, Y | 2 |
| Hosokawa, Y | 4 |
| Morozumi, I | 1 |
| Tsuchiya, M | 2 |
| Yokoyama, A | 1 |
| Hashimoto, H | 3 |
| Yamaguchi, M | 1 |
| Gong, P | 1 |
| Zhao, Y | 17 |
| Qu, YL | 1 |
| Liu, XL | 1 |
| Zhao, SY | 1 |
| Zhai, XF | 1 |
| Watts, K | 2 |
| Wills, C | 2 |
| Madi, A | 8 |
| Palles, C | 5 |
| Maughan, TS | 15 |
| Kaplan, R | 7 |
| Al-Tassan, NA | 2 |
| Kerr, R | 3 |
| Kerr, DJ | 27 |
| Houlston, RS | 2 |
| Escott-Price, V | 2 |
| Cheadle, JP | 4 |
| Nishina, T | 20 |
| Sakai, Y | 8 |
| Ishida, H | 44 |
| Amagai, K | 2 |
| Endo, S | 2 |
| Negoro, Y | 3 |
| Kuramochi, H | 10 |
| Denda, T | 22 |
| Hatachi, Y | 1 |
| Ikezawa, K | 1 |
| Nakajima, G | 3 |
| Bando, Y | 1 |
| Morimoto, M | 1 |
| Kobayashi, K | 14 |
| Hyodo, I | 18 |
| Yang, Y | 20 |
| Yuan, H | 3 |
| Tian, M | 2 |
| Nie, Y | 3 |
| Niu, J | 1 |
| Wang, G | 14 |
| Song, Y | 6 |
| van Dijk, E | 1 |
| van Werkhoven, E | 3 |
| Asher, R | 1 |
| Mooi, JK | 1 |
| Espinoza, D | 2 |
| van Essen, HF | 1 |
| van Tinteren, H | 9 |
| van Grieken, NCT | 1 |
| Tebbutt, NC | 19 |
| Ylstra, B | 2 |
| Zitkute, V | 3 |
| Kukcinaviciute, E | 4 |
| Jonusiene, V | 5 |
| Starkuviene, V | 1 |
| Sasnauskiene, A | 5 |
| Walker, BS | 1 |
| Billingsley, KG | 1 |
| Sutton, TL | 1 |
| Kolbeck, KJ | 1 |
| Korngold, EK | 1 |
| Nabavizadeh, N | 1 |
| Dewey, EN | 1 |
| Herzig, DO | 1 |
| Lopez, CD | 4 |
| Mayo, SC | 2 |
| Jin, M | 1 |
| Zhou, P | 1 |
| Ren, J | 3 |
| Cheng, J | 4 |
| Yang, K | 1 |
| Wu, G | 2 |
| Zhang, T | 13 |
| Zhang, D | 3 |
| Salerno, S | 1 |
| Ståhlberg, A | 1 |
| Holdfeldt, A | 1 |
| Bexe Lindskog, E | 1 |
| Landberg, G | 1 |
| Wang, WY | 2 |
| Zhou, H | 5 |
| Zhang, YH | 3 |
| Germani, MM | 6 |
| Allegrini, G | 27 |
| Maddalena, G | 1 |
| Randon, G | 6 |
| Antoniotti, C | 25 |
| Passardi, A | 13 |
| Zichittella, C | 1 |
| Barreca, MM | 1 |
| Cordaro, A | 1 |
| Corrado, C | 1 |
| Alessandro, R | 2 |
| Conigliaro, A | 1 |
| Kiweler, N | 1 |
| Schwarz, H | 1 |
| Nguyen, A | 1 |
| Matschos, S | 1 |
| Mullins, C | 1 |
| Piée-Staffa, A | 1 |
| Brachetti, C | 1 |
| Roos, WP | 1 |
| Schneider, G | 1 |
| Linnebacher, M | 3 |
| Brenner, W | 1 |
| Krämer, OH | 1 |
| Guan, M | 3 |
| Huo, C | 1 |
| Yu, C | 3 |
| Hu, B | 3 |
| Cai, J | 6 |
| Maruyama, K | 1 |
| Tominaga, T | 6 |
| Nonaka, T | 1 |
| Moriyama, M | 1 |
| Oyama, S | 1 |
| Ishii, M | 4 |
| Sawai, T | 6 |
| Nagayasu, T | 3 |
| Chou, J | 2 |
| Kaller, M | 3 |
| Jaeckel, S | 1 |
| Rokavec, M | 2 |
| Hermeking, H | 3 |
| Fischer, LE | 2 |
| von Weikersthal, LF | 16 |
| Kiani, A | 17 |
| Al-Batran, SE | 11 |
| Heintges, T | 15 |
| Lerchenmüller, C | 8 |
| Kahl, C | 15 |
| Seipelt, G | 10 |
| Kullmann, F | 16 |
| Stauch, M | 13 |
| Scheithauer, W | 49 |
| Giessen-Jung, C | 5 |
| Uhlig, J | 4 |
| Peuser, B | 2 |
| Weiss, L | 2 |
| Guo, J | 5 |
| Huang, L | 15 |
| Zhang, B | 9 |
| Ma, Y | 7 |
| Zhao, F | 3 |
| Wang, B | 3 |
| Jin, H | 3 |
| Zhou, F | 2 |
| Guan, J | 2 |
| Zhao, Q | 5 |
| Liu, Q | 14 |
| Martínez-Lago, N | 1 |
| Cameselle García, S | 1 |
| Alonso de Castro, B | 1 |
| Gómez-Randulfe Rodríguez, MI | 1 |
| Carmona Campos, M | 1 |
| González Villarroel, P | 2 |
| Salgado Fernández, M | 4 |
| De la Cámara Gómez, JC | 1 |
| Romero Reinoso, C | 2 |
| Cousillas Castiñeiras, A | 1 |
| Méndez Méndez, JC | 3 |
| Vidal Insua, Y | 1 |
| Fernández-Montes, A | 1 |
| Moretto, R | 10 |
| Elliott, A | 1 |
| Intini, R | 2 |
| Sartore-Bianchi, A | 6 |
| Rasola, C | 1 |
| Scartozzi, M | 12 |
| Salati, M | 1 |
| Pella, N | 7 |
| Calegari, MA | 2 |
| Carullo, M | 3 |
| Corti, F | 1 |
| Mauri, G | 2 |
| Fassan, M | 4 |
| Brodskiy, P | 1 |
| Shields, A | 1 |
| Korn, M | 1 |
| Tang, Y | 3 |
| Nan, N | 1 |
| Gui, C | 1 |
| Zhou, X | 7 |
| Jiang, W | 5 |
| Prisciandaro, M | 6 |
| Pagani, F | 3 |
| Bozzarelli, S | 2 |
| Tampellini, M | 17 |
| Fanchini, L | 3 |
| Murialdo, R | 4 |
| Clavarezza, M | 6 |
| Berenato, R | 4 |
| Ratti, M | 4 |
| Petrelli, F | 15 |
| Antonuzzo, L | 8 |
| Giordano, M | 7 |
| Rossi, A | 7 |
| Di Bartolomeo, M | 18 |
| Di Maio, M | 10 |
| Morano, F | 14 |
| Arai, H | 3 |
| Millstein, J | 4 |
| Battaglin, F | 6 |
| Kawanishi, N | 2 |
| Jayachandran, P | 3 |
| Soni, S | 7 |
| Zhou, YW | 2 |
| Long, YX | 1 |
| Liu, JY | 5 |
| Qiu, M | 4 |
| Watanabe, J | 4 |
| Maeda, H | 4 |
| Nagasaka, T | 6 |
| Yokota, M | 2 |
| Hirata, K | 17 |
| Akazawa, N | 3 |
| Yamada, T | 15 |
| Ando, T | 3 |
| Mishima, H | 37 |
| Sakamoto, J | 29 |
| Oba, K | 17 |
| Nagata, N | 15 |
| Lin, W | 3 |
| Yuan, Q | 1 |
| Lu, Y | 4 |
| Dai, P | 2 |
| Long, H | 2 |
| Xiao, Y | 1 |
| Loupakis, F | 50 |
| Mancao, C | 2 |
| Liu, T | 11 |
| Shen, L | 17 |
| Luo, F | 1 |
| Porretto, CM | 1 |
| Aparicio, J | 16 |
| Virgili Manrique, AC | 1 |
| Capdevila, J | 2 |
| Muñoz Boza, F | 1 |
| Galván, P | 1 |
| Richart, P | 1 |
| Oliveres, H | 1 |
| Páez, D | 9 |
| Hernando, J | 1 |
| Serrano, S | 1 |
| Vera, R | 6 |
| Hernandez-Yagüe, X | 2 |
| Gallego, RÁ | 1 |
| Riesco-Martinez, MC | 2 |
| García de Albeniz, X | 1 |
| Maurel, J | 15 |
| Ke, K | 1 |
| Jin, W | 3 |
| Zhu, Q | 3 |
| Mei, R | 1 |
| Zhang, R | 12 |
| Shou, L | 1 |
| Feng, J | 7 |
| Duan, T | 2 |
| Mou, Y | 1 |
| Xie, T | 4 |
| Wu, Q | 8 |
| Sui, X | 3 |
| Hiraide, T | 1 |
| Morita, Y | 7 |
| Horikawa, M | 1 |
| Sugiyama, E | 1 |
| Sato, T | 14 |
| Kahyo, T | 1 |
| Furuhashi, S | 1 |
| Takeda, M | 2 |
| Kikuchi, H | 3 |
| Hiramatsu, Y | 1 |
| Sakaguchi, T | 1 |
| Konno, H | 2 |
| Setou, M | 1 |
| Takeuchi, H | 1 |
| Iwai, M | 2 |
| Kimura, M | 7 |
| Usami, E | 3 |
| Yoshimura, T | 5 |
| Maftooh, M | 3 |
| Nasiri, SN | 1 |
| Moradi-Marjaneh, R | 2 |
| Shahidsales, S | 2 |
| Joudi-Mashhad, M | 1 |
| Ghayour-Mobarhan, M | 3 |
| Sawicka, D | 3 |
| Hryniewicka, A | 1 |
| Gohal, S | 1 |
| Sadowska, A | 2 |
| Pryczynicz, A | 1 |
| Guzińska-Ustymowicz, K | 2 |
| Sokołowska, E | 2 |
| Morzycki, JW | 1 |
| Car, H | 3 |
| Sun, J | 2 |
| Yao, N | 1 |
| Lu, P | 1 |
| Judge, SJ | 2 |
| Cho, M | 4 |
| Gholami, S | 4 |
| Torregrosa, C | 1 |
| Vaflard, P | 1 |
| Perret, A | 1 |
| Tournigand, C | 34 |
| Randrian, V | 1 |
| Doat, S | 4 |
| Neuzillet, C | 1 |
| Moulin, V | 3 |
| Stouvenot, M | 1 |
| Darbas, T | 1 |
| Auberger, B | 1 |
| Godet, T | 1 |
| Jaffrelot, M | 1 |
| Lambert, A | 1 |
| Dubreuil, O | 2 |
| Gluszak, C | 1 |
| Bernard-Tessier, A | 1 |
| Turpin, A | 2 |
| Palmieri, LJ | 2 |
| Goujon, G | 3 |
| Lecomte, T | 17 |
| Sefrioui, D | 3 |
| Locher, C | 10 |
| Grados, L | 1 |
| Gignoux, P | 1 |
| Trager, S | 1 |
| Nassif, E | 1 |
| Saint, A | 1 |
| Hammel, P | 3 |
| Bureau, M | 1 |
| Perrier, M | 1 |
| Botsen, D | 1 |
| Bourgeois, V | 1 |
| Auclin, E | 2 |
| Iimura, Y | 2 |
| Furukawa, N | 1 |
| Ishibashi, M | 1 |
| Ahiko, Y | 1 |
| Tanabe, T | 3 |
| Aikou, S | 1 |
| Shida, D | 5 |
| Nojima, M | 1 |
| Kuroda, S | 1 |
| Chrabaszcz, S | 1 |
| Rajeev, R | 1 |
| Witmer, HDD | 1 |
| Dhiman, A | 1 |
| Klooster, B | 1 |
| Gamblin, TC | 1 |
| Banerjee, A | 1 |
| Johnston, FM | 1 |
| Turaga, KK | 1 |
| Guo, Y | 10 |
| Prosperi, M | 1 |
| Braithwaite, D | 1 |
| Wang, F | 20 |
| Kibbe, W | 1 |
| Wagner, L | 1 |
| Bian, J | 1 |
| Minchev, V | 1 |
| Hristova-Avakumova, N | 1 |
| Kamenova, K | 1 |
| Atanasova, L | 1 |
| Angelov, M | 1 |
| Todorov, L | 1 |
| Surcheva, S | 1 |
| Nikolov, R | 1 |
| Xia, M | 1 |
| Zhang, Z | 15 |
| Tan, Y | 5 |
| Li, E | 1 |
| Fang, M | 2 |
| Zhu, Y | 10 |
| Hu, Z | 3 |
| Ardıl, B | 1 |
| Alper, M | 1 |
| Arnold, D | 22 |
| Eggers, E | 1 |
| Reichert, D | 1 |
| Becker, L | 1 |
| Thiebach, L | 1 |
| Ito, T | 4 |
| Takashima, A | 12 |
| Yukami, H | 1 |
| Tsuda, M | 8 |
| Suto, T | 5 |
| Sugimoto, N | 5 |
| Ojima, H | 5 |
| Takii, Y | 5 |
| Yasui, H | 12 |
| Goto, M | 5 |
| Saruta, M | 1 |
| Otsu, S | 3 |
| Shinozaki, K | 6 |
| Fujiwara, T | 4 |
| Tamura, T | 7 |
| Baba, E | 12 |
| Ueno, H | 4 |
| Ou, K | 1 |
| Gao, L | 7 |
| Cevik, M | 1 |
| Namal, E | 2 |
| Sener, ND | 1 |
| Koksal, UI | 1 |
| Cagatay, P | 1 |
| Deliorman, G | 1 |
| Ciftci, C | 1 |
| Karaalp, A | 1 |
| Susleyici, B | 1 |
| Gong, B | 1 |
| Xie, W | 2 |
| Zheng, Y | 5 |
| Jin, S | 2 |
| Ding, C | 2 |
| Xu, C | 5 |
| Dong, Z | 1 |
| Sommerhäuser, G | 7 |
| Dechow, T | 1 |
| Karthaus, M | 17 |
| Fuchs, M | 3 |
| König, A | 2 |
| Roderburg, C | 2 |
| Hoyer, I | 1 |
| Quante, M | 1 |
| Fruehauf, S | 6 |
| Müller, L | 4 |
| Reinacher-Schick, A | 13 |
| Ettrich, TJ | 3 |
| Wang, S | 11 |
| Cao, J | 10 |
| Pei, L | 1 |
| Nakao, T | 1 |
| Yoshikawa, K | 2 |
| Tokunaga, T | 2 |
| Nishi, M | 1 |
| Kashihara, H | 1 |
| Takasu, C | 2 |
| Wada, Y | 2 |
| Yoshimoto, T | 1 |
| Yamashita, S | 4 |
| Yao, F | 1 |
| Xie, Z | 1 |
| Strickler, JH | 5 |
| Cubillo, A | 4 |
| Matrana, M | 1 |
| Kozloff, M | 4 |
| Lowe, T | 1 |
| Blaney, M | 1 |
| Sahtout, M | 1 |
| Naumovski, L | 1 |
| Wainberg, ZA | 6 |
| He, MM | 2 |
| Xiao, J | 3 |
| Zhang, YQ | 1 |
| Fang, WJ | 4 |
| Hu, XH | 2 |
| Ma, ZG | 1 |
| Yao, YC | 1 |
| Zhuang, ZX | 1 |
| Zhou, FX | 1 |
| Ying, JE | 2 |
| Zou, QF | 1 |
| Guo, ZQ | 1 |
| Wu, XY | 3 |
| Jin, Y | 11 |
| Mai, ZJ | 1 |
| Wang, ZQ | 7 |
| Qiu, H | 2 |
| Shi, SM | 2 |
| Chen, SZ | 1 |
| Luo, HY | 5 |
| Zhang, DS | 4 |
| Wang, FH | 8 |
| Xu, RH | 14 |
| Diab, R | 1 |
| Rakhshan, A | 1 |
| Kaddah, A | 1 |
| Abdollahimajd, F | 1 |
| Mirzaei, HR | 1 |
| Terazawa, T | 3 |
| Ohta, K | 4 |
| Noura, S | 5 |
| Kawakami, H | 4 |
| Hasegawa, H | 11 |
| Yanagihara, K | 4 |
| Shingai, T | 3 |
| Kotaka, M | 7 |
| Hiraki, M | 2 |
| Konishi, K | 5 |
| Nakae, S | 1 |
| Kurokawa, Y | 3 |
| Shimokawa, T | 1 |
| Tsujinaka, T | 4 |
| Pan, H | 4 |
| Pan, J | 4 |
| Wu, J | 8 |
| Kasper, S | 6 |
| Moosmann, N | 8 |
| Keitel, V | 1 |
| Jacobasch, L | 1 |
| Fischer V Weikersthal, L | 1 |
| Sent, D | 1 |
| Junghanß, C | 1 |
| Lorenzen, S | 2 |
| Kaczirek, K | 5 |
| Hofmann, FO | 3 |
| D'Anastasi, M | 2 |
| Gesenhues, AB | 3 |
| Hesse, N | 3 |
| Moehler, M | 25 |
| Link, H | 5 |
| Holch, JW | 10 |
| Pranzini, E | 1 |
| Pardella, E | 1 |
| Muccillo, L | 1 |
| Leo, A | 1 |
| Nesi, I | 1 |
| Santi, A | 1 |
| Parri, M | 1 |
| Uribe, AH | 1 |
| Lottini, T | 1 |
| Sabatino, L | 1 |
| Caselli, A | 1 |
| Arcangeli, A | 1 |
| Raugei, G | 1 |
| Colantuoni, V | 1 |
| Cirri, P | 1 |
| Chiarugi, P | 1 |
| Maddocks, ODK | 1 |
| Paoli, P | 1 |
| Taddei, ML | 1 |
| Yu, W | 6 |
| Bao, X | 1 |
| Ciardiello, D | 2 |
| Chiarazzo, C | 1 |
| Famiglietti, V | 2 |
| Damato, A | 4 |
| Zampino, MG | 6 |
| Castellano, G | 1 |
| Gervaso, L | 1 |
| Bordonaro, R | 11 |
| Zichi, C | 3 |
| De Vita, F | 15 |
| Parisi, A | 2 |
| Giampieri, R | 7 |
| Berardi, R | 5 |
| Lavacchi, D | 2 |
| Tamburini, E | 13 |
| Maiorano, BA | 1 |
| Parrella, P | 2 |
| Latiano, TP | 7 |
| Normanno, N | 9 |
| De Stefano, A | 3 |
| Martini, G | 2 |
| Napolitano, S | 3 |
| Troiani, T | 9 |
| Ciardiello, F | 16 |
| Maiello, E | 27 |
| Martínez, E | 2 |
| Osorio, M | 3 |
| Finkielstein, C | 1 |
| Ortíz, I | 1 |
| Peresin, MS | 1 |
| Castro, C | 3 |
| Zheng, H | 7 |
| McCombs, JS | 1 |
| Barzi, A | 4 |
| Toumi, I | 1 |
| Yatouji, S | 1 |
| Borie, N | 1 |
| Remy, S | 1 |
| Renault, JH | 1 |
| Chazee, L | 1 |
| Hammami, M | 1 |
| Martiny, L | 1 |
| Devarenne-Charpentier, E | 1 |
| El Btaouri, H | 1 |
| Islam, MM | 1 |
| Mirza, SP | 1 |
| Lin, J | 10 |
| Huang, S | 9 |
| Qiao, Y | 1 |
| Gathirua-Mwangi, W | 1 |
| Yang, T | 3 |
| Khan, T | 1 |
| Wu, Y | 19 |
| Afable, M | 1 |
| Sousa-Squiavinato, ACM | 1 |
| Arregui Ramos, DA | 1 |
| Wagner, MS | 1 |
| Tessmann, JW | 1 |
| de-Freitas-Junior, JCM | 1 |
| Morgado-Díaz, JA | 1 |
| Hendrych, M | 1 |
| Říhová, K | 1 |
| Adamová, B | 1 |
| Hradil, V | 1 |
| Stiborek, M | 1 |
| Vlček, P | 2 |
| Hermanová, M | 1 |
| Vašíčková, J | 1 |
| Beneš, P | 1 |
| Šmarda, J | 1 |
| Kanický, V | 1 |
| Preisler, J | 1 |
| Navrátilová, J | 1 |
| Zhou, B | 3 |
| Mai, Z | 1 |
| Ye, Y | 3 |
| Xia, W | 1 |
| Qiu, X | 2 |
| Hamze, K | 1 |
| Abdallah, RH | 1 |
| Younis, NK | 1 |
| Fardoun, M | 1 |
| Darwiche, N | 1 |
| Kobeissy, F | 1 |
| Iratni, R | 1 |
| Bouhadir, K | 1 |
| Eid, AH | 1 |
| Robles, J | 1 |
| Pintado-Berninches, L | 1 |
| Boukich, I | 1 |
| Escudero, B | 1 |
| de Los Rios, V | 1 |
| Bartolomé, RA | 1 |
| Jaén, M | 1 |
| Martín-Regalado, Á | 1 |
| Fernandez-Aceñero, MJ | 1 |
| Imbaud, JI | 1 |
| Casal, JI | 1 |
| Khalij, Y | 1 |
| Belaid, I | 1 |
| Chouchane, S | 1 |
| Amor, D | 1 |
| Omezzine, A | 1 |
| Ben Rejeb, N | 1 |
| Ben Ahmed, S | 2 |
| Bouslama, A | 1 |
| Fang, Q | 1 |
| Zheng, X | 5 |
| Monzer, A | 1 |
| Wakimian, K | 1 |
| Ballout, F | 2 |
| Al Bitar, S | 1 |
| Yehya, A | 1 |
| Kanso, M | 1 |
| Saheb, N | 1 |
| Tawil, A | 1 |
| Doughan, S | 1 |
| Hussein, M | 3 |
| Mukherji, D | 3 |
| Faraj, W | 1 |
| Gali-Muhtasib, H | 2 |
| Abou-Kheir, W | 1 |
| Kibudde, S | 1 |
| Begg, W | 1 |
| Almashagbah, NA | 1 |
| Mahasneh, AA | 1 |
| Bodoor, KG | 1 |
| Wang, ZF | 1 |
| Kong, WR | 1 |
| Wang, N | 5 |
| You, YL | 1 |
| Wang, JF | 1 |
| Wang, SQ | 1 |
| Miarons, M | 1 |
| Riera, P | 1 |
| García-Gil, S | 1 |
| Gutiérrez-Nicolás, F | 2 |
| Matsuoka, H | 12 |
| Ohta, R | 2 |
| Yoshida, Y | 15 |
| Watanabe, T | 21 |
| Kosugi, C | 4 |
| Fukazawa, A | 3 |
| Matsuda, A | 3 |
| Yoshida, H | 6 |
| Hasegawa, S | 14 |
| Otsuka, T | 2 |
| Sakita, JY | 1 |
| Elias-Oliveira, J | 1 |
| Carlos, D | 1 |
| de Souza Santos, E | 1 |
| Almeida, LY | 1 |
| Malta, TM | 1 |
| Brunaldi, MO | 1 |
| Albuquerque, S | 1 |
| Araújo Silva, CL | 1 |
| Andrade, MV | 1 |
| Bonato, VLD | 1 |
| Garcia, SB | 1 |
| Cunha, FQ | 1 |
| Cebinelli, GCM | 1 |
| Martins, RB | 1 |
| Matthews, J | 1 |
| Colli, L | 1 |
| Martin, FL | 1 |
| Uyemura, SA | 1 |
| Kannen, V | 1 |
| Ko, HM | 1 |
| Jee, W | 1 |
| Park, DI | 1 |
| Kim, KI | 1 |
| Jung, JH | 2 |
| Jang, HJ | 1 |
| Wijler, LA | 1 |
| Dijk, FJ | 1 |
| Quirindongo, H | 1 |
| Raats, DAE | 1 |
| Dorresteijn, B | 1 |
| Furber, MJW | 1 |
| Kranenburg, O | 5 |
| van Dijk, M | 1 |
| Okamoto, K | 7 |
| Boldig, K | 1 |
| Ganguly, A | 1 |
| Kadakia, M | 1 |
| Rohatgi, A | 1 |
| Yang, D | 25 |
| Yang, SB | 1 |
| Sang, R | 1 |
| Deng, F | 1 |
| Engel, A | 1 |
| Goldys, E | 1 |
| Deng, W | 2 |
| Khatib, AW | 1 |
| Selub, SM | 1 |
| Uryvaey, A | 1 |
| Baranseh, J | 1 |
| Shai, A | 1 |
| Kimura, T | 4 |
| Wakabayashi, M | 1 |
| Kobori, S | 1 |
| Aoki, K | 2 |
| Minoshima, K | 1 |
| Doumoto, Y | 1 |
| Hosaka, M | 1 |
| Ushiku, H | 1 |
| Aisaki, K | 1 |
| Funatsu, K | 1 |
| Sakamoto, S | 2 |
| Tagai, N | 1 |
| Kurebayashi, H | 1 |
| Sawai, K | 1 |
| Morikawa, M | 2 |
| Koneri, K | 2 |
| Tamaki, M | 1 |
| Murakami, M | 5 |
| Hirono, Y | 1 |
| Goi, T | 2 |
| Miyata, R | 1 |
| Hanada, M | 1 |
| Ajihara, T | 1 |
| Naritomi, T | 1 |
| Fukuya, Y | 1 |
| Rendón, JP | 1 |
| Cañas, AI | 1 |
| Correa, E | 1 |
| Bedoya-Betancur, V | 1 |
| Naranjo, TW | 1 |
| Yamane, S | 1 |
| Kazama, H | 1 |
| Kanesada, K | 1 |
| Tsunedomi, R | 5 |
| Hazama, S | 14 |
| Ogihara, H | 1 |
| Hamamoto, Y | 9 |
| Shindo, Y | 3 |
| Matsui, H | 1 |
| Tokumitsu, Y | 2 |
| Yoshida, S | 9 |
| Iida, M | 2 |
| Suzuki, N | 8 |
| Takeda, S | 3 |
| Ioka, T | 1 |
| Nagano, H | 10 |
| Khalil, KA | 1 |
| Musallam, HS | 1 |
| Hassan, MA | 1 |
| Mahmoud, IA | 1 |
| Kumar, A | 1 |
| Singh, AK | 1 |
| Singh, H | 2 |
| Thareja, S | 1 |
| Kumar, P | 1 |
| Davis, SL | 1 |
| Hartman, SJ | 1 |
| Bagby, SM | 1 |
| Schlaepfer, M | 1 |
| Yacob, BW | 1 |
| Tse, T | 1 |
| Simmons, DM | 1 |
| Diamond, JR | 1 |
| Lieu, CH | 1 |
| Leal, AD | 1 |
| Cadogan, EB | 1 |
| Hughes, GD | 1 |
| Durant, ST | 1 |
| Messersmith, WA | 5 |
| Pitts, TM | 1 |
| Jurczyk, M | 1 |
| Midro, A | 1 |
| Król, M | 1 |
| Olesiak, W | 1 |
| Stąpor, D | 1 |
| Gil, A | 2 |
| Gil, K | 1 |
| Ludikhuize, MC | 1 |
| Gevers, S | 1 |
| Nguyen, NTB | 1 |
| Meerlo, M | 1 |
| Roudbari, SKS | 1 |
| Gulersonmez, MC | 1 |
| Stigter, ECA | 1 |
| Drost, J | 1 |
| Clevers, H | 3 |
| Burgering, BMT | 1 |
| Rodríguez Colman, MJ | 1 |
| Johnson, PA | 1 |
| Menegatti, S | 1 |
| Chambers, AC | 1 |
| Alibhai, D | 1 |
| Collard, TJ | 1 |
| Williams, AC | 1 |
| Bayley, H | 1 |
| Perriman, AW | 1 |
| Bruckner, HW | 2 |
| Bassali, F | 1 |
| Dusowitz, E | 1 |
| Gurell, D | 1 |
| Book, A | 1 |
| De Jager, R | 1 |
| Chang, C | 1 |
| Cao, D | 6 |
| Liu, XM | 2 |
| Zhu, WT | 2 |
| Jia, ML | 1 |
| Li, YT | 1 |
| Liu, ZQ | 2 |
| Yan, PK | 2 |
| Fulgenzi, CAM | 1 |
| Vetere, G | 1 |
| Citarella, F | 1 |
| Spagnoletti, A | 1 |
| Nappo, F | 1 |
| Tong, G | 1 |
| Parseghian, CM | 1 |
| Woods, M | 2 |
| Lee, HM | 5 |
| Alshenaifi, J | 1 |
| Willis, J | 1 |
| Nunez, S | 1 |
| Raghav, KP | 2 |
| Morris, VK | 2 |
| Shen, JP | 3 |
| Eluri, M | 1 |
| Sorokin, A | 2 |
| Kanikarla, P | 2 |
| Vilar, E | 2 |
| Rehn, M | 1 |
| Ang, A | 1 |
| Kopetz, S | 15 |
| Propper, DJ | 3 |
| Gao, F | 7 |
| Saunders, MP | 17 |
| Sarker, D | 1 |
| Hartley, JA | 1 |
| Spanswick, VJ | 1 |
| Lowe, HL | 1 |
| Hackett, LD | 1 |
| Ng, TT | 1 |
| Barber, PR | 1 |
| Weitsman, GE | 1 |
| Pearce, S | 2 |
| White, L | 1 |
| Lopes, A | 1 |
| Forsyth, S | 1 |
| Hochhauser, D | 2 |
| Sarradin, V | 1 |
| Betrian, S | 1 |
| Chaltiel, L | 1 |
| Brac De La Perriere, C | 1 |
| Delord, JP | 5 |
| LaCourse, KD | 3 |
| Zepeda-Rivera, M | 3 |
| Kempchinsky, AG | 3 |
| Baryiames, A | 3 |
| Minot, SS | 3 |
| Johnston, CD | 3 |
| Bullman, S | 3 |
| Beck, A | 3 |
| Fehrenbach, U | 3 |
| Mueller, L | 5 |
| Koenig, AO | 3 |
| V Weikersthal, LF | 3 |
| Goekkurt, E | 6 |
| Haas, S | 4 |
| Alig, AHS | 6 |
| Trarbach, T | 14 |
| Perrin, ML | 3 |
| Yardin, C | 3 |
| To, YH | 3 |
| Degeling, K | 3 |
| McCoy, M | 3 |
| Wong, R | 11 |
| Jones, I | 3 |
| Dunn, C | 4 |
| Hong, W | 5 |
| Loft, M | 3 |
| Gibbs, P | 22 |
| Tie, J | 6 |
| Okamoto, W | 5 |
| Sakai, K | 3 |
| Shitara, K | 13 |
| Nakano, Y | 7 |
| Hara, H | 4 |
| Miura, Y | 3 |
| Hironaka, S | 8 |
| Misumi, T | 3 |
| Nishio, K | 6 |
| Shah, MA | 4 |
| Grothey, A | 36 |
| Cervantes, A | 29 |
| Oh, SC | 4 |
| Fakih, M | 9 |
| Wu, C | 12 |
| Chiu, VK | 2 |
| Tomasek, J | 5 |
| Bendell, J | 5 |
| Fontaine, M | 2 |
| Hitron, M | 2 |
| Xu, B | 7 |
| Van Cutsem, E | 93 |
| Bae, J | 2 |
| Kwak, D | 2 |
| Kim, J | 6 |
| Phyu Hlaing, S | 2 |
| Saparbayeva, A | 2 |
| Hee Lee, E | 2 |
| Yoon, IS | 2 |
| Ryong Moon, H | 2 |
| Yoo, JW | 2 |
| Erol, C | 3 |
| Sendur Mehmet, AN | 2 |
| Bilgetekin, I | 2 |
| Garbioglu, DB | 2 |
| Hamdard, J | 3 |
| Akbas, S | 2 |
| Hizal, M | 2 |
| Arslan, C | 2 |
| Sevinc, A | 4 |
| Kucukarda, A | 3 |
| Erdem, D | 2 |
| Kahraman, S | 2 |
| Cakir, E | 2 |
| Demirkiran, A | 2 |
| On, S | 2 |
| Dogan, I | 2 |
| Erdogan, AP | 2 |
| Koca, S | 2 |
| Kubilay, P | 2 |
| Eren, OO | 2 |
| Cilbir, E | 2 |
| Celik, E | 2 |
| Araz, M | 3 |
| Ozyukseler, DT | 2 |
| Yildirim, ME | 2 |
| Bahceci, A | 2 |
| Taskaynatan, H | 2 |
| Oyman, A | 2 |
| Deniz, GI | 2 |
| Menekse, S | 2 |
| Kut, E | 2 |
| Gulmez, A | 2 |
| Sakin, A | 5 |
| Nayir, E | 2 |
| Acar, R | 2 |
| Sen, E | 2 |
| Inal, A | 3 |
| Turhal, S | 3 |
| Kaya, AO | 4 |
| Paydas, S | 2 |
| Tastekin, D | 2 |
| Hacibekiroglu, I | 3 |
| Cincin, I | 2 |
| Bilici, A | 4 |
| Mandel, NM | 2 |
| Dede, DS | 2 |
| Akinci, MB | 2 |
| Oksuzoglu, B | 3 |
| Uncu, D | 4 |
| Yalcin, B | 2 |
| Artac, M | 6 |
| Soueidy, C | 1 |
| Skaff, S | 1 |
| Stephan, F | 1 |
| Kattan, J | 1 |
| Hui, T | 1 |
| Qiu, Z | 1 |
| Mao, W | 1 |
| Peng, Q | 1 |
| Chang, H | 1 |
| El-Daly, SM | 1 |
| Abo-Elfadl, MT | 1 |
| Hussein, J | 1 |
| Abo-Zeid, MAM | 1 |
| Lu, K | 4 |
| Du, W | 3 |
| Sahin, IH | 1 |
| Imanirad, I | 1 |
| Felder, SI | 1 |
| Kim, RD | 3 |
| Xie, H | 2 |
| Vale, N | 1 |
| Pereira, M | 1 |
| Santos, J | 1 |
| Moura, C | 1 |
| Marques, L | 1 |
| Duarte, D | 1 |
| Nouibi, C | 1 |
| Cherif Chefchaouni, A | 1 |
| Bechar, H | 1 |
| Belahcen, MJ | 1 |
| Rahali, Y | 1 |
| Okuno, K | 8 |
| Kandimalla, R | 2 |
| Mendiola, M | 1 |
| Balaguer, F | 5 |
| Bujanda, L | 6 |
| Fernandez-Martos, C | 10 |
| Feliu, J | 9 |
| Tokunaga, M | 1 |
| Kinugasa, Y | 2 |
| Goel, A | 16 |
| Milewska, S | 1 |
| Siemiaszko, G | 1 |
| Wilczewska, AZ | 1 |
| Misztalewska-Turkowicz, I | 1 |
| Markiewicz, KH | 1 |
| Szymczuk, D | 1 |
| Lazny, R | 1 |
| Niemirowicz-Laskowska, K | 1 |
| Fekete, JT | 1 |
| Győrffy, B | 2 |
| Fan, R | 1 |
| Yin, Z | 2 |
| Huang, Y | 10 |
| Yuan, F | 1 |
| Yin, A | 2 |
| Tang, G | 2 |
| Pu, R | 1 |
| Yin, S | 1 |
| Zhen, Q | 1 |
| Wu, T | 6 |
| Yao, S | 5 |
| Feng, Y | 10 |
| Chen, C | 8 |
| Rodríguez, R | 4 |
| Alés Díaz, I | 1 |
| García-Ortiz, MV | 1 |
| Rivera, F | 38 |
| Tabernero, JM | 5 |
| Riesco, MC | 1 |
| Yusefi, M | 2 |
| Shameli, K | 2 |
| Lee-Kiun, MS | 1 |
| Teow, SY | 2 |
| Moeini, H | 1 |
| Ali, RR | 1 |
| Kia, P | 1 |
| Jie, CJ | 1 |
| Abdullah, NH | 1 |
| Janssens, K | 1 |
| Vanhoutte, G | 1 |
| Lybaert, W | 1 |
| Demey, W | 1 |
| Decaestecker, J | 2 |
| Hendrickx, K | 1 |
| Rezaei Kalantari, H | 2 |
| Zwaenepoel, K | 1 |
| Pauwels, P | 2 |
| Fransen, E | 1 |
| Op de Beeck, K | 1 |
| Van Camp, G | 1 |
| Rolfo, C | 2 |
| Peeters, M | 24 |
| Raga, MG | 1 |
| Pérez, IP | 1 |
| Veiga, RC | 1 |
| Sosa, MM | 1 |
| Aguilera, MJS | 1 |
| Rodríguez, PL | 1 |
| Bonastre, MTT | 1 |
| Urtasun, JA | 1 |
| Abad, LP | 1 |
| Hernández, IB | 1 |
| Li, F | 7 |
| Gu, NN | 1 |
| Shen, H | 1 |
| Han, CL | 1 |
| Li, KY | 1 |
| Yan, RY | 1 |
| Mi, ZK | 1 |
| Nakura, M | 1 |
| Nojima, K | 1 |
| Yamazaki, H | 1 |
| Takenaka, S | 1 |
| Takeshita, M | 1 |
| Sasaki, S | 3 |
| Fujimura, T | 1 |
| Suda, K | 2 |
| Chiku, T | 1 |
| Fukuyama, M | 1 |
| Shinoda, K | 1 |
| Hashiba, H | 1 |
| Sano, W | 1 |
| Ando, K | 2 |
| Ni, M | 2 |
| Chen, A | 1 |
| Dai, W | 1 |
| Jiang, R | 1 |
| Ling, Y | 2 |
| Yao, Q | 2 |
| Kocak, MZ | 1 |
| Er, M | 1 |
| Ugrakli, M | 1 |
| Hendem, E | 1 |
| Eryilmaz, MK | 1 |
| Proietti, A | 1 |
| Niccoli, C | 1 |
| Fanotto, V | 1 |
| Di Donato, S | 8 |
| Bergamo, F | 25 |
| Fontanini, G | 14 |
| Ugolini, C | 3 |
| Kaneko, J | 2 |
| Isogai, J | 2 |
| Hayashi, K | 7 |
| Takatsuno, Y | 1 |
| Okamoto, S | 2 |
| Hayakawa, T | 1 |
| Maejima, K | 1 |
| Iwamoto, K | 2 |
| Hyuga, S | 1 |
| Ohashi, T | 1 |
| Nakahara, Y | 2 |
| Furukawa, K | 4 |
| Moon, J | 2 |
| Asaoka, T | 2 |
| Shibasaki, Y | 1 |
| Yokobori, T | 1 |
| Sohda, M | 1 |
| Shioi, I | 1 |
| Ozawa, N | 1 |
| Komine, C | 1 |
| Suga, K | 1 |
| Nakazawa, N | 1 |
| Osone, K | 1 |
| Shiraishi, T | 4 |
| Okada, T | 5 |
| Sano, A | 1 |
| Sakai, M | 1 |
| Ogawa, H | 2 |
| Kaira, K | 2 |
| Shirabe, K | 6 |
| Saeki, H | 9 |
| Godlewska, K | 1 |
| Zapora, E | 1 |
| Chen, Q | 7 |
| Song, H | 1 |
| Xing, W | 1 |
| Song, X | 5 |
| Zhao, W | 3 |
| Ghidini, M | 4 |
| Dottorini, L | 2 |
| Iaculli, A | 1 |
| Ghidini, A | 4 |
| Luciani, A | 2 |
| Yue, Y | 1 |
| Ogawa, T | 2 |
| Kawamoto, S | 1 |
| Yamamoto, K | 7 |
| Atarashi, M | 1 |
| Terashima, T | 2 |
| Kurogi, N | 1 |
| Yan, Q | 3 |
| Lai, Q | 3 |
| Fang, Y | 4 |
| Tan, J | 2 |
| Li, A | 6 |
| Danişman-Kalindemirtaş, F | 1 |
| Özerkan, D | 1 |
| Kariper, İA | 1 |
| Bulut, H | 1 |
| Brockmueller, A | 2 |
| Samuel, SM | 1 |
| Mazurakova, A | 1 |
| Büsselberg, D | 1 |
| Kubatka, P | 1 |
| Shakibaei, M | 8 |
| Su, Y | 2 |
| Choi, HS | 1 |
| Choi, JH | 3 |
| Jang, YS | 1 |
| Seo, JW | 1 |
| Okamura, M | 2 |
| Nakamura, T | 11 |
| Peng, S | 3 |
| Xie, Y | 2 |
| Shen, D | 1 |
| Zhu, M | 2 |
| Huang, M | 3 |
| Luo, Y | 6 |
| Gan, Y | 2 |
| Wang, R | 8 |
| Han, S | 1 |
| Rong, P | 1 |
| Gong, W | 2 |
| Chai, R | 1 |
| Wan, Z | 1 |
| Zheng, B | 3 |
| Hu, X | 5 |
| Chen, B | 4 |
| Dai, Q | 3 |
| Yu, P | 1 |
| Tu, S | 1 |
| Girisa, S | 1 |
| Kunnumakkara, AB | 3 |
| Jakubauskas, M | 1 |
| Jakubauskiene, L | 1 |
| Leber, B | 2 |
| Horvath, A | 1 |
| Strupas, K | 3 |
| Stiegler, P | 2 |
| Schemmer, P | 3 |
| Zhu, R | 2 |
| Hu, G | 2 |
| Tao, K | 1 |
| Tao, F | 1 |
| Lu, Z | 4 |
| Beechinor, RJ | 1 |
| Abidalhassan, MF | 1 |
| Small, DF | 1 |
| Hoang, HK | 1 |
| Lamba, R | 1 |
| Loehfelm, TW | 1 |
| Foster, CC | 1 |
| Koontz, MZ | 1 |
| Kim, EJ | 1 |
| Mindt, S | 1 |
| Lück, A | 1 |
| Hutzschenreuter, U | 1 |
| Kollendt, M | 1 |
| Lathan, B | 1 |
| Zöller, T | 1 |
| Frank-Gleich, S | 1 |
| Lorentz, C | 1 |
| Lamberti, C | 3 |
| Sick, C | 1 |
| Zingerle, M | 1 |
| Tesch, H | 1 |
| Stein, W | 1 |
| Hebart, H | 4 |
| Stosiek, C | 1 |
| Sandner, R | 1 |
| Fries, S | 1 |
| Burkholder, I | 3 |
| Hofheinz, RD | 13 |
| Moreno-Londoño, AP | 1 |
| Castañeda-Patlán, MC | 1 |
| Sarabia-Sánchez, MA | 1 |
| Macías-Silva, M | 1 |
| Robles-Flores, M | 1 |
| Bré, J | 1 |
| Dickson, AL | 1 |
| Read, OJ | 1 |
| McKissock, FG | 1 |
| Mullen, P | 1 |
| Tang, P | 1 |
| Zickuhr, GM | 1 |
| Czekster, CM | 1 |
| Harrison, DJ | 2 |
| Yuwono, KA | 1 |
| Hutajulu, SH | 1 |
| Gofir, A | 1 |
| Nugroho, DB | 1 |
| Maughan, T | 9 |
| McDermott, R | 2 |
| Bodoky, G | 14 |
| André, T | 58 |
| Teske, AJ | 1 |
| Pfeiffer, P | 25 |
| Seitz, R | 1 |
| Catteau, A | 1 |
| Salvatore, L | 21 |
| McGregor, K | 2 |
| Leonetti, S | 1 |
| Papiani, G | 1 |
| Bensi, M | 1 |
| Murgioni, S | 3 |
| Ross, DT | 1 |
| Boquet, I | 1 |
| Nielsen, TJ | 1 |
| Galon, J | 1 |
| Varga, MG | 1 |
| Schweitzer, BL | 1 |
| Zheng, Z | 4 |
| Han, J | 4 |
| Guo, G | 1 |
| Guo, P | 2 |
| Li, D | 5 |
| Yan, Y | 2 |
| Niu, W | 2 |
| Meng, Z | 2 |
| Yu, B | 5 |
| Kang, S | 1 |
| Lee, MW | 1 |
| Song, IC | 1 |
| Lee, HJ | 8 |
| Yun, HJ | 1 |
| Jo, DY | 1 |
| Kwon, JH | 2 |
| Lee, KH | 11 |
| Ryu, H | 1 |
| De Falco, V | 1 |
| Della Corte, CM | 1 |
| Anderson, A | 1 |
| Fowlkes, NW | 1 |
| Villareal, OE | 1 |
| Coker, O | 1 |
| Morris, V | 3 |
| Altucci, L | 1 |
| Song, M | 1 |
| Di, M | 1 |
| Pan, Q | 3 |
| Du, Y | 6 |
| Xiang, T | 1 |
| He, J | 7 |
| Weng, D | 1 |
| Xia, JC | 1 |
| Kurasaka, C | 1 |
| Nishizawa, N | 1 |
| Uozumi, H | 1 |
| Ogino, Y | 2 |
| Sato, A | 14 |
| Sun, Y | 12 |
| Ni, X | 2 |
| Fu, Z | 2 |
| Liu, R | 5 |
| Zhang, CY | 1 |
| Ohori, H | 4 |
| Yuasa, Y | 2 |
| Miwa, K | 11 |
| Oki, E | 15 |
| Naitoh, T | 1 |
| Komatsu, Y | 19 |
| Hihara, M | 1 |
| Soeda, J | 1 |
| Akagi, K | 1 |
| Ochiai, A | 3 |
| Tsuchihara, K | 3 |
| Kauffels, A | 1 |
| Nowack, H | 1 |
| Bohnenberger, H | 2 |
| Spitzner, M | 3 |
| Sprenger, T | 1 |
| Ghadimi, M | 1 |
| Sperling, J | 2 |
| Yeku, OO | 1 |
| Longo, DL | 1 |
| Jahedi, M | 1 |
| Meshkini, A | 1 |
| Källberg, J | 1 |
| Harrison, A | 1 |
| March, V | 1 |
| Bērziņa, S | 1 |
| Nemazanyy, I | 1 |
| Kepp, O | 1 |
| Kroemer, G | 1 |
| Mouillet-Richard, S | 1 |
| Laurent-Puig, P | 19 |
| Taly, V | 1 |
| Xiao, W | 2 |
| Sun, S | 9 |
| Bian, Z | 5 |
| Liu, M | 5 |
| You, X | 1 |
| Santos, A | 1 |
| Cristóbal, I | 5 |
| Caramés, C | 3 |
| Luque, M | 1 |
| Sanz-Álvarez, M | 1 |
| Madoz-Gúrpide, J | 4 |
| Rojo, F | 6 |
| García-Foncillas, J | 11 |
| Mao, C | 1 |
| Ji, D | 2 |
| Ding, Y | 6 |
| Song, W | 2 |
| Song, L | 1 |
| Feng, X | 3 |
| Xu, N | 5 |
| Fukumori, C | 1 |
| Branco, PC | 1 |
| Barreto, T | 1 |
| Ishida, K | 4 |
| Lopes, LB | 1 |
| Zaidi, MY | 1 |
| Nussbaum, DP | 1 |
| Hsu, SD | 3 |
| Uronis, HE | 3 |
| Rea, CG | 1 |
| Borgonovo, K | 4 |
| Dognini, G | 2 |
| Parati, MC | 2 |
| Petrò, D | 1 |
| Ghilardi, M | 6 |
| Kataoka, K | 4 |
| Takeuchi, J | 1 |
| Ito, K | 9 |
| Beppu, N | 2 |
| Ceelen, W | 6 |
| Kanemitsu, Y | 9 |
| Ajioka, Y | 1 |
| Endo, I | 5 |
| Ikeda, M | 9 |
| Kuribayashi, M | 1 |
| Nomura, K | 1 |
| Yarimizu, A | 1 |
| Hirata, M | 1 |
| Ohashi, E | 1 |
| Kimura, K | 4 |
| Takenaka, Y | 1 |
| Yanagawa, T | 2 |
| Nishimura, Y | 2 |
| Uchino, M | 1 |
| Ikeuchi, H | 4 |
| Situ, Y | 1 |
| Thakur, A | 1 |
| Chorawala, MR | 1 |
| Patel, RS | 1 |
| Dote, S | 2 |
| Shiwaku, E | 1 |
| Kohno, E | 1 |
| Fujii, R | 2 |
| Mashimo, K | 2 |
| Morimoto, N | 2 |
| Yoshino, M | 3 |
| Odaira, N | 1 |
| Ikesue, H | 1 |
| Hirabatake, M | 1 |
| Takagi, M | 2 |
| Nishiuma, S | 1 |
| Shimato, A | 1 |
| Itakura, S | 2 |
| Shigemori, M | 1 |
| Watanabe, H | 4 |
| Hayasaka, D | 1 |
| Nakao, M | 2 |
| Tasaka, M | 1 |
| Goto, E | 2 |
| Kataoka, N | 1 |
| Yokomizo, A | 1 |
| Kobayashi, A | 2 |
| Nakata, Y | 2 |
| Miyake, M | 2 |
| Hayashi, Y | 2 |
| Hirata, T | 2 |
| Azuma, K | 1 |
| Makihara, K | 1 |
| Fukui, R | 1 |
| Tokutome, A | 1 |
| Yagisawa, K | 1 |
| Honda, S | 2 |
| Meguro, Y | 1 |
| Suzuki, S | 7 |
| Yamaguchi, D | 1 |
| Miyata, H | 1 |
| Kobayashi, Y | 11 |
| Yousef, AM | 3 |
| Zeineddine, FA | 1 |
| Zeineddine, MA | 1 |
| Tidwell, RS | 1 |
| Beaty, KA | 1 |
| Scofield, LC | 1 |
| Rafeeq, S | 1 |
| Hornstein, N | 1 |
| Lano, E | 1 |
| Eng, C | 15 |
| Matamoros, A | 1 |
| Foo, WC | 1 |
| Uppal, A | 1 |
| Scally, C | 1 |
| Mansfield, P | 1 |
| Taggart, M | 1 |
| Overman, MJ | 7 |
| Fournier, K | 1 |
| Huang, MY | 8 |
| Huang, YJ | 1 |
| Cheng, TL | 4 |
| Jhang, WY | 1 |
| Ke, CC | 1 |
| Chen, YT | 3 |
| Kuo, SH | 1 |
| Lin, IL | 1 |
| Huang, YH | 1 |
| Chuang, CH | 1 |
| Niger, M | 5 |
| Bustreo, S | 2 |
| Procaccio, L | 1 |
| Cupini, S | 12 |
| Libertini, M | 3 |
| Palermo, F | 4 |
| Kumarasamy, V | 1 |
| Kuppusamy, UR | 2 |
| Jayalakshmi, P | 1 |
| Govind, SK | 1 |
| Imai, K | 7 |
| Xia, J | 2 |
| He, S | 5 |
| Jia, H | 2 |
| Ge, Y | 1 |
| Zhou, M | 3 |
| Khalili-Tanha, G | 2 |
| Fiuji, H | 3 |
| Gharib, M | 1 |
| Moghbeli, M | 1 |
| Khalili-Tanha, N | 1 |
| Shakour, N | 1 |
| Anvari, K | 1 |
| Mozafari, MR | 1 |
| Batra, J | 1 |
| Chung, J | 1 |
| Chang, J | 1 |
| Parise, RA | 1 |
| Chu, E | 24 |
| Schmitz, JC | 3 |
| Valizadeh, M | 1 |
| Babaei, E | 1 |
| Sharifi, R | 1 |
| Yazdanbod, A | 1 |
| Tan, T | 1 |
| Mayanagi, S | 1 |
| Kanda, M | 3 |
| Honda, M | 4 |
| Kashiwabara, K | 1 |
| Muto, M | 5 |
| Yamagishi, H | 3 |
| Yoshikawa, T | 4 |
| Satake, M | 2 |
| Tanaka, H | 5 |
| Higashida, M | 3 |
| Fujiwara, Y | 7 |
| Ueno, T | 3 |
| Eucker, J | 1 |
| Pihusch, R | 1 |
| Müller, C | 3 |
| Burkart, C | 1 |
| Kasper-Virchow, S | 1 |
| Krammer-Steiner, B | 1 |
| Prager, GW | 1 |
| Geng, S | 1 |
| Zhan, H | 1 |
| Cao, L | 3 |
| Geng, L | 3 |
| Ren, X | 1 |
| Meng, L | 1 |
| Thapa, R | 1 |
| Delgado, MG | 1 |
| Gomez, MF | 1 |
| Ji, R | 1 |
| Knepper, TC | 1 |
| Hubbard, JM | 1 |
| Permuth, JB | 1 |
| Laber, DA | 1 |
| Tam, SY | 1 |
| Islam Khan, MZ | 1 |
| Chen, JY | 1 |
| Yip, JH | 1 |
| Yan, HY | 1 |
| Tam, TY | 1 |
| Law, HK | 1 |
| Wei, PL | 1 |
| Huang, CY | 1 |
| Chang, TC | 2 |
| Lin, JC | 1 |
| Lee, CC | 1 |
| Prince, GMSH | 1 |
| Makondi, PT | 1 |
| Chui, AW | 1 |
| Chang, YJ | 1 |
| Frerker, B | 1 |
| Bock, F | 1 |
| Cappel, ML | 1 |
| Kriesen, S | 1 |
| Klautke, G | 2 |
| Hildebrandt, G | 1 |
| Manda, K | 1 |
| Fukuda, K | 4 |
| Osumi, H | 5 |
| Yoshino, K | 2 |
| Nakayama, I | 4 |
| Fukuoka, S | 1 |
| Ogura, M | 10 |
| Wakatsuki, T | 8 |
| Ooki, A | 6 |
| Takahari, D | 14 |
| Chin, K | 10 |
| Hsiao, KC | 1 |
| Ruan, SY | 1 |
| Chen, SM | 1 |
| Lai, TY | 1 |
| Chan, RH | 1 |
| Zhang, YM | 1 |
| Chu, CA | 1 |
| Cheng, HC | 1 |
| Tsai, HW | 1 |
| Tu, YF | 1 |
| Chang, TT | 1 |
| Chow, NH | 1 |
| Chiang, CW | 1 |
| Wang, CY | 3 |
| Shao, C | 1 |
| McDonald, AC | 1 |
| Amonkar, MM | 1 |
| Bortnichak, EA | 1 |
| König, AO | 2 |
| Caca, K | 1 |
| Kretzschmar, A | 5 |
| Nichetti, F | 2 |
| Wasan, HS | 4 |
| Meade, AM | 11 |
| Díaz-Rubio, E | 41 |
| Fisher, D | 9 |
| Pang, Y | 2 |
| Hu, J | 13 |
| Ballhausen, A | 1 |
| Meyer-Knees, JW | 1 |
| Chang, W | 8 |
| Fu, J | 3 |
| Lin, Q | 4 |
| Zhu, Z | 2 |
| Tang, W | 5 |
| Cioce, M | 1 |
| Fumagalli, MR | 1 |
| Donzelli, S | 1 |
| Goeman, F | 1 |
| Canu, V | 1 |
| Rutigliano, D | 1 |
| Orlandi, G | 1 |
| Sacconi, A | 1 |
| Pulito, C | 1 |
| Palcau, AC | 1 |
| Fanciulli, M | 1 |
| Morrone, A | 1 |
| Diodoro, MG | 2 |
| Caricato, M | 5 |
| Crescenzi, A | 1 |
| Verri, M | 1 |
| Fazio, VM | 1 |
| Zapperi, S | 1 |
| Levrero, M | 1 |
| Strano, S | 1 |
| Grazi, GL | 2 |
| La Porta, C | 1 |
| Blandino, G | 1 |
| Fang, X | 2 |
| Zhong, C | 2 |
| Xiao, Q | 2 |
| Xu, D | 3 |
| Liao, X | 1 |
| Dong, C | 2 |
| Ding, K | 3 |
| Blachman, A | 1 |
| Birocco, AM | 1 |
| Curcio, S | 1 |
| Camperi, SA | 1 |
| Gianvincenzo, PD | 1 |
| Rodriguez, JA | 1 |
| Barredo-Vacchelli, GR | 1 |
| Cenci, G | 1 |
| Sosnik, A | 1 |
| Moya, S | 1 |
| Calabrese, GC | 1 |
| Katipally, RR | 1 |
| Martinez, CA | 1 |
| Pugh, SA | 1 |
| Bridgewater, JA | 1 |
| Primrose, JN | 8 |
| Domingo, E | 4 |
| Talamonti, MS | 1 |
| Posner, MC | 1 |
| Weichselbaum, RR | 1 |
| Pitroda, SP | 1 |
| Zhao, R | 3 |
| Ren, L | 7 |
| Ye, Q | 4 |
| Cui, Y | 5 |
| He, G | 3 |
| Feng, Q | 2 |
| Zhu, D | 4 |
| Zhou, G | 1 |
| Liang, F | 4 |
| Ye, F | 1 |
| Fan, J | 5 |
| Abbasi, S | 1 |
| Rivand, H | 1 |
| Eshaghi, F | 1 |
| Moosavi, MA | 1 |
| Amanpour, S | 1 |
| McDermott, MF | 1 |
| Rahmati, M | 1 |
| Lee, K | 3 |
| Cho, S | 2 |
| Kang, DU | 1 |
| Park, S | 4 |
| Kang, Y | 2 |
| Choe, G | 1 |
| Moon, KC | 1 |
| Lee, KS | 4 |
| Park, JH | 7 |
| Hong, C | 3 |
| Nateghi, R | 1 |
| Pourakpour, F | 1 |
| Jahromi, SAF | 1 |
| Khani, A | 1 |
| Kim, HR | 4 |
| Choi, DH | 1 |
| Han, CH | 1 |
| Kwak, JT | 1 |
| Han, B | 2 |
| Ho, DJ | 1 |
| Kang, GH | 9 |
| Chun, SY | 1 |
| Jeong, WK | 1 |
| Park, P | 1 |
| Kocyigit, A | 1 |
| Guler, EM | 1 |
| Durmus, E | 1 |
| Yenigun, VB | 1 |
| Kanimdan, E | 1 |
| Ozman, Z | 1 |
| Yasar, O | 1 |
| Goren, AC | 1 |
| Hekimoglu, ER | 1 |
| Oruc, HH | 1 |
| Aydogdu, G | 1 |
| Susan, M | 1 |
| Macasoi, I | 1 |
| Pinzaru, I | 1 |
| Dehelean, C | 1 |
| Ilia, I | 1 |
| Susan, R | 1 |
| Ionita, I | 1 |
| Teng, P | 1 |
| Fei, B | 2 |
| Ling, F | 1 |
| Ding, W | 1 |
| Wu, JZ | 1 |
| Liu, AC | 1 |
| Jiang, LL | 1 |
| Zhang, HC | 1 |
| Meng, Y | 1 |
| Liu, BY | 2 |
| Peng, GJ | 1 |
| Lou, EZ | 1 |
| Mao, Q | 1 |
| Tang, DL | 1 |
| Liu, JB | 1 |
| Shi, XP | 1 |
| Putri, S | 1 |
| Saldi, SRF | 1 |
| Khoe, LC | 2 |
| Setiawan, E | 1 |
| Megraini, A | 1 |
| Santatiwongchai, B | 1 |
| Nugraha, RR | 1 |
| Permanasari, VY | 1 |
| Nadjib, M | 1 |
| Sastroasmoro, S | 2 |
| Armansyah, A | 2 |
| Marisi, G | 2 |
| Azzali, I | 1 |
| Rebuzzi, F | 1 |
| Bartolini, G | 2 |
| Urbini, M | 1 |
| Canale, M | 1 |
| Molinari, C | 1 |
| Matteucci, L | 2 |
| Sullo, FG | 1 |
| Debonis, SA | 1 |
| Gallio, C | 1 |
| Gallo, G | 1 |
| Frassineti, GL | 9 |
| Ulivi, P | 1 |
| Wang, XB | 1 |
| Wang, XW | 1 |
| Jiang, YH | 1 |
| Ye, W | 4 |
| Shao, CF | 1 |
| Xie, JJ | 1 |
| Hashimoto, T | 2 |
| Mizusawa, J | 3 |
| Kataoka, T | 2 |
| Fukuda, H | 3 |
| Tsukamoto, S | 4 |
| Hamaguchi, T | 22 |
| Alzahrani, SM | 1 |
| Al Doghaither, HA | 1 |
| Al-Ghafari, AB | 1 |
| Pushparaj, PN | 1 |
| Verheij, FS | 2 |
| Kuhlmann, KFD | 3 |
| Silliman, DR | 2 |
| Soares, KC | 2 |
| Kingham, TP | 7 |
| Balachandran, VP | 4 |
| Drebin, JA | 3 |
| Wei, AC | 2 |
| Jarnagin, WR | 10 |
| Cercek, A | 7 |
| Kok, NFM | 4 |
| Kemeny, NE | 21 |
| Yuki, S | 11 |
| Sunakawa, Y | 18 |
| Takahashi, N | 6 |
| Asano, C | 1 |
| Abe, Y | 1 |
| Nomura, S | 1 |
| Raunkilde, L | 1 |
| Hansen, TF | 9 |
| Havelund, BM | 1 |
| Thomsen, CB | 1 |
| Rafaelsen, SR | 1 |
| Lindebjerg, J | 7 |
| Jensen, LH | 4 |
| Juřica, J | 1 |
| Šuverová, P | 1 |
| Goněc, R | 1 |
| Synek, S | 1 |
| Turjap, M | 1 |
| Badr, D | 1 |
| Fouad, MA | 1 |
| Salem, S | 1 |
| Zekri, A | 1 |
| Shouman, S | 1 |
| Shibata, Y | 4 |
| Matsumoto, N | 1 |
| Murase, R | 1 |
| Kubota, Y | 3 |
| Shimada, K | 12 |
| Fujita, KI | 2 |
| La, X | 2 |
| Tian, J | 1 |
| Xi, Y | 4 |
| Bai, W | 2 |
| An, L | 2 |
| Jamialahmadi, H | 1 |
| Nazari, SE | 1 |
| TanzadehPanah, H | 2 |
| Saburi, E | 1 |
| Khojasteh-Leylakoohi, F | 1 |
| Alaei, M | 1 |
| Mirahmadi, M | 1 |
| Babaei, F | 1 |
| Asghari, SZ | 1 |
| Mansouri, S | 1 |
| Binabaj, MM | 1 |
| Al-Asady, AM | 1 |
| Soleimani, A | 1 |
| Mehraban, S | 1 |
| Ghorbani, E | 1 |
| Ryzhikov, M | 1 |
| Cartwright, BM | 1 |
| Corso, JN | 1 |
| Lightner, J | 1 |
| Whitted, C | 1 |
| Torrenegra, RD | 1 |
| Krishnan, K | 1 |
| Palau, VE | 1 |
| Ghalambor, T | 1 |
| Cavnar, MJ | 1 |
| Merkow, RP | 1 |
| Dominguez-Rosado, I | 1 |
| Karanicolas, PJ | 1 |
| Rocha, FG | 1 |
| Fields, RC | 1 |
| Patel, RA | 1 |
| Kennecke, HF | 1 |
| Koerkamp, BG | 1 |
| Yopp, AC | 1 |
| Petrowsky, H | 3 |
| Mahalingam, D | 1 |
| Kemeny, N | 32 |
| D'Angelica, M | 5 |
| Piringer, G | 1 |
| Thaler, J | 6 |
| Anchisi, S | 2 |
| Geffriaud-Ricouard, C | 1 |
| Gueldner, M | 1 |
| Scholten, F | 1 |
| Derigs, HG | 1 |
| Bohanes, P | 4 |
| Grünberger, B | 1 |
| Schwarz, L | 1 |
| von Moos, R | 5 |
| Qin, W | 2 |
| Zhou, R | 2 |
| Mihara, Y | 1 |
| Hirasaki, M | 1 |
| Horita, Y | 5 |
| Fujino, T | 2 |
| Fukushima, H | 2 |
| Kamakura, Y | 1 |
| Uranishi, K | 1 |
| Hirano, Y | 1 |
| Ryozawa, S | 1 |
| Yasuda, M | 1 |
| Makino, Y | 1 |
| Shibazaki, S | 1 |
| Silveira, MJ | 1 |
| Martins, C | 1 |
| Cruz, T | 1 |
| Castro, F | 1 |
| Amorim-Costa, Â | 1 |
| Chester, K | 1 |
| Oliveira, MJ | 1 |
| Sarmento, B | 1 |
| Brañes, A | 1 |
| Karanicolas, P | 1 |
| Qiu, F | 2 |
| Yu, Q | 4 |
| Xi, X | 1 |
| Du, B | 2 |
| Jasinevicius, A | 1 |
| Vaitiekaite, G | 1 |
| Aleksandraviciute, B | 1 |
| Eidenaite, E | 2 |
| Sudeikis, L | 1 |
| Azarifar, Z | 1 |
| Amini, R | 2 |
| Afshar, S | 1 |
| Najafi, R | 5 |
| Malka, D | 15 |
| Verret, B | 1 |
| Faron, M | 4 |
| Caramella, C | 2 |
| Edeline, J | 1 |
| Bengrine-Lefevre, L | 7 |
| Dupont-Bierre, E | 1 |
| Goéré, D | 15 |
| Dartigues, P | 4 |
| Lacroix, L | 2 |
| Boige, V | 26 |
| Gelli, M | 4 |
| Pignon, JP | 15 |
| Ghelardi, F | 1 |
| De Grandis, MC | 1 |
| Barsotti, G | 1 |
| Formica, V | 6 |
| Boscolo, G | 2 |
| Cinieri, S | 7 |
| Ambrosini, M | 1 |
| Piva, VM | 1 |
| Dong, W | 2 |
| Jiang, T | 5 |
| Zeng, J | 3 |
| Jiang, X | 4 |
| Taniguchi, SH | 1 |
| Komine, K | 1 |
| Takenaga, N | 1 |
| Kawamura, Y | 2 |
| Kasahara, Y | 1 |
| Ouchi, K | 1 |
| Imai, H | 1 |
| Saijo, K | 1 |
| Shirota, H | 1 |
| Ishioka, C | 5 |
| Lian, J | 1 |
| Okumura, S | 2 |
| Goumard, C | 1 |
| Gayet, B | 3 |
| Fuks, D | 1 |
| Scatton, O | 1 |
| Lyskjær, I | 2 |
| Kronborg, CS | 1 |
| Rasmussen, MH | 4 |
| Sørensen, BS | 2 |
| Demuth, C | 1 |
| Rosenkilde, M | 1 |
| Johansen, AFB | 2 |
| Knudsen, M | 2 |
| Vang, S | 1 |
| Krag, SRP | 1 |
| Spindler, KG | 3 |
| Andersen, CL | 4 |
| Pooresmaeil, M | 1 |
| Behzadi Nia, S | 1 |
| Namazi, H | 1 |
| Pentheroudakis, G | 8 |
| Mavroeidis, L | 1 |
| Papadopoulou, K | 1 |
| Koliou, GA | 2 |
| Bamia, C | 1 |
| Chatzopoulos, K | 1 |
| Samantas, E | 7 |
| Mauri, D | 1 |
| Efstratiou, I | 2 |
| Pectasides, D | 8 |
| Makatsoris, T | 5 |
| Bafaloukos, D | 6 |
| Papakostas, P | 7 |
| Papatsibas, G | 1 |
| Bombolaki, I | 1 |
| Chrisafi, S | 1 |
| Kourea, HP | 1 |
| Petraki, K | 1 |
| Kafiri, G | 1 |
| Fountzilas, G | 18 |
| Kotoula, V | 4 |
| Ariyoshi, N | 1 |
| Miyauchi, H | 2 |
| Ohira, G | 1 |
| Kaneya, N | 1 |
| Arai, K | 7 |
| Yamazaki, S | 3 |
| Matsubara, H | 4 |
| Suzuki, T | 20 |
| Ishii, I | 1 |
| Fu, S | 2 |
| Gao, W | 1 |
| Lei, Y | 1 |
| Shao, J | 1 |
| Xie, K | 1 |
| Maletzki, C | 1 |
| Bock, S | 1 |
| Fruh, P | 1 |
| Macius, K | 1 |
| Witt, A | 1 |
| Prall, F | 1 |
| Almeida Junior, JC | 1 |
| Helal-Neto, E | 1 |
| Pinto, SR | 1 |
| Dos Santos, SN | 1 |
| Bernardes, ES | 1 |
| Al-Qahtani, M | 1 |
| Nigro, F | 1 |
| Alencar, LMR | 1 |
| Ricci-Junior, E | 1 |
| Santos-Oliveira, R | 1 |
| Shindoh, J | 4 |
| Kinowaki, K | 1 |
| Gonoi, W | 3 |
| Tani, K | 1 |
| Matoba, S | 3 |
| Kuroyanagi, H | 2 |
| Hashimoto, M | 7 |
| Munemoto, Y | 7 |
| Nakamura, M | 15 |
| Kuroda, H | 2 |
| Minagawa, N | 1 |
| Touyama, T | 5 |
| Takahashi, T | 24 |
| Kurosawa, S | 2 |
| Miura, T | 10 |
| Khakoo, S | 1 |
| Pedley, I | 1 |
| Ellis, R | 3 |
| Steward, W | 3 |
| Harrison, M | 4 |
| Baijal, S | 1 |
| Tahir, S | 1 |
| Ross, P | 5 |
| Raouf, S | 4 |
| Ograbek, A | 1 |
| Cunningham, D | 93 |
| Wang, QX | 1 |
| Lv, L | 2 |
| Ye, DR | 1 |
| Sun, YH | 1 |
| Pan, XX | 1 |
| Bhandari, A | 2 |
| Zhang, XH | 1 |
| Wang, OC | 1 |
| Liu, HG | 1 |
| Bonadio, RC | 1 |
| Amor Divino, PH | 1 |
| Obando, JSM | 1 |
| Lima, KCA | 1 |
| Recchimuzzi, DZ | 1 |
| Kruger, JAP | 1 |
| Saragiotto, DF | 2 |
| Capareli, FC | 2 |
| Hoff, PM | 34 |
| Conradi, LC | 1 |
| Metzger, AL | 1 |
| Kisly, M | 1 |
| Middel, P | 1 |
| Gaedcke, J | 3 |
| Ghadimi, MB | 1 |
| Liersch, T | 5 |
| Rüschoff, J | 2 |
| Beißbarth, T | 2 |
| Grade, M | 2 |
| Kim, HG | 1 |
| Kim, CW | 3 |
| Lee, DH | 1 |
| Oh, ET | 1 |
| Park, HJ | 2 |
| Abdel-Rahman, O | 10 |
| Karachiwala, H | 1 |
| Ottaiano, A | 5 |
| Scala, S | 1 |
| Napolitano, M | 1 |
| Capozzi, M | 1 |
| Rachiglio, AM | 4 |
| Roma, C | 2 |
| Trotta, AM | 1 |
| D'Alterio, C | 1 |
| Portella, L | 1 |
| Romano, C | 4 |
| Cassata, A | 5 |
| Casaretti, R | 13 |
| Silvestro, L | 2 |
| Nappi, A | 3 |
| Tafuto, S | 8 |
| Tamburini, M | 1 |
| Picone, C | 1 |
| Petrillo, A | 6 |
| Izzo, F | 8 |
| Palaia, R | 4 |
| Albino, V | 2 |
| Amore, A | 1 |
| Belli, A | 1 |
| Pace, U | 1 |
| Di Marzo, M | 1 |
| Chiodini, P | 1 |
| Botti, G | 4 |
| De Feo, G | 2 |
| Delrio, P | 7 |
| Nasti, G | 11 |
| Chen, N | 1 |
| Kong, Y | 2 |
| Geng, Q | 1 |
| Labriet, A | 2 |
| Lévesque, É | 3 |
| De Mattia, E | 7 |
| Villeneuve, L | 2 |
| Rouleau, M | 1 |
| Jonker, D | 6 |
| Couture, F | 6 |
| Simonyan, D | 2 |
| Allain, EP | 1 |
| D'Andrea, M | 7 |
| Guillemette, C | 3 |
| Geissler, M | 4 |
| Wilson, R | 3 |
| Price, T | 12 |
| Tracy, M | 1 |
| Burdon, P | 2 |
| Oshiro, H | 1 |
| Tome, Y | 1 |
| Kiyuna, T | 1 |
| Yoon, SN | 2 |
| Lwin, TM | 1 |
| Han, Q | 4 |
| Miyake, K | 1 |
| Higuchi, T | 6 |
| Sugisawa, N | 1 |
| Katsuya, Y | 1 |
| Zang, Z | 1 |
| Razmjooei, S | 1 |
| Bouvet, M | 3 |
| Clary, B | 2 |
| Singh, SR | 3 |
| Kanaya, F | 1 |
| Nishida, K | 3 |
| Hoffman, RM | 4 |
| Morine, Y | 1 |
| Ikemoto, T | 1 |
| Iwahashi, S | 1 |
| Saito, YU | 1 |
| Higashijima, J | 3 |
| Imura, S | 1 |
| Shepelytskyi, Y | 1 |
| Fox, MS | 1 |
| Davenport, K | 1 |
| Li, T | 4 |
| Albert, MS | 1 |
| Davenport, E | 1 |
| Cao, Y | 6 |
| Chang, Q | 1 |
| Ornatsky, O | 1 |
| Hedley, D | 2 |
| Chen, EX | 2 |
| Tang, X | 1 |
| Che, G | 1 |
| Yu, Y | 8 |
| He, L | 8 |
| Wang, ZH | 3 |
| Liu, JM | 2 |
| Li, CY | 3 |
| Lv, H | 3 |
| Lv, SW | 1 |
| Zhao, N | 1 |
| Ma, H | 2 |
| Lo Dico, R | 3 |
| Kaci, R | 2 |
| Naneix, AL | 2 |
| Malgras, B | 1 |
| Mathonnet, M | 6 |
| Xu, M | 4 |
| Pan, B | 1 |
| Qin, J | 1 |
| Xu, T | 2 |
| Zeng, K | 1 |
| Pan, Y | 5 |
| He, B | 3 |
| Sun, H | 3 |
| Nohria, A | 1 |
| Mohammadpour, S | 1 |
| Goodarzi, HR | 1 |
| Jafarinia, M | 1 |
| Porhoseingholi, MA | 1 |
| Nazemalhosseini-Mojarad, E | 1 |
| Opattova, A | 2 |
| Horak, J | 1 |
| Vodenkova, S | 2 |
| Kostovcikova, K | 1 |
| Cumova, A | 1 |
| Macinga, P | 1 |
| Galanova, N | 1 |
| Rejhova, A | 1 |
| Vodickova, L | 3 |
| Kozics, K | 1 |
| Turnovcova, K | 1 |
| Hucl, T | 3 |
| Sliva, D | 1 |
| Vodicka, P | 8 |
| Yamadera, M | 1 |
| Shinto, E | 2 |
| Kajiwara, Y | 1 |
| Mochizuki, S | 2 |
| Hase, K | 2 |
| Yamamoto, J | 4 |
| Zucchelli, G | 5 |
| Urbano, F | 2 |
| Ronzoni, M | 14 |
| Ricci, V | 7 |
| Cordio, S | 7 |
| Boni, L | 12 |
| Dho, SH | 1 |
| Cho, EH | 1 |
| Lee, SY | 2 |
| Jung, SH | 3 |
| Kim, LK | 1 |
| Lim, JC | 1 |
| Rao, S | 6 |
| Peri, S | 1 |
| Hoffmann, J | 1 |
| Cai, KQ | 1 |
| Harris, B | 1 |
| Rhodes, M | 1 |
| Connolly, DC | 1 |
| Testa, JR | 1 |
| Wiest, DL | 1 |
| Allard, MA | 2 |
| Beghdadi, N | 1 |
| Kitano, Y | 1 |
| Kokudo, T | 1 |
| Yamashita, YI | 1 |
| Sa Cunha, A | 2 |
| Vibert, E | 2 |
| Elias, D | 19 |
| Cherqui, D | 2 |
| Ooft, SN | 1 |
| Weeber, F | 1 |
| Dijkstra, KK | 1 |
| McLean, CM | 1 |
| Kaing, S | 1 |
| Schipper, L | 1 |
| Hoes, L | 1 |
| Vis, DJ | 1 |
| van de Haar, J | 1 |
| Prevoo, W | 2 |
| Snaebjornsson, P | 3 |
| van der Velden, D | 1 |
| Klein, M | 1 |
| Chalabi, M | 2 |
| Boot, H | 7 |
| van Leerdam, M | 1 |
| Bloemendal, HJ | 1 |
| Beerepoot, LV | 1 |
| Wessels, L | 1 |
| Cuppen, E | 1 |
| Voest, EE | 3 |
| Hou, L | 1 |
| Zhu, L | 6 |
| Hou, Y | 3 |
| Zou, H | 1 |
| Gu, Y | 5 |
| Weng, X | 1 |
| Gaiddon, C | 1 |
| Meng, X | 1 |
| Matsumoto, H | 14 |
| Ishihara, Y | 4 |
| Masumoto, S | 1 |
| Kawamoto, K | 1 |
| Takayanagi, K | 1 |
| Sawazaki, S | 1 |
| Ju, M | 1 |
| Morita, J | 1 |
| Komori, K | 3 |
| Maezawa, Y | 1 |
| Amano, S | 1 |
| Mushiake, H | 3 |
| Masuda, M | 3 |
| Kassentoft, CG | 1 |
| Laursen, MB | 1 |
| Madsen, AH | 1 |
| Iversen, LH | 1 |
| Sunesen, KG | 1 |
| Kong, XX | 1 |
| Zhou, JJ | 2 |
| Song, YM | 2 |
| Huang, XF | 1 |
| Li, GH | 1 |
| Ying, XJ | 2 |
| Dai, XY | 1 |
| Jiang, K | 2 |
| Fu, DL | 1 |
| He, JJ | 1 |
| Wang, JW | 4 |
| Sun, LF | 1 |
| Xu, JY | 1 |
| Li, JS | 1 |
| Yan, M | 3 |
| Ding, KF | 2 |
| Auvray, M | 1 |
| Artru, P | 18 |
| Hautefeuille, V | 3 |
| Sickersen, G | 1 |
| Coriat, R | 9 |
| Vernerey, D | 2 |
| Deng, R | 3 |
| Shi, L | 3 |
| Zhu, W | 2 |
| Guan, X | 3 |
| Shen, B | 3 |
| Shi, H | 3 |
| Tao, J | 1 |
| Shen, R | 1 |
| Sanchez-Vazquez, B | 1 |
| Lee, JB | 1 |
| Strimaite, M | 1 |
| Buanz, A | 1 |
| Bailey, R | 1 |
| Gershkovich, P | 1 |
| Pasparakis, G | 1 |
| Williams, GR | 2 |
| Lim, HH | 1 |
| Hopkins, AM | 1 |
| Rowland, A | 1 |
| Yuen, HY | 1 |
| Karapetis, CS | 7 |
| Sorich, MJ | 1 |
| Catalano, V | 12 |
| Vincenzi, B | 15 |
| Negri, F | 1 |
| Giordani, P | 5 |
| Alessandroni, P | 4 |
| Stragliotto, S | 1 |
| Sarti, D | 1 |
| Rocchi, MBL | 1 |
| Zagonel, V | 13 |
| Mattioli, R | 7 |
| Graziano, F | 13 |
| Tai, CC | 1 |
| Chen, WS | 14 |
| Jiang, JK | 11 |
| Yang, SH | 10 |
| Wang, HS | 10 |
| Chang, SC | 8 |
| Lan, YT | 5 |
| Lin, CC | 7 |
| Lin, HH | 3 |
| Huang, SC | 1 |
| Cheng, HH | 1 |
| Chao, Y | 1 |
| Teng, HW | 5 |
| Stramucci, L | 2 |
| Pranteda, A | 2 |
| Stravato, A | 1 |
| Amoreo, CA | 2 |
| Pennetti, A | 1 |
| Bartolazzi, A | 1 |
| Milella, M | 2 |
| Bossi, G | 2 |
| Siraj, AK | 1 |
| Kumar Parvathareddy, S | 1 |
| Pratheeshkumar, P | 1 |
| Padmaja Divya, S | 1 |
| Ahmed, SO | 1 |
| Melosantos, R | 1 |
| Begum, R | 1 |
| Concepcion, RMJA | 1 |
| Al-Sanea, N | 1 |
| Ashari, LH | 1 |
| Abduljabbar, A | 1 |
| Al-Dayel, F | 1 |
| Al-Kuraya, KS | 1 |
| Zhu, G | 3 |
| Zhao, M | 6 |
| Sun, YU | 2 |
| Ye, J | 3 |
| Kim, HB | 1 |
| Lim, HJ | 1 |
| Park, SG | 1 |
| Cheng, X | 2 |
| Long, D | 1 |
| Nakajima, Y | 4 |
| Kajiwara, A | 1 |
| Sakaki, M | 1 |
| Otoyama, Y | 1 |
| Nishihara, S | 1 |
| Usami, T | 1 |
| Nakatani, S | 1 |
| Wong, WWL | 1 |
| Zargar, M | 1 |
| Berry, SR | 2 |
| Ko, YJ | 4 |
| Riesco-Martínez, M | 2 |
| Chan, KKW | 2 |
| Agrawal, S | 2 |
| Woźniak, M | 1 |
| Łuc, M | 1 |
| Makuch, S | 1 |
| Pielka, E | 1 |
| Agrawal, AK | 1 |
| Wietrzyk, J | 3 |
| Banach, J | 1 |
| Gamian, A | 1 |
| Pizon, M | 1 |
| Ziółkowski, P | 1 |
| Wang, DS | 2 |
| Chen, G | 14 |
| Peng, JW | 3 |
| Deng, YH | 2 |
| Zhang, JW | 2 |
| Liang, HL | 2 |
| Feng, F | 2 |
| Xie, CB | 1 |
| Ren, C | 2 |
| Fan, WH | 2 |
| Ding, PR | 4 |
| Paccard, C | 1 |
| Chiron, M | 2 |
| Chang, CY | 2 |
| Pan, TM | 2 |
| Gu, J | 8 |
| Dong, D | 2 |
| Long, E | 1 |
| Tang, S | 2 |
| Feng, S | 2 |
| Raina, AJ | 1 |
| Gilbar, PJ | 1 |
| Grewal, GD | 1 |
| Holcombe, DJ | 1 |
| Lobefaro, R | 1 |
| Antista, M | 3 |
| Mosconi, S | 3 |
| Rimassa, L | 8 |
| Longarini, R | 3 |
| Farina, G | 1 |
| Gori, S | 3 |
| Corallo, S | 8 |
| Guarini, V | 1 |
| Martinetti, A | 4 |
| Macagno, M | 1 |
| Barault, L | 1 |
| Perrone, F | 6 |
| Tamborini, E | 1 |
| Milione, M | 4 |
| Di Nicolantonio, F | 1 |
| Fucà, G | 3 |
| de Braud, F | 19 |
| Igarashi, H | 1 |
| Nosho, K | 1 |
| Ishigami, K | 1 |
| Koide, H | 1 |
| Mitsuhashi, K | 1 |
| Okita, K | 3 |
| Takemasa, I | 8 |
| Nakase, H | 1 |
| Park, GB | 1 |
| Jeong, JY | 1 |
| Kim, D | 2 |
| Buchler, T | 9 |
| Cervena, K | 1 |
| Veskrnova, V | 2 |
| Vymetalkova, V | 5 |
| Zhou, T | 3 |
| Zheng, JH | 1 |
| Lin, SR | 7 |
| Tseng, FJ | 1 |
| Tsai, MJ | 1 |
| Lue, SI | 1 |
| Chia, YC | 1 |
| Woon, M | 1 |
| Fu, YS | 1 |
| Weng, CF | 1 |
| Guan, Q | 2 |
| Yan, H | 2 |
| Jiang, B | 5 |
| Yan, D | 3 |
| Ge, H | 1 |
| Liu, F | 11 |
| Ai, FY | 1 |
| Zhang, DC | 1 |
| Tian, L | 1 |
| Yang, ZY | 1 |
| Liu, SJ | 1 |
| Islam, SMA | 1 |
| Dey, A | 1 |
| Patel, R | 4 |
| Smalley, T | 1 |
| Acevedo-Duncan, M | 1 |
| Yao, Z | 3 |
| Zhao, S | 3 |
| Mi, Q | 1 |
| Zou, J | 3 |
| Du, Q | 2 |
| de Boer, NL | 2 |
| Brandt-Kerkhof, ARM | 3 |
| Madsen, EVE | 3 |
| Diepeveen, M | 1 |
| van Meerten, E | 5 |
| van Eerden, RAG | 1 |
| de Man, FM | 1 |
| Bouamar, R | 1 |
| Koolen, SLW | 1 |
| de Hingh, IHJT | 4 |
| Bakkers, C | 4 |
| Rovers, KP | 4 |
| Creemers, GM | 5 |
| Deenen, MJ | 3 |
| Kranenburg, OW | 1 |
| Constantinides, A | 1 |
| Mathijssen, RHJ | 1 |
| Burger, JWA | 4 |
| Kitazawa, M | 1 |
| Hatta, T | 1 |
| Sasaki, Y | 18 |
| Fukui, K | 1 |
| Ogawa, K | 10 |
| Fukuda, E | 1 |
| Goshima, N | 1 |
| Okita, N | 3 |
| Yamada, Y | 32 |
| Nakagama, H | 1 |
| Natsume, T | 2 |
| Horimoto, K | 1 |
| Moritani, K | 1 |
| Katayama, H | 1 |
| Chen, RM | 1 |
| Chiou, YS | 1 |
| Chong, QY | 1 |
| Poh, HM | 1 |
| Tan, TZ | 1 |
| Zhang, MY | 1 |
| Ma, L | 9 |
| Zhu, T | 2 |
| Pandey, V | 1 |
| Kumar, AP | 1 |
| Lobie, PE | 1 |
| Lindner, AU | 2 |
| Resler, AJ | 1 |
| Carberry, S | 3 |
| Oficjalska, K | 1 |
| Bacon, O | 3 |
| Lee, CS | 2 |
| Choudhry, A | 1 |
| Burke, JP | 1 |
| Sheahan, K | 3 |
| Cremona, M | 1 |
| Hennessy, BT | 2 |
| McNamara, D | 2 |
| Doherty, G | 1 |
| Ryan, EJ | 2 |
| Prehn, JHM | 2 |
| Iveson, T | 10 |
| Kerr, RS | 2 |
| Robles-Zurita, J | 1 |
| Briggs, AH | 1 |
| Cassidy, J | 51 |
| Hollander, NH | 5 |
| Haydon, A | 2 |
| Glimelius, B | 52 |
| Harkin, A | 4 |
| Allan, K | 2 |
| McQueen, J | 2 |
| Pearson, S | 1 |
| Waterston, A | 2 |
| Medley, L | 2 |
| Wilson, C | 3 |
| Essapen, S | 3 |
| Dhadda, AS | 2 |
| Falk, S | 9 |
| Rees, C | 3 |
| Olesen, RK | 2 |
| Propper, D | 4 |
| Bridgewater, J | 13 |
| Azzabi, A | 2 |
| Farrugia, D | 2 |
| Webb, A | 9 |
| Hickish, T | 12 |
| Weaver, A | 3 |
| Gollins, S | 7 |
| Wasan, H | 9 |
| Paul, J | 3 |
| Ma, CJ | 9 |
| Yeh, YS | 8 |
| Chang, YT | 2 |
| Sveen, A | 1 |
| Dienstmann, R | 2 |
| Wirapati, P | 2 |
| Neureiter, D | 3 |
| Al-Batran, S | 1 |
| Aderka, D | 2 |
| Tejpar, S | 14 |
| Okuyama, H | 1 |
| Nogami, W | 1 |
| Tona, Y | 1 |
| Tanaka, Y | 9 |
| Lu, W | 1 |
| Fu, D | 1 |
| Kong, X | 2 |
| Hwang, M | 1 |
| Kennecke, H | 3 |
| Berry, S | 5 |
| Maroun, J | 11 |
| Kavan, P | 2 |
| Aucoin, N | 1 |
| Poulin-Costello, M | 1 |
| Gillesby, B | 1 |
| Ron, DA | 1 |
| Labandeira, CM | 1 |
| Manrique, MCA | 1 |
| Núñez, MÁ | 1 |
| Cid, NG | 1 |
| Mata, JG | 1 |
| Montes, AF | 2 |
| Sheng, W | 1 |
| Dong, M | 3 |
| Hu, M | 2 |
| Guan, K | 1 |
| Hendricks, A | 1 |
| Rosenstiel, P | 1 |
| Hinz, S | 1 |
| Burmeister, G | 1 |
| Röcken, C | 3 |
| Boersch, K | 1 |
| Schafmayer, C | 1 |
| Becker, T | 3 |
| Franke, A | 1 |
| Forster, M | 1 |
| Shi, Y | 8 |
| Wan, X | 2 |
| Tan, C | 3 |
| Francescangeli, F | 1 |
| Contavalli, P | 2 |
| De Angelis, ML | 1 |
| Careccia, S | 1 |
| Signore, M | 2 |
| Haas, TL | 1 |
| Salaris, F | 1 |
| Baiocchi, M | 1 |
| Boe, A | 1 |
| Giuliani, A | 1 |
| Tcheremenskaia, O | 1 |
| Pagliuca, A | 1 |
| Guardiola, O | 1 |
| Minchiotti, G | 1 |
| Colace, L | 1 |
| Ciardi, A | 1 |
| D'Andrea, V | 1 |
| La Torre, F | 1 |
| Medema, J | 1 |
| De Maria, R | 3 |
| Zeuner, A | 1 |
| von Einem, JC | 8 |
| Michl, M | 5 |
| Rosa, F | 3 |
| Susova, S | 3 |
| Bendova, P | 2 |
| Levy, M | 3 |
| Kral, J | 1 |
| Bartu, L | 1 |
| Hughes, DJ | 1 |
| Soucek, P | 4 |
| Naccarati, A | 5 |
| Kumar, R | 2 |
| Pardini, B | 4 |
| Tamjidifar, R | 2 |
| Akbari, M | 2 |
| Tarzi, S | 2 |
| Sadeghzadeh, M | 1 |
| Abolghasemi, M | 1 |
| Poursaei, E | 1 |
| Shomali, N | 2 |
| Mahdavi, F | 1 |
| Dyhl-Polk, A | 1 |
| Vaage-Nilsen, M | 1 |
| Schou, M | 1 |
| Vistisen, KK | 2 |
| Lund, CM | 2 |
| Kümler, T | 1 |
| Appel, JM | 1 |
| Nielsen, DL | 3 |
| Liu, XY | 2 |
| Zheng, CB | 1 |
| Gou, LS | 1 |
| Qi, X | 3 |
| Zeng, X | 3 |
| Chang, CW | 1 |
| Lee, HC | 2 |
| Li, LH | 2 |
| Chiang Chiau, JS | 1 |
| Wang, TE | 1 |
| Chuang, WH | 1 |
| Chen, MJ | 3 |
| Wang, HY | 1 |
| Shih, SC | 1 |
| Liu, CY | 4 |
| Tsai, TH | 1 |
| Chen, YJ | 2 |
| Chouliaras, K | 1 |
| Russell, G | 1 |
| Levine, E | 2 |
| Howerton, R | 1 |
| Votanopoulos, K | 1 |
| Clark, C | 1 |
| Shen, P | 4 |
| Luput, L | 1 |
| Sesarman, A | 1 |
| Porfire, A | 1 |
| Achim, M | 1 |
| Muntean, D | 1 |
| Casian, T | 1 |
| Patras, L | 1 |
| Rauca, VF | 1 |
| Drotar, DM | 1 |
| Stejerean, I | 1 |
| Tomuta, I | 1 |
| Vlase, L | 1 |
| Dragos, N | 1 |
| Toma, VA | 1 |
| Licarete, E | 1 |
| Banciu, M | 1 |
| Milczarek, M | 2 |
| Chodyński, M | 1 |
| Pietraszek, A | 1 |
| Stachowicz-Suhs, M | 1 |
| Yasuda, K | 5 |
| Sakaki, T | 2 |
| Kutner, A | 2 |
| Sueur, B | 2 |
| Zaanan, A | 4 |
| de la Fouchardiére, C | 4 |
| Des Guetz, G | 9 |
| Touchefeu, Y | 3 |
| Ferru, A | 1 |
| Evrard, C | 1 |
| Chautard, R | 1 |
| Gentilhomme, L | 1 |
| Henriques, J | 2 |
| Cohen, R | 1 |
| Chiang, TY | 1 |
| Hsu, HC | 5 |
| Jane, SW | 1 |
| Chen, SC | 3 |
| Dent, P | 1 |
| Booth, L | 1 |
| Roberts, JL | 1 |
| Poklepovic, A | 1 |
| Hancock, JF | 1 |
| Mansoori, B | 2 |
| Mohammadi, A | 1 |
| Abedi-Gaballu, F | 1 |
| Abbaspour, S | 1 |
| Ghasabi, M | 1 |
| Yekta, R | 1 |
| Shirjang, S | 1 |
| Dehghan, G | 1 |
| Hamblin, MR | 1 |
| Baradaran, B | 2 |
| Carter, AM | 1 |
| Shiu, KK | 2 |
| Spooner, C | 1 |
| Stevens, D | 1 |
| Mullamitha, S | 1 |
| Dercle, L | 1 |
| Schwartz, LH | 3 |
| Qian, M | 1 |
| Eggleton, P | 1 |
| Zhao, B | 2 |
| Piessevaux, H | 2 |
| Cao, G | 4 |
| Ju, Z | 1 |
| Jin, D | 1 |
| Hsu, HT | 1 |
| Wu, LM | 1 |
| Lin, PC | 7 |
| Juan, CH | 1 |
| Huang, YY | 1 |
| Chou, PL | 1 |
| Chen, JL | 1 |
| Holma, R | 2 |
| Laatikainen, R | 1 |
| Orell, H | 1 |
| Joensuu, H | 6 |
| Peuhkuri, K | 2 |
| Poussa, T | 4 |
| Korpela, R | 4 |
| Rousseau, B | 1 |
| Granger, V | 1 |
| Gornet, JM | 1 |
| Lievre, A | 10 |
| Bignon-Bretagne, AL | 1 |
| Metges, JP | 2 |
| Baba-Hamed, N | 1 |
| Michel, P | 7 |
| Obled, S | 2 |
| Vitellius, C | 1 |
| Saban-Roche, L | 1 |
| Buecher, B | 2 |
| Trouilloud, I | 1 |
| Dior, M | 2 |
| Manfredi, S | 4 |
| Soularue, E | 1 |
| Phelip, JM | 8 |
| Vernery, D | 1 |
| Scherr, AL | 1 |
| Jassowicz, A | 1 |
| Pató, A | 1 |
| Elssner, C | 1 |
| Ismail, L | 1 |
| Schmitt, N | 1 |
| Hoffmeister, P | 1 |
| Neukirch, L | 1 |
| Gdynia, G | 1 |
| Goeppert, B | 1 |
| Schulze-Bergkamen, H | 4 |
| Jäger, D | 4 |
| Köhler, BC | 1 |
| Gao, P | 4 |
| Ding, H | 2 |
| Fang, L | 4 |
| Labianca, R | 31 |
| Galli, F | 3 |
| Rulli, E | 4 |
| Cardellino, GG | 3 |
| Mambrini, A | 2 |
| Banzi, M | 1 |
| Pusceddu, V | 2 |
| Zampino, M | 1 |
| Marchetti, P | 9 |
| Sobrero, A | 34 |
| Elnahry, AG | 1 |
| Elnahry, GA | 1 |
| Wei, L | 5 |
| Wen, J | 1 |
| Wu, D | 1 |
| Mata, E | 1 |
| González, E | 8 |
| Juez, I | 2 |
| Alonso, V | 7 |
| Iranzo, P | 1 |
| Martínez, NP | 1 |
| López, C | 2 |
| Cabrera, JM | 1 |
| González, B | 1 |
| Escudero, P | 14 |
| Pericay, C | 9 |
| Hashimoto, Y | 2 |
| Miyazaki, M | 11 |
| Aisu, N | 7 |
| Kajitani, R | 2 |
| Munechika, T | 1 |
| Matsumoto, Y | 8 |
| Shimaoka, H | 1 |
| Komono, A | 2 |
| Sakamoto, R | 1 |
| Yoshimatsu, G | 2 |
| Yoshimura, F | 2 |
| Kiyomi, F | 1 |
| Fan, Q | 1 |
| Lv, W | 1 |
| Dong, Y | 4 |
| Xiang, Z | 1 |
| Xu, R | 3 |
| Zhu, B | 1 |
| Lin, X | 4 |
| Ma, D | 7 |
| Cai, X | 4 |
| Fang, W | 2 |
| Fang, H | 3 |
| Ye, ML | 1 |
| Zhang, YP | 1 |
| Li, WJ | 1 |
| Li, MT | 1 |
| Wang, HZ | 1 |
| Yin, JW | 1 |
| Hu, Q | 2 |
| Wei, WH | 1 |
| Chang, Y | 2 |
| Yamaguchi, S | 9 |
| Ito, S | 1 |
| Torashima, Y | 1 |
| Okada, S | 3 |
| Enjoji, T | 1 |
| Tetsuo, H | 1 |
| Kuba, S | 1 |
| Kosaka, T | 2 |
| Adachi, T | 2 |
| Hidaka, M | 1 |
| Yamanouchi, K | 1 |
| Kanetaka, K | 1 |
| Takatsuki, M | 2 |
| Eguchi, S | 3 |
| Luo, DD | 2 |
| Wan, SB | 2 |
| Qu, XJ | 2 |
| Di Maggio, G | 1 |
| Giuliani, F | 15 |
| Pisconti, S | 8 |
| Rinaldi, A | 4 |
| Febbraro, A | 3 |
| Aieta, M | 2 |
| Rizzi, D | 5 |
| Colucci, G | 19 |
| Ma, S | 1 |
| Lin, T | 1 |
| Zhao, G | 4 |
| Inaba, Y | 16 |
| Aramaki, T | 4 |
| Sone, M | 2 |
| Nishiofuku, H | 6 |
| Tanaka, T | 19 |
| Matsueda, K | 4 |
| Arai, Y | 12 |
| Pothuraju, R | 1 |
| Rachagani, S | 1 |
| Krishn, SR | 1 |
| Chaudhary, S | 1 |
| Nimmakayala, RK | 1 |
| Siddiqui, JA | 1 |
| Ganguly, K | 1 |
| Lakshmanan, I | 1 |
| Cox, JL | 1 |
| Mallya, K | 1 |
| Kaur, S | 1 |
| Batra, SK | 1 |
| Han, YS | 2 |
| Lee, SH | 8 |
| Teramachi, H | 2 |
| Mundo, AI | 1 |
| Greening, GJ | 1 |
| Fahr, MJ | 1 |
| Hale, LN | 1 |
| Bullard, EA | 1 |
| Rajaram, N | 1 |
| Muldoon, TJ | 1 |
| Ren, TJ | 1 |
| Hou, JF | 1 |
| Shan, FX | 1 |
| Clarke, SJ | 11 |
| Burge, M | 6 |
| Feeney, K | 1 |
| Jones, K | 1 |
| Marx, G | 1 |
| Molloy, MP | 2 |
| Reece, WHH | 1 |
| Segelov, E | 4 |
| Das, S | 1 |
| Allen, A | 1 |
| Lv, X | 1 |
| Fukuzaki, T | 2 |
| Okimura, S | 1 |
| Taniguchi, Y | 1 |
| Fukata, T | 1 |
| Nishida, H | 1 |
| Takayama, O | 1 |
| Yoshioka, S | 1 |
| Hojo, S | 1 |
| Ohigashi, H | 1 |
| Tokuno, K | 2 |
| Harada, E | 1 |
| Hamano, K | 3 |
| Sakamoto, T | 2 |
| Murakami, K | 3 |
| Katsura, Y | 2 |
| Omura, Y | 1 |
| Masuzawa, T | 1 |
| Takeno, A | 1 |
| Moon, D | 2 |
| Kang, HK | 1 |
| Yoon, SP | 2 |
| Ma, R | 2 |
| Cao, H | 2 |
| Bendell, JC | 13 |
| Sauri, T | 1 |
| Gracián, AC | 1 |
| Alvarez, R | 3 |
| López-López, C | 2 |
| Miron, ML | 1 |
| Montagut, C | 5 |
| Vivas, CS | 1 |
| Bessudo, A | 1 |
| Plezia, P | 1 |
| Moons, V | 1 |
| Andel, J | 1 |
| Bennouna, J | 17 |
| van der Westhuizen, A | 1 |
| Samuel, L | 3 |
| Rossomanno, S | 1 |
| Boetsch, C | 1 |
| Lahr, A | 1 |
| Franjkovic, I | 1 |
| Heil, F | 1 |
| Lechner, K | 1 |
| Krieter, O | 2 |
| Hurwitz, H | 9 |
| Swierz, MJ | 1 |
| Storman, D | 1 |
| Riemsma, RP | 1 |
| Wolff, R | 2 |
| Mitus, JW | 1 |
| Pedziwiatr, M | 1 |
| Kleijnen, J | 2 |
| Bala, MM | 1 |
| Glynne-Jones, R | 4 |
| Denecke, T | 2 |
| Pratschke, J | 5 |
| Lang, H | 4 |
| Bemelmans, M | 2 |
| Rentsch, M | 2 |
| Seehofer, D | 3 |
| Bruns, CJ | 2 |
| Gebauer, B | 2 |
| Neumann, UP | 4 |
| Ricard, I | 6 |
| Wang, C | 9 |
| Zhao, C | 2 |
| Peng, Y | 6 |
| Feng, Z | 1 |
| Huang, H | 5 |
| Nakamoto, Y | 1 |
| Noda, M | 4 |
| Mikami, R | 1 |
| Tokunaga, Y | 5 |
| Okumoto, T | 1 |
| Kawamura, T | 2 |
| Fujiwara, H | 2 |
| Doi, S | 1 |
| Tomita, N | 6 |
| Mao, J | 1 |
| Du, P | 2 |
| Yang, HT | 1 |
| Wang, SY | 1 |
| Cheng, ZB | 1 |
| Buhrmann, C | 5 |
| Popper, B | 4 |
| Majeed, M | 1 |
| Aggarwal, BB | 4 |
| Hua, L | 1 |
| Feng, C | 2 |
| Mo, Q | 1 |
| Wei, M | 1 |
| Shen, Y | 4 |
| Taniguchi, K | 4 |
| Lee, MY | 2 |
| Bandu, R | 1 |
| Komura, K | 1 |
| Lee, KY | 2 |
| Kim, KP | 12 |
| Sastre, J | 24 |
| Orden, V | 1 |
| Martínez, A | 1 |
| Bando, I | 2 |
| Balbín, M | 1 |
| Bellosillo, B | 1 |
| Palanca, S | 1 |
| Peligros Gomez, MI | 1 |
| Mediero, B | 1 |
| Llovet, P | 1 |
| Moral, VM | 1 |
| Viéitez, JM | 5 |
| Calle, SG | 1 |
| Quintero, G | 5 |
| Das, M | 2 |
| Yang, Q | 3 |
| Bi, Y | 1 |
| Zhang, C | 12 |
| Shi, X | 4 |
| Horst, D | 2 |
| Berger, MD | 12 |
| Ning, Y | 14 |
| Cao, S | 26 |
| Miyamoto, Y | 17 |
| Suenaga, M | 28 |
| Schirripa, M | 24 |
| Hanna, DL | 4 |
| Puccini, A | 4 |
| Tokunaga, R | 5 |
| Naseem, M | 4 |
| Piastra, V | 1 |
| Fratantonio, D | 1 |
| Chang, CC | 2 |
| Chao, KC | 1 |
| Huang, CJ | 2 |
| Hung, CS | 1 |
| Wang, YC | 3 |
| Innominato, PF | 8 |
| Ballesta, A | 1 |
| Huang, Q | 7 |
| Focan, C | 23 |
| Chollet, P | 8 |
| Karaboué, A | 8 |
| Giacchetti, S | 16 |
| Bouchahda, M | 6 |
| Garufi, C | 20 |
| Lévi, FA | 4 |
| Maltseva, D | 1 |
| Raygorodskaya, M | 1 |
| Knyazev, E | 1 |
| Zgoda, V | 1 |
| Tikhonova, O | 1 |
| Zaidi, S | 1 |
| Nikulin, S | 1 |
| Baranova, A | 1 |
| Turchinovich, A | 1 |
| Rodin, S | 1 |
| Tonevitsky, A | 1 |
| Rezvani, H | 1 |
| Mortazavizadeh, SM | 1 |
| Allahyari, A | 1 |
| Nekuee, A | 1 |
| Najafi, SN | 1 |
| Vahidfar, M | 1 |
| Ghadyani, M | 1 |
| Khosravi, A | 1 |
| Qarib, S | 1 |
| Sadeghi, A | 1 |
| Esfandbod, M | 1 |
| Rajaeinejad, M | 1 |
| Rezvani, A | 1 |
| Hajiqolami, A | 1 |
| Payandeh, M | 2 |
| Shazad, B | 1 |
| Anjidani, N | 1 |
| Meskinimood, S | 1 |
| Alikhasi, A | 1 |
| Karbalaeian, M | 1 |
| Salari, S | 1 |
| Ren, Y | 1 |
| Cai, R | 1 |
| Yin, M | 1 |
| Kitagawa, Y | 6 |
| Ota, Y | 2 |
| Kim, S | 13 |
| Choung, S | 1 |
| Sun, RX | 1 |
| Ung, N | 1 |
| Hashemi, N | 1 |
| Fong, EJ | 1 |
| Lau, R | 1 |
| Spiller, E | 1 |
| Gasho, J | 1 |
| Foo, J | 1 |
| Mumenthaler, SM | 2 |
| Tantawy, MA | 1 |
| El-Sherbeeny, NA | 1 |
| Helmi, N | 1 |
| Alazragi, R | 1 |
| Salem, N | 1 |
| Elaidy, SM | 1 |
| Oh, HK | 1 |
| Cho, JY | 1 |
| Kim, DW | 3 |
| Kang, SB | 3 |
| Jheon, S | 1 |
| Okuno, M | 2 |
| Hatano, E | 5 |
| Toda, R | 1 |
| Nishino, H | 3 |
| Nakamura, K | 6 |
| Ishii, T | 3 |
| Seo, S | 4 |
| Taura, K | 3 |
| Yasuchika, K | 3 |
| Yazawa, T | 3 |
| Zaima, M | 3 |
| Kanazawa, A | 7 |
| Terajima, H | 3 |
| Kaihara, S | 2 |
| Adachi, Y | 7 |
| Inoue, N | 5 |
| Furumoto, K | 2 |
| Manaka, D | 4 |
| Tokuka, A | 1 |
| Furuyama, H | 2 |
| Doi, K | 3 |
| Hirose, T | 3 |
| Horimatsu, T | 6 |
| Matsumoto, S | 13 |
| Uemoto, S | 3 |
| Wu, P | 1 |
| Zhu, H | 5 |
| Zhuang, Y | 1 |
| Gu, N | 1 |
| Zheng, J | 7 |
| Yang, B | 1 |
| Zhong, D | 2 |
| Lin, M | 5 |
| Lai, J | 1 |
| Hou, P | 1 |
| Funasaka, C | 1 |
| Kanemasa, Y | 1 |
| Shimoyama, T | 4 |
| Cho, H | 1 |
| Omuro, Y | 2 |
| Wen, C | 3 |
| Zhou, Q | 6 |
| Yu, WK | 1 |
| Okazaki, S | 9 |
| Ishikawa, T | 10 |
| Takahashi, G | 4 |
| Iwai, T | 6 |
| Takeda, K | 6 |
| Ueda, K | 2 |
| Kuriyama, S | 3 |
| Koizumi, M | 3 |
| Shinji, S | 2 |
| Roseweir, AK | 2 |
| Hoorn, ST | 1 |
| Powell, AG | 1 |
| Aherne, S | 1 |
| Roxburgh, CS | 1 |
| McMillan, DC | 3 |
| Horgan, PG | 3 |
| Ryan, E | 1 |
| Vermeulen, L | 2 |
| Graham, J | 4 |
| Sansom, O | 2 |
| Church, DN | 2 |
| Tomlinson, I | 7 |
| Saunders, M | 5 |
| Iveson, TJ | 5 |
| Edwards, J | 2 |
| Chun, YJ | 1 |
| Kim, SG | 2 |
| Cho, SH | 5 |
| Baek, JY | 6 |
| Hong, S | 3 |
| Chu, CW | 1 |
| Jung, M | 3 |
| Naranjo, T | 1 |
| Iwamoto, S | 8 |
| Ide, Y | 2 |
| Ikumoto, T | 1 |
| Sano, Y | 1 |
| Kurata, T | 2 |
| Yamanaka, T | 8 |
| Duran, G | 6 |
| Cruz, R | 1 |
| Simoes, AR | 1 |
| Barros, F | 3 |
| Giráldez, JM | 1 |
| Bernárdez, B | 2 |
| Anido, U | 1 |
| Candamio, S | 5 |
| López-López, R | 2 |
| Carracedo, Á | 5 |
| Lamas, MJ | 5 |
| Kratz, JD | 1 |
| LoConte, NK | 2 |
| Martens, UM | 1 |
| Riera-Knorrenschild, J | 1 |
| Greeve, J | 1 |
| Florschütz, A | 1 |
| Wessendorf, S | 1 |
| Ettrich, T | 1 |
| Kanzler, S | 3 |
| Nörenberg, D | 2 |
| Seidensticker, M | 1 |
| Buechner-Steudel, P | 1 |
| Atzpodien, J | 2 |
| Seufferlein, T | 7 |
| Tannapfel, A | 8 |
| Reinacher-Schick, AC | 2 |
| Scarabel, L | 1 |
| Garziera, M | 1 |
| Fortuna, S | 1 |
| Asaro, F | 1 |
| Geremia, S | 1 |
| Sadahiro, S | 9 |
| Okada, K | 9 |
| Saito, G | 1 |
| Miyakita, H | 1 |
| Ogimi, T | 1 |
| Chan, LF | 1 |
| Kamei, Y | 2 |
| Xie, P | 1 |
| Mo, JL | 1 |
| Liu, JH | 8 |
| Tan, LM | 1 |
| Zhou, HH | 1 |
| Liao, L | 1 |
| Cheng, Q | 1 |
| Pei, F | 1 |
| Ye, S | 1 |
| Komori, A | 3 |
| Ura, T | 14 |
| Gootjes, EC | 1 |
| van der Stok, EP | 2 |
| Bakkerus, L | 1 |
| Labots, M | 1 |
| Zonderhuis, BM | 1 |
| Tuynman, JB | 3 |
| Meijerink, MR | 1 |
| van de Ven, PM | 1 |
| Haasbeek, CJA | 1 |
| Ten Tije, AJ | 4 |
| de Groot, JB | 1 |
| Hendriks, MP | 1 |
| Nuyttens, JJME | 1 |
| Verheul, HMW | 3 |
| Danielewicz, I | 1 |
| Argilés, G | 3 |
| Borg, C | 8 |
| Van de Wouw, AJ | 1 |
| Fedyanin, M | 1 |
| Stroyakovskiy, D | 1 |
| Kroening, H | 1 |
| Kanehisa, A | 1 |
| Egorov, A | 1 |
| Aubel, P | 1 |
| Amellal, N | 1 |
| Moiseenko, V | 1 |
| Cai, Y | 6 |
| Deng, Y | 8 |
| Raoul, JL | 7 |
| Dahan, L | 7 |
| Jouve, JL | 5 |
| Zoetemelk, M | 2 |
| Ramzy, GM | 1 |
| Rausch, M | 2 |
| Nowak-Sliwinska, P | 2 |
| Nomura, Y | 3 |
| Hashiguchi, Y | 3 |
| Shibasaki, M | 1 |
| Sakamoto, H | 2 |
| Yamagata, S | 1 |
| Aoyanagi, N | 1 |
| Kaneko, H | 2 |
| Koyama, H | 1 |
| Miyagawa, S | 2 |
| Tsushima, T | 4 |
| Tsuda, T | 2 |
| Hosokawa, A | 10 |
| Tokunaga, S | 12 |
| Shimokawa, H | 3 |
| Ozaki, Y | 2 |
| Koh, Y | 1 |
| Kishimoto, J | 1 |
| Blondy, S | 3 |
| David, V | 1 |
| Verdier, M | 2 |
| Perraud, A | 4 |
| Christou, N | 3 |
| Fujiwara, D | 1 |
| Hoshida, T | 1 |
| Noda, A | 1 |
| Takeda, T | 1 |
| Tsubaki, M | 3 |
| Nishida, S | 2 |
| Sakaguchi, K | 1 |
| Negarandeh, R | 1 |
| Salehifar, E | 1 |
| Saghafi, F | 1 |
| Jalali, H | 1 |
| Janbabaei, G | 1 |
| Abdhaghighi, MJ | 1 |
| Nosrati, A | 1 |
| Shi, WN | 1 |
| Wu, SH | 1 |
| Miao, RR | 1 |
| Sun, SY | 1 |
| Guo, ZK | 1 |
| Yu, XF | 1 |
| Cui, SX | 1 |
| Parakrama, R | 1 |
| Fogel, E | 1 |
| Chandy, C | 1 |
| Augustine, T | 1 |
| Coffey, M | 1 |
| Tesfa, L | 1 |
| Goel, S | 1 |
| Maitra, R | 1 |
| Belfiore, A | 1 |
| Centonze, G | 1 |
| Morelli, L | 2 |
| Urbani, L | 3 |
| Brich, S | 1 |
| Cillo, U | 2 |
| Cattaneo, L | 1 |
| Shuwen, H | 1 |
| Yuefen, P | 1 |
| Jiamin, X | 1 |
| Quan, Q | 2 |
| Haihong, L | 1 |
| Yizhen, J | 1 |
| Wei, W | 4 |
| Kong, N | 1 |
| Konishi, T | 5 |
| Yoshidome, H | 3 |
| Shimizu, H | 3 |
| Yoshitomi, H | 2 |
| Takayashiki, T | 2 |
| Kuboki, S | 2 |
| Takano, S | 4 |
| Ohtsuka, M | 5 |
| de la Cámara Gómez, J | 2 |
| Pellón Augusto, ML | 1 |
| Covela Rua, M | 2 |
| Quintero Aldana, G | 2 |
| Reboredo López, M | 2 |
| Valladares Ayerbes, M | 1 |
| Jorge Fernández, M | 2 |
| Ramos Vázquez, M | 1 |
| Henry, M | 1 |
| Delavari, N | 1 |
| Webber, J | 1 |
| Kobayashi, M | 6 |
| Sato, R | 1 |
| Komura, T | 1 |
| Ichikawa, H | 3 |
| Hirashima, T | 2 |
| Otake, S | 1 |
| Abe, T | 4 |
| Kakita, T | 1 |
| Oikawa, M | 1 |
| Tsuchiya, T | 2 |
| Nilsson, S | 1 |
| Stein, A | 6 |
| Kranich, AL | 1 |
| Mann, J | 5 |
| Papadimitriou, K | 1 |
| Theile, S | 1 |
| Amberg, S | 1 |
| Bokemeyer, C | 16 |
| Kashiwa, M | 1 |
| Matsushita, R | 1 |
| Dey, DK | 1 |
| Chang, SN | 2 |
| Vadlamudi, Y | 1 |
| Park, JG | 4 |
| Kang, SC | 1 |
| Ritorto, G | 3 |
| Adamo, V | 3 |
| Peverelli, G | 1 |
| Gürbüz, M | 1 |
| Akkuş, E | 1 |
| Utkan, G | 1 |
| Xiang, L | 4 |
| Ni, T | 1 |
| Jin, F | 1 |
| Deng, J | 2 |
| Shintaro, I | 1 |
| Demisse, R | 1 |
| Damle, N | 1 |
| Kim, E | 1 |
| Gong, J | 5 |
| Oesterich, L | 1 |
| McKenny, M | 1 |
| Ji, J | 4 |
| Louie, R | 1 |
| Tam, K | 1 |
| Halabi, W | 1 |
| Monjazeb, A | 1 |
| Dayyani, F | 1 |
| Schulz, C | 6 |
| Haas, M | 4 |
| Fraccaroli, A | 1 |
| Elshenawy, MA | 1 |
| Badran, A | 1 |
| Aljubran, A | 1 |
| Alzahrani, A | 1 |
| Rauf, MS | 1 |
| Eldali, A | 1 |
| Bazarbashi, S | 1 |
| Amrane, K | 1 |
| le Pennec, R | 1 |
| Schick, U | 1 |
| Abgral, R | 1 |
| Jácome, AA | 1 |
| Kee, B | 3 |
| Fogelman, D | 2 |
| Dasari, A | 3 |
| Shureiqi, I | 3 |
| Raghav, K | 3 |
| Johnson, B | 1 |
| Overman, M | 2 |
| Rogers, J | 1 |
| Ahmed, SU | 1 |
| Mehdizadeh, A | 1 |
| Rothschild, N | 1 |
| van Erning, FN | 1 |
| Nienhuijs, SW | 3 |
| Simkens, GAAM | 2 |
| Hemmer, PHJ | 3 |
| Lemmens, VEPP | 1 |
| Tanis, PJ | 5 |
| Fu, X | 3 |
| Chang, L | 1 |
| Hui, D | 1 |
| Jia, R | 1 |
| Liu, N | 1 |
| Han, Z | 2 |
| He, C | 6 |
| Lin, S | 2 |
| Ding, J | 3 |
| Zhong, Q | 1 |
| Chen, HX | 3 |
| Ao, L | 4 |
| Tamberi, S | 1 |
| Tortora, G | 3 |
| Brunella, DS | 1 |
| Grassi, E | 1 |
| Racca, P | 5 |
| Chung, HH | 1 |
| Lee, CT | 1 |
| Hu, JM | 1 |
| Chou, YC | 1 |
| Lin, YW | 2 |
| Shih, YL | 1 |
| Helderman, RFCPA | 1 |
| Löke, DR | 1 |
| Verhoeff, J | 1 |
| Rodermond, HM | 2 |
| van Bochove, GGW | 1 |
| Boon, M | 1 |
| van Kesteren, S | 1 |
| Garcia Vallejo, JJ | 1 |
| Kok, HP | 1 |
| Franken, NAP | 1 |
| Crezee, J | 1 |
| Oei, AL | 1 |
| Ramos-Esquivel, A | 2 |
| Chinchilla, R | 1 |
| Valle, M | 2 |
| Kuwata, GO | 1 |
| Ikeda, K | 3 |
| Maeda, T | 7 |
| Yamashita, K | 13 |
| Naito, K | 4 |
| Yasumoto, K | 4 |
| Takimoto, R | 4 |
| Kamigaki, T | 6 |
| Goto, S | 4 |
| Sakata, N | 1 |
| Kodama, S | 2 |
| Matsusaka, S | 21 |
| Yamamoto, N | 7 |
| Yamaguchi, T | 36 |
| Meiler, J | 1 |
| Knipp, H | 1 |
| Höhler, T | 5 |
| Reimer, P | 4 |
| Steinmetz, T | 1 |
| Berger, W | 1 |
| Linden, G | 1 |
| Reis, H | 1 |
| Markus, P | 1 |
| Paul, A | 1 |
| Dechêne, A | 1 |
| Schumacher, B | 1 |
| Kostbade, K | 1 |
| Virchow, I | 1 |
| Ting, S | 1 |
| Worm, K | 1 |
| Schmid, KW | 1 |
| Herold, T | 1 |
| Wiesweg, M | 1 |
| Schuler, M | 1 |
| Barbier, E | 3 |
| Legoux, JL | 5 |
| Bojesen, RD | 1 |
| Friis, M | 1 |
| Gögenur, I | 1 |
| de Albuquerque Ribeiro Gondinho, P | 1 |
| de Barros Silva, PG | 1 |
| Lisboa, MRP | 1 |
| Costa, BA | 1 |
| da Rocha Filho, DR | 1 |
| Gifoni, MAC | 1 |
| Lima, MVA | 1 |
| Junior, RCPL | 1 |
| Vale, ML | 1 |
| Pérez-Santiago, L | 1 |
| Dorcaratto, D | 1 |
| Garcés-Albir, M | 1 |
| Muñoz-Forner, E | 1 |
| Huerta Álvaro, M | 1 |
| Roselló Keranën, S | 1 |
| Sabater, L | 1 |
| Napier, KJ | 1 |
| Reed, SA | 1 |
| Wong, TZ | 1 |
| Kim, CY | 1 |
| Wildman-Tobriner, B | 1 |
| Nakane, M | 1 |
| Gallego, J | 6 |
| Yaeger, R | 3 |
| Paroder, V | 1 |
| Bates, DDB | 1 |
| Capanu, M | 8 |
| Tang, L | 3 |
| Chatila, W | 1 |
| Schultz, N | 1 |
| Hersch, J | 1 |
| Kelsen, D | 3 |
| Jahangirian, H | 1 |
| Umakoshi, H | 1 |
| Saleh, B | 1 |
| Rafiee-Moghaddam, R | 1 |
| Webster, TJ | 1 |
| Entezar-Almahdi, E | 1 |
| Mohammadi-Samani, S | 1 |
| Tayebi, L | 1 |
| Farjadian, F | 1 |
| Bian, X | 1 |
| Wu, JL | 1 |
| Qian, Y | 2 |
| Gou, H | 3 |
| Yat Luk, ST | 1 |
| Chan, LS | 1 |
| Shirasawa, S | 2 |
| Po, A | 1 |
| Citarella, A | 1 |
| Catanzaro, G | 1 |
| Besharat, ZM | 1 |
| Trocchianesi, S | 1 |
| Gianno, F | 1 |
| Sabato, C | 1 |
| Moretti, M | 1 |
| De Smaele, E | 1 |
| Vacca, A | 1 |
| Fiori, ME | 1 |
| Ferretti, E | 1 |
| Taylor, JC | 1 |
| Swinson, D | 2 |
| Seligmann, JF | 3 |
| Birch, RJ | 1 |
| Dewdney, A | 2 |
| Brown, V | 1 |
| Dent, J | 1 |
| Rossington, HL | 1 |
| Quirke, P | 10 |
| Morris, EJA | 1 |
| Vaghari-Tabari, M | 1 |
| Majidinia, M | 1 |
| Moein, S | 1 |
| Qujeq, D | 1 |
| Asemi, Z | 1 |
| Alemi, F | 1 |
| Mohamadzadeh, R | 1 |
| Targhazeh, N | 1 |
| Safa, A | 1 |
| Yousefi, B | 1 |
| Wang, JH | 3 |
| Wu, CC | 3 |
| Sung, YC | 2 |
| Chen, TL | 1 |
| Wang, HM | 3 |
| Tang, HC | 1 |
| Chen, JB | 1 |
| Ke, TW | 2 |
| Tsai, CS | 1 |
| Huang, HY | 1 |
| Sharma, P | 2 |
| Shimura, T | 4 |
| Banwait, JK | 1 |
| Guenter, J | 1 |
| Abadi, S | 1 |
| Lim, H | 3 |
| Chia, S | 1 |
| Woods, R | 2 |
| Jones, M | 2 |
| Rebic, N | 1 |
| Renouf, DJ | 2 |
| Laskin, J | 1 |
| Marra, M | 1 |
| Sang, J | 2 |
| Tang, R | 10 |
| Sun, Q | 2 |
| Hsu, WH | 2 |
| Yu, FJ | 3 |
| Desai, A | 1 |
| Mohammed, T | 1 |
| Patel, KN | 1 |
| Almnajam, M | 1 |
| Kim, AS | 1 |
| Cui, J | 2 |
| Mercier, F | 1 |
| Kerioui, M | 1 |
| Desmée, S | 1 |
| Guedj, J | 1 |
| Bruno, R | 4 |
| Iachetta, F | 1 |
| Tonini, G | 32 |
| Romagnani, A | 1 |
| Berselli, A | 1 |
| Boilève, A | 1 |
| De Cuyper, A | 1 |
| Larive, A | 1 |
| Mahjoubi, L | 1 |
| Najdawi, M | 1 |
| Tazdait, M | 2 |
| Tselikas, L | 2 |
| Smolenschi, C | 2 |
| Maneikyte, J | 1 |
| Bausys, A | 1 |
| Feldbacher, N | 1 |
| Hoefler, G | 2 |
| Kolb-Lenz, D | 1 |
| Birgisson, H | 1 |
| Enblad, M | 1 |
| Artursson, S | 1 |
| Ghanipour, L | 1 |
| Cashin, P | 1 |
| Graf, W | 13 |
| El-Hout, S | 1 |
| Lopez, L | 1 |
| Schaeverbeke, T | 1 |
| Richez, C | 1 |
| Kostine, M | 1 |
| Truchetet, ME | 1 |
| Gmijovic, M | 1 |
| Pecic, V | 1 |
| Stojanovic, M | 1 |
| Rashidi, G | 1 |
| Rezaeepoor, M | 1 |
| Mohammadi, C | 1 |
| Solgi, G | 1 |
| Lastraioli, E | 1 |
| Palmieri, VE | 1 |
| Castiglione, F | 1 |
| Messerini, L | 1 |
| Di Costanzo, F | 12 |
| Matsuda, C | 6 |
| Ueda, S | 4 |
| Kusaba, H | 6 |
| Okamura, S | 2 |
| Shirakawa, T | 2 |
| Yamashita, H | 8 |
| Karthikeyan, K | 1 |
| Babu, CM | 1 |
| Shaji, S | 1 |
| Ashok, AM | 1 |
| Madhu, CS | 1 |
| Selfridge, JE | 1 |
| Gorityala, S | 1 |
| Du, Z | 2 |
| Wang, JM | 1 |
| Hao, Y | 1 |
| Cioffi, G | 1 |
| Conlon, RA | 1 |
| Barnholtz-Sloan, JS | 1 |
| Saltzman, J | 1 |
| Krishnamurthi, SS | 1 |
| Vinayak, S | 1 |
| Veigl, M | 1 |
| Bajor, DL | 1 |
| Markowitz, SD | 1 |
| Meropol, NJ | 20 |
| Eads, JR | 1 |
| Shibata, S | 4 |
| Miyatani, Y | 1 |
| Beypinar, I | 1 |
| Demir, H | 1 |
| Taskoylu, BY | 1 |
| Sakalar, T | 1 |
| Ergun, Y | 1 |
| Korkmaz, M | 1 |
| Ates, O | 2 |
| Eren, T | 1 |
| Froelich, MF | 1 |
| Petersen, EL | 1 |
| Sommer, WH | 2 |
| Yin, T | 1 |
| Luo, C | 2 |
| Yu, L | 3 |
| Lapeyre-Prost, A | 2 |
| Sigrand, J | 1 |
| Le Malicot, K | 5 |
| Mary, F | 2 |
| Caroli-Bosc, FX | 1 |
| Marthey, L | 1 |
| Desrame, J | 6 |
| Perkhofer, L | 1 |
| Hoffmann, T | 3 |
| Hebart, HF | 1 |
| Herrmann, T | 3 |
| Hannig, CV | 1 |
| Büchner-Steudel, P | 1 |
| Güthle, M | 1 |
| Hermann, PC | 1 |
| Berger, AW | 1 |
| Patil, SA | 1 |
| Etheridge, AS | 1 |
| Howell, SD | 1 |
| Plummer, SJ | 1 |
| Casey, G | 2 |
| Bertagnolli, MM | 3 |
| McLeod, HL | 20 |
| Auman, JT | 2 |
| Furukawa, Y | 2 |
| Kubo, M | 1 |
| Parker, JS | 1 |
| Ratain, MJ | 2 |
| Yonesaka, K | 3 |
| Kondoh, C | 2 |
| Yamaguchi, H | 6 |
| Varma, A | 1 |
| Jayanthi, M | 1 |
| Dubashi, B | 1 |
| Shewade, DG | 1 |
| Sundaram, R | 1 |
| Srouji, RM | 1 |
| Narayan, RR | 1 |
| Boerner, T | 1 |
| Seier, K | 1 |
| Gonen, M | 7 |
| Wei, A | 2 |
| Fea, E | 2 |
| Grande, R | 2 |
| Zheng, D | 1 |
| Zhuang, J | 2 |
| Hu, D | 2 |
| Peng, X | 2 |
| Arici, S | 2 |
| Sengiz Erhan, S | 1 |
| Atci, MM | 1 |
| Cekin, R | 1 |
| Saka, B | 1 |
| Köse, E | 1 |
| Saydam, T | 1 |
| Geredeli, C | 3 |
| Cihan, S | 3 |
| Nagourney, RA | 1 |
| Evans, S | 1 |
| Tran, PH | 2 |
| Nagourney, AJ | 1 |
| Kennedy, SA | 1 |
| Morrissey, ME | 1 |
| Dunne, MR | 1 |
| O'Connell, F | 1 |
| Butler, CT | 1 |
| Cathcart, MC | 1 |
| Buckley, AM | 1 |
| Mehigan, BJ | 1 |
| Larkin, JO | 2 |
| McCormick, P | 2 |
| Kennedy, BN | 1 |
| O'Sullivan, J | 2 |
| Shan, S | 3 |
| Stack, A | 1 |
| Khanal, R | 1 |
| Denlinger, CS | 2 |
| Ermacora, P | 1 |
| Malla, SB | 1 |
| Fisher, DJ | 1 |
| Blake, A | 1 |
| Hassanieh, S | 1 |
| Redmond, KL | 1 |
| Richman, SD | 6 |
| Youdell, M | 1 |
| Walker, SM | 1 |
| Logan, GE | 1 |
| Chatzipli, A | 1 |
| Amirkhah, R | 1 |
| Humphries, MP | 1 |
| Craig, SG | 1 |
| McDermott, U | 3 |
| Seymour, MT | 29 |
| Morton, DG | 1 |
| West, NP | 1 |
| Salto-Tellez, M | 7 |
| Kennedy, RD | 1 |
| Johnston, PG | 21 |
| Koelzer, VH | 1 |
| Campo, L | 1 |
| Kaplan, RS | 5 |
| Longley, DB | 13 |
| Lawler, M | 1 |
| Brown, LC | 1 |
| Dunne, PD | 3 |
| Puerta-García, E | 1 |
| Urbano-Pérez, D | 1 |
| Carrasco-Campos, MI | 1 |
| Pérez-Ramírez, C | 1 |
| Segura-Pérez, A | 1 |
| Cañadas-Garre, M | 1 |
| Koski, S | 4 |
| Mulder, K | 1 |
| Kamiyama, H | 2 |
| Ishibashi, K | 27 |
| Dai, J | 1 |
| Jia, X | 1 |
| Oliver, JA | 1 |
| Jimenez-Luna, C | 1 |
| Cabeza, L | 1 |
| Perazzoli, G | 1 |
| Caba, O | 1 |
| Nasu, J | 4 |
| Matsumoto, T | 2 |
| Moriyama, I | 1 |
| Miguchi, M | 1 |
| Yoshida, R | 1 |
| Nozaka, K | 1 |
| Tanioka, H | 4 |
| Kurisu, Y | 1 |
| Tsuchihashi, K | 3 |
| Inukai, M | 4 |
| Kikuchi, T | 2 |
| Taflin, H | 1 |
| Odin, E | 6 |
| Carlsson, G | 13 |
| Tell, R | 1 |
| Gustavsson, B | 16 |
| Wettergren, Y | 7 |
| Voß, H | 1 |
| Wurlitzer, M | 1 |
| Smit, DJ | 1 |
| Ewald, F | 1 |
| Alawi, M | 1 |
| Spohn, M | 1 |
| Indenbirken, D | 1 |
| Omidi, M | 1 |
| David, K | 1 |
| Juhl, H | 1 |
| Simon, R | 2 |
| Sauter, G | 1 |
| Fischer, L | 1 |
| Izbicki, JR | 1 |
| Nashan, B | 1 |
| Schlüter, H | 1 |
| Jücker, M | 1 |
| Lin, PM | 1 |
| Huang, CI | 1 |
| Tai, TS | 1 |
| Chen, JH | 1 |
| Chen, CI | 2 |
| Su, YC | 1 |
| Kong, J | 2 |
| Han, SK | 1 |
| Ha, D | 1 |
| Shin, K | 1 |
| Patel, S | 2 |
| Pandey, D | 1 |
| Saklani, A | 3 |
| Miller-Phillips, L | 2 |
| Yuan, Z | 3 |
| Huang, R | 4 |
| Tang, Q | 4 |
| Ren, T | 2 |
| Shen, Z | 1 |
| Hui, F | 1 |
| Middleton, G | 8 |
| Nippgen, J | 3 |
| Burris, H | 2 |
| Nassar, A | 1 |
| Loriau, J | 1 |
| Penna, C | 3 |
| Brouquet, A | 3 |
| Benoist, S | 3 |
| Connell, LC | 2 |
| Hong, L | 1 |
| Al Sabbagh, C | 3 |
| Seguin, J | 2 |
| Agapova, E | 2 |
| Kramerich, D | 1 |
| Boudy, V | 3 |
| Mignet, N | 3 |
| Bang, YH | 1 |
| Hong, YS | 19 |
| Han, HS | 3 |
| Kim, SY | 13 |
| Eun, CK | 1 |
| Kim, JE | 2 |
| Alexander, PG | 1 |
| Pennel, KAF | 1 |
| van Wyk, HC | 1 |
| Powell, AGMT | 1 |
| Kelly, C | 2 |
| Hay, J | 1 |
| Roxburgh, CSD | 1 |
| Zhu, C | 1 |
| Guo, T | 1 |
| Zhai, Z | 2 |
| Lu, G | 2 |
| Tian, S | 1 |
| Jensen, BV | 14 |
| Punt, C | 2 |
| Garcia-Carbonero, R | 10 |
| Benavides, M | 12 |
| Le, DT | 1 |
| Farooqui, MZH | 1 |
| Marinello, P | 1 |
| Diaz, LA | 2 |
| King, BH | 1 |
| Baumgartner, JM | 1 |
| Kelly, KJ | 1 |
| Marmor, RA | 1 |
| Lowy, AM | 1 |
| Veerapong, J | 1 |
| Deng, X | 2 |
| Hou, J | 2 |
| Deng, Q | 2 |
| Zhong, Z | 2 |
| Marks, EI | 2 |
| Matera, R | 1 |
| Olszewski, AJ | 1 |
| Yakirevich, E | 1 |
| El-Deiry, WS | 9 |
| Safran, H | 1 |
| Carneiro, BA | 1 |
| Feng, M | 2 |
| Dos Santos, AM | 1 |
| Meneguin, AB | 1 |
| Akhter, DT | 1 |
| Fletcher, N | 1 |
| Houston, ZH | 1 |
| Bell, C | 1 |
| Thurecht, KJ | 1 |
| Gremião, MPD | 1 |
| Tan, X | 5 |
| Liu, P | 5 |
| Tong, JS | 1 |
| Manca, P | 1 |
| Smiroldo, V | 2 |
| Greco, FG | 1 |
| Vaiani, M | 2 |
| Calareso, G | 1 |
| Talbot, H | 1 |
| Saada, S | 1 |
| Battu, S | 4 |
| Jauberteau, MO | 3 |
| Lalloué, F | 1 |
| Schmoll, HJ | 46 |
| Kamiimabeppu, D | 1 |
| Gürsoy, P | 1 |
| Çakar, B | 2 |
| Almuradova, E | 1 |
| Karateke, M | 1 |
| Doğanavşargil, B | 1 |
| Sezak, M | 1 |
| Harman, M | 1 |
| Karabulut, B | 4 |
| Bhattacharya, S | 1 |
| Gmeiner, WH | 4 |
| Dominijanni, A | 1 |
| Haber, AO | 1 |
| Ghiraldeli, LP | 1 |
| Caudell, DL | 1 |
| D'Agostino, R | 1 |
| Pasche, BC | 1 |
| Smith, TL | 1 |
| Deng, Z | 1 |
| Kiren, S | 1 |
| Mani, C | 1 |
| Palle, K | 1 |
| Brody, JR | 3 |
| Cheng, L | 3 |
| Ni, P | 1 |
| Ni, S | 1 |
| Yao, X | 2 |
| Cen, X | 1 |
| Koch, J | 1 |
| Mönch, D | 1 |
| Maaß, A | 1 |
| Gromoll, C | 1 |
| Hehr, T | 1 |
| Leibold, T | 1 |
| Schlitt, HJ | 4 |
| Dahlke, MH | 1 |
| Renner, P | 1 |
| Dupertuis, YM | 1 |
| Boulens, N | 1 |
| Angibaud, E | 1 |
| Briod, AS | 1 |
| Viglione, A | 1 |
| Allémann, E | 1 |
| Delie, F | 1 |
| Pichard, C | 1 |
| Sun, D | 3 |
| Zou, Y | 1 |
| Gu, X | 2 |
| Ha, HA | 1 |
| Chiang, JH | 1 |
| Tsai, FJ | 1 |
| Bau, DT | 1 |
| Juan, YN | 1 |
| Lo, YH | 1 |
| Hour, MJ | 1 |
| Yang, JS | 1 |
| Watanabe, D | 1 |
| Kiyama, S | 1 |
| Kobayashi, R | 2 |
| Suzuki, A | 1 |
| Ukai, S | 1 |
| Sakamoto, N | 3 |
| Taniyama, D | 1 |
| Harada, K | 2 |
| Honma, R | 1 |
| Maruyama, R | 1 |
| Naka, K | 1 |
| Hinoi, T | 1 |
| Takakura, Y | 2 |
| Shimizu, W | 2 |
| Ohdan, H | 3 |
| Yasui, W | 2 |
| Azar, MRMH | 1 |
| Aghazadeh, H | 1 |
| Mohammed, HN | 1 |
| Sara, MRS | 1 |
| Hosseini, A | 1 |
| Mansouri, M | 1 |
| Sarand, SP | 1 |
| Marofi, F | 1 |
| Shotorbani, SS | 1 |
| Patel, KK | 1 |
| Stein, S | 1 |
| Lacy, J | 1 |
| O'Hara, M | 1 |
| Huntington, SF | 1 |
| Khosravi, N | 1 |
| Shahgoli, VK | 1 |
| Amini, M | 1 |
| Safaei, S | 1 |
| Mokhtarzadeh, A | 1 |
| Derakhshani, A | 1 |
| Baghbanzadeh, A | 1 |
| Hsieh, AC | 1 |
| Wei, X | 2 |
| Gao, WQ | 1 |
| Faruk, M | 1 |
| Ibrahim, S | 2 |
| Aminu, SM | 1 |
| Adamu, A | 1 |
| Abdullahi, A | 1 |
| Suleiman, AM | 1 |
| Rafindadi, AH | 1 |
| Mohammed, A | 1 |
| Iliyasu, Y | 1 |
| Idoko, J | 1 |
| Saidu, R | 1 |
| Randawa, AJ | 1 |
| Musa, HS | 1 |
| Ntekim, A | 1 |
| Shah, KZ | 1 |
| Abubakar, S | 1 |
| Adoke, KU | 1 |
| Manko, M | 1 |
| Awasum, CA | 1 |
| Park, SM | 1 |
| Choi, SB | 1 |
| Lee, YS | 4 |
| Lee, IK | 2 |
| Ii, T | 1 |
| Rikiyama, N | 1 |
| Noguchi, A | 2 |
| Aoki, Y | 1 |
| Sato, J | 2 |
| Kikuchi, D | 1 |
| Yamanami, H | 1 |
| Inui, M | 1 |
| Zenitani, S | 1 |
| Wada, R | 1 |
| Mikamori, M | 1 |
| Kishi, K | 2 |
| Akamatsu, H | 2 |
| Nakatsukasa, R | 1 |
| Hayashi, N | 6 |
| Urabe, S | 1 |
| Nakagawa, T | 3 |
| Michiura, T | 1 |
| Yamabe, K | 1 |
| Chen, YQ | 1 |
| Lin, CY | 1 |
| Yuan, ZW | 1 |
| Li, ZH | 1 |
| Hewitt, DB | 1 |
| Pawlik, TM | 1 |
| Cloyd, JM | 1 |
| Köstek, O | 2 |
| Housein, Z | 1 |
| Kareem, TS | 1 |
| Salihi, A | 1 |
| Ivey, AM | 1 |
| Ali, A | 1 |
| Daily, KC | 1 |
| Ramnaraign, BH | 1 |
| Tan, SA | 1 |
| Terracina, KP | 1 |
| Read, TE | 1 |
| Dang, LH | 1 |
| Iqbal, A | 1 |
| Nicoletti, M | 1 |
| Lonati, V | 2 |
| Cabiddu, M | 5 |
| Seok, H | 1 |
| Chen, R | 4 |
| Peng, W | 3 |
| Gu, Q | 1 |
| Sheng, Y | 1 |
| Shao, G | 1 |
| Yu, IS | 1 |
| Loree, JM | 1 |
| Shiraiwa, K | 1 |
| Suzuki, Y | 4 |
| Uchida, H | 2 |
| Iwashita, Y | 1 |
| Tanaka, R | 5 |
| Iwao, M | 1 |
| Tada, K | 1 |
| Hirashita, T | 1 |
| Masuda, T | 5 |
| Endo, Y | 5 |
| Inomata, M | 4 |
| Itoh, H | 1 |
| Piao, Y | 1 |
| Zhu, X | 3 |
| Qiu, L | 2 |
| Guo, W | 4 |
| Ding, D | 1 |
| Gholamzadeh Khoei, S | 1 |
| Saidijam, M | 2 |
| Jalali, A | 1 |
| Akdeniz, N | 1 |
| Kaplan, MA | 3 |
| İnanç, M | 6 |
| Kaya, S | 2 |
| Dane, F | 5 |
| Küçüköner, M | 1 |
| Demirci, A | 1 |
| Bilici, M | 1 |
| Durnalı, AG | 3 |
| Koral, L | 1 |
| Şendur, MAN | 2 |
| Türkmen, E | 2 |
| Ölmez, ÖF | 1 |
| Açıkgöz, Ö | 1 |
| Laçin, Ş | 1 |
| Şahinli, H | 1 |
| Urakçı, Z | 1 |
| Işıkdoğan, A | 3 |
| Lin, SM | 1 |
| Huang, SH | 1 |
| Xu, ZB | 1 |
| Lu, XR | 1 |
| Xu, DB | 1 |
| Chi, P | 5 |
| Nindra, U | 1 |
| Shahnam, A | 1 |
| Mahon, KL | 1 |
| Yan, Z | 3 |
| Lv, M | 1 |
| Ma, W | 1 |
| Kuhn, E | 1 |
| González Astorga, B | 1 |
| Salvà Ballabrera, F | 1 |
| Aranda Aguilar, E | 1 |
| Élez Fernández, E | 2 |
| González Flores, E | 2 |
| Vera García, R | 1 |
| López Muñoz, AM | 2 |
| Salud Salvia, A | 1 |
| Han, FY | 1 |
| Wang, PY | 1 |
| Xu, ZP | 1 |
| Villard, C | 1 |
| Habib, M | 1 |
| Nordenvall, C | 1 |
| Nilsson, PJ | 1 |
| Jorns, C | 1 |
| Sparrelid, E | 1 |
| Sun, LT | 1 |
| Zhang, LY | 1 |
| Shan, FY | 1 |
| Shen, MH | 1 |
| Ruan, SM | 1 |
| Kang, J | 2 |
| Verdina, A | 1 |
| Di Segni, M | 1 |
| Sperduti, I | 4 |
| Buglioni, S | 2 |
| Mottolese, M | 4 |
| Di Rocco, G | 1 |
| Soddu, S | 1 |
| McCann, C | 1 |
| Matveeva, A | 1 |
| McAllister, K | 1 |
| Van Schaeybroeck, S | 7 |
| Sessler, T | 1 |
| Fichtner, M | 1 |
| Rehm, M | 2 |
| Noepel-Duennebacke, S | 1 |
| Juette, H | 1 |
| Schulmann, K | 4 |
| Porschen, R | 12 |
| Stoehlmacher, J | 11 |
| Hegewisch-Becker, S | 8 |
| Raulf, A | 1 |
| Fontana, E | 2 |
| Nyamundanda, G | 1 |
| Sadanandam, A | 1 |
| Zhao, K | 1 |
| Ye, Z | 1 |
| Xing, C | 2 |
| Pimpie, C | 1 |
| Roy, P | 1 |
| Bellyei, S | 1 |
| Boronkai, Á | 1 |
| Pozsgai, E | 1 |
| Fodor, D | 1 |
| Mangel, L | 2 |
| Bryson, E | 1 |
| Sakach, E | 1 |
| Patel, U | 1 |
| Watson, M | 5 |
| Hall, K | 1 |
| Draper, A | 1 |
| Davis, C | 1 |
| Goyal, S | 1 |
| Alese, O | 1 |
| Akce, M | 1 |
| Shaib, W | 2 |
| El-Rayes, B | 2 |
| Szabo, S | 1 |
| Xuan, Y | 1 |
| Zheng, HC | 1 |
| Monti, M | 1 |
| Donati, C | 1 |
| Foca, F | 1 |
| Pagan, F | 1 |
| Rapposelli, I | 1 |
| Ruscelli, S | 2 |
| Valgiusti, M | 1 |
| Sullo, F | 1 |
| Sbaffi, S | 1 |
| Crudi, L | 1 |
| Masini, C | 1 |
| Bhatti, T | 1 |
| Moser, M | 1 |
| Tan, KT | 1 |
| Chalchal, H | 3 |
| Souied, O | 1 |
| Le, D | 1 |
| Shaw, J | 1 |
| Zaidi, A | 1 |
| Gill, D | 1 |
| Ahmed, S | 1 |
| Komori, T | 2 |
| Paku, M | 1 |
| Kim, HM | 5 |
| Sameni, HR | 1 |
| Yosefi, S | 1 |
| Alipour, M | 1 |
| Pakdel, A | 1 |
| Torabizadeh, N | 1 |
| Semnani, V | 1 |
| Bandegi, AR | 1 |
| Christenson, ES | 1 |
| Gizzi, A | 1 |
| Egleston, M | 1 |
| Seamon, KJ | 1 |
| DePasquale, M | 1 |
| Orris, B | 1 |
| Park, BH | 2 |
| Stivers, JT | 1 |
| Kang, YH | 1 |
| Lee, NH | 1 |
| Seo, CS | 1 |
| Son, CG | 1 |
| Song, F | 1 |
| Shao, Y | 2 |
| Cheng, K | 1 |
| Li, ZP | 1 |
| Luo, DY | 1 |
| Shen, YL | 1 |
| Bi, F | 7 |
| Gou, HF | 1 |
| Yarrarapu, SNS | 1 |
| Govero, AB | 1 |
| Kukhon, FR | 1 |
| Sanghavi, DK | 1 |
| Jin, G | 1 |
| She, Z | 1 |
| Deng, S | 1 |
| Ramos, H | 1 |
| Soares, MIL | 1 |
| Silva, J | 1 |
| Raimundo, L | 1 |
| Calheiros, J | 1 |
| Gomes, C | 1 |
| Reis, F | 1 |
| Monteiro, FA | 1 |
| Nunes, C | 1 |
| Reis, S | 1 |
| Bosco, B | 1 |
| Piazza, S | 1 |
| Domingues, L | 1 |
| Chlapek, P | 1 |
| Fabian, P | 1 |
| Rajado, AT | 1 |
| Carvalho, ATP | 1 |
| Veselska, R | 1 |
| Inga, A | 1 |
| Pinho E Melo, TMVD | 1 |
| Saraiva, L | 1 |
| Su, K | 1 |
| Hu, C | 2 |
| Du, X | 2 |
| Xing, B | 1 |
| Sano, F | 1 |
| Makishima, M | 1 |
| Hamano, T | 1 |
| Deligonul, A | 1 |
| Aksoy, S | 2 |
| Tezcan, G | 1 |
| Tunca, B | 1 |
| Kanat, O | 1 |
| Cubukcu, E | 1 |
| Yilmazlar, T | 1 |
| Ozturk, E | 1 |
| Egeli, U | 1 |
| Cecener, G | 1 |
| Alemdar, A | 1 |
| Evrensel, T | 1 |
| Akabane, S | 1 |
| Kochi, M | 5 |
| Taguchi, K | 3 |
| Nakashima, I | 1 |
| Sato, K | 5 |
| Hattori, M | 3 |
| Egi, H | 1 |
| Sentani, K | 1 |
| Wang, K | 6 |
| Gu, C | 1 |
| Deyme, L | 1 |
| Barbolosi, D | 1 |
| Mbatchi, LC | 1 |
| Tubiana-Mathieu, N | 6 |
| Evrard, A | 6 |
| Gattacceca, F | 1 |
| Lou, Y | 2 |
| Sreekumar, R | 1 |
| Al-Saihati, H | 1 |
| Emaduddin, M | 1 |
| Moutasim, K | 1 |
| Mellone, M | 1 |
| Kilic, S | 1 |
| Cetin, M | 1 |
| Erdemir, S | 1 |
| Navio, MS | 1 |
| Lopez, MA | 1 |
| Curtis, N | 1 |
| Yagci, T | 1 |
| Price, BD | 1 |
| Berx, G | 1 |
| Thomas, GJ | 1 |
| Tulchinsky, E | 1 |
| Mirnezami, A | 1 |
| Sayan, AE | 1 |
| Fu, Y | 1 |
| Chou, JF | 4 |
| Chatila, WK | 1 |
| Sanchez-Vega, F | 1 |
| Sperotto, NDM | 1 |
| Silva, RBM | 1 |
| Perelló, MA | 1 |
| Borsoi, AF | 1 |
| da Silva Dadda, A | 1 |
| Roth, CD | 1 |
| Freitas, RDS | 1 |
| de Souza, APD | 1 |
| Freitas, DDN | 1 |
| Picada, JN | 1 |
| de Sousa, JT | 1 |
| Nabinger, DD | 1 |
| Altenhofen, S | 1 |
| Bonan, CD | 1 |
| Rodrigues-Junior, VS | 1 |
| Bizarro, CV | 1 |
| Basso, LA | 1 |
| Machado, P | 1 |
| Fujisawa, A | 1 |
| Takahara, H | 1 |
| Kondo, Y | 3 |
| Akagami, M | 1 |
| Yokoyama, T | 5 |
| Takahara, N | 1 |
| Na, R | 1 |
| Xiao, C | 1 |
| Lu, H | 2 |
| Tang, H | 2 |
| Zhuang, G | 1 |
| Fan, G | 1 |
| Peng, Z | 2 |
| Yakar, N | 1 |
| Ergun, B | 1 |
| Ugur, L | 1 |
| Ates, UC | 1 |
| Gezer, S | 1 |
| Comert, B | 1 |
| Aomatsu, N | 1 |
| Maeda, K | 10 |
| Uchima, Y | 1 |
| Matsutani, S | 1 |
| Tsujio, G | 1 |
| Kurihara, S | 1 |
| Nishii, T | 1 |
| Tachimori, A | 1 |
| Takeuchi, K | 1 |
| Thijs, AMJ | 2 |
| Kusters, M | 2 |
| Versteeg, KS | 1 |
| Aalbers, AGJ | 2 |
| Wiezer, MJ | 2 |
| Boerma, D | 2 |
| Los, M | 2 |
| de Reuver, PR | 2 |
| Bremers, AJA | 2 |
| Kruijff, S | 2 |
| de Groot, DJA | 2 |
| Witkamp, AJ | 3 |
| van Grevenstein, WMU | 2 |
| Nederend, J | 2 |
| Lahaye, MJ | 2 |
| Fijneman, RJA | 2 |
| van 't Erve, I | 2 |
| Dijkgraaf, MGW | 2 |
| Marshall, J | 7 |
| de Gramont, A | 61 |
| Chuang, KH | 1 |
| Jie, Y | 1 |
| Hernández, C | 1 |
| Moreno, G | 1 |
| Herrera-R, A | 1 |
| Cardona-G, W | 1 |
| Adams, J | 2 |
| Casali, A | 2 |
| Campbell, K | 1 |
| Hopson, LM | 1 |
| Singleton, SS | 1 |
| Jogunoori, W | 1 |
| Mazumder, R | 1 |
| Obias, V | 1 |
| Lin, P | 1 |
| Nguyen, BN | 1 |
| Miller, L | 1 |
| White, J | 1 |
| Mishra, L | 1 |
| Karthika, C | 1 |
| Hari, B | 1 |
| Rahman, MH | 1 |
| Akter, R | 1 |
| Najda, A | 1 |
| Albadrani, GM | 1 |
| Sayed, AA | 1 |
| Akhtar, MF | 1 |
| Abdel-Daim, MM | 1 |
| Saoudi Gonzalez, N | 1 |
| Salvà, F | 1 |
| Ros, J | 1 |
| Baraibar, I | 1 |
| Marmolejo, D | 1 |
| Valdivia, A | 1 |
| Cuadra-Urteaga, JL | 1 |
| Mulet, N | 1 |
| Nakayama, Y | 1 |
| Kawamura, H | 1 |
| Takano, Y | 3 |
| Takiguchi, K | 1 |
| Kamiga, T | 1 |
| Muto, A | 1 |
| Shiraso, S | 1 |
| Yamashita, N | 3 |
| Iwao, T | 1 |
| Kono, K | 1 |
| Konno, S | 1 |
| Liu, G | 3 |
| Lai, D | 1 |
| Zhao, H | 7 |
| Ackland, S | 2 |
| Sjoquist, K | 2 |
| Chinchilla-Monge, R | 1 |
| Abbas, J | 1 |
| Poma, AM | 1 |
| Granetto, C | 10 |
| Frassoldati, A | 1 |
| Bertolini, AS | 1 |
| Machover, D | 7 |
| Almohamad, W | 1 |
| Castagné, V | 1 |
| Desterke, C | 2 |
| Gomez, L | 1 |
| Gaston-Mathé, Y | 2 |
| Boucheix, C | 1 |
| Goldschmidt, E | 4 |
| Chaudhary, N | 1 |
| Choudhary, BS | 1 |
| Shah, SG | 1 |
| Khapare, N | 1 |
| Dwivedi, N | 1 |
| Gaikwad, A | 1 |
| Joshi, N | 1 |
| Raichanna, J | 1 |
| Basu, S | 1 |
| Gurjar, M | 1 |
| P K, S | 1 |
| Gera, P | 1 |
| Patil, P | 2 |
| Gota, V | 1 |
| Dhar, SK | 1 |
| Gupta, S | 3 |
| Wu, S | 3 |
| Shen, X | 3 |
| Herting, CJ | 1 |
| Farren, MR | 1 |
| Tong, Y | 3 |
| O'Neil, B | 2 |
| Noonan, A | 1 |
| McQuinn, C | 1 |
| Mace, TA | 1 |
| El-Rayes, BF | 8 |
| Shahda, S | 1 |
| Lesinski, GB | 1 |
| Kristin, E | 1 |
| Endarti, D | 1 |
| Taroeno-Hariadi, KW | 1 |
| Trijayanti, C | 1 |
| Akalovich, S | 1 |
| Portyanko, A | 1 |
| Pundik, A | 1 |
| Mezheyeuski, A | 1 |
| Doroshenko, T | 1 |
| Hudita, A | 2 |
| Radu, IC | 2 |
| Galateanu, B | 2 |
| Ginghina, O | 2 |
| Herman, H | 1 |
| Balta, C | 1 |
| Rosu, M | 1 |
| Zaharia, C | 2 |
| Costache, M | 2 |
| Tanasa, E | 1 |
| Velonia, K | 2 |
| Tsatsakis, A | 2 |
| Hermenean, A | 1 |
| Kang, SI | 1 |
| Robling, KR | 1 |
| Abada, PB | 1 |
| Hozak, RR | 3 |
| Siegel, R | 1 |
| Fill, JA | 1 |
| Wijayawardana, S | 1 |
| Walgren, RA | 1 |
| Giles, B | 1 |
| Jones, A | 3 |
| Pitts, KR | 1 |
| Drove, N | 1 |
| Mariappan, R | 1 |
| Furihata, S | 1 |
| Yatsu, N | 1 |
| Ohno, R | 1 |
| Takamatsu, N | 1 |
| Anami, S | 2 |
| Kerr, D | 14 |
| Gray, V | 1 |
| West, H | 1 |
| Park, HE | 1 |
| Yoo, SY | 1 |
| Cho, NY | 4 |
| Bae, JM | 7 |
| Lee, HS | 4 |
| Park, KJ | 7 |
| Kim, TY | 17 |
| Gamoh, M | 4 |
| Iwanaga, I | 3 |
| Sakashita, A | 1 |
| Kotake, M | 3 |
| Takahashi, S | 4 |
| Erdoğan, MK | 1 |
| Ağca, CA | 1 |
| Aşkın, H | 1 |
| Westphalen, CB | 3 |
| Schlieker, L | 1 |
| Jelas, I | 3 |
| Iwasa, S | 9 |
| Bai, L | 3 |
| Shen, C | 1 |
| Chang, R | 2 |
| Easaw, J | 1 |
| Chang, GR | 2 |
| Kuo, CY | 1 |
| Tsai, MY | 1 |
| Lin, WL | 1 |
| Lin, TC | 13 |
| Liao, HJ | 1 |
| Chen, CH | 3 |
| Nikravesh, H | 1 |
| Khodayar, MJ | 1 |
| Behmanesh, B | 1 |
| Mahdavinia, M | 1 |
| Teimoori, A | 1 |
| Alboghobeish, S | 1 |
| Zeidooni, L | 1 |
| Wei, B | 2 |
| Porzio, G | 3 |
| Cannita, K | 7 |
| Venditti, O | 2 |
| Filippi, R | 1 |
| Ribelli, M | 1 |
| Nigro, O | 1 |
| Gelsomino, F | 2 |
| Spallanzani, A | 1 |
| Zurlo, V | 1 |
| Leo, S | 8 |
| Claudia, F | 1 |
| Lombardi, P | 2 |
| Keränen, SR | 1 |
| Aimar, G | 1 |
| Depetris, I | 1 |
| Morelli, C | 1 |
| De Tursi, M | 2 |
| Tinari, N | 2 |
| Di Pietro, FR | 1 |
| De Galitiis, F | 4 |
| Zanaletti, N | 1 |
| Vitale, P | 1 |
| Garajova, I | 1 |
| Spinelli, GP | 1 |
| Zoratto, F | 2 |
| Roberto, M | 2 |
| Ierino, D | 1 |
| D'Orazio, C | 1 |
| Ficorella, C | 9 |
| Cortellini, A | 2 |
| Peixoto, RD | 1 |
| Coutinho, AK | 2 |
| Weschenfelder, RF | 1 |
| Prolla, G | 1 |
| Rocha, D | 1 |
| Andrade, AC | 2 |
| Rego, JF | 1 |
| Fernandes, GDS | 2 |
| Crosara, M | 1 |
| Costa E Silva, M | 1 |
| Riechelmann, RP | 4 |
| Garza-Treviño, EN | 1 |
| Martínez-Rodríguez, HG | 1 |
| Delgado-González, P | 1 |
| Solís-Coronado, O | 1 |
| Ortíz-Lopez, R | 2 |
| Soto-Domínguez, A | 1 |
| Treviño, VM | 1 |
| Padilla-Rivas, GR | 1 |
| Islas-Cisneros, JF | 1 |
| Quiroz-Reyes, AG | 1 |
| Said-Fernández, SL | 1 |
| He, M | 1 |
| Yoshida, T | 6 |
| You, J | 1 |
| Chen, D | 7 |
| Siu, HWD | 1 |
| Tebbutt, N | 11 |
| Chantrill, L | 1 |
| Karapetis, C | 5 |
| Steer, C | 1 |
| Wilson, K | 8 |
| Bailey, L | 1 |
| Yip, S | 2 |
| Cuff, J | 1 |
| Thavaneswaran, S | 1 |
| Briscoe, K | 1 |
| Srivastav, R | 1 |
| Shannon, J | 1 |
| Caird, S | 1 |
| Francesconi, A | 1 |
| Wuttke, M | 1 |
| Ladwa, R | 1 |
| Elbadawy, M | 2 |
| Ayame, H | 1 |
| Abugomaa, A | 1 |
| Shibutani, M | 2 |
| Hayashi, SM | 1 |
| Takenouchi, H | 2 |
| Nakajima, M | 2 |
| Shinohara, Y | 2 |
| Kaneda, M | 2 |
| Yamawaki, H | 2 |
| Usui, T | 2 |
| Leone, AG | 1 |
| Amatu, A | 1 |
| Wincenciak, J | 1 |
| Erickson, NT | 1 |
| Lerch, MM | 3 |
| Höffkes, HG | 2 |
| Theurich, S | 1 |
| Algül, H | 1 |
| Beca, JM | 1 |
| Dai, WF | 1 |
| Pataky, RE | 1 |
| Tran, D | 1 |
| Dvorani, E | 1 |
| Isaranuwatchai, W | 1 |
| Peacock, S | 1 |
| Alvi, R | 1 |
| Cheung, WY | 1 |
| Earle, CC | 7 |
| Gavura, S | 1 |
| Yoon, YS | 1 |
| Roh, SA | 3 |
| Cho, DH | 3 |
| Kim, MB | 1 |
| Kim, JC | 8 |
| Yang, YF | 1 |
| Wang, GY | 1 |
| He, JL | 1 |
| Wu, FP | 1 |
| Zhang, YN | 1 |
| Yamauchi, S | 3 |
| Groshen, S | 13 |
| Jiao, T | 2 |
| Gao, T | 2 |
| Sun, M | 3 |
| Gopez, RF | 1 |
| West, JD | 3 |
| Hanna, D | 1 |
| Ruers, T | 2 |
| Van Coevorden, F | 3 |
| Punt, CJ | 55 |
| Pierie, JE | 1 |
| Borel-Rinkes, I | 1 |
| Ledermann, JA | 9 |
| Poston, G | 6 |
| Bechstein, W | 3 |
| Lentz, MA | 2 |
| Mauer, M | 5 |
| Nordlinger, B | 18 |
| Fan, L | 1 |
| Niu, Y | 1 |
| Mian, W | 1 |
| Xie, M | 1 |
| Mei, Q | 4 |
| Ohta, H | 2 |
| Murai, S | 1 |
| Shiouchi, H | 1 |
| Ando, Y | 7 |
| Kumazawa, S | 1 |
| Ikeda, Y | 5 |
| Kawada, K | 3 |
| Ye, M | 1 |
| He, Y | 4 |
| Zhong, J | 1 |
| Xue, ZX | 1 |
| Cai, ZZ | 1 |
| Heydari, K | 1 |
| Sharifi, MR | 1 |
| Dermani, FK | 1 |
| Soleimani Asl, S | 1 |
| Shabab, N | 1 |
| Xue, H | 1 |
| Gu, L | 1 |
| García-González, AP | 1 |
| Ritter, AD | 1 |
| Shrestha, S | 1 |
| Andersen, EC | 1 |
| Yilmaz, LS | 1 |
| Walhout, AJM | 1 |
| Scott, TA | 1 |
| Quintaneiro, LM | 1 |
| Norvaisas, P | 1 |
| Lui, PP | 1 |
| Wilson, MP | 1 |
| Leung, KY | 1 |
| Herrera-Dominguez, L | 1 |
| Sudiwala, S | 1 |
| Pessia, A | 1 |
| Clayton, PT | 1 |
| Bryson, K | 1 |
| Velagapudi, V | 1 |
| Mills, PB | 1 |
| Typas, A | 1 |
| Greene, NDE | 1 |
| Cabreiro, F | 1 |
| Kim, SB | 1 |
| Park, SJ | 8 |
| Hong, SP | 2 |
| Cheon, JH | 1 |
| Kim, WH | 1 |
| Lim, A | 1 |
| Le Sourd, S | 1 |
| Senellart, H | 4 |
| Luet, D | 1 |
| Douane, F | 1 |
| Perret, C | 1 |
| Bouvier, A | 1 |
| Métairie, S | 1 |
| Cauchin, E | 1 |
| Rougier, P | 51 |
| Matysiak-Budnik, T | 2 |
| Leal, F | 1 |
| Ferreira, FP | 1 |
| Sasse, AD | 3 |
| Tang, M | 2 |
| Du, C | 2 |
| Hou, T | 1 |
| Tu, B | 1 |
| Cao, Z | 1 |
| Jiang, L | 2 |
| Liu, B | 6 |
| Luo, J | 1 |
| Zhu, WG | 2 |
| Lim, KH | 2 |
| Lee, HY | 1 |
| Park, SB | 1 |
| Song, SY | 2 |
| Kwon, Y | 1 |
| Park, M | 3 |
| Jang, M | 1 |
| Yun, S | 1 |
| Kim, WK | 3 |
| Paik, S | 2 |
| Min, B | 1 |
| Vehling-Kaiser, U | 15 |
| Jagenburg, A | 2 |
| Yabasin, IB | 1 |
| Yu, JC | 1 |
| Wen, Q | 3 |
| Yao, Y | 3 |
| Khorrami, S | 1 |
| Zavaran Hosseini, A | 1 |
| Mowla, SJ | 2 |
| Soleimani, M | 1 |
| Rakhshani, N | 1 |
| Malekzadeh, R | 1 |
| Ji, WB | 1 |
| Um, JW | 1 |
| Ryu, JS | 2 |
| Hong, KD | 1 |
| Min, BW | 1 |
| Joung, SY | 1 |
| Kim, YS | 3 |
| Saber, A | 1 |
| Alipour, B | 1 |
| Faghfoori, Z | 1 |
| Mousavi Jam, A | 1 |
| Yari Khosroushahi, A | 1 |
| Huo, X | 1 |
| Sun, G | 3 |
| Dabkeviciene, D | 3 |
| Kirveliene, V | 1 |
| Mao, H | 3 |
| Dai, G | 2 |
| Yu, X | 4 |
| Polay Espinoza, M | 1 |
| Pion, N | 1 |
| Macari, F | 1 |
| Textoris, J | 1 |
| Auboeuf, D | 1 |
| Dutertre, M | 1 |
| Chiou, GY | 1 |
| Yang, TW | 1 |
| Huang, CC | 4 |
| Tang, CY | 1 |
| Yen, JY | 1 |
| Tsai, MC | 1 |
| Chen, HY | 1 |
| Fadhilah, N | 1 |
| Jong, YJ | 1 |
| Larsen, FO | 6 |
| Markussen, A | 2 |
| Nielsen, D | 5 |
| Colville-Ebeling, B | 1 |
| Riis, LB | 1 |
| Franck, C | 1 |
| Malfertheiner, P | 1 |
| Venerito, M | 1 |
| Passalacqua, R | 3 |
| Barni, S | 23 |
| Baker, K | 1 |
| Dunwoodie, E | 1 |
| Jones, RG | 1 |
| Newsham, A | 1 |
| Johnson, O | 1 |
| Price, CP | 1 |
| Wolstenholme, J | 1 |
| Leal, J | 1 |
| McGinley, P | 1 |
| Twelves, C | 21 |
| Hall, G | 1 |
| Pillai, R | 1 |
| Jeong, KY | 3 |
| Kim, IU | 1 |
| Sim, JJ | 3 |
| Yin, D | 1 |
| Gopez, R | 1 |
| Akihito, T | 1 |
| Ichikawa, W | 13 |
| DePaolo, RW | 2 |
| Butler, SJ | 1 |
| Richardson, L | 1 |
| Farias, N | 1 |
| Morrison, J | 1 |
| Coomber, BL | 1 |
| Gharib, AF | 1 |
| Shalaby, SM | 1 |
| Raafat, N | 1 |
| Fawzy, WMS | 1 |
| Abdel Hakim, NH | 1 |
| Crispin, A | 1 |
| Schalhorn, A | 12 |
| Quietzsch, D | 2 |
| Kruger, S | 1 |
| von Einem, J | 1 |
| Valsuani, C | 1 |
| Duwe, G | 1 |
| Knitter, S | 1 |
| Pesthy, S | 1 |
| Beierle, AS | 1 |
| Bahra, M | 2 |
| Schmelzle, M | 1 |
| Schmuck, RB | 1 |
| Lohneis, P | 1 |
| Raschzok, N | 1 |
| Öllinger, R | 1 |
| Sinn, M | 1 |
| Struecker, B | 1 |
| Sauer, IM | 1 |
| Andreou, A | 3 |
| Huang, WW | 1 |
| Hsieh, KP | 1 |
| Huang, RY | 1 |
| Yang, YH | 1 |
| Xing, X | 2 |
| Shen, Q | 1 |
| Tan, S | 2 |
| Demurtas, L | 1 |
| Puzzoni, M | 2 |
| Ziranu, P | 1 |
| Mandolesi, A | 2 |
| Loretelli, C | 1 |
| Meriggi, F | 3 |
| Cascinu, S | 27 |
| Fruth, B | 1 |
| Greene, C | 1 |
| Schilsky, RL | 13 |
| El-Khoueiry, AB | 2 |
| Watson, P | 1 |
| Benson, AB | 20 |
| Mulkerin, DL | 2 |
| Blanke, C | 4 |
| Carrato, A | 22 |
| Abad, A | 24 |
| Massuti, B | 17 |
| Longo-Muñoz, F | 1 |
| Manzano, JL | 12 |
| Gómez, A | 7 |
| García-Paredes, B | 3 |
| Dueñas, R | 6 |
| Yang, Z | 9 |
| Fukushima, M | 18 |
| Iizuka, K | 1 |
| Jin, C | 1 |
| Hong, M | 1 |
| Eshima, K | 2 |
| Xiong, W | 2 |
| Ai, YQ | 2 |
| Li, YF | 4 |
| Chen, ZT | 1 |
| Qin, JY | 2 |
| Liu, QY | 1 |
| Ju, YH | 2 |
| Li, WH | 2 |
| Miaris, N | 1 |
| Sgouros, J | 4 |
| Gerolympou, M | 1 |
| Spyropoulos, B | 1 |
| Drakopoulos, D | 1 |
| Gkoura, S | 1 |
| Res, H | 1 |
| Zhao, Z | 7 |
| Teng, N | 1 |
| Liang, X | 4 |
| Ishii, F | 1 |
| Yamauchi, Y | 3 |
| Kojima, D | 2 |
| Mera, T | 2 |
| Kato, D | 1 |
| Hamada, Y | 1 |
| Nimura, S | 1 |
| Oumrani, S | 1 |
| Guillaumot, MA | 1 |
| Brieau, B | 1 |
| Oudjit, A | 1 |
| Léandri, C | 1 |
| Brezault, C | 7 |
| Chaussade, S | 7 |
| Sobhani, N | 1 |
| Generali, D | 1 |
| Roviello, G | 2 |
| Mitsuboshi, S | 1 |
| Kozakai, H | 1 |
| Yamada, H | 11 |
| Nagai, K | 2 |
| Furukawa, T | 3 |
| Aizawa, K | 1 |
| AlShamaileh, H | 1 |
| Xiang, D | 1 |
| Yin, W | 1 |
| Barrero, RA | 1 |
| Zhang, PZ | 1 |
| Kong, L | 3 |
| Zhou, SF | 1 |
| Shigdar, S | 2 |
| Duan, W | 4 |
| Leone, F | 5 |
| Iaffaioli, RV | 5 |
| Corsi, DC | 6 |
| Ferraú, F | 3 |
| Urushibara, S | 1 |
| Tsubota, T | 1 |
| Asai, R | 1 |
| Azumi, J | 1 |
| Ashida, K | 1 |
| Shiota, G | 1 |
| Ye, R | 1 |
| Niu, B | 1 |
| Hutchins, GGA | 1 |
| Treanor, D | 1 |
| Wright, A | 1 |
| Handley, K | 2 |
| Magill, L | 2 |
| Tinkler-Hundal, E | 1 |
| Southward, K | 2 |
| Seymour, M | 9 |
| Gray, R | 7 |
| Richardson, C | 1 |
| Hernandez Borrero, LJ | 1 |
| Chionh, F | 2 |
| Lau, D | 1 |
| Yeung, Y | 1 |
| Yokokawa, T | 3 |
| Sugisaki, T | 1 |
| Machida, Y | 1 |
| Hama, T | 4 |
| Shan, Y | 1 |
| Jia, L | 1 |
| Gonzaga-López, A | 1 |
| Muñoz-Rodriguez, J | 1 |
| Guo, B | 2 |
| Xiao, N | 1 |
| Yu, K | 1 |
| Zheng, S | 4 |
| Baltruskeviciene, E | 1 |
| Kazbariene, B | 1 |
| Aleknavicius, E | 1 |
| Krikstaponiene, A | 1 |
| Venceviciene, L | 1 |
| Suziedelis, K | 1 |
| Stratilatovas, E | 1 |
| Didziapetriene, J | 1 |
| Choi, YR | 1 |
| Hur, BY | 1 |
| Han, JK | 2 |
| Ruff, P | 10 |
| Lakomy, R | 5 |
| Prausova, J | 13 |
| van Hazel, GA | 11 |
| Moiseyenko, VM | 6 |
| Soussan-Lazard, K | 2 |
| Dochy, E | 2 |
| Magherini, E | 3 |
| Macarulla, T | 6 |
| Papamichael, D | 8 |
| Kamel, KM | 1 |
| Khalil, IA | 1 |
| Rateb, ME | 1 |
| Elgendy, H | 1 |
| Elhawary, S | 1 |
| Chong, D | 1 |
| Huo, Q | 1 |
| Lévi, F | 37 |
| Saffroy, R | 2 |
| Hebbar, M | 15 |
| Innominato, P | 4 |
| Carvalho, C | 5 |
| Milano, G | 30 |
| Lemoine, A | 4 |
| Pariente, R | 1 |
| Bejarano, I | 1 |
| Rodríguez, AB | 1 |
| Pariente, JA | 1 |
| Espino, J | 1 |
| Persia, FA | 1 |
| Rinaldini, E | 1 |
| Carrión, A | 1 |
| Hapon, MB | 1 |
| Gamarra-Luques, C | 1 |
| Vu, T | 1 |
| Yuan, G | 1 |
| Datta, PK | 2 |
| Fior, R | 1 |
| Póvoa, V | 1 |
| Mendes, RV | 1 |
| Carvalho, T | 1 |
| Gomes, A | 1 |
| Figueiredo, N | 1 |
| Ferreira, MG | 1 |
| Kaiga, T | 1 |
| Funada, T | 1 |
| Taketani, A | 1 |
| Andriana, BB | 1 |
| Matsuyoshi, H | 1 |
| Caraglia, M | 5 |
| Mi, H | 1 |
| Peter, CCK | 1 |
| Fu, H | 1 |
| Lai, Z | 2 |
| Peng, J | 5 |
| Zhang, RX | 3 |
| Lei, J | 1 |
| Li, LR | 2 |
| Huang, JQ | 1 |
| Kong, LH | 2 |
| Wang, FL | 2 |
| Ke, CF | 1 |
| Zhou, WH | 1 |
| Wan, DS | 7 |
| Wu, XJ | 5 |
| De Weerdt, A | 1 |
| Dendooven, A | 1 |
| Snoeckx, A | 1 |
| Pen, J | 1 |
| Lammens, M | 1 |
| Jorens, PG | 1 |
| Hara, K | 1 |
| Uchida, E | 1 |
| Braghiroli, MI | 2 |
| Artioli, M | 1 |
| Paterlini, ACCR | 1 |
| Teixeira, MC | 1 |
| Gumz, BP | 1 |
| Girardi, DDM | 1 |
| Braghiroli, OFM | 1 |
| Costa, FP | 1 |
| Miller, CL | 1 |
| Taylor, MS | 1 |
| Qadan, M | 1 |
| Deshpande, V | 1 |
| Worthington, S | 1 |
| Smalley, R | 1 |
| Collura, C | 1 |
| Ryan, DP | 11 |
| Allen, JN | 1 |
| Blaszkowsky, LS | 1 |
| Clark, JW | 15 |
| Murphy, JE | 1 |
| Parikh, AR | 1 |
| Berger, D | 1 |
| Tanabe, KK | 1 |
| Lillemoe, KD | 1 |
| Ferrone, CR | 1 |
| Marques, RP | 1 |
| Duarte, GS | 1 |
| Sterrantino, C | 1 |
| Pais, HL | 1 |
| Quintela, A | 1 |
| Martins, AP | 1 |
| Costa, J | 1 |
| Devarasetty, M | 1 |
| Skardal, A | 1 |
| Cowdrick, K | 1 |
| Marini, F | 1 |
| Soker, S | 1 |
| Payette, E | 1 |
| Sarker, S | 1 |
| Daniele, B | 5 |
| Ferrari, D | 1 |
| Cavanna, L | 3 |
| Sozzi, P | 1 |
| Germano, D | 1 |
| Codecà, C | 1 |
| Lieto, E | 2 |
| Auricchio, A | 1 |
| Cardella, F | 1 |
| Mabilia, A | 1 |
| Basile, N | 1 |
| Castellano, P | 1 |
| Orditura, M | 6 |
| Galizia, G | 3 |
| Chan, K | 1 |
| Qi, Y | 2 |
| Ning, F | 1 |
| Wu, M | 2 |
| Cai, S | 5 |
| Esposito Abate, R | 1 |
| Lambiase, M | 4 |
| Forgione, L | 1 |
| Cardone, C | 2 |
| Iannaccone, A | 1 |
| Sacco, A | 1 |
| Biglietto, M | 4 |
| Yuan, YF | 1 |
| Lin, HC | 1 |
| Li, BK | 1 |
| Sun, P | 1 |
| Yan, SM | 1 |
| Zhang, YZ | 1 |
| An, JH | 1 |
| Liu, YX | 1 |
| Wu, XC | 1 |
| Han, SS | 1 |
| Ren, XQ | 1 |
| Qin, CJ | 1 |
| Shi, Q | 4 |
| Alberts, SR | 15 |
| Meyers, JP | 1 |
| Smyrk, TC | 2 |
| Julie, C | 3 |
| Zawadi, A | 1 |
| Mini, E | 11 |
| Van Laethem, JL | 5 |
| Sargent, DJ | 28 |
| Sinicrope, FA | 5 |
| Moussallem, T | 1 |
| Lim, C | 1 |
| Osseis, M | 2 |
| Esposito, F | 2 |
| Lahat, E | 1 |
| Fuentes, L | 1 |
| Salloum, C | 1 |
| Azoulay, D | 9 |
| Ouine, B | 1 |
| Canet, J | 1 |
| Cartier, A | 1 |
| Amar, Y | 1 |
| Cacheux, W | 3 |
| Mariani, O | 1 |
| Selves, J | 5 |
| Guyetant, S | 1 |
| Bieche, I | 2 |
| Berger, F | 2 |
| de Koning, L | 1 |
| Wei, Q | 2 |
| Gao, J | 3 |
| Que, K | 1 |
| Que, G | 1 |
| Maillard, E | 5 |
| Kirscher, S | 3 |
| Etienne, PL | 10 |
| Faroux, R | 12 |
| El Hajbi, F | 2 |
| Rinaldi, Y | 4 |
| Lavau-Denes, S | 4 |
| Baconnier, M | 2 |
| Oden-Gangloff, A | 2 |
| Genet, D | 6 |
| Paillaud, E | 3 |
| Retornaz, F | 2 |
| Bedenne, L | 12 |
| Schneiderova, M | 2 |
| Gaetano, CD | 1 |
| Jiraskova, K | 2 |
| Veskrna, K | 1 |
| Landi, S | 1 |
| Jiang, D | 2 |
| Han, C | 2 |
| de Camargo, MR | 1 |
| Gorgulho, CM | 1 |
| Rodrigues, CP | 1 |
| Penitenti, M | 1 |
| Frederico, JCL | 1 |
| Rodrigues, MAM | 1 |
| Kaneno, R | 1 |
| Kajitani, T | 1 |
| Arita, S | 2 |
| Oda, H | 1 |
| Ochiai, H | 4 |
| Siena, S | 11 |
| Koukakis, R | 8 |
| Demonty, G | 5 |
| Bubalo, JS | 1 |
| Herrington, JD | 1 |
| Takemoto, M | 1 |
| Willman, P | 1 |
| Edwards, MS | 1 |
| Williams, C | 1 |
| Fisher, A | 1 |
| Palumbo, A | 1 |
| Prenen, H | 6 |
| Köhne, CH | 49 |
| Nasir, SN | 1 |
| Abu, N | 1 |
| Ab Mutalib, NS | 1 |
| Ishak, M | 1 |
| Sagap, I | 1 |
| Mazlan, L | 1 |
| Rose, IM | 1 |
| Jamal, R | 1 |
| Cen, C | 1 |
| Ai, X | 1 |
| Lin, C | 2 |
| Tang, YC | 1 |
| Zhi, Q | 2 |
| Wu, MY | 2 |
| Gong, FR | 2 |
| Shen, M | 1 |
| Tao, M | 2 |
| Gu, DM | 1 |
| Xu, MD | 2 |
| Mohammed, MO | 1 |
| Hussain, KS | 1 |
| Haj, NQ | 1 |
| Lee, KC | 1 |
| Lin, CT | 1 |
| Chang, SF | 3 |
| Chen, CN | 1 |
| Liu, JL | 1 |
| Huang, WS | 1 |
| Codony-Servat, J | 3 |
| Cuatrecasas, M | 2 |
| Asensio, E | 1 |
| Montironi, C | 1 |
| Martínez-Cardús, A | 6 |
| Marín-Aguilera, M | 1 |
| Horndler, C | 3 |
| Martínez-Balibrea, E | 10 |
| Rubini, M | 1 |
| Jares, P | 2 |
| Reig, O | 1 |
| Victoria, I | 1 |
| Gaba, L | 1 |
| Martín-Richard, M | 4 |
| Méndez, M | 4 |
| Castells, A | 13 |
| Prat, A | 1 |
| Rosell, R | 5 |
| García-Albéniz, X | 3 |
| Camps, J | 1 |
| Nahid, NA | 1 |
| Apu, MNH | 1 |
| Islam, MR | 1 |
| Shabnaz, S | 1 |
| Chowdhury, SM | 1 |
| Ahmed, MU | 1 |
| Nahar, Z | 1 |
| Islam, MS | 2 |
| Hasnat, A | 1 |
| Virgone-Carlotta, A | 1 |
| Lemasson, M | 1 |
| Monnier, S | 1 |
| Dehoux, T | 1 |
| Delanoë-Ayari, H | 1 |
| Rivière, C | 1 |
| Rieu, JP | 1 |
| Han, L | 1 |
| Deal, AM | 3 |
| Shachar, SS | 1 |
| Walko, CM | 5 |
| Patel, JN | 2 |
| Weinberg, MS | 1 |
| Choi, SK | 1 |
| Muss, HB | 1 |
| Sanoff, HK | 5 |
| Pak, LM | 1 |
| Boucher, T | 1 |
| DeMatteo, RP | 5 |
| Acharya, G | 1 |
| Cruz Carreras, MT | 1 |
| Rice, TW | 1 |
| Lan, C | 1 |
| Jiao, G | 1 |
| Fu, W | 1 |
| Long, X | 1 |
| An, Y | 1 |
| Chen, T | 1 |
| Zheng, Q | 1 |
| Cioffi, JH | 1 |
| Estes, DJ | 1 |
| Florou, V | 1 |
| Ardalan, B | 10 |
| Kamal, T | 1 |
| Sarfraz, M | 1 |
| Arafat, M | 1 |
| Mikov, M | 1 |
| Rahman, N | 1 |
| Modest, HI | 1 |
| Su, M | 1 |
| Qin, B | 2 |
| Grem, JL | 15 |
| Mulcahy, MF | 3 |
| Catalano, PJ | 5 |
| Kauh, JS | 1 |
| Hall, MJ | 2 |
| Saltzman, JN | 1 |
| Zangmeister, J | 1 |
| Chiorean, EG | 1 |
| Cheema, PS | 1 |
| O'Dwyer, PJ | 19 |
| Karimi Dermani, F | 1 |
| Jalili-Nik, M | 1 |
| Soltani, A | 1 |
| Moussavi, S | 1 |
| Cohn, AL | 11 |
| Obermannova, R | 5 |
| Ciuleanu, TE | 8 |
| Portnoy, DC | 3 |
| Siegel, RW | 1 |
| Konrad, RJ | 1 |
| Ouyang, H | 1 |
| Melemed, SA | 1 |
| Ferry, D | 3 |
| Nasroulah, F | 7 |
| Velut, G | 1 |
| Kourie, RH | 1 |
| Amouyal, G | 1 |
| Sapoval, M | 1 |
| Pointet, AL | 2 |
| Landi, B | 5 |
| Zaimi, Y | 1 |
| Lepère, C | 5 |
| Sönnichsen, R | 1 |
| Hennig, L | 1 |
| Blaschke, V | 1 |
| Winter, K | 1 |
| Körfer, J | 1 |
| Hähnel, S | 1 |
| Monecke, A | 1 |
| Wittekind, C | 1 |
| Jansen-Winkeln, B | 1 |
| Thieme, R | 1 |
| Gockel, I | 2 |
| Grosser, K | 1 |
| Weimann, A | 2 |
| Kubick, C | 1 |
| Wiechmann, V | 1 |
| Aigner, A | 1 |
| Bechmann, I | 1 |
| Lordick, F | 9 |
| Kallendrusch, S | 1 |
| Gu, K | 1 |
| Castro-Rojas, CA | 1 |
| Esparza-Mota, AR | 1 |
| Hernandez-Cabrera, F | 1 |
| Romero-Diaz, VJ | 1 |
| Gonzalez-Guerrero, JF | 1 |
| Maldonado-Garza, H | 1 |
| Garcia-Gonzalez, IS | 1 |
| Buenaventura-Cisneros, S | 1 |
| Sanchez-Lopez, JY | 1 |
| Camacho-Morales, A | 1 |
| Barboza-Quintana, O | 1 |
| Rojas-Martinez, A | 1 |
| Shaojun, C | 1 |
| Haixin, H | 1 |
| Guisheng, L | 1 |
| Jo, YK | 2 |
| Park, NY | 1 |
| Shin, JH | 1 |
| Jo, DS | 1 |
| Bae, JE | 1 |
| Choi, ES | 1 |
| Maeng, S | 1 |
| Jeon, HB | 1 |
| Chang, JW | 1 |
| Emi, Y | 12 |
| Ogata, Y | 12 |
| Akagi, Y | 10 |
| Sakamoto, Y | 8 |
| Maehara, Y | 22 |
| Kuriyama, A | 1 |
| Endo, K | 3 |
| Shimodaira, H | 3 |
| Linnekamp, JF | 1 |
| Hooff, SRV | 1 |
| Prasetyanti, PR | 1 |
| Buikhuisen, JY | 1 |
| Fessler, E | 1 |
| Ramesh, P | 1 |
| Lee, KAST | 1 |
| Bochove, GGW | 1 |
| de Jong, JH | 1 |
| Cameron, K | 2 |
| Leersum, RV | 1 |
| Franitza, M | 1 |
| Nürnberg, P | 1 |
| Mangiapane, LR | 1 |
| Stassi, G | 2 |
| Medema, JP | 3 |
| Fan, H | 2 |
| Shida, T | 1 |
| Yoshioka, T | 3 |
| Ono, Y | 2 |
| Inoue, T | 7 |
| Torén, W | 1 |
| Ansari, D | 1 |
| Andersson, B | 1 |
| Spelt, L | 1 |
| Andersson, R | 2 |
| Zeppola, T | 1 |
| Stellato, M | 1 |
| Chiara, S | 12 |
| Tomcikova, D | 1 |
| Ferrarotto, R | 2 |
| George, B | 1 |
| Qiao, W | 1 |
| Machado, KK | 1 |
| Saltz, LB | 15 |
| Vauthey, JN | 10 |
| Hobbs, B | 1 |
| Loyer, EM | 3 |
| Cotte, AK | 1 |
| Aires, V | 1 |
| Fredon, M | 1 |
| Limagne, E | 2 |
| Derangère, V | 2 |
| Thibaudin, M | 2 |
| Humblin, E | 1 |
| Scagliarini, A | 1 |
| de Barros, JP | 1 |
| Hillon, P | 1 |
| Delmas, D | 2 |
| Trojan, J | 1 |
| Ocvirk, J | 6 |
| Schulz, H | 1 |
| Homann, N | 1 |
| Feustel, HP | 1 |
| Schatz, M | 3 |
| Kripp, M | 1 |
| Schulte, N | 1 |
| Tetyusheva, M | 1 |
| Heeger, S | 2 |
| Vlassak, S | 1 |
| Merx, K | 1 |
| Hu, F | 2 |
| Buggin, F | 1 |
| Lutrino, ES | 1 |
| Lucchetti, J | 1 |
| Arnoldi, E | 3 |
| Zou, C | 2 |
| Naghibalhossaini, F | 2 |
| Shefaghat, M | 1 |
| Mansouri, A | 1 |
| Jaberi, H | 1 |
| Tatar, M | 1 |
| Eftekhar, E | 2 |
| Osada, S | 2 |
| Gotoh, A | 1 |
| Yokoi, R | 1 |
| Tsuchiya, H | 1 |
| Sakuratani, T | 1 |
| Okumura, N | 1 |
| Hayashi, H | 8 |
| Mukai, T | 1 |
| Hermunen, K | 3 |
| Lantto, E | 1 |
| Haglund, C | 2 |
| Ding, F | 1 |
| Bai, G | 1 |
| Doi, Y | 2 |
| Yamaoku, K | 1 |
| Takata, K | 1 |
| Matsuura, H | 1 |
| Yoneyama, K | 1 |
| Kameda, Y | 2 |
| Kuang, YS | 1 |
| Ding, LD | 1 |
| Liu, SH | 2 |
| Zhu, BT | 1 |
| Wang, XN | 2 |
| Liu, HY | 2 |
| Chang, ZJ | 1 |
| Wang, YY | 1 |
| Jia, BQ | 1 |
| Tanabe, Y | 1 |
| Takano, T | 3 |
| Tessitore, A | 1 |
| Bruera, G | 5 |
| Mastroiaco, V | 1 |
| Cocciolone, V | 1 |
| Dal Mas, A | 1 |
| Calvisi, G | 1 |
| Zazzeroni, F | 1 |
| Ricevuto, E | 7 |
| Alesse, E | 1 |
| Ünal, E | 2 |
| Karaosmanoğlu, AD | 1 |
| Ozmen, MN | 1 |
| Akata, D | 1 |
| Karcaaltincaba, M | 1 |
| Tai, J | 1 |
| Yu, M | 4 |
| Ren, D | 3 |
| Mescoli, C | 2 |
| Coltelli, L | 1 |
| Lupi, C | 5 |
| Gemma, D | 2 |
| Di Fabio, F | 3 |
| Mancini, ML | 2 |
| Marcucci, L | 4 |
| Baratelli, C | 4 |
| Brizzi, MP | 5 |
| Sonetto, C | 2 |
| Scagliotti, GV | 5 |
| Wen, S | 2 |
| Shen, J | 4 |
| Pu, J | 1 |
| Liang, H | 7 |
| Schelhaas, S | 1 |
| Wachsmuth, L | 1 |
| Hermann, S | 1 |
| Rieder, N | 1 |
| Heller, A | 1 |
| Heinzmann, K | 1 |
| Honess, DJ | 1 |
| Smith, DM | 1 |
| Fricke, IB | 1 |
| Just, N | 1 |
| Doblas, S | 1 |
| Sinkus, R | 1 |
| Döring, C | 1 |
| Schäfers, KP | 1 |
| Griffiths, JR | 3 |
| Faber, C | 1 |
| Schneider, R | 1 |
| Aboagye, EO | 2 |
| Jacobs, AH | 1 |
| Lledo, G | 18 |
| Vigano, L | 3 |
| Darwish, SS | 1 |
| Cimino, M | 1 |
| Carnaghi, C | 5 |
| Donadon, M | 2 |
| Procopio, F | 1 |
| Personeni, N | 3 |
| Del Fabbro, D | 1 |
| Santoro, A | 6 |
| Torzilli, G | 1 |
| Reiser, MF | 1 |
| Baumann, AB | 1 |
| Tikhonova, IA | 1 |
| Huxley, N | 1 |
| Snowsill, T | 1 |
| Crathorne, L | 1 |
| Varley-Campbell, J | 1 |
| Napier, M | 1 |
| Hoyle, M | 2 |
| Takemoto, H | 8 |
| Takano, N | 3 |
| Kataoka, M | 3 |
| Gao, G | 1 |
| Qian, X | 2 |
| Nakayama, G | 4 |
| Sakisaka, H | 1 |
| Cashin, PH | 2 |
| Mahteme, H | 5 |
| Syk, I | 2 |
| Frödin, JE | 6 |
| Mennitto, A | 2 |
| Pellegrinelli, A | 3 |
| Mazzaferro, V | 1 |
| Murcia, O | 2 |
| Jover, R | 9 |
| Egoavil, C | 2 |
| Perez-Carbonell, L | 3 |
| Juárez, M | 2 |
| Hernández-Illán, E | 2 |
| Rojas, E | 2 |
| Alenda, C | 5 |
| Andreu, M | 8 |
| Llor, X | 8 |
| Boland, CR | 6 |
| Duo, Y | 1 |
| Bi, J | 1 |
| Mei, L | 1 |
| Bao, S | 1 |
| Shan, A | 1 |
| Price, TJ | 20 |
| Liu, GW | 1 |
| Liu, YH | 1 |
| Jiang, GS | 1 |
| Ren, WD | 1 |
| Yasar, N | 2 |
| Pastorino, A | 1 |
| Iaffaioli, V | 1 |
| Fasola, G | 4 |
| Zilocchi, C | 2 |
| Scudder, C | 3 |
| Briggs, A | 1 |
| Berardi, G | 1 |
| De Man, M | 1 |
| Laurent, S | 3 |
| Smeets, P | 3 |
| Tomassini, F | 1 |
| Ariotti, R | 1 |
| Hoorens, A | 1 |
| van Dorpe, J | 1 |
| Varin, O | 1 |
| Geboes, K | 4 |
| Troisi, RI | 1 |
| Tamura, A | 2 |
| Uesugi, N | 2 |
| Osakabe, M | 1 |
| Eizuka, M | 1 |
| Hasegawa, Y | 2 |
| Nitta, H | 2 |
| Otsuka, K | 2 |
| Sasaki, A | 1 |
| Ehara, S | 2 |
| Sugai, T | 2 |
| Ren, W | 2 |
| Jorge, AF | 1 |
| Aviñó, A | 1 |
| Pais, AACC | 1 |
| Eritja, R | 1 |
| Fàbrega, C | 1 |
| Zhan, L | 1 |
| Moran, M | 2 |
| Zeger, G | 1 |
| Astrow, SH | 2 |
| Laurinavicius, A | 1 |
| Sakurai, M | 2 |
| Umata, K | 1 |
| Ohama, T | 1 |
| Jonker, DJ | 2 |
| Tang, PA | 2 |
| Welch, SA | 1 |
| Cripps, MC | 1 |
| Asmis, T | 2 |
| Tomiak, A | 4 |
| Alcindor, T | 3 |
| Goffin, JR | 1 |
| Korpanty, GJ | 1 |
| Feilotter, H | 1 |
| Tsao, MS | 1 |
| Theis, A | 1 |
| Tu, D | 4 |
| Seymour, L | 4 |
| Spagnoletti, G | 1 |
| Li Bergolis, V | 1 |
| Piscazzi, A | 2 |
| Giannelli, F | 1 |
| Condelli, V | 1 |
| Sisinni, L | 1 |
| Bove, G | 1 |
| Storto, G | 1 |
| Landriscina, M | 3 |
| Landre, T | 3 |
| Taleb, C | 2 |
| Ghebriou, D | 1 |
| Guetz, GD | 1 |
| Zelek, L | 4 |
| Munker, S | 1 |
| Gerken, M | 1 |
| Fest, P | 1 |
| Ott, C | 1 |
| Schnoy, E | 1 |
| Fichtner-Feigl, S | 1 |
| Wiggermann, P | 1 |
| Vogelhuber, M | 1 |
| Herr, W | 1 |
| Stroszczynski, C | 4 |
| Evert, M | 1 |
| Reng, M | 1 |
| Klinkhammer-Schalke, M | 1 |
| Teufel, A | 4 |
| Jiang, S | 2 |
| Song, C | 1 |
| Miao, D | 2 |
| Lv, J | 2 |
| Zhu, JH | 1 |
| Yao, XQ | 1 |
| Sun, T | 1 |
| Tucci, M | 1 |
| Claret, L | 3 |
| Pentafragka, C | 1 |
| Karovic, S | 1 |
| Maitland, ML | 1 |
| Bironzo, P | 1 |
| Xie, C | 3 |
| Peng, P | 1 |
| Zang, A | 2 |
| Odisio, BC | 1 |
| Simoneau, E | 1 |
| Holmes, AA | 1 |
| Conrad, CH | 1 |
| Nie, J | 3 |
| Guo, M | 1 |
| Han, W | 4 |
| Yue, H | 1 |
| Yang, F | 4 |
| Xia, E | 1 |
| Wang, O | 1 |
| Catalano, C | 1 |
| da Silva Filho, MI | 1 |
| Liska, V | 3 |
| Vycital, O | 3 |
| Hemminki, K | 2 |
| Weber, ANR | 1 |
| Försti, A | 2 |
| Lin, JY | 1 |
| Chi, YJ | 1 |
| Chen, EY | 2 |
| Haller, DG | 14 |
| Dragovich, T | 1 |
| Robles, C | 1 |
| Mattek, N | 1 |
| Sanborn, RE | 1 |
| Abbas, MK | 1 |
| Huynh, M | 1 |
| Zou, F | 1 |
| Peng, R | 1 |
| Gajjar, KK | 1 |
| Vora, HH | 1 |
| Kobawala, TP | 1 |
| Trivedi, TI | 1 |
| Ghosh, NR | 1 |
| Zawiah, M | 2 |
| Al-Yacoub, S | 2 |
| Kadi, T | 2 |
| Tantawi, DA | 1 |
| Al-Ramadhani, H | 1 |
| Orlandi, A | 3 |
| Fenizia, F | 3 |
| Soto Parra, H | 1 |
| Frassinetti, GL | 1 |
| Repetto, L | 2 |
| Barone, C | 21 |
| Jiao, N | 2 |
| Shu, Y | 4 |
| McSkane, M | 1 |
| Lin, YM | 2 |
| Hsiang, YP | 1 |
| Hsu, YC | 1 |
| Cheng, KC | 1 |
| Chien, PH | 1 |
| Pan, HL | 1 |
| Lu, CC | 1 |
| Ivanova, A | 2 |
| O'Reilly, S | 5 |
| Kasbari, SS | 1 |
| Moore, DT | 1 |
| Zamboni, W | 2 |
| Grogan, W | 1 |
| Leonard, G | 2 |
| Ryan, T | 1 |
| Olowokure, OO | 1 |
| Fernando, NH | 3 |
| McCaffrey, J | 1 |
| Horgan, AM | 1 |
| Sherrill, GB | 2 |
| Yacoub, GH | 1 |
| Yan, P | 1 |
| Dietrich, D | 4 |
| Brauchli, P | 4 |
| Klingbiel, D | 1 |
| Fiocca, R | 1 |
| Delorenzi, M | 2 |
| Bosman, F | 2 |
| Roth, AD | 8 |
| Sánchez-Gundín, J | 2 |
| Fernández-Carballido, AM | 2 |
| Martínez-Valdivieso, L | 1 |
| Barreda-Hernández, D | 2 |
| Torres-Suárez, AI | 2 |
| El-Fatatry, BM | 1 |
| Ibrahim, OM | 1 |
| Hussien, FZ | 1 |
| Mostafa, TM | 1 |
| Huang, SZ | 1 |
| Liu, WY | 1 |
| Shen, AL | 1 |
| Liu, LY | 2 |
| Harty, G | 1 |
| Jarrett, J | 1 |
| Jofre-Bonet, M | 1 |
| Song, K | 1 |
| Cai, H | 5 |
| Zheng, W | 5 |
| Li, N | 8 |
| Semira, C | 2 |
| Lee, B | 3 |
| Lee, M | 4 |
| Kosmider, S | 3 |
| Shapiro, J | 4 |
| Ma, B | 7 |
| Dean, AP | 1 |
| Zimet, AS | 1 |
| Steel, SA | 1 |
| Lok, SW | 1 |
| Torres, J | 1 |
| Eastgate, M | 1 |
| Wong, HL | 4 |
| Berger, AK | 1 |
| Lücke, S | 1 |
| Abel, U | 2 |
| Haag, GM | 1 |
| Grüllich, C | 1 |
| Stange, A | 1 |
| Dietrich, M | 1 |
| Apostolidis, L | 1 |
| Freitag, A | 1 |
| Trierweiler, C | 1 |
| von Gall, C | 1 |
| Ose, J | 1 |
| Giesel, F | 1 |
| Weber, TF | 1 |
| Haberkorn, U | 6 |
| Álvarez-Gallego, R | 1 |
| Muñoz, M | 1 |
| Pond, G | 1 |
| Perea, S | 3 |
| Sánchez, G | 3 |
| Martin, M | 9 |
| Rodríguez-Pascual, J | 2 |
| Garralda, E | 2 |
| Vega, E | 2 |
| de Vicente, E | 2 |
| Quijano, Y | 2 |
| Muñoz, C | 1 |
| Ugidos, L | 1 |
| Toledo, RA | 2 |
| Hidalgo, M | 8 |
| Karavasilis, V | 3 |
| Aravantinos, G | 6 |
| Kalogeropoulou, L | 1 |
| Souglakos, I | 1 |
| Kentepozidis, N | 3 |
| Koumakis, G | 1 |
| Zarkavelis, G | 1 |
| Laschos, K | 1 |
| Petraki, C | 1 |
| Tikas, I | 1 |
| Poulios, C | 1 |
| Voutsina, A | 3 |
| Goudopoulou, A | 1 |
| Vrettou, E | 2 |
| Kalogera-Fountzila, A | 1 |
| Yazdi, M | 1 |
| Shayan, P | 4 |
| Huo, Z | 1 |
| Canon, JL | 8 |
| Akin, S | 1 |
| Kas Guner, C | 1 |
| Sturrock, M | 1 |
| Miller, IS | 1 |
| Kang, G | 1 |
| Hannis Arba'ie, N | 1 |
| O'Farrell, AC | 1 |
| Barat, A | 1 |
| Marston, G | 1 |
| Coletta, PL | 1 |
| Byrne, AT | 1 |
| Prehn, JH | 5 |
| Guillén-Ponce, C | 4 |
| Alcaide, J | 2 |
| López, R | 7 |
| Méndez Ureña, M | 2 |
| García, T | 3 |
| Martín-Valadés, JI | 1 |
| Falcó, E | 4 |
| Navalón, M | 3 |
| Ma García Tapiador, A | 1 |
| Ma López Muñoz, A | 1 |
| Barrajón, E | 1 |
| Reboredo, M | 5 |
| García Teijido, P | 1 |
| Viudez, A | 3 |
| Cárdenas, N | 1 |
| Bencardino, K | 2 |
| Park, MH | 2 |
| Baek, JH | 5 |
| Li, DD | 1 |
| Zhao, CH | 1 |
| Ding, HW | 1 |
| Ren, TS | 1 |
| Chen, CQ | 1 |
| Zhao, QC | 1 |
| Song, R | 1 |
| Gu, D | 1 |
| Xie, J | 2 |
| Ren, F | 1 |
| Li, K | 1 |
| Benhaim, L | 7 |
| Deschamps, F | 3 |
| Anwar, A | 1 |
| Uddin, N | 1 |
| Siddiqui, BS | 1 |
| Siddiqui, RA | 1 |
| Begum, S | 1 |
| Choudhary, MI | 1 |
| Eckstrom, J | 1 |
| Bartels, T | 1 |
| Abraham, I | 1 |
| Patel, H | 2 |
| Elquza, E | 1 |
| Scott, AJ | 1 |
| Malangone, S | 1 |
| Hollings, J | 1 |
| McBride, A | 1 |
| Graham, CN | 3 |
| Christodoulopoulou, A | 1 |
| Knox, HN | 2 |
| Sabatelli, L | 1 |
| Hechmati, G | 4 |
| Garawin, T | 1 |
| Shui, L | 1 |
| Wu, YS | 1 |
| Shui, P | 1 |
| Hubert, C | 2 |
| Lucidi, V | 2 |
| Weerts, J | 4 |
| Dili, A | 1 |
| Demetter, P | 1 |
| Massart, B | 1 |
| Komuta, M | 1 |
| Navez, J | 1 |
| Reding, R | 1 |
| Gigot, JF | 3 |
| Sempoux, C | 3 |
| Yue, GG | 1 |
| Tsui, SK | 1 |
| Fung, KP | 1 |
| Lau, CB | 1 |
| Oweira, H | 1 |
| Giryes, A | 1 |
| Mannhart, M | 1 |
| Decker, M | 1 |
| Grisoni, ML | 1 |
| Liebaert, F | 1 |
| Montestruc, F | 1 |
| Thiébaut, R | 1 |
| Alexandrou, C | 1 |
| Al-Aqbi, SS | 1 |
| Higgins, JA | 2 |
| Boyle, W | 1 |
| Karmokar, A | 2 |
| Andreadi, C | 1 |
| Luo, JL | 1 |
| Moore, DA | 1 |
| Viskaduraki, M | 1 |
| Blades, M | 1 |
| Murray, GI | 3 |
| Howells, LM | 4 |
| Thomas, A | 4 |
| Brown, K | 5 |
| Cheng, PN | 1 |
| Rufini, A | 1 |
| Zhou, S | 1 |
| SekharKathera, C | 1 |
| Janardhan, A | 1 |
| Edick, AM | 1 |
| Zhang, A | 1 |
| Pan, F | 3 |
| Colley, JP | 1 |
| Maynard, J | 1 |
| Humphreys, V | 1 |
| Adams, RA | 5 |
| Idziaszczyk, S | 2 |
| Harris, R | 2 |
| Lim, R | 6 |
| Ba, Y | 5 |
| Bai, Y | 3 |
| Fan, N | 1 |
| Wei, V | 1 |
| Shi, D | 2 |
| Muñoz, A | 5 |
| López-Ladrón, A | 2 |
| Ruiz de Mena, I | 1 |
| Rezaei, N | 1 |
| Boroumand, N | 1 |
| Nosrati-Tirkani, A | 1 |
| Takada, S | 1 |
| Sagawa, T | 3 |
| Fujikawa, K | 3 |
| Tahatsu, K | 1 |
| Fukai, Y | 1 |
| Hashishita, H | 1 |
| Endo, M | 3 |
| Lin, Y | 2 |
| Pan, D | 1 |
| Zheng, C | 1 |
| Krajewska, JB | 1 |
| Bartoszek, A | 1 |
| Fichna, J | 1 |
| Rodríguez-Soler, M | 1 |
| Giner-Calabuig, M | 1 |
| Alustiza, M | 1 |
| Castillejo, A | 1 |
| Barberá, V | 1 |
| Mangas-Sanjuan, C | 1 |
| Yuste, A | 1 |
| Clofent, J | 4 |
| Zapater, P | 4 |
| Delgado-Ureña, M | 1 |
| Ortega, FG | 1 |
| de Miguel-Pérez, D | 1 |
| Rodriguez-Martínez, A | 1 |
| García-Puche, JL | 1 |
| Ilyine, H | 1 |
| Lorente, JA | 1 |
| Exposito-Hernandez, J | 1 |
| Garrido-Navas, MC | 1 |
| Delgado-Ramirez, M | 1 |
| Serrano, MJ | 1 |
| Marjaneh, RM | 1 |
| Aghaee-Bakhtiari, SH | 1 |
| Yousef, M | 1 |
| Majdalawi, K | 1 |
| Al-Hiary, R | 1 |
| Tantawi, D | 1 |
| Mukred, R | 1 |
| Ajaj, AR | 1 |
| Hsiang, J | 1 |
| Stephens, C | 1 |
| Takagane, A | 2 |
| Tani, S | 2 |
| Eto, T | 1 |
| Fujii, M | 11 |
| Yuan, L | 1 |
| Mushtaq, N | 1 |
| Ullah, S | 1 |
| An, C | 1 |
| Field, K | 1 |
| Nott, L | 1 |
| Tran, B | 2 |
| Richardson, G | 1 |
| Zimet, A | 1 |
| Lipton, L | 2 |
| Tamjid, B | 1 |
| Johns, J | 2 |
| Harold, M | 1 |
| Idayu Mat Nawi, R | 1 |
| Lei Chui, P | 1 |
| Wan Ishak, WZ | 1 |
| Hsien Chan, CM | 1 |
| Kusano, M | 4 |
| Okabayashi, K | 5 |
| Nakamori, S | 2 |
| Asahara, T | 1 |
| Ohashi, Y | 8 |
| Saji, S | 13 |
| Romera, A | 1 |
| Peredpaya, S | 1 |
| Shparyk, Y | 2 |
| Bondarenko, I | 5 |
| Mendonça Bariani, G | 1 |
| Abdalla, KC | 2 |
| Roca, E | 1 |
| Franke, F | 1 |
| Melo Cruz, F | 1 |
| Ramesh, A | 1 |
| Ostwal, V | 2 |
| Shah, P | 1 |
| Rahuman, SA | 1 |
| Paravisini, A | 1 |
| Huerga, C | 1 |
| Del Campo García, A | 1 |
| Millán, S | 1 |
| Ling, J | 1 |
| Feng, L | 2 |
| Fang, G | 1 |
| Hong, D | 1 |
| Kamei, K | 1 |
| Hira, D | 1 |
| Noda, S | 2 |
| Terada, T | 1 |
| Lo, JH | 2 |
| Sales, MVC | 1 |
| Suemoto, CK | 1 |
| Apolinario, D | 1 |
| Serrao, V | 1 |
| Andrade, CS | 1 |
| Conceição, DM | 1 |
| Amaro, E | 1 |
| de Melo, BAR | 1 |
| Weldon Gilcrease, G | 1 |
| Stenehjem, DD | 1 |
| Wade, ML | 1 |
| Weis, J | 1 |
| Whisenant, J | 2 |
| Boucher, KM | 1 |
| Thorne, K | 1 |
| Orgain, N | 1 |
| Garrido-Laguna, I | 1 |
| Sharma, S | 3 |
| Zeynali-Moghaddam, S | 1 |
| Mohammadian, M | 1 |
| Kheradmand, F | 1 |
| Fathi-Azarbayjani, A | 1 |
| Esna-Ashari, O | 1 |
| Malekinejad, H | 1 |
| Ruan, H | 2 |
| Wu, L | 2 |
| Cheng, Y | 5 |
| Seo, GS | 3 |
| Tong, J | 2 |
| Ciuleanu, T | 3 |
| O'Connor, J | 1 |
| Wijayawardana, SR | 1 |
| Chu, JN | 1 |
| Ostvar, S | 1 |
| Torchia, JA | 1 |
| Reynolds, KL | 1 |
| Tramontano, A | 1 |
| Gainor, JF | 1 |
| Chung, DC | 1 |
| Hur, C | 1 |
| He, LJ | 1 |
| Ye, HZ | 1 |
| Liu, DF | 1 |
| Zhu, YB | 1 |
| Miao, DD | 1 |
| Zhang, SP | 1 |
| Jia, YW | 1 |
| Liu, XP | 1 |
| Dehlendorff, C | 3 |
| Rønholt, F | 1 |
| Johansen, JS | 6 |
| Nagata, H | 2 |
| Ishimaru, K | 1 |
| Kaneko, M | 6 |
| Hiyoshi, M | 4 |
| Otani, K | 3 |
| Shuno, Y | 2 |
| Nishikawa, T | 4 |
| Hata, K | 5 |
| Freiberg-Richter, J | 2 |
| Peveling Genannt Reddemann, C | 1 |
| Schuch, G | 3 |
| Hu, YB | 1 |
| Yan, C | 1 |
| Mu, L | 1 |
| Mi, YL | 1 |
| Tao, DD | 1 |
| Wu, YQ | 1 |
| Gong, JP | 1 |
| Qin, JC | 1 |
| Chakrabarti, S | 1 |
| Sara, J | 1 |
| Lobo, R | 1 |
| Eiring, R | 1 |
| Finnes, H | 1 |
| Mitchell, J | 2 |
| Hartgers, M | 1 |
| Okano, A | 1 |
| Halfdanarson, T | 1 |
| Bendardaf, R | 8 |
| Sharif-Askari, FS | 2 |
| Sharif-Askari, NS | 2 |
| Syrjänen, K | 5 |
| Pyrhönen, S | 12 |
| Rhoades, K | 1 |
| Smith, B | 1 |
| Honaker, MD | 1 |
| Hiret, S | 2 |
| Bertaut, A | 2 |
| Deplanque, G | 3 |
| Borel, C | 2 |
| Conroy, T | 12 |
| Seitz, JF | 20 |
| Stanbury, T | 1 |
| Denis, MG | 1 |
| Xi, J | 1 |
| Lin, HY | 1 |
| Kuo, WT | 1 |
| Hsu, CW | 2 |
| Han, D | 1 |
| Yang, R | 2 |
| Limaiem, F | 1 |
| Bouraoui, S | 1 |
| Li, XW | 1 |
| Qiu, SJ | 1 |
| Kaplan, DL | 1 |
| Lan, P | 5 |
| Saint-Jean, A | 1 |
| Reguart, N | 1 |
| Eixarch, A | 1 |
| Adán, A | 1 |
| Castellà, C | 1 |
| Sánchez-Dalmau, B | 1 |
| Sainz-de-la-Maza, M | 1 |
| Kim, Y | 3 |
| da Silva, WC | 1 |
| de Araujo, VE | 1 |
| Lima, EMEA | 1 |
| Dos Santos, JBR | 1 |
| Silva, MRRD | 1 |
| Almeida, PHRF | 1 |
| de Assis Acurcio, F | 1 |
| Godman, B | 1 |
| Kurdi, A | 1 |
| Cherchiglia, ML | 1 |
| Andrade, EIG | 1 |
| Gorbunova, V | 2 |
| Beck, JT | 1 |
| Nechaeva, M | 1 |
| Cubillo Gracian, A | 1 |
| Deming, DA | 1 |
| Ramanathan, RK | 17 |
| Torres, AH | 1 |
| Sullivan, D | 3 |
| Berlin, JD | 5 |
| Jing, C | 1 |
| Yang, JW | 1 |
| Zhang, QH | 1 |
| Akagi, J | 1 |
| Wong, GG | 1 |
| Ha, V | 1 |
| Chu, MP | 1 |
| Dersch-Mills, D | 1 |
| Ghosh, S | 1 |
| Chambers, CR | 1 |
| Sawyer, MB | 1 |
| Tan, BR | 2 |
| Reeves, JA | 1 |
| Somer, B | 1 |
| Scappaticci, F | 1 |
| Palma, JF | 1 |
| Price, R | 1 |
| Lee, JJ | 4 |
| Nicholas, A | 1 |
| Sommer, N | 1 |
| Hsu, TC | 1 |
| Wang, CC | 1 |
| Wu, B | 4 |
| Uchiumi, F | 1 |
| Tanuma, SI | 1 |
| Grigaitis, P | 1 |
| Dapkunas, J | 1 |
| Wasserman, I | 1 |
| Lee, LH | 1 |
| Ogino, S | 4 |
| Marco, MR | 1 |
| Datta, J | 1 |
| Sadot, E | 1 |
| Szeglin, B | 1 |
| Guillem, JG | 1 |
| Paty, PB | 2 |
| Weiser, MR | 1 |
| Nash, GM | 1 |
| Saltz, L | 12 |
| Barlas, A | 1 |
| Manova-Todorova, K | 1 |
| Uppada, SPB | 1 |
| Elghouayel, AE | 1 |
| Ntiamoah, P | 1 |
| Glickman, JN | 1 |
| Hamada, T | 1 |
| Kosumi, K | 1 |
| Inamura, K | 1 |
| Chan, AT | 4 |
| Nishihara, R | 1 |
| Ganesh, K | 1 |
| Dhawan, P | 1 |
| Sawyers, CL | 1 |
| Garcia-Aguilar, J | 1 |
| Giannakis, M | 1 |
| Shia, J | 4 |
| Smith, JJ | 1 |
| Sakatani, A | 1 |
| Sonohara, F | 1 |
| Kearney, MR | 1 |
| Vaccaro, GM | 1 |
| Strother, J | 1 |
| Burt, A | 1 |
| Todd, K | 1 |
| Donovan, J | 1 |
| Kampa-Schittenhelm, KM | 1 |
| Yehia, R | 1 |
| Saleh, S | 1 |
| El Abhar, H | 1 |
| Saad, AS | 1 |
| Schaalan, M | 1 |
| Ravindranathan, P | 1 |
| Pasham, D | 1 |
| Yoshihiro, T | 1 |
| Uenomachi, M | 1 |
| Ito, M | 2 |
| Mitsugi, K | 5 |
| Aikawa, T | 1 |
| Takayoshi, K | 1 |
| Ariyama, H | 4 |
| Akashi, K | 4 |
| Oyaga-Iriarte, E | 3 |
| Insausti, A | 3 |
| Sayar, O | 3 |
| Aldaz, A | 3 |
| Yasuno, M | 11 |
| Ishiguro, M | 3 |
| Mizunuma, N | 26 |
| Miyata, G | 1 |
| Shiomi, A | 1 |
| Bachet, JB | 5 |
| Douillard, JY | 34 |
| Youssof, AME | 1 |
| Alanazi, FK | 1 |
| Salem-Bekhit, MM | 1 |
| Shakeel, F | 2 |
| Haq, N | 1 |
| Sui, Y | 1 |
| Weng, W | 1 |
| Cai, G | 2 |
| Gouverneur, A | 1 |
| Coutureau, J | 1 |
| Jové, J | 2 |
| Rouyer, M | 2 |
| Grelaud, A | 2 |
| Duc, S | 1 |
| Gérard, S | 1 |
| Ravaud, A | 3 |
| Droz, C | 1 |
| Bernard, MA | 1 |
| Lassalle, R | 1 |
| Forrier-Réglat, A | 1 |
| Noize, P | 2 |
| Soveri, LM | 2 |
| Lamminmäki, A | 1 |
| Hänninen, UA | 1 |
| Karhunen, M | 1 |
| Bono, P | 2 |
| Sahin, T | 1 |
| Dizdar, O | 1 |
| Bilgin, B | 1 |
| Demir, M | 1 |
| Bozbulut, UB | 1 |
| Kilickap, S | 4 |
| Yalcin, S | 4 |
| Komarzynski, S | 1 |
| Ulusakarya, A | 2 |
| Haydar, M | 1 |
| Bossevot-Desmaris, R | 1 |
| Mocquery, M | 1 |
| Plessis, V | 1 |
| Short, SP | 1 |
| Thompson, JJ | 1 |
| Bilotta, AJ | 1 |
| Revetta, FL | 1 |
| Washington, MK | 2 |
| Williams, CS | 1 |
| Ge, XX | 1 |
| Chen, K | 7 |
| Shou, LM | 1 |
| Wang, WJ | 2 |
| Dost Gunay, FS | 1 |
| Kırmızı, BA | 1 |
| Ensari, A | 1 |
| İcli, F | 3 |
| Akbulut, H | 3 |
| Ahmed, O | 1 |
| Kiehl, M | 1 |
| Csoszi, T | 1 |
| Kafatos, G | 1 |
| Kuhn, A | 1 |
| Bjorklof, K | 1 |
| Yan, L | 2 |
| Yu, HH | 1 |
| Liu, YS | 3 |
| Wang, YS | 1 |
| Zhao, WH | 1 |
| Martínez Lago, N | 1 |
| González Villaroel, P | 1 |
| Luz Pellón Augusto, M | 1 |
| Graña Suárez, B | 1 |
| García Gómez, J | 1 |
| Umemura, K | 1 |
| Ishido, K | 1 |
| Kudo, D | 1 |
| Kimura, N | 2 |
| Morohashi, H | 2 |
| Hakamada, K | 2 |
| Tajima, Y | 10 |
| Hotta, S | 1 |
| Nakano, M | 3 |
| Kameyama, H | 2 |
| Miura, K | 4 |
| Nagahashi, M | 1 |
| Nogami, H | 1 |
| Maruyama, S | 10 |
| Wakai, T | 3 |
| Unson, S | 1 |
| Kongsaden, C | 1 |
| Wonganan, P | 1 |
| Chibaudel, B | 14 |
| Auby, D | 6 |
| Louvet, C | 51 |
| Lebrun-Ly, V | 2 |
| Dauba, J | 2 |
| Garcia, ML | 4 |
| Hamed, NB | 1 |
| Meurisse, A | 1 |
| Larsen, AK | 7 |
| Tijeras-Raballand, A | 1 |
| Bonnetain, F | 9 |
| Madurantakam Royam, M | 1 |
| Kumarasamy, C | 1 |
| Baxi, S | 1 |
| Gupta, A | 1 |
| Ramesh, N | 1 |
| Kodiveri Muthukaliannan, G | 1 |
| Jayaraj, R | 1 |
| Varghese, V | 1 |
| Magnani, L | 1 |
| Harada-Shoji, N | 1 |
| Mauri, F | 1 |
| Szydlo, RM | 1 |
| Lam, EW | 1 |
| Kenny, LM | 1 |
| Casagrande, M | 2 |
| Delfanti, S | 1 |
| Sensi, E | 6 |
| Rezkallah, KNM | 1 |
| Ahmed, A | 1 |
| Kozma, K | 1 |
| Lacas, B | 2 |
| Gasmi, M | 5 |
| Texereau, P | 5 |
| Gargot, D | 5 |
| Lombard-Bohas, C | 2 |
| Azzedine, A | 3 |
| Denis, B | 2 |
| Geoffroy, P | 2 |
| Borget, I | 2 |
| Roca-Lema, D | 1 |
| Martinez-Iglesias, O | 1 |
| Fernández de Ana Portela, C | 1 |
| Rodríguez-Blanco, A | 1 |
| Díaz-Díaz, A | 1 |
| Casas-Pais, A | 1 |
| Prego, C | 1 |
| Figueroa, A | 1 |
| He, K | 1 |
| Guo, Q | 1 |
| Huang, K | 2 |
| Ding, Q | 1 |
| Xiang, G | 1 |
| Morise, Z | 2 |
| Tanaka, C | 5 |
| Masumori, K | 2 |
| Koide, Y | 3 |
| Katsuno, H | 2 |
| Tanahashi, Y | 1 |
| Nakajima, S | 2 |
| Hanai, T | 2 |
| Kato, Y | 2 |
| Sugioka, A | 2 |
| Uyama, I | 1 |
| Bano, N | 5 |
| Ikram, R | 1 |
| Wei, F | 1 |
| Deng, SC | 1 |
| Wei, JC | 2 |
| Chen, ZP | 1 |
| Li, WL | 1 |
| Chen, HC | 5 |
| Jia, J | 3 |
| Gou, M | 1 |
| Qian, N | 1 |
| Sougiannis, AT | 1 |
| VanderVeen, BN | 1 |
| Enos, RT | 1 |
| Velazquez, KT | 1 |
| Bader, JE | 1 |
| Carson, M | 1 |
| Chatzistamou, I | 1 |
| Walla, M | 1 |
| Pena, MM | 1 |
| Kubinak, JL | 1 |
| Nagarkatti, M | 1 |
| Carson, JA | 1 |
| Murphy, EA | 1 |
| Strowitzki, MJ | 1 |
| Radhakrishnan, P | 2 |
| Pavicevic, S | 1 |
| Scheer, J | 1 |
| Kimmer, G | 1 |
| Ritter, AS | 1 |
| Tuffs, C | 1 |
| Volz, C | 1 |
| Vondran, F | 1 |
| Harnoss, JM | 1 |
| Klose, J | 1 |
| Schmidt, T | 2 |
| Schneider, M | 6 |
| Kazlauskas, A | 1 |
| Darinskas, A | 1 |
| Meškys, R | 1 |
| Tamašauskas, A | 1 |
| Urbonavičius, J | 1 |
| Santos, C | 3 |
| Azuara, D | 1 |
| Valladares, M | 7 |
| Robles-Díaz, L | 1 |
| Bugés, C | 1 |
| Navarro, V | 1 |
| Capellá, G | 3 |
| Salazar, R | 7 |
| Zhong, F | 1 |
| Guo, L | 1 |
| Ou, J | 2 |
| Yang, W | 1 |
| Hao, J | 2 |
| Zha, L | 1 |
| Xie, G | 2 |
| Sun, W | 5 |
| Salhia, B | 1 |
| Weisenberger, DJ | 1 |
| Liang, G | 1 |
| Rizzo, A | 1 |
| Palloni, A | 1 |
| Frega, G | 1 |
| Abbati, F | 1 |
| De Lorenzo, S | 1 |
| Brocchi, S | 1 |
| Brandi, G | 5 |
| Delahunty, R | 1 |
| Mckendrick, J | 6 |
| Cooray, P | 1 |
| Ananda, S | 1 |
| Desai, J | 2 |
| Torres, G | 1 |
| García, G | 1 |
| Gallego, I | 1 |
| Ortega, L | 1 |
| Sandoval, C | 1 |
| Lloansí, A | 1 |
| Ying, K | 1 |
| Chong, Y | 1 |
| Bing, D | 1 |
| Yanyan, S | 1 |
| Xuefeng, Y | 1 |
| Ke, L | 1 |
| Huijberts, S | 1 |
| Cuyle, PJ | 1 |
| Gollerkeri, A | 1 |
| Christy-Bittel, J | 1 |
| Maharry, K | 1 |
| Sandor, V | 2 |
| Schellens, JHM | 1 |
| Kumar, B | 1 |
| Murali, A | 1 |
| Bharath, AB | 1 |
| Giri, S | 1 |
| Oh, HJ | 1 |
| Wen, X | 1 |
| Jung, S | 1 |
| Iovu, H | 1 |
| Tanasa, EV | 1 |
| Georgiana Nitu, S | 1 |
| Negrei, C | 1 |
| Shtilman, M | 1 |
| Mimaki, S | 1 |
| Kawamoto, Y | 2 |
| Yamashita, R | 1 |
| Ohtsu, A | 17 |
| Conev, NV | 1 |
| Dimitrova, EG | 1 |
| Bogdanova, MK | 1 |
| Kashlov, YK | 1 |
| Chaushev, BG | 1 |
| Radanova, MA | 1 |
| Petrov, DP | 1 |
| Georgiev, KD | 1 |
| Bachvarov, CH | 1 |
| Todorov, GN | 1 |
| Kalchev, KP | 1 |
| Popov, HB | 1 |
| Manev, RR | 1 |
| Donev, IS | 1 |
| Rossowska, J | 1 |
| Klopotowska, D | 1 |
| Stachowicz, M | 1 |
| Demircan, NC | 1 |
| Gökyer, A | 1 |
| Sunal, BS | 1 |
| Hacıoğlu, MB | 1 |
| Eslame, H | 1 |
| Solak, S | 1 |
| Yılmaz, E | 1 |
| Uzunoğlu, S | 2 |
| Tunçbilek, N | 1 |
| Çiçin, I | 3 |
| Erdoğan, B | 2 |
| Lima-Fernandes, E | 1 |
| Murison, A | 1 |
| da Silva Medina, T | 1 |
| Ma, A | 1 |
| Leung, C | 1 |
| Luciani, GM | 1 |
| Haynes, J | 1 |
| Pollett, A | 1 |
| Zeller, C | 1 |
| Duan, S | 1 |
| Kreso, A | 1 |
| Barsyte-Lovejoy, D | 1 |
| Wouters, BG | 1 |
| Jin, J | 2 |
| Carvalho, DD | 1 |
| Lupien, M | 1 |
| Arrowsmith, CH | 1 |
| O'Brien, CA | 1 |
| Lee, E | 1 |
| Oh, S | 2 |
| Jung, J | 1 |
| Kim, KS | 2 |
| Moon, A | 1 |
| Zou, Q | 1 |
| He, H | 2 |
| Lei, M | 1 |
| Fan, D | 1 |
| Yun, CW | 1 |
| Bueno, L | 1 |
| Paralta Branco, F | 1 |
| Brito, CB | 1 |
| Luz, G | 1 |
| Teixeira, JA | 1 |
| Sekido, M | 1 |
| Ohkuma, R | 1 |
| Tsunoda, T | 4 |
| Ishikawa, F | 1 |
| Shibanuma, M | 1 |
| Muguruma, N | 1 |
| Fujimoto, S | 1 |
| Okada, Y | 2 |
| Kida, Y | 1 |
| Nakamura, F | 1 |
| Kitamura, S | 1 |
| Peng, H | 1 |
| Hosseini, SA | 1 |
| Zand, H | 1 |
| Cheraghpour, M | 1 |
| Nørgaard, HH | 1 |
| Hermann, HK | 1 |
| Larsen, PN | 1 |
| Hogdall, E | 1 |
| Ambrož, M | 1 |
| Lněničková, K | 1 |
| Matoušková, P | 1 |
| Skálová, L | 1 |
| Boušová, I | 1 |
| Francipane, MG | 1 |
| Bulanin, D | 1 |
| Lagasse, E | 1 |
| Saeinasab, M | 1 |
| Bahrami, AR | 1 |
| González, J | 1 |
| Marchese, FP | 1 |
| Martinez, D | 1 |
| Matin, MM | 1 |
| Huarte, M | 1 |
| Sen, K | 1 |
| Banerjee, S | 1 |
| Mandal, M | 1 |
| Khan, N | 1 |
| Jajeh, F | 1 |
| Eberhardt, EL | 1 |
| Miller, DD | 1 |
| Albrecht, DM | 1 |
| Van Doorn, R | 1 |
| Hruby, MD | 1 |
| Maresh, ME | 1 |
| Clipson, L | 1 |
| Mukhtar, H | 1 |
| Halberg, RB | 1 |
| Hotta, Y | 1 |
| Toyofuku, A | 1 |
| Ayez, N | 2 |
| Sluiter, NR | 1 |
| van der Vliet, HJ | 2 |
| Wassenaar, ECE | 1 |
| Hunting, CB | 1 |
| Been, LB | 1 |
| van Ginkel, RJ | 1 |
| Fehrmann, RSN | 1 |
| de Wilt, JHW | 1 |
| Radema, SA | 2 |
| Herbschleb, KH | 1 |
| Haj Mohammad, N | 1 |
| van Duyn, EB | 1 |
| Mastboom, WJB | 1 |
| Mekenkamp, LJM | 1 |
| van Laarhoven, HWM | 1 |
| Zwinderman, AH | 1 |
| Bouma, JM | 1 |
| Lee, SW | 3 |
| Zemla, T | 1 |
| Kabbarah, O | 1 |
| Hu, W | 1 |
| Fang, Z | 3 |
| Miao, QR | 1 |
| Hamfjord, J | 3 |
| Guren, TK | 3 |
| Dajani, O | 2 |
| Lingjærde, OC | 1 |
| Tveit, KM | 16 |
| Kure, EH | 7 |
| Pallisgaard, N | 2 |
| Lee, DW | 5 |
| Kim, HP | 1 |
| Lyu, J | 1 |
| Han, H | 2 |
| Jang, H | 2 |
| Bang, D | 2 |
| Won, JK | 1 |
| Jeong, SY | 5 |
| Ichimura, T | 3 |
| Colin, DJ | 1 |
| Dormond, O | 1 |
| Zhao, P | 1 |
| Ma, YG | 1 |
| Dai, ZJ | 1 |
| Yan, CY | 1 |
| Guan, HT | 1 |
| Burnett, A | 1 |
| Lecompte, MA | 1 |
| Trabulsi, N | 1 |
| Dubé, P | 1 |
| Gervais, MK | 1 |
| Trilling, B | 1 |
| Cloutier, AS | 1 |
| Sideris, L | 2 |
| Ndreshkjana, B | 1 |
| Çapci, A | 1 |
| Klein, V | 1 |
| Chanvorachote, P | 1 |
| Muenzner, JK | 1 |
| Huebner, K | 1 |
| Steinmann, S | 3 |
| Erlenbach-Wuensch, K | 1 |
| Geppert, CI | 1 |
| Agaimy, A | 1 |
| El-Baba, C | 1 |
| Roehe, AV | 1 |
| Tsogoeva, SB | 1 |
| Schneider-Stock, R | 1 |
| Dohan, A | 1 |
| Gallix, B | 1 |
| Guiu, B | 4 |
| Reinhold, C | 1 |
| Soyer, P | 2 |
| Jacquot, S | 1 |
| Ben Abdelghani, M | 2 |
| Khemissa-Akouz, F | 1 |
| Desseigne, F | 6 |
| Suc, E | 1 |
| Hoeffel, C | 1 |
| Spartalis, C | 1 |
| Schmidt, EM | 1 |
| Elmasry, M | 1 |
| Schulz, GB | 1 |
| Zheng, R | 1 |
| Ouyang, X | 1 |
| Iwuji, COO | 1 |
| Irving, GRB | 1 |
| Barber, S | 1 |
| Walter, H | 2 |
| Sidat, Z | 1 |
| Griffin-Teall, N | 1 |
| Singh, R | 1 |
| Foreman, N | 1 |
| Patel, SR | 2 |
| Morgan, B | 4 |
| Steward, WP | 4 |
| Gescher, A | 1 |
| Thomas, AL | 3 |
| López López, C | 1 |
| Argilés Martínez, G | 1 |
| Páez López, D | 1 |
| García Paredes, B | 1 |
| Gutiérrez Abad, D | 2 |
| Castañón López, C | 1 |
| Jiménez Fonseca, P | 1 |
| Gallego Plazas, J | 1 |
| López Doldán, MC | 1 |
| Sánchez Cánovas, M | 1 |
| Tobeña Puyal, M | 1 |
| Llorente Ayala, B | 1 |
| Juez Martel, I | 2 |
| López Flores, M | 1 |
| Carmona-Bayonas, A | 1 |
| Kuranaga, Y | 1 |
| Tahara, T | 1 |
| Shibata, T | 1 |
| Nagasaka, M | 1 |
| Funasaka, K | 1 |
| Ohmiya, N | 1 |
| Chen, SJ | 3 |
| Chung, YC | 2 |
| Chang, HL | 1 |
| Chang, HP | 2 |
| Chou, JL | 2 |
| Hsu, CP | 4 |
| Olejniczak-Kęder, A | 1 |
| Szaryńska, M | 1 |
| Wrońska, A | 1 |
| Siedlecka-Kroplewska, K | 1 |
| Kmieć, Z | 1 |
| Moon, SU | 3 |
| Park, Y | 1 |
| Park, MG | 1 |
| Song, SK | 1 |
| Jeong, SH | 1 |
| Heo, HJ | 1 |
| Jung, WY | 1 |
| Pintova, S | 1 |
| Dharmupari, S | 1 |
| Moshier, E | 1 |
| Zubizarreta, N | 1 |
| Ang, C | 2 |
| Holcombe, RF | 2 |
| Matikas, A | 2 |
| Souglakos, J | 17 |
| Katsaounis, P | 1 |
| Kotsakis, A | 3 |
| Kouroupakis, P | 1 |
| Pantazopoulos, N | 1 |
| Nikolaidi, A | 1 |
| Messaritakis, I | 1 |
| Tzovara, I | 1 |
| Hatzidaki, D | 3 |
| Prinarakis, E | 1 |
| Georgoulias, V | 22 |
| Dumont, A | 2 |
| de Rosny, C | 1 |
| Kieu, TL | 1 |
| Perrey, S | 1 |
| Berger, H | 1 |
| Fluckiger, A | 1 |
| Muller, T | 1 |
| Pais de Barros, JP | 1 |
| Pichon, L | 1 |
| Hichami, A | 1 |
| Thomas, C | 1 |
| Rébé, C | 2 |
| Rialland, M | 1 |
| Vashi, PG | 1 |
| Gorsuch, K | 1 |
| Wan, L | 1 |
| Hill, D | 1 |
| Block, C | 1 |
| Gupta, D | 1 |
| Srimuninnimit, V | 3 |
| Fedyanin, MY | 1 |
| Martos, CF | 1 |
| Ter-Ovanesov, M | 1 |
| Picard, P | 1 |
| Bury, D | 1 |
| Drea, E | 1 |
| Sondén, A | 2 |
| Gupta, R | 1 |
| Bhatt, LK | 1 |
| Momin, M | 1 |
| Alessandrino, F | 1 |
| Qin, L | 1 |
| Cruz, G | 1 |
| Sahu, S | 1 |
| Rosenthal, MH | 1 |
| Shinagare, AB | 1 |
| Chen, SH | 1 |
| Yeh, YM | 1 |
| Chen, LT | 2 |
| Hsu, CY | 1 |
| Tam, KW | 1 |
| Shan, F | 1 |
| Xiong, X | 1 |
| Qin, A | 2 |
| Liang, JY | 1 |
| Xing, BC | 1 |
| Kusumoto, T | 3 |
| Katayose, Y | 1 |
| Zheng, L | 2 |
| Van den Eynde, M | 4 |
| Berkhout, M | 1 |
| Cai, W | 1 |
| Zheng, M | 2 |
| Liu, RX | 1 |
| Chan, KW | 1 |
| Tan, H | 1 |
| Horvath, P | 1 |
| Beckert, S | 1 |
| Königsrainer, A | 2 |
| Nadalin, S | 1 |
| Königsrainer, I | 1 |
| Cruz-Gil, S | 1 |
| Sánchez-Martínez, R | 1 |
| Wagner-Reguero, S | 1 |
| Stange, D | 1 |
| Schölch, S | 1 |
| Pape, K | 1 |
| Ramírez de Molina, A | 2 |
| Neitzel, C | 1 |
| Seiwert, N | 2 |
| Göder, A | 2 |
| Diehl, E | 1 |
| Weber, C | 1 |
| Nagel, G | 1 |
| Stroh, S | 1 |
| Rasenberger, B | 1 |
| Christmann, M | 1 |
| Fahrer, J | 2 |
| Sahin, S | 1 |
| Secmeler, S | 1 |
| Can, O | 1 |
| Demir, C | 1 |
| Matsuda, E | 1 |
| Ibe, H | 1 |
| Oguma, E | 1 |
| Naitoh, K | 1 |
| Makita, K | 1 |
| Hisaka, T | 1 |
| Ishikawa, H | 7 |
| Sakai, H | 1 |
| Kawahara, R | 1 |
| Goto, Y | 1 |
| Yasunaga, M | 3 |
| Kinugasa, T | 1 |
| Fujita, F | 5 |
| Mizobe, T | 2 |
| Fukahori, M | 1 |
| Nakashima, O | 1 |
| Tanigawa, M | 1 |
| Naito, Y | 3 |
| Akiba, J | 1 |
| Yano, H | 6 |
| Okuda, K | 1 |
| Sanderson, SM | 1 |
| Dai, Z | 1 |
| Reid, MA | 1 |
| Cooper, DE | 1 |
| Richie, JP | 1 |
| Ciccarella, A | 1 |
| Calcagnotto, A | 1 |
| Mikhael, PG | 1 |
| Mentch, SJ | 1 |
| Ables, G | 1 |
| Kirsch, DG | 1 |
| Hsu, DS | 1 |
| Nichenametla, SN | 1 |
| Locasale, JW | 1 |
| Masada, T | 1 |
| Tatsumoto, S | 1 |
| Marugami, N | 2 |
| Otsuji, T | 6 |
| Kanno, M | 1 |
| Koyama, F | 2 |
| Sho, M | 2 |
| Kichikawa, K | 5 |
| Yi, BR | 1 |
| Park, MA | 1 |
| Lee, HR | 1 |
| Kang, NH | 1 |
| Choi, KJ | 1 |
| Kim, SU | 1 |
| Choi, KC | 1 |
| van Huis-Tanja, LH | 1 |
| Gelderblom, H | 9 |
| Guchelaar, HJ | 9 |
| Dede, K | 3 |
| Mersich, T | 2 |
| Besznyák, I | 2 |
| Zaránd, A | 1 |
| Salamon, F | 1 |
| Baranyai, ZS | 1 |
| Landherr, L | 3 |
| Jakab, F | 2 |
| Bursics, A | 3 |
| Ciombor, KK | 1 |
| Chan, E | 6 |
| Xynos, ID | 1 |
| Karadima, ML | 1 |
| Voutsas, IF | 2 |
| Amptoulach, S | 1 |
| Skopelitis, E | 2 |
| Kosmas, C | 13 |
| Gritzapis, AD | 2 |
| Tsavaris, N | 19 |
| Mobasheri, A | 1 |
| Lueders, C | 1 |
| Busch, F | 1 |
| Brady, J | 1 |
| Corrie, P | 1 |
| Digumarti, R | 1 |
| Adams, LM | 1 |
| Botbyl, J | 1 |
| Laubscher, KH | 1 |
| Midgley, RS | 4 |
| Mallath, M | 1 |
| Thornton, M | 1 |
| Aslam, MA | 1 |
| Tweedle, EM | 1 |
| Campbell, F | 1 |
| Jackson, R | 1 |
| Costello, E | 1 |
| Rooney, PS | 1 |
| Vlatković, N | 1 |
| Boyd, MT | 1 |
| Robinson, SM | 4 |
| Manas, DM | 3 |
| Mann, DA | 4 |
| White, SA | 4 |
| Teillet, L | 2 |
| Subtil, F | 1 |
| Le Brun-Ly, V | 1 |
| Cretin, J | 3 |
| Breysacher, G | 4 |
| Charneau, J | 2 |
| Stefani, L | 2 |
| Ramdani, M | 2 |
| Mitry, E | 19 |
| van den Broek, MA | 1 |
| Vreuls, CP | 1 |
| Winstanley, A | 1 |
| Jansen, RL | 3 |
| van Bijnen, AA | 1 |
| Dello, SA | 1 |
| Bemelmans, MH | 1 |
| Dejong, CH | 1 |
| Driessen, A | 1 |
| Olde Damink, SW | 1 |
| Schmiegel, W | 17 |
| Kubicka, S | 6 |
| Freier, W | 3 |
| Dietrich, G | 2 |
| Geißler, M | 1 |
| Pohl, M | 1 |
| Hinke, A | 8 |
| Giessen, C | 10 |
| Laubender, RP | 9 |
| Mansmann, UR | 1 |
| Funke, V | 1 |
| Lehmann-Koch, J | 1 |
| Bickeböller, M | 1 |
| Benner, A | 2 |
| Tagscherer, KE | 2 |
| Grund, K | 1 |
| Pfeifer, M | 1 |
| Herpel, E | 1 |
| Schirmacher, P | 1 |
| Chang-Claude, J | 3 |
| Brenner, H | 2 |
| Hoffmeister, M | 2 |
| Roth, W | 2 |
| Healey, E | 1 |
| Stillfried, GE | 1 |
| Eckermann, S | 1 |
| Dawber, JP | 1 |
| Clingan, PR | 9 |
| Ranson, M | 2 |
| Vañó-Galván, S | 2 |
| Longo, F | 2 |
| Grillo, E | 1 |
| Jaén, P | 2 |
| Pénichoux, J | 1 |
| Michiels, S | 3 |
| Schultheis, B | 1 |
| Kuhlmann, J | 2 |
| Ehrenberg, R | 2 |
| Hacker, UT | 2 |
| Kornacker, M | 1 |
| Boix, O | 1 |
| Lettieri, J | 1 |
| Krauss, J | 1 |
| Fischer, R | 2 |
| Hamann, S | 2 |
| Strumberg, D | 5 |
| Mross, KB | 1 |
| Cordwell, C | 1 |
| Reece, W | 1 |
| Cui, L | 2 |
| Jensen, NF | 2 |
| Tarpgaard, LS | 5 |
| Qvortrup, C | 8 |
| Rømer, MU | 2 |
| Stenvang, J | 1 |
| Hansen, TP | 1 |
| Christensen, LL | 1 |
| Hansen, F | 4 |
| Brünner, N | 5 |
| Ørntoft, TF | 1 |
| Kim, SL | 1 |
| Trang, KT | 1 |
| Kim, IH | 1 |
| Lee, SO | 1 |
| Lee, ST | 3 |
| Kim, DG | 1 |
| Kim, SW | 2 |
| Nowara, E | 1 |
| Chuah, BYS | 1 |
| Kopp, MV | 2 |
| Sakaeva, DD | 1 |
| Mitchell, EP | 7 |
| Dubey, S | 1 |
| Hei, YJ | 2 |
| Galimi, F | 2 |
| McCaffery, I | 1 |
| Loberg, R | 1 |
| Cottrell, S | 1 |
| Choo, SP | 5 |
| Kerscher, AG | 2 |
| Chua, TC | 6 |
| Gasser, M | 3 |
| Maeder, U | 2 |
| Kunzmann, V | 2 |
| Isbert, C | 1 |
| Germer, CT | 4 |
| Pelz, JO | 2 |
| van Gils, CW | 1 |
| Ottevanger, PB | 2 |
| Craven, O | 3 |
| Hughes, CA | 1 |
| Burton, A | 1 |
| Molassiotis, A | 3 |
| Gladkov, O | 1 |
| Davidenko, I | 1 |
| Vladimirova, L | 1 |
| Cheporov, S | 1 |
| Burdaeva, O | 1 |
| Bulavina, I | 1 |
| Potter, V | 1 |
| Chang, YL | 1 |
| Lokker, NA | 1 |
| Weiswald, LB | 2 |
| Richon, S | 1 |
| Massonnet, G | 1 |
| Guinebretière, JM | 1 |
| Vacher, S | 1 |
| Laurendeau, I | 1 |
| Cottu, P | 1 |
| Marangoni, E | 1 |
| Nemati, F | 2 |
| Validire, P | 1 |
| Bellet, D | 1 |
| Dangles-Marie, V | 2 |
| Berindan-Neagoe, I | 1 |
| Braicu, C | 1 |
| Pileczki, V | 1 |
| Cojocneanu Petric, R | 1 |
| Miron, N | 1 |
| Balacescu, O | 1 |
| Iancu, D | 1 |
| Shelton, JW | 1 |
| Waxweiler, TV | 1 |
| Landry, J | 2 |
| Gao, H | 2 |
| Shu, HK | 1 |
| Piccirillo, MC | 2 |
| Giordano, P | 1 |
| Lastoria, S | 3 |
| Caracò, C | 2 |
| de Lutio di Castelguidone, E | 2 |
| Daniele, G | 2 |
| Aloj, L | 2 |
| Romano, G | 2 |
| Lin, JK | 17 |
| Li, AF | 2 |
| Brodowicz, T | 6 |
| Radosavljevic, D | 2 |
| Shacham-Shmueli, E | 5 |
| Vrbanec, D | 4 |
| Plate, S | 2 |
| Mrsic-Krmpotic, Z | 2 |
| Dank, M | 1 |
| Purkalne, G | 2 |
| Messinger, D | 3 |
| Zielinski, CC | 7 |
| Nakai, T | 1 |
| Kitaguchi, H | 1 |
| Yamasaki, M | 1 |
| Truant, S | 3 |
| Desauw, C | 1 |
| Sergent-Baudson, G | 1 |
| Cattan, S | 1 |
| Piessen, G | 1 |
| Pruvot, FR | 5 |
| Moreau, LC | 1 |
| Rajan, R | 1 |
| Thirlwell, MP | 2 |
| Koch, S | 2 |
| Boxberger, F | 3 |
| Harich, HD | 1 |
| Hohenberger, W | 10 |
| Dörje, F | 1 |
| Ye, LC | 2 |
| Liu, TS | 1 |
| Zhu, DX | 2 |
| Zai, SY | 1 |
| Ye, QH | 1 |
| Qin, XY | 1 |
| Arnheim, K | 2 |
| Hochster, H | 9 |
| Alberts, S | 3 |
| Imoto, K | 4 |
| Kuwano, S | 3 |
| Takada, K | 7 |
| Magge, D | 2 |
| Zureikat, AH | 2 |
| Bartlett, DL | 2 |
| Holtzman, MP | 1 |
| Choudry, HA | 1 |
| Beumer, JH | 1 |
| Pingpank, JF | 1 |
| Holleran, JL | 3 |
| Strychor, S | 1 |
| Cunningham, DE | 1 |
| Jones, HL | 1 |
| Zeh, HJ | 1 |
| Sym, SJ | 2 |
| Bae, KS | 2 |
| Chang, HM | 4 |
| Lee, JL | 9 |
| Kang, YK | 6 |
| Shin, JG | 2 |
| Xia, Q | 1 |
| Luo, R | 1 |
| Huang, P | 1 |
| Infante, JR | 2 |
| Reid, TR | 2 |
| Edenfield, WJ | 1 |
| Cescon, TP | 1 |
| Hamm, JT | 2 |
| Malik, IA | 1 |
| Rado, TA | 1 |
| McGee, PJ | 1 |
| Richards, DA | 3 |
| Tarazi, J | 3 |
| Rosbrook, B | 2 |
| Cartwright, TH | 2 |
| de Amuriza-Chicharro, N | 1 |
| Gastalver-Martín, C | 1 |
| Cortijo-Cascajares, S | 2 |
| Ferrari-Piquero, JM | 1 |
| Vasilaki, A | 1 |
| Mathers, J | 1 |
| Burt, AD | 1 |
| Oakley, F | 3 |
| Negandhi, AA | 1 |
| Hyde, A | 1 |
| Dicks, E | 1 |
| Pollett, W | 1 |
| Younghusband, BH | 1 |
| Parfrey, P | 1 |
| Green, RC | 1 |
| Savas, S | 1 |
| Hare, JI | 1 |
| Neijzen, RW | 1 |
| Anantha, M | 1 |
| Dos Santos, N | 1 |
| Harasym, N | 1 |
| Webb, MS | 1 |
| Allen, TM | 1 |
| Bally, MB | 1 |
| Waterhouse, DN | 1 |
| Moreau, T | 3 |
| Bjarnason, GA | 6 |
| Smaaland, R | 5 |
| Iacobelli, S | 7 |
| Tumolo, S | 6 |
| Poncet, A | 1 |
| Spiegel, D | 2 |
| Bulusu, A | 1 |
| Pang, H | 4 |
| Wong, NS | 3 |
| Honeycutt, W | 2 |
| Amara, A | 1 |
| Mertens, J | 2 |
| De Bruyne, S | 2 |
| Van Damme, N | 2 |
| Troisi, R | 2 |
| Goethals, I | 1 |
| Van de Wiele, C | 2 |
| Zhang, GQ | 1 |
| Wen, XY | 1 |
| Li, JY | 1 |
| Wu, LL | 1 |
| Jiao, SC | 3 |
| Xue, HP | 1 |
| Fang, JY | 2 |
| Gupta, M | 1 |
| Han, K | 1 |
| Joshi, A | 1 |
| Sarapa, N | 1 |
| Powell, B | 1 |
| Rhee, YY | 1 |
| Oh, DY | 7 |
| Im, SA | 8 |
| Bang, YJ | 7 |
| Al-Tonbary, Y | 1 |
| Darwish, A | 1 |
| El-Hussein, A | 1 |
| Fouda, A | 1 |
| Fornaro, L | 11 |
| Vivaldi, C | 2 |
| Bracarda, S | 1 |
| Morvillo, M | 2 |
| Osawa, G | 3 |
| Yokomizo, H | 8 |
| Okayama, S | 2 |
| Sagawa, M | 2 |
| Naritaka, Y | 3 |
| Shionome, Y | 1 |
| Lin, WH | 1 |
| Shiao, HY | 1 |
| Hsieh, HP | 1 |
| Hsu, JT | 1 |
| Ouchi, T | 1 |
| Najam, R | 4 |
| Mateen, A | 4 |
| Huang, XE | 4 |
| You, SX | 1 |
| Lu, YY | 2 |
| Bennamoun, M | 5 |
| Mabro, M | 16 |
| Brusquant, D | 4 |
| Ji, JH | 1 |
| Kang, HJ | 5 |
| Shim, BY | 4 |
| Caparello, C | 1 |
| Funel, N | 1 |
| Pollina, L | 2 |
| Vasile, E | 7 |
| Lindsay, CR | 2 |
| Roxburgh, P | 1 |
| Shen, S | 2 |
| Uygun, K | 1 |
| Oven Ustaalioglu, BB | 1 |
| Yildiz, R | 4 |
| Temiz, S | 1 |
| Seker, M | 1 |
| Aksu, G | 1 |
| Cabuk, D | 2 |
| Gumus, M | 2 |
| Brown, SR | 1 |
| Richman, S | 3 |
| Gwyther, S | 1 |
| Lowe, C | 1 |
| Wadsley, J | 1 |
| Maisey, N | 1 |
| Hill, M | 12 |
| Dawson, L | 1 |
| O'Callaghan, A | 1 |
| Benstead, K | 1 |
| Chambers, P | 3 |
| Oliver, A | 1 |
| Marshall, H | 1 |
| Napp, V | 1 |
| Green, E | 5 |
| Yothers, G | 4 |
| O'Connell, M | 4 |
| Twelves, CJ | 3 |
| Rao, GH | 1 |
| Liu, HM | 1 |
| Li, BW | 1 |
| Hao, JJ | 1 |
| Yang, YL | 1 |
| Wang, MR | 1 |
| Wang, XH | 2 |
| Jin, HJ | 1 |
| Karaayvaz, M | 1 |
| Zhai, H | 1 |
| Ju, J | 2 |
| Saif, MW | 15 |
| Kaley, K | 1 |
| Brennan, M | 1 |
| Garcon, MC | 1 |
| Rodriguez, G | 1 |
| Gerger, A | 4 |
| Labonte, MJ | 5 |
| El-Khoueiry, R | 2 |
| Rumiato, E | 1 |
| Boldrin, E | 1 |
| Amadori, A | 1 |
| Saggioro, D | 1 |
| de la Cueva, A | 1 |
| Alvarez-Ayerza, N | 1 |
| Ramos, MA | 1 |
| Cebrián, A | 1 |
| Del Pulgar, TG | 1 |
| Lacal, JC | 1 |
| Maspero, F | 1 |
| Sauta, MG | 1 |
| Beretta, GD | 11 |
| Derenzini, E | 3 |
| Pietrabissa, A | 2 |
| Pinna, AD | 1 |
| Ercolani, G | 2 |
| Pantaleo, MA | 3 |
| Di Girolamo, S | 1 |
| de Rosa, F | 1 |
| Biasco, G | 6 |
| García Alfonso, P | 3 |
| Muñoz Martin, A | 1 |
| Alvarez Suarez, S | 1 |
| Blanco Codeidido, M | 1 |
| Mondejar Solis, R | 1 |
| Tapia Rico, G | 1 |
| López Martín, P | 1 |
| Ryan, EM | 1 |
| Hanly, A | 1 |
| Morrin, MM | 1 |
| McNamara, DA | 3 |
| Boers-Sonderen, MJ | 1 |
| Desar, IM | 1 |
| van Herpen, CM | 1 |
| Sun, B | 2 |
| Tseng, KC | 2 |
| Hsu, CL | 1 |
| Yang, TS | 9 |
| Chen, JS | 8 |
| Tang, RP | 1 |
| Lim, B | 1 |
| Scicchitano, A | 3 |
| Beachler, C | 3 |
| Gusani, N | 1 |
| Sarwani, N | 2 |
| Staveley-O'Carroll, K | 2 |
| Ashkenazi, A | 2 |
| Portera, C | 2 |
| Lamparella, NE | 1 |
| Saroya, BS | 1 |
| Sarwani, NE | 1 |
| Lai, CY | 3 |
| Sung, FC | 3 |
| Hsieh, LL | 4 |
| Chiou, HY | 2 |
| Wu, FY | 2 |
| Yeh, CC | 3 |
| Kim, HO | 1 |
| Lee, SJ | 4 |
| Oh, SJ | 1 |
| Moon, DH | 1 |
| Su, T | 2 |
| Jensen, SA | 14 |
| Ervin, TJ | 1 |
| Gallinson, D | 1 |
| Singh, J | 2 |
| Wallace, JA | 1 |
| Saleh, MN | 1 |
| Vallone, M | 1 |
| Phan, SC | 2 |
| Hack, SP | 3 |
| de Campos-Lobato, LF | 1 |
| Stocchi, L | 1 |
| de Sousa, JB | 1 |
| Buta, M | 1 |
| Lavery, IC | 1 |
| Fazio, VW | 1 |
| Dietz, DW | 2 |
| Kalady, MF | 1 |
| Tezuka, T | 2 |
| Hamada, C | 1 |
| Ooshiro, M | 3 |
| Kawasaki, S | 1 |
| Wen, F | 1 |
| Sang, Y | 1 |
| Nishimura, A | 5 |
| Shibata, N | 1 |
| Nielsen, BS | 2 |
| Jakobsen, A | 18 |
| Sørensen, FB | 4 |
| Dréanic, J | 2 |
| Maillet, M | 2 |
| Dhooge, M | 3 |
| Mir, O | 4 |
| Goldwasser, F | 5 |
| Misumi, N | 1 |
| Goto, T | 2 |
| Miyoshi, T | 1 |
| Hiraike, M | 1 |
| Shirasawa, H | 1 |
| Saito, O | 1 |
| Nishino, T | 1 |
| Oudo, M | 1 |
| Field, KM | 1 |
| Shapiro, JD | 2 |
| McKendrick, JJ | 3 |
| Ruzzo, A | 6 |
| Lucchesi, S | 1 |
| Abe, H | 4 |
| Mafune, K | 1 |
| Minamimura, K | 1 |
| Abe, M | 1 |
| Umemura, A | 1 |
| Boisen, MK | 4 |
| Larsen, JS | 2 |
| Østerlind, K | 1 |
| Hansen, J | 1 |
| Nielsen, SE | 5 |
| Keldsen, N | 7 |
| Jensen, BB | 3 |
| Di Biasi, B | 1 |
| Prochilo, T | 2 |
| Sabatini, T | 1 |
| Siegel, CL | 1 |
| Reidy-Lagunes, D | 1 |
| Bai, CH | 1 |
| Candy, PA | 1 |
| Phillips, MR | 1 |
| Redfern, AD | 1 |
| Colley, SM | 1 |
| Davidson, JA | 1 |
| Stuart, LM | 1 |
| Wood, BA | 1 |
| Zeps, N | 3 |
| Leedman, PJ | 1 |
| Chayahara, N | 3 |
| Mukohara, T | 1 |
| Kiyota, N | 1 |
| Tomioka, H | 1 |
| Funakoshi, Y | 1 |
| Minami, H | 1 |
| Ke, J | 1 |
| Yuan, R | 1 |
| Ueno, M | 4 |
| Palumbo, I | 1 |
| Piattoni, S | 1 |
| Valentini, V | 3 |
| Marini, V | 1 |
| Calzuola, M | 1 |
| Vecchio, FM | 2 |
| Cecchini, D | 1 |
| Falzetti, F | 1 |
| Aristei, C | 1 |
| Christensen, Rd | 1 |
| Andersen, RF | 4 |
| Johnsson, A | 3 |
| Turner, LD | 1 |
| Harrison, JD | 1 |
| Hardingham, JE | 3 |
| Lee, CK | 5 |
| Townsend, AR | 8 |
| Wrin, JW | 3 |
| Weickhardt, A | 3 |
| Simes, RJ | 5 |
| Murone, C | 3 |
| Terrazzino, S | 1 |
| Cargnin, S | 1 |
| Del Re, M | 3 |
| Danesi, R | 24 |
| Canonico, PL | 1 |
| Genazzani, AA | 1 |
| Roesler, B | 1 |
| Bielfeld, C | 1 |
| Emons, G | 1 |
| Wolff, HA | 1 |
| Rave-Fränk, M | 1 |
| Kramer, F | 1 |
| Beissbarth, T | 1 |
| Kitz, J | 1 |
| Wienands, J | 1 |
| Ghadimi, BM | 1 |
| Ebner, R | 1 |
| Ried, T | 1 |
| Teh, LK | 1 |
| Hamzah, S | 1 |
| Hashim, H | 1 |
| Bannur, Z | 1 |
| Zakaria, ZA | 1 |
| Hasbullani, Z | 1 |
| Shia, JK | 1 |
| Fijeraid, H | 1 |
| Md Nor, A | 1 |
| Zailani, M | 1 |
| Ramasamy, P | 1 |
| Ngow, H | 1 |
| Sood, S | 1 |
| Salleh, MZ | 1 |
| Foubert, F | 1 |
| Uchino, K | 3 |
| Fujisawa, M | 1 |
| Nobuhisa, T | 1 |
| Kai, K | 1 |
| Notohara, K | 1 |
| Matsukawa, A | 1 |
| Hoehler, T | 2 |
| von Wichert, G | 1 |
| Schimanski, C | 1 |
| Moehler, MH | 1 |
| Hochhaus, A | 6 |
| Hallek, M | 2 |
| Hofheinz, R | 4 |
| Sulzyc-Bielicka, V | 4 |
| Bielicki, D | 4 |
| Binczak-Kuleta, A | 1 |
| Kaczmarczyk, M | 1 |
| Pioch, W | 1 |
| Machoy-Mokrzynska, A | 1 |
| Ciechanowicz, A | 1 |
| Gołębiewska, M | 1 |
| Drozdzik, M | 1 |
| Denne, J | 1 |
| Horak, C | 1 |
| Green, G | 1 |
| Khambata-Ford, S | 1 |
| Bray, C | 1 |
| Celik, I | 4 |
| Harbison, C | 1 |
| Vilaça, N | 1 |
| Amorim, R | 2 |
| Machado, AF | 1 |
| Parpot, P | 1 |
| Pereira, MF | 1 |
| Sardo, M | 1 |
| Rocha, J | 1 |
| Fonseca, AM | 1 |
| Neves, IC | 1 |
| Baltazar, F | 2 |
| Tian, H | 1 |
| Koçer, M | 1 |
| Nazıroğlu, M | 1 |
| Lin, CH | 3 |
| Huang, CM | 2 |
| Chai, CY | 2 |
| Thalheimer, A | 2 |
| Korb, D | 1 |
| Bönicke, L | 1 |
| Wiegering, A | 2 |
| Mühling, B | 2 |
| Riedel, SS | 1 |
| Beilhack, A | 1 |
| Brändlein, S | 1 |
| Otto, C | 2 |
| Kondo, K | 5 |
| Sugiyama, Y | 10 |
| Maindrault-Goebel, F | 12 |
| Vidaurreta, M | 2 |
| López, MR | 1 |
| Gallen, M | 4 |
| Rubio, ED | 1 |
| Polesel, J | 2 |
| Corona, G | 4 |
| Dreussi, E | 1 |
| Louie, SG | 1 |
| Ely, B | 1 |
| Albain, KS | 1 |
| Gotay, C | 1 |
| Coleman, D | 1 |
| Raghavan, D | 1 |
| Shields, AF | 5 |
| Watanabe, K | 8 |
| Kawahara, H | 4 |
| Enomoto, H | 2 |
| Toyama, Y | 1 |
| Akiba, T | 2 |
| Yanaga, K | 2 |
| Pellón, ML | 1 |
| Romero, C | 2 |
| Jorge, M | 5 |
| Ramos, M | 2 |
| Varela, S | 1 |
| Alonso, MÁ | 1 |
| Oliner, KS | 7 |
| Burkes, R | 4 |
| Barugel, M | 3 |
| Humblet, Y | 11 |
| Jassem, J | 5 |
| Kocákova, I | 6 |
| Błasińska-Morawiec, M | 3 |
| Šmakal, M | 3 |
| Rother, M | 3 |
| Williams, R | 2 |
| Rong, A | 2 |
| Wiezorek, J | 2 |
| Sidhu, R | 4 |
| Patterson, SD | 2 |
| Lang, I | 11 |
| Marcuello, E | 20 |
| Lorusso, V | 16 |
| Shin, DB | 7 |
| Osborne, S | 1 |
| Andre, N | 3 |
| Waterkamp, D | 2 |
| Nasyrov, AR | 2 |
| Pirtskhalava, TL | 2 |
| Korovina, IaV | 2 |
| Ando, H | 3 |
| Kanekiyo, S | 2 |
| Hinoda, Y | 2 |
| Okayama, N | 1 |
| Oka, M | 4 |
| Joulain, F | 4 |
| Proskorovsky, I | 1 |
| Allegra, C | 5 |
| Iqbal, SU | 2 |
| Akiyama, Y | 7 |
| Aoki, T | 6 |
| Hagiwara, K | 1 |
| Hironaka, K | 1 |
| Teranishi, F | 1 |
| Osuka, F | 1 |
| Takeuchi, M | 5 |
| Nakajima, T | 8 |
| Hugen, N | 1 |
| Verhoeven, RH | 1 |
| de Hingh, IH | 4 |
| Pruijt, JF | 1 |
| Nagtegaal, ID | 4 |
| de Wilt, JH | 2 |
| Grande, C | 2 |
| París Bouzas, L | 1 |
| Villanueva, MJ | 1 |
| Campos, B | 1 |
| Gallardo, E | 3 |
| Alvarez, E | 2 |
| Casal, J | 1 |
| Mel, JR | 1 |
| Temraz, S | 2 |
| Alameddine, R | 1 |
| Shamseddine, A | 3 |
| Peddi, PF | 1 |
| Kapp, AV | 1 |
| Royer-Joo, S | 2 |
| Portera, CC | 1 |
| Kozloff, MF | 2 |
| Hashash, JG | 1 |
| Proksell, S | 1 |
| Regueiro, MD | 1 |
| Hutchinson, L | 1 |
| Behringer, D | 1 |
| Wolff, T | 1 |
| Zimber, J | 1 |
| Kettner, E | 2 |
| Pflüger, KH | 2 |
| Kirsch, A | 1 |
| Di Gennaro, E | 4 |
| Iaffaioli, VR | 2 |
| Budillon, A | 7 |
| Jang, MJ | 1 |
| Jeon, YJ | 1 |
| Chong, SY | 1 |
| Hwang, SG | 1 |
| Oh, D | 1 |
| Cho, YK | 1 |
| Ji, YG | 1 |
| Kim, NK | 7 |
| Padman, S | 1 |
| Padbury, R | 3 |
| Beeke, C | 3 |
| Bishnoi, S | 2 |
| Maddern, G | 2 |
| Berretta, M | 9 |
| Urbani, M | 1 |
| Bearz, A | 7 |
| Lutrino, S | 1 |
| Foltran, L | 1 |
| Ferrari, L | 2 |
| Talamini, R | 4 |
| Fiorica, F | 1 |
| Lleshi, A | 5 |
| Canzonieri, V | 1 |
| Lestuzzi, C | 1 |
| Borsatti, E | 1 |
| Fisichella, R | 3 |
| Tirelli, U | 7 |
| Cereda, V | 2 |
| di Bari, MG | 1 |
| Grenga, I | 3 |
| Tesauro, M | 2 |
| Raffaele, P | 1 |
| Ferroni, P | 2 |
| Guadagni, F | 4 |
| Roselli, M | 7 |
| Ma, BB | 2 |
| Chan, SL | 1 |
| Ho, WM | 2 |
| Lau, W | 1 |
| Mo, F | 1 |
| Hui, EP | 2 |
| Chan, C | 1 |
| Poon, A | 2 |
| Dattatray, RD | 1 |
| Wong, SC | 1 |
| King, AD | 1 |
| Ahuja, A | 1 |
| Kjersem, JB | 4 |
| Ikdahl, T | 7 |
| Lingjaerde, OC | 1 |
| Guren, T | 5 |
| Poston, GJ | 6 |
| Schlag, PM | 7 |
| Bechstein, WO | 9 |
| Walpole, ET | 3 |
| Finch-Jones, M | 4 |
| Jaeck, D | 5 |
| Mirza, D | 3 |
| Parks, RW | 3 |
| Tanis, E | 3 |
| Gruenberger, T | 20 |
| Matsui, T | 2 |
| Kojima, H | 2 |
| Manoochehri, M | 1 |
| Karbasi, A | 1 |
| Bandehpour, M | 1 |
| Kazemi, B | 1 |
| Schwartzberg, L | 3 |
| Yee, L | 1 |
| Dreisbach, L | 1 |
| Haddad, V | 1 |
| Sabin, A | 1 |
| Negri, FV | 2 |
| Azzoni, C | 1 |
| Bottarelli, L | 1 |
| Campanini, N | 1 |
| Wotherspoon, A | 3 |
| Tinelli, C | 3 |
| Silini, EM | 1 |
| Ardizzoni, A | 2 |
| Fukuchi, M | 2 |
| Okada, N | 20 |
| Yokoyama, M | 11 |
| Chika, N | 5 |
| Hatano, S | 7 |
| Matsuzawa, T | 3 |
| Kumamoto, K | 12 |
| Kumagai, Y | 5 |
| Mochiki, E | 2 |
| Dai, S | 1 |
| Ribecco, AS | 1 |
| Pino, MS | 2 |
| Cipriani, G | 1 |
| Marinozzi, C | 1 |
| Fioretto, L | 3 |
| Michelucci, A | 1 |
| Pfanner, E | 12 |
| Brunetti, I | 11 |
| Simi, P | 1 |
| Ferry, DR | 3 |
| Chevalier, S | 2 |
| Allegra, CJ | 10 |
| Hristova, NR | 1 |
| Fassl, A | 1 |
| Kopitz, J | 1 |
| Spencer, SK | 1 |
| Pommier, AJ | 1 |
| Morgan, SR | 1 |
| Barry, ST | 1 |
| Robertson, JD | 3 |
| Jürgensmeier, JM | 2 |
| Nakajima, A | 2 |
| Arimoto, A | 1 |
| McArt, DG | 1 |
| Blayney, JK | 2 |
| Kalimutho, M | 1 |
| Greer, S | 1 |
| Srivastava, S | 1 |
| Ong, CW | 3 |
| Arthur, K | 1 |
| Loughrey, M | 1 |
| Redmond, K | 1 |
| McCall, S | 1 |
| Rushing, C | 1 |
| Cohn, A | 5 |
| Starodub, A | 1 |
| Arrowood, C | 1 |
| Haley, S | 1 |
| Meadows, KL | 1 |
| Morse, MA | 4 |
| Blobe, GC | 3 |
| Zafar, SY | 1 |
| Deng, T | 2 |
| Liu, XJ | 2 |
| Xu, JM | 7 |
| Bai, YX | 1 |
| Ruiz-Millo, O | 1 |
| Albert-Mari, A | 1 |
| Sendra-Garcia, A | 1 |
| Jimenez-Torres, NV | 2 |
| Swieboda-Sadlej, A | 2 |
| Pastorelli, D | 2 |
| Bloom, J | 1 |
| Ricart, AD | 1 |
| Sobrero, AF | 8 |
| Swiderek, E | 1 |
| Kalas, W | 1 |
| Wysokinska, E | 1 |
| Pawlak, A | 1 |
| Rak, J | 1 |
| Strzadala, L | 1 |
| Carter, HE | 1 |
| Zannino, D | 3 |
| John Simes, R | 1 |
| Schofield, DJ | 1 |
| Howard, K | 1 |
| Zalcberg, JR | 11 |
| Yi, JH | 1 |
| Choi, JS | 2 |
| Choi, GH | 1 |
| Min, BS | 4 |
| Kuwabara, K | 10 |
| Yoshida, M | 5 |
| Sakata, Y | 8 |
| Shikina, A | 1 |
| Kubo, T | 1 |
| Fukazawa, S | 1 |
| Giordano, AV | 2 |
| Vicentini, R | 2 |
| Uslu, R | 3 |
| Yilmaz, U | 3 |
| Buyukunal, E | 1 |
| Buyukberber, S | 6 |
| Camci, C | 1 |
| Sencan, O | 2 |
| Ozdener, F | 1 |
| Cevik, D | 1 |
| Shang, J | 1 |
| Xue, G | 1 |
| Jia, Y | 1 |
| Ye, L | 2 |
| Ji, K | 1 |
| Toms, AM | 1 |
| Davies, ML | 1 |
| Ruge, F | 1 |
| Hargest, R | 1 |
| Jiang, WG | 1 |
| Moutinho, C | 1 |
| Navarro-Pérez, V | 1 |
| Musulen, E | 2 |
| Carmona, FJ | 1 |
| Cassingena, A | 1 |
| Esteller, M | 1 |
| Liu, SL | 1 |
| Qi, MH | 1 |
| Zou, X | 1 |
| Domagala, P | 3 |
| Safranow, K | 3 |
| Domagala, W | 3 |
| Xue, Y | 2 |
| Xie, L | 1 |
| Wei, J | 3 |
| Guan, W | 1 |
| Shiomi, H | 4 |
| Haraguchi, N | 3 |
| Isohashi, F | 1 |
| Yoshioka, Y | 2 |
| Ransom, D | 1 |
| Fournier, M | 1 |
| Gebski, V | 5 |
| Yip, D | 3 |
| Gordon, S | 1 |
| Heitzer, E | 1 |
| Artl, M | 1 |
| Filipits, M | 2 |
| Resel, M | 1 |
| Graf, R | 1 |
| Weißenbacher, B | 1 |
| Lax, S | 2 |
| Gnant, M | 2 |
| Wrba, F | 5 |
| Greil, R | 7 |
| Dietze, O | 2 |
| Hofbauer, F | 1 |
| Böhm, G | 1 |
| Höfler, G | 1 |
| Samonigg, H | 5 |
| Schaberl-Moser, R | 1 |
| Balic, M | 1 |
| Dandachi, N | 1 |
| Endo, A | 1 |
| Nakashima, R | 1 |
| Tanabe, K | 1 |
| Hu, T | 1 |
| Correale, P | 5 |
| Botta, C | 2 |
| Rotundo, MS | 1 |
| Guglielmo, A | 1 |
| Conca, R | 3 |
| Licchetta, A | 2 |
| Pastina, P | 2 |
| Bestoso, E | 2 |
| Ciliberto, D | 1 |
| Cusi, MG | 4 |
| Fioravanti, A | 3 |
| Guidelli, GM | 1 |
| Bianco, MT | 1 |
| Misso, G | 2 |
| Martino, E | 1 |
| Tassone, P | 2 |
| Mantovani, G | 1 |
| Ridolfi, R | 2 |
| Pirtoli, L | 1 |
| Tagliaferri, P | 3 |
| Kim, DY | 3 |
| Paek, TY | 1 |
| Oh, SY | 4 |
| Kim, YB | 2 |
| Choi, ZS | 1 |
| Suh, KW | 3 |
| Pörneczi, B | 1 |
| Mester, G | 1 |
| Fekete, A | 1 |
| Kőszegi, G | 1 |
| Passot, G | 1 |
| Gayat, E | 2 |
| Machida, N | 5 |
| Sasaki, T | 11 |
| Yachi, Y | 1 |
| Onuma, H | 1 |
| May, BH | 1 |
| Zhou, IW | 1 |
| Xue, CC | 1 |
| Zhang, AL | 1 |
| Bar, J | 1 |
| Spencer, S | 1 |
| Morgan, S | 1 |
| Brooks, L | 1 |
| Robertson, J | 3 |
| Goss, GD | 1 |
| Chiou, SH | 2 |
| Hotko, Y | 4 |
| Strickland, AH | 5 |
| Wilson, G | 6 |
| Roman, L | 4 |
| Ang, B | 1 |
| Wan, T | 1 |
| Zemelka, T | 1 |
| Schlichting, M | 4 |
| Heighway, J | 1 |
| Eggleton, SP | 1 |
| Dobi, E | 1 |
| Jary, M | 3 |
| Monnien, F | 1 |
| Curtit, E | 1 |
| Nguyen, T | 3 |
| Lakkis, Z | 3 |
| Heyd, B | 2 |
| Fratte, S | 1 |
| Cléau, D | 1 |
| Lamfichekh, N | 1 |
| Nerich, V | 2 |
| Demarchi, M | 1 |
| Chiu, J | 1 |
| Tang, V | 1 |
| Leung, R | 1 |
| Wong, H | 2 |
| Chu, KW | 1 |
| Poon, J | 1 |
| Epstein, RJ | 1 |
| Yau, T | 2 |
| Dong, L | 2 |
| Yin, X | 1 |
| Lin, F | 3 |
| Ni, W | 1 |
| Jin, R | 2 |
| Fuse, N | 7 |
| Yamanaka, Y | 3 |
| Motomura, S | 2 |
| Doi, T | 11 |
| Hatake, K | 13 |
| Iwasaki, J | 1 |
| Bae, S | 1 |
| Singh, K | 1 |
| Shimizu, T | 5 |
| Murata, S | 1 |
| Takebayashi, K | 1 |
| Miyake, T | 2 |
| Mekata, E | 3 |
| Naka, S | 1 |
| Tani, T | 4 |
| Iyama, KI | 1 |
| Kakeji, Y | 11 |
| Samura, H | 5 |
| Matsumoto, A | 3 |
| Yano, Y | 2 |
| Nakayama, M | 2 |
| Shimakawa, T | 1 |
| Katsube, T | 1 |
| Kemmochi, T | 1 |
| Egawa, T | 1 |
| Mihara, K | 1 |
| Ohkubo, Y | 1 |
| Mori, T | 24 |
| Nagashima, A | 1 |
| Makino, H | 4 |
| Yamamuro, W | 1 |
| Tsuneda, A | 1 |
| Makita, N | 1 |
| Hagino, S | 1 |
| Iwata, K | 1 |
| Kiriyama, M | 2 |
| Tomoda, M | 1 |
| Andoh, H | 2 |
| Ledermann, J | 2 |
| Ruers, TJ | 2 |
| Huh, JW | 3 |
| Lee, WY | 5 |
| Park, YA | 1 |
| Cho, YB | 5 |
| Yun, SH | 5 |
| Kim, HC | 9 |
| Chun, HK | 5 |
| Baroudi, O | 1 |
| Baroudi, T | 1 |
| Omrane, I | 1 |
| Moussa, A | 1 |
| Mezlini, A | 1 |
| Ayari, H | 1 |
| Guermazi, S | 1 |
| Bahloul, A | 1 |
| Bouzaienne, H | 1 |
| Uhrhammer, N | 1 |
| Bignon, YJ | 1 |
| El-Gaaied, AB | 1 |
| Bougatef, K | 1 |
| Bichard, D | 1 |
| Limat, S | 3 |
| Lorgis, V | 3 |
| Vincent, J | 6 |
| Berthou, J | 1 |
| Orry, D | 1 |
| Ortega-Deballon, P | 1 |
| Facy, O | 1 |
| Rat, P | 1 |
| Ladoire, S | 6 |
| Hompes, D | 2 |
| Aalbers, A | 1 |
| van Velthuysen, ML | 1 |
| Vogel, W | 1 |
| Verwaal, V | 1 |
| Shi, DB | 1 |
| Li, XX | 1 |
| Zheng, HT | 1 |
| Li, DW | 1 |
| Cai, GX | 1 |
| Peng, JJ | 1 |
| Gu, WL | 1 |
| Guan, ZQ | 1 |
| Cai, SJ | 1 |
| Di, J | 1 |
| Cui, M | 1 |
| Xing, J | 1 |
| Zhang, N | 1 |
| Dong, B | 1 |
| Su, X | 2 |
| Thiébaut, A | 1 |
| Samson, S | 1 |
| Ricordeau, P | 1 |
| Guillemot, D | 1 |
| Engelmann, BE | 1 |
| Loft, A | 1 |
| Kjær, A | 1 |
| Nielsen, HJ | 3 |
| Gerds, TA | 1 |
| Benzon, EV | 1 |
| Christensen, IJ | 4 |
| Hansson, SH | 1 |
| Kristensen, MH | 1 |
| Löfgren, J | 1 |
| Markova, E | 1 |
| Sloth, C | 1 |
| Højgaard, L | 1 |
| Nagashima, M | 1 |
| Moriyama, A | 1 |
| Sugishita, Y | 1 |
| Kadoya, K | 1 |
| Kitahara, T | 2 |
| Takagi, R | 1 |
| Urita, T | 1 |
| Oshiro, T | 1 |
| Okazumi, S | 3 |
| Katoh, R | 1 |
| Yoshita, H | 1 |
| Ueda, A | 4 |
| Kajiura, S | 2 |
| Kato, H | 2 |
| Kawabe, H | 1 |
| Tomizawa, G | 1 |
| Horikawa, N | 2 |
| Yabuhita, K | 1 |
| Note, M | 1 |
| Sugiyama, T | 3 |
| Xia, HW | 1 |
| Ge, XJ | 1 |
| Zhang, YC | 1 |
| Tang, QL | 1 |
| Kline, CL | 2 |
| Schiccitano, A | 1 |
| Sheikh, H | 1 |
| Harvey, HA | 1 |
| Mackley, HB | 1 |
| McKenna, K | 1 |
| Poritz, L | 1 |
| Messaris, E | 1 |
| Stewart, D | 3 |
| Sivik, J | 2 |
| Shi, M | 4 |
| Lu, CY | 5 |
| Hu, HM | 3 |
| Huang, ML | 3 |
| Deng, G | 1 |
| Zhang, K | 5 |
| Park, MI | 3 |
| Moon, W | 2 |
| Kim, SE | 2 |
| Ku, KH | 1 |
| Song, SE | 1 |
| Lei, H | 2 |
| Zhong, Y | 2 |
| Naeim, A | 2 |
| Ward, PR | 1 |
| Wang, HJ | 2 |
| Dichmann, R | 2 |
| Liem, AK | 2 |
| Chan, D | 3 |
| Hu, EH | 2 |
| Tchekmedyian, NS | 2 |
| Hecht, JR | 9 |
| Tamura, S | 1 |
| Kubo, N | 4 |
| Ijichi, K | 1 |
| De Re, V | 1 |
| Caggiari, L | 1 |
| De Zorzi, M | 1 |
| Racanelli, V | 1 |
| D' Andrea, M | 1 |
| Yilmaz, M | 4 |
| Turkington, RC | 1 |
| Allen, WL | 7 |
| Stevenson, L | 4 |
| McLaughlin, K | 1 |
| Diaz, T | 2 |
| Tejero, R | 1 |
| Moreno, I | 3 |
| Ferrer, G | 1 |
| Cordeiro, A | 1 |
| Artells, R | 2 |
| Navarro, A | 2 |
| Hernandez, R | 2 |
| Tapia, G | 1 |
| Monzo, M | 3 |
| Spindler, KL | 1 |
| Ploen, J | 3 |
| Nishitani, H | 3 |
| Akiyoshi, K | 4 |
| Abrams, TA | 1 |
| Meyer, G | 1 |
| Moloney, J | 1 |
| Collura, A | 3 |
| Lagrange, A | 3 |
| Svrcek, M | 3 |
| Marisa, L | 3 |
| Buhard, O | 3 |
| Guilloux, A | 1 |
| Wanherdrick, K | 2 |
| Dorard, C | 2 |
| Taieb, A | 1 |
| Saget, A | 2 |
| Loh, M | 2 |
| Soong, R | 4 |
| Platell, C | 2 |
| Mews, A | 1 |
| Iacopetta, B | 13 |
| De Thonel, A | 2 |
| Seigneuric, R | 1 |
| Marcion, G | 1 |
| Chapusot, C | 1 |
| Bouvier, AM | 1 |
| Gaub, MP | 4 |
| Senet, P | 1 |
| Delarue, P | 1 |
| Arzouk, H | 1 |
| Lacoste, C | 1 |
| Coquelle, A | 2 |
| Lefèvre, JH | 3 |
| Parc, Y | 2 |
| Biard, DS | 1 |
| Fléjou, JF | 3 |
| Garrido, C | 2 |
| Duval, A | 3 |
| Barrios, CH | 1 |
| del Giglio, A | 2 |
| Dutra, C | 1 |
| Forones, NM | 1 |
| Correa, M | 1 |
| Portella, Mdo S | 1 |
| Passos, VQ | 1 |
| Chinen, RN | 1 |
| van Eyll, B | 3 |
| López-Ríos, F | 2 |
| Plaza, C | 1 |
| García, E | 1 |
| Hernando, O | 1 |
| Rubio, C | 1 |
| Duran, AO | 4 |
| Karaca, H | 7 |
| Berk, V | 8 |
| Bozkurt, O | 4 |
| Ozaslan, E | 4 |
| Ozkan, M | 9 |
| Haller, D | 2 |
| Cartwright, T | 8 |
| McKenna, E | 3 |
| Herbertson, RA | 1 |
| Lee, FT | 1 |
| Chappell, B | 1 |
| Cavicchiolo, T | 1 |
| Saunder, T | 1 |
| O'Keefe, GJ | 1 |
| Murphy, R | 1 |
| Hopkins, W | 1 |
| Scott, FE | 1 |
| Scott, AM | 3 |
| Uehara, K | 3 |
| Mashita, N | 1 |
| Kobayashi, D | 2 |
| Fujii, T | 5 |
| Sugimoto, H | 2 |
| Koike, M | 4 |
| Nomoto, S | 1 |
| Fujiwara, M | 4 |
| Kodera, Y | 4 |
| Munakata, K | 2 |
| Ozaki, M | 3 |
| Konno, M | 1 |
| Raab, HR | 2 |
| Weitz, J | 5 |
| Hartmann, JT | 8 |
| Stoehlmacher-Williams, J | 2 |
| Ockert, D | 2 |
| Jaeger, D | 1 |
| Steger, U | 1 |
| Suedhoff, T | 1 |
| Rentsch, A | 1 |
| Elsoueidi, R | 1 |
| Craig, J | 1 |
| Mourad, H | 1 |
| Richa, EM | 1 |
| Rambach, L | 1 |
| Lee, AM | 1 |
| Diasio, RB | 8 |
| Rosmarin, D | 2 |
| Church, D | 1 |
| Johnstone, E | 3 |
| Love, S | 2 |
| Julier, P | 2 |
| Nicholson, G | 2 |
| Gonzalez-Neira, A | 4 |
| Sargent, D | 4 |
| McLeod, H | 5 |
| Zanger, UM | 1 |
| Schwab, M | 1 |
| Braun, M | 2 |
| Thompson, L | 3 |
| Ribelles, N | 3 |
| Afzal, S | 6 |
| Enghusen, H | 1 |
| Etienne-Grimaldi, MC | 13 |
| Wadelius, M | 2 |
| Garmo, H | 3 |
| Gusella, M | 6 |
| Sharma, R | 5 |
| Kleibl, Z | 2 |
| Morel, A | 9 |
| Midgley, R | 5 |
| Wheeler, HE | 1 |
| Pita, G | 3 |
| de la Torre-Montero, JC | 1 |
| Alonso, R | 1 |
| Lopez-Fernandez, LA | 4 |
| Alba, E | 2 |
| Dolan, ME | 1 |
| Lau, LF | 1 |
| Williams, DS | 2 |
| Christophi, C | 1 |
| Muralidharan, V | 1 |
| Dirican, A | 3 |
| Kucukzeybek, Y | 2 |
| Alacacioglu, A | 3 |
| Varol, U | 4 |
| Aksun, S | 1 |
| Bayoglu, IV | 2 |
| Demir, L | 2 |
| Coban, E | 2 |
| Sutcu, R | 1 |
| Tarhan, MO | 2 |
| Calderaro, J | 1 |
| Zafrani, ES | 1 |
| Hart, L | 1 |
| Rowland, K | 2 |
| Ansari, R | 3 |
| Chowhan, N | 2 |
| Keaton, M | 1 |
| Hainsworth, JD | 7 |
| Childs, BH | 2 |
| Chirica, M | 1 |
| Tranchard, H | 1 |
| Balladur, P | 1 |
| Afchain, P | 3 |
| Paye, F | 3 |
| Rahbari, NN | 2 |
| Reissfelder, C | 2 |
| Büchler, MW | 2 |
| Koch, M | 1 |
| Jennings, BA | 2 |
| Willis, G | 2 |
| Suzuki, H | 5 |
| Asao, T | 4 |
| Tsutsumi, S | 4 |
| Wada, S | 1 |
| Araki, K | 4 |
| Watanabe, A | 4 |
| Tsukagoshi, M | 1 |
| Kuwano, H | 7 |
| Morganti, AG | 2 |
| Mignogna, S | 2 |
| Caravatta, L | 2 |
| Deodato, F | 2 |
| Macchia, G | 2 |
| Plantamura, NM | 1 |
| Massaccesi, M | 1 |
| Picardi, V | 2 |
| Cilla, S | 2 |
| Shigaki, H | 1 |
| Murata, A | 3 |
| Sugihara, H | 1 |
| Etoh, K | 1 |
| Ishimoto, T | 1 |
| Iwatsuki, M | 2 |
| Baba, Y | 6 |
| Iwagami, S | 1 |
| Yoshida, N | 1 |
| Rong, Z | 1 |
| Martel, G | 1 |
| Vandenbroucke-Menu, F | 1 |
| Lapointe, R | 1 |
| Yin, H | 1 |
| Qiao, WB | 1 |
| Zhang, HY | 2 |
| You, QS | 1 |
| Chen, CF | 2 |
| DʼAngelica, MI | 1 |
| Correa-Gallego, C | 1 |
| Gewirtz, AN | 1 |
| Fong, Y | 13 |
| Pagnamenta, A | 1 |
| Kaur, K | 1 |
| Howarth, K | 1 |
| Freeman-Mills, L | 1 |
| Fernández-Rozadilla, C | 2 |
| Ruiz-Ponte, C | 2 |
| Castellvi-Bel, S | 2 |
| Taylor, J | 1 |
| Slavicek, L | 1 |
| Pavlik, T | 4 |
| Bortlicek, Z | 5 |
| Melichar, B | 7 |
| Vyzula, R | 6 |
| Finek, J | 3 |
| Majek, O | 1 |
| Dusek, L | 5 |
| Chung, M | 1 |
| Cho, MS | 1 |
| Baek, SJ | 1 |
| Hur, H | 1 |
| Ayoub, JP | 1 |
| Moore, MJ | 9 |
| Asmis, TR | 1 |
| Schwartz, JD | 1 |
| Ballal, S | 1 |
| Flis, S | 3 |
| Gnyszka, A | 2 |
| Flis, K | 2 |
| Stec, R | 2 |
| Bodnar, L | 2 |
| Smoter, M | 1 |
| Korniluk, J | 1 |
| Kuchar, A | 1 |
| Młot, B | 1 |
| Szczylik, C | 3 |
| Smith, DL | 1 |
| Sequeira, M | 1 |
| Bates, RC | 1 |
| Proia, DA | 1 |
| Schwartzberg, LS | 4 |
| Go, WY | 2 |
| Miyake, Y | 5 |
| Goto, A | 6 |
| Shirao, K | 16 |
| Ahn, JH | 2 |
| Yu, HK | 1 |
| Hong, SW | 1 |
| Kim, SJ | 1 |
| Adams, R | 3 |
| Pugh, C | 1 |
| Sydes, B | 1 |
| Sizer, B | 1 |
| Lowdell, C | 1 |
| Butler, R | 2 |
| Yamagiwa, K | 1 |
| Shigematsu, T | 1 |
| Shirai, M | 1 |
| Amemori, K | 1 |
| Sunda, K | 1 |
| Koike, C | 1 |
| Primrose, J | 2 |
| Valle, J | 4 |
| O'Reilly, D | 1 |
| Siriwardena, A | 1 |
| Hornbuckle, J | 1 |
| Peterson, M | 1 |
| Rees, M | 1 |
| Stanton, L | 1 |
| Dixon, E | 4 |
| Little, L | 1 |
| Bowers, M | 1 |
| Pugh, S | 1 |
| Garden, OJ | 2 |
| Kasliwal, MK | 1 |
| Tan, LA | 1 |
| O'Toole, JE | 1 |
| Beijers, AJ | 2 |
| Mols, F | 2 |
| Vreugdenhil, G | 5 |
| Palshof, JA | 1 |
| van den Berg, MW | 1 |
| Sloothaak, DA | 1 |
| Dijkgraaf, MG | 1 |
| van der Zaag, ES | 1 |
| Bemelman, WA | 1 |
| Bosker, RJ | 1 |
| Fockens, P | 1 |
| ter Borg, F | 1 |
| van Hooft, JE | 1 |
| Doherty, GA | 1 |
| Barbazán, J | 1 |
| Muinelo-Romay, L | 1 |
| Vieito, M | 1 |
| Díaz-López, A | 1 |
| Cano, A | 1 |
| Gómez-Tato, A | 1 |
| Casares de Cal, Mde L | 1 |
| Abal, M | 1 |
| Vamvakas, L | 9 |
| Karampeazis, A | 2 |
| Kakolyris, S | 12 |
| Christophylakis, C | 2 |
| Boukovinas, I | 3 |
| Polyzos, A | 8 |
| Choi, PR | 1 |
| Lee, GW | 1 |
| Van Nieuwenhove, Y | 1 |
| Putte, DV | 1 |
| Pattyn, P | 2 |
| Bolonesi, RM | 1 |
| Rogers, JE | 1 |
| Bécouarn, Y | 7 |
| Cany, L | 2 |
| Pulido, M | 1 |
| Beyssac, R | 1 |
| Le Morvan, V | 2 |
| Béchade, D | 1 |
| Brunet, R | 6 |
| Aitouferoukh, S | 1 |
| Lalet, C | 1 |
| Mathoulin-Pélissier, S | 1 |
| Robert, J | 6 |
| García-Girón, C | 7 |
| Cirera, L | 3 |
| Bustos, IA | 1 |
| Sotelo, MJ | 2 |
| Aguado, C | 2 |
| Feng, QY | 1 |
| Chen, JW | 1 |
| Chang, WJ | 1 |
| Love, SB | 2 |
| Larsen, M | 1 |
| Shanyinde, M | 1 |
| Waters, R | 1 |
| Grainger, L | 1 |
| Shearwood, V | 1 |
| Brooks, C | 1 |
| Gibson, O | 1 |
| Young, AM | 1 |
| Tarassenko, L | 1 |
| Han, GH | 1 |
| Huang, JX | 1 |
| Matsumura, Y | 4 |
| Hu, AP | 1 |
| Li, SL | 1 |
| Grande, E | 1 |
| Afonso, R | 1 |
| Reina, JJ | 5 |
| Campos, JM | 5 |
| Martínez, V | 1 |
| Angeles, C | 1 |
| Mross, K | 4 |
| Scheulen, M | 2 |
| Kanefendt, F | 2 |
| Sörgel, F | 1 |
| Jaehde, U | 6 |
| Moritz, B | 3 |
| Büchert, M | 2 |
| Mahamat, A | 2 |
| Chazal, M | 6 |
| Olschwang, S | 2 |
| Formento, JL | 10 |
| Formento, P | 10 |
| Sudaka, A | 1 |
| Abderrahim-Ferkoune, A | 2 |
| Benchimol, D | 3 |
| Houry, S | 2 |
| Faucheron, JL | 2 |
| Letoublon, C | 8 |
| Gilly, FN | 2 |
| Delpero, JR | 8 |
| Lasser, P | 6 |
| Pradere, B | 2 |
| Pezet, D | 12 |
| Penault-Llorca, F | 1 |
| Daher Abdi, Z | 1 |
| Prémaud, A | 1 |
| Urien, S | 2 |
| Sauvage, FL | 1 |
| Martin, J | 1 |
| Leobon, S | 1 |
| Marquet, P | 1 |
| Rousseau, A | 1 |
| Okoshi, K | 2 |
| Yamada, M | 1 |
| Arao, T | 1 |
| Matsumoto, K | 1 |
| Togashi, Y | 1 |
| Hirashima, Y | 6 |
| Okita, NT | 5 |
| Honma, Y | 3 |
| Nakagawa, K | 7 |
| Hoshino, S | 5 |
| Naito, M | 6 |
| Tanimura, S | 3 |
| Mogi, A | 2 |
| Tamura, K | 2 |
| Yamashita, Y | 8 |
| Yildiz, I | 1 |
| Oktay, E | 1 |
| Degirmenci, M | 1 |
| Barutca, S | 3 |
| Fang, JM | 1 |
| Xue, P | 1 |
| Song, WF | 2 |
| Gu, HL | 1 |
| Wang, LW | 3 |
| McRee, AJ | 1 |
| Davies, JM | 2 |
| Sanoff, HG | 1 |
| Bernard, S | 2 |
| Dees, EC | 1 |
| Keller, K | 1 |
| Fu, L | 1 |
| Wang, E | 2 |
| Alonso-Espinaco, V | 1 |
| Marmol, M | 2 |
| Ortego, J | 1 |
| Gallego, R | 3 |
| Lozano, JJ | 1 |
| Marshall, JL | 10 |
| Lou, H | 1 |
| Lou, F | 1 |
| Gong, L | 1 |
| Jing, X | 1 |
| Baldane, S | 1 |
| Dikilitas, M | 4 |
| Er, O | 4 |
| Skovlund, E | 3 |
| Kersten, C | 3 |
| Dalsgaard, AM | 1 |
| Yilmaz, MK | 2 |
| Fokstuen, T | 6 |
| Usiakova, Z | 1 |
| Kiss, I | 4 |
| Kohoutek, M | 2 |
| Benesova, V | 1 |
| Abrahamova, J | 2 |
| Zulato, E | 1 |
| De Paoli, A | 1 |
| Griguolo, G | 1 |
| Esposito, G | 1 |
| De Salvo, GL | 1 |
| Rugge, M | 1 |
| Nardin, M | 1 |
| Di Grazia, L | 1 |
| Indraccolo, S | 1 |
| Hsiao, HT | 1 |
| Xing, L | 1 |
| Ling, CC | 1 |
| Li, GC | 1 |
| Xie, S | 1 |
| Xu, W | 2 |
| Qin, Z | 1 |
| Rincón, R | 2 |
| Manso, R | 3 |
| Aguilera, O | 1 |
| Cartenì, G | 6 |
| Montesarchio, V | 3 |
| Tatangelo, F | 4 |
| Serra, O | 1 |
| Casado, E | 7 |
| Bosch, C | 4 |
| Bohn, U | 2 |
| Pérez-Carrión, R | 4 |
| Carmona, A | 2 |
| Martínez-Marín, V | 1 |
| Park, JM | 1 |
| Saito, N | 3 |
| Takiguchi, N | 3 |
| Ohue, M | 8 |
| Akaike, M | 4 |
| Kubo, Y | 1 |
| Moriya, Y | 9 |
| Liu, HC | 1 |
| Yen, LC | 3 |
| Chang, JY | 1 |
| Huang, JJ | 2 |
| Hakim, L | 1 |
| Alias, E | 1 |
| Makpol, S | 1 |
| Ngah, WZ | 1 |
| Morad, NA | 1 |
| Yusof, YA | 1 |
| Kang, KA | 1 |
| Piao, MJ | 1 |
| Kim, KC | 1 |
| Yao, CW | 1 |
| Cha, JW | 1 |
| Maeng, YH | 1 |
| Chang, WY | 1 |
| Moon, PG | 1 |
| Baek, MC | 1 |
| Hyun, JW | 1 |
| Sabino, FD | 1 |
| Campos, CF | 1 |
| Caetano, CE | 1 |
| Trotte, MN | 1 |
| Oliveira, AV | 1 |
| Marques, RG | 1 |
| Chao, TH | 1 |
| Chen, WY | 1 |
| Chen, PL | 1 |
| Mao, FC | 1 |
| Schreiber, V | 1 |
| Kitzmueller, M | 1 |
| Poxhofer, M | 1 |
| Gintersdorfer, S | 1 |
| Neudorfer, C | 1 |
| Lichtneckert, M | 1 |
| Dittrich, C | 3 |
| Czejka, M | 5 |
| Farkouh, A | 3 |
| Buchner, P | 1 |
| Georgopoulos, A | 2 |
| Schueller, J | 5 |
| Gruenberger, B | 11 |
| Vargas, GM | 1 |
| Parmar, AD | 1 |
| Sheffield, KM | 1 |
| Tamirisa, NP | 1 |
| Brown, KM | 1 |
| Riall, TS | 1 |
| Ochiai, T | 13 |
| Umeki, M | 2 |
| Miyake, H | 2 |
| Iida, T | 1 |
| Okumura, M | 1 |
| Ohno, K | 2 |
| Sakamoto, M | 1 |
| Tsumura, H | 1 |
| Naitou, H | 1 |
| Fukui, T | 2 |
| del Puerto-Nevado, L | 1 |
| Erten, C | 1 |
| Somali, I | 1 |
| Can, A | 1 |
| Akyol, M | 1 |
| Yildiz, Y | 1 |
| Koyuncu, B | 1 |
| Ward, P | 1 |
| Koca, D | 2 |
| Ünal, OÜ | 1 |
| Öztop, I | 1 |
| Andreoli, SC | 1 |
| Gasparini, NJ | 1 |
| de Carvalho, GP | 1 |
| Garicochea, B | 1 |
| Pogue, RE | 1 |
| de Andrade, RV | 1 |
| Dutton, SJ | 1 |
| Kenealy, N | 1 |
| Sharma, RA | 2 |
| Chaix, M | 1 |
| Altaf, R | 1 |
| Lund Brixen, A | 1 |
| Kristensen, B | 1 |
| Chang, YY | 1 |
| Schütte, K | 1 |
| Ehninger, G | 2 |
| Dermitzakis, EV | 1 |
| Kimiskidis, VK | 1 |
| Eleftheraki, A | 1 |
| Lazaridis, G | 1 |
| Konstantis, A | 1 |
| Basdanis, G | 6 |
| Tsiptsios, I | 1 |
| Georgiadis, G | 1 |
| Nam, JK | 1 |
| Park, JK | 2 |
| Min, do S | 1 |
| Kuh, HJ | 3 |
| Subbiah, IM | 1 |
| Blackmon, SH | 1 |
| Correa, AM | 1 |
| Vaporciyan, AA | 1 |
| Swisher, SG | 1 |
| Keefe, DM | 1 |
| Elting, LS | 2 |
| Nguyen, HT | 1 |
| Grunberg, SM | 1 |
| Bonaventura, A | 1 |
| Selva-Nayagam, S | 1 |
| Barsevick, A | 1 |
| Koczwara, B | 1 |
| Sonis, ST | 1 |
| Mei, Z | 1 |
| Cui, A | 1 |
| Tan, XF | 1 |
| Tan, HT | 1 |
| Lim, TK | 1 |
| Chung, MC | 1 |
| Landsman-Blumberg, PB | 1 |
| Carter, GC | 1 |
| Johnson, BH | 1 |
| Sedgley, R | 1 |
| Nicol, SJ | 2 |
| Shankaran, V | 3 |
| Cainap, C | 1 |
| Qin, Q | 2 |
| Ricker, JL | 1 |
| Fischer, J | 1 |
| McKee, MD | 1 |
| Carlson, DM | 1 |
| Volz, NB | 1 |
| El-Khoueiry, RE | 1 |
| Li, JE | 1 |
| Kardosh, A | 1 |
| Scherer, SJ | 1 |
| Hielscher, J | 2 |
| Scholz, M | 2 |
| Müller, S | 2 |
| Niederle, N | 5 |
| Rost, A | 2 |
| Lindig, RU | 1 |
| Rossius, L | 2 |
| Sclafani, F | 1 |
| Williams, M | 2 |
| Singer, RA | 1 |
| Lerner, A | 1 |
| Chen, HH | 3 |
| Chen, WT | 2 |
| Fang, CY | 2 |
| Chou, YH | 1 |
| Lin, BW | 1 |
| Yeh, CH | 2 |
| Hsu, HH | 1 |
| Ting, WC | 1 |
| Yang, MC | 2 |
| Tan, EC | 2 |
| Tejani, MA | 1 |
| ter Veer, A | 1 |
| Milne, D | 1 |
| Ottesen, R | 1 |
| Skibber, J | 3 |
| Weiser, M | 2 |
| Wilkinson, N | 1 |
| Cohen, SJ | 3 |
| Sameshima, S | 2 |
| Ina, K | 4 |
| Yin, Y | 6 |
| Guo, R | 1 |
| Ibrahim, JG | 2 |
| Olajide, OA | 1 |
| Atluri, PM | 1 |
| Inzerillo, JJ | 1 |
| Chay, CH | 1 |
| Ikeya, T | 1 |
| Sugano, K | 5 |
| Nagahara, H | 2 |
| Ohtani, H | 2 |
| Hirakawa, K | 5 |
| Miyamae, Y | 1 |
| Igarashi, T | 2 |
| Hirai, K | 2 |
| Tsukagoshi, H | 1 |
| Yoshinari, D | 1 |
| Sunose, Y | 1 |
| Takeyoshi, I | 3 |
| Danno, K | 2 |
| Miyazaki, S | 2 |
| Kubota, M | 1 |
| Kawada, J | 1 |
| Fukui, A | 1 |
| Iwase, K | 3 |
| Okagawa, Y | 2 |
| Hisai, H | 1 |
| Koshiba, Y | 1 |
| Wada, H | 3 |
| Miyazaki, E | 1 |
| Kanari, Y | 1 |
| Kawano, Y | 3 |
| Iyama, S | 3 |
| Miyanishi, K | 3 |
| Kobune, M | 2 |
| Kato, J | 3 |
| Haga, N | 9 |
| Sano, M | 5 |
| Mohelnikova-Duchonova, B | 2 |
| Frías, C | 1 |
| Echave, M | 1 |
| Oyagüez, I | 1 |
| Rubio, M | 1 |
| Giménez, E | 1 |
| Naoshy, S | 1 |
| Kalikaki, A | 1 |
| Politaki, H | 1 |
| Apostolaki, S | 1 |
| Papadimitraki, E | 1 |
| Georgoulia, N | 1 |
| Tzardi, M | 2 |
| Mavroudis, D | 12 |
| Dedić Plavetić, N | 1 |
| Rakušić, Z | 1 |
| Ozretić, D | 1 |
| Simetić, L | 1 |
| Krpan, AM | 1 |
| Bišof, V | 1 |
| Luccchetti, J | 1 |
| Smyth, EC | 1 |
| Nardecchia, A | 1 |
| Słomian, G | 1 |
| Świętochowska, E | 1 |
| Malinowska-Borowska, J | 1 |
| Kasperczyk, S | 1 |
| Rogalska, A | 1 |
| Nowak, P | 1 |
| Chiang, HC | 1 |
| Hsiao, KH | 1 |
| Kuo, ML | 1 |
| Shigeta, K | 3 |
| Ishii, Y | 5 |
| Zhu, LM | 1 |
| Zhao, YZ | 1 |
| Ju, HX | 1 |
| Liu, BX | 1 |
| Yang, YS | 1 |
| Zhong, HJ | 1 |
| Yao, L | 2 |
| Xia, L | 3 |
| Pan, L | 2 |
| Silvestris, N | 6 |
| Simone, G | 6 |
| Partipilo, G | 1 |
| Scarpi, E | 2 |
| Brunetti, AE | 1 |
| Paradiso, A | 6 |
| Mangia, A | 3 |
| Nan, H | 1 |
| Parikh, N | 1 |
| Jiang, ZQ | 1 |
| Maru, D | 4 |
| Elvin, P | 1 |
| Gallick, G | 1 |
| Kanterman, J | 1 |
| Sade-Feldman, M | 1 |
| Biton, M | 1 |
| Ish-Shalom, E | 1 |
| Lasry, A | 1 |
| Goldshtein, A | 1 |
| Hubert, A | 1 |
| Baniyash, M | 1 |
| Ramcharan, KS | 1 |
| Lip, GY | 1 |
| Stonelake, PS | 1 |
| Blann, AD | 1 |
| Luo, H | 2 |
| Ding, P | 1 |
| Pan, Z | 1 |
| Wan, D | 1 |
| Hjelmgren, J | 2 |
| de Liège, F | 1 |
| Lanier, J | 1 |
| Knox, H | 1 |
| Barber, B | 5 |
| Findlay, VJ | 1 |
| Nogueira, LM | 1 |
| Hurst, K | 1 |
| Quirk, D | 1 |
| Ethier, SP | 1 |
| Staveley O'Carroll, KF | 1 |
| Watson, DK | 1 |
| Camp, ER | 1 |
| Soon, SS | 1 |
| Chia, WK | 1 |
| Chan, ML | 1 |
| Ho, GF | 1 |
| Jian, X | 1 |
| Tan, CS | 1 |
| Sharma, A | 2 |
| Mehta, S | 1 |
| Ali, R | 1 |
| Toh, HC | 2 |
| Wee, HL | 1 |
| Ress, AL | 1 |
| Stiegelbauer, V | 1 |
| Schwarzenbacher, D | 1 |
| Deutsch, A | 1 |
| Perakis, S | 1 |
| Ling, H | 1 |
| Ivan, C | 1 |
| Calin, GA | 1 |
| Rinner, B | 1 |
| Pichler, M | 2 |
| Quinaux, E | 5 |
| Ni, J | 1 |
| Luo, Z | 1 |
| Thomaidis, T | 2 |
| Maderer, A | 2 |
| Formentini, A | 4 |
| Bauer, S | 1 |
| Trautmann, M | 1 |
| Schwarz, M | 1 |
| Neumann, W | 1 |
| Kittner, JM | 1 |
| Schad, A | 2 |
| Link, KH | 8 |
| Rey, JW | 1 |
| Weinmann, A | 1 |
| Hoffman, A | 1 |
| Galle, PR | 13 |
| Kornmann, M | 8 |
| Jackson, CG | 1 |
| Sharples, K | 1 |
| Thompson, PI | 1 |
| O'Donnell, A | 1 |
| Robinson, BA | 3 |
| Perez, DJ | 1 |
| Isaacs, R | 3 |
| Deva, S | 1 |
| Hinder, VA | 1 |
| Findlay, MP | 5 |
| Okabe, H | 8 |
| Hirashima, K | 1 |
| Imamura, Y | 3 |
| Chikamoto, A | 4 |
| Nakayama, N | 2 |
| Nagaraju, GP | 1 |
| Alese, OB | 1 |
| Diaz, R | 4 |
| Martino-Echarri, E | 1 |
| Henderson, BR | 1 |
| Brocardo, MG | 1 |
| Goldstein, DA | 4 |
| Ayer, T | 2 |
| Howard, DH | 2 |
| Lipscomb, J | 2 |
| Harvey, RD | 1 |
| Flowers, CR | 3 |
| Petersen, V | 1 |
| Schulze, M | 3 |
| Seraphin, J | 1 |
| Hoeffkes, HG | 1 |
| Valdix, AR | 1 |
| Schroeder, J | 1 |
| Herrenberger, J | 1 |
| Leutgeb, B | 1 |
| Kutscheidt, A | 1 |
| Lunardi, G | 1 |
| Inno, A | 2 |
| Magarotto, R | 1 |
| Duranti, S | 1 |
| Messa, MG | 1 |
| Mucchino, C | 1 |
| Cirillo, M | 2 |
| Zuo, D | 1 |
| Ying, G | 1 |
| Wu, DW | 1 |
| Chang, SW | 1 |
| Chen, TH | 1 |
| Kirstein, MM | 1 |
| Lange, A | 1 |
| Prenzler, A | 1 |
| Manns, MP | 1 |
| Vogel, A | 2 |
| Linnemann, D | 1 |
| Osterlind, K | 1 |
| Høgdall, EV | 1 |
| Chen, HM | 1 |
| Cortesi, E | 12 |
| Spadi, R | 3 |
| Amoroso, D | 4 |
| Boni, C | 4 |
| Qazi, F | 2 |
| van Kuilenburg, AB | 9 |
| Meijer, J | 1 |
| Hennekam, RC | 1 |
| Vijzelaar, R | 1 |
| Sharma, MR | 1 |
| Gray, E | 1 |
| Karrison, TG | 1 |
| di Gaetano, C | 1 |
| Novotny, J | 4 |
| Matullo, G | 1 |
| Ueno, S | 2 |
| Kuramoto, M | 1 |
| Kabashima, A | 1 |
| Takahashi, I | 2 |
| Natsugoe, S | 3 |
| Agarwal, A | 2 |
| Daly, KP | 1 |
| Butler-Bowen, H | 1 |
| Ong, SJ | 1 |
| Ong, SY | 3 |
| Chong, SS | 1 |
| Teo, YY | 1 |
| Lee, CG | 1 |
| Dutel, JL | 1 |
| Khalil, A | 3 |
| Hadengue, A | 1 |
| Dalban, C | 1 |
| Brucker, P | 1 |
| Flesch, M | 10 |
| Carola, E | 18 |
| Martin, P | 1 |
| Vaillant, E | 1 |
| Fernandez-Plana, J | 1 |
| Saigi, E | 3 |
| Tjan-Heijnen, VC | 1 |
| Faber, CG | 1 |
| van de Poll-Franse, LV | 1 |
| Fu, Q | 2 |
| Luo, S | 2 |
| Chung, IJ | 4 |
| Lee, JW | 4 |
| Jo, SJ | 2 |
| Brunner, S | 1 |
| Mey, U | 2 |
| Camenisch Gross, U | 1 |
| Freyholdt, T | 1 |
| Cathomas, R | 3 |
| Amaraneni, A | 1 |
| Seth, A | 1 |
| Itawi, EA | 1 |
| Chandana, SR | 1 |
| Bensch, F | 1 |
| van Rooijen, JM | 1 |
| Schröder, CP | 1 |
| Reyners, AK | 1 |
| Sebagh, M | 3 |
| Baillie, G | 1 |
| Faitot, F | 1 |
| Vitadello, F | 1 |
| Xu, E | 1 |
| Lai, M | 1 |
| Kameoka, S | 4 |
| Mochizuki, I | 1 |
| Vishwanath, RL | 2 |
| Bhargava, P | 2 |
| Nöpel-Dünnebacke, S | 1 |
| Stadler, ZK | 1 |
| Cao, R | 1 |
| Hu, L | 2 |
| Wang, CZ | 7 |
| Anderson, S | 1 |
| Yuan, CS | 7 |
| Zhang, XP | 1 |
| Van Buskirk, M | 2 |
| Thurston, K | 2 |
| Cade, DN | 2 |
| Rahman, A | 1 |
| Akinwande, O | 1 |
| Miller, A | 1 |
| Hayes, D | 1 |
| O'Hara, R | 1 |
| Tomalty, D | 2 |
| Martin, RC | 4 |
| Vandamme, M | 1 |
| Pauwels, W | 1 |
| Bleecker, JD | 1 |
| Kim, MK | 2 |
| Di Caro, G | 1 |
| Wong, J | 2 |
| Shalapour, S | 1 |
| Wan, J | 2 |
| Sanchez-Lopez, E | 1 |
| Wu, LW | 1 |
| Fearon, E | 1 |
| Grivennikov, SI | 1 |
| Karin, M | 1 |
| Dörsam, B | 1 |
| Kaina, B | 1 |
| Ding, HH | 1 |
| Wu, WD | 1 |
| Ji, ZY | 1 |
| Jin, JH | 1 |
| Wang, JJ | 2 |
| Mudan, S | 3 |
| Lasserre, S | 1 |
| Hermann, F | 1 |
| Yokoyama, S | 4 |
| Ieda, J | 1 |
| Mitani, Y | 1 |
| Takifuji, K | 4 |
| Hotta, T | 6 |
| Matsuda, K | 5 |
| Shively, JE | 2 |
| Yamaue, H | 5 |
| Kong, S | 1 |
| Miao, R | 1 |
| Sheng, H | 1 |
| Yüce, S | 1 |
| Seker, MM | 1 |
| Koç, S | 1 |
| Uysal, IO | 1 |
| Kaçan, T | 1 |
| Doğan, M | 2 |
| Babacan, NA | 1 |
| Lv, F | 1 |
| Xia, Z | 2 |
| Ohishi, T | 2 |
| Ohnuma, H | 1 |
| Hirakawa, M | 2 |
| Osuga, T | 1 |
| Murase, K | 1 |
| Mizuguchi, T | 2 |
| Furuhata, T | 4 |
| Petrelli, N | 5 |
| Roth, A | 6 |
| Gibson, F | 1 |
| Briani, C | 3 |
| Argyriou, AA | 3 |
| Izquierdo, C | 1 |
| Velasco, R | 3 |
| Campagnolo, M | 1 |
| Alberti, P | 3 |
| Frigeni, B | 1 |
| Cacciavillani, M | 2 |
| Cortinovis, D | 5 |
| Cazzaniga, M | 6 |
| Bruna, J | 3 |
| Cavaletti, G | 3 |
| Kalofonos, HP | 9 |
| Carlsen, AL | 1 |
| Heegaard, NH | 1 |
| Oldenhuis, CN | 1 |
| Loos, WJ | 1 |
| Esteves, B | 1 |
| van Doorn, L | 2 |
| Cotreau, MM | 1 |
| Strahs, AL | 1 |
| den Hollander, MW | 1 |
| Gietema, JA | 1 |
| de Vries, EG | 5 |
| Eskens, FA | 3 |
| Kubáčková, K | 2 |
| Pikus, T | 1 |
| Linke, Z | 2 |
| Pokorná, P | 1 |
| Custodio, AB | 1 |
| Mo, JS | 1 |
| Alam, KJ | 1 |
| Kang, IH | 1 |
| Park, WC | 1 |
| Choi, SC | 1 |
| Moon, HB | 1 |
| Yun, KJ | 1 |
| Chae, SC | 1 |
| Koeberle, D | 2 |
| Betticher, DC | 1 |
| Baertschi, D | 1 |
| Matter, K | 1 |
| Winterhalder, R | 1 |
| Borner, M | 8 |
| Moosmann, P | 1 |
| Kollar, A | 1 |
| Saletti, P | 4 |
| Frueh, M | 1 |
| Kueng, M | 1 |
| Popescu, RA | 2 |
| Schacher, S | 1 |
| Hess, V | 1 |
| Herrmann, R | 21 |
| Melezínek, I | 1 |
| Beier, F | 5 |
| Stroh, C | 3 |
| van Krieken, JH | 7 |
| Nygren, P | 6 |
| Talmon, G | 3 |
| Wade, R | 1 |
| Duarte, A | 1 |
| Simmonds, M | 1 |
| Rodriguez-Lopez, R | 1 |
| Duffy, S | 1 |
| Woolacott, N | 1 |
| Spackman, E | 1 |
| Qiao, Z | 1 |
| Qian, W | 1 |
| Ying, J | 1 |
| Tsujii, M | 1 |
| Kondo, J | 1 |
| Kato, M | 6 |
| Akasaka, T | 1 |
| Shiraishi, E | 1 |
| Hiyama, S | 2 |
| Tsujii, Y | 1 |
| Maekawa, A | 1 |
| Kawai, S | 1 |
| Fujinaga, T | 1 |
| Araki, M | 1 |
| Shinzaki, S | 1 |
| Watabe, K | 1 |
| Nishida, T | 1 |
| Iijima, H | 1 |
| Takehara, T | 1 |
| Kwak, EL | 1 |
| Heiskala, M | 1 |
| de La Bourdonnaye, G | 1 |
| Mita, M | 1 |
| Kon, M | 1 |
| Sakaguchi, Y | 1 |
| Ihaya, T | 1 |
| Choi, DR | 1 |
| Kim, BC | 1 |
| Choi, YK | 1 |
| Kim, JB | 1 |
| Song, HH | 1 |
| Tao, L | 1 |
| Yang, JK | 1 |
| Zhao, AG | 1 |
| Zhu, YJ | 1 |
| Ciarlo, A | 2 |
| Bertolini, A | 4 |
| Verusio, C | 2 |
| Aitini, E | 3 |
| Iacovelli, R | 3 |
| Dotti, KF | 3 |
| Maggi, C | 3 |
| Bajetta, E | 12 |
| Toden, S | 2 |
| Okugawa, Y | 4 |
| Jascur, T | 1 |
| Wodarz, D | 1 |
| Komarova, NL | 1 |
| Ghasemi, Z | 1 |
| Dinarvand, R | 1 |
| Mottaghitalab, F | 1 |
| Esfandyari-Manesh, M | 1 |
| Sayari, E | 1 |
| Atyabi, F | 1 |
| Nipp, RD | 1 |
| Marton, E | 1 |
| Liegl-Atzwanger, B | 1 |
| Knittelfelder, R | 3 |
| Lindner, E | 1 |
| Streubel, B | 1 |
| Linot, B | 1 |
| Palesh, O | 1 |
| Krebs, MG | 1 |
| Renehan, AG | 1 |
| Backen, A | 1 |
| Hasan, J | 1 |
| Valle, JW | 3 |
| Morris, K | 1 |
| Beech, J | 1 |
| Ashcroft, L | 1 |
| Dive, C | 2 |
| Kozak, MM | 1 |
| von Eyben, R | 1 |
| Pai, J | 1 |
| Vossler, SR | 1 |
| Limaye, M | 1 |
| Anderson, EM | 1 |
| Shaffer, JL | 1 |
| Longacre, T | 1 |
| Pai, RK | 1 |
| Koong, AC | 1 |
| Chang, DT | 1 |
| Baba, K | 1 |
| Oshita, A | 1 |
| Kohyama, M | 1 |
| Inoue, S | 3 |
| Kuroo, Y | 1 |
| Nakamura, H | 2 |
| Tazaki, T | 1 |
| Sasaki, M | 1 |
| Daimaru, Y | 1 |
| Nakamitsu, A | 1 |
| Cui, JF | 1 |
| Chen, MB | 2 |
| Zhang, QD | 1 |
| Lu, PH | 1 |
| Marks, E | 1 |
| Rizvi, SM | 1 |
| Martelli, S | 1 |
| Piacentini, P | 1 |
| Malik, H | 1 |
| Khan, AZ | 2 |
| Berry, DP | 5 |
| Cameron, IC | 1 |
| Pope, I | 1 |
| Sherlock, D | 2 |
| Helmy, S | 1 |
| Byrne, B | 1 |
| Thompson, M | 1 |
| Pulfer, A | 1 |
| Davidson, B | 1 |
| Paré-Brunet, L | 1 |
| Sebio, A | 3 |
| Salazar, J | 5 |
| Berenguer-Llergo, A | 1 |
| Río, E | 1 |
| Barnadas, A | 6 |
| Baiget, M | 9 |
| Vitello, S | 3 |
| D'Amico, M | 2 |
| Abdallah, EA | 1 |
| Fanelli, MF | 1 |
| Buim, ME | 1 |
| Machado Netto, MC | 1 |
| Gasparini Junior, JL | 1 |
| Souza E Silva, V | 1 |
| Dettino, AL | 1 |
| Mingues, NB | 1 |
| Romero, JV | 1 |
| Ocea, LM | 1 |
| Rocha, BM | 1 |
| Alves, VS | 1 |
| Araújo, DV | 1 |
| Chinen, LT | 1 |
| Nanni, O | 1 |
| Tassinari, D | 5 |
| Turci, D | 6 |
| Fontana, A | 5 |
| Mucciarini, C | 1 |
| Ragazzini, A | 1 |
| Amadori, D | 10 |
| Bruhn, MA | 1 |
| Mann, KP | 1 |
| Simes, J | 4 |
| Van Hazel, G | 4 |
| Robinson, B | 3 |
| Yoshinami, T | 1 |
| Yagi, T | 1 |
| Takeuchi, Y | 4 |
| Higashino, K | 1 |
| Yano, M | 1 |
| Nukatsuka, M | 3 |
| Nakagawa, F | 5 |
| Saito, H | 5 |
| Sakata, M | 1 |
| Uchida, J | 6 |
| Takechi, T | 5 |
| Kotasek, D | 1 |
| Burris, HA | 2 |
| Stephenson, J | 2 |
| Warner, DJ | 1 |
| Goldstein, D | 9 |
| Pilat, N | 1 |
| Grünberger, T | 1 |
| Längle, F | 2 |
| Mittlböck, M | 1 |
| Perisanidis, B | 1 |
| Kappel, S | 1 |
| Wolf, B | 1 |
| Starlinger, P | 2 |
| Kührer, I | 1 |
| Mühlbacher, F | 1 |
| Kandioler, D | 1 |
| Neumann, JH | 1 |
| Falvella, FS | 2 |
| Cheli, S | 2 |
| Mazzali, C | 1 |
| Gariboldi, M | 1 |
| Pierotti, MA | 1 |
| Sottotetti, E | 2 |
| Mennitto, R | 2 |
| Bossi, I | 3 |
| Clementi, E | 2 |
| Lin, L | 3 |
| You, H | 1 |
| Pei, Y | 1 |
| Zhang, ZY | 1 |
| Rateesh, S | 1 |
| Shekar, K | 1 |
| Naidoo, R | 1 |
| Mittal, D | 1 |
| Bhaskar, B | 1 |
| Matono, K | 1 |
| Tsuda, H | 1 |
| Ushijima, M | 1 |
| Uchida, S | 2 |
| Shirouzu, K | 6 |
| Dhelens, C | 1 |
| Bonadona, A | 1 |
| Chapuis, C | 1 |
| Potton, L | 1 |
| Bedouch, P | 1 |
| Schwebel, C | 1 |
| Ramos-Díaz, R | 1 |
| Nazco-Casariego, GJ | 1 |
| González-Perera, I | 1 |
| Pérez-Pérez, JA | 1 |
| Coinu, A | 1 |
| Benson, A | 3 |
| Guillén Ponce, C | 1 |
| Macpherson, IR | 1 |
| Wagner, A | 1 |
| Luigi Garosi, V | 1 |
| Grunert, J | 1 |
| Fakih, MG | 8 |
| Maglinte, GA | 2 |
| Esposito, C | 1 |
| Saneeymehri, SS | 1 |
| Markey, KR | 1 |
| Mahipal, A | 1 |
| Ucar, M | 1 |
| Elmali, F | 2 |
| Tung, JY | 1 |
| Hsiao, CD | 1 |
| Wang, P | 2 |
| Lee, MH | 1 |
| Rubino, L | 1 |
| Villa, E | 1 |
| Tronconi, MC | 2 |
| Gerardi, C | 1 |
| Floriani, I | 5 |
| Destro, A | 1 |
| Raschioni, C | 1 |
| Simkens, LH | 4 |
| May, A | 1 |
| Creemers, GJ | 5 |
| Loosveld, OJ | 2 |
| de Jongh, FE | 1 |
| Erdkamp, FL | 5 |
| Erjavec, Z | 3 |
| van der Torren, AM | 1 |
| Tol, J | 8 |
| Braun, HJ | 1 |
| Nieboer, P | 1 |
| van der Hoeven, JJ | 1 |
| Haasjes, JG | 1 |
| Wals, J | 4 |
| Cats, A | 7 |
| Derleyn, VA | 2 |
| Honkoop, AH | 3 |
| Utsumi, H | 1 |
| Nara, S | 1 |
| Esaki, M | 1 |
| Lutrino, SE | 2 |
| Llimpe, FR | 1 |
| Pisa, FE | 1 |
| Kim, GP | 4 |
| Dou, R | 1 |
| Stremitzer, S | 3 |
| Stift, J | 1 |
| Tamandl, D | 8 |
| Irving, GR | 1 |
| Iwuji, CO | 1 |
| Li, BL | 1 |
| Hu, XL | 1 |
| Zhao, XH | 1 |
| Sun, HG | 1 |
| Zhou, CY | 1 |
| Ye, D | 1 |
| Simms, L | 1 |
| Wakasa, K | 1 |
| Kawabata, R | 1 |
| Nakao, S | 1 |
| Hattori, H | 1 |
| Oda, S | 2 |
| Chow, AK | 2 |
| Cheng, NS | 1 |
| Lam, CS | 2 |
| Ng, L | 2 |
| Wong, SK | 1 |
| Wan, TM | 1 |
| Man, JH | 1 |
| Cheung, AH | 1 |
| Yau, TC | 2 |
| Poon, JT | 2 |
| Law, WL | 3 |
| Pang, RW | 1 |
| Ikeda, J | 1 |
| Nishisaki, H | 2 |
| Kraehe, P | 2 |
| Webber, EM | 1 |
| Kauffman, TL | 1 |
| O'Connor, E | 1 |
| Goddard, KA | 1 |
| Schoellhammer, HF | 1 |
| Goldner, B | 1 |
| Merchant, SJ | 1 |
| Kessler, J | 1 |
| Gagandeep, S | 1 |
| Das, UN | 1 |
| Bencsikova, B | 1 |
| Halamkova, J | 1 |
| Ostrizkova, L | 1 |
| Valik, D | 1 |
| Zdrazilova-Dubska, L | 1 |
| Iwayama, Y | 1 |
| Tsuruma, T | 2 |
| Toyota, N | 1 |
| Torigoe, T | 1 |
| Sato, N | 1 |
| Yokogawa, T | 1 |
| Oguchi, K | 1 |
| Kazuno, H | 2 |
| Tanaka, N | 5 |
| Osada, A | 1 |
| Caporale, M | 2 |
| Ricchini, F | 1 |
| Bernardi, FF | 1 |
| Kunieda, K | 6 |
| Kurachi, K | 2 |
| Srinivas, US | 1 |
| Dyczkowski, J | 1 |
| Mansour, WY | 1 |
| Borgmann, K | 1 |
| Dobbelstein, M | 1 |
| Vishnevskiĭ, AV | 1 |
| Andreĭtseva, OI | 1 |
| Kharazov, AF | 1 |
| Gritsiuta, AI | 1 |
| Kalinin, DV | 1 |
| Zhavoronkova, OI | 1 |
| Liu, RL | 1 |
| Deng, YZ | 1 |
| Li, WD | 1 |
| Yoshioka, R | 1 |
| Okura, N | 1 |
| Amankwatia, EB | 1 |
| Chakravarty, P | 1 |
| Carey, FA | 1 |
| Weidlich, S | 1 |
| Steele, RJ | 1 |
| Munro, AJ | 1 |
| Wolf, CR | 1 |
| Smith, G | 1 |
| Wu, XR | 1 |
| Cui, JG | 1 |
| Xia, YX | 1 |
| He, WJ | 1 |
| Yasui, M | 3 |
| Ohno, Y | 1 |
| Sekimoto, M | 5 |
| Nezu, R | 4 |
| Tokka, A | 1 |
| Liao, D | 1 |
| Bai, M | 1 |
| Dong, N | 1 |
| You, Q | 2 |
| Muhammand, S | 1 |
| Tanaka, S | 9 |
| Sasaki, E | 1 |
| Hibi, K | 4 |
| Sakuyama, T | 3 |
| Sekikawa, T | 1 |
| Nishina, H | 1 |
| Klinkhardt, U | 1 |
| Duecker, K | 1 |
| Huiskens, J | 1 |
| van Gulik, TM | 1 |
| van Lienden, KP | 1 |
| Engelbrecht, MR | 1 |
| Meijer, GA | 2 |
| van Grieken, NC | 1 |
| Schriek, J | 1 |
| Keijser, A | 1 |
| Molenaar, IQ | 1 |
| de Jong, KP | 1 |
| Dejong, KH | 1 |
| Kazemier, G | 1 |
| Ruers, TM | 1 |
| Karlberg, M | 1 |
| Vistisen, K | 1 |
| Lindh, B | 1 |
| Bjerregaard, JK | 1 |
| Terwey, JH | 2 |
| Papaxoinis, G | 4 |
| Gourgioti, G | 2 |
| Raptou, G | 2 |
| Scopa, CD | 2 |
| Azvolinsky, A | 1 |
| van Staveren, MC | 1 |
| Opdam, F | 1 |
| Maring, JG | 2 |
| Scudellari, M | 1 |
| Yang, IP | 1 |
| Wu, JY | 3 |
| Kuo, CH | 2 |
| Tseng, FY | 1 |
| James, MI | 1 |
| Iwuji, C | 1 |
| Irving, G | 1 |
| Griffin-Teal, N | 1 |
| Greaves, P | 1 |
| Dennison, A | 1 |
| Metcalfe, M | 1 |
| Garcea, G | 2 |
| Lloyd, DM | 1 |
| Rothbarth, J | 1 |
| Eggermont, AM | 1 |
| Dakhil, S | 2 |
| Saleh, M | 1 |
| Piperdi, B | 2 |
| Cline-Burkhardt, M | 1 |
| Oshiro, M | 2 |
| Roselló, S | 2 |
| Laffranchi, B | 1 |
| Jego, V | 1 |
| von Richter, O | 1 |
| Hamaya, Y | 2 |
| Guarinos, C | 1 |
| Tseng-Rogenski, SS | 1 |
| Iwaizumi, M | 3 |
| Das, R | 1 |
| Carethers, JM | 8 |
| Li, ZJ | 1 |
| Li, LF | 1 |
| Wu, WK | 2 |
| Chan, RL | 1 |
| Liu, YW | 1 |
| Ren, SX | 1 |
| Chan, KM | 2 |
| Cho, CH | 1 |
| Volovat, SR | 1 |
| Volovat, C | 1 |
| Negru, SM | 1 |
| Danciu, M | 1 |
| Scripcariu, V | 1 |
| Pinheiro, C | 1 |
| Miranda-Gonçalves, V | 1 |
| Pereira, H | 1 |
| Moyer, MP | 1 |
| Preto, A | 1 |
| Kocak, I | 2 |
| Petruzelka, L | 1 |
| Oberg, AL | 1 |
| Sueyoshi, S | 2 |
| Higashi, H | 4 |
| Matsuda, H | 1 |
| Ayadi, M | 2 |
| Bouygues, A | 1 |
| Ouaret, D | 1 |
| Ferrand, N | 1 |
| Chouaib, S | 1 |
| Thiery, JP | 1 |
| Muchardt, C | 1 |
| Sabbah, M | 1 |
| Lam, JY | 1 |
| McConnell, YJ | 2 |
| Rivard, JD | 1 |
| Temple, WJ | 2 |
| Mack, LA | 2 |
| Zhou, N | 1 |
| Bai, C | 1 |
| Zhao, RC | 1 |
| Frontini, L | 6 |
| Rota, S | 1 |
| Pepe, A | 1 |
| Signoriello, S | 1 |
| De Placido, S | 3 |
| Makoshi, Z | 1 |
| Perrott, C | 1 |
| Al-Khatani, K | 1 |
| Al-Mohaisen, F | 1 |
| Anderson, BJ | 1 |
| Peterson, LL | 1 |
| Kroep, JR | 1 |
| Polee, M | 1 |
| van Groeningen, CJ | 18 |
| Beeker, A | 1 |
| Erdkamp, F | 1 |
| Weijl, N | 1 |
| van Bochove, A | 3 |
| Kapiteijn, E | 1 |
| Stiggelbout, AM | 1 |
| Nortier, HW | 1 |
| Pérez Hoyos, MT | 1 |
| Díaz de Corcuera, I | 1 |
| Vidal Arbués, A | 1 |
| García de la Torre, M | 1 |
| Choueiri, MB | 1 |
| Gross, AM | 1 |
| Huang, JK | 1 |
| Ideker, T | 1 |
| Fanta, P | 1 |
| Kit, OI | 1 |
| Vladimirova, LY | 1 |
| Vodolazhskiy, DI | 1 |
| Abramova, NA | 1 |
| Dvadnenko, KV | 1 |
| Poschau, M | 1 |
| Dickreuter, E | 1 |
| Singh-Müller, J | 1 |
| Zscheppang, K | 1 |
| Eke, I | 1 |
| Cordes, N | 1 |
| Butzke, B | 1 |
| Oduncu, FS | 1 |
| Severin, F | 1 |
| Pfeufer, A | 1 |
| Stollenwerk, B | 1 |
| Rogowski, WH | 1 |
| Uzzan, B | 4 |
| Nicolas, P | 4 |
| Su, D | 1 |
| Jiao, S | 1 |
| Giommoni, E | 2 |
| Latiano, T | 1 |
| Pavese, I | 2 |
| Azzarello, D | 1 |
| Pastina, I | 1 |
| Mogavero, S | 1 |
| Angelini, V | 1 |
| Pazzagli, M | 1 |
| Wu, NC | 1 |
| Su, SM | 1 |
| Lin, TJ | 1 |
| Chin, J | 1 |
| Hou, CF | 1 |
| Yang, JY | 1 |
| Liu, WS | 1 |
| Chang, LC | 1 |
| Imperatori, M | 1 |
| Picardi, A | 3 |
| Vespasiani Gentilucci, U | 1 |
| Gallo, P | 1 |
| Fausti, V | 1 |
| Spalato Ceruso, M | 1 |
| Gotoh, M | 4 |
| Yoshizuka, N | 1 |
| Ozaka, M | 3 |
| Weickhardt, AJ | 1 |
| Parry, MM | 1 |
| Asadi, K | 1 |
| Mariadason, JM | 1 |
| Liu, JW | 2 |
| Gao, YJ | 1 |
| Chen, YM | 2 |
| Cheng, T | 1 |
| Mithieux, F | 1 |
| Marsot, J | 1 |
| Watkin, E | 1 |
| Chalabreysse, P | 1 |
| Scoggins, CR | 3 |
| Schreeder, M | 2 |
| Rilling, WS | 1 |
| Laing, CJ | 1 |
| Tatum, CM | 1 |
| Kelly, LR | 1 |
| Garcia-Monaco, RD | 1 |
| Sharma, VR | 1 |
| Crocenzi, TS | 1 |
| Strasberg, SM | 3 |
| Ota, M | 3 |
| Tatsumi, K | 1 |
| Suwa, H | 1 |
| Shoichi, F | 1 |
| Ichikawa, Y | 5 |
| Kunisaki, C | 2 |
| Yajima, R | 1 |
| Morita, H | 2 |
| Ikenishi, M | 1 |
| Ueda, M | 2 |
| Kuroda, A | 1 |
| Tsukazaki, H | 1 |
| Konishi, Y | 1 |
| Matsuda, T | 3 |
| Figoni, W | 1 |
| Ohtori, T | 1 |
| Matsuyama, K | 1 |
| Satoh, H | 2 |
| Sawada, Y | 1 |
| Nakatsuka, E | 1 |
| Chan, MT | 1 |
| Kemmerling, R | 1 |
| Folwaczny, M | 1 |
| Balboa-Beltrán, E | 1 |
| Truong, WT | 1 |
| Gloria, D | 1 |
| Braet, F | 1 |
| Thordarson, P | 1 |
| González-Alonso, P | 1 |
| De Divitiis, C | 1 |
| Barretta, ML | 1 |
| O'Connell, D | 1 |
| Varghese, B | 1 |
| Yip, J | 2 |
| Dolatshahi Pirooz, S | 1 |
| Li, GM | 1 |
| Ellen Martin, S | 1 |
| Machida, K | 1 |
| Liang, C | 1 |
| Yeh, CT | 2 |
| Adebayo, BO | 1 |
| Lin, YC | 2 |
| Deng, L | 1 |
| Rao, YK | 1 |
| Lee, WH | 1 |
| Wu, AT | 1 |
| Hsiao, M | 2 |
| Wu, CH | 1 |
| Wang, LS | 1 |
| Tzeng, YM | 1 |
| Patyutko, YI | 1 |
| Kotelnikov, AG | 1 |
| Mamontov, KG | 1 |
| Podluzhny, DV | 1 |
| Ponomarenko, AA | 1 |
| Kos, ME | 1 |
| Evande, RE | 1 |
| Meza, JL | 1 |
| Schwarz, JK | 1 |
| She, X | 1 |
| O'Donovan, TR | 1 |
| Rajendran, S | 1 |
| O'Sullivan, GC | 1 |
| McKenna, SL | 1 |
| Thomsen, M | 1 |
| Indrebø, G | 1 |
| Lingjærde, O | 1 |
| Möhler, M | 3 |
| D'Haens, G | 4 |
| Latini, L | 2 |
| Staines, H | 1 |
| Oum'Hamed, Z | 1 |
| Dressler, H | 1 |
| Studeny, M | 1 |
| Chan, DL | 1 |
| Šišić, I | 1 |
| Pojskić, B | 1 |
| Mekić Abazović, A | 1 |
| Kovčin, V | 1 |
| Lim, T | 1 |
| Lee, I | 2 |
| Kleist, B | 1 |
| Kempa, M | 1 |
| Meurer, T | 1 |
| Poetsch, M | 1 |
| Deschoemaeker, S | 1 |
| Di Conza, G | 1 |
| Lilla, S | 1 |
| Martín-Pérez, R | 1 |
| Mennerich, D | 1 |
| Boon, L | 1 |
| Hendrikx, S | 1 |
| Maddocks, OD | 1 |
| Marx, C | 1 |
| Myllyharju, J | 1 |
| Kietzmann, T | 1 |
| Vousden, KH | 1 |
| Zanivan, S | 1 |
| Mazzone, M | 1 |
| Skoupá, J | 1 |
| Jandová, P | 1 |
| Garde-Noguera, J | 1 |
| Gil-Raga, M | 1 |
| Evgenyeva, E | 1 |
| García, JA | 1 |
| Llombart-Cussac, A | 1 |
| Camps-Herrero, C | 1 |
| Lyu, Y | 1 |
| Deniz, K | 1 |
| Ágoston, EI | 1 |
| Baranyai, Z | 1 |
| Kulka, J | 1 |
| Harsányi, L | 1 |
| Szász, AM | 1 |
| Guo, XZ | 1 |
| Ye, XL | 1 |
| Xiao, WZ | 1 |
| Wei, XN | 1 |
| You, QH | 1 |
| Che, XH | 1 |
| Cai, YJ | 1 |
| Chen, F | 1 |
| Yu, MH | 1 |
| Atanackovic, D | 2 |
| Hildebrandt, B | 6 |
| Stübs, P | 1 |
| Brugger, W | 1 |
| Hapke, G | 1 |
| Steffens, CC | 2 |
| Illerhaus, G | 2 |
| Bluemner, E | 1 |
| Stöhlmacher, J | 1 |
| Xun, C | 1 |
| Qi, L | 1 |
| Tie-Ning, Z | 1 |
| Ning, L | 1 |
| Zhi-Xiao, C | 1 |
| Li-Wei, W | 1 |
| Sadanaga, N | 4 |
| Mezi, S | 1 |
| He, P | 2 |
| Jung, AS | 1 |
| Emile, JF | 2 |
| Aust, D | 1 |
| Lutz, MP | 6 |
| Schlag, P | 11 |
| Fisseler, A | 1 |
| Ponzetti, A | 1 |
| Pinta, F | 1 |
| Mecca, C | 2 |
| Zanini, M | 1 |
| Goto, R | 1 |
| Kurihara, M | 3 |
| Lambrechts, D | 2 |
| Thienpont, B | 1 |
| Thuillier, V | 1 |
| Sagaert, X | 1 |
| Moisse, M | 1 |
| Peuteman, G | 1 |
| Margherini, E | 1 |
| Lerchenmüller, CA | 1 |
| Killing, B | 1 |
| Depenbusch, R | 1 |
| Lange, T | 1 |
| Quidde, J | 1 |
| Lemire, M | 1 |
| Zaidi, SH | 1 |
| Zanke, BW | 1 |
| Gallinger, S | 4 |
| Hudson, TJ | 1 |
| Cleary, SP | 1 |
| To, KK | 1 |
| Leung, WW | 1 |
| Ng, SS | 2 |
| Fiore, D | 1 |
| Proto, MC | 1 |
| Pisanti, S | 1 |
| Picardi, P | 1 |
| Pagano Zottola, AC | 1 |
| Butini, S | 1 |
| Gemma, S | 1 |
| Casagni, A | 1 |
| Laezza, C | 1 |
| Vitale, M | 1 |
| Ligresti, A | 1 |
| Di Marzo, V | 1 |
| Zisterer, DM | 1 |
| Nathwani, S | 1 |
| Williams, DC | 1 |
| Campiani, G | 1 |
| Gazzerro, P | 1 |
| Bifulco, M | 1 |
| Lu, B | 1 |
| Rutnam, ZJ | 1 |
| Iwamoto, A | 3 |
| Isaakidou, A | 1 |
| Karantanos, T | 1 |
| Sioziou, A | 1 |
| Theodoropoulos, GE | 1 |
| Pektasides, D | 1 |
| Fontanella, C | 1 |
| Bonotto, M | 1 |
| Rihawi, K | 1 |
| Li, PL | 1 |
| Wang, LL | 1 |
| Du, LT | 1 |
| Yang, YM | 1 |
| Wang, CX | 1 |
| Naruse, T | 2 |
| Kimura, Y | 8 |
| Fujimoto, D | 1 |
| Yamaguchi, A | 3 |
| Soda, H | 1 |
| Kono, E | 1 |
| Park, JW | 1 |
| Ryoo, SB | 1 |
| Fujii, A | 1 |
| Adhoute, X | 1 |
| Provençal, J | 1 |
| Chone, L | 1 |
| Sobhani, I | 2 |
| Beltjens, F | 1 |
| Bengrine, L | 1 |
| Kumekawa, Y | 1 |
| Loriot, MA | 4 |
| Lafargue, JP | 1 |
| Moon, HH | 1 |
| Ku, JL | 3 |
| Xia, D | 1 |
| Tibiche, C | 1 |
| Zaman, N | 1 |
| Trifiro, M | 1 |
| O'Connor-McCourt, M | 1 |
| Sena, P | 1 |
| Mariani, F | 1 |
| Mancini, S | 1 |
| Benincasa, M | 1 |
| Magnani, G | 1 |
| Pedroni, M | 2 |
| Palumbo, C | 1 |
| Roncucci, L | 2 |
| Okumura, H | 2 |
| Murakami, H | 3 |
| Kubota, H | 3 |
| Tsuruta, A | 2 |
| Tohyama, K | 1 |
| Hirai, T | 4 |
| Lim, SH | 1 |
| Hwang, IG | 1 |
| Grapsa, D | 1 |
| Syrigos, K | 4 |
| Kwon, HY | 1 |
| Kim, IK | 1 |
| Sohn, SK | 4 |
| Tong, M | 2 |
| Azadeh, P | 1 |
| Mortazavi, N | 1 |
| Tahmasebi, A | 1 |
| Hosseini Kamal, F | 1 |
| Novin, K | 1 |
| Polverari, RS | 1 |
| Ottone, A | 2 |
| Alabiso, I | 3 |
| Bitossi, R | 2 |
| Forti, L | 3 |
| Bertona, E | 1 |
| Alabiso, O | 3 |
| Aglietta, M | 6 |
| Berruti, A | 2 |
| Zeichner, SB | 1 |
| Bartnik, CM | 1 |
| Neustadter, E | 1 |
| Freeman, K | 2 |
| Connock, M | 2 |
| Cummins, E | 1 |
| Gurung, T | 2 |
| Taylor-Phillips, S | 2 |
| Court, R | 2 |
| Clarke, A | 2 |
| Sutcliffe, P | 3 |
| Yuan, J | 1 |
| Sun, DC | 1 |
| Wang, ZK | 1 |
| Dai, GH | 2 |
| Min, J | 1 |
| Tao, D | 1 |
| Xie, D | 2 |
| Granata, V | 2 |
| Fusco, R | 1 |
| Catalano, O | 2 |
| Filice, S | 1 |
| Amato, DM | 1 |
| Ajavon, Y | 1 |
| Castaing, D | 10 |
| Kunstlinger, F | 6 |
| Afshar, M | 1 |
| Maki, C | 1 |
| Hosomi, M | 1 |
| Nishihara, M | 2 |
| Katsumata, T | 1 |
| Houssany, S | 1 |
| Renner, J | 1 |
| Boutonnet, M | 1 |
| Peigne, V | 1 |
| Soler, C | 1 |
| Dong, J | 2 |
| Rollin, J | 1 |
| Payancé, A | 1 |
| Gouilleux-Gruart, V | 2 |
| Boisdron-Celle, M | 14 |
| Azzopardi, N | 2 |
| Gruel, Y | 1 |
| Paintaud, G | 3 |
| Gamelin, E | 23 |
| Watier, H | 2 |
| Uboha, N | 1 |
| Peng, K | 1 |
| Xie, R | 2 |
| Shahriari-Ahmadi, A | 1 |
| Fahimi, A | 1 |
| Sadeghi, M | 1 |
| Rudek, MA | 2 |
| Laheru, D | 2 |
| Walker, R | 1 |
| Taylor, GE | 1 |
| Jimeno, A | 4 |
| Donehower, RC | 4 |
| Purcell, WT | 1 |
| Tummala, S | 1 |
| Kuppusamy, G | 1 |
| Satish Kumar, MN | 1 |
| Praveen, TK | 1 |
| Wadhwani, A | 1 |
| Di Francia, R | 1 |
| De Lucia, L | 9 |
| Di Paolo, M | 1 |
| Di Martino, S | 1 |
| Del Pup, L | 1 |
| De Monaco, A | 1 |
| Herath, NI | 1 |
| Devun, F | 2 |
| Lienafa, MC | 1 |
| Herbette, A | 2 |
| Denys, A | 1 |
| Sun, JS | 2 |
| Dutreix, M | 2 |
| Thomas, SA | 1 |
| Tomeh, N | 1 |
| Theard, S | 1 |
| Hu, Y | 4 |
| Gu, B | 1 |
| Leng, C | 1 |
| Dou, L | 1 |
| Bonin, S | 1 |
| Donada, M | 1 |
| Bussolati, G | 1 |
| Nardon, E | 1 |
| Annaratone, L | 1 |
| Chiaravalli, AM | 1 |
| Capella, C | 1 |
| Stanta, G | 1 |
| Laurent, M | 1 |
| Bastuji-Garin, S | 1 |
| Culine, S | 2 |
| Caillet, P | 1 |
| Audureau, E | 1 |
| Carvahlo-Verlinde, M | 1 |
| Reinald, N | 1 |
| LeThuaut, A | 1 |
| Canouï-Poitrine, F | 1 |
| Jiang, CF | 1 |
| Li, DM | 1 |
| Ge, X | 1 |
| Shi, ZM | 1 |
| Zhen, L | 1 |
| Liu, LZ | 1 |
| Jiang, BH | 1 |
| Shimamoto, Y | 2 |
| Sakoda, M | 1 |
| Chiarotto, JA | 1 |
| Dranitsaris, G | 2 |
| Cohen, SA | 1 |
| Wirtz, R | 1 |
| Gkakou, C | 1 |
| Kalogeras, KT | 2 |
| Grady, WM | 1 |
| Guan, H | 1 |
| Zeng, Z | 1 |
| Luo, P | 2 |
| Tan, Z | 1 |
| Mitchell, E | 5 |
| Kröning, H | 4 |
| Le-Guennec, S | 1 |
| Andria, M | 2 |
| Miyata, Y | 2 |
| Kusumi, T | 2 |
| Taniguchi, F | 1 |
| Manabe, M | 1 |
| Lo, L | 1 |
| Amitesh, R | 1 |
| Roder, D | 1 |
| Moore, J | 2 |
| De Bruycker, S | 1 |
| Vangestel, C | 2 |
| Van den Wyngaert, T | 1 |
| Wyffels, L | 2 |
| Wouters, A | 1 |
| Staelens, S | 2 |
| Stroobants, S | 2 |
| Chatelut, E | 7 |
| Quesada, JL | 1 |
| Roblin, X | 1 |
| Mendoza, C | 1 |
| Buc, E | 3 |
| Lin, GN | 1 |
| Liu, PP | 1 |
| Liu, DY | 1 |
| Xiao, JJ | 1 |
| Xia, ZJ | 1 |
| Ye, X | 1 |
| Bhattacharya, R | 2 |
| Boulbes, DR | 1 |
| Fan, F | 4 |
| Ellis, LM | 6 |
| Spång, N | 1 |
| Torkzad, M | 1 |
| Hug de Larauze, M | 2 |
| Guering-Meyer, V | 1 |
| Boucher, E | 6 |
| Bonnet, I | 1 |
| Andoh, M | 1 |
| Yatabe, Y | 2 |
| Kinoshita, T | 1 |
| Hendlisz, A | 6 |
| Delaunoit, T | 5 |
| Varea, R | 1 |
| Chao, G | 1 |
| Wallin, J | 1 |
| Hua, D | 4 |
| Kim, MJ | 1 |
| Meulendijks, D | 1 |
| Henricks, LM | 1 |
| Amstutz, U | 3 |
| Froehlich, TK | 1 |
| Largiadèr, CR | 4 |
| Beijnen, JH | 4 |
| de Boer, A | 2 |
| Schellens, JH | 2 |
| Maindrault-Gœbel, F | 1 |
| Dupuis, O | 4 |
| Arbaud, C | 1 |
| Wang, YW | 1 |
| Yeh, CG | 1 |
| Cellini, F | 1 |
| Padula, GD | 1 |
| Buwenge, M | 1 |
| Di Lullo, L | 3 |
| Gambacorta, MA | 1 |
| Balducci, M | 1 |
| Mattiucci, GC | 1 |
| Autorino, R | 1 |
| Boucher, TM | 1 |
| Fong, YC | 1 |
| Ohnishi, T | 6 |
| Nakamura, Y | 4 |
| Matsuura, N | 1 |
| Monden, M | 3 |
| Rogowski, W | 2 |
| Kap, EJ | 2 |
| Seibold, P | 1 |
| Scherer, D | 1 |
| Habermann, N | 1 |
| Balavarca, Y | 1 |
| Jansen, L | 1 |
| Zucknick, M | 2 |
| Becker, N | 1 |
| Ulrich, A | 2 |
| Ulrich, CM | 2 |
| Burwinkel, B | 1 |
| Elvas, F | 1 |
| Pak, K | 1 |
| Vermeulen, P | 1 |
| Gray, B | 3 |
| Miyamato, Y | 1 |
| Parekh, A | 2 |
| Flanagan, L | 1 |
| Meyer, M | 1 |
| Fay, J | 2 |
| Curry, S | 1 |
| Duessmann, H | 1 |
| John, K | 1 |
| Boland, KC | 1 |
| Kay, EW | 5 |
| Bantel, H | 1 |
| Zhang, RH | 1 |
| Kang, T | 1 |
| Casadei Gardini, A | 1 |
| Carloni, S | 1 |
| Maltoni, P | 1 |
| Dorizzi, RM | 1 |
| Cortesi, P | 1 |
| Giannini, MB | 1 |
| Lucchesi, A | 1 |
| Cavalcanti, E | 1 |
| Maiolino, P | 1 |
| Bianco, F | 1 |
| Aprea, P | 1 |
| De Bellis, M | 1 |
| Pecori, B | 1 |
| Gallo, C | 3 |
| Leone, A | 3 |
| Romano, GM | 1 |
| Le Roy, B | 1 |
| Tixier, L | 1 |
| Pereira, B | 1 |
| Sauvanet, P | 1 |
| Pétorin, C | 1 |
| Déchelotte, P | 1 |
| Balayssac, D | 1 |
| Barbara, C | 4 |
| Zheng, P | 1 |
| Qin, X | 2 |
| Xiong, BH | 1 |
| Volk, AM | 1 |
| Fritzmann, J | 1 |
| Weber, GF | 1 |
| Wulaningsih, W | 1 |
| Wardhana, A | 1 |
| Watkins, J | 1 |
| Yoshuantari, N | 1 |
| Repana, D | 1 |
| Van Hemelrijck, M | 1 |
| Karakulak, UN | 1 |
| Aladağ, E | 1 |
| Maharjan, N | 1 |
| Övünç, K | 1 |
| Fujimoto, T | 6 |
| Maruno, K | 2 |
| Fujino, S | 2 |
| Dos Santos, LV | 2 |
| Faria, TM | 1 |
| Lima, AB | 1 |
| de Moraes, ED | 1 |
| Cruz, MR | 1 |
| Lima, JP | 2 |
| Kodaz, H | 1 |
| Tozkir, H | 1 |
| Albayrak, D | 1 |
| Sharma, NK | 1 |
| Ricke, J | 1 |
| Perez, D | 1 |
| Ferguson, T | 1 |
| Rodríguez, J | 7 |
| Wolf, I | 1 |
| Ganju, V | 4 |
| Walpole, E | 1 |
| Tichler, T | 1 |
| Powell, A | 1 |
| Eliadis, P | 1 |
| Price, D | 4 |
| Moeslein, F | 1 |
| Bower, G | 3 |
| Zakari, A | 1 |
| Peyton, JD | 1 |
| Boccia, R | 1 |
| Moskowitz, M | 1 |
| Gian, V | 1 |
| Lipman, A | 1 |
| Waterhouse, D | 2 |
| LoCicero, R | 1 |
| Earwood, C | 1 |
| Lane, CM | 2 |
| Meluch, A | 1 |
| Tran, HM | 1 |
| Tovar-Camargo, OA | 1 |
| Lin, DR | 1 |
| Serrablo, A | 1 |
| Paliogiannis, P | 1 |
| Pulighe, F | 1 |
| Moro, SS | 1 |
| Borrego-Estella, V | 1 |
| Attene, F | 1 |
| Scognamillo, F | 1 |
| Santi, L | 1 |
| Bianco, MR | 1 |
| Giuffrè, MR | 1 |
| Pettinato, M | 1 |
| Bugarin, C | 1 |
| Garanzini, C | 1 |
| Savarese, L | 1 |
| Leoni, S | 1 |
| Cerrito, MG | 1 |
| Leone, BE | 1 |
| Gaipa, G | 1 |
| Grassilli, E | 1 |
| Papa, M | 1 |
| Lavitrano, M | 1 |
| Giovannoni, R | 1 |
| Shan, Z | 1 |
| Jin, Z | 1 |
| Mazzuca, F | 2 |
| Borro, M | 2 |
| Botticelli, A | 2 |
| Mazzotti, E | 1 |
| Marchetti, L | 1 |
| Gentile, G | 2 |
| La Torre, M | 2 |
| Lionetto, L | 2 |
| Simmaco, M | 2 |
| Tai, WC | 1 |
| Wong, WY | 1 |
| Lee, MM | 1 |
| Chan, BD | 1 |
| Lu, C | 2 |
| Hsiao, WL | 1 |
| Zhang, JT | 1 |
| Zhou, WL | 1 |
| Huang, G | 1 |
| Yu, F | 2 |
| Yuan, C | 1 |
| Ye, XC | 1 |
| Ling, X | 1 |
| McManus, M | 1 |
| Boulbes, D | 1 |
| Yoshii, Y | 1 |
| Yoshimoto, M | 1 |
| Kiyono, Y | 1 |
| Zhang, MR | 1 |
| Fujibayashi, Y | 1 |
| Saga, T | 1 |
| Franken, MD | 1 |
| van Oijen, MG | 1 |
| Bordonaro, AR | 1 |
| Rachiglio, M | 1 |
| Modoni, G | 1 |
| He, EY | 1 |
| Hawkins, NJ | 1 |
| Mak, G | 1 |
| Roncolato, F | 1 |
| Liauw, W | 2 |
| Clingan, P | 6 |
| Chin, M | 1 |
| Ward, RL | 1 |
| El-Shemi, AG | 1 |
| Refaat, B | 1 |
| Kensara, OA | 1 |
| Mohamed, AM | 1 |
| Idris, S | 1 |
| Ahmad, J | 1 |
| Kim, N | 1 |
| Cho, SB | 1 |
| Park, YL | 1 |
| Park, SY | 1 |
| Myung, E | 1 |
| Yu, HM | 1 |
| Son, YA | 1 |
| Myung, DS | 1 |
| Lee, WS | 2 |
| Joo, YE | 1 |
| Yusof, MM | 1 |
| Abdullah, NM | 1 |
| Sharial, MM | 1 |
| Zaatar, A | 2 |
| Xiao, L | 1 |
| Shroff, R | 1 |
| Shaw, K | 1 |
| Mills, GB | 1 |
| Wolff, RA | 4 |
| Hamilton, S | 1 |
| Meric-Bernstam, F | 1 |
| Abbruzzese, J | 3 |
| Morris, J | 3 |
| Quan, C | 1 |
| Mao, Y | 2 |
| Li, ZZ | 1 |
| Zhang, ZC | 1 |
| Qiu, MZ | 3 |
| Shao, JY | 1 |
| Malkomes, P | 1 |
| Lunger, I | 1 |
| Luetticke, A | 1 |
| Oppermann, E | 1 |
| Haetscher, N | 1 |
| Serve, H | 1 |
| Holzer, K | 1 |
| Rieger, MA | 1 |
| Tsuruta, M | 1 |
| Endo, T | 2 |
| Kondo, T | 1 |
| Umehara, M | 1 |
| Umehara, Y | 1 |
| Nishikawa, S | 3 |
| Tokura, T | 1 |
| Matsuzaka, M | 1 |
| Morita, T | 2 |
| Chong, DQ | 1 |
| Manalo, M | 1 |
| Imperial, M | 1 |
| Teo, P | 1 |
| Yong, G | 1 |
| Ng, M | 2 |
| Tan, IB | 1 |
| Chua, C | 1 |
| Thanarajasingam, G | 1 |
| Atherton, PJ | 1 |
| Novotny, PJ | 2 |
| Loprinzi, CL | 4 |
| Sloan, JA | 2 |
| Fourrier-Réglat, A | 1 |
| Robinson, P | 1 |
| Moore, N | 1 |
| Lu, YM | 1 |
| Chien, TM | 1 |
| Huang, CN | 1 |
| Lopez Lopez, R | 1 |
| Roh, JK | 6 |
| Chistyakov, V | 1 |
| Ackland, SP | 8 |
| Kopp, M | 1 |
| Udovitsa, D | 1 |
| Hall, M | 2 |
| Tseng-Rogenski, S | 2 |
| Miyajima, H | 1 |
| Kanaoka, S | 1 |
| Kosmacek, EA | 1 |
| Chatterjee, A | 1 |
| Oberley-Deegan, RE | 1 |
| Vishnubalaji, R | 1 |
| Hamam, R | 1 |
| Yue, S | 1 |
| Al-Obeed, O | 1 |
| Kassem, M | 1 |
| Liu, FF | 1 |
| Aldahmash, A | 1 |
| Alajez, NM | 1 |
| Lin, WR | 1 |
| Chiang, JM | 6 |
| Liang, KH | 1 |
| Lim, SN | 1 |
| Lai, MW | 1 |
| Tsou, YK | 1 |
| Hsieh, TY | 1 |
| Hsu, CK | 1 |
| Coşkun, HŞ | 1 |
| Korkmaz, L | 2 |
| Karaağaç, M | 2 |
| Karabulut, S | 1 |
| Faruk Aykan, N | 1 |
| Doruk, H | 1 |
| Avcı, N | 1 |
| Pozzi, C | 1 |
| Cuomo, A | 1 |
| Spadoni, I | 1 |
| Magni, E | 3 |
| Silvola, A | 1 |
| Conte, A | 1 |
| Sigismund, S | 1 |
| Ravenda, PS | 1 |
| Bonaldi, T | 1 |
| Cancelliere, C | 1 |
| Di Fiore, PP | 1 |
| Bardelli, A | 2 |
| Penna, G | 1 |
| Rescigno, M | 1 |
| Cravioto-Villanueva, A | 1 |
| Cavazos, M | 1 |
| Luna-Perez, P | 2 |
| Martinez-Gomez, H | 1 |
| Ramirez, ML | 1 |
| Solorzano, J | 1 |
| Montiel, H | 1 |
| Esquivel, J | 4 |
| Osawa, H | 1 |
| Mittmann, N | 1 |
| Giotis, A | 1 |
| Lien, K | 1 |
| Wong, WW | 1 |
| Chan, KK | 1 |
| Leuci, V | 1 |
| Maione, F | 1 |
| Rotolo, R | 1 |
| Giraudo, E | 1 |
| Sassi, F | 1 |
| Migliardi, G | 1 |
| Todorovic, M | 1 |
| Gammaitoni, L | 1 |
| Mesiano, G | 1 |
| Giraudo, L | 1 |
| Luraghi, P | 1 |
| Bussolino, F | 1 |
| Grignani, G | 1 |
| Trusolino, L | 1 |
| Bertotti, A | 1 |
| Sangiolo, D | 1 |
| McCulloch, M | 1 |
| Ly, H | 1 |
| Broffman, M | 1 |
| See, C | 1 |
| Clemons, J | 1 |
| Cabart, M | 1 |
| Frénel, JS | 1 |
| Campion, L | 1 |
| Ramée, JF | 1 |
| Lu, J | 2 |
| Fang, F | 2 |
| Miyo, M | 1 |
| Kano, Y | 2 |
| Fukusumi, T | 1 |
| Sun, ZZ | 1 |
| Ning, K | 2 |
| Tang, SC | 1 |
| Nagase, M | 4 |
| Eguchi Nakajima, T | 1 |
| Taira, K | 1 |
| Funai, S | 1 |
| Okuno, T | 3 |
| Kurimoto, T | 1 |
| Okabe, M | 1 |
| Seki, N | 3 |
| Taku, K | 4 |
| Tamura, F | 2 |
| Nakashima, K | 1 |
| Popanda, O | 1 |
| Basso, M | 5 |
| Dadduzio, V | 1 |
| Ardito, F | 2 |
| Strippoli, A | 1 |
| Vellone, M | 3 |
| Rossi, S | 1 |
| Cerchiaro, E | 1 |
| Cassano, A | 10 |
| Giuliante, F | 4 |
| Hanaka, J | 1 |
| Nakayama, H | 3 |
| Pan, W | 1 |
| Ren, H | 1 |
| Ming, L | 1 |
| Lerchenmueller, C | 1 |
| Mueller, S | 1 |
| Cortejoso, L | 3 |
| García-González, X | 1 |
| García, MI | 3 |
| Sanjurjo, M | 2 |
| Fakhri, Y | 1 |
| Dalsgaard, M | 1 |
| Lav Madsen, P | 1 |
| Sawaki, A | 1 |
| Okajima, M | 2 |
| Yamaguchi, Y | 2 |
| Wilhelm, M | 1 |
| Miller, MC | 2 |
| Link, K | 1 |
| Holdenrieder, S | 2 |
| Bertsch, T | 1 |
| Stoetzer, OJ | 1 |
| Suttmann, I | 1 |
| Braess, J | 4 |
| Birkmann, J | 1 |
| Roessler, M | 1 |
| Kraff, S | 1 |
| Salamone, SJ | 1 |
| Barreto, R | 1 |
| Waning, DL | 1 |
| Zimmers, TA | 1 |
| Bonetto, A | 1 |
| Huynh, N | 1 |
| Shulkes, A | 1 |
| Baldwin, G | 1 |
| Miranda, VC | 1 |
| Faria, LD | 1 |
| Bariani, G | 1 |
| Alex, A | 1 |
| Bezerra Neto, JE | 1 |
| Sabbaga, J | 1 |
| Lobo Dos Santos, JF | 1 |
| Song, N | 1 |
| Pogue-Geile, KL | 1 |
| Gavin, PG | 1 |
| Kim, SR | 1 |
| Johnson, NL | 1 |
| Lipchik, C | 1 |
| Petrelli, NJ | 7 |
| O'Connell, MJ | 24 |
| Wolmark, N | 3 |
| Pilancı, KN | 1 |
| Saglam, S | 3 |
| Okyar, A | 1 |
| Yucel, S | 1 |
| Pala-Kara, Z | 1 |
| Ordu, C | 1 |
| Ciftci, R | 1 |
| Iner-Koksal, U | 1 |
| Kaytan-Saglam, E | 1 |
| Boye, K | 1 |
| Jacob, H | 1 |
| Frikstad, KA | 1 |
| Nesland, JM | 1 |
| Maelandsmo, GM | 1 |
| Dahl, O | 8 |
| Nesbakken, A | 1 |
| Flatmark, K | 3 |
| Chung, SS | 1 |
| Oliva, B | 1 |
| Dwabe, S | 1 |
| Vadgama, JV | 1 |
| Ju, HQ | 1 |
| Lu, YX | 1 |
| Chen, DL | 1 |
| Tian, T | 1 |
| Mo, HY | 1 |
| Wei, XL | 1 |
| Liao, JW | 1 |
| Zeng, ZL | 1 |
| Pelicano, H | 1 |
| Aguilar, M | 1 |
| Jia, WH | 1 |
| Alzoubi, S | 1 |
| Brody, L | 2 |
| Rahman, S | 2 |
| Mahul-Mellier, AL | 1 |
| Mercado, N | 1 |
| El-Bahrawy, M | 1 |
| Silver, A | 2 |
| Boobis, A | 1 |
| Bell, JD | 1 |
| Hajji, N | 1 |
| Furushima, K | 2 |
| Koike, J | 3 |
| Yonemura, Y | 2 |
| Kitao, H | 2 |
| Kiyonari, S | 1 |
| Iimori, M | 2 |
| Niimi, S | 1 |
| Kataoka, Y | 1 |
| Akiyama, S | 5 |
| Edahiro, K | 1 |
| Nakanishi, R | 3 |
| Tokunaga, E | 3 |
| Kanaji, S | 1 |
| Smalligan, RD | 1 |
| Nadesan, S | 1 |
| Hamidou, Z | 1 |
| Garcia-Larnicol, ML | 1 |
| Ruan, Z | 2 |
| Yi, H | 1 |
| Huo, W | 1 |
| Kim, YC | 1 |
| Wang, SM | 4 |
| Ge, L | 1 |
| Wang, YF | 1 |
| Tian, JH | 2 |
| Mao, L | 1 |
| Zhang, JH | 1 |
| Shen, XP | 1 |
| Yang, KH | 2 |
| Lv, WH | 1 |
| Li, XD | 1 |
| Zhang, MQ | 1 |
| Martchenko, K | 1 |
| Schmidtmann, I | 2 |
| Thole, V | 1 |
| Becker, M | 1 |
| Wehler, TC | 2 |
| Schimanski, CC | 6 |
| Xun, Z | 1 |
| Chemama, S | 1 |
| Bayar, MA | 1 |
| Lanoy, E | 1 |
| Ammari, S | 1 |
| Stoclin, A | 1 |
| Raynard, B | 3 |
| Antoun, S | 2 |
| Ikezawa, N | 1 |
| Shoji, H | 1 |
| Daibo, K | 1 |
| Sehdev, A | 1 |
| Cramer, HM | 1 |
| Ibrahim, AA | 1 |
| Younger, AE | 1 |
| Kiyomatsu, T | 2 |
| Ryan, D | 2 |
| Murphy, ÁC | 1 |
| Hector, S | 3 |
| McCawley, N | 2 |
| Concannon, CG | 3 |
| Vijayvergia, N | 1 |
| Wong, YN | 1 |
| Dotan, E | 2 |
| Weyrech, J | 1 |
| Dagois, S | 1 |
| Sheng, YH | 1 |
| Hasnain, SZ | 1 |
| Tong, H | 1 |
| Clarke, DT | 1 |
| Lourie, R | 1 |
| Oancea, I | 1 |
| Wong, KY | 1 |
| Lumley, JW | 1 |
| Florin, TH | 1 |
| Sutton, P | 1 |
| Hooper, JD | 1 |
| McMillan, NA | 1 |
| McGuckin, MA | 1 |
| Sasse, C | 1 |
| Vossen, S | 1 |
| Van Sant, C | 1 |
| Ball, HA | 1 |
| Keating, A | 1 |
| Krivoshik, A | 1 |
| Ushijima, H | 1 |
| Horyozaki, A | 1 |
| Maeda, M | 1 |
| Mao, X | 2 |
| Xue, L | 2 |
| Chu, X | 2 |
| Stanisavljević, L | 1 |
| Myklebust, MP | 2 |
| Leh, S | 2 |
| Koshkin, S | 1 |
| Danilova, A | 1 |
| Raskin, G | 1 |
| Petrov, N | 1 |
| Bajenova, O | 1 |
| O'Brien, SJ | 1 |
| Tomilin, A | 1 |
| Tolkunova, E | 1 |
| Uthman, OA | 1 |
| Hu, YL | 1 |
| Feng, YY | 1 |
| Bian, ZH | 1 |
| Zhou, LY | 1 |
| Fei, BJ | 1 |
| Wang, YG | 1 |
| Huang, ZH | 2 |
| Azzariti, A | 2 |
| Porcelli, L | 1 |
| Brunetti, O | 1 |
| Longo, V | 1 |
| Nardulli, P | 1 |
| Signorile, M | 1 |
| Calabrese, A | 1 |
| Quatrale, AE | 1 |
| Krizkova, V | 1 |
| Dubova, M | 1 |
| Bruha, J | 2 |
| Skala, M | 1 |
| Daum, O | 1 |
| Ho, C | 3 |
| Winquist, E | 3 |
| Rayson, D | 1 |
| Stitt, L | 3 |
| Tokmakejian, S | 1 |
| Vincent, MD | 2 |
| Schmitz, R | 5 |
| Valls, AF | 1 |
| Yerbes, R | 1 |
| von Richter, S | 1 |
| Kahlert, C | 1 |
| Loges, S | 1 |
| Ruiz de Almodovar, C | 1 |
| Dhir, M | 1 |
| Novak, S | 1 |
| Euvrard, R | 1 |
| Chevriaux, A | 1 |
| Boidot, R | 1 |
| Végran, F | 1 |
| Bonnefoy, N | 1 |
| Apetoh, L | 1 |
| Liao, Z | 1 |
| Ørum-Madsen, MS | 1 |
| Nordgaard, C | 1 |
| Noer, J | 1 |
| Moreira, JM | 1 |
| Hao, L | 1 |
| Hou, A | 1 |
| Shi, C | 1 |
| Miao, H | 1 |
| Gonçalves-Ribeiro, S | 1 |
| Díaz-Maroto, NG | 1 |
| Berdiel-Acer, M | 1 |
| Soriano, A | 1 |
| Guardiola, J | 1 |
| Martínez-Villacampa, M | 4 |
| Villanueva, A | 2 |
| Molleví, DG | 2 |
| Hoshiba, T | 1 |
| Tanaka, M | 5 |
| Veelenturf, S | 1 |
| Binkhorst, L | 1 |
| Bins, S | 1 |
| Mathijssen, R | 1 |
| Nan, Q | 1 |
| Portnoy, D | 1 |
| Ronga, P | 1 |
| Paolicchi, E | 4 |
| De Gregorio, V | 1 |
| Crea, F | 4 |
| Zhuang, R | 1 |
| Cayre, A | 1 |
| Jacquin, M | 1 |
| Arbez-Gindre, F | 1 |
| Fein, F | 1 |
| Gned, D | 1 |
| Bertaggia, C | 1 |
| Veltri, A | 1 |
| Ji, Q | 1 |
| Jiang, H | 2 |
| Zhuang, X | 1 |
| Chen, CW | 2 |
| Paschall, AV | 1 |
| Redd, PS | 1 |
| Heaton, CM | 1 |
| Lee, JR | 1 |
| Nayak-Kapoor, A | 1 |
| Ahn, SJ | 2 |
| Bhandare, M | 1 |
| Pai, V | 1 |
| Bhamre, R | 1 |
| Engineer, R | 1 |
| Hokuto, D | 1 |
| Nomi, T | 1 |
| Yamato, I | 1 |
| Yasuda, S | 6 |
| Obara, S | 1 |
| Kawaguchi, C | 1 |
| Kanehiro, H | 1 |
| Porcu, L | 1 |
| Torri, V | 3 |
| Chong, LC | 1 |
| Mølck, C | 1 |
| Ryall, J | 1 |
| Failla, LM | 1 |
| Coates, JL | 1 |
| Pascussi, JM | 1 |
| Heath, JK | 1 |
| Stewart, G | 4 |
| Hollande, F | 1 |
| Safwat, MA | 1 |
| Soliman, GM | 1 |
| Sayed, D | 1 |
| Attia, MA | 1 |
| Che, J | 1 |
| Lou, Q | 1 |
| Uysal, M | 1 |
| Er, Z | 1 |
| Güler, T | 1 |
| Börüban, MC | 1 |
| Bozcuk, H | 1 |
| Díez de Corcuera, I | 1 |
| García García, T | 1 |
| Kunicka, T | 1 |
| Prochazka, P | 1 |
| Krus, I | 1 |
| Protivova, M | 1 |
| Hlavac, V | 1 |
| Novak, P | 1 |
| Pitule, P | 1 |
| Moore, M | 5 |
| Zbuk, K | 1 |
| Jeyakumar, A | 1 |
| Chan, T | 1 |
| Spratlin, J | 1 |
| Rothenstein, J | 1 |
| Kudrik, F | 1 |
| Kauh, J | 2 |
| Kambhampati, SR | 1 |
| Ramdas, N | 1 |
| Binder, P | 1 |
| Strevel, E | 1 |
| Voron, T | 1 |
| Srdjan, M | 1 |
| Jadranka, A | 1 |
| Ivan, D | 1 |
| Branimir, Z | 1 |
| Daniela, B | 1 |
| Petar, S | 1 |
| Velimir, M | 1 |
| Zoran, K | 1 |
| Zou, ZW | 1 |
| Chen, HJ | 1 |
| Yu, JL | 1 |
| Lin, XH | 1 |
| Nagayama, S | 4 |
| Hida, K | 1 |
| Matsuo, T | 2 |
| Tada, M | 3 |
| Nishitai, R | 1 |
| Mitsuyoshi, A | 1 |
| Yoshimura, K | 6 |
| Niimi, M | 2 |
| Sánchez Cendra, C | 1 |
| Yun, Q | 1 |
| Wang, SS | 1 |
| Yang, JP | 1 |
| Yang, LL | 1 |
| Fu, SZ | 1 |
| Wu, JB | 1 |
| Letocha, H | 3 |
| Fernebro, E | 4 |
| Boedigheimer, M | 1 |
| Twomey, B | 1 |
| Fattouh, K | 1 |
| Collet-Benzaquen, D | 1 |
| Provensal, AM | 1 |
| Castillo, C | 2 |
| Combemale, P | 1 |
| de la Fouchardière, A | 1 |
| Cheng, AL | 5 |
| Cornelio, G | 1 |
| Guan, Z | 1 |
| Masood, N | 1 |
| Doval, DC | 1 |
| Oh, ST | 3 |
| Gorospe, C | 1 |
| Sirachainan, E | 2 |
| Hill, A | 3 |
| Chatterjee, S | 1 |
| Kaiho, T | 2 |
| Kobayashi, S | 2 |
| Maruyama, T | 3 |
| Boulat, O | 1 |
| He, F | 1 |
| Ji, Z | 1 |
| Yao, J | 1 |
| Huang, A | 1 |
| Onesti, CE | 1 |
| Romiti, A | 2 |
| Petremolo, A | 1 |
| Occhipinti, M | 1 |
| Falcone, R | 1 |
| de la Varga, LU | 1 |
| Pascual, JR | 1 |
| Sarno, F | 1 |
| Prieto, SH | 1 |
| Lopéz-Casas, PP | 1 |
| Schade, H | 1 |
| Davis, L | 2 |
| Kabos, P | 1 |
| Gong, Y | 2 |
| Zhao, T | 1 |
| Ålgars, A | 3 |
| Sundström, J | 1 |
| Lintunen, M | 1 |
| Jokilehto, T | 1 |
| Kytölä, S | 1 |
| Kaare, M | 1 |
| Vainionpää, R | 1 |
| Orpana, A | 2 |
| Ristimäki, A | 1 |
| Carpen, O | 1 |
| Ristamäki, R | 8 |
| Mehta, AM | 1 |
| Huitema, AD | 1 |
| Burger, JW | 1 |
| Brandt-Kerkhof, AR | 1 |
| van den Heuvel, SF | 1 |
| Verwaal, VJ | 6 |
| Peters, GJ | 23 |
| Smid, K | 12 |
| Meijer, E | 1 |
| Leon, LG | 2 |
| Badran, MM | 1 |
| Mady, MM | 1 |
| Ghannam, MM | 1 |
| Jang, MH | 1 |
| Hwang, DY | 2 |
| Kim, WY | 1 |
| Lim, SD | 1 |
| Kim, WS | 2 |
| Hwang, TS | 1 |
| Yamakawa, T | 1 |
| Yamatsuji, T | 1 |
| Yoshimitsu, M | 1 |
| Toyota, K | 1 |
| Yamano, T | 2 |
| Tanishima, H | 1 |
| Shirai, Y | 2 |
| Horiuchi, T | 1 |
| Wu, IC | 2 |
| Takemura, H | 1 |
| Minamoto, T | 2 |
| Däster, S | 2 |
| Amatruda, N | 1 |
| Calabrese, D | 1 |
| Ivanek, R | 1 |
| Turrini, E | 1 |
| Droeser, RA | 1 |
| Zajac, P | 1 |
| Fimognari, C | 1 |
| Spagnoli, GC | 1 |
| Iezzi, G | 2 |
| Mele, V | 2 |
| Muraro, MG | 2 |
| Moretto R, R | 1 |
| Pilati, P | 2 |
| Benahim, E | 1 |
| Smith, CG | 2 |
| Elliott, F | 3 |
| Brown, S | 2 |
| Cheadle, J | 1 |
| Lu, TX | 1 |
| Sundaramoorthy, P | 1 |
| Sánchez-Velázquez, P | 1 |
| Töpel, I | 1 |
| Piso, P | 2 |
| Seo, K | 3 |
| Ki, SH | 1 |
| Park, EY | 1 |
| Shin, SM | 1 |
| Bertocchi, P | 1 |
| Aroldi, F | 1 |
| Pinter, T | 3 |
| Klippel, Z | 1 |
| Cesas, A | 1 |
| Croitoru, A | 1 |
| Kurteva, G | 5 |
| Salek, T | 1 |
| Reiner, M | 1 |
| Morrow, PK | 1 |
| Choi, MR | 1 |
| Whittaker, S | 1 |
| Parikh, A | 1 |
| Atreya, C | 1 |
| Korn, WM | 1 |
| Lin, YK | 2 |
| Liang, Q | 1 |
| Sun, HQ | 1 |
| She, F | 1 |
| Jiang, G | 1 |
| Geng, J | 1 |
| Dai, T | 1 |
| Nakajima, J | 1 |
| Stevenson, HL | 1 |
| Prats, MM | 1 |
| Sasatomi, E | 1 |
| Copija, A | 1 |
| Waniczek, D | 1 |
| Witkoś, A | 1 |
| Walkiewicz, K | 1 |
| Nowakowska-Zajdel, E | 1 |
| Roncato, R | 1 |
| Montico, M | 1 |
| Giodini, L | 1 |
| Solfrini, V | 1 |
| Tomochika, S | 1 |
| Tokuhisa, Y | 1 |
| Yoshino, S | 2 |
| Lee, YC | 1 |
| Su, CY | 1 |
| Lin, YF | 1 |
| Lin, CM | 2 |
| Chen, CL | 1 |
| McQuade, RM | 1 |
| Stojanovska, V | 1 |
| Bornstein, JC | 1 |
| Nurgali, K | 1 |
| Guenther, S | 1 |
| von Hohnhorst, P | 1 |
| Fang, J | 2 |
| Yagi, R | 1 |
| Okamura, T | 6 |
| Kobayashi, T | 7 |
| Kosugi, SI | 1 |
| Gea, S | 1 |
| López-Martínez, N | 1 |
| Arul, M | 1 |
| Roslani, AC | 1 |
| Cheah, SH | 1 |
| Mocellin, S | 3 |
| Baretta, Z | 1 |
| Roqué I Figuls, M | 2 |
| Solà, I | 2 |
| Hallum, S | 1 |
| Bonfill Cosp, X | 2 |
| Di Salvatore, M | 1 |
| Rossi, E | 1 |
| Guarino, D | 1 |
| Santonocito, C | 1 |
| Schinzari, G | 5 |
| Capoluongo, E | 1 |
| Bommer, UA | 1 |
| Vine, KL | 2 |
| Puri, P | 1 |
| Engel, M | 1 |
| Belfiore, L | 1 |
| Fildes, K | 1 |
| Batterham, M | 1 |
| Lochhead, A | 1 |
| Aghmesheh, M | 1 |
| Yigitbas, H | 1 |
| Yazici, P | 1 |
| Taskin, HE | 1 |
| Okoh, AK | 1 |
| Dural, C | 1 |
| Aydin, N | 1 |
| Berber, E | 1 |
| Ju, H | 1 |
| Jie, K | 1 |
| Scevola, G | 1 |
| Loreni, G | 1 |
| Rastelli, M | 1 |
| Sposato, S | 1 |
| Ramponi, S | 1 |
| Miele, V | 1 |
| Shi, W | 2 |
| Zeng, Q | 1 |
| Yang, QL | 1 |
| Staib, F | 1 |
| Göhler, T | 1 |
| Heike, M | 7 |
| Neise, M | 1 |
| Rudi, J | 4 |
| Geer, T | 1 |
| Dingeldein, G | 1 |
| Lang, C | 1 |
| Ehscheidt, P | 1 |
| Flohr, T | 1 |
| Josten, KM | 1 |
| Schmittel, A | 1 |
| Wierecky, J | 1 |
| Boller, E | 1 |
| Indorf, M | 1 |
| Wörns, MA | 1 |
| Nishikawa, Y | 2 |
| Funakoshi, T | 1 |
| Miyamoto, S | 6 |
| Matsubara, T | 1 |
| Yanagita, M | 1 |
| Nakagawa, S | 3 |
| Yonezawa, A | 1 |
| Matsubara, K | 1 |
| Nijhuis, A | 1 |
| Thompson, H | 1 |
| Adam, J | 1 |
| Parker, A | 1 |
| Gammon, L | 1 |
| Lewis, A | 1 |
| Bundy, JG | 1 |
| Soga, T | 1 |
| Jalaly, A | 1 |
| Jeffery, R | 1 |
| Suraweera, N | 1 |
| McDonald, S | 1 |
| Thaha, MA | 1 |
| Feakins, R | 1 |
| Lowe, R | 1 |
| Bishop, CL | 1 |
| Hart, LL | 4 |
| Firdaus, I | 2 |
| Mace, JR | 1 |
| McFarlane, JJ | 1 |
| Catenacci, D | 1 |
| Hsu, JJ | 1 |
| Shames, DS | 1 |
| Koeppen, H | 1 |
| Park, SR | 1 |
| Nam, BH | 1 |
| Oh, HS | 1 |
| Park, YI | 1 |
| Song, EK | 1 |
| Lee, KT | 1 |
| Kang, JH | 4 |
| Itabashi, M | 1 |
| Hamano, M | 1 |
| Hirai, E | 1 |
| Okuyama, R | 1 |
| Araida, T | 1 |
| Wood, G | 1 |
| Grenader, T | 1 |
| Nash, S | 1 |
| Gore, I | 2 |
| Braiteh, F | 1 |
| Funke, R | 1 |
| Anderson, M | 1 |
| McCall, B | 1 |
| Stroh, M | 1 |
| Wakshull, E | 1 |
| Hegde, P | 1 |
| Chang, I | 1 |
| Rhee, I | 1 |
| Asselain, B | 1 |
| Matthes, N | 1 |
| Koospal, M | 1 |
| Quenzer, A | 1 |
| Peter, S | 1 |
| Del Rio, M | 4 |
| Mollevi, C | 1 |
| Bibeau, F | 4 |
| Vie, N | 2 |
| Roger, P | 1 |
| Gongora, C | 3 |
| Martineau, P | 4 |
| Guo, JH | 1 |
| Zhang, PJ | 1 |
| Li, XT | 1 |
| Wang, XD | 1 |
| Webster, PJ | 1 |
| Littlejohns, AT | 1 |
| Gaunt, HJ | 1 |
| Prasad, KR | 1 |
| Beech, DJ | 1 |
| Burke, DA | 1 |
| Braun, MS | 3 |
| Daly, C | 1 |
| Adlard, JW | 3 |
| Barrett, JH | 2 |
| Selby, P | 3 |
| Stephens, RJ | 6 |
| Parmar, MK | 4 |
| Bruin, S | 1 |
| van Slooten, G | 1 |
| Marti, P | 1 |
| Merrouche, Y | 5 |
| Tigaud, JM | 3 |
| Rebischung, C | 4 |
| Schiavon, G | 9 |
| Pantano, F | 1 |
| Ghebremichael, M | 1 |
| Ardavanis, A | 1 |
| Ziras, N | 7 |
| Athanasiadis, A | 3 |
| Varthalitis, I | 4 |
| Amarantidis, K | 1 |
| Tsousis, S | 3 |
| Vardakis, N | 8 |
| Rothenberg, ML | 12 |
| Cox, JV | 3 |
| Butts, C | 4 |
| Navarro, M | 10 |
| Goel, R | 3 |
| Siu, LL | 3 |
| Laguerre, S | 1 |
| Besnard, T | 1 |
| Renée, N | 7 |
| Martínez C, J | 1 |
| Jarufe C, N | 1 |
| González D, R | 1 |
| Alvarez Z, M | 1 |
| Wong, CS | 1 |
| Wong, VW | 1 |
| Chan, CM | 1 |
| Wong, MC | 1 |
| Lam, MY | 1 |
| Au, TC | 1 |
| Chan, WH | 1 |
| Cheuk, W | 1 |
| Di Benedetto, F | 2 |
| Simonelli, C | 3 |
| Martellotta, F | 2 |
| Del Ben, C | 1 |
| Berretta, S | 5 |
| Spina, M | 3 |
| Pezo, RC | 1 |
| Gandhi, SJ | 1 |
| Shirley, LA | 1 |
| Pestell, RG | 2 |
| Augenlicht, LH | 1 |
| Singer, RH | 1 |
| Kweekel, DM | 4 |
| Van der Straaten, T | 4 |
| Antonini, NF | 9 |
| Müller, CI | 1 |
| Arkenau, H | 1 |
| Hahn, SA | 1 |
| Schmoll, SH | 1 |
| de Liguori Carino, N | 1 |
| van Leeuwen, BL | 1 |
| Ghaneh, P | 1 |
| Wu, A | 1 |
| Audisio, RA | 2 |
| Zanet, E | 2 |
| Ishikawa, M | 1 |
| Miyauchi, T | 1 |
| Kashiwagi, Y | 1 |
| Backus, HH | 3 |
| Wouters, D | 3 |
| Vainer, B | 6 |
| Witton, CJ | 1 |
| Jørgensen, JT | 1 |
| Sørensen, JB | 10 |
| Hickmann, L | 1 |
| Vick, B | 1 |
| Urbanik, T | 1 |
| Berger, MR | 2 |
| Weber, A | 1 |
| Hennig, IM | 1 |
| Naik, JD | 1 |
| Szubert, A | 1 |
| Anthoney, DA | 2 |
| Jackson, DP | 1 |
| Melcher, AM | 1 |
| Crawford, SM | 1 |
| Bradley, C | 3 |
| Brown, JM | 1 |
| Paré, L | 6 |
| del Rio, E | 6 |
| Altés, A | 5 |
| Hata, F | 3 |
| Yamamitsu, S | 5 |
| Shirasaka, T | 11 |
| Ben Fredj, R | 1 |
| Gross, E | 2 |
| Hassine, H | 1 |
| Saguem, S | 1 |
| Sharma, RI | 1 |
| Smith, TA | 1 |
| Mizuno, H | 1 |
| Sugiura, T | 1 |
| Udatsu, Y | 1 |
| Okazawa, M | 1 |
| Sugimura, K | 1 |
| Kusumoto, H | 1 |
| Kishimoto, T | 2 |
| Izukura, M | 1 |
| Kitada, N | 1 |
| Morimoto, S | 2 |
| Yamasaki, H | 2 |
| Fujii, C | 1 |
| Furukawa, H | 2 |
| Takara, K | 2 |
| Watari, M | 1 |
| Wong, L | 3 |
| Fehrenbacher, L | 5 |
| Abubakr, Y | 1 |
| Hedrick, E | 1 |
| Altinok, A | 1 |
| Clairambault, J | 1 |
| Goldbeter, A | 1 |
| Gibson, TB | 3 |
| Grothey, E | 1 |
| Power, DG | 3 |
| Healey-Bird, BR | 1 |
| Comandone, A | 1 |
| Granetti, C | 1 |
| Oliva, C | 1 |
| Zuradelli, M | 2 |
| Mari, E | 2 |
| Pressiani, T | 1 |
| Frustaci, S | 5 |
| Lombardi, D | 1 |
| Fratino, L | 1 |
| Bonanno, S | 1 |
| Spartà, D | 1 |
| Palmucci, S | 1 |
| Francoual, M | 8 |
| Kaufman, HL | 1 |
| Singh, D | 1 |
| Garett, C | 1 |
| Cripps, C | 3 |
| von Mehren, M | 1 |
| Dalfen, R | 1 |
| Heim, WJ | 2 |
| Conry, RM | 1 |
| Urba, WJ | 1 |
| Caterini, J | 1 |
| Kim-Schulze, S | 1 |
| Debenedette, M | 1 |
| Salha, D | 1 |
| Vogel, T | 1 |
| Elias, I | 1 |
| Berinstein, NL | 1 |
| Kornprat, P | 1 |
| Schöllnast, H | 1 |
| Cerwenka, H | 1 |
| Werkgartner, G | 1 |
| Bernhardt, G | 1 |
| Mischinger, HJ | 1 |
| Laffer, U | 11 |
| Metzger, U | 9 |
| Aeberhard, P | 5 |
| Lorenz, M | 19 |
| Harder, F | 2 |
| Maibach, R | 1 |
| Zuber, M | 1 |
| Grouls, V | 1 |
| Kamisugi, K | 2 |
| Imada, H | 3 |
| Shoji, D | 1 |
| Nakamoto, E | 2 |
| Hirata, Y | 2 |
| Nawano, K | 1 |
| Ogawa, M | 5 |
| Molloy, D | 1 |
| Smith, LN | 1 |
| Aitchison, T | 1 |
| Brake, R | 1 |
| Starnes, C | 1 |
| Radinsky, R | 1 |
| Borges, L | 1 |
| Gartner, EM | 1 |
| Griffith, KA | 1 |
| Brewer, GJ | 1 |
| Henja, GF | 1 |
| Merajver, SD | 1 |
| Zalupski, MM | 7 |
| Massutti, B | 2 |
| Constenla, M | 1 |
| Cámara, JC | 1 |
| Comella, P | 24 |
| Massidda, B | 8 |
| Filippelli, G | 5 |
| Farris, A | 11 |
| Natale, D | 7 |
| Barberis, G | 2 |
| Maiorino, L | 9 |
| Palmeri, S | 16 |
| Cannone, M | 2 |
| Condemi, G | 2 |
| Cubiella, J | 3 |
| Sempere, L | 1 |
| Xicola, RM | 3 |
| Reñé, JM | 4 |
| Bessa, X | 4 |
| Morillas, JD | 3 |
| Nicolás-Pérez, D | 3 |
| Pons, E | 1 |
| Payá, A | 3 |
| Canestrari, E | 5 |
| Maltese, P | 4 |
| Bisonni, R | 4 |
| Baldi, G | 3 |
| Giustini, L | 5 |
| Magnani, M | 5 |
| Kanate, AS | 1 |
| Auber, ML | 1 |
| Higa, GM | 1 |
| Granci, V | 2 |
| Kramar, A | 5 |
| Boissière-Michot, F | 1 |
| Thirion, A | 1 |
| Topuz, E | 1 |
| Derin, D | 1 |
| Can, G | 1 |
| Kürklü, E | 1 |
| Cinar, S | 1 |
| Aykan, F | 1 |
| Cevikbaş, A | 1 |
| Dişçi, R | 1 |
| Durna, Z | 1 |
| Sakar, B | 2 |
| Tanyeri, H | 1 |
| Deniz, G | 1 |
| Gürer, U | 1 |
| Taş, F | 1 |
| Guney, N | 2 |
| Aydiner, A | 1 |
| Croghan, G | 1 |
| Bukowski, R | 2 |
| Rudek, M | 1 |
| Messersmith, W | 1 |
| Erlichman, C | 12 |
| Pelley, R | 1 |
| Donehower, R | 2 |
| Boni, J | 1 |
| Abbas, R | 2 |
| Martins, P | 1 |
| Zacharchuk, C | 2 |
| McBride, D | 1 |
| Sakai, T | 4 |
| Maekawa, T | 1 |
| Mikami, K | 1 |
| Shirakusa, T | 1 |
| Kabbinavar, FF | 5 |
| Wallace, JF | 1 |
| Holmgren, E | 3 |
| Yi, J | 3 |
| Cella, D | 1 |
| Yost, KJ | 1 |
| Abaza, MS | 1 |
| Bahman, AM | 1 |
| Al-Attiyah, RJ | 1 |
| Kanai, M | 3 |
| Mori, Y | 3 |
| Kawamura, J | 1 |
| Nomura, A | 2 |
| Kitano, T | 3 |
| Ishiguro, H | 3 |
| Teramukai, S | 3 |
| Chiba, T | 5 |
| Sessa, C | 1 |
| Cavalli, F | 1 |
| Fields, AL | 2 |
| Bleiberg, H | 27 |
| Portier, G | 3 |
| Nitti, D | 5 |
| O'Callaghan, C | 1 |
| Langer, B | 3 |
| Martignoni, G | 5 |
| Lazorthes, F | 2 |
| Nortier, JW | 6 |
| Sedano, L | 2 |
| Cortés, A | 1 |
| Lopatriello, S | 1 |
| Donati, S | 1 |
| Fornasiero, A | 3 |
| Smergo, A | 1 |
| Lalli, A | 3 |
| Iacono, C | 1 |
| Lucenti, A | 1 |
| D'Alonzo, L | 1 |
| Negrini, C | 1 |
| Caponigro, F | 6 |
| Lacombe, D | 1 |
| Bauer, J | 2 |
| Govaerts, AS | 1 |
| Marréaud, S | 1 |
| Milano, A | 2 |
| Anthoney, A | 3 |
| Wong, AO | 2 |
| Koralewski, PM | 1 |
| Miller, WH | 1 |
| Habboubi, N | 1 |
| Garay, C | 1 |
| Olivatto, LO | 1 |
| Booth, C | 1 |
| Patiutko, IuI | 2 |
| Poliakov, AN | 1 |
| Sagaĭdak, IV | 2 |
| Kotel'nikov, AG | 2 |
| Garg, A | 1 |
| Tisdale, AW | 1 |
| Haidari, E | 1 |
| Kokkoli, E | 1 |
| Bursi, S | 4 |
| Di Paolo, A | 12 |
| Bocci, G | 9 |
| Del Tacca, M | 16 |
| Galizia, E | 2 |
| Chiorrini, S | 1 |
| Pierantoni, C | 1 |
| Scott, PA | 1 |
| Ferchow, L | 1 |
| Hobson, A | 1 |
| Curzen, NP | 1 |
| Onozawa, Y | 4 |
| Fukutomi, A | 3 |
| Asaka, M | 6 |
| Recchia, F | 4 |
| Candeloro, G | 1 |
| Necozione, S | 1 |
| Bratta, M | 1 |
| Bisegna, R | 1 |
| Rea, S | 2 |
| Kabbinavar, F | 7 |
| Irl, C | 1 |
| Zurlo, A | 1 |
| Sirohi, B | 1 |
| Pluzanska, A | 1 |
| Utracka-Hutka, B | 1 |
| Zaluski, J | 2 |
| Koralewski, P | 3 |
| Mainwaring, P | 3 |
| Chan, RT | 2 |
| Tabah-Fisch, I | 4 |
| Conti, JA | 6 |
| Kendall, TJ | 1 |
| Bateman, A | 1 |
| Armstrong, TA | 1 |
| Papa-Adams, A | 1 |
| Packham, G | 1 |
| Benyon, RC | 1 |
| Iredale, JP | 1 |
| Arimoto, Y | 1 |
| Kanamiya, Y | 1 |
| Oba, H | 1 |
| Adachi, K | 1 |
| Shintani, M | 1 |
| Nakamura, R | 1 |
| Yui, S | 1 |
| Buzzoni, R | 5 |
| Ferrario, E | 4 |
| Mariani, L | 3 |
| Bajetta, R | 2 |
| Gevorgyan, A | 1 |
| Venturino, P | 1 |
| Galassi, M | 1 |
| Koike, Y | 1 |
| Miki, C | 4 |
| Yokoe, T | 1 |
| Toiyama, Y | 4 |
| Kusunoki, M | 7 |
| Yan, TD | 3 |
| Morris, DL | 16 |
| Ito, I | 1 |
| Mukai, M | 7 |
| Ninomiya, H | 4 |
| Kishima, K | 1 |
| Tsuchiya, K | 4 |
| Tajima, T | 10 |
| Oida, Y | 1 |
| Makuuchi, H | 12 |
| Veerasarn, V | 1 |
| Boonnuch, W | 1 |
| Chinswangwatanakul, V | 1 |
| Lohsiriwat, D | 1 |
| Mahamadsolaeh, P | 1 |
| Flamen, P | 2 |
| Vanderlinden, B | 2 |
| Delatte, P | 2 |
| Ghanem, G | 1 |
| Ameye, L | 1 |
| Fisher, GA | 6 |
| Kuo, T | 2 |
| Ramsey, M | 1 |
| Schwartz, E | 1 |
| Rouse, RV | 1 |
| Cho, CD | 3 |
| Halsey, J | 3 |
| Sikic, BI | 4 |
| Fujita, K | 7 |
| Nagashima, F | 5 |
| Yamamoto, W | 4 |
| Endo, H | 3 |
| Mizuno, K | 4 |
| Matsunaga, M | 1 |
| Miya, T | 4 |
| Narabayashi, M | 3 |
| Kawara, K | 7 |
| Dintinjana, RD | 1 |
| Guina, T | 1 |
| Krznarić, Z | 1 |
| Radić, M | 1 |
| Dintinjana, M | 1 |
| Campbell, ML | 1 |
| Landry, CS | 1 |
| Slomiany, BA | 1 |
| Woodall, CE | 1 |
| McMasters, KM | 1 |
| Vente, MA | 1 |
| Wondergem, M | 1 |
| van der Tweel, I | 1 |
| van den Bosch, MA | 1 |
| Zonnenberg, BA | 1 |
| Lam, MG | 1 |
| van Het Schip, AD | 1 |
| Nijsen, JF | 1 |
| Campbell, ME | 2 |
| Morton, RF | 7 |
| Williamson, SK | 8 |
| Findlay, BP | 7 |
| Pitot, HC | 9 |
| Michael, M | 12 |
| Smith, R | 1 |
| Godwood, A | 1 |
| Oliver, S | 1 |
| Perboni, S | 1 |
| Bowers, C | 1 |
| Kojima, S | 2 |
| Asakawa, A | 1 |
| Inui, A | 1 |
| Shouji, D | 2 |
| Oya, M | 1 |
| Muto, T | 3 |
| Arkenau, HT | 5 |
| Martoni, A | 4 |
| Kim, T | 2 |
| Bhargava, A | 1 |
| Schwartz, L | 3 |
| Covey, A | 1 |
| Karrasch, M | 1 |
| Getrajdman, G | 1 |
| Mescheder, A | 1 |
| Jarnagin, W | 6 |
| Kobayashi, H | 1 |
| Iida, S | 4 |
| Azuma, M | 2 |
| Mori, R | 2 |
| Omori, A | 1 |
| Danenberg, KD | 15 |
| Danenberg, PV | 18 |
| Vakhabova, JV | 1 |
| Semenov, NN | 1 |
| Dobrova, NV | 1 |
| Lichinitser, MR | 1 |
| Nobili, S | 6 |
| Checcacci, D | 1 |
| Filippelli, F | 1 |
| Del Buono, S | 1 |
| Mazzocchi, V | 1 |
| Mazzei, T | 5 |
| Siewczynski, R | 1 |
| Hacker, U | 1 |
| Honda, T | 1 |
| Matsubara, J | 2 |
| Shimoda, T | 2 |
| Nur, U | 1 |
| Rachet, B | 1 |
| Sydes, MR | 1 |
| Cooper, N | 1 |
| Northover, JM | 1 |
| James, R | 3 |
| Coleman, MP | 1 |
| Kuefler, P | 1 |
| Hyman, W | 1 |
| Berger, M | 1 |
| Richards, D | 3 |
| Vukelja, S | 1 |
| Nugent, JE | 1 |
| Ruxer, RL | 1 |
| Boehm, KA | 4 |
| Asmar, L | 3 |
| Schlemmer, M | 1 |
| Kuehl, M | 1 |
| Rauch, J | 1 |
| Jauch, KW | 3 |
| Hentrich, M | 2 |
| Lee, JT | 1 |
| Lee, MG | 2 |
| Lee, HW | 1 |
| Lee, YJ | 2 |
| Lee, YL | 1 |
| Yoo, J | 1 |
| Ahn, BC | 1 |
| Ha, JH | 1 |
| Kaiser, C | 2 |
| Lindskog, EB | 1 |
| Niyikiza, C | 1 |
| Ota, K | 5 |
| Kurita, S | 1 |
| Nishimura, M | 1 |
| Ariyoshi, Y | 5 |
| Oyama, A | 1 |
| Hoshino, A | 1 |
| Amo, H | 1 |
| Kawahara, A | 1 |
| Hattori, S | 1 |
| Ono, M | 2 |
| Kuwano, M | 2 |
| Kage, M | 1 |
| Brown, TJ | 1 |
| Ng, R | 1 |
| Jennens, R | 1 |
| Cinc, E | 1 |
| Pho, M | 1 |
| Fox, RM | 1 |
| Sarkar, S | 3 |
| Rosen, O | 2 |
| Small, RM | 1 |
| Lubezky, N | 2 |
| Shmueli, E | 1 |
| Figer, A | 13 |
| Nakache, R | 2 |
| Klausner, JM | 1 |
| Ben-Haim, M | 2 |
| Chang, PM | 1 |
| Tzeng, CH | 8 |
| Chen, PM | 11 |
| Wang, WS | 8 |
| Mandalà, M | 2 |
| Isa, L | 2 |
| Fornarini, G | 3 |
| Marangolo, M | 5 |
| Baki, M | 1 |
| Idelevich, E | 2 |
| Greif, F | 2 |
| Mavor, E | 1 |
| Miller, R | 1 |
| Kashtan, H | 1 |
| Susmalian, S | 1 |
| Ariche, A | 1 |
| Brenner, B | 3 |
| Baruch, NB | 1 |
| Dinerman, M | 1 |
| Shani, A | 2 |
| Hénin, E | 2 |
| You, B | 2 |
| VanCutsem, E | 1 |
| Zuideveld, KP | 2 |
| Sirzen, F | 4 |
| Dartois, C | 1 |
| Freyer, G | 7 |
| Tod, M | 3 |
| Girard, P | 4 |
| Puthillath, A | 1 |
| Mashtare, T | 2 |
| Wilding, G | 3 |
| Khushalani, N | 1 |
| Steinbrenner, L | 1 |
| Ross, ME | 2 |
| Romano, K | 1 |
| Wisniewski, M | 1 |
| Fernández-Contreras, ME | 4 |
| Sánchez-Hernández, JJ | 3 |
| Herráez, B | 1 |
| Domínguez, I | 1 |
| Lozano, M | 1 |
| García De Paredes, ML | 5 |
| Gamallo, C | 4 |
| Lazaris, A | 1 |
| Gouveris, P | 4 |
| Kavantzas, N | 1 |
| Kopterides, P | 2 |
| Papathomas, T | 1 |
| Agrogiannis, G | 1 |
| Arapogiannis, G | 1 |
| Zorzos, H | 1 |
| Kyriakou, V | 2 |
| Patsouris, E | 2 |
| Morris-Stiff, G | 1 |
| Makuuchi, M | 3 |
| Pozzo, C | 10 |
| Uchida, K | 3 |
| Ishiguro, T | 10 |
| Miyazaki, T | 7 |
| Matsuki, M | 2 |
| Okita, T | 1 |
| Mitsuhashi, T | 1 |
| Carcereny, E | 1 |
| Longarón, R | 2 |
| Oliveras, A | 1 |
| Tosca, M | 1 |
| Augé, JM | 1 |
| Gascón, P | 2 |
| Gunnlaugsson, A | 1 |
| Anderson, H | 3 |
| Kjellén, E | 1 |
| Byström, P | 5 |
| Berglund, K | 1 |
| Ekelund, M | 1 |
| Påhlman, L | 16 |
| Holm, T | 1 |
| Chaves, M | 2 |
| Queralt, B | 4 |
| Gómez-España, A | 6 |
| González-Flores, E | 4 |
| Sanchez-Rovira, P | 2 |
| Maestu, I | 6 |
| Makhson, A | 2 |
| Donea, S | 1 |
| Ludwig, H | 3 |
| Loos, AH | 2 |
| Zubel, A | 4 |
| Aguilar, G | 1 |
| Palencia, S | 1 |
| Newton, E | 1 |
| Abo, A | 1 |
| Gade, TP | 1 |
| Buchanan, IM | 1 |
| Motley, MW | 1 |
| Mazaheri, Y | 1 |
| Spees, WM | 1 |
| Koutcher, JA | 1 |
| Belaguli, N | 1 |
| Berger, DH | 1 |
| Kolinsky, K | 3 |
| Shen, BQ | 1 |
| Zhang, YE | 2 |
| Kohles, J | 1 |
| Dugan, U | 2 |
| Zioncheck, TF | 1 |
| Heimbrook, D | 3 |
| Packman, K | 3 |
| Higgins, B | 3 |
| Ince, W | 1 |
| Novotny, WF | 4 |
| Wang, GB | 1 |
| Tao, KX | 1 |
| Moreira, LR | 1 |
| Schenka, AA | 1 |
| Latuff Filho, P | 1 |
| Nascimento, H | 1 |
| Passos Lima, CS | 1 |
| Silva Trevisan, MA | 1 |
| Vassallo, J | 1 |
| Postma, C | 1 |
| Eijk, PP | 1 |
| Carvalho, B | 1 |
| Mori, N | 2 |
| Ishiyama, K | 2 |
| Sakurai, N | 1 |
| Saito, K | 2 |
| Iizawa, H | 3 |
| Ikeda, E | 3 |
| Nannini, M | 1 |
| Nobili, E | 2 |
| Di Cicilia, R | 2 |
| Maleddu, A | 1 |
| Sprinzl, MF | 1 |
| Abdelfattah, M | 1 |
| Adami, B | 3 |
| Godderz, W | 2 |
| Majer, K | 1 |
| Flieger, D | 2 |
| Bidard, FC | 2 |
| Kruhøffer, M | 1 |
| Costantino, CL | 1 |
| Eshleman, JR | 1 |
| Gallmeier, E | 2 |
| van der Heijden, MS | 1 |
| Winter, JM | 2 |
| Wikiewicz, AK | 1 |
| Yeo, CJ | 1 |
| Kern, SE | 3 |
| Kay, E | 3 |
| Kenny, S | 1 |
| Kortman, GA | 1 |
| Mekenkamp, L | 1 |
| Ligtenberg, MJ | 2 |
| Hoogerbrugge, N | 1 |
| Rätz Bravo, AE | 1 |
| Hofer, S | 1 |
| Krähenbühl, S | 1 |
| Ludwig, C | 2 |
| Mattera, L | 1 |
| Escaffit, F | 1 |
| Pillaire, MJ | 1 |
| Tyteca, S | 1 |
| Hoffmann, JS | 1 |
| Gourraud, PA | 1 |
| Chevillard-Briet, M | 1 |
| Cazaux, C | 1 |
| Trouche, D | 1 |
| Jung, KH | 3 |
| Lee, N | 1 |
| Byun, JH | 3 |
| Choi, SH | 2 |
| Shin, HJ | 1 |
| Ahn, KD | 1 |
| Lee, JM | 1 |
| Kwon, HC | 3 |
| Lee, DM | 1 |
| Roh, MS | 3 |
| Kim, DC | 1 |
| Choi, HJ | 2 |
| Tumeh, JW | 1 |
| Shenoy, PJ | 1 |
| Moore, SG | 1 |
| Flowers, C | 1 |
| Yamamori, M | 3 |
| Kadowaki, Y | 1 |
| Miki, I | 2 |
| Okumura, K | 4 |
| Azuma, T | 1 |
| Kasuga, M | 1 |
| Hirai, M | 1 |
| Gil-Bazo, I | 1 |
| Schulman, KL | 2 |
| Zelt, S | 1 |
| Rodenburg, CJ | 4 |
| Schrama, JG | 2 |
| Vos, AH | 3 |
| Sinnige, HA | 6 |
| Richel, DJ | 3 |
| Dijkstra, JR | 1 |
| Vink-Börger, ME | 1 |
| Dalesio, O | 3 |
| Klinger, M | 4 |
| Eipeldauer, S | 3 |
| Hacker, S | 3 |
| Herberger, B | 5 |
| Dorfmeister, M | 2 |
| Koelblinger, C | 1 |
| Bhushan, S | 1 |
| Kozuch, P | 1 |
| Malamud, S | 1 |
| Wasserman, C | 1 |
| Homel, P | 1 |
| Mirzoyev, T | 1 |
| Grossbard, M | 1 |
| Botwood, NA | 1 |
| Maniadakis, N | 2 |
| Fragoulakis, V | 2 |
| Costantino, E | 1 |
| Maddalena, F | 1 |
| Calise, S | 1 |
| Tirino, V | 1 |
| Fersini, A | 1 |
| Ambrosi, A | 1 |
| Neri, V | 1 |
| Yokota, T | 4 |
| Yamaura, H | 4 |
| Najima, M | 2 |
| Chae, YS | 3 |
| Moon, JH | 3 |
| Ryoo, HM | 2 |
| Bae, SH | 2 |
| Kum, Y | 1 |
| Jeon, SW | 1 |
| Kang, BM | 1 |
| Park, IJ | 1 |
| Choi, GS | 3 |
| Jun, SH | 3 |
| Liao, C | 2 |
| Tan, A | 1 |
| Mo, Z | 1 |
| Gauthier, I | 1 |
| MacLean, M | 1 |
| Wells, J | 1 |
| Powers, J | 1 |
| Haviland, D | 1 |
| Dematteo, R | 3 |
| Kitano, S | 2 |
| Hirohashi, S | 1 |
| Takahashi, A | 1 |
| Sakaguchi, H | 1 |
| Matsuoka, M | 4 |
| Takahama, J | 1 |
| Higashiura, W | 1 |
| Dallas, NA | 1 |
| Gray, MJ | 1 |
| Gaur, P | 1 |
| van Buren, G | 1 |
| Samuel, S | 1 |
| Kim, MP | 1 |
| Lim, SJ | 1 |
| Popov, I | 2 |
| Milicević, M | 2 |
| Radosević-Jelić, Lj | 2 |
| Ricci, S | 12 |
| Brunetti, IM | 6 |
| Ferraldeschi, R | 1 |
| Naso, G | 2 |
| Filipponi, F | 2 |
| Goletti, O | 2 |
| Andreuccetti, M | 9 |
| Mazzer, M | 1 |
| Moroso, S | 1 |
| Puglisi, F | 4 |
| Kawabata, Y | 2 |
| Nakagawa, A | 2 |
| Uchikoshi, H | 1 |
| Tamiya, Y | 1 |
| Chun, YS | 1 |
| Laurent, A | 2 |
| Bruzzese, F | 2 |
| Pepe, S | 2 |
| Subbarayan, PR | 5 |
| Lai, A | 1 |
| Cairns, MJ | 1 |
| Tran, N | 1 |
| Zhang, HP | 1 |
| Cullen, L | 1 |
| Arndt, GM | 1 |
| Keller, A | 1 |
| Kardinal, C | 2 |
| Cohen, A | 2 |
| Schulz, J | 3 |
| Eisenberg, P | 2 |
| Forster, J | 1 |
| Wissel, P | 1 |
| Maeda, S | 2 |
| Hikiba, Y | 1 |
| Nakagawa, H | 3 |
| Hayakawa, Y | 2 |
| Shibata, W | 1 |
| Yanai, A | 1 |
| Ogura, K | 2 |
| Omata, M | 1 |
| Mehendale, SR | 3 |
| Strauss, LG | 11 |
| Hoffend, J | 1 |
| Koczan, D | 1 |
| Dimitrakopoulou-Strauss, A | 7 |
| Giusti, RM | 2 |
| Cohen, MH | 3 |
| Keegan, P | 3 |
| Pazdur, R | 28 |
| Milla, P | 1 |
| Airoldi, M | 1 |
| Weber, G | 1 |
| Drescher, A | 1 |
| Cattel, L | 2 |
| Richter, SN | 1 |
| Nadai, M | 1 |
| Palumbo, M | 1 |
| Palù, G | 1 |
| Takimoto, N | 1 |
| Sugawara, S | 1 |
| Iida, A | 2 |
| Sakakibara, T | 1 |
| Mori, K | 10 |
| Sugiura, M | 1 |
| Adachi, M | 1 |
| Otsuka, S | 3 |
| Inagaki, M | 3 |
| Nishie, M | 2 |
| Hamano, R | 2 |
| Tokunaga, N | 6 |
| Tsunemitsu, Y | 2 |
| Miyoshi, K | 3 |
| Oosaki, T | 2 |
| Iwagaki, H | 1 |
| Seki, H | 2 |
| Ozaki, T | 3 |
| Shiina, M | 2 |
| Ginés, A | 3 |
| Plasencia, C | 3 |
| Neamati, N | 1 |
| Gianni, M | 1 |
| Dentali, F | 1 |
| Lonn, E | 1 |
| Chen, SP | 2 |
| Lin, SZ | 2 |
| Kang, JC | 2 |
| Su, CC | 1 |
| Chen, YL | 2 |
| Chiu, SC | 2 |
| Pang, CY | 2 |
| Harn, HJ | 2 |
| Angitapalli, R | 1 |
| Litwin, AM | 1 |
| Kumar, PR | 1 |
| Nasser, E | 1 |
| Lombardo, J | 2 |
| Wilding, GE | 2 |
| Gentner, B | 1 |
| Croner, RS | 1 |
| Zeittraeger, I | 1 |
| Wirtz, RM | 1 |
| Roedel, F | 1 |
| Dimmler, A | 1 |
| Dorlaque, L | 1 |
| Hahn, EG | 7 |
| Brueckl, WM | 3 |
| Spłwiński, J | 1 |
| Gómez Portilla, A | 1 |
| Cendoya, I | 1 |
| Olabarría, I | 1 |
| Martínez de Lecea, C | 1 |
| Gómez Martínez de Lecea, C | 1 |
| Muriel, J | 1 |
| Magrach, L | 1 |
| Romero, E | 1 |
| Lirola, A | 1 |
| Guede, N | 1 |
| Moraza, N | 1 |
| Fernández, E | 1 |
| Kvadatze, M | 1 |
| Valdovinos, M | 1 |
| Larrabide, I | 1 |
| Ruiz de Alegría, N | 1 |
| Fernández, JL | 1 |
| Rua, O | 1 |
| Ulibarrena, MA | 1 |
| Hitre, E | 9 |
| Chang Chien, CR | 1 |
| Schischmanoff, O | 1 |
| Morere, JF | 3 |
| Sereno, M | 1 |
| Castro, JD | 1 |
| Belda, C | 1 |
| González-Barón, M | 4 |
| Chen, ML | 1 |
| Fang, CH | 1 |
| Liang, LS | 1 |
| Dai, LH | 1 |
| Wang, XK | 1 |
| Carloni, F | 1 |
| Nicoletti, S | 2 |
| Ravaioli, A | 7 |
| Sablin, MP | 1 |
| Italiano, A | 1 |
| Spano, JP | 2 |
| Aussilhou, B | 1 |
| Dokmak, S | 1 |
| Faivre, S | 4 |
| Paradis, V | 1 |
| Vilgrain, V | 1 |
| Belghiti, J | 3 |
| Biason, P | 3 |
| Pylev, AL | 1 |
| Husseini, F | 4 |
| Cals, L | 2 |
| López, JJ | 1 |
| Mahoney, MR | 4 |
| Rowland, KM | 2 |
| Philip, PA | 3 |
| Mathews, AP | 1 |
| Fitch, TR | 2 |
| Jackson, NA | 1 |
| Barrueco, J | 3 |
| Soufi-Mahjoubi, R | 2 |
| Meyerhardt, J | 1 |
| Pendyala, L | 2 |
| Fetterly, G | 2 |
| Toth, K | 4 |
| Zwiebel, JA | 2 |
| Espinoza-Delgado, I | 2 |
| Litwin, A | 2 |
| Rustum, YM | 26 |
| Egorin, MJ | 3 |
| Humeniuk, R | 1 |
| Mishra, PJ | 1 |
| Bertino, JR | 12 |
| Banerjee, D | 2 |
| Lurje, G | 3 |
| Manegold, PC | 1 |
| Pohl, A | 2 |
| Frigo, AC | 1 |
| Bolzonella, C | 1 |
| Marinelli, R | 1 |
| Barile, C | 4 |
| Bononi, A | 2 |
| Crepaldi, G | 2 |
| Menon, D | 2 |
| Stievano, L | 2 |
| Toso, S | 3 |
| Pasini, F | 4 |
| Ferrazzi, E | 3 |
| Padrini, R | 5 |
| Skof, E | 1 |
| Rebersek, M | 2 |
| Hlebanja, Z | 1 |
| Shimizu, Y | 2 |
| Teitelbaum, UR | 1 |
| DiBartolomeo, M | 1 |
| Mazier, MA | 1 |
| Fishbein, AB | 1 |
| Aung, HH | 3 |
| Panczyk, M | 1 |
| Balcerczak, E | 1 |
| Piaskowski, S | 1 |
| Jamroziak, K | 1 |
| Pasz-Walczak, G | 1 |
| Mirowski, M | 1 |
| Yokoo, K | 1 |
| Hamada, A | 1 |
| Tazoe, K | 1 |
| Lai, JI | 1 |
| Petrini, I | 2 |
| Pohlmann, PR | 1 |
| Mernaugh, RL | 1 |
| Goff, LW | 1 |
| Copur, MS | 3 |
| Norvell, M | 1 |
| Obermiller, A | 1 |
| Polansky, M | 1 |
| Ross, AC | 1 |
| Floristan, U | 1 |
| Feltes, RA | 1 |
| Sendagorta, E | 1 |
| Feito-Rodriguez, M | 1 |
| Ramírez-Marín, P | 1 |
| Vidaurrázaga, C | 1 |
| Casado-Jiménez, M | 1 |
| Bathe, OF | 2 |
| Ernst, S | 2 |
| Sutherland, FR | 1 |
| Bigam, D | 2 |
| Holland, D | 1 |
| Porter, GA | 1 |
| Koppel, J | 1 |
| Dowden, S | 2 |
| Venderbosch, S | 3 |
| Nagtegaal, I | 1 |
| Matsushita, H | 1 |
| Tsuboi, K | 4 |
| Honda, I | 1 |
| Kato, N | 1 |
| Okochi, O | 2 |
| Ueda, H | 1 |
| Demizu, M | 1 |
| Oosawa, M | 1 |
| Chihara, S | 1 |
| Nakanishi, Y | 1 |
| Maeda, C | 2 |
| Yano, K | 1 |
| Kimura, F | 2 |
| Iwakawa, S | 1 |
| Vogel, U | 2 |
| Matsen, JP | 1 |
| Andersen, PK | 1 |
| Poulsen, HE | 5 |
| Buyse, M | 23 |
| Perez-Staub, N | 4 |
| Moreno, C | 1 |
| Medina, J | 1 |
| Pérez-García, B | 1 |
| García-López, JL | 1 |
| Fidlerova, J | 1 |
| Kleiblova, P | 1 |
| Kormunda, S | 1 |
| Bilek, M | 1 |
| Bouskova, K | 1 |
| Sevcik, J | 1 |
| Knudsen, AR | 1 |
| Kannerup, AS | 1 |
| Mortensen, FV | 1 |
| Nielsen, DT | 1 |
| Shiroiwa, T | 3 |
| Fukuda, T | 3 |
| Tsutani, K | 3 |
| Svoboda, M | 1 |
| Nemecek, R | 1 |
| Rehák, Z | 1 |
| Standara, M | 1 |
| Farese, S | 1 |
| Aebi, S | 2 |
| Walther, A | 1 |
| Swanton, C | 1 |
| Gorman, S | 1 |
| Tosetto, M | 1 |
| Lyng, F | 1 |
| Howe, O | 1 |
| O'Donoghue, D | 1 |
| Hyland, J | 1 |
| Mulcahy, H | 1 |
| Thelen, A | 1 |
| Riess, H | 6 |
| Jonas, S | 1 |
| Schmeding, M | 1 |
| Bova, R | 1 |
| Neuhaus, P | 2 |
| Chu, KS | 1 |
| Wagner, M | 2 |
| Roh, V | 1 |
| Strehlen, M | 1 |
| Laemmle, A | 1 |
| Stroka, D | 1 |
| Egger, B | 1 |
| Trochsler, M | 1 |
| Hunt, KK | 1 |
| Candinas, D | 1 |
| Vorburger, SA | 1 |
| Kwok-Keung Choi, C | 1 |
| Jardim, MJ | 1 |
| Furumai, R | 1 |
| Wakeman, T | 1 |
| Goodman, BK | 1 |
| Wang, XF | 1 |
| Spiro, H | 1 |
| Yanagisawa, M | 2 |
| Fujimoto-Ouchi, K | 1 |
| Yorozu, K | 1 |
| Nagykálnai, T | 2 |
| Fujimoto, Y | 1 |
| Akasu, T | 3 |
| Fujita, S | 2 |
| Pasquali, S | 1 |
| Keese, M | 2 |
| Yagublu, V | 2 |
| Schwenke, K | 1 |
| Post, S | 2 |
| Bastiaens, P | 1 |
| Cui, F | 1 |
| Chen, JZ | 2 |
| Wan, C | 1 |
| Luo, RC | 4 |
| Hatano, N | 1 |
| Fukuoka, T | 1 |
| Usui, H | 1 |
| Zhou, JF | 2 |
| Bai, CM | 2 |
| Cheng, YJ | 1 |
| Jia, N | 1 |
| Shao, YJ | 2 |
| Bjerregaard, B | 2 |
| Mejer, J | 1 |
| Diagaradjane, P | 2 |
| Anand, P | 1 |
| Harikumar, KB | 1 |
| Kuzhuvelil, HB | 1 |
| Deorukhkar, A | 2 |
| Gelovani, J | 1 |
| Guha, S | 2 |
| Krishnan, S | 2 |
| Teng, KY | 1 |
| Ruan, DY | 1 |
| Chen, XQ | 2 |
| He, YJ | 3 |
| Spoto, C | 2 |
| Gasparro, S | 2 |
| Rizzo, S | 2 |
| Zobel, BB | 1 |
| Valeri, S | 1 |
| Coppola, R | 4 |
| Gapski, J | 1 |
| Young, S | 1 |
| Green, EM | 2 |
| Peterson, DE | 1 |
| Barker, NP | 1 |
| Akhmadullina, LI | 1 |
| Rodionova, I | 1 |
| Sherman, NZ | 1 |
| Davidenko, IS | 1 |
| Rakovskaya, GN | 1 |
| Gotovkin, EA | 1 |
| Shinkarev, SA | 1 |
| Kulikov, EP | 1 |
| Gertner, JM | 1 |
| Firsov, I | 1 |
| Tuleneva, T | 1 |
| Yarosh, A | 1 |
| Woon, CW | 1 |
| Jorga, K | 1 |
| Fagerberg, J | 1 |
| Ishizuka, M | 1 |
| Takagi, K | 3 |
| Kubota, K | 1 |
| Fukumitsu, H | 1 |
| Yazawa, N | 1 |
| Hoshikawa, T | 1 |
| Hirakawa, H | 1 |
| Ogoshi, K | 1 |
| Okines, A | 1 |
| Kuebler, JP | 3 |
| Olver, IN | 1 |
| Tapner, MJ | 1 |
| Bower, GD | 1 |
| Briggs, GM | 1 |
| Rossleigh, MA | 1 |
| Taylor, DJ | 1 |
| George, J | 1 |
| Suzuki, W | 1 |
| Shirai, T | 1 |
| Luo, W | 2 |
| Liao, WJ | 4 |
| Huang, YT | 2 |
| Xie, JT | 2 |
| Tong, R | 1 |
| McEntee, E | 1 |
| Palmirotta, R | 2 |
| Savonarola, A | 2 |
| Ludovici, G | 2 |
| Del Monte, G | 2 |
| Sugimoto, S | 1 |
| Katano, K | 1 |
| Yoshimura, H | 1 |
| Kidani, A | 1 |
| Takeda, H | 1 |
| Makino, M | 4 |
| Ozaki, N | 1 |
| Ikeguchi, M | 2 |
| Fernández-Peralta, AM | 1 |
| Daimiel, L | 1 |
| Nejda, N | 1 |
| Iglesias, D | 1 |
| Medina Arana, V | 1 |
| González-Aguilera, JJ | 1 |
| Schmidt, C | 1 |
| Chua, W | 2 |
| Dhillon, H | 2 |
| Mitchell, P | 2 |
| Liang, QL | 1 |
| Pan, DC | 1 |
| Xie, JR | 1 |
| Merl, M | 1 |
| Hoimes, C | 1 |
| Pham, T | 1 |
| Canu, B | 2 |
| Alì, G | 2 |
| Orlandi, P | 2 |
| Di Desidero, T | 2 |
| Emmenegger, U | 1 |
| Kuboki, Y | 5 |
| Konishi, F | 2 |
| Fournier, P | 1 |
| Romano, O | 2 |
| Cohen, MS | 1 |
| Al-Kasspooles, MF | 1 |
| Henry, D | 1 |
| Broward, M | 1 |
| Roby, KF | 1 |
| Brearley, SG | 1 |
| Swindell, R | 4 |
| Caputo, G | 1 |
| Novello, G | 1 |
| Manzione, L | 10 |
| Ren, DN | 1 |
| Kim, IY | 1 |
| Koh, SB | 1 |
| Chang, SJ | 1 |
| Eom, M | 1 |
| Yi, SY | 1 |
| Seong, SH | 1 |
| Kim, MD | 1 |
| Bronner, MP | 1 |
| Cho, MY | 1 |
| He, TC | 3 |
| Ozel, L | 1 |
| Ozel, MS | 1 |
| Toros, AB | 1 |
| Kara, M | 1 |
| Ozkan, KS | 1 |
| Tellioglu, G | 1 |
| Krand, O | 1 |
| Koyuturk, M | 1 |
| Berber, I | 1 |
| Kouroussis, Ch | 3 |
| Kalbakis, K | 10 |
| Massara, MC | 1 |
| Portarena, I | 1 |
| Fiaschetti, V | 1 |
| Del Vecchio Blanco, G | 1 |
| Sileri, P | 1 |
| Tosetto, L | 1 |
| Skoulidis, F | 1 |
| Pallone, F | 1 |
| Tsunoda, A | 1 |
| Yasuda, N | 1 |
| Nakao, K | 1 |
| Narita, K | 1 |
| Matsui, N | 1 |
| Triboulet, JP | 1 |
| Shi, N | 1 |
| Muñoz-Martin, A | 2 |
| Mendez-Ureña, M | 1 |
| Quiben-Pereira, R | 1 |
| Perez-Manga, G | 7 |
| Dy, GK | 2 |
| Hobday, TJ | 3 |
| Nelson, G | 2 |
| Windschitl, HE | 4 |
| Nikcevich, DA | 1 |
| Chauffert, B | 4 |
| Köberle, D | 2 |
| Ruhstaller, T | 3 |
| Mayer, G | 1 |
| Räss, A | 1 |
| Boostrom, SY | 1 |
| Nagorney, DM | 5 |
| Donohue, JH | 2 |
| Harmsen, S | 1 |
| Thomsen, K | 1 |
| Que, F | 1 |
| Kendrick, M | 1 |
| Reid-Lombardo, KM | 1 |
| Ji, X | 2 |
| Wan, F | 1 |
| Zhong, B | 1 |
| Tucker, S | 1 |
| Shi, YX | 1 |
| Xiang, XJ | 3 |
| Lansdorp-Vogelaar, I | 1 |
| van Ballegooijen, M | 1 |
| Zauber, AG | 1 |
| Habbema, JD | 1 |
| Kuipers, EJ | 1 |
| Samalin, E | 2 |
| Boyer-Gestin, C | 1 |
| Portales, F | 2 |
| Vaillant, JN | 1 |
| Colin, P | 4 |
| Yim, KL | 1 |
| Park, CM | 1 |
| Yun, HR | 1 |
| Heo, JS | 1 |
| Iwahashi, M | 2 |
| Higashiguchi, T | 2 |
| Oku, Y | 2 |
| Nasu, T | 1 |
| Townsend, A | 1 |
| Shahrokni, A | 1 |
| Rajebi, MR | 1 |
| Bambury, R | 1 |
| McCaffrey, JA | 1 |
| Réti, A | 3 |
| Pap, E | 3 |
| Adleff, V | 6 |
| Jeney, A | 3 |
| Kralovánszky, J | 8 |
| Budai, B | 7 |
| Köppler, H | 1 |
| Heymanns, J | 1 |
| Thomalla, J | 1 |
| Kleboth, K | 1 |
| Weide, R | 1 |
| Gounaris, I | 1 |
| Ahmad, A | 2 |
| Matsunaga, Y | 1 |
| Motokawa, S | 1 |
| Nakagaki, S | 1 |
| Muramatsu, T | 1 |
| Kudou, Y | 1 |
| Shino, M | 1 |
| Mammano, E | 1 |
| Tessari, E | 1 |
| Lise, M | 3 |
| Spławiński, J | 1 |
| Nakano, S | 5 |
| Daly, CL | 2 |
| Allan, JM | 1 |
| Hoshino, H | 2 |
| Tomimaru, Y | 1 |
| Ishii, H | 2 |
| Tibbe, A | 1 |
| Terstappen, LW | 1 |
| Taylor, G | 2 |
| Hasenberg, T | 1 |
| Essenbreis, M | 1 |
| Herold, A | 1 |
| Shang, E | 1 |
| Mathew, S | 1 |
| Armesilla, AL | 2 |
| Darling, JL | 2 |
| Chang, P | 1 |
| Zou, L | 1 |
| Brearley, S | 1 |
| Wardley, A | 1 |
| Farrell, C | 1 |
| Todd, C | 2 |
| Luker, K | 1 |
| Kockler, L | 2 |
| Ma, YL | 2 |
| Peng, JY | 2 |
| Shen, TY | 2 |
| Chen, HQ | 2 |
| Zhou, YK | 2 |
| Chu, ZX | 2 |
| Qin, HL | 2 |
| Paiva, CE | 1 |
| Paiva, BS | 1 |
| Garita, R | 1 |
| Michelin, OC | 1 |
| Rodriguez-Braun, E | 1 |
| Ramos, FJ | 2 |
| Vega-Villegas, ME | 2 |
| Liebscher, S | 1 |
| Kisker, O | 2 |
| Baselga, J | 2 |
| Abhyankar, V | 1 |
| Burgess, RE | 1 |
| Infante, J | 1 |
| Trowbridge, RC | 1 |
| Tortorici, M | 1 |
| Robles, RL | 1 |
| Frilling, A | 1 |
| Konopke, R | 1 |
| Parisi, F | 1 |
| Sala-Vila, A | 1 |
| Folkes, J | 1 |
| Calder, PC | 1 |
| Kim, YH | 4 |
| Chang, DK | 2 |
| Rhee, PL | 1 |
| Kim, DS | 1 |
| Yun, H | 1 |
| Godai, TI | 1 |
| Suda, T | 2 |
| Tsuchida, K | 1 |
| Sekiguchi, H | 1 |
| Sekiyama, A | 1 |
| Yoshihara, M | 1 |
| Matsukuma, S | 1 |
| Sakuma, Y | 1 |
| Tsuchiya, E | 1 |
| Miyagi, Y | 1 |
| Dohn, LH | 1 |
| Petty, RD | 1 |
| Samuel, LM | 1 |
| MacDonald, G | 1 |
| O'Kelly, T | 2 |
| Loudon, M | 1 |
| Binnie, N | 1 |
| Aly, E | 1 |
| McKinlay, A | 1 |
| Gilbert, F | 1 |
| Semple, S | 1 |
| Collie-Duguid, ES | 1 |
| Morris, JS | 2 |
| Glover, KY | 1 |
| Adinin, R | 1 |
| Valero, V | 2 |
| Yan, S | 1 |
| Tran, HT | 1 |
| Abbruzzese, JL | 10 |
| Heymach, JV | 1 |
| Kaibori, M | 1 |
| Ishizaki, M | 1 |
| Matsui, K | 1 |
| Saito, T | 4 |
| Yoshioka, K | 1 |
| Kwon, AH | 1 |
| Uen, YH | 1 |
| Wu, DC | 1 |
| Surguladze, D | 1 |
| Steiner, P | 2 |
| Prewett, M | 1 |
| Tonra, JR | 1 |
| Petrioli, R | 6 |
| Bargagli, G | 2 |
| Lazzi, S | 1 |
| Pascucci, A | 3 |
| Francini, E | 4 |
| Bellan, C | 1 |
| Martellucci, I | 1 |
| Fiaschi, AI | 2 |
| Lorenzi, B | 1 |
| Francini, G | 9 |
| Kalábová, H | 1 |
| Krcmová, L | 1 |
| Kasparová, M | 1 |
| Malírová, E | 2 |
| Melicharová, K | 1 |
| Pecka, M | 1 |
| Hyspler, R | 1 |
| Solichová, D | 1 |
| Hokama, N | 1 |
| Kubota, S | 4 |
| Amano, R | 2 |
| Yamada, N | 4 |
| Noda, E | 2 |
| Muguruma, K | 2 |
| Yashiro, M | 2 |
| Onoda, N | 1 |
| Sawada, T | 5 |
| Nakata, B | 3 |
| Ohira, M | 3 |
| Tamaru, J | 2 |
| Kikuoka, S | 1 |
| Takeuchi, I | 6 |
| Ishida, F | 1 |
| Ozawa, F | 1 |
| Moriguchi, M | 2 |
| Iwakawa, K | 1 |
| Iwagak, H | 1 |
| Kaneko, T | 2 |
| Shimizu, K | 4 |
| Mishima, T | 1 |
| Koshiishi, H | 2 |
| Matsuyama, T | 2 |
| Goto, H | 1 |
| Kakimoto, Y | 1 |
| Minami, T | 2 |
| Maruyama, M | 6 |
| Takahashi, E | 1 |
| Koshiishi, Y | 1 |
| Matsumoto, R | 1 |
| Kuroda, T | 4 |
| Mamiya, Y | 1 |
| Kon, A | 1 |
| Sobajima, J | 3 |
| Ohsawa, T | 11 |
| Inokuma, S | 6 |
| An, X | 1 |
| Gasparini, G | 4 |
| Azzarello, G | 1 |
| Basso, U | 1 |
| Pessa, S | 2 |
| Lo Re, G | 3 |
| De Paoli, P | 1 |
| Jun, L | 1 |
| Haiping, Z | 1 |
| Beibei, Y | 1 |
| Wagman, L | 2 |
| Weiland, TL | 1 |
| Lai, LL | 1 |
| Schwarz, RE | 2 |
| Molina, R | 2 |
| Dentchev, T | 1 |
| Bolton, JS | 3 |
| Bin, Q | 1 |
| de Haas, RJ | 2 |
| Wicherts, DA | 2 |
| Flores, E | 1 |
| Paule, B | 4 |
| Baeksgaard, L | 1 |
| Petersen, LN | 1 |
| Reiter, L | 1 |
| Wilson, PM | 5 |
| El-Khoueiry, A | 3 |
| Iqbal, S | 5 |
| Fazzone, W | 1 |
| Cole, S | 1 |
| Kornacki, M | 1 |
| Ladner, RD | 5 |
| Montagnani, F | 2 |
| Chiriatti, A | 3 |
| Turrisi, G | 1 |
| Fiorentini, G | 4 |
| Kopper, L | 1 |
| Tímár, J | 2 |
| Kim, LG | 1 |
| Kong, HH | 1 |
| Low, LY | 1 |
| Choi, EY | 1 |
| Na, YS | 1 |
| Noda, N | 1 |
| Shinohara, T | 2 |
| Kitai, T | 3 |
| Kawashima, M | 1 |
| Mashima, S | 1 |
| Shimahara, Y | 2 |
| Fujimura, K | 1 |
| Mune, D | 1 |
| Ohnishi, C | 1 |
| Fujisaki, E | 1 |
| Hatahara, K | 1 |
| Sukawa, Y | 1 |
| Fujii, K | 2 |
| Nishimura, S | 3 |
| Yonezawa, K | 1 |
| Shinomura, Y | 1 |
| Watkins, DJ | 1 |
| Mudan, SS | 1 |
| Karanjia, N | 1 |
| Brown, G | 4 |
| Ashley, S | 1 |
| Norman, AR | 20 |
| Gillbanks, A | 2 |
| Sawayama, H | 2 |
| Toyama, E | 2 |
| Takamori, H | 5 |
| Kim, NS | 1 |
| Park, JY | 1 |
| Kang, BW | 2 |
| Perret, G | 1 |
| Wang, BS | 1 |
| Li, JQ | 1 |
| Spector, T | 5 |
| Gamboa, EO | 1 |
| Rehmus, EH | 1 |
| Haller, N | 1 |
| Newton, K | 1 |
| Hill, J | 1 |
| Harada, T | 2 |
| Akase, T | 1 |
| Arakawa, I | 1 |
| Albrecht, H | 1 |
| Konturek, PC | 1 |
| Reulbach, U | 1 |
| Maennlein, G | 1 |
| Meyer, T | 1 |
| Garm Spindler, KL | 1 |
| Brandslund, I | 1 |
| Boer, K | 1 |
| Pover, GM | 1 |
| Morris, CD | 1 |
| Hu, XT | 1 |
| Shi, QL | 1 |
| Zhang, FB | 1 |
| Patel, BB | 2 |
| Majumdar, AP | 2 |
| Cappellani, A | 1 |
| Cacopardo, B | 1 |
| Nunnari, G | 1 |
| Izzi, I | 1 |
| Lanzafame, M | 1 |
| Basile, F | 1 |
| Schiantarelli C, C | 1 |
| Garlassi, E | 1 |
| Ridolfo, A | 1 |
| Guella, L | 1 |
| Helsby, NA | 1 |
| Lo, WY | 1 |
| Thompson, P | 4 |
| Laking, GR | 1 |
| Fredriksson, LA | 1 |
| Berglund, M | 1 |
| Kohnke, H | 1 |
| Sørbye, H | 8 |
| Seront, E | 1 |
| Marot, L | 1 |
| Coche, E | 1 |
| Gala, JL | 1 |
| Ferrari, G | 1 |
| Gemignani, F | 1 |
| Macaluso, C | 1 |
| Vanhoefer, U | 9 |
| Frieling, T | 1 |
| Lehnert, L | 1 |
| Zarate, R | 3 |
| Bandres, E | 4 |
| Patiño-Garcia, A | 1 |
| Ponz-Sarvise, M | 1 |
| Ramirez, N | 1 |
| Bitarte, N | 2 |
| Chopitea, A | 1 |
| Gacía-Foncillas, J | 1 |
| Coursier, S | 1 |
| Martelet, S | 1 |
| Guillermet, A | 1 |
| Emptoz, J | 1 |
| Villier, C | 1 |
| Bontemps, H | 1 |
| Bao, HY | 3 |
| Zhang, XC | 2 |
| Shi, GM | 2 |
| Yu, LF | 2 |
| Mou, HB | 1 |
| Deshaies, I | 1 |
| Dromain, C | 3 |
| Yuuki, S | 1 |
| Miyagishima, T | 3 |
| Kudo, M | 2 |
| Tateyama, M | 2 |
| Kunieda, Y | 1 |
| Wakahama, O | 1 |
| Maleux, G | 2 |
| Vaninbroukx, J | 1 |
| Heye, S | 1 |
| Oyen, R | 1 |
| Lin, YL | 1 |
| Chow, KC | 1 |
| Komori, H | 2 |
| Horino, K | 2 |
| Imsung, C | 1 |
| Ootao, R | 1 |
| Iyama, K | 1 |
| Minashi, K | 3 |
| Tahara, M | 5 |
| Joh, T | 4 |
| Ohrling, K | 1 |
| Edler, D | 2 |
| Hallström, M | 2 |
| Ragnhammar, P | 5 |
| Yoshioka, A | 2 |
| Takahashi, R | 1 |
| Matsuda, F | 1 |
| Higuchi, M | 1 |
| Iwatsubo, S | 1 |
| Shirakawa, A | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 4 |
| Ma, SH | 1 |
| Chen, GG | 1 |
| Lai, PB | 1 |
| de Bruijn, MT | 2 |
| Raats, DA | 2 |
| Hoogwater, FJ | 1 |
| van Houdt, WJ | 1 |
| Borel Rinkes, IH | 1 |
| Matsuura, K | 1 |
| Itoh, Y | 1 |
| Baldwin, C | 1 |
| Millette, M | 1 |
| Oth, D | 1 |
| Ruiz, MT | 1 |
| Luquet, FM | 1 |
| Lacroix, M | 1 |
| Taura, M | 1 |
| Fukuda, R | 1 |
| Suico, MA | 1 |
| Eguma, A | 1 |
| Koga, T | 1 |
| Shuto, T | 1 |
| Morino-Koga, S | 1 |
| Kai, H | 1 |
| Guijarro, M | 1 |
| Gisbert, JP | 2 |
| Rivas, N | 1 |
| Hinojar-Gutiérrez, A | 1 |
| McCollum, D | 1 |
| Baumgaertner, I | 1 |
| Pillai, M | 1 |
| Gollard, R | 1 |
| Heim, W | 3 |
| Swan, F | 1 |
| Dreiling, L | 1 |
| Mo, M | 1 |
| Malik, I | 2 |
| Boccia, RV | 1 |
| Cosgriff, TM | 2 |
| Headley, DL | 1 |
| Badarinath, S | 2 |
| Best, JH | 1 |
| Garrison, LP | 1 |
| Tondulli, L | 1 |
| Mendiboure, J | 2 |
| Castaing, M | 3 |
| Barrois, M | 1 |
| Trégouët, DA | 2 |
| Le Corre, D | 1 |
| Miran, I | 1 |
| Mulot, C | 1 |
| Beaune, P | 3 |
| Kinoshita, K | 1 |
| Akira, C | 1 |
| Watanebe, M | 1 |
| Uña Cidón, E | 1 |
| Gorden, L | 1 |
| Hauteville, D | 2 |
| Guettier, C | 2 |
| Lu, GC | 1 |
| Li, DC | 1 |
| Gervaz, P | 3 |
| Rubbia-Brandt, L | 3 |
| Andres, A | 3 |
| Majno, P | 1 |
| Morel, P | 2 |
| Mentha, G | 4 |
| Wu, Wy | 1 |
| Durando, X | 3 |
| Farges, MC | 1 |
| Abrial, C | 1 |
| Petorin-Lesens, C | 1 |
| Gillet, B | 1 |
| Vasson, MP | 1 |
| Thivat, E | 2 |
| Madroñal, C | 1 |
| Bolaños, M | 3 |
| Gil, M | 1 |
| Llombart, A | 1 |
| Castro-Carpeño, J | 1 |
| Takamoto, T | 1 |
| Sano, K | 1 |
| Maruyama, Y | 1 |
| Inoue, K | 3 |
| Ogata, S | 1 |
| Takemura, T | 1 |
| Morelli, MF | 2 |
| Santomaggio, A | 2 |
| Tudini, M | 2 |
| Mancini, M | 3 |
| Pelliccione, M | 1 |
| Calista, F | 1 |
| Guglielmi, F | 1 |
| Martella, F | 1 |
| Lanfiuti Baldi, P | 1 |
| Gebbia, N | 11 |
| Seminara, P | 4 |
| Losanno, T | 1 |
| Emiliani, A | 1 |
| Manna, G | 1 |
| De Portu, S | 1 |
| Mantovani, LG | 1 |
| Bollina, R | 1 |
| Cozzi, C | 1 |
| Grimaldi, AM | 1 |
| Testa, TE | 1 |
| Bianchessi, C | 1 |
| Xing, PY | 1 |
| Feng, FY | 3 |
| Shi, YK | 1 |
| Pessaux, P | 1 |
| Panaro, F | 1 |
| Casnedi, S | 2 |
| Zeca, I | 1 |
| Marzano, E | 1 |
| Bachellier, P | 2 |
| Koizumi, W | 3 |
| Takiuchi, H | 5 |
| Muindi, JR | 2 |
| Nagasaki, E | 1 |
| Takahara, A | 1 |
| Koido, S | 1 |
| Sagawa, Y | 1 |
| Aiba, K | 7 |
| Tajiri, H | 1 |
| Yagita, H | 1 |
| Homma, S | 2 |
| Bergougnoux, L | 1 |
| Kojima, T | 3 |
| Ikematsu, H | 1 |
| Yano, T | 2 |
| Kaneko, K | 1 |
| Koike, K | 1 |
| Hosoda, K | 1 |
| Aoki, M | 1 |
| Kido, H | 1 |
| Natsu, K | 1 |
| Tamura, H | 1 |
| Kojima, M | 2 |
| Amemiya, T | 1 |
| Kamoshida, T | 1 |
| Yasutome, M | 1 |
| Joo, EH | 1 |
| Rha, SY | 5 |
| Kang, HY | 1 |
| Koong, HN | 1 |
| Ripley, RT | 1 |
| Davis, JL | 1 |
| Kemp, CD | 1 |
| Steinberg, SM | 3 |
| Toomey, MA | 1 |
| Avital, I | 1 |
| Ni, L | 1 |
| Ma, YQ | 1 |
| Song, YG | 1 |
| Ramos, Y | 1 |
| Gonzalez, M | 1 |
| Fernandez, A | 1 |
| Mezentsev, D | 1 |
| Reis, I | 1 |
| Duncan, R | 1 |
| Podolsky, L | 2 |
| Lima, M | 1 |
| Ganjei-Azar, P | 1 |
| Pracht, M | 1 |
| Le Roux, C | 1 |
| Kerjouan, M | 1 |
| Audrain, O | 1 |
| Gebski, VJ | 1 |
| Cummins, MM | 2 |
| Broad, A | 2 |
| Forgeson, G | 1 |
| Stockler, MR | 1 |
| Chua, Y | 1 |
| Widmer, L | 1 |
| Uhlmann, C | 1 |
| Simcock, M | 1 |
| Lanz, D | 2 |
| Popescu, R | 4 |
| Zhuang, L | 1 |
| Bai, J | 1 |
| Tang, C | 2 |
| Duanmu, Z | 1 |
| Sarkar, M | 1 |
| Benitez, E | 1 |
| Singhal, S | 1 |
| Chen, MH | 2 |
| de Bock, CE | 1 |
| Garg, MB | 2 |
| Scott, N | 1 |
| Sakoff, JA | 2 |
| Scorgie, FE | 2 |
| Lincz, LF | 2 |
| Smyth, E | 1 |
| Abou-Alfa, GK | 1 |
| Lowery, M | 1 |
| Al-Olayan, A | 1 |
| Naghy, M | 1 |
| Power, D | 1 |
| Saliba, T | 1 |
| Morrow, CJ | 1 |
| Ghattas, M | 1 |
| Smith, C | 1 |
| Bönisch, H | 1 |
| Bryce, RA | 1 |
| Hickinson, DM | 1 |
| Green, TP | 1 |
| Simons, S | 1 |
| Ringsdorf, S | 1 |
| Mey, UJ | 1 |
| Schwindt, PF | 1 |
| Ko, YD | 1 |
| Schmidt-Wolf, I | 1 |
| Kuhn, W | 1 |
| Napoli, C | 3 |
| Landini, I | 2 |
| Morganti, M | 2 |
| Cianchi, F | 2 |
| Valanzano, R | 2 |
| Tonelli, F | 2 |
| Cortesini, C | 1 |
| Kataoka, H | 1 |
| Mabuchi, M | 1 |
| Mizoshita, T | 1 |
| Kubota, E | 1 |
| Tanida, S | 1 |
| Kamiya, T | 1 |
| Duffour, J | 6 |
| Roca, L | 2 |
| Bressolle, F | 4 |
| Abderrahim, AG | 1 |
| Poujol, S | 2 |
| Pinguet, F | 5 |
| Lambert, B | 1 |
| Vannoote, J | 1 |
| De Keukeleire, K | 1 |
| Verslype, C | 5 |
| Defreyne, L | 1 |
| Paesmans, M | 2 |
| Gasa, F | 1 |
| Terui, K | 1 |
| Awatsu, A | 1 |
| Sugishita, H | 1 |
| Watanabe, S | 2 |
| Tanaka, A | 2 |
| Morioka, J | 1 |
| Suemaru, K | 1 |
| Watanabe, Y | 4 |
| Kawachi, K | 1 |
| Araki, H | 3 |
| Zorzi, D | 2 |
| Contreras, CM | 1 |
| Maru, DM | 3 |
| Ribero, D | 2 |
| Motta, M | 1 |
| Ravarino, N | 1 |
| Risio, M | 1 |
| Curley, SA | 7 |
| Abdalla, EK | 5 |
| Capussotti, L | 7 |
| Schneiders, FL | 1 |
| van den Berg, HP | 1 |
| Pang, R | 1 |
| Chu, AC | 1 |
| Cheung, LW | 1 |
| Lan, XR | 1 |
| Lan, HY | 2 |
| Tan, VP | 1 |
| Poon, RT | 1 |
| Wong, BC | 1 |
| Kyula, JN | 1 |
| Doherty, J | 1 |
| Fenning, CS | 1 |
| Hsieh, YY | 2 |
| Hsu, YN | 1 |
| Chau, GY | 1 |
| King, KL | 1 |
| Boni, V | 2 |
| Villa, JC | 1 |
| Gomez, MA | 2 |
| Ajima, H | 1 |
| Ogata, H | 1 |
| Beslija, S | 1 |
| Koza, I | 1 |
| Pápai, Z | 2 |
| Faluhelyi, Z | 1 |
| Wenczl, M | 1 |
| Gazzaniga, P | 1 |
| Gradilone, A | 1 |
| Petracca, A | 1 |
| Nicolazzo, C | 1 |
| Raimondi, C | 1 |
| Bartucci, M | 1 |
| Svensson, S | 1 |
| Ricci-Vitiani, L | 2 |
| Dattilo, R | 1 |
| Biffoni, M | 1 |
| Ferla, R | 1 |
| Surmacz, E | 1 |
| Bracht, K | 1 |
| Nicholls, AM | 1 |
| Bodmer, WF | 1 |
| Guastadisegni, C | 1 |
| Colafranceschi, M | 1 |
| Ottini, L | 1 |
| Dogliotti, E | 1 |
| Haugstetter, AM | 1 |
| Loddenkemper, C | 1 |
| Lenze, D | 1 |
| Gröne, J | 1 |
| Standfuss, C | 1 |
| Petersen, I | 1 |
| Dörken, B | 4 |
| Schmitt, CA | 1 |
| Layos, L | 1 |
| Moreno, V | 3 |
| Astier, A | 1 |
| Kamil, M | 1 |
| Haron, M | 1 |
| Yosuff, N | 1 |
| Khalid, I | 1 |
| Azman, N | 1 |
| Lubner, SJ | 1 |
| Holen, KD | 4 |
| Schelman, W | 1 |
| Thomas, JP | 1 |
| Jumonville, A | 1 |
| Eickhoff, JC | 1 |
| Frederiksen, C | 1 |
| Takemura, M | 1 |
| Morimura, K | 1 |
| Osugi, H | 1 |
| Kishida, S | 1 |
| Shiraishi, R | 1 |
| Matsukawa, H | 1 |
| Tamura, I | 1 |
| Ozawa, Y | 1 |
| Imada, T | 1 |
| Agata, T | 1 |
| Noro, T | 1 |
| Shiota, M | 1 |
| Ozeki, S | 1 |
| Hatta, K | 1 |
| Ota, H | 2 |
| Tang, JT | 1 |
| Tanoue, Y | 1 |
| Tizzano, E | 1 |
| Shabaruddin, FH | 1 |
| Elliott, RA | 1 |
| Newman, WG | 1 |
| Payne, K | 1 |
| Waddell, T | 1 |
| Soe, W | 1 |
| Allen, J | 1 |
| Bentley, D | 1 |
| Lloyd, A | 1 |
| Taylor, MB | 1 |
| Gong, C | 1 |
| Shi, S | 1 |
| Qian, Z | 1 |
| Bester, L | 1 |
| Akther, J | 1 |
| Jung, JJ | 1 |
| Kim, GB | 1 |
| Yoon, HS | 1 |
| Ko, SH | 1 |
| Ko, JE | 1 |
| Marshall, MB | 1 |
| Del Monte, F | 1 |
| Kimata, T | 1 |
| Sakamoto, E | 3 |
| Kawachi, A | 1 |
| Kuroki, A | 1 |
| Kawade, Y | 1 |
| Tokui, K | 1 |
| Oyama, T | 1 |
| Uchida, T | 1 |
| Kondoh, M | 1 |
| Kho, PS | 1 |
| Moore, MM | 1 |
| Charles, KA | 1 |
| Watson, RG | 1 |
| Muhale, F | 1 |
| Thorne, LB | 1 |
| Hoskins, JM | 2 |
| Meyers, MO | 1 |
| Hudson, ML | 1 |
| Siquini, W | 1 |
| Stortoni, P | 1 |
| Marmorale, C | 1 |
| Fianchini, A | 1 |
| Mladkova, J | 1 |
| Sanda, M | 1 |
| Matouskova, E | 1 |
| Selicharova, I | 1 |
| Bergin, P | 1 |
| Hanning, F | 1 |
| Findlay, M | 7 |
| Damianovich, D | 2 |
| McKeage, MJ | 1 |
| Stathopoulos, GP | 2 |
| Batziou, C | 1 |
| Trafalis, D | 1 |
| Koutantos, J | 1 |
| Batzios, S | 1 |
| Stathopoulos, J | 1 |
| Legakis, J | 1 |
| Armakolas, A | 1 |
| Mizuno, T | 2 |
| Oriuchi, N | 1 |
| Baxevanis, CN | 1 |
| McIntyre, DJ | 2 |
| Howe, FA | 2 |
| Ladroue, C | 1 |
| Lofts, F | 5 |
| Stubbs, M | 2 |
| Jaitner, S | 1 |
| Schäffauer, AJ | 1 |
| Dietmaier, W | 1 |
| Griffith, M | 2 |
| Griffith, OL | 2 |
| Mwenifumbo, J | 1 |
| Goya, R | 1 |
| Morrissy, AS | 1 |
| Morin, RD | 2 |
| Corbett, R | 1 |
| Tang, MJ | 3 |
| Hou, YC | 3 |
| Pugh, TJ | 2 |
| Robertson, G | 1 |
| Chittaranjan, S | 2 |
| Ally, A | 1 |
| Asano, JK | 2 |
| Chan, SY | 2 |
| Li, HI | 1 |
| McDonald, H | 1 |
| Teague, K | 1 |
| Zeng, T | 1 |
| Delaney, A | 1 |
| Hirst, M | 1 |
| Morin, GB | 2 |
| Jones, SJ | 1 |
| Tai, IT | 4 |
| Marra, MA | 2 |
| Yabuki, H | 2 |
| Chiba, M | 1 |
| Igawa, A | 1 |
| Fujimoto, H | 2 |
| Sugawara, M | 1 |
| Matsuda, M | 5 |
| Mikalauskas, S | 1 |
| Mikalauskiene, L | 1 |
| Bruns, H | 1 |
| Nickkholgh, A | 1 |
| Hoffmann, K | 1 |
| Longerich, T | 1 |
| Mammoliti, S | 1 |
| Andretta, V | 1 |
| Bennicelli, E | 1 |
| Caprioni, F | 1 |
| Comandini, D | 1 |
| Guglielmi, A | 11 |
| Pessino, A | 1 |
| Sciallero, S | 1 |
| Mazzola, G | 1 |
| Lambiase, A | 2 |
| Bordignon, C | 1 |
| Van der Speeten, K | 2 |
| Stuart, OA | 1 |
| Chang, D | 3 |
| Khattak, A | 1 |
| Frago, R | 1 |
| Kreisler, E | 1 |
| Biondo, S | 1 |
| Dominguez, J | 1 |
| Escalante, E | 1 |
| Spigel, DR | 1 |
| Greco, FA | 4 |
| Shipley, D | 1 |
| Vazquez, ER | 1 |
| Clark, BL | 1 |
| Wu, XN | 1 |
| Zhao, YB | 1 |
| Ding, L | 1 |
| Ai, B | 1 |
| Zhou, MZ | 1 |
| Yanagisawa, Y | 2 |
| Shen, W | 1 |
| Tu, JK | 1 |
| Fu, ZX | 2 |
| Huang, CX | 1 |
| Li, ZY | 1 |
| Jiang, YQ | 1 |
| Duan, GL | 1 |
| Wang, QQ | 1 |
| Stutchbury, TK | 1 |
| Locke, JM | 1 |
| Chrisp, JS | 1 |
| Bremner, JB | 1 |
| Park, HM | 1 |
| Park, JS | 1 |
| Sohn, HJ | 1 |
| Kim, TG | 1 |
| Nordman, I | 1 |
| Dobbins, T | 1 |
| Ward, R | 1 |
| Chalermchai, T | 1 |
| Tantiphlachiva, K | 1 |
| Suwanrusme, H | 1 |
| Voravud, N | 1 |
| Sriuranpong, V | 1 |
| Ciccolini, J | 8 |
| Lacarelle, B | 3 |
| Mercier, C | 3 |
| McKenna, EF | 1 |
| Licitra, S | 1 |
| Aliberti, C | 1 |
| Tzekova, V | 1 |
| Collins, S | 1 |
| Gansert, J | 2 |
| Wolf, M | 1 |
| Kong, D | 1 |
| Song, T | 1 |
| Ru, T | 1 |
| Fantini, M | 1 |
| Gianni, L | 2 |
| Possenti, C | 1 |
| Drudi, F | 1 |
| Sintini, M | 1 |
| Bagli, L | 1 |
| Chung, H | 1 |
| Chaudhry, J | 1 |
| Lopez, CG | 1 |
| Ling, W | 1 |
| Snoeren, N | 1 |
| Bergman, AM | 1 |
| Tollenaar, RA | 1 |
| van der Sijp, JR | 1 |
| Schouten, SB | 1 |
| Rinkes, IH | 2 |
| van Hillegersberg, R | 1 |
| Oh, M | 1 |
| Francheschi, D | 1 |
| Livingstone, A | 1 |
| Lombardo, Y | 1 |
| Scopelliti, A | 1 |
| Cammareri, P | 1 |
| Todaro, M | 1 |
| Iovino, F | 1 |
| Gulotta, G | 1 |
| Dieli, F | 1 |
| Di Battista, M | 2 |
| Morselli-Labate, AM | 1 |
| Paragona, M | 1 |
| Corbelli, J | 1 |
| Macchini, M | 1 |
| Prandoni, P | 1 |
| Baldi, PL | 1 |
| Antonucci, A | 1 |
| Torsello, A | 1 |
| Ettorre, GM | 1 |
| Zeuli, M | 5 |
| Campanella, C | 1 |
| Vennarecci, G | 1 |
| Cognetti, F | 9 |
| Chang, MH | 1 |
| Si, Y | 1 |
| Woo, IS | 2 |
| Ciacio, O | 1 |
| Muñoz-Martin, AJ | 1 |
| Alvarez-Suarez, S | 1 |
| Jerez-Gilarranz, Y | 1 |
| Khosravi, P | 1 |
| Mariani, P | 3 |
| Boisseau, A | 1 |
| Sastre, X | 1 |
| Cucherousset, J | 1 |
| Lagorce, C | 1 |
| Schischmanoff, PO | 2 |
| Vourli, G | 1 |
| Xanthakis, I | 3 |
| Papadimitriou, C | 1 |
| Samelis, G | 2 |
| Syrigos, KN | 3 |
| Xiros, N | 1 |
| Stavropoulos, M | 2 |
| Kosmidis, P | 10 |
| Christodoulou, C | 1 |
| Linardou, H | 1 |
| Skondra, M | 1 |
| Economopoulos, T | 3 |
| Whyte, S | 1 |
| Pandor, A | 1 |
| Stevenson, M | 1 |
| Rees, A | 1 |
| Pander, J | 1 |
| Wessels, JAM | 1 |
| Vrdoljak, E | 1 |
| Omrčen, T | 1 |
| Boban, M | 1 |
| Hrabar, A | 1 |
| Tsai, PC | 1 |
| Chuang, SC | 2 |
| Hou, MF | 2 |
| Baird, R | 1 |
| Biondo, A | 1 |
| Chhaya, V | 1 |
| McLachlan, J | 1 |
| Karpathakis, A | 1 |
| Barbachano, Y | 4 |
| Knijn, N | 1 |
| Werter, MJ | 2 |
| Imholz, AL | 1 |
| Valster, FA | 1 |
| Vincent, AD | 1 |
| Teerenstra, S | 5 |
| Vaidyanathan, G | 1 |
| Groman, A | 2 |
| Nicolella, D | 1 |
| Dapretto, E | 1 |
| Valeri, N | 1 |
| Gasparini, P | 1 |
| Braconi, C | 1 |
| Paone, A | 1 |
| Lovat, F | 1 |
| Fabbri, M | 1 |
| Sumani, KM | 1 |
| Alder, H | 1 |
| Patel, T | 2 |
| Nuovo, GJ | 1 |
| Fishel, R | 1 |
| Croce, CM | 1 |
| Hasbak, P | 1 |
| Mortensen, J | 1 |
| Matsunoki, A | 1 |
| Ramiscal, JA | 1 |
| Jatoi, A | 1 |
| Sabatier, R | 1 |
| Plat, F | 1 |
| Goubely, Y | 1 |
| Molinari, N | 1 |
| Fuccio, L | 1 |
| Cennamo, V | 1 |
| Lu, SX | 1 |
| Chay, WY | 1 |
| Tan, SH | 2 |
| Lo, YL | 1 |
| Ng, HC | 1 |
| Koo, WH | 3 |
| Kang, EJ | 1 |
| Choi, YJ | 3 |
| Park, KH | 2 |
| Choi, IK | 1 |
| Seo, JH | 2 |
| Shin, SW | 2 |
| Madajewicz, S | 5 |
| Waterhouse, DM | 1 |
| Ritch, PS | 1 |
| Khan, MQ | 1 |
| Higby, DJ | 1 |
| Leichman, CG | 14 |
| Malik, SK | 1 |
| Hentschel, P | 2 |
| Gill, JF | 1 |
| George, T | 1 |
| Stasi, I | 1 |
| Fabbri, MA | 1 |
| Puglisi, M | 1 |
| Trenta, P | 1 |
| Crinò, L | 2 |
| Ababneh, Y | 1 |
| Verpoort, K | 1 |
| Schmidt, B | 1 |
| Musch, R | 1 |
| Soeling, U | 1 |
| Maintz, C | 1 |
| Fahlke, J | 2 |
| Gregory, C | 1 |
| Wang, PF | 1 |
| Long, SR | 1 |
| Tommasi, S | 2 |
| Numico, G | 1 |
| Petriella, D | 1 |
| Millaku, A | 1 |
| Gonzalez-Haba, E | 1 |
| López-Lillo, C | 1 |
| Barrueco, N | 1 |
| Alvarez, S | 1 |
| Jiménez, JL | 1 |
| Martín, ML | 1 |
| Muñóz-Fernández, MA | 1 |
| Hazama, M | 1 |
| Ho, YF | 1 |
| Lu, WC | 1 |
| Chen, RR | 1 |
| Molina-Garrido, MJ | 1 |
| Liang, XB | 1 |
| Hou, SH | 1 |
| Li, YP | 2 |
| Wang, LC | 1 |
| Mishima, Y | 3 |
| Terui, Y | 2 |
| Jithesh, PV | 3 |
| Oliver, GR | 1 |
| Proutski, I | 4 |
| Proutski, V | 1 |
| Harkin, P | 1 |
| Kadota, K | 1 |
| Huang, CL | 1 |
| Yokomise, H | 1 |
| Haba, R | 1 |
| Utsunomiya, S | 1 |
| Kawai, H | 1 |
| Gordon, MA | 2 |
| El-Khouiery, A | 1 |
| Labonte, M | 1 |
| Wilson, P | 3 |
| Sherrod, A | 3 |
| Stojadinovic, A | 1 |
| Doerfer, J | 1 |
| Fasol, U | 1 |
| Arends, J | 1 |
| Hense, J | 1 |
| Scheulen, ME | 1 |
| Nguyen, TP | 1 |
| Ettlinger, D | 1 |
| De Marchis, ML | 1 |
| Schirru, M | 1 |
| Park, KS | 1 |
| Chung, HC | 3 |
| Kitazono, M | 1 |
| Yamamoto, M | 4 |
| Morikita, T | 1 |
| Prasad, RB | 1 |
| Lorenzo Bermejo, J | 1 |
| Kim, YK | 1 |
| Hirota, M | 2 |
| Kawano, K | 1 |
| Izumi, H | 1 |
| Kohno, K | 1 |
| Samaras, P | 1 |
| Breitenstein, S | 1 |
| Haile, SR | 1 |
| Stenner-Liewen, F | 1 |
| Heinrich, S | 4 |
| Feilchenfeldt, J | 1 |
| Renner, C | 1 |
| Knuth, A | 5 |
| Pestalozzi, BC | 5 |
| Clavien, PA | 2 |
| Krieger, PM | 1 |
| Faybik, P | 1 |
| Fleischmann, E | 1 |
| Maresch, J | 1 |
| Ocean, AJ | 1 |
| Polite, B | 1 |
| Christos, P | 1 |
| Horvath, L | 2 |
| Hamilton, A | 1 |
| Matulich, D | 1 |
| Sparano, JA | 1 |
| Kindler, HL | 4 |
| Jacene, H | 1 |
| Kulesza, P | 1 |
| Laheru, DA | 2 |
| Kahn, Y | 1 |
| Spira, A | 1 |
| Dancey, J | 2 |
| Iacobuzio-Donahue, C | 2 |
| Carducci, M | 1 |
| Camacho, LH | 1 |
| Garcia, S | 1 |
| Panchal, AM | 1 |
| Lim, J | 1 |
| Hong, DS | 1 |
| Ng, C | 1 |
| Madoff, DC | 1 |
| Gayed, I | 1 |
| Kurzrock, R | 2 |
| Kumamoto, T | 2 |
| Nojiri, K | 2 |
| Matsuyama, R | 2 |
| Akiyama, H | 1 |
| Katsumoto, Y | 1 |
| Aritake, N | 1 |
| Endoh, A | 1 |
| Hosokawa, T | 1 |
| Tokita, H | 1 |
| Iwao, Y | 1 |
| Koshinaga, T | 1 |
| Miura, I | 2 |
| Itoyama, S | 2 |
| Kanoh, T | 4 |
| Tono, T | 9 |
| Tsukao, Y | 1 |
| Inatome, J | 1 |
| Kagara, N | 1 |
| Monden, T | 6 |
| Imaoka, S | 2 |
| Kagawa, S | 1 |
| Takeuchi, D | 1 |
| Ko, S | 1 |
| Mukogawa, T | 1 |
| Nishiwada, T | 1 |
| Nakamoto, T | 1 |
| Kunishige, T | 1 |
| Aoyagi, H | 1 |
| Katsuta, E | 1 |
| Someno, Y | 1 |
| Saguchi, M | 1 |
| Takahata, T | 1 |
| Hamada, S | 1 |
| Maejima, S | 1 |
| Otsuka, Y | 1 |
| Shiokawa, H | 1 |
| Kurihara, A | 2 |
| Funahashi, K | 1 |
| Shimada, H | 8 |
| Choi, MS | 1 |
| Ng, S | 1 |
| O'bichere, A | 1 |
| Daniele, S | 1 |
| Frezza, AM | 4 |
| Berti, P | 2 |
| Vespasiani, U | 2 |
| Zhou, MQ | 1 |
| Chai, H | 1 |
| Tian, R | 1 |
| Nakano, H | 4 |
| Sakurai, J | 1 |
| Koizumi, S | 2 |
| Shimamura, T | 3 |
| Makizumi, R | 1 |
| Yamada, K | 3 |
| Miyajima, N | 2 |
| Otsubo, T | 1 |
| Kidera, Y | 1 |
| Okamoto, I | 2 |
| Fumita, S | 1 |
| Makimura, C | 1 |
| Kiyota, H | 1 |
| Tsurutani, J | 1 |
| Yoshinaga, M | 2 |
| Fujiwara, K | 3 |
| Yamazoe, Y | 1 |
| Moriyama, K | 1 |
| Chiba, Y | 1 |
| Seki, A | 1 |
| Hori, S | 2 |
| Nishioka, M | 1 |
| Kurita, N | 1 |
| Iwata, T | 1 |
| Miyatani, T | 1 |
| Fridlyand, J | 1 |
| Kaiser, LD | 1 |
| Fyfe, G | 2 |
| Cushman, S | 1 |
| Aklilu, M | 1 |
| Ashton, J | 1 |
| Duret, A | 1 |
| Etienne, MC | 9 |
| Falandry, C | 2 |
| Saffery, C | 1 |
| Khan, A | 2 |
| Strimpakos, AS | 1 |
| Thomas, J | 1 |
| Compton, S | 1 |
| Chua, YJ | 1 |
| Hass, HG | 2 |
| Dietzfelbinger, H | 2 |
| Oruzio, D | 2 |
| Klein, S | 2 |
| Zellmann, K | 2 |
| Abenhardt, W | 2 |
| Puchtler, G | 2 |
| Kappauf, H | 2 |
| Mittermüller, J | 2 |
| Haberl, C | 2 |
| Franchina, T | 1 |
| Minciullo, PL | 1 |
| Pace, E | 1 |
| Colonese, F | 1 |
| Ricciardi, GR | 1 |
| Saitta, S | 1 |
| Ferraro, M | 1 |
| Spatari, G | 1 |
| Gangemi, S | 1 |
| Sogabe, S | 2 |
| Hatanaka, K | 1 |
| Usui, K | 1 |
| Katou, Y | 1 |
| Tanai, C | 1 |
| Ishihara, T | 1 |
| Nelson, MA | 1 |
| Shetty, S | 1 |
| Kulakodlu, M | 1 |
| Harley, C | 1 |
| Seal, B | 1 |
| Shah, NR | 1 |
| Shah, A | 4 |
| Rather, A | 1 |
| Caronia, D | 1 |
| de la Torre, J | 1 |
| García-Sáenz, JA | 1 |
| Alonso, MR | 1 |
| Moreno, LT | 1 |
| Benítez, J | 1 |
| Iguchi, T | 1 |
| Idani, H | 1 |
| Asami, S | 2 |
| Kanazawa, S | 1 |
| Perrocheau, G | 1 |
| Dominguez, S | 2 |
| Florentin, V | 1 |
| Urasinska, E | 1 |
| Tan, WL | 2 |
| Bhattacharya, B | 1 |
| Balasubramanian, I | 1 |
| Akram, M | 1 |
| Thakkar, B | 1 |
| Soo, RA | 2 |
| Fichtner, I | 1 |
| Tsukioka, S | 1 |
| Tsujimoto, H | 2 |
| Kiniwa, M | 1 |
| Hutchins, G | 1 |
| Beaumont, C | 1 |
| Stahlschmidt, J | 1 |
| Ibrahim, T | 2 |
| Amatori, F | 3 |
| Mercatali, L | 1 |
| Ravaioli, E | 1 |
| Flamini, E | 2 |
| Sacanna, E | 1 |
| Bertolini, F | 1 |
| Malavasi, N | 1 |
| Scarabelli, L | 1 |
| Fiocchi, F | 1 |
| Bagni, B | 1 |
| Del Giovane, C | 1 |
| Gerunda, GE | 1 |
| Depenni, R | 1 |
| Zironi, S | 3 |
| Pettorelli, E | 1 |
| Luppi, G | 3 |
| Conte, PF | 9 |
| Klaver, YL | 3 |
| Cabebe, EC | 1 |
| Frumento, P | 3 |
| Zhi, J | 2 |
| Major, P | 2 |
| Burns, I | 1 |
| Rittweger, K | 2 |
| Abt, M | 1 |
| Zissen, MH | 1 |
| Kunz, P | 1 |
| Subbarayan, M | 1 |
| Chin, FT | 1 |
| Conti, PS | 3 |
| Quon, A | 1 |
| Backshall, A | 1 |
| Keun, HC | 1 |
| Hoff, P | 3 |
| Saini, JP | 1 |
| Gilberg, F | 3 |
| Meguro, E | 1 |
| Shibata, H | 1 |
| Hoshino, Y | 2 |
| Nishi, T | 2 |
| Warita, E | 2 |
| Miyamoto, J | 1 |
| Akutsu, N | 1 |
| Xiao, H | 1 |
| Yokoyama, H | 2 |
| Okuda, N | 1 |
| Iwata, N | 1 |
| Ohashi, N | 2 |
| Nakao, A | 4 |
| Yoon, CJ | 1 |
| Shin, DY | 1 |
| Lee, YG | 1 |
| Choi, SY | 1 |
| Kang, SG | 1 |
| Cooper, A | 1 |
| Garrett, CR | 1 |
| Starling, N | 2 |
| Vázquez-Mazón, F | 1 |
| Countouriotis, AM | 1 |
| Ruiz-Garcia, A | 1 |
| Wei, G | 1 |
| Tursi, JM | 2 |
| Seki, K | 1 |
| Senzaki, K | 1 |
| Tsuduki, Y | 1 |
| Ioroi, T | 1 |
| Yamauchi, H | 1 |
| Shiraishi, Y | 1 |
| Nakata, I | 1 |
| Nishiguchi, K | 2 |
| Matsubayashi, T | 1 |
| Takakubo, Y | 1 |
| Okamura, N | 1 |
| Muhale, FA | 1 |
| Wetmore, BA | 1 |
| Thomas, RS | 1 |
| Balboa, E | 1 |
| Touris, M | 1 |
| Vidal, Y | 1 |
| Germond, C | 1 |
| Berg, W | 2 |
| Chen, BL | 2 |
| Jalava, T | 2 |
| Lebwohl, D | 3 |
| Meinhardt, G | 3 |
| Laurent, D | 3 |
| Lin, E | 3 |
| Jäger, E | 4 |
| Lloyd-Salvant, K | 1 |
| Pendergrass, K | 1 |
| Vogel, UB | 1 |
| Andersen, JT | 2 |
| Broedbaek, K | 1 |
| Petersen, M | 2 |
| Jimenez-Solem, E | 2 |
| Bertolaso, L | 2 |
| Boston, EA | 1 |
| Gaffney, EA | 1 |
| Lopez, M | 9 |
| Copetti, M | 1 |
| Tuveri, G | 1 |
| Xavier, CP | 1 |
| Lima, CF | 1 |
| Rohde, M | 1 |
| Pereira-Wilson, C | 1 |
| Rodriguez, NA | 1 |
| Ascaso, FJ | 1 |
| Pichereau, S | 1 |
| Le Louarn, A | 1 |
| Blasco, H | 1 |
| Le Guellec, C | 1 |
| Bourgoin, H | 1 |
| Burylo, AM | 1 |
| Doodeman, VD | 1 |
| Smits, PH | 1 |
| Motoori, S | 1 |
| Kawase, T | 1 |
| Nishimura, H | 1 |
| Konno, T | 1 |
| Hanai, C | 1 |
| Kitagawa, N | 1 |
| Saisho, H | 1 |
| Furuse, J | 1 |
| Mashimo, Y | 1 |
| Ezoe, Y | 1 |
| Nowacki, MP | 1 |
| Shchepotin, I | 1 |
| Perrone, G | 3 |
| Ruzzo, AM | 1 |
| Crucitti, P | 1 |
| Galluzzo, S | 1 |
| Zoccoli, A | 1 |
| Rabitti, C | 2 |
| Muda, AO | 1 |
| Hofmann, G | 1 |
| Langsenlehner, U | 1 |
| Langsenlehner, T | 1 |
| Glehr, M | 1 |
| Absenger, G | 2 |
| Szkandera, J | 1 |
| Fuerst, F | 1 |
| Krippl, P | 1 |
| Renner, W | 1 |
| Hinrichs, J | 1 |
| Tan, TH | 1 |
| Dowling, R | 2 |
| Lichtenstein, M | 1 |
| Kakefuda, R | 1 |
| Tajima, N | 1 |
| Sowa, Y | 2 |
| Vignoli, M | 1 |
| Putignano, AL | 1 |
| Papi, L | 1 |
| Genuardi, M | 1 |
| Almagro, BM | 1 |
| Steyls, MC | 1 |
| Navarro, NL | 1 |
| Domínguez, EG | 1 |
| Acosta, EH | 1 |
| Pérez, MA | 1 |
| Ceballos, EH | 1 |
| Van Loon, K | 1 |
| Hesketh, PJ | 2 |
| Sanz-Altamira, P | 1 |
| Bushey, J | 1 |
| Hesketh, AM | 1 |
| Kawahara, K | 2 |
| Ueda, R | 1 |
| Fukui, E | 1 |
| Yamada, R | 2 |
| Thompson, LC | 1 |
| Brewster, AE | 1 |
| Shepherd, SF | 1 |
| O'Mahony, MS | 1 |
| Parmar, M | 2 |
| Langley, RE | 1 |
| Garant, A | 1 |
| Des Groseilliers, S | 1 |
| Martin, L | 1 |
| Ferland, É | 1 |
| Vuong, T | 1 |
| Saridaki, Z | 2 |
| Hongo, K | 3 |
| Tanaka, J | 2 |
| Tsuno, NH | 3 |
| Sunami, E | 5 |
| Kitayama, J | 7 |
| Nagawa, H | 6 |
| Nishibori, N | 1 |
| Itoh, M | 1 |
| Kashiwagi, M | 1 |
| Arimochi, H | 1 |
| Morita, K | 1 |
| Yao, W | 1 |
| Xiong, Y | 1 |
| Nie, L | 1 |
| do O, N | 1 |
| Fuchs, R | 2 |
| Bubenzer, J | 1 |
| Spannbauer, M | 1 |
| Luedde, T | 1 |
| Trautwein, C | 1 |
| Tischendorf, JJ | 1 |
| Baraniskin, A | 1 |
| Munding, J | 1 |
| Meier, D | 1 |
| Putzu, C | 2 |
| Sandomenico, C | 3 |
| Vessia, G | 1 |
| Ionta, MT | 1 |
| Barbato, E | 1 |
| Dennie, TW | 1 |
| Fleming, RA | 1 |
| Bowen, CJ | 1 |
| Dar, MM | 1 |
| Alberti, D | 1 |
| Oliver, K | 1 |
| Loconte, N | 1 |
| Mulkerin, D | 1 |
| Paule, I | 2 |
| Boc, M | 1 |
| Khelwatty, SA | 1 |
| Seddon, AM | 1 |
| Modjtahedi, H | 1 |
| Huang, SM | 1 |
| Chien, CC | 1 |
| Lee, CL | 1 |
| Wu, HH | 1 |
| Nyström, H | 1 |
| Naredi, P | 3 |
| Hafström, L | 7 |
| Sund, M | 1 |
| Johnston, L | 1 |
| McCloskey, K | 1 |
| Heun, JM | 1 |
| Branda, ME | 1 |
| Asseburg, C | 2 |
| Frank, M | 1 |
| Griebsch, I | 2 |
| Mohr, A | 1 |
| Osowski, U | 1 |
| Schulten, J | 1 |
| Mittendorf, T | 1 |
| Hwang, WL | 1 |
| Yang, MH | 1 |
| Tsai, ML | 1 |
| Su, SH | 1 |
| Wang, HW | 1 |
| Hewish, M | 1 |
| Wilson, RH | 5 |
| Kenny, SL | 3 |
| Mitchell, JK | 1 |
| Jasani, B | 1 |
| James, MD | 1 |
| Kennedy, MJ | 3 |
| Claes, B | 1 |
| Hodgkinson, E | 1 |
| Pope, M | 1 |
| Rogers, P | 1 |
| Bessell, EM | 2 |
| Bot, BM | 1 |
| Thomas, DM | 1 |
| Bleyer, A | 1 |
| Chua, A | 1 |
| Shivasami, A | 1 |
| Wilson, BJ | 1 |
| Schatton, T | 1 |
| Zhan, Q | 1 |
| Saab, KR | 1 |
| Schanche, R | 1 |
| Waaga-Gasser, AM | 2 |
| Gold, JS | 1 |
| Murphy, GF | 1 |
| Frank, MH | 1 |
| Frank, NY | 1 |
| Ross, JS | 1 |
| Brown, C | 1 |
| Ransom, DT | 1 |
| Jeffrey, GM | 1 |
| Buck, M | 1 |
| Lowenthal, RM | 1 |
| Boland, A | 1 |
| Galluccio, N | 1 |
| Manzoni, M | 1 |
| Danova, M | 2 |
| O'Connor, JP | 1 |
| Rose, CJ | 1 |
| Jackson, A | 1 |
| Watson, Y | 1 |
| Cheung, S | 1 |
| Maders, F | 1 |
| Whitcher, BJ | 1 |
| Roberts, C | 1 |
| Buonaccorsi, GA | 1 |
| Thompson, G | 1 |
| Clamp, AR | 1 |
| Jayson, GC | 1 |
| Parker, GJ | 1 |
| Adamsen, BL | 1 |
| Kravik, KL | 2 |
| De Angelis, PM | 2 |
| Saito, S | 2 |
| Kanazawa, T | 3 |
| Kazama, S | 2 |
| Yazawa, K | 3 |
| Larsen, O | 1 |
| Kobunai, T | 3 |
| Iinuma, H | 3 |
| Horie, H | 1 |
| Urick, ME | 1 |
| Chung, EJ | 1 |
| Shield, WP | 1 |
| Gerber, N | 1 |
| White, A | 1 |
| Sowers, A | 1 |
| Thetford, A | 1 |
| Camphausen, K | 1 |
| Citrin, DE | 1 |
| Zalinski, S | 1 |
| Mariette, C | 1 |
| Farges, O | 2 |
| Henriksen, T | 1 |
| Farias, IL | 1 |
| Farias, JG | 1 |
| Rossato, L | 1 |
| Araújo, MC | 1 |
| Chiesa, J | 1 |
| Morsh, V | 1 |
| Schetinger, MR | 1 |
| Chan, JY | 1 |
| Qureshi, A | 1 |
| Verma, A | 1 |
| Landau, D | 1 |
| Gallant, JN | 1 |
| Allen, JE | 1 |
| Smith, CD | 1 |
| Dicker, DT | 1 |
| Dolloff, NG | 1 |
| Navaraj, A | 1 |
| Ankerst, DP | 1 |
| Farr, GH | 1 |
| Maples, WJ | 1 |
| Rubin, J | 7 |
| Fuloria, J | 1 |
| Steen, PD | 1 |
| Tse, VC | 1 |
| Ng, WT | 1 |
| Lee, V | 1 |
| Lee, AW | 1 |
| Chua, DT | 1 |
| Chau, J | 1 |
| McGhee, SM | 1 |
| Kuwahara, A | 1 |
| Kadoyama, K | 1 |
| Inokuma, T | 1 |
| Takemoto, Y | 1 |
| Fujishima, Y | 1 |
| Holt, K | 1 |
| Geh, JI | 1 |
| Ma, YT | 1 |
| Almeida da Cruz, L | 1 |
| Ferrari, CL | 1 |
| Riechelmann, RS | 1 |
| de Andrade, DP | 1 |
| Lima, AD | 1 |
| Afonso, S | 2 |
| Viani, G | 1 |
| Afonso, V | 1 |
| Stefano, E | 1 |
| Rocha, JA | 1 |
| Butera, A | 2 |
| Di Lucca, G | 1 |
| De Pauli, F | 1 |
| Parra, HS | 1 |
| Bethke, A | 1 |
| Kühne, K | 1 |
| Platzek, I | 1 |
| Sasaki, H | 1 |
| Matsueda, S | 1 |
| Mizota, A | 1 |
| Kondo, C | 2 |
| Nomura, M | 1 |
| Mehta, SS | 1 |
| Hessissen, M | 1 |
| Saint-Aubert, B | 1 |
| Lee, HN | 1 |
| Lim, Y | 1 |
| Won, HS | 1 |
| Chun, SH | 1 |
| Tateishi, U | 1 |
| Kambe, M | 2 |
| Gamo, M | 2 |
| Kanamaru, R | 2 |
| van Houte, BP | 1 |
| Hanauske, AR | 2 |
| Giaccone, G | 5 |
| Winder, T | 2 |
| Trillet-Lenoir, V | 3 |
| Kraemer, S | 1 |
| Veldhuis, GJ | 1 |
| Ten Bokkel Huinink, D | 1 |
| Muller, EW | 2 |
| Horinouchi, Y | 1 |
| Sakurada, T | 1 |
| Tajima, S | 1 |
| Nishisako, H | 1 |
| Teraoka, K | 1 |
| Kujime, T | 1 |
| Kawazoe, K | 1 |
| Minakuchi, K | 1 |
| Akil, H | 1 |
| Nouaille, M | 1 |
| Petit, D | 1 |
| Labrousse, F | 1 |
| Choi, S | 2 |
| Eropkin, PV | 1 |
| Rybakov, EG | 1 |
| Kashnikov, VN | 1 |
| Panina, MV | 1 |
| Polysalov, VN | 1 |
| Rutkin, IO | 1 |
| Krotova, OA | 1 |
| Tlostanova, MS | 1 |
| Jacques, N | 1 |
| Vimond, N | 1 |
| Pierga, JY | 2 |
| Guichard, P | 1 |
| Cvitkovic, F | 2 |
| Farace, F | 1 |
| Cao, B | 1 |
| Li, ST | 1 |
| Deng, WL | 1 |
| Min, BH | 1 |
| Lee, EJ | 1 |
| Yu, HS | 1 |
| Park, CK | 1 |
| Kim, KM | 1 |
| Fukase, K | 1 |
| Skamoto, J | 1 |
| Suzuki, C | 1 |
| Blomqvist, L | 1 |
| Sundin, A | 1 |
| Jacobsson, H | 1 |
| Kishino, T | 1 |
| Rai, K | 1 |
| Tsushima, M | 1 |
| Kudo, K | 1 |
| Mizuta, M | 1 |
| Yonei, T | 1 |
| Yamadori, I | 1 |
| Kiura, K | 1 |
| Ishiguro, S | 2 |
| Hiramatsu, K | 1 |
| Nishio, H | 1 |
| Takeuchi, E | 1 |
| Ebata, T | 1 |
| Nagino, M | 1 |
| Mohammed, TA | 1 |
| Dennie, T | 1 |
| de la Cruz-Morcillo, MA | 1 |
| Valero, ML | 1 |
| Callejas-Valera, JL | 1 |
| Arias-González, L | 1 |
| Melgar-Rojas, P | 1 |
| Galán-Moya, EM | 1 |
| García-Gil, E | 1 |
| García-Cano, J | 1 |
| Sánchez-Prieto, R | 1 |
| Shumaker, GC | 1 |
| Khandelwal, P | 1 |
| Smith, DA | 1 |
| Neubauer, MA | 1 |
| Mehta, N | 1 |
| Watkins, DL | 1 |
| Yassine, MR | 1 |
| Pathak, P | 1 |
| Saam, J | 1 |
| Critchfield, GC | 1 |
| Hamilton, SA | 2 |
| Roa, BB | 1 |
| Wenstrup, RJ | 1 |
| Kaldate, RR | 2 |
| Kuniyoshi, R | 1 |
| Kummar, S | 2 |
| Rose, M | 1 |
| Wadler, S | 14 |
| O'Rourke, M | 2 |
| Brenckman, W | 1 |
| Tilton, R | 1 |
| Cheng, YC | 1 |
| Sehgal, R | 1 |
| Lembersky, BC | 2 |
| Rajasenan, KK | 1 |
| Crandall, TL | 1 |
| Balaban, EP | 2 |
| Pinkerton, RA | 1 |
| Kane, P | 1 |
| Schmotzer, A | 2 |
| Zeh, H | 1 |
| Potter, DM | 1 |
| Teixeira, L | 1 |
| Nitzkorski, JR | 1 |
| Farma, JM | 1 |
| Watson, JC | 2 |
| Siripurapu, V | 1 |
| Zhu, F | 2 |
| Matteotti, RS | 1 |
| Sigurdson, ER | 4 |
| Mayerle, J | 1 |
| Bangerter, M | 1 |
| Sieber, M | 1 |
| Teschendorf, C | 1 |
| Aubele, P | 1 |
| Okumura, T | 1 |
| Ohde, Y | 1 |
| Kondo, H | 4 |
| Yusuf, SW | 1 |
| Wang, JP | 1 |
| Wu, PH | 1 |
| Opdam, FL | 1 |
| Swen, JJ | 1 |
| Wessels, JA | 1 |
| Vijayaraghavan, A | 1 |
| Efrusy, MB | 1 |
| Göke, B | 1 |
| Santas, CC | 1 |
| Abbas, M | 2 |
| Baldi, GG | 1 |
| Tuzi, A | 1 |
| Hassan, S | 1 |
| Laryea, D | 1 |
| Felth, J | 1 |
| Fryknäs, M | 1 |
| Fayad, W | 1 |
| Linder, S | 1 |
| Rickardson, L | 1 |
| Gullbo, J | 1 |
| Larsson, R | 1 |
| Rubie, C | 1 |
| Frick, VO | 1 |
| Ghadjar, P | 1 |
| Justinger, C | 1 |
| Graeber, S | 1 |
| Kollmar, O | 1 |
| Schilling, MK | 1 |
| Kawase, Y | 1 |
| Takami, Y | 1 |
| Mizuno, A | 1 |
| Uno, Y | 1 |
| Sasada, Y | 1 |
| Takamura, S | 1 |
| Kozaki, K | 1 |
| Bonnefoy, M | 1 |
| Brødbæk, K | 1 |
| Orosz, E | 1 |
| Lam, VW | 1 |
| Spiro, C | 1 |
| Laurence, JM | 1 |
| Johnston, E | 1 |
| Hollands, MJ | 1 |
| Pleass, HC | 1 |
| Richardson, AJ | 1 |
| Farrar, WL | 1 |
| Sheikh, HS | 1 |
| Gingrich, R | 1 |
| Finnberg, NK | 1 |
| Mohapatra, P | 1 |
| Preet, R | 1 |
| Choudhuri, M | 1 |
| Choudhuri, T | 1 |
| Kundu, CN | 1 |
| Fromm, AL | 1 |
| Sun, AM | 1 |
| Wang, LH | 1 |
| He, MR | 1 |
| Kumar, RV | 1 |
| Sinha, VR | 2 |
| Jego, G | 1 |
| Joly, AL | 1 |
| Gobbo, J | 1 |
| Penard-Lacronique, V | 1 |
| Zouali, H | 1 |
| Tubacher, E | 1 |
| Kirzin, S | 1 |
| Tiret, E | 1 |
| Muratore, A | 3 |
| Zimmitti, G | 2 |
| Mellano, A | 1 |
| Ternant, D | 1 |
| Piller, F | 1 |
| Vignault-Desvignes, C | 1 |
| Guan, ZZ | 3 |
| Liang, J | 3 |
| Qin, SK | 2 |
| Qi, C | 1 |
| Decosta, L | 1 |
| Egashira, A | 1 |
| Toyama, T | 1 |
| Ohga, T | 1 |
| Kohakura, F | 1 |
| Niwa, K | 2 |
| Kohnoe, S | 6 |
| Nemunaitis, J | 2 |
| Vukelja, SJ | 2 |
| Hagenstad, C | 1 |
| Campos, LT | 1 |
| Hermann, RC | 2 |
| Sportelli, P | 1 |
| Gardner, L | 1 |
| Gormley, JA | 1 |
| Hegarty, SM | 1 |
| O'Grady, A | 1 |
| Stevenson, MR | 1 |
| Burden, RE | 1 |
| Barrett, HL | 1 |
| Scott, CJ | 1 |
| Johnston, JA | 1 |
| Olwill, SA | 1 |
| Yoneda, A | 1 |
| Matsuo, M | 1 |
| Kajiyama, M | 1 |
| Kishikawa, H | 1 |
| Pilgrim, CH | 1 |
| Brettingham-Moore, K | 1 |
| Pham, A | 1 |
| Murray, W | 1 |
| Link, E | 1 |
| Smith, M | 1 |
| Usatoff, V | 1 |
| Evans, PM | 1 |
| Banting, S | 1 |
| Thomson, BN | 1 |
| Phillips, WA | 1 |
| Lacouture, ME | 1 |
| Shearer, H | 1 |
| Iannotti, N | 1 |
| Pillai, MV | 1 |
| Yassine, M | 1 |
| Viret, F | 3 |
| Crapez-Lopez, E | 1 |
| Bleuse, JP | 1 |
| McMahon, J | 1 |
| Cen, P | 1 |
| Du, XL | 1 |
| Ahmad, MZ | 2 |
| Akhter, S | 2 |
| Anwar, M | 2 |
| Singh, A | 3 |
| Ahmad, I | 1 |
| Ain, MR | 1 |
| Jain, GK | 1 |
| Khar, RK | 1 |
| Ahmad, FJ | 2 |
| Coyle, VM | 2 |
| Carson, G | 1 |
| Tatematsu, M | 2 |
| Ishikawa, K | 4 |
| Noma, H | 2 |
| Komlósi, V | 2 |
| Nagy, T | 2 |
| Bienvenu, B | 1 |
| Harker, WG | 1 |
| Birchfield, G | 1 |
| Tokaz, LK | 1 |
| Barrera, D | 1 |
| Conkling, PR | 1 |
| O'Rourke, MA | 2 |
| Reidy, D | 1 |
| Solit, D | 1 |
| Vakiani, E | 1 |
| Scales, A | 1 |
| Zhan, F | 1 |
| Sano, T | 1 |
| Rho, JK | 1 |
| Bousquet, G | 1 |
| Biau, J | 1 |
| Roulin, C | 1 |
| Robine, S | 1 |
| Rahman, M | 1 |
| Chan, AP | 1 |
| Schmid, J | 2 |
| Kehoe, J | 1 |
| Dicker, P | 2 |
| Murray, F | 1 |
| Huber, HJ | 1 |
| Tsuji, S | 1 |
| Midorikawa, Y | 1 |
| Yagi, K | 1 |
| Aburatani, H | 1 |
| Lee, PH | 3 |
| Brienza, S | 17 |
| Gomi, K | 2 |
| Chung, HJ | 1 |
| Esch, A | 1 |
| Perkins, G | 2 |
| Danenberg, K | 4 |
| Goeb, R | 1 |
| Staib, L | 4 |
| Kron, M | 1 |
| Henne-Bruns, D | 3 |
| Danenberg, P | 2 |
| Fujita, M | 5 |
| Minegaki, T | 1 |
| Franko, J | 1 |
| Goldman, CD | 1 |
| Pockaj, BA | 2 |
| Nelson, GD | 1 |
| Pelletier, E | 1 |
| Bhosle, M | 1 |
| Klingman, D | 1 |
| Bradley, WD | 1 |
| Lee, RJ | 1 |
| Schostack, K | 1 |
| Simcox, ME | 1 |
| Lestini, B | 1 |
| Bollag, G | 1 |
| Su, F | 1 |
| Smith, DH | 1 |
| Nygård, SB | 1 |
| Nielsen, KV | 1 |
| Mbatchi, L | 1 |
| Tibbitts, J | 1 |
| Ries, P | 1 |
| Norguet, E | 1 |
| Iliadis, A | 3 |
| Ouafik, L | 1 |
| Bellot, GL | 1 |
| Tan, WH | 1 |
| Tay, LL | 1 |
| Koh, D | 1 |
| Kan, S | 1 |
| Maeda, Y | 5 |
| Kamei, R | 1 |
| Maeda, N | 1 |
| Tominaga, H | 1 |
| Kashiwagi, S | 1 |
| Fuyuhiro, Y | 1 |
| Ishibashi, H | 1 |
| Sako, S | 1 |
| Mizumoto, A | 1 |
| Hirano, M | 2 |
| Ichinose, M | 1 |
| Takao, N | 1 |
| Matsuda, N | 1 |
| Togawa, T | 1 |
| Ozamto, Y | 1 |
| Chang-Yun, L | 1 |
| Elnemr, A | 1 |
| Xiao-Jun, Y | 1 |
| Chikatani, K | 1 |
| Amano, K | 2 |
| Iwama, T | 5 |
| Ono, T | 2 |
| Honjou, H | 1 |
| Onouchi, T | 1 |
| Yakabi, K | 1 |
| Manceau, G | 1 |
| Blons, H | 1 |
| Shi, Z | 1 |
| Bai, R | 1 |
| Zhu, YL | 1 |
| Wang, RF | 1 |
| Lee, CF | 1 |
| Yu, MC | 1 |
| Lee, WC | 1 |
| Kato, S | 6 |
| Ozeki, M | 1 |
| Hossain, AM | 2 |
| Stoffregen, C | 1 |
| Nicol, S | 1 |
| Samuel, T | 1 |
| Fadlalla, K | 1 |
| Mosley, L | 1 |
| Katkoori, V | 1 |
| Turner, T | 1 |
| Manne, U | 1 |
| Munakata, M | 4 |
| Yanai, T | 2 |
| Stoll, C | 1 |
| Kemper, K | 1 |
| Rodermond, H | 1 |
| Colak, S | 1 |
| Grandela, C | 1 |
| Hu-Lieskoven, S | 1 |
| Kahn, M | 2 |
| Teo, JL | 1 |
| Shriki, J | 1 |
| Stebbing, J | 1 |
| Martínez de Prado, P | 2 |
| Arrivi, A | 3 |
| Lacasta, A | 1 |
| Llanos, M | 1 |
| Antón, A | 9 |
| Miano, ST | 1 |
| Marzocca, G | 2 |
| Tabuse, K | 1 |
| Nakatani, Y | 1 |
| Fukiage, O | 1 |
| Makrantonakis, P | 1 |
| Xynogalos, S | 1 |
| Christophyllakis, Ch | 1 |
| Mwenifumbo, JC | 1 |
| Cheung, PY | 1 |
| Paul, JE | 1 |
| Ally, AA | 1 |
| Miao, L | 1 |
| Lee, A | 1 |
| Severson, T | 1 |
| Cheng, GS | 1 |
| Novik, K | 1 |
| Moore, R | 1 |
| Luk, M | 1 |
| Owen, D | 2 |
| Brown, CJ | 1 |
| Qing, H | 1 |
| Che, Y | 1 |
| Ferrero, A | 1 |
| Langella, S | 1 |
| Russolillo, N | 1 |
| Vigano', L | 1 |
| Lo Tesoriere, R | 1 |
| Tsai, WS | 1 |
| Hsieh, PS | 3 |
| Yeh, CY | 3 |
| Changchien, CR | 5 |
| Gaya, A | 1 |
| Tse, V | 1 |
| Manca, A | 1 |
| Bravo Vergel, Y | 1 |
| Meade, A | 1 |
| Stephens, R | 1 |
| Sculpher, MJ | 1 |
| Broadbridge, V | 1 |
| Jain, K | 1 |
| Luke, C | 1 |
| Atreya, CE | 1 |
| Ducker, GS | 1 |
| Feldman, ME | 1 |
| Bergsland, EK | 1 |
| Warren, RS | 4 |
| Shokat, KM | 1 |
| Biondani, P | 1 |
| Marchianò, A | 1 |
| Jin, CH | 1 |
| Wang, AH | 1 |
| Chen, JM | 1 |
| Li, RX | 1 |
| Wang, GP | 3 |
| Xing, LQ | 1 |
| Burtness, B | 1 |
| Mintzer, D | 1 |
| Ruth, K | 1 |
| Tuttle, H | 1 |
| Sylvester, J | 1 |
| Xu, HX | 2 |
| Li, CG | 2 |
| Tang, JH | 1 |
| Bhattacharya, D | 1 |
| Easthall, C | 1 |
| Willoughby, KA | 1 |
| Small, M | 1 |
| Watson, S | 1 |
| Cazier, JB | 1 |
| Crous-Bou, M | 1 |
| Guinó, E | 3 |
| González, D | 1 |
| Gonzalo, V | 1 |
| Rodrigo, L | 1 |
| Brea-Fernández, A | 1 |
| Xicola, R | 1 |
| Xia, H | 1 |
| Collette, L | 3 |
| Nishida, N | 1 |
| Mimori, K | 2 |
| Sudo, T | 1 |
| Tanaka, F | 2 |
| Shibata, K | 3 |
| Feng, WM | 1 |
| Tang, CW | 1 |
| Huang, SX | 1 |
| Zheng, YY | 1 |
| Bao, Y | 1 |
| Tao, YL | 1 |
| Laroche-Clary, A | 1 |
| Kauffmann, A | 1 |
| Laurand-Quancard, A | 1 |
| Evrard, S | 1 |
| Chandramathi, S | 1 |
| Suresh, K | 1 |
| Anita, ZB | 1 |
| Welch, S | 1 |
| Krzyzanowska, MK | 1 |
| Knox, J | 1 |
| Feld, R | 3 |
| MacKay, H | 1 |
| Petronis, J | 1 |
| Fujishima, H | 2 |
| Hong, X | 1 |
| Lou, C | 1 |
| Yoshizaki, K | 1 |
| Fujii, S | 2 |
| Nakajima, K | 3 |
| Sugito, M | 1 |
| Haregewoin, A | 1 |
| Grier, CE | 1 |
| Tojima, Y | 1 |
| Suzumura, K | 2 |
| Naganuma, T | 1 |
| Kwok, CS | 2 |
| Matthews, V | 1 |
| Wawruch, P | 1 |
| Loke, YK | 1 |
| Assy, N | 1 |
| Basher, W | 1 |
| Chetver, L | 1 |
| Shnaider, J | 1 |
| Zidan, J | 1 |
| Qian, ZY | 1 |
| D'Hoore, A | 1 |
| Fieuws, S | 1 |
| Bertrand, C | 1 |
| Legendre, H | 2 |
| Kerger, J | 1 |
| Chen, XF | 1 |
| Yin, YM | 1 |
| Røe, OD | 1 |
| Zhu, LJ | 1 |
| Guo, RH | 1 |
| Shu, YQ | 1 |
| Weber, T | 1 |
| Roitman, M | 1 |
| Tada, N | 2 |
| Nirei, T | 2 |
| Lechuga, MJ | 3 |
| Hirohashi, T | 1 |
| Shibata, A | 1 |
| Hashigaki, S | 2 |
| Lee, KA | 1 |
| Nam, YS | 1 |
| Oh, YH | 1 |
| Macedo, LT | 1 |
| da Costa Lima, AB | 1 |
| Hori, N | 1 |
| Murakoshi, K | 1 |
| Yokote, N | 1 |
| Park, LC | 1 |
| Kang, MJ | 2 |
| Gil-Calle, S | 2 |
| Cabrera, E | 1 |
| Gómez, MJ | 1 |
| Guasch, I | 3 |
| Etxeberría, A | 1 |
| Alfaro, J | 1 |
| Sarac, SB | 1 |
| Rasmussen, CH | 1 |
| Thirstrup, S | 1 |
| Colding-Jørgensen, M | 1 |
| Mosekilde, E | 1 |
| Büchel, B | 1 |
| Rhyn, P | 1 |
| Schürch, S | 1 |
| Bühr, C | 1 |
| Brittain, EH | 1 |
| Fay, MP | 1 |
| Follmann, DA | 1 |
| Tarver, K | 1 |
| Conibear, J | 1 |
| Sigurdsson, F | 1 |
| Kure, E | 1 |
| Birkemeyer, E | 1 |
| Starkhammar, H | 7 |
| Erdal, AB | 1 |
| Christoffersen, T | 1 |
| Conlon, S | 1 |
| Cummins, RJ | 1 |
| Hennebelle, I | 2 |
| El Hannani, C | 1 |
| Jacob, JH | 3 |
| Coudert, B | 5 |
| Mormont, MC | 2 |
| Waterhouse, J | 2 |
| Richardson, PG | 1 |
| Kolesar, J | 1 |
| Hideshima, T | 1 |
| Anderson, KC | 1 |
| Ng, SL | 1 |
| Burns, WI | 1 |
| Snyder, RD | 1 |
| Newnham, GM | 1 |
| McLachlan, SA | 1 |
| Liew, D | 1 |
| Dowling, AJ | 1 |
| Fujinaka, Y | 1 |
| Morita, M | 3 |
| Dexiang, Z | 1 |
| Haifu, W | 1 |
| Yunshi, Z | 1 |
| Qinghai, Y | 1 |
| Shenyong, Z | 1 |
| Bo, X | 1 |
| Xiangou, P | 1 |
| Haohao, L | 1 |
| Lechi, Y | 1 |
| Tianshu, L | 1 |
| Jia, F | 1 |
| Xinyu, Q | 1 |
| Jianmin, X | 1 |
| Metzger, T | 1 |
| Tatum, C | 1 |
| Sharma, V | 1 |
| Mizutani, N | 1 |
| Lawal, TO | 1 |
| Farris, AB | 1 |
| Subramanian, RM | 1 |
| Arii, S | 1 |
| Nie, YL | 1 |
| Zhang, MM | 1 |
| Li, YL | 1 |
| Chen, JR | 1 |
| Márquez, E | 1 |
| Rodríguez, E | 1 |
| Pascual, J | 1 |
| Alejandro, LM | 1 |
| Behrendt, CE | 1 |
| Openshaw, H | 1 |
| Qiu, W | 2 |
| Xiang, J | 3 |
| Wei, H | 2 |
| Sui, A | 2 |
| Muldoon, C | 1 |
| Mehigan, B | 1 |
| Vandebroek, A | 1 |
| Deleu, I | 1 |
| Vergauwe, P | 2 |
| Efira, A | 1 |
| Kidwell, KM | 1 |
| Ganz, PA | 1 |
| Land, SR | 1 |
| Ko, CY | 1 |
| Cecchini, RS | 1 |
| Kopec, JA | 1 |
| Bleichrodt, RP | 2 |
| Apollinari, S | 1 |
| Abbruzzese, A | 2 |
| Sperlongano, P | 1 |
| Fukasawa, T | 1 |
| Tabe, Y | 1 |
| Kigure, W | 2 |
| Saraymen, R | 1 |
| Yasuda, T | 6 |
| Shinmura, K | 1 |
| Yokomizo, K | 1 |
| Sakuraba, K | 1 |
| Kitamura, Y | 1 |
| Shirahata, A | 1 |
| Saito, M | 1 |
| Kigawa, G | 1 |
| Nemoto, H | 1 |
| Sanada, Y | 1 |
| Feng, JP | 1 |
| Zhu, YM | 1 |
| Ye, DW | 1 |
| Yeo, SG | 1 |
| Kim, KH | 1 |
| Cho, MJ | 1 |
| Kim, ES | 1 |
| Yoo, BC | 1 |
| Ferdinande, L | 1 |
| Libbrecht, L | 1 |
| Ida, S | 1 |
| Ogasawara, N | 1 |
| Esumi, H | 1 |
| Kwok, A | 1 |
| Patt, YZ | 5 |
| Barroso, E | 1 |
| Nuzzo, G | 4 |
| Laurent, C | 1 |
| Ijzermans, JN | 1 |
| Figueras, J | 3 |
| Mirza, DF | 2 |
| Isoniemi, H | 1 |
| Herrera, J | 1 |
| Sousa, FC | 1 |
| Pardo, F | 2 |
| Popescu, I | 1 |
| Bauer, KM | 1 |
| Lambert, PA | 1 |
| Hummon, AB | 1 |
| Cetin, B | 2 |
| Ozturk, SC | 1 |
| Benekli, M | 5 |
| Coskun, U | 5 |
| Goyer, P | 1 |
| Hajjam, ME | 1 |
| Maestro, ML | 1 |
| Karaca, B | 1 |
| Sezgin, C | 1 |
| Gulec, SA | 1 |
| Pennington, K | 1 |
| Wheeler, J | 1 |
| Barot, TC | 1 |
| Suthar, RR | 1 |
| Schwartzentruber, D | 1 |
| Kapaun, C | 1 |
| Wollenberg, A | 1 |
| Farid, M | 1 |
| Chowbay, B | 1 |
| Ramasamy, S | 1 |
| Orsucci, D | 1 |
| Pizzanelli, C | 1 |
| Calabrese, R | 1 |
| Ricci, G | 1 |
| Lenzi, P | 1 |
| Petrozzi, L | 1 |
| Moretti, P | 1 |
| Siciliano, G | 1 |
| Yin, XG | 1 |
| Xu, JF | 2 |
| Cheng, LZ | 1 |
| Lee, EK | 1 |
| Revil, C | 1 |
| Ngoh, CA | 1 |
| Lister, J | 1 |
| Kwon, JM | 1 |
| Lee, NS | 1 |
| Bae, EJ | 1 |
| Treska, V | 1 |
| Safranek, J | 1 |
| Lysak, D | 1 |
| Mirka, H | 1 |
| Skalicky, T | 1 |
| Slauf, F | 1 |
| Hes, O | 1 |
| Shi, MM | 1 |
| Dellas, K | 1 |
| Reese, T | 1 |
| Richter, M | 2 |
| Dunst, J | 2 |
| Capitain, O | 2 |
| Asevoaia, A | 1 |
| Poirier, AL | 2 |
| Takanashi, K | 1 |
| Katsuki, S | 1 |
| Fujita, T | 1 |
| Waga, E | 1 |
| Shimodate, Y | 1 |
| Someya, T | 1 |
| Ustuner, Z | 2 |
| Akay, OM | 1 |
| Keskin, M | 1 |
| Kuş, E | 1 |
| Bal, C | 1 |
| Gulbas, Z | 1 |
| Ku, GY | 1 |
| Haaland, BA | 1 |
| de Lima Lopes, G | 1 |
| Guo, ST | 1 |
| Jiang, CC | 1 |
| Guo, XY | 1 |
| Yang, RH | 1 |
| Tseng, HY | 1 |
| Thorne, RF | 1 |
| Zhang, XD | 2 |
| Mochinaga, S | 1 |
| Okahashi, T | 1 |
| Koga, S | 2 |
| Yakabe, T | 1 |
| Sumi, K | 1 |
| Kitahara, K | 2 |
| Noshiro, H | 1 |
| Kimura, S | 1 |
| Fujito, H | 1 |
| Hisa, A | 1 |
| Alkis, N | 2 |
| Ciltas, A | 1 |
| Yetisyigit, T | 2 |
| Dogu, GG | 1 |
| Liu, ZC | 1 |
| Liu, JG | 1 |
| Dugué, PA | 1 |
| Eleftheraki, AG | 1 |
| Nikitas, N | 1 |
| Papandreou, CN | 1 |
| Timotheadou, E | 2 |
| Koutras, A | 2 |
| Klouvas, G | 1 |
| Tsukioka, Y | 1 |
| Yabushita, K | 3 |
| Fukuoka, J | 1 |
| Shiraishi, K | 1 |
| Murakawa, Y | 2 |
| Gafson, AR | 1 |
| Goodkin, O | 1 |
| Begent, R | 1 |
| Doornebal, J | 1 |
| Lemmens, W | 1 |
| Corrie, PG | 1 |
| Bulusu, R | 1 |
| Wilson, CB | 1 |
| Armstrong, G | 1 |
| Bond, S | 1 |
| Hardy, R | 1 |
| Lao-Sirieix, S | 1 |
| Parashar, D | 1 |
| Blesing, C | 1 |
| Moody, AM | 1 |
| McAdam, K | 2 |
| Osborne, M | 1 |
| Mo, Y | 1 |
| Patel, K | 2 |
| Yerram, SR | 1 |
| Azad, NA | 1 |
| Julien, S | 1 |
| Merino-Trigo, A | 1 |
| Landron, S | 1 |
| Bigot, L | 1 |
| Lantuas, D | 1 |
| Morgand, L | 1 |
| Pham, E | 1 |
| Gonin, P | 1 |
| Job, B | 1 |
| Dessen, P | 1 |
| Bruno, A | 1 |
| Pierré, A | 1 |
| De Thé, H | 1 |
| Soliman, H | 1 |
| Nunes, M | 1 |
| Lardier, G | 1 |
| Calvet, L | 1 |
| Demers, B | 1 |
| Prévost, G | 2 |
| Vrignaud, P | 1 |
| Roman-Roman, S | 1 |
| Duchamp, O | 1 |
| Berthet, C | 1 |
| Valentino, JD | 1 |
| Elliott, VA | 1 |
| Zaytseva, YY | 1 |
| Rychahou, PG | 1 |
| Mustain, WC | 1 |
| Evers, BM | 1 |
| Prasad, S | 1 |
| Yadav, VR | 1 |
| Sung, B | 1 |
| Reuter, S | 1 |
| Kannappan, R | 1 |
| Wei, C | 1 |
| Baladandayuthapani, V | 1 |
| Glockzin, G | 2 |
| von Breitenbuch, P | 1 |
| Zhang, HX | 1 |
| Xu, LX | 1 |
| Zhang, ZQ | 1 |
| Yuan, KT | 1 |
| Xue, CL | 1 |
| Yu, HL | 1 |
| Shi, HP | 1 |
| Salut, A | 3 |
| León, AI | 1 |
| Sevilla, I | 3 |
| Esteban, B | 1 |
| García-Rico, E | 1 |
| Murias, A | 1 |
| Cortés-Funes, H | 5 |
| Nacle-López, I | 1 |
| García-Escobar, I | 1 |
| Aguilella-Vizcaíno, MJ | 1 |
| Herreros-de-Tejada, A | 1 |
| Cortés-Funes Castro, H | 1 |
| Calleja-Hernández, MÁ | 1 |
| Bollet, MA | 1 |
| Servois, V | 1 |
| Zefkili, S | 1 |
| Farkhondeh, F | 2 |
| Baranger, B | 1 |
| Turkington, R | 1 |
| Zanusso, C | 1 |
| Errante, D | 2 |
| Garassino, MC | 1 |
| Ishiyama, A | 1 |
| Eguchi, T | 3 |
| Uchida, N | 1 |
| Hosouchi, Y | 1 |
| Yashuda, N | 1 |
| Harris, DR | 1 |
| Mims, A | 1 |
| Bunz, F | 2 |
| Wienke, A | 1 |
| Edelmann, T | 1 |
| Hollerbach, S | 1 |
| Kitamura, H | 1 |
| Koike, S | 2 |
| Nakazawa, K | 1 |
| Matsumura, H | 1 |
| Yokoi, K | 2 |
| Arai, M | 1 |
| Nishizuka, SS | 1 |
| Kume, K | 1 |
| Endo, F | 1 |
| Katagiri, H | 1 |
| Noda, H | 1 |
| Iwaya, T | 1 |
| Itabashi, T | 1 |
| Maesawa, C | 1 |
| Tamura, G | 1 |
| Koeda, K | 1 |
| Wakabayashi, G | 1 |
| Jin, HR | 1 |
| Liao, Y | 1 |
| Huang, WH | 1 |
| Li, SP | 1 |
| Hamada, M | 1 |
| Okigami, M | 1 |
| Morimoto, Y | 1 |
| Matsushita, K | 2 |
| Kawamura, M | 1 |
| Hashimoto, K | 1 |
| Saigusa, S | 1 |
| Araki, T | 1 |
| Mohri, Y | 1 |
| Mizoguchi, A | 1 |
| Rong, R | 1 |
| Mo, L | 1 |
| Kuang, Y | 1 |
| Tao, Q | 1 |
| Dong, Q | 1 |
| Nichols, LL | 1 |
| Pettersson, K | 1 |
| Holmberg, C | 1 |
| Sporrong, SK | 1 |
| Ambrosy, AP | 1 |
| Kunz, PL | 1 |
| Witteles, RM | 1 |
| Mima, K | 1 |
| Kuroki, H | 1 |
| Kikuchi, K | 3 |
| Moiseyenko, V | 1 |
| Polikoff, J | 2 |
| Tellier, A | 1 |
| Castan, R | 1 |
| Jiang, WQ | 1 |
| Fu, FF | 1 |
| Li, YX | 1 |
| Wang, WB | 1 |
| Wang, HH | 1 |
| Jiang, HP | 1 |
| Teng, LS | 1 |
| Honoré, C | 1 |
| Tzanis, D | 1 |
| Park, C | 1 |
| Fajardo, AD | 1 |
| Tan, B | 1 |
| Reddy, R | 2 |
| Fleshman, J | 1 |
| Lacunza, E | 1 |
| Canzoneri, R | 1 |
| Rabassa, ME | 1 |
| Zwenger, A | 1 |
| Segal-Eiras, A | 1 |
| Croce, MV | 1 |
| Abba, MC | 1 |
| Koski, SL | 1 |
| Barker, P | 1 |
| Mookerjee, B | 1 |
| Koynov, KD | 1 |
| Pike, L | 1 |
| Fielding, A | 1 |
| Wu, XL | 1 |
| Zhang, LW | 1 |
| Chen, SS | 2 |
| Garrett, C | 1 |
| Aloia, TA | 2 |
| Wernroth, L | 1 |
| Johansson, B | 1 |
| Larsson, A | 1 |
| Woloch, C | 1 |
| Marouani, H | 1 |
| Hamdi, S | 1 |
| Graf, C | 1 |
| Hainz, M | 1 |
| Theobald, M | 1 |
| Adler, K | 1 |
| Trojan, D | 1 |
| Bombled, M | 1 |
| Méchighel, P | 1 |
| Muleris, M | 1 |
| de Reynies, A | 1 |
| Florent, JC | 1 |
| Mahuteau-Betzer, F | 1 |
| Faussat, AM | 1 |
| Lieberman, R | 1 |
| Tezcan, H | 1 |
| Roach, N | 1 |
| Mun, Y | 1 |
| Fish, S | 1 |
| Flick, ED | 1 |
| Dalal, D | 1 |
| Saelen, MG | 1 |
| Ree, AH | 2 |
| Kristian, A | 1 |
| Fleten, KG | 1 |
| Furre, T | 1 |
| Hektoen, HH | 1 |
| Uguen, T | 1 |
| Leconte, B | 1 |
| Desgrippes, R | 1 |
| Tchoundeu, B | 1 |
| Bretagne, JF | 1 |
| Baños, A | 1 |
| Constantinidou, A | 1 |
| Shurmahi, F | 1 |
| Asghar, U | 1 |
| Rossi, L | 1 |
| Veltri, E | 1 |
| Zullo, A | 1 |
| Colonna, M | 1 |
| Di Seri, M | 4 |
| Giannarelli, D | 7 |
| Ruco, L | 1 |
| Barucca, V | 1 |
| Adua, D | 1 |
| Tomao, S | 1 |
| Gencer, D | 1 |
| Wolf, PS | 1 |
| Bao, F | 1 |
| Tzeng, CW | 1 |
| Lyseng-Williamson, KA | 1 |
| Kao, TY | 1 |
| Tsai, YW | 1 |
| Rocha Lima, CM | 1 |
| Bayraktar, S | 1 |
| Flores, AM | 1 |
| MacIntyre, J | 1 |
| Montero, A | 1 |
| Baranda, JC | 1 |
| Wallmark, J | 1 |
| Raja, R | 1 |
| Stern, H | 1 |
| Amler, LC | 1 |
| Ying, HY | 1 |
| Yang, XD | 1 |
| Ning, XH | 1 |
| Chaturvedi, K | 1 |
| Tripathi, SK | 1 |
| Kulkarni, AR | 1 |
| Aminabhavi, TM | 1 |
| Mackey, HM | 1 |
| Yauch, RL | 1 |
| Graham, RA | 1 |
| Bray, GL | 1 |
| Low, JA | 1 |
| King, TM | 1 |
| Chang, MC | 1 |
| Hatwell, C | 1 |
| Bretagnol, F | 1 |
| Panis, Y | 2 |
| Demolin, G | 2 |
| Kreutz, F | 6 |
| Graas, MP | 4 |
| Longrée, L | 5 |
| Matus, G | 1 |
| Moeneclaey, N | 5 |
| Focan-Henrard, D | 7 |
| Sairanen, U | 1 |
| Blom, M | 1 |
| Rautio, M | 1 |
| Saxelin, M | 2 |
| Chachad, S | 1 |
| Purandare, S | 1 |
| Malhotra, G | 1 |
| Naidu, R | 1 |
| Tran, TH | 1 |
| Rui, H | 1 |
| Knudsen, ES | 1 |
| Elsaleh, H | 6 |
| Fluge, Ø | 1 |
| Vonen, B | 2 |
| Myrvold, HE | 1 |
| Deboever, G | 1 |
| Hiltrop, N | 1 |
| Cool, M | 1 |
| Lambrecht, G | 1 |
| Odejide, O | 1 |
| Szymonifka, J | 1 |
| Hezel, A | 1 |
| Bates, DO | 1 |
| Symonds, KE | 1 |
| Varey, AH | 1 |
| Ramani, P | 1 |
| Giantonio, BJ | 3 |
| Harper, SJ | 1 |
| Lucchetta, M | 1 |
| Gouillou, M | 1 |
| Jefford, M | 2 |
| McArthur, G | 1 |
| Copeman, M | 1 |
| Lynch, K | 1 |
| Lee, SS | 2 |
| Curran, D | 1 |
| Sartorius, U | 1 |
| Van Praagh, I | 1 |
| Belliere, A | 1 |
| Mouret-Reynier, MA | 1 |
| Kwiatkowski, F | 3 |
| Mahammedi, H | 1 |
| Dillies, AF | 1 |
| Chevrier, R | 2 |
| Francis, WP | 1 |
| Ho, T | 1 |
| Satram-Hoang, S | 1 |
| Lee, L | 1 |
| Guduru, SR | 1 |
| Gunuganti, AR | 1 |
| Reyes, C | 1 |
| Kamata, H | 1 |
| Koisumi, J | 1 |
| Lopez-Ben, S | 1 |
| Alsina, M | 1 |
| Soriano, J | 1 |
| Albiol, M | 1 |
| Guardeño, R | 1 |
| Codina-Barreras, A | 1 |
| Yu, DS | 1 |
| Solvang, H | 1 |
| Androulakis, N | 11 |
| Kabouraki, E | 1 |
| Asayama, M | 1 |
| Chen, JX | 1 |
| Shen, XH | 2 |
| Pox, C | 1 |
| Anai, H | 1 |
| Rouleau, E | 1 |
| Dieumegard, B | 1 |
| Addeo, R | 1 |
| Heberer, M | 1 |
| Cesare Spagnoli, G | 1 |
| Tatsushima, Y | 1 |
| Egashira, N | 1 |
| Narishige, Y | 1 |
| Fukui, S | 1 |
| Kawashiri, T | 1 |
| Oishi, R | 1 |
| Rana, SV | 1 |
| Voboril, Z | 1 |
| Krajina, A | 1 |
| Weiner, P | 1 |
| Nová, M | 1 |
| Ryska, A | 1 |
| Dvorák, J | 1 |
| Kim, G | 2 |
| Jung, EJ | 1 |
| Ryu, CG | 1 |
| Mirakhorli, M | 1 |
| Rahman, SA | 1 |
| Vakili, M | 1 |
| Rozafzon, R | 1 |
| Khoshzaban, A | 1 |
| Uemoto, J | 1 |
| Onodera, K | 1 |
| Bonnet, S | 1 |
| Mansmann, U | 1 |
| Matsui, S | 2 |
| Murao, S | 1 |
| Phua, LC | 1 |
| Mal, M | 1 |
| Koh, PK | 1 |
| Cheah, PY | 1 |
| Chan, EC | 2 |
| Ho, HK | 1 |
| Mummy, D | 1 |
| Koepl, L | 1 |
| Blough, D | 1 |
| Yim, YM | 1 |
| Yu, E | 1 |
| Ramsey, S | 1 |
| Tran, G | 1 |
| Kerr, A | 1 |
| Stokes, L | 1 |
| Lim, SB | 1 |
| Yu, CS | 5 |
| Winograd, E | 1 |
| Papoulas, M | 1 |
| Lahat, G | 1 |
| Klausner, J | 1 |
| Wong, RP | 1 |
| Stone, AM | 1 |
| Nohejlová Medková, A | 1 |
| Kupec, M | 1 |
| Bláha, M | 1 |
| Dong, H | 1 |
| Men, HT | 1 |
| Luo, WX | 1 |
| Ge, J | 1 |
| Tan, BX | 1 |
| Li, XR | 1 |
| Chen, DJ | 1 |
| Wu, JH | 1 |
| Dalzell, JR | 1 |
| Abu-Arafeh, A | 1 |
| Campbell, RT | 1 |
| Gramont, A | 1 |
| Kii, T | 1 |
| Kawabe, S | 2 |
| Kuwakado, S | 1 |
| Asaishi, K | 1 |
| Miyamoto, T | 1 |
| Higuchi, K | 1 |
| Ichanté, JL | 1 |
| Montoto-Grillot, C | 2 |
| Staszewska-Skurczynska, M | 1 |
| De la Cruz, JA | 1 |
| Williams, JA | 1 |
| Korytowsky, B | 1 |
| Christensen, JG | 1 |
| Lichinitser, M | 3 |
| Suresh, AV | 1 |
| Manikhas, G | 1 |
| Warner, D | 1 |
| Jain, R | 1 |
| Nakatsumi, H | 1 |
| Muto, S | 1 |
| Uebayashi, M | 1 |
| Meguro, T | 1 |
| Bélanger, AS | 1 |
| Harvey, M | 1 |
| Nishimaki, T | 1 |
| Harputluoğlu, H | 1 |
| Budakoğlu, B | 1 |
| Öztürk, MA | 1 |
| Köş, T | 1 |
| Dong, X | 1 |
| Cui, B | 1 |
| Stinco, S | 1 |
| Squadroni, M | 1 |
| Ligneau, B | 1 |
| Kraft, D | 1 |
| Descos, L | 1 |
| Maroun, JA | 3 |
| Norum, J | 2 |
| Balteskard, L | 4 |
| Edna, TH | 1 |
| Laino, R | 1 |
| Wählby, L | 2 |
| Rønning, G | 1 |
| Crucitta, E | 2 |
| Del Gaizo, F | 1 |
| Lannelli, A | 1 |
| Mancarella, S | 6 |
| Buzzi, F | 4 |
| De Cataldis, G | 3 |
| Bonino, F | 1 |
| Conte, P | 6 |
| Ricciardiello, L | 1 |
| Bazzoli, F | 1 |
| Itoh, S | 1 |
| Takamatsu, M | 1 |
| Horimi, T | 3 |
| Nan, L | 1 |
| Lindsey, JR | 1 |
| Lai, MD | 1 |
| Gagnadoux, F | 1 |
| Roiron, C | 1 |
| Carrie, E | 1 |
| Monnier-Cholley, L | 1 |
| Lebeau, B | 1 |
| Petak, I | 1 |
| Stewart, C | 1 |
| Turner, PK | 1 |
| Ashley, J | 1 |
| Tillman, DM | 1 |
| Douglas, L | 1 |
| Tan, M | 3 |
| Billups, C | 1 |
| Mihalik, R | 1 |
| Weir, A | 1 |
| Tauer, K | 1 |
| Shope, S | 1 |
| Houghton, JA | 2 |
| Liu, LX | 1 |
| Zhang, WH | 1 |
| Jiang, HC | 1 |
| Zhu, AL | 1 |
| Wu, LF | 1 |
| Qi, SY | 1 |
| Piao, DX | 1 |
| Kelsen, DP | 3 |
| Ilson, D | 1 |
| O'Reilly, E | 3 |
| Zaknoen, S | 1 |
| Baum, C | 1 |
| Statkevich, P | 1 |
| Hollywood, E | 1 |
| Cheeseman, SL | 1 |
| Joel, SP | 3 |
| Chester, JD | 2 |
| Dent, JT | 2 |
| Richards, FJ | 2 |
| Gruber, Y | 1 |
| Corovic, A | 1 |
| Pichlmeier, U | 2 |
| Nierhaus, A | 1 |
| Hossfeld, DK | 2 |
| de las Peñas, R | 1 |
| Vicent, JM | 5 |
| Garcerá, S | 2 |
| Llorca, C | 3 |
| Yuste, AL | 4 |
| Farrés, J | 1 |
| Baldwin, J | 1 |
| Skillings, JR | 2 |
| Davidson, N | 2 |
| Harper, P | 6 |
| Thompson, S | 1 |
| Maniero, A | 1 |
| Benner, SE | 1 |
| Carmichael, J | 5 |
| Popiela, T | 3 |
| Radstone, D | 1 |
| Oza, A | 3 |
| Skovsgaard, T | 4 |
| Munier, S | 1 |
| Martin, C | 4 |
| Ferrari, M | 2 |
| Ohta, M | 1 |
| Mashino, K | 1 |
| Inoue, H | 1 |
| Bogenrieder, T | 1 |
| Weitzel, C | 3 |
| Schölmerich, J | 3 |
| Landthaler, M | 1 |
| Stolz, W | 1 |
| Gennatas, K | 2 |
| Vadiaka, M | 5 |
| Paliaros, P | 1 |
| Dimitrakopoulos, A | 2 |
| Diamantis, T | 1 |
| Tsipras, H | 2 |
| Papastratis, G | 4 |
| Sugitani, M | 2 |
| Nishimura, K | 5 |
| Noguchi, H | 5 |
| Suda, S | 1 |
| Elomaa, I | 4 |
| Repo, H | 1 |
| Boulay, JL | 3 |
| Mild, G | 3 |
| Lowy, A | 3 |
| Reuter, J | 2 |
| Lagrange, M | 1 |
| Terracciano, L | 4 |
| Rochlitz, C | 4 |
| Huang, KC | 3 |
| Lai, HS | 1 |
| Hsu, CH | 2 |
| Chang, KJ | 2 |
| Prabhudesai, AG | 1 |
| Kumar, D | 1 |
| Nagy, A | 1 |
| Monson, J | 1 |
| Moylan, E | 1 |
| Jones, D | 1 |
| Dethling, J | 1 |
| Colman, J | 1 |
| Coward, L | 1 |
| MacGregor, S | 1 |
| Kliche, KO | 1 |
| Kubsch, K | 1 |
| Raida, M | 1 |
| Masri-Zada, R | 1 |
| Höffken, K | 2 |
| Lepille, D | 1 |
| Marre, A | 1 |
| Mignot, L | 1 |
| Hua, A | 1 |
| Méry-Mignard, D | 3 |
| Kornek, GV | 6 |
| Raderer, M | 8 |
| Schüll, B | 3 |
| Schmid, K | 2 |
| Huber, H | 1 |
| Lauria, R | 1 |
| De Laurentiis, M | 1 |
| Arpino, G | 1 |
| Massarelli, E | 1 |
| Ferrara, C | 1 |
| Vernaglia Lombardi, A | 1 |
| Costanzo, R | 1 |
| Catalano, G | 15 |
| Bianco, AR | 4 |
| Calvo, E | 3 |
| Cortés, J | 2 |
| González-Cao, M | 1 |
| Aramendía, JM | 1 |
| Fernández-Hidalgo, O | 2 |
| Martín-Algarra, S | 2 |
| Salgado, JE | 1 |
| Martínez-Monge, R | 2 |
| de Irala, J | 2 |
| Brugarolas, A | 2 |
| Desmoulin, F | 1 |
| Gilard, V | 1 |
| Malet-Martino, M | 1 |
| Martino, R | 1 |
| Bachmann, F | 1 |
| Glatz, K | 1 |
| Yamamura, T | 10 |
| Yabe, K | 1 |
| Oka, H | 5 |
| Kouzuma, T | 1 |
| Wakayama, T | 1 |
| Sugiura, A | 1 |
| Hagiwara, M | 1 |
| Ohdate, K | 1 |
| Okamura, R | 2 |
| Miyahara, T | 1 |
| Moriyama, Y | 1 |
| Gunji, A | 1 |
| Mikami, Y | 3 |
| Yamamura, M | 3 |
| Kubozoe, T | 2 |
| Urakami, A | 3 |
| Kimoto, M | 1 |
| Kaibara, N | 4 |
| Reid, T | 2 |
| Galanis, E | 2 |
| Sze, D | 2 |
| Wein, LM | 1 |
| Andrews, J | 2 |
| Randlev, B | 1 |
| Heise, C | 1 |
| Uprichard, M | 1 |
| Hatfield, M | 2 |
| Rome, L | 1 |
| Kirn, D | 2 |
| Fraker, DL | 2 |
| Soulen, M | 1 |
| Xila, V | 1 |
| Rokana, S | 4 |
| Margaris, E | 1 |
| Zografos, G | 3 |
| Kouraklis, G | 1 |
| Givel, JC | 3 |
| Aellen, S | 1 |
| Moubayed, H | 1 |
| Michetti, P | 1 |
| Dorta, G | 1 |
| Miyanari, N | 2 |
| Collie-Duguid, E | 1 |
| Hartung, G | 2 |
| Samel, S | 1 |
| Emig, M | 1 |
| Pilz, L | 2 |
| Willeke, F | 1 |
| Hehlmann, R | 3 |
| Queisser, W | 3 |
| Leonard, P | 2 |
| Fu, QG | 1 |
| Meng, FD | 1 |
| Shen, XD | 1 |
| Guo, RX | 1 |
| Mainwaring, CJ | 1 |
| Naylor, E | 1 |
| Jerwood, S | 1 |
| Hall, V | 1 |
| Page, A | 1 |
| James, CM | 1 |
| Fisher, MD | 3 |
| D'Orazio, AI | 1 |
| Gambill, BD | 2 |
| Fishman, AD | 1 |
| Bilchik, AJ | 3 |
| Wood, TF | 1 |
| Chawla, SP | 1 |
| Rose, DM | 1 |
| Chung, MH | 1 |
| Stern, SS | 1 |
| Foshag, LJ | 1 |
| Ramming, KP | 1 |
| Chansky, K | 2 |
| Macdonald, JS | 12 |
| Doukas, MA | 1 |
| Budd, GT | 2 |
| Giguere, JK | 1 |
| Rose, MG | 1 |
| Farrell, MP | 2 |
| Shirota, Y | 5 |
| Nihei, Z | 3 |
| Hirayama, R | 3 |
| Marsh, S | 1 |
| Pintilie, M | 1 |
| Jolivet, J | 3 |
| Fields, A | 2 |
| Lee, IM | 1 |
| Rebollo, J | 2 |
| Vincent, M | 4 |
| Whiston, F | 2 |
| Chico, IM | 1 |
| Marsh, JC | 3 |
| Catalano, P | 2 |
| Graham, DL | 1 |
| Cornfeld, MJ | 2 |
| Kjaer, M | 6 |
| Linné, T | 1 |
| Boussard, B | 4 |
| Oulid-Aïssa, D | 1 |
| De Rosa, V | 3 |
| Fiore, F | 2 |
| Lapenta, L | 1 |
| Comella, G | 14 |
| Aschele, C | 14 |
| Debernardis, D | 4 |
| Bandelloni, R | 2 |
| Drudi, G | 1 |
| Gallo, L | 6 |
| Maley, F | 3 |
| Monfardini, S | 3 |
| Violette, S | 1 |
| Festor, E | 1 |
| Pandrea-Vasile, I | 1 |
| Mitchell, V | 1 |
| Adida, C | 1 |
| Dussaulx, E | 1 |
| Lacorte, JM | 1 |
| Chambaz, J | 1 |
| Lacasa, M | 1 |
| Lesuffleur, T | 2 |
| Ishida, Y | 2 |
| Omura, K | 2 |
| Kotake, K | 6 |
| Koyama, Y | 4 |
| Shida, S | 2 |
| Kanazawa, K | 1 |
| Miyata, M | 1 |
| Nagamachi, Y | 1 |
| Iwasaki, Y | 6 |
| Omoto, R | 1 |
| Tamakuma, S | 1 |
| Kitajima, M | 7 |
| Kodaira, S | 8 |
| Cuq, P | 4 |
| Giacometti, S | 3 |
| Pelegrin, A | 2 |
| Aubert, C | 5 |
| Cano, JP | 2 |
| Kouroussis, C | 5 |
| Papadouris, S | 1 |
| Agelaki, S | 6 |
| Panopoulos, C | 1 |
| Sarra, E | 2 |
| Fina, F | 1 |
| Bezulier, K | 1 |
| Roussel, M | 1 |
| Romain, S | 1 |
| Martin, PM | 1 |
| Maung, K | 2 |
| Lee, D | 1 |
| DeGrendele, HC | 1 |
| Schilsky, R | 3 |
| Jain, VK | 1 |
| Copur, S | 1 |
| Johnson, L | 1 |
| Salman, HS | 1 |
| Cynamon, J | 2 |
| Jagust, M | 1 |
| Bakal, C | 1 |
| Rozenblit, A | 2 |
| Kaleya, R | 2 |
| Negassa, A | 1 |
| Hamada, H | 8 |
| Yasuda, D | 2 |
| Takada, J | 3 |
| Katsuki, Y | 11 |
| Ebuchi, M | 5 |
| Nagahama, T | 4 |
| Takashima, I | 3 |
| Natui, S | 1 |
| Nakazaki, H | 3 |
| Hasebe, Y | 2 |
| Takita, W | 1 |
| Seo, A | 1 |
| Takata, M | 1 |
| Teramoto, T | 2 |
| Hirano, K | 1 |
| Soma, I | 1 |
| Kanai, T | 1 |
| Fukuchi, N | 1 |
| Izawa, H | 1 |
| Ebisui, C | 1 |
| Sakita, I | 2 |
| Iizuka, N | 1 |
| Matsuoka, K | 2 |
| Tangoku, A | 1 |
| Natsui, S | 1 |
| Isshi, K | 1 |
| Gen, T | 1 |
| Katuyama, T | 1 |
| Maekawa, Y | 1 |
| Vannozzi, F | 3 |
| Cionini, L | 2 |
| Lieberman, G | 2 |
| Griffing, S | 2 |
| Harsley, SR | 1 |
| Dooley, MJ | 1 |
| Summerhayes, M | 1 |
| Rothmann, M | 2 |
| Chi, GY | 1 |
| Temple, R | 1 |
| Tsou, HH | 1 |
| Ayers, GD | 2 |
| Ohta, S | 1 |
| Katsu, K | 1 |
| Honma, S | 1 |
| Barnett, KT | 1 |
| Malafa, MP | 1 |
| Altuntas, F | 1 |
| Akbulut, KG | 1 |
| Ozturk, G | 1 |
| Cindoruk, M | 1 |
| Zanke, C | 2 |
| Hohl, H | 2 |
| Burg, H | 1 |
| Ehscheid, P | 1 |
| Schwindt, P | 1 |
| Schroeder, M | 2 |
| Klein, O | 3 |
| Baldus, M | 1 |
| Sekine, T | 1 |
| Kazumoto, T | 1 |
| Sakura, M | 1 |
| Madsen, EL | 1 |
| Sandberg, E | 4 |
| Poulsen, JP | 1 |
| Jeng, YM | 1 |
| Wu, MS | 1 |
| Schwinnen, I | 1 |
| Staib-Sebler, E | 6 |
| Gog, C | 4 |
| El-Ganainy, A | 1 |
| Gutt, C | 1 |
| Müller, HH | 8 |
| Hildner, K | 1 |
| Wils, J | 13 |
| Blijham, GH | 6 |
| Wagener, T | 2 |
| De Greve, J | 3 |
| Kok, TC | 1 |
| Couvreur, ML | 2 |
| Genicot, B | 2 |
| Baron, B | 4 |
| Kargman, S | 1 |
| Lam, EC | 1 |
| Kelly, CR | 1 |
| Luk, P | 1 |
| Kwong, E | 1 |
| Evans, JF | 1 |
| Wolfe, MM | 2 |
| Riedel, C | 5 |
| Brückl, W | 2 |
| Ott, R | 3 |
| Hanke, B | 3 |
| Baum, U | 2 |
| Fuchs, F | 1 |
| Günther, K | 1 |
| Reck, T | 2 |
| Papadopoulos, T | 1 |
| McArdle, CS | 13 |
| Taylor, I | 8 |
| Sherlock, DJ | 1 |
| Buckels, J | 2 |
| Mayer, D | 1 |
| Cain, D | 2 |
| Janciauskiene, R | 1 |
| Juozaityte, E | 1 |
| Pavalkis, D | 1 |
| Min, YJ | 1 |
| Tsalic, M | 1 |
| Bar-Sela, G | 2 |
| Beny, A | 1 |
| Visel, B | 1 |
| Haim, N | 3 |
| James, RD | 6 |
| Topham, C | 4 |
| McArdle, C | 1 |
| Stoeltzing, O | 1 |
| Reinmuth, N | 1 |
| Parry, GC | 1 |
| Parikh, AA | 1 |
| McCarty, MF | 1 |
| Bucana, CD | 1 |
| Mazar, AP | 1 |
| Pauler, DK | 1 |
| McCoy, S | 1 |
| Moinpour, C | 1 |
| Tambaro, R | 2 |
| De Maio, E | 1 |
| Pignata, S | 2 |
| Cristaudo, A | 1 |
| Vanni, B | 4 |
| Bria, E | 3 |
| Aschelter, AM | 6 |
| Santucci, B | 1 |
| Terzoli, E | 9 |
| Rao, MS | 1 |
| Segura, A | 2 |
| López-Tendero, P | 1 |
| Gironés, R | 1 |
| Pérez-Fidalgo, JA | 1 |
| Calderero, V | 2 |
| Blair, SL | 1 |
| Grant, M | 1 |
| Chu, DZ | 2 |
| Cullinane, C | 1 |
| Dean, G | 1 |
| Okabe, S | 7 |
| Tanami, H | 1 |
| Fukahara, T | 1 |
| Udagawa, M | 3 |
| Ootsukasa, S | 2 |
| Murase, N | 5 |
| Gieschke, R | 1 |
| Burger, HU | 3 |
| Reigner, B | 5 |
| Blesch, KS | 1 |
| Steimer, JL | 1 |
| Proschek, D | 1 |
| Ridwelski, K | 7 |
| Gassel, HJ | 5 |
| Lehmann, U | 1 |
| Vestweber, KH | 1 |
| Padberg, W | 1 |
| Zamzow, K | 1 |
| Grinev, MV | 1 |
| Umlil, A | 1 |
| Grégoire, N | 1 |
| Lafont, T | 2 |
| Canal, P | 3 |
| Bugat, R | 9 |
| Piedbois, P | 16 |
| Hosie, KB | 1 |
| Gilbert, JA | 1 |
| Downes, M | 2 |
| Lakin, G | 1 |
| Pemberton, G | 1 |
| Timms, K | 1 |
| Young, A | 2 |
| Stanley, A | 1 |
| Selke, B | 1 |
| Lebrun, T | 1 |
| Comte, S | 1 |
| Kovats, E | 2 |
| Schneeweiss, B | 3 |
| Lang, F | 3 |
| Lenauer, A | 3 |
| Depisch, D | 5 |
| Rooney, PH | 1 |
| Taron, M | 3 |
| Shinoura, N | 1 |
| Magné, N | 5 |
| Fischel, JL | 3 |
| Dubreuil, A | 1 |
| Marcié, S | 1 |
| Lagrange, JL | 2 |
| Alimonti, A | 3 |
| Satta, F | 2 |
| Burattini, E | 1 |
| Zoffoli, V | 1 |
| Vecchione, A | 2 |
| Zheng, CX | 1 |
| Zhan, WH | 1 |
| Cai, SR | 1 |
| He, YL | 1 |
| Lin, ZJ | 1 |
| Hidaka, S | 4 |
| Yasutake, T | 5 |
| Haseba, M | 2 |
| Tsuji, T | 6 |
| Nakagoe, T | 6 |
| Ayabe, H | 2 |
| Tagawa, Y | 4 |
| Gutzler, F | 2 |
| Boehme, M | 1 |
| Raeth, U | 2 |
| Stremmel, W | 3 |
| Carrasco, J | 1 |
| Esteban, E | 1 |
| Fra, J | 1 |
| Muñiz, I | 1 |
| Sala, M | 1 |
| Buesa, JM | 1 |
| Jiménez Lacave, A | 1 |
| Seshimo, A | 2 |
| Huguet, E | 1 |
| Bismuth, H | 11 |
| Cohen, V | 1 |
| Panet-Raymond, V | 1 |
| Sabbaghian, N | 1 |
| Morin, I | 1 |
| Batist, G | 2 |
| Rozen, R | 1 |
| Colarusso, D | 2 |
| Meyer, L | 1 |
| Climente-Martí, M | 1 |
| Merino-Sanjuán, M | 1 |
| Almenar-Cubells, D | 1 |
| Becerra, CR | 1 |
| Frenkel, EP | 2 |
| Ashfaq, R | 1 |
| Gaynor, RB | 1 |
| Brooks, A | 1 |
| Morris, D | 1 |
| Dahm, F | 1 |
| Selzner, N | 1 |
| Selzner, M | 1 |
| Oza, AM | 1 |
| Bigelow, RH | 1 |
| Garay, CA | 2 |
| Burger, BG | 1 |
| Le Bail, N | 4 |
| Fusai, G | 1 |
| Davidson, BR | 2 |
| Ambo, T | 1 |
| Sarashina, H | 1 |
| Suwa, T | 1 |
| Suzuki, M | 3 |
| Nakazato, H | 2 |
| Arnold, CN | 2 |
| Fallik, D | 1 |
| Jacob, J | 3 |
| Baulieux, J | 1 |
| Couzigou, P | 1 |
| Mahjoubi, R | 1 |
| Mahjoubi, M | 1 |
| Gilles-Amar, V | 4 |
| Krulik, M | 16 |
| Oman, M | 1 |
| Blind, PJ | 1 |
| Lindnér, P | 2 |
| Saini, A | 2 |
| Tait, D | 5 |
| Jodrell, D | 3 |
| Ross, PJ | 13 |
| Oates, J | 10 |
| Reardon, DA | 1 |
| Friedman, HS | 1 |
| Powell, JB | 1 |
| Gilbert, M | 1 |
| Yung, WK | 1 |
| Schwartz, GK | 4 |
| Wilke, HJ | 7 |
| Debrigode, C | 2 |
| Gourgou, S | 2 |
| Klump, B | 1 |
| Nehls, O | 1 |
| Okech, T | 1 |
| Hsieh, CJ | 1 |
| Gaco, V | 1 |
| Gittinger, FS | 1 |
| Sarbia, M | 1 |
| Borchard, F | 1 |
| Greschniok, A | 1 |
| Gruenagel, HH | 1 |
| Gregor, M | 1 |
| Yang, BQ | 1 |
| Jin, ML | 1 |
| Bading, JR | 3 |
| Yoo, PB | 2 |
| Fissekis, JD | 2 |
| Alauddin, MM | 2 |
| D'Argenio, DZ | 1 |
| Yoshinare, K | 2 |
| Kubota, T | 4 |
| Wada, N | 1 |
| Nishibori, H | 1 |
| Salvador, J | 1 |
| Pica, JM | 1 |
| Rueda, A | 1 |
| Lorenzo, A | 1 |
| de la Puente, CG | 1 |
| Borrega, P | 1 |
| Moreno-Nogueira, JA | 1 |
| Chevalier, V | 2 |
| Richard, D | 1 |
| Cure, H | 4 |
| Busquier, I | 2 |
| Galán, A | 3 |
| Bouzid, K | 1 |
| Khalfallah, S | 1 |
| Tujakowski, J | 1 |
| Piko, B | 1 |
| Padrik, P | 1 |
| Serafy, M | 1 |
| Pshevloutsky, EM | 1 |
| Chachoua, A | 1 |
| Speyer, J | 1 |
| Escalon, J | 1 |
| Zeleniuch-Jacquotte, A | 1 |
| Muggia, F | 1 |
| Miwa, M | 1 |
| Eda, H | 1 |
| Ura, M | 1 |
| Tanimura, H | 3 |
| Miyazaki-Nose, T | 1 |
| Hattori, K | 1 |
| Shimma, N | 1 |
| Yamada-Okabe, H | 1 |
| Ishitsuka, H | 1 |
| Ribic, CM | 1 |
| Thibodeau, SN | 1 |
| French, AJ | 1 |
| Hamilton, SR | 3 |
| Gryfe, R | 1 |
| Shepherd, LE | 1 |
| Redston, M | 1 |
| Bamias, A | 4 |
| Pavlidis, N | 4 |
| Man, S | 4 |
| Lavrenkov, K | 5 |
| Gluzman, A | 3 |
| Geffen, DB | 2 |
| Cohen, Y | 3 |
| Yan, DB | 1 |
| Pivot, X | 3 |
| Thyss, A | 2 |
| Demard, F | 1 |
| Gococo, KO | 1 |
| Kardinal, CG | 3 |
| Sumimura, J | 1 |
| Yoshidome, K | 1 |
| Tsuji, K | 2 |
| Oota, F | 1 |
| Tsuboyama, N | 1 |
| Nagai, I | 1 |
| Park, DJ | 6 |
| La Cesa, A | 4 |
| Van Rijnsoever, M | 1 |
| Joseph, D | 3 |
| McCaul, K | 2 |
| Ferns, H | 1 |
| Hwang, YH | 1 |
| Suh, CK | 1 |
| Park, SP | 1 |
| Sumpter, K | 3 |
| Harper-Wynne, C | 1 |
| Thomas, RJ | 1 |
| Garcia-Vargas, J | 1 |
| Barceló, R | 3 |
| Rubio, I | 1 |
| Mañé, JM | 1 |
| Ferreiro, J | 1 |
| López-Vivanco, G | 1 |
| Yeoh, C | 1 |
| Cassinello, J | 2 |
| Marcos, F | 2 |
| Pujol, E | 3 |
| Colmenarejo, A | 2 |
| González del Val, R | 1 |
| Valero, J | 1 |
| Oruezábal, MJ | 1 |
| Guillem, V | 1 |
| García, I | 1 |
| Arcediano, A | 2 |
| Marfà, X | 2 |
| Hills, R | 1 |
| Stowe, R | 1 |
| Nardoni, C | 1 |
| Gamucci, T | 4 |
| Gabriele, A | 3 |
| Ferraresi, V | 3 |
| Tewes, M | 1 |
| Schleucher, N | 1 |
| Achterrath, W | 3 |
| Frings, S | 2 |
| Seeber, S | 6 |
| Harstrick, A | 9 |
| Alfonso, R | 1 |
| Macías, JA | 1 |
| Manrique, I | 1 |
| Flores, L | 1 |
| Sferruzza, AD | 1 |
| Bender, RA | 1 |
| Schöffski, P | 11 |
| Voigtmann, R | 2 |
| Lutz, M | 1 |
| Kleeberg, C | 1 |
| Souchon, R | 1 |
| El-Serafi, M | 2 |
| Weiss, U | 1 |
| Burkhard, O | 1 |
| Rückle, H | 2 |
| Lichnitser, M | 1 |
| Langenbuch, T | 2 |
| Gambardella, A | 3 |
| Zonios, D | 1 |
| Papalambros, E | 4 |
| Papantoniou, N | 2 |
| Margaris, H | 2 |
| Retalis, G | 1 |
| Koufos, C | 2 |
| Keller, R | 1 |
| Fischbach, W | 1 |
| Ferretti, G | 4 |
| Di Cosimo, S | 1 |
| Asche, C | 1 |
| Romeyer, F | 1 |
| Mukherjee, J | 1 |
| Skillings, J | 1 |
| Letarte, J | 1 |
| Koike, A | 2 |
| Takagi, H | 4 |
| Baba, S | 3 |
| Mai, M | 1 |
| Ganem, G | 2 |
| Valleur, P | 1 |
| Aziza, T | 1 |
| Fagniez, PL | 1 |
| Auroux, J | 1 |
| Kobeiter, H | 1 |
| Tayar, C | 1 |
| Braud, AC | 2 |
| Haddad, E | 2 |
| Piolot, A | 1 |
| Giannakakis, T | 1 |
| Karadima, D | 1 |
| Shindou, H | 1 |
| Fukuoka, H | 1 |
| Shibasaki, S | 1 |
| Nanashima, A | 1 |
| Diasio, R | 1 |
| Thomas, RR | 2 |
| Jantscheff, P | 1 |
| Glatz-Krieger, K | 1 |
| Grunert, F | 1 |
| Micheel, B | 1 |
| Brümmer, J | 1 |
| Schramm, H | 4 |
| Hauss, J | 2 |
| Schäfer, H | 1 |
| Berger, G | 3 |
| Reszka, R | 1 |
| Pohlen, U | 1 |
| Lucas, S | 1 |
| Buhr, HJ | 1 |
| Taguchi, S | 1 |
| Adab, F | 1 |
| Thomas, G | 1 |
| Wadd, NJ | 1 |
| Rea, D | 1 |
| Philips, R | 1 |
| Bozzino, J | 1 |
| MacMillan, C | 1 |
| Counsell, R | 1 |
| McDonald, A | 2 |
| Stewart, J | 2 |
| Robinson, A | 1 |
| Davies, S | 1 |
| Murayama, C | 2 |
| Kulke, MH | 5 |
| Enzinger, PC | 7 |
| Stuart, K | 2 |
| Catarius, KJ | 1 |
| Winkelmann, J | 1 |
| Stickel, F | 1 |
| Jüngert, B | 1 |
| Brueckl, V | 1 |
| Schirner, I | 1 |
| Männlein, G | 1 |
| Hegewald, J | 1 |
| Mühldorfer, S | 1 |
| Bittorf, B | 1 |
| Belloc, J | 1 |
| Etienney, I | 1 |
| Montembault, S | 1 |
| Vayre, L | 1 |
| Ezenfis, J | 1 |
| Ohtsukasa, S | 2 |
| Hwang, JJ | 3 |
| Eisenberg, SG | 1 |
| Trocha, SD | 1 |
| Saha, SS | 1 |
| Wiese, D | 1 |
| Thompson, J | 1 |
| Morton, DL | 1 |
| Imanishi, T | 1 |
| Kuroda, Y | 3 |
| Kabeshima, Y | 1 |
| Nagao, M | 1 |
| Takasaka, H | 2 |
| Nishikawa, N | 1 |
| Nishimura, G | 2 |
| Shimoyama, S | 1 |
| Katayanagi, S | 4 |
| Tsukuda, K | 2 |
| Ota, T | 2 |
| Shimizu, N | 4 |
| Akazawa, S | 5 |
| Yamashina, T | 1 |
| Murakami, T | 1 |
| Nakazima, T | 1 |
| Sakurai, T | 1 |
| Stippel, DL | 1 |
| Töx, U | 1 |
| Gossmann, A | 1 |
| Beckurts, KT | 1 |
| Hölscher, AH | 1 |
| Nakayama, K | 1 |
| Itou, T | 1 |
| Abe, N | 1 |
| Kirsch, IR | 2 |
| Ward, S | 1 |
| Kaltenthaler, E | 2 |
| Cowan, J | 2 |
| Brewer, N | 1 |
| Lüftner, D | 1 |
| Jozereau, D | 1 |
| Possinger, K | 3 |
| Zappalà, AM | 1 |
| Fuchimoto, S | 1 |
| Sakata, T | 1 |
| Shirakawa, K | 2 |
| Nakada, H | 6 |
| Odaka, A | 3 |
| Hoshino, T | 3 |
| Murata, N | 4 |
| Hashimoto, D | 5 |
| Watayo, T | 1 |
| Nakata, H | 1 |
| Kito, A | 1 |
| Kunihiro, O | 1 |
| Togo, S | 3 |
| Kosaka, K | 1 |
| Nishihara, T | 1 |
| Umehara, A | 4 |
| La Grotta, G | 1 |
| Infante, L | 1 |
| Passera, R | 1 |
| Arpicco, S | 1 |
| Brusa, P | 1 |
| Bumma, C | 1 |
| Hsuen Lim, E | 1 |
| Seng Cheong Lim, R | 1 |
| Seng Wu, T | 1 |
| Loong Kong, H | 1 |
| van Laarhoven, HW | 3 |
| Klomp, DW | 2 |
| Kamm, YJ | 3 |
| Heerschap, A | 3 |
| Lamlum, H | 6 |
| Achille, E | 1 |
| Flesh, M | 1 |
| Couteau, C | 2 |
| Fenández-Martos, C | 1 |
| Huarte, L | 1 |
| Balcells, M | 5 |
| Wong, JY | 1 |
| Williams, LE | 1 |
| Liu, A | 1 |
| Yamauchi, DM | 1 |
| Wilczynski, S | 1 |
| Ikle, DN | 1 |
| Wu, AM | 1 |
| Yazaki, PJ | 1 |
| Doroshow, JH | 4 |
| Raubitschek, AA | 1 |
| Belvedere, O | 2 |
| Di Loreto, C | 1 |
| Cataldi, P | 1 |
| Braendengen, M | 2 |
| Øgreid, D | 2 |
| Lewis, NL | 2 |
| Diz, P | 1 |
| García López, MJ | 1 |
| España, P | 2 |
| de la Torre, A | 1 |
| Martínez del Prado, P | 1 |
| Duarte, I | 1 |
| Arizcun, A | 1 |
| Cruz, JJ | 1 |
| Köves, I | 2 |
| Orosz, Z | 3 |
| Hajnal, A | 1 |
| Miki, A | 1 |
| Ukikusa, M | 1 |
| Kojima, N | 2 |
| Ishigaki, T | 1 |
| Todo, G | 1 |
| Honecker, F | 2 |
| Artale, S | 2 |
| Pinotti, G | 2 |
| Carreca, I | 1 |
| Bonaglia, L | 1 |
| Marini, G | 4 |
| Iannelli, A | 1 |
| Beretta, E | 2 |
| Ma, T | 1 |
| Zhu, ZG | 1 |
| Ji, YB | 1 |
| Yu, YY | 1 |
| Yin, HR | 1 |
| Lin, YZ | 1 |
| Zhang, ZL | 1 |
| Zou, WG | 1 |
| Luo, CX | 1 |
| Li, BH | 1 |
| Sun, LY | 1 |
| Qian, QJ | 1 |
| Hansson, J | 1 |
| Skarlos, D | 4 |
| Janinis, J | 2 |
| Kouvatseas, G | 2 |
| Economopulos, T | 1 |
| Takeshita, H | 2 |
| Perez, N | 2 |
| Molitor, JL | 5 |
| Ibrahim, A | 1 |
| Hirschfeld, S | 1 |
| Griebel, DJ | 1 |
| Williams, GA | 1 |
| Ruth, SV | 1 |
| Zoetmulder, FA | 4 |
| Smith, EJ | 1 |
| Behling, CA | 1 |
| Nguyen, L | 1 |
| Tajima, A | 1 |
| Doctolero, RT | 1 |
| Cabrera, BL | 1 |
| Arnold, CA | 1 |
| Miyai, K | 1 |
| Matasar, MJ | 1 |
| Sundararajan, V | 1 |
| Grann, VR | 1 |
| Neugut, AI | 2 |
| Hahn, P | 1 |
| Jensen, HA | 1 |
| Wang, TL | 1 |
| Romans, K | 1 |
| Saha, S | 1 |
| Choti, M | 1 |
| Parmigiani, G | 1 |
| Shih, IeM | 1 |
| Kinzler, KW | 3 |
| Vogelstein, B | 3 |
| Lengauer, C | 1 |
| Velculescu, VE | 1 |
| Mafrici, A | 1 |
| Alberti, A | 1 |
| Corrada, E | 1 |
| Ferrari, S | 1 |
| Marenna, B | 1 |
| Choi, EA | 1 |
| Maron, DJ | 1 |
| Mick, R | 1 |
| Barsoum, J | 1 |
| Yu, QC | 1 |
| Wilson, JM | 1 |
| Spitz, FR | 1 |
| Allen, MJ | 2 |
| Ford, HE | 3 |
| Cremonesi, M | 1 |
| Rezzani, C | 1 |
| Mary, C | 1 |
| Emura, T | 2 |
| Murakami, Y | 3 |
| Kitazato, K | 1 |
| Merkelbach-Bruse, S | 1 |
| Hans, V | 1 |
| Mathiak, M | 1 |
| Sanguedolce, R | 1 |
| Büttner, R | 2 |
| Houshdaran, F | 1 |
| Gullotti, L | 1 |
| van den Bergh, EJ | 1 |
| Wagener, DJ | 7 |
| Bertino, J | 1 |
| Kelsen, DK | 1 |
| Tong, W | 3 |
| Welch, M | 1 |
| Endres, S | 1 |
| Dimery, I | 1 |
| Lewis, KG | 1 |
| Lewis, MD | 1 |
| Robinson-Bostom, L | 1 |
| Pan, TD | 1 |
| Zhu, AX | 5 |
| Puchalski, TA | 1 |
| Stanton, VP | 1 |
| Nesbitt, S | 1 |
| Charlat, O | 1 |
| Kelly, P | 1 |
| Kreconus, E | 1 |
| Chabner, BA | 1 |
| Supko, JG | 2 |
| Bukowski, RM | 3 |
| Dufour, P | 6 |
| Lokich, J | 7 |
| Schoelmerich, J | 1 |
| Collan, Y | 2 |
| Di Leo, A | 3 |
| Masutti, B | 2 |
| Ribera, F | 1 |
| Pronk, L | 1 |
| Crellin, AM | 1 |
| Sebag-Montefiore, D | 1 |
| Messruther, J | 1 |
| Francis, DL | 1 |
| Visvikis, D | 1 |
| Costa, DC | 1 |
| Croasdale, I | 1 |
| Arulampalam, TH | 1 |
| Luthra, SK | 1 |
| Ell, PJ | 1 |
| van Zuylen, L | 1 |
| Sparreboom, A | 1 |
| de Bruijn, P | 1 |
| Sklenar, I | 1 |
| Planting, AS | 3 |
| Choi, L | 1 |
| Bootle, D | 1 |
| Mueller, C | 1 |
| Verweij, J | 5 |
| Boyer, J | 1 |
| McLean, EG | 1 |
| Aroori, S | 1 |
| McCulla, A | 1 |
| Carey, PD | 2 |
| Azem, F | 1 |
| Amit, A | 1 |
| Merimsky, O | 2 |
| Lessing, JB | 1 |
| Machiavelli, MR | 3 |
| Salum, G | 1 |
| Pérez, JE | 4 |
| Ortiz, EH | 3 |
| Romero, AO | 3 |
| Bologna, F | 1 |
| Vallejo, CT | 4 |
| Lacava, JA | 3 |
| Dominguez, ME | 3 |
| Leone, BA | 4 |
| Tsamandas, AC | 1 |
| Kardamakis, D | 1 |
| Ravazoula, P | 1 |
| Zolota, V | 1 |
| Salakou, S | 1 |
| Tepetes, K | 1 |
| Kalogeropoulou, C | 1 |
| Tsota, I | 1 |
| Kourelis, T | 1 |
| Karavias, D | 1 |
| Bonikos, DS | 1 |
| Petsas, T | 1 |
| Liu, DG | 1 |
| Yu, BM | 2 |
| Wu, WQ | 2 |
| Wei, YQ | 1 |
| Zou, LQ | 1 |
| Wu, XD | 1 |
| Zhuang, W | 1 |
| Xiong, HH | 1 |
| Yang, CY | 1 |
| Sun, SR | 1 |
| Ruan, QL | 1 |
| Inokuchi, M | 1 |
| Tajima, M | 1 |
| Hillenbrand, A | 1 |
| Sander, S | 1 |
| Salonga, D | 4 |
| Fjell, B | 1 |
| Haug, T | 1 |
| Tunheim, SH | 1 |
| Reichelt, W | 1 |
| Beigi, M | 1 |
| Clausen, OP | 1 |
| Galteland, E | 1 |
| Stokke, T | 1 |
| Tham, J | 1 |
| Albertsson, M | 4 |
| Takemiya, S | 2 |
| Nishisho, I | 5 |
| Lelong, B | 1 |
| Moutardier, V | 1 |
| Baust, JG | 1 |
| Gage, AA | 1 |
| Clarke, D | 1 |
| Baust, JM | 1 |
| Van Buskirk, R | 1 |
| Kikuchi, I | 1 |
| Miyanaga, O | 1 |
| Harada, M | 3 |
| Hütter, G | 1 |
| Szélenyi, H | 2 |
| Deckert, PM | 1 |
| Keilholz, U | 1 |
| Thiel, E | 3 |
| Delperro, JR | 2 |
| Benhamou, E | 1 |
| Baton, O | 1 |
| Giovannini, M | 4 |
| Cohen, SM | 1 |
| Li, SY | 1 |
| An, P | 1 |
| Zuo, FY | 1 |
| Cai, HY | 1 |
| Toffolatti, L | 1 |
| Pei, Z | 1 |
| Qian, C | 2 |
| Gal, R | 1 |
| Sadikov, E | 1 |
| Sulkes, J | 1 |
| Klein, B | 1 |
| Koren, R | 1 |
| Messinese, S | 1 |
| Piccolomini, A | 1 |
| Ceciarini, F | 1 |
| Micheli, L | 3 |
| Nencini, C | 3 |
| Neri, A | 1 |
| Vuolo, G | 1 |
| Guarnieri, A | 1 |
| Prete, SD | 1 |
| Giorgi, G | 3 |
| Nattam, S | 1 |
| Ansari, RH | 2 |
| Kasza, K | 1 |
| Wade-Oliver, K | 1 |
| Vokes, EE | 1 |
| Quirino, M | 3 |
| Trigila, N | 3 |
| Ceyhan, C | 2 |
| Meydan, N | 2 |
| Tekten, T | 2 |
| Onbasili, AO | 1 |
| Ozturk, B | 3 |
| Unal, S | 1 |
| Bayrak, I | 1 |
| Chen, VM | 1 |
| Thrift, KM | 1 |
| Morel-Kopp, MC | 1 |
| Jackson, D | 3 |
| Ward, CM | 1 |
| Flower, RL | 1 |
| van Ruth, S | 1 |
| Oechsle, K | 1 |
| Reis, HE | 2 |
| Haag, C | 1 |
| Batran, SA | 1 |
| Büchele, T | 2 |
| Kanz, L | 1 |
| Lassere, Y | 3 |
| Carter, S | 1 |
| Samid, D | 1 |
| Polito, D | 1 |
| Debraud, F | 2 |
| Grossmann, J | 2 |
| Sawada, N | 2 |
| Gil-Delgado, MA | 2 |
| Bastian, G | 3 |
| Guinet, F | 2 |
| Taillibert, S | 1 |
| Rocher, MA | 1 |
| Khayat, D | 5 |
| Goessl, C | 1 |
| Grozdanovic, Z | 1 |
| Kumada, T | 2 |
| Sone, Y | 4 |
| Toyoda, H | 2 |
| Kiriyama, S | 2 |
| Tanikawa, M | 1 |
| Hisanaga, Y | 1 |
| Kuzuya, T | 1 |
| Nonogaki, K | 1 |
| Shimizu, J | 2 |
| Yamauti, T | 1 |
| Kawase, N | 1 |
| Fan, CW | 2 |
| Tsao, KC | 1 |
| Wu, CM | 1 |
| Novotny, W | 2 |
| Hainsworth, J | 1 |
| Baron, A | 1 |
| Ferrara, N | 1 |
| Rogers, B | 1 |
| Ross, R | 1 |
| Jansman, FG | 3 |
| Postma, MJ | 1 |
| van Hartskamp, D | 1 |
| Willemse, PH | 5 |
| Brouwers, JR | 3 |
| Zito, A | 1 |
| Montemurro, S | 3 |
| Hsieh, RK | 4 |
| Chao, TY | 1 |
| Dräger, J | 1 |
| Kerner, T | 1 |
| Deja, M | 1 |
| Löffel, J | 1 |
| Ahlers, O | 1 |
| Felix, R | 1 |
| Wust, P | 2 |
| Awad, L | 6 |
| Rixe, O | 1 |
| Favre, R | 2 |
| Merad, L | 1 |
| Laadem, A | 2 |
| Juin, P | 1 |
| Bereder, JM | 1 |
| Bernardini, D | 2 |
| Herait, P | 6 |
| Noordhuis, P | 6 |
| Holwerda, U | 1 |
| Van der Wilt, CL | 5 |
| Meijer, S | 4 |
| Pinedo, HM | 15 |
| Zappalà, AR | 2 |
| Pugliese, P | 4 |
| Cappellini, GA | 1 |
| Perrone, M | 3 |
| Liu, WM | 1 |
| Scott, KA | 1 |
| Shahin, S | 1 |
| Goetz, MP | 3 |
| Zahedy, S | 1 |
| Penland, SK | 1 |
| Venook, A | 3 |
| Blackwell, K | 1 |
| Snyder, S | 1 |
| Dewhirst, M | 1 |
| Greenberg, C | 1 |
| Simizu, M | 1 |
| Matsukura, S | 1 |
| Samejima, R | 1 |
| Hidaka, K | 1 |
| Richards, F | 2 |
| Davis, T | 1 |
| Aslanis, V | 1 |
| Locke, K | 1 |
| Slevin, ML | 5 |
| Fackler-Schwalbe, I | 1 |
| Schwalbe, B | 1 |
| Epple, M | 1 |
| Becker, A | 1 |
| Prügl, L | 1 |
| Gassel, WD | 1 |
| Stoffels, D | 1 |
| Südhoff, T | 1 |
| Kaçar, S | 1 |
| Kahya, M | 1 |
| Gürkan, A | 1 |
| Karaca, C | 1 |
| Varilsüha, C | 1 |
| Uslu, A | 1 |
| Sutherland, F | 1 |
| Walley, B | 1 |
| Ruether, D | 1 |
| Barber, FD | 1 |
| Mavligit, G | 1 |
| Mahyar-Roemer, M | 1 |
| Fritzsche, C | 1 |
| Wagner, S | 1 |
| Laue, M | 1 |
| Roemer, K | 1 |
| Kuehr, T | 1 |
| Rapoport, BL | 1 |
| Jacobs, C | 1 |
| Slevin, M | 2 |
| Payne, S | 1 |
| Kamoshida, S | 1 |
| Shiogama, K | 1 |
| Matsuyama, A | 1 |
| Shimomura, R | 1 |
| Inada, K | 1 |
| Maruta, M | 1 |
| Tsutsumi, Y | 1 |
| Hill, ME | 5 |
| Shellito, P | 2 |
| Onbasili, A | 1 |
| Kadikoylu, G | 1 |
| Bolaman, Z | 1 |
| Carlo, WF | 1 |
| Hummer, AJ | 1 |
| Price, N | 2 |
| Oberfield, RA | 1 |
| Sampson, E | 1 |
| Heatley, GJ | 1 |
| Johata, K | 1 |
| Sahara, M | 1 |
| Naka, T | 1 |
| Ochiai, M | 1 |
| Tsubota, YT | 1 |
| Liljefors, M | 2 |
| Nilsson, B | 2 |
| Ullenhag, G | 1 |
| Mellstedt, H | 2 |
| Ruotsalainen, T | 2 |
| Ollus, A | 2 |
| Ikonen, M | 1 |
| Whitehead, RP | 2 |
| Benedetti, JK | 2 |
| Williamson, S | 1 |
| Gaynor, ER | 1 |
| Balcerzak, SP | 2 |
| Polemonivi, N | 1 |
| O'Leary, E | 1 |
| Lloyd, TD | 1 |
| Dennison, AR | 1 |
| Rouits, E | 1 |
| Guérin, O | 1 |
| Tada, T | 1 |
| Kazama, Y | 1 |
| Hecker, H | 5 |
| Cho, EK | 2 |
| Oh, JH | 2 |
| Tucci, A | 2 |
| Pizza, C | 2 |
| Faithfull, S | 1 |
| Deery, P | 1 |
| Gerbrecht, BM | 1 |
| Kangas, T | 1 |
| Kim, TM | 1 |
| Yu, SJ | 1 |
| Joh, YH | 1 |
| Heo, DS | 2 |
| Burger, C | 1 |
| Rühl, A | 1 |
| Irngartinger, G | 2 |
| Ferraz, JM | 1 |
| Zinzindohoué, F | 1 |
| Berger, A | 1 |
| Cugnenc, PH | 1 |
| Jian, R | 1 |
| Zhou, ZW | 3 |
| Fan, HA | 1 |
| Hsu, SH | 1 |
| Chan, CC | 1 |
| Chen, SY | 1 |
| Hsu, YH | 1 |
| Casazza, S | 2 |
| Thirion, P | 5 |
| Carlson, RW | 2 |
| Sargent, P | 1 |
| Waters, JS | 3 |
| Katopodis, R | 1 |
| Oates, JR | 3 |
| Calviello, G | 1 |
| Di Nicuolo, F | 1 |
| Serini, S | 1 |
| Piccioni, E | 1 |
| Boninsegna, A | 1 |
| Maggiano, N | 1 |
| Ranelletti, FO | 1 |
| Palozza, P | 1 |
| Jiménez De Ayala, B | 1 |
| Velasco, A | 1 |
| Majano, PL | 1 |
| Palacios, J | 1 |
| Damjanovic, D | 1 |
| Grossi, F | 5 |
| Delvart, V | 2 |
| Pascal, G | 2 |
| Valeanu, A | 1 |
| Ghémard, O | 1 |
| César, A | 1 |
| Menoyo, A | 2 |
| LaRocca, RV | 1 |
| Glisson, SD | 1 |
| Hargis, JB | 1 |
| Kosfeld, RE | 1 |
| Leaton, KE | 1 |
| Hicks, RM | 1 |
| Amin-Zimmerman, F | 1 |
| Parvez, T | 1 |
| Mahrous, AR | 1 |
| Fawazi, A | 1 |
| Cobo, M | 1 |
| Carabantes, F | 2 |
| Villar, E | 1 |
| Graupera, J | 1 |
| Manzano, H | 2 |
| Batiste-Alentorn, E | 2 |
| Acusa, A | 1 |
| Vélez de Mendizabal, E | 1 |
| Antón, I | 1 |
| Dixon, MR | 1 |
| Stamos, MJ | 1 |
| Saggio, G | 1 |
| Nuzzo, A | 2 |
| Lullo, LD | 1 |
| Cesta, A | 2 |
| Thomas, SP | 1 |
| Salim, M | 2 |
| Schaefer, PL | 3 |
| Mailliard, JA | 7 |
| Blum, J | 1 |
| Senzer, NN | 1 |
| Grouleff, P | 1 |
| Rogers, T | 1 |
| Kelley, SK | 1 |
| Ramies, DA | 1 |
| Lum, BL | 1 |
| Eiseman, JL | 1 |
| Brown-Proctor, C | 1 |
| Kinahan, PE | 1 |
| Collins, JM | 2 |
| Anderson, LW | 1 |
| Joseph, E | 1 |
| Hamburger, DR | 1 |
| Pan, SS | 1 |
| Mathis, CA | 1 |
| Klecker, RW | 1 |
| Kimhi, O | 1 |
| Drucker, L | 1 |
| Neumann, A | 1 |
| Shapiro, H | 1 |
| Shapira, J | 1 |
| Yarkoni, S | 1 |
| Lahav, M | 1 |
| Radnay, J | 1 |
| Lishner, M | 1 |
| Sharieff, W | 1 |
| Medinger, M | 1 |
| Steinbild, S | 1 |
| Blackwell, A | 1 |
| Anderson, J | 3 |
| Moroz, P | 1 |
| Cardaci, G | 1 |
| Chouinard, E | 1 |
| Stewart, DJ | 1 |
| Huan, S | 1 |
| Hirte, H | 1 |
| Stafford, S | 1 |
| Waterfield, B | 1 |
| Roach, J | 1 |
| Lathia, C | 1 |
| Agarwal, V | 1 |
| Humphrey, R | 1 |
| Walsh, W | 1 |
| Matthews, S | 1 |
| Borzomati, D | 1 |
| Grilli, C | 1 |
| Verzì, A | 1 |
| Shirane, M | 1 |
| Hiro, J | 3 |
| Yanagi, H | 4 |
| Araake, M | 1 |
| Orita, H | 1 |
| Cerri, E | 3 |
| Masutani, S | 2 |
| Nakayama, T | 3 |
| Imamura, H | 2 |
| Tatsuta, M | 2 |
| Tomotsu, K | 1 |
| Ueda, Y | 2 |
| Tagi, T | 1 |
| Shiozaki, A | 1 |
| Tamai, H | 1 |
| Sonoyama, T | 1 |
| Ashikawa, K | 1 |
| Katayama, M | 1 |
| Hanai, A | 3 |
| Takizawa, K | 1 |
| Koide, A | 1 |
| Ohbu, M | 1 |
| Tokuoka, M | 1 |
| Kashiwazaki, M | 1 |
| Hasuike, Y | 10 |
| Masuda, N | 1 |
| Hirao, M | 1 |
| Sawamura, T | 4 |
| Gory-Delabaere, G | 1 |
| Bosquet, L | 1 |
| Bosset, JF | 3 |
| Monges, G | 1 |
| Matsushita, M | 4 |
| Iwazawa, T | 3 |
| Okamura, J | 2 |
| Gurtler, J | 1 |
| Kennedy, P | 1 |
| Brandt, DS | 1 |
| Wertheim, M | 1 |
| Shumaker, G | 1 |
| Hallman, D | 1 |
| Burger, B | 1 |
| Mauritz, R | 2 |
| Schwabe, W | 1 |
| Haeusler, P | 1 |
| Behnke, D | 1 |
| Doggrell, SA | 1 |
| Kuhfahl, J | 1 |
| Steinbrecher, C | 1 |
| Wagner, T | 2 |
| Wagner, H | 1 |
| Fritze, D | 2 |
| Schulte, F | 1 |
| Kreuser, ED | 8 |
| Stahl, M | 5 |
| Schweers, K | 1 |
| Köster, W | 2 |
| Wilke, H | 12 |
| Popov, IP | 2 |
| Jelic, SB | 1 |
| Matijasevic, MM | 1 |
| Grbic, B | 1 |
| Babic, DR | 1 |
| Bourgeon, A | 3 |
| Hadj Tahar, A | 1 |
| Gnad-Vogt, U | 1 |
| Saussele, S | 1 |
| Kreil, S | 1 |
| Presicci, PF | 1 |
| Veronesi, G | 1 |
| D'Aiuto, M | 1 |
| Spaggiari, L | 1 |
| Glasgow, SC | 1 |
| Carvalho, LP | 1 |
| Shannon, WD | 2 |
| Fleshman, JW | 1 |
| Papadopoulou-Zekeridou, P | 1 |
| Alexandridis, E | 1 |
| Delithanasis, I | 1 |
| Zekeridis, T | 1 |
| Lagra, F | 1 |
| Krokidis, X | 1 |
| Lazaridis, N | 1 |
| Christopoulou, A | 1 |
| Emmanouilides, C | 2 |
| Pegram, M | 1 |
| Robinson, R | 1 |
| Hecht, R | 1 |
| Isacoff, W | 1 |
| Goebel, FM | 1 |
| Parc, R | 1 |
| Reddy, GK | 4 |
| Gibson, AD | 1 |
| D'Andre, S | 1 |
| Cha, SS | 2 |
| Buroker, TR | 2 |
| Kugler, JW | 2 |
| Poon, MA | 5 |
| Borner, MM | 5 |
| Bernhard, J | 1 |
| Wernli, M | 2 |
| Rauch, D | 1 |
| Honegger, H | 2 |
| Tsunozaki, H | 1 |
| Krook, J | 1 |
| Fuchs, C | 2 |
| Ishizu, K | 2 |
| Benedetti, J | 3 |
| Kecmanovic, DM | 1 |
| Pavlov, MJ | 1 |
| Ceranic, MS | 1 |
| Sepetkovski, AV | 1 |
| Kovacevic, PA | 1 |
| Stamenkovic, AB | 1 |
| Kleeberg, UR | 3 |
| Hieke, K | 3 |
| Guerrero, A | 1 |
| Pellín, L | 1 |
| Toi, M | 1 |
| Takizawa, T | 1 |
| Shimizu, S | 1 |
| Carlini, LE | 1 |
| Bever, J | 1 |
| Andria, ML | 1 |
| Hill, T | 1 |
| Gold, P | 1 |
| Rogatko, A | 1 |
| Blanchard, RL | 1 |
| Tsavaris, NB | 1 |
| Katsoulas, HL | 1 |
| Kosmas, N | 1 |
| Skopeliti, M | 1 |
| Tsitsilonis, OE | 1 |
| Pohl, G | 1 |
| Rudas, M | 1 |
| Grill, R | 1 |
| Pirker, R | 1 |
| Hausmaninger, H | 2 |
| Kubista, E | 1 |
| Jakesz, R | 4 |
| Ozer, H | 1 |
| Lentz, F | 1 |
| Tran, A | 1 |
| Rey, E | 1 |
| Pons, G | 1 |
| Tréluyer, JM | 1 |
| Nielsen, JN | 4 |
| Gyldenkerne, N | 1 |
| Lindeberg, J | 1 |
| McCleod, M | 1 |
| Mass, R | 1 |
| Perrou, B | 1 |
| Nelson, B | 1 |
| Bruzzi, P | 3 |
| Sangha, S | 1 |
| Albert, A | 1 |
| Chang, AJ | 1 |
| Liu, TC | 1 |
| Kanou, Y | 1 |
| Ooshima, H | 1 |
| Kawase, J | 1 |
| Kudou, J | 1 |
| Mizuno, Y | 1 |
| Nakano, K | 1 |
| Todo, T | 1 |
| Kuroki, S | 1 |
| Cohen, JB | 1 |
| Glorioso, JC | 1 |
| Dirix, L | 5 |
| Van Belle, S | 2 |
| Gonzalez Baron, M | 2 |
| Morant, R | 5 |
| Joosens, E | 2 |
| Gruia, G | 5 |
| Sibaud, D | 1 |
| Seike, K | 1 |
| Oda, K | 1 |
| Hasegawa, R | 1 |
| Yoshikawa, R | 3 |
| Gega, M | 1 |
| Tsukamoto, K | 1 |
| Shoji, Y | 1 |
| Higasa, S | 1 |
| Hashimoto-Tamaoki, T | 2 |
| Artandi, M | 1 |
| Rosales, AM | 1 |
| Landi, E | 1 |
| Schattner, M | 1 |
| Akhurst, T | 2 |
| Lim, DH | 1 |
| Park, BB | 1 |
| Ji, SH | 1 |
| Park, KW | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Park, K | 1 |
| Mattek, NC | 1 |
| Deloughery, TG | 1 |
| Koop, DR | 1 |
| Blum, HE | 1 |
| Freeman, S | 1 |
| Post, L | 1 |
| McCormick, F | 1 |
| Sze, DY | 1 |
| Guallar, JL | 1 |
| Kidd, EA | 1 |
| Watson, MA | 1 |
| Seium, Y | 1 |
| Stupp, R | 2 |
| Philippe, M | 1 |
| Allal, A | 1 |
| Trembleau, C | 1 |
| Sahin, M | 1 |
| Erikoglu, M | 1 |
| Ozer, S | 1 |
| Tekin, A | 1 |
| Boz, S | 1 |
| Gölcük, M | 1 |
| Avunduk, MC | 1 |
| Aköz, M | 1 |
| Lima, AP | 1 |
| Massacesi, C | 3 |
| Marcucci, F | 1 |
| Cappelletti, C | 1 |
| Imperatori, L | 1 |
| Pilone, A | 2 |
| Rocchi, M | 1 |
| Laici, G | 1 |
| Bonsignori, M | 1 |
| Lippe, P | 3 |
| Dimopoulos, M | 1 |
| Chalkidou, S | 1 |
| Karina, M | 1 |
| Bacoyiannis, C | 4 |
| Samelis, GF | 1 |
| Kalfarentzos, F | 1 |
| Chong, G | 3 |
| Llosa, F | 1 |
| Yubero, A | 2 |
| Sanz-Lacalle, JJ | 1 |
| Lopez-Gómez, L | 2 |
| Gómez-Reina, MJ | 1 |
| Jankilevich, G | 1 |
| Kallinowski, B | 1 |
| Hambleton, J | 2 |
| Mass, RD | 2 |
| Hummer, A | 1 |
| Drobnjak, M | 1 |
| Motwani, M | 1 |
| Cordon-Cardo, C | 1 |
| Veronese, ML | 1 |
| Giantonio, B | 1 |
| Shults, J | 1 |
| Ismail, AS | 1 |
| Quinn, MG | 2 |
| Wright, MA | 2 |
| Ernst, A | 1 |
| Kao, V | 1 |
| Grogan, L | 2 |
| Parr, A | 1 |
| Grollman, F | 1 |
| Ng, CV | 1 |
| Shimonov, M | 1 |
| Hayat, H | 1 |
| Chaitchik, S | 3 |
| Brener, J | 1 |
| Schachter, P | 1 |
| Czerniak, A | 1 |
| Gauthier, AM | 1 |
| Michaud, LB | 1 |
| Hortobagyi, G | 1 |
| Lucia, LD | 1 |
| Cataldis, GD | 1 |
| Bu, LM | 1 |
| Gil, S | 1 |
| Ebisawa, Y | 1 |
| Tomita, I | 3 |
| Chisato, N | 1 |
| Kamiya, K | 1 |
| Asama, T | 1 |
| Ayabe, T | 1 |
| Ashida, T | 1 |
| Kohgo, Y | 1 |
| Kasai, S | 2 |
| Fernandez, FG | 1 |
| Ritter, J | 1 |
| Goodwin, JW | 2 |
| Linehan, DC | 2 |
| Hawkins, WG | 2 |
| Pessi, MA | 5 |
| Milesi, L | 1 |
| Bazan, V | 2 |
| Agnese, V | 2 |
| Rodolico, V | 1 |
| Corsale, S | 1 |
| Calò, V | 1 |
| Valerio, MR | 2 |
| Latteri, MA | 1 |
| Vieni, S | 1 |
| Grassi, N | 1 |
| Dardanoni, G | 1 |
| Tomasino, RM | 1 |
| Gebbia, V | 10 |
| Paoletti, G | 7 |
| Borsellino, N | 5 |
| Pezzella, G | 4 |
| Romito, S | 4 |
| Yildirim, Y | 1 |
| Akcali, Z | 1 |
| Ozyilkan, O | 1 |
| Tyagi, P | 3 |
| Lopez, T | 1 |
| Encarnacion, C | 1 |
| Biquet, JF | 1 |
| Materne, R | 1 |
| Delforge, M | 1 |
| Rea, DW | 1 |
| Ten Bokkel Huinink, WW | 4 |
| Groenewegen, G | 1 |
| Smit, JM | 2 |
| Steven, N | 2 |
| Bakker, JM | 1 |
| Semiond, D | 1 |
| Caruso, M | 2 |
| Agostara, B | 1 |
| Misino, A | 1 |
| Durini, E | 1 |
| Cramarossa, A | 1 |
| Di Bisceglie, M | 1 |
| Chiarenza, M | 1 |
| Guida, T | 1 |
| Leonardi, V | 1 |
| Carrozza, F | 1 |
| Nettis, G | 1 |
| Valdesi, M | 1 |
| Fortunato, S | 2 |
| Brunetti, C | 1 |
| Reichardt, P | 1 |
| Rückle-Lanz, H | 2 |
| Frickhofen, N | 1 |
| Mergenthaler, HG | 1 |
| Anak, O | 1 |
| Storojeva, I | 1 |
| Heinimann, K | 1 |
| Ballabeni, P | 1 |
| Aggarwal, S | 1 |
| Lichtman, SM | 1 |
| Coutsouvelis, J | 1 |
| Dong, PD | 1 |
| Zhang, LH | 1 |
| Ji, JF | 1 |
| Inokuchi, K | 2 |
| Takeuchi, T | 1 |
| Muneoka, K | 1 |
| Yokoyama, N | 1 |
| Hatakeyama, K | 1 |
| Arnaud, JP | 4 |
| Debois, M | 2 |
| Ollier, JC | 1 |
| Grobost, O | 2 |
| Lacourt, J | 1 |
| Guimares dos Santos, J | 1 |
| Mackiewickz, R | 1 |
| Morin, T | 1 |
| Baila, L | 1 |
| Zhu, BD | 1 |
| Nadal, C | 1 |
| Sanz, S | 1 |
| Kuroiwa, T | 1 |
| Khamly, K | 1 |
| Zhu, WR | 1 |
| Guo, YB | 1 |
| Yuan, JM | 1 |
| Paty, P | 1 |
| Morse, M | 1 |
| Blumgart, L | 3 |
| Laplanche, A | 4 |
| Luboinski, M | 2 |
| Shimizu, D | 5 |
| Hayasizaki, Y | 2 |
| Okazaki, Y | 1 |
| Coudray, AM | 2 |
| Kornprobst, M | 1 |
| Raymond, E | 10 |
| Gespach, C | 2 |
| Arii, K | 1 |
| Sung, JY | 1 |
| Han, SH | 1 |
| Codacci-Pisanelli, G | 3 |
| Lankelma, J | 2 |
| Van Gennip, AH | 4 |
| Bertè, R | 1 |
| Bidin, L | 2 |
| Civardi, G | 1 |
| Anselmi, E | 1 |
| Lazzaro, A | 1 |
| Moroni, CF | 1 |
| Palladino, MA | 1 |
| Rodinò, C | 1 |
| Vallisa, D | 1 |
| Rosales, J | 1 |
| Leong, LA | 1 |
| Kawashima, K | 1 |
| Satoh, S | 1 |
| Ikai, I | 1 |
| Katoh, K | 1 |
| Nakasato, T | 1 |
| Satoh, C | 1 |
| Ohtsuka, K | 1 |
| Cai, Q | 1 |
| Zhang, ZR | 1 |
| Tsang, KY | 1 |
| Del Vecchio, MT | 2 |
| Placa, ML | 1 |
| Intrivici, C | 2 |
| Aquino, A | 3 |
| Ferrari, F | 1 |
| Bonmassar, E | 2 |
| Elzagheid, A | 2 |
| Kapoor, M | 1 |
| Coombes, KR | 1 |
| Spalletta, B | 2 |
| Rocci, L | 1 |
| Pan, CX | 1 |
| Loehrer, P | 1 |
| Seitz, D | 1 |
| Helft, P | 1 |
| Juliar, B | 1 |
| Pletcher, W | 1 |
| Vinson, J | 1 |
| Sweeney, C | 1 |
| Dickson, JL | 1 |
| Butts, CA | 1 |
| Braud, Fd | 1 |
| Van Cutsem, EJ | 1 |
| Wade Iii, JL | 1 |
| Bearden Iii, JD | 1 |
| Borchard, E | 1 |
| Gil, J | 2 |
| Tsao-Wei, DD | 4 |
| Yun, J | 2 |
| Gordon, M | 1 |
| Press, OA | 1 |
| Rhodes, K | 1 |
| Tóvári, J | 1 |
| Gilly, R | 1 |
| Rásó, E | 1 |
| Paku, S | 1 |
| Bereczky, B | 1 |
| Varga, N | 1 |
| Vágó, A | 1 |
| Bakouboula, B | 1 |
| Morel, O | 1 |
| Douchet, MP | 1 |
| Chauvin, M | 1 |
| Niv, Y | 1 |
| Madden, M | 1 |
| Goldberg, P | 1 |
| Geddes, C | 1 |
| Van der Merwe, L | 1 |
| Wakelee, HA | 1 |
| Advani, RH | 1 |
| Ford, JM | 1 |
| Watabe, S | 1 |
| Kamano, T | 4 |
| Mok, T | 1 |
| Yeo, W | 1 |
| Lai, P | 1 |
| Koh, J | 1 |
| Wong, YY | 1 |
| King, A | 1 |
| Leow, CK | 1 |
| Giampaolo, MA | 1 |
| Mansueto, G | 1 |
| Buccilli, A | 1 |
| Ciccarese, M | 1 |
| Weihrauch, MR | 1 |
| Ansén, S | 1 |
| Jurkiewicz, E | 1 |
| Geisen, C | 1 |
| Anderson, KS | 1 |
| Gracien, E | 1 |
| Schmidt, M | 1 |
| Wittig, B | 1 |
| Diehl, V | 1 |
| Wolf, J | 1 |
| Bohlen, H | 1 |
| Nadler, LM | 1 |
| Jansen, AJ | 1 |
| Coenen, JL | 1 |
| de Graaf, JC | 1 |
| Smit, WM | 1 |
| Sleijfer, DT | 5 |
| Kamoshita, N | 2 |
| Makita, F | 1 |
| Aiba, M | 1 |
| Tokiniwa, H | 1 |
| Nagashima, T | 1 |
| Ohwada, S | 2 |
| Morishita, Y | 2 |
| García Palomo, A | 1 |
| Alonso López, C | 1 |
| León Carbonero, A | 1 |
| Adróver Cebrián, E | 1 |
| Barceló Galíndez, R | 1 |
| Arroyo Yustos, M | 1 |
| Alvarez Gallego, J | 1 |
| Czeglédi, F | 2 |
| Horváth, Z | 1 |
| Gyergyay, F | 1 |
| Lövey, J | 1 |
| Kovács, T | 2 |
| Kásler, M | 1 |
| Reed, E | 1 |
| Viguier, J | 1 |
| Miquel, C | 1 |
| Giraudeau, B | 1 |
| Sabourin, JC | 1 |
| Sarasin, A | 1 |
| Praz, F | 1 |
| Alhopuro, P | 1 |
| Alazzouzi, H | 1 |
| Sammalkorpi, H | 1 |
| Dávalos, V | 1 |
| Salovaara, R | 1 |
| Hemminki, A | 2 |
| Järvinen, H | 2 |
| Mecklin, JP | 2 |
| Schwartz, S | 1 |
| Aaltonen, LA | 2 |
| Arango, D | 1 |
| Brennan, DD | 1 |
| Farrelly, C | 1 |
| Cooney, R | 1 |
| Norris, S | 1 |
| McEniff, N | 1 |
| Massari, D | 1 |
| Trobonjac, Z | 1 |
| Rukavina, D | 1 |
| Radosević-Stasić, B | 1 |
| Cantor, M | 1 |
| Brahmandam, M | 1 |
| Namgyal, C | 1 |
| Kawasaki, T | 3 |
| Kinsella, K | 2 |
| Michelini, AL | 1 |
| Loda, M | 2 |
| Chang, DZ | 1 |
| Leonard, GD | 2 |
| Fioravanti, S | 1 |
| Harold, N | 1 |
| Schuler, B | 1 |
| Hillner, BE | 1 |
| Llorca Ferrándiz, C | 1 |
| Esquerdo Galiana, G | 1 |
| Cervera Grau, JM | 1 |
| Briceño García, HC | 1 |
| Calduch Broseta, JV | 1 |
| Del Pino Cuadrado, J | 1 |
| Rio, ED | 1 |
| Guichard, SM | 1 |
| Mayer, I | 1 |
| Jodrell, DI | 5 |
| Matin, K | 2 |
| Jacobs, SA | 1 |
| Richards, T | 1 |
| Wong, MK | 1 |
| Earle, M | 1 |
| Evans, T | 1 |
| Troetschel, M | 1 |
| Ferri, W | 1 |
| Friedland, D | 1 |
| Pinkerton, R | 1 |
| Volkin, R | 1 |
| Wieand, S | 2 |
| Masier, S | 1 |
| Cattarossi, G | 1 |
| Colussi, A | 1 |
| Galligan, L | 2 |
| Allen, W | 1 |
| Wilson, T | 1 |
| Wakui, K | 3 |
| Komatsu, N | 3 |
| Nakasaki, H | 5 |
| Nogué, M | 1 |
| Arcusa, A | 1 |
| de Mendizábal, EV | 1 |
| de Olaguer, JP | 1 |
| Boleda, M | 1 |
| Vicente, P | 2 |
| Hoeffding, LD | 1 |
| Palazzo, S | 1 |
| Iannace, C | 1 |
| Ianniello, GP | 2 |
| Pistillucci, G | 1 |
| Gemini, M | 1 |
| Persico, G | 1 |
| Choi, IS | 1 |
| Tsao-Wei, D | 2 |
| Sones, E | 1 |
| Mallik, N | 1 |
| Lim, L | 1 |
| Little, A | 1 |
| Bailey, W | 1 |
| Liechtenstein, M | 1 |
| Horvath, WL | 1 |
| Sternfeld, WC | 1 |
| Levitt, R | 4 |
| Nair, S | 2 |
| Viale, PH | 1 |
| Fung, A | 1 |
| Zitella, L | 1 |
| Karaiskou-McCaul, A | 1 |
| Kelly, D | 1 |
| Longley, D | 1 |
| Johnston, P | 1 |
| Nisticò, C | 4 |
| Hirabayashi, Y | 2 |
| Iki, K | 2 |
| Akiyama, T | 2 |
| Sadahira, Y | 1 |
| Gattuso, D | 1 |
| Morabito, A | 1 |
| Longo, R | 1 |
| Torino, F | 2 |
| Sarmiento, R | 1 |
| Vitale, S | 1 |
| Smorenburg, CH | 1 |
| van Riel, AM | 1 |
| Dercksen, W | 1 |
| Yuen, J | 1 |
| Sargeant, AM | 1 |
| Abdi, E | 3 |
| Shepherd, L | 1 |
| Mizuno, S | 1 |
| Fukushima, A | 1 |
| Matsuyama, Y | 1 |
| Ferrari, V | 1 |
| Valcamonico, F | 1 |
| Amoroso, V | 1 |
| Simoncini, E | 2 |
| Vassalli, L | 1 |
| Marpicati, P | 2 |
| Rangoni, G | 1 |
| Grisanti, S | 1 |
| Pasinetti, N | 1 |
| Yonemitsu, K | 1 |
| Sugihara, S | 1 |
| Tsuruta, Y | 1 |
| Teshima, K | 1 |
| Ehrsson, H | 1 |
| Mortensen, JP | 2 |
| Baltesgard, L | 1 |
| Wallin, I | 1 |
| Choi, MG | 1 |
| Chang, SK | 1 |
| Choi, SI | 1 |
| Lee, DS | 1 |
| Piñol, V | 1 |
| Gordon, MS | 1 |
| Nolting, A | 1 |
| Pollert, P | 1 |
| Schulthess, G | 1 |
| Kolyvanos Naumann, U | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| Bhatnagar, A | 2 |
| Harper, PG | 2 |
| Coleman, R | 2 |
| Coxon, F | 1 |
| Redfern, CH | 1 |
| Jones, JJ | 1 |
| Hawkins, R | 1 |
| Northfelt, D | 1 |
| Sreedharan, S | 1 |
| Valone, F | 1 |
| Tonachella, R | 1 |
| Tropea, F | 1 |
| Verri, C | 1 |
| Gionfra, T | 2 |
| Modugno, G | 1 |
| Gallo Curcio, C | 1 |
| Krakamp, B | 3 |
| Troidl, H | 1 |
| Xiao, JX | 1 |
| Han, M | 1 |
| Chen, LH | 1 |
| Bai, PS | 1 |
| Kates, TJ | 1 |
| Mazumdar, M | 1 |
| Yeung, H | 1 |
| Riedel, ER | 1 |
| Burt, BM | 1 |
| Larson, SM | 1 |
| Amano, M | 3 |
| Niinobu, T | 1 |
| Itani, Y | 1 |
| Higaki, N | 1 |
| Hayashida, H | 1 |
| Sakon, M | 1 |
| Shiba, Y | 1 |
| Umekita, N | 5 |
| Noda, K | 1 |
| Kitamura, M | 2 |
| Mackay, HJ | 1 |
| Billingsley, K | 1 |
| Smith, A | 1 |
| Yeung, R | 1 |
| Pond, GR | 1 |
| Croitoru, M | 1 |
| Swanson, PE | 1 |
| Krishnamurthi, S | 1 |
| Rigatos, SK | 1 |
| Stathopoulos, JG | 1 |
| Xynotroulas, JP | 1 |
| Dimou, E | 1 |
| López Vivanco, G | 1 |
| GarcíaGirón, C | 1 |
| Alonso, M | 1 |
| Castañón, C | 1 |
| Centelles, M | 1 |
| Pallis, A | 3 |
| Xenidis, N | 1 |
| Milaki, G | 1 |
| Benatti, P | 1 |
| Gafà, R | 1 |
| Barana, D | 1 |
| Marino, M | 1 |
| Scarselli, A | 1 |
| Maestri, I | 1 |
| Guerzoni, L | 1 |
| Menigatti, M | 1 |
| Roncari, B | 1 |
| Maffei, S | 1 |
| Rossi, G | 2 |
| Ponti, G | 1 |
| Santini, A | 1 |
| Losi, L | 1 |
| Di Gregorio, C | 1 |
| Oliani, C | 2 |
| Ponz de Leon, M | 1 |
| Lanza, G | 1 |
| Takita, N | 1 |
| Hata, M | 1 |
| Ohtsuka, T | 1 |
| Liu, XF | 1 |
| Koga, Y | 1 |
| Kitajima, Y | 2 |
| Nakafusa, Y | 2 |
| Ha, CW | 1 |
| Miyazaki, K | 2 |
| Cedermark, B | 1 |
| Bentzen, SM | 1 |
| Grönberg, H | 1 |
| Hultborn, R | 1 |
| Kubala, E | 1 |
| Pipková, R | 1 |
| Hladíková, J | 1 |
| Kodach, LL | 1 |
| Bos, CL | 1 |
| Durán, N | 1 |
| Peppelenbosch, MP | 1 |
| Ferreira, CV | 1 |
| Hardwick, JC | 1 |
| Grieve, R | 1 |
| Ishiguro, A | 2 |
| Saitoh, S | 2 |
| Becker, K | 2 |
| Macdonald, J | 3 |
| John, W | 1 |
| Vincent, JM | 1 |
| Perez-Enguix, D | 1 |
| Taylor, JR | 2 |
| Hollis, DR | 3 |
| Sutherland, S | 2 |
| Blanquicett, C | 2 |
| Buchsbaum, DJ | 1 |
| Eloubeidi, M | 1 |
| Vickers, SM | 1 |
| Chhieng, DC | 1 |
| Carpenter, MD | 1 |
| Sellers, JC | 1 |
| Russo, S | 1 |
| Johnson, MR | 1 |
| Ouchi, KF | 1 |
| Sekiguchi, F | 1 |
| Viti, M | 1 |
| Bhatnagar, P | 1 |
| Young, E | 1 |
| Padang, R | 1 |
| Barbado, M | 1 |
| Preisser, L | 1 |
| Verriele, V | 1 |
| Lorimier, G | 1 |
| Kurt, M | 1 |
| Babaoglu, MO | 2 |
| Yasar, U | 2 |
| Shorbagi, A | 1 |
| Guler, N | 1 |
| Yoshiyama, S | 1 |
| Vallböhmer, D | 3 |
| Cho, HK | 1 |
| Lee, ES | 1 |
| Shim, CK | 1 |
| Chung, SJ | 1 |
| Kim, DD | 1 |
| Varadhachary, GR | 1 |
| Sumiyoshi, T | 2 |
| Yoshizaki, N | 2 |
| Kuroiwa, G | 1 |
| Chirivella, I | 2 |
| Tsukada, A | 2 |
| Watanabe, E | 2 |
| Nagaoka, I | 3 |
| Futagawa, S | 3 |
| Koppe, MJ | 1 |
| Boerman, OC | 1 |
| Oyen, WJ | 2 |
| Gunes, A | 1 |
| Boruban, C | 1 |
| Gunel, N | 1 |
| Bozkurt, A | 1 |
| Rane, A | 1 |
| Hassan, M | 1 |
| Zengil, H | 1 |
| Nisi, E | 1 |
| Bottomley, A | 2 |
| McCollum, AD | 1 |
| Michelini, A | 3 |
| Martinez, J | 1 |
| Chacon, M | 1 |
| Korbenfeld, E | 1 |
| Bella, S | 1 |
| Senna, S | 1 |
| Richardet, E | 1 |
| Coppola, F | 1 |
| Bas, C | 1 |
| Hidalgo, J | 1 |
| Escobar, E | 1 |
| Reale, M | 1 |
| Smilovich, AM | 1 |
| Wasserman, E | 1 |
| Lønborg, JT | 1 |
| Bracco-Nolin, CH | 1 |
| Legat-Fagnoni, C | 1 |
| Chaigneau, L | 2 |
| Stein, U | 2 |
| Huchet, B | 1 |
| Woronoff-Lemsi, MC | 1 |
| Momiyama, N | 1 |
| Goyle, S | 1 |
| Maraveyas, A | 2 |
| Toftbagen, C | 1 |
| Shimomatsuya, T | 1 |
| Kobuchi, T | 1 |
| Kitamura, N | 1 |
| Shiraishi, S | 1 |
| Fujino, H | 1 |
| Maruhashi, K | 1 |
| Alliot, C | 1 |
| Hospers, GA | 1 |
| Schaapveld, M | 1 |
| de Jong, RS | 3 |
| de Gooyer, DJ | 1 |
| Slee, PH | 1 |
| Gerrits, CJ | 1 |
| Mulder, NH | 5 |
| Vincenzi, A | 1 |
| Naughton, MJ | 1 |
| Weeks, JC | 1 |
| Herndon, JE | 1 |
| Kalykaki, A | 3 |
| Samonis, G | 3 |
| Lundin, S | 2 |
| Bogdanow, M | 2 |
| Gorschlüter, M | 1 |
| Schmidt-Wolf, IG | 1 |
| Sauerbruch, T | 2 |
| Kaizuka, M | 1 |
| Kurumi, Y | 2 |
| Stoller, R | 1 |
| Auber, M | 1 |
| Potter, D | 1 |
| Cai, C | 1 |
| Kiefer, G | 1 |
| Ceelen, WP | 1 |
| Ooyama, A | 1 |
| Toda, E | 1 |
| Sugimoto, Y | 2 |
| Oka, T | 1 |
| Shimizu, M | 1 |
| Varette, C | 3 |
| Grazi, G | 1 |
| Ravaioli, M | 1 |
| Rivory, L | 1 |
| Beale, P | 4 |
| Ong, S | 1 |
| De Castro, J | 1 |
| de Mon, MA | 1 |
| Okita, A | 1 |
| Doihara, H | 1 |
| Suda, M | 1 |
| Nakano, T | 1 |
| Suzuki, E | 1 |
| Andou, A | 1 |
| Wang, GQ | 2 |
| Ren, JQ | 1 |
| Tang, SX | 1 |
| Ye, YL | 1 |
| Lin, SX | 1 |
| O'Neill, VJ | 1 |
| Warusavitarne, J | 1 |
| Ramanathan, P | 1 |
| Kaufman, A | 1 |
| Robinson, BG | 1 |
| Schnitzler, M | 1 |
| Miyakura, S | 1 |
| Takasaki, K | 1 |
| Dotor, E | 1 |
| Cuatrecases, M | 1 |
| Martínez-Iniesta, M | 1 |
| Vilardell, F | 1 |
| Pareja, L | 1 |
| Figueras, A | 1 |
| Serrano, T | 1 |
| de Oca, J | 1 |
| Peinado, MA | 1 |
| Germà, JR | 2 |
| Morese, R | 1 |
| Cianci, G | 1 |
| Di Rocco, ZC | 1 |
| Sánchez-Prudencio, S | 1 |
| Roda-Navarro, P | 1 |
| Lockhart, AC | 2 |
| Cropp, GF | 1 |
| Donnelly, E | 1 |
| Schumaker, RD | 1 |
| Schaaf, LJ | 2 |
| Hande, KR | 1 |
| Fleischer, AC | 1 |
| Hannah, AL | 1 |
| Jones, JA | 1 |
| Avritscher, EB | 1 |
| Cooksley, CD | 1 |
| Michelet, M | 1 |
| Bekele, BN | 1 |
| András, C | 2 |
| Farczádi, E | 1 |
| Szántó, J | 2 |
| Vincitore, M | 1 |
| Sheehan, S | 1 |
| Plantade, A | 1 |
| Kho, Y | 1 |
| Prins, NH | 1 |
| Neef, C | 1 |
| Alvarez, JV | 1 |
| López, MJ | 1 |
| Segovia, F | 1 |
| Filipovich, E | 1 |
| Castro, IG | 1 |
| Madary, A | 1 |
| Hewes, JC | 1 |
| Riddy, D | 1 |
| Morris, RW | 1 |
| Woodrooffe, AJ | 1 |
| Fuller, B | 1 |
| Crews, KR | 1 |
| Potamianou, A | 1 |
| Tselepatiotis, E | 1 |
| Christofillakis, C | 1 |
| Akazai, Y | 1 |
| Nitta, Y | 1 |
| Sturm, I | 1 |
| Rau, B | 1 |
| Hauptmann, S | 1 |
| Daniel, PT | 1 |
| Gupta, N | 1 |
| Saleem, A | 1 |
| Kötz, B | 1 |
| Osman, S | 2 |
| Phillips, R | 1 |
| Vernon, C | 1 |
| Jones, T | 3 |
| Hoskin, PJ | 1 |
| Price, PM | 3 |
| Crozier, JE | 1 |
| McKee, RF | 1 |
| Angerson, WJ | 1 |
| Anderson, JH | 5 |
| Pagenstecher, C | 1 |
| Friedrichs, N | 1 |
| Ryu, MH | 3 |
| Ha, HK | 1 |
| La Mura, N | 1 |
| Malaguarnera, M | 2 |
| Fulvi, A | 1 |
| Shehu, I | 1 |
| Melloni, G | 1 |
| Doglioni, C | 1 |
| Bandiera, A | 1 |
| Carretta, A | 1 |
| Ciriaco, P | 1 |
| Arrigoni, G | 1 |
| Zannini, P | 1 |
| Guida, C | 1 |
| Marone, P | 1 |
| Cascini, LG | 1 |
| Morrica, B | 1 |
| Parisi, V | 2 |
| Beaven, AW | 1 |
| García-Martín, E | 1 |
| Pizarro, RM | 1 |
| Martínez, C | 1 |
| Gutierrez-Martín, Y | 1 |
| Pérez, G | 2 |
| Agúndez, JA | 1 |
| Lin, EH | 1 |
| Crane, CC | 1 |
| Feig, B | 1 |
| Delcos, M | 1 |
| Vadhan, SR | 1 |
| Ross, A | 1 |
| Brown, T | 2 |
| Rodriguez-Bigas, MA | 1 |
| Janjan, N | 1 |
| Di Renzo, N | 1 |
| Mallamaci, R | 1 |
| Verderame, F | 1 |
| Callari, A | 1 |
| Tirrito, ML | 2 |
| Valenza, R | 1 |
| Tralongo, P | 1 |
| Kawakami, M | 1 |
| Kihara, C | 1 |
| Ohmura, T | 1 |
| Katsuramaki, T | 1 |
| Terstriep, S | 1 |
| Murr, R | 1 |
| Ogino, K | 1 |
| Hiroyoshi, M | 1 |
| Fujita, H | 1 |
| Itoh, T | 1 |
| Toyama, H | 1 |
| Kawai, Y | 1 |
| Makita, D | 1 |
| Tsunemi, K | 1 |
| Moritomo, H | 1 |
| Sculli, CM | 1 |
| Gorzegno, G | 1 |
| Magnino, A | 2 |
| Sperti, E | 3 |
| Miraglia, S | 1 |
| Harris, A | 1 |
| Dogliotti, L | 4 |
| Tsuruoka, Y | 1 |
| Ward, SE | 1 |
| Marples, M | 1 |
| Orr, B | 1 |
| Bach, SP | 1 |
| Williamson, SE | 1 |
| O'Dwyer, ST | 1 |
| Potten, CS | 1 |
| Watson, AJ | 1 |
| Shalan, N | 1 |
| Pasetto, LM | 1 |
| De Pangher, V | 1 |
| Giusto, M | 1 |
| Medici, M | 1 |
| Gaion, F | 1 |
| Sandri, P | 1 |
| Galligioni, E | 2 |
| Bonura, S | 1 |
| Boccalon, M | 1 |
| Mousseau, M | 4 |
| Cassan, P | 2 |
| Leduc, B | 1 |
| Berger, C | 1 |
| Dunant, A | 1 |
| Fournet, J | 1 |
| Suto, K | 1 |
| Li, KM | 1 |
| Rivory, LP | 2 |
| Hoskins, J | 1 |
| Mooney, M | 1 |
| Boron, M | 1 |
| Vena, D | 1 |
| Mosby, K | 1 |
| Grochow, L | 1 |
| Jaffe, C | 1 |
| Rubinstein, L | 1 |
| Zwiebel, J | 1 |
| Kremer, A | 2 |
| Stieber, P | 1 |
| Wilkowski, R | 1 |
| Nagel, D | 1 |
| Seidel, D | 1 |
| Nakata, E | 1 |
| Takai, Y | 1 |
| Nemoto, K | 1 |
| Ogawa, Y | 1 |
| Nomiya, T | 1 |
| Milas, L | 1 |
| Romero, RZ | 1 |
| Morales, R | 1 |
| Garcia, F | 1 |
| Huarriz, M | 1 |
| De la Haba, J | 1 |
| Segura, C | 1 |
| Douma, J | 3 |
| Akkermans-Vogelaar, JM | 1 |
| Levy, DE | 1 |
| Bjarnason, G | 2 |
| Anciaux, N | 1 |
| Gorlia, T | 1 |
| Monga, DK | 1 |
| Patiyil, S | 1 |
| Scholtens, D | 1 |
| Betensky, RA | 1 |
| Biedrzycki, BA | 1 |
| Berg, DT | 1 |
| Nagaya, M | 2 |
| Tsukikawa, S | 4 |
| Yanagi, Y | 1 |
| Isogai, A | 3 |
| Dhami, M | 1 |
| Godfrey, T | 1 |
| Kovatich, AJ | 1 |
| Lund, KA | 1 |
| Schwarting, R | 1 |
| Virzí, V | 1 |
| Mitchell, PL | 1 |
| Friedlander, M | 2 |
| White, S | 1 |
| Thomson, JA | 1 |
| Scapoli, D | 1 |
| Grigoletto, F | 1 |
| Popat, S | 1 |
| Zhao, D | 1 |
| Hearle, N | 1 |
| Chandler, I | 1 |
| Aherne, W | 1 |
| Houlston, R | 1 |
| Faggiuolo, R | 3 |
| Gerbino, A | 1 |
| Ortega, C | 1 |
| Ferraris, R | 1 |
| Mattison, LK | 1 |
| Fourie, J | 1 |
| Desmond, RA | 1 |
| Modak, A | 1 |
| Rijpkema, M | 1 |
| Kamm, YL | 2 |
| Barentsz, JO | 1 |
| Song, WX | 1 |
| Mehendale, S | 1 |
| Lee, C | 1 |
| Eckhoff, L | 1 |
| Schønnemann, K | 1 |
| Aabo, K | 2 |
| Ojima, E | 1 |
| Murphy, KM | 1 |
| Read, JA | 1 |
| Beale, PJ | 1 |
| Volker, DH | 1 |
| Smith, N | 1 |
| Childs, A | 1 |
| Yoo, PS | 1 |
| Lopez-Soler, RI | 1 |
| Longo, WE | 1 |
| Cha, CH | 1 |
| Wolpin, BM | 3 |
| Blaszkowsky, L | 2 |
| Merritt, J | 1 |
| Robbins, J | 1 |
| Schupp, J | 1 |
| Fellague-Chebra, R | 1 |
| Postel Vinay, S | 1 |
| Fey, L | 1 |
| Lainé-Cessac, P | 1 |
| Boldrini, L | 1 |
| Lastella, M | 2 |
| Giostra, E | 2 |
| Audard, V | 1 |
| Sartoretti, P | 1 |
| Dousset, B | 1 |
| Majno, PE | 2 |
| Soubrane, O | 1 |
| Terris, B | 1 |
| Canale, ML | 1 |
| Camerini, A | 1 |
| Stroppa, S | 1 |
| Porta, RP | 1 |
| Caravelli, P | 1 |
| Mariani, M | 1 |
| Balbarini, A | 1 |
| Sahajpal, A | 1 |
| Vollmer, CM | 1 |
| Chan, EK | 1 |
| Cattral, MS | 1 |
| Taylor, BR | 1 |
| Grant, DR | 1 |
| Greig, PD | 1 |
| Charnsangavej, C | 1 |
| Rosen, LS | 3 |
| Davis, ID | 2 |
| Gutheil, J | 2 |
| Schnell, FM | 2 |
| Cesano, A | 2 |
| Gayko, U | 2 |
| Chen, MG | 2 |
| Saric, J | 1 |
| Aloia, T | 1 |
| Plasse, M | 1 |
| Karam, V | 1 |
| Gotlib, V | 1 |
| Khaled, S | 1 |
| Lapko, I | 1 |
| Mar, N | 1 |
| Rouquie, D | 1 |
| Ciuchendea, R | 1 |
| Qi, R | 1 |
| Bo, L | 1 |
| Kotsakis, AP | 1 |
| Gioulbasanis, J | 1 |
| Tsetis, D | 2 |
| Sfakiotaki, G | 2 |
| Chatzidaki, D | 1 |
| Rosa, DD | 1 |
| Ismael, GF | 1 |
| de Azambuja, E | 1 |
| Braga, S | 1 |
| Cardoso, F | 1 |
| Benizri, E | 1 |
| Di Pietrantonio, D | 1 |
| Menegon, P | 1 |
| Sun, YJ | 1 |
| Guo, YW | 2 |
| Tang, XC | 1 |
| Tang, LN | 1 |
| Klumpen, HJ | 1 |
| Westermann, AM | 1 |
| Zoetekouw, L | 1 |
| Van Lenthe, H | 3 |
| Bakker, PJ | 3 |
| Martoni, AA | 1 |
| Lelli, G | 1 |
| Rojas Llimpe, FL | 1 |
| Gentile, AL | 2 |
| Mutri, V | 1 |
| Ballardini, P | 1 |
| Giaquinta, S | 1 |
| Piana, E | 2 |
| Ramani, VS | 1 |
| Gollins, SW | 1 |
| Bouzari, H | 1 |
| Amisano, M | 1 |
| Massucco, P | 1 |
| Chao, TC | 1 |
| Tiu, CM | 1 |
| de Geus-Oei, LF | 1 |
| Leer, JW | 1 |
| Corstens, FH | 1 |
| da Silva, RG | 1 |
| Tumber, A | 1 |
| Collins, LS | 1 |
| Petersen, KD | 1 |
| Thougaard, A | 1 |
| Christiansen, SJ | 1 |
| Dejligbjerg, M | 1 |
| Jensen, PB | 1 |
| Sehested, M | 1 |
| Ritchie, JW | 1 |
| Chalbos, P | 2 |
| Bressole, F | 1 |
| Gennatas, C | 2 |
| Michalaki, V | 1 |
| Mouratidou, D | 1 |
| Andreadis, C | 1 |
| Pafiti, A | 1 |
| Zhou, ZT | 1 |
| Konishi, N | 1 |
| Sato, G | 1 |
| Di Leonardo, G | 1 |
| D'Argento, E | 2 |
| Kecmanovic, D | 1 |
| Tomasevic, Z | 1 |
| Borojevic, N | 1 |
| Micev, MT | 1 |
| Kezic, I | 1 |
| Paolelli, L | 1 |
| Civitelli, S | 2 |
| Cioppa, T | 1 |
| Roviello, F | 2 |
| Nettuno, R | 1 |
| Tanzini, G | 2 |
| Lorenzi, M | 3 |
| Ciaparrone, M | 2 |
| Zannoni, G | 2 |
| La Torre, G | 1 |
| Fukuyama, R | 1 |
| Ng, KP | 1 |
| Cicek, M | 1 |
| Kelleher, C | 1 |
| Niculaita, R | 1 |
| Sizemore, N | 1 |
| MacLeod, A | 1 |
| Branch, A | 1 |
| Mohammed, N | 1 |
| MacDonald, L | 1 |
| Wakabayashi, I | 1 |
| Kasai, M | 1 |
| Muto, O | 2 |
| Okada, R | 1 |
| Mitobe, S | 1 |
| Sakuraba, H | 1 |
| Ikami, I | 1 |
| Wollert, J | 1 |
| Salgado, J | 1 |
| Zabalegui, N | 1 |
| Gil, C | 1 |
| Monreal, I | 1 |
| Aphinives, P | 1 |
| Bhudhisawasdi, V | 1 |
| Sae-seow, O | 1 |
| Uttaravichien, T | 1 |
| Baize, N | 1 |
| Gerard, B | 3 |
| Caroli-Bosc, F | 1 |
| Berthier, F | 1 |
| Pector, JC | 2 |
| Hattori, T | 4 |
| Kokubu, T | 1 |
| Mine, T | 2 |
| Itoh, K | 2 |
| Shiozaki, H | 1 |
| Shiozaki, K | 2 |
| Ohtani, T | 1 |
| Ohsawa, G | 1 |
| Gonda, T | 1 |
| Tegze, B | 1 |
| Tulassay, Z | 1 |
| Eder, JP | 1 |
| Stewart, CF | 1 |
| D'Amato, F | 1 |
| Bartel, C | 1 |
| Henry, A | 1 |
| Poethig, M | 1 |
| Masson, E | 1 |
| Wiedenmann, B | 1 |
| Milner, AD | 1 |
| Bolling, C | 1 |
| Rakhit, A | 2 |
| Fettner, S | 1 |
| Brennscheidt, U | 2 |
| Feyereislova, A | 2 |
| Doyle, DP | 1 |
| Engelking, C | 1 |
| Moran, T | 1 |
| Cirauqui, B | 1 |
| Catot, S | 1 |
| Adena, M | 1 |
| Krämer, I | 1 |
| Lipp, HP | 1 |
| Javle, MM | 1 |
| Durrani, FA | 1 |
| Lawrence, DD | 1 |
| Smith, PF | 1 |
| Creaven, PJ | 7 |
| Noel, DC | 1 |
| Iyer, RV | 1 |
| Futamura, Y | 1 |
| Hibi, S | 1 |
| Nagaoka, M | 1 |
| Yuasa, S | 1 |
| Nagao, S | 1 |
| Gelibter, AJ | 2 |
| Di Segni, S | 1 |
| Nuzzo, C | 2 |
| Wan, de S | 1 |
| Chen, YB | 1 |
| Spirovski, B | 1 |
| Sapp, CM | 1 |
| DeSimone, P | 2 |
| Molina, F | 2 |
| Bascoul-Mollevi, C | 2 |
| Copois, V | 2 |
| Bareil, C | 1 |
| Salvetat, N | 1 |
| Fraslon, C | 2 |
| Conseiller, E | 2 |
| Leblanc, B | 1 |
| Pau, B | 1 |
| Jansen, G | 1 |
| Singh, S | 1 |
| Bhinge, JR | 1 |
| Aupérin, A | 1 |
| Clavero-Fabri, MC | 1 |
| Stremsdoerfer, N | 1 |
| Nasca, S | 1 |
| Queuniet, AM | 1 |
| Lahans, T | 1 |
| Neri, B | 1 |
| Pantaleo, P | 1 |
| Grifoni, R | 1 |
| Paoletti, C | 1 |
| Rotella, V | 1 |
| Pantalone, D | 1 |
| Taddei, A | 1 |
| Mercatelli, A | 1 |
| Tonelli, P | 1 |
| Blanshard, K | 1 |
| Shannon, JA | 1 |
| Sorscher, SM | 1 |
| Hoffmann, D | 1 |
| Grunwald, T | 1 |
| Kuate, S | 1 |
| Wildner, O | 1 |
| Cho, BC | 1 |
| Jeung, HC | 2 |
| Kourousis, C | 1 |
| Heuer, T | 1 |
| Nusch, A | 1 |
| Ficarelli, R | 2 |
| Silva, R | 1 |
| Chiou, TJ | 4 |
| Yen, CC | 3 |
| Gootenberg, J | 1 |
| Cho, HJ | 1 |
| Tan, L | 2 |
| Luo, SQ | 2 |
| Manza, SG | 1 |
| Rusin, B | 1 |
| Ferris, AM | 1 |
| Vaishampayan, U | 1 |
| Heilbrun, LK | 1 |
| Venkatramanamoorthy, R | 1 |
| Tominaga, S | 2 |
| Itagaki, H | 1 |
| Onuki, M | 1 |
| Akashi, T | 1 |
| Hanaoka, T | 1 |
| Minami, K | 2 |
| Kameda, A | 1 |
| Tsutani, Y | 1 |
| Miyahara, E | 1 |
| Noso, Y | 1 |
| Almond, J | 1 |
| Ralston, S | 1 |
| Schwartz, MA | 1 |
| Korkeila, E | 3 |
| Maruta, F | 1 |
| Iinuma, N | 1 |
| Ishizone, S | 1 |
| Koide, N | 1 |
| Nakayama, J | 1 |
| Giovannini, I | 1 |
| Shomura, H | 1 |
| Yamada, A | 1 |
| Todo, S | 2 |
| Kokuba, Y | 1 |
| Ozawa, H | 2 |
| Hatate, K | 1 |
| Onosato, W | 1 |
| Ihara, A | 2 |
| Chiba, H | 1 |
| Makino, K | 1 |
| Ohura, K | 1 |
| Benedetti, G | 1 |
| Evangelista, W | 1 |
| Picone, V | 1 |
| Porcile, G | 1 |
| Orlandini, C | 2 |
| Parks, R | 1 |
| Blumgart, LH | 2 |
| Enzinger, P | 1 |
| Lawrence, C | 1 |
| Malik, Z | 1 |
| Doci, R | 2 |
| Rosati, R | 1 |
| Pedicini, V | 1 |
| Gullo, G | 1 |
| Abbadessa, G | 1 |
| Morenghi, E | 1 |
| Marcon, I | 1 |
| Garassino, I | 1 |
| Skopelitis, H | 2 |
| Papadoniou, N | 1 |
| Adoniou, E | 1 |
| Gryniatsos, J | 1 |
| Felekouras, E | 1 |
| Zacharakis, M | 1 |
| Sigala, F | 1 |
| Terashima, M | 1 |
| Bijelic, L | 1 |
| Brooks, AJ | 1 |
| Begg, EJ | 1 |
| Chapman, BA | 1 |
| Fitzharris, BM | 1 |
| Shapiro, S | 1 |
| Hughes, G | 1 |
| Al-Obaidi, MJ | 1 |
| Ramesh, S | 1 |
| Smith, J | 1 |
| Ahmad, R | 1 |
| Dawson, C | 1 |
| Riddle, P | 1 |
| Sekhar, M | 1 |
| Offterdinger, M | 1 |
| Tischer, C | 1 |
| Girod, A | 1 |
| Lommerse, PH | 1 |
| Magdeburg, R | 1 |
| Bastiaens, PI | 1 |
| Naitoh, H | 1 |
| Posey, J | 1 |
| Tchekmedyian, S | 1 |
| Hu, E | 1 |
| Amado, RG | 1 |
| Xiao, BX | 1 |
| Zeng, WS | 1 |
| Zou, ZP | 1 |
| Xu, AM | 1 |
| Diamandidou, E | 1 |
| Touroutoglou, N | 1 |
| Chatzidakis, A | 1 |
| Hiraoka, K | 1 |
| Logg, CR | 1 |
| Tai, CK | 1 |
| Haga, K | 1 |
| Lawson, GW | 1 |
| Kasahara, N | 1 |
| Andreoni, F | 2 |
| Mari, D | 1 |
| Pizzagalli, F | 1 |
| Testa, E | 1 |
| Menichetti, ET | 2 |
| Sowa, M | 3 |
| Fukunaga, Y | 1 |
| Tsujitani, S | 2 |
| Mitachi, Y | 1 |
| Iyevleva, AG | 1 |
| Buslov, KG | 1 |
| Togo, AV | 1 |
| Matsko, DE | 1 |
| Filimonenko, VP | 1 |
| Imyanitov, EN | 1 |
| McWilliams, RR | 1 |
| Morlan, BW | 1 |
| Krook, JE | 10 |
| Ames, MM | 1 |
| Ashley, AC | 1 |
| Iversen, A | 1 |
| Vejlø, C | 1 |
| Koyanagi, Y | 2 |
| Fukuoka, M | 1 |
| Laus, G | 1 |
| Martignetti, A | 1 |
| Zorzino, L | 2 |
| Lorizzo, K | 1 |
| Santoro, L | 2 |
| Boselli, S | 1 |
| De Ruvo, N | 1 |
| Drigo, A | 1 |
| Cho, YY | 1 |
| Ahn, BM | 1 |
| Kim, SN | 1 |
| Lee, IT | 1 |
| Haines, IE | 1 |
| Lazaris, AC | 1 |
| Papathomas, TG | 1 |
| Nonni, A | 1 |
| Delladetsima, J | 1 |
| Patsouris, ES | 1 |
| Sauter, A | 1 |
| Triller, J | 1 |
| Schmidt, F | 1 |
| Kickuth, R | 1 |
| Yang, DY | 1 |
| Tan, MC | 1 |
| Siegel, BA | 1 |
| Tesselaar, ME | 1 |
| Slee, PHTJ | 1 |
| Gwyther, SJ | 1 |
| Smith, DB | 1 |
| Shepherd, S | 1 |
| Griffiths, GO | 1 |
| van Halteren, HK | 2 |
| Liem, AH | 1 |
| Kallistratos, MS | 1 |
| Syrios, J | 1 |
| Mylonakis, N | 3 |
| Karabelis, A | 1 |
| Cardot, JM | 2 |
| Yao, YF | 1 |
| Zhang, HG | 2 |
| Zhang, YJ | 1 |
| Song, SP | 1 |
| Chu, DT | 2 |
| Pollera, CF | 1 |
| Signorelli, C | 1 |
| Gasperoni, S | 4 |
| Takeuchi, S | 2 |
| Abrahantes, JC | 1 |
| Burzykowski, T | 3 |
| Maehara, S | 1 |
| Makino, I | 1 |
| Imamura, S | 1 |
| Aso, M | 1 |
| Katoh, H | 1 |
| Cobo, F | 1 |
| De Celis, G | 1 |
| Pereira, A | 1 |
| Latorre, X | 1 |
| Pujadas, J | 1 |
| Albiol, S | 1 |
| Vénat-Bouvet, L | 1 |
| Saint-Marcoux, F | 1 |
| Lagarde, C | 1 |
| Peyronnet, P | 1 |
| Harrop, R | 2 |
| Drury, N | 2 |
| Shingler, W | 2 |
| Chikoti, P | 2 |
| Redchenko, I | 2 |
| Carroll, MW | 2 |
| Kingsman, SM | 2 |
| Naylor, S | 2 |
| Melcher, A | 1 |
| Nicholls, J | 1 |
| Wassan, H | 1 |
| Habib, N | 1 |
| Kulig, J | 2 |
| Richter, P | 1 |
| Klek, S | 1 |
| Sticca, RP | 1 |
| Inui, N | 1 |
| Evans, TR | 1 |
| Somanath, S | 1 |
| Schatzlein, A | 1 |
| Takagi, Y | 2 |
| Horsmans, Y | 1 |
| Rahier, J | 1 |
| Machiels, JP | 1 |
| Ceratti, A | 1 |
| He, W | 1 |
| Cao, DY | 1 |
| Xiang, B | 1 |
| Fan, LF | 1 |
| Abadie-Lacourtoisie, S | 1 |
| Xiong, JP | 1 |
| Zhong, LX | 1 |
| Tao, QS | 1 |
| Tang, XM | 1 |
| Prezerakos, P | 1 |
| Hasuike, N | 1 |
| Ono, H | 2 |
| Purim, O | 1 |
| Sulkes, A | 3 |
| Lee, FC | 1 |
| Liebmann, JE | 1 |
| Diamandidis, D | 1 |
| Eckhardt, SG | 1 |
| Javle, M | 1 |
| Justice, GR | 1 |
| Keiser, W | 1 |
| Salvatore, JR | 1 |
| Bexon, A | 1 |
| Cai, RG | 1 |
| Wu, F | 1 |
| Senesse, P | 1 |
| Kondoh, K | 1 |
| Thomsen Lønborg, J | 1 |
| Vilmar, A | 1 |
| Mård, D | 1 |
| Astrup Jensen, S | 1 |
| Aloysius, MM | 1 |
| Zaitoun, AM | 1 |
| Beckingham, IJ | 1 |
| Neal, KR | 1 |
| Aithal, GP | 1 |
| Lobo, DN | 1 |
| Celio, L | 1 |
| Denaro, A | 1 |
| Dotti, K | 1 |
| Mancin, M | 1 |
| Pusceddu, S | 1 |
| Solano, JM | 1 |
| Bakri, SJ | 1 |
| Pulido, JS | 1 |
| Oestreicher, P | 1 |
| Avninder, S | 1 |
| Agrawal, U | 1 |
| Saxena, S | 1 |
| Blanchard, P | 1 |
| Huguet, F | 1 |
| Ray-Coquard, I | 1 |
| Bachelot, T | 1 |
| Saba, C | 1 |
| Confavreux, C | 1 |
| Brantus, JF | 1 |
| Rustam, F | 1 |
| Ghesquière, H | 1 |
| Sebban, C | 1 |
| Biron, P | 1 |
| Guastalla, JP | 1 |
| Blay, JY | 1 |
| Li, YM | 1 |
| Jin, X | 1 |
| Fanciullino, R | 1 |
| Piccerelle, P | 1 |
| Hiraoka, T | 1 |
| Higuchi, S | 1 |
| Matsuzaka, S | 2 |
| Niitsu, Y | 1 |
| Hamaguchi, J | 1 |
| Kamiyama, N | 1 |
| Deguchi, K | 1 |
| Valta, P | 1 |
| Kouri, M | 2 |
| Astone, A | 3 |
| Terraz, S | 1 |
| Allal, AS | 1 |
| Tappenden, P | 2 |
| Jones, R | 1 |
| Paisley, S | 1 |
| Carroll, C | 1 |
| Yaman, E | 2 |
| Uner, A | 2 |
| Polat, M | 1 |
| Yamac, D | 1 |
| Afroza, A | 1 |
| Hasan, S | 1 |
| Rukunuzzaman, M | 1 |
| Hussain, SA | 1 |
| Amin, R | 1 |
| Ogreid, D | 3 |
| Wanderås, EH | 1 |
| Wentzel-Larsen, T | 1 |
| Sengupta, R | 1 |
| Qazi, S | 1 |
| Vachhani, H | 1 |
| Rishi, AK | 1 |
| Château, Y | 1 |
| Koo, DH | 1 |
| Hamberg, P | 1 |
| De Jong, FA | 1 |
| Brandsma, D | 1 |
| Sleijfer, S | 1 |
| Moreno-Solórzano, I | 1 |
| Ibeas-Rollan, R | 1 |
| Monzó-Planella, M | 1 |
| Moreno-Solórzano, J | 1 |
| Martínez-Ródenas, F | 1 |
| Pou-Sanchis, E | 1 |
| Hernández-Borlan, R | 1 |
| Navarro-Vigo, M | 2 |
| Ortigosa-Rodríguez, S | 1 |
| Gel-Moreno, B | 1 |
| Chang, AY | 1 |
| Lopes, G | 1 |
| Hsin, KW | 1 |
| Fong, FK | 1 |
| O'Dwyer, P | 2 |
| Issa, JP | 1 |
| Wierzbicki, R | 1 |
| Jeffery, M | 1 |
| Ahmed, IA | 1 |
| Kelly, SB | 1 |
| Anderson, JJ | 1 |
| Angus, B | 1 |
| Challen, C | 1 |
| Lunec, J | 1 |
| Takami, H | 1 |
| Gotoh, H | 1 |
| Gotoh, Y | 1 |
| Vega, ME | 1 |
| Meric, JB | 1 |
| Buechele, T | 1 |
| Bir, A | 1 |
| Tan, W | 1 |
| Fettner, SH | 1 |
| Folkvord, S | 1 |
| Seierstad, T | 1 |
| Røe, K | 1 |
| Rasmussen, H | 1 |
| Bruce, C | 1 |
| Sugimoto, M | 1 |
| Yasuda, H | 1 |
| Yamazaki, M | 6 |
| Takenoue, T | 1 |
| Higuchi, R | 1 |
| Watayo, Y | 1 |
| Yagawa, Y | 1 |
| Carroll, K | 1 |
| Miller, LL | 4 |
| Elfring, GL | 4 |
| Soulié, P | 3 |
| Valera, JS | 1 |
| Senzaki, M | 1 |
| Ishida, S | 1 |
| Yada, A | 1 |
| Hanai, M | 1 |
| Kurakata, S | 1 |
| Moon, YW | 1 |
| Yoo, NC | 1 |
| Noh, SH | 1 |
| Min, JS | 1 |
| Kim, BS | 1 |
| Kamnerdsupaphon, P | 1 |
| Lorvidhaya, V | 1 |
| Chitapanarux, I | 1 |
| Tonusin, A | 1 |
| Sukthomya, V | 1 |
| Battistelli, S | 1 |
| Armbrust, T | 1 |
| Sobotta, M | 1 |
| Füzesi, L | 1 |
| Grabbe, E | 1 |
| Ramadori, G | 1 |
| Shimamoto, H | 1 |
| Wilson, KS | 1 |
| Fitzgerald, CA | 1 |
| Barnett, JB | 1 |
| Khoo, KE | 1 |
| Salvagni, S | 1 |
| Pucci, F | 1 |
| Crocicchio, F | 1 |
| Griffiths, R | 1 |
| Hawkins, RE | 2 |
| Cha, SH | 1 |
| Braumann, D | 2 |
| Janssens, J | 1 |
| Späth-Schwalbe, E | 1 |
| Van Den Brande, J | 1 |
| Bethe, U | 2 |
| Kajiwara, T | 1 |
| Kataoka, J | 1 |
| Imamine, S | 1 |
| Iguchi, H | 1 |
| Taucher, S | 1 |
| Steger, GG | 2 |
| Tausch, C | 1 |
| Wette, V | 1 |
| Schippinger, W | 1 |
| Kwasny, W | 1 |
| Reiner, G | 1 |
| Dubsky, P | 1 |
| Poestlberger, S | 1 |
| Tschmelitsch, J | 1 |
| Barnwell, J | 2 |
| McConkey, C | 2 |
| Hills, RK | 1 |
| Williams, NS | 1 |
| Schiel, X | 1 |
| Scheidt, B | 1 |
| Reitmeier, M | 1 |
| Hoffmann, U | 1 |
| Lutz, L | 1 |
| Choi, CK | 1 |
| Tung, SY | 1 |
| Lui, L | 1 |
| Siu, S | 1 |
| Au, GK | 1 |
| Ho, JW | 1 |
| Oussoultzoglou, E | 1 |
| Rosso, E | 1 |
| Chenard-Neu, MP | 1 |
| Mehta, NN | 1 |
| Ravikumar, R | 1 |
| Coldham, CA | 1 |
| Buckels, JA | 1 |
| Hubscher, SG | 1 |
| Bramhall, SR | 1 |
| Wigmore, SJ | 1 |
| Mayer, AD | 1 |
| Paz-Ares, L | 1 |
| Quinn, S | 1 |
| Lejeune, C | 1 |
| Marimón, I | 1 |
| Andreu, J | 1 |
| Ubbelohde, U | 1 |
| Hedrick, EE | 1 |
| Scalamogna, R | 1 |
| Sagrada, P | 1 |
| Gattoni, E | 1 |
| Riccardi, A | 2 |
| Luchena, G | 1 |
| Corazza, GR | 1 |
| Oguz, M | 1 |
| B, DY | 1 |
| Nagatsuka, R | 1 |
| Kawabe, Y | 1 |
| Fuchimoto, M | 1 |
| Oka, Y | 1 |
| Imai, S | 5 |
| Koizumi, F | 1 |
| Li, HJ | 1 |
| Fu, SY | 1 |
| Ibeas, R | 1 |
| Gel, B | 1 |
| Martinez, F | 1 |
| Moreno, J | 1 |
| Bovio, H | 1 |
| Colomer, R | 1 |
| Tveit, K | 2 |
| Heikkilä, R | 2 |
| Denis, V | 1 |
| Bec, N | 1 |
| Robert, B | 1 |
| Larroque, C | 1 |
| Rubinov, K | 1 |
| Mermershtain, W | 3 |
| Ariad, S | 1 |
| London, R | 1 |
| Liddle, C | 1 |
| Shah, N | 1 |
| Tai, BC | 1 |
| Han, HC | 1 |
| Fang, WY | 1 |
| Lee, SC | 1 |
| Kandutsch, S | 1 |
| Berdah, JF | 1 |
| Chamorey, E | 2 |
| Lesbats, G | 1 |
| Teissier, E | 1 |
| Codoul, JF | 1 |
| Badetti, JL | 1 |
| Hébert, C | 1 |
| Mari, V | 1 |
| Thürmann, PA | 1 |
| Gallego-Plazas, J | 1 |
| Rothenberg, M | 1 |
| Rosen, L | 1 |
| Englisch-Fritz, C | 1 |
| Bjerregaard, J | 1 |
| Jensen, B | 1 |
| Shastri, K | 1 |
| Pilaro, AM | 1 |
| Cordoba-Rodriguez, R | 1 |
| Koti, K | 1 |
| Men, AY | 1 |
| Hughes, M | 1 |
| Weiss, KD | 1 |
| Dell'Orto, P | 1 |
| Sonzogni, A | 1 |
| Fazio, N | 1 |
| Monfardini, L | 1 |
| Chiappa, A | 1 |
| Biffi, R | 2 |
| Underhill, C | 1 |
| Gorbounova, VA | 1 |
| Biakhov, MY | 1 |
| Bazin, IS | 1 |
| Granov, DA | 1 |
| Blatter, J | 1 |
| Zuckerman, DS | 1 |
| Itimura, T | 1 |
| Syouji, D | 1 |
| Watanabe, C | 1 |
| Tazawa, K | 1 |
| Sawada, S | 1 |
| Nagata, T | 1 |
| Uotani, H | 1 |
| Hirokawa, S | 1 |
| Yamagishi, F | 1 |
| Tsukada, K | 2 |
| Torresi, U | 1 |
| Humar, B | 1 |
| Schubert, U | 2 |
| Praet, M | 1 |
| Seya, T | 1 |
| Kanazawa, Y | 1 |
| Ohaki, Y | 1 |
| Tajiri, T | 1 |
| Cohen, DJ | 1 |
| Viel, E | 1 |
| Demarchi, MF | 1 |
| Legat, C | 1 |
| Thiery-Vuillemin, A | 1 |
| Wei, WQ | 1 |
| Liu, DZ | 1 |
| Zeng, HY | 1 |
| Yang, LX | 1 |
| Zielinski, C | 2 |
| Herbst, F | 1 |
| Toda, S | 1 |
| Moriyama, J | 1 |
| Ehara, K | 1 |
| Mine, S | 1 |
| Kinoshita, Y | 1 |
| Tsutsumi, K | 1 |
| Udagawa, H | 1 |
| Katori, H | 1 |
| Hayashi, M | 1 |
| Igarashi, M | 1 |
| Hasebe, S | 1 |
| Illert, B | 1 |
| Bueter, M | 1 |
| Thiede, A | 1 |
| Fein, M | 1 |
| Meyer, D | 1 |
| Katirtzoglou, NA | 1 |
| Efficace, F | 1 |
| Coens, C | 1 |
| Fricker, J | 1 |
| Wisinski, KB | 1 |
| Wen, ZF | 1 |
| Zheng, FP | 1 |
| Li, YW | 1 |
| Feng, ZY | 1 |
| Cevik, OM | 1 |
| Punzengruber, R | 1 |
| Riemann, J | 1 |
| Wöll, E | 1 |
| Arnheim, KE | 1 |
| Delva, R | 3 |
| Dorval, E | 1 |
| Piot, G | 2 |
| Gustavsson, BG | 2 |
| Rustum, Y | 5 |
| White, RR | 1 |
| Munoz, JA | 1 |
| Raggio, G | 1 |
| Lencioni, M | 5 |
| Federici, F | 1 |
| Iannopollo, M | 1 |
| Bujko, K | 1 |
| Bujko, M | 1 |
| Franco, L | 1 |
| Cheetham, S | 1 |
| Mesak, F | 1 |
| Hind, D | 1 |
| Tumur, I | 1 |
| Eggington, S | 1 |
| Ryan, A | 1 |
| Di Fiore, F | 1 |
| López-Siles, J | 1 |
| Sánchez, A | 1 |
| Sánchez, MJ | 1 |
| Márquez, A | 1 |
| Basaran, M | 1 |
| Argon, A | 1 |
| Ustaoglu, MA | 1 |
| Tenekeci, AN | 1 |
| Aykan, NF | 2 |
| Zhang, JS | 1 |
| Song, ST | 1 |
| Tenma, K | 1 |
| Imano, H | 1 |
| Hibino, M | 1 |
| Pintoffl, JP | 1 |
| Holtmann, M | 1 |
| Ide, T | 1 |
| Ohtaka, K | 1 |
| Mitsuno, M | 1 |
| Zamboni, S | 1 |
| Mallano, A | 1 |
| Flego, M | 1 |
| Ascione, A | 1 |
| Dupuis, ML | 1 |
| Gellini, M | 1 |
| Barca, S | 1 |
| Cianfriglia, M | 1 |
| Simkens, L | 1 |
| Antonini, N | 1 |
| van Krieken, H | 1 |
| Segalla, JG | 1 |
| Federico, MH | 1 |
| Skare, NG | 1 |
| Franke, FA | 1 |
| Perdicaris, MR | 1 |
| Filho, Ude P | 1 |
| Gampel, O | 1 |
| Cabral, S | 1 |
| Ribeiro, Rde A | 1 |
| Bernard, SA | 1 |
| Braich, T | 1 |
| Evars, JP | 1 |
| Hrushesky, WJ | 2 |
| Duffy, A | 1 |
| Huitzil-Melendez, FD | 1 |
| Adams, WJ | 2 |
| Kaizer, L | 1 |
| Myers, R | 1 |
| Thiessen, JJ | 1 |
| Fine, S | 4 |
| Kühl, M | 1 |
| Rossion, I | 2 |
| Koch, B | 1 |
| Encke, A | 4 |
| Sotos, GA | 1 |
| Seiter, K | 5 |
| Goker, E | 1 |
| André, M | 1 |
| Ragusa, K | 1 |
| Ivarsson, M | 1 |
| Gerdin, B | 1 |
| Hellsing, K | 1 |
| Bermann, A | 1 |
| Franchi, F | 7 |
| Simpson, WG | 1 |
| Heys, SD | 5 |
| Whiting, PH | 1 |
| Eremin, O | 5 |
| Broom, J | 1 |
| Rinck, G | 1 |
| Van den Bos, TG | 1 |
| de Haes, HJ | 1 |
| Schadé, E | 1 |
| Veenhof, CH | 3 |
| Kraimps, JL | 1 |
| Thomas, E | 1 |
| Margerit, D | 1 |
| Ingrand, P | 1 |
| Bretaudeau, B | 1 |
| Barthes, JN | 1 |
| Daban, A | 1 |
| Barbier, J | 1 |
| Fernandez-Trigo, V | 1 |
| Shamsa, F | 1 |
| Vidal-Jové, J | 1 |
| Kern, DH | 1 |
| Miya, K | 3 |
| Fukada, D | 3 |
| Umemoto, T | 3 |
| Takao, H | 3 |
| Hanada, H | 1 |
| Maeshiro, T | 3 |
| Yamada, F | 2 |
| Awane, Y | 3 |
| Kikkawa, N | 15 |
| Tamaki, Y | 4 |
| Yagyu, T | 4 |
| Shin, E | 7 |
| Kohashi, S | 1 |
| Shiroto, H | 1 |
| Kondo, M | 1 |
| Ikuta, K | 1 |
| Uchino, J | 1 |
| Ariga, T | 2 |
| Ooshima, I | 1 |
| Kinoshita, H | 2 |
| Takeda, A | 4 |
| Yoshimura, S | 2 |
| Shouko, T | 1 |
| Tentas, K | 1 |
| Katsikas, M | 1 |
| Sakelaropoulos, N | 2 |
| Daliani, D | 1 |
| Figueredo, AT | 1 |
| Fawcet, SE | 1 |
| Molloy, DW | 1 |
| Dobranowski, J | 1 |
| Paulseth, JE | 1 |
| Links, M | 1 |
| Phadke, K | 2 |
| O'Baugh, J | 1 |
| Legge, J | 1 |
| Ross, WB | 4 |
| Van den Hout, BM | 1 |
| Taal, BG | 4 |
| Gortzak, E | 1 |
| Schwartz, EL | 4 |
| Ferguson, JE | 1 |
| Hulse, P | 1 |
| Lorigan, P | 1 |
| Jayson, G | 1 |
| Scarffe, JH | 1 |
| Foutzilas, G | 1 |
| Markantonakis, P | 1 |
| Bacoyannis, C | 3 |
| Zisiadis, A | 2 |
| Karvounis, N | 3 |
| Sobolos, K | 1 |
| Marinelli, A | 1 |
| Cloos, J | 1 |
| van de Velde, CJ | 1 |
| Kimura, O | 1 |
| Kurayoshi, K | 1 |
| Hoshino, K | 1 |
| Sugezawa, A | 1 |
| Molina Esquivel, J | 1 |
| Vargas Sandoval, G | 1 |
| Rodríguez del Rincón, E | 1 |
| Velázquez López, J | 1 |
| Fontana, T | 1 |
| Noviello, MR | 1 |
| Hanaue, H | 1 |
| Mitomi, T | 3 |
| Kurosawa, T | 1 |
| Oo, TY | 1 |
| Maoleekoonpairoj, S | 1 |
| Norman, A | 7 |
| Nicolson, V | 1 |
| Ahmed, F | 2 |
| Hanna, CL | 1 |
| McKinna, FE | 1 |
| Williams, LB | 1 |
| Morrey, D | 1 |
| Adams, M | 1 |
| Mason, MD | 1 |
| Käufer, C | 2 |
| Rauschecker, H | 1 |
| Andreesen, R | 2 |
| Ohl, U | 2 |
| Lange, HJ | 1 |
| Klaassen, U | 3 |
| Stenram, U | 1 |
| Wieand, HS | 7 |
| Gerstner, JB | 3 |
| Gesme, DH | 1 |
| Zissiadis, A | 1 |
| Zamagni, C | 1 |
| Cricca, A | 2 |
| Pannuti, F | 2 |
| Ruggeri, EM | 1 |
| Pein, F | 1 |
| Rainer, H | 2 |
| Oskam, R | 2 |
| de Peuter, RA | 1 |
| Palmer, PA | 1 |
| Franks, CR | 5 |
| Flores, MR | 1 |
| Tatulli, C | 1 |
| Taveri, R | 1 |
| Campanella, GA | 1 |
| Carrieri, G | 1 |
| Reynolds, T | 1 |
| AbdAlla, EE | 1 |
| Blair, GE | 1 |
| Jones, RA | 1 |
| Sue-Ling, HM | 1 |
| Johnston, D | 1 |
| Taguchi, T | 5 |
| Ogawa, N | 1 |
| Marshall, ME | 1 |
| Tangen, CM | 2 |
| Berenberg, JL | 1 |
| Dorval, ED | 1 |
| Regimbeau, C | 1 |
| Picon, L | 1 |
| Bérard, H | 1 |
| Ambiru, S | 2 |
| Ito, H | 2 |
| Hayashi, S | 3 |
| Nakajima, N | 2 |
| Hiddemann, W | 8 |
| Schüller, J | 6 |
| Weiss, J | 1 |
| Lohrmann, HP | 1 |
| Schmitz-Hübner, U | 1 |
| Bodenstein, H | 1 |
| Schöber, C | 4 |
| Grem, J | 2 |
| Yamao, T | 1 |
| Saito, D | 1 |
| Ohkura, H | 1 |
| Fleming, TR | 4 |
| Muggia, FM | 2 |
| Meyers, FJ | 1 |
| Weiss, GR | 1 |
| Mangalik, A | 1 |
| Kumai, K | 1 |
| Barberi-Heyob, M | 1 |
| Merlin, JL | 1 |
| Vigneron, M | 1 |
| Vaughn, D | 1 |
| Treat, J | 3 |
| McCall, JL | 1 |
| Jorgensen, JO | 1 |
| Rayter, Z | 1 |
| Leicester, RJ | 1 |
| Mansi, JL | 3 |
| Ota, J | 1 |
| Takashima, S | 4 |
| Yasutomi, M | 10 |
| Takada, O | 1 |
| Hasebe, K | 1 |
| Tsugawa, K | 1 |
| Tsuji, M | 1 |
| Demachi, H | 1 |
| Brown, TD | 1 |
| Goodman, PJ | 1 |
| Pugh, RP | 2 |
| O'Rourke, T | 1 |
| Otani, Y | 1 |
| Tsuji, R | 1 |
| Hiki, Y | 1 |
| Shinohara, K | 1 |
| Stein, BN | 1 |
| Douglass, HO | 2 |
| Driscoll, DL | 1 |
| Arcangeli, G | 2 |
| Cianci, C | 4 |
| Andersen, LJ | 1 |
| Brunsgaard, NH | 1 |
| Mejlholm, I | 1 |
| Weiber, S | 1 |
| Jiborn, H | 1 |
| Zederfeldt, B | 1 |
| André, AM | 1 |
| Grossano, DD | 1 |
| Maltoni, R | 1 |
| Riccobon, A | 1 |
| Fedriga, R | 1 |
| Milandri, C | 2 |
| Pezzi, L | 1 |
| Velotti, F | 1 |
| Santoni, A | 1 |
| Riesener, KP | 2 |
| Winkeltau, G | 2 |
| Klemm, M | 1 |
| Schumpelick, V | 2 |
| Buter, J | 2 |
| van der Graaf, WT | 1 |
| Verschueren, RC | 3 |
| Fried, G | 1 |
| Tsalik, M | 1 |
| Stein, M | 1 |
| Dale, J | 1 |
| Shida, H | 2 |
| Ban, K | 2 |
| Matsumoto, M | 6 |
| Noma, M | 1 |
| Kitazaki, M | 1 |
| Masuda, K | 2 |
| Imanari, T | 2 |
| Hisikawa, E | 1 |
| Yaguchi, H | 1 |
| Arima, H | 1 |
| Hachisu, T | 1 |
| Kashiwabara, H | 1 |
| Jablonski, KA | 1 |
| Port, RE | 2 |
| Schlemmer, HP | 2 |
| Bachert, P | 2 |
| Inaba, M | 2 |
| Mitsuhashi, J | 2 |
| Lévy, E | 4 |
| Vaillant, JC | 1 |
| Garcia, P | 1 |
| Tusquets, I | 1 |
| Font, A | 1 |
| Fabregat, X | 1 |
| Leichman, L | 6 |
| Caudry, M | 1 |
| Bonnel, C | 1 |
| Floquet, A | 1 |
| Marsault, C | 1 |
| Quétin, P | 1 |
| Pujol, J | 1 |
| Maton, O | 1 |
| Dujols, JP | 1 |
| Caudry, Y | 1 |
| Skawinski, P | 1 |
| Carlier, D | 1 |
| Darloy, F | 1 |
| Pion, JM | 2 |
| Bonneterre, J | 2 |
| Demaille, A | 1 |
| Warren, HW | 3 |
| O'Gorman, P | 2 |
| Kane, E | 2 |
| Cooke, TG | 4 |
| Patel, N | 2 |
| Johnston, A | 1 |
| Murray, LS | 1 |
| Reed, NS | 1 |
| Canney, PA | 1 |
| Kaye, SB | 2 |
| Wotherspoon, HA | 1 |
| Warren, H | 2 |
| Watson, D | 1 |
| Vinké, BJ | 1 |
| Dobbie, JW | 1 |
| el Eini, DI | 1 |
| Pratt, CB | 2 |
| Meyer, WH | 1 |
| Howlett, N | 1 |
| Douglass, EC | 1 |
| Bowman, LC | 1 |
| Poe, D | 1 |
| Mounce, K | 1 |
| Kun, LE | 1 |
| Zidani, R | 5 |
| Vannetzel, JM | 2 |
| Perpoint, B | 4 |
| Itzhaki, M | 3 |
| Misuta, K | 1 |
| Masui, H | 2 |
| Ike, H | 1 |
| Ohki, S | 3 |
| Cho, G | 1 |
| Takatsuka, Y | 3 |
| Aratake, T | 1 |
| Kawase, A | 1 |
| Kirita, T | 1 |
| Higaki, T | 1 |
| Oishi, H | 1 |
| Kono, S | 1 |
| Tomita, F | 2 |
| Kurosaka, Y | 1 |
| Kita, I | 1 |
| Haruta, A | 1 |
| Umeno, T | 1 |
| Toriya, H | 1 |
| Jyozaki, H | 1 |
| Ikeda, S | 1 |
| Nichols, PH | 1 |
| Ward, U | 3 |
| Ramsden, CW | 1 |
| Engarås, B | 1 |
| Holmberg, SB | 1 |
| Jönsson, PE | 1 |
| Tidebrant, G | 1 |
| Buer, J | 1 |
| Kirchner, H | 1 |
| Schomburg, A | 2 |
| Schüler, A | 1 |
| Manns, M | 1 |
| Lopez-Hänninen, E | 1 |
| Duensing, S | 1 |
| Poliwoda, H | 4 |
| Sips, JH | 1 |
| van Tellingen, O | 1 |
| Nooijen, WJ | 1 |
| Rodenhuis, S | 2 |
| Ten Bokkel Huinink, WJ | 1 |
| Semmler, W | 2 |
| Hohenberger, P | 8 |
| Lorenz, WJ | 2 |
| van Kaick, G | 4 |
| Villar-Grimalt, A | 3 |
| Belón, J | 2 |
| Jimeno, JM | 1 |
| Candel, MT | 3 |
| Colajori, E | 1 |
| Ono, K | 1 |
| Saijo, N | 2 |
| Begos, DG | 1 |
| Ballantyne, GH | 1 |
| Ashikaga, K | 2 |
| Kimura, C | 1 |
| Stein, TA | 1 |
| Burns, GP | 1 |
| Bailey, B | 1 |
| Citron, ML | 1 |
| Fassas, AB | 1 |
| Gattani, AM | 1 |
| Morgello, S | 1 |
| Castoldi, MC | 1 |
| Dellafiore, L | 1 |
| Pancera, G | 8 |
| Ohnishi, H | 1 |
| Nakajima, I | 1 |
| Akabane, Y | 1 |
| Kurooka, K | 2 |
| Koh, K | 2 |
| Shindo, K | 3 |
| Huber, BE | 3 |
| Austin, EA | 3 |
| Richards, CA | 2 |
| Davis, ST | 3 |
| Good, SS | 2 |
| Metzger, G | 7 |
| Massari, C | 1 |
| Comisso, M | 1 |
| Touitou, Y | 2 |
| Misset, JL | 10 |
| Sewell, GJ | 1 |
| Allsopp, M | 1 |
| Collinson, MP | 1 |
| Tyrrell, C | 1 |
| Prentice, AJ | 1 |
| Copplestone, JA | 1 |
| Pedicini, A | 1 |
| Valori, V | 1 |
| Giotta, F | 2 |
| Prete, F | 1 |
| Bergström, R | 1 |
| Martinelli, DJ | 1 |
| Bakal, CW | 1 |
| Haynes, H | 1 |
| Wiernik, PH | 4 |
| Egeli, R | 3 |
| Arma, S | 3 |
| Barras, JP | 1 |
| Martinoli, S | 3 |
| Müller, W | 3 |
| Castiglione, M | 3 |
| Schroeder, R | 1 |
| Mader, RM | 1 |
| Djavanmard, MP | 1 |
| Gnant, MF | 1 |
| Locker, G | 1 |
| Marosi, C | 2 |
| Moertel, CG | 8 |
| Carl, J | 1 |
| Brunsgaard, N | 2 |
| Nørgaard-Pedersen, B | 1 |
| Silva, RR | 2 |
| Battelli, N | 1 |
| Manocchi, P | 1 |
| Rossini, S | 1 |
| Delprete, S | 1 |
| Mazzanti, P | 1 |
| Bascioni, R | 2 |
| Battelli, T | 1 |
| Foa, P | 1 |
| Giaccon, G | 1 |
| Luporini, G | 8 |
| Kerr, I | 2 |
| Hoffman, W | 1 |
| Gorg, C | 2 |
| Preusser, P | 3 |
| Senn, HJ | 1 |
| Grison, X | 3 |
| Zittoun, J | 3 |
| Lotz, JP | 7 |
| Richaud, J | 3 |
| Hannoun, L | 3 |
| Marquet, J | 3 |
| Guillot, T | 3 |
| Kohne-Wompner, CH | 3 |
| Hagiwara, A | 1 |
| Weh, HJ | 4 |
| Dierlamm, J | 1 |
| Siegmund, R | 2 |
| Illiger, HJ | 2 |
| Hilgenfeld, U | 1 |
| Steinke, B | 3 |
| Nicolson, M | 1 |
| Ford, H | 1 |
| Husband, J | 2 |
| Evans, C | 1 |
| Carter, R | 1 |
| Bertuccelli, M | 2 |
| Muttini, MP | 1 |
| Dargenio, F | 2 |
| Klotz, HP | 2 |
| Weder, W | 3 |
| Largiadèr, F | 3 |
| Navarro-Carola, E | 1 |
| Demuynck, B | 3 |
| Beerblock, K | 4 |
| Soubrane, D | 2 |
| Grangé, JD | 3 |
| Rasi, G | 3 |
| Silecchia, G | 2 |
| Sinibaldi-Vallebona, P | 2 |
| Spaziani, E | 2 |
| Pierimarchi, P | 2 |
| Sivilia, M | 1 |
| Tremiterra, S | 1 |
| Garaci, E | 3 |
| Adler, S | 1 |
| Lang, S | 1 |
| Langenmayer, I | 1 |
| Eibl-Eibesfeldt, B | 1 |
| Rump, W | 1 |
| Emmerich, B | 1 |
| Rosso, R | 10 |
| Cartei, G | 2 |
| Cartei, F | 1 |
| Overgaard, M | 1 |
| Bertelsen, K | 1 |
| Dalmark, M | 2 |
| Gadeberg, CC | 1 |
| von der Maase, H | 2 |
| Overgaard, J | 1 |
| Sell, A | 1 |
| Del Ferro, E | 4 |
| Fedeli, A | 5 |
| Grianti, C | 1 |
| Foglietti, G | 1 |
| Olivieri, Q | 1 |
| Acetoso, M | 1 |
| Bartolucci, M | 1 |
| Saba, V | 1 |
| Lungarotti, F | 1 |
| Kameyama, M | 2 |
| Utsunomiya, J | 2 |
| Oshima, A | 2 |
| Hioki, K | 3 |
| Fukuda, I | 2 |
| Hamblin, TJ | 2 |
| Sadullah, S | 2 |
| Williamson, P | 2 |
| Stevenson, J | 1 |
| Palmer, P | 2 |
| Mori, A | 2 |
| Bertoglio, S | 1 |
| Bolli, E | 2 |
| Tixi, L | 4 |
| Chase, JL | 3 |
| Hohn, DC | 3 |
| Koster, RH | 1 |
| Weissman, DE | 1 |
| Graham, M | 1 |
| Perkins, S | 1 |
| Sheehan, RG | 1 |
| Ross, M | 1 |
| Bull, J | 1 |
| Pruitt, B | 1 |
| Periman, P | 1 |
| Ruud, C | 1 |
| Ando, J | 1 |
| Ozawa, I | 1 |
| de Takats, PG | 1 |
| Poole, CJ | 1 |
| Hoffman, K | 3 |
| Sjödén, PO | 3 |
| Hoekman, K | 1 |
| Priest, DG | 1 |
| Bunni, MA | 1 |
| Hanyu, F | 1 |
| Takei, Y | 1 |
| Noda, Y | 2 |
| Machida, T | 1 |
| Yamamoto, T | 1 |
| Di Tora, P | 2 |
| Mannella, E | 2 |
| Casaldi, V | 1 |
| Civalleri, D | 3 |
| Morandi, GB | 1 |
| Da Pian, PP | 2 |
| Padovani, A | 1 |
| Callopoli, A | 2 |
| Fischkoff, S | 1 |
| Martin, K | 1 |
| Dimitrakopoulou, A | 2 |
| Clorius, JH | 1 |
| Ostertag, H | 1 |
| Heim, M | 1 |
| Oberdorfer, F | 4 |
| Helus, F | 1 |
| Boese-Landgraf, J | 4 |
| Häring, R | 1 |
| Weber, B | 2 |
| Hopfenmüller, W | 1 |
| Hager, K | 1 |
| Pittman, K | 1 |
| Perren, T | 1 |
| Jordan, E | 1 |
| Robson, ME | 1 |
| Binder, RA | 1 |
| Hamilton, JM | 3 |
| Arbuck, SG | 4 |
| Beveridge, RA | 1 |
| Kales, AN | 1 |
| Miller, JA | 1 |
| Leach, MO | 1 |
| Collins, DJ | 1 |
| Payne, GS | 1 |
| Glaholm, J | 1 |
| McCready, VR | 1 |
| Tohno, K | 1 |
| Utsunomiya, T | 1 |
| Oikawa, H | 2 |
| Matsuzaki, H | 4 |
| Akaishi, O | 3 |
| Ozasa, T | 3 |
| Katayama, K | 1 |
| Shinohara, M | 1 |
| Mukaijo, T | 1 |
| Nakatsuka, A | 1 |
| Kido, C | 3 |
| Shiiba, K | 1 |
| Ouchi, A | 1 |
| Kunii, Y | 2 |
| Momono, S | 1 |
| Muto, I | 1 |
| Mashiko, H | 1 |
| Wada, M | 1 |
| Sugimasa, Y | 1 |
| Okamoto, T | 2 |
| Burghouts, JT | 3 |
| Croles, JJ | 2 |
| van Liessum, PA | 1 |
| de Mulder, PH | 3 |
| Kamm, Y | 1 |
| Colleoni, M | 2 |
| Scanni, A | 1 |
| Calabresi, F | 2 |
| Lehner, B | 1 |
| Frohmüller, S | 2 |
| Uges, DR | 2 |
| Roenhorst, HW | 1 |
| Yang, JC | 1 |
| Shlasko, E | 1 |
| Ritchey, JL | 1 |
| Landry, JG | 1 |
| White, DE | 1 |
| Rosenberg, SA | 1 |
| Knick, VC | 1 |
| Tibbels, S | 1 |
| Kitamura, K | 1 |
| Otsuji, E | 1 |
| Laufman, LR | 3 |
| Collier, MA | 1 |
| Sullivan, BA | 1 |
| McKinnis, RA | 1 |
| Clendennin, NJ | 1 |
| Guaspari, A | 1 |
| Brenckman, WD | 3 |
| Meyer, S | 2 |
| Vermorken, JB | 1 |
| Nieweg, MB | 1 |
| Cuesta, M | 1 |
| Spears, CP | 1 |
| Rosen, PJ | 1 |
| Jeffers, S | 1 |
| Lokich, JJ | 2 |
| Anderson, N | 2 |
| Ahlgren, JD | 3 |
| Kusano, H | 2 |
| Miyashita, K | 2 |
| Nakazaki, T | 1 |
| Yoshida, A | 1 |
| Dohden, K | 1 |
| Ohmura, K | 1 |
| Kok, RM | 1 |
| Hidalgo, OF | 1 |
| Bilbao, I | 1 |
| Tangco, E | 1 |
| Abuchaibe, O | 1 |
| Sartor, O | 1 |
| Inaba, H | 1 |
| Weiner, LM | 3 |
| Hudes, GR | 2 |
| Kitson, J | 1 |
| Walczak, J | 2 |
| Watts, P | 1 |
| Litwin, S | 2 |
| Sigurdson, E | 1 |
| Lincer, R | 1 |
| Botet, J | 3 |
| Chapman, D | 1 |
| Costa, P | 3 |
| Degardin, M | 1 |
| Horner, D | 1 |
| Brockmann, WP | 1 |
| Wiegel, T | 1 |
| Sommer, K | 1 |
| Hübener, KH | 1 |
| Tsujimura, T | 1 |
| Ezaki, K | 1 |
| Kawase, K | 1 |
| Hatanaka, T | 1 |
| Ohara, K | 2 |
| Hobara, R | 1 |
| Okamoto, M | 1 |
| Boyle, FM | 1 |
| Smith, RC | 1 |
| Levi, JA | 1 |
| Poorter, RL | 2 |
| Taat, CW | 1 |
| Spiers, EM | 1 |
| Potts, RC | 1 |
| Sharpe, SY | 1 |
| Newman, EL | 1 |
| Lavelle-Jones, M | 1 |
| Beck, JS | 1 |
| Cuschieri, A | 1 |
| Bajard, F | 1 |
| Fety, R | 1 |
| Bumann, D | 1 |
| Crone-Münzebrock, W | 2 |
| Carl, U | 1 |
| Baccanari, DP | 2 |
| Joyner, SS | 1 |
| Neoptolemos, J | 1 |
| Doughty, J | 1 |
| Budden, J | 2 |
| Soussan, A | 1 |
| Caussanel, JP | 2 |
| Jasmin, C | 3 |
| Smolensky, M | 1 |
| Bovo, G | 1 |
| Brivio, F | 1 |
| Brenna, A | 2 |
| Fumagalli, L | 1 |
| Perego, P | 1 |
| Brivio, O | 1 |
| Uggeri, F | 1 |
| Lavorato, F | 1 |
| Bratina, G | 1 |
| b1p6uller, J | 1 |
| Rowley, S | 1 |
| Lindauer, M | 1 |
| Gebert, JF | 1 |
| Moebius, U | 1 |
| Herfarth, C | 2 |
| Schackert, HK | 1 |
| Hoffmann, W | 2 |
| Thuerlimann, B | 1 |
| Rath, U | 3 |
| Olver, I | 1 |
| Svensson, C | 2 |
| Frediani, B | 1 |
| Palazzuoli, V | 1 |
| Botta, G | 1 |
| Tani, F | 1 |
| De Martino, A | 1 |
| Eatock, MM | 1 |
| Carlin, W | 1 |
| Dunlop, DJ | 1 |
| Soukop, M | 2 |
| Watson, DG | 2 |
| Brett, MC | 1 |
| Pickard, M | 1 |
| Green, B | 1 |
| Howel-Evans, A | 1 |
| Kinsella, A | 1 |
| Carlson, R | 1 |
| Allen-Mersh, T | 1 |
| Chang, A | 1 |
| Sondak, V | 1 |
| Kemeny, M | 1 |
| Gossios, K | 2 |
| Svarna, E | 1 |
| Rodriguez-Bigas, M | 1 |
| Blumenson, LE | 2 |
| Frank, C | 3 |
| Berghorn, E | 1 |
| Matei, D | 1 |
| Hagag, N | 1 |
| Avvento, L | 2 |
| Burns, P | 1 |
| Fiore, J | 1 |
| Lipera, W | 1 |
| Zarrabi, H | 1 |
| Young, H | 1 |
| Iveson, A | 1 |
| Cronin, B | 1 |
| Pratt, B | 1 |
| Flower, M | 1 |
| Nethersell, AB | 1 |
| Smyth, JF | 1 |
| Hardcastle, JD | 2 |
| Denton, G | 1 |
| Alderson, D | 1 |
| Grace, RH | 2 |
| Yosef, HM | 1 |
| Nordle, O | 1 |
| Lauri, H | 1 |
| Wählby, S | 1 |
| Jones, DV | 2 |
| Winn, RJ | 1 |
| Brown, BW | 2 |
| Levy, LB | 1 |
| Wade, JL | 1 |
| Gross, HM | 1 |
| Pendergrass, KB | 1 |
| Levin, B | 3 |
| Vermeulen, PB | 1 |
| Dirix, LY | 1 |
| Pelgrims, G | 1 |
| Van Oosterom, AT | 1 |
| Dorta, J | 1 |
| Blanco, E | 2 |
| Cruz-Hernandez, JJ | 1 |
| Gonzalez-Mancha, R | 2 |
| García-Conde, J | 3 |
| Hansen, RM | 4 |
| Ryan, L | 3 |
| Anderson, T | 3 |
| Krzywda, B | 1 |
| Quebbeman, E | 3 |
| Tormey, DC | 1 |
| Bécouarn, YH | 1 |
| Brunet, RC | 1 |
| Rouhier, ML | 2 |
| Bussières, EJ | 1 |
| Avril, AR | 1 |
| Richaud, PM | 1 |
| Dilhuydy, JM | 1 |
| Sugimachi, K | 5 |
| Kakegawa, T | 1 |
| Tomita, M | 2 |
| Akiyoshi, T | 1 |
| Gamelin, EC | 1 |
| Danquechin-Dorval, EM | 1 |
| Dumesnil, YF | 1 |
| Maillart, PJ | 1 |
| Goudier, MJ | 1 |
| Burtin, PC | 1 |
| Delva, RG | 1 |
| Lortholary, AH | 1 |
| Gesta, PH | 1 |
| Larra, FG | 1 |
| Farrer, C | 1 |
| Gordon, A | 1 |
| Sommers, SS | 1 |
| Monson, JR | 2 |
| Guillou, PJ | 3 |
| Anand, A | 2 |
| Anand, N | 1 |
| Lombardo, M | 1 |
| Fabiani, F | 1 |
| Fanini, R | 1 |
| Venturoni, L | 1 |
| Torchio, P | 1 |
| Peretti, G | 1 |
| Larsson, PA | 1 |
| Vaughn, DJ | 2 |
| Takeda, I | 1 |
| Sugiyama, K | 1 |
| Osada, T | 1 |
| Ooki, H | 1 |
| Samori, T | 1 |
| Kanno, H | 1 |
| Yoden, Y | 1 |
| Ohashi, S | 1 |
| Iwanaga, T | 1 |
| Nomura, H | 1 |
| Giannopoulos, A | 1 |
| Papadimas, V | 1 |
| Kalahanis, N | 1 |
| Karatzas, G | 1 |
| Archimandritis, A | 1 |
| Papachristodoulou, A | 1 |
| Houston, RF | 1 |
| Moorehead, RJ | 1 |
| Rossi, D | 1 |
| Casadei, V | 1 |
| Ohno, M | 2 |
| Toge, T | 2 |
| Tanemura, H | 1 |
| Oshita, H | 1 |
| Benhattar, J | 1 |
| Cerottini, JP | 1 |
| Saraga, E | 1 |
| Metthez, G | 1 |
| Doughty, JC | 1 |
| Stewart, IS | 1 |
| Reid, AW | 1 |
| Blijham, G | 4 |
| Buset, M | 1 |
| Lacave, A | 1 |
| Selleslag, J | 1 |
| Sahmoud, T | 1 |
| Bernhard, H | 1 |
| Bernhard, G | 1 |
| Lautz, D | 1 |
| Michaelis, J | 1 |
| Meyer zum Büschenfelde, KH | 2 |
| Perren, TJ | 1 |
| McAdam, WA | 1 |
| Neoptolemos, JP | 2 |
| Nicholson, M | 1 |
| Duffy, AM | 1 |
| Stenning, SP | 1 |
| Perrier, H | 2 |
| Uematsu, T | 1 |
| Nakashima, M | 1 |
| Masuike, T | 1 |
| Gustafson, P | 1 |
| Di Lauro, L | 3 |
| Santini, S | 1 |
| Gandolfo, GM | 1 |
| Vitelli, G | 1 |
| Frasca, AM | 1 |
| Ameglio, F | 2 |
| Malvaldi, G | 2 |
| Li, XM | 1 |
| Mormont, C | 1 |
| Babu, KG | 1 |
| Rasheshyam, D | 1 |
| Lalitha, N | 1 |
| Clark, J | 1 |
| Sikov, W | 2 |
| Cummings, F | 2 |
| Browne, M | 1 |
| Akerley, W | 2 |
| Wanebo, H | 1 |
| Weitberg, A | 2 |
| Kennedy, T | 1 |
| Cole, B | 1 |
| Bigley, J | 1 |
| Beitz, J | 2 |
| Darnowski, J | 1 |
| Port, JL | 1 |
| Ng, B | 1 |
| Ellis, JL | 1 |
| Nawata, S | 1 |
| Lenert, JT | 1 |
| Burt, ME | 1 |
| Ang, PT | 2 |
| Moreau, S | 2 |
| Mal, F | 2 |
| Zylberait, D | 1 |
| Porte, H | 1 |
| De Moulins, H | 1 |
| Gambiez, L | 2 |
| Wurtz, A | 1 |
| Quandalle, P | 2 |
| Dayan, A | 1 |
| Beauchemin, M | 1 |
| Chahla, D | 1 |
| Mamo, A | 1 |
| Bertrand, R | 1 |
| Testa, A | 1 |
| Majello, E | 1 |
| Cannata, G | 1 |
| Mastrandrea, G | 1 |
| Feo, M | 1 |
| Bajardi, G | 1 |
| Piga, A | 3 |
| Marcellini, M | 2 |
| Bavosi, M | 1 |
| Acito, L | 1 |
| Pancotti, A | 1 |
| Del Papa, M | 1 |
| Carle, F | 1 |
| Cellerino, R | 2 |
| Kubo, R | 2 |
| Koslowe, P | 1 |
| Vinci, M | 2 |
| Vaghi, M | 1 |
| Pirovano, M | 2 |
| Facendola, G | 2 |
| Blomgren, H | 2 |
| Taketomi, A | 2 |
| Seo, Y | 2 |
| Tomoda, H | 3 |
| Kosaka, A | 3 |
| Hojyo, M | 1 |
| Watabiki, Y | 2 |
| Ohara, M | 3 |
| Shikata, A | 3 |
| Hoshiya, Y | 2 |
| Yorozuya, K | 1 |
| Yabata, E | 1 |
| Endou, M | 1 |
| Harmantas, A | 1 |
| Rotstein, LE | 1 |
| Kido, Y | 1 |
| Tomikawa, M | 1 |
| Shiraishi, M | 1 |
| Davidson, BS | 1 |
| DuBrow, RA | 2 |
| Patt, Y | 1 |
| Ligi, M | 2 |
| Blesing, CH | 1 |
| Borden, EC | 1 |
| Figlin, R | 1 |
| York, M | 1 |
| Einhorn, L | 1 |
| Marshall, EM | 1 |
| Buys, SS | 1 |
| Froimtchuk, MJ | 1 |
| Schuchter, L | 1 |
| Ritter, L | 1 |
| Man, A | 2 |
| Yap, AK | 1 |
| Nakamori, M | 1 |
| Noguchi, K | 1 |
| Tani, M | 1 |
| Ishimoto, K | 1 |
| Dreyfus, B | 1 |
| Olivier, JP | 1 |
| Dumas, F | 1 |
| Duclos, B | 1 |
| Olivares, R | 1 |
| Leszler, A | 1 |
| Bergerat, JP | 2 |
| Audhuy, B | 1 |
| Thill, L | 1 |
| Oberling, F | 1 |
| Antón-Torres, A | 3 |
| Massutí, T | 3 |
| Barneto, I | 3 |
| Barón, JM | 1 |
| Hilgenfeld, RU | 3 |
| Streit, M | 2 |
| Susak, YM | 1 |
| Zemskov, VS | 1 |
| Yaremchuk, OY | 1 |
| Kravchenco, OB | 1 |
| Yatsyk, IM | 1 |
| Korsh, OB | 1 |
| Ron, IG | 2 |
| Lotan, A | 1 |
| Inbar, MJ | 1 |
| Bertheault-Cvitkovic, F | 3 |
| Jami, A | 2 |
| Ithzaki, M | 1 |
| Brummer, PD | 1 |
| Dasappa, V | 1 |
| King, J | 2 |
| King, DW | 1 |
| Tan, EH | 1 |
| Ruffin, WK | 1 |
| Skarlatos, J | 1 |
| Kosma, L | 1 |
| Koukourakis, M | 2 |
| Zambatis, C | 1 |
| Kapsoritakis, A | 1 |
| Mouder, N | 1 |
| Yannakakis, D | 1 |
| Messori, A | 2 |
| Bonistalli, L | 1 |
| Costantini, M | 1 |
| Trallori, G | 1 |
| Tendi, E | 1 |
| Heron, J | 1 |
| Pessi, A | 1 |
| Rabinovich, M | 1 |
| Vallejo, C | 3 |
| Machiavelli, M | 2 |
| Romero, A | 2 |
| Perez, J | 1 |
| Lacava, J | 3 |
| Cuevas, MA | 3 |
| Rodriquez, R | 1 |
| Leone, B | 2 |
| Sapia, MG | 1 |
| De Lena, M | 3 |
| Goey, SH | 1 |
| Gratama, JW | 1 |
| Mertelsmann, RH | 1 |
| Osterwalder, B | 7 |
| Stoter, G | 1 |
| Hanyu, N | 1 |
| Yin, MB | 1 |
| Gonen, O | 1 |
| Murphy-Boesch, J | 1 |
| Li, CW | 1 |
| Padavic-Shaller, K | 1 |
| Negendank, WG | 1 |
| Brown, TR | 1 |
| Mariani, G | 1 |
| Di Sacco, S | 1 |
| Bonini, R | 1 |
| Di Luca, L | 1 |
| Buralli, S | 1 |
| Bonora, D | 1 |
| Baranowska-Kortylewicz, J | 1 |
| Adelstein, SJ | 1 |
| Kassis, AI | 1 |
| Oliver, I | 1 |
| Schneider, HJ | 1 |
| Sampson, SA | 1 |
| Andreyev, HJ | 2 |
| Tilsed, JV | 1 |
| Clarke, PA | 2 |
| Biert, J | 1 |
| Wobbes, T | 1 |
| Hoogenhout, J | 1 |
| de Man, B | 1 |
| Hendriks, T | 1 |
| Walker, LG | 2 |
| Wesnes, KP | 1 |
| Walker, MB | 2 |
| Lolley, J | 2 |
| Fenton-Lee, D | 1 |
| Milan, C | 1 |
| Morvan, F | 4 |
| Kornek, G | 2 |
| Marczell, A | 2 |
| Salem, G | 1 |
| Karner, J | 1 |
| Burger, D | 1 |
| Greiner, R | 1 |
| Pidlich, J | 2 |
| Rosen, H | 2 |
| Morgan, G | 1 |
| Clinton, S | 1 |
| Hardcastle, A | 1 |
| Aherne, GW | 1 |
| Lucchi, E | 1 |
| Cady, J | 2 |
| Siderov, J | 1 |
| Olsen, JA | 1 |
| Revhaug, A | 1 |
| Prendiville, J | 3 |
| Gottardi, O | 1 |
| Duro, M | 1 |
| Pavanato, G | 1 |
| Raina, A | 1 |
| Piazza, E | 2 |
| Dallavalle, G | 2 |
| Valsecchi, R | 1 |
| Keuning, JJ | 1 |
| Presant, CA | 3 |
| Wolf, W | 3 |
| Waluch, V | 3 |
| Eberhardt, W | 1 |
| Korn, MW | 1 |
| Arita, D | 1 |
| Funato, T | 1 |
| Tezuka, F | 1 |
| Kievit, E | 1 |
| Schlüper, HM | 1 |
| Haisma, HJ | 1 |
| Boven, E | 1 |
| Rafique, M | 1 |
| Adachi, W | 2 |
| Kajikawa, S | 2 |
| Sugenoya, A | 1 |
| Amano, J | 1 |
| Nonami, T | 1 |
| Kurokawa, T | 1 |
| Taniguch, K | 1 |
| Harada, A | 1 |
| Earlam, S | 1 |
| Glover, C | 3 |
| Davies, M | 1 |
| Fordy, C | 2 |
| Allen-Mersh, TG | 3 |
| Cremona, F | 1 |
| Ruffolo, F | 1 |
| Wattanatorn, W | 1 |
| Kendle, KE | 1 |
| Hoque, A | 1 |
| Lozano, R | 1 |
| Pozdur, R | 1 |
| Chase, J | 1 |
| Carrasco, H | 1 |
| Chuang, V | 1 |
| Delpassand, ES | 1 |
| Ellis, L | 1 |
| Curley, S | 1 |
| Roh, M | 2 |
| Hageboutros, A | 1 |
| Greene, F | 1 |
| LaCreta, FP | 1 |
| Brennan, J | 1 |
| Loeffler, TM | 1 |
| Hausamen, TU | 2 |
| Wils, JA | 2 |
| Garcia-Giralt, E | 2 |
| Beuzeboc, P | 2 |
| Deffontaines, D | 2 |
| Diéras, V | 2 |
| Dorval, T | 2 |
| Jouve, M | 2 |
| Palangie, T | 2 |
| Scholl, S | 2 |
| Pouillart, P | 2 |
| Kawachi, Y | 1 |
| Sagara, T | 1 |
| Murakami, S | 1 |
| Kudo, H | 1 |
| Okayasu, I | 1 |
| Howell, JD | 3 |
| Gallagher, H | 1 |
| Maguire, R | 1 |
| Iaremchuk, AIa | 1 |
| Kravchenko, AV | 1 |
| Kamenets, LIa | 1 |
| Chernenko, OD | 1 |
| Fan, FS | 2 |
| Hsu, H | 2 |
| Schroeder, G | 2 |
| Knost, JA | 2 |
| Ghosh, C | 1 |
| Kirschling, RJ | 1 |
| Minsky, BD | 1 |
| Rowinsky, EK | 2 |
| Rocchi, MB | 2 |
| Zamparelli, G | 1 |
| Ardizzoia, A | 1 |
| Ugolini, G | 1 |
| Ghiandoni, G | 1 |
| Gunderson, LL | 2 |
| Nelson, H | 2 |
| Martenson, JA | 1 |
| Cha, S | 3 |
| Haddock, MG | 2 |
| Devine, RM | 2 |
| Fieck, JM | 2 |
| Wolff, BG | 3 |
| Dozois, RR | 2 |
| Kronawitter, U | 1 |
| Kissel, J | 2 |
| Brix, G | 2 |
| Bellemann, ME | 2 |
| Port, R | 1 |
| Somma, L | 1 |
| Del Vecchio, M | 1 |
| Zunino, F | 3 |
| Bignami, P | 1 |
| Magnani, E | 1 |
| Isacoff, WH | 1 |
| Borud, K | 1 |
| Katona, C | 2 |
| Rosta, A | 1 |
| Fónyad, G | 1 |
| Pandi, E | 1 |
| Nobile, MT | 5 |
| Barzacchi, C | 1 |
| Sanguineti, O | 2 |
| Vincenti, M | 2 |
| Di Somma, C | 1 |
| Meszaros, P | 1 |
| Stuntz, M | 1 |
| Wilmoth, G | 1 |
| Ong, J | 1 |
| Stabile, B | 1 |
| Stamos, M | 1 |
| Cvitkovic, E | 10 |
| Grandi, AM | 1 |
| Morandi, E | 1 |
| Zanzi, P | 1 |
| Bulgheroni, P | 1 |
| Guasti, L | 1 |
| Venco, A | 1 |
| Esposito, M | 1 |
| De Cian, F | 1 |
| Balletto, N | 2 |
| Vannozzi, MO | 1 |
| Mondini, G | 1 |
| Carrabetta, S | 1 |
| Bocchio, MM | 1 |
| Cantore, M | 2 |
| Rabbi, C | 1 |
| Cavazzini, G | 1 |
| Bertani, M | 1 |
| Pulica, C | 1 |
| Campo, S | 1 |
| Pari, F | 1 |
| Bezzi, A | 1 |
| Zamagni, D | 1 |
| Amadori, M | 1 |
| Smerieri, F | 1 |
| Pillasch, J | 3 |
| Metzger, R | 5 |
| Butzer, U | 1 |
| Leder, GH | 2 |
| Weindel, M | 1 |
| Safi, F | 3 |
| Beger, HG | 5 |
| Baranda, J | 1 |
| Boswell, W | 1 |
| Murad, A | 1 |
| de Andrade, CA | 1 |
| Delfino, C | 1 |
| Arikian, S | 1 |
| Doyle, J | 1 |
| Sinha, N | 1 |
| Chung, Y | 1 |
| Harrison, J | 1 |
| Berkery, R | 1 |
| Chinery, R | 1 |
| Brockman, JA | 1 |
| Peeler, MO | 1 |
| Shyr, Y | 1 |
| Beauchamp, RD | 1 |
| Coffey, RJ | 1 |
| Hatfield, AK | 1 |
| Maillard, JA | 1 |
| Wiesenfeld, M | 1 |
| Tirona, MT | 1 |
| Omodei Zorini, C | 1 |
| Buckles, J | 1 |
| Gallagher, HJ | 1 |
| Morimoto, O | 1 |
| Miya, A | 1 |
| Satomi, T | 1 |
| Hashizume, R | 1 |
| Arifuku, T | 1 |
| Nagaoka, S | 1 |
| Shuto, K | 1 |
| Takayama, W | 3 |
| Fukunaga, T | 1 |
| Aoyama, H | 1 |
| Shinoto, K | 1 |
| Imazeki, H | 1 |
| Isono, K | 3 |
| Hosoki, T | 2 |
| Oshima, I | 1 |
| Ioku, T | 1 |
| Iwashita, C | 1 |
| Shoko, T | 1 |
| Kon, H | 1 |
| Sasaki, R | 1 |
| Kawata, S | 1 |
| Pace, R | 1 |
| Giunta, S | 3 |
| Gallà, DA | 1 |
| Silecchia, GF | 1 |
| Narduzzi, C | 1 |
| Kawabata, K | 1 |
| Nio, Y | 2 |
| Imamura, M | 1 |
| Padhani, A | 1 |
| Massey, A | 2 |
| Messenger, M | 1 |
| Taplin, SC | 1 |
| Pignon, J | 1 |
| Hansen, R | 3 |
| Zee, B | 2 |
| Weinerman, B | 4 |
| Pater, J | 3 |
| Leichman, C | 2 |
| Fryer, J | 2 |
| Brufman, G | 2 |
| Isacson, R | 2 |
| Drews, M | 1 |
| Szmeja, J | 1 |
| Paszkowski, J | 1 |
| Wierzbicki, T | 1 |
| Załuski, J | 1 |
| Fundowicz, D | 1 |
| Wesnes, K | 1 |
| Gordon, D | 1 |
| Caroti, C | 3 |
| Ciferri, E | 1 |
| Verdi, E | 1 |
| Klaasen, U | 1 |
| Westerhausen, M | 1 |
| Schott, G | 1 |
| Harstick, A | 1 |
| Bade, J | 1 |
| Horster, A | 1 |
| Paillot, B | 2 |
| Rekacewicz, C | 1 |
| Laplaige, P | 2 |
| Grandjouan, S | 1 |
| Fabri, MC | 1 |
| Sabatini, CL | 1 |
| Barbieri, MR | 2 |
| Salvadori, MA | 1 |
| Acuña, LA | 1 |
| Acuña, JM | 1 |
| Langhi, MJ | 2 |
| Amato, S | 2 |
| DeLena, M | 1 |
| Vignoud, J | 1 |
| Watson, SA | 2 |
| Michael, D | 1 |
| Justin, TA | 1 |
| Grimes, S | 1 |
| Morris, TM | 2 |
| Robinson, G | 1 |
| Guichard, S | 1 |
| Ahnen, DJ | 1 |
| Feigl, P | 1 |
| Quan, G | 1 |
| Fenoglio-Preiser, C | 1 |
| Lovato, LC | 1 |
| Bunn, PA | 1 |
| Stemmerman, G | 1 |
| Wells, JD | 1 |
| Meyskens, FL | 1 |
| Doll, J | 1 |
| Kanemitsu, T | 1 |
| Miyashita, A | 1 |
| Inamura, Y | 1 |
| Owa, Y | 1 |
| Gorlick, R | 2 |
| Miles, JS | 1 |
| Longo, GS | 1 |
| Klimstra, D | 2 |
| Jhanwar, S | 1 |
| Troutt, AB | 1 |
| Bandealy, MT | 1 |
| Gonin, R | 1 |
| Loehrer, PJ | 1 |
| Monaco, F | 1 |
| Einhorn, LH | 2 |
| Allman, D | 3 |
| Weidekamm, E | 4 |
| Roos, B | 3 |
| Banken, L | 3 |
| Utoh, M | 3 |
| Palmer, MK | 2 |
| John, WJ | 1 |
| Foon, KA | 1 |
| Luis, R | 1 |
| Jaime, M | 1 |
| Franceschi, D | 1 |
| Stroomer, AE | 1 |
| Pajkos, G | 3 |
| Szentpétery, L | 1 |
| Kristó, K | 1 |
| Izsó, J | 2 |
| Bekradda, M | 3 |
| Hata, Y | 1 |
| Kawasaki, R | 1 |
| Awatani, T | 1 |
| Leccia, JR | 1 |
| Pierrefite, V | 1 |
| Lebouil, A | 1 |
| Turcant, A | 2 |
| Cailleux, A | 2 |
| Krikorian, A | 2 |
| Larra, F | 3 |
| Allain, P | 2 |
| Fabbro-Peray, P | 1 |
| Perney, P | 1 |
| Marçais, O | 1 |
| Gouze, C | 1 |
| Ribard, D | 1 |
| Bons-Rosset, F | 1 |
| Heran, B | 1 |
| Veyrac, M | 2 |
| Blanc, F | 1 |
| Munzone, E | 1 |
| Nolè, F | 2 |
| De Pas, T | 1 |
| Aapro, MS | 1 |
| Van Daele, D | 1 |
| Gil, T | 1 |
| Fernez, B | 1 |
| Bulusu, VR | 1 |
| van Laar, JA | 1 |
| Maurer, C | 1 |
| Gabel, M | 1 |
| Kolozsvary, A | 1 |
| Khil, M | 1 |
| Freytag, S | 1 |
| Bacchi, M | 3 |
| Weber, W | 2 |
| Fey, MF | 1 |
| Pagani, O | 1 |
| Leyvraz, S | 1 |
| Pestalozzi, B | 1 |
| Hanselmann, S | 2 |
| Goldhirsch, A | 2 |
| Naoe, Y | 1 |
| Rietjens, IM | 1 |
| Bernath, AM | 1 |
| Fitzgibbons, RJ | 3 |
| Burch, P | 1 |
| Colon-Otero, G | 1 |
| Peppercorn, PD | 1 |
| Reznek, RH | 1 |
| Gupta, RK | 1 |
| Pronzato, P | 1 |
| Botto, F | 1 |
| Ghio, E | 1 |
| Pensa, F | 1 |
| Tognoni, A | 1 |
| Vaira, F | 1 |
| Vigani, A | 1 |
| Neri, E | 1 |
| Capodano, G | 1 |
| Bardou, VJ | 1 |
| Pádi, E | 1 |
| Meikle, SR | 1 |
| Matthews, JC | 3 |
| Brock, CS | 1 |
| Wells, P | 1 |
| Harte, RJ | 3 |
| Cunningham, VJ | 1 |
| Price, P | 1 |
| Kujime, J | 1 |
| Yamagami, H | 2 |
| Kimura, J | 3 |
| Ohira, S | 2 |
| Iwase, H | 2 |
| Kameya, T | 2 |
| Itoh, I | 1 |
| Ohtaki, M | 2 |
| Nishishou, I | 2 |
| Sai, H | 1 |
| Nagao, N | 1 |
| O'Reilly, SM | 2 |
| Malacarne, P | 2 |
| Belsanti, V | 2 |
| Marzola, M | 3 |
| Corgna, E | 1 |
| Sdrobolini, A | 3 |
| Figoli, F | 2 |
| Algeri, R | 2 |
| Angiona, S | 1 |
| Gadeberg, C | 1 |
| Hansen, P | 1 |
| Lindberg, B | 1 |
| Sellström, H | 1 |
| Lorentz, T | 1 |
| Romero Acuña, LA | 1 |
| Romero Acuña, JM | 1 |
| Marrone, N | 1 |
| Glenn, D | 1 |
| Casillas, S | 1 |
| Jones, SC | 1 |
| Milsom, JW | 1 |
| Kasperk, R | 1 |
| Cocconi, G | 1 |
| Hietschold, SM | 1 |
| Trés, A | 1 |
| López-Vega, JM | 1 |
| Lionetto, R | 2 |
| Gozza, A | 1 |
| Barzacchi, MC | 1 |
| Geisler, J | 1 |
| Geisler, SB | 1 |
| Lønning, PE | 1 |
| Refsum, H | 1 |
| Ueland, PM | 1 |
| Conley, BA | 1 |
| Fietkau, R | 2 |
| Hocking, RA | 1 |
| Tong, A | 1 |
| Ognoskie, N | 1 |
| Meyer, W | 1 |
| Henderson, CA | 1 |
| Berg, D | 1 |
| Davies, MM | 1 |
| Hickish, TF | 1 |
| Johannesen, TB | 1 |
| Topham, CA | 1 |
| Jacques, C | 2 |
| Nicolini, A | 1 |
| Carpi, A | 2 |
| Ferrari, P | 1 |
| Sagripanti, A | 1 |
| Anselmi, L | 1 |
| Fink, D | 1 |
| Gordon, R | 1 |
| Fink, JL | 1 |
| Howell, SB | 2 |
| Cheradame, S | 1 |
| Richelme, H | 1 |
| Bouil, AL | 1 |
| Richmond, E | 1 |
| DeLap, RJ | 1 |
| Hale, HL | 1 |
| Husband, JE | 1 |
| Koss-Twardy, SG | 1 |
| Passe, SM | 1 |
| Patel, IH | 1 |
| Hohneker, JA | 1 |
| Dikken, C | 1 |
| Sitzia, J | 1 |
| Cordel, S | 1 |
| Dupas, B | 1 |
| Meflah, K | 1 |
| Yonekura, R | 1 |
| Ohshimo, H | 1 |
| Kumagai, K | 1 |
| Masuo, K | 1 |
| Yamagata, K | 1 |
| Ajani, JA | 4 |
| Dumas, P | 1 |
| Fairweather, J | 1 |
| Stewart, JM | 1 |
| Millward, MJ | 1 |
| Farrugia, DC | 2 |
| Rau, HG | 1 |
| Stieger, R | 2 |
| Filez, L | 1 |
| Cote, C | 2 |
| Rodriguez-Coria, DF | 1 |
| Arroyo, B | 1 |
| Gonzalez-Macouzet, J | 1 |
| Stubbs, RS | 1 |
| Alwan, MH | 1 |
| Booth, MW | 1 |
| Sludden, J | 1 |
| Hardy, SC | 1 |
| Lock, RE | 1 |
| Hawksworth, GM | 1 |
| Mattes, P | 2 |
| Junginger, T | 2 |
| Saeger, HD | 2 |
| Armand, JP | 2 |
| Gil-Delgado, M | 2 |
| de Gramond, A | 1 |
| Hejna, M | 2 |
| Valencak, J | 1 |
| Weinländer, G | 1 |
| Fiebiger, W | 2 |
| Miholic, J | 1 |
| Palmer, M | 2 |
| Yamane, N | 1 |
| Blom, MJ | 1 |
| Mul, EP | 1 |
| Slocum, HK | 1 |
| Leder, G | 2 |
| Pillasch, AF | 1 |
| Sunelaitis, E | 2 |
| Pressmar, J | 1 |
| DeVore, RF | 1 |
| Rivkin, SE | 1 |
| Geyer, CE | 1 |
| Sandbach, J | 1 |
| Wolf, DL | 1 |
| Mohrland, JS | 1 |
| Von Hoff, DD | 1 |
| Rohlff, C | 1 |
| Skelton, L | 1 |
| Jackman, AL | 2 |
| Page, MJ | 1 |
| Saeki, T | 2 |
| Mukaiya, M | 1 |
| Oikawa, I | 1 |
| Denno, R | 1 |
| Nutting, C | 1 |
| Folkes, A | 1 |
| Assersohn, L | 1 |
| Benepal, T | 1 |
| Alexopoulos, CG | 1 |
| Symann, M | 1 |
| Cholet, P | 1 |
| Fillet, G | 1 |
| Van Groeningen, C | 1 |
| Panagos, G | 1 |
| Unger, C | 3 |
| Blanc, C | 1 |
| Bender, H | 1 |
| Bangard, N | 1 |
| Metten, N | 1 |
| Bangard, M | 1 |
| Mezger, J | 1 |
| Biersack, HJ | 1 |
| Kern, W | 3 |
| Böttger, B | 1 |
| Kaufmann, CC | 1 |
| Schleyer, E | 2 |
| Zaers, J | 1 |
| Stevenson, JP | 2 |
| Groener, MG | 1 |
| van Ineveld, BM | 1 |
| Byttebier, G | 1 |
| van Hout, BA | 1 |
| Rutten, FF | 1 |
| Boussen, H | 1 |
| Kallel, N | 1 |
| Khomsi, F | 1 |
| Jerbi, G | 1 |
| Dhouib, R | 1 |
| Ben Safta, Z | 1 |
| Ben Abdesselem, M | 1 |
| el May, M | 1 |
| Gammoudi, A | 1 |
| Benna, F | 1 |
| Hamza, H | 1 |
| Dziri, C | 1 |
| Najah, N | 1 |
| Zaouche, A | 1 |
| Rahal, K | 1 |
| Ben Ayed, F | 1 |
| Tilsley, DW | 1 |
| Luthra, SJ | 1 |
| Brady, F | 1 |
| Guillemin, F | 1 |
| Arican, A | 1 |
| Cay, F | 1 |
| Dinçol, D | 1 |
| Karaoğuz, H | 1 |
| Demirkazik, A | 1 |
| Rao, BN | 1 |
| Merchant, TE | 1 |
| Avery, L | 1 |
| Cain, A | 1 |
| Bodner, S | 1 |
| Poquette, C | 1 |
| Lizón, J | 2 |
| Sánchez, B | 1 |
| Frau, A | 1 |
| Gorostidi, B | 1 |
| Goedkoop, R | 1 |
| Ou, Q | 1 |
| Shankar, A | 1 |
| Renaut, AJ | 1 |
| Whelan, J | 1 |
| Lippert, H | 1 |
| Rotarski, M | 1 |
| Letourneau, Y | 2 |
| Llory, JF | 2 |
| Le Rol, A | 2 |
| Mitoro, A | 2 |
| Tsujinoue, H | 2 |
| Toyokawa, Y | 1 |
| Nakatani, T | 2 |
| Fukui, H | 2 |
| Lobelle, JP | 1 |
| Dallemagne, B | 2 |
| Jehaes, C | 2 |
| Markiewicz, S | 2 |
| Miller, M | 1 |
| Imaseki, H | 2 |
| Rödel, C | 1 |
| Asato, Y | 1 |
| Yoshimi, F | 1 |
| Amemiya, R | 1 |
| Goya, T | 1 |
| Galli, C | 1 |
| Petrasch, S | 1 |
| Dörr, T | 1 |
| Kemmeries, G | 1 |
| Kaneda, K | 1 |
| Goggin, T | 1 |
| Kakisaka, A | 1 |
| Minami, M | 1 |
| Goto, J | 1 |
| Isizaki, A | 1 |
| Kino, S | 2 |
| Guarino, E | 1 |
| Restuccia, A | 1 |
| Bernard, P | 1 |
| Tuthill, C | 1 |
| Brito, RA | 1 |
| Medgyesy, D | 3 |
| Zukowski, TH | 2 |
| Royce, ME | 4 |
| Ravandi-Kashani, F | 1 |
| Rudroff, C | 1 |
| Altendorf-Hoffmann, A | 1 |
| Stangl, R | 2 |
| Scheele, J | 2 |
| Alafaci, E | 1 |
| Reynes, M | 1 |
| Oster, G | 1 |
| Ollendorf, D | 1 |
| Joulia, JM | 2 |
| Astre, C | 2 |
| Gomeni, R | 1 |
| Decker-Baumann, C | 1 |
| Buhl, K | 2 |
| von Herbay, A | 1 |
| Dueck, M | 1 |
| Moser, R | 1 |
| Mlineritsch, B | 1 |
| Schmidt, H | 1 |
| Pecherstorfer, M | 1 |
| Fridrik, M | 1 |
| Kopf, C | 1 |
| Nitsche, D | 1 |
| Kaider, A | 1 |
| Jacobson, JR | 1 |
| Modiano, M | 2 |
| Daniels, JR | 1 |
| Fletcher, WS | 1 |
| Cavaliere, F | 1 |
| Di Filippo, F | 1 |
| Cosimelli, M | 4 |
| Aloe, L | 1 |
| Arcuri, E | 1 |
| Anzà, M | 2 |
| Morace, E | 1 |
| Botti, C | 1 |
| Natoli, S | 1 |
| Tedesco, M | 1 |
| Cavaliere, R | 1 |
| Jelić, S | 1 |
| Nikolić-Tomasević, Z | 1 |
| Vian, L | 1 |
| Mochizuki, F | 1 |
| Skradis, A | 1 |
| Kolar, C | 3 |
| Kolath, J | 2 |
| Lawson, T | 1 |
| Talmadge, J | 2 |
| Stremetzne, S | 1 |
| Schunack, W | 1 |
| McGarry, W | 1 |
| Bready, B | 3 |
| Belt, RJ | 1 |
| Winn, R | 3 |
| Fata, F | 1 |
| Koehne, CH | 1 |
| Gravina, A | 2 |
| Faranda, A | 1 |
| Comis, S | 3 |
| O'Byrne, KJ | 1 |
| Braybrooke, JP | 1 |
| Bates, NP | 1 |
| Taylor, MA | 1 |
| Madigan, D | 1 |
| Ganesan, TS | 1 |
| Talbot, DC | 1 |
| Harris, AL | 1 |
| Baldelli, AM | 1 |
| Giuliodori, L | 1 |
| Agostinelli, R | 2 |
| Adjei, AA | 1 |
| Behr, TM | 1 |
| Salib, AL | 1 |
| Béhé, M | 1 |
| Angerstein, C | 1 |
| Blumenthal, RD | 1 |
| Fayyazi, A | 1 |
| Sharkey, RM | 1 |
| Ringe, B | 1 |
| Becker, H | 1 |
| Wörmann, B | 1 |
| Goldenberg, DM | 1 |
| Becker, W | 1 |
| Bensmaine, MA | 3 |
| Lucas, V | 1 |
| Dupont-André, G | 1 |
| Lawson, TA | 2 |
| Fujioka, M | 3 |
| Kishi, T | 1 |
| Shimomura, K | 1 |
| Idezuki, Y | 2 |
| Ishizaki, A | 1 |
| Kassai, S | 1 |
| Tsujita, K | 1 |
| Itou, Y | 1 |
| Ukei, T | 1 |
| Touno, T | 1 |
| Oozato, H | 1 |
| Oohata, K | 1 |
| Tukamoto, H | 2 |
| Yoneyama, Y | 2 |
| Takanishi, K | 1 |
| Matsumoto, J | 1 |
| Ohzato, H | 3 |
| Aihara, T | 1 |
| Kan, K | 1 |
| Imamoto, H | 1 |
| Guérin-Meyer, V | 1 |
| Lortholary, A | 1 |
| Genevieve, F | 1 |
| Ifrah, N | 1 |
| Antonelli, G | 1 |
| Tunesi, G | 2 |
| Baldo, C | 1 |
| Parikh, B | 1 |
| Taketani, S | 2 |
| Oyaizu, H | 1 |
| Ikebukuro, K | 2 |
| Ikehara, S | 2 |
| Ofner, D | 1 |
| Bern, M | 1 |
| Coco, F | 1 |
| Ignoffo, RJ | 1 |
| Dempke, W | 1 |
| Royce, M | 1 |
| Brito, R | 1 |
| Makower, D | 1 |
| Cohen, AM | 2 |
| Brennan, MF | 1 |
| Turnbull, AD | 1 |
| Stockman, J | 1 |
| Bertheaut-Cvitkovic, F | 1 |
| Larregain-Fournier, D | 1 |
| Walter, S | 1 |
| Marty, M | 5 |
| Ségal, V | 1 |
| Morsman, J | 1 |
| Blackie, R | 1 |
| Skarlos, DV | 1 |
| Sgouros, I | 1 |
| Florou, S | 1 |
| Suzuka, I | 1 |
| Izumi, S | 1 |
| Onoda, Y | 1 |
| Shiota, K | 1 |
| Nakagawa, J | 1 |
| Wiseman, CL | 1 |
| Weitz, I | 1 |
| Shani, J | 1 |
| Pospisil, M | 1 |
| Vannucci, L | 1 |
| Horvath, O | 1 |
| Fiserova, A | 1 |
| Krausova, K | 1 |
| Bezouska, K | 1 |
| Mosca, F | 1 |
| Bichisao, E | 1 |
| Silingardi, V | 1 |
| Sansoni, E | 1 |
| Izrael, V | 4 |
| Rudolph, KL | 1 |
| Unterhalt, M | 1 |
| Gwilt, P | 1 |
| Tempero, M | 2 |
| Connolly, M | 1 |
| Martens-Lobenhoffer, J | 1 |
| Fuhlroth, J | 1 |
| Boulanger, N | 1 |
| Schmitt, C | 3 |
| Denimal, F | 1 |
| Karoui, M | 1 |
| Dewailly, V | 1 |
| Kocha, W | 3 |
| Taylor, M | 1 |
| Keith, B | 1 |
| Sawyer, M | 1 |
| Griffeth, S | 1 |
| Tansik, RL | 1 |
| Porter, DJ | 1 |
| Lampert, S | 2 |
| Reingruber, B | 1 |
| Vetter, G | 2 |
| Dalley, D | 1 |
| Kallen, KJ | 1 |
| Hofmann, MA | 1 |
| Timm, A | 1 |
| Haba, A | 1 |
| Pritchard, DM | 1 |
| Aapro, M | 2 |
| Okamoto, R | 1 |
| Takeda, N | 1 |
| Takayasu, Y | 1 |
| Nakao, N | 1 |
| Kubota, A | 1 |
| Karasek, P | 1 |
| Jandik, P | 1 |
| Alakl, M | 2 |
| Novellino, PS | 1 |
| Trejo, YG | 1 |
| Beviacqua, M | 1 |
| Bordenave, RH | 1 |
| Rumi, LS | 1 |
| Smail, A | 1 |
| Cailliez, V | 1 |
| Ehrnrooth, E | 1 |
| Sørensen, B | 1 |
| Poulsen, JH | 1 |
| Dumont, E | 1 |
| Durston, S | 1 |
| Levy-Piedbois, C | 1 |
| Durand-Zaleski, I | 1 |
| Juhel, H | 1 |
| Bellanger, A | 1 |
| Papagianopoulos, P | 1 |
| Ride, E | 2 |
| Turner, J | 1 |
| Wardle, J | 1 |
| Evans, V | 1 |
| Kay, S | 1 |
| McArdle, RJ | 1 |
| Wendling, JL | 1 |
| Burki, F | 1 |
| Mignard, D | 2 |
| Johnson, M | 1 |
| Peillard, L | 1 |
| Catalin, J | 1 |
| Toki, J | 1 |
| Schallhorn, A | 1 |
| Hochmuth, K | 1 |
| Eida, K | 2 |
| Nogawa, T | 1 |
| Kunisaki, T | 1 |
| Tobinaga, K | 1 |
| Furukawa, M | 1 |
| Ino, M | 1 |
| Arima, S | 1 |
| Tachikawa, D | 1 |
| Futami, K | 1 |
| Yokomori, T | 1 |
| Iesato, H | 1 |
| Ohya, T | 2 |
| Nagaoka, H | 1 |
| Okabe, T | 1 |
| Lochs, H | 2 |
| Haboubi, N | 1 |
| Berdel, WE | 3 |
| Wall, JG | 1 |
| Mani, S | 3 |
| Bonny, T | 1 |
| Levin, J | 3 |
| Hohneker, J | 2 |
| Hinoshita, E | 1 |
| Uchiumi, T | 1 |
| Kinukawa, N | 1 |
| Tsuneyoshi, M | 1 |
| Ravandi, F | 2 |
| Rytting, ME | 1 |
| Osmon, C | 1 |
| Braud, EL | 1 |
| Roach, RW | 1 |
| Edwards, K | 1 |
| Jolain, B | 1 |
| Damjanov, N | 1 |
| Takasaki, M | 1 |
| Kouno, T | 1 |
| Kondo, S | 1 |
| Kawasaki, H | 1 |
| Matsunaga, T | 1 |
| Nakagawa, N | 1 |
| Yabana, T | 1 |
| Yasojima, T | 1 |
| Pelosi, E | 1 |
| Masaneo, I | 1 |
| Clara, R | 1 |
| Valetto, MR | 1 |
| Bellò, M | 1 |
| Zanon, C | 1 |
| Chiappino, I | 1 |
| Grosso, M | 1 |
| Mussa, A | 1 |
| Bisi, G | 1 |
| Csonka, C | 1 |
| Gergely, M | 1 |
| Lynch, FJ | 1 |
| Xiong, YP | 2 |
| Caradonna, SJ | 1 |
| Beck, T | 1 |
| Chevlen, EM | 1 |
| Weaver, CH | 1 |
| Bell, WN | 2 |
| White, R | 1 |
| McGuirt, C | 1 |
| Canaparo, R | 1 |
| Casale, F | 1 |
| Muntoni, E | 1 |
| Zara, GP | 1 |
| Della Pepa, C | 1 |
| Berno, E | 1 |
| Pons, N | 1 |
| Fornari, G | 1 |
| Eandi, M | 1 |
| Cwikiel, M | 1 |
| Kinhult, S | 1 |
| Eskilsson, J | 1 |
| Vanhöfer, U | 1 |
| Homerin, M | 1 |
| Hmissi, A | 1 |
| Hendler, D | 1 |
| Toh, Y | 2 |
| Nakashima, H | 1 |
| Droz, JP | 3 |
| Sculpher, M | 1 |
| Heyes, A | 1 |
| Di Paolo, AD | 1 |
| Melosi, A | 1 |
| Battistoni, M | 1 |
| Barsanti, G | 1 |
| Bleuzen, P | 2 |
| Bogdan, A | 1 |
| Lellouch, J | 1 |
| Lim, GC | 1 |
| Rampal, KG | 1 |
| Fuad, I | 1 |
| Lim, AK | 1 |
| Simmonds, PC | 1 |
| van Riel, JM | 4 |
| Molenberghs, G | 1 |
| Shahinian, AH | 2 |
| Paff, MT | 1 |
| Hsia, DW | 1 |
| Fridman, MKh | 1 |
| Kondrat'ev, VB | 1 |
| Manikhas, GM | 1 |
| Kozlov, AV | 1 |
| Nicum, S | 2 |
| Kennedy, AS | 1 |
| Harrison, GH | 1 |
| Mansfield, CM | 1 |
| Zhou, XJ | 1 |
| Balcer-Kubiczek, EK | 1 |
| Caterino, M | 1 |
| Bissett, D | 1 |
| Locker, PK | 2 |
| Pirotta, N | 2 |
| Tsujii, T | 1 |
| Terret, C | 1 |
| Erdociain, E | 1 |
| Féty-Deporte, R | 1 |
| Scott, RJ | 1 |
| Spigelman, AD | 1 |
| Janjan, NA | 1 |
| Breslin, T | 1 |
| Lenzi, R | 1 |
| Rich, TA | 1 |
| Csiki, Z | 1 |
| Gál, I | 1 |
| Takács, I | 1 |
| Antal, L | 1 |
| Szegedi, G | 1 |
| Bury, J | 1 |
| Beauduin, M | 1 |
| Herman, ML | 1 |
| Vindevoghel, A | 1 |
| Brohée, D | 2 |
| Lecomte, M | 1 |
| Joung, J | 1 |
| Cigolari, S | 1 |
| Pedicini, T | 1 |
| Arcangeli, V | 1 |
| Panzini, I | 2 |
| Sartori, S | 1 |
| Stabuc, B | 1 |
| Markovic, A | 1 |
| Plesnicar, A | 1 |
| Cizej, TE | 1 |
| Fizazi, K | 1 |
| Köstler, WJ | 1 |
| Tomek, S | 1 |
| Wiltschke, C | 1 |
| Culy, CR | 1 |
| Clemett, D | 1 |
| Wiseman, LR | 1 |
| Kanoh, Y | 1 |
| Yasue, A | 1 |
| Kinuta, M | 1 |
| Matsuda, I | 1 |
| Asakura, T | 1 |
| Shirata, Y | 1 |
| Kurisu, S | 1 |
| Taira, Y | 1 |
| Fujimori, A | 1 |
| Simon, J | 1 |
| Croockewit, A | 1 |
| Schellens, J | 1 |
| van Bronswijk, H | 1 |
| Lekkerkerker, JF | 1 |
| Koopmans, PP | 2 |
| Leo, SS | 1 |
| Todnem, K | 1 |
| Harboe, K | 1 |
| Zotova, L | 1 |
| Lind, A | 1 |
| McCann, J | 1 |
| Lo Bello, L | 1 |
| Pistone, G | 1 |
| Restuccia, S | 1 |
| Vinci, E | 1 |
| Mazzoleni, G | 1 |
| Waters, J | 1 |
| Shatari, T | 1 |
| Giuliani, R | 1 |
| Lanfranco, C | 1 |
| Gilles, V | 2 |
| Ratanatharathorn, V | 1 |
| Jirajarus, M | 1 |
| Sirilerttrakul, S | 1 |
| Konovalova, NP | 1 |
| Volkova, LM | 1 |
| Codacci-Pisanelli, D | 1 |
| Dusseau, C | 1 |
| Keenan, RA | 1 |
| Krokan, HE | 1 |
| Benoit, R | 1 |
| Chalmet, P | 1 |
| Pelley, RJ | 1 |
| Hauns, B | 1 |
| Häring, B | 2 |
| Köhler, S | 1 |
| Trippoli, S | 1 |
| Brabender, J | 2 |
| Dwivedy, S | 1 |
| Kłek, S | 1 |
| Wachol, D | 1 |
| Bock, PR | 1 |
| Hanisch, J | 1 |
| Goldberg, R | 2 |
| Manalo, J | 1 |
| Bregman, D | 1 |
| Albers, SH | 1 |
| Cazemier, M | 1 |
| Bleichrodt, R | 1 |
| van den Berg, FG | 1 |
| Watine, J | 1 |
| Soulage, C | 1 |
| Furuyama, JI | 1 |
| Bras-Gonçalves, RA | 1 |
| Poirson-Bichat, F | 1 |
| De Pinieux, G | 1 |
| Pandrea, I | 1 |
| Arvelo, F | 1 |
| Ronco, G | 1 |
| Villa, P | 1 |
| Dutrillaux, B | 1 |
| Poupon, MF | 1 |
| Coeffic, D | 1 |
| Durrani, AK | 1 |
| Lange, LM | 1 |
| Stewart, M | 2 |
| Aird, R | 1 |
| Knowles, G | 1 |
| Bowman, A | 1 |
| Wall, L | 1 |
| McLean, C | 1 |
| Di Constanzo, F | 1 |
| Pensel, RA | 1 |
| Marsh, J | 1 |
| Lena, MD | 1 |
| Dellapasqua, S | 1 |
| Daidone, MG | 1 |
| Costa, A | 2 |
| D'Attino, RM | 1 |
| Rivellini, F | 2 |
| Secondulfo, M | 1 |
| De Vivo, R | 1 |
| De Magistris, L | 1 |
| Barletta, E | 1 |
| Carratù, R | 1 |
| Witte, RS | 1 |
| Cnaan, A | 1 |
| Mansour, EG | 1 |
| Barylak, E | 1 |
| Harris, JE | 1 |
| Schutt, AJ | 1 |
| Scieszka, M | 1 |
| Zielinski, M | 1 |
| Machalski, M | 1 |
| Herman, ZS | 1 |
| Ionna, F | 1 |
| Hollis, D | 1 |
| Blesch, K | 1 |
| Boyer, M | 3 |
| Barker, C | 1 |
| Jamieson, C | 1 |
| Borras, JM | 1 |
| Sanchez-Hernandez, A | 1 |
| Martinez, M | 1 |
| Mendez, E | 1 |
| Ponton, JL | 1 |
| Espinas, JA | 1 |
| Damle, B | 1 |
| Kaul, S | 1 |
| Sonnichsen, D | 1 |
| Ferreira, I | 1 |
| Brooks, D | 1 |
| Alberts, D | 1 |
| Zaninelli, M | 1 |
| Leone, R | 1 |
| Franceschi, T | 1 |
| Fraccon, AP | 1 |
| Sabbioni, R | 1 |
| Cetto, GL | 1 |
| Sich, D | 1 |
| Dukers, DF | 2 |
| Vos, W | 2 |
| Bloemena, E | 2 |
| Happich, K | 1 |
| Martus, P | 2 |
| Parsch, H | 1 |
| Himmler, B | 1 |
| Cox, J | 2 |
| Kuperminc, M | 1 |
| Walde, D | 1 |
| Weaver, C | 1 |
| Harrison, E | 1 |
| Rosty, C | 2 |
| Recaldin, E | 1 |
| Testore, P | 1 |
| Moiseenko, VM | 1 |
| Semenova, AI | 1 |
| Orlova, RV | 1 |
| Capadano, M | 1 |
| Lynch, J | 1 |
| Goertzen, T | 1 |
| McCowan, T | 1 |
| Brand, R | 1 |
| Manola, J | 1 |
| Valone, FH | 2 |
| Ryan, LM | 1 |
| Hines, JD | 3 |
| Mueller, HH | 1 |
| Mattes, E | 1 |
| de Bree, E | 1 |
| Kaag, MM | 1 |
| van Slooten, GW | 1 |
| Romanos, J | 1 |
| Antoine, EC | 1 |
| Nizri, D | 1 |
| Kruse, A | 1 |
| Thumann, A | 1 |
| Schneider, B | 1 |
| Clemm, C | 1 |
| Clevert, HD | 1 |
| Hockertz, S | 1 |
| Kalousek, MB | 1 |
| Sengoku, H | 1 |
| Kihara, A | 1 |
| Okano, M | 1 |
| Porta, C | 1 |
| Accurso, S | 1 |
| Girino, M | 1 |
| Bontke, N | 1 |
| Dentico, P | 1 |
| Angelelli, B | 1 |
| Scicolone, S | 1 |
| Grumett, SA | 1 |
| Archer, VR | 1 |
| Mulholland, P | 1 |
| Blewitt, L | 1 |
| Beckert, B | 1 |
| Lang, N | 1 |
| Stemmler, J | 1 |
| Beykirch, M | 1 |
| Stein, J | 1 |
| Goecke, E | 1 |
| Waggershauser, T | 1 |
| Schuell, B | 1 |
| Ulrich-Pur, H | 2 |
| Penz, M | 1 |
| Wedding, U | 1 |
| Kolb, G | 1 |
| Valls, C | 1 |
| Rafecas, A | 1 |
| Fabregat, J | 1 |
| Ramos, E | 1 |
| Jaurrieta, E | 1 |
| Blot, F | 1 |
| El Otmany, A | 1 |
| Tabuchi, Y | 1 |
| Krieger, G | 1 |
| Traynor, K | 1 |
| Höpfner, M | 1 |
| Maaser, K | 1 |
| Barthel, B | 1 |
| von Lampe, B | 1 |
| Hanski, C | 1 |
| Riecken, EO | 1 |
| Zeitz, M | 2 |
| Scherübl, H | 1 |
| Malamos, N | 1 |
| Agelaki, A | 1 |
| Araki, Y | 1 |
| Isomoto, H | 1 |
| Cyjon, A | 1 |
| Neuman-Levin, M | 1 |
| Rakowsky, E | 1 |
| Belinky, A | 1 |
| Atar, E | 1 |
| Hardoff, R | 1 |
| Grivicich, I | 1 |
| Mans, DR | 1 |
| Schwartsmann, G | 1 |
| De Giorgi, U | 1 |
| Giovanis, P | 2 |
| Guadagni, S | 1 |
| Fujioka, A | 1 |
| Virkkunen, P | 1 |
| Hishikawa, Y | 1 |
| Kohno, H | 1 |
| Kimoto, T | 1 |
| Dhar, DK | 1 |
| Tachibana, M | 1 |
| Koji, T | 1 |
| Nagasue, N | 1 |
| D'Agnano, I | 1 |
| Vasselli, S | 1 |
| Perrone Donnorso, R | 1 |
| D'Angelo, C | 1 |
| Benevolo, M | 1 |
| Zupi, G | 2 |
| Tanaka-Nozaki, M | 1 |
| Onda, M | 1 |
| Grieu, F | 1 |
| Gramont, AD | 1 |
| Sarela, AI | 1 |
| Guthrie, JA | 1 |
| O'Riordain, DS | 1 |
| El-Malt, M | 1 |
| van den Broecke, C | 1 |
| Cuvelier, C | 1 |
| De Neve, W | 1 |
| de Hemptinne, B | 1 |
| Hwang, PM | 1 |
| Rago, C | 1 |
| Chan, TA | 1 |
| Murphy, MP | 1 |
| Kelso, GF | 1 |
| Smith, RA | 1 |
| Kaye, S | 1 |
| McSheehy, PM | 1 |
| Rodrigues, LM | 1 |
| Wadsworth, P | 1 |
| Price, NM | 1 |
| Müller, H | 1 |
| Nakchbandi, W | 1 |
| Chatzissavvidis, I | 1 |
| Valek, V | 2 |
| Hidemura, K | 1 |
| Kasai, Y | 1 |
| Burke, D | 1 |
| Carnochan, P | 1 |
| Jahn, M | 1 |
| Schmiegel, WH | 2 |
| Labianca, RF | 1 |
| Drees, M | 1 |
| Kühnel, J | 1 |
| Gedlicka, C | 1 |
| Watatani, M | 1 |
| Takamatsu, S | 1 |
| Toukairin, H | 1 |
| Kure, N | 1 |
| Ishizuka, N | 1 |
| Amaya, K | 1 |
| Terada, I | 1 |
| Nishijima, K | 1 |
| Gnanasampanthan, G | 1 |
| Wong, NA | 2 |
| Brett, L | 1 |
| Leitch, A | 1 |
| Dunlop, MG | 1 |
| Lessells, AM | 1 |
| Gansauge, F | 1 |
| McGavin, JK | 1 |
| Goa, KL | 1 |
| Sasson, AR | 1 |
| Bertucci, D | 1 |
| Vogelzang, NJ | 1 |
| Gargano, L | 1 |
| Caporale, A | 1 |
| Konstantatoy, E | 1 |
| Masciangelo, R | 1 |
| Adler, G | 1 |
| Eckel, F | 1 |
| Schmelz, R | 1 |
| Adelsberger, H | 1 |
| Erdmann, J | 1 |
| Quasthoff, S | 1 |
| Lersch, C | 1 |
| Mitchell, F | 1 |
| Calvert, AH | 1 |
| Judson, IR | 1 |
| de Wit, R | 1 |
| Greim, G | 1 |
| van der Born, K | 1 |
| Wanders, J | 1 |
| de Boer, RF | 1 |
| Fumoleau, P | 1 |
| Deng, YC | 1 |
| Zhen, YS | 1 |
| Xue, YC | 1 |
| Nicolaides, C | 1 |
| Dimopoulos, MA | 1 |
| Giannoulis, E | 1 |
| Dervenis, C | 1 |
| Androulakis, I | 1 |
| Kandilis, K | 1 |
| Manziuk, LV | 1 |
| Artamonova, EV | 1 |
| Sholokhov, VN | 1 |
| Strygina, EA | 1 |
| Marková, J | 1 |
| Boudný, J | 1 |
| Kala, Z | 1 |
| Hanke, I | 1 |
| Ostrízek, T | 1 |
| Leypold, J | 1 |
| Venturini, M | 2 |
| Köckerling, F | 1 |
| Hänsler, J | 1 |
| Bernatik, T | 1 |
| Becker, D | 1 |
| Schneider, T | 1 |
| Di Costanzo, E | 1 |
| Paoloni, FP | 1 |
| Moscetti, L | 1 |
| Cherubini, R | 1 |
| Abushullaih, S | 1 |
| Saad, ED | 1 |
| Munsell, M | 1 |
| Madisch, A | 1 |
| Wiedbrauck, F | 1 |
| Marquard, F | 1 |
| Stolte, M | 1 |
| Hotz, J | 1 |
| Shultz, J | 1 |
| Kasimis, B | 1 |
| Fleagle, J | 1 |
| Carlin, D | 1 |
| Hammershaimb, L | 3 |
| Keizer, HJ | 1 |
| Ten Napel, CH | 1 |
| Niezgodzki, G | 1 |
| Chipponi, J | 1 |
| Eaton, D | 1 |
| Imaeda, Y | 1 |
| Umemoto, S | 1 |
| Specchia, M | 1 |
| Martini, M | 1 |
| Pignatti, F | 1 |
| Micheel, S | 1 |
| Romel, L | 1 |
| Vargas-Chanes, D | 1 |
| Kemeny, MM | 2 |
| Adak, S | 1 |
| Smith, T | 1 |
| Lipsitz, S | 1 |
| West, WH | 1 |
| Wong, A | 2 |
| Colwell, B | 1 |
| White, RL | 1 |
| Yates, BB | 1 |
| McGuirt, PV | 1 |
| Hargreaves, D | 1 |
| Nguyen-Van-Tam, J | 1 |
| Ng, T | 1 |
| Rahóty, P | 1 |
| Hullán, L | 1 |
| Magnusson, I | 1 |
| Castiglione-Gertsch, M | 1 |
| Chung, T | 1 |
| Dangelica, MI | 1 |
| Shoup, MC | 1 |
| Nissan, A | 1 |
| Haruyama, K | 2 |
| Broisin, L | 1 |
| Guardiola, E | 1 |
| Ramaïoli, A | 1 |
| Ferrero, JM | 1 |
| Namer, M | 1 |
| Pistilli, B | 1 |
| Valeri, M | 1 |
| Namiki, Y | 1 |
| Ensminger, WD | 2 |
| Dizon, DS | 1 |
| Haasjes, J | 1 |
| Piersma, H | 1 |
| Groen, HJ | 1 |
| Potter, JD | 1 |
| Demedts, I | 1 |
| Tomlinson, SK | 1 |
| Melin, SA | 1 |
| Higgs, V | 1 |
| White, DR | 1 |
| Savage, P | 1 |
| Case, D | 1 |
| Blackstock, AW | 1 |
| Lin, FH | 1 |
| Lee, YH | 1 |
| Jian, CH | 1 |
| Wong, JM | 1 |
| Shieh, MJ | 1 |
| Pasquini, E | 1 |
| Cruciani, G | 1 |
| Oliverio, G | 1 |
| Zumaglini, F | 1 |
| Nicolini, M | 1 |
| Kourousis, Ch | 1 |
| Athanasiadis, N | 1 |
| Burger, U | 1 |
| Garin, A | 1 |
| McKendric, J | 1 |
| Ranieri, G | 1 |
| Kellermann, L | 1 |
| Morris, RG | 1 |
| McCondochie, A | 1 |
| Bader, S | 1 |
| Del Prete, S | 1 |
| Benjamin, I | 1 |
| Maisey, NR | 1 |
| Croockewit, AJ | 1 |
| de Boer, JE | 1 |
| van Loenhout, JW | 1 |
| Adimi, P | 1 |
| Wennberg, A | 2 |
| Schilling, A | 1 |
| Gewiese, B | 1 |
| Fobbe, F | 1 |
| Stiller, D | 1 |
| Gallkowski, U | 1 |
| Wolf, KJ | 1 |
| Wu, GR | 1 |
| Kuramoto, S | 1 |
| Hanawa, S | 1 |
| Yanagita, K | 1 |
| Yoshio, T | 1 |
| Ohe, Y | 1 |
| Ohmori, T | 1 |
| Fielding, LP | 1 |
| Hittinger, R | 1 |
| Fry, JS | 1 |
| Garten, L | 1 |
| Stenning, S | 1 |
| Hill, GJ | 1 |
| Holmberg, A | 1 |
| Steinberg, J | 1 |
| Gadalla, T | 1 |
| Platz, D | 1 |
| Buggisch, P | 1 |
| Eckardt, N | 1 |
| Drescher, S | 1 |
| Müllerleile, U | 1 |
| Sertoli, MR | 2 |
| Rubagotti, A | 2 |
| Vidili, MG | 2 |
| Canobbio, L | 2 |
| Fassio, T | 2 |
| Luzi Fedeli, S | 2 |
| Fowler, WC | 1 |
| Eisenberg, BL | 1 |
| Hoffman, JP | 1 |
| Rausa, L | 4 |
| Inaba, S | 1 |
| Ogino, A | 1 |
| Umeda, T | 1 |
| Moore, DF | 3 |
| Cripps, IC | 1 |
| McCormick, R | 1 |
| Temple, W | 1 |
| Bogues, W | 1 |
| Zilembo, N | 1 |
| Nelli, P | 1 |
| Reid, I | 1 |
| Sharpe, I | 1 |
| Maxwell, W | 1 |
| McDevitt, J | 1 |
| Tanner, WA | 1 |
| Fedeli, SL | 1 |
| Kleeberg, U | 1 |
| Middeke, H | 1 |
| Korsten, FW | 2 |
| Trux, FA | 1 |
| Schmieder, A | 1 |
| Evers, C | 1 |
| Ismail Ali, A | 1 |
| Simadibrata, R | 1 |
| Aziz Rani, A | 1 |
| Chudahman, M | 1 |
| Dharmika, D | 1 |
| Berlion, M | 1 |
| Berille, J | 1 |
| Gioanni, J | 1 |
| Bizzari, JP | 1 |
| Parodi, GC | 1 |
| Nanninga, AG | 1 |
| de Vries, GE | 1 |
| Okuyama, K | 1 |
| Awano, T | 1 |
| Tohnosu, N | 1 |
| Nakaichi, H | 1 |
| Funami, Y | 1 |
| Amano, H | 1 |
| Hottenrott, C | 4 |
| Maier, P | 1 |
| Reimann, M | 1 |
| Inglis, R | 2 |
| Eschwege, F | 1 |
| Ammarguellat, H | 1 |
| Ghosn, M | 2 |
| Benhamed, M | 1 |
| Theodore, C | 2 |
| Kac, J | 1 |
| Goldberg, J | 1 |
| Jimeno, J | 2 |
| Sánchez, J | 1 |
| Cruz-Hernández, J | 1 |
| Matthias, M | 3 |
| Hoksch, B | 2 |
| Boewer, C | 2 |
| Oldenkott, B | 2 |
| Lenk, H | 1 |
| Wiener, N | 1 |
| Dixon, DO | 1 |
| Freedman, LS | 1 |
| Spiegelhalter, DJ | 1 |
| Greenhouse, JB | 1 |
| Günther, E | 1 |
| Hirschmann, WD | 1 |
| Sondern, W | 1 |
| Koniczek, KH | 1 |
| Wander, HE | 1 |
| Natt, F | 1 |
| Hinrichs, HF | 1 |
| Werdier, D | 1 |
| Younes, A | 2 |
| Taylor, CW | 1 |
| Modiano, MR | 1 |
| Woodson, ME | 1 |
| Marcus, SG | 1 |
| Alberts, DS | 1 |
| Hersh, EM | 1 |
| Knauf, WU | 1 |
| Ruelfs, C | 1 |
| Ottensmeier, C | 1 |
| Musch, E | 1 |
| Koch, O | 1 |
| van de Loo, J | 1 |
| Laurensse, E | 1 |
| Boarman, D | 1 |
| Balis, FM | 1 |
| Murphy, RF | 1 |
| McAtee, N | 1 |
| Bussières, E | 1 |
| Lagarde, P | 1 |
| Martin, D | 2 |
| Wiseberg, J | 1 |
| McCulloch, W | 1 |
| Tzannou, I | 1 |
| Posner, M | 2 |
| Martin, A | 1 |
| Slapak, CA | 2 |
| Cummings, FJ | 2 |
| Robert, NJ | 1 |
| Arigoni, M | 1 |
| Barras, J | 2 |
| Schweizer, W | 2 |
| Gazit, Z | 1 |
| Weiss, DW | 1 |
| Shouval, D | 1 |
| Yechezkeli, M | 1 |
| Schirrmacher, V | 1 |
| Notter, M | 1 |
| Walter, J | 1 |
| Kedar, E | 1 |
| Guaraldi, M | 1 |
| Covizzi, M | 1 |
| Tedeschi, L | 1 |
| Luporini, A | 1 |
| Park, KG | 1 |
| Murray, JB | 1 |
| Hayes, PD | 1 |
| Ashby, JA | 1 |
| Bartolucci, R | 2 |
| Sofra, M | 1 |
| Löffler, TM | 1 |
| Planker, M | 1 |
| Burghardt, F | 1 |
| Aulbert, E | 1 |
| Lindemann, W | 1 |
| Schröder, M | 1 |
| Strohmeyer, G | 1 |
| Díaz Rubio, E | 1 |
| Camps, C | 1 |
| González Larriba, JL | 1 |
| Tohma, H | 1 |
| Shikama, T | 1 |
| Steger, G | 1 |
| Bellmunt, J | 1 |
| Albanell, J | 1 |
| Gallego, OS | 1 |
| Inoshita, G | 1 |
| Yalavarthi, P | 1 |
| Murthy, S | 1 |
| Gibson, V | 1 |
| Sergi, JS | 1 |
| Bauer, L | 1 |
| Prestifilippo, J | 1 |
| Itzakhi, M | 1 |
| Lecouturier, S | 1 |
| Descorps-Declère, A | 1 |
| Tsuchiya, S | 3 |
| Iijima, N | 2 |
| Aso, K | 2 |
| Nishiyama, K | 2 |
| Amano, T | 2 |
| Murayama, N | 2 |
| Kuusela, P | 1 |
| Beretta, A | 1 |
| Cesana, B | 2 |
| Cozzaglio, L | 2 |
| Cristoni, M | 1 |
| Sofo, L | 1 |
| Netri, G | 1 |
| Ratto, C | 1 |
| Coco, C | 1 |
| Codacci-Pisanelli, M | 1 |
| Ferri, GM | 1 |
| Grieco, A | 1 |
| Pagani, V | 1 |
| Daponte, A | 1 |
| Parziale, A | 1 |
| Iervolino, V | 1 |
| Santillo, G | 1 |
| Zarrilli, D | 1 |
| Inbar, M | 1 |
| Ahmann, FR | 1 |
| Garewal, HS | 1 |
| Urmacher, C | 1 |
| Kurtz, RC | 1 |
| Murray, M | 1 |
| Stagg, RJ | 1 |
| Lewis, BJ | 1 |
| Mulvihill, SJ | 1 |
| Grobman, BJ | 1 |
| Rayner, AA | 1 |
| Maybaum, J | 1 |
| Burton, EC | 1 |
| Shelton, DA | 1 |
| Jing, HW | 1 |
| Dusenbury, CE | 1 |
| Stetson, PL | 1 |
| Cheson, BD | 1 |
| Durante, F | 1 |
| Porcellana, M | 1 |
| Cavaliere, P | 1 |
| Anfossi, A | 1 |
| Pilati, PL | 1 |
| Altendorf-Hofmann, A | 1 |
| Gall, FP | 1 |
| Tsekova, V | 1 |
| Koĭnov, K | 1 |
| Velikova, M | 1 |
| Dudunkov, Z | 1 |
| Dimitrov, V | 1 |
| Kurtev, P | 1 |
| Ralchev, K | 1 |
| Tsai, CM | 1 |
| Gazdar, AF | 2 |
| Perng, RP | 1 |
| Kramer, BS | 2 |
| Baur, M | 1 |
| Schlappack, O | 1 |
| Havelec, L | 1 |
| Mader, R | 1 |
| Tohyama, N | 2 |
| Gandolfo, G | 1 |
| Naglieri, E | 1 |
| Cornia, E | 1 |
| Del Bufalo, D | 1 |
| Röthlin, M | 1 |
| Kusumoto, S | 1 |
| Nakayoshi, A | 1 |
| Takegawa, S | 1 |
| Kumaki, T | 1 |
| Katoh, M | 1 |
| Gotohda, H | 1 |
| Saitoh, H | 1 |
| Kinami, Y | 1 |
| Kurosawa, H | 1 |
| Fukano, M | 2 |
| Tokitoh, T | 1 |
| Lembersky, B | 1 |
| Atkins, M | 1 |
| Kirkwood, J | 1 |
| Creaven, P | 1 |
| Montini, E | 1 |
| Bonera, F | 1 |
| Braga, M | 1 |
| Ragni, F | 1 |
| Hamazoe, R | 2 |
| Murakami, A | 1 |
| Hirooka, Y | 1 |
| Maeta, M | 2 |
| Brunner, K | 2 |
| Hojo, K | 3 |
| Furusawa, M | 1 |
| Tschetter, LK | 3 |
| Delgado, F | 1 |
| García-Reinoso, J | 1 |
| Sanchis, C | 1 |
| Viciano, V | 1 |
| Asencio, F | 1 |
| Martínez-Abad, M | 1 |
| Aguilo, J | 1 |
| Sánchez, JJ | 1 |
| Pastor, MC | 1 |
| Carles, J | 1 |
| Oller, B | 1 |
| Armengol, M | 1 |
| Salva, A | 1 |
| Ribas, M | 1 |
| Cantrell, J | 1 |
| Wampler, GL | 1 |
| Gullo, JJ | 2 |
| Fryer, JG | 1 |
| Alt, DE | 1 |
| Poplin, EA | 1 |
| Kraut, M | 1 |
| Baker, L | 1 |
| Brodfuehrer, J | 1 |
| Vaitkevicius, V | 2 |
| Schiessel, R | 2 |
| Karall, M | 1 |
| Ernst, F | 1 |
| Sebesta, C | 1 |
| Hentschel, E | 1 |
| Wirth, A | 1 |
| Green, M | 1 |
| Nott, D | 1 |
| Jenkins, S | 1 |
| Katz, KH | 1 |
| Davis, CA | 1 |
| Durivage, HJ | 1 |
| Rome, LS | 1 |
| Capizzi, RL | 1 |
| Farber, LR | 1 |
| Pasquale, DN | 1 |
| Furue, H | 1 |
| Trocki, O | 1 |
| Muir, WA | 1 |
| Sisk, R | 1 |
| Schacter, L | 1 |
| Palmieri, G | 2 |
| Gridelli, C | 2 |
| Airoma, G | 2 |
| Pepe, R | 1 |
| Incoronato, P | 2 |
| Kozatsani-Halvidi, D | 1 |
| Tsaroucha, E | 1 |
| Bulger, KN | 1 |
| Slavik, M | 1 |
| Rabinovich, MG | 1 |
| Bianco, A | 1 |
| Alvarez, LA | 1 |
| Faradji, A | 2 |
| Bohbot, A | 2 |
| Damonte, J | 2 |
| Eber, M | 1 |
| Laustriat, D | 1 |
| Goetz, J | 2 |
| Wiesel, ML | 2 |
| Follea, G | 2 |
| Piemont, Y | 1 |
| Schimpfle, B | 1 |
| Wolff, H | 1 |
| Mai, C | 1 |
| Lüning, M | 1 |
| Gerard, A | 1 |
| Willems, G | 1 |
| Delvaux, G | 1 |
| Depadt, G | 1 |
| Chua, L | 1 |
| Tian, EM | 1 |
| Sridhar, K | 1 |
| Benedetto, P | 1 |
| Legaspi, A | 1 |
| Waldman, S | 1 |
| Morrell, L | 1 |
| Danhauser-Riedl, S | 1 |
| Steinhauser, G | 1 |
| Rastetter, J | 1 |
| Heim, ME | 3 |
| Klee, M | 1 |
| Rieche, K | 1 |
| Edler, L | 1 |
| Tsubono, M | 1 |
| Morimoto, H | 1 |
| Tseng, CC | 1 |
| Tobe, T | 1 |
| Yasui, K | 1 |
| Berres, M | 1 |
| Jäggi, P | 1 |
| Schiller, JH | 1 |
| Bittner, G | 1 |
| Kakuta, T | 2 |
| Sakurai, H | 1 |
| Yoshimatsu, A | 1 |
| Fukunaga, J | 1 |
| Kitahama, H | 1 |
| Okuyama, A | 1 |
| Seki, T | 1 |
| Tsurui, K | 1 |
| Saka, M | 1 |
| Sasagawa, M | 1 |
| Hishinuma, S | 1 |
| Noto, T | 1 |
| Mizutani, K | 1 |
| Gotoh, K | 1 |
| Tsukui, M | 1 |
| Ohtani, Y | 1 |
| Kawano, N | 1 |
| Houjo, K | 1 |
| Iijima, K | 1 |
| Hamahata, Y | 1 |
| McBee, P | 1 |
| Petraiuolo, W | 1 |
| Katoh, A | 2 |
| Mazy, V | 1 |
| Jacquet, N | 1 |
| Demoulin, JC | 1 |
| Sakatoku, M | 1 |
| Kikkawa, H | 1 |
| Matsu, T | 1 |
| Tatsuzawa, T | 1 |
| Masuda, S | 1 |
| Balestrino, M | 1 |
| Bisogno, A | 1 |
| Martin, JK | 1 |
| Gonzalez-Larriba, J | 1 |
| Schumacher, K | 1 |
| Roscher, R | 2 |
| Bittner, R | 1 |
| Franklin, HR | 1 |
| McVie, JG | 1 |
| Spears, PC | 1 |
| Wagman, LD | 1 |
| Leong, L | 1 |
| Terz, JJ | 1 |
| Hill, LR | 1 |
| Beatty, JD | 1 |
| Kokal, WA | 1 |
| Riihimaki, DU | 1 |
| Natali, M | 1 |
| D'Aprile, M | 1 |
| Leggio, M | 1 |
| Vici, P | 1 |
| Carpano, S | 1 |
| Angelini, F | 1 |
| Carassai, A | 1 |
| Milonakis, N | 1 |
| Sarafidou, M | 1 |
| Zamanis, N | 2 |
| Magoulas, D | 1 |
| Knöpfle, G | 1 |
| Leidig, P | 1 |
| Cianflone, SG | 1 |
| Dose, AM | 2 |
| Etzell, PS | 1 |
| Burnham, NL | 1 |
| Therneau, TM | 1 |
| Hagen, L | 1 |
| Gainey, DK | 1 |
| Cross, M | 1 |
| Athmann, LM | 1 |
| Sznol, M | 1 |
| Friedman, MA | 2 |
| Zinelis, A | 1 |
| Beldecos, D | 1 |
| Mylonacis, N | 1 |
| Valilis, P | 1 |
| Antonopoulos, A | 1 |
| Hunt, TM | 1 |
| Flowerdew, AD | 1 |
| Birch, SJ | 1 |
| Williams, JD | 1 |
| Mullee, MA | 1 |
| Pfeifle, DM | 1 |
| Laurie, JA | 3 |
| Daniele, O | 1 |
| Ghiotto, C | 1 |
| Aversa, SM | 1 |
| Morandi, P | 1 |
| Fiorentino, MV | 1 |
| North, ML | 1 |
| Johnston, J | 1 |
| Theve, T | 1 |
| Browne, MJ | 1 |
| Curt, G | 1 |
| Calabresi, P | 1 |
| Wiemann, M | 1 |
| Urba, S | 1 |
| Mortimer, JE | 1 |
| Anderson, I | 1 |
| Shepard, B | 1 |
| DuBrow, R | 1 |
| Campos, L | 1 |
| Quaraishi, M | 1 |
| Faintuch, J | 1 |
| Sammarco, P | 1 |
| Adams, L | 1 |
| Derby, S | 2 |
| Murray, P | 1 |
| Houston, C | 1 |
| Peter, R | 1 |
| Comis, RL | 2 |
| Goldberg, JA | 2 |
| Wilmott, N | 1 |
| McKillop, JH | 2 |
| Onodera, H | 1 |
| Somers, SS | 1 |
| Hase, S | 1 |
| Yoshimura, A | 1 |
| Sameshima, T | 1 |
| Ishizawa, T | 1 |
| Shimazu, H | 1 |
| Matsuoka, T | 1 |
| Wakui, A | 1 |
| Mukaiyama, T | 1 |
| Obrist, R | 1 |
| Obrecht, JP | 1 |
| Haegele, P | 1 |
| Tagnon, A | 1 |
| Duez, N | 1 |
| Domellöf, L | 1 |
| Rudenstam, CM | 1 |
| Norryd, C | 1 |
| Bergman, L | 1 |
| Nilsson, T | 1 |
| Hansson, K | 1 |
| Asklöf, G | 1 |
| Kugelberg, C | 1 |
| Colella, G | 1 |
| Casciarri, G | 1 |
| Gennari, L | 1 |
| Colla, G | 1 |
| Goldman, M | 2 |
| Lyver, A | 2 |
| Lissoni, P | 1 |
| Paolorossi, F | 1 |
| Crispino, S | 1 |
| Archili, C | 1 |
| Tancini, G | 1 |
| Hölting, T | 1 |
| Schwarz, V | 2 |
| May, D | 1 |
| Wandl, U | 2 |
| Becher, R | 2 |
| Schmidt, CG | 1 |
| McMaster, ML | 1 |
| Johnson, DH | 1 |
| Beart, RW | 1 |
| Leigh, JE | 2 |
| van Heerden, JA | 1 |
| Willmott, N | 1 |
| Bates, CD | 1 |
| Amino, K | 1 |
| Mieno, K | 1 |
| Miura, S | 1 |
| Satoi, Y | 1 |
| Ohtaki, K | 1 |
| Aoki, H | 1 |
| Shikata, J | 1 |
| Paul, AR | 1 |
| Wereldsma, JC | 1 |
| Bruggink, ED | 1 |
| Meijer, WS | 1 |
| Roukema, JA | 1 |
| van Putten, WL | 1 |
| Birsic, W | 1 |
| D'Oro, L | 1 |
| Charoensiri, S | 1 |
| Olafsdottir, M | 1 |
| Schneider, A | 1 |
| Martin, DS | 1 |
| Colofiore, J | 1 |
| Sawyer, RC | 1 |
| Salvia, B | 1 |
| Cullinan, SA | 1 |
| Everson, LK | 2 |
| Namba, M | 1 |
| Muto, K | 1 |
| Ikeguchi, S | 1 |
| Kac, JL | 1 |
| Marks, HG | 1 |
| Marks, V | 1 |
| Kremer, B | 1 |
| Teshima, Y | 1 |
| Yamagata, M | 1 |
| Sakabe, T | 1 |
| Maruyama, J | 1 |
| Morikawa, E | 1 |
| Hida, J | 1 |
| Ko, K | 1 |
| Bär, HU | 1 |
| Mennigen, R | 2 |
| Barkun, J | 1 |
| Klauke, H | 1 |
| Lumbroso, J | 1 |
| Sidibe, S | 1 |
| Bitter, R | 1 |
| Schumacher, KA | 1 |
| Gaus, W | 1 |
| Didolkar, MS | 1 |
| Kirkowa-Reimann, M | 1 |
| Runhaar, EA | 1 |
| Verwey, J | 1 |
| Neyt, JP | 1 |
| Horigome, N | 1 |
| Hanasaki, K | 1 |
| Kinosita, T | 1 |
| Sodeyama, H | 1 |
| Iida, F | 1 |
| Mitsugi, O | 1 |
| Sugahara, K | 1 |
| Rader, M | 1 |
| Zimmerman, M | 1 |
| Itri, L | 1 |
| Weinberg, V | 1 |
| Weeks, A | 1 |
| Raber, MN | 1 |
| Gravel, D | 1 |
| Chun, HG | 1 |
| Zelkowitz, RS | 1 |
| Posner, MR | 1 |
| Weitberg, AB | 1 |
| de Quay, N | 1 |
| Cuttat, JF | 1 |
| Tevaearai, H | 1 |
| Chapuis, G | 1 |
| Albe, X | 1 |
| Vassilakos, P | 1 |
| Houvenaeghel, G | 1 |
| Guerinel, G | 1 |
| Carcassonne, Y | 1 |
| Ausman, R | 1 |
| Frick, J | 1 |
| Ritch, P | 1 |
| Schulte, W | 1 |
| Haas, C | 1 |
| Beatty, P | 1 |
| Abdi, EA | 1 |
| Hanson, J | 1 |
| Harbora, DE | 1 |
| Young, DG | 1 |
| McPherson, TA | 1 |
| Miser, AW | 1 |
| Ahlquist, DA | 1 |
| Kanojia, MD | 1 |
| Bedikian, AY | 1 |
| Inzani, V | 1 |
| Stevenson, FK | 1 |
| van der Plas, J | 1 |
| Herrera, L | 3 |
| Russell, D | 1 |
| Stablein, DM | 1 |
| Schinella, R | 1 |
| Green, MD | 1 |
| Schuster, D | 1 |
| Flechtner, H | 1 |
| Worst, P | 1 |
| LoRusso, P | 1 |
| Redman, BG | 1 |
| Kinzie, J | 1 |
| Hryniuk, WM | 1 |
| Pratesi, G | 1 |
| Manzotti, C | 1 |
| Tortoreto, M | 1 |
| Prosperi, E | 1 |
| Köhler, L | 1 |
| Fuchshuber, P | 1 |
| Eypasch, E | 1 |
| McCormack, GW | 1 |
| Malliard, J | 1 |
| Arisawa, Y | 1 |
| Takabayashi, T | 1 |
| Abe, O | 1 |
| Okubo, Y | 1 |
| Maruyama, H | 1 |
| Imajo, M | 1 |
| Yaegashi, K | 1 |
| Adelstein, DJ | 2 |
| Spiess, JL | 2 |
| Giroski, P | 1 |
| Carter, SG | 2 |
| Stydnicki, KA | 2 |
| Morgan, ED | 2 |
| Collier, M | 2 |
| Knick, VB | 2 |
| Duch, DS | 2 |
| Mullin, R | 2 |
| Ferone, R | 2 |
| Wittlinger, PS | 1 |
| Drakes, T | 1 |
| Eisenberg, PD | 1 |
| Malec, M | 1 |
| Hannigan, JF | 1 |
| Fan, S | 1 |
| Liang, CL | 1 |
| Wiley, AL | 1 |
| Wirtanen, GW | 1 |
| Stephenson, JA | 1 |
| Ramirez, G | 1 |
| Demets, D | 1 |
| Joseph, RR | 1 |
| Madejewicz, S | 1 |
| Plager, J | 1 |
| Soloman, J | 1 |
| Mittelman, A | 2 |
| Quentmeier, A | 1 |
| Reichman, B | 1 |
| Vinciguerra, V | 1 |
| Michaelson, R | 1 |
| Rosenbluth, R | 1 |
| Deonarine, S | 1 |
| Greene, RF | 1 |
| Cagnazzo, P | 1 |
| Cardi, G | 1 |
| Ricciuti, FP | 1 |
| Frati, L | 1 |
| Marchei, P | 1 |
| Dobbs, BR | 1 |
| Edwards, IR | 1 |
| Perrier, DG | 1 |
| Muhrer, KH | 1 |
| Schwemmle, K | 1 |
| Nishiyama, M | 1 |
| Takagami, S | 1 |
| Kirihara, Y | 1 |
| Hirabayashi, N | 1 |
| Nosoh, Y | 1 |
| Niimoto, M | 1 |
| Farley, PC | 1 |
| McFaden, KH | 1 |
| Clerici, M | 1 |
| Montinari, F | 1 |
| Freund, M | 1 |
| Bruckner, H | 1 |
| Stablein, D | 1 |
| Kurschel, E | 1 |
| Kloke, O | 1 |
| Weinhardt, O | 1 |
| Khan, H | 1 |
| Bergner, S | 1 |
| Fiore, JJ | 1 |
| Zarrabi, MH | 1 |
| Hirano, T | 1 |
| Fukuda, Y | 1 |
| Kotake, Y | 1 |
| Migeod, F | 1 |
| Gerlach, D | 1 |
| Kress, M | 1 |
| Farroukh, R | 1 |
| Harding, MJ | 1 |
| Ferguson, JC | 1 |
| Ball, AS | 1 |
| Mann, CV | 1 |
| Clifton, MA | 1 |
| Baker, WN | 1 |
| Goode, AW | 1 |
| Scholnik, AP | 1 |
| Arnold, DJ | 1 |
| Walker, WS | 1 |
| Schwenke, P | 1 |
| Suhrland, LG | 1 |
| Balcueva, EP | 1 |
| Dimitrov, NV | 1 |
| Lagadec, B | 1 |
| Maisani, JE | 1 |
| Loiseau, JP | 1 |
| Gonzalez-Canali, G | 1 |
| Trey, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer[NCT01249638] | Phase 3 | 516 participants (Anticipated) | Interventional | 2010-12-31 | Recruiting | ||
| A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not [NCT04456699] | Phase 3 | 335 participants (Actual) | Interventional | 2020-08-19 | Completed | ||
| Targeted Therapy With or Without Dose Intensified Radiotherapy for Oligo-progressive Disease in Oncogene-addicted Lung Tumours[NCT03256981] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2017-11-27 | Active, not recruiting | ||
| Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression[NCT03808662] | Phase 2 | 107 participants (Actual) | Interventional | 2019-01-16 | Active, not recruiting | ||
| Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial): A Randomized Phase II Trial[NCT02756793] | 90 participants (Actual) | Interventional | 2016-10-31 | Active, not recruiting | |||
| TRAP - Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.[NCT03644303] | 84 participants (Anticipated) | Interventional | 2018-08-13 | Recruiting | |||
| Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver[NCT02885753] | Phase 3 | 348 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT): A Single-arm Study[NCT03727763] | Phase 2 | 30 participants (Anticipated) | Interventional | 2018-10-08 | Recruiting | ||
| BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer[NCT02292758] | Phase 2 | 36 participants (Actual) | Interventional | 2014-12-12 | Completed | ||
| Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer[NCT03925662] | Phase 3 | 40 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER[NCT00719797] | Phase 3 | 509 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY REINTRODUCTION OF FOLFOXIRI PLUS BEVACIZUMAB AT PROGRESSION Versus FOLFOX PLUS BEVACIZUMAB FOLLOWED BY FOLFIRI PLUS BEVACIZUMAB AT PROGRESSION IN FIRST- AND SECOND-LINE TREATMENT OF UNRESECTABLE METASTATIC[NCT02339116] | Phase 3 | 654 participants (Anticipated) | Interventional | 2015-02-26 | Active, not recruiting | ||
| Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.[NCT00433927] | Phase 3 | 568 participants (Anticipated) | Interventional | 2007-01-31 | Active, not recruiting | ||
| Prospective, Randomized, Open, Multicenter Phase II Trial to Investigate the Efficacy of Trifluridine/Tipiracil Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer: FIRE-8; AIO-KRK/YMO-05[NCT05007132] | Phase 2 | 153 participants (Anticipated) | Interventional | 2021-12-17 | Recruiting | ||
| Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab[NCT03368859] | Phase 2 | 70 participants (Actual) | Interventional | 2018-03-20 | Terminated (stopped due to Study may continue) | ||
| [NCT01384994] | Phase 2 | 111 participants (Anticipated) | Interventional | 2011-08-31 | Recruiting | ||
| AZD8931, an Inhibitor of EGFR, ERBB2 and ERBB3 Signalling, in Combination With FOLFIRI: a Phase I/II Study to Determine the Importance of Schedule and Activity in Colorectal Cancer[NCT01862003] | Phase 2 | 24 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case[NCT01991873] | Phase 2 | 387 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors: a Retrospective Real-world Study[NCT06119347] | 1,581 participants (Actual) | Observational | 2020-01-01 | Completed | |||
| Molecular Profiling of Colorectal Cancer: A Translational Research Study With a Next Generation Sequencing Panel.[NCT04863768] | 300 participants (Anticipated) | Observational | 2006-01-01 | Recruiting | |||
| A Phase 2 Randomized Study Comparing the Efficacy and Safety of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV+Panitumumab Combination Therapy in the Patients With Chemotherapy-Naive Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-[NCT02337946] | Phase 2 | 164 participants (Actual) | Interventional | 2014-10-16 | Completed | ||
| An Observational Study of Avastin® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma[NCT01506167] | 719 participants (Actual) | Observational | 2012-07-06 | Completed | |||
| A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colore[NCT00819780] | Phase 2 | 285 participants (Actual) | Interventional | 2009-04-24 | Completed | ||
| A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer[NCT00508404] | Phase 2 | 154 participants (Actual) | Interventional | 2007-05-09 | Completed | ||
| A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic C[NCT00364013] | Phase 3 | 1,183 participants (Actual) | Interventional | 2006-08-01 | Completed | ||
| Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors[NCT06077591] | 40 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
| MicroOrganoSphere Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)[NCT05189171] | 180 participants (Anticipated) | Observational | 2022-10-25 | Recruiting | |||
| Randomized Controlled Trial Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer[NCT01080547] | Phase 3 | 374 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy Wit[NCT01183780] | Phase 3 | 1,072 participants (Actual) | Interventional | 2010-12-02 | Completed | ||
| The Effect of Monosialotetrahexosylganglioside (GM1) in Prevention of Oxaliplatin Induced Neurotoxicity in Colorectal Cancer Patients Who Received Oxaliplatin-based Adjuvant Chemotherapy: A Multi-center, Randomized, Placebo-controlled Trial[NCT02251977] | Phase 3 | 196 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to UGT1A1 Genotyping Versus Regorafenib Monotherapy in Patients With Previously Treated Metastatic Colorectal Cancer: A Prospective, Randomized, Controlled Study[NCT03880877] | Phase 2 | 153 participants (Anticipated) | Interventional | 2019-02-26 | Recruiting | ||
| A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Chemotherapy to the Efficacy of Chemotherapy Alone in Patients With Previously Treated Metastatic Colorectal Cancer[NCT00339183] | Phase 3 | 1,186 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status[NCT01228734] | Phase 3 | 553 participants (Actual) | Interventional | 2010-09-09 | Completed | ||
| Follow-up and Registration Study of Anlotinib Combined With Adjuvant Chemotherapy in the Treatment of Locally Advanced Gastrointestinal Tumors[NCT05742620] | 100 participants (Anticipated) | Interventional | 2023-06-20 | Not yet recruiting | |||
| An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin™)[NCT01588990] | Phase 4 | 128 participants (Actual) | Interventional | 2012-06-26 | Completed | ||
| TACE Associated With Systemic Chemotherapy Versus Systemic Chemotherapy in Patients Who Failed With First Line Chemotherapy[NCT03783559] | Phase 3 | 168 participants (Actual) | Interventional | 2016-01-31 | Active, not recruiting | ||
| Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.[NCT01640405] | Phase 3 | 350 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Randomized Phase II Study to Explore the Influence of BRAF and PIK3K Status on the Efficacy of FOLFIRI Plus Bevacizumab or Cetuximab, as First Line Therapy of Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells[NCT01640444] | Phase 2 | 240 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| A Phase III, Randomized, Two-armed, Triple Blinded, Parallel, Active Controlled Non-Inferiority Clinical Trial of Stivant (AryoGen Trastuzumab) Efficacy and Safety in Comparison to Avastin in Metastatic Colorectal Cancer[NCT03288987] | Phase 3 | 126 participants (Actual) | Interventional | 2016-10-04 | Completed | ||
| Safety and Efficacy of mFOLFOX6+ Bevacizumab+PD-1 Monoclonal Antibody Treatment Combinations in Patients With Local Advanced Microsatellite Stability Colorectal Cancer --an Open Label, Multicenter, Prospective Phase Ⅱ Study (BASKETII)[NCT04895137] | Phase 2 | 42 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | ||
| An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 [NCT02743221] | Phase 2 | 154 participants (Actual) | Interventional | 2016-04-29 | Completed | ||
| Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study[NCT01839877] | Phase 2 | 58 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| An Investigator Initiated Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor (KPT-330), An Oral Selective Inhibitor Of Nuclear Export (SINE), In Patients With Metastatic Colorectal Cancer[NCT02384850] | Phase 1 | 10 participants (Actual) | Interventional | 2015-03-31 | Terminated | ||
| A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer[NCT01311050] | 46 participants (Anticipated) | Observational | 2009-01-31 | Recruiting | |||
| Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients.[NCT03721653] | Phase 2 | 218 participants (Actual) | Interventional | 2018-11-30 | Completed | ||
| Bi-weekly Cetuximab Combined With FOLFOX-6 as First-line Treatment in Metastatic Colorectal Cancer Patients With Wild-type K-ras Status[NCT01051167] | Phase 2 | 59 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Study of Avastin in Combination With Chemotherapy for the First Line Treatment of RAS Mutant Unresectable Colorectal Liver-limited Metastases[NCT01972490] | Phase 4 | 241 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Determination of the UGT1A1 Polymorphism as Guidance for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Treated With First-Line Bevacizumab and FOLFIRI (PURE FIST)[NCT02256800] | 213 participants (Actual) | Interventional | 2014-08-13 | Completed | |||
| Phase II Study on NIVolumab in Combination With FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced COloRectal Cancer RASm/BRAFm Patients[NCT04072198] | Phase 2 | 70 participants (Anticipated) | Interventional | 2019-09-26 | Recruiting | ||
| Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer[NCT02181556] | Phase 2 | 41 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)[NCT01362361] | Phase 2 | 54 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer: a Prospective Phase II Study[NCT06148402] | Phase 2 | 30 participants (Anticipated) | Interventional | 2024-01-31 | Recruiting | ||
| An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin®) in Combination With a Fixed Dose of 5-Fluorouracil (5-FU) Alone or Together With a Fixed Dose of Oxaliplatin or Irinotecan in Patients With Sta[NCT02244632] | Phase 1/Phase 2 | 105 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)[NCT06141369] | 21 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Efficacy and Safety of Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin in pMMR/MSS Locally Advanced Middle and Low Rectal Cancer: An Open, Multi-center, Prospective, Single-arm Phase II Clinical Study[NCT06056804] | Phase 2 | 20 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)[NCT02563002] | Phase 3 | 307 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Combination of Sintilimab，Celecoxib and Regorafenib in Mismatch Repair (MMR) Proficient Refractory Advanced Colorectal Cancer Without Liver Metastasis：a Single Arm Phase II SINCERE Study.[NCT05933980] | Phase 2 | 33 participants (Anticipated) | Interventional | 2023-08-20 | Not yet recruiting | ||
| Multi-center, Non-interventional, Prospective Registry Study on the Treatment of Solid Tumors With Mismatch Repair Deficiency or Microsatellite Instability[NCT06004713] | 190 participants (Anticipated) | Observational | 2023-10-07 | Recruiting | |||
| METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin[NCT05504252] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-10-05 | Recruiting | ||
| A Phase II Clinical Study of Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer Failed of Standard Chemotherapy[NCT02618356] | Phase 2 | 82 participants (Anticipated) | Interventional | 2015-12-25 | Recruiting | ||
| Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination With 5FU/or in FOLFIRI Regimen[NCT04680104] | 64 participants (Actual) | Observational | 2015-11-03 | Completed | |||
| Phase 4 Study to Characterize and Evaluate Markers of Chemoresistance in Patients With Metastatic Colorectal Cancer[NCT00559676] | Phase 4 | 200 participants (Anticipated) | Interventional | 2005-03-31 | Completed | ||
| A Randomized Phase II Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer[NCT01312857] | Phase 2 | 75 participants (Actual) | Interventional | 2011-03-31 | Active, not recruiting | ||
| Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951] | Phase 2/Phase 3 | 358 participants (Anticipated) | Interventional | 2017-06-01 | Recruiting | ||
| Association of the C677T and A1298C MTHFR Polymorphisms With Chemotherapy Effectiveness Among Patients With Metastatic Colorectal Cancer[NCT03852290] | 65 participants (Anticipated) | Observational | 2019-01-16 | Active, not recruiting | |||
| The Effect and Safety on Unresectable CRLM From RFA in Combination With Second-line Chemotherapy and Bevacizumab Compared With the Combination of Second-line Chemotherapy and Bevacizumab: a Randomized and Controlled Clinical Trial[NCT03686254] | Phase 2/Phase 3 | 160 participants (Anticipated) | Interventional | 2018-07-16 | Recruiting | ||
| Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3)[NCT03862911] | 330 participants (Anticipated) | Interventional | 2019-11-01 | Recruiting | |||
| A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT)[NCT03870607] | Phase 2 | 75 participants (Anticipated) | Interventional | 2019-03-13 | Recruiting | ||
| A Prospective, Multicenter, Open-label, Phase II Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Canc[NCT04659382] | Phase 2 | 52 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum[NCT00265850] | Phase 3 | 2,334 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| The Molecular Mechanism of RAS Wild-type Metastatic Colorectal Cancer (mCRC) Resistance to Anti Epidermal Growth Factor Receptor (EGFR) Antibody[NCT04466267] | 40 participants (Actual) | Observational | 2017-03-01 | Completed | |||
| An Open Label Randomized, Multi-Centre Exploratory Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With FOLFOX 4 Chemotherapy or Panitumumab With FOLFIRI Chemotherapy in Subjects With Wild- Type KRAS Colorectal Cancer [NCT00885885] | Phase 2 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxalipla[NCT00561470] | Phase 3 | 1,226 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Protocol for Evaluation of Oncological Treatment in Patients With CRLM Using Zebra Fish Avatars-may This Model Improve Resection Rates and Survival in Patients With Upfront Non-resectable Metastatic Disease?[NCT05289076] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2022-05-17 | Recruiting | ||
| A Prospective,Single-center,Randomized,Controlled Phase III Clinical Study Comparing Efficacy and Safety of Intraoperative Chemotherapy With 5-Fluorouracil Plus Curative Resection Versus Surgery Alone for Patients With Colorectal Cancer[NCT01465451] | Phase 3 | 695 participants (Actual) | Interventional | 2011-03-31 | Active, not recruiting | ||
| Construction and Evaluation of the Early Identification and Individualized Treatment for Oxaliplatin-induced Portal Hypertension[NCT04524676] | 25 participants (Anticipated) | Interventional | 2020-08-31 | Not yet recruiting | |||
| Surgery Outcome Treated by Neo-adjuvant Chemotherapy FOLFOXIRI Regimen in Colorectal Cancer With Liver-limited Synchronous Metastases[NCT05362825] | 89 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Diagnostic Value of Intraoperative Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases During Staging Laparoscopy for Gastric Adenocarcinoma: a Prospective, Multicentric Study.[NCT05687617] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-12-15 | Recruiting | ||
| A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer[NCT00079274] | Phase 3 | 3,397 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab[NCT01164215] | Phase 1 | 76 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Phase II Randomized Controlled Trial Of Dendritic Cell + Cytokine-Induced Killer Cell Immunotherapy With S-1 Versus S-1 Alone As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma Patients[NCT05955157] | Phase 2/Phase 3 | 52 participants (Anticipated) | Interventional | 2023-01-03 | Recruiting | ||
| Efficacy and Safety of Crisaborole Ointment, a Phosphodiesterase 4 (PDE4) Inhibitor, for the Topical Treatment of Cetuximab-Related Skin Toxicity Among Metastatic Colorectal Cancer Patients：A Prospective, Single-arm, Phase II Clinical Trial[NCT06118047] | Phase 2 | 33 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | ||
| Randomized Phase II Study of First-Line FOLFOX Plus Panitumumab Versus 5FU Plus Panitumumab in RAS And BRAF Wild-Type Metastatic Colorectal Cancer Elderly Patients[NCT02904031] | Phase 2 | 180 participants (Anticipated) | Interventional | 2016-07-31 | Active, not recruiting | ||
| Induction Chemotherapy With Folfoxiri Plus Cetuximab and Maintenance With Cetuximab or Bevacizumab Therapy in Unresectable Kras Wild-type Metastatic Colorectal Cancer Patients[NCT02295930] | Phase 2 | 143 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer.[NCT01622543] | Phase 2 | 109 participants (Actual) | Interventional | 2012-10-26 | Completed | ||
| Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC[NCT01282658] | 200 participants (Anticipated) | Observational | 2010-11-30 | Recruiting | |||
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884] | 150 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
| Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment[NCT05576545] | 73 participants (Actual) | Interventional | 2020-09-18 | Completed | |||
| Phase-II, Randomized, Multicentre Pilot Study to Evaluate the Safety and Efficacy of the Treatment With mFOLFOX-6 Plus Cetuximab Versus Initial Treatment With mFOLFOX-6 Plus Cetuximab (for 8 Cycles), Followed by Maintenance With Cetuximab Alone as First-l[NCT01161316] | Phase 2 | 194 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial[NCT02494973] | Phase 2/Phase 3 | 104 participants (Actual) | Interventional | 2015-05-26 | Suspended (stopped due to Recruitment too slow) | ||
| A Multinational, Randomized, Double-Blind Study of Aflibercept Versus Placebo With Irinotecan/ 5-FU Combination (FOLFIRI) in Patients With Metastatic Colorectal Cancer (MCRC) After Failure of an Oxaliplatin Based Regimen[NCT01661270] | Phase 3 | 332 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Phase II Study of Regorafenib as Single Agent for the Treatment of Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab[NCT02175654] | Phase 2 | 15 participants (Actual) | Interventional | 2014-06-30 | Terminated (stopped due to The trial was prematurely closed due to lack of accrual) | ||
| Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic and Safety Profile of Bevacizumab Biosimilar (BEVZ92) vs Bevacizumab (AVASTIN®), Both With FOLFOX or FOLFIRI, in First-line Treatment for mCRC Patients[NCT02069704] | Phase 1 | 142 participants (Actual) | Interventional | 2014-10-29 | Completed | ||
| A Phase I/II Study of RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma[NCT01047293] | Phase 1/Phase 2 | 47 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receivi[NCT01442649] | Phase 2 | 133 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Steam (Sequencing Triplet With Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer[NCT01765582] | Phase 2 | 280 participants (Actual) | Interventional | 2013-01-23 | Terminated | ||
| The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer[NCT05590117] | Early Phase 1 | 48 participants (Anticipated) | Interventional | 2022-10-11 | Enrolling by invitation | ||
| Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Domomedecine Plateform[NCT04263948] | 42 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | |||
| A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)[NCT00272051] | Phase 3 | 620 participants | Interventional | 2002-07-31 | Completed | ||
| A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV[NCT00305188] | Phase 3 | 879 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer[NCT00115765] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-06-01 | Completed | ||
| A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Pat[NCT00384176] | Phase 2/Phase 3 | 1,814 participants (Actual) | Interventional | 2006-08-30 | Completed | ||
| Phase II Randomized Study of Maintenance Treatment With Bevacizumab or Bevacizumab Plus Metronomic Chemotherapy After First-line Induction FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer Patients[NCT02271464] | Phase 2 | 232 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Open Label Phase II Study of FOLFIRI + Panitumumab Using Ultra-selection Technology With Next Generation High Sensitivity Genotyping of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS G[NCT01704703] | Phase 2 | 72 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafe[NCT02928224] | Phase 3 | 702 participants (Actual) | Interventional | 2016-10-13 | Completed | ||
| 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial.[NCT00145314] | Phase 3 | 571 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma[NCT01900717] | Phase 2 | 102 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer[NCT00952029] | Phase 2/Phase 3 | 492 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients[NCT04802954] | 400 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| CMAB009 Plus Irinotecan Versus Irinotecan-only as Second-line Treatment After Fluoropyrimidine and Oxaliplatin Failure in KRAS Wild-type Metastatic Colorectal Cancer Patients: Prospective, Open-label, Randomized, Phase II/III Trial[NCT01550055] | Phase 2/Phase 3 | 512 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Phase I/IIa Study Combining Curcumin (Curcumin C3-Complex, Sabinsa) With Standard Care FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer.[NCT01490996] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Genistein Combined With FOLFOX or FOLFOX-Avastin for Treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study[NCT01985763] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A Open Label, Non Randomized, Phase Two Trial in Metastatic Colorectal Cancer (mCRC) With the Combination of m FOLFIRI Plus Aflibercept as First Line Treatment: MINOAS Trial[NCT02624726] | Phase 2 | 31 participants (Actual) | Interventional | 2016-01-31 | Active, not recruiting | ||
| A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen[NCT01571284] | Phase 3 | 781 participants (Actual) | Interventional | 2012-05-30 | Completed | ||
| A Non-interventional Uncontrolled Multicenter Study to Investigate the Emergence of RAS Resistance Mutations in RAS Wild Type mCRC Patients Receiving First Line Cetuximab Treatment[NCT03401957] | 120 participants (Anticipated) | Observational [Patient Registry] | 2018-01-31 | Recruiting | |||
| Randomized Phase II Study of mFOLFOX6 + Bevacizumab or mFOLFOX6 + Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer[NCT01836653] | Phase 2 | 122 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer[NCT02077296] | 34 participants (Actual) | Observational | 2014-03-31 | Completed | |||
| An Open-Label, Pharmacokinetic Study of the Safety and Tolerability of Pazopanib in Combination With FOLFOX 6 or CapeOx in Subjects With Colorectal Cancer[NCT00387387] | Phase 1 | 50 participants (Actual) | Interventional | 2006-10-20 | Completed | ||
| Randomized Study of Classic vs Simplified Leucovorin Calcium and Fluorouracil With or Without Irinotecan in Patients Aged At Least 75 Years With Advanced Colorectal Cancer[NCT00303771] | Phase 3 | 282 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Randomized Trial of Treatment Strategy for Chemotherapy in Colorectal Cancer, FFCD 2000-05[NCT00126256] | Phase 3 | 570 participants (Anticipated) | Interventional | 2002-02-28 | Completed | ||
| An Uncontrolled, Open-label, Phase II Study in Subjects With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First Line Chemotherapy With mFOLFOX6 (Oxaliplatin/ Folinic Acid/5-fluorouracil [5-FU]) in Combination With Regorafenib[NCT01289821] | Phase 2 | 54 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer[NCT01298570] | Phase 2 | 181 participants (Actual) | Interventional | 2011-04-07 | Completed | ||
| Phase I, Open-label, Non-placebo Controlled Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI as First or Second Line Therapy in Patients With Metastatic Colorectal.[NCT00934882] | Phase 1 | 45 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With RAS-mutated Metastatic Colorectal Cancer: a Dose-escalation, Phase I/II Trial[NCT03828799] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2019-05-17 | Active, not recruiting | ||
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study[NCT05277766] | Phase 1 | 45 participants (Anticipated) | Interventional | 2022-11-21 | Recruiting | ||
| Phase 2b, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease[NCT00865709] | Phase 2 | 198 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer[NCT01564810] | Phase 4 | 150 participants (Anticipated) | Interventional | 2006-09-30 | Recruiting | ||
| A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Combinations With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer Preceded By A Phase 1 Portion[NCT00460603] | Phase 1/Phase 2 | 187 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab in the Treatment of Metastatic Colorectal Cancer[NCT00416494] | Phase 2 | 50 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| A Single Arm, Open Label, Exploratory Study of Pemetrexed and S-1 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy[NCT03843853] | Phase 2 | 0 participants (Actual) | Interventional | 2019-05-01 | Withdrawn (stopped due to cooperation terminated) | ||
| A Single Arm, Open Label, Exploratory Study of Pemetrexed and TAS-102 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy[NCT04683965] | Phase 2 | 27 participants (Anticipated) | Interventional | 2021-01-01 | Active, not recruiting | ||
| A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in C[NCT00389870] | Phase 3 | 1,198 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study[NCT02316535] | Phase 3 | 710 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients[NCT03030508] | 300 participants (Anticipated) | Observational | 2016-01-31 | Enrolling by invitation | |||
| XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study[NCT00212615] | Phase 2/Phase 3 | 116 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Avastin and Chemotherapy Followed by Avastin Alone or in Combination With Tarceva for the Treatment of Metastatic Colorectal Cancer.[NCT00598156] | Phase 3 | 249 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Randomized, Multicenter, Phase III Study, to Evaluate the Efficacy and Safety of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy After Initial Chemotherapy Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Meta[NCT00335595] | Phase 3 | 480 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers[NCT03978078] | 200 participants (Anticipated) | Interventional | 2016-09-12 | Recruiting | |||
| Tempus CRC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Colorectal Cancer (CRC) Using Comprehensive Next-Generation Sequencing (NGS)Assays[NCT05234177] | 160 participants (Anticipated) | Observational | 2022-06-21 | Recruiting | |||
| A Phase II Clinical Trial Study on Apatinib and XELOX Combination Regimen in the First-line Treatment of End-stage Colorectal Cancer Patients[NCT02829385] | Phase 2 | 53 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Predictive Impact of RAS Mutations in Circulating Tumor DNA for Efficacy of Anti-EGFR Reintroduction Treatment in Patients With Metastatic Colorectal Cancer[NCT03259009] | 73 participants (Anticipated) | Observational [Patient Registry] | 2017-10-01 | Not yet recruiting | |||
| The Oncopanel Pilot (TOP) Study[NCT02171286] | 432 participants (Actual) | Observational | 2014-10-31 | Completed | |||
| A Randomised, Open-label Phase III Study to Assess Efficacy and Safety of Bevacizumab in Combination With Capecitabine as First-line Treatment for Elderly Patients With Metastatic Colorectal Cancer[NCT00484939] | Phase 3 | 280 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)[NCT02898012] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Observational Study of the Impact of Circulating T Regulatory Cells (Tregs) on Clinical Outcome of Metastatic Colorectal Cancer (MCRC) Patients Treated With Standard Fluorouracil/Irinotecan/Bevacizumab First Line Therapy[NCT01533740] | 31 participants (Actual) | Observational | 2012-03-31 | Completed | |||
| Pre- and Post-Operative Chemotherapy With Oxaliplatin 5FU/LV Versus Surgery Alone in Resectable Liver Metastases From Colorectal Origin - Phase III Study[NCT00006479] | Phase 3 | 0 participants | Interventional | 2000-09-30 | Active, not recruiting | ||
| Simultaneous RESEction of Colorectal Cancer With Synchronous Liver MeTastases (RESECT): A Feasibility Study[NCT02954913] | 41 participants (Actual) | Interventional | 2017-02-14 | Completed | |||
| Peri-operative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis: a Prospective Randomized Clinical Trial[NCT02912052] | Phase 3 | 240 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| A Prospective Study Evaluating Diagnostic Accuracy, Outcome, and Economic Impact of Abbreviated Gadoxetate-enhanced MRI of the Liver in Patients With Metastatic Colorectal Carcinoma[NCT05314400] | 300 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | |||
| Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastasis in Breast Cancer Patients (STOMP): A Prospective Feasibility Trial[NCT03295916] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | ||
| A Phase 1b/2 Study of AMG 655 in Combination With Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects With Metastatic Colorectal Cancer[NCT00625651] | Phase 1/Phase 2 | 202 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| FOLFOXIRI Plus Bevacizumab as First-line Treatment for BRAF V600E Mutant Metastatic Colorectal Cancer: a Prospective Evaluation[NCT01437618] | 15 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.[NCT00920868] | Phase 1 | 22 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| A Randomized, Open-label Phase II Study Evaluating the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab as First-line Therapy in Subjects With Metastatic Colorectal Cancer.[NCT00439517] | Phase 2 | 302 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Epidemiological and Molecular Colorectal Cancer Registry[NCT02781337] | 2,100 participants (Anticipated) | Observational [Patient Registry] | 2012-05-31 | Recruiting | |||
| LARCID: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea[NCT00582426] | Phase 3 | 139 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Phase I Trial of Oral Capecitabine Combined With 131I-huA33 in Patients With Metastatic Colorectal Cancer[NCT00291486] | Phase 1 | 19 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473] | 200 participants (Actual) | Interventional | 2011-08-31 | Active, not recruiting | |||
| Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver [NCT00153998] | Phase 2 | 135 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal Cancer Patients as Predictive Factors for Systemic Therapy Outcome[NCT04543019] | 50 participants (Anticipated) | Observational | 2020-12-31 | Not yet recruiting | |||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Bes[NCT00492999] | Phase 2 | 64 participants (Anticipated) | Interventional | 2007-05-31 | Active, not recruiting | ||
| A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver[NCT03366155] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-06-24 | Recruiting | ||
| Biomarker-Panel Guided Maintenance Treatment With Cetuximab Monotherapy Versus Continuation After First Line Induction Therapy of Metastatic Colorectal Cancer (mCRC) : a Multicenter, Prospective, Randomized Controlled Trial[NCT02942706] | Phase 2/Phase 3 | 200 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| A Multicenter Study of Prognosis and the Efficacy Comparison of Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Patients(Clinical Risk Score≥3) of Resectable Colorectal Liver Metastasis[NCT03031444] | Phase 2/Phase 3 | 135 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| Double-blind, Phase II Study to Assess the Effectiveness of Lycopene vs Placebo to Reduce Skin Toxicity in Patients With Colorectal Carcinoma Treated With Panitumumab[NCT03167268] | Phase 2 | 28 participants (Actual) | Interventional | 2016-08-03 | Active, not recruiting | ||
| The Effectiveness of Topical Oral Vitamin D Gel in Prevention of Radiation-induced Oral Mucositis[NCT04308161] | Phase 2 | 45 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
| The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570] | Phase 2 | 40 participants (Actual) | Interventional | 2018-01-12 | Completed | ||
| A Multicenter Phase II Study of the Capecitabine, Oxaliplatin and Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer[NCT01024504] | Phase 2 | 46 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis[NCT02399410] | Phase 2 | 60 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Phase II Study Evaluating the Efficacy and Tolerance to Chemotherapy With 5-fluorouracil, Folinic Acid, Irinotecan and Bevacizumab as First-line Treatment in Patients With Metastatic Colorectal Cancer[NCT00467142] | Phase 2 | 62 participants (Actual) | Interventional | 2007-01-23 | Completed | ||
| Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥75 Years)[NCT00812864] | Phase 4 | 20 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies[NCT00610948] | Phase 1 | 74 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Open Labeled, Multicenter Phase I/II Study Evaluating the Dose Escalation/Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan as First-Line Treatment of Metastatic Colorectal Cancer[NCT00422773] | Phase 1/Phase 2 | 21 participants (Anticipated) | Interventional | 2007-01-31 | Completed | ||
| Evaluation of Individual Peripheral Blood Circulating Tumor Cells Combined With Tumor Marker Detection of Efficacy of Chemotherapy in Patients With Advanced Colorectal Cancer: A Observational Clinical Trial[NCT02948985] | 100 participants (Anticipated) | Observational [Patient Registry] | 2017-01-31 | Not yet recruiting | |||
| Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer[NCT00284258] | Phase 2/Phase 3 | 426 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Clinical Proof-of-concept Study Evaluating Efficacy and Safety of ZL-2306 (Niraparib) Combined With Brivanib or Toripalimab in Patients With Metastatic, Recurrent, and Persistent Cervical Cancer[NCT04395612] | Phase 2 | 38 participants (Anticipated) | Interventional | 2020-05-08 | Recruiting | ||
| Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711] | Phase 1 | 41 participants (Actual) | Interventional | 2015-10-31 | Terminated (stopped due to Company decision) | ||
| Assessment of Histopathological Response to Combination Chemotherapy With Oxaliplatin, Irinotecan, Fluorouracil and Bevacizumab in Patients With Peritoneal Metastasis From Colorectal Cancer[NCT02591667] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | ||
| Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer[NCT02833753] | Phase 1 | 14 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Essai De Phase III De Chimiotherapie Par FOLFOX 4 Ou Par Une Succession FOLFOX 7 - FOLFIRI Chez Des Patients Ayant Des Metastases Resecables D'Origine Colorectale - MIROX[NCT00268398] | Phase 3 | 284 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| A Randomized Phase III Study of SOX vs. COX in Patients With Advanced Colorectal Cancer[NCT00677443] | Phase 3 | 344 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Randomised Comparative Study Of Folfox6m Plus Sir-Spheres® Microspheres Versus Folfox6m Alone As First Line Treatment In Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma[NCT00724503] | 530 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| Phase II Study of Irinotecan Plus Capecitabine as the First-line or Second-line Treatment for Advanced Colorectal Cancer Patients[NCT01322152] | Phase 2 | 52 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| A Multicentre Randomised Phase II Study to Assess the Safety and Resectability in Patients With Initially Unresectable Liver Metastases Secondary to Colorectal Cancer Receiving First-line Treatment Either With mFOLFOX-6 Plus Bevacizumab or FOLFOXIRI Plus [NCT00778102] | Phase 2 | 80 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Comparison of High Tone Therapy and TENS Therapy in Chemotherapy-induced Polyneuropathy[NCT03978585] | 51 participants (Actual) | Interventional | 2019-09-03 | Completed | |||
| A Phase 1b, Open-Label, Dose-Escalation Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers[NCT00660153] | Phase 1 | 30 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Bevacizumab Maintenance Versus no Maintenance After Stop of First-line Chemotherapy in Patients With Metastatic Colorectal Cancer. A Randomized Multicenter Phase III Non-inferiority Trial[NCT00544700] | Phase 3 | 265 participants (Actual) | Interventional | 2007-11-26 | Terminated (stopped due to Data collection is completed. As no changes in the endpoints were expected in the future, no further data is needed.) | ||
| Open-label Phase 1b Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer Who Have Progressed Following Chemotherapy for Advanced or Metastatic Disease[NCT00719199] | Phase 1 | 21 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Sponsor will discontinue further development of EMD 1201081) | ||
| A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice[NCT01460745] | 60 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| Study of Blood Components as Probable Prognostic and Predictive Markers of Response to Treatment in Advanced Colon and Rectal Cancers[NCT02979470] | 100 participants (Anticipated) | Observational [Patient Registry] | 2016-09-30 | Recruiting | |||
| SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY TWO PHASE III RANDOMIZED STUDIES OF CT ALONE OR CT PLUS[NCT01878422] | Phase 3 | 350 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer[NCT00101894] | Phase 1 | 119 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicentre, Randomised Controlled Trial (CAN)[NCT02958111] | Phase 3 | 406 participants (Actual) | Interventional | 2017-01-31 | Active, not recruiting | ||
| Maintenance Treatment With Capecitabine and Bevacizumab Versus Observation After Induction Treatment With Chemotherapy and Bevacizumab as First-line Treatment in Patients With Advanced Colorectal Carcinoma[NCT00442637] | Phase 3 | 635 participants (Anticipated) | Interventional | 2007-01-31 | Active, not recruiting | ||
| Capecitabine Metronomic Chemotherapy Versus Conventional Chemotherapy as Maintenance Treatment in Metastatic Colorectal Cancer[NCT02893540] | Phase 2/Phase 3 | 250 participants (Anticipated) | Interventional | 2016-09-30 | Recruiting | ||
| Maintenance Treatment With Capecitabine Plus Cetuximab After First-line 5-Fluorouracil-based Chemotherapy Plus Cetuximab for Patients With RAS Wild-type Metastatic Colorectal Cancer: a Single Arm, Open-label, Multi-center Clinical Trial[NCT02717923] | Phase 2 | 50 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer[NCT03158610] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2018-01-29 | Terminated (stopped due to Difficult to enrollment patient) | ||
| Apatinib Versus Bevacizumab in Combination With Second-line FOLFIRI in Patients With Metastatic Colorectal Cancer That Progressed During or After First-line Bevacizumab Plus an Oxaliplatin-based Regimen: A Randomised Phase 2 Trial[NCT03271255] | Phase 2 | 80 participants (Anticipated) | Interventional | 2018-05-23 | Recruiting | ||
| TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.[NCT04392479] | Phase 3 | 202 participants (Anticipated) | Interventional | 2020-09-02 | Active, not recruiting | ||
| The Biomarkers Identification for Apatinib and Bevacizumab in the Second-line Therapy for Colorectal Cancer: A Randomised Controlled Trial[NCT03743428] | 40 participants (Anticipated) | Interventional | 2020-10-22 | Suspended (stopped due to Too slow speed for recruiting.) | |||
| Study Evaluating the Safety and Efficacy of FOLFOX Plus Apatinib or FOLFIRI Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer[NCT03193814] | Phase 2 | 50 participants (Anticipated) | Interventional | 2019-12-01 | Not yet recruiting | ||
| Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases CAIRO5 a Randomized Phase 3 Study of the Dutch Colorectal Cancer Group (DCCG)[NCT02162563] | Phase 3 | 564 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors[NCT00418938] | Phase 2 | 266 participants (Actual) | Interventional | 2006-11-01 | Completed | ||
| Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)[NCT05913674] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | ||
| Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX'[NCT00577031] | Phase 4 | 205 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-hour Infusion of 5- Fluorouracil Given Every Other Week in Adult Patients With Solid Tumors[NCT01206465] | Phase 1 | 29 participants (Actual) | Interventional | 2010-09-14 | Completed | ||
| An Open Label, Single-arm, Phase II Study to Evaluate the Efficacy and the Feasibility of Bevacizumab (Avastin) Based on a FOLFOXIRI Regimen Until Progression in Patients With Previously Untreated Metastatic Colorectal Carcinoma(OPAL-Study)[NCT00940303] | Phase 2 | 97 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Randomized Three Arm Phase III Trial on Induction Treatment With a Fluoropyrimidine-, Oxaliplatin- and Bevacizumab-based Chemotherapy for 24 Weeks Followed by Maintenance Treatment With a Fluoropyrimidine and Bevacizumab vs. Bevacizumab Alone vs. no Maint[NCT00973609] | Phase 3 | 853 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Chemotherapy With FOLFIRI Plus Bevacizumab (AvastinR) in Patients With Metastatic Colorectal Cancer Bearing Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*1/UGT1A1*28: Prospective, Phase II, Multicenter Study[NCT00628810] | Phase 2 | 86 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial[NCT00852228] | Phase 2 | 60 participants (Anticipated) | Interventional | 2008-07-31 | Active, not recruiting | ||
| Phase 2 Study to Improve Tolerance of Chemotherapy Involving Cetuximab and Multidrug FOLFIRI, With Pharmacokinetic and Pharmacogenetic Studies, in Patients With Metastatic Colorectal Cancer[NCT00559741] | Phase 2 | 80 participants (Anticipated) | Interventional | 2005-10-31 | Completed | ||
| A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094] | Phase 3 | 49 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| The Identification, Validation and Implementation of Molecular Markers to Predict Response to Fluorouracil-based Adjuvant Chemotherapy in Stage III Colorectal Cancer Patients - Prospective Clinical Observational Study[NCT03127111] | 300 participants (Anticipated) | Observational | 2022-12-01 | Not yet recruiting | |||
| Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer[NCT01718873] | Phase 3 | 230 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) as First-line Treatment for Metastatic Colorectal Cancer[NCT01219920] | Phase 3 | 244 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study[NCT01721954] | Phase 3 | 209 participants (Actual) | Interventional | 2013-05-01 | Completed | ||
| A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only[NCT01226719] | Phase 2 | 15 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Maintenance Treatment With Capecitabine Versus Observation After First Line Chemotherapy in Patients With Metastatic Colorectal Cancer: a Randomized Phase II Study[NCT02027363] | Phase 2 | 245 participants (Anticipated) | Interventional | 2010-01-31 | Active, not recruiting | ||
| Maintenance Treatment With S-1 Versus Observation After First-line Chemotherapy in Patients With Advanced Gastric Cancer: a Randomized Phase II Study[NCT03701373] | Phase 2 | 200 participants (Anticipated) | Interventional | 2016-01-01 | Recruiting | ||
| Assessment of Targeted Therapy Against Colorectal Cancer (ATTACC) Screening Protocol[NCT01196130] | 1,275 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| Randomized, Multinational, Study Of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer[NCT00851084] | Phase 2 | 268 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon[NCT00004931] | Phase 3 | 2,472 participants (Anticipated) | Interventional | 2000-02-29 | Completed | ||
| An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With Ramucirumab or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With M[NCT01111604] | Phase 2 | 158 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| [NCT00594529] | Phase 2 | 27 participants (Anticipated) | Interventional | 2008-01-31 | Recruiting | ||
| "Living Donor Liver Transplantation (LDLT) in Non Resectable Colo-rectal Cancer Liver Metastasis. The LIVERMORE Trial (LIVing Donor livEr tRansplant Modena cOloRectal mEtastasis) [Original Title in Italian: Trapianto di Fegato da Donatore Vivente Per Meta[NCT05186116] | 25 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| Open-label, Multicenter, Phase II Study Of First-line Biweekly Irinotecan, Oxaliplatin And Infusional 5-FU/LV (FOLFOXIRI) In Combination With Bevacizumab In Patients With Metastatic Colorectal Cancer[NCT01163396] | Phase 2 | 57 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLF[NCT00911170] | Phase 3 | 847 participants (Actual) | Interventional | 2009-11-03 | Completed | ||
| TACTIC: a Phase II Study of TAS-102 Monotherapy and Thalidomide Plus TAS-102 as Third-line Therapy and Beyond in Patients With Advanced Colorectal Carcinoma[NCT05266820] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-10-01 | Recruiting | ||
| Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer[NCT01418222] | Phase 2 | 194 participants (Actual) | Interventional | 2011-09-14 | Completed | ||
| A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer[NCT01399684] | Phase 2 | 127 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Risk of Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy[NCT04941625] | 150 participants (Anticipated) | Observational | 2018-02-23 | Recruiting | |||
| Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma[NCT00027833] | Phase 2 | 0 participants | Interventional | 2001-12-31 | Active, not recruiting | ||
| Comparison of Showerpatch Versus Other Measures to Protect Intravenous Catheter Entry Site During Bathing Activities[NCT02324868] | 18 participants (Actual) | Interventional | 2016-01-31 | Terminated (stopped due to logistic problems) | |||
| A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer[NCT00109070] | Phase 3 | 0 participants | Interventional | 2000-09-30 | Completed | ||
| A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab), a Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, in Combination With 5-[NCT00109226] | Phase 2 | 0 participants | Interventional | 2000-08-31 | Completed | ||
| Phase I Study of PS-341 (VELCADE) in Combination With 5FU/LV Plus Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00098982] | Phase 1 | 16 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A Multicenter, Open-Label, Randomized, Two-Arm Study of Irinotecan (CPT-11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma[NCT00012389] | Phase 3 | 0 participants | Interventional | 2000-12-31 | Completed | ||
| A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II)[NCT00025142] | Phase 2 | 0 participants | Interventional | 2001-07-31 | Completed | ||
| Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced HCC (Hepatocellular Carcinoma) Not Eligible to Curative Approach. A Phase II-b Study.[NCT00910572] | Phase 2 | 60 participants (Anticipated) | Interventional | 2007-07-31 | Completed | ||
| Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma[NCT02729506] | Phase 4 | 150 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum[NCT00003594] | Phase 3 | 1,691 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| A Phase I Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety, Efficacy and Pharmacokinetics Profiles of TSB-9-W1 in Pre-treated Patients With Metastatic Colorectal Cancer (mCRC).[NCT02249650] | Phase 1 | 21 participants (Actual) | Interventional | 2017-07-10 | Completed | ||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Open, Randomized, Controlled, Multicenter Phase II Study Comparing 5-FU/FA Plus Oxaliplatin (FOLFOX-4) Plus Cetuximab Versus 5-FU/FA Plus Oxaliplatin (FOLFOX-4) as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal [NCT00125034] | Phase 2 | 344 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Three-Arm Randomised Controlled Trial Comparing Either Continuous Chemotherapy Plus Cetuximab or Intermittent Chemotherapy With Standard Continuous Palliative Combination Chemotherapy With Oxaliplatin and a Fluoropyrimidine in First Line Treatment of Me[NCT00182715] | Phase 3 | 2,421 participants (Anticipated) | Interventional | 2005-03-31 | Active, not recruiting | ||
| Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study[NCT00208546] | Phase 3 | 750 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649] | Phase 2 | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination With Selected Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer[NCT00343408] | Phase 1 | 31 participants (Actual) | Interventional | 2005-11-29 | Completed | ||
| A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer[NCT00008294] | Phase 1 | 0 participants | Interventional | 2000-08-31 | Completed | ||
| The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver[NCT01785212] | 40 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| Role of Circulating Tumour DNA (ctDNA) Testing in Assessing for Alterations of Primary Anti-Epidermal Growth Factor Receptor (EGFR) Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients[NCT05051592] | 40 participants (Anticipated) | Observational | 2021-03-26 | Recruiting | |||
| A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma[NCT02014831] | Phase 2 | 0 participants (Actual) | Interventional | 2016-02-29 | Withdrawn (stopped due to Industry decline to supply study drug) | ||
| Biomarker-Panel Enriched Maintenance Treatment With Cetuximab Monotherapy Versus Continuation After Induction Treatment With Chemotherapy + Cetuximab in Metastatic Colorectal Cancer (mCRC)[NCT02978313] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2016-11-30 | Not yet recruiting | ||
| Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer[NCT00154102] | Phase 3 | 1,221 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab[NCT01405430] | 63 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma[NCT00168155] | Phase 2 | 70 participants | Interventional | 2002-01-31 | Completed | ||
| Phase II-III Study of an Optimized LV-5FU-Oxaliplatin Strategy in Metastatic Colorectal Cancer. Optimox2 Study. C02-2[NCT00274872] | Phase 2/Phase 3 | 600 participants (Anticipated) | Interventional | 2004-01-31 | Active, not recruiting | ||
| Phase II Study Evaluating the Interest of the Re-introduction of Pemetrexed and Platinum (Cisplatin or Carboplatin) With Prolonged Angiogenic Blocking by Bevacizumab in Non Squamous Non Small Cell Lung Cancer of Advanced Stage.[NCT01705184] | Phase 2 | 120 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing: A Randomized Trial to Assess the Role of Irinotecan and Oxaliplatin in Advanced Colorectal Cancer[NCT00008060] | Phase 3 | 0 participants | Interventional | 2000-05-31 | Completed | ||
| A Randomized, Controlled Study of Standardized Patient Coaching Versus Patient Management According to Local Practice for Patients With Hormone Receptor Positive HER2 Negative Metastatic Breast Cancer Treated With Abemaciclib[NCT04030728] | 212 participants (Anticipated) | Observational | 2020-03-31 | Not yet recruiting | |||
| Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer[NCT02117466] | Phase 1/Phase 2 | 85 participants (Actual) | Interventional | 2014-04-30 | Terminated (stopped due to Primary endpoint could no longer be reached.) | ||
| Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662] | Phase 2 | 4 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to due to poor recrutment) | ||
| Value of Contrast Enhanced Intraoperative Ultrasound Compared to Preoperative CEUS, CT and MRT in the Treatment of Colorectal Liver Metastases.[NCT01522209] | 59 participants (Actual) | Interventional | 2011-12-31 | Completed | |||
| A Phase II Trial Evaluating Multiple Metastasectomy Combined With Hepatic Artery Infusion Of Floxuridine (FUDR) And Dexamethasone (DXM), Alternating With Systemic Oxaliplatin (OXAL) And Capecitabine (CAPCIT) For Colorectal Carcinoma Metastatic To The Live[NCT00026234] | Phase 2 | 75 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer[NCT00094809] | Phase 2 | 252 participants (Actual) | Interventional | 2003-02-01 | Completed | ||
| Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases[NCT01095523] | Phase 2 | 0 participants (Actual) | Interventional | 2010-01-14 | Withdrawn | ||
| Oxaliplatin, Irinotecan, and Capecitabine as a Combination Regimen for First-Line Treatment of Advanced or Metastatic Colorectal Cancer[NCT00217711] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma[NCT02289547] | Phase 3 | 184 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| NGR005: Pilot Study of NGR-hTNF Administered at Low and High Doses in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer[NCT00675012] | Phase 2 | 24 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Randomized Phase II Study of Modified FOLFOX6 (Infusional 5-Fluorouracil/Leucovorin, Oxaliplatin) and Bevacizumab With or Without Cetuximab in Patients With Metastatic Colorectal Cancer[NCT00193219] | Phase 2 | 36 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Phase II Trial of FOLFOXIRI Plus Panitumumab as First-Line Treatment for Kras and Braf Wild-Type Metastatic Colorectal Cancer[NCT01358812] | Phase 2 | 37 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Randomized Phase III Study Post Radical Resection of Liver Metastasis of Colorectal Cancer: Bevacizumab in Combination With XELOX as Adjuvant Chemotherapy vs XELOX Alone[NCT00394992] | Phase 3 | 79 participants (Actual) | Interventional | 2006-12-31 | Terminated (stopped due to Data from the C08 study and Avant study) | ||
| Polymorphism Interaction to Predict Bevacizumab Efficacy in Advanced Breast Cancer Patients: an Exploratory Retrospective Analysis[NCT01935102] | 169 participants (Actual) | Observational | 2012-12-31 | Completed | |||
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| "Evaluation of the Restorative Efficacy of the Cosmetic Product Onco-Repair vs. Placebo on Grade 2 Hand Foot Syndrome Induced by Targeted Therapies or Conventional Chemotherapy. Randomized, Multicentre, Double Blind, Controlled Study Versus Placebo."[NCT03612011] | Phase 3 | 72 participants (Actual) | Interventional | 2018-07-12 | Completed | ||
| A Multicenter, Randomized Phase II Trial of Avastin Plus Gemcitabine Plus 5FU/Folinic Acid (A + FFG) vs. Avastin Plus Oxaliplatin Plus 5FU/Folinic Acid (A + FOLFOX 4) as Therapy for Patients With Metastatic Colorectal Cancer[NCT00192075] | Phase 2 | 84 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer[NCT00100841] | Phase 2 | 66 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Phase II Study of Oxaliplatin, Capecitabine, Cetuximab, and Bevacizumab in the Treatment of Metastatic Colorectal Cancer[NCT00290615] | Phase 2 | 30 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Phase II Clinical Trial of Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer[NCT01022541] | Phase 2 | 47 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum[NCT00056446] | Phase 3 | 855 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo[NCT00056459] | Phase 3 | 1,168 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed[NCT00070213] | Phase 3 | 460 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Metastatic Colorectal Cancer[NCT03530267] | Phase 2 | 124 participants (Actual) | Interventional | 2018-09-28 | Active, not recruiting | ||
| A Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced or Metastatic Colorectal Cancer[NCT00536809] | Phase 1 | 12 participants (Actual) | Interventional | 2007-09-26 | Completed | ||
| Comparison of Hepatectomy and Local Ablation for Resectable Synchronous and Metachronous Colorectal Liver Metastasis (HELARC) ------ a Randomized Controlled Multicenter Clinical Study[NCT02886104] | 548 participants (Anticipated) | Interventional | 2016-08-31 | Recruiting | |||
| Phase II Randomized Study of First-Line Therapy Comprising Bevacizumab and Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil (FOLFIRI) Versus Bevacizumab and Irinotecan Hydrochloride and Capecitabine (XELIRI) in Patients With Unresectable Met[NCT00423696] | Phase 2 | 145 participants (Actual) | Interventional | 2006-03-23 | Completed | ||
| Multi Center, Open Label, Single Arm Trial Evaluating Panitumumab in Combination With FOLFIRI Therapy Following First Line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer[NCT00411450] | Phase 2 | 116 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial[NCT00003287] | Phase 3 | 554 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma[NCT04000737] | Phase 2 | 125 participants (Anticipated) | Interventional | 2020-01-10 | Recruiting | ||
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients[NCT00398879] | Phase 2 | 381 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab[NCT00332163] | Phase 2 | 95 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Intravital Microscopy (IVM) in Human Solid Tumors[NCT03823144] | 50 participants (Anticipated) | Interventional | 2019-02-28 | Recruiting | |||
| Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)[NCT03517852] | 30 participants (Actual) | Interventional | 2018-08-15 | Active, not recruiting | |||
| Circulating Tumor DNA (ctDNA) as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer: A Prospective, Open-label, Randomized Controlled Study[NCT04752930] | 138 participants (Anticipated) | Interventional | 2020-08-24 | Recruiting | |||
| A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin With 5-FU/LV Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer[NCT00612586] | Phase 2 | 117 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Randomized Phase III Study of Irinotecan Plus 5-fluorouracil Plus Leucovorin and Bevacizumab (FOLFIRI+Avastin) Versus Irinotecan Plus Capecitabine and Bevacizumab (XELIRI+Avastin) as 1st Line Treatment of Locally Advanced or Metastatic Colorectal Cancer[NCT00469443] | Phase 3 | 330 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Phase II Study of the Combination of Cetuximab, Capecitabine, and Oxaliplatin With Out Without Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer[NCT00321100] | Phase 2 | 23 participants (Actual) | Interventional | 2006-04-12 | Terminated (stopped due to Enrollment closed 10/15/2008 based on data about KRAS.) | ||
| A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer[NCT00483834] | Phase 2 | 50 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin[NCT03388190] | Phase 2 | 80 participants (Actual) | Interventional | 2018-05-29 | Active, not recruiting | ||
| Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer[NCT01859221] | 39 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| A Phase II Study Of Sunitinib In Combination With Irinotecan, L-leucovorin, And 5-Fluorouracil In Patients With Unresectable Or Metastatic Colorectal Cancer[NCT00668863] | Phase 2 | 71 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Surveillance of Metabolic Parameters in Patients Who Will Receive Chemotherapy After Surgical Resection of Colorectal Cancer: KBSMC Colon Cancer Cohort[NCT02700555] | 23 participants (Actual) | Observational [Patient Registry] | 2016-02-29 | Terminated (stopped due to The patient's study enrollment was too low.) | |||
| Clinical Study of Dynamic Contrast-enhanced Magnetic Resonance Imaging Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver Metastasis of Breast Cance[NCT05550090] | 40 participants (Anticipated) | Observational | 2022-09-16 | Recruiting | |||
| Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer[NCT00159432] | Phase 2 | 63 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Efficacy and Safety of Second-line Combination Chemotherapy With Avastin in Patients With Metastatic Colorectal Cancer Who Have Received First-line Chemotherapy Plus Avastin[NCT00862342] | Phase 2 | 78 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| The Effect of ATP-Binding Cassette C2 (ABCC2) Transporter Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin -Based Chemotherapy[NCT05494320] | 120 participants (Anticipated) | Observational | 2021-08-15 | Recruiting | |||
| FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study[NCT01321957] | Phase 2 | 250 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Perioperative FOLFOXIRI and Bevacizumab Compared With Postoperative FOLFOX in Patients With Resectable Liver Metastases From Colorectal Cancer (PERIMAX). A Randomized, Multidisciplinary DGAV(CAO-V/CALGP)/AIO Phase II Trial[NCT01540435] | Phase 2 | 0 participants (Actual) | Interventional | 2012-09-30 | Withdrawn (stopped due to insufficient recruitment) | ||
| Retrospective Validation for Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy With S-1[NCT01905969] | 500 participants (Anticipated) | Observational | 2012-10-31 | Active, not recruiting | |||
| A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy[NCT02045030] | Phase 2 | 14 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to Drug (Aflibercept) no longuer available for the study) | ||
| Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study[NCT04260269] | 200 participants (Anticipated) | Observational | 2018-06-01 | Enrolling by invitation | |||
| Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study[NCT03683004] | 40 participants (Actual) | Observational | 2018-01-22 | Completed | |||
| A Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Irinotecan/5-fluorouracil/Isovorin (FOLFIRI) Administered Every 2 Weeks in Patients With Metastatic Colorectal Cancer[NCT00921661] | Phase 1 | 16 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Multicenter, Randomised, Double-Blind, Phase 3 Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (FOLFIRI) As First Line Treatment[NCT00457691] | Phase 3 | 768 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma[NCT00752570] | Phase 2 | 144 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients: An Open-label, Single-arm, Multicenter Phase II Study[NCT03053167] | Phase 2 | 100 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| A Phase II Trial of 5-Fluorouracil Plus 776C85 in Patients With Advanced Resistant Colorectal Cancer[NCT00003254] | Phase 2 | 75 participants (Actual) | Interventional | 1998-04-30 | Completed | ||
| Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma[NCT00590941] | 52 participants (Actual) | Interventional | 2005-02-28 | Completed | |||
| Usefulness of Extracorporeal Removal of sFlt-1 in Women With Severe Preeclampsia at Less Than 26 Weeks' Gestation[NCT02286284] | Phase 2 | 2 participants (Actual) | Interventional | 2015-03-31 | Terminated (stopped due to Safety of patients : CSI recommandation and promotor decision) | ||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases[NCT00537823] | Phase 2 | 9 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Poor accrual.) | ||
| Phase Ib Study of the Safety and Pharmacokinetics of Chemoembolization With Irinotecan-Eluting Beads for the Treatment of Hepatic Metastases[NCT01336985] | Phase 1 | 5 participants (Actual) | Interventional | 2011-03-28 | Terminated | ||
| A Phase II Trial of Eloxatin in Combination With 5-Fluorouracil and Leucovorin in Patients With Advanced Colorectal Carcinoma[NCT00004102] | Phase 2 | 0 participants | Interventional | 1999-01-31 | Completed | ||
| Clinical Significance of Genetic Markers in Colon Cancer[NCT00014079] | 675 participants (Actual) | Observational | 1997-09-30 | Completed | |||
| The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer[NCT03923335] | 287 participants (Anticipated) | Observational | 2019-04-30 | Not yet recruiting | |||
| Multicenter, Phase II Study of Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly[NCT02992886] | Phase 2 | 68 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Leas[NCT00510627] | Phase 4 | 0 participants (Actual) | Interventional | 2007-08-31 | Withdrawn (stopped due to Boston Scientific has decided to close the Study.) | ||
| A Phase II Study to Assess Efficacy and Safety of Capecitabine and Irinotecan Plus Bevacizumab Followed by Capecitabine and Oxaliplatin Plus Bevacizumab or the Reverse Sequence in Patients With Metastatic Colorectal Cancer[NCT02119026] | Phase 2 | 120 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined With Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer[NCT05424692] | 200 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Multicenter Phase II Trial of Oxaliplatin and Docetaxel for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck[NCT00557206] | Phase 2 | 35 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to Funding was terminated) | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00531245] | Phase 1/Phase 2 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma[NCT00868192] | Phase 2 | 38 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Medical and Economical Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases[NCT00489697] | 200 participants (Anticipated) | Interventional | 2007-01-31 | Completed | |||
| The Effects of Exercise Training on Tumor Vascularity and Response to Neoadjuvant Therapy in Operable Breast Cancer: A Phase I-II Study[NCT00405678] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Phase I Study Evaluating the Safety of Bevacizumab in Women With a History of Breast Cancer Suffering From Moderate to Severe Upper Extremity Lymphedema[NCT00318513] | Phase 1 | 35 participants | Interventional | Not yet recruiting | |||
| Angiogenesis Inhibitors and Hypertension: Clinical Aspects[NCT00511511] | 80 participants (Anticipated) | Observational | 2007-08-31 | Completed | |||
| A Pilot Study to Evaluate the Effects of Antiangiogenic Factor as an Adjunct Treatment After Photoangiolysis in Patients With Bilateral Recurrent Respiratory Papillomatosis of the Vocal Fold[NCT01020747] | Phase 1 | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Phase II Safety and Tolerability Study of Avastin When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain[NCT00476827] | Phase 2 | 16 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to Slow accrual) | ||
| A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites[NCT00908219] | Phase 2 | 0 participants (Actual) | Interventional | 2009-07-31 | Withdrawn (stopped due to Accrual closed by sponsor due to lack of accrual and study progress) | ||
| Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study[NCT00462423] | Phase 2 | 50 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer[NCT01152710] | Phase 2 | 57 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Retrospective Analysis of Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer[NCT01025349] | Phase 2 | 20 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficienc[NCT02784067] | Phase 4 | 0 participants (Actual) | Interventional | 2016-05-31 | Withdrawn (stopped due to Clinical Trial Material) | ||
| A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer[NCT00116610] | Phase 2 | 75 participants | Interventional | 2005-06-30 | Completed | ||
| A Phase I Open-Label Study of Picoplatin in Combination With 5-Fluorouracil and Leucovorin as Initial Therapy in Subjects With Metastatic Colorectal Cancer[NCT00478946] | Phase 1/Phase 2 | 43 participants (Anticipated) | Interventional | 2006-04-30 | Active, not recruiting | ||
| Phase 3 Study of Enteral Nutrition Rich in Eicosapentaenoic Acid in Patients Receiving Chemotherapy for Gastric Cancer or Colorectal Cancer[NCT01048463] | Phase 3 | 90 participants (Anticipated) | Interventional | 2009-12-31 | Recruiting | ||
| A Randomized Phase II Trial Of Capecitabine And Different Schedules Of Irinotecan As First Line Treatment For Advanced Or Metastatic Colorectal Cancer[NCT00030797] | Phase 2 | 75 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| A Phase II Study of Oral Xeloda (Capecitabine) in Combination With Intravenous Irinotecan for Patients With Locally Advanced and/or Metastatic Colorectal Cancer[NCT00022698] | Phase 2 | 67 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069] | Phase 1 | 27 participants (Actual) | Interventional | 2012-04-03 | Terminated (stopped due to Equipment that was used in the study was discontinued) | ||
| A Randomized Crossover Trial Comparing Oral Capecitabine and Intravenous Fluorouracil + Folinic Acid (Nordic FU/FA Regimen) for Patient Preference in Colorectal Cancer[NCT00212589] | Phase 3 | 60 participants | Interventional | 2002-12-31 | Completed | ||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| CPT-11 in Combination With Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Relative to Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Alone in Patients With Advanced Colorectal Cancer[NCT00004885] | Phase 3 | 430 participants (Actual) | Interventional | 1999-07-31 | Completed | ||
| Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)[NCT02942238] | 582 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | |||
| Chemotherapy Intra-Arterial Hepatic With Oxaliplatin Combined With Leucovorin Calcium and Fluorouracil IV[NCT00006050] | Phase 2 | 0 participants | Interventional | 1999-04-04 | Completed | ||
| A Phase II, Randomized, Open-label, Controlled, Dose-elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal [NCT00040391] | Phase 2 | 0 participants | Interventional | 2002-06-30 | Terminated | ||
| Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.[NCT03428529] | Phase 2/Phase 3 | 63 participants (Actual) | Interventional | 2011-01-12 | Completed | ||
| A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum (Per 04/99 Amendment) Old Title: A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum Confined to the Liver[NCT00003834] | Phase 2 | 44 participants (Actual) | Interventional | 1999-03-31 | Completed | ||
| A Phase III Study of Immediate Versus Delayed Chemotherapy for Asymptomatic Advanced Colorectal Cancer[NCT00002570] | Phase 3 | 67 participants (Actual) | Interventional | 1994-07-15 | Completed | ||
| A Randomized Study Of Continuous FOLFOX4 vs. FOLFOX4 in a Stop-and-Go Fashion in 1st Line Advanced Colorectal Cancer[NCT01023633] | Phase 4 | 300 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER[NCT00002716] | Phase 3 | 135 participants (Actual) | Interventional | 1996-01-31 | Completed | ||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| A Phase II Study of OSI-774 (Tarceva) in Combination With Oxaliplatin and Capecitabine in Previously Treated Patients With Stage IV Colorectal Cancer[NCT00123851] | Phase 2 | 32 participants | Interventional | 2003-03-31 | Completed | ||
| A Phase II Trial of Neoadjuvant Capecitabine, Oxaliplatin, and Bevacizumab for Resectable Colorectal Metastases in the Liver[NCT00118105] | Phase 2 | 0 participants (Actual) | Interventional | 2006-11-30 | Withdrawn (stopped due to Budget Constraints) | ||
| A Multicenter Study of the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin®) Plus 5-Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancers That Have Progressed After Standard Chemotherapy[NCT00066846] | Phase 2 | 0 participants | Interventional | 2003-08-31 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Randomised Study of Sequential Versus Combination Chemotherapy in Patients With Previously Untreated Advanced Colorectal Carcinoma[NCT00312000] | Phase 3 | 820 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Phase II Trial of Fluorouracil (5-FU), Leucovorin (LV), Irinotecan (CPT-11) and Bevacizumab (Anti-VEGF) in Previously Untreated Patients With Advanced Colorectal Cancer[NCT00006786] | Phase 2 | 0 participants | Interventional | 2000-11-30 | Completed | ||
| Harnessing Chronomodulation to Enhance Osteogenesis - A Pilot Randomized Controlled Trial -[NCT03911336] | Phase 4 | 0 participants (Actual) | Interventional | 2023-01-01 | Withdrawn (stopped due to Decided not to proceed) | ||
| The Kinetics of Endocannabinoids in Patients With Chemotherapy Induced Peripheral Neuropathy by Using a Portable Metered-Dose Cannabis Inhaler[NCT04376437] | 40 participants (Anticipated) | Interventional | 2022-03-15 | Not yet recruiting | |||
| A Phase I Study Of ZD1839 (Iressa) In Combination With Irinotecan, Leucovorin, And 5-Fluorouracil In Previously Untreated, Stage IV Colorectal Cancer[NCT00026364] | Phase 1 | 22 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study[NCT00072553] | Phase 2 | 0 participants | Interventional | 2003-09-30 | Active, not recruiting | ||
| A Phase II Study of Perioperative QBECO Site Specific Immunomodulator (Qu Biologics®) in Patients With Metastatic Colorectal Adenocarcinoma Within the Liver Undergoing Resection[NCT05677113] | Phase 2 | 115 participants (Anticipated) | Interventional | 2023-08-30 | Recruiting | ||
| Construction and Evaluation of the Early Identification for Oxaliplatin Induced Portal Hypertension[NCT04524650] | 370 participants (Anticipated) | Observational | 2020-08-31 | Not yet recruiting | |||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Coala-T-CBD Study: A Study of the Effect of Hemp-CBD on the Severity and Duration of Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Neurotoxic Chemotherapy for Non-Metastatic Breast, Uterine, Pancreatic, and Colorectal Cancer and All Sta[NCT04398446] | Phase 2 | 56 participants (Actual) | Interventional | 2020-05-27 | Active, not recruiting | ||
| mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or Stage IIIC Colorectal Cancer: A Randomized Controlled Clinical Research[NCT05200299] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| A Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil in Subjects With Metastatic Colorectal Cancer[NCT00111761] | Phase 2 | 43 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Phase II Trial Of Irinotecan + 5-Fluorouracil + Leucovorin + Oxaliplatin As First-Line Treatment For Metastatic Colorectal Cancer[NCT00080951] | Phase 2 | 14 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Randomized Phase II Study Evaluating Three Chemotherapies: [Irinotecan + Oxaliplatin (Irinox)], [Irinotecan + LV5FU2] and [Oxaliplatin + LV5FU2] as First Intention Treatment in Subjects With Metastatic Colorectal Cancer[NCT00066274] | Phase 2 | 0 participants | Interventional | 2002-07-23 | Completed | ||
| The Influence of Probiotics on Vancomycin-Resistant Enterococcus[NCT00591474] | 8 participants (Actual) | Interventional | 2007-12-31 | Terminated (stopped due to Participant lost to followup) | |||
| A Double-blind Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Per and Post Hepatectomy Infiltrations for Adult Pain Management[NCT01194843] | 85 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer[NCT00064181] | Phase 3 | 86 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| A UKCCCR Study of Adjuvant Chemotherapy for Colorectal Cancer[NCT00005586] | Phase 3 | 2,500 participants (Anticipated) | Interventional | 1997-10-31 | Completed | ||
| Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. A Proof-of-concept Study[NCT04189055] | Phase 2 | 72 participants (Anticipated) | Interventional | 2020-01-07 | Recruiting | ||
| FOcUs on Colorectal CAncer oUtcomes: Long-Term Study[NCT03965325] | 300 participants (Anticipated) | Observational | 2019-06-07 | Recruiting | |||
| [NCT02748772] | Phase 3 | 148 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Long-term Evaluation of the Quality of Life After Major Hepatic Resection for Malignant and Benign Diseases.[NCT00681499] | 198 participants (Actual) | Observational | 2008-02-29 | Completed | |||
| A Phase I Trial of ZD1694 (TOMUDEX® (Registered Trademark)), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease[NCT00001341] | Phase 1 | 60 participants | Interventional | 1993-09-30 | Completed | ||
| A Randomized, Controlled Phase II Clinical Trial of Fruquintinib Combined With Raltitrexed Versus Fruquintinib Monotherapy in Patients With Advanced Colorectal Cancer Who Had Failed Second-line or Above Standard Chemotherapy[NCT04582981] | Phase 2 | 136 participants (Anticipated) | Interventional | 2020-09-28 | Recruiting | ||
| The Optimisation of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer[NCT00943137] | Phase 2 | 55 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | ||
| A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the HIV-1 DNA Vaccine VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade Env) With the Plasmid Cytokine Adjuvant VRC-ADJDNA004-IL2-VP (IL-2/Ig)[NCT00069030] | Phase 1 | 70 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.[NCT03562897] | Phase 2 | 40 participants (Actual) | Interventional | 2018-10-25 | Completed | ||
| A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer[NCT01396707] | Phase 2 | 55 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Short-term Effects of Laparoscopic-assisted Small-incision Surgery Versus Conventional Laparotomy in Treatment of Resectable Colorectal Liver Metastasis[NCT02350166] | Phase 3 | 40 participants (Anticipated) | Interventional | 2013-11-30 | Recruiting | ||
| A Prospective Random Assignment Trial to Study Operative Debulking and Systemic Chemotherapy With or Without Intra-and Peri-Operative Intraperitoneal Chemotherapy for Subjects With Peritoneal Carcinomatosis From Low Grade Gastrointestinal Adenocarcinoma[NCT00052962] | Phase 3 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase[NCT00248404] | Phase 1/Phase 2 | 155 participants (Anticipated) | Interventional | 2005-09-30 | Completed | ||
| Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer[NCT01856322] | Phase 2 | 3 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to The trial was prematurely closed due to lack of accrual.) | ||
| A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).[NCT05927857] | Phase 1/Phase 2 | 45 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin[NCT03524508] | Phase 2 | 178 participants (Actual) | Interventional | 2018-09-04 | Completed | ||
| Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262] | Phase 3 | 803 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763] | 13 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628] | 10 participants (Anticipated) | Interventional | 2012-01-31 | Not yet recruiting | |||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases[NCT01042691] | Phase 1 | 10 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Aromatase Inhibitors Plus Metronomic Capecitabine in Treatment of Patients With Recurrent or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer[NCT04942899] | Phase 2 | 70 participants (Anticipated) | Interventional | 2023-08-30 | Not yet recruiting | ||
| A Phase I-II Study of Capecitabine and Oxaliplatin in Chemotherapy-Naive and Thymidylate Synthase Inhibitor Pretreated Advanced or Metastatic Colorectal Cancer[NCT00004187] | Phase 1/Phase 2 | 0 participants | Interventional | 1999-06-30 | Completed | ||
| A Phase I Study of Capecitabine In Patients With Solid Tumors[NCT00697502] | Phase 1 | 23 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma.[NCT00674167] | Phase 2 | 21 participants (Actual) | Interventional | 2007-05-31 | Active, not recruiting | ||
| Prospective, Randomized Study Aiming to Assess the Benefit of Autohypnosis Learning in the Care of Patients Treated by Adjuvant Chemotherapy for Colorectal or Breast Cancer.[NCT03429296] | 120 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Disease control is defined as maintaining Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) as the tumor assessment result during the defined time window. DCR (percentage) is defined as number of patients with success of disease control divided by total number of patients in the analysis population multiplied by 100, excluding patients who refuse treatment before the initiation of any treatment. CR: Disappearance of all evidence of disease, PR: Regression of measurable disease and no new sites, PD: Any new lesion or increase by ≥50% of previously involved sites from nadir, SD: Neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD taking as reference the MSD (NCT02292758)
Timeframe: Up to 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I (Irinotecan, Cetuximab, Bevacizumab) | 68.4 |
| Arm II (Irinotecan, Cetuximab, Placebo) | 52.9 |
The distribution of DOR by treatment group will be estimated using the method of Kaplan-Meier. Six and 12 month durable response (i.e. maintaining CR or PR without progressive disease [PD]) rates by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves. The HR with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors.CR: Disappearance of all evidence of disease, PR: Regression of measurable disease and no new sites, PD: Any new lesion or increase by ≥50% of previously involved sites from nadir (NCT02292758)
Timeframe: From the date of first tumor assessment with the response status being CR or PR to the date of 1st documented progressive disease, assessed up to 12 months
| Intervention | months (Median) |
|---|---|
| Arm I (Irinotecan, Cetuximab, Bevacizumab) | 9.2 |
| Arm II (Irinotecan, Cetuximab, Placebo) | 9.7 |
The number of participants who experienced at least one grade 3 or higher adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. (NCT02292758)
Timeframe: Up to 30 days from last dose of study treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Irinotecan, Cetuximab, Bevacizumab) | 9 |
| Arm II (Irinotecan, Cetuximab, Placebo) | 6 |
The response rate (percentage) is the percent of participants whose best response was Complete Response (CR) or Partial Response (PR) as defined by RECIST 1.1 criteria. Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients. Response rates (including complete and partial response) will be tested using Fisher's exact test. CR: Disappearance of all evidence of disease, PR: Regression of measurable disease and no new sites (NCT02292758)
Timeframe: Up to 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I (Irinotecan, Cetuximab, Bevacizumab) | 36.8 |
| Arm II (Irinotecan, Cetuximab, Placebo) | 11.8 |
The distribution of OS by group will be estimated using the method of Kaplan-Meier. Median OS by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves. The HR with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors. (NCT02292758)
Timeframe: From randomization to the date of death due to any cause, assessed up to 24 months
| Intervention | months (Median) |
|---|---|
| Arm I (Irinotecan, Cetuximab, Bevacizumab) | 19.7 |
| Arm II (Irinotecan, Cetuximab, Placebo) | 10.2 |
TTF is defined as the time from the date of randomization to the date of treatment discontinuation due to PD, death, or severe AE. The distribution of TTF by treatment group will be estimated using the method of Kaplan-Meier. Six month event-free rates by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves. The HR with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors. PD: Any new lesion or increase by ≥50% of previously involved sites from nadir (NCT02292758)
Timeframe: assessed at 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I (Irinotecan, Cetuximab, Bevacizumab) | 72.7 |
| Arm II (Irinotecan, Cetuximab, Placebo) | 38.4 |
The distribution of PFS by group will be estimated using the method of Kaplan-Meier. Median by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves. The hazard ratio (HR) with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors. Progression (PD) is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. PD: Any new lesion or increase by ≥50% of previously involved sites from nadir). (NCT02292758)
Timeframe: From the date of randomization to the date of 1st documented disease progression or death due to any cause, whichever occurs first, assessed up to 24 months
| Intervention | months (Median) |
|---|---|
| Arm I (Irinotecan, Cetuximab, Bevacizumab) | 9.7 |
| Arm II (Irinotecan, Cetuximab, Placebo) | 5.5 |
The distribution of OS by group will be estimated using the method of Kaplan-Meier. Twelve, 18- and 24-month survival rates by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves. The HR with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors. (NCT02292758)
Timeframe: From randomization to the date of death due to any cause, assessed up to 24 months
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 12-month OS rate | 18-month OS rate | 24-month OS rate | |
| Arm I (Irinotecan, Cetuximab, Bevacizumab) | 77.2 | 56.1 | 14.0 |
| Arm II (Irinotecan, Cetuximab, Placebo) | 47.1 | 11.8 | 5.9 |
The distribution of PFS by group will be estimated using the method of Kaplan-Meier. Six and 12 month PFS rates by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves. The hazard ratio (HR) with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors. Progression (PD) is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. PD: Any new lesion or increase by ≥50% of previously involved sites from nadir). (NCT02292758)
Timeframe: From the date of randomization to the date of 1st documented disease progression or death due to any cause, whichever occurs first, assessed up to 24 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6-month PFS rate | 12-month PFS rate | |
| Arm I (Irinotecan, Cetuximab, Bevacizumab) | 76.5 | 27.5 |
| Arm II (Irinotecan, Cetuximab, Placebo) | 41.2 | 17.6 |
RDI is defined as the total dose of protocol therapy a patient actually received (i.e., summation of actually received dose at each cycle) divided by the total planned dose (i.e., summation of planned dose level at each cycle) multiplied by 100. Separate RDIs will be calculated for irinotecan and cetuximab. Agent-specific RDI will be summarized by medians, and min and max values, all of which will be compared between the two treatment groups by the Wilcoxon Rank sum test. (NCT02292758)
Timeframe: Up to 2 years
| Intervention | percentage of dose received (Median) | |
|---|---|---|
| Cetuximab | Irinotecan | |
| Arm I (Irinotecan, Cetuximab, Bevacizumab) | 98.5 | 89 |
| Arm II (Irinotecan, Cetuximab, Placebo) | 95.5 | 90 |
ORR is defined as the proportion of participants with a complete response (CR) or partial response (PR) as determined by a investigator assessment based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1. (NCT03368859)
Timeframe: From randomization up to 30 days after last dose of study drug; median time on follow-up was 25.6 (0.3 - 64.4) and 37.6 (0.3 - 66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab plus FOLFIRI, respectively
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-165 Plus FOLFIRI | 5.6 |
| Bevacizumab Plus FOLFIRI | 14.7 |
OS is defined as the time from randomization until death from any cause. (NCT03368859)
Timeframe: Follow up continued until the first occurrence of radiographic progression, death from any cause or termination of the study; median follow-up time was 25.6(0.3-64.4) and 37.6(0.3-66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab + FOLFIRI, respectively
| Intervention | Months (Median) |
|---|---|
| ABT-165 Plus FOLFIRI | 7.95 |
| Bevacizumab Plus FOLFIRI | NA |
PFS is defined as the time from randomization until the first occurrence of radiographic progression determined by investigator assessment or death from any cause. (NCT03368859)
Timeframe: Follow up continued until the first occurrence of radiographic progression, death from any cause or termination of the study; median follow-up time was 25.6(0.3-64.4) and 37.6(0.3-66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab + FOLFIRI, respectively
| Intervention | Months (Median) |
|---|---|
| ABT-165 Plus FOLFIRI | 3.78 |
| Bevacizumab Plus FOLFIRI | 7.36 |
OS was defined as the time from the day of randomization (Day 0) until death by all causes. (NCT02337946)
Timeframe: Up to approximately 31 months
| Intervention | months (Median) |
|---|---|
| Group A | NA |
| Group B | NA |
Safety population was defined as all participants who received at least one dose of protocol treatment after randomization. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
| Intervention | percentage of participants (Number) |
|---|---|
| Group A | 100 |
| Group B | 100 |
"Peripheral neuropathy was defined as events classified with a preferred term (PT) of peripheral neuropathy according to Standardized MedDRA Queries." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
| Intervention | percentage of participants (Number) |
|---|---|
| Group A | 30.4 |
| Group B | 3.7 |
The PFS is the period from the date of randomization (Day 0) until the date of judgment of progression from the date of randomization, or until death by all causes, whichever comes first. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to approximately 31 months
| Intervention | months (Median) |
|---|---|
| Group A | 9.1 |
| Group B | 9.3 |
PFS rate was defined as the gross percentage of participants who survived with no evidence of progression from the day of randomization (Day 0) until 9 months after Day 0. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to 9 months after randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Group A | 46.4 |
| Group B | 47.4 |
RR was defined as the percentage of participants who had shown complete response (CR) or partial response (PR) as the best overall response in accordance with the RECIST 1.1 criteria after randomization. The best overall response was CR, followed by PR, stable disease (SD), progressive disease (PD), and not evaluable (NE). CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters as the best overall response after randomization., SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). (NCT02337946)
Timeframe: Up to approximately 31 months
| Intervention | percentage of participants (Number) |
|---|---|
| Group A | 80.4 |
| Group B | 87.7 |
TTF was defined as the time from the day of randomization (Day 0) until the day of protocol treatment discontinuation determination, the day of PD decision during protocol treatment, or death from any cause, whichever came the earliest. (NCT02337946)
Timeframe: Up to approximately 31 months
| Intervention | months (Median) |
|---|---|
| Group A | 8.1 |
| Group B | 6.1 |
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3, 4 and 5 | |
| Group A | 0 | 19.6 | 80.4 |
| Group B | 0 | 27.8 | 72.2 |
"Skin toxicity was defined as events classified with an system organ class of Skin and subcutaneous tissue disorders or a preferred term of paronychia." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Skin and subcutaneous tissue disorders | Paronychia | |
| Group A | 17.9 | 7.1 |
| Group B | 18.5 | 9.3 |
For participants with a confirmed objective response, the time from first confirmed objective response to radiologic disease progression per modified RECIST 1.0 criteria or death. For participants who responded and have not progressed or died, duration of response was censored at their last evaluable disease assessment date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 10.0 |
| Bevacizumab Plus mFOLFOX6 | 9.0 |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | NA |
| Bevacizumab Plus mFOLFOX6 | 25.4 |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | NA |
| Bevacizumab Plus mFOLFOX6 | 29.0 |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | NA |
| Bevacizumab Plus mFOLFOX6 | 29.0 |
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 57.75 |
| Bevacizumab Plus mFOLFOX6 | 53.52 |
"Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met.~Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions." (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 63.64 |
| Bevacizumab Plus mFOLFOX6 | 60.49 |
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 63.64 |
| Bevacizumab Plus mFOLFOX6 | 61.54 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 10.9 |
| Bevacizumab Plus mFOLFOX6 | 10.1 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 13.1 |
| Bevacizumab Plus mFOLFOX6 | 9.7 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 13.0 |
| Bevacizumab Plus mFOLFOX6 | 9.5 |
The resection rate was defined as the percentage of participants with a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 12.68 |
| Bevacizumab Plus mFOLFOX6 | 11.19 |
Time to progression (TTP) is defined as the time from randomization to the date of radiologic disease progression per modified RECIST 1.0 criteria. Participants not meeting criteria for disease progression by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 11.0 |
| Bevacizumab Plus mFOLFOX6 | 11.1 |
For participants with a confirmed objective response, the time from randomization to the date of first confirmed objective response. Assessments are based on the investigator's review of scans using a modified-RECIST v1.0. An objective response is defined as a best tumor response of complete or partial response. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 1.8 |
| Bevacizumab Plus mFOLFOX6 | 1.9 |
Severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) v3.0, with the exception of some dermatology/skin adverse events that were graded using CTCAE v3.0 with modifications. Fatal adverse events are classified as grade 5. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs were those that the investigator considered a reasonable possibility that might have been caused by study drug. (NCT00819780)
Timeframe: The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus mFOLFOX arm and 7.3 months for Bevacizumab Plus mFOLFOX6 arm.
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event (AE) | AE with worst grade of 3 | AE with worst grade of 4 | AE with worst grade of 5 | Serious adverse event (SAE) | AE leading to discontinuation of study drug | Any treatment-related adverse event (TRAE) | Treatment-related AE with worst grade of 3 | Treatment-related AE with worst grade of 4 | Treatment-related AE with worst grade of 5 | Serious treatment-related adverse event | TRAE leading to discontinuation of study drug | |
| Bevacizumab Plus mFOLFOX6 | 139 | 78 | 28 | 9 | 53 | 37 | 136 | 77 | 25 | 2 | 28 | 29 |
| Panitumumab Plus mFOLFOX6 | 139 | 88 | 31 | 7 | 61 | 34 | 138 | 92 | 24 | 3 | 37 | 28 |
"The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST v1.0 criteria as assessed by the Investigator.~Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline." (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 90.59 |
| Mutant KRAS | 89.66 |
Duration of response was calculated only for those participants who had a confirmed complete or partial response, and is defined as the time from first confirmed response to first observed progression. For participants who responded and did not progress by the analysis data cut-off date, duration of response was censored at their last evaluable disease assessment date. Duration of response was analyzed using the Kaplan-Meier method. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 13.0 |
| Mutant KRAS | 7.4 |
Duration of stable disease was calculated only for participants with a best response of stable disease and is defined as the time from enrollment to first observed PD. For participants who did not progress by the analysis data cut-off date, duration of SD was censored at their last evaluable disease assessment date. Duration of stable disease was estimated using Kaplan-Meier methods. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 5.9 |
| Mutant KRAS | 6.1 |
The percentage of participants with a best response of complete response or partial response by Week 17. Disease assessments are based on investigator review of scans using modified RECIST V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders. (NCT00508404)
Timeframe: Up to Week 17
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 49.41 |
| Mutant KRAS | 34.48 |
"Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments are based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders.~Complete Response (CR): disappearance of all target and non-target lesions and no new lesions.~Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions." (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 56.47 |
| Mutant KRAS | 37.93 |
Progression-free survival is the time from the date of enrollment to the date of first observed progression or death, whichever comes first. Participants who were alive and did not progress by the analysis data cut-off date were censored at the last evaluable disease assessment date. Progression-free survival was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 8.9 |
| Mutant KRAS | 7.2 |
The percentage of participants who underwent a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 15.12 |
| Mutant KRAS | 6.78 |
Time to progression is the time from the enrollment date to the date of first observed progression. For participants who had not progressed by the analysis data cutoff date, time to progressive disease was censored at their last evaluable disease assessment date. Time to disease progression was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 11.2 |
| Mutant KRAS | 7.3 |
Calculated only for those participants who underwent surgical intervention, and defined as the time from the date of first post-intervention radiographic disease assessment to the date of first observed PD. Participants with no post-intervention disease assessment had their time to relapse set to zero and censored in the analysis. Participants that had evidence of progression / recurrence at their first post-intervention disease assessment had a time to relapse of zero. For participants who had not progressed by the analysis data cut-off date, time to relapse was censored at the date of their last evaluable disease assessment. Time to relapse was analyzed using Kaplan-Meier metjhods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | NA |
| Mutant KRAS | NA |
Time to response is the time from the date of enrollment to the date of first confirmed complete or partial response. Participants with a best response of stable disease at the analysis data cut-off date were censored at their last assessment of SD and participants with all other categories of best response were censored at the maximum observed time to a first confirmed response among all responders. Time to initial objective response was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 3.8 |
| Mutant KRAS | NA |
Time to treatment failure is defined as the time from enrollment to the date the decision was made to end the treatment phase for any reason. For participants who remained in the treatment phase at the analysis data cut-off date, time to treatment failure was censored at the date of their last on-study assessment. Time to treatment failure was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS | 6.9 |
| Mutant KRAS | 5.8 |
Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 11.1 |
| Wild-type KRAS - FOLFOX | 8.8 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.4 |
| Mutant KRAS - FOLFOX | 8.0 |
The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 23.9 |
| Wild-type KRAS - FOLFOX | 19.7 |
| Mutant KRAS - FOLFOX + Panitumumab | 15.5 |
| Mutant KRAS - FOLFOX | 19.3 |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 55.21 |
| Wild-type KRAS - FOLFOX | 47.68 |
| Mutant KRAS - FOLFOX + Panitumumab | 39.53 |
| Mutant KRAS - FOLFOX | 40.28 |
Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 9.6 |
| Wild-type KRAS - FOLFOX | 8.0 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.3 |
| Mutant KRAS - FOLFOX | 8.8 |
Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria. (NCT00364013)
Timeframe: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 10.8 |
| Wild-type KRAS - FOLFOX | 9.2 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.5 |
| Mutant KRAS - FOLFOX | 9.0 |
"A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00364013)
Timeframe: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Serious adverse event | Leading to discontinuation of any study drug | Treatment-related adverse event (TRAE) | Serious treatment-related adverse event | TRAE leading to discontinuation of any study drug | |
| FOLFOX + Panitumumab | 583 | 262 | 136 | 581 | 162 | 117 |
| FOLFOX Alone | 579 | 198 | 84 | 565 | 89 | 63 |
The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Maximum improvement is the best post-baseline change. (NCT01183780)
Timeframe: Baseline Up to 171 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ramucirumab + FOLFIRI | 4.0 |
| Placebo + FOLFIRI | 6.6 |
The EQ-5D is a generic, multidimensional, health status instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status. (NCT01183780)
Timeframe: Baseline and 30-Day Follow-Up (FU) up to 171 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ramucirumab + FOLFIRI | -0.097 |
| Placebo + FOLFIRI | -0.103 |
OS was defined as the time in months from the date of randomization to the date of death from any cause. For participants not known to have died as of the cut-off date, OS was censored at the last known date alive. (NCT01183780)
Timeframe: Randomization to Date of Death from Any Cause Up to 39.36 Months
| Intervention | months (Median) |
|---|---|
| Ramucirumab + FOLFIRI | 13.3 |
| Placebo + FOLFIRI | 11.7 |
The objective response rate is equal to the proportion of participants achieving a best overall response of partial response or complete response (PR + CR). Response was defined using RECIST, v. 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level of non-target lesions; PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameter. (NCT01183780)
Timeframe: Randomization until Disease Progression Up to 38.01 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Ramucirumab + FOLFIRI | 13.4 |
| Placebo + FOLFIRI | 12.5 |
PFS was defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) [according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1] or death due to any cause, whichever was first. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. (NCT01183780)
Timeframe: Randomization to Measured PD or Date of Death from Any Cause Up to 38.01 Months
| Intervention | months (Median) |
|---|---|
| Ramucirumab + FOLFIRI | 5.7 |
| Placebo + FOLFIRI | 4.5 |
(NCT01183780)
Timeframe: Preinfusion and 1 hour postinfusion in Cycles 3, 5, 9, 13, and 17
| Intervention | micrograms/milliliter (ug/mL) (Geometric Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cmin Dose 3 (n=248) | Cmin Dose 5 (n=154) | Cmin Dose 9 (n=27) | Cmin Dose 13 (n=11) | Cmin Dose 17 (n=5) | Cmax Dose 3 (n=88) | Cmax Dose 5 (n=51) | Cmax Dose 9 (n=18) | Cmax Dose 13 (n=12) | Cmax Dose 17 (n=7) | |
| Ramucirumab + FOLFIRI | 46.3 | 65.1 | 77.9 | 75.9 | 72.0 | 221.0 | 243.0 | 262.0 | 307.0 | 253.0 |
Blood samples were tested to determine if a participant reacted to ramucirumab by producing anti-ramucirumab antibodies. Samples were identified as treatment emergent anti-drug antibody (TE ADA) if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)*100. (NCT01183780)
Timeframe: Cycles 1, 3, 5, and 30-Day FU
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Immunogenicity Any Time During Study (n=516, 512) | Immunogenicity Post-Treatment (n=477, 473) | |
| Placebo + FOLFIRI | 5.5 | 3.8 |
| Ramucirumab + FOLFIRI | 5.6 | 3.1 |
"Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 7.6 |
| Wild-type KRAS - FOLFIRI Alone | 6.6 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 6.0 |
| Mutant KRAS - FOLFIRI Alone | 7.4 |
Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date. (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 14.5 |
| Wild-type KRAS - FOLFIRI Alone | 12.5 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 11.8 |
| Mutant KRAS - FOLFIRI Alone | 11.1 |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00339183)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 April 2009. Maximum time on follow-up was 33 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 35.35 |
| Wild-type KRAS - FOLFIRI Alone | 9.82 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 13.36 |
| Mutant KRAS - FOLFIRI Alone | 13.92 |
"Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 8 April 2008. Maximum follow-up time was 17 months.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 5.9 |
| Wild-type KRAS - FOLFIRI Alone | 3.9 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 5.0 |
| Mutant KRAS - FOLFIRI Alone | 4.9 |
"Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 7.3 |
| Wild-type KRAS - FOLFIRI Alone | 5.3 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 5.5 |
| Mutant KRAS - FOLFIRI Alone | 5.5 |
"A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Serious adverse event | Leading to discontinuation of any study drug | Treatment-related adverse event (TRAE) | Serious treatment-related adverse event | TRAE leading to discontinuation of any study drug | |
| FOLFIRI Alone | 573 | 175 | 64 | 542 | 90 | 34 |
| Panitumumab Plus FOLFIRI | 584 | 232 | 123 | 577 | 124 | 97 |
The Best ORR was defined as the percentage of subjects having achieved complete response (CR) or partial response (PR) according to RECIST version 1.0 as determined by the IRC. CR: defined as disappearance of all target and all non-target lesions and no new lesions. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters, no progression of non-target lesions and no new lesions. (NCT01228734)
Timeframe: Baseline up to 333 weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Cetuximab + FOLFOX-4 | 66.3 |
| FOLFOX-4 | 40.5 |
OS was defined as the time (in months) from randomization to death. For subjects who were still alive at the analysis data cut-off date or who lost to follow-up, survival was censored at the last recorded date that the subject was known to be alive. (NCT01228734)
Timeframe: Baseline up to 333 weeks
| Intervention | months (Median) |
|---|---|
| Cetuximab + FOLFOX-4 | 20.8 |
| FOLFOX-4 | 16.5 |
PFS was defined as the duration (in months) from randomization until the first progressive disease (PD) observation as assessed by the Independent Review Committee (IRC) according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.0, or death due to any cause when death occurred within 90 days of randomization or the last tumor assessment, whichever was later. PD was defined as at least a 20% increase in the sum of longest diameter (LD) of the target lesions, taking as references the smallest sum LD since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions. (NCT01228734)
Timeframe: Baseline up to 333 weeks
| Intervention | months (Median) |
|---|---|
| Cetuximab + FOLFOX-4 | 9.2 |
| FOLFOX-4 | 7.4 |
TTF was defined as time from randomization to date of the first occurrence of radiologically confirmed PD as determined by IRC, Clinical PD according to the Investigator's assessment (if radiological confirmation of PD by IRC was unavailable), discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death within 90 days of last tumor assessment or randomization. Subjects without event were censored on the date of last tumor assessment. (NCT01228734)
Timeframe: Baseline up to 333 weeks
| Intervention | months (Median) |
|---|---|
| Cetuximab + FOLFOX-4 | 9.2 |
| FOLFOX-4 | 5.6 |
The number of subjects who underwent liver metastatic surgery after start of treatment and the outcome of surgery with respect to residual tumor after surgery (R0, R1, R2, not evaluable) were summarized. In case of resection of more than one metastasis, the worst outcome of surgery defined the overall status of a subject. R0 = No residual tumor after resection (all lesions resected completely); R1 = Metastases not resected completely with microscopic residual lesions; and R2 = Metastases not resected completely with macroscopic residual lesions. (NCT01228734)
Timeframe: Baseline up to 333 weeks
| Intervention | subjects (Number) | ||||
|---|---|---|---|---|---|
| Subjects with liver surgery | Subjects with liver surgery outcome: R0 | Subjects with liver surgery outcome: R1 | Subjects with liver surgery outcome: R2 | Subjects not evaluable | |
| Cetuximab + FOLFOX-4 | 9 | 7 | 1 | 0 | 0 |
| FOLFOX-4 | 6 | 2 | 2 | 0 | 0 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. Longitudinal NLR was assessed by treating the NLR measurements taken over the time-course of treatment as a time-dependent covariate. OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. The association between longitudinal NLR (longitudinal NLR ≤5 vs NLR >5) and OS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 2.2 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. Longitudinal NLR was assessed by treating the NLR measurements taken over the time-course of treatment as a time-dependent covariate. PFS was defined as time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as: an unequivocal and clinically meaningful increase in size of known tumors, appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. The association between longitudinal NLR (longitudinal NLR ≤5 vs N>5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.3 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. PFS was defined as the time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (carcinoembryonic antigen [CEA]) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. The association between NLR (NLR less than or equal to [≤] 5 vs greater than [>] 5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.4 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. The association between NLR (NLR ≤ 5 vs > 5) and OS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.6 |
NLR was calculated from laboratory values as ratio of Neutrophils to Lymphocytes. NLR normalization was assessed by adding first post-baseline measurement of NLR to the primary model. This is equivalent to testing whether first change in NLR is significantly associated with outcome. PFS was defined as time from start of initial treatment to documentation of first disease progression or death from any cause. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was defined as: an unequivocal and clinically meaningful increase in size of known tumors, appearance of ≥1 new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration.The association between NLR normalization (first NLR post-baseline ≤5 vs >5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 0.9 |
DDC was defined as PFS + PFS-B. In cases where a participant did not enter Phase B, then DDC was defined as PFS. PFS was defined as time from start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. PFS-B was time from start of Phase B treatment to documentation of second disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate DDC. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 14.0 |
Overall Survival in Phase B was defined as the time from the start of treatment in Phase B to death due to any cause. Kaplan-Meier methodology was used to estimate OS. (NCT01588990)
Timeframe: From the start of Phase B treatment death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase B | 14.9 |
OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. Kaplan-Meier methodology was used to estimate OS. (NCT01588990)
Timeframe: Baseline until death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 25.0 |
The results include percentage of participants who underwent potentially curative liver resection. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.6 |
PFS until first progression was defined as the time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate PFS. (NCT01588990)
Timeframe: Baseline up to first disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A | 9.2 |
PFS in Phase B (PFS-B) was defined as the time from the start of Phase B treatment to documentation of second disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate PFS. (NCT01588990)
Timeframe: From the start of Phase B treatment to disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase B | 6.7 |
Survival beyond first progression was defined as the time from the date of first disease progression to death due to any cause. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate survival beyond first disease progression. (NCT01588990)
Timeframe: Baseline until death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 12.6 |
TFS was defined as time from the start of initial treatment to documentation of first disease progression without entering Phase B, or second disease progression having entered Phase B. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate TFS. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 14.8 |
AQoL-8D provides a global utility score and consists of 8 separately scored dimensions including Independent Living, Life Satisfaction, Mental Health, Coping, Relationships, Self Worth, Pain, and Senses. Each of the 8 scales is calculated based on the answers to 3 questions. Each question is given an answer dependent utility score (0 [worst] to 1 [best]) and then these scores are combined using a multiplicative model to get the normalized scale score value, each scale ranging between 0.0 (representing death) and 1.0 (representing full health). (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase B Baseline | Phase B Visit 2 (up to 4 years) | Phase B Visit 3 (up to 4 years) | Phase B Visit 4 (up to 4 years) | Phase B Visit 5 (up to 4 years) | Phase B Visit 6 (up to 4 years) | Phase B Visit 7 (up to 4 years) | Phase B Visit 8 (up to 4 years) | Phase B Visit 9 (up to 4 years) | Phase B Visit 10 (up to 4 years) | Phase B Visit 11 (up to 4 years) | Phase B Visit 12 (up to 4 years) | Phase B Visit 13 (up to 4 years) | Phase B Visit 14 (up to 4 years) | Phase B Visit 15 (up to 4 years) | Phase B Visit 16 (up to 4 years) | Phase B Visit 17 (up to 4 years) | Phase B Visit 18 (up to 4 years) | Phase B Visit 19 (up to 4 years) | Phase B Visit 20 (up to 4 years) | Phase B Visit 21 (up to 4 years) | Phase B Visit 22 (up to 4 years) | Phase B Visit 23 (up to 4 years) | Phase B Visit 24 (up to 4 years) | Phase B EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | |
| Bevacizumab: Phase B | 0.736 | 0.773 | 0.813 | 0.878 | 0.808 | 0.809 | 0.825 | 0.910 | 0.819 | 0.856 | 0.730 | 0.960 | 0.965 | 0.958 | 0.967 | 0.942 | 0.927 | 0.931 | 0.866 | 0.887 | 0.940 | 0.919 | 0.937 | 0.950 | 0.708 | 0.788 | 0.791 | 0.989 | 0.981 | 0.875 |
AQoL-8D provides a global utility score and comprised of 35 questions from which 8 dimensions (Independent Living, Life Satisfaction, Mental Health, Coping, Relationships, Self Worth, Pain, and Senses) are derived. Each of the 8 scales is calculated based on the answers to 3 questions. Each question is given an answer dependent utility score (0 [worst] to 1 [best]) and then these scores are combined using a multiplicative model to get the normalized scale score value, each scale ranging between 0.0 (representing death) and 1.0 (representing full health). (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase A Baseline | Phase A Visit 2 (Weeks 8-9) | Phase A Visit 3 (Weeks 16-17) | Phase A Visit 4 (Weeks 24-25) | Phase A Visit 5 (Weeks 32-33) | Phase A Visit 6 (Weeks 40-41) | Phase A Visit 7 (Weeks 48-49) | Phase A Visit 8 (Weeks 56-57) | Phase A Visit 9 (Weeks 64-65) | Phase A Visit 10 (Weeks 72-73) | Phase A Visit 11 (Weeks 80-81) | Phase A Visit 12 (Weeks 88-89) | Phase A Visit 13 (Weeks 96-97) | Phase A Visit 14 (Weeks 104-105) | Phase A Visit 15 (Weeks 112-113) | Phase A Visit 16 (Weeks 120-121) | Phase A Visit 17 (Weeks 128-129) | Phase A Visit 18 (Weeks 136-137) | Phase A Visit 19 (Weeks 144-145) | Phase A Visit 20 (Weeks 152-153) | Phase A Visit 21 (Weeks 160-161) | Phase A Visit 22 (Weeks 168-169) | Phase A Visit 23 (Weeks 176-177) | Phase A EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 5 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | Survival Follow-Up 7 (up to 4 years) | |
| Bevacizumab: Phase A | 0.747 | 0.760 | 0.767 | 0.796 | 0.800 | 0.831 | 0.818 | 0.851 | 0.822 | 0.827 | 0.839 | 0.856 | 0.831 | 0.815 | 0.871 | 0.869 | 0.859 | 0.880 | 0.915 | 0.864 | 0.806 | 0.811 | 0.709 | 0.739 | 0.718 | 0.792 | 0.696 | 0.620 | 0.800 | 0.810 | 0.874 |
"EQ-5D is a standardized generic preference based health related quality of life instrument. It records how one's health is today and consists of a descriptive system. The descriptive system is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem[s] and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life." (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, end of treatment (EOT) (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase A Baseline | Phase A Visit 2 (Weeks 8-9) | Phase A Visit 3 (Weeks 16-17) | Phase A Visit 4 (Weeks 24-25) | Phase A Visit 5 (Weeks 32-33) | Phase A Visit 6 (Weeks 40-41) | Phase A Visit 7 (Weeks 48-49) | Phase A Visit 8 (Weeks 56-57) | Phase A Visit 9 (Weeks 64-65) | Phase A Visit 10 (Weeks 72-73) | Phase A Visit 11 (Weeks 80-81) | Phase A Visit 12 (Weeks 88-89) | Phase A Visit 13 (Weeks 96-97) | Phase A Visit 14 (Weeks 104-105) | Phase A Visit 15 (Weeks 112-113) | Phase A Visit 16 (Weeks 120-121) | Phase A Visit 17 (Weeks 128-129) | Phase A Visit 18 (Weeks 136-137) | Phase A Visit 19 (Weeks 144-145) | Phase A Visit 20 (Weeks 152-153) | Phase A Visit 21 (Weeks 160-161) | Phase A Visit 22 (Weeks 168-169) | Phase A Visit 23 (Weeks 176-177) | Phase A EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 5 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | Survival Follow-Up 7 (up to 4 years) | |
| Bevacizumab: Phase A | 0.830 | 0.857 | 0.865 | 0.853 | 0.869 | 0.892 | 0.872 | 0.881 | 0.894 | 0.843 | 0.898 | 0.915 | 0.844 | 0.899 | 0.878 | 0.899 | 0.873 | 0.909 | 0.947 | 0.852 | 0.933 | 0.813 | 0.900 | 0.817 | 0.768 | 0.901 | 0.819 | 0.843 | 1.000 | 0.835 | 0.816 |
"EQ-5D is a standardized generic preference based health related quality of life instrument. It records how one's health is today and consists of a descriptive system. The descriptive system is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem[s] and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life." (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase B Baseline | Phase B Visit 2 (up to 4 years) | Phase B Visit 3 (up to 4 years) | Phase B Visit 4 (up to 4 years) | Phase B Visit 5 (up to 4 years) | Phase B Visit 6 (up to 4 years) | Phase B Visit 7 (up to 4 years) | Phase B Visit 8 (up to 4 years) | Phase B Visit 9 (up to 4 years) | Phase B Visit 10 (up to 4 years) | Phase B Visit 11 (up to 4 years) | Phase B Visit 12 (up to 4 years) | Phase B Visit 13 (up to 4 years) | Phase B Visit 14 (up to 4 years) | Phase B Visit 15 (up to 4 years) | Phase B Visit 16 (up to 4 years) | Phase B Visit 17 (up to 4 years) | Phase B Visit 18 (up to 4 years) | Phase B Visit 19 (up to 4 years) | Phase B Visit 20 (up to 4 years) | Phase B Visit 21 (up to 4 years) | Phase B Visit 22 (up to 4 years) | Phase B Visit 23 (up to 4 years) | Phase B Visit 24 (up to 4 years) | Phase B EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | |
| Bevacizumab: Phase B | 0.814 | 0.859 | 0.894 | 0.897 | 0.866 | 0.837 | 0.876 | 0.874 | 0.908 | 0.811 | 0.806 | 0.844 | 1.000 | 1.000 | 0.844 | 0.833 | 0.844 | 0.833 | 0.827 | 0.816 | 0.844 | 0.844 | 0.827 | 0.844 | 0.809 | 0.740 | 0.772 | 0.827 | 0.827 | 1.000 |
FACT-C is one part of the FACIT Measurement System, which comprehensively assesses the health-related QoL of cancer participants and participants with other chronic illnesses. It is composed of 27 items of the general version of the FACT-C as a general core QoL measure and has a disease-specific subscale containing 9 colorectal cancer-specific items. It consists of total 36 items, summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range from 0 to 28, emotional well-being (6 items) range from 0 to 24, colorectal cancer subscale (9 items) range from 0 to 36; higher subscale score=better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. Total possible score range: 0 to 144. High scale score represents a better QoL. (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase B Baseline | Phase B Visit 2 (up to 4 years) | Phase B Visit 3 (up to 4 years) | Phase B Visit 4 (up to 4 years) | Phase B Visit 5 (up to 4 years) | Phase B Visit 6 (up to 4 years) | Phase B Visit 7 (up to 4 years) | Phase B Visit 8 (up to 4 years) | Phase B Visit 9 (up to 4 years) | Phase B Visit 10 (up to 4 years) | Phase B Visit 11 (up to 4 years) | Phase B Visit 12 (up to 4 years) | Phase B Visit 13 (up to 4 years) | Phase B Visit 14 (up to 4 years) | Phase B Visit 15 (up to 4 years) | Phase B Visit 16 (up to 4 years) | Phase B Visit 17 (up to 4 years) | Phase B Visit 18 (up to 4 years) | Phase B Visit 19 (up to 4 years) | Phase B Visit 20 (up to 4 years) | Phase B Visit 21 (up to 4 years) | Phase B Visit 22 (up to 4 years) | Phase B Visit 23 (up to 4 years) | Phase B Visit 24 (up to 4 years) | Phase B EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | |
| Bevacizumab: Phase B | 103.47 | 108.71 | 108.19 | 114.89 | 110.60 | 111.28 | 114.78 | 120.39 | 108.08 | 110.50 | 109.33 | 125.00 | 119.00 | 117.00 | 126.00 | 123.00 | 127.00 | 126.00 | 127.00 | 126.00 | 123.00 | 124.00 | 126.00 | 130.00 | 101.67 | 98.72 | 102.50 | 126.33 | 125.00 | 124.67 |
FACT-C is one part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, which comprehensively assesses the health-related QoL of cancer participants and participants with other chronic illnesses. It is composed of 27 items of the general version of the FACT-C as a general core QoL measure and has a disease-specific subscale containing 9 colorectal cancer-specific items. It consists of total 36 items, summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range from 0 to 28, emotional well-being (6 items) range from 0 to 24, colorectal cancer subscale (9 items) range from 0 to 36; higher subscale score=better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. Total possible score range: 0 to 144. High scale score represents a better QoL. (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase A Baseline | Phase A Visit 2 (Weeks 8-9) | Phase A Visit 3 (Weeks 16-17) | Phase A Visit 4 (Weeks 24-25) | Phase A Visit 5 (Weeks 32-33) | Phase A Visit 6 (Weeks 40-41) | Phase A Visit 7 (Weeks 48-49) | Phase A Visit 8 (Weeks 56-57) | Phase A Visit 9 (Weeks 64-65) | Phase A Visit 10 (Weeks 72-73) | Phase A Visit 11 (Weeks 80-81) | Phase A Visit 12 (Weeks 88-89) | Phase A Visit 13 (Weeks 96-97) | Phase A Visit 14 (Weeks 104-105) | Phase A Visit 15 (Weeks 112-113) | Phase A Visit 16 (Weeks 120-121) | Phase A Visit 17 (Weeks 128-129) | Phase A Visit 18 (Weeks 136-137) | Phase A Visit 19 (Weeks 144-145) | Phase A Visit 20 (Weeks 152-153) | Phase A Visit 21 (Weeks 160-161) | Phase A Visit 22 (Weeks 168-169) | Phase A Visit 23 (Weeks 176-177) | Phase A EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 5 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | Survival Follow-Up 7 (up to 4 years) | |
| Bevacizumab: Phase A | 103.84 | 103.33 | 106.34 | 109.66 | 109.39 | 111.30 | 111.40 | 113.51 | 113.92 | 115.11 | 114.00 | 115.99 | 113.54 | 112.36 | 119.48 | 116.38 | 113.69 | 112.94 | 117.55 | 115.86 | 106.00 | 112.00 | 105.00 | 103.94 | 102.89 | 104.00 | 105.50 | 109.00 | 119.00 | 103.61 | 115.00 |
Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Bevacizumab: Phase A and Phase B | 3.1 | 8.6 |
Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Bevacizumab: Phase A | 3.1 | 8.6 |
Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: From the start of Phase B treatment to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Bevacizumab: Phase B | 0 | 0 |
Safety was assessed on the basis of reports of adverse events, laboratory-test results, and vital sign measurements. Adverse events were categorized According to the Common Toxicity Criteria of the National Cancer Institute, version 5.0, in which a grade of 1 indicates mild adverse events, a grade of 2 moderate adverse events, a grade of 3 serious adverse events, and a grade of 4 life-threatening adverse events (NCT03288987)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab) | 76 |
| Bevacizumab + FOLFIRI-3 (Roche Bevacizumab) | 44 |
Anti-drug antibody assessment (NCT03288987)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab) | 1 |
| Bevacizumab + FOLFIRI-3 (Roche Bevacizumab) | 1 |
Tumor response was defined as partial and complete responses, according to the RECIST criteria ( version 1.1). The definitions were as follows: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), decrease of at least 30% in the lesion that has the largest diameter; Objective Response Rate (ORR) = CR + PR. (NCT03288987)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab) | 17 |
| Bevacizumab + FOLFIRI-3 (Roche Bevacizumab) | 5 |
Overall survival OS was defined as the time from date of randomization to date of death due to any cause (NCT03288987)
Timeframe: Up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab) | 30 |
| Bevacizumab + FOLFIRI-3 (Roche Bevacizumab) | 17 |
PFS is defined as the time from the date of randomization to the first date of documentation progression (per investigator assessment) or death as a result of any cause. (NCT03288987)
Timeframe: PFS was measured from the start of chemotherapy to the date of disease progression or to the date of death if no progression whichever came first, assessed up to 12 months
| Intervention | Day (Median) |
|---|---|
| Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab) | 232 |
| Bevacizumab + FOLFIRI-3 (Roche Bevacizumab) | 210 |
"Time to treatment failure was defined as the time from the date of randomization to the date of each of the following,~The treatment modalities did not destroy or modify the cancer cells,~The tumor either became larger (disease progression) or stayed the same size after treatment,~Death due to any cause,~Discontinuation of treatment" (NCT03288987)
Timeframe: Up to 12 months
| Intervention | Day (Median) |
|---|---|
| Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab) | 73 |
| Bevacizumab + FOLFIRI-3 (Roche Bevacizumab) | 73 |
DCR was the proportion of patients with confirmed CR, PR or stable disease (SD) as best overall response. SD defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify for PD. (NCT02743221)
Timeframe: Baseline and every 8 weeks (maximum follow-up duration: 17.9 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 66 |
| Capecitabine + Bevacizumab | 59 |
The DR was calculated among patients with CR or PR as the time (months) from the first documentation of response to the first documentation of objective tumor progression or death due to any cause, whichever occurred first. (NCT02743221)
Timeframe: Baseline and every 8 weeks (maximum follow-up duration: 16.6 months)
| Intervention | months (Median) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 7.9 |
| Capecitabine + Bevacizumab | 9.9 |
As per RECIST v1.1, Complete Response (CR) was disappearance of all target lesions; Partial Response (PR) was at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The ORR was the proportion of patients who presented CR or PR with confirmation at subsequent time point or at least 4 weeks later. (NCT02743221)
Timeframe: Baseline and every 8 weeks (maximum follow-up duration: 17.9 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 26 |
| Capecitabine + Bevacizumab | 23 |
The OS was defined as the time from the date of randomisation to the date of death. If death was not confirmed, or patient was alive at study cut-off date, survival time was censored at the date of last follow-up or at the study cut-off date, whichever was earlier. (NCT02743221)
Timeframe: Baseline up to death or study cut-off (maximum follow-up duration: 19.9 months)
| Intervention | months (Median) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 18.0 |
| Capecitabine + Bevacizumab | 16.2 |
The progression free survival (PFS), defined as the time from the date of randomisation until the date of the investigator-assessed radiological disease progression or death due to any cause according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive disease (PD) was defined at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) and an absolute increase of at least 5 mm in the sum of lesions or the appearance of new lesions. (NCT02743221)
Timeframe: Baseline and every 8 weeks (maximum follow-up duration: 17.9 months)
| Intervention | months (Median) |
|---|---|
| Trifluridine/Tipiracil + Bevacizumab | 9.2 |
| Capecitabine + Bevacizumab | 7.8 |
"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Overall survival (OS)~Overall survial is defined as length of time from start of treatment that patients are still alive. For this time-to-event variables the Kaplan-Meier method was intended to be used" (NCT02384850)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Selinexor 40 mg+ mFOLFOX6 | 0 |
| Selinexor 20mg + mFOLFOX6 | 2 |
"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Overall response rate (RR) (acc. to RECIST v1.1)~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed byCT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT02384850)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Selinexor 40 mg+ mFOLFOX6 | 0 |
| Selinexor 20mg + mFOLFOX6 | 1 |
"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Progression free survival (PFS) The disease status was measured by CT/MRI and evaluated according to RECIST 1.1 criteria every 8 weeks during treatment, at End of Treatment and every 3 weeks during Follow-up to determine time until patient has Progressive Disease (PD). PD is defined according to RECIST v1.1 at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression." (NCT02384850)
Timeframe: 2 years
| Intervention | months (Mean) |
|---|---|
| Selinexor 40 mg+ mFOLFOX6 | NA |
| Selinexor 20mg + mFOLFOX6 | NA |
"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Toxicity (acc. to NCI Common Terminology Criteria for Adverse Events (CTC AE) v4.03)" (NCT02384850)
Timeframe: treatment start to up to 30 days after last dose
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patients with AEs of any CTCAE Grade | Patients with AEs of at least CTCAE Grade 3 | Patients with Selinexor related AEs of any Grade | Patients with Selinexor related AEs of at least Grade 3 | Patients with chemotherapy related AEs of any Grade | Patients with chemotherapy related AEs of at least Grade 3 | Patients with AEs leading to discontinuation | Patients with at least 1 SAE | Patients with at least 1 SAE related to Selinexor | Patients with at least 1 SAE related to chemotherapy | |
| Selinexor 20mg + mFOLFOX6 | 6 | 6 | 4 | 5 | 6 | 3 | 2 | 3 | 1 | 3 |
| Selinexor 40 mg+ mFOLFOX6 | 4 | 4 | 4 | 4 | 4 | 4 | 2 | 2 | 1 | 1 |
"Primary objective is the determination of the maximum tolerated dose (MTD) of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer.~Criteria to assess MTD was the experience of AEs > grade 3, discontinuation from study treatment due to adverse events or withdrawal of consent by the patients." (NCT02384850)
Timeframe: 28 days of treatment
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Discontinuation due to Adverse events | Discontinuation due to Withdrawal of Consent | Discontinuation due to Progressive Disease | |
| Selinexor 20mg + mFOLFOX6 | 2 | 2 | 2 |
| Selinexor 40 mg+ mFOLFOX6 | 2 | 2 | 0 |
Overall survival is defined as the time from the date of the patient's inclusion to the patient's death (all causes). For alive patients the date of the latest news is taken into account (NCT02181556)
Timeframe: Up to 2 years after the end of the treatment
| Intervention | Months (Median) |
|---|---|
| FOLFIRI + Aflibercept | 18.63 |
"The progression-free survival is the time from inclusion to the first radiological progression or death (all causes). For patients alive without progression date of last news will be considered.~Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions compared the little sum of diameters observed durin the study (NADIR), or a measurable increase in a non-target lesion, or the appearance of new lesions" (NCT02181556)
Timeframe: up to 12 months
| Intervention | Months (Median) |
|---|---|
| FOLFIRI + Aflibercept | 8.16 |
"Progression was evaluated by CT scan, according to RECIST criteria (version 1.1) definition by the investigator. Death was also considered as an event (all causes).~Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions compared the little sum of diameters observed during the study (NADIR), or a measurable increase in a non-target lesion, or the appearance of new lesions" (NCT02181556)
Timeframe: 6 months
| Intervention | Nb of patients alive without progression (Number) |
|---|---|
| FOLFIRI + Aflibercept | 22 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who discontinued study treatment due to an AE was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab | 21 |
| Standard of Care (SOC) | 20 |
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who experienced at least one AE was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab | 149 |
| Standard of Care (SOC) | 142 |
ORR was defined as the percentage of the participants who experienced a Complete Response (CR; disappearance of all target lesions) or a Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions) and was assessed using RECIST 1.1 as assessed by the central imaging vendor. The percentage of participants who experienced a CR or PR was presented for the first course of study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pembrolizumab | 45.1 |
| Standard of Care (SOC) | 33.1 |
OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of analysis were censored at the date of last known contact. HR and associated 95% CIs from a Cox proportional hazard model with Efron's method of tie handling and with a single treatment covariate was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab | NA |
| Standard of Care (SOC) | 36.7 |
PFS was defined as the time from randomization to the first documented disease progression (PD) per RECIST 1.1 based on blinded central imaging vendor review or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Hazards ratio (HR) and associated 95% confidence intervals (CIs) from a Cox proportional hazard model with Efron's method of tie handling and with a single treatment covariate was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab | 16.5 |
| Standard of Care (SOC) | 8.2 |
Survival time will be defined as the time from registration to death. Time to event distributions will be estimated using the Kaplan-Meier method. Overall Survival (OS) will be compared between Arm A and Arm B. (NCT00265850)
Timeframe: Up to 5 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFOX or FOLFIRI + Bevacizumab | 29.0 |
| Arm B: FOLFOX or FOLFIRI + Cetuximab | 30.0 |
PFS will be measured from study entry until first documented progression or death from any cause. Time to event distributions will be estimated using the Kaplan-Meier method. PFS will be compared between Arm A and Arm B. (NCT00265850)
Timeframe: Up to 5 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFOX or FOLFIRI + Bevacizumab | 10.6 |
| Arm B: FOLFOX or FOLFIRI + Cetuximab | 10.5 |
"The overall ORR was the percentage of evaluable participants who achieved complete response [CR] or partial response [PR] according to RECIST criteria version 1.0.~CR reflected the disappearance of all tumor lesions (with no new tumors)~PR reflected a pre-defined reduction in tumor burden~Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/FOLFIRI | 11.1 |
| Aflibercept/FOLFIRI | 19.8 |
"Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011).~OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)
| Intervention | months (Median) |
|---|---|
| Placebo/FOLFIRI | 12.06 |
| Aflibercept/FOLFIRI | 13.50 |
"PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC.~PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.~The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred." (NCT00561470)
Timeframe: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)
| Intervention | months (Median) |
|---|---|
| Placebo/FOLFIRI | 4.67 |
| Aflibercept/FOLFIRI | 6.90 |
Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay. (NCT00561470)
Timeframe: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo
| Intervention | participants (Number) | |
|---|---|---|
| At least one positive sample in the ADA assay | At least one positive sample in the NAb assay | |
| Aflibercept/FOLFIRI | 8 | 1 |
| Placebo/FOLFIRI | 18 | 2 |
"All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization.~The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported." (NCT00561470)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Treatment-Emergent Adverse Event (TEAE) | Serious TEAE | TEAE leading to Death | TEAE causing permanent treatment discontinuation | |
| Aflibercept/FOLFIRI | 606 | 294 | 37 | 164 |
| Placebo/FOLFIRI | 592 | 198 | 29 | 73 |
"A secondary endpoint for this study was to investigate the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Mutant KRAS Arm A | 67.1 |
| Mutant KRAS Arm D | 65.0 |
"The primary endpoint for this study was to compare the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS Arm A | 74.6 |
| Wild-type KRAS Arm D | 71.5 |
Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event-free rates (percentage) are report below for mutant KRAS patients. (NCT00079274)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Mutant KRAS Arm A | 87.9 |
| Mutant KRAS Arm D | 82.7 |
Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event free rates (percentage) are reported below for Wild-type KRAS Patients. (NCT00079274)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS Arm A | 87.3 |
| Wild-type KRAS Arm D | 85.6 |
The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years
| Intervention | percentage of patients (Number) |
|---|---|
| Mutant KRAS Arm A | 55.6 |
| Mutant KRAS Arm D | 72.3 |
The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years
| Intervention | percentage of patients (Number) |
|---|---|
| Wild-type KRAS Arm A | 51.1 |
| Wild-type KRAS Arm D | 73.3 |
Changes in CEA level from baseline to week 28 during treatment. (NCT01622543)
Timeframe: Baseline and at 28 weeks
| Intervention | ng/mL (Mean) |
|---|---|
| Folfox Plus Bevacizumab and Reolysin | -14209.4 |
| Folfox Plus Bevacizumab | -1107.99 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response Rate =Proportion of (CR + PR) observed over all randomized patients. (NCT01622543)
Timeframe: 19 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Folfox Plus Bevacizumab and Reolysin | 27 |
| Folfox Plus Bevacizumab | 18 |
Time from randomization to death from any cause or censored at the time of last known alive (NCT01622543)
Timeframe: From date of randomization to death from any cause or censored at the time of last known alive, assessed up to 49 months
| Intervention | Months (Median) |
|---|---|
| Folfox Plus Bevacizumab and Reolysin | 19.3 |
| Folfox Plus Bevacizumab | 20.0 |
Time from the day of randomization until the first observation of objective disease relapse or progression, or the appearance of new lesions or death due to any cause. If a patient had not relapsed/progressed or died, PFS was censored on the date of last disease assessment defined as the earliest test date of target lesion or non-target lesions (if patient had no target lesions). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01622543)
Timeframe: 19 months
| Intervention | Months (Median) |
|---|---|
| Folfox Plus Bevacizumab and Reolysin | 7.33 |
| Folfox Plus Bevacizumab | 9.13 |
OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the earliest between the last date of the participants was known to be alive and the study cut-off date. Analysis was performed by Kaplan-Meier method. (NCT01661270)
Timeframe: 31.6 months
| Intervention | months (Median) |
|---|---|
| Placebo | 11.93 |
| Aflibercept | 14.59 |
Objective response rate was defined as the proportion of participants with confirmed complete response (CR) or confirmed partial response (PR), as assessed by Investigators and the IRC according to RECIST 1.0 criteria, relative to the total number of participants in the relevant analysis population. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions. (NCT01661270)
Timeframe: 26.6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 3.7 |
| Aflibercept | 18.4 |
PFS was defined as the time interval from the date of randomization to the date of first observation of either tumor progression or death due to any cause. Tumor assessment was performed by Independent Review Committee (IRC) as per response evaluation criteria in solid tumors (RECIST) version 1.0. Progression was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study or absolute increase and at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was calculated by Kaplan-Meier estimates. (NCT01661270)
Timeframe: 26.7 months
| Intervention | months (Median) |
|---|---|
| Placebo | 5.59 |
| Aflibercept | 6.93 |
"To compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI, by means of comparing the truncated AUC calculated from start of the first infusion until start of the second infusion (i.e. at Cycle 1; AUC0-336h)~For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80-125%." (NCT02069704)
Timeframe: AUC0-336 hrs: 0 to 336 hours after start of the first infusion
| Intervention | ng.h/mL (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 16500000 |
| Avastin® (Bevacizumab, Ref. Product). | 16600000 |
"To compare the PK profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI, by means of comparing the truncated area under the concentration-versus-time curve calculated over a dosage interval at steady state (i.e. at Cycle 7; AUCss).~For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80-125%." (NCT02069704)
Timeframe: AUCss: 0 to 336 hours after the administration of Cycle 7 infusion (Week 13).
| Intervention | ng.h/mL (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 35900000 |
| Avastin® (Bevacizumab, Ref. Product). | 35700000 |
Secondary PK endpoints included the Cmax calculated at Cycle 1 (Cmax,sd ) (NCT02069704)
Timeframe: Cmax, sd: 0 to 336 hours after start of the first infusion.
| Intervention | ng/mL (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 120000 |
| Avastin® (Bevacizumab, Ref. Product). | 123000 |
Secondary PK endpoints included the Cmax calculated at Cycle 7 (Cmax, ss ) (NCT02069704)
Timeframe: Cmax, ss: 0 to 336 hours post-dose after the administration of Cycle 7 infusion (Week 13)
| Intervention | ng/mL (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 195000 |
| Avastin® (Bevacizumab, Ref. Product). | 200000 |
Secondary PK endpoints included the Ctrough calculated at Cycle 1 (Ctrough,sd ) (NCT02069704)
Timeframe: Ctrough, sd: 0 to 336 hours after start of the first infusion.
| Intervention | ng/mL (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 344 |
| Avastin® (Bevacizumab, Ref. Product). | 349 |
Secondary PK endpoints included the Ctrough calculated at Cycle 7 (Ctrough,ss) (NCT02069704)
Timeframe: Ctrough, ss: 0 to 336 hours after the administration of the Cycle 7 infusion.
| Intervention | ng/mL (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 69600 |
| Avastin® (Bevacizumab, Ref. Product). | 69300 |
Secondary PK endpoints included the t1/2 calculated at Cycle 7 (NCT02069704)
Timeframe: t1/2: 0 to 336 hours after the administration of the Cycle 7 infusion.
| Intervention | h (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 294 |
| Avastin® (Bevacizumab, Ref. Product). | 289 |
Secondary PK endpoints included the Kel calculated at Cycle 7 (Ctrough,ss) (NCT02069704)
Timeframe: Kel: 0 to 336 hours after the administration of the Cycle 7 infusion.
| Intervention | l/h (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 0.00236 |
| Avastin® (Bevacizumab, Ref. Product). | 0.00240 |
"Compare PFS between the randomized treatment arms. Progression-free survival (PFS) was defined as the time from the randomization date to the date of disease progression using RECIST v1.1, or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions plus 5 mm absolute increase, and/or unequivocal progression of known non-target lesion, and/or the appearance of new lesions." (NCT02069704)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 weeks.
| Intervention | months (Median) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 10.8 |
| Avastin® (Bevacizumab, Ref. Product) | 11.1 |
Secondary PK endpoints included the Vd calculated at Cycle 7 (NCT02069704)
Timeframe: Vd: 0 to 336 hours after the administration of the Cycle 7 infusion.
| Intervention | L (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 4.06 |
| Avastin® (Bevacizumab, Ref. Product). | 3.86 |
Immunogenicity profile by means of measurement of ADA developed de novo (seroconversion) after cycle 5, cycle 8, and 12 months after first drug administration (pre-dose). (NCT02069704)
Timeframe: At baseline, and on Day 1 (pre-dose) of Cycles: 1, 5 and 8, and 12 months after first drug administration
| Intervention | participants (Number) | |
|---|---|---|
| Seroconversion | No seroconversion | |
| Avastin® (Bevacizumab, Ref. Product) | 0 | 71 |
| Bevacizumab Biosimilar (BEVZ92) | 2 | 67 |
"To compare efficacy in terms of ORR between arms. Clinical and radiological tumor assessments were performed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 using computed tomography (CT) or magnetic resonance imaging (MRI) scans.~Objective response (OR) is defined as a best overall response of partial response (PR) or complete response (CR) as defined by RECIST v1.1. All participants who did not meet the criteria for CR or PR by the end of the study were considered non-responders." (NCT02069704)
Timeframe: Every four weeks. Up to 48 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| ORR (CR+PR) | Stable disease | Progressive disease | unevaluable | |
| Avastin® (Bevacizumab, Ref. Product) | 40 | 25 | 2 | 4 |
| Bevacizumab Biosimilar (BEVZ92) | 35 | 27 | 4 | 5 |
Compare the safety profile by means of the frequency and severity of TEAEs and SAEs reported in each treatment arm. (NCT02069704)
Timeframe: From first study dose and up to 30 days after the end of study treatment for each patient, for an average of 11 months
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Any TEAE (any causality) | Any grade>=3 TEAE | Any TEAE leading to discontinuation | Any treatment-related TEAE | Any grade >=3 treatment-related TEAE | Any serious TEAE | Any bleeding event | |
| Avastin® (Bevacizumab, Ref. Product) | 71 | 49 | 6 | 70 | 70 | 21 | 19 |
| Bevacizumab Biosimilar (BEVZ92) | 66 | 44 | 13 | 63 | 63 | 19 | 14 |
Number of patients who experienced a Dose Limiting Toxicity (DLT). DLT will be assessed in the first 28 days of dosing. Patients need to get dosed with 2 rounds/sessions of all chemotherapy agents in the first 28 days in order to be evaluable for DLT assessment. The primary endpoint is safety as summarized by dose limiting toxicity (DLT). (NCT01047293)
Timeframe: December 2011
| Intervention | participants (Number) |
|---|---|
| ARM 1 RAD001 5 mg QOD | 0 |
| ARM 2 5mg RAD001 QD | 1 |
| ARM 3 10mg RAD001 QD | 1 |
(NCT01047293)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| All Patients | 87 |
OS was defined as the time from the date of randomization to the date of death from any cause. (NCT01765582)
Timeframe: Randomization until death due to any cause (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 33.97 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 28.32 |
| Arm C: FOLFOX + Bevacizumab | 30.65 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 28.32 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT01765582)
Timeframe: Randomization up to approximately 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 100 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 98.9 |
| Arm C: FOLFOX + Bevacizumab | 100 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 99.4 |
ORR1 was the percentage of participants with complete response (CR) or partial response (PR) during first-line therapy as assessed by investigator according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1). CR was defined as disappearance of all extranodal target lesions and all pathological lymph nodes had to have decreased to <10 millimeter (mm) in short axis. PR was defined as at least a 30% decrease in the sum of longest diameters of target lesions, taking as reference the baseline sum diameters. ORR1 = CR + PR (NCT01765582)
Timeframe: Randomization up to disease progression during first-line therapy or death, whichever occurs first (up to approximately 3 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 72.0 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 72.8 |
| Arm C: FOLFOX + Bevacizumab | 62.1 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 72.4 |
PFS1 was defined as time from randomization to the first occurrence of disease progression during first-line therapy, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first. Disease progression was defined as sum of longest diameters increased by at least 20% from the smallest value on study. The sum of longest diameters must also demonstrate an absolute increase of at least 5 mm. (NCT01765582)
Timeframe: Randomization up to disease progression during first-line therapy or death, whichever occurs first (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 11.86 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 11.37 |
| Arm C: FOLFOX + Bevacizumab | 9.46 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 11.70 |
The proportion of participants considered by the investigator to be unresectable at study enrollment who subsequently underwent attempted curative resections of metastases was calculated as follows: number of participants considered by the investigator to be unresectable at study enrollment who subsequently underwent attempted curative resections of metastases divided by total number of participants in each arm. This outcome represents a measure of the rate of conversion from unresectable to resectable disease. (NCT01765582)
Timeframe: Randomization up to approximately 3 years
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 0.24 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 0.17 |
| Arm C: FOLFOX + Bevacizumab | 0.14 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 0.21 |
Reported here is the proportion of participants who underwent liver metastases resections calculated as follows: number of participants who underwent liver metastases resections divided by total number of participants in each arm. (NCT01765582)
Timeframe: Randomization up to approximately 3 years
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 0.17 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 0.10 |
| Arm C: FOLFOX + Bevacizumab | 0.08 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 0.14 |
Time to PFS2 was defined as time from randomization to the first occurrence of disease progression after reinduction of second-line therapy, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first. Disease progression was defined as sum of longest diameters increased by at least 20% from the smallest value on study. The sum of longest diameters must also demonstrate an absolute increase of at least 5mm. (NCT01765582)
Timeframe: Randomization up to disease progression during second-line therapy or death, whichever occurs first (up to approximately 3 years)
| Intervention | months (Median) |
|---|---|
| Arm A: Concurrent FOLFOXIRI + Bevacizumab | 18.76 |
| Arm B: Sequential FOLFOXIRI + Bevacizumab | 13.17 |
| Arm C: FOLFOX + Bevacizumab | 14.75 |
| Arms A + B: Pooled FOLFOXIRI + Bevacizumab | 15.08 |
Best overall response of complete or partial response within irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 49 |
| Irinotecan and Bevacizumab Without Panitumumab | 46 |
Best overall response of complete or partial response in participants treated with irinotecan and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 14 |
| Irinotecan and Bevacizumab Without Panitumumab | 15 |
Best overall response of complete or partial response within oxaliplatin stratum (NCT00115765)
Timeframe: Overall study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 190 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 196 |
Best overall response of complete or partial response in participants treated with irinotecan and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 31 |
| Irinotecan and Bevacizumab Without Panitumumab | 28 |
Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 29 |
| Irinotecan and Bevacizumab Without Panitumumab | 27 |
Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm. (NCT00115765)
Timeframe: Overall study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 26 |
| Irinotecan and Bevacizumab Without Panitumumab | 18 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median. (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 47 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 45 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 19.4 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 24.5 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 71 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 46 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 10.1 |
| Irinotecan and Bevacizumab Without Panitumumab | 11.7 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.4 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.0 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.0 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 9.8 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.5 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 11.1 |
| Irinotecan and Bevacizumab Without Panitumumab | 11.9 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.8 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 6.6 |
| Irinotecan and Bevacizumab Without Panitumumab | 6.0 |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum. (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 5.7 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 5.9 |
Duration of Response is calculated as the time from the first recording of CR/PR until the patient progresses, regardless of whether the patient was still taking study medication. Only confirmed responses are included in the calculation. For patients who had not progressed, the end date used in the calculation of duration of response is the data cut-off date of 15th November 2009. (NCT00384176)
Timeframe: Up until data cut-off date of 15/11/2007
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 8.6 |
| Bevacizumab 5 mg/kg | 9.6 |
"Objective response rate is Complete Response (CR) + Partial Response (PR) as defined below:~CR = Disappearance of all target lesions. PR = At least a 30% decrease in the sum of longest diameters (LDs) of target lesions, taking as reference the baseline sum of LDs." (NCT00384176)
Timeframe: Up until data cut-off
| Intervention | Participants (Number) |
|---|---|
| Cediranib 20 mg | 328 |
| Bevacizumab 5 mg/kg | 337 |
Number of months from randomisation to the date of death from any cause (NCT00384176)
Timeframe: Randomisation until data cut-off
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 22.8 |
| Bevacizumab 5 mg/kg | 21.3 |
Percentage change in tumour size from baseline to first RECIST assessment (Week 8) ((Week 8 - baseline)/baseline)*100 (NCT00384176)
Timeframe: Baseline to Week 8
| Intervention | Percentage change in tumour size (Mean) |
|---|---|
| Cediranib 20 mg | -23.2 |
| Bevacizumab 5 mg/kg | -22.1 |
Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression. (NCT00384176)
Timeframe: Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 9.9 |
| Bevacizumab 5 mg/kg | 10.3 |
Time to worsening of symptoms, as measured by the FACT colorectal symptom index (FCSI), will be defined as the time when a sustained clinically important deterioration in the total score from the FCSI has been recorded. (NCT00384176)
Timeframe: Baseline through to data cut-off
| Intervention | Days (Median) |
|---|---|
| Cediranib 20 mg | 170 |
| Bevacizumab 5 mg/kg | 245 |
DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Doublet Arm | 6.06 |
| Phase 3:Control Arm | NA |
DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Doublet Arm | 5.70 |
| Phase 3:Control Arm | 5.75 |
DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 4.80 |
| Phase 3:Control Arm | NA |
DOR was defined as the time from first radiographic evidence of response to the earliest documented disease progression (PD) or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 4.80 |
| Phase 3:Control Arm | 5.75 |
DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 4.80 |
| Phase 3:Doublet Arm | 6.06 |
DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 4.80 |
| Phase 3:Doublet Arm | 5.70 |
ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 3: Doublet Arm | 20.4 |
| Phase 3:Control Arm | 1.9 |
ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 3: Doublet Arm | 15.9 |
| Phase 3:Control Arm | 3.7 |
ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 3: Triplet Arm | 26.1 |
| Phase 3:Control Arm | 3.7 |
ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 3: Triplet Arm | 26.1 |
| Phase 3: Doublet Arm | 20.4 |
ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 3: Triplet Arm | 26.1 |
| Phase 3: Doublet Arm | 15.9 |
PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Doublet Arm | 4.21 |
| Phase 3:Control Arm | 1.51 |
PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Doublet Arm | 4.27 |
| Phase 3:Control Arm | 1.58 |
PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 4.30 |
| Phase 3:Control Arm | 1.51 |
PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 4.47 |
| Phase 3:Control Arm | 1.58 |
PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 4.30 |
| Phase 3: Doublet Arm | 4.21 |
PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 4.47 |
| Phase 3: Doublet Arm | 4.27 |
Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Doublet Arm | 1.48 |
| Phase 3:Control Arm | 1.45 |
Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Doublet Arm | 1.48 |
| Phase 3:Control Arm | 2.63 |
Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 1.43 |
| Phase 3:Control Arm | 1.45 |
Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 1.48 |
| Phase 3:Control Arm | 2.63 |
Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 1.43 |
| Phase 3:Doublet Arm | 1.48 |
Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 1.48 |
| Phase 3:Doublet Arm | 1.48 |
The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register. (NCT02928224)
Timeframe: 2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days)
| Intervention | Liter/hour (Geometric Mean) |
|---|---|
| Pharmacokinetic Population of Encorafenib | 0.0154 |
The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register. (NCT02928224)
Timeframe: 2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days)
| Intervention | Liter/hour (Geometric Mean) |
|---|---|
| Pharmacokinetic Population of Encorafenib | 19.0 |
The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register. (NCT02928224)
Timeframe: 2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days)
| Intervention | Liter/hour (Geometric Mean) |
|---|---|
| Pharmacokinetic Population of Encorafenib | 16.4 |
ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of complete response (CR) or partial response (PR), where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 millimeter [mm] short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 3: Triplet Arm | 26.1 |
| Phase 3:Control Arm | 1.9 |
OS was defined as the time from randomization to death due to any cause. (NCT02928224)
Timeframe: From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.7 weeks for doublet arm and 52.4 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Doublet Arm | 9.40 |
| Phase 3:Control Arm | 5.88 |
OS was defined as the time from randomization to death due to any cause. (NCT02928224)
Timeframe: From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.7 weeks for doublet arm and 89.1 weeks for triplet arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 9.82 |
| Phase 3: Doublet Arm | 9.40 |
OS was defined as the time from randomization to death due to any cause. (NCT02928224)
Timeframe: From randomization to death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 9.82 |
| Phase 3:Control Arm | 5.88 |
OS was defined as the time from randomization to death due to any cause. (NCT02928224)
Timeframe: From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.1 weeks for triplet arm and 52.4 weeks for control arm)
| Intervention | Months (Median) |
|---|---|
| Phase 3: Triplet Arm | 9.03 |
| Phase 3: Control Arm | 5.42 |
DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to the earliest documented PD or death due to underlying disease (maximum treatment exposure of 280 weeks)
| Intervention | Months (Median) |
|---|---|
| Combined Safety Lead-in | 8.15 |
DOR was defined as the time from first radiographic evidence of response to the earliest documented disease progression (PD) or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to the earliest documented PD or death due to underlying disease (maximum treatment exposure of 280 weeks)
| Intervention | Months (Median) |
|---|---|
| Combined Safety Lead-in | 6.47 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Nanogram/milliliter (Geometric Mean) |
|---|---|
| Combined Safety Lead-in | 3.41 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Nanogram/milliliter (Geometric Mean) |
|---|---|
| Combined Safety Lead-in | 55.3 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Nanogram/milliliter (Geometric Mean) |
|---|---|
| Combined Safety Lead-in | 55400 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Nanogram/milliliter (Geometric Mean) |
|---|---|
| Combined Safety Lead-in | 18.9 |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants with dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure. (NCT02928224)
Timeframe: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Safety Lead-in | 26 |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants reporting AEs were reported in this outcome measure. (NCT02928224)
Timeframe: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Safety Lead-in | 37 |
(NCT02928224)
Timeframe: Cycle 1 (up to 28 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Safety Lead-in (CSLI) | 5 |
ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Combined Safety Lead-in | 41.7 |
ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Combined Safety Lead-in | 52.8 |
PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 280 weeks)
| Intervention | Months (Median) |
|---|---|
| Combined Safety Lead-in | 5.59 |
PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 280 weeks)
| Intervention | Months (Median) |
|---|---|
| Combined Safety Lead-in | 8.08 |
Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 280 weeks)
| Intervention | Months (Median) |
|---|---|
| Combined Safety Lead-in | 1.45 |
Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 280 weeks)
| Intervention | Months (Median) |
|---|---|
| Combined Safety Lead-in | 1.45 |
Clinically notable shifts was defined as worsening by at least 2 grades or to >= Grade 3 based on CTCAE version 4.03 where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening and Grade 5: death. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 3: Triplet Arm | 8 |
| Phase 3: Doublet Arm | 8 |
| Phase 3: Control Arm | 5 |
The EORTC QLQ-C30 questionnaire consisted of 30 questions generating 5 functional scores (physical, role, cognitive, emotional, & social); a global health (GH) status/global quality of life scale score; 3 symptom scale scores (fatigue, pain, & nausea & vomiting); & 6 standalone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, & diarrhea) & perceived financial burden. All items were graded by severity experienced during previous week & used 4-point-scale (1: not at all, 2: a little, 3: quite a bit, 4: very much). The scores were converted to health-related quality of life (HRQoL) scale ranging from 0-100. Higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity). (NCT02928224)
Timeframe: Baseline, Cycle(C)1 Day(D)1 , C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)
| Intervention | Units on a scale (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 1 Day 1 | Change at Cycle 2 Day 1 | Change at Cycle 3 Day 1 | Change at Cycle 4 Day 1 | Change at Cycle 5 Day 1 | Change at Cycle 6 Day 1 | Change at Cycle 7 Day 1 | Change at Cycle 8 Day 1 | Change at Cycle 9 Day 1 | Change at Cycle 10 Day 1 | Change at Cycle 11 Day 1 | Change at Cycle 12 Day 1 | Change at Cycle 13 Day 1 | Change at End of Treatment | Change at 30 Day Follow Up | |
| Phase 3:Control Arm | 62.8 | -3.4 | -1.9 | -0.2 | 1.4 | -2.2 | -4.5 | 1.7 | 0.0 | -4.8 | 2.1 | 33.3 | 4.2 | 0.0 | -15.5 | -24.6 |
The EORTC QLQ-C30 questionnaire consisted of 30 questions generating 5 functional scores (physical, role, cognitive, emotional, & social); a global health (GH) status/global quality of life scale score; 3 symptom scale scores (fatigue, pain, & nausea & vomiting); & 6 standalone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, & diarrhea) & perceived financial burden. All items were graded by severity experienced during previous week & used 4-point-scale (1: not at all, 2: a little, 3: quite a bit, 4: very much). The scores were converted to health-related quality of life (HRQoL) scale ranging from 0-100. Higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity). (NCT02928224)
Timeframe: Baseline, Cycle(C)1 Day(D)1 , C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)
| Intervention | Units on a scale (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 1 Day 1 | Change at Cycle 2 Day 1 | Change at Cycle 3 Day 1 | Change at Cycle 4 Day 1 | Change at Cycle 5 Day 1 | Change at Cycle 6 Day 1 | Change at Cycle 7 Day 1 | Change at Cycle 8 Day 1 | Change at Cycle 9 Day 1 | Change at Cycle 10 Day 1 | Change at Cycle 11 Day 1 | Change at Cycle 12 Day 1 | Change at Cycle 13 Day 1 | Change at Cycle 14 Day 1 | Change at Cycle 15 Day 1 | Change at Cycle 16 Day 1 | Change at Cycle 17 Day 1 | Change at Cycle 18 Day 1 | Change at Cycle 19 Day 1 | Change at Cycle 20 Day 1 | Change at Cycle 21 Day 1 | Change at End of Treatment | Change at 30 Day Follow Up | |
| Phase 3: Triplet Arm | 62.8 | -2.4 | -1.6 | 0.7 | 0.2 | -1.1 | -4.0 | -2.5 | -2.6 | -5.8 | -3.3 | -5.2 | 0.0 | 0.0 | -1.2 | 3.6 | -16.7 | -27.8 | -16.7 | 0.0 | -25 | 0.0 | -14.1 | -17.4 |
The EORTC QLQ-C30 questionnaire consisted of 30 questions generating 5 functional scores (physical, role, cognitive, emotional, & social); a global health (GH) status/global quality of life scale score; 3 symptom scale scores (fatigue, pain, & nausea & vomiting); & 6 standalone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, & diarrhea) & perceived financial burden. All items were graded by severity experienced during previous week & used 4-point-scale (1: not at all, 2: a little, 3: quite a bit, 4: very much). The scores were converted to health-related quality of life (HRQoL) scale ranging from 0-100. Higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity). (NCT02928224)
Timeframe: Baseline, Cycle(C)1 Day(D)1 , C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)
| Intervention | Units on a scale (Mean) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 1 Day 1 | Change at Cycle 2 Day 1 | Change at Cycle 3 Day 1 | Change at Cycle 4 Day 1 | Change at Cycle 5 Day 1 | Change at Cycle 6 Day 1 | Change at Cycle 7 Day 1 | Change at Cycle 8 Day 1 | Change at Cycle 9 Day 1 | Change at Cycle 10 Day 1 | Change at Cycle 11 Day 1 | Change at Cycle 12 Day 1 | Change at Cycle 13 Day 1 | Change at Cycle 14 Day 1 | Change at Cycle 15 Day 1 | Change at Cycle 16 Day 1 | Change at Cycle 17 Day 1 | Change at Cycle 18 Day 1 | Change at Cycle 19 Day 1 | Change at Cycle 20 Day 1 | Change at Cycle 21 Day 1 | Change at Cycle 22 Day 1 | Change at Cycle 23 Day 1 | Change at End of Treatment | Change at 30 Day Follow Up | |
| Phase 3:Doublet Arm | 60.7 | -4.3 | 3.8 | 3.5 | 4.2 | 4.3 | 5.6 | 4.3 | 4.2 | -5.6 | -2.8 | 3.9 | -4.6 | -3.2 | -6.0 | 2.8 | -5.6 | -2.8 | -8.3 | -8.3 | -8 | -16.7 | -16.7 | 0.0 | -13.1 | -10.4 |
The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the participant and ranges from 0 to 100 (higher is better quality health). (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)
| Intervention | Units on a scale (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 1 Day 1 | Change at Cycle 2 Day 1 | Change at Cycle 3 Day 1 | Change at Cycle 4 Day 1 | Change at Cycle 5 Day 1 | Change at Cycle 6 Day 1 | Change at Cycle 7 Day 1 | Change at Cycle 8 Day 1 | Change at Cycle 9 Day 1 | Change at Cycle 10 Day 1 | Change at Cycle 11 Day 1 | Change at Cycle 12 Day 1 | Change at Cycle 13 Day 1 | Change at End of Treatment | Change at 30 Day Follow Up | |
| Phase 3:Control Arm | 68.3 | -2.1 | -2.4 | -1.4 | -0.4 | 2.5 | -3.6 | 2.4 | -2.8 | -8.1 | -1.8 | 4.0 | 1.5 | -2.0 | -12.7 | -11.0 |
The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the participant and ranges from 0 to 100 (higher is better quality health). (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)
| Intervention | Units on a scale (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 1 Day 1 | Change at Cycle 2 Day 1 | Change at Cycle 3 Day 1 | Change at Cycle 4 Day 1 | Change at Cycle 5 Day 1 | Change at Cycle 6 Day 1 | Change at Cycle 7 Day 1 | Change at Cycle 8 Day 1 | Change at Cycle 9 Day 1 | Change at Cycle 10 Day 1 | Change at Cycle 11 Day 1 | Change at Cycle 12 Day 1 | Change at Cycle 13 Day 1 | Change at Cycle 14 Day 1 | Change at Cycle 15 Day 1 | Change at Cycle 16 Day 1 | Change at Cycle 17 Day 1 | Change at Cycle 18 Day 1 | Change at Cycle 19 Day 1 | Change at Cycle 20 Day 1 | Change at Cycle 21 Day 1 | Change at End of Treatment | Change at 30 Day Follow Up | |
| Phase 3: Triplet Arm | 69.0 | 0.8 | 1.4 | 3.0 | 4.0 | 3.3 | 1.3 | 1.4 | 4.1 | 0.3 | 0.2 | 0.2 | -4.0 | -3.0 | -4.0 | -3.4 | -10.4 | -18.3 | 7.0 | 8.0 | 8.0 | 8.0 | -8.5 | -11.1 |
The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the participant and ranges from 0 to 100 (higher is better quality health). (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)
| Intervention | Units on a scale (Mean) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 1 Day 1 | Change at Cycle 2 Day 1 | Change at Cycle 3 Day 1 | Change at Cycle 4 Day 1 | Change at Cycle 5 Day 1 | Change at Cycle 6 Day 1 | Change at Cycle 7 Day 1 | Change at Cycle 8 Day 1 | Change at Cycle 9 Day 1 | Change at Cycle 10 Day 1 | Change at Cycle 11 Day 1 | Change at Cycle 12 Day 1 | Change at Cycle 13 Day 1 | Change at Cycle 14 Day 1 | Change at Cycle 15 Day 1 | Change at Cycle 16 Day 1 | Change at Cycle 17 Day 1 | Change at Cycle 18 Day 1 | Change at Cycle 19 Day 1 | Change at Cycle 20 Day 1 | Change at Cycle 21 Day 1 | Change at Cycle 22 Day 1 | Change at Cycle 23 Day 1 | Change at End of Treatment | Change at 30 Day Follow Up | |
| Phase 3:Doublet Arm | 66.5 | -0.9 | 1.9 | 4.2 | 5.6 | 5.1 | 2.9 | 3.6 | 2.0 | -4.0 | -8.1 | -0.1 | -0.6 | -4.1 | -0.4 | 4.2 | 3.3 | 1.7 | -3.3 | -5.5 | 2.0 | -5.0 | -5.0 | -5.0 | -8.0 | -5.9 |
FACT-C= Functional Assessment of Chronic Illness Therapy (FACIT), which assessed HRQoL of cancer participants & participants with other chronic illnesses. It consists of total 36 items (27 items of general version of FACT-C and disease-specific subscale containing 9 CRC-specific items), summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range:0-28, emotional well-being (6 items) range: 0-24, colorectal cancer subscale (9 items) range: 0-36; higher subscale score= better QoL. All single-item measures range: 0= 'Not at all' to 4= 'Very much'. Table summarizes functional well-being subscale, individual questions are linearly scaled & combined to form functional well-being subscale score (range 0-28). High score represents better QoL. (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)
| Intervention | Units on a scale (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 1 Day 1 | Change at Cycle 2 Day 1 | Change at Cycle 3 Day 1 | Change at Cycle 4 Day 1 | Change at Cycle 5 Day 1 | Change at Cycle 6 Day 1 | Change at Cycle 7 Day 1 | Change at Cycle 8 Day 1 | Change at Cycle 9 Day 1 | Change at Cycle 10 Day 1 | Change at Cycle 11 Day 1 | Change at Cycle 12 Day 1 | Change at Cycle 13 Day 1 | Change at End of Treatment | Change at 30 Day Follow Up | |
| Phase 3:Control Arm | 16.8 | -1.4 | -0.9 | -0.7 | -1.8 | -1.6 | -1.9 | -0.5 | -2.1 | -2.6 | 0.5 | -4.5 | -4.5 | -8.0 | -3.1 | -4.2 |
FACT-C= Functional Assessment of Chronic Illness Therapy (FACIT), which assessed HRQoL of cancer participants & participants with other chronic illnesses. It consists of total 36 items (27 items of general version of FACT-C and disease-specific subscale containing 9 CRC-specific items), summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range:0-28, emotional well-being (6 items) range: 0-24, colorectal cancer subscale (9 items) range: 0-36; higher subscale score= better QoL. All single-item measures range: 0= 'Not at all' to 4= 'Very much'. Table summarizes functional well-being subscale, individual questions are linearly scaled & combined to form functional well-being subscale score (range 0-28). High score represents better QoL. (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)
| Intervention | Units on a scale (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 1 Day 1 | Change at Cycle 2 Day 1 | Change at Cycle 3 Day 1 | Change at Cycle 4 Day 1 | Change at Cycle 5 Day 1 | Change at Cycle 6 Day 1 | Change at Cycle 7 Day 1 | Change at Cycle 8 Day 1 | Change at Cycle 9 Day 1 | Change at Cycle 10 Day 1 | Change at Cycle 11 Day 1 | Change at Cycle 12 Day 1 | Change at Cycle 13 Day 1 | Change at Cycle 14 Day 1 | Change at Cycle 15 Day 1 | Change at Cycle 16 Day 1 | Change at Cycle 17 Day 1 | Change at Cycle 18 Day 1 | Change at Cycle 19 Day 1 | Change at Cycle 20 Day 1 | Change at Cycle 21 Day 1 | Change at End of Treatment | Change at 30 Day Follow Up | |
| Phase 3: Triplet Arm | 16.3 | -0.2 | -0.3 | -0.2 | 0.4 | 0.7 | 0.7 | 0.5 | 0.9 | -1.9 | -1.7 | -1.5 | -1.5 | -2.0 | -2.4 | -2.3 | -4.2 | -6.7 | -5.0 | -7.0 | -6.0 | -9.0 | -2.4 | -3.5 |
FACT-C= Functional Assessment of Chronic Illness Therapy (FACIT), which assessed HRQoL of cancer participants & participants with other chronic illnesses. It consists of total 36 items (27 items of general version of FACT-C and disease-specific subscale containing 9 CRC-specific items), summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range:0-28, emotional well-being (6 items) range: 0-24, colorectal cancer subscale (9 items) range: 0-36; higher subscale score= better QoL. All single-item measures range: 0= 'Not at all' to 4= 'Very much'. Table summarizes functional well-being subscale, individual questions are linearly scaled & combined to form functional well-being subscale score (range 0-28). High score represents better QoL. (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)
| Intervention | Units on a scale (Mean) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 1 Day 1 | Change at Cycle 2 Day 1 | Change at Cycle 3 Day 1 | Change at Cycle 4 Day 1 | Change at Cycle 5 Day 1 | Change at Cycle 6 Day 1 | Change at Cycle 7 Day 1 | Change at Cycle 8 Day 1 | Change at Cycle 9 Day 1 | Change at Cycle 10 Day 1 | Change at Cycle 11 Day 1 | Change at Cycle 12 Day 1 | Change at Cycle 13 Day 1 | Change at Cycle 14 Day 1 | Change at Cycle 15 Day 1 | Change at Cycle 16 Day 1 | Change at Cycle 17 Day 1 | Change at Cycle 18 Day 1 | Change at Cycle 19 Day 1 | Change at Cycle 20 Day 1 | Change at Cycle 21 Day 1 | Change at Cycle 22 Day 1 | Change at Cycle 23 Day 1 | Change at End of Treatment | Change at 30 Day Follow Up | |
| Phase 3:Doublet Arm | 16.2 | -0.9 | -0.6 | -0.2 | -0.1 | -0.2 | 0.6 | -0.1 | 0.2 | -0.8 | -1.3 | -0.5 | -1.1 | -3.2 | -4.0 | -1.5 | -0.7 | -0.7 | -3.0 | -6.0 | -5.0 | -5.0 | -12.0 | -9.0 | -2.2 | -0.8 |
"The PGIC is a measure of participant's perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other participant reported outcome (PROs). For this assessment, participants answered the following question: Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse." (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)
| Intervention | Units on a scale (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 1 Day 1 | Change at Cycle 2 Day 1 | Change at Cycle 3 Day 1 | Change at Cycle 4 Day 1 | Change at Cycle 5 Day 1 | Change at Cycle 6 Day 1 | Change at Cycle 7 Day 1 | Change at Cycle 8 Day 1 | Change at Cycle 9 Day 1 | Change at Cycle 10 Day 1 | Change at Cycle 11 Day 1 | Change at Cycle 12 Day 1 | Change at Cycle 13 Day 1 | Change at End of Treatment | Change at 30 Day Follow Up | |
| Phase 3:Control Arm | 3.9 | 0.0 | -0.3 | -0.5 | -0.5 | -0.7 | -0.8 | -1.1 | -1.0 | -1.0 | -0.3 | 0.0 | -0.5 | -1.0 | 0.4 | 0.7 |
"The PGIC is a measure of participant's perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other participant reported outcome (PROs). For this assessment, participants answered the following question: Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse." (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)
| Intervention | Units on a scale (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 1 Day 1 | Change at Cycle 2 Day 1 | Change at Cycle 3 Day 1 | Change at Cycle 4 Day 1 | Change at Cycle 5 Day 1 | Change at Cycle 6 Day 1 | Change at Cycle 7 Day 1 | Change at Cycle 8 Day 1 | Change at Cycle 9 Day 1 | Change at Cycle 10 Day 1 | Change at Cycle 11 Day 1 | Change at Cycle 12 Day 1 | Change at Cycle 13 Day 1 | Change at Cycle 14 Day 1 | Change at Cycle 15 Day 1 | Change at Cycle 16 Day 1 | Change at Cycle 17 Day 1 | Change at Cycle 18 Day 1 | Change at Cycle 19 Day 1 | Change at Cycle 20 Day 1 | Change at Cycle 21 Day 1 | Change at End of Treatment | Change at 30 Day Follow Up | |
| Phase 3: Triplet Arm | 3.8 | -0.1 | -0.7 | -0.9 | -0.9 | -0.9 | -0.8 | -1.1 | -1.2 | -0.8 | -0.5 | -0.9 | -0.9 | -1.3 | -1.1 | -1.2 | -2.0 | -1.3 | -2.0 | -3.0 | -3.0 | -3.0 | 0.3 | -0.1 |
"The PGIC is a measure of participant's perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other participant reported outcome (PROs). For this assessment, participants answered the following question: Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse." (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)
| Intervention | Units on a scale (Mean) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 1 Day 1 | Change at Cycle 2 Day 1 | Change at Cycle 3 Day 1 | Change at Cycle 4 Day 1 | Change at Cycle 5 Day 1 | Change at Cycle 6 Day 1 | Change at Cycle 7 Day 1 | Change at Cycle 8 Day 1 | Change at Cycle 9 Day 1 | Change at Cycle 10 Day 1 | Change at Cycle 11 Day 1 | Change at Cycle 12 Day 1 | Change at Cycle 13 Day 1 | Change at Cycle 14 Day 1 | Change at Cycle 15 Day 1 | Change at Cycle 16 Day 1 | Change at Cycle 17 Day 1 | Change at Cycle 18 Day 1 | Change at Cycle 19 Day 1 | Change at Cycle 20 Day 1 | Change at Cycle 21 Day 1 | Change at Cycle 22 Day 1 | Change at Cycle 23 Day 1 | Change at End of Treatment | Change at 30 Day Follow Up | |
| Phase 3:Doublet Arm | 3.8 | 0.1 | -0.8 | -1.2 | -1.1 | -1.1 | -1.2 | -1.0 | -1.1 | -0.9 | -0.6 | -1.1 | -0.8 | -0.9 | -1.5 | -1.6 | -0.7 | -1.0 | -1.0 | -0.5 | -2.0 | -2.0 | -2.0 | -2.0 | 0.1 | 0.5 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Nanogram/milliliter *hour (Geometric Mean) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Combined Safety Lead-in | 1960 | 1540 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Nanogram/milliliter *hour (Geometric Mean) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Combined Safety Lead-in | 841000 | 970000 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Nanogram/milliliter *hour (Geometric Mean) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Combined Safety Lead-in | 11300 | 6660 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Nanogram/milliliter *hour (Geometric Mean) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Combined Safety Lead-in | 206 | 70.0 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Nanogram/milliliter (Geometric Mean) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Combined Safety Lead-in | 654 | 524 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Nanogram/milliliter (Geometric Mean) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Combined Safety Lead-in | 195000 | 199000 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Nanogram/milliliter (Geometric Mean) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Combined Safety Lead-in | 3360 | 2490 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Nanogram/milliliter (Geometric Mean) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Combined Safety Lead-in | 59.9 | 20.5 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Hours (Median) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Combined Safety Lead-in | 1.98 | 1.04 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Hours (Median) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Combined Safety Lead-in | 3.77 | 3.05 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Hours (Median) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Combined Safety Lead-in | 2.00 | 2.00 |
(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)
| Intervention | Hours (Median) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Combined Safety Lead-in | 2.00 | 1.58 |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants according to incidence of dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Dose interruptions | Dose modifications | Discontinuation due to AEs | |
| Combined Safety Lead-in | 30 | 16 | 8 |
Clinically notable shifts was defined as worsening by at least 2 grades or to more than or equal to (>=) Grade 3 based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening and Grade 5: death. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Activated Partial Thromboplastin Time - Hyper | Hemoglobin - Hyper | Hemoglobin - Hypo | Leukocytes - Hyper | Leukocytes - Hypo | Lymphocytes - Hyper | Lymphocytes - Hypo | Neutrophils - Hypo | Platelets - Hypo | Prothrombin Intl. Normalized Ratio - Hyper | |
| Phase 3: Doublet Arm | 9 | 0 | 30 | 0 | 9 | 3 | 47 | 8 | 5 | 2 |
| Phase 3: Triplet Arm | 9 | 0 | 97 | 0 | 2 | 12 | 25 | 4 | 1 | 3 |
| Phase 3:Control Arm | 4 | 0 | 17 | 0 | 51 | 4 | 57 | 65 | 4 | 2 |
Clinically notable shifts was defined as worsening by at least 2 grades or to >= Grade 3 based on CTCAE version 4.03 where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening and Grade 5: death. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alanine Aminotransferase - Hyper | Albumin - Hypo | Alkaline Phosphatase - Hyper | Aspartate Aminotransferase - Hyper | Bilirubin - Hyper | Calcium - Hyper | Calcium - Hypo | Creatine Kinase - Hyper | Creatinine - Hyper | Glucose - Hyper | Glucose - Hypo | Magnesium - Hyper | Magnesium - Hypo | Potassium - Hyper | Potassium - Hypo | Sodium - Hyper | Sodium - Hypo | Troponin I - Hyper | Urate - Hyper | |
| Phase 3: Control Arm | 10 | 17 | 18 | 9 | 12 | 0 | 7 | 3 | 6 | 4 | 1 | 2 | 9 | 5 | 9 | 2 | 5 | 0 | 1 |
| Phase 3: Doublet Arm | 7 | 16 | 12 | 7 | 13 | 0 | 8 | 1 | 11 | 16 | 0 | 1 | 4 | 10 | 7 | 1 | 4 | 0 | 2 |
| Phase 3: Triplet Arm | 11 | 50 | 13 | 11 | 11 | 1 | 15 | 18 | 45 | 8 | 4 | 0 | 11 | 14 | 5 | 1 | 10 | 0 | 4 |
Newly occurring clinically notable changes was defined as participants not meeting the criterion at baseline and meeting criterion post-baseline. The criterion included: heart rate- decrease from baseline > 25% and to a value < 50 and increase from baseline > 25% and to a value > 100. QT interval- new > 450 (millisecond) msec, new > 480 msec, new > 500 msec, increase from baseline > 30 msec and increase from baseline > 60 msec. QTcF- new > 450 msec, new > 480 msec, new > 500 msec, increase from baseline > 30 msec and increase from baseline > 60 msec. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heart Rate - Decrease from baseline > 25% and to a value < 50 | Heart Rate - Increase from baseline > 25% and to a value > 100 | QT Interval - New > 450 millisecond (msec) | QT Interval - New > 480 msec | QT Interval - New > 500 msec | QT Interval - increase from baseline > 30 msec | QT Interval - increase from baseline > 60 msec | QTcF - New > 450 msec | QTcF - New > 480 msec | QTcF - New > 500 msec | QTcF - increase from baseline > 30 msec | QTcF - increase from baseline > 60 msec | |
| Phase 3: Control Arm | 0 | 28 | 7 | 2 | 0 | 32 | 10 | 23 | 5 | 2 | 24 | 5 |
| Phase 3: Doublet Arm | 4 | 24 | 30 | 7 | 5 | 99 | 21 | 51 | 18 | 6 | 75 | 20 |
| Phase 3: Triplet Arm | 1 | 27 | 17 | 4 | 3 | 97 | 22 | 39 | 9 | 1 | 59 | 12 |
Newly occurring clinically notable changes was defined as participants not meeting the criterion at baseline and meeting criterion post-baseline. The criterion included: low/high systolic blood pressure (SBP): <= 90 millimeters of mercury (mmHg) with decrease from baseline of >= 20mmHg or >= 160mmHg with increase from baseline of >= 20mmHg, low or high diastolic blood pressure (DBP): <= 50mmHg with decrease from baseline of >= 15mmHg or >= 100mmHg with increase from baseline of >= 15mmHg, low or high pulse: <= 50 beats/min with decrease from baseline of >= 15 beats/min or >= 120 beats/min with increase from baseline of >= 15 beats/min, low or high temperature: <= 36 degree Celsius (deg C) or >= 37.5 deg C. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Diastolic Blood Pressure - High | Diastolic Blood Pressure - Low | Pulse Rate - High | Pulse Rate - Low | Systolic Blood Pressure - High | Systolic Blood Pressure - Low | Temperature - High | Temperature - Low | |
| Phase 3: Control Arm | 7 | 5 | 20 | 3 | 5 | 10 | 25 | 55 |
| Phase 3: Doublet Arm | 6 | 27 | 14 | 4 | 13 | 28 | 23 | 84 |
| Phase 3: Triplet Arm | 8 | 21 | 23 | 3 | 19 | 37 | 33 | 93 |
Visual acuity was measured using the Snellen visual acuity conversion chart. This was determined by establishing the smallest optotypes that could be identified correctly by the participant at a given observation distance. Snellen visual acuity was reported as a Snellen fraction (m/M) in which the numerator (m) indicated the test distance and the denominator (M) indicated the distance at which the gap of the equivalent Landolt ring subtends 1 minute of arc. The LogMAR score was calculated as - log(m/M). The maximum increase in score of <= 0, 0 to < 0.1, 0.1 to < 0.2, 0.2 to < 0.3 and >=0.3 relative to baseline in LogMAR were reported in this endpoint. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline <=0 to >0-<0.1 | Baseline <=0 to 0.1-<0.2 | Baseline <=0 to 0.2-<0.3 | Baseline <=0 to >=0.3 | Baseline <=0 to missing score | Baseline >0-<0.1 to <=0 | Baseline >0-<0.1 to 0.1-<0.2 | Baseline >0-<0.1 to 0.2-<0.3 | Baseline >0-<0.1 to >=0.3 | Baseline >0-<0.1 to missing score | Baseline 0.1-<0.2 to <=0 | Baseline 0.1-<0.2 to >0-<0.1 | Baseline 0.2-<0.3 to <=0 | Baseline 0.2-<0.3 to >0-<0.1 | Baseline 0.2-<0.3 to 0.1-<0.2 | Baseline 0.2-<0.3 to missing score | Baseline >=0.3 to <=0 | Baseline >=0.3 to >0-<0.1 | Baseline >=0.3 to 0.1-<0.2 | Baseline >=0.3 to 0.2-<0.3 | Baseline >=0.3 to missing score | Baseline 0.1-<0.2 to 0.2-<0.3 | Baseline 0.1-<0.2 to missing score | |
| Phase 3: Control Arm | 0 | 0 | 0 | 0 | 129 | 0 | 0 | 0 | 0 | 30 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 13 | 0 | 7 |
| Phase 3: Doublet Arm | 8 | 3 | 0 | 1 | 86 | 6 | 2 | 1 | 0 | 25 | 1 | 0 | 0 | 0 | 1 | 4 | 2 | 0 | 1 | 0 | 19 | 3 | 9 |
| Phase 3: Triplet Arm | 33 | 15 | 4 | 6 | 9 | 17 | 7 | 4 | 3 | 3 | 5 | 1 | 1 | 3 | 3 | 1 | 9 | 4 | 1 | 2 | 1 | 0 | 0 |
Left ventricular ejection fraction (LVEF) abnormalities were defined according to CTCAE version 4.03 where Grade 0: Non-missing value below Grade 2, Grade 2: LVEF between 40% and 50% or absolute change from baseline between -10% and < -20%, Grade 3: LVEF between 20% and 39% or absolute change from baseline <= -20%, Grade 4: LVEF lower than 20%. Categories with at least 1 non-zero data values showing any shift in Grade from baseline to 1 day after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. Grade 0 to Grade 0) were not reported. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Baseline Grade 0 to Grade 2 post baseline | Baseline Grade 0 to Grade 3 post baseline | Baseline Grade 0 to missing grade | Baseline Grade 2 to missing grade | Baseline missing grade to Grade 0 post baseline | |
| Phase 3: Control Arm | 0 | 0 | 186 | 2 | 0 |
| Phase 3: Doublet Arm | 0 | 1 | 205 | 3 | 0 |
| Phase 3: Triplet Arm | 27 | 1 | 17 | 0 | 1 |
Number of participants with an ORR - the portion of patients with a tumor size reduction of a predefined amount for a minimum time period (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Genistein | 6 |
The number of participants with best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Genistein | 8 |
Overall Survival - Number of months still living since baseline (NCT01985763)
Timeframe: up to 50 months
| Intervention | months (Median) |
|---|---|
| Genistein | 36.5 |
Percent change in tumor size after cycle 6. Each cycle is 21 days. (NCT01985763)
Timeframe: end of Cycle 6
| Intervention | Percent change (Median) |
|---|---|
| Genistein | -43.0 |
Patients monitored for progression. Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse. (NCT01985763)
Timeframe: up to 50 months
| Intervention | months (Median) |
|---|---|
| Genistein | 11.5 |
"Best Overall Response Rate (ORR) as measured by radiologic RECIST criteria. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.~SD - target lesion SD, non target lesions Non-PD, and no new lesions. PR - target lesion CR, non target lesions Incomplete response/SD and no new lesions; or target lesion PR, non target lesions Non-PD, and no new lesions.~PD - target lesions PD, non target lesions Any, can have new lesions; or target lesions Any, non target lesions PD, can have new lesions; or target lesions Any, non target lesions Any, have new lesions." (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| PR | SD | PD | Not evaluable | |
| Genistein | 6 | 3 | 2 | 2 |
Number of adverse events to assess tolerability of genistein treatment. Evaluation of side effects conducted every 14 days before each chemotherapy/genistein cycle. (NCT01985763)
Timeframe: up to 6 months
| Intervention | events (Number) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Genistein | 250 | 119 | 24 | 0 |
"Patients monitored for progression during the study period and 1 year following.~Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse." (NCT01985763)
Timeframe: 6 month and 12 month
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months | 12 months | |
| Genistein | 69 | 38 |
"Response Rate (RR) as measured by radiologic RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.~Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01985763)
Timeframe: end of Cycle 6
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| PR | SD | PD | Not evaluable | |
| Genistein | 8 | 1 | 2 | 2 |
Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance was calculated using the Cockroft-Gault or Modification of Diet in Renal Disease (MDRD). (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | mL/min (Mean) |
|---|---|
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 71.4 |
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | participants (Number) |
|---|---|
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 182 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue - Baseline | Fatigue - Change at Cycle 3 | Fatigue - Change at Cycle 5 | Fatigue - Change at Cycle 7 | Fatigue - Change at Cycle 9 | Fatigue - Change at Cycle 11 | Fatigue - Change at Cycle 13 | Fatigue - Change at Cycle 15 | Fatigue - Change at Cycle 17 | Fatigue - Change at Cycle 19 | Fatigue - Change at Cycle 21 | Fatigue - Change at Cycle 23 | Fatigue - Change at Cycle 25 | Fatigue - Change at Cycle 27 | Fatigue - Change at Cycle 29 | Fatigue - Change at Cycle 31 | Fatigue - Change at Cycle 33 | Fatigue - Change at Cycle 35 | Fatigue - Change at EOT | Nausea and Vomiting - Baseline | Nausea and Vomiting - Change at Cycle 3 | Nausea and Vomiting - Change at Cycle 5 | Nausea and Vomiting - Change at Cycle 7 | Nausea and Vomiting - Change at Cycle 9 | Nausea and Vomiting - Change at Cycle 11 | Nausea and Vomiting - Change at Cycle 13 | Nausea and Vomiting - Change at Cycle 15 | Nausea and Vomiting - Change at Cycle 17 | Nausea and Vomiting - Change at Cycle 19 | Nausea and Vomiting - Change at Cycle 21 | Nausea and Vomiting - Change at Cycle 23 | Nausea and Vomiting - Change at Cycle 25 | Nausea and Vomiting - Change at Cycle 27 | Nausea and Vomiting - Change at Cycle 29 | Nausea and Vomiting - Change at Cycle 31 | Nausea and Vomiting - Change at Cycle 33 | Nausea and Vomiting - Change at Cycle 35 | Nausea and Vomiting - Change at EOT | Pain - Baseline | Pain - Change at Cycle 3 | Pain - Change at Cycle 5 | Pain - Change at Cycle 7 | Pain - Change at Cycle 9 | Pain - Change at Cycle 11 | Pain - Change at Cycle 13 | Pain - Change at Cycle 15 | Pain - Change at Cycle 17 | Pain - Change at Cycle 19 | Pain - Change at Cycle 21 | Pain - Change at Cycle 23 | Pain - Change at Cycle 25 | Pain - Change at Cycle 27 | Pain - Change at Cycle 29 | Pain - Change at Cycle 31 | Pain - Change at Cycle 33 | Pain - Change at Cycle 35 | Pain - Change at EOT | Dyspnoea - Baseline | Dyspnoea - Change at Cycle 3 | Dyspnoea - Change at Cycle 5 | Dyspnoea - Change at Cycle 7 | Dyspnoea - Change at Cycle 9 | Dyspnoea - Change at Cycle 11 | Dyspnoea - Change at Cycle 13 | Dyspnoea - Change at Cycle 15 | Dyspnoea - Change at Cycle 17 | Dyspnoea - Change at Cycle 19 | Dyspnoea - Change at Cycle 21 | Dyspnoea - Change at Cycle 23 | Dyspnoea - Change at Cycle 25 | Dyspnoea - Change at Cycle 27 | Dyspnoea - Change at Cycle 29 | Dyspnoea - Change at Cycle 31 | Dyspnoea - Change at Cycle 33 | Dyspnoea - Change at Cycle 35 | Dyspnoea - Change at EOT | Insomnia - Baseline | Insomnia - Change at Cycle 3 | Insomnia - Change at Cycle 5 | Insomnia - Change at Cycle 7 | Insomnia - Change at Cycle 9 | Insomnia - Change at Cycle 11 | Insomnia - Change at Cycle 13 | Insomnia - Change at Cycle 15 | Insomnia - Change at Cycle 17 | Insomnia - Change at Cycle 19 | Insomnia - Change at Cycle 21 | Insomnia - Change at Cycle 23 | Insomnia - Change at Cycle 25 | Insomnia - Change at Cycle 27 | Insomnia - Change at Cycle 29 | Insomnia - Change at Cycle 31 | Insomnia - Change at Cycle 33 | Insomnia - Change at Cycle 35 | Insomnia - Change at EOT | Appetite loss - Baseline | Appetite loss - Change at Cycle 3 | Appetite loss - Change at Cycle 5 | Appetite loss - Change at Cycle 7 | Appetite loss - Change at Cycle 9 | Appetite loss - Change at Cycle 11 | Appetite loss - Change at Cycle 13 | Appetite loss - Change at Cycle 15 | Appetite loss - Change at Cycle 17 | Appetite loss - Change at Cycle 19 | Appetite loss - Change at Cycle 21 | Appetite loss - Change at Cycle 23 | Appetite loss - Change at Cycle 25 | Appetite loss - Change at Cycle 27 | Appetite loss - Change at Cycle 29 | Appetite loss - Change at Cycle 31 | Appetite loss - Change at Cycle 33 | Appetite loss - Change at Cycle 35 | Appetite loss - Change at EOT | Constipation - Baseline | Constipation - Change at Cycle 3 | Constipation - Change at Cycle 5 | Constipation - Change at Cycle 7 | Constipation - Change at Cycle 9 | Constipation - Change at Cycle 11 | Constipation - Change at Cycle 13 | Constipation - Change at Cycle 15 | Constipation - Change at Cycle 17 | Constipation - Change at Cycle 19 | Constipation - Change at Cycle 21 | Constipation - Change at Cycle 23 | Constipation - Change at Cycle 25 | Constipation - Change at Cycle 27 | Constipation - Change at Cycle 29 | Constipation - Change at Cycle 31 | Constipation - Change at Cycle 33 | Constipation - Change at Cycle 35 | Constipation - Change at EOT | Diarrhoea - Baseline | Diarrhoea - Change at Cycle 3 | Diarrhoea - Change at Cycle 5 | Diarrhoea - Change at Cycle 7 | Diarrhoea - Change at Cycle 9 | Diarrhoea - Change at Cycle 11 | Diarrhoea - Change at Cycle 13 | Diarrhoea - Change at Cycle 15 | Diarrhoea - Change at Cycle 17 | Diarrhoea - Change at Cycle 19 | Diarrhoea - Change at Cycle 21 | Diarrhoea - Change at Cycle 23 | Diarrhoea - Change at Cycle 25 | Diarrhoea - Change at Cycle 27 | Diarrhoea - Change at Cycle 29 | Diarrhoea - Change at Cycle 31 | Diarrhoea - Change at Cycle 33 | Diarrhoea - Change at Cycle 35 | Diarrhoea - Change at EOT | Financial difficulties - Baseline | Financial difficulties - Change at Cycle 3 | Financial difficulties - Change at Cycle 5 | Financial difficulties - Change at Cycle 7 | Financial difficulties - Change at Cycle 9 | Financial difficulties - Change at Cycle 11 | Financial difficulties - Change at Cycle 13 | Financial difficulties - Change at Cycle 15 | Financial difficulties - Change at Cycle 17 | Financial difficulties - Change at Cycle 19 | Financial difficulties - Change at Cycle 21 | Financial difficulties - Change at Cycle 23 | Financial difficulties - Change at Cycle 25 | Financial difficulties - Change at Cycle 27 | Financial difficulties - Change at Cycle 29 | Financial difficulties - Change at Cycle 31 | Financial difficulties - Change at Cycle 33 | Financial difficulties - Change at Cycle 35 | Financial difficulties - Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 29.16 | 7.35 | 8.40 | 9.54 | 7.89 | 11.30 | 8.33 | 7.41 | 6.70 | 8.93 | 10.39 | 10.80 | 7.66 | 9.66 | 11.67 | 14.07 | 15.15 | 14.44 | 12.31 | 5.88 | 6.68 | 6.98 | 6.61 | 6.20 | 8.97 | 6.82 | 6.85 | 3.45 | 6.56 | 3.99 | 7.87 | 4.02 | 7.25 | 1.67 | 13.33 | 3.03 | 3.33 | 6.64 | 20.47 | 2.68 | 2.52 | 3.00 | 2.72 | 6.64 | 5.16 | 7.26 | 9.39 | 8.74 | 7.25 | 8.33 | 5.75 | 5.07 | 4.17 | 10.00 | 7.58 | 6.67 | 10.85 | 13.45 | 3.63 | 5.75 | 6.98 | 6.89 | 8.19 | 6.36 | 3.58 | 5.16 | 6.78 | 3.79 | 4.04 | 1.23 | 3.03 | -1.75 | 16.67 | 16.67 | 16.67 | 6.53 | 24.15 | 0.37 | -0.08 | -2.37 | -0.24 | 2.56 | 0.65 | -2.19 | -1.92 | 1.64 | 0.74 | -0.93 | -0.00 | -1.52 | -3.33 | -4.44 | -6.06 | -3.33 | 5.31 | 17.38 | 9.10 | 9.02 | 9.84 | 9.98 | 14.53 | 10.67 | 10.74 | 8.91 | 9.84 | 13.04 | 12.38 | 11.49 | 15.94 | 15.00 | 15.56 | 15.15 | 16.67 | 12.03 | 12.71 | 2.42 | 3.77 | 2.63 | 5.35 | 4.42 | 4.58 | 4.92 | 5.43 | 8.33 | 6.06 | 9.26 | 5.75 | 1.45 | 6.67 | 22.22 | 12.12 | 10.00 | 3.78 | 10.37 | 11.72 | 10.85 | 14.63 | 11.44 | 15.46 | 11.26 | 11.02 | 10.34 | 15.25 | 14.07 | 18.52 | 10.34 | 13.64 | 16.67 | 20.00 | 18.18 | 30.00 | 7.31 | 20.12 | -1.83 | -1.32 | -0.99 | -0.49 | 3.30 | 1.11 | -0.27 | 0.77 | 1.67 | 4.44 | 2.94 | -4.60 | -2.90 | 0.00 | -2.22 | -3.03 | 0.00 | 2.97 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 0.77 | -0.02 | -0.03 | -0.04 | -0.05 | -0.07 | -0.05 | -0.06 | -0.05 | -0.05 | -0.09 | -0.14 | -0.08 | -0.08 | -0.08 | -0.12 | 0.02 | -0.05 | -0.11 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. The VAS recorded the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. This information can be used as a quantitative measure of health outcome as judged by the individual respondents. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 72.81 | -1.85 | -2.15 | -2.20 | -2.74 | -3.10 | -2.36 | -1.05 | -1.91 | -3.06 | -2.13 | -5.77 | -7.28 | -4.94 | -8.80 | -6.69 | -7.90 | -8.88 | -6.67 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent).EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at the end of treatment (EOT) (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 68.61 | -3.34 | -4.70 | -3.63 | -3.97 | -5.85 | -2.26 | -3.05 | -1.18 | -2.36 | -5.56 | -6.86 | -8.05 | -10.14 | -8.33 | -9.44 | -11.36 | -5.83 | -8.82 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28).Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical - Baseline | Physical - Change at Cycle 3 | Physical - Change at Cycle 5 | Physical - Change at Cycle 7 | Physical - Change at Cycle 9 | Physical - Change at Cycle 11 | Physical - Change at Cycle 13 | Physical - Change at Cycle 15 | Physical - Change at Cycle 17 | Physical - Change at Cycle 19 | Physical - Change at Cycle 21 | Physical - Change at Cycle 23 | Physical - Change at Cycle 25 | Physical - Change at Cycle 27 | Physical - Change at Cycle 29 | Physical - Change at Cycle 31 | Physical - Change at Cycle 33 | Physical - Change at Cycle 35 | Physical - Change at EOT | Role - Baseline | Role - Change at Cycle 3 | Role - Change at Cycle 5 | Role - Change at Cycle 7 | Role - Change at Cycle 9 | Role - Change at Cycle 11 | Role - Change at Cycle 13 | Role - Change at Cycle 15 | Role - Change at Cycle 17 | Role - Change at Cycle 19 | Role - Change at Cycle 21 | Role - Change at Cycle 23 | Role - Change at Cycle 25 | Role - Change at Cycle 27 | Role - Change at Cycle 29 | Role - Change at Cycle 31 | Role - Change at Cycle 33 | Role - Change at Cycle 35 | Role - Change at EOT | Emotional - Baseline | Emotional - Change at Cycle 3 | Emotional - Change at Cycle 5 | Emotional - Change at Cycle 7 | Emotional - Change at Cycle 9 | Emotional - Change at Cycle 11 | Emotional - Change at Cycle 13 | Emotional - Change at Cycle 15 | Emotional - Change at Cycle 17 | Emotional - Change at Cycle 19 | Emotional - Change at Cycle 21 | Emotional - Change at Cycle 23 | Emotional - Change at Cycle 25 | Emotional - Change at Cycle 27 | Emotional - Change at Cycle 29 | Emotional - Change at Cycle 31 | Emotional - Change at Cycle 33 | Emotional - Change at Cycle 35 | Emotional - Change at EOT | Cognitive - Baseline | Cognitive - Change at Cycle 3 | Cognitive - Change at Cycle 5 | Cognitive - Change at Cycle 7 | Cognitive - Change at Cycle 9 | Cognitive - Change at Cycle 11 | Cognitive - Change at Cycle 13 | Cognitive - Change at Cycle 15 | Cognitive - Change at Cycle 17 | Cognitive - Change at Cycle 19 | Cognitive - Change at Cycle 21 | Cognitive - Change at Cycle 23 | Cognitive - Change at Cycle 25 | Cognitive - Change at Cycle 27 | Cognitive - Change at Cycle 29 | Cognitive - Change at Cycle 31 | Cognitive - Change at Cycle 33 | Cognitive - Change at Cycle 35 | Cognitive- Change at EOT | Social - Baseline | Social - Change at Cycle 3 | Social - Change at Cycle 5 | Social - Change at Cycle 7 | Social - Change at Cycle 9 | Social - Change at Cycle 11 | Social - Change at Cycle 13 | Social - Change at Cycle 15 | Social - Change at Cycle 17 | Social - Change at Cycle 19 | Social - Change at Cycle 21 | Social - Change at Cycle 23 | Social - Change at Cycle 25 | Social - Change at Cycle 27 | Social - Change at Cycle 29 | Social - Change at Cycle 31 | Social - Change at Cycle 33 | Social - Change at Cycle 35 | Social - Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 81.79 | -3.73 | -3.95 | -4.62 | -4.36 | -6.99 | -4.99 | -3.54 | -5.10 | -5.68 | -5.70 | -7.87 | -5.75 | -6.59 | -7.67 | -9.33 | -5.45 | -10.00 | -11.16 | 79.91 | -6.26 | -5.66 | -6.68 | -6.55 | -8.76 | -7.36 | -7.18 | -9.58 | -9.84 | -9.78 | -10.65 | -10.92 | -10.14 | -10.83 | -14.44 | -15.15 | -15.00 | -12.11 | 78.96 | 1.14 | 0.74 | 1.58 | 1.69 | 0.08 | 0.93 | 2.51 | 2.91 | 1.39 | 0.06 | 1.75 | 4.98 | 1.57 | 2.64 | 1.30 | 0.25 | -0.00 | -2.87 | 86.90 | -1.77 | -1.87 | -1.99 | -2.18 | -4.27 | -2.83 | -2.28 | -3.45 | -5.00 | -5.56 | -5.71 | -6.90 | -5.80 | -6.67 | -5.56 | -10.61 | -11.67 | -4.98 | 80.57 | -2.05 | -2.86 | -4.78 | -4.56 | -7.09 | -5.56 | -6.18 | -5.56 | -5.28 | -5.56 | -7.62 | -4.60 | -2.17 | -5.00 | -7.78 | -1.52 | -1.67 | -9.01 |
Abnormal electrolytes parameters included: hyponatremia, hypernatremia, hypocalcemia, hypercalcemia, hypokalemia, and hyperkalemia. Number of participants with each of these parameters were analyzed by grades ( All Grades and Grades 3-4 as per NCI CTCAE Version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hyponatremia: All Grades | Hyponatremia: Grades 3-4 | Hypernatremia: All Grades | Hypernatremia: Grades 3-4 | Hypocalcemia: All Grades | Hypocalcemia: Grades 3-4 | Hypercalcemia: All Grades | Hypercalcemia: Grades 3-4 | Hypokalemia: All Grades | Hypokalemia: Grades 3-4 | Hyperkalemia: All Grades | Hyperkalemia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 181 | 32 | 75 | 1 | 213 | 5 | 52 | 2 | 121 | 16 | 166 | 10 |
Abnormal hematological parameters included: anaemia, thrombocytopenia, leukopenia and neutropenia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4 as per NCI CTCAE (Version 4.03), where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Anaemia: All Grades | Anaemia: Grades 3-4 | Thrombocytopenia: All Grades | Thrombocytopenia: Grades 3-4 | Leukopenia: All Grades | Leukopenia: Grades 3-4 | Neutropenia: All Grades | Neutropenia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 535 | 14 | 293 | 13 | 532 | 72 | 450 | 227 |
Non-gradeable biochemistry parameters included; chloride, urea, total protein, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH). Number of participants with
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Chloride| Chloride>ULN | BUN | BUN>ULN | UREA | UREA>ULN | LDH | LDH>ULN | Total proteins | Total proteins>ULN | | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 135 | 217 | 41 | 83 | 60 | 250 | 79 | 423 | 162 | 77 |
Renal and liver function parameters included: creatinine, hyperbilirubinemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Creatinine: All Grades | Creatinine: Grades 3-4 | Hyperbilirubinemia: All Grades | Hyperbilirubinemia: Grades 3-4 | AST: All Grades | AST: Grades 3-4 | ALT: All Grades | ALT: Grades 3-4 | Alkaline phosphatase: All Grades | Alkaline phosphatase: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 161 | 2 | 130 | 9 | 342 | 12 | 270 | 10 | 465 | 23 |
A theoretical cycle is a 2 week period i.e. 14 days. A cycle is delayed if duration of previous cycle is greater than 14+2 days ; dose modification includes dose reduction and dose omission. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| No delay and no dose modification | Any delay and/or dose modification | Delay only | Delay and Aflibercept modified | Delay and FOLFIRI modified | Delay and Aflibercept and Folfiri modified | Only Aflibercept modified | Only FOLFIRI modified | Both Aflibercept and FOLFIRI modified | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 119 | 660 | 163 | 39 | 308 | 97 | 5 | 43 | 5 |
The INR is a derived measure of the prothrombin time. The INR is the ratio of a participant's prothrombin time to a normal control sample. Normal range (without anti coagulation therapy): 0.8-1.2; Targeted range (with anti coagulation therapy) 2.0-3.0. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| INR<1.5 | INR>=1.5 to <3 | INR>=3 to <5 | INR>=5 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 106 | 0 | 2 | 2 |
Other abnormal biochemistry parameters included: hypoglycemia, hyperglycemia and hypoalbuminemia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE Version 4.03, where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Hypoglycemia: All Grades | Hypoglycemia: Grades 3-4 | Hyperglycemia: All Grades | Hyperglycemia: Grades 3-4 | Hypoalbuminemia: All Grades | Hypoalbuminemia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 90 | 6 | 403 | 30 | 241 | 6 |
Proteinuria is defined as the presence of excess proteins in the urine (assessed either by spot sample, dipstick/ urine protein or 24 hour urine collection). Hematuria is defined as the presence of blood in urine (positive dipstick for RBC or reported AE). Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. Hypertension (high blood pressure) is defined as having a blood pressure reading of more than 140/90 mmHg over a number of weeks. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Proteinuria with hematuria | Proteinuria with hypertension | Proteinuria with hematuria and hypertension | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 72 | 4 | 3 |
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria were analyzed by grades (Grades 1, 2, 3 ,4) as per NCI CTCAE Version 4.03 where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 286 | 123 | 54 | 5 |
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. A serious AE (SAE): Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Version 4.03 was used to assess severity (Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling) of AEs. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Any TEAE (All Grades) | Any TEAEs (Grades 3-4) | Any serious TEAE | Any serious related TEAE | Any TEAE leading to death | Any TEAE (permanent treatment discontinuation) | Any TEAE (premature treatment discontinuation) | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 769 | 609 | 272 | 159 | 47 | 208 | 104 |
Urinary protein creatinine ratio (UPCR) corresponds to the ratio of the urinary protein and urinary creatinine concentration (expressed in mg/dL). This ratio provides an accurate quantification of 24-hours urinary protein excretion. There is a high correlation between morning UPCR and 24-hour proteinuria in participants with normal or reduced renal functions. Normal ratio is < or = 1. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| UPCR<=1 | UPCR>=1 to <=2 | UPCR>=2 to <=3 | UPCR>3 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 265 | 51 | 24 | 27 |
DC was defined as the proportion of participants who had a best response rating of CR, PR, or stable disease (SD) according to RECIST criteria that was achieved during treatment or within 30 days after termination of study treatment. CR and PR were confirmed not earlier than 4 weeks following the initial detection of response. A minimum of 8 weeks (allowing a minus 7-day time window) between start of study treatment and the first follow-up tumor assessment with SD as response was required to assign SD as best overall response. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks
| Intervention | Proportion of participants (Number) |
|---|---|
| Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 0.8537 |
DOR was defined as the time from the date of first documented objective response of PR or CR, whichever was noted earlier, to first subsequent disease progression or death (if death occurred before progression was documented). DOR was defined for responders only (that is, subjects with CR or PR). DOR for subjects without disease progression or death before progression was right censored at the date of their last tumor assessment. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks
| Intervention | Days (Median) |
|---|---|
| Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 257 |
DOSD was only evaluated in participants failing to achieve a best response of CR or PR, but who achieved SD. DOSR was defined as the time (in days) from date of start of study treatment to the date at which disease progression or death (if death occurred before progression was first documented). The date the tumor scan was performed was used for this calculation. DOSD for participants without disease progression or death before progression at the time of analysis were censored at the date of their last tumor assessment. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks
| Intervention | Days (Median) |
|---|---|
| Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 231 |
OR was defined as the best tumor response (confirmed complete response [CR] or partial response [PR]) observed by MRI or CT scan assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. CR and PR were confirmed not earlier than 4 weeks following the initial detection of response. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). Any pathological lymph nodes (whether target or non target) must have a reduction in short axis to < 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing nontarget lesions and no appearance of new lesions. (NCT01289821)
Timeframe: From start of treatment until 30 days after termination of study medication, an average of 47 weeks. Assessed every 8 weeks.
| Intervention | Proportion of participants (Number) |
|---|---|
| Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 0.4390 |
OS was calculated as the time from first date of receiving study treatment to date of death due to any cause. Participants alive at the time of analysis were censored at their last date of follow-up. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks
| Intervention | Days (Median) |
|---|---|
| Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 772 |
PFS was defined as time from the date of start of study treatment to the date of first observed disease progression (radiological according to central assessment or clinical), or death due to any cause, if death occurred before progression was documented. PFS for participants without disease progression or death at the date of database cutoff were right-censored at the last date of tumor assessment. Participants who had no tumor evaluation after baseline and no clinical progression post baseline and who did not die were censored at Day 1 in the analysis. PD = At least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non target lesions or the appearance of one or more new lesions will also constitute PD. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks
| Intervention | Days (Median) |
|---|---|
| Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6) | 258 |
To compare overall survival (OS) between ARM A and ARM B. OS is defined as the time from randomization until death as a result of any cause. (NCT01298570)
Timeframe: 5.5 years
| Intervention | Months (Median) |
|---|---|
| Arm A | 13.8 |
| Arm B | 11.7 |
To compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients failing one prior oxaliplatin-containing regimen for metastatic colorectal cancer. PFS is defined as the time from randomization until metastatic colorectal cancer (mCRC) progression or death as a result of any cause. Radiographic response will be measured by RECIST, Response Evaluation Criteria In Solid Tumors Criteria, indicating if subject experienced a Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), no response or less response than Partial or Progressive; or Progressive Disease (PD), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01298570)
Timeframe: 5.5 years
| Intervention | Months (Median) |
|---|---|
| Arm A | 6.1 |
| Arm B | 5.3 |
To compare the pharmacokinetic (PK) profile of FOLFIRI between a subset of patients receiving regorafenib (ARM A) and patients receiving placebo (Arm B). The Area Under the Curve (AUC) levels of the irinotecan metabolite SN-38 were compared. (NCT01298570)
Timeframe: 28 days
| Intervention | AUC/dose=(ng/mL*h)/(mg/m^2) (Median) | |
|---|---|---|
| Cycle 1 | Cycle 2 | |
| Arm A | 0.68 | 0.59 |
| Arm B | 0.63 | 0.72 |
Toxicity Assessments were made according to NCI CTCAE v. 4.0 . Severe events (grades 3-4) that occurred in a higher percentage of regorafenib treated participants as compared to placebo are reported below. (NCT01298570)
Timeframe: 3 years
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| neutropenia | diarrhea | hypophosphatemia | hypertension | elevated lipase | |
| Arm A | 41 | 15 | 14 | 8 | 8 |
| Arm B | 30 | 5 | 0 | 2 | 3 |
Duration of Response was defined as the time from date of first response (Complete Response (CR) or Partial Response (PR)) to the date when Progressive Disease (PD) was first documented or to the date of death, whichever occurred first according to Response Evaluation Criteria in Solid Tumors (RECIST). Subjects still having CR or PR and alive at the time of analysis were censored at their last date of tumor evaluation. CR was defined as disappearance of tumor lesions, PR as a decrease of at least 30% and PD as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks
| Intervention | months (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 7.5 |
| Matching Placebo + mFOLFOX6 | 6.7 |
Overall response of a subject was defined as the best tumor response (Complete Response (CR) or Partial Response (PR)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.
| Intervention | participants (Number) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 45 |
| Matching Placebo + mFOLFOX6 | 61 |
Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT00865709)
Timeframe: From randomization of the first subject until 33 months later.
| Intervention | days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 535 |
| Matching Placebo + mFOLFOX6 | 552 |
Progression-free Survival (PFS) was defined as the time from date of randomization to disease progression or death due to any cause, whichever occurred first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.
| Intervention | Months (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 9.1 |
| Matching Placebo + mFOLFOX6 | 8.7 |
Time to progression (TTP) was defined as the time from date of randomization to disease progression. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.
| Intervention | Months (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 | 9.2 |
| Matching Placebo + mFOLFOX6 | 9.0 |
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response. CR: disappearance of all lesions and no appearance of new lesions. PR: >=30% decrease in sum of LD of target lesions taking as reference the baseline sum LD, without progression of nontarget lesions and no appearance of new lesions. Progression: >=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation. (NCT00460603)
Timeframe: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)
| Intervention | days (Median) |
|---|---|
| Phase 2: Axitinib + FOLFOX | 434.0 |
| Phase 2: Bevacizumab + FOLFOX | NA |
| Phase 2: Axitinib + Bevacizumab + FOLFOX | 343.0 |
Time in days from randomization date to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). (NCT00460603)
Timeframe: Every 3 months after discontinuation of study treatment until death due to any cause or 1 year after randomization of the last participant
| Intervention | days (Median) |
|---|---|
| Phase 2: Axitinib + FOLFOX | 552.0 |
| Phase 2: Bevacizumab + FOLFOX | 659.0 |
| Phase 2: Axitinib + Bevacizumab + FOLFOX | 601.0 |
Percentage of participants with objective response (OR) based assessment of confirmed complete response(CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR defined as disappearance of all lesions and no appearance of new lesions. Confirmed PR defined as >=30 percent (%) decrease in sum of the longest dimensions (LD) of the target lesions taking as reference the baseline sum LD , without progression of nontarget lesions and no appearance of new lesions. Confirmed responses are those that persist on repeat imaging study >=4 weeks after initial documentation of response. (NCT00460603)
Timeframe: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 2: Axitinib + FOLFOX | 28.6 |
| Phase 2: Bevacizumab + FOLFOX | 48.8 |
| Phase 2: Axitinib + Bevacizumab + FOLFOX | 39.0 |
"Time in days from date of randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was Death). Progression: >=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation." (NCT00460603)
Timeframe: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)
| Intervention | days (Median) |
|---|---|
| Phase 2: Axitinib + FOLFOX | 336 |
| Phase 2: Bevacizumab + FOLFOX | 485 |
| Phase 2: Axitinib + Bevacizumab + FOLFOX | 381 |
TTF is defined as the time from the randomization to the date of the first documentation of PD, symptomatic deterioration, death due to any cause, or treatment discontinuation due to adverse event, refusal or other reasons. Progression: >=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation. (NCT00460603)
Timeframe: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)
| Intervention | days (Median) |
|---|---|
| Phase 2: Axitinib + FOLFOX | 187.0 |
| Phase 2: Bevacizumab + FOLFOX | 241.0 |
| Phase 2: Axitinib + Bevacizumab + FOLFOX | 238.0 |
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. CL/F for axitinib (AG-013736) in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
| Intervention | Liter per hour (L/hr) (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 8 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 30.01 | 30.08 |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 47.10 | 33.33 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 28.49 | 28.90 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. AUClast for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose. (NCT00460603)
Timeframe: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | ng*hr/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 39212.03 | 45087.71 |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 40955.29 | 36533.84 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 52164.28 | 95123.13 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). Pharmacokinetic (PK) parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. AUClast for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6 and 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
| Intervention | nanogram hour per milliliter (ng*hr/mL) (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 8 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 119.02 | 95.70 |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 106.76 | 143.68 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 97.05 | 117.47 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. AUClast for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | ng*hr/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 3394758.83 | 3554899.52 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). AUClast for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | ng*hr/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 12081.58 | 11496.32 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. AUClast for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | ng*hr/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 4814.87 | 5231.71 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 4308.71 | 5303.66 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose. (NCT00460603)
Timeframe: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | ng*hr/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 36314.14 | 38983.80 |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 41460.50 | 36776.79 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 52430.15 | 96632.41 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. AUC (t - ∞] for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
| Intervention | ng*hr/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 8 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 190.51 | 224.46 |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 113.20 | 168.07 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 205.41 | 178.46 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | ng*hr/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 4987528.96 | 5114888.84 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | ng*hr/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 13055.88 | 12459.89 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | ng*hr/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 5955.70 | 6744.06 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 5137.31 | 6430.67 |
"PROs included assessment of symptom severity and interference which were measured using M.D. Anderson Symptom Assessment Inventory-Diarrhea (MDASI-D), 20-item questionnaire which assesses the severity of 14 symptoms over the past 24 hours, as well as symptoms interference with 6 areas of function (e.g., walking, work, mood), when the symptom was at its worst. Each item is scored from 0 to 10, with '0' indicating that the symptom was either not present or did not interfere with their activities, and '10' indicating that the symptom was as bad as you can imagine or interfered completely with their life. The 2 subscales, symptom severity score and symptom interference score were average of respective items and ranged from 0 to 10, higher score indicating greater severity or interference of symptoms." (NCT00460603)
Timeframe: Cycle 1 Day 1 (baseline), every 2 weeks for the first 2 months (Cycle 2 Day 1 [C2D1], Cycle 3 Day 1, and Cycle 4 Day 1) then monthly thereafter starting Cycle 6 Day 1, and 28 days after the last dose
| Intervention | units on scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Severity Scale: Baseline (n=41,43,40) | Severity Scale: C2D1 (n=37,37,37) | Severity Scale: C3D1 (n=32,38,32) | Severity Scale: C4D1 (n=23,37,30) | Severity Scale: C5D1 (n=23,34,29) | Severity Scale: C6D1 (n=15,38,26) | Severity Scale: C7D1 (n=12,30,22) | Severity Scale: C8D1 (n=17,29,22) | Severity Scale: C9D1 (n=11,24,21) | Severity Scale: C10D1 (n=14,27,21) | Severity Scale: C11D1 (n=10,20,19) | Severity Scale: C12D1 (n=11,23,16) | Severity Scale: C13D1 (n=8,13,12) | Severity Scale: C14D1 (n=8,17,14) | Severity Scale: C15D1 (n=7,11,9) | Severity Scale: C16D1 (n=7,17,14) | Severity Scale: C17D1 (n=5,11,6) | Severity Scale: C18D1 (n=6,14,9) | Severity Scale: C19D1 (n=4,8,16) | Severity Scale: C20D1 (n=5,14,8) | Severity Scale: C21D1 (n=4,5,5) | Severity Scale: C22D1 (n=3,11,8) | Severity Scale: C23D1 (n=4,5,3) | Severity Scale: C24D1 (n=5,11,7) | Severity Scale: C25D1 (n=4,5,5) | Severity Scale: C26D1 (n=4,6,7) | Severity Scale: C27D1 (n=4,3,4) | Severity Scale: C28D1 (n=4,5,7) | Severity Scale: C29D1 (n=2,3,4) | Severity Scale: C30D1 (n=3,6,3) | Severity Scale: C31D1 (n=1,1,3) | Severity Scale: C32D1 (n=2,4,4) | Severity Scale: C33D1 (n=0,0,2) | Severity Scale: C34D1 (n=2,4,3) | Severity Scale: C35D1 (n=0,0,1) | Severity Scale: C36D1 (n=2,3,2) | Severity Scale: C37D1 (n=0,1,0) | Severity Scale: C38D1 (n=2,2,1) | Severity Scale: C39D1 (n=0,1,0) | Severity Scale: C40D1 (n=2,2,2) | Severity Scale: C42D1 (n=2,2,1) | Severity Scale: Follow_Up (n=4,15,14) | Interference Scale: Baseline (n=41,43,40) | Interference Scale: C2D1 (n=37,37,36) | Interference Scale: C3D1 (n=31,38,30) | Interference Scale: C4D1 (n=23,36,30) | Interference Scale: C5D1 (n=23,34,29) | Interference Scale: C6D1 (n=15,38,26) | Interference Scale: C7D1 (n=12,30,22) | Interference Scale: C8D1 (n=17,29,22) | Interference Scale: C9D1 (n=11,24,21) | Interference Scale: C10D1 (n=14,27,21) | Interference Scale: C11D1 (n=10,20,19) | Interference Scale: C12D1 (n=10,23,16) | Interference Scale: C13D1 (n=8,13,12) | Interference Scale: C14D1 (n=8,17,14) | Interference Scale: C15D1 (n=7,11,9) | Interference Scale: C16D1 (n=7,17,14) | Interference Scale: C17D1 (n=5,11,6) | Interference Scale: C18D1 (n=6,14,9) | Interference Scale: C19D1 (n=4,8,6) | Interference Scale: C20D1 (n=5,14,8) | Interference Scale: C21D1 (n=4,5,5) | Interference Scale: C22D1 (n=3,11,8) | Interference Scale: C23D1 (n=4,5,3) | Interference Scale: C24D1 (n=5,11,7) | Interference Scale: C25D1 (n=4,5,5) | Interference Scale: C26D1 (n=4,6,7) | Interference Scale: C27D1 (n=4,3,4) | Interference Scale: C28D1 (n=4,5,7) | Interference Scale: C29D1 (n=2,3,4) | Interference Scale: C30D1 (n=3,6,3) | Interference Scale: C31D1 (n=1,1,3) | Interference Scale: C32D1 (n=2,4,4) | Interference Scale: C33D1 (n=0,0,2) | Interference Scale: C34D1 (n=2,4,3) | Interference Scale: C35D1 (n=0,0,1) | Interference Scale: C36D1 (n=2,3,2) | Interference Scale: C37D1 (n=0,1,0) | Interference Scale: C38D1 (n=2,2,1) | Interference Scale: C39D1 (n=0,1,0) | Interference Scale: C40D1 (n=2,2,2) | Interference Scale: C42D1 (n=2,2,1) | Interference Scale: Follow Up (n=4,15,14) | |
| Phase 2: Axitinib + Bevacizumab + FOLFOX | 2.18 | 0.80 | 0.63 | 0.64 | 0.60 | 0.96 | 0.26 | 0.42 | 0.76 | 0.77 | 0.57 | 0.38 | 0.73 | -0.05 | 0.71 | 0.05 | 0.72 | 0.61 | 0.81 | -0.06 | 1.20 | 0.09 | 1.05 | -0.20 | -0.30 | -0.13 | 0.34 | -0.43 | -0.09 | 0.64 | 1.55 | 1.29 | 0.89 | 0.43 | 0.79 | -0.18 | NA | 0.86 | NA | 0.43 | 0.00 | 0.29 | 2.47 | 0.78 | 1.09 | 1.15 | 1.19 | 0.99 | 0.55 | 0.48 | 0.75 | 0.99 | 0.84 | 0.38 | 0.31 | 0.29 | 0.70 | -0.01 | 1.17 | 1.00 | 1.04 | 0.35 | 1.83 | 0.83 | 1.28 | 0.55 | 0.90 | 0.33 | 1.63 | 0.19 | 1.33 | 1.06 | 2.33 | 2.17 | 1.92 | 1.11 | 1.67 | 1.33 | NA | -0.17 | NA | 0.25 | 0.00 | 0.91 |
| Phase 2: Axitinib + FOLFOX | 1.62 | 0.63 | 0.68 | 0.88 | 0.72 | 0.70 | 0.28 | 0.28 | -0.15 | 0.28 | 0.15 | 0.32 | -0.09 | 0.03 | 0.28 | -0.30 | -0.20 | 0.02 | -0.18 | -0.06 | -0.25 | 0.57 | 0.30 | 0.91 | 0.25 | -0.05 | -0.21 | 0.12 | 3.00 | 1.05 | -0.50 | 0.11 | NA | 0.04 | NA | 0.29 | NA | 0.13 | NA | 0.18 | 0.18 | 1.29 | 2.50 | 0.46 | 0.60 | 0.92 | 0.65 | 0.32 | 0.43 | 0.01 | -0.14 | -0.18 | 0.42 | 0.03 | -0.50 | -0.10 | -0.52 | -0.02 | -0.90 | 0.06 | 0.04 | 0.27 | -0.04 | 0.44 | 0.21 | 2.00 | 0.00 | 0.33 | 0.04 | 0.71 | 3.25 | 0.94 | 0.00 | 0.08 | NA | 0.17 | NA | 0.17 | NA | 0.08 | NA | 0.42 | 0.25 | 1.33 |
| Phase 2: Bevacizumab + FOLFOX | 2.20 | 0.04 | -0.22 | -0.40 | -0.34 | 0.09 | -0.16 | -0.13 | -0.03 | 0.06 | -0.05 | 0.47 | 0.10 | 0.38 | 0.42 | 0.11 | 0.21 | 0.31 | 0.34 | 0.15 | 0.27 | 0.81 | 0.64 | 0.37 | -0.03 | 0.46 | 0.07 | 0.74 | -0.14 | 0.45 | -0.64 | 0.80 | NA | 0.75 | NA | 1.24 | 0.86 | 1.68 | 0.86 | 1.29 | 1.25 | -0.00 | 2.79 | -0.08 | -0.57 | -0.54 | -0.59 | -0.18 | -0.59 | -0.10 | -0.39 | 0.15 | -0.51 | 0.17 | -0.31 | 0.15 | 0.27 | -0.48 | -0.29 | 0.04 | 0.54 | -0.08 | -0.97 | 0.74 | 1.13 | 0.30 | 0.10 | 0.67 | 0.11 | 0.97 | -0.56 | 1.08 | -0.17 | 1.50 | NA | 1.25 | NA | 1.89 | 0.83 | 2.25 | 0.50 | 2.50 | 2.58 | -0.21 |
CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. CL for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | L/hr (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 147.43 | 137.34 |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 128.28 | 144.62 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 99.36 | 53.92 |
CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. CL for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | L/hr (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 0.01 | 0.02 |
CL is a quantitative measure of the rate at which a drug substance is removed from the body. CL for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | L/hr (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 8 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 26.09 | 27.34 |
CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. CL for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | L/hr (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 27.51 | 24.29 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 30.74 | 24.56 |
PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. Cmax for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose. (NCT00460603)
Timeframe: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 16160.85 | 16249.77 |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 34436.94 | 39730.46 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 19622.74 | 34180.87 |
PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3.Cmax for axitinib (AG-013736) in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 8 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 35.57 | 27.51 |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 27.14 | 42.48 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 24.23 | 32.62 |
PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. Cmax for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 26460.05 | 26850.12 |
Cmax for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 1910.25 | 1788.69 |
PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. Cmax for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 278.81 | 318.99 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 265.05 | 374.03 |
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. t1/2 for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | hours (Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 0.26 | 0.25 |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 0.19 | 0.14 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 0.39 | 0.24 |
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. t1/2 for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1
| Intervention | hours (Mean) | |
|---|---|---|
| Cycle 1 Day 8 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 3.26 | 6.12 |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 2.23 | 3.09 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 3.47 | 1.73 |
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. t1/2 for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | hours (Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 205.97 | 210.22 |
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. t1/2 for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | hours (Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + FOLFIRI (Cohort 4) | 6.45 | 6.75 |
Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. t1/2 for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1
| Intervention | hours (Mean) | |
|---|---|---|
| Cycle 1 Day 1 | Cycle 2 Day 1 | |
| Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3) | 20.63 | 23.30 |
| Phase 1: Axitinib + FOLFOX (Cohort 5) | 18.38 | 19.86 |
"Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions." (NCT00416494)
Timeframe: From time of treatment until documented progression or death from any cause, whichever came first, assesed up to 60 months.
| Intervention | months (Median) |
|---|---|
| Initial Cohort | 10.1 |
| Second Cohort | 10.4 |
Average months of survival of participants after receiving study drug. (NCT00416494)
Timeframe: From time of treatment until death from any cause, assesed up to 60 months.
| Intervention | months (Median) |
|---|---|
| Initial Cohort | 19.6 |
| Second Cohort | 24.8 |
"Restaging scans occurred every 9 weeks from time of study drug initiation until disease progression.~Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~The definitions were:~Complete response (CR)- Disappearance of all target lesions Partial response (PD)- At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Stable disease (SD)- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive disease (PD) - At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions" (NCT00416494)
Timeframe: After all subjects were evaluated for restaging which occured every 9 weeks from drug initiation until disease progression, assesed up to 24 months.
| Intervention | percentage of participants with response (Number) |
|---|---|
| Initial Cohort | 63 |
| Second Cohort | 42 |
Number of participants with adverse events (NCT00416494)
Timeframe: After all participants went off study drug regimine.
| Intervention | participants with adverse event (Number) |
|---|---|
| Initial Cohort | 19 |
| Second Cohort | 29 |
"Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions." (NCT00416494)
Timeframe: From time of treatment until documented progression, assesed up to 60 months.
| Intervention | months (Median) |
|---|---|
| Initial Cohort | 10.1 |
| Second Cohort | 10.4 |
Duration of follow-up is defined as the time in days from randomization until disease progression or death, or time to censoring for overall survival. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Days (Mean) |
|---|---|
| Bevacizumab + Capecitabine | 540.5 |
| Capecitabine | 479.2 |
Duration of response was defined as the time in months from the first confirmed complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurred first. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Capecitabine | 9.7 |
| Capecitabine | 9.4 |
Overall survival was defined as the time in months from randomization to death from any cause. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Capecitabine | 20.7 |
| Capecitabine | 17.0 |
Reported is the percentage of participants requiring additional treatment for malignancy in the survival follow-up period. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Bevacizumab + Capecitabine | 50.7 |
| Capecitabine | 49.3 |
Progression-free survival was defined as the time in months from the date of randomization to the date of disease progression or death from any cause, whichever occurred first. All measurable lesions (maximum of 5 per organ and 10 in total, those with the longest diameter and suitability for accurate repeated measurements) were identified as target lesions (TL). A sum of the longest diameter for all TLs was calculated and reported as the baseline sum longest diameter (SLD). All other lesions were identified as non-TLs and recorded at baseline. PD was defined as ≥ 20% increase in the sum of the longest diameter of TLs, taking as reference the smallest SLD recorded since treatment started, the unequivocal progression of existing non-TLs, or the appearance of 1 or more new lesions. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Capecitabine | 9.1 |
| Capecitabine | 5.1 |
Time to response was defined as the time in months from the date of first study treatment to the date of the first documentation of complete response (CR) or partial response (PR), whichever occurred first. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. Participants who did not have a confirmed response were censored at the date of the last evaluable tumor assessment, or if that was unavailable, at the date of the first dose of study medication. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Capecitabine | NA |
| Capecitabine | NA |
BOR was defined as the best response (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD], not evaluable [NE], or not assessed [NA]) recorded from the start of study treatment until disease progression (PD) or death. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since treatment started. For non-TLs, SD was defined as the persistence of 1 or more lesions. PD was defined as ≥ 20% increase in the sum of the longest diameter of TLs, taking as reference the smallest SLD recorded since treatment started, the unequivocal progression of existing non-TLs, or the appearance of 1 or more new lesions. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not assessed | |
| Bevacizumab + Capecitabine | 2.9 | 17.1 | 54.3 | 10.0 | 15.7 |
| Capecitabine | 1.4 | 8.6 | 48.6 | 21.4 | 20.0 |
The ECOG performance status is a scale used to quantify cancer patients' general well-being and activities of daily life. The scale ranges from 0 to 5, with 0 denoting perfect health and 5 indicating death. The 6 categories are 0=Asymptomatic (Fully active, able to carry on all predisease activities without restriction), 1=Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), 2=Symptomatic, < 50% in bed during the day (Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours), 3=Symptomatic, > 50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours), 4=Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair), 5=Death. Reported is the percentage of participants in each of the 6 ECOG performance status categories. (NCT00484939)
Timeframe: Baseline to the Safety Follow-up which occurred 28 days after the last dose of treatment (up to 5 years 8 months).
| Intervention | Percentage of participants (Number) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 7 ECOG = 0 (n=117,110) | Week 7 ECOG = 1 | Week 7 ECOG = 2 | Week 7 ECOG = 3 | Week 7 ECOG = 4 | Week 7 ECOG = 5 | Week 16 ECOG = 0 (n=88,77) | Week 16 ECOG = 1 | Week 16 ECOG = 2 | Week 16 ECOG = 3 | Week 16 ECOG = 4 | Week 16 ECOG = 5 | Week 25 ECOG = 0 (n=66,42) | Week 25 ECOG = 1 | Week 25 ECOG = 2 | Week 25 ECOG = 3 | Week 25 ECOG = 4 | Week 25 ECOG = 5 | Week 34 ECOG = 0 (n=48,24) | Week 34 ECOG = 1 | Week 34 ECOG = 2 | Week 34 ECOG = 3 | Week 34 ECOG = 4 | Week 34 ECOG = 5 | Safety Follow-up ECOG = 0 (n=89,82) | Safety Follow-up ECOG = 1 | Safety Follow-up ECOG = 2 | Safety Follow-up ECOG = 3 | Safety Follow-up ECOG = 4 | Safety Follow-up ECOG = 5 | |
| Bevacizumab + Capecitabine | 50.4 | 47.0 | 1.7 | 0.9 | 0.0 | 0.0 | 50.0 | 45.5 | 3.4 | 1.1 | 0.0 | 0.0 | 43.9 | 48.5 | 6.1 | 1.5 | 0.0 | 0.0 | 39.6 | 58.3 | 0.0 | 2.1 | 0.0 | 0.0 | 33.7 | 47.2 | 12.4 | 6.7 | 0.0 | 0.0 |
| Capecitabine | 34.5 | 58.2 | 5.5 | 1.8 | 0.0 | 0.0 | 36.4 | 51.9 | 11.7 | 0.0 | 0.0 | 0.0 | 45.2 | 45.2 | 9.5 | 0.0 | 0.0 | 0.0 | 33.3 | 58.3 | 8.3 | 0.0 | 0.0 | 0.0 | 32.9 | 45.1 | 14.6 | 4.9 | 1.2 | 1.2 |
"BOR defined as percentage of subjects, whose BOR was either (confirmed) complete response (CR) or partial response (PR), relative to the number of subjects belonging to the study population of interest. CR defined as Disappearance of all target lesions plus disappearance of all non-target lesions & without appearance of any new lesions; confirmed minimum 4 weeks later. PR defined as At least 30% reduction in the SOLD of target lesions plus no significant change in non-target lesions to qualify for either CR or PD without appearance of new lesions; confirmed minimum 4 weeks later" (NCT00439517)
Timeframe: Evaluations were performed every 8 weeks until disease progression, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
| Intervention | percentage of participants (Number) |
|---|---|
| UFOX + Cetuximab | 37.5 |
| FOLFOX4 + Cetuximab | 51.3 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00439517)
Timeframe: Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
| Intervention | months (Median) |
|---|---|
| UFOX + Cetuximab | 12.9 |
| FOLFOX4 + Cetuximab | 15.5 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00439517)
Timeframe: Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 31 Aug 2011
| Intervention | months (Median) |
|---|---|
| UFOX + Cetuximab | 16.8 |
| FOLFOX4 + Cetuximab | 18.4 |
Duration from randomization until progression or death due to any cause. Only deaths within 12 weeks of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment. Response and progression were assessed by the Investigators using response evaluation criteria in solid tumors (RECIST) 1.0 criteria (NCT00439517)
Timeframe: Time from randomization to disease progression, death, or last tumor assessment reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
| Intervention | months (Median) |
|---|---|
| UFOX + Cetuximab | 6.6 |
| FOLFOX4 + Cetuximab | 8.2 |
Please refer to Adverse Events section for details of individual serious adverse events and other adverse events (NCT00439517)
Timeframe: Time from first dose up to 30 days after last dose of study treatment, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
| Intervention | participants (Number) |
|---|---|
| UFOX + Cetuximab | 151 |
| FOLFOX4 + Cetuximab | 149 |
The EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QOL. (NCT00439517)
Timeframe: at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Baseline | Cycle 3 | Cycle 6 | |
| FOLFOX4 + Cetuximab | 0.734 | 0.758 | 0.771 |
| UFOX + Cetuximab | 0.747 | 0.782 | 0.758 |
TPQ was used to investigate which features of chemotherapy treatment are the most relevant in ensuring patient satisfaction. The most essential characteristics of a cancer medication are shown at baseline and at cycle 3, along with percentage of subjects selecting that characteristic. (NCT00439517)
Timeframe: at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline: Does not increase your risk of infection | Baseline: Does not interfere with daily activities | Baseline: Does not make you vomit | Baseline: Does not give you diarrhea | Cycle 3: Does not increase your risk of infection | Cycle 3: Does not interfere with daily activities | Cycle 3: Does not make you vomit | Cycle 3: Does not give you diarrhea | |
| FOLFOX4 + Cetuximab | 16 | 15 | 14 | 5 | 15 | 11 | 10 | 4 |
| UFOX + Cetuximab | 18 | 17 | 4 | 9 | 15 | 10 | 4 | 15 |
"All of the single-item measures of the FACT-C are assessed on ordinal response categories ranging from 0=Not at all to 4=Very much. For scoring purposes the response scores are reversed on negatively phrased questions. The principle for scoring the sub-scales is the same in all cases: subscale score = (Sum of items × Number of items in the subscale) / numbers of items answered. The lowest possible total score is 0 and the highest is 136. A high scale score represents a high QOL." (NCT00439517)
Timeframe: At baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. Cycles were 4 weeks long unless dosing delays
| Intervention | scores on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Baseline | Cycle 3 | Cycle 6 | |
| FOLFOX4 + Cetuximab | 96.45 | 95.89 | 94.70 |
| UFOX + Cetuximab | 98.22 | 95.41 | 94.75 |
Non-protocol medical care visits and consultations (NCT00439517)
Timeframe: From randomisation until final visit, reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009
| Intervention | visits or consultations (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Emergency room visit | Hospital oupatient clinic visit | Practice visit | Home visit | General Practitioner consultation | Specialist consultation | Nurse consultation | Other consultation | |
| FOLFOX4 + Cetuximab | 26 | 35 | 159 | 130 | 124 | 84 | 123 | 18 |
| UFOX + Cetuximab | 34 | 40 | 71 | 15 | 65 | 62 | 15 | 19 |
Quality of life (QoL) is evaluated using FACIT-D scale. FACIT-D is composed of 38 items, whose responses range from 0 to 4. The total FACIT-D score may range from 0 to 152. The 38 items compose five subscales, each evaluating a different component of the (QOL). For calculating the subscale score, some items are computed in a reverse fashion, so that higher FACIT-D scores indicate a better (QoL). Descriptive statistics (mean, standard deviation, median, minimum and maximum) are used to summarize FACIT-D scores (total and subscales) by study group at each time point. (NCT00582426)
Timeframe: Baseline to Day 168
| Intervention | Units on a scale (Mean) |
|---|---|
| Octreotide Long Acting Release | 0.5 |
| Standard Treatment | 3.4 |
Number of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis. (NCT00582426)
Timeframe: 6 months overall
| Intervention | Episodes/patients/day (Mean) |
|---|---|
| Octreotide Long Acting Release | 21.6 |
| Standard Treatment | 20.4 |
The percentage of patients developing diarrhea (incidence of grade 1 to 4) during treatment, considering only the worst grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0=None, 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. (NCT00582426)
Timeframe: 6 month overall
| Intervention | Percentage of Participants (Number) |
|---|---|
| Octreotide Long Acting Release | 76.1 |
| Standard Treatment | 78.9 |
For patient, chemotherapy dose reduction due to diarrhea as counted each time it occurred. Chemotherapy dose reduction because of other adverse events related to chemotherapy was not considered. (NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of participants (Number) |
|---|---|
| Octreotide Long Acting Release | 26.9 |
| Standard Treatment | 11.3 |
(NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of Participants (Number) |
|---|---|
| Octreotide Long Acting Release | 4.5 |
| Standard Treatment | 7.0 |
(NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of Participants (Number) |
|---|---|
| Octreotide Long Acting Release | 1.5 |
| Standard Treatment | 1.4 |
(NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of patients (Number) |
|---|---|
| Octreotide Long Acting Release | 6 |
| Standard Treatment | 4.2 |
Mean number of episodes of diarrhea is evaluated by patient diaries recorded by cycle. (cycle 1 to cycle 7.) (NCT00582426)
Timeframe: at each cycle (28 days per cycle)
| Intervention | Episodes/patient/cycle (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 (n=20, 18) | Cycle 2 (n=36,38) | Cycle 3 (n=33,39) | Cycle 4 (n=24, 27) | Cycle 5 (n=20,29) | Cycle 6 (n=22, 22) | Cycle 7 (n= 16, 20) | |
| Octreotide Long Acting Release | 2.6 | 8.2 | 6.9 | 8.6 | 8.1 | 6.1 | 4.8 |
| Standard Treatment | 2.2 | 5.9 | 6.7 | 7.1 | 7 | 5.8 | 6.6 |
Grade (severity)of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence;or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. (NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of Episodes (Number) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Octreotide Long Acting Release | 65.4 | 23.3 | 11.3 | 0 |
| Standard Treatment | 66.9 | 27.2 | 5.9 | 0 |
Lesions that can be accurately measured in at least one dimension (longest diameter (LD) to be recorded) as > 20 mm with conventional techniques (CT, MRI) or as > 10 mm with spiral CT scan. All measurable lesions up to maximum of 5 lesions per organ and 10 lesions in total representative of all involved organs should be identified as target lesions and recorded and measured at baseline. Complete Response is defined as Disappearance of all target lesions. Partial Response is defined at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. (NCT00582426)
Timeframe: Day 56, Day 84, Day 112, Day 140, Day 168
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Day 56 (N=11,2) | Day 84 (N=5,3) | Day 112 (N=1,1) | Day 140 (N=9,1) | Day 168 (N=2,1) | |
| Octreotide Long Acting Release | 45.5 | 60.0 | 100 | 44.4 | 100 |
| Standard Treatment | 0.0 | 100 | 0.0 | 100 | 100 |
Grade (severity) of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0 = None, 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. (NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Octreotide Long Acting Release | 41.2 | 25.5 | 33.3 | 0 |
| Standard Treatment | 26.8 | 51.8 | 21.4 | 0 |
"Gamma camera imaging were performed on four occasions (1-4 hours, Day 1, Day 2 or 3, and Day 4 or 5) following completion of the initial infusion and 7+2 days post-therapy infusion in week 2, and again in week 3 or 4 and week 5 following the therapy infusion.~Dosimetry analysis was performed on the series of gamma camera whole-body planar images.~Tumor radioactivity content after the initial infusion was estimated from the geometric mean of anterior and posterior regions of interest counts. The counts for each organ were corrected for background using regions of interest drawn adjacent to each tumor. Resultant counts were converted to activity using a camera sensitivity factor calculated from a gamma camera standard of known activity which was scanned at the same time." (NCT00291486)
Timeframe: 5 weeks
| Intervention | Gy (Mean) |
|---|---|
| All Patients | 13.83 |
| Cohorts 2 and 3; 30 mCi 131I-huA33 | 13.15 |
| Cohorts 4 and 5: 40 mCi 131I-huA33 | 14.89 |
"Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v3.0). DLT was defined as any of the following related events:~Any grade 2 or greater allergic reaction related to huA33. Any grade ≥ 3 non-haematological toxicity related to 131I-huA33 or capecitabine.~These toxicities included palmar plantar erythema, but skin rash thought to be related to huA33 protein was not a DLT as previous studies have shown no relation of this toxicity to dose of huA33 or radioiodine dose.~Capecitabine cardiotoxicity grade ≥ 3 - including vasospasm, acute coronary syndrome and arrhythmia, necessitated the cessation of study drug in the affected patient but were not considered DLT as these are recognized as idiosyncratic in nature and not known to be related to capecitabine dose.~Any grade ≥ 4 neutropenia ≥ 7 days in duration or any thrombocytopenia with a platelet count < 10 x 10^9/L." (NCT00291486)
Timeframe: 7 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 | 0 |
| Cohort 2 | 2 |
| Cohort 3 | 0 |
| Cohort 4 | 0 |
| Cohort 5 | 0 |
T1/2 biological is the clearance of the isotope from the whole body. Following the initial 131I-huA33 infusion, gamma camera scans were acquired over a 1 week period (1-4 hours, Day 1, Day 2 or 3, and Day 4 or 5). Whole body clearance, or biological half time, T1/2 biological, was calculated from the whole body anterior and posterior planar images. A region of interest (ROI) was calculated to encompass the whole body, and for each ROI at each time point, the mean counts per pixel per minute was normalised to imaging time point Day 1. (NCT00291486)
Timeframe: 1 week
| Intervention | hours (Mean) | ||
|---|---|---|---|
| Whole Body Clearance (T1/2 biologic) | Normal Organ Clearance in the Liver (T1/2 biological - liver) | Normal Organ Clearance in the kidney (T1/2 biological - kidney) | |
| Cohorts 1-5 | 219.56 | 62.29 | 104.89 |
"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 13II-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks
| Intervention | ml/hr (Mean) | |
|---|---|---|
| Initial dose CL | Therapy dose CL | |
| Cohort 5; 1250 mg/m2/Day Capecitabine | 34.65 | 35.53 |
| Cohorts 1 and 2; 1500 mg/m2/Day Capecitabine | 34.88 | 26.88 |
| Cohorts 3 and 4; 1000 mg/m2/Day Capecitabine | 40.54 | 39.41 |
"Gamma camera imaging with anterior and posterior whole body scans using conjugate view methodology were performed on four occasions (1-4 hours, Day 1, Day 2 or 3, and Day 4 or 5) following completion of the intravenous initial infusion.~Dosimetric analysis was performed on the series of gamma camera whole-body planar images acquired in all patients following the first infusion.~Organ radioactivity content was estimated from the geometric mean of anterior and posterior regions of interest counts. The counts for each organ were corrected for background using regions of interest drawn adjacent to each organ where whole body thickness was comparable." (NCT00291486)
Timeframe: 1 week
| Intervention | cGy/MBq (Mean) | ||||
|---|---|---|---|---|---|
| Liver | Spleen | Kidney | Lung | Red Marrow | |
| Cohorts 1-5 | 0.12 | 0.18 | 0.14 | 0.09 | 0.056 |
"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 131I-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks
| Intervention | mcg.hr/mL (Mean) | |
|---|---|---|
| AUC after initial 131I-huA33 infusion | AUC after therapy 131I-huA33 infusion | |
| Cohorts 1-5 | 130.43 | 592.46 |
"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 13II-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks
| Intervention | mL/hr (Mean) | |
|---|---|---|
| CL after initial 131I-huA33 infusion | CL after therapy 131I-huA33 infusion | |
| Cohorts 1-5 | 36.72 | 32.60 |
"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 131I-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks
| Intervention | mcg/mL (Mean) | |
|---|---|---|
| Cmax after initial 131I-huA33 infusion | Cmax after therapy 131I-huA33 infusion | |
| Cohorts 1-5 | 1.53 | 5.52 |
"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 131I-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks
| Intervention | hours (Mean) | |||
|---|---|---|---|---|
| T½α after initial 131I-huA33 infusion | T½α after therapy 131I-huA33 infusion | T½β after initial 131I-huA33 infusion | T½β after therapy 131I-huA33 infusion | |
| Cohorts 1-5 | 15.78 | 28.63 | 100.24 | 152.60 |
"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 131I-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks
| Intervention | mL (Mean) | |
|---|---|---|
| V1 after initial 131I-huA33 infusion | V1 after therapy 131I-huA33 infusion | |
| Cohorts 1-5 | 3204.26 | 3363.69 |
Serum samples for human anti-human antibody (HAHA) assessment were collected prior to each 131I-huA33 infusion, at weekly intervals during weeks 0-7, then alternate weeks until the end-of-study visit. Measurement of immune responses to huA33 in patients serum was performed using a BIAcore 2000 biosensor (Biacore AB, Uppsala, Sweden). (NCT00291486)
Timeframe: 13 weeks
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-treatment72460703 | Pre-treatment72460704 | Pre-treatment72460705 | Pre-treatment72460706 | Pre-treatment72460702 | Week 172460703 | Week 172460704 | Week 172460705 | Week 172460706 | Week 172460702 | Week 272460703 | Week 272460704 | Week 272460705 | Week 272460706 | Week 272460702 | Week 372460703 | Week 372460704 | Week 372460705 | Week 372460706 | Week 372460702 | Week 472460703 | Week 472460704 | Week 472460702 | Week 472460705 | Week 472460706 | Week 572460703 | Week 572460704 | Week 572460705 | Week 572460702 | Week 572460706 | Week 672460703 | Week 672460704 | Week 672460706 | Week 672460702 | Week 672460705 | Week 872460702 | Week 872460703 | Week 872460704 | Week 872460705 | Week 872460706 | Week 10-1172460703 | Week 10-1172460704 | Week 10-1172460705 | Week 10-1172460706 | Week 10-1172460702 | Week 12-1372460703 | Week 12-1372460704 | Week 12-1372460705 | Week 12-1372460706 | Week 12-1372460702 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative HAHA | Positive HAHA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 2 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 4 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 5 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 2 | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 3 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 4 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 5 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 4 | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 3 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 4 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 3 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 5 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 5 | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 1 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 1 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 2 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 2 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 3 | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 5 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 1 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Duration of response is defined as the delay between response (complete or partial) and disease progression according to RECIST V1.0. Therefore, this criterion can only be assessed in in subjects who have responded. Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.). Progression is defined as a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, or appearance of one or several new lesions (RECIST V1.0) Radiologic assessment was carried out every four cycles (8 weeks) with centralized external secondary review. (NCT00467142)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Folfiri and Bevacizumab | 9.5 |
Objective response defined as complete or partial responses according to RECIST v1.0. Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).Radiologic assessment was carried out every four cycles (8 weeks) with centralized external secondary review. (NCT00467142)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Folfiri and Bevacizumab | 47.5 |
Tumour Response Rate per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR) - Disappearance of all target lesions which is confirmed if determined by two observations not less than 4 weeks apart; Partial Response (PR) - >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00724503)
Timeframe: Through study completion, up to 60 months
| Intervention | percentage of participants (Number) |
|---|---|
| B: FOLFOX + SIR-Spheres | 76.4 |
| A: FOLFOX Alone | 68.1 |
PFS defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as an increase in the sum of the longest diameters of ≥ 20% and an absolute increase in the sum of the longest diameters of ≥ 5 mm, or the appearance of a new lesion. (NCT00724503)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
| Intervention | Months (Median) |
|---|---|
| mFOLFOX6 Plus SIRT | 10.7 |
| mFOLFOX6 Alone | 10.2 |
OS was defined as the time from randomization to death from any cause. For participants without an event of death, OS was censored at the last-known alive date. OS was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (prior to each cycle, and within 7 days prior to surgery; at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
| Intervention | months (Median) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 32.2 |
| Bevacizumab + FOLFOXIRI | NA |
PD was defined, using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, as at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of one or more new lesions. The percentage of participants experiencing PD or death was calculated as [number of participants with event divided by the number of participants analyzed] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 89.7 |
| Bevacizumab + FOLFOXIRI | 68.3 |
Among participants with curative resection (complete resection [R0] or microscopic residual tumor [R1]), relapse was defined as the first new occurrence of cancer or death. The percentage of participants who experienced relapse was calculated as [number of participants with a relapse event divided by the number of participants initially classified as R0 or R1 following resective surgery] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 76.9 |
| Bevacizumab + FOLFOXIRI | 57.1 |
(NCT00778102)
Timeframe: Up to 5 years (prior to each cycle, and within 7 days prior to surgery; at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 48.7 |
| Bevacizumab + FOLFOXIRI | 19.5 |
Using RECIST version 1.0, participants were considered to have achieved CR upon the disappearance of all target and non-target lesions. Participants who achieved PR demonstrated at least a 30% decrease in the sum of the largest diameter of target lesions, taking as reference the Screening sum largest diameter. Responses were confirmed by repeat assessments no less than 4 weeks after criteria for response were first met. The collective percentage of participants with confirmed best overall response of CR or PR was calculated as [number of participants meeting RECIST criteria for CR or PR divided by the number of participants analyzed] multiplied by 100. Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 61.5 |
| Bevacizumab + FOLFOXIRI | 80.5 |
At the time of resective surgery, participants were evaluated for histopathological response as defined through pathologist review of the resected metastatic lesions, including assessment of margin status and tumor cell viability. Histopathological response classification was based upon the percentage of viable tumor cells, as described previously. The collective percentage of participants assessed as having a complete or major response was calculated as [number of participants with complete or major response divided by the number of participants who completed the assessment] multiplied by 100. Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 57.1 |
| Bevacizumab + FOLFOXIRI | 52.4 |
PFS was defined, using RECIST version 1.0, as the time from randomization to the date of first documented PD or death from any cause. PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of one or more new lesions. For participants without documented PD or death, PFS was censored at the time of last tumor assessment. PFS was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
| Intervention | months (Median) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 11.5 |
| Bevacizumab + FOLFOXIRI | 18.6 |
RFS was defined as the time from curative resection (complete resection [R0] or microscopic residual tumor [R1]) to the date of first diagnosis of relapse. For participants with curative resection and without relapse, RFS was censored at the last known relapse-free assessment. RFS was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
| Intervention | months (Median) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 8.1 |
| Bevacizumab + FOLFOXIRI | 17.1 |
Time to resection was defined as the time from randomization to the date of first resective surgery. For participants who did not undergo resective surgery, time to resection was censored at Day 1. Time to resection was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at Screening; prior to each cycle, and within 7 days prior to surgery; and at time of surgery)
| Intervention | months (Median) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 4.4 |
| Bevacizumab + FOLFOXIRI | 4.3 |
Time to response according to RECIST version 1.0 was defined as the time from randomization to the date of first documented CR or PR. Participants were considered to have achieved CR upon the disappearance of all target and non-target lesions. Participants who achieved PR demonstrated at least a 30% decrease in the sum of the largest diameter of target lesions, taking as reference the Screening sum largest diameter. Responses were confirmed by repeat assessments no less than 4 weeks after criteria for response were first met. For participants who did not complete a confirmatory tumor assessment, time to response was censored at the date of last tumor assessment, or if unavailable, at the date of first dose. Time to response was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)
| Intervention | months (Median) |
|---|---|
| Bevacizumab + mFOLFOX-6 | 3.1 |
| Bevacizumab + FOLFOXIRI | 3.1 |
Following resective surgery, participants were evaluated for complete resection (R0) or the presence of microscopic (R1) or macroscopic (R2) residual tumor. The percentage of participants within each residual tumor classification was calculated as [number of participants with R0, R1, and/or R2 divided by the total number of participants] multiplied by 100. Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| R0, R1, or R2 | R0 or R1 | R0 | |
| Bevacizumab + FOLFOXIRI | 61.0 | 51.2 | 48.8 |
| Bevacizumab + mFOLFOX-6 | 48.7 | 33.3 | 23.1 |
Complications related to the first resective surgery were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, and classified according to severity. The NCI-CTCAE severity classification criteria are as follows: Grade 5 equals (=) resulting in death; Grade 4 = life-threatening; Grade 3 = severe; Grade 2 = moderate; and Grade 1 = mild. The percentage of participants experiencing a given adverse event (AE) by severity grade was calculated as [number of participants with an AE divided by the number of participants who underwent first resective surgery] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
| Intervention | percentage of participants (Number) | ||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any complication, Total | Any complication, Grade 1 | Any complication, Grade 2 | Any complication, Grade 3 | Any complication, Grade 4 | Any complication, Grade 5 | Bleeding, Total | Bleeding, Grade 1 | Bleeding, Grade 2 | Bleeding, Grade 3 | Cardiovascular, Total | Cardiovascular, Grade 2 | Cardiovascular, Grade 3 | Cardiovascular, Grade 4 | Infections, Total | Infections, Grade 1 | Infections, Grade 2 | Infections, Grade 3 | Infections, Grade 4 | Liver insufficiency, Total | Liver insufficiency, Grade 5 | Neural disorder, Total | Neural disorder, Grade 2 | Noninfected perihepatic fluid collections, Total | Noninfected perihepatic fluid collections, Grade 2 | Other complication, Total | Other complication, Grade 1 | Other complication, Grade 2 | Other complication, Grade 3 | Other complication, Grade 4 | Pulmonary, Total | Pulmonary, Grade 3 | Renal impairment, Total | Renal impairment, Grade 2 | Renal impairment, Grade 4 | Wound healing, Total | Wound healing, Grade 1 | Wound healing, Grade 3 | Wound healing, Grade 4 | |
| Bevacizumab + FOLFOXIRI | 52.0 | 4.0 | 12.0 | 24.0 | 12.0 | 0 | 8.0 | 0 | 4.0 | 4.0 | 4.0 | 4.0 | 0 | 0 | 32.0 | 12.0 | 0 | 16.0 | 4.0 | 0 | 0 | 0 | 0 | 4.0 | 4.0 | 28.0 | 8.0 | 8.0 | 12.0 | 0 | 4.0 | 4.0 | 4.0 | 4.0 | 0 | 12.0 | 0 | 4.0 | 8.0 |
| Bevacizumab + mFOLFOX-6 | 73.7 | 15.8 | 36.8 | 10.5 | 0 | 10.5 | 15.8 | 5.3 | 5.3 | 5.3 | 10.5 | 0 | 5.3 | 5.3 | 26.3 | 10.5 | 5.3 | 5.3 | 5.3 | 10.5 | 10.5 | 5.3 | 5.3 | 0 | 0 | 52.6 | 26.3 | 21.1 | 0 | 5.3 | 5.3 | 5.3 | 10.5 | 5.3 | 5.3 | 5.3 | 5.3 | 0 | 0 |
Complications related to the second resective surgery were evaluated using the NCI-CTCAE version 3.0, and classified according to severity. The NCI-CTCAE severity classification criteria are as follows: Grade 5 = resulting in death; Grade 4 = life-threatening; Grade 3 = severe; Grade 2 = moderate; and Grade 1 = mild. The percentage of participants experiencing a given AE by severity grade was calculated as [number of participants with an AE divided by the number of participants who underwent second resective surgery] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any complication, Total | Any complication, Grade 1 | Any complication, Grade 2 | Any complication, Grade 3 | Any complication, Grade 3a | Bleeding, Total | Bleeding, Grade 1 | Bleeding, Grade 2 | |
| Bevacizumab + FOLFOXIRI | 66.7 | 33.3 | 0 | 33.3 | 0 | 33.3 | 33.3 | 0 |
| Bevacizumab + mFOLFOX-6 | 100.0 | 0 | 66.7 | 0 | 33.3 | 33.3 | 0 | 33.3 |
At the time of resective surgery, participants were evaluated for histopathological response as defined through pathologist review of the resected metastatic lesions, including assessment of margin status and tumor cell viability. Histopathological response classification was based upon the percentage of viable tumor cells, where 'Complete response' was considered for those with 0 percent (%) viable tumor cells, 'Major response' for those with 1% to 49% viable tumor cells, 'Minor response' for 50% to 99% viable tumor cells, and 'No response' for 100% viable tumor cells. The response could not be determined in some cases and was documented as 'Unknown.' The percentage of participants within each response category was calculated as [number of participants with a given response divided by the number of participants who completed the assessment] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete response | Major response | Minor response | No response | Unknown | |
| Bevacizumab + FOLFOXIRI | 4.8 | 47.6 | 33.3 | 0 | 14.3 |
| Bevacizumab + mFOLFOX-6 | 0 | 57.1 | 28.6 | 0 | 14.3 |
Disease control is defined as incidence of objective response or stable disease on study up to starting a new anti-tumor therapy. (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | % of participants (Number) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 79.52 | 66.67 |
| Panitumumab Plus FOLFIRI | 72.41 | 52.94 |
Duration of response is defined as time from first confirmed objective response to disease progression per modified RECIST version 1.0 (by central assessment). (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 8.9 | 15.2 |
| Panitumumab Plus FOLFIRI | 12.7 | 10.2 |
Objective response rate is defined as incidence of either a confirmed complete response (CR) or partial response (PR) on study up to starting a new anti-tumor therapy and will be based on modified RECIST version 1.0 (responder) by central assessment. (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | % of patients (Number) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 19.28 | 3.33 |
| Panitumumab Plus FOLFIRI | 32.18 | 11.76 |
Overall survival is defined as time from the date of randomization to the date of death due to any cause. Subjects who have not died or are lost to follow-up at the analysis cutoff date will be censored at their last contact date. (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 21.4 | 13.5 |
| Panitumumab Plus FOLFIRI | 18.0 | 8.7 |
Progression-free survival is defined as time from the date of randomization to the date of first progression per modified RECIST version 1.0 (based on central review of the radiographic scans), or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later). (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 9.2 | 6.4 |
| Panitumumab Plus FOLFIRI | 7.7 | 3.7 |
Time to progression is defined as time from the date of randomization to the date of radiographic disease progression per modified RECIST version 1.0 (per central assessment). (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS | Mutant KRAS | |
| Bevacizumab Plus FOLFIRI | 9.4 | 7.4 |
| Panitumumab Plus FOLFIRI | 11.1 | 4.5 |
Time to response is defined as time from the date of randomization to the date of first confirmed objective response (NCT00418938)
Timeframe: From randomization up to 65 months.
| Intervention | months (Median) | |
|---|---|---|
| Wild-type KRAS (n=91,91) | Mutant KRAS (n=36,32) | |
| Bevacizumab Plus FOLFIRI | 3.7 | 1.8 |
| Panitumumab Plus FOLFIRI | 2.1 | 2.2 |
For participants with a best overall response of CR or PR, the duration of overall response was measured from the time that the criteria for CR or PR (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of overall response was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 8.52 |
For participants with a best overall response of CR, PR, or SD during first line treatment, the duration of stable response was measured from the time that the criteria for CR, PR, or SD (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of stable response was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 10.39 |
Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive. (NCT00577031)
Timeframe: Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 50.76 |
Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive. Median overall survival was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 23.15 |
The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than [<]10 millimeters [mm]). No new lesions. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 58.79 |
CR and PR were defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. Short axis was used in sum for target nodes, while longest diameter was used in sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 54.64 |
CR and PR were defined using RECIST v1.0. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 49.24 |
Stable response defined as participants with a best overall response of CR, PR, or stable disease (SD), defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 52.63 |
Treatment-failure was defined as discontinuation of treatment for any reason, including the following qualifying events: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 82.74 |
PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented that neither a relapse nor a new colorectal cancer had occurred. Median PFS was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline and Day 1 of every cycle until disease progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 9.70 |
PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented neither a relapse nor a new colorectal cancer had occurred. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00577031)
Timeframe: Baseline and Day 1 of every cycle until disease progression or death up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 50.25 |
Time to overall response (CR or PR) was calculated as the time between the date of start of treatment until first documented response (CR or PR defined per RECIST v1.0). Participants who did not achieve CR or PR were censored at the date of progression, death, or at last adequate tumor assessment date. Median time to CR or PR overall response was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 3.93 |
Time to treatment-failure was defined as the time from the first day of treatment to discontinuation of treatment for any reason, including: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). For participants who did not experience a qualifying event, their data were censored at the earlier of either the date of last tumour assessment or the date of the last intake of study medication. Median time to treatment-failure was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 6.69 |
"Quality of life (QoL) assessments were used to derive pre-specified QoL scores according to the QoL manual EQ-5D-3 Level (3L) user guide for instrument version 4.0. The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The visual analog scale (VAS) component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The overall health score absolute changes were calculated for each participant as follows: (score at the end of treatment minus score at baseline). EQ-5D health states were converted into EQ-5D-3L raw index value by applying the scoring algorithm based on the European EQ-net VAS set. The raw index was chosen instead of rescaled index, since the questionnaire was used in order to obtain a quality of life assessment. The raw index scores ranged from 0 (worst health state) to 100 (best health state)." (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles), at end-of-treatment up to 5 years
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Last visit | Absolute change from baseline | |
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 80.24 | 74.94 | -5.30 |
The percentage of participants who underwent surgery during the study period with an evaluation of their disease status after surgery. The surgery during the study period was described by reason: curative, palliative, biopsy, other, or unknown. Residual disease status after surgery was described as: no residual disease due to radical surgery, presence of residual disease, unknown or not applicable. (NCT00577031)
Timeframe: At surgery, at least 6 to 8 weeks after last dose of bevacizumab up to 5 years
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Curative, no residual disease | Curative, residual disease | Curative, unknown | Curative, not applicable | Palliative, no residual disease | Palliative, residual disease | Palliative, unknown | Palliative, not applicable | Biopsy, residual disease | Biopsy, not applicable | Unknown, unknown | Unknown, not applicable | Other, residual disease | Other, not applicable | |
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 55.77 | 13.46 | 3.85 | 7.69 | 3.85 | 7.69 | 3.85 | 1.92 | 1.92 | 1.92 | 1.92 | 3.85 | 1.92 | 3.85 |
"The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.~The K-Ras and/or the B-Raf gene mutation status of participants was evaluated by the central laboratory using tumor samples. Wild-type participants did not have a mutation in either gene." (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Wild-type (n=18) | Gene mutation (n=15) | |
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 88.89 | 66.67 |
Pharmacokinetics of 5-FU - Cmax plasma levels (NCT01206465)
Timeframe: 22, 23, 45 & 46 hours during the 48 hour infusion
| Intervention | mg/m^2 (Mean) |
|---|---|
| 22 Hours | 1147 |
| 23 Hours | 1159 |
| 45 Hours | 1123 |
| 46 Hours | 1113 |
Plasma concentrations versus time (at all time points) (NCT01206465)
Timeframe: Pre-treatment, end of infusion, at 15, 30, and 60 min, and then at 2, 4, 6, 8, 12, 22, 23, 24, 45, and 46 hours for PDX.
| Intervention | ng/ml *hr (Mean) |
|---|---|
| 75 mg/m^2 | 12,818 |
| 94 mg/m^2 | 16300 |
| 118 mg/m^2 | 15680 |
| 148 mg/m^2 | 23570 |
| 185 mg/m^2 | 42121 |
Recommended dose of PDX given in combination with a fixed dose of 5-FU administered as a 48-hour infusion given every other weekMaximum tolerated dose will have been exceeded when 2 patients entered at a given dose level experience specified dose-limiting toxicities in the initial cycle (NCT01206465)
Timeframe: During the initial course (day 1 & 15 of a 4 week schedule)
| Intervention | mg per meter square (Number) |
|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 148 |
Time to disease progression in all Participants (NCT01206465)
Timeframe: restaging imaging done after each two 4-week course until time of progression (longest time to progression = 588 days)
| Intervention | days (Median) |
|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 112 |
Participants remained on study as long as they did not progress, and wished to continue on study (no limit on number of cycles) (NCT01206465)
Timeframe: "., From the time the subject signs the consent form and ending 4 weeks following the final chemotherapy, an average of 3 years"
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| gr 3-4 neutropenia | gr 3-4 thrombocytopenia | gr 3-4 anemia | gr 3-4 diarrhea | gr 3-4 mucositis | gr 3-4 dehydration | gr 3-4 fatigue | |
| Treatment (Enzyme Inhibitor Therapy) | 4 | 0 | 4 | 1 | 5 | 1 | 1 |
Number of Participants with Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase (NCT01206465)
Timeframe: Prior to the first dose of protocol therapy
| Intervention | percentage of patients (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| SLC19A1 80G>A | gamma glutamyl hydrolase (GGH) 401C>T | gamma glutamyl hydrolase (GGH) 452C>T | folyl polyglutamate synthase (FPGS) rs10760502A>G | folyl polyglutamate synthase (FPGS) rs1544105C>T | methylene tetrahydrofolate reductase (MTHFR 677C>T | methylene tetrahydrofolate reductase MTHFR 1298A>C | thymidylate synthase 28-bp tandem repeats (2 or 3) | |
| Heterozygous | 40.7 | 37.0 | 11.1 | 4.0 | 55.6 | 25.9 | 33.3 | 48.2 |
| Homozygous Variant | 7.4 | 7.4 | 0 | 0 | 18.5 | 18.5 | 14.8 | 37.0 |
| Wild Type | 51.9 | 55.6 | 88.9 | 96.0 | 25.9 | 55.6 | 51.9 | 14.8 |
Disease control rate was calculated by adding complete and partial responses and stable disease. (NCT01718873)
Timeframe: At weeks 12 and 24 from randomization and every 3 months thereafter, assessed up to 90 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab Before Chemotherapy | 107 |
| Bevacizumab With Chemotherapy | 103 |
"Objective response rate (ORR), according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, was the primary end point and was defined as the number of complete plus partial responses divided by the number of enrolled patients.~Per RECIST v 1.1 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT01718873)
Timeframe: Objective response was assessed by computed tomographic scan or other appropriate imaging at weeks 12 and 24 from randomization, and every 3 months thereafter, assessed up to 90 months.
| Intervention | participants (Number) |
|---|---|
| Bevacizumab Before Chemotherapy | 65 |
| Bevacizumab With Chemotherapy | 66 |
Overall survival was defined as the time from randomization to the date of death. Patients alive at the time of the final analysis were censored on the date of the last follow-up information available. (NCT01718873)
Timeframe: assessed up to 90 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab Before Chemotherapy | 29.8 |
| Bevacizumab With Chemotherapy | 24.1 |
"Progression-free survival was defined as the time from randomization to the date of progression or death, whichever occurred first. Patients without progression were censored on the date of the last follow-up visit.~Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions." (NCT01718873)
Timeframe: assessed up to 90 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab Before Chemotherapy | 11.7 |
| Bevacizumab With Chemotherapy | 10.5 |
Toxic effects were scored according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0. For the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0 scale score range from 1 to 4. A high score, that is 3 and 4, represents a high level of toxicity, whereas the minimum values, that is 1 and 2, represents a mild/modest level of toxicity. (NCT01718873)
Timeframe: up to 4 weeks after the end of the treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab Before Chemotherapy | 108 |
| Bevacizumab With Chemotherapy | 113 |
OS defined as the time interval between the date of randomization and the date of death from any cause. (NCT01721954)
Timeframe: From date of randomization until the date of death from any cause assessed up 3 yrs 8 months
| Intervention | months (Median) |
|---|---|
| mFOLFOX6 Plus SIRT | 25.9 |
| mFOLFOX6 Alone | 25.0 |
PFS defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as an increase in the sum of the longest diameters of ≥ 20% and an absolute increase in the sum of the longest diameters of ≥ 5 mm, or the appearance of a new lesion. (NCT01721954)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years 8 months.
| Intervention | months (Median) |
|---|---|
| mFOLFOX6 Plus SIRT | 11.8 |
| mFOLFOX6 Alone | 11.2 |
The Percentage of Patients Who Experience an Objective Benefit From Treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01226719)
Timeframe: 18 months
| Intervention | percentage of evaluable participants (Number) |
|---|---|
| FOLFOXIRI+Panitumumab Regimen | 75 |
The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death (NCT01226719)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| FOLFOXIRI+Panitumumab Regimen | NA |
The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01226719)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| FOLFOXIRI+Panitumumab Regimen | 13.3 |
To determine the rate of complete (R0) resection for patients treated with this regimen. (NCT01226719)
Timeframe: 18 months
| Intervention | percentage of patients with surgery (Number) |
|---|---|
| FOLFOXIRI+Panitumumab Regimen | 100 |
The analyses of safety will be based on the frequency of adverse events and their severity for patients who received at least one dose of study treatment. (NCT01226719)
Timeframe: 18 months
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rash | Diarrhea | Fatigue | Nausea | Mucositis | Peripheral neuropathy | Vomiting | Anorexia | Cold sensitivity | Constipation | Dehydration | Leukopenia | Anemia | Hypokalemia | Hypomagnesemia | Nail changes | Neutropenia | Taste alteration | Thrombocytopenia | Weight loss | Abdominal pain | Alopecia | Depression | Dizziness | Insomnia | Alkaline phosphatase increased | ALT increased | Anxiety | AST increased | Asthenia | Back pain | Blood bicarbonate increased | Decreased ejection fraction | Dry mouth | Dysesthesia | Dyspepsia | Edema | Epistaxis | Flashers | Hand-foot syndrome | Hematochezia | Hemorrhoids | Hyperpigmentation | Hypertension | Hypoalbuminemia | Hyponatremia | Infection - other | Infusion related reaction | Memory loss | Oral infection | Paraphasia | Pruritus | Speech impairment | Swollen tongue | |
| FOLFOXIRI+Panitumumab Regimen | 12 | 9 | 8 | 8 | 7 | 6 | 5 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
"Summary of overall objective response rate based on tumor assessment by the Independent Review Committee (IRC) as per Response Evaluation Criteria in Solid Tumours (RECIST) criteria. ORR was defined as the proportion of patients with confirmed Complete Response (CR) or confirmed Partial Response (PR) relative to the total number of patients in the analysis population.~Per RECIST v 1.0 target lesions evaluation and assessed by tumor imaging: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): >=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.~The study was not powered for comparison of ORR between the two arms (non-comparative, open-label study)." (NCT00851084)
Timeframe: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)
| Intervention | percentage of participants (Number) |
|---|---|
| mFOLFOX6 Only | 45.9 |
| mFOLFOX6 + Aflibercept | 49.1 |
"Overall survival was defined as the time from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earliest between the last date the patient was known to be alive and the study cutoff date.~The study was not powered for comparison of OS between the two arms (non-comparative, open-label study)." (NCT00851084)
Timeframe: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)
| Intervention | months (Median) |
|---|---|
| mFOLFOX6 Only | 22.31 |
| mFOLFOX6 + Aflibercept | 19.45 |
"PFS was defined as the time from the date of randomization to the date of tumor progression or death from any cause, whichever occurred first. PFS was based on tumor assessment by the Independent Review Committee (IRC). PFS was estimated from Kaplan-Meier Curves.~The study was not powered for comparison of PFS between the two arms (non-comparative, open-label study).~Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions." (NCT00851084)
Timeframe: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)
| Intervention | Months (Median) |
|---|---|
| mFOLFOX6 Only | 8.77 |
| mFOLFOX6 + Aflibercept | 8.48 |
PFS rate at 12 months was defined as the percentage of patients alive without disease progression at 12 months after randomization. The primary efficacy analysis was based on assessment by the Independent Review Committee (IRC). The study was not powered for comparison of PFS rate at 12 months between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. (NCT00851084)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| mFOLFOX6 Only | 21.2 |
| mFOLFOX6 + Aflibercept | 25.8 |
The antidrug antibody (ADA) assay was evaluated for participants receiving aflibercept. (NCT00851084)
Timeframe: Any time post baseline and 90 days after the last infusion of aflibercept, according to baseline status
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| ADA Negative post-baseline | ADA Positive (drug specific) post-baseline | ADA Negative 90 days after last dose | ADA Positive 90 days after last dose | |
| Negative or Missing | 105 | 7 | 45 | 0 |
| Positive | 1 | 2 | 1 | 1 |
Summary of treatment-emergent adverse events in the safety population. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used in this study to grade the severity of AEs. (NCT00851084)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Treatment Emergent Adverse Event (TEAE) | Grade 3-4 TEAE | Treatment emergent Serious Adverse Event (SAE) | TEAE leading to death | Premature treatment discontinuation | Permanent treatment discontinuation | |
| mFOLFOX6 + Aflibercept | 119 | 108 | 55 | 8 | 34 | 37 |
| mFOLFOX6 Only | 115 | 87 | 32 | 2 | NA | 26 |
DoR was measured from the time measurement criteria are first met for Complete Response or Partial Response or until the first date that the criteria for disease progression or death from any cause. whichever is first recorded. As defined according to RECIST v1.1, CR is the disappearance of all non-nodal target lesions, and PR is the short axes of any target lymph nodes reduced to < 10 mm and at least a 30% decrease in the sum of the diameters of target lesions including the short axes of any target lymph nodes.) (NCT01111604)
Timeframe: Criteria First Met for CR or PR until Disease Progression or Death from Any Cause (Up to 95 Weeks)
| Intervention | Weeks (Median) |
|---|---|
| mFOLFOX-6 | 35.6 |
| mFOLFOX-6 + Ramucirumab | NA |
| mFOLFOX-6 + Icrucumab | NA |
A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals. (NCT01111604)
Timeframe: 31 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| mFOLFOX-6 + Ramucirumab | 0 |
Overall survival is defined as the time from baseline to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS will be censored on the last date the participant is known to be alive. (NCT01111604)
Timeframe: Baseline Until Death from Any Cause (Up to 163 Weeks)
| Intervention | Weeks (Median) |
|---|---|
| mFOLFOX-6 | 53.6 |
| mFOLFOX-6 + Ramucirumab | 41.7 |
| mFOLFOX-6 + Icrucumab | 42.0 |
The ORR is the percentage of participants with Complete Response (CR, the disappearance of target lesions and any pathological lymph nodes [target or non-target] taking as reference the baseline sum of diameters in response to treatment) or Partial Response (PR, at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters in response to treatment) according to RECIST v1.1 from the start of the treatment until disease progression. (NCT01111604)
Timeframe: Baseline until Disease Progression (Up to 95 Weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| mFOLFOX-6 | 14 |
| mFOLFOX-6 + Ramucirumab | 3.8 |
| mFOLFOX-6 + Icrucumab | 3.8 |
Maximum concentration (1 hour post end of infusion, Cmax) is the concentration measured in serum. (NCT01111604)
Timeframe: Cycle 5, 1 Hour Post End of Infusion
| Intervention | microgram/milliliter (µg/mL) (Geometric Mean) |
|---|---|
| mFOLFOX-6 + Ramucirumab | NA |
| mFOLFOX-6 + Icrucumab | 201 |
Trough (prior to infusion, Ctrough) concentrations measured in serum. (NCT01111604)
Timeframe: Cycle 5, Prior to Infusion
| Intervention | µg/mL (Geometric Mean) |
|---|---|
| mFOLFOX-6 + Ramucirumab | 53.6 |
| mFOLFOX-6 + Icrucumab | 146 |
PFS is defined as the time from baseline until the date of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or death from any cause, whichever was first. Participants who die without a reported prior progression will be considered to have progressed on the day of their death. Participants who did not progress, are lost to follow-up, or have missed two or more scheduled tumor assessments will be censored at the day of their last radiographic tumor assessment, if there are no post-baseline tumor measurements for a randomized and treated participant, the participant will be censored at the date of randomization. If death or progressive disease (PD) occurs after 2 or more missing radiographic visits, censoring will occur at the date of the last radiographic visit prior to the last visit. (NCT01111604)
Timeframe: Baseline until Disease Progression or Death from Any Cause (Up to 95 Weeks)
| Intervention | Weeks (Median) |
|---|---|
| mFOLFOX-6 | 18.4 |
| mFOLFOX-6 + Ramucirumab | 21.4 |
| mFOLFOX-6 + Icrucumab | 15.9 |
A summary of serious AEs (SAEs) and all other non-serious AEs regardless of causality, is located in the Reported Adverse Events module. (NCT01111604)
Timeframe: Baseline up to 165 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Any TEAE | Any SAE | Any Grade ≥3 AE | Any AE leading to discontinuation (any drug) | |
| mFOLFOX-6 | 49 | 11 | 30 | 6 |
| mFOLFOX-6 + Icrucumab | 52 | 12 | 31 | 11 |
| mFOLFOX-6 + Ramucirumab | 52 | 18 | 37 | 18 |
Median time from randomization to date of death caclulated using the Kaplan-Meier method. Participants were censored on the date of last contact (i.e., the date the participant was last known to be alive) if they were not known to have died. (NCT00911170)
Timeframe: From randomization to the data cut-off date of 8 June 2012. Median time on study was 11.6 months and the maximum was 27.6 months.
| Intervention | months (Median) |
|---|---|
| Placebo | 24.6 |
| Pegfilgrastim | 21.8 |
The percentage of participants with a complete response (CR) or partial response (PR) defined by the RECIST v1.1 criteria at any time during the study. Response was be determined by the investigator's assessment of radiographic scans. CR: Disappearance of all non-nodal target lesions and the disappearance of all non-nodal non-target lesions, and no new lesions. All nodal lesions must have reduction of short axis to < 10 mm. PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters and no new lesions and/or unequivocal progression of existing non-target lesions, or, the disappearance of all non-nodal target lesions with persistence of one or more non-target lesion(s). (NCT00911170)
Timeframe: From randomization to the data cut-off date of 8 June 2012. Median time on study was 11.6 months and the maximum was 27.6 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 56.7 |
| Pegfilgrastim | 58.1 |
Grade 3/4 febrile neutropenia (FN) is defined as: • A temperature ≥ 38.0°C (≥ 100.4°F) and absolute neutrophil count (ANC) < 1.0 × 10^9/L, where ANC was measured the same day or within ± 1 calendar day of a temperature ≥ 38.0°C (≥ 100.4°F), or • An ANC < 1.0 × 10^9/L in combination with: - documented sepsis or infection, OR - neutropenia-related hospitalization where ANC was measured the same day or within ± 1 calendar day. Participants monitored their oral temperatures and maintained diaries to record their temperature twice per day: once in the morning and once in the evening, as well as whenever they suspect they had fever throughout the first 4 cycles of chemotherapy treatment. (NCT00911170)
Timeframe: Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 5.7 |
| Pegfilgrastim | 2.4 |
Grade 3/4 severe neutropenia is defined as neutropenia with absolute neutrophil count (ANC) <1.0 x 10^9/L. (NCT00911170)
Timeframe: Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 17.0 |
| Pegfilgrastim | 3.6 |
"Grade 4 febrile neutropenia (FN) is defined as:~A temperature ≥ 38.0ºC (≥ 100.4ºF) and absolute neutrophil count (ANC) < 0.5 × 10^9/L, where ANC is measured the same day or within +/- 1 calendar day of a temperature ≥ 38.0ºC (≥ 100.4ºF), or~An ANC <0.5 × 10^9/L in combination with:~Documented sepsis or infection, OR~Neutropenia-related hospitalization where ANC is measured the same day or within +/- 1 calendar day." (NCT00911170)
Timeframe: Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 3.5 |
| Pegfilgrastim | 2.4 |
Grade 4 severe neutropenia is defined as neutropenia with absolute neutrophil count (ANC) <0.5 x 10^9/L. (NCT00911170)
Timeframe: Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 8.3 |
| Pegfilgrastim | 2.4 |
Time from randomization to date of radiological disease progression or death from any cause, whichever event occurs first, calculated using the Kaplan-Meier method. Participants without either event by the analysis data cutoff date were censored on the date of their last evaluable disease assessment. Disease progression based on the investigator's assessment of radiographic scans using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Clinical progression without radiological assessment was not be considered a disease progression in this analysis. Progression defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00911170)
Timeframe: From randomization to the data cut-off date of 8 June 2012. Median time on study was 11.6 months and the maximum was 27.6 months.
| Intervention | months (Median) |
|---|---|
| Placebo | 10.1 |
| Pegfilgrastim | 9.7 |
Time from randomization to date of radiological disease progression calculated using the Kaplan-Meier method. Participants without progression were censored on the date of their last radiographic tumor assessment. Disease progression based on the investigator's assessment of scans using the RECIST v1.1. Clinical progression without radiological assessment was not considered a disease progression. Progression defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00911170)
Timeframe: From randomization to the data cut-off date of 8 June 2012. Median time on study was 11.6 months and the maximum was 27.6 months.
| Intervention | months (Median) |
|---|---|
| Placebo | 11.1 |
| Pegfilgrastim | 10.8 |
A serious adverse event (SAE) is defined as an adverse event that - is fatal; - is life threatening (places the participant at immediate risk of death); - requires inpatient hospitalization or prolongation of existing hospitalization; - results in persistent or significant disability/incapacity; - is a congenital anomaly/birth defect; - other significant medical hazard. AEs were assessed for severity according to National Cancer Institute, Common Terminology Criteria for Adverse Events, Version 3.0, based on this general guideline: Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. (NCT00911170)
Timeframe: Approximately 8 weeks (4 treatment cycles)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | Worst Grade of > 2 | Worst Grade of > 3 | Worst Grade of > 4 | Serious adverse events | Severe adverse events | Life-threatening adverse events | Fatal adverse events | Leading to discontinuation of IP | Leading to discontinuation from study treatment | |
| Pegfilgrastim | 344 | 240 | 115 | 31 | 68 | 106 | 27 | 10 | 3 | 8 |
| Placebo | 355 | 254 | 119 | 45 | 55 | 103 | 43 | 11 | 1 | 9 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified World Health Organisation (WHO) criteria) as assessed by an IRC. (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 45.6 |
| FOLFOX-4 Alone | 35.7 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC. (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 57.3 |
| FOLFOX-4 Alone | 34.0 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC. (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 33.8 |
| FOLFOX-4 Alone | 52.5 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments as assessed by IRC (based on modified WHO criteria). (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 85.2 |
| FOLFOX-4 Alone | 81.0 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00125034)
Timeframe: Time from first assessment of Complete Response or Partial Response to disease progression,death or last tumor assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 9.0 |
| FOLFOX-4 Alone | 5.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00125034)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 18.3 |
| FOLFOX-4 Alone | 18.0 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00125034)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 13.4 |
| FOLFOX-4 Alone | 17.5 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00125034)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 22.8 |
| FOLFOX-4 Alone | 18.5 |
No residual tumor after on-study surgery for metastases. (NCT00125034)
Timeframe: Time from first dose up to 30 days after the last dose of study treatment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 8 |
| FOLFOX-4 Alone | 4 |
"Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00125034)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 7.2 |
| FOLFOX-4 Alone | 7.2 |
"Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00125034)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 5.5 |
| FOLFOX-4 Alone | 8.6 |
"Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00125034)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 8.3 |
| FOLFOX-4 Alone | 7.2 |
Please refer to Adverse Events section for further details (NCT00125034)
Timeframe: time from first dose up to 30 after last dose of study treatment, reported between day of first patient dose of study treatment, 27 Jul 2005, until cut-off date 30 Nov 2008
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 170 |
| FOLFOX-4 Alone | 165 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 46.9 |
| FOLFIRI Alone | 38.7 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 31.3 |
| FOLFIRI Alone | 36.1 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | percentage participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 57.3 |
| FOLFIRI Alone | 39.7 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: Evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 84.3 |
| FOLFIRI Alone | 85.5 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00154102)
Timeframe: Time from first assessment of complete response or partial response to disease progression, death or last tumor assessment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 9.6 |
| FOLFIRI Alone | 7.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 16.2 |
| FOLFIRI Alone | 16.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 23.5 |
| FOLFIRI Alone | 20.0 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 19.9 |
| FOLFIRI Alone | 18.6 |
Participants with no residual tumor after on-study surgery for metastases (NCT00154102)
Timeframe: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007
| Intervention | Participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 29 |
| FOLFIRI Alone | 10 |
"Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 8.9 |
| FOLFIRI Alone | 8.0 |
"Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 9.9 |
| FOLFIRI Alone | 8.4 |
"Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 7.4 |
| FOLFIRI Alone | 7.7 |
Please refer to Adverse Events section for further details (NCT00154102)
Timeframe: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 599 |
| FOLFIRI Alone | 597 |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL. (NCT00154102)
Timeframe: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | scores on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| At baseline | At week 8 | At week 16 | At week 24 | At week 32 | At week 40 | |
| Cetuximab Plus FOLFIRI | 58.88 | 59.02 | 60.77 | 61.83 | 59.68 | 63.43 |
| FOLFIRI Alone | 60.33 | 61.83 | 63.29 | 64.06 | 65.07 | 64.02 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning. (NCT00154102)
Timeframe: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | scores on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| At baseline | At week 8 | At week 16 | At week 24 | At week 32 | At week 40 | |
| Cetuximab Plus FOLFIRI | 75.21 | 74.14 | 73.72 | 76.31 | 74.04 | 76.58 |
| FOLFIRI Alone | 77.28 | 76.71 | 76.67 | 77.98 | 75.64 | 78.07 |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 2 |
| Placebo | 8 |
Dose delay or reduction in chemotherapy doses due to neutropenia (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 5 |
| Placebo | 26 |
Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 41 |
| Placebo | 53 |
Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC < 1.0 x 10^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 3 |
| Placebo | 10 |
Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) < 1 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 16 |
| Placebo | 51 |
Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) <0.5 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 13 |
| Placebo | 17 |
Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of neutropenia (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 7 |
| Placebo | 9 |
Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 34 |
| Placebo | 37 |
Kaplan-Meier estimate of the median time to disease progression or death (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment
| Intervention | Days (Median) |
|---|---|
| Pegfilgrastim (Neulasta) | 318 |
| Placebo | 322 |
Death from any cause through the end of the follow-up period (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment
| Intervention | Participants (Number) |
|---|---|
| Pegfilgrastim (Neulasta) | 47 |
| Placebo | 49 |
The toxicity assessments were made according to the common terminology criteria for adverse events (CTCAE version 3.0) of the National Cancer Institute. Number of participants with Grade 1 to 5 adverse events are reported here. (NCT00193219)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 31 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00193219)
Timeframe: 18 months
| Intervention | percentage of patients (Number) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 55 |
Measured from the date of first treatment until the date of death from any cause (NCT00193219)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 25.7 |
Progression Free Survival (PFS) is defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death. (NCT00193219)
Timeframe: 18 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab/Cetuximab/FOLFOX | 9 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. (NCT00192075)
Timeframe: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG | 12.7 |
| A + FOLFOX 4 | 7.9 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. (NCT00192075)
Timeframe: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A + FOLFOX 4 - Avastin Subgroup | 5.2 |
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact. (NCT00192075)
Timeframe: randomization to the date of death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG | 20.6 |
| A + FOLFOX 4 | 19.7 |
Defined as the time from randomization to the first observation of disease progression, or death due to any cause. (NCT00192075)
Timeframe: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG | 8.6 |
| A + FOLFOX 4 | 9.5 |
Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause. (NCT00192075)
Timeframe: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG - Avastin Subgroup | 13.7 |
| A + FOLFOX 4 - Avastin Subgroup | 11.5 |
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00192075)
Timeframe: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG | 8.6 |
| A + FOLFOX 4 | 9.7 |
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00192075)
Timeframe: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | months (Median) |
|---|---|
| A+FFG - Avastin Subgroup | 13.7 |
| A + FOLFOX 4 - Avastin Subgroup | 13.8 |
Percentage of participants who were alive at 12 months and 24 months. (NCT00192075)
Timeframe: randomization to the date of death from any cause (up to 24 months)
| Intervention | percentage of participants alive (Number) | |
|---|---|---|
| 12-Month Survival | 24-Month Survival | |
| A + FOLFOX 4 - Avastin Subgroup | 83.3 | 66.7 |
| A+FFG - Avastin Subgroup | 75.6 | 50.4 |
Includes all Grade 3-4 hematologic toxicities and all non-hematologic toxicities with either >=1 Grade 4 or >=2 Grade 3 adverse events (NCT00192075)
Timeframe: every cycle (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia (Grade 3) | Neutropenia (Grade 4) | Thrombocytopenia (Grade 3) | Thrombocytopenia (Grade 4) | Leukopenia (Grade 3) | Leukopenia (Grade 4) | Anemia (Grade 3) | Anemia (Grade 4) | Febrile neutropenia (Grade 3) | Febrile neutropenia (Grade 4) | Diarrhea (Grade 3) | Diarrhea (Grade 4) | Small intestinal obstruction (Grade 3) | Small intestinal obstruction (Grade 4) | Fatigue (Grade 3) | Fatigue (Grade 4) | Cerebral infarction (Grade 3) | Cerebral infarction (Grade 4) | Hyperglycemia (Grade 3) | Hyperglycemia (Grade 4) | Dehydration (Grade 3) | Dehydration (Grade 4) | Deep vein thrombosis (Grade 3) | Deep vein thrombosis (Grade 4) | Myocardial infarction (Grade 3) | Myocardial infarction (Grade 4) | Subdural hematoma (Grade 3) | Subdural hematoma (Grade 4) | Perirectal abscess (Grade 3) | Perirectal abscess (Grade 4) | Hypoxia (Grade 3) | Hypoxia (Grade 4) | |
| A + FOLFOX 4 - Avastin Subgroup | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| A+FFG - Avastin Subgrouup | 3 | 5 | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. (NCT00192075)
Timeframe: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Overall Response Rate (CR+PR) | Stable Disease (SD) | Disease Control Rate (CR+PR+SD) | Progressive Disease | Unknown | |
| A + FOLFOX 4 - Avastin Subgroup | 1 | 8 | 9 | 8 | 17 | 1 | 0 |
| A+FFG - Avastin Subgroup | 0 | 0 | 0 | 11 | 11 | 6 | 1 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. (NCT00192075)
Timeframe: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Overall Response Rate (CR+PR) | Stable Disease (SD) | Disease Control Rate (CR+PR+SD) | Progressive Disease | Unknown | |
| A + FOLFOX 4 | 2 | 15 | 17 | 16 | 33 | 7 | 2 |
| A+FFG | 1 | 3 | 4 | 21 | 25 | 14 | 3 |
(NCT00100841)
Timeframe: From randomization to the first documented disease progression
| Intervention | months (Median) |
|---|---|
| Treatment (Combination Chemotherapy) | 9.6 |
The primary objective is to evaluate safety in all treated patients specifically the rate of serious adverse events which were defined as grade 5 events, grade 4 hemorrhage or thrombosis or bowel perforation (NCT00100841)
Timeframe: The duration of the study
| Intervention | participants (Number) | |
|---|---|---|
| Grade 5 Death | Grade 4 venous thrombosis | |
| Treatment (Combination Chemotherapy) | 2 | 2 |
Average months of survival of participants after receiving study drug. (NCT00290615)
Timeframe: From time of treatment until death from any cause, assesed up to 60 months.
| Intervention | months (Median) |
|---|---|
| Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab | 18.8 |
"Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.~This is the average number of months participants survived without showing progressive disease." (NCT00290615)
Timeframe: From time of treatment until documented progression or death from any cause, whichever came first, assesed up to 60 months.
| Intervention | months (Median) |
|---|---|
| Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab | 10.3 |
"Restaging scans occurred every 9 weeks from time of study drug initiation until disease progression.~Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~The definitions were:~Complete response (CR)- Disappearance of all target lesions Partial response (PD)- At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Stable disease (SD)- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive disease (PD) - At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions" (NCT00290615)
Timeframe: After all subjects were evaluated for restaging which occured every 9 weeks from drug initiation until disease progression, assesed up to 24 months.
| Intervention | percentage of participants with response (Number) |
|---|---|
| Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab | 43 |
Number of participants with adverse events (NCT00290615)
Timeframe: After all participants went off study drug regimine.
| Intervention | participants with adverse event (Number) |
|---|---|
| Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab | 30 |
The overall response is defined as the number of participants whose tumor response was classified as a complete response (CR; disappearance of all target lesions) or partial response (PR; 30% decrease in the sum of the longest diameter of target lesions) per Response Evaluation Criteria in Solid Tumors. Response was measured for participants in Phase II only. To determine response, radiographic images were taken at baseline, 8 weeks, and every 8 weeks thereafter until the participant withdrew from the study. (NCT00536809)
Timeframe: Baseline to response (up to 135 days)
| Intervention | participants (Number) |
|---|---|
| Lap. 1000 mg/Oxaliplatin 130 mg/m^2/Capecitabine 1500 mg/m^2 | 2 |
"Objective response rate is defined as the percentage of participants with a best response of complete response or partial response based on investigator review of scans using modified RECIST criteria. A complete or partial response was confirmed no less than 4 weeks after the criteria for response were first met. Participants with no post-baseline radiographic tumor assessment(s) were considered non-responders.~CR: disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions (defined as a ≥ 25% increase in lesion size) and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or PD and no new lesions." (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS | 23 |
| Mutant KRAS | 16 |
Duration of response is defined as the time from the date of first response to the date of first progression of disease during second-line treatment (as evaluated by the investigator) or death (if the death was due to disease progression but not detected earlier) in the subset of participants who responded (CR or PR, as evaluated by the investigator). Duration of response was analyzed using Kaplan-Meier methods; participants who responded but did not progress while on study were censored at the date of last tumor assessment. (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.
| Intervention | weeks (Median) |
|---|---|
| Wild-type KRAS | 29 |
| Mutant KRAS | 23 |
Overall survival is defined as as the number of days from Study Day 1 to the date of death due to any cause. Overall survival was analyzed using the Kaplan-Meier method; participants who were lost to follow-up or who had not died at the end of the study (52 weeks after the last participant was enrolled) were censored at the date of last contact. (NCT00411450)
Timeframe: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Wild-type KRAS | 50 |
| Mutant KRAS | 31 |
Progression-free survival time was defined as the time from Study Day 1 to the date of disease progression (based on investigator assessment) or the date of death due to any cause. Participants who terminated from the study early (eg, prior to disease progression due to fully withdrawn informed consent) were censored at their last tumor assessment. (NCT00411450)
Timeframe: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Wild-type KRAS | 26 |
| Mutant KRAS | 19 |
Time to progression is defined as the time from study Day 1 to the date of observed disease progression. Time to progression was analyzed using Kaplan-Meier methods; participants who did not have disease progression were censored at the date of last evaluable tumor assessment. (NCT00411450)
Timeframe: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Wild-type KRAS | 26 |
| Mutant KRAS | 17 |
Time to response of second-line treatment is defined as the time from study Day 1 to the date of first documentation of CR or PR, calculated for those participants with an objective tumor response of CR or PR. (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.
| Intervention | weeks (Median) |
|---|---|
| Wild-type KRAS | 9.1 |
| Mutant KRAS | 9.3 |
Time to failure of second-line treatment is defined as the time from study Day 1 to the date of the earliest of the following events: end of second-line therapy due to any reason except for complete response and curative surgery; progressive disease; or death due to any cause. Time to treatment failure was analyzed using Kaplan-Meier methods; participants who did not discontinue second-line treatment or discontinue due to complete response or curative surgery, who were still alive, and who did not have disease progression were censored at the date of the last contact. (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.
| Intervention | weeks (Median) |
|---|---|
| Wild-type KRAS | 19 |
| Mutant KRAS | 15 |
The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST criteria as assessed by the investigator. Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline. (NCT00411450)
Timeframe: Week 17 and Week 25
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 17 | Week 25 | |
| Mutant KRAS | 58 | 58 |
| Wild-type KRAS | 64 | 64 |
The immunogenicity of panitumumab was evaluated using 2 different screening immunoassays for the detection of anti-panitumumab antibodies: an acid dissociation bridging enzyme-linked immunosorbent assay (ELISA; detecting high-affinity antibodies) and a Biacore® biosensor immunoassay (detecting both high and low-affinity antibodies). When either of the 2 screening assays yielded a positive result, that particular sample was subjected to an in vitro bioassay for the detection of neutralizing antibodies. (NCT00411450)
Timeframe: Prior to first dose and 28 days after the last dose of second-line treatment
| Intervention | participants (Number) | |
|---|---|---|
| Binding antibody positive | Neutralizing antibody positive | |
| Panitumumab Plus FOLFIRI | 1 | 0 |
The severity of adverse events (AEs) was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, except for panitumumab related skin toxicities, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. The relationship of each adverse event to the panitumumab and/or FOLFIRI regimen was assessed by the investigator. A serious adverse event was defined as an adverse event that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. (NCT00411450)
Timeframe: From the first dose date to 30 days after the last dose date. The median time frame is 4.5 months.
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | Grade 3 or higher adverse event | Panitumumab-related adverse events | Chemotherapy-related adverse events | ≥ grade 3 panitumumab-related adverse events | ≥ grade 3 chemotherapy-related adverse events | Serious adverse events | Serious panitumumab-related adverse events | Serious chemotherapy-related adverse events | Life-threatening adverse events | Ended second-line treatment due to adverse events | Ended panitumumab due to adverse events | Ended FOLFIRI due to adverse events | Death due to adverse events | Panitumumab infusion reactions | Deaths during study | |
| Panitumumab Plus FOLFIRI | 115 | 94 | 107 | 112 | 56 | 65 | 46 | 15 | 24 | 18 | 18 | 20 | 28 | 8 | 2 | 71 |
Laboratory toxicities were graded according to CTCAE version 3. (NCT00411450)
Timeframe: From the first dose date to 30 days after the last dose date. The median time frame is 4.5 months.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Anemia | Neutropenia | Hypomagnesaemia | Hypokalemia | Hypocalcaemia | Hyperbilirubinaemia | |
| Panitumumab Plus FOLFIRI | 1 | 4 | 8 | 1 | 3 | 1 |
Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments were based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. A complete or partial response was confirmed no less than 4 weeks after the criteria for response were first met. Participants with no radiographic tumor assessment(s) at Week 17 or 25 were considered non-responders. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions (defined as a ≥ 25% increase in lesion size) and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions. (NCT00411450)
Timeframe: Week 17 and Week 25
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 17 | Week 25 | |
| Mutant KRAS | 14 | 14 |
| Wild-type KRAS | 20 | 22 |
"The progression-free survival rate is defined as the Kaplan-Meier (KM) estimator of progression-free survival at Week 17 and Week 25 reported as the probability of being event (disease progression or death)-free. Tumor assessments were evaluated by the investigator according to modified RECIST criteria.~PD: At least a 20% increase in the size of target lesions since the treatment started or at least a 25% increase in the size of non-target lesions and the lesion(s) measure ≥ 10 mm, or the appearance of any new lesions. Participants who withdraw from the study prior to completion of Week 17 or 25 radiographic tumor assessments were censored at the last evaluable tumor assessment." (NCT00411450)
Timeframe: Week 17 and Week 25
| Intervention | percent probability (Number) | |
|---|---|---|
| Week 17 | Week 25 | |
| Mutant KRAS | 55 | 41 |
| Wild-type KRAS | 67 | 52 |
Best overall response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) while on study. Tumor response was assessed by CT scan or MRI of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified RECIST criteria. CR: Disappearance of all target and non-target lesions and no new lesions. PR: Either the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or PD (≥ 25% increase in lesion size) and no new lesions, or, at least a 30% decrease in the size of target lesions with no progression of existing non-target lesions, and no new lesions. (NCT00332163)
Timeframe: Response was assessed at Weeks 9 and 13 and then every 8 weeks for the Q2W regimen, or at Weeks 10, 14, 22 and then every 9 weeks for the Q3W regimen until the end of treatment; median treatment duration was 13 and 17 weeks in each group respectively.
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-emptive Skin Treatment | 15 |
| Reactive Skin Treatment | 11 |
Overall Survival is defined as the time from the date of randomization to the date of death. Participants who did not die while on study or who were lost-to-follow-up were censored at their last contact date. Overall survival was analyzed using all data regardless of whether it was collected during second- or third-line treatment. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.
| Intervention | months (Median) |
|---|---|
| Pre-emptive Skin Treatment | 11.2 |
| Reactive Skin Treatment | 13.6 |
"The percentage of participants who developed at least 1 incidence of ≥ grade 2 skin toxicities of any type during the 6-week skin treatment period. Analysis of this endpoint was based on adverse event data associated with the Skin and Subcutaneous Tissue Disorders system organ class. Adverse events were graded according to the National Cancer Institute (NCI) CTCAE version 3.0." (NCT00332163)
Timeframe: 6 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-emptive Skin Treatment | 40 |
| Reactive Skin Treatment | 62 |
(NCT00332163)
Timeframe: 6 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-emptive Skin Treatment | 6 |
| Reactive Skin Treatment | 11 |
Skin toxicities were assessed by the study clinician and graded according to the modified Common Toxicity Criteria for Adverse Events (CTCAE) v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-emptive Skin Treatment | 29 |
| Reactive Skin Treatment | 62 |
Defined as the time from the date of randomization to the first date of observed disease progression or death due to any cause (whichever comes first). Participants who were alive and had not progressed while on study were censored at the date of last progression-free tumor assessment. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.
| Intervention | months (Median) |
|---|---|
| Pre-emptive Skin Treatment | 4.7 |
| Reactive Skin Treatment | 4.1 |
Tumor response was assessed by CT scan or MRI of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified response evaluation criteria in solid tumors (RECIST). Disease control rate is defined as the percentage of participants with a CR, PR or stable disease (SD) at the Week 9/10 assessment visit and a corresponding response (CR or PR) confirmed at the Week 13/14 assessment visit for the Q2W/Q3W regimens. SD: Neither sufficient shrinkage or increase in target lesions to qualify for PR or PD, with no progression of non-target lesions and no new lesions. (NCT00332163)
Timeframe: Week 9 with confirmed response at Week 13 for the FOLFIRI and panitumumab Q2W regimen or at Week 10 with confirmed response at Week 14 for the irinotecan and panitumumab Q3W regimen.
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-emptive Skin Treatment | 63 |
| Reactive Skin Treatment | 64 |
Tumor response was assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified response evaluation criteria in solid tumors (RECIST). Response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) at the Week 9/10 assessment visit and a corresponding CR or PR confirmed at the Week 13/14 assessment visit for the Q2W/Q3W regimens. CR: Disappearance of all target and non-target lesions and no new lesions. PR: Either the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease (PD; ≥ 25% increase in lesion size) and no new lesions, or, at least a 30% decrease in the size of target lesions with no progression of existing non-target lesions, and no new lesions. (NCT00332163)
Timeframe: Week 9 with confirmed response at Week 13 for the FOLFIRI and panitumumab Q2W regimen or at Week 10 with confirmed response at Week 14 for the irinotecan and panitumumab Q3W regimen.
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-emptive Skin Treatment | 6 |
| Reactive Skin Treatment | 6 |
Time to the first most severe grade ≥ 2 of all the specific skin-related toxicities of interest was defined as the time from the first dose of panitumumab to the date of the first occurrence of the most severe specific ≥ grade 2 skin toxicity of interest during the 6-week skin treatment period. Participants who did not experience any specific skin-related toxicity of grade ≥ 2 were censored at their last skin toxicity assessment during the 6-week skin toxicity assessment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks
| Intervention | weeks (Median) |
|---|---|
| Pre-emptive Skin Treatment | NA |
| Reactive Skin Treatment | 2.7 |
The time to the first occurrence of specific grade 2 or higher skin toxicities of interest was defined as the time from the first dose of panitumumab to the date of first occurrence of specific ≥ grade 2 skin toxicities of interest. Participants who did not experience specific skin-related toxicities were censored at their last skin toxicity assessment during the skin toxicity assessment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks
| Intervention | weeks (Median) |
|---|---|
| Pre-emptive Skin Treatment | NA |
| Reactive Skin Treatment | 2.1 |
"Time from the date of randomization to the date of observed disease progression or death due to disease progression. Participants who did not have documented disease progression were censored at the date of last tumor assessment; participants who died for reasons other than disease progression while on study were censored at the date of death. PD: At least a 20% increase in the size of target lesions, recorded since the treatment started, or at least a 25% increase in size of non-target lesions and the lesion(s) measure > 10 mm in one dimension, or the appearance of one or more new lesions.~Time to progression was analyzed using the Kaplan-Meier method. This analysis excludes any data collected during follow-up for participants who began third-line treatment." (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.
| Intervention | months (Median) |
|---|---|
| Pre-emptive Skin Treatment | 4.9 |
| Reactive Skin Treatment | 4.1 |
Time-to-treatment failure is defined as the time from the date of randomization to the first date of any of the following events: discontinuation of study therapy due to any reason (except for complete response and curative surgery), progression of disease, or death due to any cause. Participants who did not discontinue, who were still alive, and who did not have disease progression were censored at the date of last contact. Time to treatment failure was analyzed using the Kaplan-Meier method. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.
| Intervention | months (Median) |
|---|---|
| Pre-emptive Skin Treatment | 3.1 |
| Reactive Skin Treatment | 4.2 |
Skin-related quality of life was assessed using the DLQI. The DLQI questionnaire asks participants to evaluate the degree that their skin condition has affected their quality of life in the last week. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); The DLQI score is calculated by summing the scores for all questions, resulting in a maximum of 30 and a minimum of 0; higher scores indicate a more impaired quality of life. (NCT00332163)
Timeframe: Baseline and Weeks 2, 3, 4, 5, 6 and 7
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (n=46, 44) | Change from Baseline to Week 2 (n=42, 41) | Change from Baseline to Week 3 (n=44, 42) | Change from Baseline to Week 4 (n=42, 42) | Change from Baseline to Week 5 (n=44, 42) | Change from Baseline to Week 6 (n=42, 38) | Change from Baseline to Week 7 (n=40, 40) | |
| Pre-emptive Skin Treatment | 0.3 | 0.7 | 1.3 | 1.7 | 1.3 | 1.6 | 2.0 |
| Reactive Skin Treatment | 0.1 | 1.6 | 4.2 | 3.8 | 2.7 | 2.3 | 2.6 |
The percentage of participants with a most severe grade of 2, 3 or 4 specific skin toxicity of interest reported during the 6-week skin treatment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 2 | Grade 3 | Grade 4 | |
| Pre-emptive Skin Treatment | 23 | 6 | 0 |
| Reactive Skin Treatment | 40 | 21 | 0 |
OS was the duration from enrollment to death due to any cause. For participants who are alive, OS is censored at the last contact. (NCT00612586)
Timeframe: Randomization up to 22.8 months
| Intervention | months (Median) |
|---|---|
| Enzastaurin + 5-FU/LV + Bev | NA |
| Placebo + 5FU/LV + Bev | NA |
OS was the duration from first line therapy to death due to any cause. For participants who are alive, OS is censored at the last contact. (NCT00612586)
Timeframe: Start of first line therapy (approximately 3 months prior to randomization) to date of death from any cause up to 27 months post randomization
| Intervention | months (Median) |
|---|---|
| Enzastaurin + 5-FU/LV + Bev | 20.0 |
| Placebo + 5FU/LV + Bev | NA |
PFS was defined as the time from first line therapy to the first observation of disease progression or death due to any cause. Progressive disease was determined using a modified version of RECIST Assessment and was defined as at least a 20% increase in sum of longest diameter of target lesions. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00612586)
Timeframe: Start of first line therapy to measured progressive disease or death up to 24 months
| Intervention | months (Median) |
|---|---|
| Enzastaurin + 5-FU/LV + Bev | 8.9 |
| Placebo + 5FU/LV + Bev | 11.3 |
PFS was defined as the time from randomization to the first observation of disease progression or death due to any cause. Progressive disease was determined using a modified version of Response Evaluation Criteria in Solid Tumor (RECIST) Assessment and was defined as at least a 20% increase in sum of longest diameter of target lesions. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00612586)
Timeframe: Randomization to measured progressive disease or death up to 17.2 months
| Intervention | months (Median) |
|---|---|
| Enzastaurin + 5-FU/LV + Bev | 5.8 |
| Placebo + 5FU/LV + Bev | 8.1 |
A summary of serious and all other non-serious AEs is located in the Reported Adverse Event module. (NCT00612586)
Timeframe: Randomization up to 17.2 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Serious AEs | Other Non-Serious AEs | |
| Enzastaurin + 5-FU/LV + Bev | 15 | 53 |
| Placebo + 5FU/LV +Bev | 11 | 52 |
Follow-up for survival to be done at 3 month intervals for 2 years, then 6 month intervals for up to 5 years from study registration (NCT00321100)
Timeframe: From dose of first study drug to last timepoint known to be alive (median follow-up for all patients was 25.9 months)
| Intervention | months (Median) |
|---|---|
| Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab | 18 |
| Cetuximab, Oxaliplatin, Capecitabine | 42.5 |
"Per Response Evaluation Criteria In Solid Tumors (RECISTv1.0) assessed by CT, MRI, x-ray scan:~Complete response (CR): Disappearance of all lesions Partial response (PR): >=30% decrease in the sum of the longest diameter of target lesions (SoL); from baseline SoL Stable disease (SD): Neither PR, PD, or CR Progressive disease (PD): >=20% increase in the SoL; from smallest SoL. Or appearance of new lesion" (NCT00321100)
Timeframe: every 6-9 weeks; from dose of first study drug to event
| Intervention | months (Median) |
|---|---|
| Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab | 8.7 |
| Cetuximab, Oxaliplatin, Capecitabine | 14.4 |
"Objective response rate calculated by the proportion of overall response: CR+PR. Patients were categorized by one of the following (1-4 per RECISTv1.0 criteria on CT, MRI, x-ray; 4-9 considered failure to respond/disease progression):~complete response (CR): Disappearance of all lesions~partial response (PR): >=30% decrease in the sum of the longest diameter of target lesions (SoL); from baseline SoL~stable disease (SD): Neither PR, PD, or CR~progressive disease (PD): >=20% increase in the SoL; from smallest SoL. Or appearance of new lesion~early death from malignant disease~early death from toxicity~early death from other cause~9) unknown (not assessable, insufficient data)" (NCT00321100)
Timeframe: every 6-9 weeks; from date of first study drug dose until off treatment date (median of 8 cycles; range <1-19)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Overall response | Complete response | Partial response | Stable disease | |
| Cetuximab, Oxaliplatin, Capecitabine | 8 | 1 | 7 | 3 |
| Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab | 4 | 1 | 3 | 7 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | L/hour (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 32.9 |
CL is calculated as dose divided by AUC 0-∞ (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | L/hour (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 23.0 |
DR is defined as the time from the first objective documentation of complete or partial response that is subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurs first. The definition of censorship is the same as PFS. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)
| Intervention | weeks (Median) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 28.3 |
ORR is defined as the percentage of participants with best overall response of either a confirmed complete (CR) or partial response (PR) relative to the number of participants in FAS. Based on the response evaluation criteria in solid tumors (RECIST), CR is defined as the disappearance of all target lesions and PR is defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesion. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)
| Intervention | percentage of participants (Median) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 36.6 |
Concentration at 22 hour post start of 5-FU infusion were to be used as Css if 5-FU concentrations suggested steady state at 22 hours time point. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng/mL (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 650 |
"PFS is defined as the time from the date of enrollment to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurs first.~PFS data was censored on the day following the date of the last tumor assessment documenting absence of progressive disease for patients who 1) were given anti-tumor treatment other than the study treatment prior to observing objective tumor progression; 2) were removed from the study prior to documentation of objective tumor progression; and 3) were ongoing at the time of the analysis." (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)
| Intervention | weeks (Median) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 28.9 |
Terminal phase half-life of irinotecan was calculated as ln 2/ kel. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | hours (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 5.36 |
Vss was calculated using following equation: CL x mean residence time (MRT), where MRT = the area under the first moment curve from zero time to infinity (AUMC 0-∞)/AUC 0-∞- (infusion time/2), AUMC 0-∞ = the area under the first moment curve from zero time to time t (AUMC t)+ ((t x Ct*)/ kel) + (Ct* / kel^2), AUMC t is calculated using the linear trapezoidal method. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | L (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 160 |
AUC 0-24 was determined using the Linear/Log trapezoidal method. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng.h/mL (Mean) | ||
|---|---|---|---|
| Sunitinib AUC 0-24 | SU012662 AUC 0-24 | Total (sunitinib + SU0122662) AUC 0-24 | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 1161 | 346 | 1507 |
"AUC last of irinotecan and its metabolite SN-38 were calculated using the Linear/Log trapezoidal method.~AUC∞ of irinotecan was calculated using following equation; AUC last+(C*t/kel), where Ct* is the estimated concentration at the time of the last quantifiable concentration, kel is terminal phase rate constant that is estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile." (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng.h/mL (Mean) | ||
|---|---|---|---|
| Irinotecan AUC last | Irinotecan AUC ∞ | SN-38 AUC last | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 13100 | 13800 | 274 |
Plasma concentrations were assessed at predose, 2, 4, 6, 8, and 24 hours postdose and Cmax and Ctrough of sunitinib, its metabolite SU012662, and the total (sunitinib + SU0122662) were determined. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| Sunitinib Cmax | Sunitinib Ctrough | SU012662 Cmax | SU012662 Ctrough | Total (sunitinib + SU0122662) Cmax | Total (sunitinib + SU0122662) Ctrough | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 54.3 | 41.8 | 15.8 | 11.3 | 70.0 | 53.1 |
Plasma samples were assessed at prior to initiation of irinotecan (and l-leucovorin) infusion, 1, 2 (predose for 5-FU bolus), 4, 8, and 24 hours after initiation of irinotecan infusion, and Cmax of irinotecan and its metabolite SN-38 were determined. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Irinotecan Cmax | SN-38 Cmax | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 1963 | 25.1 |
Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Treatment emergent adverse events | Serious adverse events | CTCAE grade 3 or 4 adverse events | CTCAE grade 5 adverse events | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 71 | 32 | 70 | 1 |
(NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | hours (Mean) | |
|---|---|---|
| Irinotecan tmax | SN-38 tmax | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 2 | 4 |
(NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | hours (Mean) | ||
|---|---|---|---|
| Sunitinib Tmax | SU012662 Tmax | Total (sunitinib + SU0122662) Tmax | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 6 | 4 | 6 |
Progression-free survival was measured from the start of treatment until the time the subject is first recorded as having disease progression (progression = 20% increase in sum of longest diameters of target measurable lesions over smallest sum observed or baseline, progression of non-measurable disease in the opinion of treating physician, appearance of new lesion/site, death due to disease), or death due to any cause. If a subject has not progressed or died, progression-free survival was censored at the time of last follow-up or the start of another treatment, whichever came first. (NCT00159432)
Timeframe: Up to 6 years
| Intervention | Months (Median) |
|---|---|
| Oxaliplatin Followed by Bevacizumab, With Capecitabine | 15.8 |
Summary of grade 3 (per CTCAE v3.0) or higher toxicities which generally is described as a severe adverse reaction or symptom. (NCT00159432)
Timeframe: Baseline, every 2 weeks of each cycle, and at end of treatment, up to 18 months.
| Intervention | Participants (Number) |
|---|---|
| Oxaliplatin Followed by Bevacizumab, With Capecitabine | 51 |
DR was defined as the time from the first objective documentation of CR or PR that was subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months
| Intervention | Weeks (Median) |
|---|---|
| FOLFIRI + Sunitinib | 30.1 |
| FOLFIRI + Placebo | 39.0 |
Objective disease response: participants with a confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as the disappearance of all target lesions. PR was defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months
| Intervention | Participants (Number) |
|---|---|
| FOLFIRI + Sunitinib | 124 |
| FOLFIRI + Placebo | 128 |
OS was defined as the time from randomization to the date of death due to any cause. OS data were censored on the day following the date of the last contact at which the patient was known to be alive. (NCT00457691)
Timeframe: Baseline up to 30 months
| Intervention | Weeks (Median) |
|---|---|
| FOLFIRI + Sunitinib | 87.9 |
| FOLFIRI + Placebo | 85.9 |
PFS defined as time from date of randomization to date of first documentation of objective tumour progression or death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: First dose of study treatment up to 30 months
| Intervention | Weeks (Median) |
|---|---|
| FOLFIRI + Sunitinib | 33.6 |
| FOLFIRI + Placebo | 36.6 |
"EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problem); 3 indicates worst health state (eg, confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain. Score is transformed and results in total score range -1.11 to 1.000; higher score indicates better health state." (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | 0.04 | 0.04 | 0.03 | 0.05 | 0.05 | 0.09 |
| FOLFIRI + Sunitinib | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | 0.01 |
EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | 3.3 | 4.3 | 6.6 | 4.3 | 4.0 | 9.0 |
| FOLFIRI + Sunitinib | 1.0 | 1.7 | 1.8 | 3.8 | -0.9 | -1.6 |
Symptom Interference score is comprised of the sum 6 function items from MDASI core (general activity, walking, work, mood, relations with other people, and enjoyment of life). Participant asked to rate how much symptoms have interfered in past 24 hours; each item rated from 0 to 10, with 0=did not interfere and 10=interfered completely; lower scores indicated better outcome (range: 0 to 60). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
| Intervention | scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | -1.3 | -1.7 | -1.2 | -0.2 | -1.7 | -1.0 |
| FOLFIRI + Sunitinib | 0.0 | -0.1 | 0.2 | -0.5 | 2.1 | 3.1 |
Symptom Intensity score is comprised of the sum of 13 MDASI core items (ie, pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or tingling). Participant asked to rate severity of each symptom at their worst in past 24 hours; each item rated from 0 to 10, with 0=symptom not present and 10=as bad as you can imagine; lower scores indicated better outcome (range: 0 to 130). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until end of treatment (EOT)/withdrawal
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | 0.4 | 0.9 | 1.8 | 2.7 | 1.2 | -2.7 |
| FOLFIRI + Sunitinib | 1.7 | 0.8 | 1.0 | 0.7 | 0.8 | 5.0 |
(NCT00537823)
Timeframe: 30 days following surgery
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)
| Intervention | percentage of change of longest diameter (Median) |
|---|---|
| Arm 1 - Wildtype | -23.8 |
| Arm 2 K-Ras 12/13 Codon Mutation | -14.3 |
Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 4 |
| Arm 2 K-Ras 12/13 Codon Mutation | 2 |
Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
(NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not reported on pathology report | Mild | Aborted surgery | None | |
| Arm 1 - Wildtype | 1 | 1 | 1 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 0 | 1 |
"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Not reported on pathology report | Aborted surgery | Score 0 | |
| Arm 1 - Wildtype | 3 | 1 | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 1 |
Liver only vs distant disease (NCT00537823)
Timeframe: Up to 5 years
| Intervention | participants (Number) | |
|---|---|---|
| Liver only | Distant disease | |
| Arm 1 - Wildtype | 0 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 |
"Duration of overall response was measured from the time that measurement criteria are met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the onset of progression. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date).~Missing onset of progression data because of refusal or because of death was replaced.~If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements." (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 244.0 |
| B: XELOX + BEV Followed by XELIRI + BEV | 315 |
The primary variable was duration of disease control (DDC) and was defined as the sum of progression free survival intervals during first line and second line treatment (= time from the beginning of first line treatment until onset of progression during second line treatment). Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). (NCT02119026)
Timeframe: screening, every 8 to 9 weeks until progression, at end of treatment (other than progression), every 3 months until progression, death or up to 24 months (whatever comes first)
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 373.00 |
| B: XELOX + BEV Followed by XELIRI + BEV | 370.00 |
The first line PFS was defined as the progression free survival interval during first line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced. If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements. (NCT02119026)
Timeframe: at progression of disease (PD) in first line therapy or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 241 |
| B: XELOX + BEV Followed by XELIRI + BEV | 280 |
The rate of overall response was measured as the response rate from randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Intervention | Participants (Count of Participants) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 32 |
| B: XELOX + BEV Followed by XELIRI + BEV | 36 |
Overall survival was measured as the time from the randomization date to the date of death. Patients without death date were censored at the date of the last tumor assessment (exception: availability of validated information about a later exitus date or a prolonged survival - in such a case the date of the follow-up assessment was either defined as the exitus date or replaced the last tumor assessment date) or the date of refusal. (NCT02119026)
Timeframe: date of death or date of last tumor assessment (28d safety f-u) in patients without death
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 593.0 |
| B: XELOX + BEV Followed by XELIRI + BEV | 643 |
"The second line PFS was defined as the progression free survival interval during second line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced.~If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements." (NCT02119026)
Timeframe: at progression of disease (PD) in second line therapy or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 129 |
| B: XELOX + BEV Followed by XELIRI + BEV | 155 |
Time to overall response was measured from the time of randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). Patients without response were censored at the date of the last tumor assessment, the date of death or the date of refusal. (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 185.0 |
| B: XELOX + BEV Followed by XELIRI + BEV | 178.0 |
Best response in first line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT02119026)
Timeframe: Baseline, every 8-9 weeks, 28d Safety follow-up
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Progressive Disease (PD) | Stable Disease (SD) | Partial Response (PR) | Complete Response (CR) | |
| A: XELIRI + BEV Followed by XELOX + BEV | 4 | 21 | 26 | 2 |
| B: XELOX + BEV Followed by XELIRI + BEV | 1 | 23 | 30 | 0 |
Best response in second line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT02119026)
Timeframe: Baseline, every 8-9 weeks, 28d Safety follow-up
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Progressive Disease (PD) | Stable Disease (SD) | Partial Response (PR) | Complete Response (CR) | Not available (NA) | |
| A: XELIRI + BEV Followed by XELOX + BEV | 7 | 11 | 6 | 0 | 8 |
| B: XELOX + BEV Followed by XELIRI + BEV | 8 | 13 | 2 | 0 | 1 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
"Overall response rate = complete response + partial response~Complete response = disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart.~Partial response = at least a 30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be non unequivocal progression of non-target lesions and no new lesions." (NCT00868192)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Pemetrexed and Bevacizumab | 41 |
OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Pemetrexed and Bevacizumab | 79 |
OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) |
|---|---|
| Pemetrexed and Bevacizumab | 25.7 |
PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Pemetrexed and Bevacizumab | 56 |
PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) |
|---|---|
| Pemetrexed and Bevacizumab | 7.9 |
A CA-125 response was defined as at least a 50% reduction in CA-125 levels from a pretreatment sample following guidelines described by the Gynecological Cancer Intergroup. (NCT00868192)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| 50% CA-125 response | 75% CA-125 response | No CA-125 response | |
| Pemetrexed and Bevacizumab | 17 | 8 | 2 |
OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) | ||
|---|---|---|---|
| Platinum-free interval of <6 months | Platinum-free interval of 6-12 months | Platinum-free interval of >12 months | |
| Pemetrexed and Bevacizumab | 16.7 | 24.9 | 28.0 |
PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) | ||
|---|---|---|---|
| Platinum-free interval of <6 months | Platinum-free interval of 6-12 months | Platinum-free interval of >12 months | |
| Pemetrexed and Bevacizumab | 6.7 | 4.7 | 16.8 |
As measured by RECIST criteria (NCT00868192)
Timeframe: 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Pemetrexed and Bevacizumab | 0 | 14 | 18 | 2 |
Detailed serious adverse events and other adverse events are shown in the adverse event module of the results. (NCT00868192)
Timeframe: 6 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 3/4 hematologic toxicity | Most common non-hematologic toxicity - fatigue | Grade 3 renal toxicity | Gastrointestinal toxicity | Subsequently developed hematologic malignancies | |
| Pemetrexed and Bevacizumab | 53 | 94 | 6 | 91 | 6 |
Prior to each treatment,the area of reappearance of disease was measured and the % change from baseline was calculated. The change was then added to the % change from the previous treatment to generate a cumulative total % change of reappearance of RRP from baseline. The additive nature of this parameter resulted in % greater than 100% if the area of vocal fold affected by the RRP increased over the baseline measurement. (NCT01020747)
Timeframe: 6 months
| Intervention | total percentage change (Mean) |
|---|---|
| Bevacizumab Treated Vocal Fold | 85.3 |
| Untreated Vocal Fold | 225.3 |
The objective response rate is defined as the percentage of patients showing complete or partial response. (NCT00462423)
Timeframe: The median duration of follow-up for surviving patients was 41.6 months.
| Intervention | Percentage of participants (Number) |
|---|---|
| Single Arm, Open Label | 36 |
The duration of overall survival was defined as the number of months between the start date of protocol treatment and the date of death (irrespective of cause), and was right-censored at the date of last contact for patients who were alive as of the data cutoff. (NCT00462423)
Timeframe: April 2007 through December 2010
| Intervention | months (Median) |
|---|---|
| Single Arm, Open Label | 16.8 |
Median time of progression-free survival from first treatment according to RECIST 1.0 (NCT00462423)
Timeframe: From start of treatment to disease progressin; median duration of follow-up for surviving patients was 41.6 months.
| Intervention | Months (Median) |
|---|---|
| Single Arm, Open Label | 7.63 |
Progression-free survival at 4 months from first treatment as determined by RECIST 1.0 (NCT00462423)
Timeframe: 4 months.
| Intervention | percentage of patients (Number) |
|---|---|
| Single Arm, Open Label | 75 |
The duration of overall complete response was assessed from the time that measurement criteria were met for complete response until the first date that recurrent or progressive disease was objectively documented. Participants without observed progressive disease after an objective complete response were censored at the date of the last tumor assessment. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Number) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 12.45 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 12.68 |
Duration of overall response was assessed from the time that measurement criteria were first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease was documented. It was analyzed for responders only. Participants without observed progressive disease after an objective response were censored at the date of the last tumor assessment. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 7.0 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 7.7 |
Overall Survival is defined as the time from start of treatment to the date of death. Participants who did not die were censored at the last date the participant was known to be alive. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 22.9 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 20.5 |
Survival was measured as the time from start of treatment to the date of death or till one year whichever occurred first. (NCT00022698)
Timeframe: Up to Month 12
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 67 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 71 |
Time to disease progression was assessed as the time from start of treatment to the time the participant was first recorded as having disease progression or died due to causes other than disease progression. If a participant never progressed while being followed, he/she was censored at the date of the last tumor assessment or the date of the last dose if no post-baseline tumor measurement was available. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 6.1 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 7.6 |
The time to objective response is defined as the time from start of treatment to the date of first objective response. Participants who never responded during study were censored at the last tumor assessment or the date of last dose, whichever was later, or at the date of death if occurring prior to response. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 5.5 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 4.3 |
Time to treatment failure was assessed as the time from start of treatment to the time the participant was withdrawn due to any of the reasons such as adverse events, progressive disease, insufficient therapeutic response, death, failure to return, or refused treatment, did not cooperate or withdrew consent. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 5.8 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 7.3 |
An adverse event (AEs) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. A serious adverse event is defined as any event which was fatal (resulted in death), life-threatening (with immediate risk of death), resulted in a new or prolongation of a current hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, considered medically significant by the investigator, required intervention to prevent one or more of the outcomes listed above. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | Number of participants (Number) | |||
|---|---|---|---|---|
| Any AEs | SAEs | Deaths During Study | Deaths During Follow-up | |
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 15 | 10 | 0 | 13 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 52 | 25 | 3 | 23 |
| Total Participants (Cohort 1 + Cohort 2) | 67 | 35 | 3 | 36 |
Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST 1.0). CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as a greater than or equal to (>/=) 30% decrease in the sum of the longest diameter (LD) of the target lesions, taking as reference the baseline sum of LD. Participants who did not have a post-baseline tumor measurement were considered non-responders in the assessment of ORR. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| CR | PR | |
| Cohort 1, Initial Regimen:(Capecitabine + Irinotecan) | 7 | 40 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 2 | 42 |
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
The number of participants in Part 2 who died during the study. (NCT00111761)
Timeframe: From enrollment until last contact. Maximum follow-up was 16 months.
| Intervention | participants (Number) |
|---|---|
| Panitumumab With FOLFIRI | 6 |
Objective tumor response (complete or partial) in Part 2 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease. (NCT00111761)
Timeframe: Until disease progression (median 47 weeks)
| Intervention | Participants (Number) |
|---|---|
| Panitumumab With FOLFIRI | 8 |
The number of participants with grade 3 or grade 4 diarrhea in Part 1 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC). (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
| Intervention | Participants (Number) |
|---|---|
| Panitumumab With IFL | 11 |
The number of participants with grade 3 or grade 4 diarrhea in Part 2 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC). (NCT00111761)
Timeframe: Until disease progression (median 47 weeks)
| Intervention | Participants (Number) |
|---|---|
| Panitumumab With FOLFIRI | 6 |
Objective tumor response (complete or partial) in Part 1 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
| Intervention | Participants (Number) |
|---|---|
| Panitumumab With IFL | 9 |
Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 1 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 25 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 24.3 |
Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 2 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 16 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With FOLFIRI | 41.1 |
Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date. (NCT00111761)
Timeframe: From enrollment until death. Maximum follow-up time was 25 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 73.1 |
Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date. (NCT00111761)
Timeframe: From enrollment until death. Maximum follow-up time was 16 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 73.1 |
Kaplan-Meier estimate of the median time from the first dose of study drug to disease progression or death if due to disease progression (whichever comes first) in Part 1 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 25 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 35.0 |
Kaplan-Meier estimate of median time from the first dose of study drug to first observed disease progression or death if the death was due to disease progression (whichever comes first) in Part 2 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until death or diease progression. Maximum follow-up time was 16 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With FOLFIRI | 47.3 |
Median time to first observed objective tumor response (complete or partial) among responders in Part 1 of the study. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 5.9 |
Kaplan-Meier estimate of the median time from the date of first dose of panitumumab or chemotherapy to the date the decision was made to end treatment for any reason in Part 1 of the study. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
| Intervention | Weeks (Median) |
|---|---|
| Panitumumab With IFL | 24.3 |
Here is the number of participants with an adverse event. For a detailed list of adverse events see the adverse event module. (NCT00052962)
Timeframe: 2003-2008
| Intervention | Participants (Number) |
|---|---|
| Arm 1 Surgery + Post op Chemotherapy | 7 |
| Arm 2 Surgery + CHPP | 6 |
(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| Proton Radiation and Chemotherapy | 0 |
865 reviews available for fluorouracil and Colorectal Cancer
| Article | Year |
|---|---|
Antiproliferative and palliative activity of flavonoids in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2021 |
Systematic review and meta-analysis of tumour microsatellite-instability status as a predictor of response to fluorouracil-based adjuvant chemotherapy in colorectal cancer.
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Instability; Micr | 2022 |
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Feb | 2021 |
Intra-Arterial Therapy for Unresectable Colorectal Liver Metastases: Which and When? A Commentary on "Intra-Arterial Therapy for Unresectable Colorectal Liver Metastases: A Meta-Analysis".
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2021 |
Adjuvant treatment of colon cancer with microsatellite instability - the state of the art.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; DNA Mismatch Repair; Fluorouracil; | 2022 |
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2022 |
Adjuvant intra-arterial chemotherapy for patients with resected colorectal liver metastases: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2022 |
Proton pump inhibitors and colorectal cancer: A systematic review.
Topics: Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Proton Pump Inhibitors | 2021 |
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Colonic Neo | 2022 |
Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2022 |
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 2022 |
MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Reg | 2022 |
Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA-Compliant single-arm Meta-Analysis of noncomparative clinical studies and randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2022 |
Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Fluorouracil; Hu | 2022 |
After thirty years of experience with early postoperative intraperitoneal 5-fluorouracil now saying goodbye.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt | 2022 |
Comparison between diagnostic performance of intestinal Fusobacterium nucleatum, Bacteroides fragilis and Escherichia coli in 5-fluorouracil resistance to colorectal cancer: A meta‑analysis.
Topics: Bacteroides fragilis; Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; | 2022 |
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II | 2022 |
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II | 2022 |
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II | 2022 |
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II | 2022 |
Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy.
Topics: Animals; Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Lipids | 2022 |
A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla | 2022 |
Leukocytoclastic vasculitis presenting clinically as bullous pyoderma gangrenosum following leucovorin, fluorouracil and oxaliplatin chemotherapy: a rare case report and literature review.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouraci | 2022 |
Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer: A systematic review network meta-analysis of randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2023 |
Versatile use of Carmofur: A comprehensive review of its chemistry and pharmacology.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Colorectal Neoplasms; COVID-19; Fluorouracil; Humans | 2022 |
Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Ge | 2022 |
The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dietary Suppleme | 2022 |
Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer.
Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Signal Transduction; Thymidyl | 2022 |
Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Fluorou | 2023 |
Curcumin, calebin A and chemosensitization: How are they linked to colorectal cancer?
Topics: Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Curcumin; Cytostatic Agents; Drug Resistance, Neo | 2023 |
Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebral Infarction; Colorectal Neoplasms; Fluoroura | 2023 |
Hepatic artery infusion for unresectable colorectal cancer liver metastases: Palliation and conversion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2023 |
A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; East A | 2023 |
Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Clinical Tria | 2023 |
5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review).
Topics: Capecitabine; Cell Division; Cell Membrane; Colorectal Neoplasms; Fluorouracil; Humans | 2023 |
High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy.
Topics: Colorectal Neoplasms; Cytostatic Agents; Drug-Related Side Effects and Adverse Reactions; Fluorourac | 2023 |
Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Colon | 2023 |
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Prodrugs | 2020 |
FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Cycle Proteins; Colorectal N | 2020 |
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Ca | 2020 |
Response to: Optic neuritis induced by 5-fluorouracil chemotherapy: case report and review of the literature.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Magnetic Resonance Imaging; Optic Neuritis | 2020 |
Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colo | 2020 |
Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Topics: Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Colorectal Neoplasms; Embolization, | 2020 |
The efficacy and safety of panitumumab supplementation for colorectal cancer: A meta-analysis of randomized controlled studies.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neo | 2020 |
The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments.
Topics: Antineoplastic Agents; Apoptosis; Colorectal Neoplasms; Fluorouracil; Humans; Oxaliplatin; p38 Mitog | 2020 |
Recent Advances in Polymer Nanomaterials for Drug Delivery of Adjuvants in Colorectal Cancer Treatment: A Scientific-Technological Analysis and Review.
Topics: Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; Nanostructures; Polymers | 2020 |
Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update.
Topics: Animals; Autophagy; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Pharmacog | 2020 |
5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Colorectal Neoplasms; Drug Resistance, Neoplasm; Energy | 2020 |
Undiagnosed Case of Signet Ring Cell Colorectal Carcinoma: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; | 2020 |
MicroRNAs and Apoptosis in Colorectal Cancer.
Topics: Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; MicroRNAs; RNA, Ne | 2020 |
The actual management of colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Electroporation; | 2020 |
Controversies in the treatment of RAS wild-type metastatic colorectal cancer.
Topics: Advisory Committees; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colo | 2021 |
Recent Advances in Designing 5-Fluorouracil Delivery Systems: A Stepping Stone in the Safe Treatment of Colorectal Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biological | 2020 |
MicroRNAs and colorectal cancer chemoresistance: New solution for old problem.
Topics: ATP-Binding Cassette Transporters; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Drug R | 2020 |
Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colorectal Neopla | 2021 |
Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis.
Topics: Bevacizumab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Oxaliplatin | 2021 |
Intraarterial Chemotherapy for Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hep | 2021 |
Potentially Resectable mCRC-treated with Cetuximab Combined with Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; | 2020 |
Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm | 2021 |
Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Peritone | 2022 |
Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.
Topics: Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined | 2021 |
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Topics: Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Mutation; Proto-Oncogene Proteins | 2021 |
[A Case of Liver Metastasis of Colorectal Cancer in a Hemodialysis Patient, Underwent Liver Resection and Chemotherapy after Colorectal Resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colon, Sigmoid; Colorectal Neoplasms; Fluorouracil; | 2021 |
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Fluorou | 2021 |
Multiple strategies with the synergistic approach for addressing colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette | 2021 |
Up-to-date role of aflibercept in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2021 |
[FOLFIRI plus Ramucirumab Treatment for Metastatic Colorectal Cancer-Narrative Review of Real-World Evidence in Japan].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2021 |
The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2021 |
Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; British Columbia; Camptothecin; Cohort | 2022 |
Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neopla | 2017 |
[Cetuximab in association with an oxaliplatin-based chemotherapy as first-line treatment of metastatic colorectal cancer.]
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Fluorouracil; Human | 2017 |
FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur | 2017 |
FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2017 |
Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemical and D | 2017 |
Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis.
Topics: Administration, Oral; Antineoplastic Agents; Colorectal Neoplasms; Databases, Bibliographic; Disease | 2018 |
Oral versus intravenous fluoropyrimidines for colorectal cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuva | 2017 |
Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Campt | 2018 |
The paradigm of tumor shrinkage and rapid liver remnant hypertrophy for conversion of initially unresectable colorectal liver metastasis: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Carcinoma; C | 2017 |
Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; | 2017 |
Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2017 |
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Current status and future prospective of Curcumin as a potential therapeutic agent in the treatment of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Curcumin; Fluorouraci | 2018 |
Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal | 2018 |
Efficacy and safety of FOLFIRI and biotherapy versus FOLFIRI alone for metastatic colorectal cancer patients: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Camptothecin; Colorectal Neoplas | 2017 |
Hepatobiliary phase liver MR imaging findings after Oxaliplatin-based chemotherapy in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical and Dru | 2018 |
A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2018 |
[Metastatic colorectal cancer: To stop or not to stop?]
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo | 2018 |
FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2018 |
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2018 |
Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm | 2018 |
Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Hypoxia; Colorectal Neoplasms; Disea | 2018 |
Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2018 |
New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2018 |
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2018 |
New Trends in Liposome-based Drug Delivery in Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Colon; Colorectal Neoplasms; Drug Delivery | 2019 |
The role of microRNAs in 5-FU resistance of colorectal cancer: Possible mechanisms.
Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplasti | 2019 |
Recent advances in understanding colorectal cancer.
Topics: Antibodies; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Microsatellite Instability; | 2018 |
Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Fluorour | 2018 |
Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brazil; Cetuximab; Colorectal Neoplasms | 2018 |
Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.
Topics: Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; MicroRNAs; | 2019 |
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarke | 2019 |
FOLFOXIRI plus biologics in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2019 |
Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian Peop | 2019 |
Efficacy and safety of high-dose vs low-dose leucovorin in patients with colorectal cancer: systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect | 2020 |
[Oxaliplatin in colorectal carcinoma: from palliation to cure].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 2004 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boro | 2003 |
The evolving role of oxaliplatin in the management of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2003 |
OncoSurge: a strategy for long-term survival in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2003 |
An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens.
Topics: Alleles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2013 |
Adenocarcinoma of the colon in children: case series and mini-review of the literature.
Topics: Abdomen; Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Barium Sulfate; | 2013 |
FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2013 |
Chemotherapeutic options for colorectal cancer patients with cardiovascular diseases.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Colorectal Neoplasms; Fluorouracil; Global Health; H | 2013 |
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.
Topics: Alleles; Alternative Splicing; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug-Relate | 2013 |
Options for metastatic colorectal cancer beyond the second line of treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2014 |
Methods of overcoming treatment resistance in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Enzyme Inhibito | 2014 |
Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; M | 2013 |
Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Cardiomyopathies; Colorectal Neoplasm | 2013 |
FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2014 |
Raltitrexed-based chemotherapy for advanced colorectal cancer.
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induce | 2014 |
Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2014 |
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; D | 2014 |
How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy.
Topics: Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Folic Acid; Folic Acid Antagonists; | 2015 |
Sequencing of treatment in metastatic colorectal cancer: where to fit the target.
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2014 |
A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2014 |
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
Topics: Alanine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Role of cetuximab in first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dise | 2014 |
Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Hypertriglyceridemia and hyperglycemia induced by capecitabine: a report of two cases and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Capecitabine; Colorectal Neopl | 2015 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2014 |
Use of microRNAs in directing therapy and evaluating treatment response in colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Chemoradiotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidin | 2014 |
A simple technique to estimate best- and worst-case survival in patients with metastatic colorectal cancer treated with chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2014 |
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biotransformation; Camptothecin; | 2014 |
Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2014 |
Oxaliplatin-induced Lhermitte sign. A case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2014 |
Diagnosis and management of DNA mismatch repair-deficient colorectal cancer.
Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; C | 2015 |
Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2015 |
A review of the evolution of systemic chemotherapy in the management of colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug D | 2015 |
The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana | 2015 |
[Molecular pathology of colorectal cancer].
Topics: Adenocarcinoma; Algorithms; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Colorectal | 2015 |
Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2015 |
Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Cardiotoxicity; Chest Pain; Co | 2016 |
Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Instabil | 2015 |
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); | 2015 |
Microsatellite instability testing and its role in the management of colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2015 |
Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2015 |
MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combinat | 2015 |
[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Camptoth | 2015 |
Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; C | 2015 |
Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis.
Topics: Antimetabolites, Antineoplastic; Body Surface Area; Colorectal Neoplasms; Dose-Response Relationship | 2016 |
Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cam | 2016 |
Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2016 |
Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal | 2015 |
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bev | 2016 |
Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Mo | 2015 |
TAS-102: a novel antimetabolite for the 21st century.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2016 |
Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 2015 |
Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla | 2016 |
Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore | 2016 |
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Colorectal Ne | 2016 |
Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases.
Topics: Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Veno-Occlusive D | 2016 |
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combine | 2016 |
Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Campt | 2016 |
Chinese Herbal Medicine and Fluorouracil-Based Chemotherapy for Colorectal Cancer: A Quality-Adjusted Meta-Analysis of Randomized Controlled Trials.
Topics: Colorectal Neoplasms; Complementary Therapies; Drugs, Chinese Herbal; Fluorouracil; Humans; Phytothe | 2016 |
Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; DNA Repair; DNA-Binding Proteins; Endonuc | 2016 |
Mitomycin-C+fluoropyrimidines in heavily pretreated metastatic colorectal cancer: a systematic review and evidence synthesis.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta | 2016 |
Liver Metastases in Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2016 |
Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Colorectal Neoplasms; Drugs, Chinese | 2016 |
Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, T | 2016 |
Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; | 2016 |
Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasm | 2017 |
Selective internal radiation therapy for liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Surv | 2016 |
Unresectable liver metastases in colorectal cancer: review of current strategies.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2016 |
Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization; Colorectal Neoplasms; | 2017 |
Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients.
Topics: Animals; Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; DNA Mismatch Repair; Fluorour | 2017 |
Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Coordination Complexes; DNA Damage; Drug Ther | 2017 |
Second-line systemic therapy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2017 |
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2008 |
[Current therapeutic options for liver metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Catheter Ablation; Colorect | 2008 |
FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highl | 2008 |
Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2008 |
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Biological Clocks; Cell Cycle; Circadian Rhythm; Colorectal Neoplasm | 2008 |
Regional chemotherapy for liver-limited metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2008 |
[Molecular targets for colon cancer. VEGF, EGFR - and what else?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capec | 2008 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore | 2009 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore | 2009 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore | 2009 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore | 2009 |
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
[Colorectal carcinoma--primary treatment in case of advanced metastization].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Le | 2008 |
Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2009 |
MicroRNA and colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; CpG Islands; Down-Regulation; Fluorouracil; G | 2009 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2008 |
Treatment of colorectal liver metastases: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasm | 2009 |
Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms | 2009 |
Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2010 |
The role of targeted therapy in the treatment of advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2008 |
Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2009 |
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fatty Liver; Fluorouracil; Humans; Liver; Liver Neoplas | 2009 |
The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2009 |
Microsatellite instability: a predictive marker in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Clinical Trials as | 2009 |
Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2009 |
A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
[Colorectal cancers: prognostic and predictive factors of response to treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetu | 2009 |
Second-line chemotherapy in advanced and metastatic CRC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2009 |
Thymidylate synthase gene variations: predictive and prognostic markers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fluorouracil; Gene Express | 2009 |
What's new in ... colorectal cancer. Meaningful progress in therapy options.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2009 |
A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mismatch | 2009 |
Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dru | 2010 |
Genetic prognostic and predictive markers in colorectal cancer.
Topics: beta Catenin; Biomarkers, Tumor; Camptothecin; Capecitabine; Chromosomes, Human, Pair 18; Colorectal | 2009 |
[Chemotherapy of elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2009 |
A novel K-ras mutation in colorectal cancer. A case report and literature review.
Topics: Adenocarcinoma, Mucinous; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineop | 2009 |
Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Cli | 2009 |
Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2009 |
KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, | 2009 |
Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2009 |
Chemotherapy, which drugs and when.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; C | 2009 |
[The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Human | 2009 |
Selective internal radiation therapy for liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluor | 2009 |
[Pathological diagnosis for individualized therapy of colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
[Chemotherapy for colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetux | 2009 |
[Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
[Expression of dihydropyrimidine dehydrogenase in primary colorectal cancer and liver metastasis--a relationship between mRNA levels in cancer cells and protein levels in cancerous tissue and effect of 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Enzyme-Li | 2009 |
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2011 |
Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color | 2010 |
Evolution of capecitabine dosing in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2010 |
Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combine | 2009 |
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2010 |
Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost Sa | 2010 |
Surgical therapies in metastatic colorectal cancer with a potential for cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2011 |
Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progress | 2010 |
[Transition of chemotherapy for metastatic colorectal cancer and recent advances].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; | 2010 |
[Recent developments of pharmacogenomics in the treatment of colorectal cancers].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Biotr | 2010 |
Meta-analysis: perioperative regional liver chemotherapy for improving survival and preventing liver metastases in patients with colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepa | 2010 |
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2010 |
Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2010 |
Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Ch | 2011 |
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Colorectal Neoplasms; Dihydropyrimidin | 2010 |
Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2010 |
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.
Topics: Adenocarcinoma; Age Factors; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Cap | 2011 |
Capecitabine-based chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2011 |
Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Camptothecin; Chemotherapy, Adju | 2011 |
Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetab | 2010 |
Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, An | 2010 |
Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2010 |
Chemotherapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neo | 2010 |
XELOX in colorectal cancer: a convenient option for the future?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials | 2011 |
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Huma | 2011 |
5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2012 |
Adjuvant treatment of colon cancer: what is next?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2011 |
Biomarker-based selection of therapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers; Capecitabine; Colorectal Neoplasms; Deoxy | 2011 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2011 |
Colorectal cancer treatment.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Intestinal Ob | 2010 |
Common side effects and interactions of colorectal cancer therapeutic agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Evolution of systemic therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2011 |
Unilateral hand-foot syndrome: does it take sides? Case report and literature review.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Ha | 2012 |
Bevacizumab in metastatic colorectal cancer and carcino-embryonic antigen kinetics: case report and review of literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biom | 2011 |
DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2011 |
[State of art of the radiofrequency ablation of colorectal liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Catheter Ablation; Colorec | 2011 |
Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neopl | 2011 |
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2011 |
[Neoadjuvant therapy concepts for liver metastases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
[Is there alternative to FOLFOX adjuvant chemotherapy for stage III colorectal cancer patients?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Choice Behav | 2012 |
Oxaliplatin: a review of approved uses.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; | 2012 |
Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Colorectal Neoplas | 2012 |
Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt | 2012 |
[Chemotherapy for advanced colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Molecul | 2011 |
[A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2011 |
[Current view and possibilities of chemotherapy sensitivity and resistance assays and metabolic enzyme analysis in individualized chemotherapy for the patients with colorectal cancer].
Topics: Aged; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Male; Mi | 2011 |
[FOLFOX-related hypersensitivity reactions: clinical presentation and management].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Hypersensitivity; Fluorou | 2011 |
A preclinical and clinical review of aflibercept for the management of cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother | 2012 |
Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis.
Topics: Capecitabine; Colorectal Neoplasms; Databases, Genetic; Deoxycytidine; Fluorouracil; Folic Acid; Gen | 2012 |
Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hu | 2012 |
Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
[Fluorouracil implants for colorectal cancer: a systematic review and meta-analysis].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Randomized Controlled Trials as T | 2012 |
Chemotherapy and molecular-targeted treatment for unresectable hepatic metastases: a Japanese perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2012 |
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Circadian Clocks; Colorectal Ne | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2012 |
Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms | 2012 |
Colorectal liver metastases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablati | 2013 |
Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis.
Topics: Adult; Aged; Anaphylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Col | 2012 |
Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cardiovascular Agents; Colorectal Neoplasms; | 2013 |
Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2013 |
[Colorectal carcinoma: what's new?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Col | 2012 |
Role of microsatellite instability in the management of colorectal cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Colore | 2013 |
Oncological management of unresectable liver metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
[Modified FOLFOX6(mFOLFOX6)in metastatic colorectal carcinoma patients with poor performance status].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; | 2012 |
FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Therapeutic advances in the management of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colo | 2001 |
The role of genomic instabilities in affecting treatment responses of colorectal cancer.
Topics: Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Hum | 2002 |
Chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplas | 2002 |
Targeting vascular endothelial growth factor in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2002 |
Adjuvant therapy of colorectal cancer: the next step forward.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fluo | 2002 |
[Review of comparative studies of postoperative adjuvant chemotherapy after curatively resected colorectal cancer in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2002 |
Regional therapy of hepatic metastases.
Topics: Antineoplastic Agents; Catheter Ablation; Colorectal Neoplasms; Cryosurgery; Embolization, Therapeut | 2002 |
Chemotherapy in colorectal cancer: new options and new challenges.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms | 2002 |
The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2002 |
Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2001 |
Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II | 2001 |
Review of the role of CPT-11 in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2001 |
Oral fluoropyrimidine treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials | 2001 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; | 2001 |
Thymidylate synthase: a critical target for cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2002 |
Adjuvant therapy of colon cancer: a review.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, | 2002 |
Thymidylate synthase pharmacogenetics in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Huma | 2001 |
Capecitabine (Xeloda): from the laboratory to the patient's home.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, P | 2002 |
Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instability.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Genetic | 2002 |
Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2002 |
[Progress in adjuvant therapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2002 |
Current status of capecitabine in the treatment of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherap | 2002 |
Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials | 2002 |
Complications of hepatic artery infusion: a review of 4580 reported cases.
Topics: Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Bone Marrow Diseases; Catheters, Indwe | 2001 |
[The role of the regional (intra-arterial) chemotherapy in the treatment of hepatic metastases of colorectal cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2003 |
The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic | 2003 |
Predictive markers for colorectal cancer: current status and future prospects.
Topics: Antineoplastic Agents; Base Pair Mismatch; Biomarkers; Colorectal Neoplasms; Drug Resistance, Neopla | 2003 |
Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Data Interp | 2002 |
[Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review].
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Fra | 2003 |
Palliative treatment of patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inh | 2003 |
[Chemotherapy for colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2003 |
Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Flox | 2003 |
Hepatic resection after down-staging of unresectable hepatic colorectal metastases.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Liver Neop | 2003 |
Management of colorectal liver metastases.
Topics: Antimetabolites, Antineoplastic; Balloon Occlusion; Catheter Ablation; Colorectal Neoplasms; Combine | 2003 |
Irinotecan: promising activity in the treatment of malignant glioma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2003 |
Optimal use of the combination of irinotecan and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2003 |
Practical considerations in the use of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color | 2003 |
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2003 |
Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonography, Computed Tomog | 2003 |
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antine | 2003 |
Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2003 |
Current treatments and future perspectives in colorectal and gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2003 |
[Oral fluoropyrimidines in the treatment of colorectal carcinoma].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 18 | 2004 |
Tailoring chemotherapy in advanced colorectal cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NAD | 2003 |
Campto effective and flexible chemotherapy for advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2003 |
Colorectal cancer: integrating oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C | 2003 |
[Therapeutic strategies in colorectal cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color | 2003 |
Current and ongoing trials with irinotecan in the United States.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2003 |
Alternative schedules with irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2003 |
Induction therapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Inf | 2003 |
Review article: colorectal cancer chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Ne | 2003 |
[Controversy of treatment for advanced colorectal cancer--intermedisine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl | 2003 |
Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2003 |
Pharmacogenomics in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Cisplatin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP) | 2003 |
Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2003 |
[Polymorphism in colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genetic Predisposition to D | 2003 |
[Immunohistologic evaluation of TS, DPD, and p53 protein expression in patients with colorectal cancer having liver and pulmonary metastases].
Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Liver Neoplasms; Lun | 2003 |
[Adjuvant chemotherapy for colorectal cancer: Its efficacy and problems].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 2003 |
[Molecular biological analysis of 5-fluorouracil sensitivity in colorectal neoplasm].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Resi | 2003 |
[Response marker to 5-FU after curative surgery in colorectal cancer].
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, N | 2003 |
[Application and problems in hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hep | 2003 |
[Home chemotherapy and outpatient treatment for metastatic colorectal cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2003 |
[Doxifluridine for treatment of colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Floxuridine; Flu | 2003 |
[Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
[5-fluorouracil and leucovorin therapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2003 |
[Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2003 |
[Effect of systemic chemotherapy by 5-FU with low dose CDDP (in the hospital) and UFT with low dose CDDP (in outpatient clinic) in unresectable recurrent colorectal cancer].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2003 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials a | 2003 |
[Complications of hepatic artery chemotherapy for liver metastases in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Cholangitis, Sclerosing | 2003 |
[Adjuvant chemotherapy for colorectal carcinoma after curative resection].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
[Long-term prognosis for colorectal carcinoma treated with adjuvant immunochemotherapy].
Topics: Antimetabolites, Antineoplastic; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Cytokin | 2003 |
[Guidance and informed consent in colon cancer therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colorectal Neoplasms; Fluor | 2003 |
[Treatment for recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2003 |
Successful treatment of radiofrequency-induced biliary lesions by interventional endoscopic retrograde cholangiography (ERC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Carcinoma, Hepatocellula | 2003 |
[Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colo | 2003 |
Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; | 2003 |
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycyt | 2003 |
[Chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administrat | 2003 |
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neopla | 2003 |
Integrating oxaliplatin and capecitabine in adjuvant therapy of high-risk colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trial | 2003 |
Development of new agents for the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I | 2003 |
[Palliative therapy of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dise | 2003 |
[Chemotherapy of advanced colorectal carcinoma: treatment options for elderly patients].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Top | 2003 |
First-line treatment strategies to improve survival in patients with advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; H | 2004 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2003 |
Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy | 2004 |
The role of new agents in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2004 |
Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clini | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2004 |
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2004 |
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; D | 2004 |
[Oral 5-FU and digestive cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2004 |
Adjuvant therapy for rectal cancer in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cli | 2004 |
[Hepatic arterial infusion chemotherapy for colorectal liver metastases].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Ad | 2004 |
[Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2004 |
Systemic treatment of advanced colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2004 |
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Therapy, Co | 2004 |
Current approaches to first-line treatment of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2004 |
Oxaliplatin plus oral fluoropyrimidines in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Progress in the development of novel treatments for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2004 |
Current strategies in previously untreated advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; C | 2004 |
Current status of adjuvant therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; | 2004 |
Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Fluorour | 2004 |
Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo | 2004 |
[New therapy options in colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
[Surgery of liver metastasis from colorectal cancer following irinotecan and 5FU-folinic acid].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Huma | 2004 |
Developments in combination chemotherapy for colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, | 2004 |
Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2004 |
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; | 2004 |
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; | 2004 |
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; | 2004 |
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; | 2004 |
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
Topics: Activities of Daily Living; Algorithms; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitab | 2004 |
Implementation of capecitabine (Xeloda) into a cancer centre: UK experience.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Cancer Care Facilities; Cap | 2004 |
Implications of capecitabine (Xeloda) for cancer nursing practice.
Topics: Administration, Oral; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabi | 2004 |
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovori | 2004 |
Evidence-based update of chemotherapy options for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Campt | 2004 |
[Advances in palliative and adjuvant chemotherapy of colon cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deo | 2004 |
Meta-analysis of new treatment strategies for metastatic colorectal cancer.
Topics: Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neop | 2004 |
Strategies for palliative care in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Huma | 2004 |
Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine | 2004 |
Pharmacogenomics and colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Repair; Fluorouracil; Gene | 2004 |
Current perspectives in the treatment of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clini | 2004 |
Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2004 |
[Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2004 |
Which drug combination for colorectal cancer?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt | 2004 |
[Colorectal cancer: current treatment options].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colo | 2004 |
Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clini | 2004 |
[Recent results of irinotecan therapy in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antine | 2004 |
Chemotherapy in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 2004 |
[Second-line chemotherapy for advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administrat | 2005 |
Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2004 |
Systemic therapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2005 |
Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Clinical Trials a | 2005 |
Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Adjuvant therapy of colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt | 2005 |
Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluor | 2005 |
Perspectives in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 2004 |
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2005 |
[Surgical treatment of hepatic metastases of colorectal neoplasms].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2004 |
[Colon cancer: molecular markers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; | 2005 |
Critical evaluation of current treatments in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2005 |
The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2005 |
New combinations in metastatic colorectal cancer: what are our expectations?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2005 |
Benefit-risk assessment of irinotecan in advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2005 |
Indications and effect on survival of standard chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2005 |
New chemotherapeutic strategies in colorectal cancer.
Topics: Administration, Oral; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neop | 2005 |
Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2005 |
Clinical management of oxaliplatin-associated neurotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 2005 |
Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycyti | 2005 |
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase | 2005 |
The development of clinical research in CRC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2005 |
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
Topics: Colorectal Neoplasms; Fluorouracil; Mutation; Predictive Value of Tests; Prognosis; Proto-Oncogene P | 2005 |
Current therapies for advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2005 |
Management of advanced colorectal cancer in older patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neo | 2005 |
Capecitabine: effective oral fluoropyrimidine chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, | 2005 |
(Neo-)adjuvant treatments in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2005 |
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinic | 2005 |
Role of genomic markers in colorectal cancer treatment.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Gene Exp | 2005 |
Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Drug Delivery System | 2005 |
[Chemotherapy of patients with colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2005 |
Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Repeats; | 2005 |
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2004 |
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clini | 2005 |
[5-Fluorouracil-induced small bowel toxicity in a patient with colorectal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Ileitis | 2005 |
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2005 |
[Molecular biology in clinical cancer research: the example of digestive cancers].
Topics: Adenocarcinoma; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen | 2005 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt | 2005 |
Metastatic colorectal cancer: is there one standard approach?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2005 |
Elderly patients with advanced colorectal cancer: which therapy is the safest?
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorecta | 2005 |
A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2005 |
Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2005 |
[Drug therapy of patients with metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2005 |
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2005 |
Managing patients treated with bevacizumab combination therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2005 |
The future development of bevacizumab in colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2005 |
Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioma | 2005 |
[Recent progress of chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2005 |
Capecitabine/Oxaliplatin combinations in advanced colorectal cancer: summary of recent randomized studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2005 |
Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2005 |
The role of bevacizumab as first-line therapy for colon cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2005 |
Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.
Topics: Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hum | 2006 |
Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe?
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Col | 2006 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neop | 2005 |
Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cancer Vaccines; Cis | 2006 |
Polymorphisms in the thymidylate synthase gene predict response to 5-fluorouracil therapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Polymorphism, Genetic; | 2006 |
Use of hyperthermic intraperitoneal chemotherapy (HIPEC) in management of peritoneal carcinomatosis from colorectal origin.
Topics: Antineoplastic Agents; Appendiceal Neoplasms; Carcinoma; Colorectal Neoplasms; Combined Modality The | 2005 |
[Adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug C | 2006 |
Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Chemotherapy, Adjuv | 2006 |
Capecitabine in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Fo | 2005 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
[The modern treatment of colorectal cancer. Present and future].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A | 2006 |
Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2006 |
Predicting the outcome of chemotherapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bioma | 2006 |
First- and second-line therapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug A | 2006 |
[Irinotecan for the treatment of metastatic colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2006 |
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Ana | 2006 |
Biological agents versus chemotherapy in the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
[Capecitabine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clini | 2006 |
[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Cli | 2006 |
[IFL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2006 |
[Adjuvant treatment of colorectal cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capeci | 2006 |
Surgical adjuvant therapy for colorectal cancer: current approaches and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trial | 2006 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Metastatic colorectal cancer: Therapeutic options.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
[Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Dihydrouracil Dehydrogenase | 2006 |
Capecitabine: a new adjuvant option for colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Cause of Death; Colorectal Neop | 2006 |
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2006 |
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2006 |
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2006 |
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2006 |
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Update on capecitabine in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxy | 2006 |
Methyl-group metabolism and the response of colorectal cancer to 5-fluorouracil.
Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Methylation; Fluorouracil; Folic Acid; | 2006 |
Bevacizumab in combination with 5-fluorouracil-based chemotherapy in the second-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
Bevacizumab in older patients and patients with poorer performance status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
[Request for a compassionate use of biotherapies in oncology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
[Present status and prospect of irinotecan application in adjuvant therapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2006 |
[Colorectal liver metastases. Neoadjuvant chemotherapy: aspects of medical and surgical oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diseas | 2007 |
[Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2006 |
Oral capecitabine (Xeloda) in cancer treatment.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2007 |
[Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
Topics: Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2007 |
Biological therapy update in colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2007 |
Oxaliplatin in the treatment of colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 2007 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
Capecitabine in the treatment of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplas | 2007 |
[Surgery and chemotherapy for colorectal cancer: current status and perspective].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Col | 2007 |
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Clinical Trials as Topic; C | 2007 |
[Pre-operative chemotherapy for patients with hepatic metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2007 |
Presurgical chemotherapy in patients being considered for liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Fluorouraci | 2007 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2007 |
[Are antiangiogenic antibodies universal for solid tumor?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
Topics: Adult; Antiemetics; Antineoplastic Agents, Phytogenic; Ataxia; Camptothecin; Capecitabine; Central N | 2008 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Treatment of advanced colorectal cancer in the elderly.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; | 2007 |
Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Biotransformation; Clinical Trials as Topic; Colorectal Neoplasms; | 2007 |
[Progress of chemotherapy in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Com | 2007 |
[Palliative chemotherapy and radiotherapy for metastatic colorectal cancer].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, | 2008 |
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2008 |
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans | 2008 |
Advances in neoadjuvant therapy for colorectal cancer with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2008 |
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2008 |
Exploring alternative individualized treatment strategies in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biological Therapy; Chemotherapy, Adjuvant; Colorecta | 2007 |
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2007 |
Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2007 |
[Antibody treatment in colorectal cancer--what the surgeon needs to know].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2008 |
Capecitabine: an overview of the side effects and their management.
Topics: Administration, Oral; Age Factors; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2008 |
The role of molecular markers in predicting response to therapy in patients with colorectal cancer.
Topics: Algorithms; Antibody-Dependent Cell Cytotoxicity; Biomarkers, Tumor; Chromosomes, Human, Pair 18; Cl | 2008 |
Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2008 |
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana | 2008 |
Systemic treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; ErbB Receptors; | 2008 |
Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2008 |
[Pharmacology of regional chemotherapy of colorectal liver metastases].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Dose | 1995 |
[Results of resection and adjuvant therapy of liver metastases of primary colorectal tumors--a review of the literature].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regiona | 1995 |
Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neopla | 1994 |
Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials.
Topics: Carcinoma, Squamous Cell; Circadian Rhythm; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasm | 1994 |
[Chemotherapy and radiochemotherapy of colorectal cancers: adjuvant and palliative therapeutic procedures].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color | 1994 |
5-fluorouracil modulation in the chemotherapy of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Interfer | 1994 |
[What is the value of arterial chemotherapy in treatment of colorectal liver metastases].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Floxu | 1994 |
Biochemical modulation as an approach to reversal of antimetabolite resistance.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1994 |
[Adjuvant and palliative regional therapy of liver metastases in colorectal tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region | 1995 |
Metastatic colorectal cancer: advances in biochemical modulation and new drug development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neoplasms; Diar | 1995 |
Update on regional treatments for hepatobiliary malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; | 1995 |
[Combined chemotherapy with 5-FU+cis-platin or UFT+cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Colorectal Neop | 1995 |
[Biomodulation of 5-fluorouracil by interferon].
Topics: Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination; | 1995 |
Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluor | 1995 |
The role of interferons in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1993 |
Cancers of the large bowel and hepatobiliary tract.
Topics: Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Pancreatic N | 1994 |
Hepatic artery chemotherapy for colorectal liver metastases.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infu | 1995 |
Adjuvant chemotherapy for colorectal cancer.
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Levamisole; Neoplasm Staging; Pr | 1995 |
[Treatment of metastases of colorectal cancers].
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Recurrence, Local | 1994 |
Cytokine-based biotherapy of gastrointestinal tumors.
Topics: Clinical Trials as Topic; Colorectal Neoplasms; Cytokines; Drug Synergism; Fluorouracil; Gastrointes | 1994 |
Cerebral demyelination with 5-fluorouracil and levamisole.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colorec | 1994 |
The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1994 |
Current approaches to metastatic colorectal cancer.
Topics: Adjuvants, Pharmaceutic; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedul | 1994 |
Chemotherapy for colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 1994 |
Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 1994 |
Biochemical modulation of fluoropyrimidines: the "GISCAD" studies. GISCAD (Italian Group for the Study of Digestive Tract Cancer).
Topics: Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Digestive System | 1993 |
[Targeting therapy of gastric and colorectal cancer].
Topics: Colorectal Neoplasms; Drug Delivery Systems; Fat Emulsions, Intravenous; Fluorouracil; Humans; Infus | 1994 |
Systemic treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 1994 |
Colorectal carcinoma: current problems and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region | 1994 |
[Problems of randomized controlled study on surgical adjuvant chemotherapy for colorectal cancer in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 1993 |
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1994 |
Hepatic arterial chemotherapy for metastatic colorectal carcinoma.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 1994 |
Folate metabolites as modulators of antitumor drug activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Biotransformation; Cell Line; | 1993 |
What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? Advanced Colorectal Meta-analysis Project.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 1993 |
Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1993 |
Recent advances in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Drug Administra | 1993 |
Systemic treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr | 1993 |
Unexpected fatal toxicity related to low-dose leucovorin with 5-fluorouracil treatment in metastatic colorectal cancer.
Topics: Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Pneumonia, Staphylococcal; Sto | 1993 |
Thymidylate synthase inhibition, a dead end?
Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorou | 1995 |
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Health Care Costs; | 1996 |
Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fl | 1996 |
Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule?
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasms; Floxuridine; Fluo | 1996 |
Role of chemotherapy for advanced colorectal cancer: new opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 1996 |
Cancers of the large bowel and hepatobiliary tract.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as | 1996 |
Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study?
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colore | 1994 |
[Recent advance in chemotherapy for advanced colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 1996 |
[Progress of adjuvant chemotherapy in colon cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 1996 |
[Immunotherapy of colorectal cancers].
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; BCG Vaccine; Colore | 1996 |
Combining 5-fluorouracil with interferon-alpha in the treatment of advanced colorectal cancer: optimism followed by disappointment.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 1996 |
Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluor | 1996 |
Biochemical and molecular studies of human methenyltetrahydrofolate synthetase.
Topics: Animals; Antimetabolites, Antineoplastic; Carbon-Nitrogen Ligases; Colorectal Neoplasms; Drug Therap | 1996 |
New concepts for the development and use of antifolates.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combination; Fluoroura | 1996 |
[Diagnosis and therapy for metastatic liver cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Basement Membrane; Colorectal Neoplasms; Co | 1996 |
How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp | 1995 |
Intraarterial infusion chemotherapy for unresectable hepatic metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 1996 |
Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; | 1996 |
Intra-hepatic arterial drug delivery.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Col | 1996 |
Chronotherapy for gastrointestinal cancers.
Topics: Antineoplastic Agents; Chronotherapy; Clinical Trials as Topic; Colorectal Neoplasms; Drug Delivery | 1996 |
Current treatment modalities in advanced colorectal carcinoma.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Interferons; Methotrexate; Prognosis; Quality of Life | 1996 |
Colorectal cancer--an undertreated disease.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1996 |
Hepatic arterial infusion for metastatic colorectal cancer: the price of "success".
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu | 1996 |
Infusional 5-FU for advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 1995 |
CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Col | 1996 |
Colorectal cancer: the challenge.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Therapy, Combina | 1996 |
Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Huma | 1996 |
Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chronotherapy; Colorectal Neoplasms; Drug Ad | 1996 |
[Sequential methotrexate and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1996 |
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.
Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug; | 1997 |
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Damage; DNA, Neoplasm; Drug Resistance; F | 1997 |
The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1996 |
Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1997 |
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: the Royal Marsden Hospital experience.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Esophageal Neoplasms; Fluorouracil; Gastroint | 1997 |
Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
Topics: Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Fr | 1997 |
Pre- and/or post-operative immunochemotherapy for advanced digestive cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colorectal Neopla | 1997 |
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clin | 1996 |
The French experience with infusional 5-fluorouracil in advanced colorectal cancer.
Topics: Antidotes; Antimetabolites, Antineoplastic; Chronotherapy; Colorectal Neoplasms; Dose-Response Relat | 1996 |
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience.
Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Clinical Trials as Topic; | 1996 |
High-dose infusional 5-FU in the treatment of advanced colorectal cancer: a summary of the European experience.
Topics: Antidotes; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Res | 1996 |
[Prognostic factors of advanced colorectal cancers].
Topics: Colorectal Neoplasms; Fluorouracil; Genes, p53; Humans; Prognosis | 1997 |
[First line chemotherapy of advanced colorectal cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans | 1997 |
The role of adjuvant radiation therapy in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms | 1997 |
The role of adjuvant chemotherapy in the treatment of colorectal cancer.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1997 |
Experimental chemotherapeutic agents for the treatment of colorectal carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as | 1997 |
Colorectal cancer--is there an alternative to 5-FU?
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorect | 1997 |
Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Flox | 1997 |
[Oxaliplatin: the first DACH platinum in clinical practice].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 1997 |
[Chemotherapy of advanced colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chronotherapy; Colorectal Neoplasms; Drug Ad | 1997 |
A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1997 |
[Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)].
Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin | 1997 |
The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col | 1997 |
[Colorectal cancer: a controllable disease].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1997 |
Chemotherapy of colorectal cancer: history and new themes.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 1997 |
Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Drug | 1997 |
Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1997 |
Biomodulation of 5-fluorouracil with antifolates.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 1997 |
Trimetrexate: review and current clinical experience in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 1997 |
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; | 1998 |
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; | 1998 |
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; | 1998 |
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; | 1998 |
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; | 1998 |
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; | 1998 |
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; | 1998 |
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; | 1998 |
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; | 1998 |
Beyond 5-fluorouracil monochemotherapy in colorectal cancer--it is time.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 1997 |
Mature results from three large controlled studies with raltitrexed ('Tomudex').
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 1998 |
Interferon use in solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal | 1998 |
Biomodulation of Fluorouracil in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clin | 1998 |
Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1998 |
Oxaliplatin for the treatment of advanced colorectal cancer: future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col | 1998 |
Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Cell Division; Clinical Trials as Topic; Colorectal Neoplasms; Flox | 1998 |
[Adjuvant therapy of colorectal carcinoma--1998 status].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Dose | 1998 |
5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; H | 1998 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Campt | 1998 |
A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, I | 1998 |
Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorec | 1998 |
[Multidisciplinary treatment for colorectal liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1998 |
National Cancer Institute Clinical Trials Program in Colorectal Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplas | 1998 |
[What's new in adjuvant therapy of colorectal cancers?].
Topics: Adjuvants, Immunologic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1998 |
Therapy for advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1998 |
Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Floxuridine; Flu | 1998 |
Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 1998 |
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma | 1998 |
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma | 1998 |
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma | 1998 |
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma | 1998 |
Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 1998 |
Clinical development of eniluracil: current status.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Oral fluoropyrimidines in the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 1998 |
[Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 1998 |
[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam | 1998 |
[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothec | 1998 |
[Irinotecan in combination for colon cancer].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1999 |
[Leucovorin and 5-FU for advanced gastrointestinal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, | 1999 |
[Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trial | 1999 |
Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, P | 1999 |
Chemotherapy of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; | 1998 |
Recent insights into the molecular basis of intrinsic resistance of colorectal cancer: new challenges for systemic therapeutic approaches.
Topics: Antimetabolites, Antineoplastic; Cell Death; Colorectal Neoplasms; Combined Modality Therapy; Drug R | 1998 |
Colorectal cancer in adolescents.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colon; Colore | 1999 |
Which 5-fluorouracil regimen?--the great debate.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; | 1999 |
Regional IL-2-based immunochemotherapy of colorectal liver metastases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cance | 1999 |
Fluoropyrimidines: a critical evaluation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neopla | 1999 |
Potential of Xeloda in colorectal cancer and other solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1999 |
Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Monitoring; Fluorouracil; Head and Neck | 1999 |
Clinical implications of 5-FU modulation.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; DNA, Neoplasm; Drug Combina | 1999 |
Schedule dependency of 5-fluorouracil.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Cell Cycle; Clinical Trials as Topic; Colorec | 1999 |
Advanced colorectal cancer: which regimes should we recommend?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 1999 |
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Glutamates; | 1999 |
[The efficacy and limitation of hepatic arterial infusion chemotherapy for colorectal liver metastases].
Topics: Administration, Oral; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therap | 1999 |
In situ standardised AgNOR analysis: a simplified method for routine use to determine prognosis and chemotherapy efficiency in colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Nuclear | 2000 |
Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1999 |
Where do we stand with 5-fluorouracil?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chro | 1999 |
Drug resistance in colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle; Colorectal Neoplasms; Drug Resistance, Neoplas | 1999 |
New drugs in therapy of colorectal cancer: preclinical studies.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydro | 1999 |
Oral fluoropoyrimidines.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydro | 1999 |
Oxaliplatin: a new therapeutic option in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 1999 |
Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1999 |
Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1999 |
The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Prodrugs; Thym | 1999 |
Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 1999 |
[Pharmacokinetic monitoring].
Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug | 2000 |
[Adjuvant intra-arterial chemotherapy after curative resection of liver metastasis from colorectal cancer. Results of a pilot study in 30 patients].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; F | 1999 |
New possibilities in chemotherapy for colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color | 1999 |
[Improvements in palliative treatment of colorectal carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 2000 |
Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Follow-Up Studies; | 2000 |
Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 1999 |
New directions in the treatment of colorectal cancer: a look to the future.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality The | 2000 |
[New combination therapies for gastrointestinal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal | 2000 |
[Adjuvant chemotherapy for colorectal carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A | 2000 |
The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2000 |
Adjuvant therapy of colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, | 2000 |
Oral therapy for colorectal cancer: how to choose.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Availabilit | 2000 |
Recent meta-analyses in colorectal cancer.
Topics: Adjuvants, Immunologic; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Follow-Up Stud | 2000 |
Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical | 2000 |
[Infusiontherapy with 5-fluorouracil ("infusional" 5-FU) in solid tumors].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2000 |
[State of the treatment for gastrointestinal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II a | 2000 |
Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Databases, Bibliographic; Disease Progr | 2000 |
Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu | 2000 |
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2000 |
[The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatectomy; Hepat | 2000 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms | 2000 |
Oral fluoropyrimidines in the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 2000 |
[Colon carcinoma. Consensus of therapeutic strategies].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Che | 2000 |
Pharmacology and clinical status of capecitabine.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal | 2000 |
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?
Topics: Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluoroura | 2000 |
Current treatment options for advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; H | 2000 |
Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Folic Acid Antagonists; Humans; | 2000 |
Chronotherapy with 5-fluorouracil and other drugs in gastrointestinal malignancies. Chronotherapy Group of the European Organization for Research and Treatment of Cancer.
Topics: Animals; Antineoplastic Agents; Chronobiology Phenomena; Chronotherapy; Clinical Trials as Topic; Co | 2000 |
Trimetrexate as a biochemical modulator of 5-fluorouracil and leucovorin in colorectal cancer.
Topics: Antidotes; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; Fluorour | 2000 |
Oxaliplatin in colorectal cancer: an overview.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col | 2000 |
Oral fluoropyrimidines in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycyti | 2000 |
Combination chemotherapy and colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2000 |
Rational development of capecitabine.
Topics: Animals; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxyc | 2000 |
ABC of colorectal cancer: adjuvant therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2000 |
Treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Colorectal Ne | 2000 |
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; C | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
[Fluorinated pyrimidines in oral treatment of advanced colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2000 |
The role of irinotecan in colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 1999 |
5-fluorouracil alone versus 5-fluorouracil plus folinic acid in the treatment of colorectal carcinoma: meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2000 |
The changing face of chemotherapy in colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; | 2001 |
[Hepatic arterial infusion chemotherapy for liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fema | 2000 |
[Progress in chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Tria | 2000 |
[Recent advances is surgical adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2000 |
Therapeutic approaches to metastasis confined to the liver.
Topics: Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Colorectal | 2001 |
Determinants of prognosis and response to therapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2001 |
Oxaliplatin: a new agent for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2001 |
[Molecular markers as basis for chemotherapy?].
Topics: Biomarkers, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Gene Expression Re | 2000 |
Role of oral chemotherapy in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2000 |
Colorectal cancer: chemotherapy treatment overview.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cl | 2000 |
Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trial | 2000 |
Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Prot | 2000 |
Second-line therapy in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Co | 2000 |
Safety of oxaliplatin in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 2000 |
Oxaliplatin with 5-FU or as a single agent in advanced/metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2000 |
Oxaliplatin in colorectal cancer: current studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 2000 |
Intrahepatic therapy for resected hepatic metastases from colorectal carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as | 2000 |
Novel combinations with oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Cli | 2000 |
Efficacy of oxaliplatin in the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl | 2000 |
Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Synergism; Fluorouracil; | 2001 |
Capecitabine in colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2001 |
Oral eniluracil/5-FU for advanced colon and breast carcinomas.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplas | 2001 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli | 2001 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli | 2001 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli | 2001 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli | 2001 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli | 2001 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli | 2001 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli | 2001 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli | 2001 |
Irinotecan in the treatment of colorectal cancer: clinical overview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli | 2001 |
Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Interfer | 2001 |
Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neopla | 2001 |
Clinical pharmacokinetics of capecitabine.
Topics: Antacids; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Doceta | 2001 |
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2001 |
[Multidisciplinary treatment for liver metastasis using cytokines].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2001 |
Chemotherapy in elderly patients with colorectal cancer.
Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Geriatric | 2001 |
A systematic overview of chemotherapy effects in colorectal cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colo | 2001 |
[New chemotherapies for colorectal cancer treatment].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2001 |
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2001 |
Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 2001 |
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2001 |
[Oxaliplatin: a first DACH-platinum in oncology].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as T | 2001 |
[Oxaliplatin in combination with 5-fluoro-uracil and folinic acid as treatment of metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Clinical Trials, Phase II as Topic; C | 2001 |
[Preclinical studies of oxaliplatin in combination chemotherapy].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2001 |
[Levofolinate and fluorouracil combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Colorectal Neopl | 2001 |
The evolution of fluoropyrimidine therapy: from intravenous to oral.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color | 2001 |
Answering patients' needs: oral alternatives to intravenous therapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color | 2001 |
Optimizing the use of irinotecan in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2001 |
Integrating oxaliplatin into the management of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2001 |
Capecitabine: a novel agent for the treatment of solid tumors.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; D | 2001 |
[Standard therapy of CPT-11 for colorectal cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli | 2001 |
[5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2001 |
Cancers of the large bowel and hepatobiliary tract.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2001 |
Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2001 |
Disease management considerations: disease management considerations.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Tria | 2001 |
Therapy of disseminated colorectal cancer: the emerging role of intratumoral molecular biology.
Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Oxidoreductases; Thy | 2001 |
Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.
Topics: Absorption; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2001 |
Hepatic artery infusional chemotherapy for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Equipm | 2001 |
[Chemotherapy of colorectal carcinoma].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemo | 2001 |
Rational development of capecitabine.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase | 2002 |
[The new chemotherapy of colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 2002 |
[Evidence for and practical use of arterial infusion chemotherapy for liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2002 |
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Incidence; Logi | 2002 |
Prediction of the response of colorectal cancer to systemic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Chemothe | 2002 |
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2001 |
Randomized clinical trials in advanced and metastatic colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Evidence-Based Medicine; Fluorouracil; Humans | 2002 |
Intrahepatic arterial infusion of chemotherapy: pharmacologic principles.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fl | 2002 |
Intrahepatic arterial infusion of chemotherapy: clinical results.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluor | 2002 |
The treatment of advanced colorectal cancer: where are we now and where do we go?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2002 |
Capecitabine/irinotecan combination regimens in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic | 2002 |
Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer.
Topics: Colorectal Neoplasms; Cytological Techniques; Drug Resistance, Neoplasm; Floxuridine; Fluorouracil; | 2002 |
Capecitabine: fulfilling the promise of oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Raltitrexed: current clinical status and future directions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2002 |
Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clini | 2002 |
[Systemic chemotherapy for advanced colorectal cancer with liver metastasis].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusi | 2002 |
[Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2002 |
Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisp | 1992 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No!
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Forecasting; Humans; Infusio | 1992 |
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.
Topics: Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; M | 1992 |
[Systemic chemotherapy in metastatic colorectal adenocarcinomas].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fem | 1992 |
The value of adjuvant therapy after radical surgery for colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 1992 |
[Biochemical modulation of 5-FU with interferon].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Admini | 1992 |
[High-dose leucovorin and 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Fluorodeoxyur | 1992 |
[Advances in the treatment of advanced colorectal cancer].
Topics: Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dr | 1990 |
[Current status of adjuvant therapy in patients with colorectal cancer: report and commentary on the Consensus Conference, 16-18 April 1990, National Cancer Institute, Bethesda, Maryland].
Topics: Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Staging; Palliative | 1991 |
Chemotherapy of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1991 |
Modulation of fluoropyrimidines by leucovorin: rationale and status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1991 |
Developments of the fluoropyrimidines as inhibitors of thymidylate synthetase: pharmacologic and clinical aspects.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Hum | 1991 |
5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature.
Topics: Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Meta-Analysis as | 1991 |
[5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorou | 1991 |
Sequential methotrexate/5-fluorouracil in advanced colorectal cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1991 |
Chemotherapy for patients not benefitting from 5-fluorouracil therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 1991 |
[The biochemical modulation of 5-fluorouracil by leucovorin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Clinical Trials as Topic; Colorec | 1991 |
Systemic therapy for colorectal cancer: an overview.
Topics: Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans | 1991 |
Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas.
Topics: Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; | 1991 |
120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Colorectal Neopl | 1991 |
Adjuvant therapy of colorectal cancer: an overview.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Leucov | 1991 |
Role of adjuvant therapy in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colorectal Neopl | 1991 |
[Experimental models for hepatic metastases from colorectal tumors].
Topics: Animals; Azoxymethane; Colectomy; Colorectal Neoplasms; Cyclosporins; Disease Models, Animal; Fluoro | 1991 |
[Therapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1991 |
Biochemical modulation of 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 1990 |
[Intra-arterial and intravenous chemotherapy in the treatment of hepatic metastases of colorectal origin: review of the literature and preliminary results].
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery | 1990 |
Clinical trials with 5-fluorouracil, folinic acid and cisplatin in patients with gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Evaluation; Fl | 1990 |
Clinical trial with 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination; | 1990 |
5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemistry, Clinical; Colonic Neoplas | 1990 |
Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience.
Topics: Animals; Clinical Trials as Topic; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination; | 1990 |
Consensus panel considers adjuvant therapy for colon and rectal cancer, identifies levamisole--fluorouracil as standard in colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1990 |
Systemic therapy in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Comb | 1990 |
Management of colorectal cancer.
Topics: Adenocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hu | 1990 |
Modulation of 5-fluorouracil efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Fluorouracil; | 1990 |
Treatment of advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; | 1989 |
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dru | 1989 |
[Chemotherapy of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1989 |
Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1989 |
5-Fluorouracil by protracted venous infusion. A review of current progress.
Topics: Catheterization; Colorectal Neoplasms; Fluorouracil; Forecasting; Humans; Infusions, Intravenous | 1989 |
Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1989 |
5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1989 |
Cytostatic drug therapy in disseminated colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col | 1988 |
[Therapy concepts in colorectal liver metastases. What is proven, what is open to discussion?].
Topics: Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluorouracil; Hepatectomy; Humans; Inf | 1988 |
Adjuvant cytotoxic chemotherapy for colorectal cancer: the present position.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 1988 |
Colorectal cancer. Are adjuvant therapies beneficial?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 1988 |
Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1988 |
Preclinical and clinical biochemical modulation of 5-fluorouracil by leucovorin and uridine.
Topics: Animals; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Mice; Tumor Cells, Cultured; Uridin | 1988 |
1873 trials available for fluorouracil and Colorectal Cancer
| Article | Year |
|---|---|
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2021 |
A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPA
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuxi | 2022 |
Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2021 |
Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinical-Biomolecular Markers Significantly Associated With Toxicity.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neo | 2022 |
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Fluo | 2022 |
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo | 2022 |
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hep | 2022 |
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluor | 2022 |
A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Surviv | 2022 |
A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2022 |
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasm | 2022 |
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo | 2022 |
Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2022 |
Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neopla | 2022 |
Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chromosome Deletion; Chromosomes; Colon | 2022 |
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic | 2022 |
Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bevacizumab; Camptothecin; Cetuximab; | 2022 |
Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell-Free Nucleic Acids; Colonic Neopl | 2022 |
[The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating Tu | 2022 |
Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2022 |
Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC s
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trial | 2022 |
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line tre
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bev | 2022 |
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2022 |
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Bevacizumab; C | 2022 |
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2022 |
The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Frail Elde | 2023 |
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2022 |
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla | 2023 |
Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2022 |
Triplet (FOLFOXIRI) Versus Doublet (FOLFOX or FOLFIRI) Regimen as First Line Treatment in Metastatic Colorectal Carcinoma, a Prospective Phase II, Randomized Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2022 |
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
Topics: Bevacizumab; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; F-Box-WD Re | 2022 |
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
Topics: Bevacizumab; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; F-Box-WD Re | 2022 |
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
Topics: Bevacizumab; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; F-Box-WD Re | 2022 |
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
Topics: Bevacizumab; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; F-Box-WD Re | 2022 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Colonic Neoplasms; Colorect | 2023 |
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2023 |
Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials.
Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorourac | 2023 |
Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Appendiceal Neoplasms; Colorectal | 2023 |
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; C | 2023 |
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Female; Flu | 2023 |
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; | 2023 |
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; C | 2023 |
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; | 2023 |
Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2023 |
Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2023 |
Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2023 |
Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Fluorouracil; Human | 2023 |
A randomized controlled, open-label early phase II trial comparing incidence of FOLFIRI.3-induced diarrhoea between Hangeshashinto and oral alkalization in Japanese patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Campto | 2019 |
SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2019 |
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Fluorouracil; Human | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2019 |
Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: a multicenter, open-label randomized controlled study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorect | 2019 |
Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuxim | 2020 |
Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Disease-F | 2020 |
Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2020 |
A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Com | 2020 |
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Chemotherapy, Adjuvan | 2019 |
Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinic | 2019 |
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2019 |
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo | 2020 |
Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Diet Records; Diet, Ca | 2020 |
Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2020 |
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2020 |
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2020 |
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2020 |
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2020 |
Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2020 |
Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal N | 2020 |
The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2020 |
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2020 |
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect | 2020 |
Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neop | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2020 |
Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals | 2020 |
Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-RAS status for unresectable colorectal liver metastasis (BECK study): Long-term results of survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neop | 2020 |
A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic An | 2020 |
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2020 |
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panit
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2020 |
Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2020 |
Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2020 |
Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Cytoreduction Sur | 2020 |
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Flu | 2020 |
Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorec | 2020 |
A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO Trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Combined Modality T | 2020 |
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2020 |
Immune characterization of metastatic colorectal cancer patients post reovirus administration.
Topics: Adult; Antigen-Presenting Cells; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy | 2020 |
First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorect | 2020 |
Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cy | 2020 |
Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.
Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neo | 2020 |
Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2020 |
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2020 |
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect | 2020 |
Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2020 |
The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Double-B | 2020 |
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological | 2020 |
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological | 2020 |
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological | 2020 |
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological | 2020 |
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Drug A | 2020 |
Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combine | 2020 |
Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal | 2020 |
Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2020 |
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2020 |
Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic C | 2020 |
5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Class I Phosphati | 2020 |
Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect | 2020 |
Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2020 |
Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2021 |
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biologi | 2021 |
Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptot | 2020 |
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2020 |
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm | 2021 |
Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Surv | 2021 |
A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2021 |
Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2021 |
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2021 |
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disea | 2021 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2020 |
Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy.
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Combined Chemotherapy Protocols; Colo | 2021 |
Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2021 |
A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2021 |
Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeuti | 2021 |
Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal | 2021 |
[Capecitabine and Oxaliplatin(CAPOX)plus Bevacizumab as Second-Line Chemotherapy for Metastatic Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal | 2021 |
Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2021 |
Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2021 |
A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C | 2021 |
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cap | 2021 |
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2021 |
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom | 2021 |
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2021 |
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2021 |
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2021 |
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Colorectal | 2021 |
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2021 |
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect | 2022 |
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Proteins; | 2017 |
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo | 2017 |
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuva | 2017 |
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuva | 2017 |
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuva | 2017 |
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuva | 2017 |
Feasibility of Modified FOLFOX in Elderly Patients Aged ≥80 Years with Metastatic Gastric Cancer or Colorectal Cancer.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2017 |
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect | 2017 |
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2017 |
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dis | 2017 |
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2017 |
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2017 |
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2017 |
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2017 |
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2017 |
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2017 |
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2017 |
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2017 |
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2017 |
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2017 |
A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Image Interp | 2018 |
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combin | 2018 |
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arylamine | 2017 |
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2017 |
Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC).
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Intraoperative Care; In | 2017 |
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2017 |
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplas | 2018 |
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore | 2017 |
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2018 |
Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2018 |
Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deo | 2018 |
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2018 |
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2018 |
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immun | 2018 |
Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal | 2017 |
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2018 |
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2018 |
EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuxi | 2018 |
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2018 |
Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Ca | 2018 |
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2018 |
Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothec | 2018 |
A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorect | 2018 |
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizum | 2018 |
Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal N | 2018 |
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cohort Studies; Colore | 2018 |
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2018 |
A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Canada; Colorectal Neoplas | 2018 |
Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2018 |
UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2018 |
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2018 |
A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neo | 2018 |
Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Height; Camptothecin; | 2018 |
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dou | 2018 |
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacologica | 2018 |
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L | 2018 |
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L | 2018 |
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L | 2018 |
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L | 2018 |
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
Topics: Adult; Aged; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorour | 2018 |
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che | 2019 |
AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect | 2018 |
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK cli
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK cli
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK cli
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK cli
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diseas | 2018 |
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as | 2018 |
A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2018 |
Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2019 |
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Clinical Decision-Making; C | 2018 |
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Campto | 2018 |
A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2018 |
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Topics: Adult; Aged; Antibodies; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2018 |
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2019 |
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2019 |
Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2019 |
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm | 2019 |
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2019 |
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2019 |
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Beva | 2019 |
Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD8-Positive | 2019 |
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neo | 2019 |
Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Cetuxima | 2019 |
A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2019 |
L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; | 2019 |
Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2019 |
mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema | 2019 |
Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2019 |
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; | 2019 |
Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2019 |
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; | 2019 |
Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neopl | 2019 |
Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, random
Topics: Adult; Bevacizumab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Cytored | 2019 |
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; | 2019 |
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell-Free Nucleic Acids; Clinical | 2019 |
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy | 2019 |
Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cu | 2019 |
Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Colorectal Neopla | 2019 |
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2019 |
Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuxim | 2019 |
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2019 |
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camp | 2019 |
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2013 |
Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2013 |
An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2013 |
Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2013 |
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2013 |
A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoembryonic Antigen; C | 2013 |
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2013 |
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axit | 2013 |
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimeta | 2013 |
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2013 |
Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2013 |
Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Topics: Ablation Techniques; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineop | 2013 |
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
Topics: Aged; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2013 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorect | 2013 |
3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dideoxynucleoside | 2013 |
Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2013 |
Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think!
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Col | 2013 |
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimeta | 2013 |
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2013 |
Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2013 |
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Effects of 5-fluorouracil on oxidative stress and calcium levels in the blood of patients with newly diagnosed colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Calcium; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; | 2013 |
A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Colorectal Neopl | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
[Effectiveness of combined systemic and regional chemotherapy in treating patients with metastatic colorectal cancer after extrahepatic progression of the disease].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Reg | 2013 |
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2013 |
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2013 |
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas | 2013 |
Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2013 |
A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal | 2013 |
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2014 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2013 |
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2013 |
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2013 |
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Proteins; Capecitabine; Colorectal | 2013 |
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2014 |
The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2014 |
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2013 |
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Chemotherapy, Adjuvant; Colo | 2014 |
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2014 |
Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colore | 2014 |
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Topics: Adiponectin; Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2014 |
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2014 |
Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Colorectal Neo | 2014 |
Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites | 2013 |
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.
Topics: Adipokines; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2014 |
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2014 |
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2014 |
Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2016 |
Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheterization, Central Venous; Cohor | 2014 |
Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplasti | 2014 |
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2014 |
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase I-II study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2015 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2015 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2015 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2015 |
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2014 |
Mitomycin C and high-dose 5-fluorouracil with folinic acid as a therapeutic option for heavily pretreated patients with metastatic colorectal cancer: prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; D | 2014 |
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2014 |
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2014 |
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; | 2014 |
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research G
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2014 |
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2014 |
Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2014 |
A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohor | 2014 |
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetu | 2014 |
Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2014 |
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic | 2014 |
Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final r
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2014 |
Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal | 2014 |
FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-on
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 2014 |
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cet | 2014 |
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; | 2014 |
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2015 |
Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cytokine-I | 2014 |
A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy.
Topics: Adult; Area Under Curve; Body Surface Area; Colorectal Neoplasms; Dose-Response Relationship, Drug; | 2014 |
Association between chemotherapy and plasma adipokines in patients with colorectal cancer.
Topics: Adipokines; Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colo | 2014 |
Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil-based chemotherapy in colorectal cancer.
Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; An | 2014 |
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; China; Colorectal Neoplas | 2014 |
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2014 |
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2014 |
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2014 |
Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer.
Topics: Amino Acid Substitution; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; | 2015 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camp | 2015 |
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2015 |
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administ | 2014 |
A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorect | 2015 |
A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorecta | 2015 |
Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarke | 2014 |
A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevaci | 2015 |
Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colorectal Neoplasms; Fluo | 2014 |
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2014 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Oxaliplatin and ototoxicity: is it really safe for hearing?
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co | 2014 |
Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2015 |
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2015 |
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2015 |
Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2015 |
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom | 2015 |
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2015 |
Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Double-Blind Method; Dru | 2015 |
Phase II study on hepatic arterial infusion chemotherapy using percutaneous catheter placement techniques for liver metastases from colorectal cancer (JFMC28 study).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2015 |
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2015 |
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Codon; Colorectal Neoplasms; Female | 2015 |
Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Fe | 2015 |
Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetam | 2015 |
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2015 |
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Class I Phosphat | 2015 |
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Co | 2015 |
Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Prognostic value of HLA class I expression in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2015 |
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Capecitabine; Colorectal Ne | 2015 |
Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2015 |
A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Codon; | 2015 |
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Ca | 2015 |
Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free | 2015 |
Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Fem | 2015 |
Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colorectal Neoplasms; Curcumin; | 2015 |
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2015 |
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2015 |
The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2016 |
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2016 |
Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2015 |
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2015 |
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo | 2015 |
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biom | 2015 |
Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2015 |
The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2014 |
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2015 |
[HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; | 2015 |
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2015 |
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Be | 2016 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptoth | 2015 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptoth | 2015 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptoth | 2015 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptoth | 2015 |
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.
Topics: Adult; Aged; Antigens, CD; Antigens, CD20; Antigens, Differentiation, Myelomonocytic; Antineoplastic | 2015 |
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuxi | 2015 |
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2016 |
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2015 |
[Safety evaluation of intraoperative peritoneal chemotherapy with Lobaplatin for advanced colorectal cancers].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cyclobu | 2015 |
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2015 |
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neo | 2016 |
Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2016 |
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disea | 2015 |
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2016 |
Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Co | 2016 |
Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cape | 2016 |
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing A
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2016 |
High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neo | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu | 2016 |
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2016 |
[Efficacy evaluation of heat-sensitive moxibustion for chemotherapy symptoms of large intestine cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2015 |
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2016 |
Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoradioth | 2016 |
Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined | 2016 |
Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2016 |
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neo | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Class I Phosphatidylinositol 3-Kinases; C | 2016 |
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Colorectal Neoplasms; CpG Islands; DNA Methylatio | 2016 |
Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2016 |
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2016 |
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2016 |
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2016 |
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabi | 2016 |
Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neoplasms; | 2016 |
Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2016 |
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; | 2016 |
Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2016 |
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2016 |
Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2016 |
Clinical effects of bevacizumab targeted treatment on advanced colorectal cancer with liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2016 |
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2017 |
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2016 |
LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Topics: AC133 Antigen; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Co | 2016 |
Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Surv | 2016 |
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Line, Tumor; Cell Movemen | 2016 |
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2016 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2016 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2016 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2016 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2016 |
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antineoplastic Combined Chemotherap | 2016 |
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2016 |
Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2017 |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Co | 2017 |
Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvan | 2016 |
Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2017 |
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2017 |
Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2016 |
Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2017 |
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2017 |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-V
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2017 |
Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Haplotypes; Humans; Male; Methy | 2017 |
Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bev | 2017 |
Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Ca | 2017 |
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
Topics: Adenocarcinoma; Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Ant | 2017 |
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Ag | 2017 |
Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuxi | 2017 |
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Mono | 2017 |
mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2017 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R | 2008 |
High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2008 |
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2008 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2008 |
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2008 |
Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; DNA, Neoplasm; Drug The | 2008 |
Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Chemotherapy, Ad | 2008 |
Efficacy of a continuous venous infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: a prospective randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colo | 2008 |
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2008 |
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2008 |
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Camptothecin; Carcinoembryonic A | 2008 |
Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2008 |
Cytotoxic chemotherapy for incurable colorectal cancer: living with a PICC-line.
Topics: Activities of Daily Living; Adult; Aged; Antimetabolites, Antineoplastic; Catheterization, Central V | 2008 |
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2009 |
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2009 |
Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2008 |
Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cultured M | 2008 |
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoquinolines; Aniline Compounds; Antineoplastic Combined Chemothe | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2008 |
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2008 |
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acid | 2009 |
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2008 |
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2008 |
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Diseas | 2009 |
[Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined M | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Stud | 2009 |
Preoperative chemoradiation for locally advanced rectal cancer with capecitabine 2,000 mg/m2/day.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neopl | 2008 |
A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2008 |
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2008 |
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Di | 2008 |
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Di | 2008 |
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Di | 2008 |
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Di | 2008 |
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec | 2009 |
A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; | 2009 |
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2008 |
No socioeconomic inequalities in colorectal cancer survival within a randomised clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Thera | 2008 |
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2008 |
Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colorectal | 1972 |
A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Carriers; F | 2009 |
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2009 |
Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dih | 2009 |
A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluoroura | 2009 |
A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Codon; | 2009 |
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2008 |
Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta | 2009 |
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2009 |
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplas | 2009 |
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2009 |
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2009 |
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 8 | 2009 |
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2009 |
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptot | 2009 |
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2009 |
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorect | 2009 |
Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2009 |
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2009 |
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2009 |
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chemotherapy | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
[Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2009 |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2009 |
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec | 2009 |
Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplas | 2009 |
A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Dis | 2009 |
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2009 |
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neopl | 2009 |
FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Ana | 2009 |
Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated | 2009 |
Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2009 |
[Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
[Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2009 |
A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black or African Ame | 2009 |
Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.
Topics: Abdominal Pain; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea | 2009 |
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Australia; Brachytherapy; Camptothecin; Chemotherapy, | 2009 |
Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Le | 2009 |
[Effect of Shenqi Fuzheng injection combined with chemotherapy in treating advanced colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drugs, Chinese Herbal; Fluorou | 2009 |
Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies | 2010 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2010 |
Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2010 |
Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2009 |
Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study).
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; | 2009 |
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2009 |
A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ca | 2010 |
Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne | 2010 |
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2009 |
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2009 |
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2009 |
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2009 |
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2009 |
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2009 |
Early supplementation of parenteral nutrition is capable of improving quality of life, chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: results from a prospective, randomize
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body W | 2010 |
Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neopla | 2009 |
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2010 |
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized | 2010 |
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2010 |
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2010 |
Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cat | 2010 |
A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2010 |
Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2010 |
Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium; Colorectal Neoplasms; Drug Administration S | 2010 |
Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2010 |
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Capecitabine; Colorectal Neop | 2011 |
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 2011 |
Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ch | 2010 |
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; | 2010 |
Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplas | 2011 |
Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2010 |
Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2010 |
Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemot | 2010 |
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2010 |
A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2010 |
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2010 |
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2010 |
[Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2010 |
Dietary methionine restriction with FOLFOX regimen as first line therapy of metastatic colorectal cancer: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diet; Disease Progressio | 2010 |
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2010 |
[Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Calcium Gl | 2010 |
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2010 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni | 2011 |
Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2011 |
Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Colorectal Neoplasms; Cross-O | 2011 |
Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy | 2010 |
A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Colorecta | 2010 |
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2010 |
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Emboliza | 2010 |
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Molecular markers in circulating tumour cells from metastatic colorectal cancer patients.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antigens, CD; Antineoplastic | 2010 |
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms | 2010 |
A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2010 |
[Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplas | 2010 |
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2011 |
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2011 |
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2011 |
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2011 |
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
Treatment of colorectal cancer with and without bevacizumab: a phase III study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant | 2010 |
A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2011 |
Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2012 |
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2011 |
Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
[Efficacy and safety of bevacizumab plus capecitabine for metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2010 |
[Influence of FOLFOX regimen on the immunologic function in patients with advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2010 |
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2011 |
Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co | 2010 |
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2010 |
Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2011 |
Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 2011 |
Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2011 |
Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De | 2011 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De | 2011 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De | 2011 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De | 2011 |
Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Gluconate; Capecita | 2010 |
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2011 |
Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2010 |
Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2011 |
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2011 |
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplas | 2012 |
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Cont | 2011 |
The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drugs | 2011 |
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal | 2011 |
Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cos | 2010 |
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2011 |
Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2012 |
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma | 2011 |
Phase II study of FOLFOX4 with "wait and go" strategy as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2011 |
[Immune enhancing effect of modified sijunzi decoction on patients with colorectal cancer undergoing chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drugs, Chinese Herbal; Female; | 2011 |
Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2011 |
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che | 2011 |
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che | 2011 |
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2011 |
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2011 |
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2011 |
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2011 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2012 |
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dis | 2011 |
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort St | 2012 |
Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ant | 2011 |
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Disease Progress | 2011 |
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2011 |
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2011 |
Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, H | 2012 |
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2011 |
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2012 |
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Neoadjuvant treatment of colorectal liver metastases is associated with altered contrast enhancement on computed tomography.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2011 |
Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2012 |
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cam | 2011 |
[Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2011 |
[Chemotherapy in patients with non-resectable colorectal cancer metastases to the liver: systemic or regional?].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2011 |
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease | 2011 |
Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 2012 |
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2012 |
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2011 |
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine | 2011 |
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2011 |
Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Clock | 2011 |
A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2011 |
A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2011 |
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2011 |
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2011 |
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorec | 2011 |
Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area U | 2011 |
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Topics: Adenocarcinoma; Aged; Algorithms; Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Colorect | 2012 |
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2011 |
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2011 |
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorect | 2012 |
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2011 |
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2011 |
The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2011 |
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2012 |
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2012 |
Fast track multi-discipline treatment (FTMDT trial) versus conventional treatment in colorectal cancer--the design of a prospective randomized controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Protocols; Colorectal Neoplas | 2011 |
Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: results of a randomised multicentre trial.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male | 2012 |
A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Multi-center phase II study of FLOX for advanced colorectal cancer patients in Japan: SWIFT 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2011 |
A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2012 |
Phase III aflibercept-chemotherapy combination trial shows benefit in previously treated metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2011 |
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal N | 2011 |
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2012 |
A clinical study on safety and efficacy of Aidi injection combined with chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal | 2011 |
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 2012 |
Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from Stage III colorectal cancer after curative resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2012 |
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Fr | 2012 |
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2012 |
Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2013 |
First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2012 |
The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2012 |
Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2012 |
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diabe | 2012 |
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2012 |
Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Colorectal Neoplasms; | 2012 |
A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2012 |
Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic | 2012 |
Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable fo
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothe | 2012 |
Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2012 |
A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 2012 |
Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; | 2012 |
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Case | 2012 |
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Chemoradio | 2013 |
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2013 |
Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under C | 2012 |
Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2013 |
Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2012 |
Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2012 |
Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Surv | 2012 |
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Circadian Clocks; Colorectal Ne | 2012 |
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antibodies, Monoclonal, Humanized; Antineoplast | 2012 |
Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2012 |
Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineopla | 2013 |
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diseas | 2012 |
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2012 |
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2012 |
Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; | 2013 |
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2012 |
Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2012 |
Evaluation of predictive markers for patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; C- | 2012 |
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Surv | 2012 |
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2013 |
Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carcinoma; Chemotherapy, Adj | 2013 |
Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capeci | 2013 |
Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Combined Mo | 2012 |
XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; | 2013 |
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2013 |
Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Effect of portal vein chemotherapy on liver metastasis after surgical resection of colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colorectal Neoplasms; Fluoro | 2012 |
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Topics: 3' Untranslated Regions; Adult; Aged; Alleles; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2012 |
A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2012 |
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
Topics: Administration, Intravenous; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2013 |
[Effects of qisheng mixture on chemotherapy induced myelosuppression in patients with colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2012 |
Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: results of a phase I/II study.
Topics: Absorbable Implants; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Peripher | 2013 |
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Colorectal Neoplasms; Cost- | 2013 |
Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Chemoth | 2013 |
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2013 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2013 |
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camp | 2013 |
Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bridged | 2012 |
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2013 |
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2013 |
Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2002 |
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptot | 2002 |
Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2002 |
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biopsy, Needle; Colorectal Neoplasms; Dose-Res | 2002 |
Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2002 |
Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2002 |
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Etoposide; Fluorouracil; Human | 2002 |
High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection.
Topics: Adult; Aged; Colon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; L | 2002 |
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplasti | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Ne | 2002 |
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2002 |
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2002 |
Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2002 |
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2002 |
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine.
Topics: Animals; Antimetabolites, Antineoplastic; Bile; Biotransformation; Capecitabine; Colorectal Neoplasm | 2002 |
[Final results of a randomized clinical trial of adjuvant intraportal chemotherapy for colorectal cancer: Intraportal Chemotherapy for Colorectal Cancer Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2002 |
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
Topics: Adenoviruses, Human; Adult; Aged; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease | 2002 |
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2002 |
Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2002 |
Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regiona | 2001 |
Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Colorectal Ne | 2002 |
Oxaliplatin combinations as first-line therapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2002 |
N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Re | 2002 |
The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.
Topics: Adult; Aged; Camptothecin; Canada; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Admi | 2002 |
Irinotecan in 5-fluorouracil-refractory colorectal cancer.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administrati | 2002 |
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Intravenous versus intrahepatic arterial 5-fluorouracil/leucovorin for treatment of colorectal cancer metastases.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Hepatic | 2002 |
Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Nee | 2002 |
Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptotheci | 2002 |
[Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche | 2002 |
Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2002 |
Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2002 |
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2003 |
Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Dose-Response | 2002 |
High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Di | 2003 |
Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2003 |
Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2003 |
Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Sch | 2003 |
Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Floxuridine; Fluorouraci | 2003 |
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2003 |
First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2003 |
Skin testing and hypersensitivity reactions to oxaliplatin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Hy | 2003 |
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp | 2002 |
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2003 |
Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2003 |
Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2003 |
[Interferon-alpha in adjuvant treatment of colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 2002 |
Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec | 2003 |
Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Enzy | 2003 |
PET-FDG as predictor of therapy response in patients with colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorodeoxyglucose F18; Fluoro | 2003 |
Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2003 |
A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Bayes Theorem; Colorectal Neoplasms; | 2003 |
Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2003 |
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2003 |
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2003 |
A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorect | 2003 |
Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2003 |
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2003 |
A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined M | 2003 |
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms | 2003 |
A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogen | 2003 |
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto | 2003 |
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2003 |
Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2003 |
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C | 2003 |
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C | 2003 |
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C | 2003 |
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C | 2003 |
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C | 2003 |
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C | 2003 |
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C | 2003 |
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C | 2003 |
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C | 2003 |
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Squar | 2003 |
Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
Lessons learned from raltitrexed--quality assurance, patient education and intensive supportive drugs to optimise tolerability.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Health Edu | 2003 |
Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2003 |
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2003 |
5-fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2003 |
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastroint
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sch | 2003 |
Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2003 |
Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Administration, Oral; Aged; Antimetabolites, Antineoplastic; | 2004 |
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2003 |
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2003 |
[Interim analysis of a prospective, randomized multi-center study by the "Liver Metastases" Study Group: adjuvant intra-arterial chemotherapy after curative liver resection of colorectal metastases].
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1998 |
Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2003 |
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2003 |
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Anti | 2003 |
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal | 2003 |
Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronotherapy; Colorectal Neoplasm | 2003 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2004 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal | 2003 |
Randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP, 5-FU and dl-leucovorin for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neopla | 2003 |
Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2004 |
A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administrat | 2003 |
Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admi | 2003 |
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; | 2004 |
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 2004 |
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2003 |
[Long term survival in metastatic colorectal cancer treated with leucovorin and 5-fluoro-uracil chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2004 |
Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma | 2004 |
FDA drug approval summaries: oxaliplatin.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Approval; Drug | 2004 |
Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Carcinoma; Cecum | 2004 |
Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2003 |
The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colorectal Neoplas | 2004 |
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2004 |
Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Confidence Intervals; Drug Administration Schedule; Female; Fluor | 2004 |
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Circadian Rhythm; Colorectal Neoplasms; Fluorouracil; Humans; | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorecta | 2004 |
Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2004 |
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
Topics: Adult; Aged; Amidines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Coloni | 2004 |
Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2004 |
A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progre | 2004 |
Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2004 |
Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Dru | 2004 |
Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colorectal | 2004 |
Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 2004 |
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colo | 2004 |
Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2004 |
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dis | 2004 |
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2004 |
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2004 |
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2004 |
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2004 |
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2004 |
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2004 |
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2004 |
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2004 |
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2004 |
Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA Topoisomeras | 2004 |
Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2004 |
Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 2004 |
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; | 2004 |
5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2004 |
High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Child | 2004 |
Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2004 |
Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neoplasms; | 2004 |
The toxicity rates of two different regimens of irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2003 |
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2004 |
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2004 |
A new perspective on cardiotoxicity of 5-fluorouracil. A novel research tool 'cardiac ultrasonic integrated backscatter analysis' indicates transient, subclinical myocardial dysfunction due to high-dose leucovorin and infusional 5-fluorouracil regimen.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combin | 2004 |
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2004 |
Prolonged cytostatic tumor dormancy induced by serial exchange of chemotherapy in colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Clinical | 2004 |
Bevacizumab improves the efficacy of 5-fluorouracil/leucovorin in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2004 |
Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Ant | 2004 |
Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dietary Fiber; Dietary Supplemen | 2004 |
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Do | 2004 |
First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2004 |
A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2004 |
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2004 |
Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survi | 2004 |
[Comparing the effect of adjuvant chemotherapy by portal vein infusion with intraluminal chemotherapy for colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional | 2004 |
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2004 |
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2004 |
Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Confidence Intervals | 2004 |
Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam | 2004 |
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Drug Administration Schedule; | 2004 |
Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2004 |
Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protoc | 2004 |
Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2004 |
Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2004 |
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Canada; | 2005 |
Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2004 |
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2004 |
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2004 |
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2004 |
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2004 |
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2004 |
Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2004 |
Second-line treatment of advanced colorectal cancer with a weekly simultaneous 24-hour infusion of 5-fluorouracil and sodium-folinate: a multicentre phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2004 |
Application of adjuvant chemotherapy in colorectal cancer -- a survey in the region of Essen, Germany.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Germany; | 2005 |
Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2004 |
Bevacizumab for advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Clinic | 2004 |
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2005 |
Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Colorectal Neoplasms; | 2004 |
Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2005 |
A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2005 |
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capec | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2005 |
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2005 |
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
[Trial of outpatient anti-cancer chemotherapy with infusion of 5-FU and cisplatin for advanced gastric and colorectal cancers].
Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; C | 2005 |
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Mid | 2005 |
Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto | 2005 |
Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2005 |
A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cyc | 2005 |
Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.
Topics: Adenoviridae; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neop | 2005 |
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2005 |
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2005 |
Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology G
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cross-Over Studie | 2005 |
High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2005 |
Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorecta | 2005 |
Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecit | 2005 |
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2005 |
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2005 |
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2005 |
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2005 |
A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Color | 2005 |
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2005 |
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2005 |
Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2005 |
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Celecoxib; Col | 2005 |
Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 2005 |
Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2005 |
[Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2005 |
[Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chronob | 2005 |
[Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronobiolog | 2005 |
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecit | 2005 |
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2005 |
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2005 |
A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2005 |
Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2005 |
[Problems of case accumulation in a clinical trial of hepatic arterial infusion after resection of hepatic metastases: A summary of the study design and questionnaire survey of the participating centers in study no. 29-0003 of the Japanese Foundation for
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administ | 2005 |
[Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronothe | 2005 |
Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, | 2005 |
Randomized controlled trial to evaluate laparoscopic surgery for colorectal cancer: Japan Clinical Oncology Group Study JCOG 0404.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2005 |
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2005 |
Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2005 |
Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alkaline Phosphatase; Antineoplastic Combined | 2005 |
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2005 |
Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2005 |
Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Dose-Response | 2005 |
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; | 2005 |
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neo | 2005 |
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2005 |
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; D | 2005 |
Double-blind randomised trial comparing 5-fluorouracil plus leucovorin to placebo for metastatic colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Colorectal Neoplasms; Doubl | 2005 |
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2005 |
Correlation between expression of orotate phosphoribosyl transferase and 5-fluorouracil sensitivity, as measured by apoptosis index in colorectal cancer tissue.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Apoptosis; Biological Assay; Colorectal | 2005 |
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2005 |
Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; D | 2005 |
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; | 2005 |
Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Color | 2005 |
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Campt | 2005 |
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials a | 2005 |
Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free | 2006 |
Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2005 |
A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2005 |
Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2005 |
A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Colorectal Neoplasms; Disease-Free Survival; D | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2005 |
Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2006 |
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Flu | 2005 |
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dih | 2006 |
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2005 |
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic A | 2006 |
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherap | 2006 |
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bio | 2005 |
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2005 |
Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2006 |
Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2005 |
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2005 |
A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2006 |
Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Die | 2005 |
FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2005 |
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Age | 2005 |
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined M | 2006 |
Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Creatini | 2006 |
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Colo | 2006 |
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2006 |
Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2006 |
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr | 2006 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemot | 2006 |
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug R | 2006 |
Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2006 |
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2006 |
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2006 |
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2006 |
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2006 |
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2006 |
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2006 |
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2006 |
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2006 |
Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Creatinine; Drug Administratio | 2006 |
Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2006 |
Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytid | 2006 |
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorectal Ne | 2006 |
Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients.
Topics: Administration, Inhalation; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carbon Diox | 2006 |
Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 2006 |
FOLFOX2 regimen in the treatment of advanced colorectal cancer: a comparison between elderly and young patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorec | 2006 |
Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2006 |
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2006 |
FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neo | 2006 |
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2006 |
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2006 |
The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Datab | 2006 |
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2006 |
Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2006 |
Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Gen | 2006 |
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2006 |
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2006 |
Nucleosomes in colorectal cancer patients during radiochemotherapy.
Topics: Aged; Biomarkers, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Huma | 2006 |
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2006 |
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2006 |
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Can
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chronotherapy; Color | 2006 |
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Can
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chronotherapy; Color | 2006 |
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Can
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chronotherapy; Color | 2006 |
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Can
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chronotherapy; Color | 2006 |
Repeated hepatic intra-arterial chemotherapy based on results of anticancer drug sensitivity test in patients with synchronous hepatic metastases from colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relati | 2006 |
Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2006 |
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2006 |
Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2007 |
Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adj | 2006 |
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fe | 2006 |
Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2006 |
Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Biomarkers; Body Composition; Campt | 2007 |
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2006 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administr | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2006 |
Peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Co | 2006 |
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis.
Topics: Adult; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Parente | 2007 |
Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2006 |
Weekly fluorouracil at 425 mg/m(2) plus low-dose folinic acid for 24 weeks as adjuvant treatment for colorectal cancer: assessment of toxicity and delivery.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dose-Response Relation | 2006 |
Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2007 |
Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2007 |
A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ca | 2006 |
Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Ce | 2007 |
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2006 |
[Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2006 |
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Respo | 2006 |
[Prophylactic hepatic arterial infusion chemotherapy after curative surgery of colorectal liver metastases--the viewpoint from patients' quality of life].
Topics: Angiography; Catheterization; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, | 2006 |
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2007 |
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2007 |
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec | 2007 |
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celeco | 2007 |
[A phase I study of modified FOLFOX 6 therapy for advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2007 |
The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; | 2007 |
Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2006 |
Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorec | 2007 |
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Austral | 2007 |
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2008 |
Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camp | 2007 |
A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2007 |
Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Dis | 2007 |
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2007 |
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2008 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cell Survival; Colorec | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheterization; | 2007 |
Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2007 |
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxyc | 2007 |
Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2007 |
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2007 |
Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Diseas | 2007 |
Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2007 |
Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2007 |
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2007 |
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2007 |
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2007 |
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2007 |
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2007 |
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2007 |
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2007 |
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2007 |
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2007 |
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2007 |
Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2008 |
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2007 |
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2007 |
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2007 |
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; | 2007 |
Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Combined Chemo | 2008 |
Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; | 2007 |
A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2007 |
Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost of Illness; | 2007 |
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2007 |
[10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2007 |
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2007 |
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptotheci | 2007 |
A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Colorectal Neopl | 2007 |
Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2007 |
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2007 |
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2008 |
Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2007 |
Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2007 |
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2007 |
Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2007 |
Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Deoxyc | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2007 |
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2008 |
FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Stud | 2007 |
An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Combined Modalit | 2007 |
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2008 |
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2007 |
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
FOLFIRI chemotherapy for metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2007 |
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; E | 2008 |
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neop | 2008 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemot | 2008 |
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal | 2007 |
The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2008 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2007 |
Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2008 |
Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2008 |
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with
Topics: Adult; Aged; Aminoquinolines; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Cam | 2008 |
[Comparative study on treatment of advanced colorectal cancer by Aidi injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2007 |
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne | 2008 |
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2008 |
Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2008 |
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2008 |
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans | 2008 |
Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasm | 2008 |
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2008 |
[A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2008 |
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2008 |
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplast | 2007 |
Perioperative chemotherapy for resectable hepatic metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Fluorou | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2008 |
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2008 |
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2008 |
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2008 |
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2008 |
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2008 |
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2008 |
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2008 |
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2008 |
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Colorec | 2008 |
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2008 |
Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Respo | 2008 |
A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2008 |
A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1995 |
Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Digestive System | 1994 |
The influence of early postoperative intraperitoneal chemotherapy on human wound healing.
Topics: Adult; Aged; Biocompatible Materials; Collagen; Colorectal Neoplasms; Combined Modality Therapy; Dou | 1994 |
Survival after systemic therapy for metastatic colorectal cancer.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Palliative Care; Prospective Stu | 1995 |
Trials in palliative care.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasms; Palliative Care; Randomized Contr | 1995 |
Colorectal carcinoma.
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Intraoperative Period; Postopera | 1995 |
[A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil with both leucovorin and cisplatin against liver metastases of colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administ | 1995 |
[Preventive chemotherapy for residual liver after resection of hepatic metastasis from colorectal cancer].
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Hu | 1995 |
[Study of hepatic arterial infusion chemotherapy for prophylaxis of liver metastases of colorectal cancer after hepatic resection].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1995 |
[Evaluation of prophylactic hepatic arterial infusion chemotherapy after hepatectomy for metastases from colorectal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Su | 1995 |
[Assessment of serial carcinoembryonic antigen (CEA): monitor to evaluate efficacy of continuous intrahepatic chemotherapy for nonresectable liver metastases of colorectal carcinomas].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic | 1995 |
[The study of chemotherapy via the reservoir to colo-rectal cancer patients with liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1995 |
[Experience in intra-hepatic-arterial chemotherapy and hepatic resection for metastatic colorectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1995 |
5-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Colorectal Neopla | 1995 |
A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 1995 |
[Clinical evaluation of leucovorin and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1995 |
[Chrono-chemotherapy and dose intensity].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronobiology | 1995 |
Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; H | 1995 |
[Is radiotherapy necessary in the control of colorectal cancer?].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Cobalt Radioisotopes; Colectomy; Colonic | 1995 |
Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1995 |
Combination 5-fluorouracil (5-FU) and alpha interferon (IFN) in metastatic colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Inter | 1995 |
Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Chi-Square Distribution; Colorectal Neoplasms; Combined Modality | 1995 |
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1995 |
Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Canc
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1995 |
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche | 1994 |
Failure to increase 5-fluorouracil activity with interferon-alpha 2a in the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Interferon alpha-2; Interferon-alph | 1995 |
A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Interleukin-2; Leucovorin; Male; Mi | 1995 |
Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect | 1995 |
[Early phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administr | 1995 |
Treatment of advanced colorectal carcinoma with 5-fluorouracil, leucovorin and Roferon-A: a Southwest Oncology Study Group Study.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Interfer | 1994 |
[Treatment of acute chemically induced diarrhea by inhibition of enkephalinase. Results of a pilot study].
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Diarrhe | 1995 |
[Intraportal infusion of 5-FU and lipiodol-aclarubicin after hepatic resection for colorectal liver metastasis].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therape | 1995 |
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1995 |
Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer.
Topics: Adult; Aged; Catheters, Indwelling; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusion Pum | 1995 |
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chem | 1995 |
[Late phase II trial of high-dose l-leucovorin and 5-fluorouracil in advanced colorectal carcinoma. l-Leucovorin and 5-FU Study Group (Japan Eastern Group)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche | 1995 |
[A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
Topics: Adult; Aged; Anorexia; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorou | 1995 |
[Biochemically modulated chemotherapy with high-dose L-leucovorin and 5-fluorouracil for multiple liver metastasis from colorectal cancer].
Topics: Adenocarcinoma; Aged; Anorexia; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Live | 1995 |
A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle | 1995 |
[Effect of prophylactic intra-arterial infusion of anticancer drugs on post hepatic resection for hepatic metastasis of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1994 |
[Home therapy approach in cancer patients-chemotherapy (case 2-2)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Home Infusion Th | 1994 |
Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; F | 1995 |
Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged; Neo | 1995 |
Metastatic or locally advanced colorectal cancer treated with 5-fluorouracil and low dose leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Co | 1994 |
The AXIS colorectal cancer trial: randomization of over 2000 patients. The AXIS Steering Group.
Topics: Aged; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Male | 1994 |
Experimental colonic healing in relation to timing of 5-fluorouracil therapy.
Topics: Animals; Colon; Colorectal Neoplasms; Fluorouracil; Male; Rats; Rats, Wistar; Time Factors; Wound He | 1994 |
Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1995 |
A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fem | 1994 |
5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1995 |
5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1995 |
[Continuous intraarterial infusion of 5-fluorouracil plus leucovorin for liver metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche | 1995 |
[Pharmacokinetic study of UFT in cancer patients receiving maintenance dialysis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1995 |
Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendicea | 1995 |
Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1995 |
A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 1995 |
Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen. French Northern Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Cytara | 1995 |
A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1994 |
Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Fluid Compartments; Colorectal Neo | 1994 |
Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1994 |
Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma.
Topics: Colorectal Neoplasms; Dextrins; Dialysis Solutions; Drug Administration Schedule; Drug Stability; Fe | 1994 |
Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors.
Topics: Adolescent; Carcinoma; Child; Child, Preschool; Colorectal Neoplasms; Drug Administration Schedule; | 1994 |
Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Colo | 1994 |
[A study of regional chemotherapy: hepatic arterial infusion for metastatic liver tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepat | 1994 |
[Evaluation of prophylactic intra-hepatic-arterial infusion chemotherapy after resection of hepatic metastases from colorectal primaries].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Do | 1994 |
[Intraarterial infusion combination therapy with LV and 5-FU in hepatic metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1994 |
[Hepatic arterial infusion after hepatectomy for liver metastases of colorectal carcinoma to prevent residual hepatic recurrence].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Floxuridine; Flu | 1994 |
[The significance of portal infusion chemotherapy for prevention of recurrence in residual liver after hepatectomy for metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 1994 |
[A study of preoperative administration of 5'-DFUR in patients with colo-rectal cancer].
Topics: Administration, Oral; Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans | 1994 |
The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1994 |
Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion, and oral allopurinol. A randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colo | 1994 |
Phase II study with iododoxorubicin in measurable advanced colorectal adenocarcinoma. Effective rescue using weekly high-dose 5-fluorouracil (WFU). Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD), Work Group of SEOM (Spanish Medical Onc
Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle | 1994 |
Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 1994 |
[The usefulness of pre- and immediately postoperative chemotherapy in colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1994 |
Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; | 1994 |
Sequential treatment with high-dose methotrexate and fluorouracil in advanced colorectal cancer. Experience of the Southern Italian Oncology Group (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1994 |
Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorec | 1994 |
[Status of portal perfusion in colorectal cancer. Swiss Study Group for Clinical Cancer Research].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1994 |
Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1994 |
Estimated treatment responses in metastatic colorectal carcinoma based on longitudinal carcinoembryonic antigen series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Ne | 1993 |
Experience with 5FU + L-leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 1993 |
5-Fluorouracil combined with the pure [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study of two consecutive regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1993 |
5-Fluorouracil modulation in colorectal carcinoma experience of German investigators.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Germany; Humans; Immunologic Factors; Int | 1993 |
Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1994 |
Continuous-infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: clinical evidence of incomplete cross-resistance.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Drug Resistance; Fluorouracil; Humans; Infusions | 1994 |
Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug Administ | 1994 |
Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma. Results of a chronopharmacologic phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Colorectal Neoplasms; | 1994 |
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female; | 1994 |
A randomized feasibility study evaluating the effect of radiotherapy alone or combined with 5-fluorouracil in the treatment of locally recurrent or inoperable colorectal carcinoma.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middl | 1993 |
Local and systemic toxicity of intra-hepato-arterial chemotherapy for treatment of unresectable liver metastases of colorectal cancer with 5-Fluorouracil and high dose Leucovorin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Colore | 1993 |
[Some problems of TS measurement after administration of fluoropyrimidines in colorectal cancer. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Dipyridamole; Female; Fluorouracil; Humans | 1993 |
A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capillary Permeabi | 1993 |
Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans | 1993 |
Re: "Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis".
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Interferon Type I; Liver Neoplasms; Recombinant Proteins | 1994 |
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1994 |
Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1994 |
Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Female; Fluorouraci | 1994 |
Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1993 |
5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1993 |
Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1993 |
[Intermittent hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-A | 1993 |
[A randomized trial of intrahepatic infusion chemotherapy for unresectable colorectal liver metastases. Sendai Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Epir | 1993 |
Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1993 |
Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; | 1993 |
Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Feasibi | 1993 |
Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; H | 1993 |
A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Double-Blind Method; Drug Administration Schedule; Femal | 1993 |
Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Aged, 80 and over; Carcinoembryonic Antigen; Colorectal Neopla | 1993 |
Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 1993 |
Combination chemotherapy with tauromustine (TCNU), 5-fluorouracil and leucovorin in advanced colorectal carcinoma: a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1993 |
A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1993 |
[The chemoradiotherapy of advanced colorectal carcinoma--the results and toxicity in a pilot study with 44 patients].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1993 |
Continuous hepatic artery infusion of 5-fluorouracil for metastatic colorectal cancer localised to the liver.
Topics: Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Inf | 1993 |
Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastrointestina
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1993 |
Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1995 |
A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Circadian Rhythm; Colorectal Neoplasms; Disease-Free S | 1995 |
Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1995 |
A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fe | 1996 |
'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dr | 1995 |
Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration S | 1995 |
A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Cohort Studies; Colorectal Neopl | 1995 |
Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1996 |
Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; H | 1995 |
Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 1996 |
Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; | 1995 |
Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1995 |
5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1995 |
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1995 |
Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Disease-Fre | 1996 |
High dose folinic acid and 5-fluorouracil bolus and continuous infusion for patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1995 |
Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 1996 |
Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combination; Femal | 1996 |
Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1996 |
[Comparative study of the combined effect of HCFU and dipyridamole (DP) in colorectal carcinoma--TS inhibition rate. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Dru | 1996 |
Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 1996 |
Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1996 |
[Evaluation of chemotherapy in the treatment of advanced colorectal cancer--pilot study of 5-FU by biochemical modulation].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 1996 |
[Effect of leucovorin and 5-FU for advanced colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1996 |
[Progress in development of chemotherapy of colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr | 1996 |
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Europe; Female; Fluorour | 1996 |
Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1996 |
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1996 |
Measurement of 5-fluorouracil in scalp hair: a possible index of patient compliance with oral adjuvant chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Mod | 1996 |
A Bayesian analysis of bivariate survival data from a multicentre cancer clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Cisplatin; Colorectal Neoplasms; Dose | 1995 |
Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1995 |
Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Adm | 1996 |
A report of infusional 5-fluorouracil and subcutaneous alpha-2A-interferon in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Drug Ther | 1996 |
Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1996 |
A pilot study of adjuvant hepatic arterial infusion chemotherapy, associating 5-fluorouracil and leucovorin, after resection of colorectal cancer liver metastases.
Topics: Aged; Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fema | 1995 |
Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationsh | 1996 |
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1996 |
Sequential methotrexate and 5-fluorouracil as second-line chemotherapy for advanced colorectal cancer patients pretreated with 5-fluorouracil and leucovorin: a GISCAD study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1996 |
[Clinical study of ambulatory cancer chemotherapy for advanced colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Col | 1995 |
[Continuous hepatic arterial infusion chemotherapy with low-dose CDDP plus 5-FU for liver metastases from colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug A | 1996 |
[Clinical evaluation of hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Doxorubicin; | 1996 |
[Evaluation of prophylactic hepatic arterial infusion chemotherapy after hepatectomy for metastases from colorectal cancer--the second report].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatectomy; Hepatic Artery; Human | 1996 |
[The preventive effect of weekly high-dose 5-FU infusion (WHF) after resection of hepatic metastasis from colorectal cancer].
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; H | 1996 |
[The effect of intraportal chemotherapy in terms of administered dose of 5-FU].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps, Implantabl | 1996 |
Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Calcium; Colorectal Neoplasms; Fem | 1996 |
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col | 1996 |
A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Colorectal Neopl | 1996 |
Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1996 |
5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 1996 |
Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1996 |
Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group--third study on colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplas | 1996 |
Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Berberine Alkaloids; Biopsy; Colo | 1996 |
Advanced colorectal carcinoma: redefining the role of oral ftorafur.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 1996 |
Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidotes; Antineoplastic Combined Chemotherapy Protocols; | 1996 |
5-Fluorouracil continuous infusion in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal N | 1996 |
Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modalit | 1996 |
Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 1997 |
Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Antimetabolites, Antineoplastic; Antineoplastic Age | 1996 |
Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 1996 |
The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments.
Topics: Aged; Antimetabolites, Antineoplastic; Cognition Disorders; Colorectal Neoplasms; Combined Modality | 1996 |
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 1997 |
Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
Topics: Adult; Aged; Agranulocytosis; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dise | 1997 |
Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1997 |
Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1997 |
Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1997 |
High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1997 |
Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasm | 1997 |
Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hum | 1997 |
Adjuvant therapy for resectable colorectal carcinoma with 5-fluorouracil portal vein infusion.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorourac | 1997 |
Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 1997 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Colorectal Neoplasms; Drug Interactions | 1997 |
The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1996 |
The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
Topics: Administration, Oral; Adult; Aged; Anemia; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Co | 1996 |
The French experience with infusional 5-fluorouracil in advanced colorectal cancer.
Topics: Antidotes; Antimetabolites, Antineoplastic; Chronotherapy; Colorectal Neoplasms; Dose-Response Relat | 1996 |
High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1996 |
First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbop | 1996 |
Infusion pumps for systemic and intra-arterial chemotherapy of colorectal liver metastases.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cost Savings; E | 1997 |
[Immunological monitoring of patients with disseminated colorectal cancer under thermochemotherapy].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hot | 1997 |
Factors predictive of response and survival in patients with metastatic colorectal cancer in Taiwan.
Topics: Adjuvants, Immunologic; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasm | 1997 |
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 1997 |
Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chi-Square Distribution; Colorectal | 1997 |
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand break
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Damage; DNA, | 1997 |
Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents | 1997 |
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Fe | 1997 |
[Effects of adjuvant hyaluronidase in tumors refractory to chemotherapy. Review of the literature and pharmacokinetics of cisplatin after regional administration in animals and humans].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma 256, Walker; Chemotherapy | 1997 |
Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomar | 1997 |
Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; H | 1997 |
UFT plus leucovorin vs 5-FU plus leucovorin for metastatic colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug C | 1997 |
5-FU or UFT combined with leucovorin for previously untreated metastatic colorectal Ca.
Topics: Adult; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combina | 1997 |
[Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration | 1997 |
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resist | 1997 |
Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1997 |
A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; In | 1997 |
A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Re | 1997 |
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cath | 1997 |
[Combined treatment of large bowel cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1997 |
The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial.
Topics: Antimetabolites, Antineoplastic; Cognition Disorders; Colorectal Neoplasms; Combined Modality Therap | 1997 |
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1998 |
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Drug Admini | 1998 |
5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; | 1997 |
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Fe | 1997 |
Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1998 |
[Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hum | 1997 |
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Topics: Cell Division; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Ge | 1998 |
Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Female | 1998 |
Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protoc | 1998 |
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Capecitabine | 1998 |
Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Enzyme I | 1998 |
[The evaluation of weekly hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Female; F | 1998 |
Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 1998 |
A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationsh | 1998 |
Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche | 1998 |
Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 1998 |
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1998 |
Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 1998 |
A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracil-pretreated colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colorectal Neoplasms; Drug Admini | 1998 |
5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1998 |
[Method of preventing hepatic artery occlusion during continuous intrahepatic arterial infusion chemotherapy of 5-FU].
Topics: Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Colorectal N | 1998 |
[Clinical evaluation of intermittent hepatic arterial infusion therapy for metastatic liver tumor of gastric and colorectal cancer].
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; C | 1998 |
High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1998 |
Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Female; F | 1998 |
Biomodulation with sequential intravenous IFN-alpha2b and 5-fluorouracil as second-line treatment in patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal | 1998 |
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 1998 |
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fe | 1998 |
Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1998 |
Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorecta | 1998 |
[Adjuvant radio-chemotherapy is effective in the treatment of Dukes B and C rectal cancer: results of a randomized controlled Norwegian trial].
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Norway; Radiotherapy, Adjuvant | 1998 |
Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases.
Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Floxuridine; Fluorouracil; Hepatic Artery; Humans; | 1998 |
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Color | 1998 |
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phy | 1998 |
A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Inte | 1998 |
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1997 |
Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug A | 1998 |
Anticancer effects of preoperative chemotherapy on colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 1998 |
Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor | 1998 |
Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1998 |
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 1998 |
Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1998 |
[Multicenter phase II study of the Liver Metastases Study Group of weekly intra-arterial 24-hour high dose therapy with 5-FU and folinic acid (FA) in liver metastases of colorectal tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1998 |
[Intra-arterial (5-FU/FA and FUDR) versus systemic chemotherapy (5-FU/FA) of non-resectable colorectal liver metastases].
Topics: Adult; Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 1998 |
5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Colorectal Neopl | 1998 |
Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.
Topics: Adult; Age Factors; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neop | 1998 |
S-phase accumulation precedes apoptosis induced by preoperative treatment with 5-fluorouracil in human colorectal carcinoma cells.
Topics: Apoptosis; Colorectal Neoplasms; DNA, Neoplasm; Female; Flow Cytometry; Fluorouracil; Humans; Immuno | 1999 |
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 1999 |
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 1999 |
[Biochemical modulation of 5-FU--effect of low dose CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin | 1999 |
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Ag | 1999 |
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Color | 1999 |
Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer.
Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Feasibility St | 1999 |
A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas | 1999 |
Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas | 1999 |
Oxaliplatin pharmacokinetics during a four-hour infusion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Colorectal Neopl | 1999 |
A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1999 |
An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Cost-Benefit Analysis; Costs and Cost Analysis; Fluorou | 1999 |
[Adjuvant chemotherapy after curative surgery for non-metastatic colorectal carcinomas (2-year results of 52 cases)].
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colo | 1999 |
Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 1999 |
A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 1999 |
High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma.
Topics: Amifostine; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combinat | 1999 |
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplas | 1999 |
Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Clocks; Colonic Neoplasms; C | 1999 |
[Treatment for advanced colorectal carcinoma with 5-fluorouracil plus low-dose leucovorin].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone | 1999 |
Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Hu | 1999 |
[Irinotecan in the second-line therapy of metastatic colorectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas | 1999 |
[Peripheral 5-FU blood concentration after high-dose injection into the hepatic artery: potential preventive effect on extrahepatic metastatic foci].
Topics: Adult; Aged; Area Under Curve; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Hepatic Arte | 1999 |
Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1999 |
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Co | 1999 |
Impact of uracil/tegafur plus oral calcium folinate on resource utilization.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1999 |
Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 1999 |
Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1999 |
Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Interactions | 1999 |
Intra-arterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 1999 |
Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Cisplat | 1999 |
The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colorectal | 1999 |
Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer.
Topics: Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ch | 1999 |
Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Aci | 1999 |
Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 1999 |
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
Topics: Adult; Aged; Animals; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; | 1999 |
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1999 |
[Clinical trial of prophylactic hepatic arterial chemotherapy for liver metastases in patients with Dukes' C colorectal cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Adm | 1999 |
[Cooperative study of intraarterial preventive chemotherapy after resection of hepatic metastasis from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1999 |
[Evaluation of the non-effective cases of irresectable multiple liver metastasis of colorectal cancer receiving hepatic arterial infusion chemotherapy].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorou | 1999 |
[Efficacy of intra-arterial chemotherapy on life prolongation in patients with hepatic metastasis from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Modality T | 1999 |
[Efficacy and side effect of continuous intra-arterial infusion of high-dose 5-FU for liver metastases of colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Femal | 1999 |
[The efficacy and limitation of hepatic arterial infusion chemotherapy for colorectal liver metastases].
Topics: Administration, Oral; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therap | 1999 |
Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Chi-Square Distribution; Chromatogra | 1999 |
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasm | 1999 |
[Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; | 1999 |
A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dis | 1999 |
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 1999 |
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co | 2000 |
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co | 2000 |
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co | 2000 |
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co | 2000 |
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1999 |
Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Colorectal Ne | 1999 |
Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Color | 1999 |
[Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1999 |
Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug | 2000 |
Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1999 |
High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic C | 2000 |
Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 1999 |
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 1999 |
Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil.
Topics: Adjuvants, Immunologic; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Colorectal Neop | 2000 |
Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chronot | 2000 |
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxyc | 2000 |
Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Colon; Colorec | 2000 |
Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Diseas | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Cisplatin containing chemotherapy influences HLA-DR expression on monocytes from cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorecta | 1999 |
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur | 2000 |
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur | 2000 |
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur | 2000 |
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur | 2000 |
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur | 2000 |
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur | 2000 |
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur | 2000 |
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur | 2000 |
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur | 2000 |
Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2000 |
Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2000 |
Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2000 |
A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; In | 1999 |
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug R | 2000 |
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Admi | 2000 |
Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Sch | 2000 |
[Regional chemotherapy of the liver after resection of liver metastases in colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 2000 |
Preoperative UFT administration for patients with advanced colorectal cancer--increased uptake of 5-fluorouracil by tumor tissue is a prognostic factor.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Ne | 2000 |
[The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administ | 2000 |
Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2000 |
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Ne | 2000 |
Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms | 1999 |
Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; C | 1999 |
Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2000 |
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Topics: Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam | 2000 |
Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2000 |
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neo | 2000 |
Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Colorectal Neoplasms; | 2000 |
Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Dose and time dependencies of 5-fluorouracil pharmacokinetics.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Dr | 2000 |
Avoidance of colostomy placement in advanced colorectal cancer with twice weekly hypofractionated radiation plus continuous infusion 5-fluorouracil.
Topics: Colorectal Neoplasms; Colostomy; Contraindications; Dose Fractionation, Radiation; Drug Administrati | 2000 |
Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2000 |
Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 2000 |
5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2000 |
Can mitomycin C represent a valid partner for 5-fluorouracil in second-line chemotherapy of colorectal cancer?
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2000 |
Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2000 |
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2000 |
[Evaluation of hepatic resection following hepatic arterial infusion chemotherapy for colorectal liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda | 2000 |
[Indication for hepatic resection after hepatic arterial infusion chemotherapy for multiple liver metastases of colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorourac | 2000 |
[Arterial infusion chemotherapy for liver metastases from colorectal cancer--therapeutic effects of different protocols].
Topics: Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Doxorubicin; Drug Administration Schedule; E | 2000 |
Prevention of hepatic artery occlusion during continuous infusion of fluorouracil using liposteroid.
Topics: Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Colorectal Neoplasms; Dexamethasone; F | 2000 |
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; C | 2000 |
Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2000 |
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2000 |
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 2000 |
Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2000 |
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2001 |
Phase II study of combined 5-fluorouracil/ Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2001 |
Double-blind pilot-study on the efficacy of enzyme therapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chymotrypsin; Colorectal Neo | 2000 |
Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor | 2000 |
Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2001 |
Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dox | 2001 |
5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Endpoint Determination; Female; | 2001 |
Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal | 2001 |
Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Topics: Actuarial Analysis; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antin | 2001 |
Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma.
Topics: Abdominal Neoplasms; Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined | 2001 |
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
A United Kingdom coordinating committee on cancer research study of adjuvant chemotherapy for colorectal cancer: preliminary results.
Topics: Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Ne | 2001 |
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2001 |
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2001 |
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2001 |
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2001 |
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2001 |
Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial.
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluor | 2001 |
Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Conjunctivitis; D | 2001 |
Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Ar | 2001 |
Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cance
Topics: Administration, Oral; Aged; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Female; Fluo | 2001 |
Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2001 |
Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemothera | 2001 |
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 2001 |
Double-blind randomised placebo-controlled phase III study of an E. coli extract plus 5-fluorouracil versus 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blood Cell Count; Color | 2001 |
Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2001 |
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neoplasms; | 2001 |
Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Dose-Response | 2001 |
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2001 |
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Ne | 2001 |
Optimal duration of oral adjuvant chemotherapy with Carmofur in the colorectal cancer patients: the Kansai Carmofur Study Group trial III.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplas | 2001 |
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorect | 2001 |
Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2001 |
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2001 |
Liver metastases from colorectal cancer: regional intra-arterial treatment following failure of systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug R | 2001 |
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2001 |
Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels.
Topics: Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Do | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2001 |
Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2001 |
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2001 |
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromatography, High Pressure | 2001 |
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2001 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2002 |
Epirubicin, cisplatin and continuous-infusion 5-fluorouracil (ECF regimen) in the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Diseas | 2001 |
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Deoxyuridine; Enzyme Inhib | 2002 |
P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell D | 2002 |
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2002 |
Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Femal | 2002 |
A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2002 |
Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2002 |
Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluo | 2001 |
Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta | 2001 |
Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil | 2002 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect | 2002 |
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2002 |
Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Female; F | 2002 |
Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chrono | 2002 |
Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antig | 2002 |
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 2002 |
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial.
Topics: Adenoviridae; Adenovirus E1B Proteins; Aged; Antibodies, Viral; Antineoplastic Combined Chemotherapy | 2001 |
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2002 |
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2002 |
Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Topics: Adjuvants, Immunologic; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic | 2002 |
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2002 |
Chronotherapy of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbop | 2002 |
Pharmaco-economic comparative evaluation of combination chronotherapy vs. standard chemotherapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Costs and Cost | 2002 |
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2002 |
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2002 |
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2002 |
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2002 |
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2002 |
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2002 |
Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Mutationa | 2002 |
A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2002 |
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2002 |
Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2002 |
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2002 |
General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Colorectal Neo | 1992 |
Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Hepar | 1992 |
Intraperitoneal 5-fluorouracil in the management of colorectal liver cancer.
Topics: Adult; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Liver Neopla | 1992 |
Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr | 1992 |
Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Ev | 1992 |
Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma.
Topics: Adult; Aged; Colorectal Neoplasms; Conjunctivitis; Diarrhea; Drug Administration Schedule; Female; F | 1992 |
Cisplatinum in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug A | 1992 |
Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1992 |
Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intra | 1992 |
A phase 2 trial of recombinant interleukin-2 and 5-fluorouracil in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1992 |
Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Interactions; Fema | 1992 |
Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Results of a randomized multicenter trial. The Association of Medical Oncology (AIO) of the German Cancer Society.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1992 |
Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr | 1992 |
A phase I-II study of 14-days continuous infusion of 5-fluorouracil with weekly bolus leucovorin in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1992 |
Continuous regional treatment with fluoropyrimidines for metastases from colorectal carcinomas: influence of modulation with leucovorin.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Hepatic Arter | 1992 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No!
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Forecasting; Humans; Infusio | 1992 |
Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluor | 1992 |
Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; | 1992 |
A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1992 |
A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Ne | 1992 |
Bayesian subset analysis in a colorectal cancer clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Colorectal Neoplasms; Dose-Response R | 1992 |
Application of Bayesian statistics to decision making during a clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Cisplatin; Colorectal Neoplasms; Comb | 1992 |
Description of the statistical aspects of a study for advanced colorectal cancer patients.
Topics: Bayes Theorem; Cisplatin; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationshi | 1992 |
A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leuco | 1992 |
Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Liver | 1992 |
Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan-Kettering experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; | 1992 |
Modulation of fluorouracil with recombinant alfa interferon: M. D. Anderson Clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Fluorouracil; | 1992 |
A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1992 |
A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
Topics: Adult; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluatio | 1992 |
Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluati | 1992 |
Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer--results of a clinical phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; | 1992 |
The value of adjuvant therapy after radical surgery for colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 1992 |
Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1992 |
A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colore | 1992 |
[Final evaluation of the randomized multicenter study SAKK 40/81: adjuvant portal chemotherapy of curatively resected colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1992 |
Randomized clinical trial with a weekly regimen of 5-FU vs 5-FU + intermediate-dose folinic acid in the treatment of advanced colo-rectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combi | 1992 |
Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cytotoxicity, Immunologic; Dru | 1992 |
A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastases.
Topics: Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation; Female; Fluorouracil; | 1992 |
Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC).
Topics: Adult; Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; D | 1992 |
[Fluorouracil as monotherapy or combined with folinic acid in the treatment of metastasizing colorectal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouraci | 1992 |
[Chemotherapy for advanced and recurrent cancer patients--the effect of combination chemotherapy using cisplatin, peplomycin, mitomycin C, adriamycin, and 5-fluorouracil].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colorectal Neopla | 1990 |
A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1992 |
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Colo | 1992 |
Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa).
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemothera | 1992 |
Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1992 |
Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma.
Topics: Adult; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Bio | 1992 |
Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer).
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C | 1991 |
5-Fluorouracil by protracted venous infusion: a review of recent clinical studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Drug Evaluat | 1991 |
5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug E | 1991 |
Treatment of advanced colorectal cancer by 5-fluorouracil-leucovorin combination with or without allopurinol: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colorec | 1991 |
A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1991 |
A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Aspartic Acid; Colorectal Neoplasms; | 1991 |
Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Female; Floxu | 1991 |
Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and i.v. 5-fluorouracil (5-FU) chemotherapy for unresectable colorectal liver metastases: an alternative to FUdR-based regimens?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Floxuridine; | 1991 |
[5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorou | 1991 |
Thymopentin and interleukin-2 in combination with 5-fluorouracil and leucovorin in metastatic colorectal adenocarcinoma: preliminary results.
Topics: Adenocarcinoma; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Femal | 1991 |
Preliminary report of high dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1991 |
Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1991 |
Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1991 |
A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colorectal Neopla | 1991 |
A phase II pilot study of the combined application of hyperthermia and intra-hepato-arterial chemotherapy using cisplatinum and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Modality T | 1991 |
[Chemotherapy of colorectal cancer. Screening systems--value of special cytostatic drug combinations].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Evaluation; Fl | 1991 |
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 1991 |
Sequential combination of methotrexate (MTX), 5-fluorouracil (FU), and high-dose folinic acid (FA) in advanced colorectal cancer: double biochemical modulation?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1991 |
A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Synergis | 1991 |
Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1991 |
The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche | 1991 |
Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug A | 1991 |
Role of adjuvant therapy in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colorectal Neopl | 1991 |
Phase I evaluation of spirogermanium and 5-fluorouracil in colorectal carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorec | 1991 |
Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1991 |
A randomized study of on-line plasma perfusion over protein A-sepharose and 5-fluorouracil chemotherapy in patients with metastatic colorectal carcinoma.
Topics: Chromatography, Gel; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; | 1991 |
Hepatic artery ligation with and without portal infusion of 5-FU. A randomized study in patients with unresectable liver metastases from colorectal carcinoma. The E.O.R.T.C. Gastrointestinal Cancer Cooperative Group (G.I. Group).
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1991 |
A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; | 1991 |
Tumor necrosis factor in advanced colorectal cancer: a phase II study. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society.
Topics: Adenocarcinoma; Adult; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule | 1990 |
[Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Colorectal Neoplasms; Combined Mo | 1990 |
'AXIS': a new type of cancer trial.
Topics: Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intravenous; Pelvi | 1990 |
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial.
Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusion Pump | 1990 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1990 |
Folinic acid plus high-dose 5-fluorouracil with allopurinol protection in the treatment of advanced colorectal carcinoma.
Topics: Aged; Allopurinol; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination | 1990 |
A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis.
Topics: Allopurinol; Colorectal Neoplasms; Consumer Behavior; Double-Blind Method; Fluorouracil; Humans; Leu | 1990 |
Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with allopurinol, folinic acid and dipyridamol.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Ne | 1990 |
Fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leucovorin; Male; Ran | 1990 |
A phase I-II study on the toxicity and therapeutic efficacy of 5-fluorouracil in combination with leucovorin and cisplatinum in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1990 |
Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience.
Topics: Animals; Clinical Trials as Topic; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination; | 1990 |
Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases.
Topics: Adolescent; Adult; Aged; Colorectal Neoplasms; Embolization, Therapeutic; Female; Fluorouracil; Hepa | 1990 |
A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer.
Topics: Adult; Aged; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug Evaluation; Drug Sy | 1990 |
Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer.
Topics: Adult; Aged; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule | 1990 |
A randomized study of combined 5-fluorouracil and plasma perfusion over protein A-sepharose in human advanced colorectal carcinoma.
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Liver Ne | 1990 |
A randomized controlled trial of oral 5-FU versus placebo in colorectal cancer: results of 10 years observation time.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Time Factors | 1990 |
Sequential methotrexate, 5-fluorouracil, and leucovorin in metastatic measurable colorectal cancer. Does it work?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr | 1990 |
Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.
Topics: Colorectal Neoplasms; Female; Fluorouracil; Humans; Interferon alpha-2; Interferon-alpha; Male; Midd | 1990 |
Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Infusion | 1990 |
Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda | 1990 |
Regional chemotherapy for colorectal liver metastases: a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases.
Topics: Adult; Aged; Albumins; Angiotensin II; Colorectal Neoplasms; Drug Evaluation; Fluorouracil; Hepatic | 1990 |
[High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer. High-Dose Leucovorin and 5-FU Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1990 |
Randomized phase II study of a combination of cisplatin (DDP), 5-fluorouracil (5-FU), and allopurinol (HPP) versus 5-FU in advanced colorectal carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neop | 1990 |
Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1990 |
Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1990 |
Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venou | 1990 |
Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma.
Topics: Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination | 1990 |
A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms | 1989 |
A controlled clinical trial including folinic acid at two distinct dose levels in combination with 5-fluorouracil (5FU) for the treatment of advanced colorectal cancer: experience of the Mayo Clinic and North Central Cancer Treatment Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dose | 1988 |
Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1989 |
[Intra-portal chemoprevention and therapy of liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Comb | 1989 |
[Is there a primary indication for regional therapy of liver metastases of gastrointestinal tumors?].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hu | 1989 |
[Can the occurrence of extrahepatic metastases in regional chemotherapy of the liver be prevented by adding systemic chemotherapy? A randomized multicenter study].
Topics: Adenocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps | 1989 |
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dru | 1989 |
[Chemotherapy of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1989 |
[Mitomycin C plus HCFU adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma. (Second report): 5-year survival rate. Cooperative Study Group of Kyushu and Chugoku for HCFU Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1989 |
[Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum].
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials | 1989 |
[Effects of prophylactic intraportal chemotherapy on liver function, blood profile and survival in patients with colo-rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 1989 |
[Initial results of adjuvant portal liver infusion following radical surgery of colorectal cancer (Swiss Study Group for Epidemiologic and Clinical Cancer Research Study 40/81)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1989 |
Value of in vivo tissue testing in predicting the clinical response to regional perfusion chemotherapy in colorectal cancer patients with liver metastases.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorect | 1989 |
[Regional chemotherapy of liver metastases in colorectal carcinoma. Intra-arterial vs intravenous plus intra-arterial therapy].
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Evaluation Studies as Topic; Female; F | 1989 |
Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju | 1989 |
[European topic: liver surgery II--regional chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo | 1989 |
Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1989 |
Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil | 1989 |
Adjuvant chemoimmuno- and immunotherapy in Dukes' stage B2 and C colorectal carcinoma: a 7-year follow-up analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical T | 1989 |
Cancer control research in the North Central Cancer Treatment Group (NCCTG).
Topics: Allopurinol; Anorexia; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Colorectal Neoplas | 1989 |
High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood; Clinical Trials as Topic; Col | 1989 |
Improvements in fluorouracil chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1989 |
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.
Topics: Aged; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Interaction | 1989 |
Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Ne | 1989 |
5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1989 |
Correlation of dose intensity and prognosis in adjuvant chemotherapy: an extended controversy.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorecta | 1989 |
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Humans; Levamisole; Lymp | 1989 |
Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1989 |
Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. A randomized study.
Topics: Adenocarcinoma; Blood Chemical Analysis; Colorectal Neoplasms; Combined Modality Therapy; Female; Fl | 1989 |
Cytostatic drug therapy in disseminated colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col | 1988 |
The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Half-Life; Humans; Infusions, | 1988 |
[Chemotherapy of inoperable colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1988 |
Postoperative adjuvant therapy.
Topics: Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans | 1988 |
Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1988 |
Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1988 |
The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal | 1988 |
5-Fluorouracil (FUra) and folinic acid (FA) therapy in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1988 |
Clinical experience with CF-FUra.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1988 |
A randomized trial of 5-fluorouracil alone versus 5-fluorouracil and high dose leucovorin in untreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Ne | 1988 |
5-Fluorouracil and 5-formyltetrahydrofolate in advanced malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colorect | 1988 |
Clinical experience with 5-FU/DDP +/- OHDW combination chemotherapy in patients with advanced colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Colorectal Neop | 1988 |
5-Fluorouracil and folinic acid: summary of clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colorect | 1988 |
3584 other studies available for fluorouracil and Colorectal Cancer
| Article | Year |
|---|---|
Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Colorectal Neoplasms; Endodeoxyribonucleases; Fluorouracil; H | 2007 |
In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives.
Topics: Acetamides; Animals; Antigens, Neoplasm; Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbo | 2009 |
Novel cinnamaldehyde-based aspirin derivatives for the treatment of colorectal cancer.
Topics: Acrolein; Animals; Antineoplastic Agents; Apoptosis; Aspirin; Cell Cycle Checkpoints; Cell Line, Tum | 2018 |
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
Topics: Adamantane; Antineoplastic Agents; Aza Compounds; Cell Proliferation; Cell Survival; Colorectal Neop | 2019 |
Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chalcones; | 2019 |
Synthesis and in-vitro anti-cancer evaluations of multi-methoxylated asymmetrical diarylpentanoids as intrinsic apoptosis inducer against colorectal cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dose-R | 2020 |
Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Docetaxel | 2020 |
Discovery of 4-(3,5-dimethoxy-4-(((4-methoxyphenethyl)amino)methyl)phenoxy)-N-phenylaniline as a novel c-myc inhibitor against colorectal cancer in vitro and in vivo.
Topics: Amino Acid Sequence; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; | 2020 |
Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, T | 2020 |
Discovery of a potent β-catenin destabilizer for overcoming the resistance of 5-fluorouracil in colorectal cancer.
Topics: Alkaloids; Antineoplastic Agents; beta Catenin; Cell Survival; Colorectal Neoplasms; Dose-Response R | 2021 |
Targeting Colorectal Cancer with Conjugates of a Glucose Transporter Inhibitor and 5-Fluorouracil.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Disease Model | 2021 |
Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Colorectal Neoplasms; Dos | 2021 |
LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; | 2021 |
Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Camp | 2021 |
NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms | 2021 |
Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Screening Assay | 2021 |
S-Adenosylmethionine Increases the Sensitivity of Human Colorectal Cancer Cells to 5-Fluorouracil by Inhibiting P-Glycoprotein Expression and NF-κB Activation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2021 |
Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Cross-Secti | 2021 |
Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo | 2021 |
Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2021 |
Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition.
Topics: Apoptosis; Casein Kinase Ialpha; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; | 2021 |
LncRNA HCG11 promotes 5-FU resistance of colon cancer cells through reprogramming glucose metabolism by targeting the miR-144-3p-PDK4 axis.
Topics: Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Glucose; Humans; MicroRNAs; | 2022 |
Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Cost-B | 2022 |
Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; Colorectal Neoplasms; Drug Resi | 2021 |
Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplas | 2021 |
Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin β3/SRC pathway.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Epigene | 2021 |
Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Base Pairin | 2021 |
Antitumor Activity of Zinc Nanoparticles Synthesized with Berberine on Human Epithelial Colorectal Adenocarcinoma (Caco-2) Cells through Acting on Cox-2/NF-kB and p53 Pathways.
Topics: Adenocarcinoma; Animals; Apoptosis; bcl-2-Associated X Protein; Berberine; Caco-2 Cells; Caspase 3; | 2022 |
RING-finger protein 6 promotes colorectal tumorigenesis by transcriptionally activating SF3B2.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Case-Control | 2021 |
Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Colorect | 2021 |
Antioxidant and antiproliferative potential of ethanolic extracts from Moringa oleifera, Tropaeolum tuberosum and Annona cherimola in colorrectal cancer cells.
Topics: Annona; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2021 |
Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Ph | 2021 |
[A Case of Long-Term Survival after Administration of Regorafenib for Stage Ⅳ Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouraci | 2021 |
Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu | 2022 |
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiogenesis Inhibitors; Antineoplastic Agents | 2021 |
Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neopl | 2022 |
Alterations in hepatic fatty acids reveal depletion of total polyunsaturated fatty acids following irinotecan plus 5-fluorouracil treatment in an animal model of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2021 |
The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer.
Topics: Adenoma; Colorectal Neoplasms; Fluorouracil; Humans; Hypoglycemic Agents; Incidence; Metformin | 2022 |
[A case of pembrolizumab responding to recurrent small bowel mucinous adenocarcinoma with Peutz-Jeghers syndrome].
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pr | 2021 |
Twist and Vimentin protein expression in colorectal cancer tissues and their relationship with oxaliplatin-based postoperative adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2022 |
Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2022 |
Sanguisorba officinalis L. suppresses 5-fluorouracil-sensitive and-resistant colorectal cancer growth and metastasis via inhibition of the Wnt/β-catenin pathway.
Topics: Animals; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Ep | 2022 |
Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Decision | 2022 |
Combined Primary Resection with Hepatic Artery Infusion Pump Implantation Is Safe for Unresectable Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2022 |
Plakophilin3 loss leads to increased adenoma formation and rectal prolapse in APC
Topics: Adenoma; Animals; Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Disease Progression; | 2022 |
p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atlases as Topic; Breast Neoplasms; Camptothe | 2021 |
Redox-sensitive cyclophilin A elicits chemoresistance through realigning cellular oxidative status in colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Cell | 2021 |
Anemoside B4 sensitizes human colorectal cancer to fluorouracil-based chemotherapy through src-mediated cell apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 9; Colorectal Neoplasms; Drug Resistanc | 2021 |
Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2021 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 2023 |
Neoadjuvant intra-arterial versus intravenous chemotherapy in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2021 |
MLH1 mediates cytoprotective nucleophagy to resist 5-Fluorouracil-induced cell death in colorectal carcinoma.
Topics: Autophagy; Cell Death; Cell Line, Tumor; Colorectal Neoplasms; Cytoprotection; DNA Damage; Fluoroura | 2022 |
Lactobacillus plantarum-derived metabolites sensitize the tumor-suppressive effects of butyrate by regulating the functional expression of SMCT1 in 5-FU-resistant colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Butyrates; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluoro | 2022 |
Assessment of Drug-drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboxylesteras | 2022 |
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Cetuximab; Colonic Neoplasm | 2022 |
The development of a novel oral 5-Fluorouracil in-situ gelling nanosuspension to potentiate the anticancer activity against colorectal cancer cells.
Topics: Colorectal Neoplasms; Delayed-Action Preparations; Drug Liberation; Fluorouracil; Gels; Humans | 2022 |
Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α).
Topics: Adult; Aged; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms | 2022 |
Suppression of DYRK1A/B Drives Endoplasmic Reticulum Stress-mediated Autophagic Cell Death Through Metabolic Reprogramming in Colorectal Cancer Cells.
Topics: Animals; Apoptosis; Autophagic Cell Death; Autophagy; Cell Line, Tumor; Cell Proliferation; Cellular | 2022 |
Circular RNA protein tyrosine kinase 2 (circPTK2) promotes colorectal cancer proliferation, migration, invasion and chemoresistance.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neop | 2022 |
BIX-01294 enhances the effect of chemotherapy on colorectal cancer by inhibiting the expression of stemness genes.
Topics: Animals; Azepines; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorecta | 2022 |
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Colonic Neoplasms; Colorectal Neoplasms | 2022 |
ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.
Topics: Animals; beta Catenin; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Fluorouracil; | 2022 |
Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Replicat | 2022 |
TIMP-2 regulates 5-Fu resistance via the ERK/MAPK signaling pathway in colorectal cancer.
Topics: Aged; Animals; Butadienes; Cell Survival; Colorectal Neoplasms; Cytokines; Drug Resistance, Neoplasm | 2022 |
Panitumumab Associated Acute Pancreatitis.
Topics: Acute Disease; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colonic | 2022 |
[A Long-Survival Case of Lower Rectal Cancer with Unresectable Liver Metastases Treated with FOLFOXIRI plus Bevacizumab(BEV)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fem | 2021 |
CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CDX2 Transcription Factor; Cell Lin | 2022 |
[Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neopl | 2022 |
Angiotensin II Receptor Antagonist, Valsartan, Has Beneficial Effect in Lung Metastasis of Colorectal Cancer Treated with Fluorouracil.
Topics: Angiotensin Receptor Antagonists; Animals; Colorectal Neoplasms; Fluorouracil; Humans; Lung Neoplasm | 2023 |
Effect of Thymidine Phosphorylase Gene Demethylation on Sensitivity to 5-Fluorouracil in Colorectal Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Decitabine; | 2022 |
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Fluoro | 2022 |
Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer.
Topics: Colorectal Neoplasms; Female; Fluorouracil; Follicle Stimulating Hormone; Gonadal Steroid Hormones; | 2022 |
Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene | 2022 |
Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer.
Topics: B7-H1 Antigen; Biomarkers, Tumor; CD8 Antigens; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2022 |
Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2022 |
Comparison of
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla | 2022 |
[Effect of Astragali Radix-Curcumae Rhizoma compatibility combined with 5-fluorouracil on Th17/Treg balance and tumor-related mRNA and protein expression in orthotopic xenograft model mice of CT26.WT colorectal carcinoma].
Topics: Animals; Colorectal Neoplasms; Drugs, Chinese Herbal; Fluorouracil; Heterografts; Humans; Male; Mice | 2022 |
Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug-Related | 2022 |
Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoembryonic Antigen; | 2022 |
The therapeutic potential of γ-Al
Topics: Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Nanoparticles; Sulfhydryl Compounds; S | 2022 |
Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation.
Topics: Ablation Techniques; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A | 2022 |
Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis.
Topics: Animals; Azoxymethane; Bile Acids and Salts; Carcinogenesis; Cell Proliferation; Cholesterol; Colore | 2022 |
Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer.
Topics: Angiotensins; Animals; Colorectal Neoplasms; Fluorouracil; Matrix Metalloproteinase 2; Mice; Valsart | 2022 |
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Choline deficiency-related multi-omics characteristics are susceptible factors for chemotherapy-induced thrombocytopenia.
Topics: Antineoplastic Agents; Choline; Choline Deficiency; Colorectal Neoplasms; Fluorouracil; Humans; Leuk | 2022 |
[Prehepatectomy Chemotherapy Using Circadian Chrono-HAI for Liver Metastases from Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2022 |
Up-regulated FNDC1 accelerates stemness and chemoradiation resistance in colorectal cancer cells.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Neoplasm Proteins; Neoplastic Stem Cel | 2022 |
Circular RNA sterile alpha motif domain containing 4A contributes to cell 5-fluorouracil resistance in colorectal cancer by regulating the miR-545-3p/6-phosphofructo-2-kinase/fructose-2,6-bisphosphataseisotype 3 axis.
Topics: Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Fructose; Humans; MicroRNAs; Phosphofructoki | 2022 |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2022 |
Circ_0014130 is involved in the drug sensitivity of colorectal cancer through miR-197-3p/PFKFB3 axis.
Topics: Cell Proliferation; Colorectal Neoplasms; Drug Resistance; Fluorouracil; Humans; MicroRNAs; Phosphof | 2022 |
Cases in the management of metastatic colorectal cancer: regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2021 |
Measures to mitigate treatment-related toxicities in third-line metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2021 |
ATF4-mediated microRNA-145/HDAC4/p53 axis affects resistance of colorectal cancer cells to 5-fluorouracil by regulating autophagy.
Topics: Activating Transcription Factor 4; Animals; Autophagy; Cell Line, Tumor; Colorectal Neoplasms; Drug | 2022 |
Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.
Topics: Aerosols; Cohort Studies; Colorectal Neoplasms; Feasibility Studies; Fluorouracil; Humans; Leucovori | 2022 |
A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; Biomarkers, Tumor; Chemothe | 2022 |
[Tumor-associated macrophages: New targets to thwart 5-FU chemoresistance in colorectal cancers?]
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fl | 2022 |
Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer.
Topics: Capecitabine; Cardiotoxicity; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndr | 2022 |
Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
The Effect of 5-Fluorouracil on the Adhesion Process in Patients Operated on for Colorectal Cancer.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Postoperative Complications; Quality of Life; Tissue Adh | 2022 |
Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (N | 2022 |
Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neoplasms; Flu | 2022 |
Acoustic Bioprinting of Patient-Derived Organoids for Predicting Cancer Therapy Responses.
Topics: Acoustics; Bioprinting; Colorectal Neoplasms; Fluorouracil; Humans; Organoids | 2022 |
Synergistic antitumor activity of 5-fluorouracil and atosiban against microsatellite stable colorectal cancer through restoring GATA3.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; GATA3 Tr | 2022 |
Cancer Trial Impact: Understanding Implementation of the Short Course Oncology Treatment (SCOT) Trial Findings in colorectal cancer at a National Level.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo | 2022 |
Downregulation of KRAB zinc finger proteins in 5-fluorouracil resistant colorectal cancer cells.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Fluorouracil; Hu | 2022 |
Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chem | 2022 |
Methionine restriction enhances the chemotherapeutic sensitivity of colorectal cancer stem cells by miR-320d/c-Myc axis.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluo | 2022 |
Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis.
Topics: Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Drug Resistance, Neopla | 2022 |
Discoidin domain receptor 1a (DDR1a) confers 5-fluorouracil cytotoxicity in LoVo cell via PI3K/AKT/Bcl-2 pathway.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Discoidin Domain Receptor 1; Discoidin Domain Rec | 2022 |
FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis.
Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Ferroptosis; | 2022 |
[A Case Report for Peritoneal Recurrences by Laparoscopic Surgery after Colorectal Cancer Resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neo | 2022 |
Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo | 2022 |
Clinical Efficacy of Bevacizumab Plus XELOX Chemotherapy in Colorectal Cancer and Application Value of Mindfulness-Based Stress Reduction Intervention.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deo | 2022 |
SPOCK1 silencing decreases 5-FU resistance through PRRX1 in colorectal cancer.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Exp | 2022 |
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Ne | 2022 |
Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Reg | 2022 |
Differential effects of 5-fluorouracil and oxaliplatin on autophagy in chemoresistant colorectal cancer cells.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouraci | 2022 |
Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hep | 2022 |
Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness.
Topics: Apoptosis Regulatory Proteins; beta Catenin; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Colo | 2022 |
5-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information.
Topics: Colorectal Neoplasms; Fluorouracil; HT29 Cells; Humans; Neoplasm Recurrence, Local; Tumor Microenvir | 2022 |
Mir-675-5p supports hypoxia-induced drug resistance in colorectal cancer cells.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouraci | 2022 |
The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Colonic Neoplasms; Colorectal Neoplasms; DNA; Epige | 2023 |
RASSF4 inhibits cell proliferation and increases drug sensitivity in colorectal cancer through YAP/Bcl-2 pathway.
Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; DNA-Bind | 2022 |
Efficacy of risk-stratified indicators for adjuvant chemotherapy with fluorouracil and oxaliplatin after hepatectomy for colorectal cancer liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female | 2022 |
AP4 suppresses DNA damage, chromosomal instability and senescence via inducing MDC1/Mediator of DNA damage Checkpoint 1 and repressing MIR22HG/miR-22-3p.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Cycle Proteins; Chromosomal Instability; Colorec | 2022 |
Colorectal Cancer Patient-Derived 2D and 3D Models Efficiently Recapitulate Inter- and Intratumoral Heterogeneity.
Topics: Carcinogenesis; Colorectal Neoplasms; Fluorouracil; Humans; Organoids | 2022 |
Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Ne | 2022 |
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells.
Topics: B7-H1 Antigen; beta Catenin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluo | 2022 |
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; | 2022 |
Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
circEXOC6B interacting with RRAGB, an mTORC1 activator, inhibits the progression of colorectal cancer by antagonizing the HIF1A-RRAGB-mTORC1 positive feedback loop.
Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Feedback; Fluorouracil; Gene Expression | 2022 |
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla | 2022 |
Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells.
Topics: Animals; Apoptosis; Axin Protein; beta Catenin; Caveolin 1; Cell Line, Tumor; Cell Proliferation; Co | 2022 |
Extracellular vesicles derived from Lactobacillus plantarum restore chemosensitivity through the PDK2-mediated glucose metabolic pathway in 5-FU-resistant colorectal cancer cells.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Extracellular Vesicles; Fluoroura | 2022 |
Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Reg | 2022 |
Saturated Fatty Acids in Cell Membrane Lipids Induce Resistance to 5-Fluorouracil in Colorectal Cancer Cells.
Topics: Colorectal Neoplasms; Fatty Acids; Fatty Acids, Monounsaturated; Fluorouracil; Humans; Membrane Lipi | 2022 |
[Comparative Safety Assessment of Ramucirumab plus FOLFIRI and Bevacizumab plus FOLFIRI in Second- and Later-Line Treatment in Japanese Patients with Metastatic Colorectal Carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2022 |
Inhibition of the Wnt/b-catenin pathway using PNU-74654 reduces tumor growth in in vitro and in vivo models of colorectal cancer.
Topics: Animals; Apoptosis; Benzamides; beta Catenin; Catenins; Cell Line, Tumor; Cell Movement; Cell Prolif | 2022 |
Establishment of In Vitro and In Vivo Anticolorectal Cancer Efficacy of Lithocholic Acid-Based Imidazolium Salts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Hum | 2022 |
Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy by Narayan et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2022 |
Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost- | 2022 |
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fem | 2022 |
Simulating Colorectal Cancer Trials Using Real-World Data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop | 2022 |
Does dihydropyrimidine dehydrogenase level modify plasma antioxidant capacity in colorectal cancer patients treated with fluoropyrimidines?
Topics: Antimetabolites, Antineoplastic; Antioxidants; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NA | 2021 |
METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, | 2022 |
Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Flavanones; F | 2022 |
Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort Studies; Colorectal Neopl | 2022 |
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon a
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colonic Neoplasms; Colorecta | 2022 |
Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; | 2022 |
Investigation of
Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Methylenet | 2022 |
Kif4A mediates resistance to neoadjuvant chemoradiotherapy in patients with advanced colorectal cancer via regulating DNA damage response.
Topics: Cisplatin; Colorectal Neoplasms; DNA Damage; Fluorouracil; Humans; Kinesins; Neoadjuvant Therapy | 2022 |
Knockdown of circ_0004585 enhances the chemosensitivity of colorectal cancer cells to 5-fluorouracil via the miR-874-3p/CCND1 axis.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclin D1; Fluorouracil; Humans | 2023 |
Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Diseases, M | 2022 |
LINC02418 upregulates EPHA2 by competitively sponging miR-372-3p to promote 5-Fu/DDP chemoresistance in colorectal cancer.
Topics: Cisplatin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation | 2022 |
Development and validation of a cancer-associated fibroblast-derived lncRNA signature for predicting clinical outcomes in colorectal cancer.
Topics: Adenocarcinoma; Breast Neoplasms; Cancer-Associated Fibroblasts; Colorectal Neoplasms; Female; Fluor | 2022 |
SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Mitochondri | 2022 |
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2022 |
5-Fluorouracil drug delivery system based on bacterial nanocellulose for colorectal cancer treatment: Mathematical and in vitro evaluation.
Topics: Antineoplastic Agents; Biocompatible Materials; Colorectal Neoplasms; Delayed-Action Preparations; D | 2022 |
Provider imaging practices and outcomes of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2022 |
Anti-tumoral Effect of
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluoro | 2023 |
Functional Phosphoproteomics in Cancer Chemoresistance Using CRISPR-Mediated Base Editors.
Topics: Adenine; Amino Acids; Clustered Regularly Interspaced Short Palindromic Repeats; Colorectal Neoplasm | 2022 |
Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorect | 2022 |
Long-term resistance to 5-fluorouracil promotes epithelial-mesenchymal transition, apoptosis evasion, autophagy, and reduced proliferation rate in colon cancer cells.
Topics: Apoptosis; Autophagy; Cadherins; Cell Line, Tumor; Cell Proliferation; Claudin-3; Colonic Neoplasms; | 2022 |
Disulfiram increases the efficacy of 5-fluorouracil in organotypic cultures of colorectal carcinoma.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Copper; Disulfiram; Fluorouracil; Humans; Spheroids, Cellula | 2022 |
The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Deferoxamine; | 2022 |
2-Nucleobase-substituted 4,6-Diaminotriazine Analogs: Synthesis and Anti-cancer Activity in 5-Fluorouracil-sensitive and Resistant Colorectal Cancer Cells.
Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; | 2023 |
A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome.
Topics: Biomarkers, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Gene Expression Profiling; | 2022 |
Topics: 5' Untranslated Regions; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydr | 2023 |
Targeting mitochondrial tyrosyl-tRNA synthetase YARS2 suppresses colorectal cancer progression.
Topics: Adenosine Triphosphate; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Mutation; Reac | 2022 |
Novel therapeutic diiminoquinone exhibits anticancer effects on human colorectal cancer cells in two-dimensional and three-dimensional
Topics: Catenins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2022 |
Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal N | 2022 |
Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer.
Topics: Colorectal Neoplasms; Cross-Sectional Studies; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Hum | 2022 |
A serum metabolomics study based on LC-MS: Chemosensitization effects of Rauvolfia vomitoria Afzel. combined with 5- fluorouracil on colorectal cancer mice.
Topics: Animals; Cell Line, Tumor; Chromatography, Liquid; Colorectal Neoplasms; Fatty Acids; Fluorouracil; | 2022 |
Mast cell-T cell axis alters development of colitis-dependent and colitis-independent colorectal tumours: potential for therapeutically targeting via mast cell inhibition.
Topics: Animals; Colitis; Colorectal Neoplasms; Fluorouracil; Humans; Mast Cells; Mice | 2022 |
The Antitumor Effect of Timosaponin A3 through c-Myc Inhibition in Colorectal Cancer Cells and Combined Treatment Effect with 5-FU or Doxorubicin.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cholecalciferol; Colorectal Neop | 2022 |
Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorect | 2022 |
Managing life-threatening 5-fluorouracil cardiotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Camptothecin; Cardiotoxici | 2022 |
Lipid-polymer nanocarrier platform enables X-ray induced photodynamic therapy against human colorectal cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Folic Acid; Humans; Lip | 2022 |
Initiating Treatment with Low Fluorouracil Dose and Titrating According to Blood Levels in Patients Treated with a 46-Hour Continuous Infusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluor | 2023 |
[A Case of Unilateral Interstitial Lung Disease in a Patient Treated with Oxaliplatin, 5-Fluorouracil, and Leucovorin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Le | 2022 |
[A Case of BRAF V600E-Mutant Colorectal Cancer Treated Effectively by Encorafenib, Binimetinib, and Cetuximab Triple Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; | 2022 |
[A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; | 2022 |
Evaluation of the Effects of Genistein In Vitro as a Chemopreventive Agent for Colorectal Cancer-Strategy to Improve Its Efficiency When Administered Orally.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Genistein; Humans; Reactive Oxygen | 2022 |
Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coloni | 2023 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Colorectal Neopla | 2022 |
Modulating the activity of fluoropyrimidines against colorectal cancer by Vitamin D and its analogs.
Topics: Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Vitamin D | 2022 |
Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRAS
Topics: Colorectal Neoplasms; Fluorouracil; Glucose; Humans; Proto-Oncogene Proteins p21(ras); Tumor Suppres | 2022 |
A rapid high throughput bioprinted colorectal cancer spheroid platform for
Topics: Bioprinting; Cell Line; Colorectal Neoplasms; Fluorouracil; Humans; Oxaliplatin; Spheroids, Cellular | 2022 |
Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival times.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neo | 2022 |
Letter re: "Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer".
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Fluorouracil; Hu | 2022 |
Rapamycin Liposomes Combined with 5-Fluorouracil Inhibits Angiogenesis and Tumor Growth of APC
Topics: Animals; Azoxymethane; Colitis; Colorectal Neoplasms; Dextran Sulfate; Disease Models, Animal; Fluor | 2022 |
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials.
Topics: Bevacizumab; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hu | 2022 |
The
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Genotype; Humans | 2023 |
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Drug Resistance, Ne | 2023 |
5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2023 |
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota | 2022 |
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota | 2022 |
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota | 2022 |
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota | 2022 |
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota | 2022 |
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota | 2022 |
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota | 2022 |
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota | 2022 |
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota | 2022 |
Effect of 5-Fluoro-Uracile + Oxaliplatin chemotherapy on the histological response of PEritoneal and hePatIc corectal metasTases in a mOuse model: PEPITO experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Liver N | 2023 |
Effect of 5-Fluoro-Uracile + Oxaliplatin chemotherapy on the histological response of PEritoneal and hePatIc corectal metasTases in a mOuse model: PEPITO experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Liver N | 2023 |
Effect of 5-Fluoro-Uracile + Oxaliplatin chemotherapy on the histological response of PEritoneal and hePatIc corectal metasTases in a mOuse model: PEPITO experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Liver N | 2023 |
Effect of 5-Fluoro-Uracile + Oxaliplatin chemotherapy on the histological response of PEritoneal and hePatIc corectal metasTases in a mOuse model: PEPITO experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Liver N | 2023 |
Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colorectal Neopla | 2023 |
Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colorectal Neopla | 2023 |
Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colorectal Neopla | 2023 |
Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colorectal Neopla | 2023 |
5-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy.
Topics: Animals; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Fluorouracil; Hydrogen-Ion Conc | 2023 |
5-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy.
Topics: Animals; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Fluorouracil; Hydrogen-Ion Conc | 2023 |
5-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy.
Topics: Animals; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Fluorouracil; Hydrogen-Ion Conc | 2023 |
5-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy.
Topics: Animals; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Fluorouracil; Hydrogen-Ion Conc | 2023 |
Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cellulitis; Cetu | 2023 |
microRNA-143 interferes the EGFR-stimulated glucose metabolism to re-sensitize 5-FU resistant colon cancer cells via targeting hexokinase 2.
Topics: Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplas | 2023 |
LOXL2 reduces 5-FU sensitivity through the Hedgehog/BCL2 signaling pathway in colorectal cancer.
Topics: Amino Acid Oxidoreductases; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal | 2023 |
Enhancement of the antitumor effect of 5-fluorouracil with modulation in drug transporters expression using PI3K inhibitors in colorectal cancer cells.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Co | 2023 |
EIF3D promotes resistance to 5-fluorouracil in colorectal cancer through upregulating RUVBL1.
Topics: Animals; Apoptosis; ATPases Associated with Diverse Cellular Activities; bcl-2-Associated X Protein; | 2023 |
Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal | 2022 |
Assessment of patients' knowledge of their treatment with capecitabine at the National Institute of Oncology in Rabat.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms | 2023 |
Circ-ERBB2 knockdown sensitized colorectal cancer cells to 5-FU via miR-181a-5p/PTEN/Akt pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; MicroRNAs; Proto-O | 2023 |
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 2023 |
Folic-Acid-Conjugated Thermoresponsive Polymeric Particles for Targeted Delivery of 5-Fluorouracil to CRC Cells.
Topics: Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Fluorouracil; Folic Acid; Humans; Nanopa | 2023 |
New Transcriptomic Biomarkers of 5-Fluorouracil Resistance.
Topics: Biomarkers; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Membrane Proteins | 2023 |
Glochodpurnoid B from
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Endoplasmic Reticulum Stress; Fluorouracil; Human | 2023 |
Gamma-Aminobutyric Acid Type A Receptor Subunit Pi is a potential chemoresistance regulator in colorectal cancer.
Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplasti | 2023 |
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating MicroRNA; Colonic Neoplasm | 2023 |
Chitosan coated magnetic cellulose nanowhisker as a drug delivery system for potential colorectal cancer treatment.
Topics: Cellulose; Chitosan; Colorectal Neoplasms; Drug Delivery Systems; Drug Liberation; Fluorouracil; Hum | 2023 |
Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
[Hydroxysafflor yellow A inhibits proliferation, migration, and chemoresistance of colorectal cancer cells through Akt/mTOR-autophagy pathway].
Topics: Autophagy; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fl | 2023 |
[Cases of Advanced Colorectal Cancer with Nephrotic Syndrome after FOLFIRI plus Ramucirumab Administration].
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorec | 2022 |
[Two Cases of Stage Ⅳ Colorectal Cancer with Long-Term Survival following Single-Agent Chemotherapy with Capecitabine-A Case Reports].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuv | 2022 |
Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Drug Re | 2023 |
Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?
Topics: Adrenergic beta-Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Ne | 2023 |
[A Case of Liver Metastasis of Colorectal Cancer Successfully Treated with Hepatic Arterial Infusion Chemotherapy after Systemic Chemotherapy Was Difficult to Administer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2023 |
[FOLFIRI plus RAM Therapy in Later Line of Unresectable Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2023 |
Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2023 |
Beneficial Proapoptotic Effect of Heterobasidion Annosum Extract in Colorectal Cancer Xenograft Mouse Model.
Topics: Animals; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Ki-67 Antigen; Mic | 2023 |
The Gut Microbiota Metabolite Urolithin B Prevents Colorectal Carcinogenesis by Remodeling Microbiota and PD-L1/HLA-B.
Topics: Animals; B7-H1 Antigen; Carcinogenesis; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Gastr | 2023 |
STAT3 regulates 5-Fu resistance in human colorectal cancer cells by promoting Mcl-1-dependent cytoprotective autophagy.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, N | 2023 |
[Two Cases of Transfusion-Free Hepatectomy Following Chemotherapy for H3 Grade of Simultaneous Liver Metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Femal | 2023 |
METTL14-dependent maturation of pri-miR-17 regulates mitochondrial homeostasis and induces chemoresistance in colorectal cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; | 2023 |
The Novel 5-Fluorouracil Loaded Ruthenium-based Nanocarriers Enhanced Anticancer and Apoptotic Efficiency while Reducing Multidrug Resistance in Colorectal Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line | 2023 |
7
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Heterograf | 2023 |
A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model.
Topics: Administration, Oral; Animals; Colorectal Neoplasms; Fluorouracil; Rats; Tegafur; Uracil | 2023 |
Fasting-mimicking diet synergizes with ferroptosis against quiescent, chemotherapy-resistant cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fasting; Ferropto | 2023 |
Curcumol Reduces Aerobic Glycolysis and Overcomes Chemoresistance by Inducing Cdh1-Mediated Skp2 Ubiquitination.
Topics: Antigens, CD; Cadherins; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorour | 2023 |
Loss of exosomal miR-200b-3p from hypoxia cancer-associated fibroblasts promotes tumorigenesis and reduces sensitivity to 5-Flourouracil in colorectal cancer via upregulation of ZEB1 and E2F3.
Topics: Cancer-Associated Fibroblasts; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cell Transforma | 2023 |
Resveratrol Modulates Chemosensitisation to 5-FU via β1-Integrin/HIF-1α Axis in CRC Tumor Microenvironment.
Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; | 2023 |
Probiotic Supplementation Attenuates Chemotherapy-Induced Intestinal Mucositis in an Experimental Colorectal Cancer Liver Metastasis Rat Model.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Diarrhea; Fluorouracil; Male; Mucositis; Probi | 2023 |
TIMP-2 as a predictive biomarker in 5-Fu-resistant colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers; Cell Line, Tumor; Colorectal Neoplasms; Drug R | 2023 |
A Case of Heavily Pretreated HER2+ Colorectal Liver Metastases Responsive to Hepatic Arterial Infusion Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2023 |
Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study.
Topics: Colorectal Neoplasms; Drug Monitoring; Fluorouracil; Germany; Humans; Prospective Studies | 2023 |
Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids.
Topics: beta Catenin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Colonic Neopl | 2023 |
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent.
Topics: Antimetabolites; Colorectal Neoplasms; DNA; Enzyme Inhibitors; Fluorodeoxyuridylate; Fluorouracil; H | 2023 |
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
Topics: Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndrome; Humans; Imm | 2023 |
Effect of intra-operative chemotherapy with 5-fluorouracil and leucovorin on the survival of patients with colorectal cancer after radical surgery: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2023 |
Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Factors; Cetuximab; Colonic | 2023 |
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; | 2023 |
Alarmin IL-33 orchestrates antitumoral T cell responses to enhance sensitivity to 5-fluorouracil in colorectal cancer.
Topics: Alarmins; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; I | 2023 |
Relationship between anticancer sensitivities and cellular respiration properties in 5-fluorouracil-resistant HCT116 human colorectal cancer cells.
Topics: Adenosine Triphosphate; Cell Respiration; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluoroura | 2023 |
In vivo self-assembled small RNA targets H19 lncRNA for the treatment of colorectal cancer.
Topics: Animals; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; Lung Neoplasms; Mice; Micro | 2023 |
Hepatic arterial infusion with nanoliposomal irinotecan leads to significant regression of tumor size of colorectal liver metastases in a CC531 rat model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colonic N | 2023 |
Combination Therapy, Including Bevacizumab, for Advanced Colorectal Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neop | 2023 |
Tumor tropic delivery of FU.FA@NSs using mesenchymal stem cells for synergistic chemo-photodynamic therapy of colorectal cancer.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; Hydrogen Peroxi | 2023 |
Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Secretome | 2023 |
SNHG15 promotes chemoresistance and glycolysis in colorectal cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; | 2023 |
Knockdown of hnRNPAB reduces the stem cell properties and enhances the chemosensitivity of human colorectal cancer stem cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fl | 2023 |
Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells.
Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Disease Progression; Fluorouracil; Gene | 2023 |
Development and cytotoxicity evaluation of multiple nanoemulsions for oral co-delivery of 5-fluorouracil and short chain triglycerides for colorectal cancer.
Topics: Colorectal Neoplasms; Emulsions; Fluorouracil; Humans; Surface-Active Agents; Triglycerides; Viscosi | 2023 |
Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorect | 2023 |
Correlation between recurrence-free survival and overall survival after upfront surgery for resected colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diseas | 2023 |
[Educational Project of Self-Removal of the Intravenous Central Venous Access Port Guided by Patients with Advanced Colorectal Cancer Instructed by a Nurse in the University Hospital].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization, Central Venous; | 2023 |
Protein Kinase D1 Correlates with Less Lymph Node Metastasis Risk, Enhanced 5-FU Sensitivity, and Better Prognosis in Colorectal Cancer.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Prognosis; Protein Kinases | 2023 |
Liver cirrhosis following oxaliplatin-based adjuvant chemotherapy for rectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Chemotherapy, Adjuva | 2023 |
Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colonic N | 2023 |
XPF-ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colorectal Neoplasms; DN | 2023 |
Blastocystis sp. reduces the efficacy of 5-fluorouracil as a colorectal cancer chemotherapeutic treatment.
Topics: Animals; Blastocystis; Colorectal Neoplasms; Cysts; Fluorouracil; Humans; Male; Rats; Rats, Wistar | 2023 |
Initially unresectable colorectal liver metastases: the best therapeutic regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hum | 2023 |
Atorvastatin calcium alleviates 5-fluorouracil-induced intestinal damage by inhibiting cellular senescence and significantly enhances its antitumor efficacy.
Topics: Animals; Atorvastatin; Cellular Senescence; Colorectal Neoplasms; Endothelial Cells; Fluorouracil; H | 2023 |
Dual targeting of TGF-β and PD-L1 inhibits tumor growth in TGF-β/PD-L1-driven colorectal carcinoma.
Topics: B7-H1 Antigen; Colorectal Neoplasms; Fluorouracil; Humans; Transforming Growth Factor beta; Tumor Mi | 2023 |
Scutellaria baicalensis enhances 5-fluorouracil-based chemotherapy via inhibition of proliferative signaling pathways.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; Mice; Scu | 2023 |
Restoration of miR-650 leads to down-regulation of KISS1, a possible route involved in overcoming 5-FU resistance and induction of apoptosis in CRC cells in-vitro.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Drug Resista | 2023 |
CX43 down-regulation promotes cell aggressiveness and 5-fluorouracil-resistance by attenuating cell stiffness in colorectal carcinoma.
Topics: Cell Communication; Colorectal Neoplasms; Connexin 43; Connexins; Down-Regulation; Fluorouracil; Gap | 2023 |
Poor Prognosis in Patients With Stage III Colorectal Cancer Receiving Adjuvant FOLFOX/CAPOX Therapy Is Predicted by the Presence of Many Poorly Differentiated Clusters.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Neoplasm | 2023 |
Targeting PTGES/PGE2 axis enhances sensitivity of colorectal cancer cells to 5-fluorouracil.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinoprostone; Drug Resistance, Neoplasm; Fluorouracil; Human | 2023 |
Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer.
Topics: Abdominal Pain; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Human | 2023 |
Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Proteomics; | 2023 |
PCTAIRE Protein Kinase 1 (PCTK1) Suppresses Proliferation, Stemness, and Chemoresistance in Colorectal Cancer through the BMPR1B-Smad1/5/8 Signaling Pathway.
Topics: Bone Morphogenetic Protein Receptors, Type I; Cell Line, Tumor; Cell Proliferation; Colorectal Neopl | 2023 |
Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2023 |
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
The B56γ3-containing protein phosphatase 2A attenuates p70S6K-mediated negative feedback loop to enhance AKT-facilitated epithelial-mesenchymal transition in colorectal cancer.
Topics: Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Feedback; Fluorouracil; Humans; Phosphatidy | 2023 |
Evaluation and Comparison of Real-World Databases for Conducting Research in Patients With Colorectal Cancer.
Topics: Aged; Benchmarking; Colorectal Neoplasms; Databases, Factual; Female; Fluorouracil; Humans; Male; Me | 2023 |
Engineered multitargeting exosomes carrying miR-323a-3p for CRC therapy.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB | 2023 |
Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colonic Neoplasms; Colorecta | 2023 |
Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Interleukin-6; Liver Neoplasms; Organoids; Pentoxifyllin | 2023 |
Dermatan Sulfate/Chitosan Nanoparticles Loaded with an Anti-Inflammatory Peptide Increase the Response of Human Colorectal Cancer Cells to 5-Fluorouracil.
Topics: Anti-Inflammatory Agents; Cell Line, Tumor; Chitosan; Colorectal Neoplasms; Dermatan Sulfate; Fluoro | 2023 |
Inhibition of IRE1 RNase activity modulates tumor cell progression and enhances the response to chemotherapy in colorectal cancer.
Topics: Animals; Apoptosis; Colorectal Neoplasms; Endoribonucleases; Fluorouracil; Mice; Mice, Inbred BALB C | 2023 |
CRISPR/Cas9-mediated inactivation of miR-34a and miR-34b/c in HCT116 colorectal cancer cells: comprehensive characterization after exposure to 5-FU reveals EMT and autophagy as key processes regulated by miR-34.
Topics: Autophagy; Cell Line, Tumor; Colorectal Neoplasms; CRISPR-Cas Systems; Fluorouracil; Gene Expression | 2023 |
PAIP 2020: Microsatellite instability prediction in colorectal cancer.
Topics: Artificial Intelligence; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Instability; Pro | 2023 |
Propolis Enhances 5-Fluorouracil Mediated Antitumor Efficacy and Reduces Side Effects in Colorectal Cancer: An in Vitro and in Vivo Study.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; F | 2023 |
In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; bcl-2-Associated X Protein; Caspases; Colorectal Neo | 2023 |
Acetylation of aldehyde dehydrogenase ALDH1L2 regulates cellular redox balance and the chemosensitivity of colorectal cancer to 5-fluorouracil.
Topics: Acetylation; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Re | 2023 |
Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; | 2023 |
Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Col | 2023 |
Peficitinib ameliorates 5-fluorouracil-induced intestinal damage by inhibiting aging, inflammatory factors and oxidative stress.
Topics: Animals; Cellular Senescence; Colorectal Neoplasms; Fluorouracil; Humans; Intestinal Mucosa; Mice; M | 2023 |
SIRT1 promotes the progression and chemoresistance of colorectal cancer through the p53/miR-101/KPNA3 axis.
Topics: alpha Karyopherins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neo | 2023 |
Combined Hepatic Arterial Infusion Pump and Systemic Chemotherapy in the Modern Era for Chemotherapy-Naive Patients with Unresectable Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2023 |
Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Prod | 2023 |
ASO Visual Abstract: Combined Hepatic Artery Infusion Pump and Systemic Chemotherapy in the Modern Era for Chemotherapy-Naive Patients with Unresectable Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2023 |
Rebound increase in microRNA levels at the end of 5-FU-based therapy in colorectal cancer patients.
Topics: Circulating MicroRNA; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; MicroRNAs | 2023 |
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Capecitabine; Col | 2023 |
Tumor-associated macrophages confer colorectal cancer 5-fluorouracil resistance by promoting MRP1 membrane translocation via an intercellular CXCL17/CXCL22-CCR4-ATF6-GRP78 axis.
Topics: Activating Transcription Factor 6; Chemokines, CXC; Colorectal Neoplasms; Endoplasmic Reticulum Chap | 2023 |
Targeting transforming growth factor beta (TGF-β) using Pirfenidone, a potential repurposing therapeutic strategy in colorectal cancer.
Topics: Cadherins; Colorectal Neoplasms; Fluorouracil; Humans; Pyridones; Tumor Microenvironment | 2023 |
Vactosertib potently improves anti-tumor properties of 5-FU for colon cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; F | 2023 |
Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers.
Topics: Achyrocline; Animals; Carcinoma; Colonic Neoplasms; Colorectal Neoplasms; Drug Tapering; Fluorouraci | 2023 |
ASO Visual Abstract: Current Practices in Hepatic Artery Infusion (HAI) Chemotherapy-An International Survey of the HAI Consortium Research Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2023 |
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
LIMK1 m
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Flu | 2023 |
PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Chemotherapy, Adjuvan | 2023 |
scFv biofunctionalized nanoparticles to effective and safe targeting of CEA-expressing colorectal cancer cells.
Topics: Carcinoembryonic Antigen; Colorectal Neoplasms; Fluorouracil; Humans; Nanoparticles; Single-Chain An | 2023 |
Adjuvant Hepatic Artery Infusion Chemotherapy: Still Swimming in Dark Water?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2024 |
Expression of CD44 is regulated by ELF3 in 5-FU treated colorectal cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistance, Neoplasm; | 2024 |
The role of p62 in cell death and survival of 5-fluorouracil and oxaliplatin-resistant colorectal cancer cells.
Topics: Apoptosis; Cell Death; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorourac | 2023 |
Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo | 2023 |
In vitro co-delivery of 5-fluorouracil and all-trans retinoic acid by PEGylated liposomes for colorectal cancer treatment.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Lipopolysaccharides; Liposomes; Polyet | 2023 |
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Col | 2023 |
FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Colorectal Neoplasms; Fluorou | 2023 |
Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Protein-beta; Cell L | 2019 |
Laparoscopic versus open two-stage hepatectomy for bilobar colorectal liver metastases: A bi-institutional, propensity score-matched study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2019 |
Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
Green encapsulation of LDH(Zn/Al)-5-Fu with carboxymethyl cellulose biopolymer; new nanovehicle for oral colorectal cancer treatment.
Topics: Administration, Oral; Capsules; Carboxymethylcellulose Sodium; Colorectal Neoplasms; Drug Carriers; | 2019 |
Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Topics: Aged; Alternative Splicing; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Co | 2019 |
MCT1 relieves osimertinib-induced CRC suppression by promoting autophagy through the LKB1/AMPK signaling.
Topics: Acrylamides; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Aniline Compounds; | 2019 |
NSG mice as hosts for oncological precision medicine.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Huma | 2020 |
Colorectal Adenocarcinoma: Imaging using 5-Fluoracil Nanoparticles Labeled with Technetium 99 Metastable.
Topics: Adenocarcinoma; Colorectal Neoplasms; Fluorouracil; Humans; Nanoparticles; Radiopharmaceuticals; Tec | 2019 |
Dynamic Changes in Normal Liver Parenchymal Volume During Chemotherapy for Colorectal Cancer: Liver Atrophy as an Alternate Marker of Chemotherapy-Associated Liver Injury.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Bevacizumab | 2019 |
Downregulation of CD44v6 Enhances Chemosensitivity by Promoting Apoptosis and Inhibiting Autophagy in Colorectal Cancer HT29 Cells.
Topics: Apoptosis; Autophagy; Beclin-1; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Fluoroura | 2019 |
Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings.
Topics: Adult; Aged; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Middle Aged; N | 2019 |
Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Caco-2 Cells; Cell Survival; Colorectal Neoplasms; Drug | 2019 |
Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; | 2019 |
Impact of age on toxicity and efficacy of 5-FU-based combination chemotherapy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2019 |
CAC1 knockdown reverses drug resistance through the downregulation of P-gp and MRP-1 expression in colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily | 2019 |
Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sul | 2019 |
Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2019 |
In-Vivo Retention of 5-Fluorouracil Using
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Fluor | 2019 |
Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colorectal Neoplasms; Female; F | 2019 |
miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L.
Topics: Cell Line; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Drug Resista | 2019 |
Bacterial Biofilm Bioinspired Persistent Luminescence Nanoparticles with Gut-Oriented Drug Delivery for Colorectal Cancer Imaging and Chemotherapy.
Topics: Animals; Biofilms; Cell Line; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Diagnostic Imag | 2019 |
Evaluation of a new histological grading system for assessing the response to chemotherapy of peritoneal metastases from colorectal cancer: A mouse model study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Models, Anima | 2020 |
miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Cell | 2019 |
The clinical conundrum of managing 5-fluorouracil-induced vasospasm in colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neop | 2019 |
EMAST status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for Stage II/III colorectal cancer.
Topics: Aged; Chemotherapy, Adjuvant; Colon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorourac | 2020 |
Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line, Tumor; Colorecta | 2019 |
Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Fema | 2019 |
A novel therapeutic anti‑CD55 monoclonal antibody inhibits the proliferation and metastasis of colorectal cancer cells.
Topics: Antibodies, Monoclonal; CD55 Antigens; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Comp | 2019 |
RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance.
Topics: Animals; Cell Proliferation; Colorectal Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; | 2019 |
Multicentre study of perioperative
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2019 |
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; | 2019 |
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; | 2019 |
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; | 2019 |
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; | 2019 |
Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway.
Topics: Animals; Apoptosis; Base Sequence; Colorectal Neoplasms; Dichloroacetic Acid; Drug Resistance, Neopl | 2020 |
[Effectiveness of Allergy Regimen for Allergic Reactions to Oxaliplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Hypersensitivity; Fluorou | 2019 |
[A Case Altered Consciousness Due to 5-Fluorouracil-Induced Hyperammonemia in a Patient with Recurrent Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Consciousn | 2019 |
Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neopl | 2019 |
Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2020 |
Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Dose-Response | 2020 |
Ferritin Light Chain (FTL) competes with long noncoding RNA Linc00467 for miR-133b binding site to regulate chemoresistance and metastasis of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoferritins; Apoptosis; Binding Sites; Biomarkers, Tumor; | 2020 |
Solid lipid nanoparticles self-assembled from spray dried microparticles.
Topics: Administration, Oral; Aerosols; Caco-2 Cells; Cell Survival; Colorectal Neoplasms; Delayed-Action Pr | 2019 |
Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Evolution; Clinical Trials, Phase III as | 2020 |
Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2019 |
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2020 |
MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer.
Topics: Autophagy; Cell Proliferation; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Ge | 2019 |
Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carboxylic Ester Hydrolases; Colorectal Neoplasms; Disease-Free Surv | 2019 |
APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy.
Topics: Adenomatous Polyposis Coli; Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neop | 2020 |
Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Cell Proliferation; | 2019 |
Evaluation and Clinical Significance of Jagged-1-activated Notch Signaling by APEX1 in Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Co | 2019 |
BET inhibitor bromosporine enhances 5-FU effect in colorectal cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carbamates; Cell Cycle; Cell Cyc | 2020 |
[Primary appendiceal signet ring cell carcinoma:a case report].
Topics: Appendiceal Neoplasms; Carcinoma, Signet Ring Cell; Colorectal Neoplasms; Female; Fluorouracil; Huma | 2019 |
Cost-effectiveness analysis of selective first-line use of biologics for unresectable
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Produ | 2019 |
Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Caco-2 Cells; Cell Line, Tumor; Class I Phosphati | 2019 |
Identification of bioactive compounds in Lactobacillus paracasei subsp. paracasei NTU 101-fermented reconstituted skimmed milk and their anti-cancer effect in combination with 5-fluorouracil on colorectal cancer cells.
Topics: Antineoplastic Agents; Autophagy-Related Protein 5; Cell Line, Tumor; Cell Survival; Colorectal Neop | 2019 |
ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2019 |
Upregulated OCT3 has the potential to improve the survival of colorectal cancer patients treated with (m)FOLFOX6 adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Colorect | 2019 |
Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature.
Topics: Administration, Intravenous; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Glucocortico | 2020 |
PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; | 2020 |
Modified TLR-mediated downregulation of miR-125b-5p enhances CD248 (endosialin)-induced metastasis and drug resistance in colorectal cancer cells.
Topics: Antigens, CD; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; | 2020 |
LncRNA HAND2-AS1 inhibits 5-fluorouracil resistance by modulating miR-20a/PDCD4 axis in colorectal cancer.
Topics: Adenocarcinoma; Animals; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colorectal Neoplasms; Drug | 2020 |
Clerodane Diterpene Ameliorates Inflammatory Bowel Disease and Potentiates Cell Apoptosis of Colorectal Cancer.
Topics: Animals; Apoptosis; Azoxymethane; Biomarkers, Tumor; Caco-2 Cells; Cell Cycle; Cell Proliferation; C | 2019 |
Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Evaluation Studies as Topic; F | 2020 |
Knockdown of TMEM45A overcomes multidrug resistance and epithelial-mesenchymal transition in human colorectal cancer cells through inhibition of TGF-β signalling pathway.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, | 2020 |
LncRNA NEAT1 knockdown attenuates autophagy to elevate 5-FU sensitivity in colorectal cancer via targeting miR-34a.
Topics: 3' Untranslated Regions; Apoptosis; Autophagy; Autophagy-Related Proteins; Cell Proliferation; Cell | 2020 |
Atypical Protein Kinase-C inhibitors exhibit a synergistic effect in facilitating DNA damaging effect of 5-fluorouracil in colorectal cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Damage; DNA Fragmentation; DNA | 2020 |
Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colorectal Neopl | 2019 |
FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Auranofin; Cell Line, Tumor; Colorectal Neo | 2020 |
Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Colorectal Neopla | 2019 |
Promotion of the Warburg effect is associated with poor benefit from adjuvant chemotherapy in colorectal cancer.
Topics: Adult; Aged; Antioxidants; Carbohydrate Metabolism; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fe | 2020 |
Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK.
Topics: Animals; Caco-2 Cells; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neo | 2019 |
Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2020 |
Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuxi | 2019 |
Characterization of CD44-positive Cancer Stem-like Cells in COLO 201 Cells.
Topics: Animals; Biomarkers; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Cell Transformation, Neopla | 2020 |
A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
Cooperation of SRPK2, Numb and p53 in the malignant biology and chemosensitivity of colorectal cancer.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Disease Progre | 2020 |
Relaxin-FOLFOX-IL-12 triple combination therapy engages memory response and achieves long-term survival in colorectal cancer liver metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Interle | 2020 |
Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.
Topics: Adenomatous Polyposis Coli Protein; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bev | 2020 |
Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2020 |
A pre-existing population of ZEB2
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epit | 2020 |
Expression quantitative trait loci in ABC transporters are associated with survival in 5-FU treated colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Case-Contro | 2020 |
Prognostic and Diagnostic Values of miR-506 and SPON 1 in Colorectal Cancer with Clinicopathological Considerations.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Chemotherap | 2021 |
Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardio | 2020 |
SPZ1 promotes deregulation of Bim to boost apoptosis resistance in colorectal cancer.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bcl-2-Like Protein | 2020 |
Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Colorectal Neo | 2020 |
Hepatic arterial infusion chemotherapy for colorectal liver metastases revisited.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2020 |
Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Cell Line, Tumor; Cell Proliferation; Col | 2020 |
Synthesis, CYP24A1-Dependent Metabolism and Antiproliferative Potential against Colorectal Cancer Cells of 1,25-Dihydroxyvitamin D
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Synergism; Epit | 2020 |
Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect | 2020 |
EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
(Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, | 2020 |
Hyaluronic acid-decorated liposomal nanoparticles for targeted delivery of 5-fluorouracil into HT-29 colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Colorectal Neoplasms; Dr | 2020 |
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2020 |
Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Cetu | 2020 |
CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer.
Topics: Aged; Animals; Chemokine CXCL13; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorourac | 2020 |
Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cross-Sectional Studies; Femal | 2020 |
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neop | 2020 |
Knockdown of Atg7 Induces Nuclear-LC3 Dependent Apoptosis and Augments Chemotherapy in Colorectal Cancer Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 7; Beclin-1; | 2020 |
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur | 2020 |
5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Colorectal Neoplasms; Femal | 2020 |
Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2020 |
MicroRNA-375-3p enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neop | 2020 |
Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2020 |
S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Dihydrouracil Dehy | 2020 |
Nanocomplexes loaded with miR-128-3p for enhancing chemotherapy effect of colorectal cancer through dual-targeting silence the activity of PI3K/AKT and MEK/ERK pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Male; MAP Kina | 2020 |
Hepatic Arterial Infusion Chemotherapy of 5-Fluorouracil for Patients with Unresectable Liver Metastases from Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2020 |
Adjuvant therapy for colorectal cancer in 2020: has anything changed this millennium?
Topics: Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin | 2020 |
Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Biomarkers, Tumor; | 2020 |
Casein Kinase 2α Enhances 5-Fluorouracil Resistance in Colorectal Cancer Cells by Inhibiting Endoplasmic Reticulum Stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Casein Kinase II; Cell Line, Tumor; Colorectal Neopl | 2020 |
Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2020 |
Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Disease Models, A | 2020 |
CircDDX17 reduces 5-fluorouracil resistance and hinders tumorigenesis in colorectal cancer by regulating miR-31-5p/KANK1 axis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Carcinogenesis; Cell | 2020 |
Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Prot | 2020 |
Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplas | 2020 |
[A Case of Nephrotic Syndrome Induced by FOLFIRI plus Ramucirumab for Metastatic Descending Colon Cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2019 |
[Questionnaire Survey on Adjuvant Chemotherapy for Colorectal Cancer in Yamaguchi Prefecture].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2019 |
[Experience of Using Aflibercept Beta and FOLFIRI Chemotherapy for Metastatic Colorectal Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2019 |
Yeast Extract Induces Apoptosis and Cell Cycle Arrest via Activating p38 Signal Pathway in Colorectal Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Prol | 2020 |
IRX5 prompts genomic instability in colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumo | 2020 |
FOLFOXIRI reintroduction in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2020 |
Prodigiosin impairs autophagosome-lysosome fusion that sensitizes colorectal cancer cells to 5-fluorouracil-induced cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagosomes; Autophagy; Caco-2 Cells; Cell Death; Cell | 2020 |
Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Capecitabine; Carboxylesteras | 2020 |
Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Cape | 2020 |
Calebin A Potentiates the Effect of 5-FU and TNF-β (Lymphotoxin α) against Human Colorectal Cancer Cells: Potential Role of NF-κB.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line; Cell Proliferation; Cell Survival; C | 2020 |
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2020 |
Comparative lipidomics of 5-Fluorouracil-sensitive and -resistant colorectal cancer cells reveals altered sphingomyelin and ceramide controlled by acid sphingomyelinase (SMPD1).
Topics: Cell Line, Tumor; Ceramides; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Fluor | 2020 |
Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; | 2020 |
A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2020 |
Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal Cancer.
Topics: Cell Line, Tumor; Colectomy; Colon; Colorectal Neoplasms; CpG Islands; DNA Methylation; Drug Resista | 2020 |
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Campt | 2020 |
Association between aberrant dynein cytoplasmic 1 light intermediate chain 1 expression levels, mucins and chemosensitivity in colorectal cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytoplasmic Dyneins; F | 2020 |
Knockdown of the α5 laminin chain affects differentiation of colorectal cancer cells and their sensitivity to chemotherapy.
Topics: Antimetabolites, Antineoplastic; Cell Dedifferentiation; Colorectal Neoplasms; Fluorouracil; Gene Kn | 2020 |
TUSC3 induces drug resistance and cellular stemness via Hedgehog signaling pathway in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Prolifer | 2020 |
Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema | 2020 |
Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response.
Topics: Anthracyclines; Cell Proliferation; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Fluorour | 2020 |
Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study.
Topics: Antineoplastic Agents; Antiprotozoal Agents; Apoptosis; Caspases; Cell Cycle; Cell Survival; Colorec | 2020 |
Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Combined Therapeutic Effects of
Topics: Animals; Antimetabolites, Antineoplastic; Blood Circulation; Cell Line, Tumor; Cell Survival; Cetuxi | 2020 |
Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neopl | 2020 |
[Clinical Efficacy of mFOLFOX6 for Advanced Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Japan; L | 2020 |
Toosendanin-induced apoptosis in colorectal cancer cells is associated with the κ-opioid receptor/β-catenin signaling axis.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; A | 2020 |
[Perioperative Chemotherapies for Patients with Colorectal Liver Metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Combined Modality | 2020 |
Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Acids; Ce | 2020 |
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2020 |
Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2020 |
Defining Early Multidisciplinary Goals: NEXTO Trial in High-Risk Colorectal Cancer with Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Color | 2020 |
Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy.
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Binding Si | 2020 |
Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2020 |
TRIBE2 results and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2020 |
TRIBE2 results and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2020 |
Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colorectal Neoplasms; | 2020 |
[Three Cases of Augmented Chemotherapy-Induced Peripheral Neuropathy after Changing from mFOLFOX6 to FOLFIRI Therapy in Patients with Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2020 |
Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Sect | 2020 |
SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression.
Topics: Animals; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Fluoro | 2020 |
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2020 |
Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents, Immunological; Antineoplastic Combi | 2020 |
Effects of postoperative adjuvant chemotherapy and palliative chemotherapy on the gut microbiome in colorectal cancer.
Topics: Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Gastrointestinal Microbiom | 2020 |
5-Fluorouracil induced dysregulation of the microbiome-gut-brain axis manifesting as depressive like behaviors in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Behavior, Animal; Colorectal Neoplasms; Depression; Diseas | 2020 |
Splenic enlargement induced by preoperative chemotherapy is a useful indicator for predicting liver regeneration after resection for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hepatect | 2020 |
Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Color | 2020 |
Synergistic therapy with tangeretin and 5-fluorouracil accelerates the ROS/JNK mediated apoptotic pathway in human colorectal cancer cell.
Topics: Apoptosis; Cell Survival; Colorectal Neoplasms; DNA Fragmentation; Down-Regulation; Drug Synergism; | 2020 |
Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report.
Topics: Acneiform Eruptions; Adenocarcinoma; Administration, Topical; Aloe; Antineoplastic Agents; Antineopl | 2021 |
DJ‑1 is a new prognostic marker and predicts chemotherapy efficacy in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2020 |
Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2020 |
EGFR inhibition in colorectal cancer with liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB Receptors; Female; Fluoro | 2020 |
Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo | 2020 |
FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases.
Topics: Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Flu | 2020 |
CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; CCCTC-Binding Factor; Cell Proliferation; Color | 2020 |
[The development of a general drug resistance score model based on MIC
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Reg | 2020 |
NKX6.1 Represses Tumorigenesis, Metastasis, and Chemoresistance in Colorectal Cancer.
Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Transformation, Ne | 2020 |
The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms | 2020 |
Association of C677T and A1298C
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2020 |
Involvement of Corticotropin-releasing Hormone-related Peptides in Cellular Stress Caused by Anticancer Drugs in Colorectal Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Corticotropin-Releasing Hormone; Fluo | 2020 |
Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2020 |
Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; CDX2 Transcription Factor; Col | 2021 |
Age is an individual risk factor for not being referred to adjuvant chemotherapy in patients resected for UICC III colorectal cancer: a nationwide cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Colorectal N | 2020 |
FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2020 |
Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2020 |
Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm | 2021 |
Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-C | 2020 |
The Potential Anticancer Activity of 5-Fluorouracil Loaded in Cellulose Fibers Isolated from Rice Straw.
Topics: Antimetabolites, Antineoplastic; Cell Line; Cell Line, Tumor; Cellulose; Colorectal Neoplasms; Drug | 2020 |
ASO Author Reflections: Implementation of a New Hepatic Artery Infusion Program for Colorectal Liver Metastases is Safe, Feasible, and Effective.
Topics: Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplas | 2020 |
In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Topics: Animals; Colon; Colorectal Neoplasms; DNA Demethylation; Drug Resistance, Neoplasm; Female; Fluorour | 2020 |
Hedgehog-GLI signalling promotes chemoresistance through the regulation of ABC transporters in colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Cell Line, Tumor; Colorectal Ne | 2020 |
Addressing the variation in adjuvant chemotherapy treatment for colorectal cancer: Can a regional intervention promote national change?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2021 |
Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer.
Topics: Andrographis; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2020 |
Microsatellite instability and sensitivity to fluoropyrimidine and oxaliplatin containing first-line chemotherapy in metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2020 |
Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colore | 2021 |
Metformin Inhibited Proliferation and Metastasis of Colorectal Cancer and presented a Synergistic Effect on 5-FU.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colo | 2020 |
Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Capeci | 2021 |
5-Fluorouracil Rechallenge After Cardiotoxicity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Col | 2020 |
Circ_0007031 enhances tumor progression and promotes 5-fluorouracil resistance in colorectal cancer through regulating miR-133b/ABCC5 axis.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluoroura | 2020 |
Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2020 |
Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2020 |
Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Administration, Intravenous; Adolescent; Adult; Aged; Aged | 2020 |
Rapidly progressive interstitial lung disease under FOLFOX treatment for colorectal cancer associated with systemic sclerosis: two case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2021 |
Molecular mechanisms of liver damage during neoadjuvant treatment for hepatic metastases of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hum | 2020 |
Inhibition of semaphorin 4D enhances chemosensitivity by increasing 5-fluorouracile-induced apoptosis in colorectal cancer cells.
Topics: Antigens, CD; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorour | 2020 |
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; | 2020 |
Case report on 5-fluorouracil induced cerebrovascular accident.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal N | 2021 |
Hyperammonemia with impaired consciousness caused by continuous 5-fluorouracil infusion for colorectal cancer: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Consciousness; Female; F | 2020 |
The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Femal | 2021 |
Anti-tumor effect of single-chain antibody to Reg3a in colorectal cancer.
Topics: Animals; Antineoplastic Agents, Immunological; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Move | 2020 |
Genetic influence of
Topics: Administration, Oral; Capecitabine; Chromatography, Liquid; Colorectal Neoplasms; Dihydrouracil Dehy | 2020 |
Extrahepatic recurrence rates in patients receiving adjuvant hepatic artery infusion and systemic chemotherapy after complete resection of colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2020 |
Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; China; Colorectal Neoplas | 2020 |
Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo | 2020 |
Antitumor effects of curcumin on the proliferation, migration and apoptosis of human colorectal carcinoma HCT‑116 cells.
Topics: Animals; Apoptosis; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Curcumin; Fluorouracil; | 2020 |
The conversion of RAS status in metastatic colorectal cancer patients after first-line biological agent treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Factors; Cetuximab; Colorect | 2021 |
Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Colorectal Neoplasms; Drug | 2021 |
Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiopoietin-2; Antineoplastic Combined Chemothera | 2020 |
Inhibitory effect of bound polyphenol from foxtail millet bran on miR-149 methylation increases the chemosensitivity of human colorectal cancer HCT-8/Fu cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Proliferation; Colorectal Neoplasms; D | 2021 |
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Bi | 2021 |
Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subf | 2020 |
Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2021 |
5-FU inhibits migration and invasion of CRC cells through PI3K/AKT pathway regulated by MARCH1.
Topics: Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Female; Fl | 2021 |
MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression.
Topics: AC133 Antigen; Colorectal Neoplasms; DNA Methylation; DNA Mismatch Repair; DNA Modification Methylas | 2020 |
Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Extracellular Matrix; Extracel | 2020 |
Synergistic Antiproliferative Effect of Ribociclib (LEE011) and 5-Fluorouracil on Human Colorectal Cancer.
Topics: Aminopyridines; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; C | 2020 |
Lactobacillus-derived metabolites enhance the antitumor activity of 5-FU and inhibit metastatic behavior in 5-FU-resistant colorectal cancer cells by regulating claudin-1 expression.
Topics: Antimetabolites, Antineoplastic; Claudin-1; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Th | 2020 |
Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Drug De | 2020 |
Results from the PROPHYLOCHIP-PRODIGE 15 trial.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Peritoneal Neoplasms; Retrospective Studies | 2020 |
LncRNA NEAT1 remodels chromatin to promote the 5-Fu resistance by maintaining colorectal cancer stemness.
Topics: Cell Line, Tumor; Cell Proliferation; Chromatin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fe | 2020 |
Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema | 2021 |
What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2021 |
Thermosensitive hydrogels for local delivery of 5-fluorouracil as neoadjuvant or adjuvant therapy in colorectal cancer.
Topics: Alginates; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemotherapy, Adjuvant; Colorectal Neop | 2020 |
Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B | 2021 |
The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cohort S | 2021 |
HIF1α promotes tumor chemoresistance via recruiting GDF15-producing TAMs in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Cells, Cultured; Colorectal Neoplasms; Drug Resistance, Neoplasm; F | 2021 |
Use of spectral tracking technique to evaluate the changes in left ventricular function in patients undergoing chemotherapy for colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomechanical Phenomena; Cardiotoxicity; Colo | 2021 |
Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fem | 2021 |
Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Comb | 2020 |
Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluoroura | 2020 |
Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine | 2021 |
Epigenetically regulated gene expression profiles reveal four molecular subtypes with prognostic and therapeutic implications in colorectal cancer.
Topics: Biomarkers, Tumor; Cetuximab; Colorectal Neoplasms; DNA Methylation; DNA, Neoplasm; Epigenesis, Gene | 2021 |
Understanding the role of colon-specific microparticles based on retrograded starch/pectin in the delivery of chitosan nanoparticles along the gastrointestinal tract.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Chitosan; Colon; Colo | 2021 |
Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Cell Line, Tumor; | 2020 |
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu | 2021 |
Overexpression of sortilin is associated with 5-FU resistance and poor prognosis in colorectal cancer.
Topics: Adaptor Proteins, Vesicular Transport; Aged; Aged, 80 and over; Animals; Cell Line, Tumor; Colorecta | 2021 |
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2021 |
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2021 |
The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2021 |
Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Delayed-Acti | 2021 |
Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties.
Topics: Animals; Colorectal Neoplasms; Fluorouracil; Humans; Mice; Mice, Nude; Polymers | 2021 |
Three dimensional cultivation increases chemo- and radioresistance of colorectal cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Col | 2021 |
Antitumor Effect of 5-Fluorouracil-Loaded Liposomes Containing n-3 Polyunsaturated Fatty Acids in Two Different Colorectal Cancer Cell Lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasm | 2021 |
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Hepatocellular; C | 2021 |
Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cetuximab; Col | 2021 |
Novel quinazolinone MJ‑33 induces AKT/mTOR‑mediated autophagy‑associated apoptosis in 5FU‑resistant colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Survival; Colorectal Neop | 2021 |
Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2021 |
KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; | 2021 |
miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Col | 2021 |
Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Cost-Be | 2021 |
Suppression of Nanog inhibited cell migration and increased the sensitivity of colorectal cancer cells to 5-fluorouracil.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; C | 2021 |
Patient-derived organoids in cellulosic sponge model chemotherapy response of metastatic colorectal cancer.
Topics: Animals; Antineoplastic Agents; Cell Culture Techniques; Cells, Cultured; Collagen; Colorectal Neopl | 2021 |
Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
Topics: Adaptor Proteins, Signal Transducing; Animals; Annexin A5; Antineoplastic Combined Chemotherapy Prot | 2021 |
Predictive value of KRAS mutation and excision repair cross-complementing 1 (ERCC1) protein overexpression in patients with colorectal cancer administered FOLFOX regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Repair; DNA-Binding Protei | 2021 |
[Two Cases of Resectable Liver Metastasis from Colorectal Cancer with Pathological Complete Response after Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu | 2020 |
[Case Series of the TAS-102 plus Bevacizumab(Bev)Combination Therapy in Unresectable Advanced Colorectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations | 2020 |
[Laparoscopic Abdominoperineal Resection Following Intensive Chemotherapy for Stage Ⅳ Rectal Cancer with Unresectable Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2020 |
Delivery of Rapamycin by Liposomes Synergistically Enhances the Chemotherapy Effect of 5-Fluorouracil on Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colo | 2021 |
Who Will Benefit? Using Radiomics to Predict Response to Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Liver Ne | 2021 |
Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2020 |
In Reply: Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2020 |
Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Combi | 2021 |
In vitro anticancer activity of hydrogen sulfide and nitric oxide alongside nickel nanoparticle and novel mutations in their genes in CRC patients.
Topics: Alleles; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Mutationa | 2021 |
Lactobacillus Kefiri LKF01 (Kefibios
Topics: Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Diarrhea; Endpoint Determination; F | 2021 |
GABA-producing Lactobacillus plantarum inhibits metastatic properties and induces apoptosis of 5-FU-resistant colorectal cancer cells via GABA
Topics: Antineoplastic Agents; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; gam | 2021 |
Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Nano | 2021 |
FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which "Side" Are You On?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2021 |
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bio | 2021 |
Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Chroma | 2021 |
Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort | 2021 |
Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Ne | 2021 |
Impact of PIN1 Inhibition on Tumor Progression and Chemotherapy Sensitivity in Colorectal Cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Gene Expression | 2022 |
The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2021 |
[Construction of artificial neural network model for predicting the efficacy of first-line FOLFOX chemotherapy for metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2021 |
PTPN6 promotes chemosensitivity of colorectal cancer cells via inhibiting the SP1/MAPK signalling pathway.
Topics: Caco-2 Cells; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; HT29 Cell | 2021 |
Bilateral adrenal haematoma complicated by adrenal insufficiency in a patient treated with bevacizumab.
Topics: Adrenal Insufficiency; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neopl | 2021 |
Albumin-stabilized layered double hydroxide nanoparticles synergized combination chemotherapy for colorectal cancer treatment.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorec | 2021 |
Conversion therapy in patients with colorectal liver metastases.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineopl | 2021 |
Jiedu Sangen decoction inhibits chemoresistance to 5-fluorouracil of colorectal cancer cells by suppressing glycolysis via PI3K/AKT/HIF-1α signaling pathway.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Fluorourac | 2021 |
HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Cell Survival; Chemoth | 2021 |
Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Colorectal Neop | 2021 |
Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and witho
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Biomarkers, Tumor; Clini | 2021 |
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Consensus; Fluor | 2021 |
Exosome-Mediated Transfer of circ_0000338 Enhances 5-Fluorouracil Resistance in Colorectal Cancer through Regulating MicroRNA 217 (miR-217) and miR-485-3p.
Topics: Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; Drug Resistance, Neop | 2021 |
Combination of tumor cell anti-adhesion and anti-tumor effect to prevent recurrence after cytoreductive surgery in a mice model.
Topics: Animals; Antineoplastic Agents; Biological Availability; Colorectal Neoplasms; Combined Modality The | 2021 |
Effective chemotherapy and targeted therapy supplemented with stereotactic radiotherapy of a patient with metastatic colon cancer following renal transplantation: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diabetes Mell | 2021 |
Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2021 |
Inhibition of chaperone‑mediated autophagy reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Chaperone-Mediated Autophagy; Colorectal Neoplasms; | 2021 |
Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Calcium; Camptothecin; Colorectal Neopla | 2021 |
Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorecta | 2022 |
Co-administration of 5FU and propolis on AOM/DSS induced colorectal cancer in BALB-c mice.
Topics: Animals; Anti-Infective Agents; Antimetabolites, Antineoplastic; Azoxymethane; Carcinogens; Colorect | 2021 |
Inhibition of Human Uracil DNA Glycosylase Sensitizes a Large Fraction of Colorectal Cancer Cells to 5-Fluorodeoxyuridine and Raltitrexed but Not Fluorouracil.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Screening Assays, An | 2021 |
Topics: Colorectal Neoplasms; Coptis chinensis; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Fluorourac | 2021 |
Low curcumin concentration enhances the anticancer effect of 5-fluorouracil against colorectal cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Curcumin; Down-Regul | 2021 |
Andrographis overcomes 5-fluorouracil-associated chemoresistance through inhibition of DKK1 in colorectal cancer.
Topics: Andrographis; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Prolifera | 2021 |
Rare presentation of subglottic soft-tissue swelling following FOLFOX therapy in a patient with metastatic oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Esophageal Neoplasms; Fluorour | 2021 |
Prophylactic Administration of Recombinant Human Thrombopoietin in the Secondary Prevention of Thrombocytopenia Induced by XELOX Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo | 2021 |
A selective p53 activator and anticancer agent to improve colorectal cancer therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycl | 2021 |
Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway.
Topics: Animals; beta Catenin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fl | 2021 |
Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2021 |
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Bi | 2021 |
Tumor budding as a predictive marker for 5-fluorouracil response in adjuvant-treated stage III colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2021 |
Tenacissoside G synergistically potentiates inhibitory effects of 5-fluorouracil to human colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Lin | 2021 |
Vanillin downregulates NNMT and attenuates NNMT‑related resistance to 5‑fluorouracil via ROS‑induced cell apoptosis in colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzaldehydes; Cell Line, Tumor; Colorect | 2021 |
A438079 affects colorectal cancer cell proliferation, migration, apoptosis, and pyroptosis by inhibiting the P2X7 receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Movement; Cell Prolifera | 2021 |
The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; DNA | 2021 |
LncRNA ENSG00000254615 Modulates Proliferation and 5-FU Resistance by Regulating p21 and Cyclin D1 in Colorectal Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms | 2021 |
Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, | 2021 |
The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy.
Topics: Animals; Antimalarials; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Cel | 2021 |
A rare presentation of panitumumab-involved interstitial lung disease: Spontaneous pneumomediastinum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2021 |
Multiple stage IV colorectal cancers in a patient who received multidisciplinary treatment, including chemotherapy and Japanese Kampo medicine: A case report.
Topics: Adenocarcinoma; Aged; Bevacizumab; Colorectal Neoplasms; Drug Therapy; Fluorouracil; Humans; Japan; | 2021 |
Pulsatilla Decoction Combined with 5-Fluorouracil Triggers Immunogenic Cell Death in Colorectal Cancer Cells.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplas | 2022 |
Stability of calcium levofolinate, 5-fluorouracil and oxaliplatin (FOLFOX) mixture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium; Colorectal Neoplasms; Fluorouracil; Humans; | 2022 |
New Hybrids Based on Curcumin and Resveratrol: Synthesis, Cytotoxicity and Antiproliferative Activity against Colorectal Cancer Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; CHO | 2021 |
Sensitive High-Throughput Assays for Tumour Burden Reveal the Response of a
Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Colorectal Neoplasms; Drosophila mela | 2021 |
Mice with dysfunctional TGF-β signaling develop altered intestinal microbiome and colorectal cancer resistant to 5FU.
Topics: Animals; Antineoplastic Agents; Azoxymethane; Colon; Colorectal Neoplasms; Dextran Sulfate; Female; | 2021 |
Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camp | 2021 |
Benefit of intensive chemotherapy for elderly patients aged 80 years or older with metastatic colorectal cancer: a state-wide multicenter cohort study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal | 2021 |
Demethylzeylasteral Exerts Antitumor Effects
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Huma | 2022 |
Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2021 |
C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in Mestizo patients with metastatic colorectal cancer.
Topics: Case-Control Studies; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Genetic Predisposition | 2021 |
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2021 |
Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2021 |
Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Prolifer | 2021 |
[Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplasms; Consensus | 2021 |
MicroRNA-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expre | 2021 |
Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cos | 2021 |
5-FU resistant colorectal cancer cells possess improved invasiveness and β
Topics: Antineoplastic Agents; Cell Adhesion; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; | 2021 |
A Bioactive Compound from
Topics: Cell Death; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; F | 2021 |
Bioinspired silk fibroin nano-delivery systems protect against 5-FU induced gastrointestinal mucositis in a mouse model and display antitumor effects on HT-29 colorectal cancer cells
Topics: Colorectal Neoplasms; Fibroins; Fluorouracil; HT29 Cells; Humans; Mucositis | 2021 |
Prognostic Implications of Chemotherapy-Induced Neutropenia in Stage III Colorectal Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color | 2021 |
Anti-cancer effects of the aqueous extract of Orostachys japonica A. Berger on 5-fluorouracil-resistant colorectal cancer via MAPK signalling pathways in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Crassulaceae; | 2021 |
[Establishment of a Needle-Removal Method Considering Anticancer Drug Exposure after Continuous Administration of Fluorouracil Using an Infusion Pump].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2021 |
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Color | 2021 |
Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2021 |
Quercetin and Luteolin Improve the Anticancer Effects of 5-Fluorouracil in Human Colorectal Adenocarcinoma
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Luteolin; Q | 2022 |
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B | 2021 |
Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Cu | 2021 |
Risk of arterial and venous thromboembolic events among patients with colorectal carcinoma: a real-world, population-based study.
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Humans; Logistic Models; Male; | 2021 |
Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Colorectal Neoplasms; Epithelial-Mesen | 2021 |
Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colorectal N | 2021 |
The combined effect of dichloroacetate and 3-bromopyruvate on glucose metabolism in colorectal cancer cell line, HT-29; the mitochondrial pathway apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Co | 2021 |
Downregulation of miRNA-14669 Reverses Vincristine Resistance in Colorectal Cancer Cells through PI3K/AKT Signaling Pathway.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Fluor | 2022 |
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Case-Control Studies; Colorectal Neopla | 2021 |
Fluorouracil Bolus Use in Infusional Regimens Among Oncologists-A Survey by Brazilian Group of Gastrointestinal Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brazil; Colorectal Neoplasms; Cross-Sectional Studie | 2021 |
Chemosensitivity analysis and study of gene resistance on tumors and cancer stem cell isolates from patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; CD24 Antigen; Colorectal Neoplasms; Drug Resistance, | 2021 |
Knockdown of circNRIP1 sensitizes colorectal cancer to 5‑FU via sponging miR‑532‑3p.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proli | 2021 |
Primary Tumor-Related Complications Among Patients With Unresectable Stage IV Colorectal Cancer in the Era of Targeted Therapy: A Competing Risk Regression Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; | 2021 |
Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Cycle; Cell Proliferation; Cell Surv | 2021 |
Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Top | 2021 |
Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2017 |
Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Aspartate Aminotransferase, Cytoplasmic; Cell Line, Tumor; Cell Pro | 2017 |
MTA3 regulates malignant progression of colorectal cancer through Wnt signaling pathway.
Topics: Adult; Aged; Apoptosis; Carcinogenesis; Cell Proliferation; Colorectal Neoplasms; Cyclin D1; Cyclin | 2017 |
An apple oligogalactan enhances the growth inhibitory effect of 5-fluorouracil on colorectal cancer.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Drug | 2017 |
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Topics: Aged; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2017 |
High expression of atonal homolog 8 predicts a poor clinical outcome in patients with colorectal cancer and contributes to tumor progression.
Topics: Adult; Aged; Aged, 80 and over; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Cell | 2017 |
The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer.
Topics: Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Cell Proliferation; Colorectal | 2018 |
Down-regulation of long non-coding RNA RP11-708H21.4 is associated with poor prognosis for colorectal cancer and promotes tumorigenesis through regulating AKT/mTOR pathway.
Topics: Adult; Aged; Animals; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Movement; | 2017 |
Bacterial Metabolism Affects the C. elegans Response to Cancer Chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Caenorhabditis elegans; Camptothecin; Colorectal Neoplasms; Comamona | 2017 |
Host-Microbe Co-metabolism Dictates Cancer Drug Efficacy in C. elegans.
Topics: Animals; Antineoplastic Agents; Autophagy; Caenorhabditis elegans; Cell Death; Colorectal Neoplasms; | 2017 |
Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer.
Topics: Adenoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonoscopy; Colorectal Neop | 2018 |
Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2017 |
Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; ATPases Associated with Diverse Cellular Activities; Color | 2017 |
Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2017 |
Cisatracurium-induced proliferation impairment and death of colorectal cancer cells, HCT116 is mediated by p53 dependent intrinsic apoptotic pathway in vitro.
Topics: Apoptosis; Atracurium; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Fluorouraci | 2017 |
5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer.
Topics: Acetylation; Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chromatin; Colorect | 2017 |
MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells.
Topics: Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Drug Resi | 2017 |
Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2017 |
Secretion metabolites of probiotic yeast, Pichia kudriavzevii AS-12, induces apoptosis pathways in human colorectal cancer cell lines.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Caco-2 Cells; Caspase 3; Caspas | 2017 |
Hepatoprotective Effect of Carboxymethyl Pachyman in Fluorouracil-Treated CT26-Bearing Mice.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apopto | 2017 |
Effect of mTHPC-mediated photodynamic therapy on 5-fluorouracil resistant human colorectal cancer cells.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dose-Response Relati | 2017 |
Anti-angiogenic therapy with contrast-enhanced ultrasound in colorectal cancer patients with liver metastasis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Area Under Cur | 2017 |
Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism.
Topics: Cellular Reprogramming; Colonic Neoplasms; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistan | 2017 |
Musashi-1 promotes a cancer stem cell lineage and chemoresistance in colorectal cancer cells.
Topics: Biomarkers; Cell Line, Tumor; Cell Lineage; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluores | 2017 |
Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2017 |
Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicit | 2017 |
Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Cost-Benefit | 2017 |
MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cel | 2017 |
Enhancing 5-Fluorouracil Efficacy in a Primary Colorectal Cancer by Long-lasting Calcium Supplementation.
Topics: Animals; Antimetabolites, Antineoplastic; Calcium Compounds; Colorectal Neoplasms; Fluorouracil; Foc | 2017 |
Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Benzothiazo | 2017 |
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phas | 2017 |
Characterization of cancer stem cell drug resistance in the human colorectal cancer cell lines HCT116 and SW480.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Neoplastic | 2017 |
Assessment of neutralizing interleukin-4 effect on CD133 gene expression in colon cancer cell line.
Topics: AC133 Antigen; Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Prolif | 2017 |
Role of cyclooxygenase-2 inhibitors in the survival outcome of colorectal cancer patients: A population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect | 2017 |
A colon targeted drug delivery system based on alginate modificated graphene oxide for colorectal liver metastasis.
Topics: Alginates; Animals; Colon; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Glucuronic Aci | 2017 |
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; | 2017 |
AQP9-induced cell cycle arrest is associated with RAS activation and improves chemotherapy treatment efficacy in colorectal cancer.
Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Aquaporins; Cell Cycle Checkpoints; Cell Line, Tu | 2017 |
Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Topics: Activation, Metabolic; Administration, Oral; Animals; Antimetabolites, Antineoplastic; Colorectal Ne | 2017 |
Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells.
Topics: Chemoradiotherapy; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Re | 2017 |
Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colorectal Neoplasms; Female; Fluoro | 2019 |
Elevated Expression of ERCC6 Confers Resistance to 5-Fluorouracil and Is Associated with Poor Patient Survival in Colorectal Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Helicases; DNA Repair Enzymes; D | 2017 |
Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model.
Topics: Animals; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Carnosine; Cell Proliferation; Colorect | 2017 |
Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasm | 2017 |
Tumour growth increased following antiangiogenic interruption: the challenge of tumour evaluation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; F | 2017 |
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Organopl | 2017 |
Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm | 2018 |
Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells.
Topics: Animals; Apoptosis; Aptamers, Nucleotide; Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; Dow | 2017 |
WNT/β-Catenin Signaling Inhibitor IC-2 Suppresses Sphere Formation and Sensitizes Colorectal Cancer Cells to 5-Fluorouracil.
Topics: beta Catenin; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Gene Expression Regulation, Ne | 2017 |
Small-molecule CB002 restores p53 pathway signaling and represses colorectal cancer cell growth.
Topics: Aniline Compounds; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplas | 2017 |
Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2017 |
Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
Topics: 3' Untranslated Regions; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cel | 2017 |
Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2017 |
Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Case-Co | 2018 |
Therapeutic response assessment using 3D ultrasound for hepatic metastasis from colorectal cancer: Application of a personalized, 3D-printed tumor model using CT images.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2017 |
Chitosan-Coated Cinnamon/Oregano-Loaded Solid Lipid Nanoparticles to Augment 5-Fluorouracil Cytotoxicity for Colorectal Cancer: Extract Standardization, Nanoparticle Optimization, and Cytotoxicity Evaluation.
Topics: Antineoplastic Agents; Cell Survival; Chitosan; Cinnamomum zeylanicum; Colorectal Neoplasms; Drug Ca | 2017 |
Synergistic antitumor effect of 3-bromopyruvate and 5-fluorouracil against human colorectal cancer through cell cycle arrest and induction of apoptosis.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cyc | 2017 |
Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro.
Topics: Adenocarcinoma; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Melatonin | 2018 |
Evaluation of cytotoxic and antitumoral properties of Tessaria absinthioides (Hook & Arn) DC, "pájaro bobo", aqueous extract.
Topics: Animals; Antineoplastic Agents, Phytogenic; Asteraceae; Cell Line, Tumor; Colorectal Neoplasms; Dise | 2017 |
STRAP Promotes Stemness of Human Colorectal Cancer via Epigenetic Regulation of the NOTCH Pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Epigenesis, Genetic; Fluorouracil; HCT11 | 2017 |
Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; | 2017 |
Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2017 |
Raman endoscopy for monitoring the anticancer drug treatment of colorectal tumors in live mice.
Topics: Animals; Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Docetaxel; Endoscopy; Fluorouracil; | 2017 |
FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur | 2017 |
Bifidobacterium Infantis Ameliorates Chemotherapy-Induced Intestinal Mucositis Via Regulating T Cell Immunity in Colorectal Cancer Rats.
Topics: Animals; Antineoplastic Agents; Bifidobacterium longum subspecies infantis; Cell Line; Colorectal Ne | 2017 |
Scutellaria barbata D. Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neo | 2017 |
Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2017 |
Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febr | 2018 |
Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2017 |
Bioengineered Submucosal Organoids for In Vitro Modeling of Colorectal Cancer.
Topics: Acinar Cells; Animals; Bioengineering; Cell Line, Tumor; Collagen; Colorectal Neoplasms; Drug Resist | 2017 |
Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitab | 2017 |
Fluorescence-Guided Surgery in the Combined Treatment of Peritoneal Carcinomatosis from Colorectal Cancer: Preliminary Results and Considerations.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Coloring Agents; Co | 2018 |
Participation of CCL1 in Snail-Positive Fibroblasts in Colorectal Cancer Contribute to 5-Fluorouracil/Paclitaxel Chemoresistance.
Topics: 3T3 Cells; Animals; Cancer-Associated Fibroblasts; Cell Line, Tumor; Chemokine CCL1; Coculture Techn | 2018 |
Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuxim | 2017 |
XRCC2-Deficient Cells are Highly Sensitive to 5-Fluorouracil in Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Checkpoint Kinase | 2017 |
Early small bowel perforation due to aflibercept.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2017 |
Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothe | 2017 |
Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2017 |
Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway.
Topics: Aged; Apoptosis; Cell Proliferation; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistance, Ne | 2017 |
MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis.
Topics: 3' Untranslated Regions; Adenomatous Polyposis Coli Protein; Aged; Antimetabolites, Antineoplastic; | 2017 |
Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells.
Topics: Acrylamides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colorect | 2017 |
Low Concentration of 5-Fluorouracil Increases the Effectiveness of Tumor RNA to Activate Murine Dendritic Cells.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cancer Vaccines; | 2017 |
Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2017 |
Long-Term Outcomes After R0 Resection of Synchronous Peritoneal Metastasis from Colorectal Cancer Without Cytoreductive Surgery or Hyperthermic Intraperitoneal Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2018 |
Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemother | 2018 |
LOC285629 regulates cell proliferation and motility in colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Cell Proliferation; Colorectal Neoplasms; | 2018 |
Hedyotis diffusa Willd inhibits proliferation and induces apoptosis of 5‑FU resistant colorectal cancer cells by regulating the PI3K/AKT signaling pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Cell Survival; Colorect | 2018 |
The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Down-Regulation; Drug Res | 2018 |
Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Co | 2018 |
Preparation and Bioactivity Assessment of Chitosan-1-Acetic Acid-5-Flurouracil Conjugates as Cancer Prodrugs.
Topics: Acetic Acid; Animals; Antineoplastic Agents; Cell Line, Tumor; Chitosan; Colorectal Neoplasms; Fluor | 2017 |
Effect of AICAR and 5-Fluorouracil on X-ray Repair, Cross-Complementing Group 1 Expression, and Consequent Cytotoxicity Regulation in Human HCT-116 Colorectal Cancer Cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Apoptosis; | 2017 |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2017 |
DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bangladesh; Colorectal Neoplasms; Dihydrouracil Dehydr | 2018 |
In-depth phenotypic characterization of multicellular tumor spheroids: Effects of 5-Fluorouracil.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Spher | 2017 |
Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2017 |
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma | 2018 |
5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Corpus Callosum; Fluorouracil; Humans; | 2017 |
Therapeutic inhibition of SGK1 suppresses colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colo | 2017 |
Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Ch | 2017 |
Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Dose-Res | 2017 |
Cross-linked guar gum and sodium borate based microspheres as colon-targeted anticancer drug delivery systems for 5-fluorouracil.
Topics: Administration, Oral; Antineoplastic Agents; Borates; Colorectal Neoplasms; Delayed-Action Preparati | 2017 |
Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway.
Topics: Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Diterpenes; Dose-Response Relations | 2017 |
miR-200c as a Predictive Biomarker for 5-Fluorouracil Chemosensitivity in Colorectal Cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Drug Res | 2018 |
5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; H | 2018 |
Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Colorectal Neopl | 2018 |
Insulin-like growth factor 1 inhibits autophagy of human colorectal carcinoma drug-resistant cells via the protein kinase B/mammalian target of rapamycin signaling pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Colorectal Neoplasms; Drug | 2018 |
Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboxylesterase; Colorectal Neoplasms; DNA Topoisom | 2018 |
Up-regulation of UVRAG by HDAC1 Inhibition Attenuates 5FU-induced Cell Death in HCT116 Colorectal Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Cell Death; Colorectal Neoplasms; DNA Damage; Epigenesis, Genetic; | 2018 |
Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2018 |
Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLFOX Adjuvant Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2019 |
Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Differentiation; Cell Proliferati | 2018 |
[Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Thymidylate synthase: a predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment.
Topics: Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Regulation, Neoplasti | 2018 |
The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemica | 2018 |
Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Animals; Caspases; CD8-Positive T-Lymphocytes; Cell D | 2018 |
PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3/NF-kB/TP pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Datasets as Topic; Diseas | 2018 |
Loss of ABCB4 attenuates the caspase-dependent apoptosis regulating resistance to 5-Fu in colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cas | 2018 |
The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
Topics: Caco-2 Cells; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genotype; HCT116 Cells; HT29 Cells; | 2017 |
Effective Timing of Surgical Resection of Colorectal Cancer Liver Metastases During Chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cadherins; Cell Line, Tumor; Colorectal Neoplasms; E2F1 Tr | 2018 |
Knockdown of aquaporin-5 sensitizes colorectal cancer cells to 5-fluorouracil via inhibition of the Wnt-β-catenin signaling pathway.
Topics: Aquaporin 5; beta Catenin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Knock | 2018 |
[Four Cases of Locally Advanced Colorectal Cancer Resected after Neoadjuvant Chemotherapy with mFOLFOX6 plus Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu | 2017 |
Overexpression of CREPT confers colorectal cancer sensitivity to fluorouracil.
Topics: Adenoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Cell Cycle; | 2018 |
Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neopl | 2018 |
TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Ge | 2018 |
Nucleoside diphosphate kinase 2 confers acquired 5-fluorouracil resistance in colorectal cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Fluor | 2018 |
Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artifacts; Biological Transport; Cell Trans | 2018 |
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Cont | 2018 |
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cet | 2018 |
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colorectal Neoplasms; CpG Islands; DNA M | 2018 |
Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy.
Topics: Animals; Antagomirs; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Drug D | 2018 |
Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer.
Topics: Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leu | 2018 |
Prognostic Impact of R0 Resection and Targeted Therapy for Colorectal Cancer with Synchronous Peritoneal Metastasis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; | 2018 |
The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism.
Topics: ATP Binding Cassette Transporter, Subfamily B; Carcinoma; Cell Cycle; Cell Movement; Cell Proliferat | 2018 |
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2018 |
Correlation between CT morphologic appearance and histologic findings in colorectal liver metastasis after preoperative chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2018 |
β‑arrestin2 promotes 5‑FU‑induced apoptosis via the NF‑κB pathway in colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites; beta-Arrestin 2; Cell Line, Tumor; Cell Proliferation; Cel | 2018 |
DNA-based nanoscaffolds as vehicles for 5-fluoro-2'-deoxyuridine oligomers in colorectal cancer therapy.
Topics: Cell Line, Tumor; Cholesterol; Colorectal Neoplasms; Deoxyuridine; DNA; Drug Resistance, Neoplasm; F | 2018 |
GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
Topics: Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene | 2018 |
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
Topics: Activin Receptors, Type II; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2018 |
Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Drug Resistance, Neopl | 2018 |
Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture.
Topics: Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Hedgehog | 2018 |
Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells.
Topics: CDC2 Protein Kinase; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neoplasms; Fluorouracil; HCT116 | 2018 |
Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2018 |
Ubiquitin-Specific Peptidase 22 Contributes to Colorectal Cancer Stemness and Chemoresistance via Wnt/β-Catenin Pathway.
Topics: AC133 Antigen; Animals; beta Catenin; Caco-2 Cells; Cell Line, Tumor; Colorectal Neoplasms; Drug Res | 2018 |
Knockdown of long non‑coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells.
Topics: Adult; Aged; Biomarkers; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; | 2018 |
Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspase Inhibitors; Caspases; Cell | 2018 |
FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colorectal Neoplasms; Fatal Outcom | 2018 |
Fast-Track Two-Stage Hepatectomy Using a Hybrid Interventional Radiology/Operating Suite as Alternative Option to Associated Liver Partition and Portal Vein Ligation for Staged Hepatectomy Procedure.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Embolization | 2018 |
DNA methylation-mediated repression of miR-181a/135a/302c expression promotes the microsatellite-unstable colorectal cancer development and 5-FU resistance via targeting PLAG1.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; DNA-Binding Proteins | 2018 |
Anticancer and Antimigration Effects of a Combinatorial Treatment of 5-Fluorouracil and Lactobacillus paracasei subsp. paracasei NTU 101 Fermented Skim Milk Extracts on Colorectal Cancer Cells.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Movement; Cell Survival; Colorectal Neoplasms; Combi | 2018 |
Beta-elemene increases chemosensitivity to 5-fluorouracil through down-regulating microRNA-191 expression in colorectal carcinoma cells.
Topics: beta Catenin; Colorectal Neoplasms; Down-Regulation; Fluorouracil; Gene Expression Regulation, Neopl | 2018 |
Dihydroartemisinin potentiates antitumor activity of 5-fluorouracil against a resistant colorectal cancer cell line.
Topics: Antimalarials; Antimetabolites, Antineoplastic; Apoptosis; Artemisinins; Colorectal Neoplasms; Drug | 2018 |
Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2018 |
MiR-519d reduces the 5-fluorouracil resistance in colorectal cancer cells by down-regulating the expression of CCND1.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Cyclin D1; Down-Regulation; | 2018 |
Posterior Reversible Encephalopathy Syndrome (PRES) Presenting as Status Epilepticus: A Case Report and Literature Review.
Topics: Antihypertensive Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2016 |
Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2018 |
Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells.
Topics: Apoptosis; Azetidines; Cell Line, Tumor; Colorectal Neoplasms; Cyclin D1; Cyclin-Dependent Kinase In | 2018 |
Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrouracil Dehydrogenase | 2018 |
The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer.
Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Adult; Aged; Antineoplastic Combined Chem | 2018 |
How should BRAF V600E-mutated colorectal cancer be treated?
Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2018 |
Overcoming stemness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling.
Topics: Animals; Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Ne | 2018 |
Upregulation of HOXA10 Protein Expression Predicts Poor Prognosis for Colorectal Cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Chemotherapy, Adjuvant; Colorectal Neopl | 2018 |
Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin.
Topics: Antineoplastic Agents; Autophagy; Cell Survival; Colorectal Neoplasms; Flavonoids; Fluorouracil; HCT | 2018 |
Patrinia scabiosaefolia Inhibits Growth of 5-FU-Resistant Colorectal Carcinoma Cells via Induction of Apoptosis and Suppression of AKT Pathway.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorect | 2019 |
Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost- | 2018 |
Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fe | 2019 |
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect | 2018 |
Resveratrol Chemosensitizes TNF-β-Induced Survival of 5-FU-Treated Colorectal Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Ce | 2018 |
miR-106a Reduces 5-Fluorouracil (5-FU) Sensitivity of Colorectal Cancer by Targeting Dual-Specificity Phosphatases 2 (DUSP2).
Topics: 3' Untranslated Regions; Cell Line, Tumor; Cell Proliferation; Cell Survival; China; Colorectal Neop | 2018 |
Investigation of the relationship among fatigue, self-efficacy and quality of life during chemotherapy in patients with breast, lung or gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
Anti-angiogenic drug scheduling optimisation with application to colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Prolifera | 2018 |
Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2018 |
Investigation into Enhancing Capecitabine Efficacy in Colorectal Cancer by Inhibiting Focal Adhesion Kinase Signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Calcium Compounds; Capecitabine; Cell Line, | 2018 |
A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo.
Topics: A549 Cells; ADAM17 Protein; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Movement; Ce | 2018 |
Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor; | 2018 |
Bcl-2-associated athanogene 3(BAG3) is associated with tumor cell proliferation, migration, invasion and chemoresistance in colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antimetabolites, Antineoplastic; Apoptosis Regulatory Pr | 2018 |
A natural flavonoid lawsonaringenin induces cell cycle arrest and apoptosis in HT-29 colorectal cancer cells by targeting multiple signalling pathways.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prolife | 2018 |
A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2019 |
Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Turmeric extract, with absorbable curcumin, has potent anti-metastatic effect in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Curcuma; Curcumin; Fluoroura | 2018 |
Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevaciz | 2018 |
ZBTB7 evokes 5-fluorouracil resistance in colorectal cancer through the NF‑κB signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; DNA-Binding Protei | 2018 |
Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Arginase; Arginine; Argininosuccinate | 2018 |
Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells.
Topics: Acetylation; Animals; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Colorectal Neoplasms; DN | 2018 |
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2018 |
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2018 |
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2018 |
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2018 |
Crocin synergistically enhances the antiproliferative activity of 5-flurouracil through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer.
Topics: Animals; Antioxidants; Carotenoids; Cell Proliferation; Colitis; Colorectal Neoplasms; Dextran Sulfa | 2018 |
Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; | 2018 |
Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Antimetabolites, Antineoplastic; Cell Prolif | 2018 |
Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorecta | 2019 |
Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; CpG Islands; | 2018 |
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluo | 2018 |
Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil Dehydro | 2018 |
Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cetuximab; Colorectal Neoplasms; Female; | 2018 |
The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Biodiversity; Cell Line, Tumor; Colorectal Ne | 2018 |
Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemoth | 2019 |
Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Antifungal Agents; Antineoplastic Agents; Co | 2018 |
Safety evaluation of simultaneous resection of colorectal primary tumor and liver metastasis after neoadjuvant therapy: A propensity score matching analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
[Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2018 |
ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer.
Topics: Apoptosis; Carcinogenesis; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, | 2018 |
Colorectal cancer combination therapy using drug and gene co-delivered, targeted poly(ethylene glycol)-ε-poly(caprolactone) nanocarriers.
Topics: Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Carriers; Dr | 2018 |
Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2018 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Bi | 2019 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Bi | 2019 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Bi | 2019 |
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Bi | 2019 |
Effects of Adjuvant Chemotherapy on Cognitive Function of Patients With Early-stage Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; | 2019 |
A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Capecitabine; Colonic N | 2019 |
Nuclear factor I/B promotes colorectal cancer cell proliferation, epithelial-mesenchymal transition and 5-fluorouracil resistance.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms | 2019 |
A new chalcone derivative, 3-phenyl-1-(2,4,6-tris(methoxymethoxy)phenyl)prop-2-yn-1-one), inhibits phorbol ester-induced metastatic activity of colorectal cancer cells through upregulation of heme oxygenase-1.
Topics: Cell Movement; Cell Proliferation; Chalcone; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor | 2018 |
MiR-30-5p suppresses cell chemoresistance and stemness in colorectal cancer through USP22/Wnt/β-catenin signaling axis.
Topics: beta Catenin; Caco-2 Cells; Cell Line; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; D | 2019 |
Isoliquiritigenin-mediated p62/SQSTM1 induction regulates apoptotic potential through attenuation of caspase-8 activation in colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Cell Survival; Chalcones; Co | 2018 |
Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2019 |
Nrf2 is a key factor in the reversal effect of curcumin on multidrug resistance in the HCT‑8/5‑Fu human colorectal cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; | 2018 |
Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2018 |
Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance.
Topics: Animals; Antineoplastic Agents; Cell Dedifferentiation; Cell Proliferation; Cells, Cultured; Colorec | 2019 |
Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotox | 2019 |
Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2018 |
Neoadjuvant Capecitabine Results in Similar Total Lymph Node Harvests as 5-Fluorouracil but an Increased Number of Lymph Nodes Containing Adenocarcinoma on Resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colorectal | 2018 |
HER2 as a potential biomarker guiding adjuvant chemotherapy in stage II colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplas | 2019 |
Chemotherapy-induced
Topics: Animals; Apoptosis; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Progression; Dr | 2018 |
Laparoscopic repair of bevacizumab-induced vesicovaginal fistula in metastatic colon cancer - a video vignette.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cecal Neo | 2019 |
Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy.
Topics: Aged; Autophagy; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neopla | 2018 |
Chemotherapy-induced liver injury in metastatic colorectal cancer: about 48 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2018 |
Overexpression of miR-215-3p sensitizes colorectal cancer to 5-fluorouracil induced apoptosis through regulating CXCR1.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Dose-Response Relationshi | 2018 |
A Biodegradable Stent with Surface Functionalization of Combined-Therapy Drugs for Colorectal Cancer.
Topics: Absorbable Implants; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, T | 2018 |
5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cardiotoxicity; Cardiovascular Diseases | 2019 |
Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplasti | 2018 |
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembry | 2019 |
MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Butadienes; Cell Line, Tumor; Cell Survival; C | 2019 |
Autophagy facilitates anticancer effect of 5-fluorouracil in HCT-116 cells.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Cell Prolif | 2018 |
Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Drug Interaction | 2019 |
Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2019 |
[The inhibition of angiogenic pathway in second line treatment of metastatic colorectal cancer.]
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Campt | 2018 |
Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Topics: Acrylamides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Color | 2019 |
Exogenous interleukin-1α signaling negatively impacts acquired chemoresistance and alters cell adhesion molecule expression pattern in colorectal carcinoma cells HCT116.
Topics: Apoptosis; Cell Adhesion Molecules; Cell Cycle Checkpoints; Cell Shape; Colorectal Neoplasms; Down-R | 2019 |
SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherap | 2019 |
Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; D | 2019 |
Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Colorectal Neoplasms; Drug Resist | 2019 |
Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2019 |
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinica | 2019 |
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinica | 2019 |
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinica | 2019 |
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinica | 2019 |
Bacterial Ghosts Carrying 5-Fluorouracil: A Novel Biological Carrier for Targeting Colorectal Cancer.
Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Membrane; Cell Wall; Colorectal Neoplasms; Drug | 2019 |
Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal N | 2019 |
Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
Topics: Adult; Aged; Animals; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cell Line, Tumor; Cell | 2019 |
Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Cetuximab; Cohort Studies; | 2019 |
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2019 |
The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorecta | 2019 |
Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Stu
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Circadian Rhythm; Colorect | 2018 |
Serine Threonine Kinase 17A Maintains the Epithelial State in Colorectal Cancer Cells.
Topics: Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Epithelial Cel | 2019 |
Values of applying white blood cell counts in the prognostic evaluation of resectable colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Basophils; Capecitabine; Chemotherapy, | 2019 |
Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Differe | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer.
Topics: Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Hospitalization; Humans; Logistic Models | 2019 |
Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2019 |
Esculetin enhances the inhibitory effect of 5-Fluorouracil on the proliferation, migration and epithelial-mesenchymal transition of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell | 2019 |
Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco | 2019 |
[A Case of Complete Pathological Response of Unresectable Synchronous Colorectal Hepatic Metastasis with Icterus after FOLFOX plus Panitumumab Therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatecto | 2018 |
[A Case of Resistance to Systemic Therapy in Hypermutation of Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Le | 2018 |
Cepharanthine combined with 5-fluorouracil inhibits the growth of p53-mutant human colorectal cancer cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzylisoquinolines; Cell Line, | 2020 |
FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Co | 2019 |
A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents, Immunological; An | 2019 |
(-)-Epigallocatechin Gallate (EGCG) Enhances the Sensitivity of Colorectal Cancer Cells to 5-FU by Inhibiting GRP78/NF-κB/miR-155-5p/MDR1 Pathway.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Catechin; Colorectal Neoplasms; DNA Damage | 2019 |
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bio | 2019 |
SSRP1 promotes colorectal cancer progression and is negatively regulated by miR-28-5p.
Topics: Aged; Animals; Apoptosis; Cell Movement; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Diseas | 2019 |
Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer-a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2019 |
PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
Topics: Animals; B7-H1 Antigen; Cisplatin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HC | 2019 |
The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 | 2019 |
Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota.
Topics: Animals; Azoxymethane; Colitis; Colon; Colonic Neoplasms; Colorectal Neoplasms; Dextran Sulfate; Dis | 2019 |
High hepatic expression of PDK4 improves survival upon multimodal treatment of colorectal liver metastases.
Topics: Aged; Animals; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Down-Regulati | 2019 |
Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Caco-2 Cells; Cell Line, | 2019 |
PAR2 Inhibition Enhanced the Sensitivity of Colorectal Cancer Cells to 5-FU and Reduced EMT Signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Colorectal Neo | 2019 |
Down-regulation of miR-543 expression increases the sensitivity of colorectal cancer cells to 5-Fluorouracil through the PTEN/PI3K/AKT pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Colorect | 2019 |
ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield.
Topics: 1-Acylglycerol-3-Phosphate O-Acyltransferase; Animals; Antimetabolites, Antineoplastic; Autophagy; B | 2019 |
Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2019 |
Cysteine-rich intestinal protein 1 suppresses apoptosis and chemosensitivity to 5-fluorouracil in colorectal cancer through ubiquitin-mediated Fas degradation.
Topics: Animals; Apoptosis; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dr | 2019 |
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2019 |
Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Bevacizum | 2020 |
Effect of FOLFOX6 chemotherapy on serum VEGF expression in advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 2019 |
Guar gum modified upconversion nanocomposites for colorectal cancer treatment through enzyme-responsive drug release and NIR-triggered photodynamic therapy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Delayed-Action Preparations; Fluorouracil; Ga | 2019 |
p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2019 |
Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biological Availability; Cell Survival; Colorectal | 2019 |
Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Clo | 2019 |
Cloning, expression of the truncation of recombinant peroxidase derived from millet bran and its reversal effects on 5-Fu resistance in colorectal cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cloning, Molecular; Colorectal Neoplasms; Drug Resi | 2019 |
RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer.
Topics: Apoptosis; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Prognosis; R | 2019 |
Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydroxycholecalciferols; Down-Regulation; D | 2019 |
Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2019 |
Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells.
Topics: Animals; Cell Differentiation; Cell Proliferation; Cell Self Renewal; Colorectal Neoplasms; Enhancer | 2019 |
Sex-Dependent Adverse Drug Reactions to 5-Fluorouracil in Colorectal Cancer.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Asian People; Cell Line, Tumor; Cell Survival; Color | 2019 |
Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling.
Topics: Adult; Aged; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; | 2019 |
Cytoplasmic E-Cadherin Expression Is Associated With Higher Tumour Level of VEGFA, Lower Response Rate to Irinotecan-based Treatment and Poorer Prognosis in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2019 |
PGC-1α Controls Mitochondrial Biogenesis in Drug-Resistant Colorectal Cancer Cells by Regulating Endoplasmic Reticulum Stress.
Topics: Antioxidants; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Cytoprotection; Drug Resistance, Ne | 2019 |
Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Data Mining; Fluor | 2019 |
Central venous catheter misplaced in the epidural space.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Catheterization, Central Venous; Centra | 2019 |
Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Cu | 2019 |
Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models.
Topics: Animals; Antineoplastic Agents; Azoxymethane; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; | 2019 |
ROS/JNK/c-Jun axis is involved in oridonin-induced caspase-dependent apoptosis in human colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Colore | 2019 |
The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemoresistant Colorectal Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; | 2019 |
Antiproliferative Effects of Hop-derived Prenylflavonoids and Their Influence on the Efficacy of Oxaliplatine, 5-fluorouracil and Irinotecan in Human ColorectalC Cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Beer; Caco-2 Cells; Caspases | 2019 |
Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers; Cell Cycle; Cell Line, Tumor; Color | 2019 |
SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF.
Topics: Animals; Apoptosis Inducing Factor; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; CRIS | 2019 |
Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2019 |
Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell | 2019 |
Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer.
Topics: Animals; Aptamers, Nucleotide; Biomarkers, Pharmacological; Carcinoembryonic Antigen; Cell Adhesion; | 2019 |
Epigenetically Down-Regulated Acetyltransferase PCAF Increases the Resistance of Colorectal Cancer to 5-Fluorouracil.
Topics: Acetylation; Animals; Apoptosis; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Cyclin D1; | 2019 |
Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2019 |
Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2019 |
Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Cell Culture Techniques; Coculture Techniques; Colorectal Neoplasms | 2019 |
MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer.
Topics: Animals; Colorectal Neoplasms; Disease Models, Animal; DNA Mismatch Repair; Fluorouracil; Humans; Mi | 2019 |
Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; | 2019 |
Evaluating Immunotherapy in Nonmetastatic Colorectal Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che | 2019 |
Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells.
Topics: AC133 Antigen; Animals; Benzoquinones; beta Catenin; Cell Adhesion; Chick Embryo; Colorectal Neoplas | 2019 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; | 2019 |
In vivo effects of chemotherapy on oncogenic pathways in colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Proliferation; Colorec | 2019 |
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2019 |
Induced miR-31 by 5-fluorouracil exposure contributes to the resistance in colorectal tumors.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Drug Resis | 2019 |
Synergistic Effect of Combined Treatment with Longan Flower Extract and 5-Fluorouracil on Colorectal Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell S | 2020 |
Effects of 5-FU and anti-EGFR antibody in combination with ASA on the spherical culture system of HCT116 and HT29 colorectal cancer cell lines.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Autophagy; Cell Cyc | 2019 |
Synergistic effect of kaempferol and 5‑fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Fluorour | 2019 |
Theragnosis by a miR-141-3p molecular beacon: simultaneous detection and sensitization of 5-fluorouracil resistant colorectal cancer cells through the activation of the TRIM13-associated apoptotic pathway.
Topics: Antagomirs; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistance | 2019 |
Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1β secretion in 5-fluorouracil-treated MDSC: implication in cancer treatment.
Topics: Animals; Antineoplastic Agents; beta-Arrestin 2; Caspase 1; Cell Line, Tumor; Colorectal Neoplasms; | 2019 |
Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Folate pathway genes linked to mitochondrial biogenesis and respiration are associated with outcome of patients with stage III colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
Potent antitumor activity of Laccaic acid and Phenethyl isothiocyanate combination in colorectal cancer via dual inhibition of DNA methyltransferase-1 and Histone deacetylase-1.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2019 |
5-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Chemical and Drug Induced Liver Injury; Colorecta | 2019 |
Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemo | 2019 |
The long non-coding RNA HOTAIRM1 suppresses cell progression via sponging endogenous miR-17-5p/ B-cell translocation gene 3 (BTG3) axis in 5-fluorouracil resistant colorectal cancer cells.
Topics: Animals; Base Sequence; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; | 2019 |
Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine | 2019 |
Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chemotherapy, | 2019 |
IPO5 promotes the proliferation and tumourigenicity of colorectal cancer cells by mediating RASAL2 nuclear transportation.
Topics: Active Transport, Cell Nucleus; Adult; Aged; Animals; beta Karyopherins; Carrier Proteins; Cell Line | 2019 |
Inhibition of KHSRP sensitizes colorectal cancer to 5-fluoruracil through miR-501-5p-mediated ERRFI1 mRNA degradation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluo | 2020 |
Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Exosomes; Fl | 2019 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2019 |
A more physiological approach to lipid metabolism alterations in cancer: CRC-like organoids assessment.
Topics: Animals; Antineoplastic Agents; Coenzyme A Ligases; Colorectal Neoplasms; Down-Regulation; Fluoroura | 2019 |
Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Do | 2019 |
Efficacy and tolerability of adjuvant therapy in ≥70-year-old patients with T3N0M0 colorectal cancer: An observational study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2020 |
Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2019 |
Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Dise | 2019 |
Dietary methionine influences therapy in mouse cancer models and alters human metabolism.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Diet; Disease Models, Animal; Female; Fluorouracil; | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-β via their tumor-tropic effect in cellular and xenograft mouse models.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Engineering; Cell Line; Cell Line, Tumor; Colon; Colo | 2013 |
MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
Topics: Aged; Biomarkers, Pharmacological; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neo | 2013 |
Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Analysis of Variance; Angiogenesis Inhibitors; | 2013 |
Aflibercept.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl | 2013 |
Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2013 |
Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; Curcumi | 2013 |
The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer.
Topics: Adult; Aged; Apoptosis; Biomarkers, Tumor; Colorectal Neoplasms; Endoplasmic Reticulum Chaperone BiP | 2013 |
An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; Cation Transport | 2013 |
Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biom | 2013 |
Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II | 2013 |
The PEA-15/PED protein regulates cellular survival and invasiveness in colorectal carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; A | 2013 |
Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2013 |
[Panitumumab-induced trichomegaly].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin | 2013 |
Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2013 |
Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell | 2013 |
High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Line | 2013 |
Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; Caspas | 2013 |
Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort S | 2013 |
Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Analysis of Variance; Antimetabolites, Antineoplast | 2013 |
A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Survival; Colorectal Neoplasms; Drug Sc | 2013 |
5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Color | 2013 |
In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Camptothecin; Chemoradiotherapy; Colorectal Neoplasm | 2013 |
Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette | 2013 |
Unresectable colorectal liver metastases: the safety and efficacy of conversion therapy using hepatic arterial infusion immunochemotherapy with 5-fluorouracil and polyethylene glycol-interferon α-2a.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; | 2013 |
High-dose FOLFIRI, surgery, and radiofrequency ablation for patients with unresectable liver metastases from colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Abla | 2013 |
Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2013 |
Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); | 2013 |
Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colon; Colorectal Neoplasms; Dihydroura | 2013 |
The impact of glycemic levels in patients with colon cancer.
Topics: Antineoplastic Agents; Blood Glucose; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diet; Fluorourac | 2013 |
Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2014 |
[Secondary necrotizing fasciitis associated with panitumumab].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Causal | 2013 |
Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cell Cycle; Colorectal Neopla | 2013 |
MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland.
Topics: Adult; Aged; Amino Acid Substitution; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Ne | 2013 |
Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.
Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Combinat | 2013 |
Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2013 |
Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
[Changes of lymphocyte subsets before and after chemotherapy in colorectal carcinoma patients].
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
Identification of HOXB8 and KLK11 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Colorectal Neopla | 2013 |
Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2013 |
Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic | 2013 |
A novel aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment.
Topics: Animals; Aurora Kinase A; Aurora Kinases; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluoroura | 2013 |
Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2013 |
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cet | 2013 |
Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2013 |
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Will PICCOLO affect metastatic colorectal cancer therapy?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine | 2013 |
Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Design; D | 2013 |
miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.
Topics: 3' Untranslated Regions; Animals; Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Binding | 2013 |
Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; | 2014 |
DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity.
Topics: 5' Untranslated Regions; Antimetabolites, Antineoplastic; Carbohydrate Sulfotransferases; Colorectal | 2013 |
Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2013 |
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherap | 2013 |
Unusual ischemic complication of bevacizumab treatment for metastatic colorectal carcinoma.
Topics: Abdominal Pain; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Base Sequence; China; Colorectal Neoplasms; Dihydroura | 2013 |
Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neop | 2013 |
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2013 |
Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2013 |
Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Dr | 2013 |
Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biom | 2013 |
On 5-fluorouracil therapy of colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combine | 2013 |
A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrouracil Deh | 2013 |
Visualising and quantifying angiogenesis in metastatic colorectal cancer : A comparison of methods and their predictive value for chemotherapy response.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cape | 2013 |
Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic A | 2013 |
[Risk factors for hyperammonemia during mFOLFOX6 treatment].
Topics: Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Flu | 2013 |
Financial incentives in cancer care and impact on prescribing practice.
Topics: Aged; Antineoplastic Agents; Australia; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Pres | 2013 |
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2013 |
[Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2013 |
Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorecta | 2013 |
Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Tumor site- and stage-specific associations between allelic variants of glutathione S-transferase and DNA-repair genes and overall survival in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Topics: Alleles; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cohort Studies; Colorectal Neoplasms; D | 2013 |
Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients.
Topics: Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Ca | 2013 |
Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cell Proli | 2014 |
Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic | 2014 |
Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neop | 2014 |
Bilateral optic disc oedema and associated optic neuropathy in the setting of FOLFOX chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2013 |
STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Chemorad | 2014 |
Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug-Rela | 2013 |
Oxaliplatin-induced liver injury mimicking metastatic tumor on images: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagno | 2013 |
Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Flu | 2013 |
Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Potentiation of 5-fluorouracil encapsulated in zeolites as drug delivery systems for in vitro models of colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Carrier | 2013 |
The effects of silencing of PI3K p85α on 5-FU-induced colorectal cancer cells apoptosis.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Cell Li | 2013 |
Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2013 |
Noninvasive visualization of tumor growth in a human colorectal liver metastases xenograft model using bioluminescence in vivo imaging.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Models, Animal; Disease Prog | 2013 |
A 5-fluorouracil-loaded polydioxanone weft-knitted stent for the treatment of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Drug-Eluting Stents; Fluorour | 2013 |
Platinum-sensitivity in metastatic colorectal cancer: towards a definition.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease | 2013 |
Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Camptothecin; Col | 2013 |
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2013 |
Beyond exon 2--the developing story of RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB R | 2013 |
Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma.
Topics: Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Pressure; Carcino | 2013 |
[Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinic | 2013 |
Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2013 |
Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2013 |
Crohn's disease with worsening symptoms.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Colectomy; Colorectal Neoplasms; Combined Mo | 2013 |
Gastrointestinal cancer: AVEX: opportunities in elderly patients with mCRC.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; B | 2013 |
Polymorphisms of folate metabolism-related genes and survival of patients with colorectal cancer in the Korean population.
Topics: Aged; Asian People; Colorectal Neoplasms; Female; Fluorouracil; Folic Acid; Humans; Male; Metabolic | 2014 |
Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2013 |
Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne | 2013 |
The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemical and Drug Induced | 2013 |
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimeta | 2013 |
Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer.
Topics: Apoptosis; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Carcinogenesis; | 2014 |
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil.
Topics: Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Case-Control Stu | 2013 |
Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2013 |
Over-expression of the ATP5J gene correlates with cell migration and 5-fluorouracil sensitivity in colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Colorecta | 2013 |
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2013 |
Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2013 |
Notch1-dependent regulation of p27 determines cell fate in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Colorectal Neop | 2013 |
Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Cell L | 2014 |
Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Role of cyclin polymorphisms in predicting outcome of 5-fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle.
Topics: Colorectal Neoplasms; Cyclin D; Fluorouracil; Humans; Polymorphism, Single Nucleotide | 2013 |
The interplay between epigenetic silencing, oncogenic KRas and HIF-1 regulatory pathways in control of BNIP3 expression in human colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Hypoxia; Colorectal Neoplasms; DNA Methylation; Drug Resistanc | 2013 |
Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
C-reactive protein is a negative independent factor in patients with stage IV colorectal cancer undergoing oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
A small cog in a big wheel: PIK3CA mutations in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuv | 2013 |
Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2014 |
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptotic Protease-Activating Factor 1; B | 2014 |
Death associated protein 1 is correlated with the clinical outcome of patients with colorectal cancer and has a role in the regulation of cell death.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Mo | 2014 |
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cell Line, | 2014 |
Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer.
Topics: Acrolein; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cinnamomum aromaticum; Colo | 2014 |
Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Cohort Studies; | 2014 |
Effects of metformin on CD133+ colorectal cancer cells in diabetic patients.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Apoptosis; beta | 2013 |
TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; | 2014 |
Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2014 |
Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Cell Line, Tumor; CHO Cells; Cis | 2014 |
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2014 |
Predicting distant metastasis and chemoresistance using plasma miRNAs.
Topics: Antineoplastic Agents; Case-Control Studies; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female | 2014 |
[Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Topics: Abdominal Abscess; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2014 |
Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cass | 2014 |
Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2014 |
TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cell Differe | 2014 |
[Efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2013 |
Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2014 |
Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Calcium-Binding Proteins; Cell Line, Tumor; Cell | 2014 |
Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell L | 2014 |
Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas | 2014 |
[Assessment of host status in patients treated with mFOLFOX6 adjuvant chemotherapy after colorectal cancer surgery].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chemotherapy, Adjuvant | 2013 |
[Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2013 |
[Protocol for the administration of modified FOLFOX6 (mFOLFOX6) in patients with unresectable/recurrent colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2013 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2014 |
Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2014 |
Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Case-Contr | 2014 |
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Icariin-mediated inhibition of NF-κB activity enhances the in vitro and in vivo antitumour effect of 5-fluorouracil in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; | 2014 |
GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy.
Topics: Aged; Cell Death; Cell Line, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survi | 2014 |
Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohort Studies; Colorectal N | 2014 |
Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.
Topics: Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dela | 2014 |
Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; | 2014 |
Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resist | 2013 |
Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2014 |
Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinote
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Knockdown of astrocyte elevated gene-1 inhibits tumor growth and modifies microRNAs expression profiles in human colorectal cancer cells.
Topics: Base Sequence; Cell Adhesion Molecules; Cell Line, Tumor; Colorectal Neoplasms; DNA Primers; Fluorou | 2014 |
FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2014 |
Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Ce | 2014 |
How we treat metastatic colon cancer in older adults.
Topics: Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; An | 2013 |
Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Ch | 2014 |
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2014 |
Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplas | 2014 |
Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines.
Topics: Aged; Cell Line, Tumor; Colorectal Neoplasms; Disease-Free Survival; Epithelial-Mesenchymal Transiti | 2014 |
The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2014 |
Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarke | 2014 |
Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom | 2014 |
SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Drug Resi | 2014 |
Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; | 2014 |
Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Databases, Factual; Female; Fluorou | 2014 |
Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; D | 2014 |
Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.
Topics: Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Femal | 2014 |
Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2014 |
Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antibodies, Mono | 2014 |
Hepatocellular carcinoma and nodular regenerative hyperplasia after chemotherapy for metastatic colorectal carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colorectal Neoplasms; Drug Therapy; Fluorouracil; | 2014 |
Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 2014 |
Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Digestive | 2014 |
Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2014 |
Whole-liver radiotherapy concurrent with chemotherapy as a palliative treatment for colorectal patients with massive and multiple liver metastases: a retrospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Ascites; Bilirubin; Colorectal Neoplasms; Combined Modality T | 2014 |
FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2014 |
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; | 2015 |
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined | 2014 |
Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Dis | 2014 |
DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor | 2014 |
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Survival | 2014 |
Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2014 |
Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells.
Topics: Animals; Apolipoproteins A; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Endoplasmic Reticulum | 2014 |
[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine | 2013 |
Intradural tumor recurrence after resection of extradural metastasis: a rare but potential complication of intraoperative durotomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Colorectal Neoplasms; C | 2014 |
Bridge-to-surgery stent placement versus emergency surgery for acute malignant colonic obstruction.
Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Colonic Diseases; Color | 2014 |
A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Prognostic factors for metastatic colorectal cancer after first-line chemotherapy with FOLFOX-4 or FOLFIRI regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2014 |
Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region | 2014 |
A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2014 |
A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cell Phone; Colorectal | 2014 |
Role of SLC6A6 in promoting the survival and multidrug resistance of colorectal cancer.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; | 2014 |
Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2014 |
Overcoming the challenges of primary tumor management in patients with metastatic colorectal cancer unresectable for cure and an asymptomatic primary tumor.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Colonos | 2014 |
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined | 2015 |
First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Color | 2014 |
The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer:
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pr | 2014 |
Decreased ARID1A expression facilitates cell proliferation and inhibits 5-fluorouracil-induced apoptosis in colorectal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Color | 2014 |
RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2014 |
Maintenance therapy for colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2014 |
Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis | 2014 |
The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2014 |
Antitumor activity of electrospun polylactide nanofibers loaded with 5-fluorouracil and oxaliplatin against colorectal cancer.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; M | 2016 |
Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; b | 2014 |
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2014 |
miR-200 family in CRC primary tumors and metastases.
Topics: Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; MicroRNAs | 2014 |
Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neopla | 2014 |
Deregulation of miR-200b, miR-200c and miR-429 indicates its potential relevant role in patients with colorectal cancer liver metastasis.
Topics: Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; MicroRNAs | 2014 |
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
Beclin 1 and UVRAG confer protection from radiation-induced DNA damage and maintain centrosome stability in colorectal cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Cell Lin | 2014 |
Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2014 |
Gelam honey and ginger potentiate the anti cancer effect of 5-FU against HCT 116 colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Biological Factors; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2014 |
Epigenetic alterations are involved in the overexpression of glutathione S-transferase π-1 in human colorectal cancers.
Topics: Caco-2 Cells; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Epigenesis, Genetic; Fluorour | 2014 |
Effects of TachoSil and 5-fluorouracil on colonic anastomotic healing.
Topics: Anastomosis, Surgical; Animals; Antimetabolites; Colon; Colorectal Neoplasms; Drug Combinations; Fib | 2014 |
The synergistic effect of rapamycin combined with 5-fluorouracil in BALB/cByJNarl mice bearing CT-26 tumor cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell | 2014 |
Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2014 |
Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2014 |
Impact of liver-directed therapy in colorectal cancer liver metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheter Ablation; Colorec | 2014 |
Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2014 |
Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2014 |
Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2014 |
FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cold Temperatu | 2014 |
The role of adjuvant chemotherapy in stage II colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autonomic Nervou | 2014 |
Differential protein expression and novel biomarkers related to 5-FU resistance in a 3D colorectal adenocarcinoma model.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Chr | 2014 |
Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; | 2014 |
Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Austr | 2014 |
Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autocrine Communication; Cell | 2014 |
Unbiased proteomic and transcript analyses reveal that stathmin-1 silencing inhibits colorectal cancer metastasis and sensitizes to 5-fluorouracil treatment.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Colorectal Neoplasms; Epithelial-Mesenchymal Tr | 2014 |
Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2014 |
Cetuximab or bevacizumab in metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2014 |
Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2015 |
Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; | 2014 |
Capecitabine: toxic epidermal necrolysis and Stevens-Johnson syndrome.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hu | 2014 |
Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2015 |
[Retrospective analysis of the bevacizumab and CapeOX combination in untreated metastatic/recurrent colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
[Tolerability of XELOX in postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2014 |
Successful treatment with entecavir for reactivation of hepatitis B virus following systemic chemotherapy in a hepatitis B surface antigen-negative patient with colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Colorectal Neoplasms; Fluoro | 2014 |
[The efficacy and safety of FOLFIRI or combined FOLFIRI and bevacizumab treatment as second-line chemotherapy for metastatic colorectal cancer patients aged 75 years and older].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
[Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana | 2014 |
KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2014 |
UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2014 |
A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2014 |
Fatal outcome of posterior "reversible" encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2014 |
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizuma | 2014 |
Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Col | 2014 |
Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colo | 2014 |
Gene signatures of drug resistance predict patient survival in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; C | 2015 |
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2014 |
Aidi injection combined with FOLFOX4 chemotherapy regimen in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug-Related Side | 2014 |
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Focal Adhesion Kinase 1; He | 2014 |
Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Differentiati | 2014 |
Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2014 |
Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2014 |
SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition | 2014 |
Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Aspirin; Capecitabin | 2014 |
Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer.
Topics: AC133 Antigen; Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Pro | 2014 |
Knockdown of β3GnT8 reverses 5-fluorouracil resistance in human colorectal cancer cells via inhibition the biosynthesis of polylactosamine-type N-glycans.
Topics: Amino Sugars; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance | 2014 |
Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2014 |
Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2014 |
HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Colorectal Neoplasms; | 2014 |
Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy.
Topics: Adenomatous Polyposis Coli; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2014 |
Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2014 |
Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2015 |
Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response | 2014 |
Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Wester | 2014 |
Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A Pilot Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2017 |
Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2014 |
Frequent intragenic rearrangements of DPYD in colorectal tumours.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neopl | 2015 |
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl | 2015 |
Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fema | 2015 |
Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Safety and efficacy of radiofrequency ablation with aflibercept and FOLFIRI in a patient with metastatic colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colorectal Neoplasms; Comb | 2014 |
Effect of Smad3/4 on chemotherapeutic drug sensitivity in colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Survival; Colorectal Neoplasm | 2015 |
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 2015 |
[Function of death associated protein kinase(DAPK) in colorectal cancer chemoresistance].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Prol | 2014 |
Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2014 |
A 21-year-old patient with a HER2-positive colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2015 |
Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2015 |
MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; | 2015 |
Natural products and chemotherapeutic agents on cancer: prevention vs. treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Biologic | 2014 |
miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Down-Reg | 2015 |
FOLFOXIRI and bevacizumab in metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot | 2014 |
A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colecto | 2015 |
Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis.
Topics: Aberrant Crypt Foci; Animals; Antibodies, Blocking; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Lipoic acid induces p53-independent cell death in colorectal cancer cells and potentiates the cytotoxicity of 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Caspases; Cell Death; Cell Survival; Colorectal Neopl | 2015 |
CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5-fluorouracil.
Topics: Aged; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cell Adhesion Molecules; Cell Line, | 2015 |
Upregulation of CD147 promotes cell invasion, epithelial-to-mesenchymal transition and activates MAPK/ERK signaling pathway in colorectal cancer.
Topics: Basigin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal T | 2014 |
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co | 2014 |
Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
MicroRNA 196B regulates FAS-mediated apoptosis in colorectal cancer cells.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Caco-2 Cells; Case-Control Studies; Caspase 3; Cas | 2015 |
Always look at the bright side of drugs?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2015 |
MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.
Topics: Animals; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Flu | 2015 |
Inhibition of STAT3/cyclinD1 pathway promotes chemotherapeutic sensitivity of colorectal caner.
Topics: Aged; Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Cyclin D1; Drug Resistance, Neop | 2015 |
The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cell Culture Techniques; Cell Li | 2015 |
Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2015 |
Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Color | 2015 |
Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas.
Topics: Adenocarcinoma; Animals; Aptamers, Nucleotide; Chitosan; CHO Cells; Colorectal Neoplasms; Cricetinae | 2015 |
Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2015 |
FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2015 |
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2015 |
Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2015 |
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2015 |
The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoxazoles; Cadherins; Carrier Proteins; Cell Line, Tum | 2015 |
A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Campt | 2015 |
Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis".
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2015 |
Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; G | 2015 |
Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistan | 2015 |
[A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal | 2015 |
Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasm | 2016 |
Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cohort Studies; Colorectal Neo | 2015 |
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dih | 2015 |
Overexpression of DHX32 contributes to the growth and metastasis of colorectal cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carbonic Anhydrase IX; Carbonic Anhydrases; Ce | 2015 |
Use of extracorporeal membrane oxygenation for mechanical circulatory support in a patient with 5-fluorouracil induced acute heart failure.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Cardiotoxicity; Colorectal Neoplasms; Extrac | 2015 |
Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency.
Topics: Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Female; Fluorouraci | 2016 |
Validation of a fast and low-cost alkaline lysis method for gDNA extraction in a pharmacogenetic context.
Topics: Alkalies; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA, Neoplasm; Fluorouracil; Gen | 2015 |
Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neopla | 2015 |
[Incidence and management of adverse events in FOLFOX plus bevacizumab therapy for colorectal cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2015 |
Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore | 2015 |
Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Ne | 2015 |
Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Colorectal Neoplasms; Female; Fluoroura | 2015 |
KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort S | 2015 |
[Transfection of thymidine phosphorylase cDNA with lentiviral vector enhances the anticancer effect of 5'-deoxy-5-fluorouridine on colorectal cancer cell lines HT29 and LS174T].
Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; Colorectal Neoplasms; DNA, Complementary; Floxur | 2015 |
Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; | 2015 |
Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell | 2015 |
Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer.
Topics: Alginates; Animals; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Curcumin; Drug Synergism; F | 2015 |
Colorectal liver metastases: making the unresectable resectable using irreversible electroporation for microscopic positive margins - a case report.
Topics: Ablation Techniques; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neo | 2015 |
Growth inhibitory effect of polyunsaturated fatty acids (PUFAs) on colon cancer cells via their growth inhibitory metabolites and fatty acid composition changes.
Topics: Antimetabolites, Antineoplastic; Arachidonate 5-Lipoxygenase; Cell Line, Tumor; Colorectal Neoplasms | 2015 |
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA, Neoplasm; Drug Combinations; Equilibrati | 2015 |
5-Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neoplasms; DNA Breaks, Double | 2015 |
[Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Agents; Capecitabine; Colecto | 2015 |
Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer.
Topics: Aged; Animals; Apoptosis; Colorectal Neoplasms; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug R | 2015 |
Radiological Morphology of Colorectal Liver Metastases after Preoperative Chemotherapy Predicts Tumor Viability and Postoperative Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy | 2015 |
MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
Topics: Adenoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colorectal Neoplas | 2015 |
Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells.
Topics: Antineoplastic Agents; Chemoradiotherapy; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluoroura | 2015 |
Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting ABCF1.
Topics: Apoptosis; ATP-Binding Cassette Transporters; Base Sequence; Cell Line, Tumor; Cell Survival; Colore | 2015 |
miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms | 2015 |
Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cyt | 2015 |
Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor.
Topics: AC133 Antigen; Amyloid Precursor Protein Secretases; Animals; Antigens, CD; Antineoplastic Agents; C | 2015 |
Colorectal cancer: to stack or sequence therapy?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2015 |
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2015 |
Drug development: Mix and match.
Topics: Antineoplastic Agents; Cancer Vaccines; Colorectal Neoplasms; Drug Approval; Fluorouracil; Genes, ra | 2015 |
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarke | 2015 |
The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adju | 2015 |
Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool.
Topics: Administration, Intravenous; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabol | 2015 |
Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal | 2015 |
Vascular-targeted TNFα improves tumor blood vessel function and enhances antitumor immunity and chemotherapy in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow; Cell Line; Cell Line, Tumor; Cell-Penetrating | 2015 |
Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; C | 2015 |
Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
MiR-320e is a novel prognostic biomarker in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2015 |
Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.
Topics: Antineoplastic Agents; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cel | 2015 |
Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2015 |
MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; Drug Res | 2015 |
Time required to start multicentre clinical trials within the Italian Medicine Agency programme of support for independent research.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Breas | 2015 |
Chemotherapeutic treatment of colorectal cancer in pregnancy: case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 2015 |
Systemic capillary leak syndrome in a patient receiving adjuvant oxaliplatin for locally advanced colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Colorectal Neoplasms; Fluor | 2016 |
Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2015 |
ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2015 |
[The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2015 |
EGFR and β1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; ErbB R | 2015 |
The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2016 |
[Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Ne | 2015 |
Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Hum | 2015 |
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemic | 2015 |
Relationship between DNA repair gene XPD751 single-nucleotide polymorphisms and prognosis of colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Disease Progression; DNA Repair; Female; Fluorouracil; Genotype; | 2015 |
Suppression of KLF8 induces cell differentiation and sensitizes colorectal cancer to 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Transformat | 2015 |
Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Che | 2015 |
Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Expression of Folate Pathway Genes in Stage III Colorectal Cancer Correlates with Recurrence Status Following Adjuvant Bolus 5-FU-Based Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival; | 2015 |
A Study on Drug Interaction between Warfarin and Capecitabine with Special Reference to the Co-Administered Term or the Discontinuation Term of Capecitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neo | 2015 |
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2015 |
Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Gene Frequency; Genet | 2015 |
Decreased expression of PinX1 protein predicts poor prognosis of colorectal cancer patients receiving 5-FU adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Prote | 2015 |
Dissolution and degradation of Fmoc-diphenylalanine self-assembled gels results in necrosis at high concentrations in vitro.
Topics: Animals; Cell Survival; Colorectal Neoplasms; Dipeptides; Fluorenes; Fluorouracil; Humans; Hydrogels | 2015 |
Clinical Usefulness of 5-FU Metabolic Enzymes as Predictive Markers of Response to Chemotherapy in Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Female; Flu | 2016 |
[Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot | 2015 |
Truncating mutation in the autophagy gene UVRAG confers oncogenic properties and chemosensitivity in colorectal cancers.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Autophagy; Carcinogenesis; Cell Line, Tumor; | 2015 |
4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype.
Topics: 4-Butyrolactone; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pr | 2015 |
Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biocompatible Materials; Cell Line, Tumor; | 2015 |
MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm | 2015 |
Lithium Modulates Autophagy in Esophageal and Colorectal Cancer Cells and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; E | 2015 |
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials, Pha | 2016 |
Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2015 |
Therapeutic efficacy and toxicity of bolus application of chemotherapy protocol in the treatment of metastatic colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; H | 2015 |
Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neoplasms; Combined | 2015 |
Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil | 2016 |
PHD1 regulates p53-mediated colorectal cancer chemoresistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Chemoradiotherapy; Colorectal Neoplasms; Drug Resistance, | 2015 |
[Cost-effectiveness Analysis of Panitumumab Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 for First-line Treatment of Patients with Wild-type RAS Metastatic Colorectal Cancer--Czech Republic Model Adaptation].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neop | 2015 |
High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2016 |
Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer.
Topics: Alginates; Antimetabolites; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Pro | 2015 |
Predictive Significance of VEGF and HIF-1α Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2015 |
[Occurrence, intratumoral heterogeneity, prognostic and predictive potential of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases].
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bi | 2015 |
Downregulation of VMP1 confers aggressive properties to colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colore | 2015 |
Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
Topics: Adamantane; Animals; Antineoplastic Agents; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Fem | 2015 |
Maintenance therapy for metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; | 2015 |
Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation.
Topics: Animals; Caco-2 Cells; Cell Proliferation; Colorectal Neoplasms; DNA Damage; Fluorouracil; Gynostemm | 2015 |
The effect of 5-fluorouracil/leucovorin chemotherapy on CpG methylation, or the confounding role of leukocyte heterogeneity: An illustration.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; CpG Islands; DNA | 2015 |
Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette | 2015 |
Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; | 2016 |
Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neo | 2015 |
Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Pr | 2015 |
MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Binding S | 2015 |
Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo | 2015 |
Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chemothera | 2015 |
Clinical Usefulness of 5-FU Metabolic Enzymes as Predictive Markers of Response to Chemotherapy in Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Female; Flu | 2016 |
Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colitis, Microscopic; Colorecta | 2015 |
Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; D | 2015 |
Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caco-2 C | 2016 |
[Gastrointestinal surgeons should master the adjuvant therapy of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2015 |
Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2016 |
Autophagy is upregulated during colorectal carcinogenesis, and in DNA microsatellite stable carcinomas.
Topics: Apoptosis; Autophagy; Bevacizumab; Carcinogenesis; Chloroquine; Colorectal Neoplasms; Fluorouracil; | 2015 |
Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2015 |
In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.
Topics: Adenocarcinoma; Adenosine Triphosphate; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Anti | 2016 |
Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug | 2015 |
Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; | 2016 |
Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circad | 2015 |
Periostin expression in intra-tumoral stromal cells is prognostic and predictive for colorectal carcinoma via creating a cancer-supportive niche.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Adhesion Molecules; Cell Lin | 2016 |
Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Cell Line, Tumor; Colorec | 2015 |
[Prognostic Factors of Stage 3 Colorectal Cancer in 433 Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo | 2015 |
Absence of DAB2IP promotes cancer stem cell like signatures and indicates poor survival outcome in colorectal cancer.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; Epithelial-Mesenchyma | 2015 |
Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
[Influence of the Site of Port Insertion on the Flow Velocity of 5-FU Continuous Intravenous Injection by Using a Compression-Type Portable Continuous Infuser for Colorectal Cancer Patients].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2015 |
[Septic shock and Tissierella praeacuta].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cholecystitis | 2016 |
[Association between RIPK4 relative copy number and prognosis of colorectal cancer patient after oxaliplatin-based chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color | 2015 |
Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cape | 2015 |
5-Fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Del | 2016 |
The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cholesterol; Colorectal Neoplasms; Disease Models, | 2016 |
Fluorouracil-induced Hyperammonemia in a Patient with Colorectal Cancer.
Topics: Adult; Colorectal Neoplasms; Fluorouracil; Humans; Hyperammonemia; Male | 2015 |
Down-regulation of SNX1 predicts poor prognosis and contributes to drug resistance in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Colorec | 2016 |
Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade.
Topics: Animals; Apoptosis; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Proliferation; Chromones; Colo | 2016 |
A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2016 |
Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort St | 2018 |
MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Movement; Cell Prolifer | 2016 |
Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA- | 2016 |
Maintenance treatment in metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; | 2015 |
Maintenance treatment in metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; | 2015 |
Maintenance treatment in metastatic colorectal cancer - Authors' reply.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; | 2015 |
FOLFOX chemotherapy can safely be given to neutropenic patients with early-stage colorectal cancer for higher dose intensity and fewer visits.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropeni | 2016 |
The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Cell Line; Cell Li | 2016 |
[Impact of platelet count on prognosis of stage II-III colorectal cancer receiving adjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 2015 |
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2016 |
BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?
Topics: Adult; Aged; Aged, 80 and over; Australia; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabin | 2016 |
Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NAD | 2015 |
Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Class I | 2015 |
Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluorine Radioisotopes; | 2016 |
Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2016 |
A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling.
Topics: ADAM Proteins; ADAM17 Protein; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms | 2016 |
Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Centra | 2016 |
A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; C | 2015 |
Bevacizumab safety in Japanese patients with colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2016 |
B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; B7 Antigens; Biomarkers, Tumor; Blotting, Western; Cell | 2016 |
Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co | 2016 |
Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fl | 2016 |
Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ch | 2016 |
Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Dise | 2016 |
E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; E2F1 Transcription Factor; Fema | 2016 |
SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.
Topics: Adenosine Triphosphatases; Aged; Aged, 80 and over; Alcohol Oxidoreductases; Antineoplastic Combined | 2016 |
Early Prediction of Tumor Response to Treatment: Preclinical Validation of 99mTc-Duramycin.
Topics: Animals; Bacteriocins; Biological Transport; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluorou | 2016 |
Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach.
Topics: Antimetabolites, Antineoplastic; Caspase 3; Cell Proliferation; Colorectal Neoplasms; Female; Fluoro | 2016 |
miR-450b-5p Suppresses Stemness and the Development of Chemoresistance by Targeting SOX2 in Colorectal Cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Down-Regulatio | 2016 |
The hypoxia-mimetic agent CoCl₂ induces chemotherapy resistance in LOVO colorectal cancer cells.
Topics: bcl-2-Associated X Protein; bcl-Associated Death Protein; Cell Hypoxia; Cell Line, Tumor; Cell Proli | 2016 |
KCTD12 Regulates Colorectal Cancer Cell Stemness through the ERK Pathway.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Colorectal | 2016 |
Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
Topics: Adenosine Triphosphatases; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cohort Studies; Colorectal | 2016 |
Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Coronary Vasospasm; Fluorouracil; Humans; | 2016 |
Hepatic Arterial Infusion Chemotherapy for Life Threatening Patients due to Liver Metastases from Colorectal Cancer with Cetuximab.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal N | 2015 |
Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate and is an Indicator Of Hepatotoxicity In Patients Receiving FOLFOX for Colorectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemical and Drug Induced Liver In | 2015 |
Timing of adjuvant chemotherapy in colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brazil; Chemotherapy, Adjuvant; | 2016 |
Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cohort | 2015 |
Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Catechin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, N | 2016 |
Impact of novel histopathological factors on the outcomes of liver surgery for colorectal cancer metastases.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; C | 2016 |
The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; | 2016 |
High expression of Zinc-finger protein X-linked promotes tumor growth and predicts a poor outcome for stage II/III colorectal cancer patients.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caco-2 Cells; Cell Cycle Checkpoints; Cell Line | 2016 |
Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrouracil Dehydrogenas | 2016 |
Mechanistic study of the anti-cancer effect of Gynostemma pentaphyllum saponins in the Apc(Min/+) mouse model.
Topics: Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms | 2016 |
5-Fluorouracil induces apoptosis of colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; | 2016 |
Clinical and therapeutic significance of sirtuin-4 expression in colorectal cancer.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cell Survival; Colorectal Neoplasms; Drug Resistance | 2016 |
Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Colorectal Neopla | 2016 |
(64)Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133(+) cells in an HT-29 tumor model: Sensitization with a nucleic acid antimetabolite.
Topics: AC133 Antigen; Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Colorectal Neoplasms; C | 2016 |
Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clin | 2016 |
The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2016 |
Paricalcitol Enhances the Chemopreventive Efficacy of 5-Fluorouracil on an Intermediate-Term Model of Azoxymethane-Induced Colorectal Tumors in Rats.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azoxymethane; Blotting, Western; Carcinogen | 2016 |
Effect of Recepteur d'Origine Nantais expression on chemosensitivity and tumor cell behavior in colorectal cancer.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Lymphangiogenesis; Neovascu | 2016 |
Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Di | 2016 |
LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclic AMP Response | 2016 |
Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Camptothecin; Cetuximab; Colorecta | 2016 |
Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.
Topics: AC133 Antigen; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colon; Colorect | 2016 |
Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorect | 2016 |
Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2016 |
Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2016 |
Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorect | 2016 |
Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status.
Topics: Colorectal Neoplasms; DNA Mismatch Repair; Endodeoxyribonucleases; Fluorouracil; Frameshift Mutation | 2016 |
MnTnBuOE-2-PyP protects normal colorectal fibroblasts from radiation damage and simultaneously enhances radio/chemotherapeutic killing of colorectal cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senesc | 2016 |
MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1.
Topics: 3' Untranslated Regions; Animals; Antimetabolites, Antineoplastic; Cell Movement; Cell Proliferation | 2016 |
GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad | 2016 |
Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm | 2016 |
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2016 |
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; | 2016 |
Full-length LGR5-positive cells have chemoresistant characteristics in colorectal cancer.
Topics: Adenocarcinoma; Alternative Splicing; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Ce | 2016 |
Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2016 |
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2016 |
[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Anti-tumor and immunomodulatory activities of an exopolysaccharide from Rhizopus nigricans on CT26 tumor-bearing mice.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dru | 2016 |
Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity.
Topics: Animals; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistan | 2016 |
miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Fluor | 2016 |
B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu.
Topics: B7 Antigens; Cell Line, Tumor; Colorectal Neoplasms; Deubiquitinating Enzymes; DNA Damage; DNA Repai | 2016 |
Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2016 |
Reply to 'Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients' by C. Cremolini et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2016 |
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2016 |
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Campt | 2016 |
Incompatibility between irinotecan and fluorouracil injections.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas | 2016 |
[Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; C | 2016 |
Combination Therapy of Lactobacillus plantarum Supernatant and 5-Fluouracil Increases Chemosensitivity in Colorectal Cancer Cells.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Antigens, CD; Antineoplastic Agents; Apoptosis; Axin | 2016 |
MicroRNA-874 inhibits growth, induces apoptosis and reverses chemoresistance in colorectal cancer by targeting X-linked inhibitor of apoptosis protein.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Female; Fluo | 2016 |
Molecular correlates and prognostic value of tmTNF-α expression in colorectal cancer of 5-Fluorouracil-Based Adjuvant Therapy.
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Prognosis; Signal | 2016 |
Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2016 |
5-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRI.
Topics: Aged; Colorectal Neoplasms; Coronary Angiography; Diagnosis, Differential; Echocardiography; Female; | 2016 |
Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Compositio | 2016 |
Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorour | 2016 |
Combination treatment with flavonoid morin and telomerase inhibitor MST‑312 reduces cancer stem cell traits by targeting STAT3 and telomerase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Colorectal Ne | 2016 |
Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents; Cell Line; Colorectal Neoplasms; Flu | 2016 |
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Topics: Acetylation; Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; | 2016 |
Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female | 2016 |
[The Molecular Aspect of the Antitumor Effect of Oxaliplatin in Combination with 5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Gene Expression | 2016 |
When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neo | 2016 |
Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Drug Resista | 2016 |
Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.
Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expre | 2016 |
Last line therapy with sorafenib in colorectal cancer: A retrospective analysis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2016 |
Inhibition of phosphoserine phosphatase enhances the anticancer efficacy of 5-fluorouracil in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Enzy | 2016 |
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Topics: Administration, Intravenous; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Composition | 2016 |
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem | 2016 |
Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2016 |
Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bevacizumab; C | 2016 |
Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer.
Topics: Biomarkers, Tumor; Calnexin; Cell Death; Cell Survival; Clone Cells; Colorectal Neoplasms; Endoplasm | 2016 |
Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Epidural analgesia combined with a comprehensive physiotherapy program after Cytoreductive Surgery and HIPEC is associated with enhanced post-operative recovery and reduces intensive care unit stay: A retrospective study of 124 patients.
Topics: Analgesia, Epidural; Analgesia, Patient-Controlled; Antineoplastic Combined Chemotherapy Protocols; | 2016 |
MUC13 protects colorectal cancer cells from death by activating the NF-κB pathway and is a potential therapeutic target.
Topics: Animals; Antigens, Surface; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Cell Line, Tu | 2017 |
Anisomycin-induced GATA-6 degradation accompanying a decrease of proliferation of colorectal cancer cell.
Topics: Anisomycin; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; | 2016 |
MicroRNA-149 Increases the Sensitivity of Colorectal Cancer Cells to 5-Fluorouracil by Targeting Forkhead Box Transcription Factor FOXM1.
Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2016 |
Primary cultures of human colon cancer as a model to study cancer stem cells.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Colonic Neoplasms | 2016 |
ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
Topics: AC133 Antigen; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; ATP Binding Cassette Transpo | 2016 |
Glucose deprivation induces chemoresistance in colorectal cancer cells by increasing ATF4 expression.
Topics: Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Bi | 2016 |
Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; ATP-Binding Cassette Transporters; Colorectal Neoplasms; Dise | 2016 |
Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; F | 2016 |
TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Axl Receptor Tyrosine Kina | 2016 |
Robotic-Assisted Placement of an Hepatic Artery Infusion Pump and Catheter for Regional Chemotherapy of the Liver.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2016 |
Role of γ-glutamyl cyclotransferase as a therapeutic target for colorectal cancer based on the lentivirus-mediated system.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Disease Progression; Fluorouracil; gamma-Glutamyl | 2016 |
Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Colorectal Neoplasms; Drug Resistanc | 2016 |
Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cancer-Associated Fibroblasts; Cell Line, Tumor; Colorectal Neopla | 2016 |
Decellularized matrices as in vitro models of extracellular matrix in tumor tissues at different malignant levels: Mechanism of 5-fluorouracil resistance in colorectal tumor cells.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Cell Proliferation; | 2016 |
Capecitabine and the Risk of Fingerprint Loss.
Topics: Capecitabine; Carcinoma, Hepatocellular; Colorectal Neoplasms; Dermatoglyphics; Female; Fluorouracil | 2017 |
The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients treated with targeted agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 2016 |
Knockdown of FOXK1 alone or in combination with apoptosis-inducing 5-FU inhibits cell growth in colorectal cancer.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Fluorourac | 2016 |
FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuxi | 2016 |
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2016 |
Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine | 2016 |
Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2016 |
Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Colorectal Neo | 2016 |
Response to 'Comment on 'The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome''.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Veno-Occ | 2016 |
Glucose-regulated protein 78 contributes to the proliferation and tumorigenesis of human colorectal carcinoma via AKT and ERK pathways.
Topics: Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Co | 2016 |
Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Dihydrouracil | 2016 |
Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bili | 2017 |
CD133+CD24lo defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CD24 Anti | 2016 |
Bevacizumab in colorectal cancer: it should have worked.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bev | 2016 |
Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2016 |
Peritoneal Carcinomatosis in Colorectal Cancers - Management Perspective Needs a Change.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modalit | 2017 |
The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2016 |
Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell | 2016 |
The A
Topics: Adenosine A2 Receptor Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2016 |
Gold nanoparticles enhance 5-fluorouracil anticancer efficacy against colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Drug Delivery Systems; Drug Libera | 2016 |
Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; CD | 2016 |
Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2017 |
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2017 |
Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; CpG Islands; DNA Met | 2016 |
Microsatellite instability & survival in patients with stage II/III colorectal carcinoma.
Topics: Adult; Aged; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; H | 2016 |
Gap junction composed of connexin43 modulates 5‑fluorouracil, oxaliplatin and irinotecan resistance on colorectal cancers.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Connexin | 2016 |
Interstitial lung disease caused by oxaliplatin. An uncommon but not unknown complication.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2017 |
Use of 5-Fluorouracil Loaded Micelles and Cisplatin in Thermosensitive Chitosan Hydrogel as an Efficient Therapy against Colorectal Peritoneal Carcinomatosis.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmac | 2017 |
Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.
Topics: Amphiregulin; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu | 2016 |
Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal | 2016 |
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorecta | 2017 |
[Difference analysis of chemotherapy efficacy among different primary tumor sites in metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Colon, Transvers | 2016 |
Anti-EGFR antibody sensitizes colorectal cancer stem-like cells to Fluorouracil-induced apoptosis by affecting autophagy.
Topics: AC133 Antigen; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cetuximab; Colo | 2016 |
Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression.
Topics: Animals; Antimetabolites, Antineoplastic; beta Catenin; Cell Movement; Cell Proliferation; Colorecta | 2016 |
Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Proliferation; Colorectal Neoplasms; Drug Resista | 2016 |
53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Checkpoint Kinase 2; Colorectal | 2017 |
5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2017 |
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemo | 2016 |
Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Male; Mi | 2016 |
Restoration of the tumor-suppressor function to mutant p53 by Ganoderma lucidum polysaccharides in colorectal cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Fluoro | 2017 |
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem | 2017 |
Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution.
Topics: Administration, Intravenous; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Chloride | 2017 |
Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 12; Colorectal Neoplasms; Com | 2016 |
Preparation and characterization of polymeric nanoparticles surface modified with chitosan for target treatment of colorectal cancer.
Topics: Chitosan; Colorectal Neoplasms; Drug Liberation; Fluorouracil; HT29 Cells; Humans; Kinetics; Nanopar | 2017 |
BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB Receptors; F | 2017 |
Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chronic Disease | 2017 |
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2017 |
Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Cell Line, Tumor; Colorectal Neo | 2016 |
Induction of hypoxia and necrosis in multicellular tumor spheroids is associated with resistance to chemotherapy treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Hypoxia; Colorectal Neoplasms; Drug Resistance, Neopl | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
[Aflibercept: focus on tolerability.]
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2016 |
Elevated expression of TrpC5 and GLUT1 is associated with chemoresistance in colorectal cancer.
Topics: Aged; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene | 2017 |
Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Calcium Compounds; Cell Death; Ce | 2017 |
"
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cecal | 2016 |
5-Fluorouracil inhibits cell migration by induction of Sestrin2 in colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Antioxidants; Benzothiazoles; Cell Movement; Colorectal Neoplasms; | 2017 |
Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorec | 2017 |
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic | 2017 |
Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells.
Topics: Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Gene | 2018 |
WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomarkers, Tumor; Cell L | 2017 |
FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Binding Sites; Colorectal Neoplasms; Dose-Respo | 2017 |
Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2017 |
Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
Topics: Actins; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana | 2017 |
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
Topics: Acid Phosphatase; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B | 2017 |
FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2017 |
Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuxi | 2017 |
Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer.
Topics: Aged; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplas | 2017 |
Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; | 2017 |
Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Pharmacological; Cell Cycle; | 2017 |
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort S | 2017 |
Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
Topics: Biomarkers, Tumor; Carcinogenesis; Cell Death; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluo | 2017 |
A New Technique of Radiofrequency-assisted Ultrasound-guided Needle-localized Laparoscopic Resection of Disappearing Colorectal Liver Metastases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Catheter Ablation | 2017 |
microRNA-577 suppresses tumor growth and enhances chemosensitivity in colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; China; Colorectal | 2017 |
Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2017 |
CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through enhancing autophagy in colorectal cancer.
Topics: Adenomatous Polyposis Coli Protein; Animals; Apoptosis; Autophagy; Base Sequence; Cell Line, Tumor; | 2017 |
Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cetuximab; Colorectal Neop | 2017 |
Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.
Topics: Aged; Ammonia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta | 2017 |
Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance.
Topics: Amino Acids; Apoptosis; Cell Hypoxia; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; | 2017 |
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2017 |
Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2017 |
Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; C | 2017 |
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2017 |
The extracellular domain of E cadherin linked to invasiveness in colorectal cancer: a new resistance and relapses monitoring serum-bio marker?
Topics: Adult; Aged; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; C | 2017 |
Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 2017 |
AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Colorectal Neoplasms; DNA Breaks, Double-Stranded; Fluo | 2017 |
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Hepatic arterial infusion chemotherapy for metastases from colorectal cancer: is it really the end of an era?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluoroura | 2008 |
Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2008 |
Nonparametric estimation of mean residual functions.
Topics: Algorithms; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as | 2009 |
Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
Topics: Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Cytidine Deaminase; Deoxyc | 2008 |
Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, | 2008 |
Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors.
Topics: Adenosine Triphosphatases; Algorithms; Antineoplastic Agents; bcl-2 Homologous Antagonist-Killer Pro | 2008 |
Liver resection for colorectal liver metastases in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2008 |
Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Acti | 2008 |
Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy.
Topics: Aged; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Therapy; Enzyme Activation; Fem | 2008 |
Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Folic Acid Antagonists; Gene Expression Regula | 2008 |
Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, | 2008 |
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-X Protein; Camptothecin; Cell Line, Tumor; Cel | 2008 |
Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Colorectal | 2008 |
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers; Chromatography, High Pressure Liquid; Colo | 2009 |
Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biological Transpo | 2008 |
[Efficacy of 5-FU hepatic arterial infusion with l-leucovorin for patients with unresectable colorectal liver metastasis].
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Hum | 2008 |
[Comparative survey on current status and the differences of treatment using modified FOLFOX6 regimen in patients with colorectal cancer in two general hospitals].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2008 |
Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apopt | 2008 |
Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2008 |
FOLFOX2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2008 |
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Leuc | 2008 |
Management of colorectal liver metastases after complete response to neoadjuvant chemotherapy. A case of computertomography-guided wire marking of the liver tumor.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
[The prevention of diarrhea while under capecitabine therapy].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fluoro | 2008 |
[Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Con | 2008 |
Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum | 2008 |
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplas | 2009 |
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Haplotypes; H | 2008 |
Priorities and uncertainties of administering chemotherapy in a pregnant woman with newly diagnosed colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; H | 2009 |
KRAS status predicts response to cetuximab for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2008 |
Expression of beta-F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study.
Topics: Blotting, Western; Cell Hypoxia; Colorectal Neoplasms; DNA-Binding Proteins; DNA, Mitochondrial; Fem | 2008 |
Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined M | 2008 |
Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms | 2008 |
Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2008 |
Commentary 2008: 25 or 50 years later?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neopl | 2008 |
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2008 |
The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capec | 2008 |
Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
[The combined treatment of colorectal cancer with liver metastases].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Drug Delivery Systems; Endoc | 2009 |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptotheci | 2009 |
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2009 |
Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chest Pain; Colorectal Neoplasms; Coronary Vaso | 2008 |
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2008 |
Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
The desmoplastic reaction surrounding hepatic colorectal adenocarcinoma metastases aids tumor growth and survival via alphav integrin ligation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Adhesion; Cell Proliferation; Colla | 2008 |
Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2008 |
Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; C-Reactive Prote | 2008 |
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Femal | 2008 |
Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage II colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 2008 |
Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
Topics: Aged; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Embolization, Therapeutic; Fluorode | 2008 |
Effects of nutritional support in patients with colorectal cancer during chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Body Mass Index; Camptothecin; Color | 2008 |
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2009 |
What is the standard chemotherapy for colorectal cancer patients with resectable liver metastases?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 2009 |
[Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetu | 2008 |
[The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Cyclin D1; Dihydrouracil Dehydrogenase (N | 2008 |
Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice.
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Appetite Stimulants; Body Weight; Cachexia; Cell | 2008 |
Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Re | 2008 |
Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; DNA-Binding Protein | 2008 |
Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dis | 2008 |
Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm | 2009 |
Tissue levels of reduced folates in patients with colorectal carcinoma after infusion of folinic acid at various dose levels.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou | 2008 |
In vitro antiproliferative characteristics of flavonoids and diazepam on SNU-C4 colorectal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Cell Line, Tumor; Cell Pro | 2009 |
Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil | 2009 |
Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colo | 2009 |
Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2009 |
ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Codon; Colorectal Neoplasms; DNA-Bindi | 2009 |
[Report from the 44th Congress of the American Society of Clinical Oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms | 2008 |
Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, A | 2009 |
Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, A | 2009 |
A dilemma in geriatric oncology: malignant bowel obstruction in an 81-year-old man.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2008 |
Recurrent disease four years after surgery and adjuvant chemotherapy.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2008 |
[Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Fem | 2008 |
[The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2008 |
Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptoth | 2009 |
rNAPc2 inhibits colorectal cancer in mice through tissue factor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; C | 2009 |
Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors.
Topics: Animals; Antineoplastic Agents; Collagenases; Colorectal Neoplasms; Convection; Energy Metabolism; E | 2009 |
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum | 2009 |
[Synergistic use of epidermal growth factor and 5-fluorouracil for the treatment of human colorectal cancer in BALB/C nude mice subcutaneous xenograft model].
Topics: Animals; Caco-2 Cells; Cell Line, Tumor; Colorectal Neoplasms; Epidermal Growth Factor; Fluorouracil | 2009 |
Correlation between thymidylate synthase protein expression and gene polymorphism with clinicopathological parameters in colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Colorectal Neoplasms; Fema | 2009 |
[Combination of hepatic arterial infusion therapy and FOLFOX for colorectal cancer with multiple unresectable liver metastases causing severe liver dysfunction].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2009 |
To widen the setting of cancer patients who could benefit from metronomic capecitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxyc | 2009 |
Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression.
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Mismatch Repa | 2009 |
Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.
Topics: Alleles; Antimetabolites, Antineoplastic; Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; Flu | 2009 |
Fatal drug-drug interaction of brivudine and capecitabine.
Topics: Adverse Drug Reaction Reporting Systems; Aged, 80 and over; Antimetabolites, Antineoplastic; Antivir | 2009 |
The p400/Tip60 ratio is critical for colorectal cancer cell proliferation through DNA damage response pathways.
Topics: Apoptosis; Cell Proliferation; Colorectal Neoplasms; DNA Damage; DNA Helicases; DNA-Binding Proteins | 2009 |
In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antit | 2009 |
Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo | 2009 |
A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; | 2009 |
Unresectable liver metastases from colorectal cancer and hepatic arterial infusion chemotherapy: how, when and to whom?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cathet | 2009 |
Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer.
Topics: Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fees, Pharmaceutical; Female; Fluorouracil; | 2009 |
Targeted therapy for advanced colorectal cancer--more is not always better.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma; Colorectal Neopl | 2009 |
Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2009 |
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig | 2009 |
Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colorectal Neoplasm | 2009 |
Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.
Topics: AC133 Antigen; Animals; Antigens, CD; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
The CAIRO and FOCUS studies: which lesson is to be learned?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2009 |
[The optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disposable Equip | 2009 |
Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Colorectal | 2009 |
RNA modulators of complex phenotypes in mammalian cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Death; Colorectal Neoplasms; Drug Resistanc | 2009 |
Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth.
Topics: Angiogenesis Inducing Agents; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell L | 2009 |
Panaxadiol, a purified ginseng component, enhances the anti-cancer effects of 5-fluorouracil in human colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Proliferation; Cell Survival; Colorec | 2009 |
Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Dis | 2009 |
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colo | 2009 |
[Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2009 |
[A case of resection of synchronous multiple liver metastases from colorectal cancer after FOLFOX chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; L | 2009 |
Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Colorectal Neoplasms; D | 2009 |
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Antineoplastic Combined C | 2009 |
5 flourouracil-induced apical ballooning syndrome: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Coronary Disease; Female; Fluorouracil; | 2009 |
Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromatography, High | 2009 |
The association of methylation in the promoter of APC and MGMT and the prognosis of Taiwanese CRC patients.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA Methylation | 2009 |
Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2009 |
Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Profilin | 2009 |
Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2009 |
Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BALB 3T3 Cells; Cell Cycle; Cell | 2009 |
Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Camptothecin; C | 2009 |
[Advanced hepatic resection for malignancy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce | 2009 |
Epigenetic reversal of acquired resistance to 5-fluorouracil treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Cell Line, Tumor; Colorectal N | 2009 |
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progress | 2009 |
Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as To | 2009 |
Asian ginseng enhances the anti-proliferative effect of 5-fluorouracil on human colorectal cancer: comparison between white and red ginseng.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2009 |
ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP B | 2009 |
Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fas-Associated Death Dom | 2010 |
Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; D | 2009 |
Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma; Colorectal Neo | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Subacute cutaneous lupus erythematosus induced by capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Erupt | 2009 |
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Clini | 2009 |
The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2009 |
[Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationsh | 2009 |
MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Denmark; Disease-Free | 2009 |
Perforating dermatosis in a patient receiving bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2009 |
Deriving the intrahepatic arteriovenous shunt rate from CT images and biochemical data instead of from arterial perfusion scintigraphy in hepatic arterial infusion chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Catheters, Indwelling; Colorectal Neoplasm | 2009 |
Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Abla | 2009 |
Molecular markers of chemotherapy in advanced colorectal cancer: back to square one.
Topics: Antineoplastic Agents; Colorectal Neoplasms; DNA Mismatch Repair; Drug Resistance, Neoplasm; Fluorou | 2009 |
[Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2009 |
Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2009 |
Radiation and chemotherapy bystander effects induce early genomic instability events: telomere shortening and bridge formation coupled with mitochondrial dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bystander Effect; Colorectal Neoplasms; Combin | 2009 |
Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Ne | 2009 |
Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab, chemotherapy and KRAS status in mCRC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Mice; | 2009 |
Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Protein | 2009 |
Cetuximab for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2009 |
Long-term results of hepatectomy after hepatic arterial infusion chemotherapy for initially unresectable hepatic colorectal metastases.
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorou | 2009 |
Fluorescence lifetime imaging microscopy of chemotherapy-induced apoptosis resistance in a syngenic mouse tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Base Sequence; Caspase 3; Colorectal Neoplasms; Disease M | 2010 |
Current role of bevacizumab in colorectal cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2009 |
[Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2009 |
Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Line, Tumor; Cell Proliferation; Color | 2009 |
[Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Age Factors; Aged; Antineoplastic Combined Chemothe | 2009 |
Health utility scores of colorectal cancer based on societal preference in Japan.
Topics: Adaptation, Psychological; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2009 |
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Combined Che | 2010 |
Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, | 2009 |
Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; CA-19-9 Antigen; Camptothe | 2009 |
Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2009 |
Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
Radioembolization of liver metastases in patients with colorectal cancer: a nonsurgical treatment with combined modality potential.
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2009 |
[Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dexamethasone; Do | 2009 |
Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-Fu on human carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell C | 2009 |
Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2010 |
Metastatic colorectal cancer: is surgery necessary?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; | 2009 |
Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA-Binding Prote | 2009 |
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplast | 2010 |
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell L | 2009 |
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2010 |
Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neopla | 2010 |
Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2009 |
Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomark | 2009 |
American ginseng berry enhances chemopreventive effect of 5-FU on human colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Prolif | 2009 |
Effect of early preoperative 5-fluorouracil on the integrity of colonic anastomoses in rats.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Colorectal Neop | 2009 |
Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2009 |
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2009 |
Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fl | 2009 |
Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2009 |
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2010 |
Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2009 |
Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonosco | 2009 |
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Stop and go: yes or no?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2009 |
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.
Topics: Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2010 |
Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; bcl-2-Associated X | 2010 |
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2009 |
Trichomegaly of the eyelashes after colorectal cancer treatment with the epidermal growth factor receptor inhibitor cetuximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; C | 2009 |
Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Pro | 2010 |
The impact of new treatment options for advanced colorectal cancer on routine care: results of a retrospective analysis of 206 consecutive patients treated in a community-based oncology group practice in Germany.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2010 |
Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2010 |
[Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; D | 2009 |
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta | 2010 |
MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colo | 2010 |
Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.
Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2009 |
Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelium; Fluoro | 2009 |
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Sur | 2010 |
The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Blotting, Western; Cell Line, Tumor | 2010 |
[Proteomic research of biomarker of colorectal cancer metastasis].
Topics: Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis | 2009 |
Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2010 |
Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.
Topics: Acute Coronary Syndrome; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2009 |
Improved first-line chemotherapy: a better chance for surgery?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
The effect of three lipid emulsions differing in fatty acid composition on growth, apoptosis and cell cycle arrest in the HT-29 colorectal cancer cell line.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Count; Cell Cycle; Cell Survival; C | 2010 |
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
Topics: Aged; Alleles; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Codon; Colorectal N | 2009 |
Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistan | 2009 |
[Hepatic resection after neoadjuvant therapy for initially unresectable colorectal liver metastases].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal | 2009 |
Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2010 |
Serum homocysteine, cholesterol, retinol, alpha-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin.
Topics: Adult; Aged; alpha-Tocopherol; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2009 |
[The prognosis of patients with an allergic reaction in the treatment of mFOLFOX6 therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2009 |
[Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2009 |
[Hepatic metastatectomy of colorectal cancer following mFOLFOX6 treatment--analysis of 7 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2009 |
[Switching to direct intrahepatic arterial infusion of 5-FU after a progression of liver metastases from colorectal carcinoma treated with systemic infusion of FOLFOX].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2009 |
[A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
[A curative resection with the combination of portal vein branch embolization and systemic chemotherapy in a patient with synchronous multiple and bilobar colorectal liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C | 2009 |
[Two resected cases of pulmonary metastasis from post operative colorectal cancer after preoperative chemotherapy with FOLFOX].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2009 |
[Chemotherapy with bevacizumab (BV)+modified FOLFOX6 for unresectable colorectal cancer].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2009 |
[Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anaphylaxis; Anti-Allergic Agents | 2010 |
Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2009 |
Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Ca | 2010 |
[Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; He | 2010 |
[Validation study of KRAS mutation in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2010 |
CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
Topics: AC133 Antigen; Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Che | 2010 |
Genome-wide identification of chemosensitive single nucleotide polymorphism markers in colorectal cancers.
Topics: Aged; Antineoplastic Agents; Biomarkers; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasm | 2010 |
[Evaluation of bevacizumab for advanced colorectal cancer].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2010 |
[Chemotherapy for elderly colorectal cancer patients in a regional hospital--problems in regional cancer care].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
[Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2010 |
Treatment results of FOLFOX chemotherapy before surgery for lymph node metastasis of advanced colorectal cancer with synchronous liver metastasis: the status of LN metastasis and vessel invasions at the primary site in patients who responded to FOLFOX.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col | 2010 |
MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
[Effect of delayed-release 5-fluorouracil implants on colorectal cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Delayed-Action Preparations; Female; | 2010 |
A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relatio | 2010 |
Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
5-FU and mismatch repair deficient colorectal cancer: is it time to consider a change in practice?
Topics: Antimetabolites, Antineoplastic; Base Pair Mismatch; Colorectal Neoplasms; DNA, Neoplasm; Fluorourac | 2010 |
Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost A | 2009 |
The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2011 |
[Silencing of Adrm1 by RNA interference suppresses proliferation of colorectal cancer cells].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colore | 2009 |
Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antir | 2010 |
Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?
Topics: Adenocarcinoma; Aged; Antimetabolites; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylase | 2010 |
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
Prognostic value of perineural invasion in patients with stage II colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2010 |
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemot | 2010 |
Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
Chemotherapy-associated peripheral sensory neuropathy assessed using in vivo corneal confocal microscopy.
Topics: Aged; Capecitabine; Carcinoma; Colorectal Neoplasms; Cornea; Deoxycytidine; Fluorouracil; Humans; Ma | 2010 |
[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycyti | 2010 |
Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2010 |
Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
Topics: Aneurysm; Angiogenesis Inhibitors; Angiomyolipoma; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2010 |
rTSbeta as a novel 5-fluorouracil resistance marker of colorectal cancer: a preliminary study.
Topics: Biomarkers; Cell Line, Tumor; Colorectal Neoplasms; Cytological Techniques; Drug Resistance, Neoplas | 2010 |
Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2010 |
Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2010 |
Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Analysis of Variance; Antineoplastic Combined Che | 2010 |
Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2010 |
[Analysis of a case of oxaliplatin - induced persistence sensory neuropathy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 2010 |
Role of local liver therapy for hepatic metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colorectal Neoplasms; Fluorouraci | 2009 |
Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; BH3 Interacting Domain Death Agonist Protein; Ca | 2010 |
Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa.
Topics: Animals; Apoptosis; Cell Cycle; Colorectal Neoplasms; Fluorouracil; Genes, p53; Genes, ras; HCT116 C | 2010 |
Evaluation of efficacy and safety of generic levofolinate in patients who received colorectal cancer chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; Cycli | 2010 |
TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line; Cell L | 2010 |
[Optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients (2nd report)-influence of temperature on outflow speed of the medicinal solution].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disposable Equip | 2010 |
Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free S | 2010 |
FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2010 |
Steroids, cancer and vertebral fractures: a dreaded combination.
Topics: Adrenal Cortex Hormones; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2011 |
Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2010 |
HnRNP K and PDI marked response to chemotherapy to human colorectal cancer cells.
Topics: Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Electrophoresi | 2010 |
Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2010 |
Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col | 2010 |
Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
Topics: Age Factors; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analy | 2010 |
Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; | 2010 |
Combined treatment with dendritic cells and 5-fluorouracil elicits augmented NK cell-mediated antitumor activity through the tumor necrosis factor-alpha pathway.
Topics: Animals; Antibodies, Blocking; Antigen Presentation; Antigens, Neoplasm; Cancer Vaccines; Cell Extra | 2010 |
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
In defense of hepatic arterial infusion for hepatic metastases of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2010 |
[Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 2011 |
Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch?
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Resistance, Neop | 2010 |
[PI3K p85alpha gene silencing by RNA interference promotes 5-fluorouracil-induced apoptosis of colorectal cancer LoVo cells].
Topics: Apoptosis; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Colorectal Neoplasms; Fluoroura | 2010 |
Clubbing and hypertrophic osteoarthropathy in two patients taking long-term bevacizumab for metastatic colorectal cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma | 2011 |
Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I | 2010 |
Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Induction; Fluorouracil; HT29 Cells; Humans; | 2010 |
Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blotting, Western; Col | 2010 |
VEGF -460T → C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Female; Fluo | 2011 |
Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo.
Topics: Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasms; D | 2011 |
Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer.
Topics: Adenocarcinoma; Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin | 2011 |
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Cisplatin; Colorectal Neoplasms; DNA | 2010 |
Treatment considerations in elderly colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2010 |
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Confidence In | 2011 |
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuv | 2011 |
Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Fluoroura | 2011 |
Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neopla | 2010 |
[Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
[Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Colorectal Neoplasms; Creatine; | 2010 |
Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ato | 2011 |
A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Carcinoma; Cell Migration Assays; Cell Transformation, Neopla | 2010 |
Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Pro | 2010 |
Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2010 |
Special report: laboratory testing to allow area under the curve (AUC)-targeted 5-fluorouracil dosing for patients administered chemotherapy for cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adjuvant; Clinical Trials as Topic; | 2010 |
Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2011 |
Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost A | 2010 |
Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Adhesion; Cel | 2010 |
5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.
Topics: Antimetabolites, Antineoplastic; Biocompatible Materials; Cell Line, Tumor; Collagen; Colorectal Neo | 2010 |
Cellular senescence predicts treatment outcome in metastasised colorectal cancer.
Topics: Cellular Senescence; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; | 2010 |
High frequency of hand foot syndrome with capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cross-Sectional St | 2010 |
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2011 |
miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation.
Topics: Binding Sites; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neopl | 2010 |
[Selection of anticancer drug for poorly-differentiated adenocarcinoma of colorectum from the level of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase activities in cancer tissue].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cell Differentiation; Colorectal Neoplasms; Dihydrourac | 2010 |
[HAI chemotherapy for liver metastases of colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor | 2010 |
Primary site resection is superior for incurable metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2010 |
Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasm | 2010 |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; | 2010 |
5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Delivery Systems; Female; Fluor | 2010 |
Successful right hepatectomy after four treatments of yttrium-90 microspheres (SIR-Spheres) and concomitant FOLFOX as bridging therapy to resection of colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2010 |
[Interstitial lung disease associated with combination chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2010 |
Multi-modality therapy for metastatic colorectal cancer-ready for prime time?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Colectomy; Colonoscopy | 2010 |
[Performance of a portable continuous infusion pump (SUREFUSER A) in continuous infusion of 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Colorectal Neoplasms; Female; | 2010 |
Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistan | 2010 |
The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal | 2011 |
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, West | 2010 |
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; C | 2010 |
S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Com | 2010 |
Can localised (19)F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carbon Dioxide; Colon; Colorectal N | 2011 |
[mRNA quantification. The next challenge in routine diagnostics].
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2010 |
[Microsatellite instability. A new predictive marker (?)].
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemothera | 2010 |
Alternative expression analysis by RNA sequencing.
Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Datab | 2010 |
[Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome].
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycyt | 2010 |
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
Dietary glycine protects from chemotherapy-induced hepatotoxicity.
Topics: Animals; Antineoplastic Agents; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neo | 2011 |
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ap | 2011 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, P | 2010 |
Outcomes in the management of obstructive unresectable stage IV colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2010 |
Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal | 2010 |
Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; beta-Cyclodextrins; Breast Neoplasms; Cell | 2011 |
Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Carcinoembry | 2010 |
Reporting time-to-event endpoints and response rates in 4 decades of randomized controlled trials in advanced colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Outcom | 2011 |
Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neop | 2010 |
EGFR antibodies in colorectal cancer: where do they belong?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
Treatment of colorectal cancer with unresectable synchronous liver-only metastases with combined therapeutic modalities.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colorectal Neoplasms; Combi | 2011 |
Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Cell Cycle; Colorectal Neopla | 2010 |
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
5-Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma: a clinical experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, | 2011 |
Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.
Topics: AC133 Antigen; Adenomatous Polyposis Coli; Aged; Aged, 80 and over; Animals; Antigens, CD; Antineopl | 2011 |
Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Camptotheci | 2011 |
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2011 |
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2010 |
Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
[Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2010 |
Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2010 |
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2).
Topics: Base Pair Mismatch; Colorectal Neoplasms; Down-Regulation; Drug Resistance; Fluorouracil; Gene Expre | 2010 |
Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biomarkers; Chromosomes, Human, Pair 18; Color | 2011 |
Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neopl | 2011 |
Bevacizumab-based therapy and complication risk after colonic stent placement: is it time for a warning?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2010 |
Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur | 2011 |
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biologic | 2011 |
ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Ca | 2010 |
Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabo | 2011 |
Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2010 |
Comment on 'capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2011 |
Generalized pairwise comparisons of prioritized outcomes in the two-sample problem.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aptamers, Nucleotide; Colorectal Neoplasms; Disease- | 2010 |
The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information.
Topics: Antimetabolites, Antineoplastic; Biopsy; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neopl | 2010 |
Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Prolifera | 2011 |
Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2011 |
Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Ch | 2010 |
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Co | 2011 |
A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Capeci | 2010 |
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2011 |
5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Czech Republic; Disease-Free Survival; Ferred | 2011 |
Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2011 |
Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; F | 2011 |
Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2010 |
Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up | 2010 |
Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
[Prehepatectomy chemotherapy using hepatic artery infusion plus systemic chemotherapy for liver metastases from colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2010 |
[The efficacy of cetuximab for metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
[Two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer].
Topics: Aged; Angiogenesis Inducing Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antin | 2010 |
[The expression of thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) protein in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colorect | 2010 |
[Adjuvant chemotherapy with FOLFOX4 regimen after curative resection of liver metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2010 |
[Two-stage hepatectomy combined with converting chemotherapy achieved a successful treatment for initially unresectable multiple bilobar colorectal liver metastases].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
[Roles of hepatectomy for colorectal liver metastases with necrotic foci caused by prior anti-cancer therapies].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
[A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2010 |
[Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2010 |
Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma; Cell Line, Tumor | 2011 |
Changing management and survival in patients with stage IV colorectal cancer.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antineoplastic Agents; Australia; Camptothecin; Capecit | 2011 |
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2012 |
miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Carrier Proteins; Cell Line, Tumor; Colorectal Neoplasms; Dru | 2011 |
Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2011 |
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
Topics: Adenocarcinoma; Anti-Allergic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies | 2011 |
Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolizati | 2011 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2011 |
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2011 |
R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2011 |
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Antibodies, Monoclona | 2011 |
Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal | 2011 |
A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2011 |
Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Coronary Vasospasm; Defi | 2012 |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breas | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2011 |
Hepatic arterial infusion chemotherapy prior to standard systemic chemotherapy in patients with highly advanced unresectable liver metastases from colorectal cancer: a report of three patients.
Topics: Angiography; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto | 2011 |
Expression of p21WAF1 in Astler-Coller stage B2 colorectal cancer is associated with survival benefit from 5FU-based adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2011 |
Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer.
Topics: Animals; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Mice; Pyr | 2011 |
In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Col | 2011 |
Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modalit | 2011 |
Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Cy | 2011 |
The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr | 2011 |
18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Capeci | 2011 |
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2011 |
Efficacy and safety of hepatic arterial infusion of fluorouracil with leucovorin as salvage treatment for refractory liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2011 |
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Systems pharmacology assessment of the 5-fluorouracil pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorou | 2011 |
Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco | 2011 |
Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor | 2011 |
The influence of toxicity constraints in models of chemotherapeutic protocol escalation.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Cell Cycle; Colorectal Neoplasms; Drug Administrati | 2011 |
Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Line, Tumor; Colorectal Neoplasms; Fluoro | 2011 |
Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2011 |
Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana | 2010 |
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Biomar | 2011 |
[Two cases of advanced colorectal cancer which demonstrated the reversibility of oxaliplatin-mediated increase in splenic volume].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2011 |
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2012 |
Single nucleotide polymorphisms of integrin alpha-2 and beta-3 genes are not associated with relapse-free and overall survival in colorectal cancer patients.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female | 2011 |
Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Brachytherapy; Chemotherapy, | 2011 |
Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorecta | 2011 |
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Female; F | 2011 |
Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Heart Diseases; Humans; Lupus Ery | 2011 |
Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms | 2012 |
[A case of toxicity caused by drug interaction between capecitabine and phenytoin in patient with colorectal cancer].
Topics: Adult; Anticonvulsants; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycy | 2011 |
Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
Topics: Adenocarcinoma; Anastomotic Leak; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth | 2011 |
How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Chemotherapy, Adjuvant; C | 2011 |
Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Colorectal Neoplasms, | 2011 |
Do we need oncology trials tailored for the elderly or frail?
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne | 2011 |
CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling.
Topics: AC133 Antigen; Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, | 2012 |
5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemothe | 2012 |
In vitro cytotoxic effect of ethanol extract prepared from sporophyll of Undaria pinnatifida on human colorectal cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Colorectal Neoplasms; Cul | 2012 |
Attenuated expression of HRH4 in colorectal carcinomas: a potential influence on tumor growth and progression.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell | 2011 |
Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Colorectal Neoplasms; | 2011 |
Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidin | 2011 |
Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2011 |
Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data.
Topics: Antineoplastic Agents; Bayes Theorem; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Empirical R | 2011 |
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2011 |
Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.
Topics: Afatinib; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neopla | 2011 |
A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment.
Topics: Aged; Cell Cycle; Cell Division; Colon; Colorectal Neoplasms; Complement System Proteins; Cyclins; F | 2011 |
Type IV collagen as a tumour marker for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2011 |
Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 3; Caspase 7; Caspase 9; Cell Survival; | 2011 |
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies; Antigens, CD; Antimetabolites, Antineoplastic; | 2011 |
First-line treatment of advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamil | 2011 |
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2011 |
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2011 |
DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Colorectal Neo | 2011 |
FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2011 |
Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo | 2011 |
Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Colorectal Neoplasms; Cytoprotection; DNA Repair; Drug Th | 2011 |
Can the CIMP status be used to stratify the colorectal cancer patients who respond to adjuvant chemotherapy?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cp | 2011 |
Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACH
Topics: Adenocarcinoma; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Correlation between TBARS levels and glycolytic enzymes: the importance to the initial evaluation of clinical outcome of colorectal cancer patients.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bioma | 2011 |
Overexpression of neurone glial-related cell adhesion molecule is an independent predictor of poor prognosis in advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Adhesion Molecules; Colorectal Neoplasms; Female; F | 2011 |
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2011 |
Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2011 |
Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2011 |
Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Fluorouracil; Humans; Japan | 2011 |
Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2011 |
Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2011 |
[Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2011 |
FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C | 2011 |
Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Anti | 2011 |
[A case of severe bevacizumab-induced ischemic pancolitis, treated with conservative management].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2011 |
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; | 2011 |
[Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2011 |
Expression of p53 and DR5 in normal and malignant tissues of colorectal cancer: correlation with advanced stages.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colorectal Neoplasms; Female; Fluor | 2011 |
Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; | 2011 |
Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.
Topics: Adaptation, Physiological; Algorithms; Antimetabolites, Antineoplastic; Bayes Theorem; Capecitabine; | 2012 |
[End results of combined treatment in metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Chemot | 2011 |
DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal | 2011 |
The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2011 |
[Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2012 |
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2011 |
Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Autophagy; Cell | 2012 |
Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; | 2011 |
Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2011 |
Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2011 |
Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; | 2011 |
Chemotherapy for older patients with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cardiovascular Diseases; Colorectal Neoplasms; | 2011 |
SNPs and haplotypes in DPYD and outcome of capecitabine--Letter.
Topics: Carcinoma; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Sid | 2011 |
SNPs and Haplotypes in DPYD and Outcome of Capecitabine-Letter.
Topics: Carcinoma; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Sid | 2011 |
Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2012 |
Sequential chemotherapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2011 |
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2012 |
Novel activity of acriflavine against colorectal cancer tumor cells.
Topics: Acriflavine; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA T | 2011 |
Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Proliferation; | 2011 |
[Cetuximab-associated skin ulceration in patient with metastatic colorectal cancer: a case report].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combine | 2011 |
Revisiting the frontiers of pharmacogenomics of colon cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco | 2011 |
The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Dihydr | 2011 |
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2012 |
5-fluorouracil increases the chemopreventive potentials of resveratrol through DNA damage and MAPK signaling pathway in human colorectal cancer cells.
Topics: Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Movement; Cell | 2011 |
Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
[Lentivirus-mediated RNA interference suppresses APRIL expression and enhances chemosensitivity in colorectal cancer cells].
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, | 2011 |
Tailoring of drug delivery of 5-fluorouracil to the colon via a mixed film coated unit system.
Topics: Antimetabolites, Antineoplastic; Cellulose; Colon; Colorectal Neoplasms; Delayed-Action Preparations | 2011 |
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; DNA Primers; Fluor | 2011 |
Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur | 2012 |
Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
[FOLFOX as adjuvant chemotherapy after curative resection of distant metastatic lesions in patients with colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2011 |
[Four cases of locally advanced colorectal cancer resected successfully after preoperative chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2011 |
mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Dihydrouracil D | 2011 |
Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2012 |
Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Beva | 2012 |
Feasibility of Assam Bora rice starch as a compression coat of 5-fluorouracil core tablet for colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cellulose; Colorectal Neoplasms; Drug Carriers; Fluorourac | 2012 |
A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; C | 2012 |
[Induced nausea and vomiting induced by mFOLFOX6 and FOLFIRI with advanced colorectal cancer: a retrospective survey].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2011 |
Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab.
Topics: 3' Untranslated Regions; 5' Untranslated Regions; Alleles; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2011 |
Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2011 |
Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tu | 2012 |
A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo.
Topics: Animals; Apoptosis; Blotting, Western; Breast Neoplasms; Caspase 8; Caspase Inhibitors; Colorectal N | 2011 |
Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers; Caspases; Chemotherapy, Adjuvant; Colo | 2012 |
Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2012 |
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Canada; Clinical Trials as Topic; C | 2012 |
The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet | 2012 |
Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 2012 |
Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combin | 2012 |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2012 |
Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2012 |
Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-L | 2011 |
Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.
Topics: 3' Flanking Region; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Color | 2012 |
[Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Treatment results of peritonectomy combined with perioperative chemotherapy for colorectal cancer-patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neo | 2011 |
[Therapeutic effect of mFOLFOX6 for synchronous unresectable liver metastases from colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2011 |
[Recurrance of disappearing colorectal liver metastases after mFOLFOX6 regimen].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2011 |
[The clinical outcome of mFOLFOX6 treatment for colorectal cancer patients who underwent resection of liver metastasis -comparison between synchronous and metachronous liver metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2011 |
[Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion o
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2011 |
[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2011 |
Prediction of response to anticancer treatment as simple as the resolution of ordinary differential equations?
Topics: Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Decision Support Techniques; Femal | 2012 |
Induced pluripotent stem cell-related genes influence biological behavior and 5-fluorouracil sensitivity of colorectal cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Colorectal Neoplasms; Female; Fluorour | 2012 |
Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2011 |
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort | 2012 |
Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; bcl-2-Associated X Protein; | 2012 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2011 |
[Safety and efficacy of FOLFOX and FOLFIRI in elderly patients with colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorourac | 2011 |
Targeting colorectal cancer stem cells with inducible caspase-9.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Caspa | 2012 |
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD; Beva | 2013 |
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Management of obstructive colorectal cancer: evaluation of preoperative bowel decompression using ileus tube drainage.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colorectal | 2012 |
Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer.
Topics: Alternative Splicing; Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neop | 2013 |
PAK1-dependent MAPK pathway activation is required for colorectal cancer cell proliferation.
Topics: Animals; Anthracenes; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, | 2012 |
Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chi-Square Distributi | 2012 |
Impact of chemotherapy-related prognostic factors on long-term survival in patients with stage III colorectal cancer after curative resection.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Ther | 2013 |
The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2012 |
Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Fluorou | 2013 |
Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; C | 2012 |
Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2012 |
Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorec | 2012 |
Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco | 2013 |
Loss of E-cadherin promotes the growth, invasion and drug resistance of colorectal cancer cells and is associated with liver metastasis.
Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; beta Catenin; Cadherins; Cell Adhes | 2012 |
Identification of Nkx2-3 and TGFB1I1 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Cell | 2012 |
Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.
Topics: Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Protein | 2012 |
Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothec | 2012 |
Infections of Blastocystis hominis and microsporidia in cancer patients: are they opportunistic?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blastocystis hominis; Breast Neoplasms; Col | 2012 |
STAT5a-targeting miRNA enhances chemosensitivity to cisplatin and 5-fluorouracil in human colorectal cancer cells.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; | 2012 |
Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2013 |
Differences in tissue degeneration between preoperative chemotherapy and preoperative chemoradiotherapy for colorectal cancer.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colorect | 2012 |
Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Co | 2012 |
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2012 |
Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Ad | 2011 |
The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort | 2012 |
The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2012 |
SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Division; Cell Hypoxia; Colorectal | 2012 |
A case of therapy-related acute myeloid leukemia following 5-fluorouracil chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone | 2012 |
Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Data-driven assessment of the association of polymorphisms in 5-Fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2012 |
LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Chromatography, Liquid; Colorectal Neoplasms; Drug Monitoring | 2013 |
A valid formulation of the analysis of noninferiority trials under random effects meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal N | 2012 |
Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2012 |
Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosomes; Caspases; Chemotherapy | 2012 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Ca | 2012 |
X-ACT: an important step on an unfinished journey.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycy | 2012 |
A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2012 |
FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antimetabolites, Antineoplastic; Basic-Leucine Zipper Tr | 2012 |
Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 | 2012 |
Oxaliplatin-induced hepatoportal sclerosis, portal hypertension, and variceal bleeding successfully treated with transjugular intrahepatic portosystemic shunt.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2012 |
Fate of metastatic foci after chemotherapy and usefulness of contrast-enhanced intraoperative ultrasonography to detect minute hepatic lesions.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2012 |
Inadvertent severe acute kidney injury and oxaliplatin.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorecta | 2013 |
Predicting acute and persistent neuropathy associated with oxaliplatin.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cohort | 2013 |
Metastatic paediatric colorectal carcinoma.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2012 |
Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2012 |
Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colo | 2012 |
Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms | 2012 |
Central venous port system-related complications in outpatient chemotherapy for colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.
Topics: Angiogenesis Inducing Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cap | 2012 |
[Side effect analyses in consideration of renal functions for capecitabine-administered patients].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycy | 2012 |
Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fl | 2012 |
Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study.
Topics: Aged; Analysis of Variance; Antimetabolites, Antineoplastic; C-Peptide; Colorectal Neoplasms; Diabet | 2013 |
Hydroxymethylglutaryl-coenzyme a synthase 2 expression is associated with chemoradiotherapy responses in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Chemoradiot | 2012 |
Feasibility and short-term outcome of adjuvant FOLFOX after resection of colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2013 |
KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Class I Phosphatidyl | 2012 |
Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Comparative label-free LC-MS/MS analysis of colorectal adenocarcinoma and metastatic cells treated with 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antioxidants; Cell Adhesion; Cell Line, Tumor; Chro | 2012 |
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Complete calcification of colorectal liver metastases on imaging after chemotherapy does not indicate sterilization of disease.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Colo | 2012 |
Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorecta | 2013 |
Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiomyopathies; Colo | 2012 |
Adenovirus KH901 promotes 5-FU antitumor efficacy and S phase in LoVo cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; bcl-2-Associated X Protein; Blotting, Western; Cell L | 2012 |
A complex oncosurgical approach to increasing the resectability of colorectal cancer metastases - a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Emboliza | 2014 |
[A case of advanced primary colorectal carcinoma accompanied by liver metastasis in which ileus developed due to marked fibrosis with cicatricial formation in primary colorectal cancer treated by chemotherapy including bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc | 2012 |
Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bloo | 2012 |
MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.
Topics: 3' Untranslated Regions; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; | 2013 |
Effects of reduced dose intensity of modified FOLFOX6 in patients with metastatic or recurrent colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2011 |
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
[Comparison of targeting distribution of two kinds of fluorouracil magnetic albumin microspheres in colorectal neoplasm nude mice in vivo under magnetic field].
Topics: Animals; Colorectal Neoplasms; Fluorouracil; Humans; Magnetics; Mice; Mice, Nude; Microspheres; Tiss | 2012 |
Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycy | 2012 |
Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome.
Topics: 2-Propanol; Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Camphor; Capecita | 2010 |
[A case of colorectal neuroendocrine carcinoma effectively treated with bevacizumab+levofolinate+5-FU chemotherapy].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; | 2012 |
Conditionally replicative adenovirus-based mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apopto | 2013 |
A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Colorectal Neoplasms; Dose-Response Relations | 2012 |
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.
Topics: Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptot | 2012 |
Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Cy | 2012 |
Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2012 |
Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2012 |
N-3 PUFAs have antiproliferative and apoptotic effects on human colorectal cancer stem-like cells in vitro.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferat | 2013 |
Effectiveness of oxaliplatin desensitization protocols.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
New strategy in hepatic metastatic colorectal cancer: tomotherapy and capecitabine followed by hepatic surgical resection.
Topics: Antineoplastic Agents; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorou | 2012 |
Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.
Topics: Biomarkers, Pharmacological; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Galanin; | 2012 |
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2013 |
Genetic disruption of USP9X sensitizes colorectal cancer cells to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; F | 2012 |
[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2012 |
A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor | 2012 |
The antitumor natural compound falcarindiol promotes cancer cell death by inducing endoplasmic reticulum stress.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Diyne | 2012 |
In vivo real-time imaging of chemotherapy response on the liver metastatic tumor microenvironment using multiphoton microscopy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal | 2012 |
Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Autophagy-Related Protein 12; Autoph | 2013 |
[Expressions of orotate phosphoribosyltransferase in colorectal carcinoma and its correlations with toxicities of chemotherapy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; In | 2012 |
Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2012 |
Capecitabine-induced chest pain relieved by diltiazem.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Calcium Channel Blockers; Cap | 2012 |
Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2013 |
Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2013 |
The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Anti | 2013 |
Inhibition of monocarboxylate transporter 2 induces senescence-associated mitochondrial dysfunction and suppresses progression of colorectal malignancies in vivo.
Topics: Animals; Autophagy; Biomarkers, Tumor; Cell Cycle; Cell Nucleus; Cell Proliferation; Cell Transforma | 2012 |
Delayed repeated intraperitoneal chemotherapy after cytoreductive surgery for colorectal and appendiceal carcinomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colorectal Neopl | 2012 |
RHBDD2: a 5-fluorouracil responsive gene overexpressed in the advanced stages of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Case-Control Studies; Colon; | 2012 |
[Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2012 |
Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2012 |
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.
Topics: Aged; Biomarkers; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Huma | 2012 |
Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cel | 2013 |
Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo | 2012 |
Assam Bora rice starch based biocompatible mucoadhesive microsphere for targeted delivery of 5-fluorouracil in colorectal cancer.
Topics: Adhesiveness; Animals; Antimetabolites, Antineoplastic; Coated Materials, Biocompatible; Colorectal | 2012 |
Extensive characterization of sphere models established from colorectal cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; C | 2013 |
A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2012 |
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycy | 2012 |
First description of an uterine perforation potentially imputable to treatment with bevacizumab.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2013 |
Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopla | 2013 |
Effects of ellagic acid on chemosensitivity to 5-fluorouracil in colorectal carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X | 2012 |
S-1 in colorectal cancer: a new standard of care?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; D | 2012 |
Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2012 |
Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Car | 2012 |
Cytotoxicity and antitumour activity of 5-fluorouracil-loaded polyhydroxybutyrate and cellulose acetate phthalate blend microspheres.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cellulose; Colorectal Neoplasms; Drug Ca | 2013 |
Laparoscopic resection of colorectal cancer facilitates simultaneous surgery of synchronous liver metastases.
Topics: Adult; Aged; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Ad | 2013 |
[Chronotherapy with 5-fluorouracil folinic acid and oxaliplatin delivered over 48 hours every second week in colorectal cancer. The CHC-Liège experience (Belgium)].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal N | 2013 |
High and low dose folinic acid, 5-fluorouracil bolus and continuous infusion for poor-prognosis patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2012 |
Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combi | 2013 |
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2012 |
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2013 |
HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne | 2013 |
Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell L | 2012 |
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Topics: Alleles; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2013 |
Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.
Topics: Age Factors; Aged; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A | 2013 |
Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats.
Topics: 1,2-Dimethylhydrazine; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil | 2013 |
CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.
Topics: AC133 Antigen; Activated-Leukocyte Cell Adhesion Molecule; Aldehyde Dehydrogenase 1 Family; Animals; | 2012 |
Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calci | 2013 |
Importance of methanogenic flora in intestinal toxicity during 5-fluorouracil therapy for colon cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Colon; Colorectal Neoplasms; Female; Fluorouracil; Human | 2013 |
Hepatic arterial infusion of irinotecan, 5-Fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2012 |
Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2013 |
Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal | 2013 |
Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2013 |
UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2012 |
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2013 |
CEA fluctuation during a single fluorouracil-based chemotherapy cycle for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil | 2013 |
[Two cases of long-term survival of metastatic colorectal cancer following treatment with polysaccharide K and mFOLFOX6 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 2012 |
[Predictive value of Köhne's index on the efficacy of FOLFIRI regimen in the treatment of unresectable liver metastatsis of colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2012 |
Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy.
Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms | 2013 |
Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antibodies, Monoclonal, Humanized; Antineoplastic | 2013 |
[Cost analysis of XELOX and FOLFOX-4 chemotherapy regimens for colorectal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2012 |
The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Proliferation; Colorectal Neoplasm | 2013 |
Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Colorectal Neoplasms; DNA-Binding Prot | 2012 |
Cardiotoxicity with 5-fluorouracil based agents: rechallenge cannot currently be safely advised.
Topics: Chest Pain; Colorectal Neoplasms; Deoxycytidine; Diltiazem; Female; Fluorouracil; Humans; Male | 2013 |
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Colorectal Neoplasms; Female; Fl | 2012 |
Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Pilot study of the early start of chemotherapy after resection of primary colorectal cancer with distant metastases (Pearl Star 01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom | 2013 |
Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Association between MTHFR polymorphisms and overall survival of colorectal cancer patients in Northeast China.
Topics: Aged; Asian People; Chemotherapy, Adjuvant; China; Colorectal Neoplasms; Female; Fluorouracil; Follo | 2013 |
New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Tria | 2002 |
ERBITUX as a single agent and in combination in colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2002 |
Capecitabine in the management of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxy | 2001 |
Colorectal cancer. A novel approach to adjuvant chemotherapy with fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; | 2002 |
Another NICE mess.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2002 |
[Preliminary clinical evaluation of low-dose cisplatin and continuous infusion of 5-FU (LFP) chemotherapy after weekly high-dose 5-FU therapy for the treatment of liver metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dose-Response | 2002 |
[The prevention of negative side effects in homeochemotherapy].
Topics: Abdominal Pain; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neop | 2002 |
Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; | 2002 |
Increased sensitivity of colorectal cancer cell lines with microsatellite instability to 5-fluorouracil in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Base Pair Mismatch; Carrier P | 2002 |
Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2002 |
Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2002 |
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2002 |
FDA evaluating oxaliplatin for advanced colorectal cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 2002 |
A biological perspective on the selection of stage II colorectal cancer patients for adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials | 2002 |
Relationships between body composition parameters and fluorouracil pharmacokinetics.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Surface Area; Body | 2002 |
Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Color | 2002 |
Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Colorectal Neoplasms | 2002 |
Chronomodulated chemotherapy in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Clinical Trials as To | 2002 |
[Study of cut-off values for orotate phosphoribosyl transferase (OPRT) in colorectal cancer using maximal chi 2 values].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Fluorouraci | 2002 |
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosome | 2002 |
DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Chromosomes, Human, Pair 20; Colorect | 2002 |
Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil | 2002 |
Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplas | 2002 |
[Colorectal cancer: curative treatment and surveillance].
Topics: Colonoscopy; Colorectal Neoplasms; Fluorouracil; Humans; Immunosuppressive Agents; Neoadjuvant Thera | 2002 |
Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Thera | 2002 |
[Therapy of colorectal carcinoma in internal medicine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 2002 |
Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Colorectal Neoplasms; DNA; DNA Primers; Drug Resista | 2002 |
Superior venocaval obstruction secondary to central venous catheter-related thromboses in two patients with metastatic colorectal carcinoma receiving weekly 5-flurouracil. Should adjusted-dose warfarin be used as thromboprophylaxis?
Topics: Aged; Anticoagulants; Antineoplastic Agents; Catheterization, Central Venous; Colorectal Neoplasms; | 2002 |
Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorou | 2001 |
25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2001 |
First-line capecitabine is as effective as 5-fluorouracil/leucovorin in treating advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase III as T | 2001 |
Clinical colorectal cancer: thymidylate synthase as a molecular biomarker.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Immu | 2001 |
Capecitabine combinations in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic | 2001 |
Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fluorourac | 2001 |
Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neop | 2003 |
Oxaliplatin: a welcome addition to our therapeutic armamentarium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2002 |
Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2002 |
Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2002 |
Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2002 |
Lessons learned from the Saltz and Mayo Clinic regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2002 |
Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Syne | 2002 |
Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2002 |
Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Northern; Ca | 2003 |
Clinical colorectal cancer: oral chemotherapy comes of age.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2001 |
Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Humans; Loss of Heterozy | 2002 |
Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Division; Colorectal Neoplasms; Combined Modality Therapy; Drug Synergism; | 2001 |
[Gleaning from the American Oncology Congress. A new standard in colorectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2002 |
Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bystander Effect; Capecitabine; Cell Division; Cell Memb | 2002 |
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2002 |
Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2002 |
[Resection made possible following hepatic arterial infusion in 2 cases of hepatic metastases from colorectal cancer].
Topics: Aged; Aged, 80 and over; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Hepat | 2002 |
[5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Hepatectomy and intraarterial infusion chemotherapy for liver metastasis from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infusions, | 2002 |
[Evaluation of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2002 |
[Hepatic arterial infusion of IL-2 and chemotherapy for unresectable liver metastasis from colorectal cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colectomy; Colorectal Neoplasms; Female; F | 2002 |
[Pharmacological study on levofolinate in intraperitoneal leucovorin-5-FU chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2002 |
Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Survival; Clinical Enzyme Test | 2002 |
Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adjuva | 2002 |
Variability in administration of 5-fluorouracil and folinic acid in standard treatment regimens for advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Fluorouracil; Humans; Infus | 2002 |
Choice of chemotherapy regimen for advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Health Care Surv | 2002 |
Design and analysis of non-inferiority mortality trials in oncology.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Controlle | 2003 |
Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cl | 2002 |
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms; | 2002 |
[Chemotherapy improves prognosis in colorectal carcinoma. Soon oral therapy at home?].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, | 2002 |
[Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplati | 2002 |
[Rules to carry out hepatic arterial infusion chemotherapy at home for patients with liver metastasis of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepat | 2002 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorect | 2003 |
Indicators for surgical resection and intraoperative radiation therapy for pelvic recurrence of colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2003 |
Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age.
Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal | 2003 |
Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases.
Topics: Antimetabolites, Antineoplastic; Catheterization; Colorectal Neoplasms; Disease-Free Survival; Femal | 2003 |
Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cam | 2002 |
Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; be | 2003 |
Oxaliplatin (Eloxatin) for advanced colon cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseas | 2003 |
Hepatic artery infusion for liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 2003 |
Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouraci | 2003 |
Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Division; Cell Survival; Colorectal Neoplasms; End | 2003 |
Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines.
Topics: Active Transport, Cell Nucleus; Apoptosis; Colorectal Neoplasms; Disulfiram; DNA; Drug Synergism; Fl | 2003 |
Pattern mixture models for longitudinal quality of life studies in advanced stage disease.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T | 2003 |
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Flu | 2003 |
Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.
Topics: Antidiarrheals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Tri | 2003 |
Quality of life in patients with colorectal metastasis and intrahepatic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2003 |
[Cytoreductive surgery as an alternative to palliative operations in oncology (the model of treatment of stage IV colorectal cancer)].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 2002 |
Population pharmacokinetics of oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2003 |
A pilot study of adjuvant intraperitoneal 5-fluorouracil using 4% icodextrin as a novel carrier solution.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Co | 2003 |
Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms.
Topics: Antimetabolites, Antineoplastic; Cell Survival; Chromosome Aberrations; Colorectal Neoplasms; Drug R | 2003 |
5-Fluorouracil efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Caspase 8; Caspase 9; Caspases; | 2003 |
Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2003 |
Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bacitracin; Camptothecin; Colo | 2003 |
[Influence of combination of low dosage 131I-labeled anti-carcinoembryonic antigen antibody C50 and 5-fluorouracil on tumor growth of colorectal cancer xenografts in nude mice].
Topics: Animals; Antibodies; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms | 2003 |
Chromosomal imbalances associated with acquired resistance to fluoropyrimidines in human colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Chromosome Aberrations; Colorectal Neoplasms; DNA, Neoplasm; Drug R | 2003 |
Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy, Needle; Cell Division; Co | 2003 |
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Alleles; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deo | 2003 |
5-fluorouracil, folinic acid and oxaliplatin administered via hepatic arterial infusion as regional second-line therapy for advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2003 |
Hepatic artery chemotherapy and colorectal liver metastases.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Floxuridine; Fluor | 2003 |
Hepatic artery chemotherapy and colorectal liver mestastases.
Topics: Antineoplastic Agents; Catheters, Indwelling; Colorectal Neoplasms; Controlled Clinical Trials as To | 2003 |
Oxaliplatin for colorectal cancer in the United States: better late than never.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Approval; Europe; Fluorou | 2003 |
Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Azacitidine; Base Pair Mismat | 2003 |
[The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Cisplatin; Colore | 2003 |
Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats.
Topics: Adenocarcinoma; Animals; Colorectal Neoplasms; Disease Models, Animal; Female; Fluorine Radioisotope | 2003 |
Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Primers; Female; Fluorouracil; Gene Expre | 2003 |
[Modeling 5-FU clearance during a chronomodulated infusion].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Chronothe | 2003 |
Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Capecitabine; Cell Division; Colorectal | 2003 |
Chemotherapy with irinothecan, 5-fluorouracil and folinic acid in the first-line management of advanced colorectal carcinoma: retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Fr | 2003 |
Hepatic cryotherapy and regional chemotherapy with or without resection for liver metastases from colorectal carcinoma: how many are too many?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Moda | 2003 |
Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dihydr | 2003 |
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2003 |
[A case report of complete remission of liver metastases from colorectal cancer treated with continuous hepatic arterial infusion].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modal | 2003 |
Cancer chronotherapy: principles, applications, and perspectives.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronobiology Pheno | 2003 |
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasms; CpG Islands; DNA Methyl | 2003 |
Multifocal inflammatory leukoencephalopathy: use of thallium-201 SPECT and proton MRS.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Aspartic Acid; Axons; Biopsy; Brain; Brain | 2003 |
Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2003 |
Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2003 |
Validation of the role of angiogenesis as a chemotherapeutic target.
Topics: Adaptation, Physiological; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2003 |
Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2003 |
Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2003 |
Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2003 |
Anything in modulation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2003 |
Quantitation of dihydropyrimidine dehydrogenase (DPD) mRNA expression levels in normal colon and colorectal cancer tumor paraffin-embedded tissue specimens.
Topics: Antineoplastic Agents; Colon; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil | 2003 |
Another study of how to give fluorouracil?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2003 |
Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study.
Topics: Aged; Aged, 80 and over; Amifostine; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea | 2003 |
Bevacizumab, bleeding, thrombosis, and warfarin.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antineoplastic Combined C | 2003 |
Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone?
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Floxuridine; Fluorouraci | 2003 |
A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Canada; Clinical Trials, Phase III as T | 2003 |
Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuva | 2003 |
Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance.
Topics: Adenocarcinoma; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineo | 2003 |
[Liposome encapsulation of cystostatic drugs and starch microspheres improve tumor targeting in locoregional therapy. An animal experiment study of CC 531 liver tumor].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Delivery System | 1998 |
Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasm | 2003 |
Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Models, Animal; Drug Adminis | 2003 |
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2003 |
Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2003 |
Capecitabine in colorectal, breast, and other solid tumors: novel therapeutic approaches. Selected abstracts from ASCO 2003.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deox | 2003 |
Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: impact on adjuvant treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil | 2003 |
[Evaluation of hepatic arterial infusion chemotherapy with low-dose leucovorin and 5-FU from reservoir for multiple liver metastases by colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorectal Neoplasms; D | 2003 |
Microsatellite instability in colon cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; | 2003 |
Catheter occlusion by calcium carbonate: a well-known problem persists in spite of better knowledge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Carbonate; Catheterization, Central Venous; | 2003 |
[Radiofrequency ablation therapy combined with intrahepatic arterial infusion chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplati | 2003 |
[Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Deh | 2003 |
[Concentration of 5-FU after hepatic artery infusion chemotherapy for liver metastases of colorectal cancer].
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; | 2003 |
[Relationship between effectiveness of hepatic artery injection chemotherapy and serum VEGF].
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoembryonic Antigen; Chemoembo | 2003 |
[Efficacy of circadian chronotherapy via hepatic arterial infusion].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Female; F | 2003 |
[Validity of two-hour continuous hepatic arterial infusion chemotherapy with low-dose 5-FU for unresectable liver metastasis from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2003 |
[Effect of cimetidine with chemotherapy on stage IV colorectal cancer].
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Colorectal | 2003 |
Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma: an asian experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Colorectal Neoplasms; Fem | 2003 |
In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fl | 2003 |
CD44 variant 6 expression predicts response to treatment in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2004 |
Scheduling of fluorouracil: a forget-me-not in the jungle of doublets.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2004 |
Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle Proteins; Colorectal Neoplasms; DNA-Binding Pro | 2004 |
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration | 2003 |
Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients.
Topics: 3' Untranslated Regions; Aged; Case-Control Studies; Colorectal Neoplasms; Diet; DNA; Electrophoresi | 2004 |
[Clinical benefit of bronchial arterial infusion chemotherapy to pulmonary metastasis from colorectal cancer--report of two cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Cisplatin; Colorectal Neoplasms; | 2003 |
Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Dihydrouracil Dehydrogenase | 2004 |
An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cu | 2003 |
Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, T | 2004 |
First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2004 |
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; G | 2004 |
Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2003 |
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.
Topics: Chromosomes, Human, Pair 18; Colorectal Neoplasms; DNA, Neoplasm; Drug Resistance, Neoplasm; Electro | 2004 |
Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antimetabolites, Antineoplas | 2003 |
Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colorectal Neop | 2004 |
Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects an | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.
Topics: 5' Untranslated Regions; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Chemotherapy, Adjuvant; | 2004 |
19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorine Radioisotopes; Fluorouracil; Humans; Liver Neopl | 2004 |
Inflammation of actinic keratoses during capecitabine therapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxyc | 2004 |
Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Dihydrouracil Dehydroge | 2004 |
Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colore | 2004 |
Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18FDG and 18FLT PET.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Dideoxynucleosides; Fluorodeoxyglucose F18; Fluorouraci | 2004 |
Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Flu | 2004 |
Successful transfer of frozen-thawed embryos obtained after subtotal colectomy for colorectal cancer and before fluorouracil-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Mod | 2004 |
The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2004 |
[First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fem | 2004 |
Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis.
Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Regulation, | 2004 |
A longterm follow-up study of thymidylate synthase as a predictor for survival of patients with liver tumours receiving hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Epirubicin; Femal | 2004 |
Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; | 2004 |
Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
[Colorectal cancer: what should be the management of primary tumour?].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colon; Colonoscopy; Colorectal Neoplasms; D | 2004 |
Cryosurgery--a putative approach to molecular-based optimization.
Topics: Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Death; Cell Line, Tumor; Cell S | 2004 |
Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cell Division; Cell Line, Tumor; | 2004 |
Combination of Targeting Gene-ViroTherapy with 5-FU enhances antitumor efficacy in malignant colorectal carcinoma.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Cell Line; Ce | 2004 |
Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
Topics: Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Carcinoma; Cell Adhesion Molecules; C | 2004 |
Mature results of adjuvant colon cancer trials from the fluorouracil-only era.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms | 2004 |
Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2004 |
Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma; Colorectal Neoplas | 2004 |
An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigens; Antineoplastic Agents | 2004 |
PET concerns in bevacizumab treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizu | 2004 |
p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female | 2004 |
Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2004 |
The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.
Topics: Base Sequence; Camptothecin; Cell Division; Cell Line, Tumor; Colorectal Neoplasms; Cyclin-Dependent | 2004 |
Bevacizumab targeted therapy: validation of angiogenesis as a key target for advanced colorectal cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2004 |
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
Topics: Acyltransferases; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bi | 2004 |
[Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method].
Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Profiling; H | 2004 |
[Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Deh | 2004 |
[Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2004 |
[Occlusion of central venous port catheters after simultaneous 24 h infusions of 5-FU and calcium-folinic acid in patients with gastrointestinal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Carbonate; Catheterization, Central Ve | 2004 |
Mitochondrial p53 levels parallel total p53 levels independent of stress response in human colorectal carcinoma and glioblastoma cells.
Topics: Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Doxorubicin; Flow Cytome | 2004 |
New treatments for colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetux | 2004 |
Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2004 |
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2004 |
Hepatic artery infusion chemotherapy for metastatic colorectal cancer to the liver at the lahey clinic: comparison between two methods of treatment, surgical versus percutaneous catheter placement.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brachial Artery; Catheterization, Peripheral; Colorect | 2004 |
Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colon; Colorectal Neoplasms; Enzyme-Linked Immuno | 2004 |
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Intera | 2004 |
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Intera | 2004 |
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Intera | 2004 |
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Intera | 2004 |
Two-stage liver resection and chemotherapy for bilobar colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2004 |
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base | 2004 |
Chemotherapy and survival in colorectal cancer patients with and without microsatellite instability: can MSI be a prognostic marker?
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Repeats; | 2004 |
Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.
Topics: Administration, Oral; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil | 2004 |
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm | 2003 |
Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal | 2004 |
An in vitro short time-high dose drug exposure assay for predicting 5FU-resistance of colorectal cancer.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Biological Assay; Cell Survival; Colorectal | 2004 |
Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Colorectal Neo | 2004 |
Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Docosahexaenoic Acids; Dose-Respon | 2005 |
Thymidylate synthase expression pattern is a prognostic factor in patients of colorectal cancer treated with 5-fluorouracil.
Topics: Aged; Cell Nucleus; Colorectal Neoplasms; Female; Fluorescent Antibody Technique; Fluorouracil; Huma | 2004 |
Roles of infusional high-dose 5-fluorouracil with leucovorin in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2004 |
Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2004 |
Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2004 |
Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fema | 2004 |
Bevacizumab proves active in wide range of cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.
Topics: Animals; Arabinofuranosyluracil; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; HT29 Cel | 2004 |
Fluorouracil induces apoptosis and surface molecule modulation of peripheral blood leukocytes.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Blood Cells; CD18 Antigens; Cell Adhesion Molecules; | 2004 |
Bevacizumab in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2004 |
Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil | 2004 |
[Two cases of resection of synchronous bilobar multiple liver metastases from colorectal cancer after hepatic arterial infusion chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infu | 2004 |
[Two case reports of complete regression of liver metastases from colorectal cancer after locoregional immunochemotherapy].
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorect | 2004 |
[Evaluation of hepatic artery infusion chemotherapy for liver metastasis of colorectal cancer using a side-hole catheter].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Catheterization; Catheterization, Peripheral; | 2004 |
[The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr | 2004 |
[Host immunity in colorectal cancer patients treated with low-dose Leucovorin plus 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2004 |
[Evaluation of prophylactic hepatic arterial infusion chemotherapy after curative hepatectomy for metastatic colorectal cancer].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Art | 2004 |
[The use of radio frequency ablation (RFA) for colorectal liver metastases in one patient].
Topics: Catheter Ablation; Colorectal Neoplasms; Fluorouracil; Hepatitis B; Humans; Infusions, Intra-Arteria | 2004 |
[Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2004 |
Re: Verwaal VJ, van Tinteren H, Ruth SV, et al.: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61-67.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Color | 2004 |
Adjuvant hepatic arterial infusion after curative resection of colorectal liver metastases using removable intra-arterial catheters with shape-memory alloy.
Topics: Adult; Aged; Alloys; Antimetabolites, Antineoplastic; Catheters, Indwelling; Chemotherapy, Adjuvant; | 2004 |
Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Contraindication | 2004 |
Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCR.
Topics: Actins; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); F | 2004 |
Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor | 2004 |
Long-term survival after salvage surgery for colorectal lung metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C | 2005 |
[Successes in late solid tumors. New therapy offer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2004 |
[The present and future of home care chemotherapy for patients with advanced and recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2004 |
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer.
Topics: Adenocarcinoma, Mucinous; Aged; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free | 2005 |
Adjuvant chemotherapy in colorectal cancer.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colectomy; Colorectal | 2004 |
The development of the FOLFOX regimens as a treatment standard of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Ne | 2005 |
Evolution of FOLFOX regimens in the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Co | 2005 |
The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2005 |
5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chi-Square Distribution; Clinical Trials a | 2005 |
[Colorectal carcinoma--approval of eloxatine in adjuvant therapy--better chances for recovery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2004 |
Estimation of the time of pulmonary metastasis in colorectal cancer patients with isolated synchronous liver metastasis.
Topics: Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hep | 2005 |
Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Dose-Response Relatio | 2005 |
Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2005 |
Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2005 |
Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deficiency Diseases; Dihydropyrimidine Dehydr | 2004 |
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma; | 2005 |
The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytoto | 2004 |
Costs of treatment of colorectal cancer in different settings in Germany.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Costs and | 2004 |
Hepatic arterial infusion after liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Dex | 2005 |
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Austria; Bio | 2005 |
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.
Topics: Colorectal Neoplasms; Disease Progression; Drug Screening Assays, Antitumor; Female; Fluorouracil; H | 2005 |
Bevacizumab plus fluorouracil: the value of being part of a developing story.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2005 |
Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, | 2005 |
Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
Topics: Animals; Antibodies, Viral; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality | 2005 |
Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Differenti | 2005 |
Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy.
Topics: Adult; Aged; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Catheterization | 2005 |
An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoro | 2005 |
Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cluster Analysis; Colorectal Neopla | 2005 |
Determination of operation time in colorectal diseases: preoperative chemotherapy application.
Topics: Abdominal Wall; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Th | 2005 |
Therapy for colorectal cancer.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms | 2005 |
Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle Proteins; Colorectal | 2005 |
Hypersensitivity reactions to oxaliplatin in two asian patients.
Topics: Adult; Anti-Allergic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2005 |
Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colo | 2005 |
Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2005 |
Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line.
Topics: Adenocarcinoma; Andrographis; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Mu | 2005 |
[Systemic therapy for colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2005 |
Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Cycle Proteins; Cell Membrane; Colorect | 2005 |
[Improving longevity in advanced intestinal cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2005 |
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2005 |
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 2005 |
Controversy in folinic acid administration after fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2005 |
Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, N | 2005 |
[Expression of metabolic enzymes of fluoropyrimidines in primary colorectal cancer and its clinical significance].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorec | 2005 |
[Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Ne | 2005 |
Slow evolution of liver metastasis from colon cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Colectomy; Colorectal Neoplasms; Disease-Free Survival; | 2005 |
FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2005 |
Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
[Clinical research of intraperitoneal chemotherapy plus Shenmai Injection in treating advanced colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorecta | 2005 |
Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays.
Topics: Antimetabolites, Antineoplastic; Bone Morphogenetic Proteins; Cell Line, Tumor; Cell Proliferation; | 2005 |
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Caspase Inhibitors; Cas | 2005 |
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto | 2005 |
Oncologic emergencies secondary to advanced colorectal cancer successfully treated with oxaliplatin/5-fluorouracil/leucovorin: report of three cases.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 2005 |
Chemotherapy for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2005 |
[Combined chemotherapy with oral leucovorin (LV) + tegafur/uracil (UFT) and hepatic arterial infusion (HAI) therapy for liver metastasis of colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr | 2005 |
[A case of cerebral infarction caused by disseminated intravascular coagulation during hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cerebral Infarction; Colorectal Neoplasms; Dis | 2005 |
Lectin-mediated cytotoxicity and specificity of 5-fluorouracil conjugated with peanut agglutinin (5-Fu-PNA) in vitro.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Respons | 2005 |
Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2005 |
Analysis of dose-response effects on gene expression data with comparison of two microarray platforms.
Topics: Algorithms; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationshi | 2005 |
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronothera | 2005 |
Adjuvant therapy: new treatment options with oxaliplatin-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 2005 |
Recent data with oxaliplatin-containing regimens in the adjuvant treatment of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 2005 |
Adjuvant irinotecan regimens in combination with infusional 5-fluorouracil/leucovorin fail to improve outcomes in surgically resected colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trial | 2005 |
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemot | 2005 |
Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2005 |
[Reversible cardiogenic shock under 5-fluorouracil treatment].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car | 2005 |
Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Interactions; Drug-Related Side Effects and Advers | 2005 |
[Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 2005 |
Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers | 2005 |
ERCC1 and clinical resistance to platinum-based therapy.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; DNA Repair; DNA-Binding Proteins; Drug Resista | 2005 |
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Codon; Colorectal Neoplasms; DNA Repair; DNA-Binding | 2005 |
SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
Topics: Allelic Imbalance; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Chrom | 2005 |
Abdominal rash after transarterial chemoembolization via the right inferior phrenic artery.
Topics: Abdomen; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Arteries; Chemoembolization, | 2005 |
SMS 201-995 enhances S-phase block induced by 5-fluorouracil in a human colorectal cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neopl | 2005 |
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Color | 2005 |
[Healing for more patients].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemo | 2005 |
Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorecta | 2005 |
Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.
Topics: Animals; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Dr | 2005 |
Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboxylestera | 2005 |
Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neopla | 2005 |
Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrourac | 2005 |
Recurrence and 5-FU sensitivity of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrourac | 2005 |
Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunohisto | 2005 |
Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo | 2005 |
ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; DNA-Binding Proteins; Endonucleases; Female; F | 2003 |
Prognostic factors in patients with colorectal cancer receiving adjuvant chemotherapy or chemoradiotherapy: a pooled analysis of two randomized studies.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorourac | 2005 |
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Response Relation | 2005 |
In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin | 2005 |
First-line treatment options for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2004 |
Overlap coefficient for assessing the similarity of pharmacokinetic data between ethnically different populations.
Topics: Clinical Trials as Topic; Colorectal Neoplasms; Confidence Intervals; Cross-Cultural Comparison; Dat | 2005 |
[A clinical study of hepatic arterial infusion chemotherapy with low-dose CDDP and 5-FU for liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorecta | 2005 |
Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2005 |
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant | 2006 |
[Colorectal carcinoma].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2005 |
Treatment of advanced colorectal and gastric cancer with 5-fluorouracil and calcium n-methyltetrahydrofolate.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; F | 1989 |
Perfusion chemotherapy for colorectal liver metastases: a randomized study comparing FUDR against 5-FU/BCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorectal Neoplasms; Floxuridine; Fluor | 1989 |
[Expression of dihydropyrimidine dehydrogenase in human colorectal carcinoma and its clinical implications].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Deh | 2005 |
Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Diges | 2005 |
[Radiofrequency ablation (RFA) in colorectal cancer with hepatic metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasm | 2005 |
[Chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2005 |
[A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Combined | 2005 |
[Hepatic arterial infusion (HAI) chemotherapy achieved a complete response (CR) for multiple liver metastases of colorectal cancer--two case reports].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2005 |
Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum | 2005 |
Microsatellite instability and colorectal cancer prognosis.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Antimetabolites, Ant | 2005 |
The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluo | 2006 |
Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer.
Topics: Antineoplastic Agents; Apoptosis; CARD Signaling Adaptor Proteins; Colorectal Neoplasms; CpG Islands | 2006 |
[Irinotecan in combination with 5-fluorouracil and leucovorin in the treatment of metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neo | 2005 |
Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Down-Regulation; Drug Interactions | 2006 |
Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Capecitabine; Cohort Stud | 2005 |
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2005 |
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2005 |
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecit | 2006 |
Unresectable hepatic colorectal metastases: need for new surgical strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2006 |
Irinotecan with bolus and infusional 5-flurouracil and folinic acid for patients with advanced or metastatic colorectal cancer previously treated with 5-flurouracil: a possible alternative to single-agent irinotecan in a 'real-life' setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2005 |
Longterm results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: longterm survival can be achieved in patients with multiple bilateral liver metastase
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cryotherapy; Female; Fluorouracil; Foll | 2006 |
Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype.
Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma; Colorectal Neoplasms; DNA Primers; DNA, Compleme | 2006 |
Capecitabine-induced severe hypertriglyceridemia: report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycy | 2006 |
in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Pr | 2006 |
Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydr | 2006 |
Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; C | 2005 |
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials | 2005 |
Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappaB and upregulation of BCL-2 and BCL-XL.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Carrier Proteins; Colorectal Neoplasms; C | 2006 |
[Clinical administration of oxaliplatin for patients previously treated for refractory advanced or recurrent colorectal cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 2006 |
Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Ad | 2006 |
On prejudice and facts and choices.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
[Chemotherapy and MSI status].
Topics: Antimetabolites, Antineoplastic; Chromosomal Instability; Colorectal Neoplasms; Fluorouracil; Humans | 2005 |
An integrated psychological strategy for advanced colorectal cancer patients.
Topics: Adaptation, Psychological; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Col | 2006 |
Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experiences.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorect | 2006 |
Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2006 |
Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases.
Topics: Acetates; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; | 2006 |
Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Cytokines; Dihydrour | 2006 |
Reader comments on the cost of cancer care.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2006 |
[Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2006 |
[Method of levofolinate.5-FU administration by hepatic arterial infusion therapy for hepatic metastasis from colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarr | 2006 |
Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2006 |
[Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2006 |
Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Colorec | 2006 |
Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mutational An | 2006 |
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of T3 human colorectal carcinoma.
Topics: 5'-Nucleotidase; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; CD3 Complex; Colorectal | 2006 |
[Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer].
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colorectal Neoplasms; Drug Therapy, Combination; | 2006 |
5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer.
Topics: Animals; Cell Count; Cell Survival; Colorectal Neoplasms; Disease Models, Animal; Flow Cytometry; Fl | 2006 |
5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis.
Topics: Aged; Aged, 80 and over; Colon; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fl | 2006 |
Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Haplotype | 2006 |
Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Huma | 2006 |
Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorour | 2006 |
Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2006 |
Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capec | 2006 |
A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Therapy, Comb | 2006 |
Individualizing chemotherapeutic treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bilirubin; Biomark | 2006 |
In response to: 'On prejudice and facts and choices', an editorial by Kohne and Folprecht.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Choice Behavior; Clinical T | 2006 |
[Outpatient based colorectal cancer treatment--the current status, challenges and future outlook].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2006 |
Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Colorectal Neopl | 2006 |
Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Base Pair Mismatch; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm | 2006 |
The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Chemotherapy, Adjuvant; C | 2006 |
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Disease-Free Survi | 2007 |
Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemother | 2006 |
Neoadjuvant therapy with bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8.
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Base Sequence; Caco-2 Cells; Cell | 2006 |
Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients.
Topics: Aged; Alanine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Combined Modality Therapy | 2006 |
Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
Topics: Antibodies, Monoclonal; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; | 2006 |
[Clinical study of 5-Fluorouracil and l-Leucovorin therapy for 56 patients with advanced recurrent colorectal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
Adaptive design: estimation and inference with censored data in a semiparametric model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Computer Simulation; Confidenc | 2007 |
Prognostic impact of orotate phosphoribosyl transferase activity in resectable colorectal cancers treated by 5-fluorouracil-based adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal | 2006 |
Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut.
Topics: Animals; Antioxidants; Apoptosis; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Admin | 2006 |
Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Deoxyuridine; Fe | 2007 |
Turning point for colorectal cancer clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studi | 2006 |
Progress with biological agents in metastatic colorectal cancer leads to many challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplas | 2006 |
Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2006 |
A computationally simple bivariate survival estimator for efficacy and safety.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biometry; Clinical Trials, Ph | 2006 |
Case-based discussion for the management of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Monitoring; | 2006 |
Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Clinical Trials as | 2006 |
Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cyclohexanecarboxylic | 2006 |
Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.
Topics: Adult; Aged; Anemia; Black or African American; Breath Tests; Carbon Dioxide; Colorectal Neoplasms; | 2006 |
Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
Topics: Adult; Aged; Colorectal Neoplasms; Contrast Media; Female; Fluorouracil; Gadolinium DTPA; Humans; Im | 2007 |
Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Adhesion; Cell Proliferation; Cell Shape; | 2007 |
Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA-Binding Prote | 2006 |
The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; | 2006 |
Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy.
Topics: 5' Untranslated Regions; Alleles; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neop | 2006 |
Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease | 2006 |
Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2006 |
Is thymidylate synthase a reliable predictor for response and survival during hepatic arterial infusion for hepatic metastases from colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Genotype; Hepati | 2006 |
Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma.
Topics: Adenine; Aged; Alleles; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Mutational Ana | 2007 |
Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; | 2006 |
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Caco-2 Cells; Capecitabine; Carcino | 2006 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2007 |
A case of acute myocardial infarction during 5-fluorouracil infusion.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Coronary Angiography; Creatine Kinase, MB For | 2006 |
Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies | 2007 |
Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Benefits and risks of neoadjuvant therapy for liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hum | 2006 |
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo | 2006 |
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo | 2006 |
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo | 2006 |
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo | 2006 |
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2006 |
Suppression of colorectal tumor growth by regulated survivin targeting.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Caspases; Cell Line; Cel | 2006 |
OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Data Interpretation, Statistic | 2006 |
The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil D | 2007 |
Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2006 |
Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast | 2007 |
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T | 2007 |
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T | 2007 |
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T | 2007 |
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T | 2007 |
FDG-PET in colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Clinic | 2006 |
Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; | 2006 |
Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Base Pair Mismatch; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm | 2006 |
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relati | 2007 |
Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Drug | 2007 |
Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort St | 2006 |
Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplas | 2006 |
Role of IKK and oscillatory NFkappaB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorourac | 2007 |
A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cancer Care Faciliti | 2007 |
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor | 2007 |
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Color | 2007 |
5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administrat | 2006 |
Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 2006 |
[A phase I study of combination-therapy using personalized peptide vaccine and UFT/UZEL for advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; | 2006 |
[Two cases of multiple liver metastases from colorectal cancer which responded well to hepatic arterial infusion (HAI) using 5-fluorouracil and l-leucovorin].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2006 |
[Hepatic arterial infusion of low-dose leucovorin/5-FU chemotherapy for unresectable hepatic metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; | 2006 |
[The relationship between plasma level of VEGF or soluble Flt-1 and efficacy of hepatic arterial chemotherapy in patients with liver metastasis of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic | 2006 |
Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Col | 2006 |
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxa
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA-Bindin | 2007 |
Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis.
Topics: Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia | 2007 |
Old age: biologic versus chronologic.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; | 2007 |
Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2007 |
Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Erythema; | 2007 |
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2007 |
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neopl | 2007 |
Compression coated systems for colonic delivery of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Boswellia; Chemistry, Pharmaceutical; Colon; Colorectal Ne | 2007 |
Integrating Chinese and conventional medicine in colorectal cancer treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidin | 2007 |
[Chemotherapy for elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combine | 2007 |
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2007 |
Mechanistic analysis and comparison of viral fusogenic membrane proteins for their synergistic effects on chemotherapy.
Topics: Animals; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, | 2007 |
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
Topics: 5' Untranslated Regions; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neo | 2007 |
Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Colorectal Neoplasms; Dihydrouracil Dehy | 2007 |
[Construction of lentivirus producing PLC-gamma1 siRNA and its effect on apoptosis of human colorectal carcinomas cell lines].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasm | 2007 |
[Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcium; Colorectal Neoplas | 2007 |
[Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; C | 2007 |
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2007 |
Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Huma | 2007 |
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemo | 2007 |
Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2007 |
Size matters. What can we learn from a small randomized trial?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Interpretat | 2007 |
[Outpatient chemotherapy of an advanced or metastatic colorectal cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2006 |
[Present status of home therapy cancer patients using an infusor].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2006 |
[The future of chemotherapy at home--from outpatient chemotherapy to chemotherapy at home].
Topics: Ambulatory Care; Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2006 |
Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square Distribution; Color | 2007 |
The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
[Comparisons of standard treatments for colorectal cancer between Japan and Western Countries].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2007 |
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Chemothe | 2007 |
Two cases of severe liver injury possibly related to 5-fluorouracil and calcium folinate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Cholestasis, Intrahepatic; Colorectal Neoplasms; Fluorou | 2007 |
Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2007 |
Quantitative imaging of apoptosis commitment in colorectal tumor cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; DNA D | 2007 |
Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
Topics: Aged; Antimetabolites; Collagen; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; F | 2008 |
Antitumour effects on human colorectal carcinomas cells by stable silencing of phospholipase C-gamma 1 with lentivirus-delivered siRNA.
Topics: Apoptosis; Cell Adhesion; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Laminin; Len | 2007 |
Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2007 |
Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model.
Topics: Animals; Colorectal Neoplasms; Cytosine Deaminase; Disease Models, Animal; Female; Flucytosine; Fluo | 2007 |
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2008 |
Measurement of DPD and TS transcripts aimed to predict clinical benefit from fluoropyrimidines: confirmation of the trend in Russian colorectal cancer series and caution regarding the gene referees.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Artifa | 2007 |
Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2007 |
[A case of liver failure associated with liver damage due to mFOLFOX 6 after resection for multiple liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 2007 |
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2007 |
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Ce | 2007 |
Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal | 2007 |
Questions about the role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cryotherapy; Data Interpretati | 2007 |
Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy.
Topics: Age Factors; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluor | 2007 |
Treatment of superior vena cava (SVC) syndrome and inferior vena cava (IVC) thrombosis in a patient with colorectal cancer: combination of SVC stenting and IVC filter placement to palliate symptoms and pave the way for port implantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization, Peripheral; Colorectal Neoplasms; C | 2008 |
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Topics: Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydr | 2007 |
Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2007 |
Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; C | 2007 |
Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer.
Topics: Adenoviridae; Adenovirus E1B Proteins; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting | 2008 |
[Myocardial ischaemia as a result of treatment with capecitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fl | 2007 |
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorec | 2008 |
Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2007 |
Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian Peopl | 2007 |
Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antidotes; Antimetabolites, Antineoplastic; Antineopl | 2007 |
Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2007 |
Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Cohor | 2008 |
[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 2007 |
In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines.
Topics: Blotting, Western; Carcinoembryonic Antigen; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplas | 2007 |
The synergistic effect of 5-aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein | 2006 |
Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chemot | 2007 |
Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availab | 2008 |
The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gastr | 2008 |
Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal N | 2007 |
Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Pai | 2007 |
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2007 |
Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever.
Topics: Adenocarcinoma; Amyloidosis, Familial; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryo | 2007 |
Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycy | 2007 |
Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Cont | 2007 |
The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2007 |
Regression of radiation-induced macular edema after systemic bevacizumab.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetab | 2007 |
Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials | 2007 |
Isolated splenic metastasis from colorectal mucinous carcinoma.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co | 2006 |
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Di | 2007 |
In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Proliferation; Colorectal Neop | 2007 |
[Drug information brochure for patients undergoing FOLFOX 4 chemotherapy based on survey of adverse reactions].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Information | 2007 |
[A case of resection of synchronous multiple liver metastases from colorectal cancer after hepatic infusion chemotherapy and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined | 2007 |
Swainsonine reduces 5-fluorouracil tolerance in the multistage resistance of colorectal cancer cell lines.
Topics: Animals; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Tole | 2007 |
Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Feasibility Studi | 2008 |
Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2008 |
Carcinoma-rectum in an 11 years old boy.
Topics: Child; Colorectal Neoplasms; Fluorouracil; Humans; Laparotomy; Leucovorin; Male | 2007 |
Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; C | 2008 |
Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2008 |
Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; CpG Islands; DNA Methylation; Female; Fluorouraci | 2007 |
The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cohort Stud | 2008 |
Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diabetes M | 2007 |
Comments on final report of the AIO Colorectal Cancer Group Study: fluorouracil/oxaliplatin versus capecitabine/oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2007 |
Capecitabine plus oxaliplatin in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2007 |
5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; HT29 Cells; Hu | 2008 |
Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Colorecta | 2007 |
Progression-free survival is a surrogate for survival in advanced colorectal cancer.
Topics: Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Leucovorin | 2007 |
CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin | 2008 |
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxyc | 2008 |
Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases.
Topics: Adenocarcinoma; Adenoma; Aged; Antineoplastic Agents; Colon; Colonic Polyps; Colonoscopy; Colorectal | 2007 |
Central venous access port-related complications in outpatient chemotherapy for colorectal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter | 2007 |
Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydropyrimi | 2007 |
Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2007 |
CAIRO and FOCUS.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2007 |
[Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2007 |
Adjuvant chemotherapy of colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Su | 2007 |
Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Colorectal Neoplasms; Drug | 2008 |
Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; | 2008 |
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2007 |
Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2008 |
[Results of hepatic arterial infusion chemotherapy with 5-FU and leucovorin for unresectable liver metastases from colorectal cancer].
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusio | 2008 |
Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2008 |
Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2007 |
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; C | 2008 |
Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admi | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2008 |
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabi | 2008 |
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore | 2008 |
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Chemotherapy, Adjuvant; Colectomy; Color | 2008 |
[Chemotherapy in patients with colorectal carcinoma: applicability of data from clinical trials for the individual patient].
Topics: Age Factors; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Mod | 2008 |
Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2008 |
Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, | 2008 |
Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fibroblast Growth Factor 7; Fl | 2008 |
Systemic therapy for metastatic colorectal cancer: current questions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Capecitabine; Clinical Trial | 2008 |
[Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2008 |
[A successfully resected case of colorectal cancer with multiple liver metastases treated with FOLFIRI after failure of mFOLFOX6].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colonoscopy; Colore | 2008 |
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine | 2008 |
Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasm | 2008 |
A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad | 2008 |
[Evaluation of efficacy and influence factors of transarterial interventional therapy in patients with liver metastasis from malignancy of alimentary tract].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, T | 2007 |
Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2008 |
[Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; | 2008 |
Sequential vs combination colorectal cancer therapy sparks debate.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Color | 2008 |
[Expression of APRIL in colorectal carcinoma tissues and effects of chemotherapeutic agents on APRIL expression in colorectal carcinoma SW480 cells].
Topics: Adult; Aged; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; | 2008 |
CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; | 2008 |
[Therapy of colorectal carcinoma. To combine saves lives].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2004 |
Will we ever be ready for blood level-guided therapy?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Body Surface Area; Colorectal Neoplasms; Drug Admin | 2008 |
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Cape | 2008 |
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Color | 2008 |
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Color | 2008 |
Chemotherapy in elderly patients with colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2008 |
Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2008 |
5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorect | 2008 |
Adjuvant chemotherapy for rectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival | 2008 |
SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; Colorectal Neopl | 2008 |
Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2008 |
[Non-resectable metastases from colorectal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carboxylesterase; Colorectal Neopla | 2008 |
XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2007 |
[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian Peop | 2007 |
[Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2008 |
[Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2008 |
Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast.
Topics: Amino Acid Sequence; Antibodies, Monoclonal; Apoptosis; Blotting, Western; Carcinoembryonic Antigen; | 2008 |
Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine.
Topics: Antimetabolites, Antineoplastic; Brazil; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; | 2008 |
Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
Cimetidine and colorectal cancer--old drug, new use?
Topics: Antimetabolites, Antineoplastic; Cimetidine; Colorectal Neoplasms; Drug Synergism; Fluorouracil; For | 1995 |
Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer.
Topics: Acute-Phase Proteins; Biomarkers, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Fluorourac | 1995 |
Prognostic implications of chemoresistance-sensitivity assays for colorectal and appendiceal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Cell Survival; Colorectal Neoplasms; Dose | 1995 |
Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Chemoth | 1995 |
Long-term survival in two cases of colorectal carcinoma following a new chemotherapy regimen and subsequent metastasectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 1995 |
Chemotherapy for colorectal carcinoma: observations regarding recent clinical trials using biochemical modulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1995 |
Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1995 |
A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1995 |
The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat.
Topics: Administration, Topical; Animals; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Fl | 1995 |
Inhibitory effect of simultaneous intraportal administration of 5-fluorouracil, uracil and degradable starch microspheres on experimental hepatic micrometastasis, is of colon cancer.
Topics: Animals; Colorectal Neoplasms; Fluorouracil; Infusions, Intravenous; Liver Neoplasms; Male; Mice; Mi | 1994 |
Chemotherapy of colorectal cancer.
Topics: Colorectal Neoplasms; Fluorouracil; Humans | 1995 |
Re: Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Synergism; Fluor | 1995 |
A new complication of chemotherapy administered via permanent indwelling central venous catheter.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Carbonate; Catheterization, Cen | 1995 |
Dermatological toxicity from chemotherapy containing 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1994 |
Dutch trial casts doubt on colorectal adjuvant therapy.
Topics: Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; E | 1995 |
Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line.
Topics: beta 2-Microglobulin; Blotting, Northern; Colorectal Neoplasms; DNA Probes; Drug Synergism; Drug The | 1995 |
Chemotherapy for colorectal carcinoma: one small step forward, one step backward.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Survival Rate | 1995 |
Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions.
Topics: Carcinoma; Catheterization, Peripheral; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Stability | 1995 |
[Home therapy approach in cancer patients-chemotherapy (case 2-3)--intra-arterial infusion cancer chemotherapy for hepatic metastasis of colorectal cancer--case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic | 1994 |
[Surgical therapy of liver metastases. Therapeutic procedures, results and prognostic factors].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chem | 1994 |
Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach.
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Data Interpretation, Statistical; Female; Fluorou | 1994 |
Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells.
Topics: Cell Cycle; Cell Survival; Colorectal Neoplasms; DNA, Neoplasm; DNA, Ribosomal; Dose-Response Relati | 1994 |
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.
Topics: Actins; Adult; Aged; Base Sequence; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Regu | 1995 |
[Two cases of hepatic metastasis of colorectal cancer treated effectively by intrahepatic arterial infusion immunotherapy using OK-432, rIL-2, MMC and 5-FU].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sch | 1994 |
[The potentiation of toxic effects by the combined administration of 5-fluorouracil and folinic acid salts].
Topics: Clinical Trials as Topic; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination; Fluoroura | 1994 |
The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.
Topics: Ascites; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Fluorouracil; Humans; Injection | 1994 |
Management of advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1994 |
Drug monitoring of 5-fluorouracil: in vivo 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; H | 1994 |
Regional chemotherapy for colorectal liver metastases: thirty years without patient benefit.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Incidence; Infusions, Intra | 1994 |
5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin.
Topics: Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouraci | 1994 |
[The evolution of the liver metastases from colorectal carcinoma treated with hepatic intra-arterial chemotherapy. The echographic and CT aspects].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Floxuridine; Fluoro | 1994 |
Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1994 |
Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.
Topics: Animals; Biotransformation; Cell Division; Cell Survival; Chromatography, High Pressure Liquid; Colo | 1994 |
Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens.
Topics: Carboplatin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Evaluation; Drug Stabi | 1994 |
5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1994 |
Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche | 1993 |
Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1994 |
Local and systemic toxicity of intra-hepatic-arterial 5-FU and high-dose or low-dose leucovorin for liver metastases of colorectal cancer.
Topics: Aged; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 1994 |
[Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1993 |
Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats.
Topics: Animals; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Cytotoxicity, Immunologic; Fluo | 1994 |
Adjuvant 5-fluorouracil plus levamisole in colon cancer: the plot thickens?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 1994 |
[TS inhibition rate and flow cytometric analysis of DNA content in preoperative chemotherapy with biochemical modulator].
Topics: Administration, Oral; Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dipyridamole; DNA, | 1994 |
Cytokinetic effects of interferon in colorectal cancer tumors: implications in the design of the interferon/5-fluorouracil combinations.
Topics: Adult; Aged; Cell Cycle; Colorectal Neoplasms; Drug Interactions; Flow Cytometry; Fluorouracil; Huma | 1993 |
[Weekly hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouraci | 1993 |
Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.
Topics: Aged; Colorectal Neoplasms; Drug Resistance; Female; Fluorouracil; Humans; Infusions, Intravenous; I | 1993 |
[Treatment of liver metastases of colorectal tumors using intra-arterial fluorouracil to the liver, administered with a completely implantable access system and a portable infusion pump].
Topics: Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Infusions, Intra-Arteria | 1993 |
[Treatment of advanced colorectal cancer with long-term continuous infusion of 5-fluorouracil].
Topics: Aged; Ambulatory Care; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hum | 1994 |
Potentiation of 5-fluorouracil induced inhibition of thymidylate synthase in human colon tumors by leucovorin is dose dependent.
Topics: Binding Sites; Colonic Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Syner | 1993 |
[Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Fema | 1994 |
[5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1994 |
Fluorouracil and leucovorin: there is a choice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1993 |
Response to "More is not always better: a case for low-dose leucovorin".
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 1993 |
Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma.
Topics: Colorectal Neoplasms; Female; Fluorine Radioisotopes; Fluorouracil; Humans; Liver; Liver Neoplasms; | 1993 |
[Are there prognostic parameters for predicting the success of regional chemotherapy in nonresectable liver metastases of colorectal cancer?].
Topics: Adult; Aged; Biomarkers, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouraci | 1993 |
Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon.
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Drug Synergism; Fluorouracil; Humans; | 1993 |
The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1993 |
[Continuous intra-hepatic-arterial infusion of low dose 5-fluorouracil for colorectal cancer patients with unresectable liver metastases].
Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusion Pum | 1993 |
[Arterial infusion chemotherapy of 5-FU and leucovorin for patients with liver metastases from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1993 |
[Intra-arterial chemotherapy with 5-FU (weekly high dose 5-FU HAI) for the prevention of tumor recurrence in residual liver after hepatic resection of metastasis from colorectal cancer].
Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans; | 1993 |
[Efficacy of hepatic arterial and intraportal infusion chemotherapy for liver metastasis of colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colorectal | 1993 |
Perfusion of colorectal liver metastases and uptake of fluorouracil assessed by H2(15)O and [18F]uracil positron emission tomography (PET).
Topics: Colorectal Neoplasms; Fluorine Radioisotopes; Fluorouracil; Humans; Liver Neoplasms; Oxygen Radioiso | 1993 |
Continuous intravenous infusion of leucovorin and 5-fluorouracil for the treatment of advanced colorectal and breast cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; | 1993 |
In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase.
Topics: Animals; Cell Division; Colorectal Neoplasms; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; | 1993 |
Follow-up study of patients treated with monoclonal antibody-drug conjugate: report of 77 cases with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 1993 |
[The treatment of liver metastases of colorectal tumors using intra-arterial fluorouracil via hepatic artery, administered with a completely implantable access system and a portable infusion pump].
Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Inf | 1993 |
[Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pr | 1993 |
Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues.
Topics: Adenocarcinoma; Colorectal Neoplasms; Culture Techniques; Fluorouracil; Folic Acid; Humans; Leucovor | 1993 |
Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.
Topics: Adult; Aged; Animals; Colorectal Neoplasms; Female; Fluorodeoxyuridylate; Fluorouracil; Gas Chromato | 1993 |
More is not always better: a case for low-dose leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 1993 |
[Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1993 |
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
Topics: Adenocarcinoma; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols | 1993 |
A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase.
Topics: Amino Acid Sequence; Animals; Base Sequence; Cloning, Molecular; Colorectal Neoplasms; Cytosine Deam | 1993 |
[Treatment of advanced gastric and colorectal cancer with 5-FU, leucovorin and interferon-alpha].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1993 |
Intermittent continuous intravenous infusion of 5-fluorouracil; a useful approach in disseminated colorectal cancer?
Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middl | 1993 |
Response of soluble IL-2 receptor levels to repeated cycles of IL-2 immunotherapy/chemotherapy.
Topics: Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Interleukin-2; Leukocy | 1993 |
Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Infusions, | 1993 |
Marked fluctuations in drug plasma concentrations caused by use of portable pumps for fluorouracil continuous infusion.
Topics: Ambulatory Care; Colorectal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Infusion Pumps | 1993 |
[Follow up of liver metastases using computed tomography in colorectal cancer treated with interferon-alpha and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Follow-U | 1993 |
Have enteric infections a role in 5-fluorouracil-associated diarrhea?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bacterial Infections; Colorectal Neoplasms; Diarrhea; | 1995 |
5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Topics: Animals; Carcinoma; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Synergism; Enzyme | 1995 |
Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma.
Topics: Adult; Antineoplastic Agents; Carcinoma; Chemotaxis, Leukocyte; Chemotherapy, Adjuvant; Colorectal N | 1995 |
Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer.
Topics: Base Sequence; Cell Death; Cloning, Molecular; Colorectal Neoplasms; Cytosine Deaminase; Escherichia | 1996 |
Adjuvant treatment for colorectal cancer.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1996 |
Bioavailability of subcutaneous 5-fluorouracil: a case report.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biological Availability; Carcinoma; Colorectal Neoplasms | 1996 |
p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluoroura | 1996 |
Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Female | 1996 |
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Body Weight; Colorectal Neoplasms; Deoxygluc | 1996 |
Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fema | 1995 |
Re: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu | 1996 |
Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions | 1996 |
[The clinical evaluation of hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer employing an implanted port system].
Topics: Aged; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantabl | 1996 |
[Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo].
Topics: Animals; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Lung Neoplasms; Mice; Mice, | 1996 |
p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neo | 1996 |
Response to regional chemotherapy in patients with variant hepatic arterial anatomy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusio | 1996 |
Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Colorectal Neoplasms; DNA Damage; DNA, N | 1996 |
[Rhythmic component of twelve hours].
Topics: Adult; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Bone Marrow Cells; Buthionine Sulf | 1996 |
Adjuvant treatment of colorectal cancer in The Netherlands: a commentary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro | 1996 |
Canities--reversal with chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm | 1995 |
Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival.
Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Chromatography, | 1996 |
Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Appendiceal Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans | 1996 |
[Locoregional therapy for liver metastases of colorectal cancer].
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm | 1996 |
[Hepatic intra-arterial 5-fluorouracil and CDDP administration in patients with colorectal cancer metastasis to the liver].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorecta | 1996 |
[Indication of prophylactic hepatic arterial-infusion chemotherapy after hepatic resection for liver metastases from colorectal cancer].
Topics: Colorectal Neoplasms; Doxorubicin; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusi | 1996 |
Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliar | 1996 |
Interferons as biochemical modulators.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Synergism; Fl | 1996 |
Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Doxorubicin; Drug Screening Ass | 1996 |
5-Fluorouracil in colorectal cancer, a never ending story.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 1996 |
Primary resection and synchronous regional hepatic chemotherapy or cryotherapy for colorectal cancer with liver metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; | 1996 |
Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost-B | 1996 |
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal N | 1996 |
Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; | 1997 |
p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis.
Topics: Adult; Aged; Colorectal Neoplasms; Disease Progression; Drug Therapy, Combination; Female; Fluoroura | 1996 |
[Clinical study of home hepatic arterial infusion chemotherapy for liver metastasis from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disposable Eq | 1996 |
Major upper gastrointestinal haemorrhage associated with hepatic arterial chemoperfusion.
Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Duodenal Ulcer; Female; Fluorouracil; Gastrointestina | 1996 |
Simultaneous 3D NMR spectroscopy of proton-decoupled fluorine and phosphorus in human liver during 5-fluorouracil chemotherapy.
Topics: Absorption; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fl | 1997 |
Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2'deoxyuridine in patients with liver metastases from colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Feasibility Studies; Fluorouracil; Huma | 1996 |
Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemot | 1997 |
Combined preoperative irradiation and direct postoperative 5-fluorouracil without negative effects on early anastomotic healing in the rat colon.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Colorectal Neop | 1996 |
Role of portal vein chemotherapy following failure of previous treatment for advanced colorectal hepatic metastases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, | 1997 |
Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil | 1997 |
Role of interferon as a modulator of fluoropyrimidines: reply to a recent editorial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Interfer | 1997 |
5-Fluorouracil-based treatment of patients with advanced colorectal carcinoma outside clinical trials: importance of limited toxicity.
Topics: Antidotes; Antineoplastic Agents; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Hum | 1997 |
5-Fluorouracil revisited: a new perspective for treatment planning.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans | 1997 |
Enhancing the effect of anticancer drugs against the colorectal cancer cell line with electroporation.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cell Division; Cisplatin; Colorectal Neoplasms; Electropo | 1996 |
Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer.
Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Ce | 1997 |
Adverse effects of intraportal chemotherapy on natural killer cell activity in colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Chemotherapy, Adjuvant; Colorect | 1997 |
Regional adjuvant chemotherapy after partial hepatectomy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Chemotherapy, Ad | 1997 |
High-performance liquid chromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Erythrocytes; Fluorouracil; Humans; Reproduci | 1997 |
[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Flo | 1997 |
Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as | 1997 |
Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats.
Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Differentiatio | 1997 |
Locally advanced primary colorectal cancer: IOERT and EBRT +/-5-FU.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Huma | 1997 |
Locally recurrent colorectal cancer: IOERT and EBRT +/-5-FU and maximal resection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Femal | 1997 |
Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report.
Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enterocolitis; Fluorouracil; Human | 1997 |
Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorine Radioisotopes; | 1997 |
[Determination of dihydropyrimidine dehydrogenase in the prediction of toxic side effects of 5-fluorouracil].
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydro | 1997 |
Should patients with advanced colorectal cancer be treated with chemotherapy?
Topics: Antimetabolites, Antineoplastic; Clinical Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Di | 1997 |
Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1997 |
Use of intraperitoneal 5-fluorouracil and chlorhexidine for prevention of recurrence of perforated colorectal carcinoma in a rat model.
Topics: Animals; Anti-Infective Agents, Local; Antimetabolites, Antineoplastic; Chlorhexidine; Colorectal Ne | 1997 |
Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Fluorouracil; Follow | 1997 |
[Combined intra-arterial locoregional and systemic treatment of nonresectable hepatic metastases of colorectal carcinoma].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic | 1997 |
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.
Topics: Actins; Aged; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration | 1997 |
A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America.
Topics: Argentina; Brazil; Chemotherapy, Adjuvant; Colorectal Neoplasms; Costs and Cost Analysis; Drug Combi | 1997 |
Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colo | 1997 |
Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; CCAAT-Enhancer-Binding Proteins; Col | 1997 |
First line protracted venous infusion fluorouracil with CisDDP or carboplatine in advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; | 1997 |
[Hepatic arterial chemotherapy for liver cancer over a period of 8 years].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Epirubicin; Female; | 1997 |
[Continuous hepatic arterial infusion of fluorouracil with leucovorin for liver metastases from colorectal cancer].
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antidotes; Colorectal Neoplasms; Drug Administ | 1997 |
[Evaluation of CTA for arterial infusion chemotherapy for liver metastasis from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Hep | 1997 |
[A new two-part therapy for multiple bilobar liver metastases of colorectal cancer--treatment of one lobe with partial hepatectomy and the other with arterial chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda | 1997 |
[Hepatectomy and intra-arterial infusion chemotherapy for hepatic metastasis of colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorourac | 1997 |
[Combination hepatic intra-arterial 5-fluorouracil and CDDP administration with oral regimen in patients with colorectal cancer metastasis to the liver].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne | 1997 |
[Complication due to arterial infusion chemotherapy for liver metastasis from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Choles | 1997 |
A pilot study of multimodality therapy for initially unresectable liver metastases from colorectal carcinoma: hepatic resection after hepatic arterial infusion chemotherapy and portal embolization.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modal | 1997 |
5-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1997 |
Previous intravenous chemotherapy does not alter response rate or survival time of patients with hepatic metastases from colorectal cancer treated by hepatic artery chemotherapy.
Topics: Antidotes; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms; Fluorour | 1997 |
Can antioxidants enhance chemotherapy?
Topics: Antioxidants; Apoptosis; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug | 1998 |
Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model.
Topics: Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colore | 1998 |
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas | 1998 |
Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F1 | 1998 |
[Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; H | 1998 |
Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Colo | 1998 |
5-Fluorouracil and mitomycin-C in colorectal cancer: unacceptable conclusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Mitomyci | 1998 |
Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female; Flu | 1998 |
No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; beta-Alanine; Circadian Rhythm; Colorectal Neoplasms; Dihydrouracil | 1998 |
[Combined therapy of metastatic liver neoplasms: intrahepatic chemoembolization and systemic chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 1998 |
A clinically applicable assay for tumoral thymidylate synthase combining reverse transcriptase-PCR and high-performance liquid chromatography.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Colorectal Neopl | 1998 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 1998 |
Irinotecan and 5-fluorouracil in colorectal cancer: time for a pause?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Clinical Trials, Phase II | 1998 |
Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cytosine | 1998 |
Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells.
Topics: Antimetabolites, Antineoplastic; Cell Count; Colorectal Neoplasms; Drug Resistance, Neoplasm; Floxur | 1998 |
Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fatty Liver; Female; Fluorouraci | 1998 |
Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorine Radioisotopes; Fluorouracil; Humans; | 1998 |
18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil.
Topics: Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Drug Interactions | 1998 |
[Low-dose leucovorin and interferon-alpha as modulators of 5-fluorouracil for adjuvant chemotherapy of colorectal cancer].
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Dose-Response Rel | 1998 |
Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
Topics: Acridines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; | 1998 |
[Intra-arterial preventive chemotherapy for residual liver after resection of hepatic metastasis from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorou | 1998 |
[Efficacy of combination therapy (hepatectomy and prophylactic arterial chemoinfusion) for liver metastases of colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Drug Administratio | 1998 |
[Preoperative CEA level predicts outcomes of hepatic resection for liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Neoplasms; Comb | 1998 |
Sources of error in tissue and tumor measurements of 5-[18F]fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Feasibility Studies; Fluorine Ra | 1998 |
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcino | 1998 |
5-Fluorouracil and mitomycin-C in colorectal cancer: unacceptable conclusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Mitomyci | 1998 |
Irinotecan: toward clinical end points in drug development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, P | 1998 |
Thymidylate synthase as a predictor of response.
Topics: Actins; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical T | 1998 |
US pivotal studies of irinotecan in colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 1998 |
Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neop | 1998 |
Radiologically placed hepatic artery catheter allows selection of patients with high-volume liver metastases for regional chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Catheterization, Peripheral; | 1998 |
Vasopressin selectively increases 5-fluorouracil uptake by colorectal liver metastases following hepatic artery bolus infusion.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Models, Animal; Dose-Respons | 1998 |
[Adjuvant regional arterial port chemotherapy after resection of colorectal liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin | 1998 |
[Continuous intravenous infusional 5-FU compared with bolus administration in metastatic colorectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, I | 1998 |
Patterns of serum CEA fall after hepatic arterial chemotherapy as sole therapy and combined with cryotherapy for colorectal metastases.
Topics: Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality T | 1998 |
Improved survival in patients with advanced colorectal carcinoma failing 5-fluorouracil who received irinotecan hydrochloride and have high intratumor C-fos expression.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans | 1998 |
Managing the side effects of chemotherapy for colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drugs, Investigational; Fluorouracil; Hum | 1998 |
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinoteca | 1998 |
Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Synergism; Fluorouracil; | 1998 |
Irinotecan may extend survival in people with metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, P | 1998 |
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carrier Pr | 1997 |
Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Colonic Neoplasms; Col | 1997 |
Clinical applications of the histoculture drug response assay.
Topics: Antineoplastic Agents; Cell Culture Techniques; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 1995 |
5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer.
Topics: Animals; Body Weight; Colorectal Neoplasms; Female; Fluorouracil; Leucovorin; Metabolic Clearance Ra | 1995 |
Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as | 1996 |
CT of calcified liver metastases in colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Calcinosis; Colorectal Neoplasms; Fluorouracil; Humans; Liver Disea | 1998 |
Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Di | 1998 |
Interleukin-2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5-fluorouracil resistance.
Topics: Animals; Butyrates; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Interleukin-2; Li | 1998 |
Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; | 1998 |
Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms; Drug Administration Schedule; | 1998 |
Second line treatment options in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance, Multiple; Dru | 1998 |
Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Half- | 1998 |
The natural history of liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1998 |
Hepatic cryotherapy and subsequent hepatic arterial chemotherapy for colorectal metastases to the liver.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; Femal | 1998 |
Autoregulation of 5-fluorouracil metabolism.
Topics: Animals; Antidotes; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Hemostas | 1998 |
Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1999 |
Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Colorectal Neoplasms; Disease Models, Animal; Drug Combin | 1999 |
A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Asialoglycoprotein Receptor; Cell Membrane; Co | 1999 |
The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluorouracil; Huma | 1999 |
Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Aorta; Colorectal Neoplasms; Female; Fluorine Ra | 1999 |
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aspartic Acid; Co | 1999 |
Quality of life in advanced colorectal cancer.
Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Interferon a | 1999 |
Treatment of colorectal carcinoma in adolescents and young adults with surgery, 5-fluorouracil/leucovorin/interferon-alpha 2a and radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant | 1999 |
The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Camptothecin; Colorectal Neoplasms | 1999 |
Electrochemotherapy against colorectal carcinoma: comparison of in vitro cytotoxicity of 5-fluorouracil, cisplatin and bleomycin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bleomycin; Cell Membrane Permeability; Cisplatin; Co | 1999 |
Second line therapies move to the forefront in colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, C | 1999 |
Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cispla | 1999 |
[Efficacy and toxicity spectrum of continuous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal tumors].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; | 1999 |
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Ne | 1999 |
Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery.
Topics: Animals; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Fluorouracil; Injec | 1999 |
Hospitalization for 5-FU toxicity in metastatic colorectal cancer: incidence and cost.
Topics: Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasms; Cost of Illness; Drug Hyperse | 1999 |
Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Bayes Theorem; Body Fluid Compartments; Circadian Rhythm; Col | 1999 |
Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; | 1999 |
Adjuvant regional chemotherapy after hepatic resection for colorectal metastases.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co | 1999 |
The integrated treatment of peritoneal carcinomatosis. A preliminary experience.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Carcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cance | 1999 |
Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Survival; Cloning, Molecular; Colorectal Neoplasms; DNA, | 1999 |
[Comparative study of histopathological effects of preoperative chemotherapy using UFT and in vitro MTT assay of colonoscopy specimens from patients with colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Colorectal Neoplasms; Drug Administrati | 1999 |
Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biotransformation; Body Weight; Chromatogr | 1999 |
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Female | 1999 |
Positive interaction between 5-FU and FdUMP[10] in the inhibition of human colorectal tumor cell proliferation.
Topics: Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Drug Synergism; Fluorodeoxyuri | 1999 |
[Intraarterial infusion therapy for unresectable liver metastasis of colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fe | 1999 |
[Complete responses in patients with unresectable liver metastases from colorectal cancer with weekly high-dose 5-FU plus one-shot CDDP HAI].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administ | 1999 |
[Management after hepatectomy of colorectal cancer metastases to the liver--intrahepatic arterial infusion chemotherapy and repeated hepatectomy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1999 |
[Complications related to hepatic arterial infusion chemotherapy for liver metastasis from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin | 1999 |
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1999 |
Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFN-gamma through caspase 3 and caspase 8.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Blotting, | 1999 |
[Hemodynamics at hepatoarterial infusion of 5-FU in a chronic renal failure patient maintained by hemodialysis].
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; I | 1999 |
Cancer immunomodulation by carbohydrate ligands for the lymphocyte receptor NKR-P1.
Topics: Animals; Antigens, Surface; Antimetabolites, Antineoplastic; Azoxymethane; Carcinogens; Colorectal N | 2000 |
Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Interactions; Female; Fluor | 2000 |
Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma.
Topics: Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C | 2000 |
Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cos | 1999 |
Standard dose (Mayo regimen) 5-fluorouracil and low dose folinic acid: prohibitive toxicity?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administ | 2000 |
alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; beta-Alanine; Colonic Neoplasms; Colorectal Neoplasms; Dru | 2000 |
Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2000 |
[Evaluation of hepatic toxicity following high-dose 5-FU arterial infusion chemotherapy: analysis of 42 cases of colorectal liver metastases].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Atrophy; Chemical and Drug Induced Liver Injury; Color | 2000 |
Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2000 |
Changes in thymidylate synthase mRNA in blood leukocytes from patients with colorectal cancer after bolus administration of 5-fluorouracil.
Topics: Adult; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Injectio | 2000 |
Hepatic arterial chemotherapy: still on trial.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra- | 2000 |
Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts.
Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Divis | 2000 |
Recent advances in colorectal chemotherapy: oral fluorinated pyrimidines, oxaliplatin and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2000 |
Morphological change, loss of deltapsi(m) and activation of caspases upon apoptosis of colorectal adenocarcinoma induced by 5-FU.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Nucleus; Colorectal Neopl | 2000 |
Theoretical considerations and in vitro concentration response studies with two human colorectal carcinoma cell lines. The rational experimental base for clinical studies in regional chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Data Interpret | 2000 |
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Intestinal Di | 2000 |
[Thymidylate synthase activity after preoperative administration of 5-FU in patients with gastric or colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administ | 2000 |
Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.
Topics: Adenocarcinoma; Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; | 2000 |
Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Drug Resistance, Neoplasm; Dru | 2000 |
[Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer].
Topics: Antineoplastic Agents; Autoantibodies; Cisplatin; Colorectal Neoplasms; Drug Screening Assays, Antit | 2000 |
[Weekly low-dose CPT-11 and HCFU for advanced colorectal cancer on an outpatient treatment basis].
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Pr | 2000 |
Technetium-99m labelled macroaggregated albumin arterial catheter perfusion scintigraphy: prediction of gastrointestinal toxicity in hepatic arterial chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Catheterization, Peripheral; Colorectal Neopl | 2000 |
[The role of interval surgery and irradiation in the treatment of primarily non-resectable rectal cancers].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; | 2000 |
dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Cell Survival; Cells, Cultured; Colon; Colonic Neoplasms; Colorectal | 2000 |
Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2000 |
Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis | 2000 |
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Endothelium, Vascular; Fluorouracil; | 2000 |
Adjuvant chemotherapy for colorectal cancer: a Malaysian experience.
Topics: Adolescent; Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; | 1997 |
Chemotherapy for advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorourac | 2000 |
Validation of fluorouracil metabolite analysis in excised tumor. Lability of anabolites.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Models, Animal; Female; Fluo | 2000 |
[Apropos the article by M. V. Grinev and F. Kh. Abdusamatov "Cytoreductive surgery in the treatment of stage-4 colorectal cancer--is it justified?"].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; | 2000 |
Survival of colorectal cancer cell lines treated with paclitaxel, radiation, and 5-FU: effect of TP53 or hMLH1 deficiency.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytog | 2000 |
Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Division; Colorectal Neoplasms; DNA, Neopla | 2000 |
Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Colorectal Neoplasms; Drug Resistance; | 2000 |
Moving beyond fluorouracil for colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2000 |
Electrochemotherapy for colorectal cancer with commonly used chemotherapeutic agents in a mouse model.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cisplatin; Colorectal Neoplasms; Disease Models, Animal; | 2000 |
Tumour site, sex, and survival in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fl | 2000 |
Tumour site, sex, and survival in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; | 2000 |
Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2000 |
Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluorine | 2000 |
'Hold the Mayo': solid facts or pulp fiction?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; | 2000 |
Future treatment options with capecitabine.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neop | 2000 |
Role of BAX in the apoptotic response to anticancer agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; A | 2000 |
Adjuvant chemotherapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasm | 2000 |
[Case report--efficacy of short-term intraarterial 5-fluorouracil for liver metastasis from colorectal cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Dr | 2000 |
[Thymidylate synthase and dihydropyrimidine dehydrogenase activity in a metastatic liver tumor from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fl | 2000 |
[Continuous hepatic arterial infusion of 5-fluorouracil with leucovorin for unresectable liver metastases from colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug | 2000 |
[Efficacy of combination therapy for multiple liver metastases of colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality T | 2000 |
[Three cases in which CR was obtained in residual metastatic lesions by intrahepatic arterial infusion after resection of hepatic metastases from colorectal carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Drug Adminis | 2000 |
[Complications related to arterial infusion chemotherapy in patients with hepatic metastasis from colorectal cancer].
Topics: Adult; Aged; Arterial Occlusive Diseases; Biliary Fistula; Colorectal Neoplasms; Common Bile Duct; E | 2000 |
Surrogate endpoints for new colorectal cancer drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hum | 2000 |
A novel weekday-on/weekend-off UFT schedule.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2000 |
Can we predict response to 5-FU?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Genes, p5 | 2000 |
[Effect of Ruboxyl (nitroxyl derivative of daunorubicin) on hepatic metastases of colorectal carcinoma].
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Daunoru | 2000 |
Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm | 2000 |
Analysis of uracil DNA glycosylase in human colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Glycosylases; Dr | 2001 |
[Anaphylactoid shock due to folinic acid during treatment of metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anaphylaxis; Antimetabolites, Antineoplastic; Colorectal Ne | 2000 |
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Hu | 2001 |
[The prospects of the outpatient clinic or home anti-cancer chemotherapy for unresectable recurrence of colorectal cancer].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrh | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Interpretat | 2001 |
[Ambulatory chemotherapy schedule for metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2001 |
Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2001 |
Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2001 |
Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Biomarkers, T | 2001 |
Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Intestinal Absorption; | 2001 |
Quality of life in cancer patients treated by chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2000 |
Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody | 2001 |
Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2001 |
Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 2001 |
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Biomark | 2001 |
CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoembryonic Antigen; Colorectal | 2001 |
Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor | 2001 |
[The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine | 2001 |
[Oral cytostatic drug in colorectal carcinoma. Selective tumor therapy at home].
Topics: Administration, Oral; Ambulatory Care; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neo | 2001 |
A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2001 |
The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administra | 2001 |
Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colectomy; Colorec | 2001 |
[Correlation between 5-fluorouracil (5-FU) sensitivity as measured by collagen gel droplet embedded culture drug sensitivity test (CD-DST) and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydr
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Dru | 2001 |
Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2001 |
A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; D | 2001 |
[Results and limitations of arterial infusion therapy for liver metastases from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; | 2001 |
The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy.
Topics: Antibiotics, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; | 2001 |
[Tumoral levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in elderly colorectal cancer patients].
Topics: Age Factors; Aged; Aged, 80 and over; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Enzy | 2001 |
[Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?].
Topics: Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorec | 2001 |
The microsatellite instability phenotype in human colorectal carcinoma: relationship to sex, age, and tumor site.
Topics: Adult; Age Factors; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans | 2001 |
Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuva | 2001 |
[Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2001 |
Researchers urge caution with standard regimen for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2001 |
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Colorectal Neoplasms; | 2001 |
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2001 |
Xeloda in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color | 2001 |
Growth inhibition and apoptosis induced by P2Y2 receptors in human colorectal carcinoma cells: involvement of intracellular calcium and cyclic adenosine monophosphate.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Cell Division; Colorect | 2001 |
Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer.
Topics: Adult; Aged; Cell Cycle Proteins; Colorectal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasm | 2001 |
Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NAD | 2001 |
Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells.
Topics: Antineoplastic Agents; Carrier Proteins; Colorectal Neoplasms; Drug Delivery Systems; Drug Resistanc | 2001 |
Intra-arterial hepatic chemotherapy (IAHC) for liver metastases from colorectal cancer: need of guidelines for catheter positioning, port management, and anti-coagulant therapy.
Topics: Antimetabolites, Antineoplastic; Catheters, Indwelling; Colorectal Neoplasms; Fluorouracil; Hepatic | 2001 |
Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo.
Topics: Animals; Blotting, Western; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; M | 2001 |
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2001 |
Expression of metallothionein in colorectal cancers and synchronous liver metastases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 2001 |
p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cell Nucleus; Chemotherapy, Adjuvant; Colorectal Neopla | 2001 |
A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Primers; DNA, Neoplasm; Enhancer Elements | 2001 |
Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer.
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2001 |
Healing of experimental colonic anastomoses: effects of combined preoperative high-dose radiotherapy and intraperitoneal 5-fluorouracil.
Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Colonic Disease | 2001 |
Thymidine phosphorylase (TP) activation: convenience through innovation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxy | 2001 |
Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Colorectal Neoplasms; Ferredoxin-NADP Red | 2001 |
Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Bone Marrow; Carb | 2001 |
Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorectal Neoplasms | 2001 |
Pharmacodynamics induced by direct electric current for the treatment of 5-fluorouracil resistant tumor: an animal experiment.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Electric | 2001 |
Correlation between tumour blood flow and fluorouracil distribution in a hypovascular liver metastasis model.
Topics: Animals; Antimetabolites, Antineoplastic; Antipyrine; Calibration; Colorectal Neoplasms; Fluorouraci | 2000 |
The potential clinical value of GML and the p53 gene as a predictor of chemosensitivity for colorectal cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Proteins | 2001 |
[Adjuvant short-term continuous hepatoarterial infusion of 5-FU for advanced colorectal cancer using a removable hepatoarterial catheter].
Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Catheterization; Chemotherapy, Adjuv | 2001 |
[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Dehydrogen | 2001 |
[Four cases of multiple liver metastasis of colorectal cancer treated with hepatic resection after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; | 2001 |
Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as | 2001 |
Adjuvant chemotherapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 2001 |
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Colorect | 2001 |
Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Biomarkers, Tumor; Chemotherapy, Adjuva | 2001 |
Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Nucleus; Co | 2001 |
A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Codon; Colorectal Ne | 2001 |
[The advantages and disadvantages of administering anti-cancer chemotherapy at home].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fluorouracil; Home | 2001 |
Toxicity of irinotecan in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2001 |
[Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2002 |
Activity of boanmycin against colorectal cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Colorectal Neoplas | 2001 |
Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo | 2001 |
[Combination therapy including mutamycin (mitomycin C) in the treatment of advanced colorectal and gastric cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2001 |
[Personal experience with intra-arterial locoregional chemotherapy of liver metastases from colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Doxorubicin; Female | 2001 |
Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2002 |
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiovascular Diseases; Colorectal Ne | 2002 |
[5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases].
Topics: Aged; Colitis; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2002 |
Cimetidine in colorectal cancer--are the effects immunological or adhesion-mediated?
Topics: Antimetabolites, Antineoplastic; Cell Adhesion; Chemotherapy, Adjuvant; Cimetidine; Colorectal Neopl | 2002 |
Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2002 |
Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas | 2002 |
Vive la difference: sex and fluorouracil toxicity.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Sex Facto | 2002 |
Capecitabine monotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hu | 2001 |
Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluor | 2002 |
Thymidylate synthase levels: prognostic, predictive, or both?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2002 |
Echogenicity of liver metastases from colorectal carcinoma is an independent prognostic factor in patients treated with regional chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Female; Flox | 2002 |
Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil | 2002 |
Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2002 |
Prognostic factors for patients with metastatic colorectal cancer receiving protracted venous infusion of 5-FU.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans | 2002 |
Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.
Topics: Aged; Alleles; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Colorectal Neo | 2002 |
Thymidylate synthase polymorphism and survival of colorectal cancer patients treated with 5-fluorouracil.
Topics: Colorectal Neoplasms; Fluorouracil; Genetic Predisposition to Disease; Polymorphism, Genetic; Progno | 2002 |
[Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Colorectal Neoplasms; | 2002 |
Predictive values of sex and tumour site for survival benefit from 5FU in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasm | 2002 |
A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier.
Topics: Aluminum Silicates; Antimetabolites, Antineoplastic; Bentonite; Cations; Chromatography, Ion Exchang | 2002 |
Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorour | 2002 |
[Patient preference for oral chemotherapy].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Capsule instead of infusion--new oral chemotherapy option].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Femal | 2002 |
[Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms].
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2002 |
Cyclin D1 overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not k-ras mutation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; beta Catenin; Biomarkers, Tumor; Cell Division; Colore | 2002 |
Is the NICE process flawed?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Liver Ne | 2002 |
[Treatment for patients with liver metastasis from colorectal cancer--expansion of hepatic arterial infusion therapy].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver | 2002 |
Baseline quality of life predicts survival in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Cohort Studies; Colorec | 2002 |
[Recent advances in the diagnosis and treatment of colorectal cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; Feces; Fluoro | 2002 |
Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Colorectal Neoplasms; Dihydrouracil Dehydrogenase | 2002 |
Liver tumors: follow-up with P-31 MR spectroscopy after local chemotherapy and chemoembolization.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Fluorouraci | 1992 |
[Preoperative regional radiofrequency thermochemotherapy of colorectal cancer: clinical and pathological studies].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diathermy; F | 1992 |
[Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 1992 |
In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Survival; Colony-Forming Units Assay; Colorecta | 1992 |
Intraportal 5-fluorouracil for colorectal cancer: the AXIS trial.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans | 1992 |
Adjuvant treatment with 5-fluorouracil for colorectal cancer.
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Research Design | 1992 |
Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination.
Topics: Adenocarcinoma; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1992 |
Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma.
Topics: Aged; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; | 1992 |
[Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1992 |
Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance; | 1992 |
Chemotherapy for colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Colorectal Neopl | 1992 |
[Cytotoxic effects of the combination of a new nitrosourea, fotemustine, combined with 5-fluorouracil and folinic acid depend on the sequence of their administration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colorectal Neoplasms; Dose-Response R | 1992 |
[Signification of liver metastases of colorectal cancer with special reference to recurrence in the residual liver after hepatic resection].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubi | 1992 |
[Advance of chemotherapy and radiotherapy in colorectal cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1992 |
[Adjuvant treatment of rectal carcinoma: also a step forward?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal | 1992 |
On some applications of Bayesian methods in cancer clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials as Topic; Colorectal | 1992 |
The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer.
Topics: Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil | 1992 |
Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Thym | 1992 |
Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.
Topics: Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Drug Interactions; Fluorourac | 1992 |
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1992 |
Sequential methotrexate and fluorouracil in colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1992 |
Continuous 24-hour infusion of folinic acid does not increase the response rate of 5-fluorouracil but only the toxicity.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fema | 1992 |
Best treatment for colorectal cancer and confirmatory trials.
Topics: Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Randomized Control | 1992 |
Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 1992 |
High dose alpha-2b interferon + folinic acid in the modulation of 5-fluorouracil. A phase II study in advanced colorectal cancer with evidence of an unfavourable cost/benefit ratio.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorou | 1992 |
[Adjuvant therapeutic possibilities in carcinoma of colon and rectum].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colectomy; | 1992 |
Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 1992 |
[Antineoplastic chemotherapy in digestive tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Hum | 1991 |
Multiple confirmatory trials. How can additional studies be of value?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1991 |
5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA, Neoplasm; | 1991 |
Treatment of advanced colorectal cancer with mitoxantrone, high dose folinic acid and fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1991 |
Divergent patterns of incorporation of bromodeoxyuridine and iododeoxyuridine in human colorectal tumor cell lines.
Topics: Bromodeoxyuridine; Cell Division; Colorectal Neoplasms; DNA, Neoplasm; Floxuridine; Fluorouracil; Ga | 1991 |
Clinical trials referral resource. Treatment of advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trial | 1991 |
Colorectal metastases to the liver: present results and future strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1991 |
[Regional chemotherapy of diffuse liver metastases of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1991 |
[The adjuvant chemotherapy of patients with colorectal carcinoma (preliminary report)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adju | 1991 |
[A combined method for treating metastases of colorectal carcinoma to the liver].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colorectal | 1991 |
Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; | 1991 |
[Hepatic arterial infusion of high dose 5-FU in weekly schedule for liver metastases from colorectal cancer employing a newly developed pump "Koken Infusor"].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouraci | 1991 |
[Five-hour hepatic arterial infusion of high-dose 5-FU on weekly schedule for liver metastases from colorectal cancer].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluation; Fluorouracil; Humans; Infusions | 1991 |
Therapeutic potential of differentiating agents in colon cancer treatment.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; Col | 1991 |
[Continuous infusion chemotherapy using an infusional port in colorectal cancer with liver metastases].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colo | 1991 |
[Intra-arterial infusion chemotherapy using an implantable reservoir in the treatment of hepatic metastases in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Colorectal Neop | 1991 |
[Effects and complications of continuous hepatic arterial infusion chemotherapy using implantable reservoir for liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Colorectal Neoplasms; Drug Administ | 1991 |
Mechanisms of relapse for colorectal cancer: implications for intraperitoneal chemotherapy.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusi | 1991 |
Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Fem | 1991 |
Rational basis for the metabolic modulation of 5-fluorouracil by leucovorin and interferon alpha.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; Clinical Trials as Topic; | 1991 |
Fluorouracil and recombinant interferon alfa-2a in advanced gastrointestinal neoplasms.
Topics: Colorectal Neoplasms; Combined Modality Therapy; Drug Evaluation; Fluorouracil; Humans; Interferon a | 1991 |
Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
[Is there a reliable adjuvant (intraoperative) chemotherapy of colorectal cancer?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin | 1990 |
A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorour | 1991 |
[Treatment of colorectal cancer with antineoplastic agents. Too early to introduce routine adjuvant therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Levamiso | 1991 |
Colorectal liver metastases.
Topics: Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Microspheres | 1991 |
[Systemic chemotherapy of colorectal cancer--recent approaches].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Modality T | 1991 |
5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr | 1991 |
Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1991 |
Therapeutic doses of dipyridamole failed to potentiate 5-fluorouracil tumor activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Female; Fluorour | 1991 |
[Adjuvant chemotherapy in colonic carcinoma?].
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colon | 1991 |
[Value of CEA determination in follow-up of patients with liver metastasis of colorectal cancers with loco-regional chemotherapy].
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil | 1991 |
What is the value of methotrexate in the treatment of advanced colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Fluorouracil; Human | 1991 |
[Colorectal carcinogenesis, tumor progression and chemoresistance].
Topics: Camptothecin; Cell Transformation, Neoplastic; Colorectal Neoplasms; Drug Resistance; Fluorouracil; | 1990 |
5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Fluorouracil; Human | 1990 |
Stimulation of clonal growth of human colorectal tumor cells by IL-3 and GM-CSF. Modulation of 5-FU cytotoxicity by GM-CSF.
Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colorectal Neoplasms; Combined Modality The | 1990 |
Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay.
Topics: Breast Neoplasms; Carbazilquinone; Cisplatin; Colorectal Neoplasms; DNA, Neoplasm; Doxorubicin; Drug | 1990 |
[Treatment of liver metastases from colorectal cancer--major hepatic resection and continuous hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Hep | 1990 |
Anti-proliferative effects of tumor necrosis factor, gamma interferon and 5-fluorouracil on human colorectal carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Division; Cell Line; Colorectal Neop | 1990 |
[Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Colorectal Ne | 1990 |
[A study of low-dose intermittent intra-arterial infusion chemotherapy for liver metastasis in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1990 |
[Clinical evaluation and problem of intra-arterial infusion chemotherapy of liver metastasis from digestive organ cancer].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps, Implantabl | 1990 |
[Hepatic arterial infusion chemotherapy using implantable reservoir in colorectal liver metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Doxorubicin; Fluoro | 1990 |
[Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 1990 |
[Continuous hepatic arterial infusion chemotherapy using implantable reservoir in liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Neoplasms; Drug | 1990 |
Inhibition of liver metastases in nude mice by the combined action of 5-fluorouracil and interferon.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relatio | 1990 |
[A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum].
Topics: Adenocarcinoma; Administration, Oral; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Lymph | 1990 |
Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer.
Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Hum | 1990 |
Modification of 5-fluorouracil activity by high-dose methotrexate or leucovorin in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Ne | 1990 |
Regional chemotherapy in liver metastases of colorectal carcinoma: monitoring with arterial computed tomography.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorub | 1990 |
5-Fluorouracil plus tauromustine in advanced colorectal cancer: unexpected negative results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1990 |
Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1990 |
[Fluorouracil and high-dose folinic acid in the treatment of advanced colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1990 |
[Primary and metastatic liver tumors--evaluation of tumor regression and response with regional cytostatic drug therapy by sonography and fine needle puncture histology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Hepatocellular; Carmustin | 1990 |
[Is levamisole combined with fluorouracil efficient in colorectal cancer?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Levamiso | 1990 |
A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1990 |
Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1990 |
Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer.
Topics: Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Interleukin-2; Killer Cells, Lymphokine-Ac | 1990 |
[Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration].
Topics: Colorectal Neoplasms; Combined Modality Therapy; Delayed-Action Preparations; Fluorouracil; Humans; | 1990 |
Effectiveness and low toxicity of hepatic artery infusion with fluorouracil and mitomycin for metastatic colorectal cancer confined to the liver. The Swiss Group for Clinical and Epidemiological Cancer Research (SAKK).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1990 |
A feasibility study of high-dose cisplatin and 5-fluorouracil with glutathione protection in the treatment of advanced colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Adminis | 1990 |
Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1990 |
A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Resistance; Female; Fluorouracil; Fol | 1990 |
Hepatic arterial infusion (HAI) chemotherapy for liver metastases of colorectal cancer using 5-FU.
Topics: Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Infusions, Intra | 1990 |
[Cardiac side effects of 5-fluorouracil].
Topics: Aged; Arrhythmias, Cardiac; Colorectal Neoplasms; Electrocardiography; Female; Fluorouracil; Heart; | 1990 |
An evaluation of combination 5-fluorouracil and spirogermanium in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1990 |
The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
Topics: Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplas | 1990 |
[Evaluation of reservoir inserted for the prevention of liver metastasis of colorectal cancer].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatectomy; Humans; Infusion Pump | 1990 |
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa | 1990 |
[Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Li | 1990 |
Biochemical modulation of 5-fluorouracil by PALA.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colo | 1990 |
5-Fluorouracil and levamisole in colorectal carcinoma.
Topics: Adjuvants, Immunologic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Levam | 1990 |
The combined effect of interferon and 5-FU on tumor-cell metastasis in the nude mouse.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluor | 1989 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid | 1989 |
[Clinical use of magnetic resonance spectroscopy and positron emission tomography in oncology].
Topics: Colorectal Neoplasms; Energy Metabolism; Fluorouracil; Humans; Liver Neoplasms; Magnetic Resonance S | 1989 |
[Intra-arterial chemotherapy of local recurrences of gastrointestinal tumors].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorectal Neopla | 1989 |
[Plasma and tissue concentration of tegafur by a new soft capsule type suppository in colorectal carcinoma].
Topics: Aged; Aged, 80 and over; Capsules; Colorectal Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; | 1989 |
Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1989 |
[Locoregional chemotherapy of liver tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1989 |
[Availability of intermittent chemotherapy by reservoir in liver metastasis of colo-rectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Evaluation Studie | 1989 |
[Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Colorectal Neoplasms; Combined Moda | 1989 |
[Study of long-survival cases with liver metastasis of colorectal cancer by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Neoplasms; Doxo | 1989 |
[Complications of intra-arterial infusion chemotherapy in patients with colorectal cancer with liver metastasis, with special reference to IA-5-FU induced sclerosing cholangitis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cholangitis, Sclerosin | 1989 |
Intra-arterial hepatic chemotherapy for metastatic liver from colo-rectal carcinoma origin.
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery | 1989 |
Regional chemotherapy for hepatic metastases from colorectal carcinoma.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms | 1989 |
Treatment of liver metastases from colorectal cancer with continuous high dose intra-arterial floxuridine (FUDR) and systemic fluorouracil: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; | 1989 |
[Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neoplasms; Com | 1989 |
[The study of transcatheter arterial chemo-lipiodol administration in liver metastasis of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1989 |
Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Fluorouracil; Human | 1989 |
Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluatio | 1989 |
A phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 1989 |
[Synchronous hepatic metastases of colorectal adenocarcinoma: what is the course? Apropos of 36 cases].
Topics: Adenocarcinoma; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, In | 1989 |
[Early adjuvant intraportal chemotherapy with 5-fluorouracil after hepatic resection of colorectal metastasis: a preliminary clinical and pharmacokinetic study].
Topics: Adult; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; I | 1989 |
A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Female; | 1989 |
Sequential high dose methotrexate, 5-fluorouracil and folinic acid does not improve response rates in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1989 |
Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fem | 1989 |
Treatment with 5-FU, VCR and BCNU in tumor bearing nude mice.
Topics: Adenocarcinoma; Animals; Carmustine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Mice; Mice, | 1989 |
Bolus fluorouracil for metastatic colorectal carcinoma?
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Neoplasm Metastasis; Progn | 1989 |
[Hepatic arterial infusion chemotherapy using totally implantable reservoir in liver metastases in colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Carcinoemb | 1989 |
[Portal vein infusion therapy of the prevention of liver metastasis from colorectal carcinomas].
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouraci | 1989 |
Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 1989 |
Clinical experience with leucovorin and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1989 |
Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer.
Topics: Adult; Aged; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; | 1989 |
Phase II evaluation of 5-fluorouracil, folinic acid and cisplatin in advanced-stage colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1989 |
Treatment of metastatic colorectal adenocarcinoma with fluorouracil and high-dose leucovorin: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 1989 |
Intrahepatic 5-FU retreatment of liver metastases of colorectal cancer that were progressive under previous systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Cause of Death; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Art | 1989 |
Treatment of metastatic colorectal carcinoma. Recent advances in use of fluorouracil.
Topics: Adenocarcinoma; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps; Leucovorin | 1989 |
Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1989 |
Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Color | 1989 |
Assessment of serial carcinoembryonic antigen: determinations to monitor the therapeutic progress and prognosis of metastatic liver disease treated by regional chemotherapy.
Topics: Adult; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Cancer, Regional Perfusion; Cohort | 1989 |
Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug A | 1989 |
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines.
Topics: Carcinoma; Cell Survival; Colorectal Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; L | 1988 |
[Rationale and current results of loco-regional chemotherapy in hepatic metastases of colorectal carcinoma].
Topics: Antineoplastic Agents; Carmustine; Cisplatin; Colorectal Neoplasms; Doxorubicin; Floxuridine; Fluoro | 1987 |
The antiproliferative effects of fluoropyrimidine derivatives against human tumor xenografts in a subrenal capsule assay.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Colorectal Neoplasms; Floxuridine; Fluor | 1988 |
[Pre- and post-operative adjuvant chemotherapy of colorectal cancer. Part 1. Drug concentration in tissues following UFT administration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Postoper | 1988 |
[Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Dos | 1988 |
A phase II study of sequential methotrexate and 5-fluorouracil in colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1988 |
Regional injection of 5-fluorouracil and starch microspheres in colorectal cancer.
Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Fluorouracil; Humans | 1988 |
High-dose folinic acid and 5-fluorouracil in the treatment of advanced colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bloo | 1988 |
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1988 |
High-dose weekly oral leucovorin and 5-fluorouracil in previously untreated patients with advanced colorectal carcinoma: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; | 1988 |
Role of dose, schedule and route of administration of 5-formyltetra-hydrofolate: preclinical and clinical investigations.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; | 1988 |
Another effective chemotherapy combination for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 1988 |